PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mackey, K; Ayers, CK; Kondo, KK; Saha, S; Advani, SM; Young, S; Spencer, H; Rusek, M; Anderson, J; Veazie, S; Smith, M; Kansagara, D				Mackey, Katherine; Ayers, Chelsea K.; Kondo, Karli K.; Saha, Somnath; Advani, Shailesh M.; Young, Sarah; Spencer, Hunter; Rusek, Max; Anderson, Johanna; Veazie, Stephanie; Smith, Mia; Kansagara, Devan			Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							HEALTH-CARE-SYSTEM; CHALLENGE; US	Background: Data suggest that the effects of coronavirus disease 2019 (COVID-19) differ among U.S. racial/ethnic groups. Purpose: To evaluate racial/ethnic disparities in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates and COVID-19 outcomes, factors contributing to disparities, and interventions to reduce them. Data Sources: English-language articles in MEDLINE, PsycINFO, CINAHL, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus, searched from inception through 31 August 2020. Gray literature sources were searched through 2 November 2020. Study Selection: Observational studies examining SARS-CoV-2 infections, hospitalizations, or deaths by race/ethnicity in U.S. settings. Data Extraction: Single-reviewer abstraction confirmed by a second reviewer; independent dual-reviewer assessment of quality and strength of evidence. Data Synthesis: 37 mostly fair-quality cohort and cross-sectional studies, 15 mostly good-quality ecological studies, and data from the Centers for Disease Control and Prevention and APM Research Lab were included. African American/Black and Hispanic populations experience disproportionately higher rates of SARS-CoV-2 infection, hospitalization, and COVID-19-related mortality compared with non-Hispanic White populations, but not higher case-fatality rates (mostly reported as in-hospital mortality) (moderate- to high-strength evidence). Asian populations experience similar outcomes to non-Hispanic White populations (low-strength evidence). Outcomes for other racial/ethnic groups have been insufficiently studied. Health care access and exposure factors may underlie the observed disparities more than susceptibility due to comorbid conditions (low-strength evidence). Limitations: Selection bias, missing race/ethnicity data, and incomplete outcome assessments in cohort and cross-sectional studies must be considered. In addition, adjustment for key demographic covariates was lacking in ecological studies. Conclusion: African American/Black and Hispanic populations experience disproportionately higher rates of SARS-CoV-2 infection and COVID-19-related mortality but similar rates of case fatality. Differences in health care access and exposure risk may be driving higher infection and mortality rates.	[Mackey, Katherine; Ayers, Chelsea K.; Kondo, Karli K.; Saha, Somnath; Young, Sarah; Anderson, Johanna; Veazie, Stephanie; Kansagara, Devan] VA Portland Hlth Care Syst, VA Evidence Synth Program, 3710 SW US Vet Hosp Rd,P3MED, Portland, OR 97239 USA; [Mackey, Katherine; Kondo, Karli K.; Saha, Somnath; Spencer, Hunter; Rusek, Max; Kansagara, Devan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Advani, Shailesh M.] NHGRI, Social Behav Res Branch, NIH, Bethesda, MD 20892 USA; [Smith, Mia] Oregon Hlth & Sci Univ Portland State Univ Sch Pu, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Oregon Health & Science University; Portland State University	Mackey, K (corresponding author), VA Portland Hlth Care Syst, VA Evidence Synth Program, 3710 SW US Vet Hosp Rd,P3MED, Portland, OR 97239 USA.			Spencer, Hunter/0000-0002-5710-1836; Kondo, Karli/0000-0002-4635-5056	Department of Veterans Affairs, Veterans Health Administration, Health Services Research Development	Department of Veterans Affairs, Veterans Health Administration, Health Services Research Development(US Department of Veterans Affairs)	By the Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development.	ABEDI V, 2020, J RACIAL ETHN HEALTH; Adegunsoye A, 2020, ANN AM THORAC SOC, V17, P1336, DOI 10.1513/AnnalsATS.202006-583RL; Agency for Healthcare Research and Quality, 2014, METHODS GUIDE EFFECT; Ahmed SM, 2020, 200920311 MEDRXIV, DOI 10.1101/2020.05.05.20092031; Anyane-Yeboa A, 2020, J INTERN MED, V288, P479, DOI 10.1111/joim.13117; Artiga S, 2020, DISPARITIES HLTH HLT; Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598; Baggett TP, COVID 19 OUTBREAK LA, DOI 10.1101/2020.04.12.20059618; Berkman ND, 2015, J CLIN EPIDEMIOL, V68, P1312, DOI 10.1016/j.jclinepi.2014.11.023; Bilal U, 2020, SPATIAL INEQUITIES C, DOI [10.1101/2020.05.01.20087833, DOI 10.1101/2020.05.01.20087833]; Blitz MJ, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100212; Caraballo C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238829; Centers for Disease Control and Prevention, COVIDVIEW KEY UPD WE; Centers for Disease Control and Prevention National Center for Health Statistics, 2020, HLTH DISP RAC HISP O; Chamie G, 2021, CLIN INFECT DIS, V73, pS127, DOI 10.1093/cid/ciaa1234; Chow DS, 2020, DISPROPORTIONATE RIS, DOI [10.1101/2020.05.04.20090878, DOI 10.1101/2020.05.04.20090878]; Ebinger JE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236240; Emeruwa UN, 2020, OBSTET GYNECOL, V136, P1040, DOI 10.1097/AOG.0000000000004088; Flannery DD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd5709; Fox T, 2021, ACTA DIABETOL, V58, P33, DOI 10.1007/s00592-020-01592-8; Goldfarb IT, 2020, OBSTET GYNECOL, V136, P300, DOI 10.1097/AOG.0000000000004005; Goldstein Joshua Robert, 2020, medRxiv, DOI 10.1101/2020.05.21.20109116; Golestaneh L, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100455; Gross CP, 2020, J GEN INTERN MED, V35, P3097, DOI 10.1007/s11606-020-06081-w; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Guha Avirup, 2020, medRxiv, DOI 10.1101/2020.04.19.20071944; Holtgrave DR, 2020, ANN EPIDEMIOL, V48, P9, DOI 10.1016/j.annepidem.2020.06.010; Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580; Karaye IM, 2020, AM J PREV MED, V59, P317, DOI 10.1016/j.amepre.2020.06.006; Khanijahani A., COUNTY LEVEL PROPORT, DOI [10.1101/2020.06.03.20120667, DOI 10.1101/2020.06.03.20120667]; Khazanchi R, 2020, J GEN INTERN MED, V35, P2784, DOI 10.1007/s11606-020-05882-3; Khose S, 2020, J COMMUN HEALTH, V45, P696, DOI 10.1007/s10900-020-00854-4; Kilbourne AM, 2006, AM J PUBLIC HEALTH, V96, P2113, DOI 10.2105/AJPH.2005.077628; Killerby ME, 2020, MMWR-MORBID MORTAL W, V69, P790, DOI 10.15585/mmwr.mm6925e1; Kim EJ, 2020, J GEN INTERN MED, V35, P2441, DOI 10.1007/s11606-020-05881-4; Kim L, 2021, CLIN INFECT DIS, V72, P206, DOI DOI 10.1093/cid/ciaa1012; Kupferschmidt K, 2020, SCIENCE; Lara OD, 2020, CANCER-AM CANCER SOC, V126, P4294, DOI 10.1002/cncr.33084; Li AY, 2020, AM J MED SCI, V360, P348, DOI 10.1016/j.amjms.2020.06.015; Martinez DA, 2020, JAMA-J AM MED ASSOC, V324, P392, DOI 10.1001/jama.2020.11374; McCarty TR, 2020, CLIN INFECT DIS PUBL; Millett GA, 2020, ANN EPIDEMIOL, V47, P37, DOI 10.1016/j.annepidem.2020.05.003; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Moscola J, 2020, JAMA-J AM MED ASSOC, V324, P893, DOI 10.1001/jama.2020.14765; Nayak Aditi, 2020, medRxiv, DOI 10.1101/2020.04.10.20060962; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Quinn SC, 2014, BIOSECUR BIOTERROR, V12, P263, DOI 10.1089/bsp.2014.0032; Quinn SC, 2011, AM J PUBLIC HEALTH, V101, P285, DOI 10.2105/AJPH.2009.188029; Reichberg SB, 2020, CLIN INFECT DIS, V71, P3204, DOI 10.1093/cid/ciaa922; Rentsch Christopher T, 2020, medRxiv, DOI [10.1101/2020.04.09.20059964, 10.1101/2020.05.12.20099135]; Rosenberg E.S., 2020, ANN EPIDEMIOL, V48, P23, DOI [10.1016/j.annepidem.2020.06.004, DOI 10.1016/j.annepidem.2020.06.004]; Saha S, 2008, J GEN INTERN MED, V23, P654, DOI 10.1007/s11606-008-0521-4; Salacup G, 2021, J MED VIROL, V93, P416, DOI 10.1002/jmv.26252; Sehra ST, 2020, J MED VIROL, V92, P2406, DOI 10.1002/jmv.26095; Shah P, 2020, ANN MED, V52, P354, DOI 10.1080/07853890.2020.1791356; Soyemi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084380; Sy Karla Therese L, 2020, medRxiv, DOI [10.1101/2020.05.28.20115949, 10.1093/aje/kwaa277]; Thomas SB, 2008, ANN NY ACAD SCI, V1136, P111, DOI 10.1196/annals.1425.018; Vahidy FS, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039849; van Gerwen M, 2021, J MED VIROL, V93, P907, DOI 10.1002/jmv.26337; Wells GA, NEWCASTLE OTTAWA SCA; Whittle RS, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01731-6; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039; Zhang CH, 2020, J RURAL HEALTH, V36, P433, DOI 10.1111/jrh.12476	67	328	328	12	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					362	+		10.7326/M20-6306	http://dx.doi.org/10.7326/M20-6306			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX4DA	33253040	Green Published			2023-01-03	WOS:000629294000019
J	Shackleton, N; Li, EL; Gibb, S; Kvalsvig, A; Baker, M; Sporle, A; Bentley, R; Milne, BJ				Shackleton, Nichola; Li, Eileen; Gibb, Sheree; Kvalsvig, Amanda; Baker, Michael; Sporle, Andrew; Bentley, Rebecca; Milne, Barry J.			The relationship between income poverty and child hospitalisations in New Zealand: Evidence from longitudinal household panel data and Census data	PLOS ONE			English	Article							HEALTH; INEQUALITIES	Background Very little high quality evidence exists on the causal relationship between income poverty and childhood health. We provide a comprehensive overview of the association between household income poverty and hospitalisations for children. Methods We used New Zealand's Integrated Data Infrastructure (IDI) to link income poverty data from the Survey of Family, Income and Employment (SoFIE; n = 21,759 households) and the 2013 New Zealand Census (n = 523,302 households) to publicly funded hospital records of children aged 0-17 (SoFIE: n = 39,459; Census, n = 986,901). Poverty was defined as equivalised household income below 60% of the median income, calculated both before and after housing costs, and using both self-reported and tax-recorded income. Results Correlations for the association between income poverty and hospitalisation were small (ranging from 0.02 to 0.05) and risk ratios were less than 1.35 for all but the rarest outcome-oral health hospitalisation. Weak or absent associations were apparent across age groups, waves of data collection, cumulative effects, and for estimates generated from fixed effects models and random effect models adjusted for age and ethnicity. Alternative measures of deprivation (area-level deprivation and material deprivation) showed stronger associations with hospitalisations (risk ratios ranged from 1.27-2.55) than income-based poverty measures. Conclusion Income poverty is at best weakly associated with hospitalisation in childhood. Measures of deprivation may have a stronger association. Income measures alone may not be sufficient to capture the diversity of household economic circumstances when assessing the poverty-health relationship.	[Shackleton, Nichola; Li, Eileen; Milne, Barry J.] Univ Auckland, Ctr Methods & Policy Applicat Social Sci, Auckland, New Zealand; [Gibb, Sheree; Kvalsvig, Amanda; Baker, Michael] Univ Otago, Dept Publ Hlth, Wellington, New Zealand; [Sporle, Andrew] Univ Auckland, Dept Stat, Auckland, New Zealand; [Bentley, Rebecca] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Hlth Equity, Melbourne, Australia	University of Auckland; University of Otago; University of Auckland; University of Melbourne	Milne, BJ (corresponding author), Univ Auckland, Ctr Methods & Policy Applicat Social Sci, Auckland, New Zealand.	b.milne@auckland.ac.nz		Gibb, Sheree/0000-0002-9708-8816; Li, Eileen/0000-0001-8251-4942	Health Research Council of New Zealand [HRC17-250]	Health Research Council of New Zealand(Health Research Council of New Zealand)	This research was funded by a grant (Ref HRC17-250) from the Health Research Council of New Zealand (www.https://hrc.govt.nz) awarded to BM (Principal Investigator) and NS, SG, AK, MB, AS and RB (named investigators). The sponsors played no role in the study design, data collection, analysis, decision to publish, and the preparation of the manuscript.	Alexander K., 2014, LONG SHADOW FAMILY B; Alkire S, 2011, J ECON INEQUAL, V9, P289, DOI 10.1007/s10888-011-9181-4; Alkire S, 2011, J PUBLIC ECON, V95, P476, DOI 10.1016/j.jpubeco.2010.11.006; Alkire S, 2008, MANY DIMENSIONS OF POVERTY, P89; Anderson P, 2012, NEW ZEAL MED J, V125, P25; [Anonymous], 2005, NZ MED J; Atkinson J., 2014, NZDEP2013 INDEX DEPR; Baker MG, 2012, LANCET, V379, P1112, DOI 10.1016/S0140-6736(11)61780-7; Barker C, 2016, AGE, V150, P863; Boston J., 2014, CHILD POVERTY NZ; Bourguignon F., 2003, J ECON INEQUAL, V1, P25, DOI [DOI 10.1023/A:1023913831342, 10.1023/A:1023913831342]; Byrnes CA, 2010, J PAEDIATR CHILD H, V46, P521, DOI 10.1111/j.1440-1754.2010.01853.x; Carter K, 2009, 4 SOFIE U OT; Carter KN, 2010, INT J EPIDEMIOL, V39, P653, DOI 10.1093/ije/dyp215; Conger RD, 2010, J MARRIAGE FAM, V72, P685, DOI 10.1111/j.1741-3737.2010.00725.x; CONGER RD, 1994, CHILD DEV, V65, P541, DOI 10.1111/j.1467-8624.1994.tb00768.x; Cooper K., 2013, DOES MONEY AFFECT CH; Cooper K, 2017, DOES MONEY AFFECT CH, P203; Currie A, 2007, J HEALTH ECON, V26, P213, DOI 10.1016/j.jhealeco.2006.08.003; Dale M, 2014, OUR CHILDREN OUR CHO; DeWalt Darren A, 2009, Pediatrics, V124 Suppl 3, pS265, DOI 10.1542/peds.2009-1162B; Doyle O, 2005, IMPACT PARENTAL INCO; Easton B, 2002, EC HLTH STATUS HOUSE; Gunasekara FI, 2012, NEW ZEAL MED J, V125, P95; Gutierrez RG, 2003, STATA J, V3, P412; Hargreaves DS, 2015, HEALTH AFFAIR, V34, P2113, DOI 10.1377/hlthaff.2015.0709; Jensen J., 1988, INCOME EQUIVALENCES; Marmot M, 2015, LANCET, V386, P2442, DOI 10.1016/S0140-6736(15)00150-6; Mills Clair, 2012, BMC Public Health, V12, P384, DOI 10.1186/1471-2458-12-384; Milne BJ, 2019, INT J EPIDEMIOLOGY; MOH NZ, 2019, ANN DAT EXPL 2018 19; Najman JM, 2010, J ADOLESCENT HEALTH, V46, P538, DOI 10.1016/j.jadohealth.2009.12.001; OECD, 2018, POOR CHILDR RICH COU; Perry B, 2017, MAT WELLBEING NEW ZE; Perry B, 2018, HOUSEHOLD INCOMES NE; Power C, 1997, BRIT MED BULL, V53, P210; Propper C, 2007, HEALTH ECON, V16, P1245, DOI 10.1002/hec.1221; Rabe-Hesketh S., 2012, MULTILEVEL LONGITUDI; Salmond C, 2006, SOC SCI MED, V62, P1474, DOI 10.1016/j.socscimed.2005.08.008; Salmond C, 2005, NZDEP2001 INDEX DEPR; Sanders LM, 2009, ARCH PEDIAT ADOL MED, V163, P131, DOI 10.1001/archpediatrics.2008.539; Shackleton N, 2018, COMMUNITY DENT ORAL, V46, P288, DOI 10.1111/cdoe.12364; Shackleton N, 2017, J EARLY CHILD RES, V15, P238, DOI 10.1177/1476718X15606479; Shonkoff JP, 2012, PEDIATRICS, V129, pE232, DOI 10.1542/peds.2011-2663; Simpson J, 2017, TE OHONGA AKE HLTH S; St John S, 2008, END LIF CAR CLIN PRO; StataCorp, 2017, STATA STAT SOFTWARE, DOI DOI 10.2307/2234838; Statistics New Zealand, 2017, STAT STAND ETHN ETHN; Thomson WM, 2004, COMMUNITY DENT ORAL, V32, P345, DOI 10.1111/j.1600-0528.2004.00173.x; Violato M, 2009, SOC SCI MED, V69, P955, DOI 10.1016/j.socscimed.2009.06.036; Wickham S, 2016, ARCH DIS CHILD, V101, P759, DOI 10.1136/archdischild-2014-306746	51	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0243920	10.1371/journal.pone.0243920	http://dx.doi.org/10.1371/journal.pone.0243920			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PV4UT	33439879	Green Published, gold			2023-01-03	WOS:000609985300027
J	Alnaas, AA; Watson-Siriboe, A; Tran, S; Negussie, M; Henderson, JA; Osterberg, JR; Chon, NL; Harrott, BM; Oviedo, J; Lyakhova, T; Michel, C; Reisdorph, N; Reisdorph, R; Shearn, CT; Lin, H; Knight, JD				Alnaas, Aml A.; Watson-Siriboe, Abena; Tran, Sherleen; Negussie, Mikias; Henderson, Jack A.; Osterberg, J. Ryan; Chon, Nara L.; Harrott, Beckston M.; Oviedo, Julianna; Lyakhova, Tatyana; Michel, Cole; Reisdorph, Nichole; Reisdorph, Richard; Shearn, Colin T.; Lin, Hai; Knight, Jefferson D.			Multivalent lipid targeting by the calcium-independent C2A domain of synaptotagmin-like protein 4/granuphilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; PLASMA-MEMBRANE; INSULIN GRANULES; GRANUPHILIN; BINDING; EXOCYTOSIS; SIMULATIONS; PARAMETERS; INSIGHTS	Synaptotagmin-like protein 4 (Slp-4), also known as granuphilin, is a Rab effector responsible for docking secretory vesicles to the plasma membrane before exocytosis. Slp-4 binds vesicular Rab proteins via an N-terminal Slp homology domain, interacts with plasma membrane SNARE complex proteins via a central linker region, and contains tandem C-terminal C2 domains (C2A and C2B) with affinity for phosphatidylinositol(4,5)-bisphosphate (PIP2). The Slp-4 C2A domain binds with low nanomolar apparent affinity to PIP2 in lipid vesicles that also contain background anionic lipids such as phosphatidylserine but much weaker when either the background anionic lipids or PIP2 is removed. Through computational and experimental approaches, we show that this high-affinity membrane binding arises from concerted interaction at multiple sites on the C2A domain. In addition to a conserved PIP2-selective lysine cluster, a larger cationic surface surrounding the cluster contributes substantially to the affinity for physiologically relevant lipid compositions. Although the K398A mutation in the lysine cluster blocks PIP2 binding, this mutated protein domain retains the ability to bind physiological membranes in both a liposome-binding assay and MIN6 cells. Molecular dynamics simulations indicate several conformationally flexible loops that contribute to the nonspecific cationic surface. We also identify and characterize a covalently modified variant that arises through reactivity of the PIP2-binding lysine cluster with endogenous bacterial compounds and binds weakly to membranes. Overall, multivalent lipid binding by the Slp-4 C2A domain provides selective recognition and high-affinity docking of large dense core secretory vesicles to the plasma membrane.	[Alnaas, Aml A.; Watson-Siriboe, Abena; Tran, Sherleen; Negussie, Mikias; Henderson, Jack A.; Osterberg, J. Ryan; Chon, Nara L.; Harrott, Beckston M.; Oviedo, Julianna; Lyakhova, Tatyana; Lin, Hai; Knight, Jefferson D.] Univ Colorado, Dept Chem, Denver, CO 80202 USA; [Michel, Cole; Reisdorph, Nichole; Reisdorph, Richard] Univ Colorado, Dept Pharmaceut Sci, Sch Med, Anschutz Med Campus, Aurora, CO USA; [Shearn, Colin T.] Univ Colorado, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, Sch Med, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Lin, H; Knight, JD (corresponding author), Univ Colorado, Dept Chem, Denver, CO 80202 USA.	Hai.Lin@ucdenver.edu; Jefferson.Knight@ucdenver.edu		Negussie, Mikias/0000-0001-6060-6926; Lin, Hai/0000-0002-3525-9122	NIH [R15GM102866]; Camille and Henry Dreyfus Foundation [TH-14-028, TH-18-061]; University of Colorado Denver Undergraduate Research Opportunity Program; University of Colorado Denver LABCOATS program [NIH 5R25GM083333]; NSF [CHE-140070, ACI-1548562]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Camille and Henry Dreyfus Foundation; University of Colorado Denver Undergraduate Research Opportunity Program; University of Colorado Denver LABCOATS program; NSF(National Science Foundation (NSF))	This work was funded by the NIH grant R15GM102866. The authors acknowledge support from the Camille and Henry Dreyfus Foundation (TH-14-028 to H. L. and TH-18-061 to J. D. K.) and the University of Colorado Denver Undergraduate Research Opportunity Program (to S. T., J. A. H., and T. L.). T. L. was supported by a fellowship through the University of Colorado Denver LABCOATS program (NIH 5R25GM083333 to Prof Sonia Flores). This work used XSEDE under grant CHE-140070, supported by NSF grant ACI-1548562. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	[Anonymous], 2007, FORCE FIELD MANUAL S, P1; Aon JC, 2008, APPL ENVIRON MICROB, V74, P950, DOI 10.1128/AEM.01790-07; Brandt DS, 2012, BIOCHEMISTRY-US, V51, P7654, DOI 10.1021/bi3007115; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Cho W, 2006, BBA-MOL CELL BIOL L, V1761, P838, DOI 10.1016/j.bbalip.2006.06.014; Chon NL, 2015, BIOCHEMISTRY-US, V54, P5696, DOI 10.1021/acs.biochem.5b00422; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; Corbalan-Garcia S, 2014, BBA-BIOMEMBRANES, V1838, P1536, DOI 10.1016/j.bbamem.2014.01.008; Corbin JA, 2004, BIOCHEMISTRY-US, V43, P16161, DOI 10.1021/bi049017a; Coudevylle N, 2008, J BIOL CHEM, V283, P35918, DOI 10.1074/jbc.M804094200; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FELLER SE, 1995, J CHEM PHYS, V103, P4613, DOI 10.1063/1.470648; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2003, J BIOL CHEM, V278, P15390, DOI 10.1074/jbc.M213090200; Fukuda M, 2013, TRAFFIC, V14, P949, DOI 10.1111/tra.12083; Galvez-Santisteban M, 2012, NAT CELL BIOL, V14, P838, DOI 10.1038/ncb2541; Gaylord N. G., 1962, J POLYM SCI, V62, pS24; Geoghegan KF, 1999, ANAL BIOCHEM, V267, P169, DOI 10.1006/abio.1998.2990; Gomi H, 2005, J CELL BIOL, V171, P99, DOI 10.1083/jcb.200505179; Guerrero-Valero M, 2009, P NATL ACAD SCI USA, V106, P6603, DOI 10.1073/pnas.0813099106; Gurtovenko AA, 2008, J PHYS CHEM B, V112, P1953, DOI 10.1021/jp0750708; HALL D, 1984, J COMPUT CHEM, V5, P441, DOI 10.1002/jcc.540050504; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Jo S, 2009, BIOPHYS J, V97, P50, DOI 10.1016/j.bpj.2009.04.013; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jurkiewicz P, 2012, BBA-BIOMEMBRANES, V1818, P609, DOI 10.1016/j.bbamem.2011.11.033; Kalli AC, 2014, BIOCHEMISTRY-US, V53, P1724, DOI 10.1021/bi5000299; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klauda JB, 2010, J PHYS CHEM B, V114, P7830, DOI 10.1021/jp101759q; Lai CL, 2010, J MOL BIOL, V402, P301, DOI 10.1016/j.jmb.2010.07.037; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Lyakhova TA, 2014, CHEM PHYS LIPIDS, V182, P29, DOI 10.1016/j.chemphyslip.2013.10.009; MacDougall DD, 2018, J GEN PHYSIOL, V150, P783, DOI 10.1085/jgp.201711944; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Martos-Maldonado MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05695-3; MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468; Miyamoto K, 2017, PROTEIN SCI, V26, P2451, DOI 10.1002/pro.3301; Mizuno K, 2016, SCI REP-UK, V6, DOI 10.1038/srep23909; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Osna NA, 2016, WORLD J GASTROENTERO, V22, P6192, DOI 10.3748/wjg.v22.i27.6192; Pant S, 2020, J COMPUT CHEM, V41, P489, DOI 10.1002/jcc.26109; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Posner MG, 2018, J BIOL CHEM, V293, P9335, DOI 10.1074/jbc.RA118.002279; PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020; Reisdorph N, 2018, J CHROMATOGR B, V1084, P132, DOI 10.1016/j.jchromb.2018.03.031; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024; SEELIG J, 1978, BIOCHEMISTRY-US, V17, P3310, DOI 10.1021/bi00609a021; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Shearn CT, 2016, REDOX BIOL, V7, P68, DOI 10.1016/j.redox.2015.11.013; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Torii S, 2004, J BIOL CHEM, V279, P22532, DOI 10.1074/jbc.M400600200; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Tran HT, 2019, BIOPHYS J, V116, P1025, DOI 10.1016/j.bpj.2019.01.035; Tsuboi T, 2006, MOL BIOL CELL, V17, P2101, DOI 10.1091/mbc.E05-11-1047; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Venable RM, 2013, J PHYS CHEM B, V117, P10183, DOI 10.1021/jp401512z; Wan CJ, 2015, CHEM PHYS LIPIDS, V186, P61, DOI 10.1016/j.chemphyslip.2015.01.003; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Yamaoka M, 2015, WORLD J DIABETES, V6, P508, DOI 10.4239/wjd.v6.i3.508; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Yu M, 2007, MOL BIOL CELL, V18, P688, DOI 10.1091/mbc.E06-10-0914; Zhou A, 2013, BIOCHEMISTRY-US, V52, P3446, DOI 10.1021/bi400230u	70	3	3	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100159	10.1074/jbc.RA120.014618	http://dx.doi.org/10.1074/jbc.RA120.014618			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33277360	gold, Green Published			2023-01-03	WOS:000672866400137
J	Jansz, TT; Ozyilmaz, A; van Reekum, FE; Boereboom, FTJ; de Jong, PA; Verhaar, MC; van Jaarsveld, BC				Jansz, Thijs T.; Ozyilmaz, Akin; van Reekum, Franka E.; Boereboom, Franciscus T. J.; de Jong, Pim A.; Verhaar, Marianne C.; van Jaarsveld, Brigit C.			Progression of coronary artery calcification in conventional hemodialysis, nocturnal hemodialysis, and kidney transplantation	PLOS ONE			English	Article							STAGE RENAL-DISEASE; VASCULAR CALCIFICATION; CARDIOVASCULAR-DISEASE; MINERAL METABOLISM; NATURAL-HISTORY; CALCIUM; CINACALCET; MORTALITY; COHORT	Introduction Cardiovascular disease is the leading cause of death in end-stage renal disease (ESRD) and is strongly associated with vascular calcification. An important driver of vascular calcification is high phosphate levels, but these become lower when patients initiate nocturnal hemodialysis or receive a kidney transplant. However, it is unknown whether nocturnal hemodialysis or kidney transplantation mitigate vascular calcification. Therefore, we compared progression of coronary artery calcification (CAC) between patients treated with conventional hemodialysis, nocturnal hemodialysis, and kidney transplant recipients. Methods We measured CAC annually up to 3 years in 114 patients with ESRD that were transplantation candidates: 32 that continued conventional hemodialysis, 34 that initiated nocturnal hemodialysis (>= 4x 8 hours/week), and 48 that received a kidney transplant. We compared CAC progression between groups as the difference in square root transformed volume scores per year (Delta CAC SQRV) using linear mixed models. Reference category was conventional hemodialysis. Results The mean age of the study population was 53 +/- 13 years, 75 (66%) were male, and median dialysis duration was 28 (IQR 12-56) months. Median CAC score at enrollment was 171 (IQR 10-647), which did not differ significantly between treatment groups (P = 0.83). Compared to conventional hemodialysis, CAC progression was non-significantly different in nocturnal hemodialysis -0.10 (95% CI -0.77 to 0.57) and kidney transplantation -0.33 (95% CI -0.96 to 0.29) in adjusted models. Conclusions Nocturnal hemodialysis and kidney transplantation are not associated with significantly less CAC progression compared to conventional hemodialysis during up to 3 years follow-up. Further studies are needed to confirm these findings, to determine which type of calcification is measured with CAC in end-stage renal disease, and whether that reflects cardiovascular risk.	[Jansz, Thijs T.; van Reekum, Franka E.; Verhaar, Marianne C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Nephrol & Hypertens, Utrecht, Netherlands; [Jansz, Thijs T.; Boereboom, Franciscus T. J.] Dianet Dialysis Ctr, Utrecht, Netherlands; [Ozyilmaz, Akin] Dialysis Ctr Groningen, Groningen, Netherlands; [Ozyilmaz, Akin] Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands; [de Jong, Pim A.] Univ Med Ctr Groningen, Dept Radiol, Utrecht, Netherlands; [van Jaarsveld, Brigit C.] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Nephrol, Amsterdam, Netherlands; [van Jaarsveld, Brigit C.] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam Cardiovasc Sci ACS, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Groningen; University of Groningen; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	van Jaarsveld, BC (corresponding author), Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Nephrol, Amsterdam, Netherlands.; van Jaarsveld, BC (corresponding author), Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam Cardiovasc Sci ACS, Amsterdam, Netherlands.	b.jaarsveld@amsterdamumc.nl		van Jaarsveld, Brigit/0000-0001-5871-4952	Amgen; Baxter; Fresenius Medical Care; Novartis; Roche; Shire Pharmaceuticals; Wellerdieck de Goede Foundation; Friends of UMC Utrecht	Amgen(Amgen); Baxter; Fresenius Medical Care; Novartis(Novartis); Roche(Roche Holding); Shire Pharmaceuticals; Wellerdieck de Goede Foundation; Friends of UMC Utrecht	The NOCTx study was supported by unrestricted grants from Amgen, Baxter, Fresenius Medical Care, Novartis, Roche and Shire Pharmaceuticals. T.T. Jansz was supported financially by a grant from the Wellerdieck de Goede Foundation with mediation from Friends of UMC Utrecht. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, AM J KIDNEY DIS, V67, pA4; Bellasi A, 2009, J NEPHROL, V22, P255; Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624; Daugirdas JT, 2012, J AM SOC NEPHROL, V23, P727, DOI 10.1681/ASN.2011070688; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; Hokanson JE, 2004, AM J ROENTGENOL, V182, P1327, DOI 10.2214/ajr.182.5.1821327; Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1; Jansz TT, 2018, AM J NEPHROL, V48, P369, DOI 10.1159/000494665; Jansz TT, 2018, CLIN KIDNEY J, V11, P353, DOI 10.1093/ckj/sfx124; Khan AM, 2012, CLIN J AM SOC NEPHRO, V7, P2017, DOI 10.2215/CJN.02160212; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Leenders NHJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28629-x; Lomashvili KA, 2005, J AM SOC NEPHROL, V16, P2495, DOI 10.1681/ASN.2004080694; Lomashvili KA, 2014, KIDNEY INT, V85, P1351, DOI 10.1038/ki.2013.521; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Malluche HH, 2015, J AM SOC NEPHROL, V26, P2534, DOI 10.1681/ASN.2014070686; Mazzaferro S, 2009, CLIN J AM SOC NEPHRO, V4, P685, DOI 10.2215/CJN.03930808; Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P1662, DOI 10.1111/j.1600-6143.2004.00573.x; Moe SM, 2004, NEPHROL DIAL TRANSPL, V19, P2387, DOI 10.1093/ndt/gfh303; Nakamura S, 2009, CLIN J AM SOC NEPHRO, V4, P1892, DOI 10.2215/CJN.04320709; Pierratos A, 1998, J AM SOC NEPHROL, V9, P859; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725; RICHARDSON PD, 1989, LANCET, V2, P941; Sabour S, 2008, J CLIN EPIDEMIOL, V61, P572, DOI 10.1016/j.jclinepi.2007.07.004; Seyahi N, 2012, NEPHROL DIAL TRANSPL, V27, P2101, DOI 10.1093/ndt/gfr558; Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507; ter Braake AD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20241-3; Vervloet M, 2017, KIDNEY INT, V91, P808, DOI 10.1016/j.kint.2016.09.024; Vervloet MC, 2017, NAT REV NEPHROL, V13, P27, DOI 10.1038/nrneph.2016.164; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Wolf M, 2016, TRANSPLANTATION, V100, P184, DOI 10.1097/TP.0000000000000823; Yuen D, 2006, NEPHROL DIAL TRANSPL, V21, P1407, DOI 10.1093/ndt/gfl021; Zoccali C, 2015, NEPHROL DIAL TRANSPL, V30, P352, DOI 10.1093/ndt/gfv021	34	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2020	15	12							e0244639	10.1371/journal.pone.0244639	http://dx.doi.org/10.1371/journal.pone.0244639			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TQ	33378347	Green Published, gold			2023-01-03	WOS:000605651300042
J	Wei, AH; Dohner, H; Pocock, C; Montesinos, P; Afanasyev, B; Dombret, H; Ravandi, F; Sayar, H; Jang, JH; Porkka, K; Selleslag, D; Sandhu, I; Turgut, M; Giai, V; Ofran, Y; Cakar, MK; de Sousa, AB; Rybka, J; Frairia, C; Borin, L; Beltrami, G; Cermak, J; Ossenkoppele, GJ; La Torre, I; Skikne, B; Kumar, K; Dong, Q; Beach, CL; Roboz, GJ				Wei, A. H.; Dohner, H.; Pocock, C.; Montesinos, P.; Afanasyev, B.; Dombret, H.; Ravandi, F.; Sayar, H.; Jang, J. -H.; Porkka, K.; Selleslag, D.; Sandhu, I.; Turgut, M.; Giai, V.; Ofran, Y.; Cakar, M. Kizil; de Sousa, A. Botelho; Rybka, J.; Frairia, C.; Borin, L.; Beltrami, G.; Cermak, J.; Ossenkoppele, G. J.; La Torre, I.; Skikne, B.; Kumar, K.; Dong, Q.; Beach, C. L.; Roboz, G. J.		QUAZAR AML 001 Trial Investigators	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK MYELODYSPLASTIC SYNDROMES; CONVENTIONAL CARE REGIMENS; TREATMENT OUTCOMES; RESIDUAL DISEASE; YOUNGER ADULTS; OLDER PATIENTS; GROUP-B; AML; CHEMOTHERAPY; AZACYTIDINE	BACKGROUND Although induction chemotherapy results in remission in many older patients with acute myeloid leukemia (AML), relapse is common and overall survival is poor. METHODS We conducted a phase 3, randomized, double-blind, placebo-controlled trial of the oral formulation of azacitidine (CC-486, a hypomethylating agent that is not bioequivalent to injectable azacitidine), as maintenance therapy in patients with AML who were in first remission after intensive chemotherapy. Patients who were 55 years of age or older, were in complete remission with or without complete blood count recovery, and were not candidates for hematopoietic stem-cell transplantation were randomly assigned to receive CC-486 (300 mg) or placebo once daily for 14 days per 28-day cycle. The primary end point was overall survival. Secondary end points included relapse-free survival and health-related quality of life. RESULTS A total of 472 patients underwent randomization; 238 were assigned to the CC-486 group and 234 were assigned to the placebo group. The median age was 68 years (range, 55 to 86). Median overall survival from the time of randomization was significantly longer with CC-486 than with placebo (24.7 months and 14.8 months, respectively; P<0.001). Median relapse-free survival was also significantly longer with CC-486 than with placebo (10.2 months and 4.8 months, respectively; P<0.001). Benefits of CC-486 with respect to overall and relapse-free survival were shown in most subgroups defined according to baseline characteristics. The most common adverse events in both groups were grade 1 or 2 gastrointestinal events. Common grade 3 or 4 adverse events were neutropenia (in 41% of patients in the CC-486 group and 24% of patients in the placebo group) and thrombocytopenia (in 22% and 21%, respectively). Overall health-related quality of life was preserved during CC-486 treatment. CONCLUSIONS CC-486 maintenance therapy was associated with significantly longer overall and relapse-free survival than placebo among older patients with AML who were in remission after chemotherapy. Side effects were mainly gastrointestinal symptoms and neutropenia. Quality-of-life measures were maintained throughout treatment. (Supported by Celgene; QUAZAR AML-001 ClinicalTrials.gov number NCT01757535.)	[Wei, A. H.] Monash Univ, Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia; [Wei, A. H.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia; [Dohner, H.] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany; [Pocock, C.] Kent & Canterbury Hosp, Canterbury, Kent, England; [Montesinos, P.] Inst Carlos III, Ctr Invest Biomed Red Canc, Madrid, Spain; [Montesinos, P.] Hosp Univ & Politecn La Fe, Valencia, Spain; [Afanasyev, B.] Pavlov First St Petersburg State Med Univ, Raisa Gorbacheva Mem Res Inst Pediat Oncol Hemato, St Petersburg, Russia; [Dombret, H.] Univ Paris, Hop St Louis, AP HP, Dept Hematol, Paris, France; [Dombret, H.] Univ Paris, Inst Rech St Louis, Paris, France; [Ravandi, F.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Sayar, H.] Indiana Univ, Canc Ctr, Indianapolis, IN 46204 USA; [Jang, J. -H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Porkka, K.] Univ Helsinki, Hosp Dist Helsinki & Uusimaa HUS, Comprehens Canc Ctr, Hematol Res Unit Helsinki, Helsinki, Finland; [Porkka, K.] Univ Helsinki, iCAN Digital Precis Canc Ctr Med, Helsinki, Finland; [Selleslag, D.] AZ Sint Jan Brugge Oostende AV, Brugge, Belgium; [Sandhu, I.] Univ Alberta Hosp, Edmonton, AB, Canada; [Turgut, M.] Ondokuz Mayis Univ, Samsun, Turkey; [Cakar, M. Kizil] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Ankara, Turkey; [Giai, V.] Antonio & Biagio Cesare Arrigo Hosp, Alessandria, Italy; [Frairia, C.] Citta Salute & Sci, Turin, Italy; [Borin, L.] Osped San Gerardo, Monza, Italy; [Beltrami, G.] Osped Policlin San Martino, Genoa, Italy; [Ofran, Y.] Rambam Med Ctr, Haifa, Israel; [Ofran, Y.] Fac Med Technion, Haifa, Israel; [de Sousa, A. Botelho] Ctr Hosp Univ Lisboa Cent, Hosp Capuchos, Lisbon, Portugal; [Rybka, J.] Wroclaw Med Univ, Wroclaw, Poland; [Cermak, J.] Ustav Hematol & Krevni Transfuze, Prague, Czech Republic; [Ossenkoppele, G. J.] Vrije Univ, Amsterdam Univ, Locat VUMC, Med Ctr, Amsterdam, Netherlands; [La Torre, I.] Celgene Bristol Myers Squibb, Boudry, Switzerland; [Skikne, B.; Kumar, K.; Dong, Q.; Beach, C. L.] Bristol Myers Squibb, Princeton, NJ USA; [Skikne, B.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Roboz, G. J.] Weill Cornell Med, New York, NY USA; [Roboz, G. J.] New York Presbyterian Hosp, New York, NY USA	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Ulm University; University of Kent; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitari i Politecnic La Fe; Pavlov First Saint Petersburg State Medical University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; UTMD Anderson Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Alberta; Ondokuz Mayis University; Dr. Abdurrahman Yurtaslan Oncology Hospital; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; A.O.U. Citta della Salute e della Scienza di Torino; San Gerardo Hospital; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Wroclaw Medical University; Institute of Hematology Prague; University of Amsterdam; Vrije Universiteit Amsterdam; Bristol-Myers Squibb; University of Kansas; University of Kansas Medical Center; Cornell University; NewYork-Presbyterian Hospital	Wei, AH (corresponding author), Alfred Hosp, Commercial Rd, Melbourne, Vic 3004, Australia.	andrew.wei@monash.edu	Kızıl Çakar, Merih/GYA-1392-2022; Kızıl Çakar, Merih/GYA-4832-2022; Sill, Heinz/AAV-4643-2021; geissler, klaus/L-8925-2013; Porkka, Kimmo/O-2323-2016	Sill, Heinz/0000-0003-0993-4371; , Justyna/0000-0001-7965-3589; geissler, klaus/0000-0003-1921-7034; Porkka, Kimmo/0000-0003-4112-5902; Almeida, Antonio/0000-0003-4361-0928; Wei, Andrew/0000-0002-7514-3298; Montesinos, Pau/0000-0002-3275-5593; Ofran, Yishai/0000-0002-5521-1337	Celgene	Celgene(Bristol-Myers SquibbCelgene Corporation)	Supported by Celgene (a wholly owned subsidiary of Bristol Myers Squibb).; We thank the patients, families, coinvestigators, and all personnel who participated in this trial; and Sheila Truten, Brian Kaiser, and Kelly Dittmore (of Medical Communication Company) for editorial and writing assistance with an early draft of the manuscript, funded by the sponsor.	[Anonymous], CEPL HIST DIH SUMM P; [Anonymous], RYD MID SUMM PROD CH; Baer MR, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.6531; Baer MR, 2011, LEUKEMIA, V25, P800, DOI 10.1038/leu.2011.9; Blum W, 2017, LEUKEMIA, V31, P34, DOI 10.1038/leu.2016.252; Brune M, 2006, BLOOD, V108, P88, DOI 10.1182/blood-2005-10-4073; BUCHNER T, 1985, J CLIN ONCOL, V3, P1583; Buyse M, 2011, BLOOD, V117, P7007, DOI 10.1182/blood-2011-02-337725; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; de Lima M, 2018, BIOL BLOOD MARROW TR, V24, P2017, DOI 10.1016/j.bbmt.2018.06.016; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Garcia-Manero G, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.905.905; Garcia-Manero G, 2011, J CLIN ONCOL, V29, P2521, DOI 10.1200/JCO.2010.34.4226; Goldstone AH, 2001, BLOOD, V98, P1302, DOI 10.1182/blood.V98.5.1302; Grimwade D, 2016, BLOOD, V127, P29, DOI 10.1182/blood-2015-07-604496; Grovdal M, 2010, BRIT J HAEMATOL, V150, P293, DOI 10.1111/j.1365-2141.2010.08235.x; Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001; Hourigan CS, 2013, NAT REV CLIN ONCOL, V10, P460, DOI 10.1038/nrclinonc.2013.100; Huls G, 2019, BLOOD, V133, P1457, DOI 10.1182/blood-2018-10-879866; J-HH C, 2015, J CLIN ENDOCRINOL ME, V100, pE1378, DOI 10.1210/jc.2015-2262; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; Laille E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135520; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125; Lowenberg B, 1998, J CLIN ONCOL, V16, P872; Lowenberg B, 2010, BLOOD, V115, P2586, DOI 10.1182/blood-2009-10-246470; Medeiros BC, 2019, AM J HEMATOL, V94, P803, DOI 10.1002/ajh.25484; Molica M, 2019, AM J HEMATOL, V94, P1254, DOI 10.1002/ajh.25620; National Cancer Institute, CANC STAT FACTS LEUK; National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID; National Comprehensive Cancer Network, 2019, NCCN CLIN PRACT GUID; Ossenkoppele G, 2013, BLOOD, V121, P2166, DOI 10.1182/blood-2013-01-480590; PALVA IP, 1991, EUR J HAEMATOL, V47, P229; Ravandi F, 2018, BLOOD ADV, V2, P1356, DOI 10.1182/bloodadvances.2018016378; Schlenk RF, 2017, LEUKEMIA, V31, P1217, DOI 10.1038/leu.2017.22; Stone RM, 2017, NEW ENGL J MED, V377, P454, DOI 10.1056/NEJMoa1614359; Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Vosberg S, 2019, GENE CHROMOSOME CANC, V58, P839, DOI 10.1002/gcc.22806	41	136	138	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	2020	383	26					2526	2537		10.1056/NEJMoa2004444	http://dx.doi.org/10.1056/NEJMoa2004444			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN1KP	33369355	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000604245400008
J	Matangila, JR; Nyembu, RK; Telo, GM; Ngoy, CD; Sakobo, TM; Massolo, JM; Muyembe, BM; Mvwala, RK; Ilunga, CK; Limbole, EB; Ntalaja, JM; Kongo, RM				Matangila, Junior Rika; Nyembu, Ritha Kibambe; Telo, Gloire Mosala; Ngoy, Christian Djuba; Sakobo, Taty Msueun; Massolo, Joel Mbembo; Muyembe, Blandine Mbo; Mvwala, Richard Kapela; Ilunga, Cedric Kabemba; Limbole, Emmanuel Bakilo; Ntalaja, Jeff Mukengeshay; Kongo, Roger Minga			Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study	PLOS ONE			English	Article								Objectives To describe the clinical characteristics of patients infected with SARS-CoV-2 at Clinique Ngaliema, a public hospital, in Kinshasa, in the Democratic Republic of Congo (DRC). Methods This retrospective study analyzed medical records including socio-demographics, past medical history, clinical manifestation, comorbidities, laboratory data, treatment and disease outcome of 160 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection. Results The median age of patients was 54 years (IQR: 38-64), and there was no significant gender difference (51% of male). The most common comorbidities were hypertension (55 [34%]), diabetes (31 [19%]) and obesity (13 [8%]). Fever (93 [58%]), cough (92 [57%]), fatigue (87 [54%]), shortness of breath (72 [45%]) and myalgia (33 [21%]) were the most common symptoms, upon admission. Patients were categorized into mild (92 [57%]), moderate (19 [12%]) and severe (49 [31%]). Severe patients were older and were more likely to have comorbidities, compared to mild ones. The majority of patients (92% [147 of 160]) patients received hydroxychloroquine or chloroquine phosphate. Regression model revealed that older age, lower SpO2, higher heart rate and elevated AST at admission were all risk factors associated with in-hospital death. The prevalence of COVID-19 and malaria co-infection was 0.63% and 70 (44%) of all patients received antimalarial treatment before hospitalization. Conclusion Our findings indicated that the epidemiological and clinical feature of COVID-19 patients in Kinshasa are broadly similar to previous reports from other settings. Older age, lower SpO2, tachycardia, and elevated AST could help to identify patients at higher risk of death at an early stage of the illness. Plasmodium spp co-infection was not common in hospitalized COVID-19 patients.	[Matangila, Junior Rika; Nyembu, Ritha Kibambe; Telo, Gloire Mosala; Ngoy, Christian Djuba; Sakobo, Taty Msueun; Massolo, Joel Mbembo; Muyembe, Blandine Mbo; Mvwala, Richard Kapela; Ilunga, Cedric Kabemba; Limbole, Emmanuel Bakilo; Ntalaja, Jeff Mukengeshay; Kongo, Roger Minga] Clin Ngaliema, Kinshasa, DEM REP CONGO; [Matangila, Junior Rika] Univ Kinshasa, Dept Med Trop, Kinshasa, DEM REP CONGO; [Nyembu, Ritha Kibambe] Clin Univ Kinshasa, Dept Biol Med, Kinshasa, DEM REP CONGO; [Ilunga, Cedric Kabemba] Clin Univ Kinshasa, Dept Med Interne, Kinshasa, DEM REP CONGO	Universite de Kinshasa; Universite de Kinshasa; Universite de Kinshasa	Matangila, JR (corresponding author), Clin Ngaliema, Kinshasa, DEM REP CONGO.; Matangila, JR (corresponding author), Univ Kinshasa, Dept Med Trop, Kinshasa, DEM REP CONGO.	matangilaj@yahoo.fr						Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Doumas M, 2020, J HUM HYPERTENS, V34, P764, DOI 10.1038/s41371-020-0380-y; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.46234/ccdcw2020.032; Giudicessi JR, 2020, HEART RHYTHM, V17, P1487, DOI 10.1016/j.hrthm.2020.04.045; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188; Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324; Ielapi N, 2020, BIOMARK MED, V14, P713, DOI 10.2217/bmm-2020-0201; Katherine Simbana-Rivera LG-BJGFS-GRFVOPL-CSrALVOPO-P, 2020, INT AN PAND COR DIS; Kazadi W, 2004, AM J TROP MED HYG, V71, P97, DOI 10.4269/ajtmh.2004.71.97; Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112; Lei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301; Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744; Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775; Mandina MN, 2020, ANN AFR MED; Nkengasong JN, 2020, LANCET, V395, P841, DOI 10.1016/S0140-6736(20)30464-5; Parohan M, 2020, HEPATOL RES, V50, P924, DOI 10.1111/hepr.13510; Republique democratique du Congo MdlSSG, 2020, PROT PRIS CHARG EP C; Sun YXH, 2020, CLIN INFECT DIS, V71, P786, DOI 10.1093/cid/ciaa322; Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783; Wee Liang En, 2020, J Clin Virol, V128, P104436, DOI 10.1016/j.jcv.2020.104436; WHO, 2020, WHO ANN COVID 19 OUT; WHO, 2020, TECHNICAL REPORT; Xie J, 2020, MAYO CLIN PROC, V95, P1138, DOI 10.1016/j.mayocp.2020.04.006; Zhao KC, 2020, EUR J CLIN MICROBIOL, V39, P2279, DOI 10.1007/s10096-020-03976-8; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu Y, 2020, J INFECTION, V81, P154, DOI [10.1016/j.jinf.2020.03.033, 10.1016/j.jinf.2020.02.022]	29	13	13	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2020	15	12							e0244272	10.1371/journal.pone.0244272	http://dx.doi.org/10.1371/journal.pone.0244272			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8CZ	33338063	Green Published, gold			2023-01-03	WOS:000601313500030
J	Stone, JH; Frigault, MJ; Serling-Boyd, NJ; Fernandes, AD; Harvey, L; Foulkes, AS; Horick, NK; Healy, BC; Shah, R; Bensaci, AM; Woolley, AE; Nikiforow, S; Lin, N; Sagar, M; Schrager, H; Huckins, DS; Axelrod, M; Pincus, MD; Fleisher, J; Sacks, CA; Dougan, M; North, CM; Halvorsen, YD; Thurber, TK; Dagher, Z; Scherer, A; Wallwork, RS; Kim, AY; Schoenfeld, S; Sen, P; Neilan, TG; Perugino, CA; Unizony, SH; Collier, DS; Matza, MA; Yinh, JM; Bowman, KA; Meyerowitz, E; Zafar, A; Drobni, ZD; Bolster, MB; Kohler, M; D'Silva, KM; Dau, J; Lockwood, MM; Cubbison, C; Weber, BN; Mansour, MK				Stone, John H.; Frigault, Matthew J.; Serling-Boyd, Naomi J.; Fernandes, Ana D.; Harvey, Liam; Foulkes, Andrea S.; Horick, Nora K.; Healy, Brian C.; Shah, Ruta; Bensaci, Ana Maria; Woolley, Ann E.; Nikiforow, Sarah; Lin, Nina; Sagar, Manish; Schrager, Harry; Huckins, David S.; Axelrod, Matthew; Pincus, Michael D.; Fleisher, Jorge; Sacks, Chana A.; Dougan, Michael; North, Crystal M.; Halvorsen, Yuan-Di; Thurber, Tara K.; Dagher, Zeina; Scherer, Allison; Wallwork, Rachel S.; Kim, Arthur Y.; Schoenfeld, Sara; Sen, Pritha; Neilan, Tomas G.; Perugino, Cory A.; Unizony, Sebastian H.; Collier, Deborah S.; Matza, Mark A.; Yinh, Janeth M.; Bowman, Kathryn A.; Meyerowitz, Eric; Zafar, Amna; Drobni, Zsofia D.; Bolster, Marcy B.; Kohler, Minna; D'Silva, Kristin M.; Dau, Jonathan; Lockwood, Megan M.; Cubbison, Caroline; Weber, Brittany N.; Mansour, Michael K.		BACC Bay Tocilizumab Trial	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-CENTER; PNEUMONIA	BackgroundThe efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. MethodsWe performed a randomized, double-blind, placebo-controlled trial involving patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two of the following signs: fever (body temperature >38 degrees C), pulmonary infiltrates, or the need for supplemental oxygen in order to maintain an oxygen saturation greater than 92%. Patients were randomly assigned in a 2:1 ratio to receive standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placebo. The primary outcome was intubation or death, assessed in a time-to-event analysis. The secondary efficacy outcomes were clinical worsening and discontinuation of supplemental oxygen among patients who had been receiving it at baseline, both assessed in time-to-event analyses. ResultsWe enrolled 243 patients; 141 (58%) were men, and 102 (42%) were women. The median age was 59.8 years (range, 21.7 to 85.4), and 45% of the patients were Hispanic or Latino. The hazard ratio for intubation or death in the tocilizumab group as compared with the placebo group was 0.83 (95% confidence interval [CI], 0.38 to 1.81; P=0.64), and the hazard ratio for disease worsening was 1.11 (95% CI, 0.59 to 2.10; P=0.73). At 14 days, 18.0% of the patients in the tocilizumab group and 14.9% of the patients in the placebo group had had worsening of disease. The median time to discontinuation of supplemental oxygen was 5.0 days (95% CI, 3.8 to 7.6) in the tocilizumab group and 4.9 days (95% CI, 3.8 to 7.8) in the placebo group (P=0.69). At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen. Patients who received tocilizumab had fewer serious infections than patients who received placebo. ConclusionsTocilizumab was not effective for preventing intubation or death in moderately ill hospitalized patients with Covid-19. Some benefit or harm cannot be ruled out, however, because the confidence intervals for efficacy comparisons were wide. (Funded by Genentech; ClinicalTrials.gov number, NCT04356937.) The efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant effect on disease progression, independence from supplemental oxygen, or death.	[Stone, John H.; Frigault, Matthew J.; Serling-Boyd, Naomi J.; Fernandes, Ana D.; Harvey, Liam; Foulkes, Andrea S.; Horick, Nora K.; Healy, Brian C.; Sacks, Chana A.; Dougan, Michael; North, Crystal M.; Halvorsen, Yuan-Di; Thurber, Tara K.; Dagher, Zeina; Scherer, Allison; Wallwork, Rachel S.; Kim, Arthur Y.; Schoenfeld, Sara; Sen, Pritha; Neilan, Tomas G.; Perugino, Cory A.; Unizony, Sebastian H.; Collier, Deborah S.; Matza, Mark A.; Yinh, Janeth M.; Bowman, Kathryn A.; Meyerowitz, Eric; Zafar, Amna; Drobni, Zsofia D.; Bolster, Marcy B.; Kohler, Minna; D'Silva, Kristin M.; Dau, Jonathan; Lockwood, Megan M.; Mansour, Michael K.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Woolley, Ann E.; Nikiforow, Sarah; Weber, Brittany N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Lin, Nina; Sagar, Manish] Boston Med Ctr, Boston, MA USA; [Shah, Ruta; Bensaci, Ana Maria; Cubbison, Caroline] North Shore Med Ctr, Salem, MA USA; [Schrager, Harry; Huckins, David S.] Newton Wellesley Hosp, Newton, MA USA; [Axelrod, Matthew; Pincus, Michael D.] Beth Israel Lahey Hlth, Burlington, MA USA; [Fleisher, Jorge] St Elizabeths Med Ctr, Brighton, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Boston Medical Center; Newton Wellesley Hospital; St. Elizabeth's Medical Center	Stone, JH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Rheumatol Unit, 55 Fruit St, Boston, MA 02114 USA.	jhstone@mgh.harvard.edu	Drobni, Zsofia D/G-6562-2019	Scherer, Allison/0000-0003-3735-3873; Bowman, Kathryn/0000-0003-4222-5286; Patel, Naomi/0000-0002-6038-0346; Wallwork, Rachel/0000-0002-0073-7438; Drobni, Zsofia Dora/0000-0002-1355-5318; Bolster, Marcy/0000-0002-5413-9345; Zafar, Amna/0000-0003-2010-3018	Genentech	Genentech(Roche HoldingGenentech)	Supported by Genentech.	Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964; Antony SJ, 2021, J MED VIROL, V93, P491, DOI 10.1002/jmv.26288; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Campins L, 2020, CLIN EXP RHEUMATOL, V38, P578; Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021; Centers for Disease Control, US COVID 19 CAS DEAT; Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971; Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449; Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695; Del Valle DM., 2020, NAT MED 0824; Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218612]; Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jordan SC, 2020, CLIN INFECT DIS, V71, P3168, DOI 10.1093/cid/ciaa812; Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001; Knorr JP, 2020, J MED VIROL, V92, P2813, DOI 10.1002/jmv.26191; Lin AF, 2020, CLIN INFECT DIS, V71, P2061, DOI 10.1093/cid/ciaa490; North CM, 2020, NEW ENGL J MED, V383, P1406, DOI 10.1056/NEJMp2019989; Park M., 2020, MPR 0707; Perez-Saez MJ, 2020, AM J TRANSPLANT, V20, P3182, DOI 10.1111/ajt.16192; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Potere N., 2020, ANN RHEUM DIS; Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006; Quartuccio L, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104444; Roche, 2020, ROCHE PROVIDES UPDAT; Rojas-Marte G, 2020, QJM-INT J MED, V113, P546, DOI 10.1093/qjmed/hcaa206; Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008; Herrero FS, 2021, J INTERN MED, V289, P259, DOI 10.1111/joim.13145; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	40	787	805	3	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2020	383	24					2333	2344		10.1056/NEJMoa2028836	http://dx.doi.org/10.1056/NEJMoa2028836			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU3ER	33085857	Bronze, Green Published			2023-01-03	WOS:000627165900012
J	Barbosa, AMP; Enriquez, EMA; Rodrigues, MRK; Prudencio, CB; Atallah, AN; Reyes, DRA; Hallur, RLS; Nunes, SK; Pinheiro, FA; Sartorao, CI; Andrade, GLP; Berghmans, B; de Bie, R; Lima, SAM; Rudge, MVC				Barbosa, Angelica Mercia Pascon; Enriquez, Eusebio Mario Amador; Rodrigues, Meline Rossetto Kron; Prudencio, Caroline Baldini; Atallah, Alvaro Nagib; Reyes, David Rafael Abreu; Hallur, Raghavendra Lakshmana Shetty; Nunes, Sthefanie Kenickel; Pinheiro, Fabiane Affonso; Sartorao Filho, Carlos Isaias; Andrade, Gabriela Lopes Piemonte; Berghmans, Bary; Bie, Rob de; Lima, Silvana Andrea Molina; Rudge, Marilza Vieira Cunha		Diamater Study Grp	Effectiveness of the pelvic floor muscle training on muscular dysfunction and pregnancy specific urinary incontinence in pregnant women with gestational diabetes mellitus: A systematic review protocol	PLOS ONE			English	Review								Background There is ample evidence that gestational diabetes mellitus has a direct influence on urinary incontinence and pelvic floor muscles. There are no standardized pelvic floor muscle exercise programs in the literature for the physiotherapy and differ in the type of exercise, intensity, type and duration of application, and the frequency and duration of treatment sessions. The aim of this systematic review will be to investigate that Pelvic Floor Muscle Training can prevent and/or decrease the pregnancy specific urinary incontinence in women with gestational diabetes mellitus or gestational hyperglycemia. Methods We will perform a systematic review according to the Cochrane methodology of Randomized Controlled Trials. An overall search strategy will be developed and adapted for Embase, MEDLINE, LILACS, and CENTRAL databases, with the date of consultation until June 2020. The MeSH terms used will be "Pregnancy", "Hyperglycemia", "Diabetes Mellitus, Type 2", "Diabetes Mellitus, Type 1", "Pregnancy in Diabetics", "Diabetes, Gestational", "Urinary Incontinence", "Pelvic Floor Muscle Strength". Primary outcomes: improvement or cure of pregnancy specific urinary incontinence (which can be assessed by questionnaires, and tools such as tampon test, voiding diary, urodynamic study). Secondary outcomes: improvement of pelvic floor muscle strength (pelvic floor functional assessment, perineometer, electromyography, functional ultrasonography), improved quality of life (questionnaires), presence or absence of postpartum Urinary Incontinence and adverse effects. Quality assessment by Cochrane instrument. Metanalysis if plausible, will be performed by the software Review Manager 5.3. Discussion The present study will be the first to analyze the effectiveness of pelvic floor exercises in pregnant women with Gestational Diabetes Mellitus or Hyperglycemia, who suffer from pregnancy specific urinary incontinence. Randomized Controlled Trials design will be chosen because they present the highest level of evidence. It is expected to obtain robust and conclusive evidence to support clinical practice, in addition to promoting studies on the theme and contributing to new studies.	[Barbosa, Angelica Mercia Pascon] Sao Paulo State Univ UNESP, Sch Philosophy & Sci, Dept Physiotherapy & Occupat Therapy, Marilia, SP, Brazil; [Enriquez, Eusebio Mario Amador; Prudencio, Caroline Baldini; Reyes, David Rafael Abreu; Hallur, Raghavendra Lakshmana Shetty; Nunes, Sthefanie Kenickel; Pinheiro, Fabiane Affonso; Sartorao Filho, Carlos Isaias; Rudge, Marilza Vieira Cunha] Sao Paulo State Univ UNESP, Botucatu Med Sch FMB, Dept Gynecol & Obstet, Botucatu, SP, Brazil; [Rodrigues, Meline Rossetto Kron] Guarulhos Univ UNG, Stricto Sensu Grad Program Nursing UNIVERITAS, Guarulhos, SP, Brazil; [Atallah, Alvaro Nagib] Fed Univ Sao Paulo EPM UNIFESP, Paulista Sch Med, Discipline Evidence Based Med, Sao Paulo, Brazil; [Andrade, Gabriela Lopes Piemonte] Univ Oeste Paulista UNOESTE, Dept Physiotherapy, Presidente Prudente, SP, Brazil; [Berghmans, Bary; Bie, Rob de] Maastricht Univ, Med Ctr, Pelv Care Ctr Maastricht, Maastricht, Netherlands; [Lima, Silvana Andrea Molina] Sao Paulo State Univ UNESP, Botucatu Med Sch FMB, Dept Nursing, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Guarulhos; Universidade Federal de Sao Paulo (UNIFESP); Universidade do Oeste Paulista; Maastricht University; Universidade Estadual Paulista	Barbosa, AMP (corresponding author), Sao Paulo State Univ UNESP, Sch Philosophy & Sci, Dept Physiotherapy & Occupat Therapy, Marilia, SP, Brazil.	angelicapascon@gmail.com	Carvalho, Carolina Neiva Frota de/GXI-0411-2022; DE OLIVEIRA, RAFAEL GUILEN/AAS-6494-2020; de Aquino Nava, Guilherme GTA Thomaz/C-3653-2015; Barker, Maegan/ABD-6702-2021; Baldini Prudencio, Caroline/A-7915-2016; Sartorao-Filho, Carlos izaias/AAQ-3078-2021	DE OLIVEIRA, RAFAEL GUILEN/0000-0002-1700-5890; de Aquino Nava, Guilherme GTA Thomaz/0000-0003-3607-2375; Baldini Prudencio, Caroline/0000-0002-2070-3606; HALLUR, RAGHAVENDRA/0000-0003-4300-109X; Rossignoli, Patricia/0000-0001-6946-1145; Affonso Pinheiro, Fabiane/0000-0002-2223-7522; Amador Enriquez, Eusebio Mario/0000-0002-3288-9014	Sao Paulo Research Foundation-FAPESP, government agency in Sao Paulo, Brazil [FAPESP 2018/17534-1]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 2016/01743-5]	Sao Paulo Research Foundation-FAPESP, government agency in Sao Paulo, Brazil; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This ongoing (2018-2020) project (FAPESP 2018/17534-1) is funded by the Sao Paulo Research Foundation-FAPESP, government agency located in Sao Paulo, Brazil. Linked with the thematic project Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, FAPESP 2016/01743-5. The funders had not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; [Anonymous], 2014, REV MAN REVMAN COMP; Boutron I, 2019, COCHRANE HDB SYSTEMA, P177; Rudge MVC, 2011, REV BRAS GINECOL OBS, V33, P207, DOI 10.1590/S0100-72032011000500001; Davenport MH, 2018, BRIT J SPORT MED, V52, DOI 10.1136/bjsports-2018-099780; Dumoulin C, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005654.pub4; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Barbosa AMP, 2011, CLINICS, V66, P1341, DOI 10.1590/S1807-59322011000800006; Perales M, 2016, EARLY HUM DEV, V94, P43, DOI 10.1016/j.earlhumdev.2016.01.004; Santos Paula Clara, 2006, Acta Med Port, V19, P349; Stafne SN, 2012, BJOG-INT J OBSTET GY, V119, P1270, DOI 10.1111/j.1471-0528.2012.03426.x; Van Kampen M, 2015, INT UROGYNECOL J, V26, P1575, DOI 10.1007/s00192-015-2684-y; Woodley Stephanie J, 2020, Cochrane Database Syst Rev, V5, pCD007471, DOI 10.1002/14651858.CD007471.pub4	15	2	2	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0241962	10.1371/journal.pone.0241962	http://dx.doi.org/10.1371/journal.pone.0241962			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD8LW	33284811	Green Published, gold			2023-01-03	WOS:000597930500010
J	Schaffert, N; Janzen, TB; Ploigt, R; Schluter, S; Vuong, V; Thaut, MH				Schaffert, Nina; Janzen, Thenille Braun; Ploigt, Roy; Schlueter, Sebastian; Vuong, Veronica; Thaut, Michael H.			Development and evaluation of a novel music-based therapeutic device for upper extremity movement training: A pre-clinical, single-arm trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; CHRONIC STROKE; PARKINSONS-DISEASE; CEREBRAL-PALSY; MOTOR FUNCTION; REHABILITATION; PERFORMANCE; PILOT; AGE; TECHNOLOGIES	Restoration of upper limb motor function and patient functional independence are crucial treatment targets in neurological rehabilitation. Growing evidence indicates that music-based intervention is a promising therapeutic approach for the restoration of upper extremity functional abilities in neurologic conditions such as cerebral palsy, stroke, and Parkinson's Disease. In this context, music technology may be particularly useful to increase the availability and accessibility of music-based therapy and assist therapists in the implementation and assessment of targeted therapeutic goals. In the present study, we conducted a preclinical, single-arm trial to evaluate a novel music-based therapeutic device (SONATA) for upper limb extremity movement training. The device consists of a graphical user interface generated by a single-board computer displayed on a 32" touchscreen with built-in speakers controlled wirelessly by a computer tablet. The system includes two operational modes that allow users to play musical melodies on a virtual keyboard or draw figures/shapes whereby every action input results in controllable sensory feedback. Four motor tasks involving hand/finger movement were performed with 21 healthy individuals (13 males, aged 26.4 +/- 3.5 years) to evaluate the device's operational modes and main features. The results of the functional tests suggest that the device is a reliable system to present pre-defined sequences of audiovisual stimuli and shapes and to record response and movement data. This preliminary study also suggests that the device is feasible and adequate for use with healthy individuals. These findings open new avenues for future clinical research to further investigate the feasibility and usability of the SONATA as a tool for upper extremity motor function training in neurological rehabilitation. Directions for future clinical research are discussed.	[Schaffert, Nina] Univ Hamburg, Inst Human Movement Sci, Dept Movement & Training Sci, Hamburg, Germany; [Schaffert, Nina; Ploigt, Roy; Schlueter, Sebastian] BeSB GmbH Berlin, Sound Engn, Berlin, Germany; [Janzen, Thenille Braun] Univ Fed ABC, Ctr Math Comp & Cognit, Sao Bernardo Do Campo, Brazil; [Vuong, Veronica; Thaut, Michael H.] Univ Toronto, Fac Mus, Mus & Hlth Sci Res Collaboratory, Toronto, ON, Canada	University of Hamburg; Universidade Federal do ABC (UFABC); University of Toronto	Schaffert, N (corresponding author), Univ Hamburg, Inst Human Movement Sci, Dept Movement & Training Sci, Hamburg, Germany.; Schaffert, N (corresponding author), BeSB GmbH Berlin, Sound Engn, Berlin, Germany.	nina.schaffert@uni-hamburg.de	Braun Janzen, Thenille/M-6870-2014	Braun Janzen, Thenille/0000-0001-9578-8539; Schaffert, Nina/0000-0002-9588-5969				Altenmuller E, 2009, ANN NY ACAD SCI, V1169, P395, DOI 10.1111/j.1749-6632.2009.04580.x; Alves-Pinto A, 2017, NEUROPSYCH DIS TREAT, V13, P2705, DOI 10.2147/NDT.S145104; Alves-Pinto A, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1072301; Aminov A, 2018, J NEUROENG REHABIL, V15, P1, DOI [10. 1186/s12984-018-0370-2, DOI 10.1186/S12984-018-0370-25870176]; Babaiasl M, 2016, DISABIL REHABIL-ASSI, V11, P263, DOI 10.3109/17483107.2014.1002539; Barry G, 2014, J NEUROENG REHABIL, V11, DOI [10.1186/1743-0003-11-60, 10.1186/1743-0003-11-33]; Bertani R, 2017, NEUROL SCI, V38, P1561, DOI 10.1007/s10072-017-2995-5; Bhatt E, 2007, EXP BRAIN RES, V182, P435, DOI 10.1007/s00221-007-1001-5; Bienkiewicz MMN, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00249; Blank R, 2009, NEUROSCI LETT, V450, P65, DOI 10.1016/j.neulet.2008.11.010; Bo J, 2009, J NEUROPHYSIOL, V102, P2744, DOI 10.1152/jn.00393.2009; Bove M, 2007, BRAIN RES, V1153, P84, DOI 10.1016/j.brainres.2007.03.063; Boyd LA, 2009, NEUROBIOL LEARN MEM, V92, P35, DOI 10.1016/j.nlm.2009.02.009; Boyd LA, 2007, NEUROREHAB NEURAL RE, V21, P444, DOI 10.1177/1545968307300438; Braunlich K, 2019, EUR J NEUROSCI, V49, P849, DOI 10.1111/ejn.14227; Broderick MP, 2009, EXP BRAIN RES, V197, P223, DOI 10.1007/s00221-009-1925-z; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Chong HJ, 2013, J EXERC REHABIL, V9, P420, DOI 10.12965/jer.130050; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Fujioka T, 2018, ANN NY ACAD SCI, V1423, P264, DOI 10.1111/nyas.13706; Ghai S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00488; Ghai S, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00142; Grau-Sanchez J, 2020, NEUROSCI BIOBEHAV R, V112, P585, DOI 10.1016/j.neubiorev.2020.02.027; Grau-Sanchez J, 2018, ANN NY ACAD SCI, V1423, P318, DOI 10.1111/nyas.13590; Hatem SM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00442; Himmelmann K, 2006, DEV MED CHILD NEUROL, V48, P417, DOI 10.1017/S0012162206000922; Kamper DG, 2006, ARCH PHYS MED REHAB, V87, P1262, DOI 10.1016/j.apmr.2006.05.013; Kirk P, 2016, 34TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, CHI 2016, P1781, DOI 10.1145/2858036.2858376; Knight A, 2017, MUSIC THER PERSPECT, V35, P219, DOI 10.1093/mtp/miw025; Koelsch S, 2009, ANN NY ACAD SCI, V1169, P374, DOI 10.1111/j.1749-6632.2009.04592.x; Koshimori Y, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01245; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Lampe R, 2015, NEUROPSYCH DIS TREAT, V11, P1929, DOI 10.2147/NDT.S84090; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lim HA, 2011, J MUSIC THER, V48, P124, DOI 10.1093/jmt/48.2.124; Lodha N, 2012, NEUROPSYCHOLOGIA, V50, P2536, DOI 10.1016/j.neuropsychologia.2012.06.025; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Magee WL, 2008, BRIT J MUSIC THER, V22, P3, DOI 10.1177/135945750802200102; Magee WL, 2008, NORD J MUSIC THER, V17, P124, DOI 10.1080/08098130809478204; Magrinelli F, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/9832839; Malcolm MP, 2009, TOP STROKE REHABIL, V16, P69, DOI 10.1310/tsr1601-69; Mesterman R, 2010, J CHILD NEUROL, V25, P36, DOI 10.1177/0883073809336677; Moore O, 2007, MOVEMENT DISORD, V22, P2192, DOI 10.1002/mds.21659; Morris JH, 2013, DISABIL REHABIL, V35, P291, DOI 10.3109/09638288.2012.691942; Nieuwboer A, 2009, EUR J NEUROSCI, V29, P1422, DOI 10.1111/j.1460-9568.2009.06681.x; NISSEN MJ, 1987, COGNITIVE PSYCHOL, V19, P1, DOI 10.1016/0010-0285(87)90002-8; Parker V M, 1986, Int Rehabil Med, V8, P69; Plasschaert VFP, 2019, DEV MED CHILD NEUROL, V61, P899, DOI 10.1111/dmcn.14141; Raghavan P, 2015, PHYS MED REH CLIN N, V26, P599, DOI 10.1016/j.pmr.2015.06.008; Ripolles P, 2016, BRAIN IMAGING BEHAV, V10, P1289, DOI 10.1007/s11682-015-9498-x; Robertson EM, 2007, J NEUROSCI, V27, P10073, DOI 10.1523/JNEUROSCI.2747-07.2007; Rodriguez-Fornells A, 2012, ANN NY ACAD SCI, V1252, P282, DOI 10.1111/j.1749-6632.2011.06425.x; Rojo N, 2011, BRAIN INJURY, V25, P787, DOI 10.3109/02699052.2011.576305; Russo RN, 2019, DEV MED CHILD NEUROL, V61, P1080, DOI 10.1111/dmcn.14185; Sajan JE, 2017, DEV NEUROREHABIL, V20, P361, DOI 10.1080/17518423.2016.1252970; Sakzewski L, 2009, PEDIATRICS, V123, pE1111, DOI 10.1542/peds.2008-3335; Schneider S, 2007, J NEUROL, V254, P1339, DOI 10.1007/s00415-006-0523-2; Schrag A, 2000, J NEUROL NEUROSUR PS, V69, P308, DOI 10.1136/jnnp.69.3.308; Schwartze M, 2011, BEHAV BRAIN RES, V216, P685, DOI 10.1016/j.bbr.2010.09.015; Seidler RD, 2012, J MOTOR BEHAV, V44, P445, DOI 10.1080/00222895.2012.672348; Sheng B, 2016, MED ENG PHYS, V38, P587, DOI 10.1016/j.medengphy.2016.04.004; Sihvonen AJ, 2017, LANCET NEUROL, V16, P648, DOI 10.1016/S1474-4422(17)30168-0; Silveira TM, 2021, NORD J MUSIC THER, V30, P314, DOI 10.1080/08098131.2020.1795704; Sleimen-Malkoun R, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-11; STELMACH GE, 1988, J GERONTOL, V43, pP18, DOI 10.1093/geronj/43.1.P18; Street A, 2020, TOP STROKE REHABIL, V27, P541, DOI 10.1080/10749357.2020.1729585; Street AJ, 2019, NORD J MUSIC THER, V28, P382, DOI 10.1080/08098131.2019.1606848; Thaut M. H., 2014, HDB NEUROLOGIC MUSIC, P311; Thaut M.H., 2014, CURR PHYS MED REHABI, V2, P106, DOI [10.1007/s40141-014-0049-y, DOI 10.1007/S40141-014-0049-Y]; Thaut MH, 2002, NEUROPSYCHOLOGIA, V40, P1073, DOI 10.1016/S0028-3932(01)00141-5; Thaut MH, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01185; Thaut MH, 2010, MUSIC PERCEPT, V27, P281, DOI 10.1525/MP.2010.27.4.281; Thaut MH, 2010, MUSIC PERCEPT, V27, P263, DOI 10.1525/MP.2010.27.4.263; Thaut MH, 2009, ANN NY ACAD SCI, V1169, P406, DOI 10.1111/j.1749-6632.2009.04585.x; Tomlinson CL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002815.pub2; Tong YN, 2015, NEUROL RES, V37, P434, DOI 10.1179/1743132815Y.0000000034; Turcotte J, 2005, PSYCHOL AGING, V20, P251, DOI 10.1037/0882-7974.20.2.251; van Vugt FT, 2015, BRAIN RES, V1606, P54, DOI 10.1016/j.brainres.2015.02.026; Vanbellingen T, 2011, BRAIN COGNITION, V77, P48, DOI 10.1016/j.bandc.2011.06.003; VANDEWINCKEL A, 2018, J NEUROENG REHABIL, V15, DOI DOI 10.1186/S12984-017-0340-0; Vercruysse S, 2014, CEREB CORTEX, V24, P3154, DOI 10.1093/cercor/bht170; Villeneuve Myriam, 2014, Front Hum Neurosci, V8, P662, DOI 10.3389/fnhum.2014.00662; Waller SM, 2008, NEUROREHABILITATION, V23, P29; Ward A, 2019, MUSIC THER PERSPECT, V37, P151, DOI 10.1093/mtp/miz006; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Wishart LR, 2000, J GERONTOL B-PSYCHOL, V55, pP85, DOI 10.1093/geronb/55.2.P85; Yoo J, 2009, MUSIC THER PERSPECT, V27, P16, DOI 10.1093/mtp/27.1.16; Zhang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26875; Zhuang P, 1998, ACTA NEUROL SCAND, V97, P131	90	3	3	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2020	15	11							e0242552	10.1371/journal.pone.0242552	http://dx.doi.org/10.1371/journal.pone.0242552			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM0RU	33211773	Green Published, gold			2023-01-03	WOS:000603518300068
J	Tsiklidis, EJ; Sims, C; Sinno, T; Diamond, SL				Tsiklidis, Evan J.; Sims, Carrie; Sinno, Talid; Diamond, Scott L.			Using the National Trauma Data Bank (NTDB) and machine learning to predict trauma patient mortality at admission	PLOS ONE			English	Article							ARTIFICIAL NEURAL-NETWORK; GLASGOW COMA SCALE; HYPOTENSION; HEMORRHAGE; OUTCOMES; MODEL	A 400-estimator gradient boosting classifier was trained to predict survival probabilities of trauma patients. The National Trauma Data Bank (NTDB) provided 799233 complete patient records (778303 survivors and 20930 deaths) each containing 32 features, a number further reduced to only 8 features via the permutation importance method. Importantly, the 8 features can all be readily determined at admission: systolic blood pressure, heart rate, respiratory rate, temperature, oxygen saturation, gender, age and Glasgow coma score. Since death was rare, a rebalanced training set was used to train the model. The model is able to predict a survival probability for any trauma patient and accurately distinguish between a deceased and survived patient in 92.4% of all cases. Partial dependence curves (P-survival vs. feature value) obtained from the trained model revealed the global importance of Glasgow coma score, age, and systolic blood pressure while pulse rate, respiratory rate, temperature, oxygen saturation, and gender had more subtle single variable influences. Shapley values, which measure the relative contribution of each of the 8 features to individual patient risk, were computed for several patients and were able to quantify patient-specific warning signs. Using the NTDB to sample across numerous patient traumas and hospital protocols, the trained model and Shapley values rapidly provides quantitative insight into which combination of variables in an 8-dimensional space contributed most to each trauma patient's predicted global risk of death upon emergency room admission.	[Tsiklidis, Evan J.; Sinno, Talid; Diamond, Scott L.] Univ Penn, Inst Med & Engn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Sims, Carrie] Univ Penn, Dept Trauma Surg, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diamond, SL (corresponding author), Univ Penn, Inst Med & Engn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.	sld@seas.upenn.edu	Sinno, Talid/N-7088-2017	Sinno, Talid/0000-0003-2489-1613	NIH [U01-HL-131053]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH U01-HL-131053 (S.L.D, T.S.) Funder website: https://report.nih.gov/Funder Information: Andrei Kindzelski (kindzelskial@nhlbi.nih.gov) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed N, 2020, INJURY, V51, P91, DOI 10.1016/j.injury.2019.10.005; Bhandarkar Prashant, 2017, Int J Crit Illn Inj Sci, V7, P14, DOI 10.4103/2229-5151.201950; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Comittee on Trauma AC of S, 2017, NTDB VERS 2016; DiRusso SM, 2000, J TRAUMA, V49, P212, DOI 10.1097/00005373-200008000-00006; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edwards DF, 1999, NEUROLOGY, V53, P351, DOI 10.1212/WNL.53.2.351; Estahbanati HK, 2002, BURNS, V28, P579, DOI 10.1016/S0305-4179(02)00045-1; Fernandez A, 2018, J ARTIF INTELL RES, V61, P863, DOI 10.1613/jair.1.11192; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Haldar M, 2018, ARXIV E PRINTS, P1927; Liu NT, 2017, SHOCK, V48, P504, DOI 10.1097/SHK.0000000000000898; Liu X.-Y., 2009, IEEE T SYSTEMS MAN C, V39, P539, DOI [10.1109/TSMCB.2008.2007853, DOI 10.1109/TSMCB.2008.2007853]; Lundberg S. M., 2018, ARXIV; Lundberg SM, 2018, NAT BIOMED ENG, V2, P749, DOI 10.1038/s41551-018-0304-0; Marble RP, 1999, ARTIF INTELL MED, V15, P299, DOI 10.1016/S0933-3657(98)00059-1; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; Mitchell RJ, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0563-5; Neal ML, 2013, NIH PUBLIC ACCESS, V7, P97; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Reisner AT, 2013, AM J PHYSIOL-HEART C, V304, pH620, DOI 10.1152/ajpheart.00621.2012; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Rogers FB, 2015, INJURY, V46, P525, DOI 10.1016/j.injury.2014.08.043; Shapley L.S., 1953, CONTRIBUTIONS THEORY, V28, P307, DOI DOI 10.1515/9781400881970-018; Tsiklidis E, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1418; Tsiklidis EJ, 2019, AM J PHYSIOL-HEART C, V317, pH73, DOI 10.1152/ajpheart.00774.2018; Ursino M, 1998, AM J PHYSIOL-HEART C, V275, pH1733, DOI 10.1152/ajpheart.1998.275.5.H1733; Walczak S, 2005, IEEE T INF TECHNOL B, V9, P468, DOI 10.1109/TITB.2005.847510; World Health Organization, 2017, DEPR OTH COMM MENT D; Zenati MS, 2002, J TRAUMA, V53, P232, DOI 10.1097/00005373-200208000-00007; Zhang J, 2003, ACTA POLYM SIN, P30	33	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2020	15	11							e0242166	10.1371/journal.pone.0242166	http://dx.doi.org/10.1371/journal.pone.0242166			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ5ZL	33201935	Green Published, gold			2023-01-03	WOS:000595003900042
J	Hall, J; Jones, L; Robertson, G; Hiley, R; Nathwani, D; Perry, MR				Hall, Jennifer; Jones, Leah; Robertson, Gail; Hiley, Robin; Nathwani, Dilip; Perry, Meghan Rose			'The Mould that Changed the World': Quantitative and qualitative evaluation of children's knowledge and motivation for behavioural change following participation in an antimicrobial resistance musical	PLOS ONE			English	Article							HEALTH; HYGIENE; BUG	Background A primary school musical ("The Mould that Changed the World") was developed as a unique public engagement strategy to combat antimicrobial resistance (AMR) by engaging children in the story of the discovery of antibiotics, the risks of drug-resistant infections and the importance of prudent antibiotic use. Methods The musical intervention was implemented in two UK primary schools by music specialists through a series of workshops, associated learning resources and performances to relatives. Participating children (n = 182), aged 9 to 11 years, were given an online questionnaire in the classroom before rehearsals began and at two weeks post-performance with a six-month evaluation in one school. The impact of the musical was analysed using generalised linear models to control for confounding factors. For the qualitative evaluation, fifteen participating children were selected randomly from each school to take part in semi-structured focus groups (n = 5 per group) before rehearsals began and two weeks post-performance. Findings Knowledge gain was demonstrated with children being more likely to answer questions on key messages of the musical correctly at two weeks post- performance (response rate 88%, n = 161) compared with the pre-rehearsal questionnaire (response rate 99%, n = 180) (bacteria can become resistant to antibiotics OR 4.63, C.I. 2.46-9.31 p<0.0001, antibiotic resistant infections can be life threatening OR 3.26 C.I. 1.75-6.32 p = 0.0001, prudent use of antibiotics will slow the rise of antibiotic resistant infections OR 2.16, C.I. 1.39-3.38, p = 0.0006). Long term knowledge gain was demonstrated by a consistent level of correct answers on key messages between two weeks (response rate 95%, n = 89) and 6 months post musical (response rate 71%, n = 67). Following the musical children participating in the focus groups (n = 30) articulated a greater understanding of AMR and the risks of antibiotic overuse. They discussed motivation to minimise personal antibiotic use and influence attitudes to antibiotics in their family and friends. Interpretation This study demonstrates that musical theatre can improve both short and long-term knowledge. It demonstrates a hitherto infrequently reported change in attitude and motivation to change behaviour in children at an influential age for health beliefs. This unique public health tool has the potential for high impact particularly if rolled out within national education programmes for primary school aged children.	[Hall, Jennifer; Perry, Meghan Rose] Western Gen Hosp, Reg Infect Dis Unit, Edinburgh, Midlothian, Scotland; [Jones, Leah; Nathwani, Dilip; Perry, Meghan Rose] British Soc Antimicrobial Chemotherapy, Birmingham, W Midlands, England; [Jones, Leah] Publ Hlth England, London, England; [Robertson, Gail] Univ Edinburgh, Sch Math, Edinburgh, Midlothian, Scotland; [Hiley, Robin] Charades Theatre Co, Edinburgh, Midlothian, Scotland; [Nathwani, Dilip] Univ Dundee, Dundee, Scotland; [Perry, Meghan Rose] Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland; [Perry, Meghan Rose] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland	University of Edinburgh; Public Health England; University of Edinburgh; University of Dundee; University of Edinburgh; University of Edinburgh	Perry, MR (corresponding author), Western Gen Hosp, Reg Infect Dis Unit, Edinburgh, Midlothian, Scotland.; Perry, MR (corresponding author), British Soc Antimicrobial Chemotherapy, Birmingham, W Midlands, England.; Perry, MR (corresponding author), Univ Edinburgh, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland.; Perry, MR (corresponding author), Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland.	meghan.perry@ed.ac.uk			British Society of Antimicrobial Chemotherapy	British Society of Antimicrobial Chemotherapy	This study was funded by British Society of Antimicrobial Chemotherapy (www.bsac.org.uk) and funds awarded to author RH. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	[Anonymous], 2005, LANCET, V365, P579; [Anonymous], 2018, R LANG ENV STAT COMP; [Anonymous], 2002, J SCH HLTH WILEY ONL, DOI [10.1111/j.1746-1561.2002.tb07339.x, DOI 10.1111/J.1746-1561.2002.TB07339.X]; [Anonymous], 2011, WEATHER, V66, pi, DOI 10.1002/wea.699; Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Buchman TG, 2008, J AM COLL SURGEONS, V207, P265, DOI 10.1016/j.jamcollsurg.2008.02.035; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Cuijpers P, 2002, ADDICT BEHAV, V27, P1009, DOI 10.1016/S0306-4603(02)00295-2; Damerell P, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/015016; Dawes RM, 1999, MESSAGE PSYCHOLOGIST, V12; Fox J, 2018, R COMPANION APPL REG, P608; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Glik, 2002, YOUTH PERFORMING ART; Grewe ME, 2015, SEX EDUC-SEX SOC LEA, V15, P303, DOI 10.1080/14681811.2015.1022820; Huttner B, 2010, LANCET INFECT DIS, V10, P17, DOI 10.1016/S1473-3099(09)70305-6; Joronen K, 2008, J ADV NURS, V63, P116, DOI 10.1111/j.1365-2648.2008.04634.x; KMIETOWICZ Z, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K3038; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Lecky DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104556; Lecky DM, 2010, J ANTIMICROB CHEMOTH, V65, P2674, DOI 10.1093/jac/dkq356; McNulty CAM, 2007, HEALTH EDUC, V107, P10, DOI 10.1108/09654280710716851; McParland, 2018, WHAT ARE ACTIVE INGR; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Morgan DL, 2013, INTEGRATING QUALITAT; Ogden J, 2016, HEALTH PSYCHOL REV, V10, P274, DOI 10.1080/17437199.2016.1190295; Perry CL, 1999, TOB CONTROL, V8, P169, DOI 10.1136/tc.8.2.169; Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits 2010-2011, 2010, JAMA JAMA NETWORK; Price L, 2018, J ANTIMICROB CHEMOTH, V73, P1464, DOI 10.1093/jac/dky076; Sambamurthy V, 2000, INFORM SYST RES, V11, P105, DOI 10.1287/isre.11.2.105.11780; Tobler N.S., 2000, J PRIM PREV, V20, P275, DOI [DOI 10.1023/A:1021314704811, 10.1023/A:1021314704811]; Trepka MJ, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e6; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Van Hecke O, 2019, J ANTIMICROB CHEMOTH, V74, P1741, DOI 10.1093/jac/dkz091; Williamson J, 2018, LANCET INFECT DIS, V18, P955	36	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0240471	10.1371/journal.pone.0240471	http://dx.doi.org/10.1371/journal.pone.0240471			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PG8YH	33119647	Green Published, gold			2023-01-03	WOS:000600013600073
J	Hadjadj, D; Deshmukh, S; Jabado, N				Hadjadj, Djihad; Deshmukh, Shriya; Jabado, Nada			Entering the era of precision medicine in pediatric oncology	NATURE MEDICINE			English	Editorial Material							MUTATIONS; CLASSIFICATION; GENES	The Zero Childhood Cancer Program's multi-platform sequencing approach identified molecular alterations in 94% of a cohort of 247 pediatric patients with high-risk cancers, which has enabled more-precise diagnoses and alternative therapeutic recommendations.	[Hadjadj, Djihad; Jabado, Nada] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Deshmukh, Shriya; Jabado, Nada] McGill Univ, Dept Expt Med, Montreal, PQ, Canada; [Jabado, Nada] McGill Univ, Dept Pediat, Montreal, PQ, Canada; [Jabado, Nada] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Jabado, N (corresponding author), McGill Univ, Dept Human Genet, Montreal, PQ, Canada.; Jabado, N (corresponding author), McGill Univ, Dept Expt Med, Montreal, PQ, Canada.; Jabado, N (corresponding author), McGill Univ, Dept Pediat, Montreal, PQ, Canada.; Jabado, N (corresponding author), McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada.	nada.jabado@mcgill.ca	Hadjadj, Djihad/AAD-5882-2022; Dji, Hadjadj/GQQ-2555-2022	Deshmukh, Shriya/0000-0001-9086-3261				Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Cunningham RM, 2018, NEW ENGL J MED, V379, P2468, DOI 10.1056/NEJMsr1804754; DuBois SG, 2019, SCIENCE, V363, P1175, DOI 10.1126/science.aaw4153; Grobner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Steliarova-Foucher E, 2017, LANCET ONCOL, V18, P719, DOI 10.1016/S1470-2045(17)30186-9; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054	11	8	8	1	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2020	26	11					1684	1685		10.1038/s41591-020-1119-6	http://dx.doi.org/10.1038/s41591-020-1119-6		OCT 2020	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	OT0SR	33077957				2023-01-03	WOS:000579706700004
J	Porciello, G; Montagnese, C; Crispo, A; Grimaldi, M; Libra, M; Vitale, S; Palumbo, E; Pica, R; Calabrese, I; Cubisino, S; Falzone, L; Poletto, L; Martinuzzo, V; Prete, M; Esindi, N; Thomas, G; Cianniello, D; Pinto, M; De Laurentiis, M; Pacilio, C; Rinaldo, M; D'Aiuto, M; Serraino, D; Massarut, S; Evangelista, C; Steffan, A; Catalano, F; Banna, GL; Scandurra, G; Ferrau, F; Rossello, R; Antonelli, G; Guerra, G; Farina, A; Messina, F; Riccardi, G; Gatti, D; Jenkins, DJA; Minopoli, A; Grilli, B; Cavalcanti, E; Celentano, E; Botti, G; Montella, M; Augustin, LSA				Porciello, Giuseppe; Montagnese, Concetta; Crispo, Anna; Grimaldi, Maria; Libra, Massimo; Vitale, Sara; Palumbo, Elvira; Pica, Rosa; Calabrese, Ilaria; Cubisino, Serena; Falzone, Luca; Poletto, Luigina; Martinuzzo, Valentina; Prete, Melania; Esindi, Nadia; Thomas, Guglielmo; Cianniello, Daniela; Pinto, Monica; De Laurentiis, Michelino; Pacilio, Carmen; Rinaldo, Massimo; D'Aiuto, Massimiliano; Serraino, Diego; Massarut, Samuele; Evangelista, Chiara; Steffan, Agostino; Catalano, Francesca; Banna, Giuseppe L.; Scandurra, Giuseppa; Ferrau, Francesco; Rossello, Rosalba; Antonelli, Giovanna; Guerra, Gennaro; Farina, Amalia; Messina, Francesco; Riccardi, Gabriele; Gatti, Davide; Jenkins, David J. A.; Minopoli, Anita; Grilli, Bruna; Cavalcanti, Ernesta; Celentano, Egidio; Botti, Gerardo; Montella, Maurizio; Augustin, Livia S. A.			Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial	PLOS ONE			English	Article							METABOLIC SYNDROME; PHYSICAL-ACTIVITY; FRUIT INTAKE; ADHERENCE; HEALTH; RISK; MORTALITY; NUTRITION; PATTERNS; INFLAMMATION	Evidence suggests a beneficial role of the Mediterranean Diet (MedDiet) on health-related quality of life (HRQoL) in healthy subjects. HRQoL is relevant in cancer therapy and disease outcomes, therefore we investigated the association between adherence to the MedDiet and HRQoL in breast cancer survivors participating in the multicentre trial DEDiCa. Diet and HRQoL were assessed at baseline in a subgroup of 309 women enrolled within 12 months of breast cancer diagnosis without metastasis (stages I-III, mean age 52 +/- 1 yrs, BMI 27 +/- 7 kg/m(2)). The 14-item PREDIMED questionnaire was used to analyse adherence to the MedDiet. HRQoL was assessed with three validated questionnaires measuring physical, mental, emotional and social factors: EQ-5D-3L, EORTC QLQ-C30 and EORTC QLQ-BR23. Analysis of variance (ANOVA) and multivariate analyses were performed to assess the possible role of the MedDiet on HRQoL. Patients with higher adherence to MedDiet (PREDIMED score >7) showed significantly higher scores for physical functioning (p = 0.02) and lower scores on the symptomatic pain scale (p = 0.04) assessed by the EORTC QLQ-C30 questionnaire compared to patients with a lower adherence to MedDiet (PREDIMED score <= 7). Higher scores from the EQ-5D-3L indicating higher well-being were observed mainly in participants with higher MedDiet adherence (p = 0.05). In adjusted multivariate analyses significant positive associations were found between MedDiet, physical functioning (p = 0.001) and EQ 5D-3L score (p = 0.003) while inverse associations were found with pain and insomnia symptoms (p = 0.005 and p = 0.029, respectively). These results suggest that higher adherence to the MedDiet in breast cancer survivors is associated with better aspects of quality of life, specifically higher physical functioning, better sleep, lower pain and generally higher well-being confirming findings in healthy subjects.	[Porciello, Giuseppe; Montagnese, Concetta; Crispo, Anna; Grimaldi, Maria; Vitale, Sara; Palumbo, Elvira; Pica, Rosa; Cubisino, Serena; Falzone, Luca; Prete, Melania; Celentano, Egidio; Montella, Maurizio; Augustin, Livia S. A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Epidemiol & Biostat Unit, Naples, Italy; [Libra, Massimo] Univ Catania, Dept Biomed & Biotechnol Sci Oncol, Clin & Gen Pathol Sect, Catania, Italy; [Calabrese, Ilaria; Riccardi, Gabriele] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy; [Poletto, Luigina; Martinuzzo, Valentina; Serraino, Diego; Evangelista, Chiara] IRCCS, Canc Epidemiol Unit, Natl Canc Inst Ctr Riferimento Oncol, Aviano, Italy; [Esindi, Nadia] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia; [Esindi, Nadia] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia; [Thomas, Guglielmo] Clin Mediterranea, Naples, Italy; [Cianniello, Daniela; De Laurentiis, Michelino; Pacilio, Carmen; Rinaldo, Massimo] Ist Nazl Tumori IRCCS Fdn G Pascale, Div Breast Oncol, Naples, Italy; [Pinto, Monica] Ist Nazl Tumori IRCCS Fdn G Pascale, Rehabil Med Unit, Naples, Italy; [D'Aiuto, Massimiliano] Clin Villa Fiorita, Aversa, Italy; [Massarut, Samuele] IRCCS, Div Breast Canc Surg, Ctr Riferimento Oncol, Aviano, Italy; [Steffan, Agostino] Natl Canc Inst Ctr Riferimento Oncol IRCCS, Immunopathol & Canc Biomarkers Unit, Aviano, Italy; [Catalano, Francesca; Banna, Giuseppe L.; Scandurra, Giuseppa] Cannizzaro Hosp, Catania, Italy; [Ferrau, Francesco; Rossello, Rosalba; Antonelli, Giovanna] Osped San Vincenzo, Taormina, Italy; [Guerra, Gennaro; Farina, Amalia; Messina, Francesco] Osped Evangel Betania, Naples, Italy; [Gatti, Davide] Univ Verona, Rheumatol Unit, Verona, Italy; [Jenkins, David J. A.] Univ Toronto, Dept Nutr Sci, Fac Med, Toronto, ON, Canada; [Jenkins, David J. A.] St Michaels Hosp, Clin Nutr & Risk Factor Modificat Ctr, Toronto, ON, Canada; [Jenkins, David J. A.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Minopoli, Anita; Grilli, Bruna; Cavalcanti, Ernesta] Ist Nazl Tumori IRCCS Fdn G Pascale, Lab Med Unit, Naples, Italy; [Botti, Gerardo] Ist Nazl Tumori IRCCS Fdn G Pascale, Sci Directorate, Naples, Italy	IRCCS Fondazione Pascale; University of Catania; University of Naples Federico II; University of Sydney; University of Sydney; Mediterranean Clinic; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale; IRCCS Aviano (CRO); University of Verona; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Montagnese, C (corresponding author), Ist Nazl Tumori IRCCS Fdn G Pascale, Epidemiol & Biostat Unit, Naples, Italy.	c.montagnese@istitutotumori.na.it	Calabrese, Ilaria/AHE-4887-2022; Serraino, Diego/J-3915-2018; Celentano, Egidio/AAC-8984-2022; Stefanadis, Christodoulos/ABH-2232-2020; Libra, Massimo/L-8241-2018; Montagnese, Concetta/AAC-8706-2022; Augustin, Livia/AAC-9009-2022; De Laurentiis, Michelino/AAC-6321-2022; Falzone, Luca/AAC-2085-2019; Libra, Massimo/ABF-6654-2020; Porciello, Giuseppe/AAA-7491-2020; Massarut, Samuele/J-2995-2018	Serraino, Diego/0000-0003-0565-8920; Stefanadis, Christodoulos/0000-0001-5974-6454; Libra, Massimo/0000-0002-7232-7737; Montagnese, Concetta/0000-0002-3662-2413; Augustin, Livia/0000-0002-6673-8281; De Laurentiis, Michelino/0000-0001-9009-1572; Falzone, Luca/0000-0001-7349-6826; Libra, Massimo/0000-0002-7232-7737; Porciello, Giuseppe/0000-0002-8731-2773; Massarut, Samuele/0000-0003-4717-0544; gatti, davide/0000-0002-7471-3076; Prete, Melania/0000-0002-5386-0819; Banna, Giuseppe Luigi/0000-0003-0764-3650; Calabrese, Ilaria/0000-0002-4222-4665	Italian Ministry of Health [PE-201302358099]; Lega Italiana per la Lotta Contro i Tumori (LILT Nazionale) Progetto Cinque Per Mille 2013 and Progetto Cinque Per Mille 2015	Italian Ministry of Health(Ministry of Health, Italy); Lega Italiana per la Lotta Contro i Tumori (LILT Nazionale) Progetto Cinque Per Mille 2013 and Progetto Cinque Per Mille 2015	This trial is funded by a grant of the Italian Ministry of Health (Grant no. PE-201302358099) and Lega Italiana per la Lotta Contro i Tumori (LILT Nazionale) Progetto Cinque Per Mille 2013 and Progetto Cinque Per Mille 2015. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Martinez-Gonzalez MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043134; Augustin LSA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3064-4; Babio N, 2009, PUBLIC HEALTH NUTR, V12, P1607, DOI 10.1017/S1368980009990449; Bloomfield HE, 2016, ANN INTERN MED, V165, P491, DOI 10.7326/M16-0361; Bonaccio M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003003; Bower JE, 2008, J CLIN ONCOL, V26, P768, DOI 10.1200/JCO.2007.14.3248; Brown JC, 2012, COMPR PHYSIOL, V2, P2775, DOI 10.1002/cphy.c120005; Buckland G, 2013, INT J CANCER, V132, P2918, DOI 10.1002/ijc.27958; Cella D, 2002, ARCH PHYS MED REHAB, V83, pS10, DOI 10.1053/apmr.2002.36959; Chim K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-401; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Cleeland CS, 2003, CANCER-AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382; Cottet V, 2009, AM J EPIDEMIOL, V170, P1257, DOI 10.1093/aje/kwp257; Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459; Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5; Dodd M J, 2001, Oncol Nurs Forum, V28, P465; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fiorentino Lavinia, 2007, Curr Treat Options Neurol, V9, P337, DOI 10.1007/s11940-007-0019-0; Forsyth C, 2018, RHEUMATOL INT, V38, P737, DOI 10.1007/s00296-017-3912-1; Fung TT, 2009, CIRCULATION, V119, P1093, DOI 10.1161/CIRCULATIONAHA.108.816736; Galilea-Zabalza I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198974; Gartner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568; Gong XH, 2017, QUAL LIFE RES, V26, P1541, DOI 10.1007/s11136-017-1496-6; Heistaro S, 2001, J EPIDEMIOL COMMUN H, V55, P227, DOI 10.1136/jech.55.4.227; Sanchez PH, 2012, EUR J CLIN NUTR, V66, P360, DOI 10.1038/ejcn.2011.146; Humphries B, 2018, PHARMACY-BASEL, V6, DOI 10.3390/pharmacy6020053; Ibrahim EM, 2011, MED ONCOL, V28, P753, DOI 10.1007/s12032-010-9536-x; Ilie G, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00783; Inoue-Choi M, 2013, J CLIN ONCOL, V31, P1758, DOI 10.1200/JCO.2012.45.4462; Kim NH, 2018, BMC WOMENS HLTH, P18, DOI [10.1186/s12905-018-0516-1, DOI 10.1186/S12905-018-0516-1]; Kurtz ME, 2001, CANCER PRACT, V9, P11, DOI 10.1046/j.1523-5394.2001.91004.x; La Vecchia C, 2009, NUTR REV, V67, pS126, DOI 10.1111/j.1753-4887.2009.00174.x; Lopez-Miranda J, 2010, NUTR METAB CARDIOVAS, V20, P284, DOI 10.1016/j.numecd.2009.12.007; Luisi MLE, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01366; Meeske K, 2007, QUAL LIFE RES, V16, P947, DOI 10.1007/s11136-007-9215-3; Meyerhardt JA, 2009, ARCH INTERN MED, V169, P2102, DOI 10.1001/archinternmed.2009.412; Mezzetti M, 1998, J NATL CANCER I, V90, P389, DOI 10.1093/jnci/90.5.389; Munoz MA, 2009, BRIT J NUTR, V101, P1821, DOI 10.1017/S0007114508143598; Mursu J, 2011, ARCH INTERN MED, V171, P1625, DOI 10.1001/archinternmed.2011.445; Nourissat A, 2008, EUR J CANCER, V44, P1238, DOI 10.1016/j.ejca.2008.04.006; Orchard TS, 2018, J ACAD NUTR DIET, V118, P578, DOI 10.1016/j.jand.2017.09.024; Pierce JP, 2007, J CLIN ONCOL, V25, P2345, DOI 10.1200/JCO.2006.08.6819; Rossi M, 2013, DIABETOLOGIA, V56, P2405, DOI 10.1007/s00125-013-3013-y; Sanchez-Villegas A, 2009, ARCH GEN PSYCHIAT, V66, P1090, DOI 10.1001/archgenpsychiatry.2009.129; Scalone L, 2013, VALUE HEALTH, V16, P814, DOI 10.1016/j.jval.2013.04.008; Schwingshackl L, 2015, CANCER MED-US, V4, P1933, DOI 10.1002/cam4.539; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Serra-Majem L, 2004, PUBLIC HEALTH NUTR, V7, P927, DOI 10.1079/PHN2004564; Serra-Majem L, 2019, MOL ASPECTS MED, V67, P1, DOI 10.1016/j.mam.2019.06.001; Serra-Majem L, 2009, BRIT J NUTR, V101, pS21, DOI 10.1017/S0007114509990559; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-112; Turati F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030326; van den Brandt PA, 2017, INT J CANCER, V140, P2220, DOI 10.1002/ijc.30654; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; Wayne SJ, 2006, BREAST CANCER RES TR, V96, P227, DOI 10.1007/s10549-005-9018-6; Willett Walter C., 1995, American Journal of Clinical Nutrition, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S	62	16	16	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2020	15	10							e0239803	10.1371/journal.pone.0239803	http://dx.doi.org/10.1371/journal.pone.0239803			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3TB	33031478	Green Published			2023-01-03	WOS:000581809800055
J	McKinney, CA; Bedenice, D; Pacheco, AP; Oliveira, BCM; Paradis, MR; Mazan, M; Widmer, G				McKinney, Caroline A.; Bedenice, Daniela; Pacheco, Ana P.; Oliveira, Bruno C. M.; Paradis, Mary-Rose; Mazan, Melissa; Widmer, Giovanni			Assessment of clinical and microbiota responses to fecal microbial transplantation in adult horses with diarrhea	PLOS ONE			English	Article							AKKERMANSIA-MUCINIPHILA; COLITIS	Background and aims Fecal microbial transplantation (FMT) is empirically implemented in horses with colitis to facilitate resolution of diarrhea. The purpose of this study was to assess FMT as a clinical treatment and modulator of fecal microbiota in hospitalized horses with colitis. Methods A total of 22 horses with moderate to severe diarrhea, consistent with a diagnosis of colitis, were enrolled at two referral hospitals (L1: n = 12; L2: n = 10). FMT was performed in all 12 patients on 3 consecutive days at L1, while treatment at L2 consisted of standard care without FMT. Manure was collected once daily for 4 days from the rectum in all colitis horses, prior to FMT for horses at L1, and from each manure sample used for FMT. Fecal samples from 10 clinically healthy control horses housed at L2, and 30 healthy horses located at 5 barns in regional proximity to L1 were also obtained to characterize the regional healthy equine microbiome. All fecal microbiota were analyzed using 16S amplicon sequencing. Results and conclusions As expected, healthy horses at both locations showed a greater alpha-diversity and lower beta-diversity compared to horses with colitis. The fecal microbiome of healthy horses clustered by location, with L1 horses showing a higher prevalence of Kiritimatiellaeota. Improved manure consistency (lower diarrhea score) was associated with a greater alpha-diversity in horses with colitis at both locations (L1: r = -0.385, P = 0.006; L2: r = -0.479, P = 0.002). Fecal transplant recipients demonstrated a greater overall reduction in diarrhea score (median: 4 +/- 3 grades), compared to untreated horses (median: 1.5 +/- 3 grades, P = 0.021), with a higher incidence in day-over-day improvement in diarrhea (22/36 (61%) vs. 10/28 (36%) instances, P = 0.011). When comparing microbiota of diseased horses at study conclusion to that of healthy controls, FMT-treated horses showed a lower mean UniFrac distance (0.53 +/- 0.27) than untreated horses (0.62 +/- 0.26, P<0.001), indicating greater normalization of the microbiome in FMT-treated patients.	[McKinney, Caroline A.; Bedenice, Daniela; Paradis, Mary-Rose; Mazan, Melissa] Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA 02155 USA; [Pacheco, Ana P.] Oregon State Univ, Carlson Coll Vet Med, Dept Clin Sci, Corvallis, OR 97331 USA; [Oliveira, Bruno C. M.] Univ Estadual Paulista UNESP, Fac Med Vet, Aracatuba, Brazil; [Oliveira, Bruno C. M.; Widmer, Giovanni] Tufts Univ, Cummings Sch Vet Med, Dept Infect Dis & Global Hlth, North Grafton, MA USA	Tufts University; Oregon State University; Universidade Estadual Paulista; Tufts University	Bedenice, D (corresponding author), Tufts Univ, Cummings Sch Vet Med, Dept Clin Sci, North Grafton, MA 02155 USA.	Daniela.bedenice@tufts.edu		McKinney, Caroline/0000-0003-3167-2558	Dorothy Russell Havemeyer Foundation [V320001 PV1215]; American College of Veterinary Internal Medicine Resident Research grant [102783-00001]; National Institute of Allergy and Infectious Disease (NIAID) [R21AI125891]	Dorothy Russell Havemeyer Foundation; American College of Veterinary Internal Medicine Resident Research grant; National Institute of Allergy and Infectious Disease (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding was provided by the Dorothy Russell Havemeyer Foundation grant V320001 PV1215 (MRP, DB)(http://www.havemeyerfoundation.org/research.htm), the American College of Veterinary Internal Medicine Resident Research grant 102783-00001 (CM, DB) (https://www.acvim.org/Awards-Grants/Fellowships_Grants) and the National Institute of Allergy and Infectious Disease (NIAID) award R21AI125891 (GW) (https://www.niaid.nih.gov/research/research-funded-niaid).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold CE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232905; Biddle AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077599; Byndloss MX, 2018, MUCOSAL IMMUNOL, V11, P1299, DOI 10.1038/s41385-018-0010-y; Cani PD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01765; Chapman A, 2009, ACUTE DIARRHEA HOSPI; Chen HT, 2020, EXP THER MED, V19, P2650, DOI 10.3892/etm.2020.8512; Cohen ND, 1999, J AM VET MED ASSOC, V214, P382; Collado MC, 2007, APPL ENVIRON MICROB, V73, P7767, DOI 10.1128/AEM.01477-07; Costa MC, 2015, VET J, V205, P74, DOI 10.1016/j.tvjl.2015.03.018; Costa MC, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0335-7; Costa MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041484; Costa Marcio C., 2012, Animal Health Research Reviews, V13, P121, DOI 10.1017/S1466252312000035; Daly K, 2012, BRIT J NUTR, V107, P989, DOI 10.1017/S0007114511003825; Derrien M, 2008, APPL ENVIRON MICROB, V74, P1646, DOI 10.1128/AEM.01226-07; Dias DPM, 2018, PESQUI VET BRASIL, V38, P1564, DOI [10.1590/1678-5150-PVB-5521, 10.1590/1678-5150-pvb-5521]; Divers T.J, 2014, 11 INT EQ COL RES S; Dojka MA, 1998, APPL ENVIRON MICROB, V64, P3869; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Edwards JE, 2020, ANIM MICROBIOME, V2, DOI 10.1186/s42523-020-0023-1; Ericsson AC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166523; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Garber A, 2020, J EQUINE VET SCI, V88, DOI 10.1016/j.jevs.2020.102943; Hamilton MJ, 2013, GUT MICROBES, V4, P125, DOI 10.4161/gmic.23571; Hashimoto-Hill S, 2011, J VET INTERN MED, V25, P1414, DOI 10.1111/j.1939-1676.2011.00808.x; Hassel F, 2006, ENTERITIS COLITIS HO; Jea Suez, 2018, CELL, V174; Kamada N, 2013, NAT IMMUNOL, V14, P685, DOI 10.1038/ni.2608; Laustsen LEJ, 2018, P EUR WORKSH EQ NUTR; Li DT, 2016, BIOTECHNOL ADV, V34, P1210, DOI 10.1016/j.biotechadv.2016.08.003; Liu SX, 2017, WORLD J GASTROENTERO, V23, P8570, DOI 10.3748/wjg.v23.i48.8570; Looft T, 2012, GUT MICROBES, V3, P463, DOI 10.4161/gmic.21288; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; McGuckin MA, 2011, NAT REV MICROBIOL, V9, P265, DOI 10.1038/nrmicro2538; McKinney CA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230148; Morrison PK, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02295-6; Morrison PK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03017; Mullen KR, 2018, EQUINE VET EDUC, V30, P151, DOI 10.1111/eve.12559; Naylor RJ, 2009, EQUINE VET EDUC, V21, P494, DOI 10.2746/095777309X468140; Oliveira BCM, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.01408-18; Peakall R, 2012, BIOINFORMATICS, V28, P2537, DOI 10.1093/bioinformatics/bts460; Pereira GQ, 2018, J VET INTERN MED, V32, P707, DOI 10.1111/jvim.15072; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Rodriguez C, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0514-5; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Spring S, 2016, ISME J, V10, P2801, DOI 10.1038/ismej.2016.84; Staley C, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0549-6; Steelman SM, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-231; Ter Braak CJF, 2012, CANOCO REFERENCE MAN; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Westcott SL, 2017, MSPHERE, V2, DOI 10.1128/mSphereDirect.00073-17	51	9	9	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0244381	10.1371/journal.pone.0244381	http://dx.doi.org/10.1371/journal.pone.0244381			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4VV	33444319	gold, Green Published			2023-01-03	WOS:000609988100091
J	Klein, LS; Gogolla, N				Klein, Lexandra S.; Gogolla, Nadine			How mice feel each other's pain or fear	SCIENCE			English	Editorial Material							NEURAL BASIS; EMPATHY; BEHAVIOR		[Klein, Lexandra S.; Gogolla, Nadine] Max Planck Inst Neurobiol, Circuits Emot Res Grp, Martinsried, Germany; [Klein, Lexandra S.] Int Max Planck Res Sch Mol Life Sci, Munich, Germany	Max Planck Society	Gogolla, N (corresponding author), Max Planck Inst Neurobiol, Circuits Emot Res Grp, Martinsried, Germany.	ngogolla@neuro.mpg.de		Klein, Alexandra/0000-0002-0997-3648	Max Planck Society; European Research Council (ERC) under the European Union [758448]; L'Agence Nationale de la RechercheDeutsche Forschungsgemeinschaft (ANR-DFG) project "SAFENET" [ANR-17 CE37-0021]; Gogolla laboratory	Max Planck Society(Max Planck SocietyFoundation CELLEX); European Research Council (ERC) under the European Union(European Research Council (ERC)); L'Agence Nationale de la RechercheDeutsche Forschungsgemeinschaft (ANR-DFG) project "SAFENET"(French National Research Agency (ANR)); Gogolla laboratory	We thank the Gogolla laboratory for their support and enthusiasm, the Max Planck Society, the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (ERC-2017-STG, grant 758448 to N.G.), and the L'Agence Nationale de la RechercheDeutsche Forschungsgemeinschaft (ANR-DFG) project "SAFENET" (ANR-17 CE37-0021) for financial support.	Allsop SA, 2018, CELL, V173, P1329, DOI 10.1016/j.cell.2018.04.004; Bartal IBA, 2011, SCIENCE, V334, P1427, DOI 10.1126/science.1210789; Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536; Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785; Carrillo M, 2019, CURR BIOL, V29, P1301, DOI 10.1016/j.cub.2019.03.024; Chen CY, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02584; Corradi-Dell'Acqua C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10904; de Waal FBM, 2008, ANNU REV PSYCHOL, V59, P279, DOI 10.1146/annurev.psych.59.103006.093625; de Waal FBM, 2017, NAT REV NEUROSCI, V18, P498, DOI 10.1038/nrn.2017.72; Decety Jean, 2015, AJOB Neurosci, V6, P3; Guzman YF, 2009, BEHAV BRAIN RES, V201, P173, DOI 10.1016/j.bbr.2009.02.024; Kim A, 2019, GENES BRAIN BEHAV, V18, DOI 10.1111/gbb.12521; Meyza KZ, 2017, NEUROSCI BIOBEHAV R, V76, P216, DOI 10.1016/j.neubiorev.2016.10.028; Smith ML, 2021, SCIENCE, V371, P153, DOI 10.1126/science.abe3040; Wicker B, 2003, NEURON, V40, P655, DOI 10.1016/S0896-6273(03)00679-2	15	3	3	5	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	2021	371	6525					122	+		10.1126/science.abf5940	http://dx.doi.org/10.1126/science.abf5940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PQ4MV	33414207				2023-01-03	WOS:000606520400020
J	Wakuma, B; Mosisa, G; Etafa, W; Mulisa, D; Tolossa, T; Fetensa, G; Besho, M; Gebre, M; Tsegaye, R				Wakuma, Bizuneh; Mosisa, Getu; Etafa, Werku; Mulisa, Diriba; Tolossa, Tadesse; Fetensa, Getahun; Besho, Merga; Gebre, Mohammed; Tsegaye, Reta			Postpartum modern contraception utilization and its determinants in Ethiopia: A systematic review and meta-analysis	PLOS ONE			English	Review							WOMEN; PERIOD; PREGNANCY; INTERVAL; TOWN	Background Contraceptive use is the best and most cost-effective strategy to reduce feto-maternal adverse effects of short birth intervals. More than two-thirds of women in developing countries who do not want to conceive are not using contraception methods. Although there were various primary studies in different parts of the country, there is no nationally representative evidence on postpartum modern contraception utilization and its determinants in Ethiopia. Objective This review was aimed to determine the best available pieces of evidence to pool the magnitude of postpartum modern contraception utilization and find out its determinants. Methods Published studies were extensively searched by using electronic databases and unpublished studies were identified from the digital library. All observational studies conducted on the magnitude of postpartum modern contraception utilization and its determinants in Ethiopia were included. Data were extracted on the Microsoft Excel spreadsheet and analyzed using STATA 14.1 version. A random-effects model was used to estimate the pooled magnitude of postpartum modern contraception utilization with a 95% confidence interval (CI). Inverse variance (I2) was used to identify the presence of heterogeneity and forest plot was used to estimate the pooled magnitude of postpartum contraception utilization. The presence of publication bias was assessed by funnel plots and Egger's statistical tests. Sub-group analysis was computed to minimize underlying heterogeneity. Findings In this review, 19 primary studies were included. The pooled magnitude of postpartum modern contraception utilization in Ethiopia was 45.79% (95%CI 36.45%, 55.13%). The review found that having more than four Antenatal care visits(ANC), having postnatal care visit (PNC), having a formal education, history of family planning use, history of counseling on family planning, and having greater than four alive children as significant determinants of postpartum modern contraception utilization. Conclusion The magnitude of postpartum modern contraception utilization in Ethiopia was low. ANC visit, PNC visit, maternal educational status, history of previous family planning use, counseling on family planning, and number of alive children were found to be significant determinants of postpartum modern contraception utilization. Therefore, strengthening focused ANC and PNC services to encourage women in utilizing modern contraception during the postnatal period is needed.	[Wakuma, Bizuneh; Mosisa, Getu; Etafa, Werku; Mulisa, Diriba; Fetensa, Getahun; Besho, Merga; Tsegaye, Reta] Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia; [Tolossa, Tadesse] Wollega Univ, Inst Hlth Sci, Dept Publ Hlth, Nekemte, Ethiopia; [Gebre, Mohammed] Wollega Univ, Inst Hlth Sci, Dept Pharm, Nekemte, Ethiopia; [Gebre, Mohammed] Addis Ababa Univ, Sch Pharm, Dept Pharmacol & Clin Pharm, Coll Hlth Sci, Addis Ababa, Ethiopia	Addis Ababa University	Wakuma, B (corresponding author), Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia.	buzuna2014@gmail.com	Hirko, Getahun Fetensa/ABY-0109-2022; Kebebew, Getu Mosisa/ABI-5268-2020; Ebi, Werku Etafa/Q-2742-2019	Ebi, Werku Etafa/0000-0001-9576-8888; Dedefo, Mohammed Gebre/0000-0003-2262-0158				Abera Y, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0178-1; Abraha Teklehaymanot Huluf, 2018, BMC Res Notes, V11, P641, DOI 10.1186/s13104-018-3754-2; Abraha TH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5941-4; Abraha TH, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017012; Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Anguzu R, 2018, CONTRACEP REPROD MED, V3, DOI 10.1186/s40834-018-0059-8; [Anonymous], 2015, ENERGY STORAGE IND O, V3, P22; [Anonymous], 2019, TRENDS MATERNAL MORT; [Anonymous], 2014, PROGR STRAT POSTP FA; Apanga PA, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.10.5301; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Belete GA, 2019, UTILIZATION ASS FACT; Berta M, 2018, ETHIOP J HEALTH SCI, V28, P207, DOI 10.4314/ejhs.v28i2.12; BRiz GOMEz Antonio, 2003, ORALIA ANALISIS DISC, V6, P7; Brown W, 2014, STUD FAMILY PLANN, V45, P73, DOI 10.1111/j.1728-4465.2014.00377.x; Bwazi C., 2014, Health, V6, P1724, DOI 10.4236/health.2014.614205; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; CSA Ethiopia and ICF, 2016, ETH DEM HLTH SURV 20; DaVanzo J, 2007, BJOG-INT J OBSTET GY, V114, P1079, DOI 10.1111/j.1471-0528.2007.01338.x; Demie T., 2018, J WOMENS HLTH CARE, V7, P2167, DOI DOI 10.4172/2167-0420.100042618; Derso T, PREVALENCE DETERMINA; Dona A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5981-9; Ethiopian Public Health Institute (EPHI) and ICF [Ethiopia], 2019, ETH MIN HLTH SURV 20; Gaffield ME, 2014, GLOB HEALTH-SCI PRAC, V2, P4, DOI 10.9745/GHSP-D-13-00156; Gebremariam A, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1613-0; Gebremedhin AY, 2018, CONTRACEP REPROD MED, V3, DOI 10.1186/s40834-017-0054-5; Gejo NG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217167; Gizaw W, 2017, INSIGHTS REPROD MED, V1, P8; Gonie A, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0539-7; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hounkponou F, 2019, OPEN ACCESS J CONTR, V10, P19, DOI 10.2147/OAJC.S219709; Institute JB, 2006, MET STAT ASS REV INS, P20032007; Jalang'o R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4510-6; Mahmood SE, 2011, INDAN J COMMUNITY HE, V23, P56; MALAHLELA MK, 2013, J SOCIAL SCI, V37, P137, DOI DOI 10.1080/09718923.2013.11893212; Mody SK, 2014, CONTRACEPTION, V89, P516, DOI 10.1016/j.contraception.2014.01.001; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Rutaremwa G, 2018, PAN AFR MED J, V30, DOI 10.11604/pamj.2018.30.303.15105; Rutaremwa G, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1611-y; Rutstein S., 2008, DHS WORKING PAPERS; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Tafere Tadese Ejigu, 2018, Contracept Reprod Med, V3, P28, DOI 10.1186/s40834-018-0081-x; Taye EB, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4464-0; Tedla Z., 2017, POSTPARTUM CONTRACEP; Teka Takele Teshome, 2018, BMC Res Notes, V11, P581, DOI 10.1186/s13104-018-3698-6; Tirah H, THESIS; Tura G, 2016, J WOMENS HLTH CARE, V5, DOI DOI 10.4172/2167-0420.1000340; Wendt A, 2012, PAEDIATR PERINAT EP, V26, P239, DOI 10.1111/j.1365-3016.2012.01285.x; Wudineh KG, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2138-x	49	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243776	10.1371/journal.pone.0243776	http://dx.doi.org/10.1371/journal.pone.0243776			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315904	Green Published, gold			2023-01-03	WOS:000600186100023
J	Kumanyika, S; Dietz, WH				Kumanyika, Shiriki; Dietz, William H.			Solving Population-wide Obesity - Progress and Future Prospects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kumanyika, Shiriki] Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA; [Kumanyika, Shiriki] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dietz, William H.] George Washington Univ, Sch Publ Hlth, Milken Inst, Washington, DC USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; George Washington University	Kumanyika, S (corresponding author), Drexel Univ, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.; Kumanyika, S (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.			Kumanyika, Shiriki/0000-0002-7798-4306				Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Institute of Medicine, 2012, ACCELERATING PROGR O; Lancet Commission on Obesity, 2019, GLOB SYND OB UND CLI; Ogden CL, 2020, JAMA-J AM MED ASSOC, V324, P1208, DOI 10.1001/jama.2020.14590; Yadav R, 2020, DIABETES METAB SYND, V14, P1355, DOI 10.1016/j.dsx.2020.07.030	5	21	23	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	2020	383	23					2197	2200		10.1056/NEJMp2029646	http://dx.doi.org/10.1056/NEJMp2029646			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB8PZ	33264824				2023-01-03	WOS:000596577700007
J	Gomord, V; Stordeur, V; Fitchette, AC; Fixman, ED; Tropper, G; Garnier, L; Desgagnes, R; Viel, S; Couillard, J; Beauverger, G; Trepout, S; Ward, BJ; van Ree, R; Faye, L; Vezina, LP				Gomord, Veronique; Stordeur, Virginie; Fitchette, Anne-Catherine; Fixman, Elizabeth D.; Tropper, Guy; Garnier, Lorna; Desgagnes, Rejean; Viel, Sebastien; Couillard, Julie; Beauverger, Guillaume; Trepout, Sylvain; Ward, Brian J.; van Ree, Ronald; Faye, Loic; Vezina, Louis-P			Design, production and immunomodulatory potency of a novel allergen bioparticle	PLOS ONE			English	Article							VIRUS-LIKE PARTICLES; DUST-MITE ALLERGEN; DER-P-II; TRANSIENT EXPRESSION; CYTOPLASMIC TAIL; VACCINE DELIVERY; IMMUNOTHERAPY; PLANTS; IMMUNOGENICITY; RECOMBINANT	Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.	[Gomord, Veronique; Stordeur, Virginie; Fitchette, Anne-Catherine; Beauverger, Guillaume; Faye, Loic] ANGANY Innovat, Val De Reuil, France; [Gomord, Veronique; Tropper, Guy; Desgagnes, Rejean; Couillard, Julie; Vezina, Louis-P] ANGANY Inc, Quebec City, PQ, Canada; [Fixman, Elizabeth D.; Ward, Brian J.] McGill Univ, Ctr Hlth, Res Inst RI MUHC, Montreal, PQ, Canada; [Garnier, Lorna; Viel, Sebastien] Hop Lyon Sud, Hosp Civils Lyon, Serv Immunol Biol, Pierre Benite, France; [Trepout, Sylvain] Inst Curie, Plateforme Microscopie Elect, IR2 Inserm, INSERM US43,CNRS UMS2016, Orsay, France; [van Ree, Ronald] Dept Expt Immunol Mol & Translat Allergy, Amsterdam, Netherlands	McGill University; CHU Lyon; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Gomord, V (corresponding author), ANGANY Innovat, Val De Reuil, France.; Gomord, V (corresponding author), ANGANY Inc, Quebec City, PQ, Canada.	veronique.gomord@angany.com	GARNIER, Lorna/ACB-8668-2022; Viel, Sebastien/A-7258-2016	Viel, Sebastien/0000-0002-5085-443X; Gomord, veronique/0000-0001-7062-9136; Trepout, Sylvain/0000-0002-5822-407X	Angany Innovation; Angany Inc.	Angany Innovation; Angany Inc.	This work was supported by Angany Innovation (previously known as Angany Genetics) and by Angany Inc. Angany Innovation provided support in the form of salaries for authors VG, VS, ACF, GB, LF, and ST and Angany Inc. for authors GT, RD, JC and LPV. The authors BJW and RVR have received honoraria from Angany Inc. As the funders of the study, Angany Innovation and Angany Inc. participated in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	[Anonymous], 2015, Plant J, V84, P846, DOI 10.1111/tpj.13066; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; Antonis AFG, 2006, VACCINE, V24, P5481, DOI 10.1016/j.vaccine.2006.03.089; Anzaghe M, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0827-1; Aricigil M, 2016, AM J RHINOL ALLERGY, V30, pE193, DOI 10.2500/ajra.2016.30.4379; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barber D, 2012, CLIN EXP ALLERGY, V42, P1129, DOI 10.1111/j.1365-2222.2012.03993.x; Barman S, 2004, J VIROL, V78, P5258, DOI 10.1128/JVI.78.10.5258-5269.2004; Bordas-Le Floch V, 2012, INT ARCH ALLERGY IMM, V158, P157, DOI 10.1159/000331143; Bronnert M, 2012, CLIN EXP ALLERGY, V42, P1406, DOI 10.1111/j.1365-2222.2012.04035.x; Buyel JF, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01893; Canto T, 2016, ADV EXP MED BIOL, V896, P287, DOI 10.1007/978-3-319-27216-0_18; Chaisri U, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188627; Chapman TJ, 2013, J IMMUNOL, V191, P4423, DOI 10.4049/jimmunol.1300042; Chen BJ, 2005, J VIROL, V79, P13673, DOI 10.1128/JVI.79.21.13673-13684.2005; Chlanda P, 2017, J VIROL, V91, DOI 10.1128/JVI.00947-17; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; Compans RW, 2012, Cross-protective influenza vaccine, Patent No. [US20120052082 A1, 20120052082]; Cornelius C, 2016, EBIOMEDICINE, V11, P58, DOI 10.1016/j.ebiom.2016.07.023; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; D'Aoust MA, 2008, PLANT BIOTECHNOL J, V6, P930, DOI 10.1111/j.1467-7652.2008.00384.x; D'Aoust MA, 2010, PLANT BIOTECHNOL J, V8, P607, DOI 10.1111/j.1467-7652.2009.00496.x; Dai S., 2018, J IMMUNOL SCI, V2, P36; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; Dhama K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01803; Diwakar L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012647; Durham SR, 2016, J ALLERGY CLIN IMMUN, V137, P339, DOI 10.1016/j.jaci.2015.12.1298; Elliott Jesse, 2017, CMAJ Open, V5, pE373, DOI 10.9778/cmajo.20160066; Engeroff P, 2018, ALLERGY, V73, P341, DOI 10.1111/all.13268; Faye L, 2010, PLANT BIOTECHNOL J, V8, P525, DOI 10.1111/j.1467-7652.2010.00521.x; FORD SA, 1990, CLIN EXP ALLERGY, V20, P27, DOI 10.1111/j.1365-2222.1990.tb02771.x; Glesner J, 2019, J IMMUNOL, V203, P2545, DOI 10.4049/jimmunol.1900580; Gomord V., 2014, Production commerciale de peptidases c1a par expression transitoire chez les plantes, Patent No. [WO2014170597A1, 2014170597]; Gomord V, 2010, PLANT BIOTECHNOL J, V8, P564, DOI 10.1111/j.1467-7652.2009.00497.x; Gomord W, 2004, PLANT BIOTECHNOL J, V2, P83, DOI 10.1111/j.1467-7652.2004.00062.x; Hakkaart GAJ, 1998, INT ARCH ALLERGY IMM, V115, P150, DOI 10.1159/000023895; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P45, DOI 10.1046/j.1365-2222.1998.00164.x; HARBOE N, 1973, SCAND J IMMUNOL, V2, P161; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HIATT A, 1992, FEBS LETT, V307, P71, DOI 10.1016/0014-5793(92)80904-U; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Huang ZF, 2020, INT ARCH ALLERGY IMM, V181, P81, DOI 10.1159/000504320; Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064; Jensen-Jarolim E, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0060-5; Kang SM, 2012, EXPERT REV VACCINES, V11, P995, DOI 10.1586/ERV.12.70; Kettner A, 2018, J ALLERGY CLIN IMMUN, V142, P678, DOI 10.1016/j.jaci.2018.01.052; Klimek L, 2018, ALLERGO J, V27, P22, DOI 10.1007/s40629-018-0074-y; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; LEAK LV, 1971, J CELL BIOL, V50, P300, DOI 10.1083/jcb.50.2.300; Li CP, 2013, HUM IMMUNOL, V74, P531, DOI 10.1016/j.humimm.2013.01.002; Lienard D, 2007, PLANT BIOTECHNOL J, V5, P93, DOI 10.1111/j.1467-7652.2006.00221.x; Lomonossoff GP, 2016, SCIENCE, V353, P1237, DOI 10.1126/science.aaf6638; LYNCH NR, 1994, INT ARCH ALLERGY IMM, V105, P70, DOI 10.1159/000236805; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Manzano-Szalai K, 2014, VIRAL IMMUNOL, V27, P438, DOI 10.1089/vim.2014.0059; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Montero-Morales L, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00242; Morefield GL, 2011, AAPS J, V13, P191, DOI 10.1208/s12248-011-9261-1; Neimert-Andersson T, 2008, ALLERGY, V63, P518, DOI 10.1111/j.1398-9995.2008.01644.x; Pacciani V, 2012, ANN ALLERG ASTHMA IM, V109, P442, DOI 10.1016/j.anai.2012.09.001; Pagny S, 2000, PLANT CELL, V12, P739, DOI 10.1105/tpc.12.5.739; Pattenden LK, 2005, TRENDS BIOTECHNOL, V23, P523, DOI 10.1016/j.tibtech.2005.07.011; Peacey M, 2007, BIOTECHNOL BIOENG, V98, P968, DOI 10.1002/bit.21518; Pfaar O, 2019, ALLERGY, V74, P3, DOI 10.1111/all.14077; Reginald K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21792-1; Roy P, 2008, HUM VACCINES, V4, P5, DOI 10.4161/hv.4.1.5559; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Senti G, 2019, INT ARCH ALLERGY IMM, V178, P141, DOI 10.1159/000493647; Senti G, 2016, IMMUNOL ALLERGY CLIN, V36, P25, DOI 10.1016/j.iac.2015.08.006; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Simon D, 2018, INT ARCH ALLERGY IMM, V177, P324, DOI 10.1159/000494931; Singha S, 2018, ACS NANO, V12, P10621, DOI 10.1021/acsnano.8b05950; Soongrung T, 2020, ALLERGY, V75, P1232, DOI 10.1111/all.14096; Spertini F, 2016, J ALLERGY CLIN IMMUN, V138, P162, DOI 10.1016/j.jaci.2016.02.044; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; Stelter S, 2020, PLANT BIOTECHNOL J, V18, P402, DOI 10.1111/pbi.13207; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Thunberg S, 2009, ALLERGY, V64, P919, DOI 10.1111/j.1398-9995.2008.01905.x; Tsabouri S, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00082; van Hage M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00081; Vezina LP, 2009, PLANT BIOTECHNOL J, V7, P442, DOI 10.1111/j.1467-7652.2009.00414.x; Vogel R, 2011, ANAL CHEM, V83, P3499, DOI 10.1021/ac200195n; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Weldon WC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012466; Willmott GR, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/45/454116; Yamashita S, 2017, J OLEO SCI, V66, P157, DOI 10.5650/jos.ess16169; Zeltins A, 2017, ANTIBIOTICS-BASEL, V6, DOI 10.3390/antibiotics6030018; Zhang J, 2019, ACS APPL MATER INTER, V11, P42904, DOI 10.1021/acsami.9b13556	92	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2020	15	12							e0242867	10.1371/journal.pone.0242867	http://dx.doi.org/10.1371/journal.pone.0242867			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB7NK	33259521	Green Published, gold			2023-01-03	WOS:000596503200025
J	Modak, BK; Gorai, P; Pandey, DK; Dey, A; Malik, T				Modak, Biplob Kumar; Gorai, Partha; Pandey, Devendra Kumar; Dey, Abhijit; Malik, Tabarak			An evidence based efficacy and safety assessment of the ethnobiologicals against poisonous and non-poisonous bites used by the tribals of three westernmost districts of West Bengal, India: Anti-phospholipase A(2) and genotoxic effects	PLOS ONE			English	Article							MEDICINAL-PLANTS; HEMIDESMUS-INDICUS; NORTHWEST REGION; MYOCARDIAL-INFARCTION; ETHNOBOTANICAL SURVEY; VENOM NEUTRALIZATION; ARISTOLOCHIC ACID; TRADITIONAL USE; ROOT EXTRACT; SNAKEBITES	Introduction To explore the ethnobiological wisdom of the tribals of three western districts of West Bengal, India against poisonous and non-poisonous bites and stings, a quantitative approach was adopted. These age-old yet unexplored knowledge can be utilized in finding lead-molecules against poisonous and non-poisonous animal-bites. Further, an evidence-based approach is needed to assess the venom-neutralization ability of plants by experimental studies. Materials and methods During 2008-2009 and 2012-2017, 11 ethnomedicinal surveys were carried out to explore the use of medicinal flora and fauna via conducting open semi-structured interviews with 47 traditional healers (THs) or informants. The retrieved dataset was statistically evaluated using seven quantitative-indexes: use-value (UV), informants'-consensus-factor (ICF), fidelity-level (FL), relative-importance (RI), cultural importance-index (CI), index of agreement on remedies (IAR) and cultural agreement-index (CAI). Anti-phospholipaseA(2) (PLA(2)) properties of selected plant extracts were also examined. In addition, the cytotoxicity and genotoxicity of the water extract of the plants showing high FL as well as significant PLA(2) inhibitory potential were investigated using Allium cepa root tip assay. Results A total of 41 traditional-formulations (TFs) containing 40 plant species (of 39 genera from 28 families) and 3 animal species were prescribed by the THs. Fabaceae exhibited most number of medicinal plants. Piper nigrum (1.78) and Apis cerana indica and Crossopriza lyoni (both 0.21) exhibited the highest UV among the plants and the animals respectively. Stinging of centipede and dog/cat/hyena bite displayed highest ICF (1.00 each). Among the plants, the maximum RI (0.91) and CI (4.98) values were observed for Aristolochia indica. IAR (1.00) was recorded maximum for Achyranthes aspera, Gloriosa superba, Lycopodium cernuum, Smilax zeylanica and Streblus asper. Maximum CAI value was noted for Piper nigrum (5.5096). Among the animals, Apis cerana indica (0.31) and Crossopriza lyoni (1.52) displayed the highest RI and CI values respectively. Crossopriza lyoni (0.99) and Apis cerana indica (1.3871) exhibited maximum IAR and CAI values respectively. Plants showing higher FL exhibited higher anti-PLA(2) activity via selective inhibition of human-group PLA(2). In addition, Allium cepa root tip assay has indicated the safety and/or toxicity of the plant parts prescribed by the THs. Root water extracts of Aristolochia indica and Gloriosa superba exhibited significant genotoxicity and cytotoxicity. Conclusions Three western districts of West Bengal is the natural abode for many tribal and non-tribal communities. A noteworthy correlation was established between the plants used against poisonous-bites and their anti-PLA(2) activity. A few plant parts used by the THs also exhibited high toxicity. Such alternative medical practices serve as the only option in these underprivileged and backward areas during medical-exigencies.	[Modak, Biplob Kumar; Gorai, Partha] Sidho Kanho Birsha Univ, Dept Zool, Lagda, W Bengal, India; [Pandey, Devendra Kumar] Lovely Profess Univ, Lovely Fac Technol & Sci, Dept Biotechnol, Phagwara, Punjab, India; [Dey, Abhijit] Presidency Univ, Dept Life Sci, Kolkata, W Bengal, India; [Malik, Tabarak] Univ Gondar, Coll Med & Hlth Sci, Dept Med Biochem, Gondar, Ethiopia	Lovely Professional University; Presidency University, Kolkata; University of Gondar	Dey, A (corresponding author), Presidency Univ, Dept Life Sci, Kolkata, W Bengal, India.; Malik, T (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Dept Med Biochem, Gondar, Ethiopia.	abhijit.dbs@presiuniv.ac.in; malikitrc@gmail.com	MODAK, BIPLOB/ADP-7531-2022; Pandey, Devendra Kumar/W-7574-2019; MALIK, TABARAK/M-3672-2014	Pandey, Devendra Kumar/0000-0002-1582-9407; MALIK, TABARAK/0000-0002-8332-7927; PANDEY, DEVENDRA/0000-0002-1816-6215; Modak, Biplob Kumar/0000-0003-1161-5337				Akwu NA, 2019, S AFR J BOT, V125, P371, DOI 10.1016/j.sajb.2019.08.009; Alam MI, 1996, PHYTOTHER RES, V10, P58, DOI 10.1002/(SICI)1099-1573(199602)10:1&lt;58::AID-PTR775&gt;3.0.CO;2-F; Alam MI, 1998, TOXICON, V36, P1423, DOI 10.1016/S0041-0101(98)00076-2; Allen GE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053188; Ananthi R, 2010, J ETHNOPHARMACOL, V127, P558, DOI 10.1016/j.jep.2009.10.034; [Anonymous], 2009, NOTE BACKWARD REGION; Azaizeh H, 2003, FITOTERAPIA, V74, P98, DOI 10.1016/S0367-326X(02)00285-X; Bharathi P., 2006, Journal of Medical Sciences (Pakistan), V6, P420; Bhattacharjee P, 2013, J ETHNOPHARMACOL, V145, P220, DOI 10.1016/j.jep.2012.10.056; Rodrigues CFB, 2019, MAR DRUGS, V17, DOI 10.3390/md17070403; Bruschi P, 2011, J ETHNOPHARMACOL, V138, P543, DOI 10.1016/j.jep.2011.09.055; Cardoso FF, 2018, BBA-GEN SUBJECTS, V1862, P2728, DOI 10.1016/j.bbagen.2018.08.002; Celik TA, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/189252; Chatterjee I, 2006, J ETHNOPHARMACOL, V106, P38, DOI 10.1016/j.jep.2005.11.031; Cook F. E. M., 1995, Economic botany data collection standard.; Cupo P, 2015, REV SOC BRAS MED TRO, V48, P642, DOI 10.1590/0037-8682-0237-2015; Datta S, 2018, SUSTAIN ENVIRON RES, V28, P171, DOI 10.1016/j.serj.2018.01.005; de Moura VM, 2015, J ETHNOPHARMACOL, V161, P224, DOI 10.1016/j.jep.2014.12.020; DEARAUJO AL, 1987, TOXICON, V25, P1181, DOI 10.1016/0041-0101(87)90136-X; Debnath P, 2020, SCI TOTAL ENVIRON, V713, DOI 10.1016/j.scitotenv.2020.136592; Dey A, 2012, J ETHNOPHARMACOL, V143, P68, DOI 10.1016/j.jep.2012.05.064; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Giday M, 2009, J ETHNOPHARMACOL, V124, P513, DOI 10.1016/j.jep.2009.05.009; GRIEGO RD, 1995, J AM ACAD DERMATOL, V33, P1019, DOI 10.1016/0190-9622(95)90296-1; Gupta Prabha Nini, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-213974; Gupta Y K, 2012, Toxicol Int, V19, P89, DOI 10.4103/0971-6580.97194; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Harrison RA, 2011, J PROTEOMICS, V74, P1768, DOI 10.1016/j.jprot.2011.06.019; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Jadot I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020297; Kadir MF, 2012, J ETHNOPHARMACOL, V144, P627, DOI 10.1016/j.jep.2012.10.003; Kala CP, 2015, INDIAN J NAT PROD RE, V6, P56; Kammoun M, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-30; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Khan H, 2007, J ENZYM INHIB MED CH, V22, P722, DOI [10.1080/14756360601164853, 10.1080/14756360601164853 ]; Kini RM, 2003, TOXICON, V42, P827, DOI 10.1016/j.toxicon.2003.11.002; Konar AK, 2010, SOCIALCHANGE, V40, P157, DOI DOI 10.1177/004908571004000204; Kufer J, 2005, J PHARM PHARMACOL, V57, P1127, DOI 10.1211/jpp.57.9.0008; Kularatne SAM, 2016, WILD ENVIRON MED, V27, P262, DOI 10.1016/j.wem.2015.12.018; Lee JKC, 2017, TRANSL ANDROL UROL, V6, P91, DOI 10.21037/tau.2016.11.13; Leme DM, 2009, MUTAT RES-REV MUTAT, V682, P71, DOI 10.1016/j.mrrev.2009.06.002; Liman R, 2018, FOOD CHEM TOXICOL, V121, P444, DOI 10.1016/j.fct.2018.09.022; Liu D, 2018, CARYOLOGIA, P71; Marcussi S, 2007, CURR TOP MED CHEM, V7, P743, DOI 10.2174/156802607780487614; Mendes SS, 2012, REV BRAS FARMACOGN, V22, P76, DOI 10.1590/S0102-695X2011005000180; Michl J, 2013, J ETHNOPHARMACOL, V149, P235, DOI 10.1016/j.jep.2013.06.028; Modak BK, 2009, INDIAN J LANDSCAPE S, V32, P67; Mohapatra B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001018; Mors WB, 2000, PHYTOCHEMISTRY, V55, P627, DOI 10.1016/S0031-9422(00)00229-6; Oliveira ES, 2010, J ETHNOPHARMACOL, V130, P54, DOI 10.1016/j.jep.2010.04.010; Omara T, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-019-0187-0; Ortiz E, 2015, TOXICON, V93, P125, DOI 10.1016/j.toxicon.2014.11.233; Otero R, 2000, J ETHNOPHARMACOL, V73, P233, DOI 10.1016/S0378-8741(00)00321-4; Otero R, 2000, J ETHNOPHARMACOL, V71, P505, DOI 10.1016/S0378-8741(99)00197-X; Otero R, 2000, J ETHNOPHARMACOL, V71, P493, DOI 10.1016/S0378-8741(00)00243-9; Pesnya DS, 2017, CARYOLOGIA, V70, P55, DOI 10.1080/00087114.2016.1272313; PHILLIPS O, 1994, CONSERV BIOL, V8, P225, DOI 10.1046/j.1523-1739.1994.08010225.x; Prain D., 1903, 1 INDIAN REPRINT 196, P1; Prajitha V, 2016, S AFR J BOT, V102, P18, DOI 10.1016/j.sajb.2015.06.018; Rahman MM, 2017, CHEM ECOL, V33, P434, DOI 10.1080/02757540.2017.1316491; Cesar PHS, 2021, BIOTECHNOL APPL BIOC, V68, P486, DOI 10.1002/bab.1943; Samy RP, 2008, J ETHNOPHARMACOL, V115, P302, DOI 10.1016/j.jep.2007.10.006; Sanyal MN, 1994, FLORA BANKURA DISTRI; Szczypa Katarzyna, 2015, Pol Merkur Lekarski, V39, P199; Tardio J, 2008, ECON BOT, V62, P24, DOI 10.1007/s12231-007-9004-5; Thomas E, 2009, J ETHNOPHARMACOL, V122, P60, DOI 10.1016/j.jep.2008.11.021; Trotter RT., 1986, PLANTS INDIGENOUS ME, P91, DOI [10.4324/9781315060385-6, DOI 10.4324/9781315060385-6]; Ureyen CM, 2015, WIEN KLIN WOCHENSCHR, V127, P577, DOI 10.1007/s00508-015-0801-z; Ushanandini S, 2006, PHYTOTHER RES, V20, P851, DOI 10.1002/ptr.1951; VISHWANATH BS, 1987, TOXICON, V25, P929, DOI 10.1016/0041-0101(87)90155-3; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; Warrell DA, 2010, LANCET, V375, P77, DOI 10.1016/S0140-6736(09)61754-2; Yildiz A, 2006, EMERG MED J, V23, DOI 10.1136/emj.2005.030007; Zheng XL, 2009, J ETHNOPHARMACOL, V124, P197, DOI 10.1016/j.jep.2009.04.042	74	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2020	15	11							e0242944	10.1371/journal.pone.0242944	http://dx.doi.org/10.1371/journal.pone.0242944			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT2ZY	33253320	Green Published, gold			2023-01-03	WOS:000608488200117
J	Regina, J; Papadimitriou-Olivgeris, M; Burger, R; Le Pogam, MA; Niemi, T; Filippidis, P; Tschopp, J; Desgranges, F; Viala, B; Kampouri, E; Rochat, L; Haefliger, D; Belkoniene, M; Fidalgo, C; Kritikos, A; Jaton, K; Senn, L; Bart, PA; Pagani, JL; Manuel, O; Lhopitallier, L				Regina, Jean; Papadimitriou-Olivgeris, Matthaios; Burger, Raphael; Le Pogam, Marie-Annick; Niemi, Tapio; Filippidis, Paraskevas; Tschopp, Jonathan; Desgranges, Florian; Viala, Benjamin; Kampouri, Eleftheria; Rochat, Laurence; Haefliger, David; Belkoniene, Mehdi; Fidalgo, Carlos; Kritikos, Antonios; Jaton, Katia; Senn, Laurence; Bart, Pierre-Alexandre; Pagani, Jean-Luc; Manuel, Oriol; Lhopitallier, Loic			Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: An observational retrospective study	PLOS ONE			English	Article								Background This study aims to describe the epidemiology of COVID-19 patients in a Swiss university hospital. Methods This retrospective observational study included all adult patients hospitalized with a laboratory confirmed SARS-CoV-2 infection from March 1 to March 25, 2020. We extracted data from electronic health records. The primary outcome was the need to mechanical ventilation at day 14. We used multivariate logistic regression to identify risk factors for mechanical ventilation. Follow-up was of at least 14 days. Results 145 patients were included in the multivariate model, of whom 36 (24.8%) needed mechanical ventilation at 14 days. The median time from symptoms onset to mechanical ventilation was 9 center dot 5 days (IQR 7.00, 12.75). Multivariable regression showed increased odds of mechanical ventilation with age (OR 1.09 per year, 95% CI 1.03-1.16, p = 0.002), in males (OR 6.99, 95% CI 1.68-29.03, p = 0.007), in patients who presented with a qSOFA score >= 2 (OR 7.24, 95% CI 1.64-32.03, p = 0.009), with bilateral infiltrate (OR 18.92, 3.94-98.23, p<0.001) or with a CRP of 40 mg/l or greater (OR 5.44, 1.18-25.25; p = 0.030) on admission. Patients with more than seven days of symptoms on admission had decreased odds of mechanical ventilation (0.087, 95% CI 0.02-0.38, p = 0.001). Conclusions This study gives some insight in the epidemiology and clinical course of patients admitted in a European tertiary hospital with SARS-CoV-2 infection. Age, male sex, high qSOFA score, CRP of 40 mg/l or greater and a bilateral radiological infiltrate could help clinicians identify patients at high risk for mechanical ventilation.	[Regina, Jean; Papadimitriou-Olivgeris, Matthaios; Burger, Raphael; Filippidis, Paraskevas; Tschopp, Jonathan; Desgranges, Florian; Viala, Benjamin; Kampouri, Eleftheria; Rochat, Laurence; Haefliger, David; Kritikos, Antonios; Manuel, Oriol; Lhopitallier, Loic] Lausanne Univ Hosp, Infect Dis Serv, Lausanne, Switzerland; [Regina, Jean; Papadimitriou-Olivgeris, Matthaios; Burger, Raphael; Filippidis, Paraskevas; Tschopp, Jonathan; Desgranges, Florian; Viala, Benjamin; Kampouri, Eleftheria; Rochat, Laurence; Haefliger, David; Belkoniene, Mehdi; Fidalgo, Carlos; Kritikos, Antonios; Jaton, Katia; Senn, Laurence; Bart, Pierre-Alexandre; Pagani, Jean-Luc; Manuel, Oriol; Lhopitallier, Loic] Univ Lausanne, Lausanne, Switzerland; [Papadimitriou-Olivgeris, Matthaios; Senn, Laurence] Lausanne Univ Hosp, Serv Hosp Prevent Med, Lausanne, Switzerland; [Burger, Raphael; Belkoniene, Mehdi; Fidalgo, Carlos; Bart, Pierre-Alexandre] Lausanne Univ Hosp, Serv Internal Med, Lausanne, Switzerland; [Le Pogam, Marie-Annick; Niemi, Tapio] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland; [Jaton, Katia] Lausanne Univ Hosp, Inst Microbiol, Lausanne, Switzerland; [Pagani, Jean-Luc] Lausanne Univ Hosp, Serv Intens Care, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Lhopitallier, L (corresponding author), Lausanne Univ Hosp, Infect Dis Serv, Lausanne, Switzerland.; Lhopitallier, L (corresponding author), Univ Lausanne, Lausanne, Switzerland.	loic.lhopitallier@chuv.ch	Le Pogam, Marie-Annick/AAU-5486-2020; Papadimitriou-Olivgeris, Matthaios/AAN-7206-2020; Pagani, Jean-Luc/AAY-3042-2020	Le Pogam, Marie-Annick/0000-0003-1672-3644; Papadimitriou-Olivgeris, Matthaios/0000-0003-0565-5105; Filippidis, Paraskevas/0000-0002-6784-7420; Kampouri, Eleftheria/0000-0001-8019-3073; Regina, Jean/0000-0003-2219-9834; Senn, Laurence/0000-0001-7198-1625; Desgranges, Florian/0000-0002-0409-1689				[Anonymous], 2012, Kidney Int Suppl (2011), V2, P163; [Anonymous], 2002, Bull World Health Organ, V80, P983; Bauer TT, 2006, J INTERN MED, V260, P93, DOI 10.1111/j.1365-2796.2006.01657.x; Chang SH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015966; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Gong J., 2020, MEDRXIV, DOI 10.1101/2020.03.17.20037515; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Hua J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03044-9; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Lagi F, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.17.2000556; Ling L, 2020, CRIT CARE RESUSC, V22, P119; Lu J., 2020, ACP RISK GRADE SIMPL, DOI [10.1101/2020.02.20.20025510, DOI 10.1101/2020.02.20.20025510]; Maitra S, 2018, CLIN MICROBIOL INFEC, V24, P1123, DOI 10.1016/j.cmi.2018.03.032; McGinley A, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5310; Papdimitriou-Olivgeris M, 2020, EUR J INTERN MED, V74, P86, DOI 10.1016/j.ejim.2019.12.022; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; van Smeden M, 2019, STAT METHODS MED RES, V28, P2455, DOI 10.1177/0962280218784726; World Health Organization (Who), 2020, SITUATION REPORT; Xu Zhe, 2020, Lancet Respir Med, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan L., 2020, EPIDEMIOLOGY, V27, P2002, DOI [10.1101/2020.02.27.20028027, DOI 10.1101/2020.02.27.20028027]; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	27	28	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2020	15	11							e0240781	10.1371/journal.pone.0240781	http://dx.doi.org/10.1371/journal.pone.0240781			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0NB	33186355	gold, Green Submitted, Green Published			2023-01-03	WOS:000593949800053
J	Doan, T; Worden, L; Hinterwirth, A; Arzika, AM; Maliki, R; Abdou, A; Zhong, LN; Chen, CD; Cook, C; Lebas, E; O'Brien, KS; Oldenburg, CE; Chow, ED; Porco, TC; Lipsitch, M; Keenan, JD; Lietman, TM				Thuy Doan; Worden, Lee; Hinterwirth, Armin; Arzika, Ahmed M.; Maliki, Ramatou; Abdou, Amza; Zhong, Lina; Chen, Cindi; Cook, Catherine; Lebas, Elodie; O'Brien, Kieran S.; Oldenburg, Catherine E.; Chow, Eric D.; Porco, Travis C.; Lipsitch, Marc; Keenan, Jeremy D.; Lietman, Thomas M.			Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD MORTALITY	BACKGROUND Mass distribution of azithromycin to preschool children twice yearly for 2 years has been shown to reduce childhood mortality in sub-Saharan Africa but at the cost of amplifying macrolide resistance. The effects on the gut resistome, a reservoir of antimicrobial resistance genes in the body, of twice-yearly administration of azithromycin for a longer period are unclear. METHODS We investigated the gut resistome of children after they received twice-yearly distributions of azithromycin for 4 years. In the Niger site of the MORDOR trial, we enrolled 30 villages in a concurrent trial in which they were randomly assigned to receive mass distribution of either azithromycin or placebo, offered to all children 1 to 59 months of age every 6 months for 4 years. Rectal swabs were collected at baseline, 36 months, and 48 months for analysis of the participants' gut resistome. The primary outcome was the ratio of macrolide-resistance determinants in the azithromycin group to those in the placebo group at 48 months. RESULTS Over the entire 48-month period, the mean (+/- SD) coverage was 86.6 +/- 12% in the villages that received placebo and 83.2 +/- 16.4% in the villages that received azithromycin. A total of 3232 samples were collected during the entire trial period; of the samples obtained at the 48-month monitoring visit, 546 samples from 15 villages that received placebo and 504 from 14 villages that received azithromycin were analyzed. Determinants of macrolide resistance were higher in the azithromycin group than in the placebo group: 7.4 times as high (95% confidence interval [CI], 4.0 to 16.7) at 36 months and 7.5 times as high (95% CI, 3.8 to 23.1) at 48 months. Continued mass azithromycin distributions also selected for determinants of non-macrolide resistance, including resistance to beta-lactam antibiotics, an antibiotic class prescribed frequently in this region of Africa. CONCLUSIONS Among villages assigned to receive mass distributions of azithromycin or placebo twice yearly for 4 years, antibiotic resistance was more common in the villages that received azithromycin than in those that received placebo. This trial showed that mass azithromycin distributions may propagate antibiotic resistance.	[Thuy Doan; Worden, Lee; Hinterwirth, Armin; Zhong, Lina; Chen, Cindi; Cook, Catherine; Lebas, Elodie; O'Brien, Kieran S.; Oldenburg, Catherine E.; Porco, Travis C.; Keenan, Jeremy D.; Lietman, Thomas M.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94158 USA; [Thuy Doan; Oldenburg, Catherine E.; Porco, Travis C.; Keenan, Jeremy D.; Lietman, Thomas M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94158 USA; [Oldenburg, Catherine E.; Porco, Travis C.; Lietman, Thomas M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94158 USA; [Chow, Eric D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Lietman, Thomas M.] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94158 USA; [Arzika, Ahmed M.; Maliki, Ramatou] Carter Ctr, Niamey, Niger; [Abdou, Amza] Minist Hlth, Niamey, Niger; [Abdou, Amza] Programme Natl Sante Oculaire, Niamey, Niger; [Lipsitch, Marc] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health	Doan, T (corresponding author), Univ Calif San Francisco, 490 Illinois St,Fl 2, San Francisco, CA 94158 USA.	thuy.doan@ucsf.edu			Bill and Melinda Gates Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02047981.	Arzika AM, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002835; Burstein R, 2019, NATURE, V574, P353, DOI 10.1038/s41586-019-1545-0; Carlet J, 2012, ANTIMICROB RESIST IN, V1, DOI 10.1186/2047-2994-1-11; Chang HH, 2015, MICROBIOL MOL BIOL R, V79, P101, DOI 10.1128/MMBR.00039-14; Doan T, 2019, NAT MED, V25, P1370, DOI 10.1038/s41591-019-0533-0; Doan T, 2019, NEW ENGL J MED, V380, P2271, DOI 10.1056/NEJMc1901535; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Emerson PM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005402; Ernst MD, 2004, STAT SCI, V19, P676, DOI 10.1214/088342304000000396; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Keenan JD, 2018, NEW ENGL J MED, V378, P1583, DOI [10.1056/NEJMoa1715474, 10.1056/nejmoa1715474]; Keenan JD, 2019, NEW ENGL J MED, V380, P2207, DOI 10.1056/NEJMoa1817213; Kim D, 2016, GENOME RES, V26, P1721, DOI 10.1101/gr.210641.116; Lakin SM, 2017, NUCLEIC ACIDS RES, V45, pD574, DOI 10.1093/nar/gkw1009; Lehtinen S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007763; Lietman TM, 2018, CLIN INFECT DIS, V66, pS275, DOI 10.1093/cid/ciy004; Lipsitch M, 2001, TRENDS MICROBIOL, V9, P438, DOI 10.1016/S0966-842X(01)02130-8; Lipsitch M, 2001, CLIN INFECT DIS, V32, P1044, DOI 10.1086/319604; Mack I, 2020, CLIN INFECT DIS, V70, P1501, DOI 10.1093/cid/ciz893; Murray DM, 1988, DESIGN ANAL GROUP RA; O'Brien KS, 2019, LANCET INFECT DIS, V19, pE14, DOI 10.1016/S1473-3099(18)30444-4; Pouwels KB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218134; Pouwels KB, 2018, J ANTIMICROB CHEMOTH, V73, P1700, DOI 10.1093/jac/dky031; Ray KJ, 2019, ANN EPIDEMIOL, V39, P63, DOI 10.1016/j.annepidem.2019.09.002; Rovira P, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01980; Sie A, 2019, AM J TROP MED HYG, V100, P1121, DOI 10.4269/ajtmh.18-0791; Taylor HR, 2014, LANCET, V384, P2142, DOI 10.1016/S0140-6736(13)62182-0; Doan T, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0344-6; van Schaik W, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0087; World Health Organization, 2019, WHO REL 2019 AWARE C; ZIV J, 1977, IEEE T INFORM THEORY, V23, P337, DOI 10.1109/TIT.1977.1055714	32	43	44	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	2020	383	20					1941	1950		10.1056/NEJMoa2002606	http://dx.doi.org/10.1056/NEJMoa2002606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OQ4VG	33176084	Green Accepted, Bronze			2023-01-03	WOS:000588782400011
J	Bischoff-Ferrari, HA; Vellas, B; Rizzoli, R; Kressig, RW; da Silva, JAP; Blauth, M; Felson, DT; McCloskey, EV; Watzl, B; Hofbauer, LC; Felsenberg, D; Willett, WC; Dawson-Hughes, B; Manson, JE; Siebert, U; Theiler, R; Staehelin, HB; Molino, CDRC; Chocano-Bedoya, PO; Abderhalden, LA; Egli, A; Kanis, JA; Orav, EJ				Bischoff-Ferrari, Heike A.; Vellas, Bruno; Rizzoli, Rene; Kressig, Reto W.; da Silva, Jose A. P.; Blauth, Michael; Felson, David T.; McCloskey, Eugene V.; Watzl, Bernhard; Hofbauer, Lorenz C.; Felsenberg, Dieter; Willett, Walter C.; Dawson-Hughes, Bess; Manson, JoAnn E.; Siebert, Uwe; Theiler, Robert; Staehelin, Hannes B.; de Godoi Rezende Costa Molino, Caroline; Chocano-Bedoya, Patricia O.; Abderhalden, Lauren A.; Egli, Andreas; Kanis, John A.; Orav, Endel J.		DO-Hlth Res Grp	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults The DO-HEALTH Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONTREAL COGNITIVE ASSESSMENT; LOWER-EXTREMITY FUNCTION; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; PHYSICAL-ACTIVITY; METAANALYSIS; PREVENTION; ASSOCIATION	This randomized trial compares the effects of vitamin D, omega-3s, and a strength-training exercise program alone or in combination vs no supplementation and control exercise on changes in blood pressure, physical and cognitive function, nonvertebral fractures, and infections over 3 years among older adults. Importance The benefits of vitamin D, omega-3 fatty acids, and exercise in disease prevention remain unclear. Objective To test whether vitamin D, omega-3s, and a strength-training exercise program, alone or in combination, improved 6 health outcomes among older adults. Design, Setting, and Participants Double-blind, placebo-controlled, 2 x 2 x 2 factorial randomized clinical trial among 2157 adults aged 70 years or older who had no major health events in the 5 years prior to enrollment and had sufficient mobility and good cognitive status. Patients were recruited between December 2012 and November 2014, and final follow-up was in November 2017. Interventions Participants were randomized to 3 years of intervention in 1 of the following 8 groups: 2000 IU/d of vitamin D-3, 1 g/d of omega-3s, and a strength-training exercise program (n = 264); vitamin D-3 and omega-3s (n = 265); vitamin D-3 and exercise (n = 275); vitamin D-3 alone (n = 272); omega-3s and exercise (n = 275); omega-3s alone (n = 269); exercise alone (n = 267); or placebo (n = 270). Main Outcomes and Measures The 6 primary outcomes were change in systolic and diastolic blood pressure (BP), Short Physical Performance Battery (SPPB), Montreal Cognitive Assessment (MoCA), and incidence rates (IRs) of nonvertebral fractures and infections over 3 years. Based on multiple comparisons of 6 primary end points, 99% confidence intervals are presented and P < .01 was required for statistical significance. Results Among 2157 randomized participants (mean age, 74.9 years; 61.7% women), 1900 (88%) completed the study. Median follow-up was 2.99 years. Overall, there were no statistically significant benefits of any intervention individually or in combination for the 6 end points at 3 years. For instance, the differences in mean change in systolic BP with vitamin D vs no vitamin D and with omega-3s vs no omega-3s were both -0.8 (99% CI, -2.1 to 0.5) mm Hg, with P < .13 and P < .11, respectively; the difference in mean change in diastolic BP with omega-3s vs no omega-3s was -0.5 (99% CI, -1.2 to 0.2) mm Hg; P = .06); and the difference in mean change in IR of infections with omega-3s vs no omega-3s was -0.13 (99% CI, -0.23 to -0.03), with an IR ratio of 0.89 (99% CI, 0.78-1.01; P = .02). No effects were found on the outcomes of SPPB, MoCA, and incidence of nonvertebral fractures). A total of 25 deaths were reported, with similar numbers in all treatment groups. Conclusions and Relevance Among adults without major comorbidities aged 70 years or older, treatment with vitamin D-3, omega-3s, or a strength-training exercise program did not result in statistically significant differences in improvement in systolic or diastolic blood pressure, nonvertebral fractures, physical performance, infection rates, or cognitive function. These findings do not support the effectiveness of these 3 interventions for these clinical outcomes. Question Do vitamin D, omega-3, and a strength-training exercise program alone or in combination prevent 6 health outcomes among relatively healthy adults aged 70 years or older? Findings In this randomized trial that included 2157 adults aged 70 years or older, 3-year treatment with vitamin D-3 (2000 IU/d), with omega-3 fatty acids (1 g/d), or with a strength-training exercise program did not result in statistically significant differences in improvement in systolic or diastolic blood pressure, nonvertebral fractures, physical performance, infection rate, or cognition. Meaning These findings do not support the use of vitamin D, omega-3, or a strength-training exercise program for these clinical outcomes among relatively healthy older adults.	[Bischoff-Ferrari, Heike A.; de Godoi Rezende Costa Molino, Caroline; Chocano-Bedoya, Patricia O.; Abderhalden, Lauren A.; Egli, Andreas] City Hosp Waid & Triemli, Univ Zurich Hosp, Ctr Aging & Mobil, Zurich, Switzerland; [Bischoff-Ferrari, Heike A.; Theiler, Robert; de Godoi Rezende Costa Molino, Caroline; Chocano-Bedoya, Patricia O.; Abderhalden, Lauren A.; Egli, Andreas] Univ Zurich, Zurich, Switzerland; [Bischoff-Ferrari, Heike A.; Theiler, Robert] Univ Hosp Zurich, Dept Geriatr Med & Aging Res, Zurich, Switzerland; [Bischoff-Ferrari, Heike A.] City Hosp Waid & Triemli, Univ Clin Acute Geriatr Care, Zurich, Switzerland; [Vellas, Bruno] Ctr Hosp Univ Toulouse, Inst Vieillissement, Gerontopole Toulouse, Toulouse, France; [Vellas, Bruno] Univ Toulouse III, UMR INSERM 1027, Toulouse, France; [Rizzoli, Rene] Geneva Univ Hosp & Fac Med, Div Bone Dis, Geneva, Switzerland; [Kressig, Reto W.] Univ Dept Geriatr Med Felix Platter, Basel, Switzerland; [Kressig, Reto W.] Univ Basel, Basel, Switzerland; [da Silva, Jose A. P.] Ctr Hosp Coimbra, Coimbra, Portugal; [da Silva, Jose A. P.] Univ Coimbra, Coimbra, Portugal; [da Silva, Jose A. P.] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal; [Blauth, Michael] Med Univ Innsbruck, Dept Trauma Surg, Innsbruck, Austria; [Felson, David T.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England; [Felson, David T.] Boston Univ, Sch Med, Rheumatol, Boston, MA 02118 USA; [McCloskey, Eugene V.] Univ Sheffield, MRC Arthrit Res UK Ctr Integrated Res Musculoskel, Sheffield, S Yorkshire, England; [McCloskey, Eugene V.] Univ Sheffield, Mellanby Ctr Bone Res, Dept Oncol & Metab, Acad Unit Bone Metab, Sheffield, S Yorkshire, England; [Watzl, Bernhard] Max Rubner Inst, Dept Physiol & Biochem Nutr, Karlsruhe, Germany; [Hofbauer, Lorenz C.] Dresden Univ, Med Ctr, Dept Med 3, Ctr Hlth Aging, Dresden, Germany; [Hofbauer, Lorenz C.] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany; [Felsenberg, Dieter] Charite Univ Med Berlin, Dept Radiol, Ctr Muscle & Bone Res, Berlin, Germany; [Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA; [Dawson-Hughes, Bess] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Manson, JoAnn E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria; [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA USA; [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, Program Cardiovasc Res, Boston, MA 02115 USA; [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA; [Staehelin, Hannes B.] Univ Basel, Dept Geriatr, Basel, Switzerland; [Kanis, John A.] Univ Sheffield, Sch Med, Ctr Metab Dis, Sheffield, S Yorkshire, England; [Kanis, John A.] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia; [Orav, Endel J.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA	Triemli Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University of Zurich; University Zurich Hospital; Triemli Hospital; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Geneva; University of Basel; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade de Coimbra; Medical University of Innsbruck; University of Manchester; Boston University; University of Sheffield; University of Sheffield; Technische Universitat Dresden; Technische Universitat Dresden; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University; United States Department of Agriculture (USDA); Harvard University; Brigham & Women's Hospital; Harvard Medical School; UMIT - Private University for Health Sciences, Medical Informatics & Technology GmbH; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Basel; University of Sheffield; Australian Catholic University; Harvard University; Harvard T.H. Chan School of Public Health	Bischoff-Ferrari, HA (corresponding author), Univ Hosp Zurich, Dept Geriatr Med & Aging Res, RAE B, Ramistr 100, CH-8091 Zurich, Switzerland.	heike.bischoff@usz.ch	de G. R. C. Molino, Caroline/J-9504-2015; Da Silva, Jose/K-9769-2018	de G. R. C. Molino, Caroline/0000-0001-6925-1201; Da Silva, Jose/0000-0002-2782-6780; Felson, David/0000-0002-2668-2447; Siebert, Uwe/0000-0001-6425-7671; Chocano-Bedoya, Patricia O./0000-0002-6980-3931	Medical Research Council [MR/P020941/1] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abu Mweis S, 2018, J HUM NUTR DIET, V31, P67, DOI 10.1111/jhn.12493; Ainsworth BE, COMPENDIUM PHYS ACTI; Aloia JF, 2019, J CLIN ENDOCR METAB, V104, P1441, DOI 10.1210/jc.2018-01418; Beveridge LA, 2015, JAMA INTERN MED, V175, P745, DOI 10.1001/jamainternmed.2015.0237; Bischoff-Ferrari HA, 2021, CONTEMP CLIN TRIALS, V100, DOI 10.1016/j.cct.2020.106124; Bischoff-Ferrari HA, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen-2018-000678; Bischoff-Ferrari HA, 2016, JAMA INTERN MED, V176, P175, DOI 10.1001/jamainternmed.2015.7148; Bischoff-Ferrari HA, 2012, NEW ENGL J MED, V367, P40, DOI 10.1056/NEJMoa1109617; Bischoff-Ferrari HA, 2010, ARCH INTERN MED, V170, P813, DOI 10.1001/archinternmed.2010.67; Bischoff-Ferrari HA, 2012, J BONE MINER RES, V27, P160, DOI 10.1002/jbmr.551; Chonchol M, 2008, NEPHROL DIAL TRANSPL, V23, P269, DOI 10.1093/ndt/gfm537; Del Gobbo LC, 2016, JAMA INTERN MED, V176, P1155, DOI 10.1001/jamainternmed.2016.2925; Givens DI, 2008, P NUTR SOC, V67, P273, DOI 10.1017/S0029665108007167; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Kalache A, 2003, Adv Gerontol, V11, P7; Krause R, 1998, LANCET, V352, P709, DOI 10.1016/S0140-6736(05)60827-6; Krishnan K, 2017, ASSESSMENT, V24, P772, DOI 10.1177/1073191116654217; Kwon S, 2009, J NUTR HEALTH AGING, V13, P538, DOI 10.1007/s12603-009-0104-z; Lassere MN, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-27; Li NN, 2014, CLIN NUTR, V33, P226, DOI 10.1016/j.clnu.2013.08.013; Li YC, 2004, J STEROID BIOCHEM, V89-90, P387, DOI 10.1016/j.jsbmb.2004.03.004; Lips P, 2019, EUR J ENDOCRINOL, V180, pP23, DOI 10.1530/EJE-18-0736; Llewellyn DJ, 2010, ARCH INTERN MED, V170, P1135, DOI 10.1001/archinternmed.2010.173; Luis CA, 2009, INT J GERIATR PSYCH, V24, P197, DOI 10.1002/gps.2101; Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]; Manson JE, 2019, NEW ENGL J MED, V380, P23, DOI 10.1056/NEJMoa1811403; Markwick A, 2012, J CLIN EXP NEUROPSYC, V34, P750, DOI 10.1080/13803395.2012.672966; Miller PE, 2014, AM J HYPERTENS, V27, P885, DOI 10.1093/ajh/hpu024; Mirhosseini N, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00087; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633; Pradelli L, 2012, CRIT CARE, V16, DOI 10.1186/cc11668; Sangha O, 2003, ARTHRIT RHEUM-ARTHR, V49, P156, DOI 10.1002/art.10993; Scragg RKR, 2019, J ENDOCRINOL INVEST, V42, P1391, DOI 10.1007/s40618-019-01056-z; Swart KMA, 2018, AM J CLIN NUTR, V107, P1043, DOI 10.1093/ajcn/nqy078; Uusi-Rasi K, 2015, JAMA INTERN MED, V175, P703, DOI 10.1001/jamainternmed.2015.0225; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; World Health Organization, 2015, AG HLTH; Zittermann A, 2006, PROG BIOPHYS MOL BIO, V92, P39, DOI 10.1016/j.pbiomolbio.2006.02.001	41	87	90	3	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2020	324	18					1855	1868		10.1001/jama.2020.16909	http://dx.doi.org/10.1001/jama.2020.16909			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB0RF	33170239	Bronze, Green Published			2023-01-03	WOS:000596034800017
J	Rattanathammethee, T; Tuitemwong, P; Thiennimitr, P; Sarichai, P; Pombejra, SN; Piriyakhuntorn, P; Hantrakool, S; Chai-Adisaksopha, C; Rattarittamrong, E; Tantiworawit, A; Norasetthada, L				Rattanathammethee, Thanawat; Tuitemwong, Pimchanok; Thiennimitr, Parameth; Sarichai, Phinitphong; Pombejra, Sarisa Na; Piriyakhuntorn, Pokpong; Hantrakool, Sasinee; Chai-Adisaksopha, Chatree; Rattarittamrong, Ekarat; Tantiworawit, Adisak; Norasetthada, Lalita			Gut microbiota profiles of treatment-naive adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy	PLOS ONE			English	Article							COLONIZATION; ANTIBIOTICS; DOMINATION; INFECTION; THERAPY	The intestinal bacterial flora of febrile neutropenic patients has been found to be significantly diverse. However, there are few reports of alterations of in adult acute myeloid leukemia (AML) patients. Stool samples of each treatment-naive AML patient were collected the day before initiation of induction chemotherapy (pretreatment), on the first date of neutropenic fever and first date of bone marrow recovery. Bacterial DNA was extracted from stool samples and bacterial 16s ribosomal RNA genes were sequenced by next-generation sequencing. Relative abundance, overall richness, Shannon's diversity index and Simpson's diversity index were calculated. No antimicrobial prophylaxis was in placed in all participants. Ten cases of AML patients (4 male and 6 female) were included with a median age of 39 years (range: 19-49) and all of patients developed febrile neutropenia. Firmicutes dominated during the period of neutropenic fever, subsequently declining after bone marrow recovery a pattern in contrast to that shown by Bacteroidetes and Proteobacteria. Enterococcus was more abundant in the febrile neutropenia period compared to pretreatment (mean difference +20.2; p < 0.0001) while Escherichia notably declined during the same period (mean difference -11.2; p = 0.0064). At the operational taxonomic unit (OTU) level, there was a significantly higher level of overall richness in the pretreatment period than in the febrile neutropenic episode (mean OTU of 203.1 vs. 131.7; p = 0.012). Both of the diversity indexes of Shannon and Simpson showed a significant decrease during the febrile neutropenic period. Adult AML patients with a first episode of febrile neutropenia after initial intensive chemotherapy demonstrated a significant decrease in gut microbiota diversity and the level of diversity remained constant despite recovery of bone marrow.	[Rattanathammethee, Thanawat; Piriyakhuntorn, Pokpong; Hantrakool, Sasinee; Chai-Adisaksopha, Chatree; Rattarittamrong, Ekarat; Tantiworawit, Adisak; Norasetthada, Lalita] Chiang Mai Univ, Fac Med, Dept Internal Med, Div Hematol, Chiang Mai, Thailand; [Tuitemwong, Pimchanok] Chiang Mai Univ, Fac Med, Dept Internal Med, Chiang Mai, Thailand; [Thiennimitr, Parameth; Sarichai, Phinitphong] Chiang Mai Univ, Fac Med, Dept Microbiol, Chiang Mai, Thailand; [Thiennimitr, Parameth] Chiang Mai Univ, Res Ctr Microbial Divers & Sustainable Utilizat, Chiang Mai, Thailand; [Pombejra, Sarisa Na] Chulalongkorn Univ, Fac Sci, Dept Microbiol, Bangkok, Thailand	Chiang Mai University; Chiang Mai University; Chiang Mai University; Chiang Mai University; Chulalongkorn University	Rattanathammethee, T (corresponding author), Chiang Mai Univ, Fac Med, Dept Internal Med, Div Hematol, Chiang Mai, Thailand.	thanawat_r@outlook.com	Piriyakhuntorn, Pokpong/ABC-1664-2021; Thiennimitr, Parameth/AAA-3854-2021	Piriyakhuntorn, Pokpong/0000-0001-9730-8260; Rattanathammethee, Thanawat/0000-0003-2731-4889; Sarichai, Phinitphong/0000-0003-2892-0522; Na Pombejra, Sarisa/0000-0002-5472-0674	faculty of Medicine, Chiang Mai University, Thailand [MED-2559-03947]	faculty of Medicine, Chiang Mai University, Thailand	TR received the research grant from faculty of Medicine, Chiang Mai University, Thailand. (study code: MED-2559-03947) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; [Anonymous], 2016, EVIDENCE, V8, pe1000; [Anonymous], 2015, NUCLEIC ACIDS RES, V43, pD204; [Anonymous], 2012, NUCLEIC ACIDS RES, V40, pD71; [Anonymous], 2009, EUROPEAN J ENDOVASCU, V37, pS1; [Anonymous], 2011, CLIN INFECT DIS S5, V52, pS397; [Anonymous], 2013, NUCLEIC ACIDS RES, V41, pD43; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bai L, 2017, J MED MICROBIOL, V66, P1297, DOI 10.1099/jmm.0.000568; Bow EJ, 1997, J CLIN ONCOL, V15, P2254, DOI 10.1200/JCO.1997.15.6.2254; Buffie CG, 2013, NAT REV IMMUNOL, V13, P790, DOI 10.1038/nri3535; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Deschasaux M, 2018, NAT MED, V24, P1526, DOI 10.1038/s41591-018-0160-1; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; EFSA (European Food Safety Authority), 2008, EFSA J, V6, p120r, DOI 10.2903/j.efsa.2008.120r; Galloway-Pena JR, 2016, CANCER-AM CANCER SOC, V122, P2186, DOI 10.1002/cncr.30039; Gaulke CA, 2018, NAT MED, V24, P1495, DOI 10.1038/s41591-018-0210-8; Hakim H, 2018, CLIN INFECT DIS, V67, P541, DOI 10.1093/cid/ciy153; He Y, 2018, NAT MED, V24, P1532, DOI 10.1038/s41591-018-0164-x; Holler E, 2014, BIOL BLOOD MARROW TR, V20, P640, DOI 10.1016/j.bbmt.2014.01.030; James V. A., 2004, BEDE ROLL FRATERNITY, V39, pxiii; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Khalil F, 2007, ARCH PATHOL LAB MED, V131, P1281; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Montassier E, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0301-4; Nearing JT, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00028; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rashidi A, 2020, CANCER-AM CANCER SOC, V126, P1434, DOI 10.1002/cncr.32641; Ribosomal Database Project, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI [10.1093/nar/gkt124424288368, DOI 10.1093/NAR/GKT124424288368]; Schneider SM, 2000, EUR J NUTR, V39, P248, DOI 10.1007/s003940070003; Schwabkey ZI, 2020, ANNU REV MED, V71, P137, DOI 10.1146/annurev-med-052918-122440; Shannon CE, 1997, M D COMPUT, V14, P306; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038/163688a0; Song YJ, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-019-0693-7; Taur Y, 2012, CLIN INFECT DIS, V55, P905, DOI 10.1093/cid/cis580; The Lancet Global Health, 2016, LANCET GLOB HEALTH, V4, pe427; Ubeda C, 2010, J CLIN INVEST, V120, P4332, DOI 10.1172/JCI43918; van der Velden WJFM, 2014, BRIT J HAEMATOL, V167, P441, DOI 10.1111/bjh.13113; van Vliet MJ, 2009, CLIN INFECT DIS, V49, P262, DOI 10.1086/599346; Weber D, 2019, CLIN INFECT DIS, V68, P1303, DOI 10.1093/cid/ciy711; Wingett Steven W, 2018, F1000Res, V7, P1338, DOI 10.12688/f1000research.15931.2; 2006, APPL ENV MICROBIOL, V72, P5069	44	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2020	15	10							e0236460	10.1371/journal.pone.0236460	http://dx.doi.org/10.1371/journal.pone.0236460			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8XL	33112882	Green Published, gold, Green Submitted			2023-01-03	WOS:000588374000029
J	Cao, Y; Zheng, YX; Niu, JB; Zhu, CM; Yang, DC; Rong, F; Liu, GP				Cao, Yang; Zheng, Yixin; Niu, Jingbin; Zhu, Chunmei; Yang, Decai; Rong, Fen; Liu, Guoping			Efficacy of Banxia Xiexin decoction for chronic atrophic gastritis: A systematic review and meta-analysis	PLOS ONE			English	Review								Background Banxia Xiexin decoction (BXD), a classical formula of traditional Chinese medicine (TCM), has been wildly used for chronic atrophic gastritis (CAG) patients with the cold-heat complex syndrome in China, and achieved satisfied effects. However, the clinical effects of it remains unclear. Purpose The purpose of this article is to evaluate the clinical efficacy and safety of BXD for CAG treatment. Methods We searched seven electronic databases including Ovid, Embase, PubMed, Cochrane Library, Wan-fang database, VIP (Chinese Scientific Journals Database) and CNKI (China National Knowledge Infrastructure) from their inception to September 21, 2020. We used Jadad scale and Cochrane Collaboration's risk of bias tool to make evaluation of methodological quality. Revman 5.3 statistical software was used for statistical processing to evaluate the clinical efficacy and safety of BXD. Results 26 randomized controlled trials (RCTs) totaling 1985 patients were identified for analysis. Meta-analysis showed that BXD treatment was more effective (RR 1.29; 95%CI 1.24, 1.35; P<0.00001) and safe (MD 0.33; 95%CI 0.18, 0.58; P = 0.0002) than Chinese patent medicine + western medicine. Furthermore, BXD had improvement on symptoms scores such as stomach distending pain, and belching. Besides, BXD was more effective in inhibiting Helicobacter Pylori (HP), improving HP-related inflammation, and relieving the degree of glandular atrophy, intestinal metaplasia (IM), and dysplasia of gastric mucosa (GM). Conclusions The meta-analysis showed that BXD was more effective and safer for CAG patients than the control group. However, due to limitations of methodological quality and small sample size of the included studies, further standardized research of rigorous design should be needed.	[Cao, Yang; Zheng, Yixin; Niu, Jingbin; Zhu, Chunmei; Yang, Decai; Liu, Guoping] Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Shanghai, Peoples R China; [Rong, Fen] Shanghai Univ Tradit Chinese Med, Sch Publ Hlth, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine	Liu, GP (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Shanghai, Peoples R China.; Rong, F (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Publ Hlth, Shanghai, Peoples R China.	rf97328@163.com; 13564133729@163.com			National Natural Science Foundation of China [81873236, 81270050]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Guoping Liu is supported by National Natural Science Foundation of China, No. 81873236, 81270050. http://www.nsfc.gov.cn.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamu MA, 2010, EUR J EPIDEMIOL, V25, P439, DOI 10.1007/s10654-010-9482-0; [Anonymous], 2016, PATRIMOINESS MELANGE, P155; [Anonymous], 2012, QUADERNI MAT, V5, P161; [Anonymous], 2017, REV PRESCRIRE, V37, P507; [Anonymous], 2016, PROPTER NOS, V1, P62; Aoki K, 2005, ANN EPIDEMIOL, V15, P598, DOI 10.1016/j.annepidem.2004.11.002; Bai Y, 2019, J TRADIT CHIN MED, V39, P867; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cui G N, 2019, J LIAO NING U TCM, V21, P87; Dai YK, 2017, PLOS ONE, V127, P2017, DOI [10.1371/journal.pone.0181906, DOI 10.1371/J0URNAL.P0NE.0181906]; Dinis-Ribeiro M, 2012, ENDOSCOPY, V44, P74, DOI 10.1055/s-0031-1291491; Dong H J, 2017, HAINAN MED, V28, P566; Fang Wen-Jie, 2017, Afr J Tradit Complement Altern Med, V14, P297, DOI 10.21010/ajtcam.v14i4.33; Gao Z J, 2019, J SICHUAN TRADITIONA, V37, P212; Graham DY, 2010, GUT, V59, P1143, DOI 10.1136/gut.2009.192757; Han J J, 2016, CLIN RES PRACTICE, V1, P136; Hou S J, 2016, WORLD LATEST MED INF, V16, P110; Hu C N, 2017, J CLIN MED, V4, P18171; [胡诚毅 Hu Chengyi], 2017, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V23, P213; Hui C M, 2019, J JILIN MED U, V40, P218; Katai H, 2018, GASTRIC CANCER, V21, P144, DOI 10.1007/s10120-017-0716-7; Ke X, 2013, J PRACTICAL TRADITIO, V27, P128; Kong YJ, 2014, WORLD J GASTROENTERO, V20, P5903, DOI 10.3748/wjg.v20.i19.5903; Li Y H, 2016, J NEW CHINESE MED, V48, P68; Li Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017003; Ling J S, 2018, SHANXI J TCM, V34, P10; Liu H, 2014, THESIS; Liu M X, 2018, CJGMCM, V33, P3520; Ma JZ, 2018, CHIN J INTEGR TRADIT, V38, P888; Ma L Y, 2019, WORLD LATEST MED INF, V19, P134; Park Yo Han, 2015, J Cancer Prev, V20, P25, DOI 10.15430/JCP.2015.20.1.25; Pei Y F, 2018, CJGMCM, V33, P1217; Peoples Columba, 2013, SPACE POLICY, V29, P135; Perna S, 2018, CLIN PHARMACOL-ADV A, V10, P141, DOI 10.2147/CPAA.S164785; Pimentel-Nunes P, 2019, ENDOSCOPY, V51, P365, DOI 10.1055/a-0859-1883; Qi X., 2018, SHANDONG CHEM IND, V47, P41, DOI [10.3969/j.issn.1008-021X.2018.14.015, DOI 10.3969/J.ISSN.1008-021X.2018.14.015]; Qiu S J, 2015, CLIN MED ENG, V21, P9; Ren H N, 2016, HUNAN J TRADITIONAL, V32, P161; Tan J J, 2018, HUNAN J TRADITIONAL, V34, P64; Wang G, 2012, THESIS; Wang N N, 2019, CONT MED S, V17, P180; Wang Q H, 2011, CLIN MED ENG, V18, P1146; Wang R, 2016, INT J EMBED SYST, V8, P146, DOI 10.1504/IJES.2016.076108; Wang Y W, 2020, SHAANXI J TRADITIONA, V41, P499; Wen L, 2017, CHINA HLTH STANDARD, V8, P102; Wu Y Z, 2013, J PRACTICAL TRADITIO, V27, P41; Xu P., 2017, ELECT J CLIN MED LIT, V4, P5333; Xu S, 2010, CLIN J TRADITIONAL C, V22, P495; Yang J, 2014, BIOTECHNOL ADV, V32, P804, DOI 10.1016/j.biotechadv.2013.11.004; Yang T, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117456; Yang W T, 2013, CLIN J CHINESE MED, V5, P67; Yang Z Q, 2016, CHINA HEATH STANDARD, V7, P128; Ying Y, 2015, J NEW CHINESE MED, V47, P76; Yu J Z, 2015, HE NAN TRADITIONAL C, V35, P2611; Yu X., 2019, GINSENG RES, V31, P47, DOI [10.19403/j.cnki.1671-1521.2019.01.012, DOI 10.19403/J.CNKI.1671-1521.2019.01.012]; Yuan C Y, 2013, LIAONING J TRADITION, V11, P1583; Zheng J, 2014, THESIS; Zhong P, 2016, CHINESE J ETHNOMEDIC, V25, P83; Zuo J, 2019, J LIAONING U TRADITI, V21, P26, DOI DOI 10.13194/J.ISSN.1673-842X.2019.09.007; 2013, ANCIENT NEAR E MONOG, V5, P14	60	6	6	7	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0241202	10.1371/journal.pone.0241202	http://dx.doi.org/10.1371/journal.pone.0241202			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8WV	33108375	gold, Green Published			2023-01-03	WOS:000588372400008
J	Barnes, CO; Jette, CA; Abernathy, ME; Dam, KMA; Esswein, SR; Gristick, HB; Malyutin, AG; Sharaf, NG; Huey-Tubman, KE; Lee, YE; Robbiani, DF; Nussenzweig, MC; West, AP; Bjorkman, PJ				Barnes, Christopher O.; Jette, Claudia A.; Abernathy, Morgan E.; Dam, Kim-Marie A.; Esswein, Shannon R.; Gristick, Harry B.; Malyutin, Andrey G.; Sharaf, Naima G.; Huey-Tubman, Kathryn E.; Lee, Yu E.; Robbiani, Davide F.; Nussenzweig, Michel C.; West, Anthony P., Jr.; Bjorkman, Pamela J.			SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies	NATURE			English	Article							CRYO-EM STRUCTURE; SPIKE; REVEALS	Eight structures of human neutralizing antibodies that target the SARS-CoV-2 spike receptor-binding domain are reported and classified into four categories, suggesting combinations for clinical use. The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein(1-5) show promise therapeutically and are being evaluated clinically(6-8). Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies(5) in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs(9). Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.	[Barnes, Christopher O.; Jette, Claudia A.; Abernathy, Morgan E.; Dam, Kim-Marie A.; Esswein, Shannon R.; Gristick, Harry B.; Huey-Tubman, Kathryn E.; Lee, Yu E.; West, Anthony P., Jr.; Bjorkman, Pamela J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA; [Malyutin, Andrey G.] CALTECH, Beckman Inst, Pasadena, CA 91125 USA; [Sharaf, Naima G.] CALTECH, Div Chem & Chem Engn, Pasadena, CA USA; [Robbiani, Davide F.; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Nussenzweig, Michel C.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Robbiani, Davide F.] Univ Svizzera Italiana, Inst Res Biomed, Bellinzona, Switzerland	California Institute of Technology; California Institute of Technology; California Institute of Technology; Rockefeller University; Howard Hughes Medical Institute; Universita della Svizzera Italiana	Bjorkman, PJ (corresponding author), CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA.	bjorkman@caltech.edu		Robbiani, Davide F./0000-0001-7379-3484; Malyutin, Andrey/0000-0003-1716-5437; Esswein, Shannon/0000-0002-5142-0190; Dam, Kim-Marie/0000-0002-1416-4757; Sharaf, Naima/0000-0002-3662-9228	US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-c76SF00515]; DOE Office of Biological and Environmental Research; National Institutes of Health, National Institute of General Medical Sciences [P41GM103393]; NIH [P01-AI138938-S1, P50 8 P50 AI150464-13]; Caltech Merkin Institute for Translational Research; George Mason University Fast Grant; Hanna Gray Fellowship Program from the Howard Hughes Medical Institute; Postdoctoral Enrichment Program from the Burroughs Wellcome Fund	US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); DOE Office of Biological and Environmental Research(United States Department of Energy (DOE)); National Institutes of Health, National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Caltech Merkin Institute for Translational Research; George Mason University Fast Grant; Hanna Gray Fellowship Program from the Howard Hughes Medical Institute; Postdoctoral Enrichment Program from the Burroughs Wellcome Fund	We thank J. Vielmetter, P. Hoffman, and the Protein Expression Center in the Beckman Institute at Caltech for expression assistance, J. Vielmetter and J. Keeffe for setting up automated polyreactivity assays, J. Keeffe for construct design, and N. Koranda for help with cloning and protein purification. Electron microscopy was performed in the Caltech Beckman Institute Resource Center for Transmission Electron Microscopy with assistance from S. Chen. We thank the Gordon and Betty Moore and Beckman Foundations for gifts to Caltech to support the Molecular Observatory (J. Kaiser, director), and S. Russi, A. Cohen and C. Smith and the beamline staff at SSRL for data collection assistance. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences under contract no. DE-AC02-c76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. This work was supported by NIH grant P01-AI138938-S1 (P.J.B. and M.C.N.), the Caltech Merkin Institute for Translational Research (P.J.B.), NIH grant P50 8 P50 AI150464-13 (P.J.B.), and a George Mason University Fast Grant (P.J.B.). C.O.B was supported by the Hanna Gray Fellowship Program from the Howard Hughes Medical Institute and the Postdoctoral Enrichment Program from the Burroughs Wellcome Fund. M.C.N. is a Howard Hughes Medical Institute Investigator.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Atwal G.S., 2020, REGN COV2 ANTIBODY C, DOI 10.1101/2020.08.02.233320; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Beilsten-Edmands J, 2020, ACTA CRYSTALLOGR D, V76, P385, DOI 10.1107/S2059798320003198; Bell JM, 2016, METHODS, V100, P25, DOI 10.1016/j.ymeth.2016.02.018; Briney B, 2019, NATURE, V566, P393, DOI 10.1038/s41586-019-0879-y; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Bunkoczi G, 2011, ACTA CRYSTALLOGR D, V67, P303, DOI 10.1107/S0907444910051218; Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Davis MI, 2005, P NATL ACAD SCI USA, V102, P5981, DOI 10.1073/pnas.0502101102; Dunbar J, 2014, NUCLEIC ACIDS RES, V42, pD1140, DOI 10.1093/nar/gkt1043; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Gristick HB, 2016, NAT STRUCT MOL BIOL, V23, P906, DOI 10.1038/nsmb.3291; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Hurlburt Nicholas K, 2020, bioRxiv, DOI [10.1038/s41467-020-19231-9, 10.1101/2020.06.12.148692]; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Kreye Jakob, 2020, bioRxiv, DOI 10.1101/2020.08.15.252320; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Lefranc MP, 2015, NUCLEIC ACIDS RES, V43, pD413, DOI 10.1093/nar/gku1056; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230; Liu Hejun, 2020, Immunity, V53, P1272, DOI [10.1101/2020.08.02.233536, 10.1016/j.immuni.2020.10.023]; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Marillet S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00034; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; NIH, 2020, CLIN TRIALS MON ANT; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Scharf L, 2015, CELL, V162, P1379, DOI 10.1016/j.cell.2015.08.035; Schoofs T, 2019, IMMUNITY, V50, P1513, DOI 10.1016/j.immuni.2019.04.014; Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Terwilliger TC, 2018, NAT METHODS, V15, P905, DOI 10.1038/s41592-018-0173-1; US National Library of Medicine, 2020, STUD LY3819253 LY CO; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988; Wang Bei, 2020, bioRxiv, DOI 10.1101/2020.07.14.203414; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701; Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu F., 2020, MEDRXIV, DOI 10.1101/2020.03.30.20047365; Wu NC, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108274; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yuan M, 2020, SCIENCE, V369, P1119, DOI 10.1126/science.abd2321; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092; Zhou DM, 2020, NAT STRUCT MOL BIOL, V27, P950, DOI 10.1038/s41594-020-0480-y; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6; Zost SJ, 2020, NAT MED, V26, DOI [10.1101/2020.05.12.091462, 10.1038/s41591-020-0998-x]	70	614	635	24	108	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 24	2020	588	7839					682	+		10.1038/s41586-020-2852-1	http://dx.doi.org/10.1038/s41586-020-2852-1		OCT 2020	22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8KJ	33045718	Bronze, Green Accepted			2023-01-03	WOS:000595450700001
J	Zimmerman, A; Fox, S; Griffin, RD; Nelp, T; Thomaz, EBAF; Mvungi, M; Mmbaga, BT; Sakita, F; Gerardo, CJ; Vissoci, JRN; Staton, CA				Zimmerman, Armand; Fox, Samara; Griffin, Randi; Nelp, Taylor; Thomaz, Erika Barbara Abreu Fonseca; Mvungi, Mark; Mmbaga, Blandina T.; Sakita, Francis; Gerardo, Charles J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.			An analysis of emergency care delays experienced by traumatic brain injury patients presenting to a regional referral hospital in a low-income country	PLOS ONE			English	Article							ADJUSTED LIFE YEARS; TRIAGE SCORE SATS; GLOBAL BURDEN; OUTCOMES; EPIDEMIOLOGY; DISABILITY; QUALITY; SYSTEMS; AFRICA; TIME	Background Trauma is a leading cause of death and disability worldwide. In low- and middle-income countries (LMICs), trauma patients have a higher risk of experiencing delays to care due to limited hospital resources and difficulties in reaching a health facility. Reducing delays to care is an effective method for improving trauma outcomes. However, few studies have investigated the variety of care delays experienced by trauma patients in LMICs. The objective of this study was to describe the prevalence of pre- and in-hospital delays to care, and their association with poor outcomes among trauma patients in a low-income setting. Methods We used a prospective traumatic brain injury (TBI) registry from Kilimanjaro Christian Medical Center in Moshi, Tanzania to model nine unique delays to care. Multiple regression was used to identify delays significantly associated with poor in-hospital outcomes. Results Our analysis included 3209 TBI patients. The most common delay from injury occurrence to hospital arrival was 1.1 to 4.0 hours (31.9%). Most patients were evaluated by a physician within 15.0 minutes of arrival (69.2%). Nearly all severely injured patients needed and did not receive a brain computed tomography scan (95.0%). A majority of severely injured patients needed and did not receive oxygen (80.8%). Predictors of a poor outcome included delays to lab tests, fluids, oxygen, and non-TBI surgery. Conclusions Time to care data is informative, easy to collect, and available in any setting. Our time to care data revealed significant constraints to non-personnel related hospital resources. Severely injured patients with the greatest need for care lacked access to medical imaging, oxygen, and surgery. Insights from our study and future studies will help optimize resource allocation in low-income hospitals thereby reducing delays to care and improving trauma outcomes in LMICs.	[Zimmerman, Armand; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA; [Fox, Samara] Yale Sch Med, New Haven, CT USA; [Griffin, Randi] Duke Univ, Dept Evolutionary Anthropol, Durham, NC USA; [Nelp, Taylor; Gerardo, Charles J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC 27710 USA; [Thomaz, Erika Barbara Abreu Fonseca] Univ Fed Maranhao, Sao Luis, Maranhao, Brazil; [Mvungi, Mark; Mmbaga, Blandina T.; Sakita, Francis] Kilimanjaro Christian Med Ctr, Moshi, Tanzania; [Mmbaga, Blandina T.] Kilimanjaro Clin Res Inst, Moshi, Tanzania; [Mmbaga, Blandina T.; Sakita, Francis] Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania	Duke University; Yale University; Duke University; Duke University; Universidade Federal do Maranhao; Kilimanjaro Christian Medical Centre	Staton, CA (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27708 USA.; Staton, CA (corresponding author), Duke Univ, Med Ctr, Dept Surg, Div Emergency Med, Durham, NC 27710 USA.	catherine.staton@duke.edu	THOMAZ, ERIKA/AAU-7752-2021; Mmbaga, Blandina Theophil/AAR-8707-2021; THOMAZ, ERIKA/AAU-7762-2021	THOMAZ, ERIKA/0000-0003-4156-4067; Mmbaga, Blandina Theophil/0000-0002-5550-1916; Sakita, Francis/0000-0001-5879-6564; Zimmerman, Armand/0000-0002-1216-581X; Staton, Catherine/0000-0002-6468-2894	KCMC MEPI [T84HA21123-02]; U.S. National Institutes of Health; Duke Division of Emergency Medicine; NSF Graduate Research Fellowship; e Fogarty International Center [K01 TW010000-01A1]	KCMC MEPI; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Duke Division of Emergency Medicine; NSF Graduate Research Fellowship(National Science Foundation (NSF)); e Fogarty International Center	This project was made possible by the Mentored Research Training Program in collaboration with the HRSA-funded KCMC MEPI grant #T84HA21123-02; U.S. National Institutes of Health and the Duke Division of Emergency Medicine. Randi Griffin would like to cknowledge support from the NSF Graduate Research Fellowship. Dr. Staton would like to acknowledge salary support funding from the Fogarty International Center (Staton, dK01 TW010000-01A1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelgadir J, 2017, WORLD NEUROSURG, V102, P526, DOI 10.1016/j.wneu.2017.03.019; Alibhai A, 2019, AFR J EMERG MED, V9, pS38, DOI 10.1016/j.afjem.2019.01.004; Amu H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201833; [Anonymous], 2014, INJURIES AND VIOLENC; Anonymous, 2012, MMWR-MORBID MORTAL W, V59, P1, DOI DOI 10.3791/3636; [Anonymous], 2015, HAINAN TODAY; [Anonymous], 2017, HEART LUNG CIRC, V26, pe125; Baker T, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-140; Beavogui Kezely, 2015, J Vasc Interv Neurol, V8, P30; Berg LM, 2019, ANN EMERG MED, V74, P345, DOI 10.1016/j.annemergmed.2019.04.012; Bruijns SR, 2008, EMERG MED J, V25, P398, DOI 10.1136/emj.2007.051177; Carney N, GUIDELINES MANAGEMEN, P244; Carter EJ, 2014, J NURS SCHOLARSHIP, V46, P106, DOI 10.1111/jnu.12055; Casalino E, 2013, EMERG MED J, V30, P638, DOI 10.1136/emermed-2012-201404; Cavallaro FL, 2013, ACTA OBSTET GYN SCAN, V92, P496, DOI 10.1111/aogs.12071; Dalwai MK, 2014, SAMJ S AFR MED J, V104, P372, DOI [10.7196/SAMJ.7604, 10.7196/samj.7604]; Dalwai M, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000160; de Andrade L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103577; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352; Diamond MB, 2018, INJURY PREV, V24, P272, DOI 10.1136/injuryprev-2016-042254; Eaton J, 2017, WORLD NEUROSURG, V108, P650, DOI 10.1016/j.wneu.2017.09.084; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Gottschalk SB, 2006, EMERG MED J, V23, P149, DOI 10.1136/emj.2005.028332; Groenland CN, 2019, CRIT CARE MED, V47, P1564, DOI 10.1097/CCM.0000000000003957; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Haglund MM, 2019, J NEUROSURG, V131, P993, DOI 10.3171/2019.4.JNS181747; Hansmann A, 2017, AFR J EMERG MED, V7, pS10, DOI 10.1016/j.afjem.2017.10.001; Hashmi ZG, 2013, J TRAUMA ACUTE CARE, V75, P60, DOI 10.1097/TA.0b013e31829880a0; Horwitz LI, 2010, ANN EMERG MED, V55, P133, DOI 10.1016/j.annemergmed.2009.07.023; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson KD, 2011, ADV EMERG NURS J, V33, P39, DOI 10.1097/TME.0b013e318207e86a; Kawooya MG, 2012, J CLIN IMAG SCI, V2, DOI 10.4103/2156-7514.97747; Kawooya MG, 2011, J CLIN IMAG SCI, V1, DOI 10.4103/2156-7514.90035; Khan BA, 2016, J PAK MED ASSOC, V66, P509; Kobusingye OC, 2005, B WORLD HEALTH ORGAN, V83, P626; Krebs E, 2017, WORLD NEUROSURG, V102, P571, DOI 10.1016/j.wneu.2017.03.001; London JA, 2001, J TRAUMA, V51, P747, DOI 10.1097/00005373-200110000-00021; Maier D, 2014, WORLD NEUROSURG, V81, P478, DOI 10.1016/j.wneu.2013.08.014; McKenna P, 2019, CLIN EXP EMERG MED, V6, P189, DOI 10.15441/ceem.18.022; McQueen K, 2016, WORLD J SURG, V40, P249, DOI 10.1007/s00268-015-3284-1; Mock C., 2004, GUIDELINES ESSENTIAL; Morley C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203316; Mould-Millman NK, 2017, PREHOSP DISASTER MED, V32, P273, DOI 10.1017/S1049023X17000061; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Ngoya PS, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.2016.25.99.9736; Nielsen K, 2012, PREHOSP EMERG CARE, V16, P381, DOI 10.3109/10903127.2012.664245; Obermeyer Z, 2015, B WORLD HEALTH ORGAN, V93, P577, DOI 10.2471/BLT.14.148338; Ormond DR, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18239; Rocha TAH, 2020, J NEUROSURG, V132, P1961, DOI 10.3171/2019.2.JNS182098; Rominski S, 2014, AFR J EMERG MED, V4, P71, DOI 10.1016/j.afjem.2013.11.001; Rosedale K, 2011, SAMJ S AFR MED J, V101, P537; Rosseau G, 2020, J NEUROSURG, V132, P1256, DOI 10.3171/2019.11.JNS191823; Sasser SM, 2006, B WORLD HEALTH ORGAN, V84, P507, DOI 10.2471/BLT.06.033605; Schuur JD, 2013, HEALTH AFFAIR, V32, P2129, DOI 10.1377/hlthaff.2013.0730; Singer AJ, 2011, ACAD EMERG MED, V18, P1324, DOI 10.1111/j.1553-2712.2011.01236.x; Smart LR, 2017, WORLD NEUROSURG, V105, P238, DOI 10.1016/j.wneu.2017.05.101; Staton CA, 2017, INT J INJ CONTROL SA, V24, P69, DOI 10.1080/17457300.2015.1061562; Sunyoto T, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0531-3; Twomey M, 2012, EMERG MED J, V29, P650, DOI 10.1136/emermed-2011-200503; Wangara AA, 2019, INT J EMERG MED, V12, DOI 10.1186/s12245-019-0221-3; Wllper AP, 2008, HEALTH AFFAIR, V27, pW84, DOI 10.1377/hlthaff.27.2.w84; Wong JC, 2016, EUR J NEUROL, V23, P382, DOI 10.1111/ene.12877; Yeboah D, 2014, WORLD J SURG, V38, P1707, DOI 10.1007/s00268-014-2452-z	64	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2020	15	10							e0240528	10.1371/journal.pone.0240528	http://dx.doi.org/10.1371/journal.pone.0240528			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3TU	33045030	Green Published, gold			2023-01-03	WOS:000581811700044
J	Boubakri, A; Leri, M; Bucciantini, M; Najjaa, H; Ben Arfa, A; Stefani, M; Neffati, M				Boubakri, Abdelbasset; Leri, Manuela; Bucciantini, Monica; Najjaa, Hanen; Ben Arfa, Abdelkarim; Stefani, Massimo; Neffati, Mohamed			Allium roseumL. extract inhibits amyloid beta aggregation and toxicity involved in Alzheimer's disease	PLOS ONE			English	Article							ANTIMICROBIAL ACTIVITIES; GM1 GANGLIOSIDE; ANTIOXIDANT; OLIGOMERS; KAEMPFEROL	Allium roseumis an important medicinal and aromatic plant, specific to the North African flora and a rich source of important nutrients and bioactive molecules including flavonoids and organosulfur compounds whose biological activities and pharmacological properties are well known. In the present study, the inhibition of amyloid beta protein toxicity by the ethanolic extract of this plant is investigated for the first time. Preliminary biochemical analyses identified k AE mpferol and luteolin-7-o-glucoside as the more abundant phenolic compounds. The effects ofA.roseumextract (ARE) on aggregation and aggregate cytotoxicity of amyloid beta-42 (A beta(42)), whose brain aggregates are a hallmark of Alzheimer's disease, were investigated by biophysical (ThT assay, Dynamic light scattering and transmission electron microscopy) and cellular assays (cytotoxicity, aggregate immunolocalization, ROS measurement and intracellular Ca(2+)imaging). The biophysical data suggest that ARE affects the structure of the A beta(42)peptide, inhibits its polymerization, and interferes with the path of fibrillogenesis. The data with cultured cells shows that ARE reduces Ass(42)aggregate toxicity by inhibiting aggregate binding to the cell membrane and by decreasing both oxidative stress and intracellular Ca2+. Accordingly, ARE could act as a neuroprotective factor against A beta aggregate toxicity in Alzheimer's disease.	[Boubakri, Abdelbasset; Najjaa, Hanen; Ben Arfa, Abdelkarim; Neffati, Mohamed] Inst Reg Arides, Lab Ecosyst Pastoraux & Valorisat Plantes Spontan, Medenine, Tunisia; [Boubakri, Abdelbasset] Univ Gabes, Dept Biol, Fac Sci, Cite Erriadh, Zrig Gabes, Tunisia; [Leri, Manuela; Bucciantini, Monica; Stefani, Massimo] Univ Florence, Dept Clin & Expt Biomed Sci Mario Serio, Viale Morgagni, Florence, Italy; [Leri, Manuela] Univ Florence, Dept Neurosci, Psychol, Area Med & Hlth Child, Viale Pieraccini, Florence, Italy	Institut des Regions Arides; Universite de Gabes; University of Florence; University of Florence	Bucciantini, M (corresponding author), Univ Florence, Dept Clin & Expt Biomed Sci Mario Serio, Viale Morgagni, Florence, Italy.	monica.bucciantini@unifi.it	Boubakri, Abdelbasset/AAY-8784-2020	Boubakri, Abdelbasset/0000-0001-8755-8362; Leri, Manuela/0000-0002-3785-0805	Tunisian Ministry of Higher Education and Scientific Research; ANCC-COOP/Airalzh ONLUS through the University of Florence [0043966.30-10-359, D.R.595/2016]	Tunisian Ministry of Higher Education and Scientific Research; ANCC-COOP/Airalzh ONLUS through the University of Florence	The first author, Abdelbasset Boubakri, had a fellowship accorded by the Tunisian Ministry of Higher Education and Scientific Research. The latter had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Manuela Leri was supported by ANCC-COOP/Airalzh ONLUS (Reg. n. 0043966.30-10-359 2014) through the University of Florence (D.R.595/2016).	Akaishi T, 2008, NEUROSCI LETT, V444, P280, DOI 10.1016/j.neulet.2008.08.052; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; Bahaeddin Z, 2018, APPL PHYSIOL NUTR ME, V43, P558, DOI 10.1139/apnm-2017-0585; Beg T, 2018, CNS NEUROL DISORD-DR, V17, P421, DOI 10.2174/1871527317666180508123050; Birasuren Bayarmaa, 2013, Prev Nutr Food Sci, V18, P188, DOI 10.3746/pnf.2013.18.3.188; Calamai M, 2013, FEBS LETT, V587, P1385, DOI 10.1016/j.febslet.2013.03.014; Churches QI, 2014, BIOORG MED CHEM LETT, V24, P3108, DOI 10.1016/j.bmcl.2014.05.008; Cuenod A, 1954, FLORE ANAL SYNOPTIQU; De Strooper B, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006304; Demuro A, 2013, J NEUROSCI, V33, P3824, DOI 10.1523/JNEUROSCI.4367-12.2013; Dewanto V, 2002, J AGR FOOD CHEM, V50, P3010, DOI 10.1021/jf0115589; Dhouafli Z, 2018, IND CROP PROD, V111, P823, DOI 10.1016/j.indcrop.2017.11.045; Dutra Rafael C, 2016, Pharmacol Res, V112, P4, DOI 10.1016/j.phrs.2016.01.021; Dziri S, 2012, J FUNCT FOODS, V4, P423, DOI 10.1016/j.jff.2012.01.010; Enache TA, 2017, BIOELECTROCHEMISTRY, V114, P13, DOI 10.1016/j.bioelechem.2016.11.003; Evangelisti E, 2016, SCI REP-UK, V6, DOI 10.1038/srep32721; Feart C, 2013, P NUTR SOC, V72, P140, DOI 10.1017/S0029665112002959; Grossi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071702; Gupta VB, 2009, PHYTOTHER RES, V23, P111, DOI 10.1002/ptr.2574; Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270; Han XJ, 2017, MOL MED REP, V16, P4521, DOI 10.3892/mmr.2017.7203; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hong S, 2014, NEURON, V82, P308, DOI 10.1016/j.neuron.2014.02.027; Ladiwala ARA, 2011, J BIOL CHEM, V286, P3209, DOI 10.1074/jbc.M110.173856; Leri M, 2018, BBA-GEN SUBJECTS, V1862, P1432, DOI 10.1016/j.bbagen.2018.03.023; Leri M, 2016, J NUTR BIOCHEM, V30, P153, DOI 10.1016/j.jnutbio.2015.12.009; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Luccarini I, 2015, NEUROBIOL AGING, V36, P648, DOI 10.1016/j.neurobiolaging.2014.08.029; Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m; Muller M, 2011, ANTIOXID REDOX SIGN, V14, P1225, DOI 10.1089/ars.2010.3421; Najjaa H, 2011, INT J FOOD PROP, V14, P371, DOI 10.1080/10942910903203164; Sengupta U, 2016, EBIOMEDICINE, V6, P42, DOI 10.1016/j.ebiom.2016.03.035; Sharoar MG, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-104; Snoussi M, 2016, IND CROP PROD, V89, P533, DOI 10.1016/j.indcrop.2016.05.048; Song KS, 2012, FOOD SCI BIOTECHNOL, V21, P845, DOI 10.1007/s10068-012-0109-y; Stefani M, 2014, BIOFACTORS, V40, P482, DOI 10.1002/biof.1171; Sun BS, 1998, J AGR FOOD CHEM, V46, P4267, DOI 10.1021/jf980366j; Tsuchiya H, 2015, MOLECULES, V20, P18923, DOI 10.3390/molecules201018923	38	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2020	15	9							e0223815	10.1371/journal.pone.0223815	http://dx.doi.org/10.1371/journal.pone.0223815			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YT	32997672	Green Published, Green Submitted, gold			2023-01-03	WOS:000577103100004
J	Bushuven, S; Dettenkofer, M; Sippel, S; Koenig, S; Bushuven, S; Schneider-Brachert, W				Bushuven, Stefan; Dettenkofer, Markus; Sippel, Sonia; Koenig, Sarah; Bushuven, Stefanie; Schneider-Brachert, Wulf			Speaking up behavior and cognitive bias in hand hygiene: Competences of German-speaking medical students	PLOS ONE			English	Article							PATIENT SAFETY; HEALTH-CARE; FEEDBACK; OVERCONFIDENCE; DOCTORS; ERRORS	Introduction Infection prevention and speaking up on errors are core qualities of health care providers. Heuristic effects (e.g. overconfidence) may impair behavior in daily routine, while speaking up can be inhibited by hierarchical barriers and medical team factors. Aim of this investigation was to determine, how medical students experience these difficulties for hand hygiene in daily routine. Methods On the base of prior investigations we developed a questionnaire with 5-point Likert ordinal scaled items and free text entries. This was tested for validity and reliability (Cronbach's Alpha 0.89). Accredited German, Swiss and Austrian universities were contacted and medical students asked to participated in the anonymous online survey. Quantitative statistics used parametric and non-parametric tests and effect size calculations according to Lakens. Qualitative data was coded according to Janesick. Results 1042 undergraduates of 12 universities participated. All rated their capabilities in hand hygiene and feedback reception higher than those of fellow students, nurses and physicians (p<0.001). Half of the participants rating themselves to be best educated, realized that faulty hand hygiene can be of lethal effect. Findings were independent from age, sex, academic course and university. Speaking-up in case of omitted hand hygiene was rated to be done seldomly and most rare on persons of higher hierarchic levels. Qualitative results of 164 entries showed four main themes: 1) Education methods in hand hygiene are insufficient, 2) Hierarchy barriers impair constructive work place culture 3) Hygiene and feedback are linked to medical ethics and 4) There is no consequence for breaking hygiene rules. Discussion Although partially limited by the selection bias, this study confirms the overconfidence-effects demonstrated in post-graduates in other settings and different professions. The independence from study progress suggests, that the effect occurs before start of the academic course with need for educational intervention at the very beginning. Qualitative data showed that used methods are insufficient and contradictory work place behavior in hospitals are frustrating. Even 20 years after "To err is human", work place culture still is far away from the desirable.	[Bushuven, Stefan] Healthcare Assoc Constance GLKN, Inst Anesthesiol Intens Care Emergency Med & Pain, Hegau Bodensee Hosp Singen & Hegau Jugendwerk Gai, Radolfzell am Bodensee, Germany; [Bushuven, Stefan; Dettenkofer, Markus] Healthcare Assoc Constance GLKN, Inst Hosp Hyg & Infect Prevent, Radolfzell am Bodensee, Germany; [Bushuven, Stefan] Ludwig Maximilians Univ Munchen, Inst Didact & Educ Res Med, Clin Univ Munich, Munich, Germany; [Sippel, Sonia; Koenig, Sarah] Univ Hosp Wuerzburg, Inst Med Teaching & Med Educ Res, Wurzburg, Germany; [Bushuven, Stefanie] Healthcare Assoc Constance GLKN, Clin Orthoped Hand & Trauma Surg, Hegau Bodensee Hosp Singen, Radolfzell am Bodensee, Germany; [Schneider-Brachert, Wulf] Univ Hosp Regensburg, Dept Infect Control & Infect Dis, Regensburg, Germany	University of Munich; University of Wurzburg; University of Regensburg	Bushuven, S (corresponding author), Healthcare Assoc Constance GLKN, Inst Anesthesiol Intens Care Emergency Med & Pain, Hegau Bodensee Hosp Singen & Hegau Jugendwerk Gai, Radolfzell am Bodensee, Germany.; Bushuven, S (corresponding author), Healthcare Assoc Constance GLKN, Inst Hosp Hyg & Infect Prevent, Radolfzell am Bodensee, Germany.; Bushuven, S (corresponding author), Ludwig Maximilians Univ Munchen, Inst Didact & Educ Res Med, Clin Univ Munich, Munich, Germany.	S.Bushuven@gmx.de		Bushuven, Stefan/0000-0001-6272-0714				Ahmed M, 2013, ANN SURG, V258, P958, DOI 10.1097/SLA.0b013e31828c88fc; [Anonymous], 2004, LANGUES LIT MONDE AR, V5, P69; [Anonymous], 2019, STAT ANZAHL STUDENTE; Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x; Braithwaite J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012467; Brennan PA, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4461; BROWN JD, 1992, J EXP SOC PSYCHOL, V28, P3, DOI 10.1016/0022-1031(92)90029-J; Bushuven S., 2018, AM J INFECT CONTROL; Bushuven S, 2019, INFECT CONT HOSP EP, V40, P943, DOI 10.1017/ice.2019.156; Christensen SS, 2019, J NURS MANAGE, V27, P264, DOI 10.1111/jonm.12677; Dwyer J, 2018, ACAD MED, V93, P602, DOI 10.1097/ACM.0000000000002047; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; Eckmanns T, 2006, INFECT CONT HOSP EP, V27, P931, DOI 10.1086/507294; Emich KJ, 2014, COGNITION EMOTION, V28, P1382, DOI 10.1080/02699931.2014.881329; Etchegaray J.M., 2017, J PATIENT SAF; Haessler S, 2012, BMJ QUAL SAF, V21, P499, DOI 10.1136/bmjqs-2011-000396; Harris M M, 1994, Gastroenterol Nurs, V16, P269, DOI 10.1097/00001610-199406000-00007; Havens D H, 2000, J Pediatr Health Care, V14, P77, DOI 10.1067/mph.2000.105383; Hoerger M, 2010, CYBERPSYCH BEH SOC N, V13, P697, DOI 10.1089/cyber.2009.0445; Hooper P, 2015, POSTGRAD MED J, V91, P251, DOI 10.1136/postgradmedj-2014-133045; Janesick V. J, 2003, STRATEGIES QUALITATI, P46; Jochemsen-Van der Leeuw HGAR, 2015, MED TEACH, V37, P482, DOI 10.3109/0142159X.2014.956061; Keeble C, 2015, OPEN J EPIDEMIOLOGY, V5, P155, DOI DOI 10.4236/OJEPI.2015.53020; Khazaal Y, 2014, J MED INTERNET RES, V16, P44, DOI 10.2196/jmir.2759; Kiesewetter J, 2014, MED TEACH, V36, P505, DOI 10.3109/0142159X.2014.891008; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Landgren Rachel, 2016, Hosp Pediatr, V6, P738; Makary MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2139; Malmendier U, 2005, J FINANC, V60, P2661, DOI 10.1111/j.1540-6261.2005.00813.x; Moore DA, 2008, PSYCHOL REV, V115, P502, DOI 10.1037/0033-295X.115.2.502; Morrell BLM, 2020, NURS EDUC PERSPECT, V41, P197, DOI 10.1097/01.NEP.0000000000000441; Mubeen S., 2014, EUROPEAN J ED RES, V3, P129, DOI [10.12973/eu-jer.3.3.129, DOI 10.12973/EU-JER.3.3.129]; Neo JRJ, 2016, AM J INFECT CONTROL, V44, P691, DOI 10.1016/j.ajic.2015.11.034; Norcini J, 2010, MED EDUC, V44, P16, DOI 10.1111/j.1365-2923.2009.03542.x; Offner D, 2016, AM J INFECT CONTROL, V44, P666, DOI 10.1016/j.ajic.2015.12.040; Organization WH, 2009, WHO GUID HAND HYG HL; Pelaccia T, 2017, MED TEACH, V39, P136, DOI 10.1080/0142159X.2016.1248924; Pittet D, 2009, INFECT CONT HOSP EP, V30, P611, DOI 10.1086/600379; Prims JP, 2017, JUDGM DECIS MAK, V12, P29; Qasmi S.A., 2018, AM J INFECT CONTROL; Ramani S, 2012, MED TEACH, V34, P787, DOI 10.3109/0142159X.2012.684916; Reynolds M, 2017, BMJ QUAL SAF, V26, P240, DOI 10.1136/bmjqs-2015-004717; Sandroni A., 2018, SURVEY OVERCONFIDENC; Schwappach DLB, 2016, Z EVIDENZ FORTBILD Q, V114, P5, DOI 10.1016/j.zefq.2016.05.011; Schwappach DLB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104720; Skodova M, 2015, REV LAT-AM ENFERM, V23, P708, DOI 10.1590/0104-1169.0459.2607; Squintani, 2004, SURVEY OVERCONFIDENC; The Lancet HIV, 2015, LANCET HIV, V2, pe115; The Lancet HIV, 2016, LANCET HIV, V3, pe191; Till A, 2016, BRIT J HOSP MED, V77, P471, DOI 10.12968/hmed.2016.77.8.471; Van De Mortel TF, 2012, J ADV NURS, V68, P569, DOI 10.1111/j.1365-2648.2011.05758.x	51	3	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2020	15	9							e0239444	10.1371/journal.pone.0239444	http://dx.doi.org/10.1371/journal.pone.0239444			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY3AW	32986726	Green Published, gold			2023-01-03	WOS:000576267900018
J	Satpathy, S; Patra, A; Hussain, MD; Kazi, M; Aldughaim, MS; Ahirwar, B				Satpathy, Swaha; Patra, Arjun; Hussain, Muhammad Delwar; Kazi, Mohsin; Aldughaim, Mohammed S.; Ahirwar, Bharti			A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells	PLOS ONE			English	Article							BONE LOSS; ESTROGEN; GENISTEIN; DAIDZEIN; FRACTURE; FLAVONOIDS; DIFFERENCE; MIRIFICA; UTERUS; LINN.	Pueraria tuberosa (Roxb. ex Willd.) DC., known as Indian Kudzu belongs to family Fabaceae and it is solicited as "Rasayana" drugs in Ayurveda. In the present study, we analyzed the efficacy of an ethyl acetate fraction from the tuber extract of Pueraria tuberosa (fraction rich in antioxidant compounds, FRAC) against menopausal osteoporosis, and breast and ovarian cancer cells. The FRAC from Pueraria tuberosa was characterized for its phenolic composition (total phenolic and flavonoid amount). Antioxidant property (in vitro assays) of the FRAC was also carried out followed by the analysis of the FRAC for its antiosteoporotic and anticancer potentials. The antiosteoporotic activity of FRAC was investigated in ovariectomy-induced osteoporosis in rats. The cytotoxicity effect was determined in breast and ovarian cancer cells. Gas chromatography/mass spectrometry (GC/MS) analysis of the FRAC was performed to determine its various phytoconstituents. Docking analysis was performed to verify the interaction of bioactive molecules with estrogen receptors (ERs). The FRAC significantly improved various biomechanical and biochemical parameters in a dose-dependent manner in the ovariectomized rats. FRAC also controlled the increased body weight and decreased uterus weight following ovariectomy in rats. Histopathology of the femur demonstrated the restoration of typical bone structure and trabecular width in ovariectomized animals after treatment with FRAC and raloxifene. The FRAC also exhibited in vitro cytotoxicity in the breast (MCF-7 and MDA-MB-231) and ovarian (SKOV-3) cancer cells. Furthermore, genistein and daidzein exhibited a high affinity towards both estrogen receptors (alpha and beta) in the docking study revealing the probable mechanism of the antiosteoporotic activity. GC/MS analysis confirmed the presence of other bioactive molecules such as stigmasterol, beta-sitosterol, and stigmasta-3,5-dien-7-one. The FRAC from Pueraria tuberosa has potential for treatment of menopausal osteoporosis. Also, the FRAC possesses anticancer activity.	[Satpathy, Swaha; Patra, Arjun; Ahirwar, Bharti] Guru Ghasidas Univ, Inst Pharm, Bilaspur, CG, India; [Hussain, Muhammad Delwar] Calif Hlth Sci Univ, Coll Pharm, Dept Pharmaceut & Biomed Sci, Clovis, CA 93612 USA; [Kazi, Mohsin] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh, Saudi Arabia; [Aldughaim, Mohammed S.] King Fahad Med City, Res Ctr, Riyadh, Saudi Arabia; [Satpathy, Swaha] Sambalpur Univ, Dept Biotechnol & Bioinformat, Sambalpur, Odisha, India	Guru Ghasidas Vishwavidyalaya; California Health Sciences University (CHSU); King Saud University; King Fahad Medical City; Sambalpur University	Satpathy, S (corresponding author), Guru Ghasidas Univ, Inst Pharm, Bilaspur, CG, India.; Hussain, MD (corresponding author), Calif Hlth Sci Univ, Coll Pharm, Dept Pharmaceut & Biomed Sci, Clovis, CA 93612 USA.; Satpathy, S (corresponding author), Sambalpur Univ, Dept Biotechnol & Bioinformat, Sambalpur, Odisha, India.	swaha22@rediffmail.com; dhussain@chsu.edu	Kazi, Mohsin/B-4417-2010	Kazi, Mohsin/0000-0002-5611-0378	University Grants Commission, New Delhi, India [F.NO.563/2016(IC)]	University Grants Commission, New Delhi, India(University Grants Commission, India)	The authors deeply acknowledge University Grants Commission, New Delhi, India, for financial support as Raman Fellowship [F.NO.563/2016(IC)] to AP.	Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161; Arjun P, 2009, PHARMACOGN MAG, V5, P51; Bidwell JP, 2013, CURR OSTEOPOROS REP, V11, P117, DOI 10.1007/s11914-013-0139-2; Desai S, 2017, J ETHNOPHARMACOL, V199, P1, DOI 10.1016/j.jep.2017.01.031; El-Shitany NA, 2010, PHYTOMEDICINE, V17, P116, DOI 10.1016/j.phymed.2009.05.012; Gaete L, 2012, J MED FOOD, V15, P1081, DOI 10.1089/jmf.2011.0322; Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996; GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107; Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337; Harisa GI, 2017, SAUDI PHARM J, V25, P120, DOI 10.1016/j.jsps.2016.05.007; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Hertrampf T, 2007, BONE, V40, P1529, DOI 10.1016/j.bone.2007.02.006; Hirota K, 2010, J AGR FOOD CHEM, V58, P5821, DOI 10.1021/jf903911e; Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175; Jia M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/364604; Kaplan JR, 2004, ILAR J, V45, P89, DOI 10.1093/ilar.45.2.89; Keshri G, 2007, CONTRACEPTION, V76, P400, DOI 10.1016/j.contraception.2007.07.009; Kharazmi M, 2014, ANN RHEUM DIS, V73, P1594, DOI 10.1136/annrheumdis-2013-205080; Kolios L, 2010, PLANTA MED, V76, P850, DOI 10.1055/s-0029-1240798; Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108; Madaan R, 2011, INDIAN J PHARM SCI, V73, P666, DOI 10.4103/0250-474X.100242; Maji AK, 2014, NAT PROD RES, V28, P2111, DOI 10.1080/14786419.2014.928291; Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009-0024; Nadia ME, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/706905; Nazrun AS, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/142702; Occhiuto F, 2007, PHYTOTHER RES, V21, P130, DOI 10.1002/ptr.2037; OMI N, 1995, BONE, V17, pS163, DOI 10.1016/8756-3282(95)00329-C; Patra A, 2018, INT J NANOMED, V13, P2869, DOI 10.2147/IJN.S153094; Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675; Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104; Powers Chelsea N., 2015, In Silico Pharmacology, V3, P4, DOI 10.1186/s40203-015-0008-z; Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140-6736(10)62349-5; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sanchez-Rodriguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-124; Satpathy S, 2018, S AFR J BOT, V117, P247, DOI 10.1016/j.sajb.2018.05.033; Satpathy S, 2017, J LIQ CHROMATOGR R T, V40, P499, DOI 10.1080/10826076.2017.1329743; Satpathy Swaha, 2015, J Complement Integr Med, V12, P251, DOI 10.1515/jcim-2015-0034; Shirwaikar A, 2003, J ETHNOPHARMACOL, V89, P245, DOI 10.1016/j.jep.2003.08.004; Spigno G, 2009, J FOOD ENG, V93, P210, DOI 10.1016/j.jfoodeng.2009.01.006; Subramanian S, 2012, INT J PHARM SCI RES, V3, P228, DOI 10.13040/IJPSR.0975-8232.3(1).227-34; Sulaiman C. T., 2015, Asian Pacific Journal of Reproduction, V4, P153; Suthon S, 2016, J NAT MED-TOKYO, V70, P225, DOI 10.1007/s11418-016-0965-5; Tanaka T, 2011, J AGR FOOD CHEM, V59, P13230, DOI 10.1021/jf2031617; Urasopon N, 2008, MATURITAS, V59, P137, DOI 10.1016/j.maturitas.2008.01.001; Wasnich RD, 1998, J CLIN DENSITOM, V1, P259, DOI 10.1385/JCD:1:3:259; World Health Organization Scientific Group, 2007, SCI GROUP ASS OST PR; Yogesh HS, 2011, J ETHNOPHARMACOL, V134, P334, DOI 10.1016/j.jep.2010.12.013	47	6	6	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0240068	10.1371/journal.pone.0240068	http://dx.doi.org/10.1371/journal.pone.0240068			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4VV	33444328	gold, Green Published			2023-01-03	WOS:000609988100093
J	Cui, Y; Guo, LT; Mu, QX; Cheng, Q; Kang, L; He, YN; Tang, M; Wu, QY				Cui, Yu; Guo, Langtao; Mu, Qixia; Cheng, Qin; Kang, Lu; He, Yani; Tang, Min; Wu, Qunying			Sleep deprivation did not enhance the success rate of chloral hydrate sedation for non-invasive procedural sedation in pediatric patients	PLOS ONE			English	Article							SAFETY; EFFICACY	Study objective In Asian countries, oral chloral hydrate is the most commonly used sedative for non-invasive procedures. Theoretically, mild sleep deprivation could be considered as one of assisted techniques. However, there is no consensus on sleep deprivation facilitating the sedation during non-painful procedures in children. The aim of our study is to analyze the clinical data of children undergoing non-invasive procedural sedation retrospectively and to evaluate the association between mild sleep deprivation and sedative effects in non-invasive procedures. Measurements Consecutive patients undergoing chloral hydrate sedation for non-invasive procedures between December 1, 2019 to June 30, 2020 were included in this study. The propensity score analysis with 1: 1 ratio was used to match the baseline variables between patients with sleep deprivation and non-sleep deprivation. The primary outcome was the failure rate of sedation with the initial dose. The secondary outcomes included the failure rate of sedation after supplementation of chloral hydrate, the incidence of major and minor adverse events, initial and supplemental dose of chloral hydrate, and the length of sedation time. Main results Of the 7789 patients undergoing chloral hydrate sedation, 6352 were treated with sleep deprivation and 1437 with non-sleep deprivation. After propensity score matching, 1437 pairs were produced. The failure rate of sedation with initial chlorate hydrate was not significantly different in two groups (8.6% [123/1437] vs. 10.6% [152/1437], p = 0.08), nor were the failure rates with supplemental chlorate hydrate (0.8% [12/1437] vs. 0.9% [13/1437], p = 1) and the length of sedation time (58 [45, 75] vs. 58 [45, 75] min; p = 0.93). Conclusions The current results do not support sleep deprivation have a beneficial effect in reducing the pediatric chloral hydrate sedation failure rate. The routine use of sleep deprivation for pediatric sedation is unnecessary.	[Cui, Yu; Guo, Langtao; Mu, Qixia; Cheng, Qin; Kang, Lu; He, Yani; Tang, Min; Wu, Qunying] UESTC Chengdu Womens & Childrens Cent Hosp, Dept Anesthesiol, Affiliated Hosp, Sch Med, Chengdu, Sichuan, Peoples R China		Cui, Y (corresponding author), UESTC Chengdu Womens & Childrens Cent Hosp, Dept Anesthesiol, Affiliated Hosp, Sch Med, Chengdu, Sichuan, Peoples R China.	cuiyu19831001@163.com	guo, langtao/GVS-1692-2022	Cui, Yu/0000-0002-1481-9389				Caldwell JC, 2006, ENVIRON HEALTH PERSP, V114, P1457, DOI 10.1289/ehp.8692; Karaoui M, 2018, AM J OPHTHALMOL, V192, P39, DOI 10.1016/j.ajo.2018.05.003; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Lei H, 2020, ACTA ANAESTH SCAND, V64, P464, DOI 10.1111/aas.13509; Malia L, 2019, AM J EMERG MED, V37, P85, DOI 10.1016/j.ajem.2018.04.063; Mataftsi A, 2017, BRIT J OPHTHALMOL, V101, P1423, DOI 10.1136/bjophthalmol-2016-309449; Ong HT, 2004, CLIN NEUROPHYSIOL, V115, P951, DOI 10.1016/j.clinph.2003.11.012; Seo JS, 2013, EMERG MED J, V30, DOI 10.1136/emermed-2011-200997; Shields CH, 2004, PEDIATRICS, V113, P1204, DOI 10.1542/peds.113.5.1204; Shuangquan Qu, 2017, CHIN J ANESTHSIOL, V37, P1254; Thomas DA, 1996, EUR RESPIR J, V9, P932, DOI 10.1183/09031936.96.09050932; Valenzuela DG, 2016, INT J PEDIATR OTORHI, V83, P175, DOI 10.1016/j.ijporl.2016.02.006; Wilson ME, 2014, J PEDIAT OPHTH STRAB, V51, P154, DOI 10.3928/01913913-20140311-01; Zielinska M, 2019, PEDIATR ANESTH, V29, P583, DOI 10.1111/pan.13615	14	2	2	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2021	16	1							e0245338	10.1371/journal.pone.0245338	http://dx.doi.org/10.1371/journal.pone.0245338			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4SP	33434236	Green Published, gold			2023-01-03	WOS:000609979700015
J	Barbora, A; Bohar, O; Sivan, AA; Magory, E; Nause, A; Minnes, R				Barbora, Ayan; Bohar, Oryan; Sivan, Ariel Alexander; Magory, Eyal; Nause, Ariel; Minnes, Refael			Higher pulse frequency of near-infrared laser irradiation increases penetration depth for novel biomedical applications	PLOS ONE			English	Article							PHOTODYNAMIC THERAPY; OPTICAL-PROPERTIES; LIGHT; CANCER; PHOTOSENSITIZERS; NANOPARTICLE; TISSUES	Background The clinical efficiency of laser treatments is limited by the low penetration of visible light used in certain procedures like photodynamic therapy (PDT). Second Harmonic Generation (SHG) PDT is an innovative technique to overcome this limitation that enables the use of Near Infrared (NIR) light instead of visible light. NIR frequency bands present an optical window for deeper penetration into biological tissue. In this research, we compare the penetration depths of 405 and 808 nm continuous wave (CW) lasers and 808 nm pulsed wave (PW) laser in two different modes (high and low frequency). Methods Increasing thicknesses of beef and chicken tissue samples were irradiated under CW and PW lasers to determine penetration depths. Results The 808 nm CW laser penetrates 2.3 and 2.4 times deeper than the 405 nm CW laser in beef and chicken samples, respectively. 808 nm PW (pulse frequency-500 Hz) penetrates deeper than CW laser at the same wavelength. Further, increasing the pulse frequency achieves higher penetration depths. High frequency 808 nm PW (pulse frequency-71.4 MHz) penetrates 7.4- and 6.0-times deeper than 405 nm CW laser in chicken and beef, respectively. Conclusions The results demonstrate the higher penetration depths of high frequency PW laser compared to low frequency PW laser, CW laser of the same wavelength and CW laser with half the wavelength. The results indicate that integrating SHG in the PDT process along with pulsed NIR light may allow the treatment of 6-7 times bigger tumours than conventional PDT using blue light.	[Barbora, Ayan; Bohar, Oryan; Sivan, Ariel Alexander; Magory, Eyal; Nause, Ariel; Minnes, Refael] Ariel Univ, Dept Phys, Fac Nat Sci, Ariel, Israel	Ariel University	Minnes, R (corresponding author), Ariel Univ, Dept Phys, Fac Nat Sci, Ariel, Israel.	refaelm@ariel.ac.il	Minnes, Refael/ABC-8780-2021; Minnes, Refael/A-2369-2017	Nause, Ariel/0000-0001-6248-7254; Minnes, Refael/0000-0002-1857-4905	Ariel Scientific Innovations (ASI) [AC19069]	Ariel Scientific Innovations (ASI)	RM, AC19069, Ariel Scientific Innovations (ASI), https://www.ariel.ac.il/wp/arielrnd/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas Hisham Abdussamad, 2013, ISRN Optics, DOI 10.1155/2013/451208; Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942; Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Allegra A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050448; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; [Anonymous], 2016, J LARGE SCALE RES FA, V2, pA49; Arslan H, 2018, SAKARYA NIVERSITESI, P1, DOI 10.16984/saufenbilder.332802; Ash C, 2017, LASER MED SCI, V32, P1909, DOI 10.1007/s10103-017-2317-4; Barbosa RI, 2020, J PHOTOCH PHOTOBIO B, V209, DOI 10.1016/j.jphotobiol.2020.111914; Bedi N, 2020, TRANSL ANDROL UROL, V9, P1518, DOI 10.21037/tau.2019.09.12; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Demidova TN, 2004, INT J IMMUNOPATH PH, V17, P245, DOI 10.1177/039463200401700304; Dharmaratne P, 2020, EUR J MED CHEM, V200, DOI 10.1016/j.ejmech.2020.112341; Dias LD, 2020, LASER PHYS LETT, V17, DOI 10.1088/1612-202X/ab95a9; Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007; Hamblin MR, 2020, PHOTOCHEM PHOTOBIOL, V96, P506, DOI 10.1111/php.13190; Han DH, 2018, RSC ADV, V8, P32344, DOI 10.1039/c8ra05285a; Hudson DE, 2013, PHOTOMED LASER SURG, V31, P163, DOI 10.1089/pho.2012.3284; Jacques SL, 2013, PHYS MED BIOL, V58, pR37, DOI 10.1088/0031-9155/58/11/R37; Joensen J, 2012, PHOTOMED LASER SURG, V30, P688, DOI 10.1089/pho.2012.3306; Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]; Kachynski AV, 2014, NAT PHOTONICS, V8, P455, DOI 10.1038/nphoton.2014.90; Liang C, 2020, J MATER CHEM B, V8, P4748, DOI 10.1039/d0tb00098a; Listrat Anne, 2016, ScientificWorldJournal, V2016, P3182746, DOI 10.1155/2016/3182746; Minnes R, 2008, J PHYS CHEM B, V112, P3268, DOI 10.1021/jp0768423; Minnes R, 2007, J PORPHYR PHTHALOCYA, V11, P577, DOI 10.1142/S1088424607000679; Nause A., 2019, P 10 INT PARTICLE AC, DOI [10.18429/JACoW-IPAC2019-TUXXPLM3, DOI 10.18429/JACOW-IPAC2019-TUXXPLM3]; Oyama J, 2020, PHOTODIAGN PHOTODYN, V30, DOI 10.1016/j.pdpdt.2020.101682; Perekatova V, 2016, BIOMED OPT EXPRESS, V7, P3979, DOI 10.1364/BOE.7.003979; Pogue BW, 1997, APPL OPTICS, V36, P7257, DOI 10.1364/AO.36.007257; Pu Y, 2013, J APPL PHYS, V114, DOI 10.1063/1.4825319; Queiros C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13997; Sandell JL, 2011, J BIOPHOTONICS, V4, P773, DOI 10.1002/jbio.201100062; Smith AM, 2009, NAT NANOTECHNOL, V4, P710, DOI 10.1038/nnano.2009.326; Sordillo LA, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.5.056004; Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012; Swamy PCA, 2020, COORDIN CHEM REV, V411, DOI 10.1016/j.ccr.2020.213233; Xu C, 2020, BIOCONJUGATE CHEM, V31, P1708, DOI 10.1021/acs.bioconjchem.0c00297; Xu XX, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00488; Yang K, 2020, CHEM COMMUN, V56, P5865, DOI 10.1039/d0cc02001j; Yano T, 2020, PHOTOCHEM PHOTOBIOL, V96, P517, DOI 10.1111/php.13206; Zalesny RS, 2005, INT J PHYTOREMEDIAT, V7, P177, DOI 10.1080/16226510500214632; Zhou XY, 2017, RSC ADV, V7, P52125, DOI 10.1039/c7ra07334h	43	11	12	5	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0245350	10.1371/journal.pone.0245350	http://dx.doi.org/10.1371/journal.pone.0245350			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411831	gold, Green Published			2023-01-03	WOS:000608044300127
J	Trump, S; Lukassen, S; Anker, MS; Chua, RL; Liebig, J; Thurmann, L; Corman, VM; Binder, M; Loske, J; Klasa, C; Krieger, T; Hennig, BP; Messingschlager, M; Pott, F; Kazmierski, J; Twardziok, S; Albrecht, JP; Eils, J; Hadzibegovic, S; Lena, A; Heidecker, B; Burgel, T; Steinfeldt, J; Goffinet, C; Kurth, F; Witzenrath, M; Volker, MT; Muller, SD; Liebert, UG; Ishaque, N; Kaderali, L; Sander, LE; Drosten, C; Laudi, S; Eils, R; Conrad, C; Landmesser, U; Lehmann, I				Trump, Saskia; Lukassen, Soeren; Anker, Markus S.; Chua, Robert Lorenz; Liebig, Johannes; Thurmann, Loreen; Corman, Victor Max; Binder, Marco; Loske, Jennifer; Klasa, Christina; Krieger, Teresa; Hennig, Bianca P.; Messingschlager, Marey; Pott, Fabian; Kazmierski, Julia; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jurgen; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Burgel, Thore; Steinfeldt, Jakob; Goffinet, Christine; Kurth, Florian; Witzenrath, Martin; Volker, Maria Theresa; Muller, Sarah Dorothea; Liebert, Uwe Gerd; Ishaque, Naveed; Kaderali, Lars; Sander, Leif-Erik; Drosten, Christian; Laudi, Sven; Eils, Roland; Conrad, Christian; Landmesser, Ulf; Lehmann, Irina			Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19	NATURE BIOTECHNOLOGY			English	Article							IMMUNITY; INFLAMMATION; ASSOCIATION; MORTALITY; ACE2	Single-cell analysis reveals how anti-hypertensive drugs affect the risk of severe disease in patients with COVID-19 who have hypertension. In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.	[Trump, Saskia; Thurmann, Loreen; Loske, Jennifer; Messingschlager, Marey; Lehmann, Irina] Charite Med Univ Berlin, Mol Epidemiol Unit, Berlin, Germany; [Trump, Saskia; Thurmann, Loreen; Loske, Jennifer; Messingschlager, Marey; Lehmann, Irina] Free Univ Berlin, Berlin, Germany; [Trump, Saskia; Thurmann, Loreen; Loske, Jennifer; Messingschlager, Marey; Lehmann, Irina] Humboldt Univ, Berlin, Germany; [Trump, Saskia; Anker, Markus S.; Thurmann, Loreen; Corman, Victor Max; Loske, Jennifer; Messingschlager, Marey; Lena, Alessia; Heidecker, Bettina; Burgel, Thore; Steinfeldt, Jakob; Goffinet, Christine; Lehmann, Irina] Berlin Inst Hlth BIH, Berlin, Germany; [Lukassen, Soeren; Chua, Robert Lorenz; Liebig, Johannes; Krieger, Teresa; Hennig, Bianca P.; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jurgen; Ishaque, Naveed; Eils, Roland; Conrad, Christian] Berlin Inst Hlth BIH, Ctr Digital Hlth, Berlin, Germany; [Lukassen, Soeren; Anker, Markus S.; Chua, Robert Lorenz; Corman, Victor Max; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jurgen; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Burgel, Thore; Goffinet, Christine; Ishaque, Naveed; Eils, Roland; Conrad, Christian; Landmesser, Ulf] Charite Univ Med Berlin, Berlin, Germany; [Lukassen, Soeren; Anker, Markus S.; Chua, Robert Lorenz; Liebig, Johannes; Corman, Victor Max; Hennig, Bianca P.; Pott, Fabian; Kazmierski, Julia; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jurgen; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Burgel, Thore; Steinfeldt, Jakob; Ishaque, Naveed; Drosten, Christian; Eils, Roland; Conrad, Christian; Landmesser, Ulf] Free Univ Berlin, Berlin, Germany; [Lukassen, Soeren; Anker, Markus S.; Chua, Robert Lorenz; Liebig, Johannes; Krieger, Teresa; Hennig, Bianca P.; Twardziok, Sven; Albrecht, Jan Philipp; Eils, Jurgen; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Burgel, Thore; Steinfeldt, Jakob; Goffinet, Christine; Ishaque, Naveed; Drosten, Christian; Eils, Roland; Conrad, Christian; Landmesser, Ulf] Humboldt Univ, Berlin, Germany; [Anker, Markus S.; Hadzibegovic, Sara; Lena, Alessia; Heidecker, Bettina; Steinfeldt, Jakob; Landmesser, Ulf] Campus Benjamin Franklin, Dept Cardiol, Berlin, Germany; [Anker, Markus S.; Hadzibegovic, Sara; Lena, Alessia] Charite Univ Med Berlin, Dept Cardiol Campus Virchow, Div Cardiol & Metab, Berlin, Germany; [Anker, Markus S.] Ctr Cardiovasc Res DZHK, Berlin, Germany; [Anker, Markus S.] Berlin Inst Hlth Ctr Regenerat Therapies BCRT, Berlin, Germany; [Anker, Markus S.; Corman, Victor Max; Pott, Fabian; Kazmierski, Julia; Goffinet, Christine] Charite Univ Med Berlin, Inst Virol, Berlin, Germany; [Binder, Marco] German Canc Res Ctr, Res Grp Dynam Early Viral Infect & Innate Antivir, Heidelberg, Germany; [Klasa, Christina; Kaderali, Lars] Univ Med Greifswald, Inst Bioinformat, Greifswald, Germany; [Pott, Fabian; Kazmierski, Julia] Berlin Inst Hlth BIH, Berlin, Germany; [Kurth, Florian; Witzenrath, Martin; Sander, Leif-Erik] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany; [Kurth, Florian] Univ Med Ctr Hamburg Eppendorf, Dept Med, Dept Trop Med, Bernhard Nocht Inst Trop Med & I, Hamburg, Germany; [Volker, Maria Theresa; Muller, Sarah Dorothea; Laudi, Sven] Univ Hosp Leipzig, Dept Anesthesiol & Intens Care, Leipzig, Germany; [Liebert, Uwe Gerd] Univ Hosp Leipzig, Inst Virol, Leipzig, Germany; [Eils, Roland; Lehmann, Irina] German Ctr Lung Res DZL, Berlin, Germany; [Eils, Roland] Heidelberg Univ, Fac Med, Hlth Data Sci Unit, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, BioQuant, Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Greifswald Medical School; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University; Leipzig University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Lehmann, I (corresponding author), Charite Med Univ Berlin, Mol Epidemiol Unit, Berlin, Germany.; Lehmann, I (corresponding author), Free Univ Berlin, Berlin, Germany.; Lehmann, I (corresponding author), Humboldt Univ, Berlin, Germany.; Lehmann, I (corresponding author), Berlin Inst Hlth BIH, Berlin, Germany.; Eils, R; Conrad, C (corresponding author), Berlin Inst Hlth BIH, Ctr Digital Hlth, Berlin, Germany.; Eils, R; Conrad, C; Landmesser, U (corresponding author), Charite Univ Med Berlin, Berlin, Germany.; Eils, R; Conrad, C; Landmesser, U (corresponding author), Free Univ Berlin, Berlin, Germany.; Eils, R; Conrad, C; Landmesser, U; Lehmann, I (corresponding author), Humboldt Univ, Berlin, Germany.; Landmesser, U (corresponding author), Campus Benjamin Franklin, Dept Cardiol, Berlin, Germany.; Laudi, S (corresponding author), Univ Hosp Leipzig, Dept Anesthesiol & Intens Care, Leipzig, Germany.; Eils, R; Lehmann, I (corresponding author), German Ctr Lung Res DZL, Berlin, Germany.; Eils, R (corresponding author), Heidelberg Univ, Fac Med, Hlth Data Sci Unit, Heidelberg, Germany.; Eils, R (corresponding author), Heidelberg Univ, BioQuant, Heidelberg, Germany.	sven.laudi@medizin.uni-leipzig.de; roland.eils@charite.de; christian.conrad@charite.de; ulf.landmesser@charite.de; irina.lehmann@charite.de	Thürmann, Loreen/AAD-4716-2022; Binder, Marco/E-9717-2011; Corman, Victor M/K-1319-2019; Pott, Fabian/AAN-2549-2021; Ishaque, Naveed/AAF-3454-2020; Lukassen, Soeren/A-3737-2019; Trump, Saskia/ABG-5182-2021; Goffinet, Christine/L-4878-2019; Eils, Roland/B-6121-2009	Thürmann, Loreen/0000-0003-1109-1924; Binder, Marco/0000-0002-5805-6109; Corman, Victor M/0000-0002-3605-0136; Pott, Fabian/0000-0003-3700-1691; Ishaque, Naveed/0000-0002-8426-901X; Lukassen, Soeren/0000-0001-7045-6327; Goffinet, Christine/0000-0002-3959-004X; Eils, Roland/0000-0002-0034-4036; Conrad, Christian/0000-0001-7036-342X; Anker, Markus S/0000-0002-4406-8555; Steinfeldt, Jakob/0000-0003-1387-2054; Kazmierski, Julia/0000-0002-7962-2165; Kurth, Florian/0000-0002-3807-473X; Messingschlager, Marey/0000-0002-7316-8192; Liebig, Johannes/0000-0002-9188-036X; Twardziok, Sven/0000-0002-0326-5704; Heidecker, Bettina/0000-0002-3811-7920; Lehmann, Irina/0000-0001-8875-5587; Chua, Robert Lorenz/0000-0001-5945-9957; Trump, Saskia/0000-0002-9894-1807; Lena, Alessia/0000-0002-1550-7870	Clinician Scientist Program of the University of Leipzig, Medical Faculty; German Cardiovascular Research Center; BIH COVID-19 research program; European Commission (ESPACE) [874719]; European Commission (Horizon 2020); BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI) [031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A, 031A532B]; BMBF-funded Medical Informatics Initiative (HiGHmed) [01ZZ1802A - 01ZZ1802Z]; OrganoStrat [01KX2021]; Illumina GmbH	Clinician Scientist Program of the University of Leipzig, Medical Faculty; German Cardiovascular Research Center; BIH COVID-19 research program; European Commission (ESPACE); European Commission (Horizon 2020)(European Commission); BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI); BMBF-funded Medical Informatics Initiative (HiGHmed); OrganoStrat; Illumina GmbH	We thank all patients from the Pa-COVID-19 and the SC2 cohort studies for kindly donating nasopharyngeal samples and clinical data. We also thank A. Krannich and Charite - Universitatsmedizin Berlin for help in sample procurement and annotation and for supporting sample processing, respectively. We thank A. Seidel and G. Szczepankiewicz for supporting patient recruitment at the University Hospital Leipzig. We thank H. G. Krausslich for initial discussions, as well as C. Spann and D. Schweinoch for their help with the in vitro experiment. M.T.V. holds a scholarship from the Clinician Scientist Program of the University of Leipzig, Medical Faculty. M.S.A. has received research support from the German Cardiovascular Research Center. This study was supported by the BIH COVID-19 research program (C.G., C.C., C.D., N.I., L.-E.S., R.E. and I.L.), the European Commission (ESPACE, 874719, Horizon 2020, C.C. and R.E.), the BMBF-funded de.NBI Cloud within the German Network for Bioinformatics Infrastructure (de.NBI; 031A537B, 031A533A, 031A538A, 031A533B, 031A535A, 031A537C, 031A534A and 031A532B, J.E. and R.E.), the BMBF-funded Medical Informatics Initiative (HiGHmed, 01ZZ1802A - 01ZZ1802Z, R.E.) and OrganoStrat (01KX2021, C.G.). We thank Illumina GmbH for financial support via the allocation of reagents and sequencing flow cells, as well as M. Vossmann, M. Allgaier and O. Kratke for the realization of the sequencing runs at the Illumina Solutions Center Berlin. We thank B. Timmermann and his team for the realization of the sequencing runs at the MPI for Molecular Genetics Berlin. This publication is part of the Human Cell Atlas (www.humancellatlas.org/publications).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/nmeth.4463, 10.1038/NMETH.4463]; Benelli G., 2020, SARS COV2 COMORBIDIT, DOI [10.1101/2020.04.14.20053090, DOI 10.1101/2020.04.14.20053090]; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Cha SA, 2018, KOREAN J PHYSIOL PHA, V22, P447, DOI 10.4196/kjpp.2018.22.4.447; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Chung MK, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102907; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dinh QN, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/406960; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Guba M, 2000, SHOCK, V13, P190, DOI 10.1097/00024382-200003000-00004; Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Huang SJ, 2020, HYPERTENS RES, V43, P824, DOI 10.1038/s41440-020-0485-2; Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924; Jayedi A, 2019, HEART, V105, P686, DOI 10.1136/heartjnl-2018-314216; Kintscher U, 2020, HYPERTENSION, V76, pE34, DOI 10.1161/HYPERTENSIONAHA.120.15841; Klein N, 2013, CRIT CARE MED, V41, pE334, DOI 10.1097/CCM.0b013e31828a6688; Kurth F, 2020, INFECTION, V48, P619, DOI 10.1007/s15010-020-01464-x; Lee Ivan T, 2020, medRxiv, DOI 10.1101/2020.05.08.20092866; Lee JS, 2020, NAT REV IMMUNOL, V20, P585, DOI 10.1038/s41577-020-00429-3; Liang X, 2020, J INFECTION, V81, pE44, DOI 10.1016/j.jinf.2020.06.060; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liu S, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-0538-1; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Lukassen S, 2020, EMBO J, V39, DOI 10.15252/embj.20105114; Lumpuy-Castillo J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186471; Madhur MS, 2013, HYPERTENSION, V62, P13, DOI 10.1161/HYPERTENSIONAHA.113.01410; Magalhaes GS, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00730; Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923; McMaster WG, 2015, CIRC RES, V116, P1022, DOI 10.1161/CIRCRESAHA.116.303697; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Moerman T, 2019, BIOINFORMATICS, V35, P2159, DOI 10.1093/bioinformatics/bty916; Nawijn MC, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209841; Neufeldt C.J, 2020, SARS COV 2 INFECT IN, DOI [10.1101/2020.07.21.212639, DOI 10.1161/CIRCRESAHA.120.317134]; Nyambuya TM, 2020, CLIN IMMUNOL, V210, DOI 10.1016/j.clim.2019.108313; Olofsson PS, 2016, NAT BIOTECHNOL, V34, P1066, DOI 10.1038/nbt.3663; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Ocaranza MP, 2020, NAT REV CARDIOL, V17, P116, DOI 10.1038/s41569-019-0244-8; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Ravindra N.G., 2020, BIORXIV, DOI [10.1101/2020.05.06.081695, DOI 10.1101/2020.05.06.081695]; Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Romero C, 2015, NAT REV ENDOCRINOL, V11, P242, DOI 10.1038/nrendo.2015.6; Sanyaolu Adekunle, 2020, SN Compr Clin Med, V2, P1069, DOI 10.1007/s42399-020-00363-4; Sarzani R, 2020, AM J PHYSIOL-LUNG C, V319, pL325, DOI 10.1152/ajplung.00189.2020; Soler MJ, 2008, CURR HYPERTENS REP, V10, P410, DOI 10.1007/s11906-008-0076-0; Souza LL, 2012, J CELL PHYSIOL, V227, P2117, DOI 10.1002/jcp.22940; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Travaglini KJ, 2020, NATURE, V587, DOI 10.1038/s41586-020-2922-4; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; Wenzel U, 2016, J AM SOC NEPHROL, V27, P677, DOI 10.1681/ASN.2015050562; Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339; Young MD, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa151; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570	66	69	73	3	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2021	39	6					705	716		10.1038/s41587-020-00796-1	http://dx.doi.org/10.1038/s41587-020-00796-1		DEC 2020	12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	SQ1MI	33361824	Bronze			2023-01-03	WOS:000601625500001
J	Borie, R; Savale, L; Dossier, A; Ghosn, J; Taille, C; Visseaux, B; Jebreen, K; Diallo, A; Tesmoingt, C; Morer, L; Goletto, T; Faucher, N; Hajouji, L; Neukirch, C; Phillips, M; Stelianides, S; Bouadma, L; Brosseau, S; Ottaviani, S; Pluvy, J; Le Pluart, D; Debray, MP; Raynaud-Simon, A; Descamps, D; Khalil, A; Timsit, JF; Lescure, FX; Descamps, V; Papo, T; Humbert, M; Crestani, B; Dieude, P; Vicaut, E; Zalcman, G				Borie, Raphael; Savale, Laurent; Dossier, Antoine; Ghosn, Jade; Taille, Camille; Visseaux, Benoit; Jebreen, Kamel; Diallo, Abourahmane; Tesmoingt, Chloe; Morer, Lise; Goletto, Tiphaine; Faucher, Nathalie; Hajouji, Linda; Neukirch, Catherine; Phillips, Mathilde; Stelianides, Sandrine; Bouadma, Lila; Brosseau, Solenn; Ottaviani, Sebastien; Pluvy, Johan; Le Pluart, Diane; Debray, Marie-Pierre; Raynaud-Simon, Agathe; Descamps, Diane; Khalil, Antoine; Timsit, Jean Francois; Lescure, Francois-Xavier; Descamps, Vincent; Papo, Thomas; Humbert, Marc; Crestani, Bruno; Dieude, Philippe; Vicaut, Eric; Zalcman, Gerard		Bichat Kremlin-Bicetre AP-HP COVID	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study	PLOS ONE			English	Article							INTERLEUKIN-1; PNEUMONIA; MORTALITY; BLOCKADE; WUHAN; ARDS	Background The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. Material and methods A cohort study was designed to evaluate whether a therapeutic algorithm using steroids with or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients with a >= 5-day evolution since symptoms onset, with hyper-inflammation (CRP >= 50mg/L), requiring 3-5 L/min oxygen, received methylprednisolone alone. Patients needing >= 6 L/min received methylprednisolone + subcutaneous anakinra daily either frontline or in case clinical deterioration upon corticosteroids alone. Death rate and death or intensive care unit (ICU) invasive ventilation rate at Day 15, with Odds Ratio (OR) and 95% CIs, were determined according to logistic regression and propensity scores. A Bayesian analysis estimated the treatment effects. Results Of 108 consecutive patients, 70 patients received glucocorticoids alone. The control group comprised 63 patients receiving standard of care. In the corticosteroidstanakinra group (n = 108), death rate was 20.4%, versus 30.2% in the controls, indicating a 30% relative decrease in death risk and a number of 10 patients to treat to avoid a death (p = 0.15). Using propensity scores a per-protocol analysis showed an OR for COVID-19-related death of 0.9 (95%CI [0.80-1.01], p = 0.067). On Bayesian analysis, the posterior probability of any mortality benefit with corticosteroids+/-anakinra was 87.5%, with a 7.8% probability of treatment-related harm. Pre-existing diabetes exacerbation occurred in 29 of 108 patients (26.9%). Conclusion In COVID-19 non-ICU inpatients at the cytokine release phase, corticosteroids with or without anakinra were associated with a 30% decrease of death risk on Day 15.	[Borie, Raphael; Taille, Camille; Morer, Lise; Goletto, Tiphaine; Hajouji, Linda; Neukirch, Catherine; Phillips, Mathilde; Stelianides, Sandrine; Brosseau, Solenn; Pluvy, Johan; Crestani, Bruno; Zalcman, Gerard] Univ Paris, Univ Hosp Bichat Claude Bernard, Pulmonol & Thorac Oncol Dept, AP HP, Paris, France; [Savale, Laurent; Humbert, Marc] Paris Saclay Univ, Kremlin Bicetre Univ Hosp, Pulmonol Dept, AP HP, Le Kremlin Bicetre, France; [Dossier, Antoine; Papo, Thomas] Univ Paris, Univ Hosp Bichat Claude Bernard, Internal Med Dept, AP HP, Paris, France; [Ghosn, Jade; Le Pluart, Diane; Lescure, Francois-Xavier] Univ Paris, Univ Hosp Bichat Claude Bernard, Infect Dis Dept, AP HP, Paris, France; [Visseaux, Benoit; Descamps, Diane] Univ Paris, Univ Hosp Bichat Claude Bernard, Virol Dept, AP HP, Paris, France; [Jebreen, Kamel; Diallo, Abourahmane; Vicaut, Eric] Univ Paris, Univ Hosp Lariboisiere, Biostat & Clin Res Dept, AP HP, Paris, France; [Tesmoingt, Chloe; Raynaud-Simon, Agathe] Univ Paris, Univ Hosp Bichat Claude Bernard, Pharm Dept, AP HP, Paris, France; [Faucher, Nathalie] Univ Paris, Univ Hosp Bichat Claude Bernard, Geriatr Dept, AP HP, Paris, France; [Bouadma, Lila; Timsit, Jean Francois] Univ Paris, Univ Hosp Bichat Claude Bernard, Intens Care Dept, AP HP,Med & Infect Dis ICU, Paris, France; [Ottaviani, Sebastien; Dieude, Philippe] Univ Paris, Univ Hosp Bichat Claude Bernard, Rheumatol Dept, AP HP, Paris, France; [Debray, Marie-Pierre; Khalil, Antoine] Univ Paris, Univ Hosp Bichat Claude Bernard, Radiol Dept, AP HP, Paris, France; [Descamps, Vincent] Univ Paris, Univ Hosp Bichat Claude Bernard, Dermatol Dept, AP HP, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Zalcman, G (corresponding author), Univ Paris, Univ Hosp Bichat Claude Bernard, Pulmonol & Thorac Oncol Dept, AP HP, Paris, France.	gerard.zalcman@aphp.fr	Humbert, Marc/ABD-5112-2021; Dossier, Antoine/AGG-9850-2022	Borie, Raphael/0000-0002-9906-0024; Taille, Camille/0000-0001-9768-5728				Alfaraj SH, 2019, TRAVEL MED INFECT DI, V29, P48, DOI 10.1016/j.tmaid.2019.03.004; Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706; Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0; Beigel JH, 2020, N ENGL J MED, V383, P1813; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Caly Leon, 2020, Antiviral Res, V178, P104787, DOI 10.1016/j.antiviral.2020.104787; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004; COVID19 APHP Grp, 2020, LANCET, V395, P1760, DOI 10.1016/S0140-6736(20)31210-1; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117; Fadel R, 2020, CLIN INFECT DIS, V71, P2114, DOI 10.1093/cid/ciaa601; Farag NS, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105738; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Kernan KF, 2019, GENES IMMUN, V20, P520, DOI 10.1038/s41435-018-0030-3; Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; McCandless LC, 2009, STAT MED, V28, P94, DOI 10.1002/sim.3460; Meduri GU, 2007, CHEST, V131, P954, DOI 10.1378/chest.06-2100; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Navarro-Millan I, 2020, ARTHRITIS RHEUMATOL, V72, P1990, DOI 10.1002/art.41422; Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; ROBINS JM, 1994, J AM STAT ASSOC, V89, P846, DOI 10.2307/2290910; Rotz SJ, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26642; Seam N, 2016, INTENS CARE MED, V42, P924, DOI 10.1007/s00134-015-4160-z; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2; Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	41	8	8	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2020	15	12							e0243961	10.1371/journal.pone.0243961	http://dx.doi.org/10.1371/journal.pone.0243961			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1IW	33326457	Green Published, gold			2023-01-03	WOS:000600176400066
J	Stens, NA; Hisdal, J; Bakke, EF; Kaur, N; Sharma, A; Stranden, E; Thijssen, DHJ; Hoiseth, LO				Stens, Niels A.; Hisdal, Jonny; Bakke, Espen F.; Kaur, Narinder; Sharma, Archana; Stranden, Einar; Thijssen, Dick H. J.; Hoiseth, Lars Oivind			Factors mediating the pressor response to isometric muscle contraction: An experimental study in healthy volunteers during lower body negative pressure	PLOS ONE			English	Article							ARTERIAL-BLOOD PRESSURE; STATIC EXERCISE; CARDIAC-OUTPUT; STROKE VOLUME; CARDIOPULMONARY BAROREFLEXES; CARDIOVASCULAR-RESPONSES; SYMPATHETIC RESPONSES; CIRCULATORY RESPONSES; HEMODYNAMIC-RESPONSES; HANDGRIP EXERCISE	Whilst both cardiac output (CO) and total peripheral resistance (TPR) determine mean arterial blood pressure (MAP), their relative importance in the pressor response to isometric exercise remains unclear. This study aimed to elucidate the relative importance of these two different factors by examining pressor responses during cardiopulmonary unloading leading to step-wise reductions in CO. Hemodynamics were investigated in 11 healthy individuals before, during and after two-minute isometric exercise during lower body negative pressure (LBNP; -20mmHg and -40mmHg). The blood pressure response to isometric exercise was similar during normal and reduced preload, despite a step-wise reduction in CO during LBNP (-20mmHg and -40mmHg). During -20mmHg LBNP, the decreased stroke volume, and consequently CO, was counteracted by an increased TPR, while heart rate (HR) was unaffected. HR was increased during -40 mmHg LBNP, although insufficient to maintain CO; the drop in CO was perfectly compensated by an increased TPR to maintain MAP. Likewise, transient application of LBNP (-20mmHg and -40mmHg) resulted in a short transient drop in MAP, caused by a decrease in CO, which was compensated by an increase in TPR. This study suggests that, in case of reductions of CO, changes in TPR are primarily responsible for maintaining the pressor response during isometric exercise. This highlights the relative importance of TPR compared to CO in mediating the pressor response during isometric exercise.	[Stens, Niels A.; Thijssen, Dick H. J.] Radboud Univ Nijmegen Med Ctr, Res Inst Hlth Sci, Dept Physiol, Nijmegen, Netherlands; [Stens, Niels A.; Hisdal, Jonny; Kaur, Narinder; Stranden, Einar] Oslo Univ Hosp, Dept Vasc Surg, Div Cardiovasc & Pulm Dis, Sect Vasc Invest, Oslo, Norway; [Hisdal, Jonny] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Bakke, Espen F.] Norwegian Armed Forces Med Serv, Inst Aviat Med, Oslo, Norway; [Kaur, Narinder] Dermatol Ctr Telemark, Porsgrunn, Norway; [Sharma, Archana] Oslo Univ Hosp, Dept Endocrinol, Oslo, Norway; [Sharma, Archana; Hoiseth, Lars Oivind] Oslo Univ Hosp, Dept Anesthesiol, Oslo, Norway; [Thijssen, Dick H. J.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Liverpool, Merseyside, England	Radboud University Nijmegen; University of Oslo; University of Oslo; University of Oslo; University of Oslo; Liverpool John Moores University	Hoiseth, LO (corresponding author), Oslo Univ Hosp, Dept Anesthesiol, Oslo, Norway.	Lars.Oivind.Hoiseth@hotmail.com	Stens, Niels/AAX-5355-2021	Stens, Niels/0000-0001-7487-151X; Hoiseth, Lars Oivind/0000-0003-0669-8297				Alam M, 1937, J PHYSIOL-LONDON, V89, P372, DOI 10.1113/jphysiol.1937.sp003485; ARROWOOD JA, 1993, J APPL PHYSIOL, V74, P2559, DOI 10.1152/jappl.1993.74.5.2559; Augustyniak RA, 2001, AM J PHYSIOL-HEART C, V280, pH1645, DOI 10.1152/ajpheart.2001.280.4.H1645; BERGENWALD L, 1981, J PHYSIOL-LONDON, V318, P445; Berger A, 2016, J AM SOC HYPERTENS, V10, P527, DOI 10.1016/j.jash.2016.04.003; Binder K, 2013, EUR J APPL PHYSIOL, V113, P183, DOI 10.1007/s00421-012-2428-3; BROWN E, 1966, J PHYSIOL-LONDON, V183, P607, DOI 10.1113/jphysiol.1966.sp007887; CHANEY RH, 1988, AM J CARDIOL, V62, P1058, DOI 10.1016/0002-9149(88)90548-6; CHANG CM, 1994, AVIAT SPACE ENVIR MD, V65, P615; Chirinos JA, 2010, AM J PHYSIOL-HEART C, V298, pH320, DOI 10.1152/ajpheart.00334.2009; Conviser JM, 2017, J SCI MED SPORT, V20, P196, DOI 10.1016/j.jsams.2016.01.003; Elstad M, 2009, ACTA PHYSIOL, V195, P289, DOI 10.1111/j.1748-1716.2008.01887.x; ERIKSEN M, 1990, J PHYSIOL-LONDON, V426, P423, DOI 10.1113/jphysiol.1990.sp018147; ERIKSEN M, 1990, MED BIOL ENG COMPUT, V28, P555, DOI 10.1007/BF02442607; Franklin Barry A, 2003, J Cardiovasc Nurs, V18, P116; FREY MAB, 1988, J APPL PHYSIOL, V65, P1752, DOI 10.1152/jappl.1988.65.4.1752; FREY MAB, 1986, AVIAT SPACE ENVIR MD, V57, P531; Goswami N, 2019, PHYSIOL REV, V99, P807, DOI 10.1152/physrev.00006.2018; Grotle AK, 2020, AUTON NEUROSCI-BASIC, V228, DOI 10.1016/j.autneu.2020.102698; GUZ A, 1987, J PHYSIOL-LONDON, V393, P499, DOI 10.1113/jphysiol.1987.sp016836; Hammond RL, 2000, AM J PHYSIOL-HEART C, V278, pH818, DOI 10.1152/ajpheart.2000.278.3.H818; Hatzaras I, 2007, CARDIOLOGY, V107, P103, DOI 10.1159/000094530; Hisdal J, 2004, EUR J APPL PHYSIOL, V91, P336, DOI 10.1007/s00421-003-0982-4; Hisdal J, 2003, AVIAT SPACE ENVIR MD, V74, P874; Hisdal J, 2001, AM J PHYSIOL-REG I, V281, pR213, DOI 10.1152/ajpregu.2001.281.1.R213; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; IELLAMO F, 1993, EUR J APPL PHYSIOL, V66, P381, DOI 10.1007/BF00599609; IMHOLZ BPM, 1990, CARDIOVASC RES, V24, P214, DOI 10.1093/cvr/24.3.214; Incognito AV, 2018, AM J PHYSIOL-REG I, V314, pR114, DOI 10.1152/ajpregu.00266.2017; Kiviniemi AM, 2012, ACTA PHYSIOL, V206, P51, DOI 10.1111/j.1748-1716.2012.02447.x; Laszlo Z, 1998, AVIAT SPACE ENVIR MD, V69, P32; LEVENHAGEN DK, 1994, AM J PHYSIOL, V267, pH593, DOI 10.1152/ajpheart.1994.267.2.H593; LEWIS SF, 1983, CLIN SCI, V64, P593, DOI 10.1042/cs0640593; LIND AR, 1964, CLIN SCI, V27, P229; LIND AR, 1967, J PHYSIOL-LONDON, V192, P595, DOI 10.1113/jphysiol.1967.sp008319; Lindhard J, 1920, SKAND ARCH PHYSIOL, V40, P196, DOI 10.1111/j.1748-1716.1920.tb01419.x; MARTIN CE, 1974, J CLIN INVEST, V54, P104, DOI 10.1172/JCI107731; MITCHELL JH, 1974, ANNU REV MED, V25, P369, DOI 10.1146/annurev.me.25.020174.002101; Morrison SF, 2001, AM J PHYSIOL-REG I, V281, pR683, DOI 10.1152/ajpregu.2001.281.3.R683; Mortensen KH, 2016, EUR RADIOL, V26, P1009, DOI 10.1007/s00330-015-3920-z; Mueller PJ, 2018, COMPR PHYSIOL, V8, P103, DOI 10.1002/cphy.c160040; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; Pinheiro J., 2021, LINEAR NONLINEAR MIX; R Development Core Team, 2020, LANG ENV STAT COMP; Reed AS, 2000, J PHYSIOL-LONDON, V525, P253, DOI 10.1111/j.1469-7793.2000.t01-1-00253.x; Rstudio, 2020, RSTUDIO INTEGRATED D; SAGIV M, 1991, INT J SPORTS MED, V12, P41, DOI 10.1055/s-2007-1024653; Samora M, 2019, J APPL PHYSIOL, V127, P408, DOI 10.1152/japplphysiol.00270.2019; SANDERS JS, 1988, J AM COLL CARDIOL, V12, P1241, DOI 10.1016/0735-1097(88)92607-1; SCHERRER U, 1988, CIRCULATION, V78, P49, DOI 10.1161/01.CIR.78.1.49; SEALS DR, 1988, J APPL PHYSIOL, V64, P2197, DOI 10.1152/jappl.1988.64.5.2197; Sheriff DD, 1998, AM J PHYSIOL-HEART C, V275, pH767, DOI 10.1152/ajpheart.1998.275.3.H767; Shoemaker J. K., 1985, J APPL PHYSIOL, V103, P228; Somani YB, 2018, AM J HYPERTENS, V31, P362, DOI 10.1093/ajh/hpx173; STEFADOUROS MA, 1974, CIRCULATION, V49, P1185, DOI 10.1161/01.CIR.49.6.1185; Stewart JM, 2007, AM J PHYSIOL-HEART C, V293, pH1908, DOI 10.1152/ajpheart.00439.2007; Stewart JM, 2007, AM J PHYSIOL-HEART C, V292, pH215, DOI 10.1152/ajpheart.00681.2006; Teixeira AL, 2018, AM J PHYSIOL-HEART C, V314, pH593, DOI 10.1152/ajpheart.00576.2017; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; THORESEN M, 1980, ACTA PHYSIOL SCAND, V109, P333, DOI 10.1111/j.1748-1716.1980.tb06604.x; TOSKA K, 1993, J PHYSIOL-LONDON, V472, P501, DOI 10.1113/jphysiol.1993.sp019958; Toska K, 2010, ACTA PHYSIOL, V200, P211, DOI 10.1111/j.1748-1716.2010.02144.x; Watanabe K, 2014, AM J PHYSIOL-HEART C, V306, pH251, DOI 10.1152/ajpheart.00699.2013; Yamagata T, 2020, CLIN EXP HYPERTENS, V42, P595, DOI 10.1080/10641963.2020.1747482	64	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2020	15	12							e0243627	10.1371/journal.pone.0243627	http://dx.doi.org/10.1371/journal.pone.0243627			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE8QN	33296410	Green Published, gold, Green Accepted			2023-01-03	WOS:000598626100030
J	Manjavidze, T; Rylander, C; Skjeldestad, FE; Kazakhashvili, N; Anda, EE				Manjavidze, Tinatin; Rylander, Charlotta; Skjeldestad, Finn Egil; Kazakhashvili, Nata; Anda, Erik Eik			The impact of antenatal care utilization on admissions to neonatal intensive care units and perinatal mortality in Georgia	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; PRENATAL-CARE; PRETERM BIRTH; APNCU INDEX; ADEQUACY; RISK; ASSOCIATION; DEATHS; AUDIT	Introduction Appropriate antenatal care (ANC) utilization has direct, significant effects on perinatal mortality (PM). Georgia has one of the highest PM rates (11.7 per 1000 births) in Europe and launched a more intensive ANC programme in 2018. Aim To evaluate the associations between the Adequacy of Prenatal Care Utilization (APNCU) index and neonatal intensive care unit (NICU) admission and PM in Georgia. Methods The Georgian Birth Registry (GBR), with linkage to the Vital Registration System, was used as the main data source; 148,407 eligible mothers and singleton newborns were identified during the observation period (2017-2019). The main exposure was ANC utilization, measured by the APNCU index, and the hospitalization registry was used to validate NICU admissions. Logistic regression analysis was used to assess the associations between the exposure and outcomes while controlling for potential confounders. Results The overall PM rate was 11.6/1000 births, and the proportion of newborns with a NICU admission was 7.8%. 85% of women initiated ANC before gestational age week 12. According to the APNCU index, 16% of women received inadequate, 10% intermediate, 38% adequate, and 36% intensive care. Women who received intermediate care had the lowest odds of PM (adjusted odds ratio [AOR] = 0.56, 95% confidence interval [CI] 0.45-0.70), and newborns of women who received inadequate care had the highest odds of NICU admission (AOR = 1.16, 95% CI 1.09-1.23) and PM (AOR = 1.18, 95% CI 1.02-1.36). Conclusion ANC utilization is significantly associated with newborn asmissions to NICU and PM in Georgia. Women received inadequate care experienced the highest odds of newborn admissions to NICU and PM.	[Manjavidze, Tinatin; Rylander, Charlotta; Skjeldestad, Finn Egil; Anda, Erik Eik] Arctic Univ Norway, Dept Community Med, Fac Hlth Sci, Univ Tromso, Tromso, Norway; [Kazakhashvili, Nata] Ivane Javakhishvili Tbilisi State Univ, Dept Publ Hlth, Fac Med, Tbilisi, Georgia	UiT The Arctic University of Tromso; Ivane Javakhishvili Tbilisi State University	Manjavidze, T (corresponding author), Arctic Univ Norway, Dept Community Med, Fac Hlth Sci, Univ Tromso, Tromso, Norway.	tinatin.manjavidze@uit.no	Rylander, Charlotta/AAE-2033-2022; manjavidze, tinatin/AAE-4483-2021	Skjeldestad, Finn Egil/0000-0001-9875-4991; manjavidze, tinatin/0000-0003-1340-6256	Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education	Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education	The project is fully funded by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 1996, PUBLIC HLTH REP, V111, P408; Australian Government Department of Health, 2019, CLIN PRACT GUID PREG; Beauclair R, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-204; Beeckman K, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-213; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Chollat C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00247; Costantine MM, 2009, OBSTET GYNECOL, V114, P354, DOI 10.1097/AOG.0b013e3181ae98c2; De Lange TE, 2008, AUST NZ J OBSTET GYN, V48, P50, DOI 10.1111/j.1479-828X.2007.00801.x; Diguisto C, 2018, J PEDIATR-US, V203, P150, DOI 10.1016/j.jpeds.2018.07.072; Dowswell T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000934.pub2; Gamkrelidze AK, 2018, HLTH CARE STAT YB; Georgia Government, 2017, NAT STRAT SUPP MAT; Ghimire PR, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071428; Gilbert NL, 2010, INT J GYNECOL OBSTET, V109, P155, DOI 10.1016/j.ijgo.2009.12.009; Heaman MI, 2019, J OBSTET GYNAECOL CA, V41, P947, DOI 10.1016/j.jogc.2018.09.006; Heaman Maureen I, 2008, BMC Pregnancy Childbirth, V8, P15, DOI 10.1186/1471-2393-8-15; Koroukian SM, 2002, J CLIN EPIDEMIOL, V55, P296, DOI 10.1016/S0895-4356(01)00471-1; Kotelchuck M, 2003, J CLIN EPIDEMIOL, V56, P286, DOI 10.1016/S0895-4356(02)00592-9; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Lavin T, 2018, BJOG-INT J OBSTET GY, V125, P140, DOI 10.1111/1471-0528.14645; Linard M, 2018, BJOG-INT J OBSTET GY, V125, P587, DOI 10.1111/1471-0528.14794; Logavlen VV, 2019, DAN MED J, V66; Manjavidze T, 2020, RISK MANAG HEALTHC P, V13, P313, DOI 10.2147/RMHP.S243207; Miller S, 2016, LANCET, V388, P2176, DOI 10.1016/S0140-6736(16)31472-6; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; National Collaborating Centre for Women's and Children's Health, 2008, UK ROYAL COLL OBST G; Partridge S, 2012, AM J PERINAT, V29, P787, DOI 10.1055/s-0032-1316439; Richardus JH, 2003, BJOG-INT J OBSTET GY, V110, P97; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Shin D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060838; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; VanderWeele TJ, 2009, J CLIN EPIDEMIOL, V62, P438, DOI 10.1016/j.jclinepi.2008.08.001; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Vogel JP, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-19; WHO, 2022, WHO RECOMMENDATIONS; Yeoh PL, 2018, INT J QUAL HEALTH C, V30, P466, DOI 10.1093/intqhc/mzy041; Zhang B, 2017, J HUAZHONG U SCI-MED, V37, P605, DOI 10.1007/s11596-017-1779-8; Zonneveld R, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0941-6	42	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2020	15	12							e0242991	10.1371/journal.pone.0242991	http://dx.doi.org/10.1371/journal.pone.0242991			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PB8MS	33264324	gold, Green Published			2023-01-03	WOS:000596569200055
J	Venkatesh, KK; Pate, V; Boggess, KA; Jones, HE; Funk, MJ; Smid, MC				Venkatesh, Kartik K.; Pate, Virginia; Boggess, Kim A.; Jones, Hendree E.; Funk, Michele Jonsson; Smid, Marcela C.			Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population A Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NEONATAL ABSTINENCE SYNDROME; MATERNAL-FETAL-MEDICINE; ACADEMY-OF-PEDIATRICS; FOR-DISEASE-CONTROL; AMERICAN-COLLEGE; JOINT-WORKSHOP; WOMEN; HEALTH; HOSPITALIZATIONS; GYNECOLOGISTS	Background: Opioid and psychotropic prescriptions are common during pregnancy. Little is known about coprescriptions of both medications in this setting. Objective: To describe opioid prescription among women who are prescribed psychotropics compared with women who are not. Design: Cross-sectional study. Setting: U.S. commercial insurance beneficiaries from Market-Scan (2001 to 2015). Participants: Pregnant women at 22 weeks' gestation or greater who were insured continuously for 3 months or more before pregnancy through delivery. Measurements: Opioid prescription, dosage thresholds (morphine milligram equivalents [MME] of >= 50/day and >= 90/day), number of opioid agents (>= 2), and duration (>= 30 days) among those with and without prescription of psychotropics, from 2011 to 2015. Results: Among 958 980 pregnant women, 10% received opioids only, 6% psychotropics only, and 2% opioids with coprescription of psychotropics. Opioid prescription was higher among women prescribed psychotropics versus those who were not (26.5% vs. 10.7%). From 2001 to 2015, psychotropic prescription overall increased from 4.4% to 7.6%, opioid prescription without coprescription of psychotropics decreased from 11.9% to 8.4%, and opioids with coprescription decreased from 28.1% to 22.0%. Morphine milligram equivalents of 50 or greater per day decreased for women with and without coprescription (29.6% to 17.3% and 22.8% to 18.5%, respectively); MME of 90 or greater per day also decreased in both groups (15.0% to 4.7% and 11.5% to 4.2%, respectively). Women prescribed opioids only were more likely to have an antepartum hospitalization compared with those with neither prescription, as were women with coprescription versus those prescribed psychotropics only. Compared with those prescribed opioids only, women with coprescriptions were more likely to exceed MME of 90 or greater per day and to be prescribed 2 or more opioid agents and for 30 days or longer. Number and duration of opioids increased with benzodiazepine and gabapentin coprescription. Limitation: Inability to determine appropriateness of prescribing or overdose events. Conclusion: Opioids are frequently coprescribed with psychotropic medication during pregnancy and are associated with antepartum hospitalization. A substantial proportion of pregnant women are prescribed opioids at doses that increase overdose risk and exceed daily recommendations.	[Venkatesh, Kartik K.] Ohio State Univ, Columbus, OH 43210 USA; [Pate, Virginia; Funk, Michele Jonsson] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA; [Pate, Virginia; Funk, Michele Jonsson] Univ N Carolina, Ctr Womens Hlth Res, Chapel Hill, NC 27515 USA; [Boggess, Kim A.; Jones, Hendree E.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Smid, Marcela C.] Univ Utah Hlth, Salt Lake City, UT USA; [Venkatesh, Kartik K.] Ohio State Univ, Div Maternal Fetal Med, Dept Obstet & Gynecol, 395 West 12th Ave,Floor 5, Columbus, OH 43210 USA; [Funk, Michele Jonsson] Univ N Carolina, Gillings Sch Publ Hlth, Dept Epidemiol, 104B Market St, Chapel Hill, NC 27599 USA; [Boggess, Kim A.; Jones, Hendree E.] Univ N Carolina, Div Maternal Fetal Med, Dept ObStet & Gynecol, 3010 Old Clin Bldg, Chapel Hill, NC 27599 USA; [Smid, Marcela C.] Dept Obstet & Gynecol, Div Maternal Fetal Med, 50 North Med Dr, Salt Lake City, UT 84132 USA	University System of Ohio; Ohio State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Utah System of Higher Education; University of Utah; University System of Ohio; Ohio State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Venkatesh, KK (corresponding author), Ohio State Univ, Div Maternal Fetal Med, Dept Obstet & Gynecol, 395 West 12th Ave,Floor 5, Columbus, OH 43210 USA.	katik.venkatesh@osumc.edu	Funk, Michele Jonsson/F-6885-2011	Funk, Michele Jonsson/0000-0002-3756-7540; Venkatesh, Kartik/0000-0002-8043-556X	Women's Reproductive Health Research (WRHR K12) [1K12 HD085816]	Women's Reproductive Health Research (WRHR K12)	Dr. Smid is supported by the Women's Reproductive Health Research (WRHR K12, 1K12 HD085816) Career Development Program.	Ailes Elizabeth C, 2015, MMWR Morb Mortal Wkly Rep, V64, P37; [Anonymous], 2015, Obstet Gynecol, V125, P1268, DOI 10.1097/01.AOG.0000465192.34779.dc; Bacak SJ, 2005, AM J OBSTET GYNECOL, V192, P592, DOI 10.1016/j.ajog.2004.10.638; Badreldin N, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.04.003; Bateman BT, 2017, OBSTET GYNECOL, V130, P29, DOI 10.1097/AOG.0000000000002093; Bohnert ASB, 2019, NEW ENGL J MED, V380, P71, DOI 10.1056/NEJMra1802148; Butler AM, 2017, OBSTET GYNECOL, V129, P629, DOI 10.1097/AOG.0000000000001927; Centers for Disease Control and Prevention, 2018, CDC GUID PRESCR OP C; Chapman SLC, 2013, WOMEN HEALTH, V53, P479, DOI 10.1080/03630242.2013.804025; Clapp MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.01.174; Coleman-Cowger VH, 2012, PSYCHOL ADDICT BEHAV, V26, P345, DOI 10.1037/a0025355; Creanga AA, 2012, OBSTET GYNECOL, V119, P924, DOI 10.1097/AOG.0b013e31824ea276; Dawson AL, 2016, MMWR-MORBID MORTAL W, V65, P41, DOI 10.15585/mmwr.mm6503a1; Desai RJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2102; Desai RJ, 2014, OBSTET GYNECOL, V123, P997, DOI 10.1097/AOG.0000000000000208; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Gazmararian JA, 2002, OBSTET GYNECOL, V100, P94, DOI 10.1016/S0029-7844(02)02024-0; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Haight SC, 2018, MMWR-MORBID MORTAL W, V67, P845, DOI 10.15585/mmwr.mm6731a1; Handal M, 2011, EUR J CLIN PHARMACOL, V67, P953, DOI 10.1007/s00228-011-1030-7; Hanley GE, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-242; Holbrook A, 2012, AM J DRUG ALCOHOL AB, V38, P575, DOI 10.3109/00952990.2012.696168; Huybrechts KF, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3326; Kelly JP, 2008, PAIN, V138, P507, DOI 10.1016/j.pain.2008.01.027; Madsen AM, 2018, OBSTET GYNECOL, V131, P150, DOI 10.1097/AOG.0000000000002407; Margulis AV, 2013, PHARMACOEPIDEM DR S, V22, P16, DOI 10.1002/pds.3284; Markus AR, 2013, WOMEN HEALTH ISS, V23, pE273, DOI 10.1016/j.whi.2013.06.006; Metz TD, 2016, OBSTET GYNECOL, V128, P1233, DOI 10.1097/AOG.0000000000001695; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Park Y, 2017, PSYCHIAT SERV, V68, P1112, DOI 10.1176/appi.ps.201600408; Prabhu M, 2018, OBSTET GYNECOL, V132, P459, DOI 10.1097/AOG.0000000000002741; Reardon JM, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0075-4; Reddy UM, 2017, OBSTET GYNECOL, V130, P10, DOI 10.1097/AOG.0000000000002054; Sanz EJ, 2005, LANCET, V365, P482, DOI 10.1016/S0140-6736(05)17865-9; Schiff DM, 2018, OBSTET GYNECOL, V132, P466, DOI 10.1097/AOG.0000000000002734; Smid M, 2018, OBSTET GYNECOL, V131, P163, DOI 10.1097/AOG.0000000000002426; Smid MC, 2019, OBSTET GYNECOL, V133, P1131, DOI 10.1097/AOG.0000000000003279; Virginia Department of Health Office of the Chief Medical Examiner, 2015, PREGN ASS DEATHS DRU; Wachman EM, 2011, J ADDICT MED, V5, P293, DOI 10.1097/ADM.0b013e3182266a3a; Williams AR, 2016, NEW ENGL J MED, V375, P813, DOI 10.1056/NEJMp1604223	41	7	7	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2020	173			11			S19	S28		10.7326/M19-3249	http://dx.doi.org/10.7326/M19-3249			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QI2TF	33253018				2023-01-03	WOS:000618828900004
J	Hanna, TP; King, WD; Thibodeau, S; Jalink, M; Paulin, GA; Harvey-Jones, E; O'Sullivan, DE; Booth, CM; Sullivan, R; Aggarwal, A				Hanna, Timothy P.; King, Will D.; Thibodeau, Stephane; Jalink, Matthew; Paulin, Gregory A.; Harvey-Jones, Elizabeth; O'Sullivan, Dylan E.; Booth, Christopher M.; Sullivan, Richard; Aggarwal, Ajay			Mortality due to cancer treatment delay: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ADJUVANT CHEMOTHERAPY INITIATION; III COLON-CANCER; BREAST-CANCER; TREATMENT INTERVAL; CLINICAL IMPACT; TREATMENT TIME; LUNG-CANCER; STAGE-II; SURVIVAL; SURGERY	Objective To quantify the association of cancer treatment delay and mortality for each four week increase in delay to inform cancer treatment pathways. Design Systematic review and meta-analysis. Data sources Published studies in Medline from 1 January 2000 to 10 April 2020. Eligibility criteria for selecting studies Curative, neoadjuvant, and adjuvant indications for surgery, systemic treatment, or radiotherapy for cancers of the bladder, breast, colon, rectum, lung, cervix, and head and neck were included. The main outcome measure was the hazard ratio for overall survival for each four week delay for each indication. Delay was measured from diagnosis to first treatment, or from the completion of one treatment to the start of the next. The primary analysis only included high validity studies controlling for major prognostic factors. Hazard ratios were assumed to be log linear in relation to overall survival and were converted to an effect for each four week delay. Pooled effects were estimated using DerSimonian and Laird random effect models. Results The review included 34 studies for 17 indications (n=1 272 681 patients). No high validity data were found for five of the radiotherapy indications or for cervical cancer surgery. The association between delay and increased mortality was significant (P<0.05) for 13 of 17 indications. Surgery findings were consistent, with a mortality risk for each four week delay of 1.06-1.08 (eg, colectomy 1.06, 95% confidence interval 1.01 to 1.12; breast surgery 1.08, 1.03 to 1.13). Estimates for systemic treatment varied (hazard ratio range 1.01-1.28). Radiotherapy estimates were for radical radiotherapy for head and neck cancer (hazard ratio 1.09, 95% confidence interval 1.05 to 1.14), adjuvant radiotherapy after breast conserving surgery (0.98, 0.88 to 1.09), and cervix cancer adjuvant radiotherapy (1.23, 1.00 to 1.50). A sensitivity analysis of studies that had been excluded because of lack of information on comorbidities or functional status did not change the findings. Conclusions Cancer treatment delay is a problem in health systems worldwide. The impact of delay on mortality can now be quantified for prioritisation and modelling. Even a four week delay of cancer treatment is associated with increased mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers. Policies focused on minimising system level delays to cancer treatment initiation could improve population level survival outcomes.				tim.hanna@kingstonhsc.ca		Jalink, Matthew/0000-0002-2269-8521; Thibodeau, Stephane/0000-0002-7849-1685; Sullivan, Richard/0000-0002-6435-1825; Paulin, Gregory/0000-0001-8752-0102; Aggarwal, Ajay/0000-0001-9645-6659; Hanna, Timothy/0000-0003-3228-6042	Ontario Institute for Cancer Research by the Government of Ontario [IA-035]; UK Research and Innovation Economic and Social Research Council [ES/P010962/1]; Ontario Graduate Scholarship; Chen-Aronson Fellowship in Causes of Cancer; Canada Research Chair in Population Cancer Care; National Institute for Health Research (NIHR) Advanced Fellowship [NIHR300599]	Ontario Institute for Cancer Research by the Government of Ontario; UK Research and Innovation Economic and Social Research Council; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Chen-Aronson Fellowship in Causes of Cancer; Canada Research Chair in Population Cancer Care; National Institute for Health Research (NIHR) Advanced Fellowship(National Institute for Health Research (NIHR))	There was no project specific funding for this work. TPH holds a research chair provided by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario (#IA-035). RS is funded through the UK Research and Innovation Economic and Social Research Council (ES/P010962/1). DEO is supported by an Ontario Graduate Scholarship and a Chen-Aronson Fellowship in Causes of Cancer. CMB is supported as the Canada Research Chair in Population Cancer Care. AA is supported by a National Institute for Health Research (NIHR) Advanced Fellowship (NIHR300599). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the Government of Ontario, the National Institute for Health Research, or the Department of Health and Social Care,	[Anonymous], 2020, GUARDIAN 1026; Bagaria SP, 2019, J INVEST SURG, V32, P350, DOI 10.1080/08941939.2017.1421732; Barton M.B., 2013, REV OPTIMAL RADIOTHE; Bayraktar UD, 2011, CANCER-AM CANCER SOC, V117, P2364, DOI 10.1002/cncr.25720; Becerra AZ, 2017, ANN SURG ONCOL, V24, P1610, DOI 10.1245/s10434-016-5622-4; Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749; Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508; Booth CM, 2014, ANN ONCOL, V25, P1783, DOI 10.1093/annonc/mdu204; Booth CM, 2013, CANCER-AM CANCER SOC, V119, P1243, DOI 10.1002/cncr.27823; Boyle JM, 2020, CLIN ONCOL-UK, V32, pE135, DOI 10.1016/j.clon.2019.12.008; CHEN C, 2019, PLOS ONE, V15, DOI DOI 10.1371/J0URNAL.P0NE.0221946; Chen YP, 2016, ONCOTARGET, V7, P14973, DOI 10.18632/oncotarget.7789; Chen Z, 2008, RADIOTHER ONCOL, V87, P3, DOI 10.1016/j.radonc.2007.11.016; Cheung WY, 2009, DIS COLON RECTUM, V52, P1054, DOI 10.1007/DCR.0b013e3181a51173; Chu AT, 2019, CANCER-AM CANCER SOC, V125, P2011, DOI 10.1002/cncr.32048; Corbett CJ, 2019, UROLOGY, V132, P143, DOI 10.1016/j.urology.2019.05.038; DAVIS C, 2017, BMJ-BRIT MED J, V359, DOI DOI 10.1136/BMJ.J4530; Dossa F, 2017, LANCET GASTROENTEROL, V2, P501, DOI 10.1016/S2468-1253(17)30074-2; Eaglehouse YL, 2019, BREAST CANCER RES TR, V178, P441, DOI 10.1007/s10549-019-05404-8; Ferlay J., 2018, GLOBAL CANC OBSERVAT; Flemming JA, 2017, EJSO-EUR J SURG ONC, V43, P1447, DOI 10.1016/j.ejso.2017.04.014; Gagliato DD, 2014, J CLIN ONCOL, V32, P735, DOI 10.1200/JCO.2013.49.7693; GIRINSKY T, 1993, INT J RADIAT ONCOL, V27, P1051, DOI 10.1016/0360-3016(93)90522-W; Gore JL, 2009, CANCER-AM CANCER SOC, V115, P988, DOI 10.1002/cncr.24052; Graboyes EM, 2019, JAMA OTOLARYNGOL, V145, P166, DOI 10.1001/jamaoto.2018.2716; Gupta S, 2016, CLIN ONCOL-UK, V28, P739, DOI 10.1016/j.clon.2016.07.010; Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6; Harnett CE, 2020, TIMES COLONIST; Harris JP, 2018, JAMA OTOLARYNGOL, V144, P349, DOI 10.1001/jamaoto.2017.3406; Hebert-Croteau N, 2004, BREAST CANCER RES TR, V88, P187, DOI 10.1007/s10549-004-0594-7; Hershman D, 2006, CANCER-AM CANCER SOC, V107, P2581, DOI 10.1002/cncr.22316; Hershman DL, 2006, BREAST CANCER RES TR, V99, P313, DOI 10.1007/s10549-006-9206-z; Institute of Medicine; Committee on Quality of Health Care in America, 2001, SHAP FUT CROSS QUAL; Jhawar S, 2017, INT J RADIAT ONCOL, V98, P1132, DOI 10.1016/j.ijrobp.2017.03.045; Kanarek NF, 2014, AM J MED, V127, P443, DOI 10.1016/j.amjmed.2013.12.023; Kim RH, 2017, SURGERY, V161, P1633, DOI 10.1016/j.surg.2016.11.024; Kulkarni GS, 2009, J UROLOGY, V182, P1318, DOI 10.1016/j.juro.2009.06.041; Liao CT, 2017, EUR J CANCER, V72, P226, DOI 10.1016/j.ejca.2016.11.010; Lievens Y, 2019, LANCET ONCOL, V20, pE112, DOI 10.1016/S1470-2045(18)30917-3; Lima ISF, 2011, CANCER-AM CANCER SOC, V117, P3833, DOI 10.1002/cncr.25954; Luengo-Fernandez R, 2013, LANCET ONCOL, V14, P1165, DOI 10.1016/S1470-2045(13)70442-X; Massarweh NN, 2015, ANN SURG, V262, P312, DOI 10.1097/SLA.0000000000000859; Mateo AM, 2020, ANN SURG ONCOL, V27, P1679, DOI 10.1245/s10434-019-08050-y; McMillan MT, 2017, INT J RADIAT ONCOL, V98, P1142, DOI 10.1016/j.ijrobp.2017.04.004; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Murphy CT, 2016, J CLIN ONCOL, V34, P169, DOI 10.1200/JCO.2015.61.5906; Neal RD, 2015, BRIT J CANCER, V112, pS92, DOI 10.1038/bjc.2015.48; NHS, 2017, ACH WORLD CLASS CANC; NHS England, 2020, CLIN GUID MAN ESS CA; Olivotto IA, 2009, J CLIN ONCOL, V27, P16, DOI 10.1200/JCO.2008.18.1891; Polverini AC, 2016, ANN SURG ONCOL, V23, P3392, DOI 10.1245/s10434-016-5486-7; Raphael MJ, 2016, BREAST CANCER RES TR, V160, P17, DOI 10.1007/s10549-016-3960-3; Salazar MC, 2017, JAMA ONCOL, V3, P610, DOI 10.1001/jamaoncol.2016.5829; Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022; Sanford RA, 2016, ANN SURG ONCOL, V23, P1515, DOI 10.1245/s10434-015-5020-3; Sharma S, 2016, ORAL ONCOL, V56, P17, DOI 10.1016/j.oraloncology.2016.02.010; Shin DW, 2013, ANN SURG ONCOL, V20, P2468, DOI 10.1245/s10434-013-2957-y; The Royal College of Radiologists, 2019, TIM DEL RAD RAD GUID, V4th; Tsai CH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034351; Turner MC, 2018, J AM COLL SURGEONS, V226, P670, DOI 10.1016/j.jamcollsurg.2017.12.048; Urbach DR, 2020, CAN MED ASSOC J, V192, pE585, DOI 10.1503/cmaj.200791; van Dijk LV, 2020, RADIOTHER ONCOL, V142, P115, DOI 10.1016/j.radonc.2019.09.022; Xu F, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0107993, DOI 10.1371/J0URNAL.P0NE.0107993]	63	301	305	20	75	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	2020	371								m4087	10.1136/bmj.m4087	http://dx.doi.org/10.1136/bmj.m4087			27	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OM0SF	33148535	Green Published, hybrid			2023-01-03	WOS:000585739500014
J	Al-Khalil, O; Valeri, F; Senn, O; Rosemann, T; Di Gangi, S				Al-Khalil, Omar; Valeri, Fabio; Senn, Oliver; Rosemann, Thomas; Di Gangi, Stefania			Effects of a DRG-based hospital reimbursement on the health care utilization and costs in Swiss primary care: A retrospective "quasi-experimental" analysis	PLOS ONE			English	Article							PAYMENT; DESIGNS; SERIES	Introduction In Switzerland, a nationwide Swiss Diagnosis related Groups (Swiss DRG) system for hospital reimbursement was introduced in 2012. However, the impact of DRG systems on primary care is still unclear with respect to number of consultations and costs. The aim of this study was to investigate the effect of the implementation of DRG on costs and volumes in the primary care sector, on a nationwide basis in Switzerland. Methods The study retrospectively analysed yearly data, from 2008 to 2014, of almost 60 Swiss health insurers that covered almost all Swiss general practitioners, with a total number of patients which represented approximately 76% of the Swiss population. GP consultations, total numbers and rates, and the relative costs reimbursed (TARMED tariff values) in the Swiss federal states, cantons, which already introduced a DRG-like system before 2012 (AP-DRG), were compared to the GP consultations and costs reimbursed in the other cantons (DRG-naive). Regression discontinuity design analysis and mixed regression models, at cantonal level, were performed to evaluate the effect of the nationwide implementation of the Swiss DRG on health care demand and costs in the primary care setting. Change in outcome level and yearly trend pattern difference between groups (AP-DRG vs. DRG-naive) were examined. Results Overall, the total number of GP consultations and the relative TARMED values increased from 2008 to 2014. In the DRG naive, 15 cantons: in 2008, the number of GP consultations were 13,114,126, with a TARMED value of 1,194,957,157 CHF, and in 2014, the GP consultation were 13,752,511, with a TARMED value of 1,513,861,260 CHF. In the AP-DRG group, 11 cantons, the total number of GP consultations increased from 8,787,646, in 2008, to 9,347,168 in 2014 and the TARMED value increased from 896,673,657 CHF in 2008, to 1,100,203,508 CHF in 2014. The yearly trend pattern of GP consultations and TARMED values, in the AP-DRG group, were not significantly different from the respective trends in the DRG- naive and, overall, no significant change was detected in consultations and costs trends before and after 2012. Discussion/Conclusion This study found no evidence of any effect of the introduction of the SwissDRG on the yearly trend of primary care consultations and costs. Nevertheless, potential negative impacts on vulnerable patients, as chronically ill patients, could not be excluded and further investigation is required.	[Al-Khalil, Omar; Valeri, Fabio; Senn, Oliver; Rosemann, Thomas; Di Gangi, Stefania] Univ Zurich, Inst Primary Care, Zurich, Switzerland; [Al-Khalil, Omar; Valeri, Fabio; Senn, Oliver; Rosemann, Thomas; Di Gangi, Stefania] Univ Hosp Zurich, Zurich, Switzerland; [Al-Khalil, Omar] Univ Bern, Bern Univ Hosp, Dept Infect Dis, Bern, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; University of Bern; University Hospital of Bern	Al-Khalil, O (corresponding author), Univ Zurich, Inst Primary Care, Zurich, Switzerland.; Al-Khalil, O (corresponding author), Univ Hosp Zurich, Zurich, Switzerland.; Al-Khalil, O (corresponding author), Univ Bern, Bern Univ Hosp, Dept Infect Dis, Bern, Switzerland.	omar.al-khalil@insel.ch		Di Gangi, Stefania/0000-0002-2847-6399				[Anonymous], **NON-TRADITIONAL**; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2010, EINFUHRUNG LEISTUNGS; [Anonymous], 2006, BER GES; Barnighausen T, 2017, J CLIN EPIDEMIOL, V89, P21, DOI 10.1016/j.jclinepi.2017.03.012; Bocking W, 2005, J PUBLIC HEALTH-HEID, V13, P128, DOI 10.1007/s10389-005-0103-4; Busato A, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-31; Busse R., EUROPEAN OBSERVATORY; Busse R, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f3197; Cassell A, 2018, BRIT J GEN PRACT, V68, pE245, DOI 10.3399/bjgp18X695465; Chanturidze T, 2016, HEALTH POLICY, V120, P987, DOI 10.1016/j.healthpol.2016.07.007; De Maio FG, 2007, J EPIDEMIOL COMMUN H, V61, DOI 10.1136/jech.2006.052969; DESHARNAIS S, 1991, EVAL HEALTH PROF, V14, P228, DOI 10.1177/016327879101400206; Fassler M, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14080; Fischer W, 2008, DRG FAMILIE CH 9116; Hobbs FDR, 2016, LANCET, V387, P2323, DOI 10.1016/S0140-6736(16)00620-6; Imbens G, 2012, REV ECON STUD, V79, P933, DOI 10.1093/restud/rdr043; Insa K, 2018, SWISS MED WKLY, V148, DOI 10.4414/smw.2018.14575; 김성화, 2015, [JOURNAL OF THE KOREAN HOUSING ASSOCIATION, 한국주거학회논문집], V26, P1, DOI 10.6107/JKHA.2015.26.1.001; Kone I, 2019, INT J HEALTH PLAN M, V34, P56, DOI 10.1002/hpm.2669; Kutz A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8332; Lee C, 2019, ASIA-PAC J PUBLIC HE, V31, P499, DOI 10.1177/1010539519872325; Leu A, 2018, HEALTH POLICY, V122, P577, DOI 10.1016/j.healthpol.2018.03.001; Moscoe E, 2015, J CLIN EPIDEMIOL, V68, P132, DOI 10.1016/j.jclinepi.2014.06.021; Mukhtar TK, 2018, BRIT J GEN PRACT, V68, pE370, DOI 10.3399/bjgp18X695981; OECD health statistics, 2018, OECD HLTH STAT HLTH; Or Z, 2014, HEALTH POLICY, V117, P146, DOI 10.1016/j.healthpol.2014.05.006; Rachamin Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227280; Thommen D, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13972; van Oostrom SH, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-61; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wangmo T, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4220-0; Wasserfallen JB, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14097	33	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0241179	10.1371/journal.pone.0241179	http://dx.doi.org/10.1371/journal.pone.0241179			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8WV	33108373	Green Accepted, Green Published, gold			2023-01-03	WOS:000588372400035
J	Galvez-Garcia, G; Albayay, J; Fonseca, F; Bascour-Sandoval, C				Galvez-Garcia, German; Albayay, Javier; Fonseca, Fernando; Bascour-Sandoval, Claudio			Joint and individual effectiveness of galvanic cutaneous stimulation and tactile stimulation at decreasing Simulator Adaptation Syndrome	PLOS ONE			English	Article							INDUCED MOTION SICKNESS; SOPITE SYNDROME; VIBRATION; NEURONS; CORTEX; NECK	This research was focused on investigating the effectiveness of galvanic cutaneous stimulation and tactile stimulation jointly and individually at mitigating Simulator Adaptation Syndrome. Forty drivers (mean age = 23.1 +/- 3.4 years old, twenty women) participated in a driving simulation experiment. Total scores of the Simulator Sickness Questionnaire, head movements (an index of body balance), and driving performance variables were compared across four different stimulation conditions: i) baseline (where no stimulation was presented), ii) galvanic cutaneous stimulation and iii) tactile stimulation deployed individually, and iv) both techniques deployed jointly. The results showed that both techniques presented in conjunction alleviate Simulator Adaptation Syndrome and improve driving performance more effectively than when they are presented in isolation. Importantly, reduced head movements were only revealed when galvanic cutaneous stimulation was applied. We concluded that the reduction of this syndrome is due to an improvement of body balance (elicited by galvanic cutaneous stimulation), and a distraction from the symptoms (elicited by tactile stimulation). We encourage the use of both techniques simultaneously to decrease Simulator Adaptation Syndrome.	[Galvez-Garcia, German; Fonseca, Fernando] Univ La Frontera, Dept Psicol, Temuco, Chile; [Galvez-Garcia, German] Univ Lyon 2, Dept Psychol Cognit & Neuropsychol, Inst Psychol, Lab Etud Mecanismes Cognitifs, Bron, France; [Albayay, Javier] Univ Padua, Dipartimento Psicol Gen, Padua, Italy; [Bascour-Sandoval, Claudio] Univ Autonoma Chile, Fac Ciencias Salud, Carrera Kinesiol, Temuco, Chile; [Bascour-Sandoval, Claudio] Univ La Frontera, Dept Med Interna, Temuco, Chile	Universidad de La Frontera; Universite Lyon 2; University of Padua; Universidad Autonoma de Chile; Universidad de La Frontera	Galvez-Garcia, G (corresponding author), Univ La Frontera, Dept Psicol, Temuco, Chile.; Galvez-Garcia, G (corresponding author), Univ Lyon 2, Dept Psychol Cognit & Neuropsychol, Inst Psychol, Lab Etud Mecanismes Cognitifs, Bron, France.	german.galvez@ufrontera.cl	Bascour, Claudio/AAR-5889-2021; Gálvez-García, Germán/AGB-9683-2022; Gálvez-García, Germán/ACN-8491-2022	Bascour, Claudio/0000-0002-6250-8518; Gálvez-García, Germán/0000-0001-7390-4180; Albayay, Javier/0000-0003-2119-6316	FONDECYT from National Research and Development Agency (ANID, Chile) [1200326]; Home Office Research of the Universidad de La Frontera [DI20-2004]; ANID scholarship [72180384]	FONDECYT from National Research and Development Agency (ANID, Chile); Home Office Research of the Universidad de La Frontera; ANID scholarship	This research was supported by a FONDECYT project (1200326) from National Research and Development Agency (ANID, Chile) and by the Home Office Research of the Universidad de La Frontera (project DI20-2004) granted to German Galvez-Garcia, and ANID scholarship granted to Javier Albayay (PFCHA/DOCTORADO BECAS CHILE/2017 [72180384]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albayay J, 2019, BRAIN COGNITION, V137, DOI 10.1016/j.bandc.2019.103618; [Anonymous], 1993, INT J WILDLAND FIRE, V3, P203, DOI DOI 10.1207/S15327108IJAP0303_3; [Anonymous], 1991, SLUZBENI GLASNIK SR, V3, P195; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; Bates D, 2018, LME4 LINEAR MIXED EF; Bonnet CT, 2006, HUM MOVEMENT SCI, V25, P800, DOI 10.1016/j.humov.2006.03.001; Bos JE, 1998, BRAIN RES BULL, V47, P537, DOI 10.1016/S0361-9230(98)00088-4; Bos JE, 2015, J VESTIBUL RES-EQUIL, V25, P23, DOI 10.3233/VES-150541; Bos JE, 2011, DISPLAYS, V32, P189, DOI 10.1016/j.displa.2010.09.005; Cevette MJ, 2012, AVIAT SPACE ENVIR MD, V83, P549, DOI 10.3357/ASEM.3239.2012; Chu H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-84; D'Amour S, 2017, EXP BRAIN RES, V235, P2811, DOI 10.1007/s00221-017-5009-1; Domeyer JE, 2013, ACCIDENT ANAL PREV, V53, P127, DOI 10.1016/j.aap.2012.12.039; Duzmanska N, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02132; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Galvez-Garcia G, 2020, APPL ERGON, V82, DOI 10.1016/j.apergo.2019.102931; Galvez-Garcia G, 2017, APPL ERGON, V58, P13, DOI 10.1016/j.apergo.2016.05.004; Galvez-Garcia G, 2015, ERGONOMICS, V58, P1365, DOI 10.1080/00140139.2015.1005168; Galvez-Garcia G, 2015, HUM FACTORS, V57, P649, DOI 10.1177/0018720814554948; Galvez-Garcia G, 2012, NEUROSCI LETT, V530, P18, DOI 10.1016/j.neulet.2012.09.056; Galvez-Garcia G, 2012, PSYCHOL RES-PSYCH FO, V76, P364, DOI 10.1007/s00426-011-0349-0; Gavgani AM, 2017, AUTON NEUROSCI-BASIC, V203, P41, DOI 10.1016/j.autneu.2016.12.004; Golding JF, 1998, BRAIN RES BULL, V47, P507, DOI 10.1016/S0361-9230(98)00091-4; Gopinath T., 2019, SCI REP, V9, P1; GRUSSER OJ, 1990, J PHYSIOL-LONDON, V430, P559; GRUSSER OJ, 1990, J PHYSIOL-LONDON, V430, P537; Guariglia C, 2000, NEUROREPORT, V11, P1945, DOI 10.1097/00001756-200006260-00027; Helland A, 2016, ACCIDENT ANAL PREV, V94, P180, DOI 10.1016/j.aap.2016.05.008; Heutink J, 2019, ERGONOMICS, V62, P65, DOI 10.1080/00140139.2018.1518543; Jones J., 2011, THESIS; Keshavarz B, 2018, TRANSPORT RES F-TRAF, V54, P47, DOI 10.1016/j.trf.2018.01.007; Keshavarz Behrang, 2016, Virtual, Augmented and Mixed Reality. 8th International Conference, VAMR 2016, held as part of HCI International 2016. Proceedings: LNCS 9740, P147, DOI 10.1007/978-3-319-39907-2_14; Keshavarz B., 2014, HDB VIRTUAL ENV DESI, P652, DOI [10.1201/b17360-32, DOI 10.1201/B17360-32]; Keshavarz B, 2015, EXP BRAIN RES, V233, P1353, DOI 10.1007/s00221-015-4209-9; Keshavarz B, 2014, APPL ERGON, V45, P521, DOI 10.1016/j.apergo.2013.07.009; Lackner JR, 2014, EXP BRAIN RES, V232, P2493, DOI 10.1007/s00221-014-4008-8; Lawson BD, 1998, ACTA ASTRONAUT, V43, P181, DOI 10.1016/S0094-5765(98)00153-2; Lazorthes G, 1981, SYSTEME NERVEUX PERI; Lefcheck JS, 2016, METHODS ECOL EVOL, V7, P573, DOI 10.1111/2041-210X.12512; Lenth RV, 2016, J STAT SOFTW, V69, P1, DOI 10.18637/jss.v069.i01; Lucot JB, 1998, J VESTIBUL RES-EQUIL, V8, P61; Matsangas P, 2014, AVIAT SPACE ENVIR MD, V85, P672, DOI 10.3357/ASEM.3891.2014; Mayo AM, 2011, PSYCHOL SCI, V22, P118, DOI 10.1177/0956797610392927; McElreath R., 2020, STAT RETHINKING BAYE, DOI DOI 10.1093/scipol/sct046; Merhi O, 2007, HUM FACTORS, V49, P920, DOI 10.1518/001872007X230262; Oman C M, 1982, Acta Otolaryngol Suppl, V392, P1; OMAN CM, 1990, CAN J PHYSIOL PHARM, V68, P294, DOI 10.1139/y90-044; Perennou DA, 2001, ARCH PHYS MED REHAB, V82, P440, DOI 10.1053/apmr.2001.21986; Pinheiro J., 2020, NLME LINEAR NONLINEA; Reason JT., 1975, MOTION SICKNESS; Reed N., 2007, P 1 INT S VIS IND MO, P156; Reed-Jones JG, 2009, COMP TECHNIQUES REDU, DOI [10.17077/drivingassessment.1332, DOI 10.17077/DRIVINGASSESSMENT.1332]; Reed-Jones RJ, 2008, NEUROSCI LETT, V435, P204, DOI 10.1016/j.neulet.2008.02.047; Sang FDYP, 2003, AVIAT SPACE ENVIR MD, V74, P998; Seno T, 2011, ATTEN PERCEPT PSYCHO, V73, P1467, DOI 10.3758/s13414-011-0129-3; Seno T, 2009, VISION RES, V49, P2973, DOI 10.1016/j.visres.2009.09.017; Singmann H., 2020, NEW METHODS COGNITIV, P4, DOI [DOI 10.4324/9780429318405-2, 10.4324/9780429318405-2]; Smart LJ, 2002, HUM FACTORS, V44, P451, DOI 10.1518/0018720024497745; Stanney KM, 1997, PROCEEDINGS OF THE HUMAN FACTORS AND ERGONOMICS SOCIETY 41ST ANNUAL MEETING, 1997, VOLS 1 AND 2, P1138, DOI 10.1177/107118139704100292; Stanney KM, 1998, PRESENCE-TELEOP VIRT, V7, P327, DOI 10.1162/105474698565767; Team R, RSTUDIO INT DEV R; The MathWorks, 2012, MATLAB STAT TOOLB; VITTE E, 1994, EXP BRAIN RES, V102, P141; Wada T, 2012, HUM FACTORS, V54, P226, DOI 10.1177/0018720812436584; Walter HJ, 2019, HUM MOVEMENT SCI, V64, P389, DOI 10.1016/j.humov.2019.03.006; Webb CM, 2009, AVIAT SPACE ENVIR MD, V80, P541, DOI 10.3357/ASEM.2454.2009; Weech S, 2020, EXP BRAIN RES, V238, P427, DOI 10.1007/s00221-019-05718-5; Weech S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194137; Wei Y, 2018, ERGONOMICS, V61, P933, DOI 10.1080/00140139.2018.1427805; Wesley A.D., 2005, P HUM FACT ERG SOC A, V49, P1960; Wibirama S, 2018, ENTERTAIN COMPUT, V26, P117, DOI 10.1016/j.entcom.2018.02.003; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]; Yagi T, 2000, ACTA OTO-LARYNGOL, V120, P182	73	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2020	15	10							e0240627	10.1371/journal.pone.0240627	http://dx.doi.org/10.1371/journal.pone.0240627			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3UY	33057365	gold, Green Published			2023-01-03	WOS:000581814700058
J	Xu, J; Brosseau, JP; Shi, HB				Xu, Jie; Brosseau, Jean-Philippe; Shi, Hubing			Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy	ONCOGENE			English	Review							CELL-INTRINSIC PD-1; LYSOSOMAL DEGRADATION; DOWN-REGULATION; HIV-1 NEF; OPPORTUNITIES; MOTIF	Cancer immunotherapy using immune-checkpoint blockade has displayed promising clinical effects, but prevalent antibody-based inhibitors face multiple challenges such as low response rate, acquired resistance, and adverse effects. The intracellular expression of PD-1/PD-L1 in recycling endosomes and their active trafficking to membrane highlight the importance of depleting rather than interfering with checkpoint proteins. Preclinical investigations on the therapeutic effects of lead compounds that function by degrading immune checkpoint ligands and receptors have reported highly promising results. By harnessing the degradation capabilities of the lysosome, proteasome and autophagosomes, different small molecules and peptides potently induced degradation of checkpoint proteins and enhanced anti-tumor immunity. Both in vitro and in vivo experiments support the therapeutic efficacy of these molecules. Thus, targeted degradation through endo-lysosomal, autophagic, proteasomal, or endoplasmic reticulum-related pathways may provide promising strategies for tackling the challenges in cancer immunotherapy.	[Xu, Jie] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Xu, Jie] Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China; [Brosseau, Jean-Philippe] Ctr Hosp Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Brosseau, Jean-Philippe] Univ Sherbrooke, Dept Biochem & Funct Genom, Sherbrooke, PQ, Canada; [Shi, Hubing] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Lab Tumor Targeted & Immune Therapy,Clin Res Ctr, Chengdu, Peoples R China; [Shi, Hubing] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China	Fudan University; Fudan University; University of Sherbrooke; Sichuan University	Xu, J (corresponding author), Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.; Xu, J (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China.	jie_xu@fudan.edu.cn	Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Shi, Hubing/0000-0002-2926-3440	National Natural Science Foundation of China [82030104, 81874050, 81572326]; Basic Research Projects of Shanghai Science and Technology Innovation Action Plan [20JC1410700]; National Key R & D Program of China [2016YFC0906002]; Startup Research Funding of Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Projects of Shanghai Science and Technology Innovation Action Plan; National Key R & D Program of China; Startup Research Funding of Fudan University	This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.	Baek K, 2020, NAT CHEM BIOL, V16, P2, DOI 10.1038/s41589-019-0414-3; Brosseau JP, 2020, ADV EXP MED BIOL, V1248, P251, DOI 10.1007/978-981-15-3266-5_11; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cha JH, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036863; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chamberlain PP, 2019, NAT CHEM BIOL, V15, P937, DOI 10.1038/s41589-019-0362-y; Chen SL, 2019, CURR TOP MED CHEM, V19, P180, DOI 10.2174/1568026619666190308131805; Delport A, 2019, MOLECULES, V24, DOI 10.3390/molecules24183272; Deng SY, 2020, ADV EXP MED BIOL, V1248, P431, DOI 10.1007/978-981-15-3266-5_18; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386; Dua P, 2015, NUCLEIC ACID THER, V25, P180, DOI 10.1089/nat.2014.0516; Dvela-Levitt M, 2019, CELL, V178, P521, DOI 10.1016/j.cell.2019.07.002; Endicott SJ, 2021, AUTOPHAGY, V17, P612, DOI 10.1080/15548627.2020.1725378; Esfahani K, 2019, NEW ENGL J MED, V380, P2375, DOI 10.1056/NEJMc1903064; Fan XL, 2014, NAT NEUROSCI, V17, P471, DOI 10.1038/nn.3637; Gao HY, 2020, ACS MED CHEM LETT, V11, P237, DOI 10.1021/acsmedchemlett.9b00597; Gao HL, 2013, SCI REP-UK, V3, DOI 10.1038/srep02534; Gomez-Navarro N, 2016, J CELL BIOL, V215, P769, DOI 10.1083/jcb.201610031; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greillier L, 2018, TRANSL LUNG CANCER R, V7, P639, DOI 10.21037/tlcr.2018.10.08; Hakenberg OW, 2017, EXPERT OPIN BIOL TH, V17, P1309, DOI 10.1080/14712598.2017.1353076; Hsu JM, 2018, CANCER RES, V78, P6349, DOI 10.1158/0008-5472.CAN-18-1892; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kiran S, 2020, CHEM COMMUN, V56, P285, DOI 10.1039/c9cc09131a; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Li H, 2017, HEPATOLOGY, V66, P1920, DOI 10.1002/hep.29360; Liang LX, 2018, CELL CHEM BIOL, V25, P761, DOI 10.1016/j.chembiol.2018.03.010; Liu Y, 2019, TRANSL LUNG CANCER R, V8, P1125, DOI 10.21037/tlcr.2019.11.26; Lyle C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56208-1; Meng XB, 2018, NATURE, V564, P130, DOI 10.1038/s41586-018-0756-0; Neklesa T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.259; Pu N, 2019, CANCER LETT, V460, P42, DOI 10.1016/j.canlet.2019.06.013; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Riggs NL, 1999, VIROLOGY, V258, P203, DOI 10.1006/viro.1999.9736; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Steven B, 2019, LYSOSOME TARGETING C, V584, P291; Sun XY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0101-6; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Valdor R, 2019, P NATL ACAD SCI USA, V116, P20655, DOI 10.1073/pnas.1903542116; Verdura S, 2020, AGING-US, V12, P8, DOI 10.18632/aging.102646; Wang HB, 2020, ADV EXP MED BIOL, V1248, P325, DOI 10.1007/978-981-15-3266-5_14; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wang YG, 2020, CANCER BIOL MED, V17, P583, DOI 10.20892/j.issn.2095-3941.2020.0066; Wei Z, 2019, CELL REP, V28, P554, DOI 10.1016/j.celrep.2019.05.033; Wu JJ, 2018, CANCER MED-US, V7, P4004, DOI 10.1002/cam4.1675; Yang Q, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00447; Yao H, 2019, PALMITOYLATION IS CR; Yao H, 2020, ADV EXP MED BIOL, V1248, P295, DOI 10.1007/978-981-15-3266-5_13; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yao H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01774; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015	56	10	10	2	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7106	7113		10.1038/s41388-020-01491-w	http://dx.doi.org/10.1038/s41388-020-01491-w		OCT 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33024277				2023-01-03	WOS:000575700700001
J	Algazi, AP; Othus, M; Daud, AI; Lo, RS; Mehnert, JM; Truong, TG; Conry, R; Kendra, K; Doolittle, GC; Clark, JI; Messino, MJ; Moore, DF; Lao, C; Faller, BA; Govindarajan, R; Harker-Murray, A; Dreisbach, L; Moon, J; Grossmann, KF; Ribas, A				Algazi, Alain P.; Othus, Megan; Daud, Adil, I; Lo, Roger S.; Mehnert, Janice M.; Thach-Giao Truong; Conry, Robert; Kendra, Kari; Doolittle, Gary C.; Clark, Joseph, I; Messino, Michael J.; Moore, Dennis F., Jr.; Lao, Christopher; Faller, Bryan A.; Govindarajan, Rangaswamy; Harker-Murray, Amy; Dreisbach, Luke; Moon, James; Grossmann, Kenneth F.; Ribas, Antoni			Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial	NATURE MEDICINE			English	Article							ADVANCED BRAF(V600)-MUTANT MELANOMA; ACQUIRED-RESISTANCE; DOUBLE-BLIND; VEMURAFENIB; COMBINATION; DABRAFENIB; TRAMETINIB; EVOLUTION; STRATEGY; EFFICACY	The randomized phase 2 trial S1320 comparing different dosing schedules of BRAF/MEK inhibitor combination inBRAF-mutated advanced melanoma shows intermittent therapy does not result in superior progression-free survival in patients. Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenicBRAF(V600)in melanoma(1,2). We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whether intermittent dosing of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improves progression-free survival in patients with metastatic and unresectableBRAF(V600)melanoma. Patients were enrolled at 68 academic and community sites nationally. All patients received continuous dabrafenib and trametinib during an 8-week lead-in period, after which patients with non-progressing tumors were randomized to either continuous or intermittent dosing of both drugs on a 3-week-off, 5-week-on schedule. The trial has completed accrual and 206 patients with similar baseline characteristics were randomized 1:1 to the two study arms (105 to continuous dosing, 101 to intermittent dosing). Continuous dosing yielded a statistically significant improvement in post-randomization progression-free survival compared with intermittent dosing (median 9.0 months versus 5.5 months,P = 0.064, pre-specified two-sided alpha = 0.2). Therefore, contrary to the initial hypothesis, intermittent dosing did not improve progression-free survival in patients. There were no differences in the secondary outcomes, including overall survival and the overall incidence of treatment-associated toxicity, between the two groups.	[Algazi, Alain P.; Daud, Adil, I] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Othus, Megan; Moon, James] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Lo, Roger S.; Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA USA; [Mehnert, Janice M.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Thach-Giao Truong] Kaiser Permanente Northern Calif, Vallejo, CA USA; [Conry, Robert] Univ Alabama Birmingham, Birmingham, AL USA; [Kendra, Kari] Ohio State Univ, Columbus, OH 43210 USA; [Doolittle, Gary C.] Univ Kansas Hosp Westwood, Canc Ctr, Westwood, KS USA; [Clark, Joseph, I] Loyola Univ, Chicago, IL 60611 USA; [Messino, Michael J.] Southeast COR NCORP Asheville, Messino Canc Ctr Asheville, Asheville, NC USA; [Moore, Dennis F., Jr.] Wichita NCORP, Canc Ctr Kansas, Wichita, KS USA; [Lao, Christopher] Univ Michigan, Ann Arbor, MI 48109 USA; [Faller, Bryan A.] Heartland NCORP, Missouri Baptist Med Ctr Canc Ctr, St Louis, MO USA; [Govindarajan, Rangaswamy] Univ Arkansas, Little Rock, AR 72204 USA; [Harker-Murray, Amy] Froedtert, Milwaukee, WI USA; [Harker-Murray, Amy] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Dreisbach, Luke] Eisenhower Med Ctr, Rancho Mirage, CA USA; [Grossmann, Kenneth F.] Huntsman Canc Inst, Salt Lake City, UT USA	University of California System; University of California San Francisco; Fred Hutchinson Cancer Center; University of California System; University of California Los Angeles; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Kaiser Permanente; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Loyola University Chicago; Cancer Center of Kansas; University of Michigan System; University of Michigan; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Medical College of Wisconsin; Huntsman Cancer Institute	Algazi, AP (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	alain.algazi@ucsf.edu		Othus, Megan/0000-0001-8176-6371	National Cancer Institute's Cancer Therapeutics Evaluation Program (NCI-CTEP); NCI/NIH [CA180888, CA180819, CA180820, CA180850, CA239767, CA189808, CA46282, CA189858, CA189830, CA233230, CA189829, CA189954, CA189860, CA189822, CA189953, CA180834, CA189809, CA189957, CA189958, R35 CA197633, P01 CA244118]	National Cancer Institute's Cancer Therapeutics Evaluation Program (NCI-CTEP); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge B. Suttle and D. Ouellet for their work on the pharmacokinetic modeling for dabrafenib and trametinib. We also acknowledge M. Voi, T. Haas and E. Gasal from Novartis for their critical reading of the manuscript and for their helpful comments. S1320 is an intergroup trial led by the SWOG Cancer Research Network with funding and supervision from the National Cancer Institute's Cancer Therapeutics Evaluation Program (NCI-CTEP). Research reported in this publication was supported by NCI/NIH awards CA180888, CA180819, CA180820, CA180850, CA239767, CA189808, CA46282, CA189858, CA189830, CA233230, CA189829, CA189954, CA189860, CA189822, CA189953, CA180834, CA189809, CA189957 and CA189958 (to SWOG), R35 CA197633 (to A.R.) and P01 CA244118 (to A.R. and R.S.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Glaxo-Smith-Kline, the manufacturer of dabrafenib and trametinib at the time of study initiation, reviewed and approved the study protocol and provided the study drugs to NCI-CTEP. Novartis, the manufacturer of the study drugs at the time of study completion, reviewed and commented on the final study manuscript. All data analysis was completed by M.O. and J.M. at the SWOG statistical center. All authors had full access to all of the study data and they had sole responsibility for the decision to submit the paper for publication and for the contents of the submitted manuscript.	Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; de Moura CR, 2020, TRANSL ONCOL, V13, P275, DOI 10.1016/j.tranon.2019.10.003; Dreno B, 2017, LANCET ONCOL, V18, P404, DOI 10.1016/S1470-2045(17)30072-4; Dummer R, 2018, LANCET ONCOL, V19, P1315, DOI 10.1016/S1470-2045(18)30497-2; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Minami S, 2013, LUNG CANCER, V82, P271, DOI 10.1016/j.lungcan.2013.07.022; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Schreuer M, 2017, LANCET ONCOL, V18, P464, DOI 10.1016/S1470-2045(17)30171-7; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Somasundaram R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00452-4; Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401; Tate SC, 2016, BRIT J CANCER, V114, P669, DOI 10.1038/bjc.2016.40; Valpione S, 2018, EUR J CANCER, V91, P116, DOI 10.1016/j.ejca.2017.12.007; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Xue YH, 2017, NAT MED, V23, P929, DOI 10.1038/nm.4369; Yu HA, 2017, LUNG CANCER, V112, P195, DOI 10.1016/j.lungcan.2017.08.017	20	42	43	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2020	26	10					1564	+		10.1038/s41591-020-1060-8	http://dx.doi.org/10.1038/s41591-020-1060-8		OCT 2020	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	NX8MD	33020646	Green Accepted			2023-01-03	WOS:000575801100005
J	Mandereau-Bruno, L; Leger, D; Delmas, MC				Mandereau-Bruno, Laurence; Leger, Damien; Delmas, Marie-Christine			Obstructive sleep apnea: A sharp increase in the prevalence of patients treated with nasal CPAP over the last decade in France	PLOS ONE			English	Article							POPULATION; GENDER	Introduction Obstructive sleep apnea (OSA) is a frequent condition. In the absence of treatment, OSA is associated with a higher risk of traffic accidents and a large variety of diseases. The objectives of this study were to describe the characteristics of patients treated for OSA in France and assess the time trends in treatment. Methods The French National Health Data System is an individual database with data on all healthcare reimbursements for the entire French population. Based on this database, we included all patients aged 20 years or over who were treated with continuous positive airway pressure (CPAP) or mandibular advancement splint (MAS) between 2009 and 2018. Negative binomial models, adjusted for age, were used to assess time trends in treatment prevalence and incidence rates. Results In 2017, 2.3% of French adults aged >= 20 years were treated with CPAP (men: 3.3%; women: 1.3%). The highest prevalence was observed in people aged 70-74 years (5.0%). From 2009 to 2018, the annual prevalence of CPAP increased 3-fold and the annual incidence 1.9-fold. During the same period, the rate of patients reimbursed for MAS (first prescription or renewal) was multiplied by 7.6. The proportion of patients treated with CPAP in 2017 who were no longer treated in the subsequent year was 6.9%. Discussion The sharp increase in the incidence of OSA treatment probably reflects a better recognition of the disease in France. However, the prevalence of OSA treatment remains lower than expected based on the international literature. Further studies are needed to identify the obstacles to an optimal management of individuals with OSA in France.	[Mandereau-Bruno, Laurence; Delmas, Marie-Christine] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, France; [Leger, Damien] Univ Paris, EA 7330 VIFASOM, Paris, France; [Leger, Damien] Univ Paris, APHP Hotel Dieu, Ctr Sommeil & Vigilance, Paris, France	Institute of Public Health Surveillance; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Delmas, MC (corresponding author), French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, France.	marie-christine.delmas@santepubliquefrance.fr		DELMAS, Marie-Christine/0000-0001-6415-3899				[Anonymous], 2013, REV EUR STAND POP RE; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Fuentes S, 2020, DIABETES METAB, V46, P472, DOI 10.1016/j.diabet.2019.12.006; Fuhrman C, 2012, SLEEP MED, V13, P852, DOI 10.1016/j.sleep.2012.04.005; Giskes K, 2008, OBESITY, V16, P1377, DOI 10.1038/oby.2008.54; Guglielmi O, 2019, SLEEP MED, V57, P100, DOI 10.1016/j.sleep.2019.01.042; Haute Autorite de sante, 2014, REV CAT HOM DISP MED; Heinzer R, 2015, LANCET RESP MED, V3, P310, DOI 10.1016/S2213-2600(15)00043-0; Institut national de la sante et de la recherche medicale Kantar Health Roche Sas, 2012, OBEPI 2012 ENQ NAT S; Javaheri S, 2017, J AM COLL CARDIOL, V69, P841, DOI 10.1016/j.jacc.2016.11.069; Kapsimalis F, 2002, SLEEP, V25, P412; Mandereau-Bruno L., 2017, Bulletin Epidemiologique Hebdomadaire, P586; McIsaac DI, 2015, ANESTHESIOLOGY, V123, P253, DOI 10.1097/ALN.0000000000000692; Myers KA, 2013, JAMA-J AM MED ASSOC, V310, P731, DOI 10.1001/jama.2013.276185; Namen AM, 2016, ANN AM THORAC SOC, V13, P2027, DOI 10.1513/AnnalsATS.201603-152OC; REDLINE S, 1994, AM J RESP CRIT CARE, V149, P722, DOI 10.1164/ajrccm.149.3.8118642; Reutrakul S, 2017, CHEST, V152, P1070, DOI 10.1016/j.chest.2017.05.009; Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33; Richard JB, 2015, RESULTATS DETAILLES; Rotenberg BW, 2016, J OTOLARYNGOL-HEAD N, V45, DOI 10.1186/s40463-016-0156-0; Senaratna CV, 2017, SLEEP MED REV, V34, P70, DOI 10.1016/j.smrv.2016.07.002; Societe de Pneumologie de Langue Francaise SocieteFrancaise d'Anesthesie Reanimation Societe Francaise deCardiologie SFdMdT Societe Francaise d'ORL, 2010, REV MAL RESPIR, V27, P806; Thornton JD, 2010, SLEEP, V33, P1255, DOI 10.1093/sleep/33.9.1255; Tufik S, 2010, SLEEP MED, V11, P441, DOI 10.1016/j.sleep.2009.10.005; Tuppin P, 2017, REV EPIDEMIOL SANTE, V65, pS149, DOI 10.1016/j.respe.2017.05.004; Verdot C., 2017, B EPID MIOL HEBDOMAD, V13, P234; Vernay M, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-215; Wickwire EM, 2020, SLEEP, V43, DOI 10.1093/sleep/zsaa122; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Young T, 2002, ARCH INTERN MED, V162, P893, DOI 10.1001/archinte.162.8.893; Young Terry, 2009, WMJ, V108, P246	33	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2021	16	1							e0245392	10.1371/journal.pone.0245392	http://dx.doi.org/10.1371/journal.pone.0245392			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4SP	33434230	Green Published, gold			2023-01-03	WOS:000609979700048
J	Peng, R; Li, HL; Yang, LJ; Zeng, LN; Yi, QS; Xu, PP; Pan, XC; Zhang, LL				Peng, Rong; Li, Hailong; Yang, Lijun; Zeng, Linan; Yi, Qiusha; Xu, Peipei; Pan, Xiangcheng; Zhang, Lingli			The efficacy and safety of prokinetics in critically ill adults receiving gastric feeding tubes: A systematic review and meta-analysis	PLOS ONE			English	Review							ENTERAL NUTRITION TOLERANCE; DOUBLE-BLIND; INTENSIVE-CARE; NOSOCOMIAL PNEUMONIA; CLINICAL-OUTCOMES; METOCLOPRAMIDE; ERYTHROMYCIN; CISAPRIDE; INTOLERANCE; ASSOCIATION	Background Intolerance to gastric feeding tubes is common among critically ill adults and may increase morbidity. Administration of prokinetics in the ICU is common. However, the efficacy and safety of prokinetics are unclear in critically ill adults with gastric feeding tubes. We conducted a systematic review to determine the efficacy and safety of prokinetics for improving gastric feeding tube tolerance in critically ill adults. Methods Randomized controlled trials (RCTs) were identified by systematically searching the Medline, Cochrane and Embase databases. Two independent reviewers extracted the relevant data and assessed the quality of the studies. We calculated pooled relative risks (RRs) for dichotomous outcomes and the mean differences (MDs) for continuous outcomes with the corresponding 95% confidence intervals (CIs). We assessed the risk of bias using the Cochrane risk-of-bias tool and used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to rate the quality of the evidence. Results Fifteen RCTs met the inclusion criteria. A total of 10 RCTs involving 846 participants were eligible for the quantitative analysis. Most studies (10 of 13, 76.92%) showed that prokinetics had beneficial effects on feeding intolerance in critically ill adults. In critically ill adults receiving gastric feeding, prokinetic agents may reduce the ICU length of stay (MD -2.03, 95% CI -3.96, -0.10; P = 0.04; low certainty) and the hospital length of stay (MD -3.21, 95% CI -5.35, -1.06; P = 0.003; low certainty). However, prokinetics failed to improve the outcomes of reported adverse events and all-cause mortality. Conclusion As a class of drugs, prokinetics may improve tolerance to gastric feeding to some extent in critically ill adults. However, the certainty of the evidence suggesting that prokinetics reduce the ICU or hospital length of stay is low. Prokinetics did not significantly decrease the risks of reported adverse events or all-cause mortality among critically ill adults.	[Peng, Rong; Li, Hailong; Zeng, Linan; Yi, Qiusha; Xu, Peipei; Pan, Xiangcheng; Zhang, Lingli] Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China; [Peng, Rong; Li, Hailong; Zeng, Linan; Yi, Qiusha; Xu, Peipei; Pan, Xiangcheng; Zhang, Lingli] Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Sichuan, Peoples R China; [Peng, Rong; Li, Hailong; Zeng, Linan; Yi, Qiusha; Xu, Peipei; Pan, Xiangcheng; Zhang, Lingli] Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China; [Peng, Rong] Chengdu Univ, Dept Clin Nutr, Affiliated Hosp, Chengdu, Sichuan, Peoples R China; [Yang, Lijun] Chengdu Univ, Dept Gen Practice Med, Affiliated Hosp, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Chengdu University; Chengdu University	Zhang, LL (corresponding author), Sichuan Univ, West China Univ Hosp 2, Dept Pharm, Chengdu, Sichuan, Peoples R China.; Zhang, LL (corresponding author), Sichuan Univ, West China Univ Hosp 2, Evidence Based Pharm Ctr, Chengdu, Sichuan, Peoples R China.; Zhang, LL (corresponding author), Sichuan Univ, Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China.	zhanglingli@scu.edu.cn			National Major Science and Technology Projects of China [2017ZX09304029]; Sichuan Province Science and Technology Major Project [2017JY0067]; Major Project of Sichuan health committee [18ZD042]; Major Project of Sichuan Province Science and Technology in field of social development [20ZDYF3101]; Sichuan Science and Technology Program [2020YJ0198]; Project of Education Department of Sichuan Province [18ZB0146]; Project of Chengdu Municipal Health Commission [2020088]; major Project of Affiliated Hospital of Chengdu University [2020YZZ04]	National Major Science and Technology Projects of China; Sichuan Province Science and Technology Major Project; Major Project of Sichuan health committee; Major Project of Sichuan Province Science and Technology in field of social development; Sichuan Science and Technology Program; Project of Education Department of Sichuan Province; Project of Chengdu Municipal Health Commission; major Project of Affiliated Hospital of Chengdu University	The study was supported by National Major Science and Technology Projects of China (Award Number: 2017ZX09304029, Recipient: Lingli Zhang), Sichuan Province Science and Technology Major Project (Award Number: 2017JY0067, Recipient: Lingli Zhang), the Major Project of Sichuan health committee (Award Number: 18ZD042, Recipient: Lingli Zhang), the Major Project of Sichuan Province Science and Technology in field of social development (Award Number: 20ZDYF3101, Recipient: Lingli Zhang), Sichuan Science and Technology Program (Award Number: 2020YJ0198, Recipient: Rong Peng), the Project of Education Department of Sichuan Province (Award Number: 18ZB0146, Recipient: Rong Peng), the Project of Chengdu Municipal Health Commission (Award Number: 2020088, Recipient: Rong Peng), the major Project of Affiliated Hospital of Chengdu University (Award Number: 2020YZZ04, Recipient: Rong Peng). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta-Escribano J, 2014, NUTR HOSP, V29, P1345, DOI 10.3305/nh.2014.29.6.7286; [Anonymous], 2012, IRCT201112014578N; [Anonymous], 2015, CN01873462, DOI 70. 2015/08/006111 C; [Anonymous], 2015, IRCT201408104365N; [Anonymous], 2011, IRCT201009094722N2; [Anonymous], 2015, NCT02528760; [Anonymous], 2017, IRCT201610297494N24; [Anonymous], 2014, IRCT201412044365N; [Anonymous], 2014, NCT02379624; Berne JD, 2002, J TRAUMA, V53, P422, DOI 10.1097/00005373-200209000-00004; Blaser AR, 2014, ACTA ANAESTH SCAND, V58, P914, DOI 10.1111/aas.12302; Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0; Boivin MA, 2001, CRIT CARE MED, V29, P1916, DOI 10.1097/00003246-200110000-00011; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Chapman MJ, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1420-4; Chapman MJ, 2000, CRIT CARE MED, V28, P2334, DOI 10.1097/00003246-200007000-00026; Chen JH, 2005, WORLD J GASTROENTERO, V11, P2802, DOI 10.3748/wjg.v11.i18.2802; Deane AM, 2018, JPEN-PARENTER ENTER, V42, P949, DOI 10.1002/jpen.1038; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Dive A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1502-3; Doi M, 2020, ACUTE MED SURG, V7, DOI 10.1002/ams2.442; Euctr ES, PHASE 2 MULTICENTER; Furukawa TA, 2007, JAMA-J AM MED ASSOC, V297, P468, DOI 10.1001/jama.297.5.468-b; Goldhill DR, 1997, CRIT CARE MED, V25, P447, DOI 10.1097/00003246-199703000-00013; Gungabissoon U, 2015, JPEN-PARENTER ENTER, V39, P441, DOI 10.1177/0148607114526450; Guo Jian-hong, 2012, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V24, P674; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hayakawa M, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0053-4; Heyland DK, 2019, INTENS CARE MED, V45, P647, DOI 10.1007/s00134-019-05593-2; Heyland DK, 1996, AM J RESP CRIT CARE, V154, P1678, DOI 10.1164/ajrccm.154.6.8970354; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Hu BC, 2020, JPEN-PARENTER ENTER, V44, P855, DOI 10.1002/jpen.1693; Kooshki A, 2018, BIOMED RES THER, V5, P2528, DOI 10.15419/bmrat.v5i7.462; Lew CCH, 2017, JPEN-PARENTER ENTER, V41, P744, DOI 10.1177/0148607115625638; Lewis K, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1441-z; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; MacLaren R, 2001, CLIN THER, V23, P1855, DOI 10.1016/S0149-2918(00)89081-5; Makar JK, 2016, SAUDI J ANAESTH, V10, P308, DOI 10.4103/1658-354X.174902; Malekolkottab M, 2017, J COMP EFFECT RES, V6, P127, DOI 10.2217/cer-2016-0067; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Meissner W, 2003, CRIT CARE MED, V31, P776, DOI 10.1097/01.CCM.0000053652.80849.9F; Mokhtari M, 2009, CRIT CARE, V1, pS56; Nassaji M., 2010, Eastern Mediterranean Health Journal, V16, P371; Nct, 2018, ITOPRIDE FEEDING INT; Nct. A Randomized, 2013, DOUBLE BLIND STUDY E; Nguyen N, 2006, CRIT CARE, V10; Nursal TZ, 2007, J CLIN NEUROSCI, V14, P344, DOI 10.1016/j.jocn.2005.11.011; Peng R, 2020, CLIN NUTR, V39, P307, DOI 10.1016/j.clnu.2019.11.027; Pinilla JC, 2001, JPEN-PARENTER ENTER, V25, P81, DOI 10.1177/014860710102500281; Rafie F, 2018, J MED PLANTS, V17, P66; Rajan V, 2017, HEPATOLOGY, V66, p138A; Reignier J, 2002, CRIT CARE MED, V30, P1237, DOI 10.1097/00003246-200206000-00012; Ritz MA, 2005, INTENS CARE MED, V31, P949, DOI 10.1007/s00134-005-2663-8; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Shariatpanahi ZV, 2010, J CRIT CARE, V25, P647, DOI 10.1016/j.jcrc.2009.12.008; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; SPAPEN HD, 1995, CRIT CARE MED, V23, P481, DOI 10.1097/00003246-199503000-00011; Sun Renhua, 2018, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V30, P715, DOI 10.3760/cma.j.issn.2095-4352.2018.08.001; Sustic A, 2005, CROAT MED J, V46, P239; Tamion F, 2003, INTENS CARE MED, V29, P1717, DOI 10.1007/s00134-003-1898-5; Taylor S, 2011, J INTENSIVE CARE SOC, V12, P75; Taylor SJ, 2016, CLIN NUTR ESPEN, V14, P1, DOI 10.1016/j.clnesp.2016.04.020; Tctr, EFFICACY SAFETY ORAL; Wan X, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-135; Warusevitane A, 2015, STROKE, V46, P454, DOI 10.1161/STROKEAHA.114.006639; Yanagida Y, 2013, INTENS CARE MED, V39, pS242; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025	70	8	8	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2021	16	1							e0245317	10.1371/journal.pone.0245317	http://dx.doi.org/10.1371/journal.pone.0245317			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY4UJ	33428672	gold, Green Published			2023-01-03	WOS:000630036100056
J	Obakiro, SB; Kiyimba, K; Napyo, A; Kanyike, AM; Mayoka, WJ; Nnassozi, AG; Aguti, B; Akech, GM; Waako, JP				Obakiro, Samuel Baker; Kiyimba, Kenedy; Napyo, Agnes; Kanyike, Andrew Marvin; Mayoka, Wilberforce John; Nnassozi, Aishah Ggalabuzi; Aguti, Beatrice; Akech, Gabriel Madut; Waako, John Paul			Appropriateness and affordability of prescriptions to diabetic patients attending a tertiary hospital in Eastern Uganda: A retrospective cross-sectional study	PLOS ONE			English	Article							PREVALENCE	Background Irrational prescription of drugs can lead to high cost of treatment thus limiting access to essential medicines. We assessed the affordability and appropriateness of prescriptions written for diabetic patients in Eastern Uganda. Methods We collected secondary data from the health management information system registers of patients who attended the outpatient medical clinic at Mbale regional referral hospital from January 2019 to December 2019. The average cost of the prescriptions was calculated and adjusted odds ratios for predictors for unaffordability estimated using logistic regression. Computed scores for indicators of rational drug prescription were used to assess the extent of rational prescribing. Results The median cost per prescription was USD 11.34 (IQR 8.1, 20.2). Majority of the diabetic patients (n = 2462; 94.3%, 95% CI: 93.3-95.1%) could not afford the prescribed drugs. Predictors for unaffordability were if a prescription contained: >= 4 medicines (AOR = 12.45; 95% CI: 3.9-39.7); an injectable (AOR = 5.47; 95%CI: 1.47-20.32) and a diagnosis of diabetes mellitus with other comorbidities (AOR = 3.36; 95%CI: 1.95-5.78). Having no antidiabetic drug prescribed was protective for non-affordability (AOR = 0.38; 95%CI: 0.24-0.61). The average number of drugs per prescription was 2.8. The percentage prescription of drugs by generic name and from the essential medicine and health supplies list of Uganda were (6160/7461; 82.6%, 96% CI: 81.7%-83.4%) and (6092/7461; 81.7%, 95% CI: 80.8%-82.5%) respectively against WHO standard of 100%. Conclusion The majority of diabetic patients (94.3%) in Eastern Uganda cannot afford to buy prescribed medicines. The government should therefore ensure that essential medicines are readily accessible in public health facilities.	[Obakiro, Samuel Baker; Kiyimba, Kenedy; Nnassozi, Aishah Ggalabuzi; Waako, John Paul] Busitema Univ, Dept Pharmacol & Therapeut, Fac Hlth Sci, Tororo, Uganda; [Napyo, Agnes; Kanyike, Andrew Marvin; Aguti, Beatrice; Akech, Gabriel Madut] Busitema Univ, Dept Publ & Community Hlth, Fac Hlth Sci, Tororo, Uganda; [Mayoka, Wilberforce John] Mbale Reg Referral Hosp Uganda, Infect Dis Clin, Mbale, Uganda		Obakiro, SB (corresponding author), Busitema Univ, Dept Pharmacol & Therapeut, Fac Hlth Sci, Tororo, Uganda.	sobakiro@fhs.busitema.ac.ug	Kanyike, Andrew Marvin/AAA-2925-2022; Obakiro, Samuel Baker/AAM-2659-2020	Kanyike, Andrew Marvin/0000-0002-8138-9083; Obakiro, Samuel Baker/0000-0001-9258-2519; Gabriel Madut, Akech/0000-0002-3505-1102; Kiyimba, Kenedy/0000-0001-8031-9051	VLIR-UOS grant [UG2018SIN236A102]; Belgian government	VLIR-UOS grant; Belgian government	This study was funded by the VLIR-UOS grant (UG2018SIN236A102) awarded to John Paul Waako (JPW). The VLIR-UOS project is financed by the Belgian government. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akunne AA, 2019, PHARM PHARM, V10, P48, DOI [10.4236/pp.2019.101005, DOI 10.4236/PP.2019.101005]; [Anonymous], 2017, J MOL BIOMARKERS DIA, V8, P1, DOI [10.4172/2155-9929.S2-026, DOI 10.4172/2155-9929.S2-026, DOI 10.5334/LABPHON.19]; [Anonymous], 2017, CANC DISCOVERY, V7, pOF12; Assah F, 2017, DIABETES MELLITUS DE, P33, DOI [10.1007/978-3-319-41559-8_3, DOI 10.1007/978-3-319-41559-8_3]; Bahendeka S, 2016, TROP MED INT HEALTH, V21, P405, DOI 10.1111/tmi.12663; Chaudhary PK., 2019, INT J RES MED SCI, V7, P669, DOI [DOI 10.18203/2320-6012.IJRMS20190915, 10.18203/2320-6012.ijrms20190915]; Chaudhury A, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00006; Chow CK, 2018, LANCET DIABETES ENDO, V6, P798, DOI 10.1016/S2213-8587(18)30233-X; Demoz GT, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222985; Desalegn AA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-170; Fundacio Institut Catala de Farmacologia, 2018, BUTLLETI GROC, V31, P1; Gong SW, 2018, HEALTH POLICY PLANN, V33, P937, DOI 10.1093/heapol/czy076; Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002; Kaiser AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226169; Mahmood M, 2018, CLIN INVESTIG LOND, V07, P5, DOI [10.4172/clinical-investigation.1000123, DOI 10.4172/CLINICAL-INVESTIGATI0N.1000123]; Ministry of Health, 2015, MID TERM REV HLTH SE; Purnima Ashok, 2020, Journal of Drug Delivery and Therapeutics, V10, P42, DOI 10.22270/jddt.v10i3.3977; Qian D, 2018, DIABETES THER, V9, P1945, DOI 10.1007/s13300-018-0482-5; Rathish D, 2019, J HEALTH POPUL NUTR, V38, DOI 10.1186/s41043-019-0161-9; Sharma T, 2018, INT J BASIC CLIN PHA, V7, P956, DOI [10.18203/2319-2003.ijbcp20181642, DOI 10.18203/2319-2003.IJBCP20181642]; Uganda Bureau of Statistics, 2017, UG NAT HOUS SURV 201; Vialle-Valentin CE, 2015, HEALTH POLICY PLANN, V30, P1044, DOI 10.1093/heapol/czu107; World Health Organisation (WHO), 2014, ALL HEAL POL SYST RE, V2014; Wu YL, 2014, INT J MED SCI, V11, P1185, DOI 10.7150/ijms.10001; 2019, FRONTIERS PLANT SCI, V10, P1	25	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2021	16	1							e0245036	10.1371/journal.pone.0245036	http://dx.doi.org/10.1371/journal.pone.0245036			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR2KR	33400703	Green Published, gold			2023-01-03	WOS:000607070700027
J	Cance, JD; Doyle, E				Cance, Jessica Duncan; Doyle, Erin			Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Cance, Jessica Duncan] RTI Int, Community Hlth Res Div, Res Triangle Pk, NC USA; [Doyle, Erin] Texas State Board Pharm, Austin, TX USA	Research Triangle Institute	Cance, JD (corresponding author), RTI Int, 3040 E Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA.	jcance@rti.org	Cance, Jessica/AAU-1224-2021	Cance, Jessica/0000-0002-2797-0037				Davis CS, 2021, INT J DRUG POLICY, V93, DOI 10.1016/j.drugpo.2020.102905; Drug Enforcement Administration, COVID 19 INF PAG; Kaiser Family Foundation, KFFS STAT HLTH FACTS; National Academies of Science Engineering and Medicine, 2019, MED OP US DIS SAV LI; Ochalek TA, 2020, JAMA-J AM MED ASSOC, V324, P1673, DOI 10.1001/jama.2020.17477; whitehouse, PROCL DECL NAT EM NO	6	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2020	324	23					2442	2444		10.1001/jama.2020.22154	http://dx.doi.org/10.1001/jama.2020.22154			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG8IH	33320215	Green Published			2023-01-03	WOS:000599972000023
J	Nascimento, MS; Baggio, DM; Fascina, LP; do Prado, C				Nascimento, Milena Siciliano; Baggio, Diana Milena; Fascina, Linus Pauling; do Prado, Cristiane			Impact of social isolation due to COVID-19 on the seasonality of pediatric respiratory diseases	PLOS ONE			English	Article							AIR-POLLUTION; DAY-CARE; INFECTIONS; SYMPTOMS	Introduction Respiratory tract diseases are the major cause of morbidity and mortality in children under the age of 5 years, constituting the highest rate of hospitalization in this age group. Objectives To determine the prevalence of hospitalizations for respiratory diseases in childhood in the last 5 years and to assess the impact of social isolation due to COVID-19 on the seasonal behavior of these diseases. Methods A cross-sectional clinical study was carried out, with a survey of all patients aged 0 to 17 years who were admitted with a diagnosis of respiratory diseases between January 2015 and July 2020. The database was delivered to the researchers anonymized. The variables used for analysis were date of admission, date of discharge, length of stay, age, sex and diagnosis. In order to make the analysis possible, the diagnoses were grouped into upper respiratory infection (URI), asthma / bronchitis, bronchiolitis and pneumonia. Results 2236 admissions were included in the study. Children under 5 years old account for 81% of hospitalizations for respiratory disease in our population. In the adjusted model, an average reduction of 38 hospitalizations was observed in the period of social isolation (coefficient: -37.66; 95% CI (- 68.17; -7.15); p = 0.016). Conclusion The social isolation measures adopted during the COVID-19 pandemic dramatically interfered with the seasonality of childhood respiratory diseases. This was reflected in the unexpected reduction in the number of hospitalizations in the pediatric population during this period.	[Nascimento, Milena Siciliano; Baggio, Diana Milena; Fascina, Linus Pauling; do Prado, Cristiane] Hosp Israelite Albert Einstein, Dept Pediat, Sao Paulo, Brazil	Hospital Israelita Albert Einstein; Universidade Federal de Sao Paulo (UNIFESP)	Nascimento, MS (corresponding author), Hosp Israelite Albert Einstein, Dept Pediat, Sao Paulo, Brazil.	milenasn@einstein.br						Antunes Bianca Brandão de Paula, 2020, Rev. bras. ter. intensiva, V32, P213, DOI 10.5935/0103-507x.20200028; Aquino EML, 2020, CIENC SAUDE COLETIVA, V25, P2423, DOI 10.1590/1413-81232020256.1.10502020; Caudri D, 2009, AM J RESP CRIT CARE, V180, P491, DOI 10.1164/rccm.200903-0327OC; de Hoog MLA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-107; de Oliveira TG, 2011, EINSTEIN-SAO PAULO, V9, P514, DOI [10.1590/S1679-45082011AO1908, 10.1590/s1679-45082011ao1908]; Farhat SCL, 2005, BRAZ J MED BIOL RES, V38, P227, DOI 10.1590/S0100-879X2005000200011; Fisman D, 2012, CLIN MICROBIOL INFEC, V18, P946, DOI 10.1111/j.1469-0691.2012.03968.x; Gosai A, 2009, AUST NZ J PUBL HEAL, V33, P521, DOI 10.1111/j.1753-6405.2009.00447.x; Gouveia N, 2018, ENVIRON POLLUT, V232, P385, DOI 10.1016/j.envpol.2017.08.125; Green RS, 2010, INT J PUBLIC HEALTH, V55, P113, DOI 10.1007/s00038-009-0076-0; Hatoun J, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-006460; Itaya T, 2020, INT J INFECT DIS, V97, P78, DOI 10.1016/j.ijid.2020.05.088; Kuitunen I, 2020, PEDIATR INFECT DIS J, V39, pE423, DOI 10.1097/INF.0000000000002845; MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158; Natali Renata Martins de T, 2011, Rev. paul. pediatr., V29, P584; da Silva JLR, 2011, J BRAS PNEUMOL, V37, P759, DOI 10.1590/S1806-37132011000600009; Sakamoto H, 2020, JAMA-J AM MED ASSOC, V323, P1969, DOI 10.1001/jama.2020.6173; Schuez-Havupalo L, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014635; Smith B, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp3022008; Sonego M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116380; Vissing NH, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-0933; Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020; Yen CY, 2019, J MICROBIOL IMMUNOL, V52, P902, DOI 10.1016/j.jmii.2019.08.013; Zomer TP, 2016, EPIDEMIOL INFECT, V144, P2552, DOI 10.1017/S0950268816000911	24	27	28	4	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243694	10.1371/journal.pone.0243694	http://dx.doi.org/10.1371/journal.pone.0243694			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WM	33306735	gold, Green Published			2023-01-03	WOS:000600144200063
J	Linsky, TW; Vergara, R; Codina, N; Nelson, JW; Walker, MJ; Su, W; Barnes, CO; Hsiang, TY; Esser-Nobis, K; Yu, K; Reneer, ZB; Hou, YXJ; Priya, T; Mitsumoto, M; Pong, A; Lau, UY; Mason, ML; Chen, J; Chen, A; Berrocal, T; Peng, H; Clairmont, NS; Castellanos, J; Lin, YR; Josephson-Day, A; Baric, RS; Fuller, DH; Walkey, CD; Ross, TM; Swanson, R; Bjorkman, PJ; Gale, M; Blancas-Mejia, LM; Yen, HL; Silva, DA				Linsky, Thomas W.; Vergara, Renan; Codina, Nuria; Nelson, Jorgen W.; Walker, Matthew J.; Su, Wen; Barnes, Christopher O.; Hsiang, Tien-Ying; Esser-Nobis, Katharina; Yu, Kevin; Reneer, Z. Beau; Hou, Yixuan J.; Priya, Tanu; Mitsumoto, Masaya; Pong, Avery; Lau, Uland Y.; Mason, Marsha L.; Chen, Jerry; Chen, Alex; Berrocal, Tania; Peng, Hong; Clairmont, Nicole S.; Castellanos, Javier; Lin, Yu-Ru; Josephson-Day, Anna; Baric, Ralph S.; Fuller, Deborah H.; Walkey, Carl D.; Ross, Ted M.; Swanson, Ryan; Bjorkman, Pamela J.; Gale, Michael, Jr.; Blancas-Mejia, Luis M.; Yen, Hui-Ling; Silva, Daniel-Adriano			De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2	SCIENCE			English	Article								We developed a de novo protein design strategy to swiftly engineer decoys for neutralizing pathogens that exploit extracellular host proteins to infect the cell. Our pipeline allowed the design, validation, and optimization of de novo human angiotensin-converting enzyme 2 (hACE2) decoys to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The best monovalent decoy, CTC-445.2, bound with low nanomolar affinity and high specificity to the receptor-binding domain (RBD) of the spike protein. Cryo-electron microscopy (cryo-EM) showed that the design is accurate and can simultaneously bind to all three RBDs of a single spike protein. Because the decoy replicates the spike protein target interface in hACE2, it is intrinsically resilient to viral mutational escape. A bivalent decoy, CTC-445.2d, showed similar to 10-fold improvement in binding. CTC-445.2d potently neutralized SARS-CoV-2 infection of cells in vitro, and a single intranasal prophylactic dose of decoy protected Syrian hamsters from a subsequent lethal SARS-CoV-2 challenge.	[Linsky, Thomas W.; Vergara, Renan; Codina, Nuria; Nelson, Jorgen W.; Walker, Matthew J.; Yu, Kevin; Priya, Tanu; Mitsumoto, Masaya; Pong, Avery; Lau, Uland Y.; Mason, Marsha L.; Chen, Jerry; Chen, Alex; Berrocal, Tania; Peng, Hong; Clairmont, Nicole S.; Castellanos, Javier; Lin, Yu-Ru; Josephson-Day, Anna; Walkey, Carl D.; Swanson, Ryan; Blancas-Mejia, Luis M.; Silva, Daniel-Adriano] Neoleukin Therapeut Inc, Seattle, WA 98102 USA; [Su, Wen; Yen, Hui-Ling] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China; [Barnes, Christopher O.; Bjorkman, Pamela J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA; [Hsiang, Tien-Ying; Esser-Nobis, Katharina; Hou, Yixuan J.; Gale, Michael, Jr.] Univ Washington, Dept Immunol, Ctr Innate Immun & Immune Dis, Seattle, WA 98195 USA; [Reneer, Z. Beau; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, Athens, GA 30602 USA; [Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Fuller, Deborah H.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Ross, Ted M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA	University of Hong Kong; California Institute of Technology; University of Washington; University of Washington Seattle; University System of Georgia; University of Georgia; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University System of Georgia; University of Georgia	Silva, DA (corresponding author), Neoleukin Therapeut Inc, Seattle, WA 98102 USA.	dadriano@neoleukin.com	Hou, Yixuan/P-6443-2019; Esser-Nobis, Katharina/AHC-4180-2022; Yen, Hui-Ling/GNH-5083-2022; Yen, Hui-Ling/C-4501-2009	Hou, Yixuan/0000-0002-8323-7243; Vergara, Renan/0000-0002-3680-5105; Yen, Hui-Ling/0000-0003-2493-3609; Esser-Nobis, Katharina/0000-0002-9027-0391; Nelson, Jorgen/0000-0002-0202-2460; Walker, Matt/0000-0001-5541-9245; Codina, Nuria/0000-0003-3945-2242; Mitsumoto, Masaya/0000-0003-4926-1757; Yu, Kevin/0000-0002-6725-0413; Linsky, Thomas/0000-0002-1632-3395	NIH [AI145296, AI127463, P50 8 P50 AI150464-13, R01 AI089728]; Department of Defense; Caltech Merkin Institute for Translational Research; Hanna Gray Fellowship Program from the Howard Hughes Medical Institute; Post-doctoral Enrichment Program from the Burroughs Wellcome Fund; NIH NIAID [HHSN272201400006C]; North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill; North Carolina Coronavirus Relief Fund; Georgia Research Alliance	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Caltech Merkin Institute for Translational Research; Hanna Gray Fellowship Program from the Howard Hughes Medical Institute; Post-doctoral Enrichment Program from the Burroughs Wellcome Fund; NIH NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill; North Carolina Coronavirus Relief Fund; Georgia Research Alliance	This work was supported by NIH grants AI145296 and AI127463 and a Department of Defense grant subcontract to M.G.; NIH grant P50 8 P50 AI150464-13 and the Caltech Merkin Institute for Translational Research to P.J.B.; the Hanna Gray Fellowship Program from the Howard Hughes Medical Institute and the Post-doctoral Enrichment Program from the Burroughs Wellcome Fund to C.O.B; NIH NIAID grant HHSN272201400006C to H.-L.Y.; and NIH grant R01 AI089728 to R.S.B. Electron microscopy was performed at the Caltech Beckman Institute Resource Center for Transmission Electron Microscopy. This project was also supported by the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. T.M.R. is supported by the Georgia Research Alliance as an Eminent Scholar. "Neoleukin" is a trademark of Neoleukin Therapeutics, Inc. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the position of Neoleukin.	Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583; Baker Matthew P, 2010, Self Nonself, V1, P314, DOI 10.4161/self.1.4.13904; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106; Cao LX, 2020, SCIENCE, V370, P426, DOI 10.1126/science.abd9909; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Chan KK, 2020, SCIENCE, V369, P1261, DOI 10.1126/science.abc0870; Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6; Chevalier A, 2017, NATURE, V550, P74, DOI 10.1038/nature23912; Doud MB, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006271; Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003; Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003; Ettinger MP, 2003, JAMA-J AM MED ASSOC, V289, P1826, DOI 10.1001/jama.289.14.1826; Findeisen M, 2019, NATURE, V574, P63, DOI 10.1038/s41586-019-1601-9; Gao GP, 2004, BLOOD, V103, P3300, DOI 10.1182/blood-2003-11-3852; Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9; Hartung HP, 2004, J NEUROL, V251, P1, DOI 10.1007/s00415-004-1201-x; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hu J., 2020, 161323 BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Leaver-Fay A, 2011, METHOD ENZYMOL, P545, DOI [10.1016/S0076-6879(11)87019-9, 10.1016/B978-0-12-381270-4.00019-6]; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272; Marcos E, 2018, WIRES COMPUT MOL SCI, V8, DOI 10.1002/wcms.1374; Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111; Mukovozov I, 2008, THROMB HAEMOSTASIS, V99, P874, DOI 10.1160/TH07-11-0654; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Quijano-Rubio A, 2020, CURR OPIN CHEM BIOL, V56, P119, DOI 10.1016/j.cbpa.2020.02.002; Sauerborn M, 2010, TRENDS PHARMACOL SCI, V31, P53, DOI 10.1016/j.tips.2009.11.001; Schoof M., 2020, 238469 BIORXIV, DOI [10.1101/2020.08.08.238469, DOI 10.1101/2020.08.08.238469]; Sesterhenn F, 2020, SCIENCE, V368, P730, DOI 10.1126/science.aay5051; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Silva DA, 2019, NATURE, V565, P186, DOI 10.1038/s41586-018-0830-7; Silva DA, 2016, METHODS MOL BIOL, V1414, P285, DOI 10.1007/978-1-4939-3569-7_17; Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003760; Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237; Tovey MG, 2011, THER ADV DRUG SAF, V2, P113, DOI 10.1177/2042098611406318; Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260; Walter J. D, 2020, 045419 BIORXIV, DOI [10.1101/2020.04.16.045419, DOI 10.1101/2020.04.16.045419]; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Whitehead TA, 2012, NAT BIOTECHNOL, V30, P543, DOI 10.1038/nbt.2214; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405; Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21; Zhou JF, 2020, P NATL ACAD SCI USA, V117, P1059, DOI 10.1073/pnas.1908723117	48	87	89	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	2020	370	6521					1208	+		10.1126/science.abe0075	http://dx.doi.org/10.1126/science.abe0075			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB1EC	33154107	Green Published, Green Accepted			2023-01-03	WOS:000596071300060
J	Rahmartani, LD; Carson, C; Quigley, MA				Rahmartani, Lhuri D.; Carson, Claire; Quigley, Maria A.			Prevalence of prelacteal feeding and associated risk factors in Indonesia: Evidence from the 2017 Indonesia Demographic Health Survey	PLOS ONE			English	Article							CARE WORKERS; PROMOTION; NEWBORNS; FORMULA; MOTHERS; INFANT; IMPACT; BIRTH; PACKS; URBAN	Background Prelacteal feeding (PLF) is a recognised challenge to optimal breastfeeding but remains common in Indonesia. Meanwhile, PLF-related epidemiological research is limited, particularly in this setting. This study examines the prevalence and determinants of overall PLF as well as common PLF types (formula, other milk, and honey) in Indonesia. Methods Data from 6127 mothers whose last child was <= 23-month-old were drawn from the 2017 Indonesia Demographic and Health Survey. Multivariable modified Poisson regression was used to measure the prevalence ratio (PR) for selected PLF risk factors. PLF was defined as anything to drink other than breast milk within three days after birth, before breastmilk flows. Additional analyses were performed on mothers who gave formula, other milk, and honey. Results About 45% babies in Indonesia received PLF with formula being the most frequent (25%), followed by other milk (14%), plain water (5%), and honey (3%). Factors associated with higher prevalence of any PLF were higher wealth quintiles in rural area (PR 1.07; 95% CI 1.03-1.11 per increase in quintile), baby perceived to be small at birth (PR 1.23; 95% CI 1.12-1.35), caesarean deliveries at either public (PR 1.27; 95% CI 1.13-1.44) or private facilities (PR 1.15; 95% CI 1.01-1.31), and not having immediate skin-to-skin contact after birth (PR 1.32; 95% CI 1.23-1.42). PLF was less prevalent among mothers who gave birth to second/subsequent child (PR 0.82; 95% CI 0.76-0.88) and who had an antenatal card (PR 0.89; 95% CI 0.80-0.99). These patterns did not apply uniformly across all PLF types. For example, honey was more common among home births than deliveries at health facilities, but formula and other milk were more common among caesarean deliveries. Conclusions Mapping risk factors for PLF, especially by types, could help to design more targeted interventions to reduce PLF and improve breastfeeding practices in Indonesia.	[Rahmartani, Lhuri D.; Carson, Claire; Quigley, Maria A.] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Oxford, England; [Rahmartani, Lhuri D.] Univ Indonesia, Fac Publ Hlth, Dept Epidemiol, Depok, Jawa Barat, Indonesia	University of Oxford; University of Indonesia	Rahmartani, LD (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Oxford, England.; Rahmartani, LD (corresponding author), Univ Indonesia, Fac Publ Hlth, Dept Epidemiol, Depok, Jawa Barat, Indonesia.	lhuri.rahmartani@dph.ox.ac.uk		Quigley, Maria/0000-0002-8058-6181; Rahmartani, Lhuri/0000-0001-9968-5318	Medical Research Council [MR/L019671/1]; U.S. Agency for International Development (USAID); Jardine Scholarship	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U.S. Agency for International Development (USAID)(United States Agency for International Development (USAID)); Jardine Scholarship	This study was conducted as part of LDR's Doctor of Philosophy in Population Health at the University of Oxford. LDR receives the Jardine Scholarship (https://www.jardines.com) for her doctoral study at the Nuffield Department of Population Health, University of Oxford. LDR is supervised by CC, who is funded by a Career Development Award MR/L019671/1 from the Medical Research Council (https://mrc.ukri.org).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Permission to use the 2017 Indonesia Demographic and Health Survey (IDHS) dataset was obtained from the Demographic and Health Surveys (DHS) Program, which was implemented by ICF and funded by the U.S. Agency for International Development (USAID). We thank ICF, National Population and Family Planning Board (BKKBN), Statistics Indonesia (BPS), and the Ministry of Health (Kemenkes) for conducting the survey, as well as all mothers who participated in the survey.	Akuse RM, 2002, EUR J CLIN NUTR, V56, P729, DOI 10.1038/sj.ejcn.1601385; Albokhary AA, 2014, SAUDI MED J, V35, P1400; Amele EA, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0604-3; [Anonymous], 2016, FUEL CELLS B, V3, P8; [Anonymous], 2019, LAP NAS RISK; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; [Anonymous], 2016, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003519.PUB3; [Anonymous], 2018, J CANC RES THER, V14, pS622; Barati Z, 2018, NUTR FOOD SCI, V48, P589, DOI 10.1108/NFS-07-2017-0144; Belachew AB, 2016, ARCH PUBLIC HEALTH, V74, DOI 10.1186/s13690-016-0117-0; Benedict RK, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12697; Bennett DA, 2001, AUST NZ J PUBL HEAL, V25, P464, DOI 10.1111/j.1467-842X.2001.tb00294.x; Berde AS, 2017, PUBLIC HEALTH NUTR, V20, P1953, DOI 10.1017/S1368980017000659; Berde AS, 2017, AFR HEALTH SCI, V17, P690, DOI 10.4314/ahs.v17i3.11; BKKBN BPS Kemenkes RI ICF International., 2018, SURV DEM DAN KES IND; Callen Jennifer, 2005, Adv Neonatal Care, V5, P93, DOI 10.1016/j.adnc.2004.12.005; Callen Jennifer, 2005, Adv Neonatal Care, V5, P72, DOI 10.1016/j.adnc.2004.12.003; Croft TN, 2018, GUIDE DHS STAT DHS 7; Feeley AB, 2016, MATERN CHILD NUTR, V12, P64, DOI 10.1111/mcn.12304; Flaherman VJ, 2018, PUBLIC HEALTH NUTR, V21, P2689, DOI 10.1017/S1368980018001453; General Directorate of Statistics (GDS) Ministry of Health ICF, 2018, TIM DEM HLTH SURV 20; Hyde MJ, 2012, BIOL REV, V87, P229, DOI 10.1111/j.1469-185X.2011.00195.x; ICF International, DHS OV ICF INT; ICF International, SURV SEARCH RES IND; Inayati DA, 2012, INT BREASTFEED J, V7, DOI 10.1186/1746-4358-7-3; ITSB, 2016, J SCI ENG RES, V3, P63; Kementerian Kesehatan (Kemenkes-MOH) RI, 2009, BUK KES IBU DAN AN; Khanal V, 2014, J PEDIATR GASTR NUTR, V59, P162, DOI 10.1097/MPG.0000000000000429; Khanal V, 2013, INT BREASTFEED J, V8, DOI 10.1186/1746-4358-8-9; Li RW, 2005, NUTR REV, V63, P103, DOI 10.1111/j.1753-4887.2005.tb00128.x; McKenna KM, 2009, J MIDWIFERY WOM HEAL, V54, P78, DOI 10.1016/j.jmwh.2008.07.012; Mercado K, 2019, ADV NEONAT CARE, V19, P474, DOI 10.1097/ANC.0000000000000684; Merewood A, 2008, ARCH PEDIAT ADOL MED, V162, P823, DOI 10.1001/archpedi.162.9.823; Ministry of Health and Sports (MoHS) ICF., 2017, MYANM DEM HLTH SURV; National Population and Family Planning Board (BKKBN) Statistics Indonesia (BPS) Ministry of Health (Kemenkes) ICF, 2018, IND DEM HLTH SURV 20; Nguyen PH, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-932; PerezEscamilla R, 1996, J NUTR, V126, P2765; Philippine Statistics Authority (PSA) ICF, 2018, PHIL NAT DEM HLTH SU; Nguyen P, 2020, ARCH DIS CHILD, V105, P122, DOI 10.1136/archdischild-2019-316937; Pries AM, 2016, MATERN CHILD NUTR, V12, P38, DOI 10.1111/mcn.12271; R Bunga Ch, 2013, PENELITIAN GIZI DAN, V36, P54; Rahmawati W., 2016, INDONES J HUM NUTR, V3, P20, DOI [10.21776/ub.ijhn.2016.003.Suplemen.3, DOI 10.21776/UB.IJHN.2016.003.SUPLEMEN.3]; Requejo JH, 2015, LANCET, V385, P466, DOI 10.1016/S0140-6736(14)60925-9; Rollins NC, 2016, LANCET, V387, P491, DOI 10.1016/S0140-6736(15)01044-2; Rosenberg KD, 2008, AM J PUBLIC HEALTH, V98, P290, DOI 10.2105/AJPH.2006.103218; Sallam SA, 2013, BREASTFEED MED, V8, P312, DOI 10.1089/bfm.2012.0040; Smith HA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006462.pub4; StataCorp, 2017, INVENTORSTATA STAT S; Statistics Indonesia (Badan Pusat Statistik-BPS) Macro International, 2008, MACR IND DEM HLTH SU; Statistics Indonesia (Badan Pusat Statistik-BPS) National Population and Family Planning Board (BKKBN) Kementerian Kesehatan (Kemenkes-MOH) ICF International, 2013, IND DEM HLTH SURV 20; Susiloretni KA, 2015, MATERN CHILD HLTH J, V19, P1515, DOI 10.1007/s10995-014-1656-z; Takele WW, 2018, ARCH PUBLIC HEALTH, V76, DOI 10.1186/s13690-018-0308-y; Temesgen H, 2018, INT BREASTFEED J, V13, DOI 10.1186/s13006-018-0193-6; The DHS Program, PROT PRIV DHS RESP; Titaley CR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-485; Utomo B, 1997, HLTH SOCIAL DIMENSIO; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; WHO, ACC MED REAS US BREA; WHO, INF YOUNG CHILD FEED; WHO, BOT 2018; WHO/UNICEF, 1989, ROL MIDW NURS PROT P; World Bank Country and Lending Groups, WORLD BANK COUNTR LE; World Bank Group, OV IND 2019; World Health Organization, 10 STEPS SUCC BREAST; Zarshenas M, 2019, BIRTH-ISS PERINAT C, V46, P137, DOI 10.1111/birt.12385; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	66	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2020	15	12							e0243097	10.1371/journal.pone.0243097	http://dx.doi.org/10.1371/journal.pone.0243097			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PC7AH	33270720	Green Published, gold			2023-01-03	WOS:000597149100078
J	Marcin, T; Eser, P; Prescott, E; Prins, LF; Kolkman, E; Bruins, W; van der Velde, AE; Gil, CP; Iliou, MC; Ardissino, D; Zeymer, U; Meindersma, EP; Van't Hof, AWJ; de Kluiver, EP; Wilhelm, M				Marcin, Thimo; Eser, Prisca; Prescott, Eva; Prins, Leonie F.; Kolkman, Evelien; Bruins, Wendy; van der Velde, Astrid E.; Pena Gil, Carlos; Iliou, Marie-Christine; Ardissino, Diego; Zeymer, Uwe; Meindersma, Esther P.; Van't Hof, Arnoud W. J.; de Kluiver, Ed P.; Wilhelm, Matthias			Training intensity and improvements in exercise capacity in elderly patients undergoing European cardiac rehabilitation - the EU-CaRE multicenter cohort study	PLOS ONE			English	Article							CORONARY-ARTERY-DISEASE; CARDIOVASCULAR PREVENTION; ASSOCIATION	Objectives Guidelines for exercise intensity prescription in Cardiac Rehabilitation (CR) are inconsistent and have recently been discussed controversially. We aimed (1) to compare training intensities between European CR centres and (2) to assess associations between training intensity and improvement in peak oxygen consumption (VO2) in elderly CR patients. Methods Peak VO2, heart rate and work rate (WR) at the first and second ventilatory thresholds were measured at start of CR. Training heart rate was measured during three sessions spread over the CR. Multivariate models were used to compare training characteristics between centres and to assess the effect of training intensity on change in peak VO2. Results Training intensity was measured in 1011 out of 1633 EU-CaRE patients in 7 of 8 centers and the first and secondary ventilatory threshold were identified in 1166 and 817 patients, respectively. The first and second ventilatory threshold were found at 44% (SD 16%) and 78% (SD 9%) of peak WR and 78% (SD 9%) and 89% (SD 5%) of peak heart rate, respectively. Training intensity and session duration varied significantly between centres but change in peak VO2 over CR did not. Training above the first individual threshold (beta 0.62, 95% confidence interval [0.25-1.02]) and increase in training volume per hour (beta 0.06, 95%CI [0.01-0.12]) were associated with a higher change in peak VO2. Conclusion While training intensity and volume varied greatly amongst current European CR programs, changes in peak VO2 were similar and the effect of training characteristics on these changes were small.	[Marcin, Thimo; Eser, Prisca; Wilhelm, Matthias] Univ Bern, Dept Cardiol, Ctr Prevent Cardiol, Sports Med,Bern Univ Hosp, Bern, Switzerland; [Marcin, Thimo] Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland; [Prescott, Eva] Bispebjerg Frederiksberg Univ Hosp, Dept Cardiol, Copenhagen, Denmark; [Prins, Leonie F.; Kolkman, Evelien] Diagram BV, Zwolle, Netherlands; [Bruins, Wendy; van der Velde, Astrid E.; Meindersma, Esther P.; Van't Hof, Arnoud W. J.; de Kluiver, Ed P.] Isala Heart Ctr, Zwolle, Netherlands; [Pena Gil, Carlos] Complexo Hosp Univ Santiago Compostela, Dept Cardiol, SERGAS IDIS CIBERCV, Santiago De Compostela, Spain; [Iliou, Marie-Christine] AP HP, Dept Cardiac Rehabil, Paris, France; [Ardissino, Diego] Parma Univ Hosp, Dept Cardiol, Parma, Italy; [Zeymer, Uwe] Klinikum Ludwigshafen, Inst Herzinfarktforsch Ludwigshafen, Ludwigshafen, Germany; [Meindersma, Esther P.] Radboud Univ Nijmegen, Dept Cardiol, Nijmegen, Netherlands; [Van't Hof, Arnoud W. J.] Maastricht Univ, Dept Cardiol, Med Ctr, Maastricht, Netherlands; [Van't Hof, Arnoud W. J.] Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands; [Van't Hof, Arnoud W. J.] Zuyderland Med Ctr, Dept Cardiol, Heerlen, Netherlands	University of Bern; University Hospital of Bern; University of Bern; University of Copenhagen; Bispebjerg Hospital; Complexo Hospitalario Universitario de Santiago de Compostela; Assistance Publique Hopitaux Paris (APHP); University of Parma; University Hospital of Parma; Institute Heart Attack Research; Ludwigshafen Hospital; Radboud University Nijmegen; Maastricht University; Maastricht University	Marcin, T (corresponding author), Univ Bern, Dept Cardiol, Ctr Prevent Cardiol, Sports Med,Bern Univ Hosp, Bern, Switzerland.; Marcin, T (corresponding author), Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland.	thimo.marcin@insel.ch	Ardissino, Diego/AAC-4041-2022; Eser, Prisca/AAE-3758-2021; de Kluiver, Ed/AAX-7135-2021; Wilhelm, Matthias/AAS-9456-2020; Prescott, Eva/AAJ-7441-2020	Wilhelm, Matthias/0000-0003-4541-3995; van 't Hof, Arnoud/0000-0002-2344-7564; solinas, emilia/0000-0003-3532-1317; Eser, Prisca/0000-0001-9734-0682; Bruins, Wendy/0000-0003-3287-1321; Marcin, Thimo/0000-0001-7229-5985; Pena-Gil, Carlos/0000-0002-5263-5572	Swiss State Secretariat for Education, Research and Innovation [15.0139]; European Union [634439]; Diagram B.V.	Swiss State Secretariat for Education, Research and Innovation; European Union(European Commission); Diagram B.V.	For the Swiss consortium partner (TM, PE, MW), funding was received by the Swiss State Secretariat for Education, Research and Innovation under contract number 15.0139. All other authors received funding by the European Union's Horizon 2020 research and innovation programme under grant agreement No 634439. LP and EK received support in the form of a salary from Diagram B.V., a contract research organization. The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BELARDINELLI R, 1995, J AM COLL CARDIOL, V26, P975, DOI 10.1016/0735-1097(95)00267-1; Boyde M, 2018, PATIENT EDUC COUNS, V101, P2162, DOI 10.1016/j.pec.2018.07.010; Davos CH, 2019, EUR J PREV CARDIOL, V26, P1918, DOI 10.1177/2047487319871870; Ekkekakis P, 2011, SPORTS MED, V41, P641, DOI 10.2165/11590680-000000000-00000; Hansen D, 2019, EUR J PREV CARDIOL, V26, P1921, DOI 10.1177/2047487319859450; Hansen D, 2012, SPORTS MED, V42, P11, DOI 10.2165/11595460-000000000-00000; Hung RK, 2014, MAYO CLIN PROC, V89, P1644, DOI 10.1016/j.mayocp.2014.07.011; Martin BJ, 2013, MAYO CLIN PROC, V88, P455, DOI 10.1016/j.mayocp.2013.02.013; Mezzani A, 2013, EUR J PREV CARDIOL, V20, P442, DOI 10.1177/2047487312460484; Mitchell BL, 2019, BRIT J SPORT MED, V53, P1342, DOI 10.1136/bjsports-2018-099153; Nieuwland W, 2002, INT J CARDIOL, V84, P15, DOI 10.1016/S0167-5273(02)00059-1; Oliveira BRR, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01105; Piepoli MF, 2010, EUR J CARDIOV PREV R, V17, P1, DOI 10.1097/HJR.0b013e3283313592; Prescott E, 2019, EUR J PREV CARDIOL, V26, P1052, DOI 10.1177/2047487319839819; Price KJ, 2016, EUR J PREV CARDIOL, V23, P1715, DOI 10.1177/2047487316657669; Thomas RJ, 2019, J AM COLL CARDIOL, V74, P133, DOI 10.1016/j.jacc.2019.03.008; VANHEES L, 1994, J AM COLL CARDIOL, V23, P358, DOI 10.1016/0735-1097(94)90420-0; Wasserman K, 2012, PRINCIPLES EXERCISE, V5th	18	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2020	15	11							e0242503	10.1371/journal.pone.0242503	http://dx.doi.org/10.1371/journal.pone.0242503			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0NB	33186408	Green Published, gold			2023-01-03	WOS:000593949800024
J	Oetjens, MT; Luo, JZ; Chang, A; Leader, JB; Hartzel, DN; Moore, BS; Strande, NT; Kirchner, HL; Ledbetter, DH; Justice, AE; Carey, DJ; Mirshahi, T				Oetjens, Matthew T.; Luo, Jonathan Z.; Chang, Alexander; Leader, Joseph B.; Hartzel, Dustin N.; Moore, Bryn S.; Strande, Natasha T.; Kirchner, H. Lester; Ledbetter, David H.; Justice, Anne E.; Carey, David J.; Mirshahi, Tooraj			Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients	PLOS ONE			English	Article								Background Empirical data on conditions that increase risk of coronavirus disease 2019 (COVID-19) progression are needed to identify high risk individuals. We performed a comprehensive quantitative assessment of pre-existing clinical phenotypes associated with COVID-19-related hospitalization. Methods Phenome-wide association study (PheWAS) of SARS-CoV-2-positive patients from an integrated health system (Geisinger) with system-level outpatient/inpatient COVID-19 testing capacity and retrospective electronic health record (EHR) data to assess pre-COVID-19 pandemic clinical phenotypes associated with hospital admission (hospitalization). Results Of 12,971 individuals tested for SARS-CoV-2 with sufficient pre-COVID-19 pandemic EHR data at Geisinger, 1604 were SARS-CoV-2 positive and 354 required hospitalization. We identified 21 clinical phenotypes in 5 disease categories meeting phenome-wide significance (P<1.60x10(-4)), including: six kidney phenotypes, e.g. end stage renal disease or stage 5 CKD (OR = 11.07, p = 1.96x10(-8)), six cardiovascular phenotypes, e.g. congestive heart failure (OR = 3.8, p = 3.24x10(-5)), five respiratory phenotypes, e.g. chronic airway obstruction (OR = 2.54, p = 3.71x10(-5)), and three metabolic phenotypes, e.g. type 2 diabetes (OR = 1.80, p = 7.51x10(-5)). Additional analyses defining CKD based on estimated glomerular filtration rate, confirmed high risk of hospitalization associated with pre-existing stage 4 CKD (OR 2.90, 95% CI: 1.47, 5.74), stage 5 CKD/dialysis (OR 8.83, 95% CI: 2.76, 28.27), and kidney transplant (OR 14.98, 95% CI: 2.77, 80.8) but not stage 3 CKD (OR 1.03, 95% CI: 0.71, 1.48). Conclusions This study provides quantitative estimates of the contribution of pre-existing clinical phenotypes to COVID-19 hospitalization and highlights kidney disorders as the strongest factors associated with hospitalization in an integrated US healthcare system.	[Oetjens, Matthew T.; Luo, Jonathan Z.; Chang, Alexander; Leader, Joseph B.; Hartzel, Dustin N.; Moore, Bryn S.; Strande, Natasha T.; Kirchner, H. Lester; Ledbetter, David H.; Justice, Anne E.; Carey, David J.; Mirshahi, Tooraj] Geisinger, Danville, PA USA		Carey, DJ; Mirshahi, T (corresponding author), Geisinger, Danville, PA USA.	tmirshahi@geisinger.edu; djcarey@geisinger.edu		Justice, Anne/0000-0002-8903-8712; Strande, Natasha/0000-0001-5148-9772; Luo, Jonathan/0000-0003-2567-1516	NIH-NIGMS (NIH.GOV) [GM111913]	NIH-NIGMS (NIH.GOV)	This work was supported by GM111913 from the NIH-NIGMS (NIH.GOV) to T.M. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bush WS, 2016, NAT REV GENET, V17, P129, DOI 10.1038/nrg.2015.36; Caillard S, 2020, KIDNEY INT, V98, P1549, DOI 10.1016/j.kint.2020.08.005; Carey DJ, 2016, GENET MED, V18, P906, DOI 10.1038/gim.2015.187; Carroll RJ, 2014, BIOINFORMATICS, V30, P2375, DOI 10.1093/bioinformatics/btu197; Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249; Griffith Gareth J, 2020, Nat Commun, V11, P5749, DOI 10.1038/s41467-020-19478-2; Hamer M, 2020, P NATL ACAD SCI USA, V117, P21011, DOI 10.1073/pnas.2011086117; Hamer M, 2020, BRAIN BEHAV IMMUN, V87, P184, DOI 10.1016/j.bbi.2020.05.059; Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2; Kim L, 2020, CLIN INFECT DIS; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Ng JH, 2020, KIDNEY INT; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Saran R, 2019, AM J KIDNEY DIS, V73, pSVII; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4	19	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2020	15	11							e0242182	10.1371/journal.pone.0242182	http://dx.doi.org/10.1371/journal.pone.0242182			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0MJ	33180868	Green Published, gold			2023-01-03	WOS:000593948000016
J	Timerga, A; Kelta, E; Kenenisa, C; Zawdie, B; Habte, A; Haile, K				Timerga, Abebe; Kelta, Endryas; Kenenisa, Chala; Zawdie, Belay; Habte, Aklilu; Haile, Kassahun			Serum electrolytes disorder and its associated factors among adults admitted with metabolic syndrome in Jimma Medical Center, South West Ethiopia: Facility based crossectional study	PLOS ONE			English	Article							HYPONATREMIA; PREVALENCE; HYPOKALEMIA; POTASSIUM	Background Electrolytes play an important role in controlling acid base balance, blood clotting, and body fluid and muscle contractions. Serum electrolytes concentrations are most commonly used tests for assessment of a patient's clinical conditions, and are associated with morbidity and mortality. Any derangements from the normal range of electrolyte levels in the body is described as electrolyte disorders. The Current study was aimed to determine serum electrolytes disorder and its associated factors among adults admitted with metabolic syndrome at Jimma medical center, South West Ethiopia. Methods A Facility based cross sectional study was conducted on 256 patients admitted medical center with metabolic syndrome during the study period. The World Health Organization stepwise assessment tools and patients' medical records were used to collect information on factors associated with electrolyte disorders. Bivariable and Multivariable logistic regression analyses were performed to identify factors associated with electrolyte disorder at the level of significance of p value <0.25 with 95% confidence interval of crude odds ratio and <0.05 with 95% confidence interval of adjusted odds ratio respectively. Results The overall prevalence of electrolyte disorders was 44.1% (95%CI:40.99-47.20) with hyponatremia 42.9% (95%CI:39.81-45.99) as the leading electrolyte disorder followed by hypokalemia 20.7% (95%CI:18.17-23.23), hypochloremia 17.6% (95%CI:15.22-19.98) and hypocalcemia 9.4% (95%CI:7.57-11.22). Non-formal education [AOR: 6.81; 95%CI:(3.48,17.01)] alcohol consumption [AOR: 4.28; 95%CI:(1.71,10.70)], diuretics, diuretics [AOR: 4.39; 95%CI:(2.10,9.15)], antidiabetics [AOR: 5.18; 95%CI:(2.44,11.00)], and body mass index [AOR: 11.51; 95%CI:(3.50,18.81)] were identified as independent factors for electrolyte disturbance in multivariable logistic regression. Conclusion The finding of the study revealed that nearly half the study participants with metabolic syndromes had electrolyte disorder. Educational status, habit of alcohol consumption, diuretics, antidiabetics, and having higher body mass index were the independent factors associated with electrolyte disorders. Determination of Serum electrolytes, proper administration of diuretic and health education on behavioral factors were the necessary measures that should be done by concerned bodies to reduce electrolytes disorder.	[Timerga, Abebe] Wolkite Univ, Biochem Unit, Dept Biomed Sci, Coll Med & Hlth Sci, Wolkite, Ethiopia; [Kelta, Endryas; Kenenisa, Chala; Zawdie, Belay] Jimma Univ, Biochem Unit, Fac Med Sci, Dept Biomed Sci,Inst Hlth, Jimma, Ethiopia; [Habte, Aklilu] Wachamo Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Reprod Hlth Unit, Hosanna, Ethiopia; [Haile, Kassahun] Wolkite Univ, Coll Med & Hlth Sci, Hematol Unit, Dept Med Lab Sci, Wolkite, Ethiopia	Jimma University	Timerga, A (corresponding author), Wolkite Univ, Biochem Unit, Dept Biomed Sci, Coll Med & Hlth Sci, Wolkite, Ethiopia.	abebetimerga125@gmail.com	Habte, Aklilu/ABB-7649-2020; hailegebireal, aklilu habte/ABD-1527-2020	hailegebireal, aklilu habte/0000-0002-5719-4294; Haile, Kassahun/0000-0002-2520-9244				Ahmed SS, 2014, KYAMC J, V5, P458; Ali K, 2016, INT J GEN MED, V9, P267, DOI 10.2147/IJGM.S110872; [Anonymous], 2019, NAT ELECTRON, V2, P1, DOI 10.1038/s41928-019-0203-8; [Anonymous], 2015, NATL ASSEMBLY PAKIST, V2, P2; [Anonymous], 1995, WOOL RES ORG NZ NEWS, V2, P2; Atchley DW, 1933, J CLIN INVEST, V12, P297, DOI 10.1172/JCI100504; Babaliche P, 2017, INDIAN J CRIT CARE M, V21, P819, DOI 10.4103/ijccm.IJCCM_257_17; Cai XL, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040183; CARL JC, 1985, PHYS ACTIVITY EXERCI, V100, P1; Chandini PJ, 2015, INT J CONT MED, V4, P12; Edae C. K., 2018, Journal of Nutrition Fasting and Health, V6, P60, DOI 10.22038/jnfh.2018.35602.1153; Editorial, 2016, NAT CLIM CHANGE, V6, P1, DOI [10.1038/nclimate2911, DOI 10.1038/s41598-016-0001-8]; Girdhar A, 2018, IET IMAGE PROCESS, V12, P1, DOI 10.1049/iet-ipr.2017.0162; Goldberg A, 2004, AM J MED, V117, P242, DOI 10.1016/j.amjmed.2004.03.022; Hawkins RC, 2003, CLIN CHIM ACTA, V331, P171, DOI 10.1016/S0009-8981(03)00112-8; Iqbal R, 2019, PAK HEART J, V52, P27; John M, 2011, ANN I SUPER SANITA, V47, P445; Kimura T, 2016, INTERNAL MED, V55, P3085, DOI 10.2169/internalmedicine.55.7000; Kwon H, 2016, INT UROL NEPHROL, V48, P451, DOI 10.1007/s11255-016-1215-1; Liamis G, 2014, WORLD J CLIN CASES, V2, P488, DOI 10.12998/wjcc.v2.i10.488; Liamis G, 2013, AM J MED, V126, P256, DOI 10.1016/j.amjmed.2012.06.037; Longo DL, 2012, HARRISONS PRINCIPLES; Luo JC, 2016, CLIN J AM SOC NEPHRO, V11, P90, DOI 10.2215/CJN.01730215; Mannesse CK, 2013, AGEING RES REV, V12, P165, DOI 10.1016/j.arr.2012.04.006; McPhee S.J., 2010, CURRENT MED DIAGNOSI; MESSERLI FH, 1987, ARCH INTERN MED, V147, P1725, DOI 10.1001/archinte.147.10.1725; Mohan S, 2013, AM J MED, V126, P1127, DOI 10.1016/j.amjmed.2013.07.021; Muller M, 2018, EUR J INTERN MED, V54, P46, DOI 10.1016/j.ejim.2018.04.008; Onyiriuka NA, 2018, SRI LANKA J DIABETES, V8, P8; Palmer BF, 2017, NEW ENGL J MED, V377, P1368, DOI 10.1056/NEJMra1704724; Perron P, 2016, PLOS ONE, V8, P1; REID A, 2012, JRSM SHORT REPORTS, V3, P1; Rossi Joseph, 2007, Acute Card Care, V9, P82, DOI 10.1080/17482940701210179; ROWE JW, 1980, METABOLISM, V29, P498, DOI 10.1016/0026-0495(80)90074-8; Ruff RL, 1999, NEUROLOGY, V53, P1556, DOI 10.1212/WNL.53.7.1556; Sarguru D, 2016, INT J PHARM SCI REV, V40, P251; Sharma R., 2013, INT J ADV PHARM SCI, V4, P1; Strong KL, 2004, SOZ PRAVENTIV MED, V49, P269, DOI 10.1007/s00038-004-3076-0; Thaman RG., 2013, J PHYS PHARM ADV, V3, P48, DOI [10.5455/jppa.20130317071355, DOI 10.5455/JPPA.20130317071355]; VIJAY PANDEY V, 2017, J APPL PHARM SCI, V7, P189; WHO, 1995, PROGRAMME SUBSTANCE	41	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2020	15	11							e0241486	10.1371/journal.pone.0241486	http://dx.doi.org/10.1371/journal.pone.0241486			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PT	33152003	Green Published, gold			2023-01-03	WOS:000591376200009
J	Vunjak-Novakovic, G				Vunjak-Novakovic, Gordana			Dynamic Hydrogels for Investigating Vascularization	CELL STEM CELL			English	Editorial Material								Extracellular matrix is known to regulate vascularization by a sequence of multiple factors including mechanical forces. In this issue of Cell Stem Cell, Wei et al. (2020) investigate the roles of matrix biomechanics on early stages of vasculogenesis by using hydrogels with tunable stiffness and stress relaxation.	[Vunjak-Novakovic, Gordana] Columbia Univ, New York, NY 10032 USA	Columbia University	Vunjak-Novakovic, G (corresponding author), Columbia Univ, New York, NY 10032 USA.	gv2131@columbia.edu						Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Iruela-Arispe ML, 2009, DEV CELL, V16, P222, DOI 10.1016/j.devcel.2009.01.013; Paek J, 2019, ACS NANO, V13, P7627, DOI 10.1021/acsnano.9b00686; Ronaldson-Bouchard K, 2018, CELL STEM CELL, V22, P310, DOI 10.1016/j.stem.2018.02.011; Skylar-Scott MA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2459; Wei Z, 2020, CELL STEM CELL, V27, P798, DOI 10.1016/j.stem.2020.08.005; Yu CH, 2011, P NATL ACAD SCI USA, V108, P20585, DOI 10.1073/pnas.1109485108	7	1	2	3	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	NOV 5	2020	27	5					697	698		10.1016/j.stem.2020.10.009	http://dx.doi.org/10.1016/j.stem.2020.10.009			3	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	OP8DT	33157044	Bronze			2023-01-03	WOS:000588320400003
J	Majeed, M; Bhatti, KH; Amjad, MS; Abbasi, AM; Bussmann, RW; Nawaz, F; Rashid, A; Mehmood, A; Mahmood, M; Khan, WM; Ahmad, KS				Majeed, Muhammad; Bhatti, Khizar Hayat; Amjad, Muhammad Shoaib; Abbasi, Arshad Mehmood; Bussmann, Rainer W.; Nawaz, Fahim; Rashid, Audil; Mehmood, Ansar; Mahmood, Majid; Khan, Wisal Muhammad; Ahmad, Khawaja Shafique			Ethno-veterinary uses of Poaceae in Punjab, Pakistan	PLOS ONE			English	Article							MEDICINAL-PLANTS; ETHNOVETERINARY PRACTICES; ETHNOMEDICINAL-USES; TRADITIONAL KNOWLEDGE; ETHNOBOTANICAL SURVEY; ETHNOPHARMACOLOGICAL FIELD; DIFFERENT AILMENTS; DAIRY ANIMALS; DISTRICT; INVENTORY	Plant species of the Poaceae family are not only used as fodder and forage but also contribute substantially to the treatment of various health disorders, particularly in livestock. Consequently, the present study was aimed to document the therapeutic uses of Poaceae practiced by the inhabitants of the Punjab Province for the treatment of various veterinary health disorders. Semi structured interviews, group discussion and field walks were conducted to collect the data. Quantitative indices including cultural significance index (CSI), relative frequency of citations (RFC), fidelity level (FL), relative popularity level (RPL), and Jaccard Index (JI) were used for the data analysis. Traditional uses of 149 species belonging to 60 genera and 16 tribes of 5 sub families of Poaceae were recorded. Whole plants and leaves were the most consistently used parts with 40.94 and 29.53%. The plants were mainly given orally as fodder (59 reports) without processing followed by decoction (35 reports). Most of the species were employed to treat infectious diseases (25.93%), and digestive disorders (14.10%). Triticum aestivum had the highest CSI, RFC and RPL levels at 8.00, 0.96, 1.00, respectively, followed by Oryza sativa and Poa annua. Likewise, T. aestivum and Saccharum spontaneum had 100% FL and ROP. Jaccard index ranged from 12.25 to 0.37. Twelve plant species namely Chrysopogon zizanioides (anti-inflammatory), Pennisetum lanatum (improve bull fertility), Cymbopogon citratus (glandular secretion), Sorghum saccharatum and Themeda triandra (malaria), Aristida funiculate (anticancer), Koeleria argentia (skin allergies), Tetrapogon villosus (antibacterial), Cynodon radiatus (eyes infection), Sporobolus nervosa (Jaundice), Enneapogon persicus (antifungal), and Panicum repens (dysfunctional cattle organs) were reported for the first time, with novel ethnoveterinary uses. The inhabitants of the study area had a strong association with their surrounding plant diversity and possessed significant knowledge on therapeutic uses of Poaceae to treat various health disorders in animals. Plant species with maximum cultural and medicinal values could be a potential source of novel drugs to cure health disorders in animals and human as well.	[Majeed, Muhammad; Bhatti, Khizar Hayat; Rashid, Audil] Univ Gujrat, Dept Bot, Hafiz Hayat Campus, Gujrat, Punjab, Pakistan; [Amjad, Muhammad Shoaib] Women Univ Azad Jammu & Kashmir, Dept Bot, Bagh, Ajk, Pakistan; [Abbasi, Arshad Mehmood] COMSATS Univ Islamabad, Dept Environm Sci, Abbottabad Campus, Abbottabad, Khyber Pakhtunk, Pakistan; [Bussmann, Rainer W.] Ilia State Univ, Inst Bot, Dept Ethnobot, La Paz, Bolivia; [Nawaz, Fahim] Univ Agr, Dept Agron, MNS, Multan, Pakistan; [Mehmood, Ansar; Ahmad, Khawaja Shafique] Univ Poonch Rawalakot UPR, Dept Bot, Azad Jammu Kashmir, Pakistan; [Mahmood, Majid] Univ Poonch Rawalakot UPR, Dept Zool, Azad Jammu Kashmir, Pakistan; [Khan, Wisal Muhammad] Islamia Coll Peshawar, Dept Bot, Peshawar, Pakistan	University of Gujrat; COMSATS University Islamabad (CUI); University of Peshawar	Ahmad, KS (corresponding author), Univ Poonch Rawalakot UPR, Dept Bot, Azad Jammu Kashmir, Pakistan.	shafiquebot@yahoo.com	Amjad, Muhammad Shoaib/GQQ-1505-2022; Ahmad, Khawaja Shafique/A-8115-2016; Nawaz, Fahim/L-8954-2017; Rashid, Audil/AET-5232-2022; Abbasi, Arshad Mehmood/J-9314-2015; Ahmad, Khawaja Shafique/Q-4069-2019; Bussmann, Rainer W/A-6105-2010; Mehmood, Ansar/N-9859-2017	Ahmad, Khawaja Shafique/0000-0001-8814-9878; Nawaz, Fahim/0000-0001-7753-5087; Rashid, Audil/0000-0003-3872-8681; Abbasi, Arshad Mehmood/0000-0001-9978-3866; Ahmad, Khawaja Shafique/0000-0001-8814-9878; Bussmann, Rainer W/0000-0002-3524-5273; Mahmood, Majid/0000-0001-6680-3541; Mehmood, Ansar/0000-0002-6120-5646				Abbasi AM, 2013, J ETHNOPHARMACOL, V148, P528, DOI 10.1016/j.jep.2013.04.050; Abubakar S, 1999, THESIS U EDINBURGH; Adebayo JO, 2011, J ETHNOPHARMACOL, V133, P289, DOI 10.1016/j.jep.2010.11.024; Ahmad F., 2012, J MED PLANTS RES, V6, P1955; Ahmad F, 2010, J MED PLANTS RES, V4, P362; Ahmad F, 2009, AFR J BIOTECHNOL, V8, P231; Ahmad I, 2011, J INEQUAL APPL, DOI 10.1186/1029-242X-2011-75; Ahmad Rizwan, 2017, J Tradit Complement Med, V7, P195, DOI 10.1016/j.jtcme.2016.05.002; Ahmed MJ, 2015, J ETHNOPHARMACOL, V159, P209, DOI 10.1016/j.jep.2014.11.016; Akhtar MS, 2000, SMALL RUMINANT RES, V38, P99, DOI 10.1016/S0921-4488(00)00163-2; Akhtar N, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-25; Alawa JP, 2002, PREV VET MED, V54, P79, DOI 10.1016/S0167-5877(01)00273-2; Albuquerque Ulysses Paulino de, 2005, Acta Bot. Bras., V19, P27, DOI 10.1590/S0102-33062005000100004; Ali SI, 2015, FLORA PAKISTAN KARAC, P1993; Ali-Shtayeh MS, 2000, J ETHNOPHARMACOL, V73, P221, DOI 10.1016/S0378-8741(00)00316-0; [Anonymous], 2013, 2 AL MIZAN, V1, P18; [Anonymous], 2014, EVID-BASED COMPL ALT, DOI DOI 10.1155/2014/635371; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; [Anonymous], 1998, OFFICE OFFICIAL PUBL, V2, P125; [Anonymous], 2015, AM J ANAL CHEM, V6, P228; [Anonymous], 1996, J ORTHOP TRAUMA S1, V10, P1; Anyasor GN, 2010, AFR J BIOTECHNOL, V9, P4880; Asase A, 2005, J ETHNOPHARMACOL, V99, P273, DOI 10.1016/j.jep.2005.02.020; Aziz MA, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0212-0; Babu R. H., 2013, J PHARM RES, V1, P947; Bachaya HA, 2009, J ETHNOPHARMACOL, V123, P325, DOI 10.1016/j.jep.2009.02.043; Bano A, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-43; Monteiro Maria Vivina Barros, 2011, Acta Amaz., V41, P233, DOI 10.1590/S0044-59672011000200007; Benitez G, 2012, J ETHNOPHARMACOL, V139, P429, DOI 10.1016/j.jep.2011.11.029; Camou-Guerrero A, 2008, HUM ECOL, V36, P259, DOI 10.1007/s10745-007-9152-3; Choudhary BA, 2014, INDIAN RES J PHARM S, V2, P124; Choudhury PR, 2015, J ETHNOPHARMACOL, V166, P135, DOI 10.1016/j.jep.2015.03.026; Church DC, 1993, DIGESTIVE PHYSL NUTR, V33; da Silva M, 2006, INT BIODETER BIODEGR, V57, P163, DOI 10.1016/j.ibiod.2006.02.003; Deeba F, 2009, DOCUMENTATION ETHNO; Deeba F, 2009, INT J AGRIC BIOL, V11, P535; Di Sanzo P, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-19; Dilshad SMR, 2010, PAK VET J, V30, P167; Dilshad SMR, 2008, J ETHNOPHARMACOL, V117, P393, DOI 10.1016/j.jep.2008.02.011; Edwards SV, 2005, P NATL ACAD SCI USA, V102, P6550, DOI 10.1073/pnas.0501846102; Esakkimuthu S, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0240-9; Ettebong EO, 2012, ASIAN PAC J TROP MED, V5, P673, DOI 10.1016/S1995-7645(12)60105-9; Fahmeeda Rehman, 2017, Pure and Applied Biology, V6, P740, DOI 10.19045/bspab.2017.60079; Farooq Z, 2008, J ETHNOPHARMACOL, V118, P213, DOI 10.1016/j.jep.2008.03.015; Faruque MO, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00040; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Geng YF, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0153-z; Giday M, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-34; Gohre A, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0116-9; Harun N, 2017, J ETHNOBIOL ETHNOMED, P13, DOI 10.1186/s13002-017-0138-y; Hassan HU, 2014, IRISH VET J, V67, DOI 10.1186/2046-0481-67-6; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Heinrich M, 2009, J ETHNOPHARMACOL, V124, P1, DOI 10.1016/j.jep.2009.03.043; Hussain K., 2010, ETHNOBOTANICAL LEAFL, V14, P807; Hussain M, 2015, INDIAN RES J PHARM S, V6, P235; Ikram S., 2014, J MED PLANTS STUD, V2, P58; Iqbal Z, 2004, J ETHNOPHARMACOL, V93, P265, DOI 10.1016/j.jep.2004.03.046; Iqbal Z, 2002, PARASITIC RES DOMEST; Jabbar A, 2006, J ETHNOPHARMACOL, V108, P152, DOI 10.1016/j.jep.2006.04.015; JAIN S K, 1977, P157; Kayani S, 2014, J ETHNOPHARMACOL, V156, P47, DOI 10.1016/j.jep.2014.08.005; Kayani SA, 2007, PAK J BOT, V39, P1173; Khan FM, 2009, PAK VET J, V29, P75; Khan M. A., 2012, Pakistan Journal of Weed Science Research, V18, P495; Khan M. A., 2010, Ethnobotany Research and Applications, V8, P107; Khan MPZ, 2015, J ETHNOPHARMACOL, V173, P191, DOI 10.1016/j.jep.2015.07.029; Khan Z. R., 1997, Insect Science and its Application, V17, P143; Khattak NS, 2015, J ETHNOPHARMACOL, V171, P273, DOI 10.1016/j.jep.2015.05.048; Kumar V, 2015, IJPR, V5, P338; Kunwar RM, 2018, J ETHNOBIOL ETHNOMED, V14, DOI 10.1186/s13002-018-0242-7; Ladio A, 2007, J ARID ENVIRON, V69, P695, DOI 10.1016/j.jaridenv.2006.11.008; Lans C., 2007, J ETHNOBIOL ETHNOMED, V3, P1, DOI DOI 10.1186/1746-4269-3-3; Lans C, 2011, J ETHNOBIOL ETHNOMED, V7, DOI 10.1186/1746-4269-7-21; Lapuz A. M. R., 2016, International Journal of Chemical Engineering and Applications, V7, P204, DOI 10.7763/IJCEA.2016.V7.573; Lateef M., 2003, INT J AGRIC BIOL, V5, P86; Leonti M, 2010, J ETHNOPHARMACOL, V130, P379, DOI 10.1016/j.jep.2010.05.021; Mahmood A, 2013, J ETHNOPHARMACOL, V148, P714, DOI 10.1016/j.jep.2013.05.035; Manoj PDS, 2015, IEEE T COMPUT, V64, P3022, DOI 10.1109/TC.2015.2389827; Martin GJ, 1995, ETHNOBOTANY METHODS, P268; Martinez E, 2011, ELECTRON PROC THEOR, P7, DOI 10.4204/EPTCS.68.3; Maryam Arshad, 2011, Middle East Journal of Scientific Research, V9, P209; Matekaire T., 2004, International Journal of Applied Research in Veterinary Medicine, V2, P269; Mayer M, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-016-0106-y; Mazhar-ul-Islam, 2012, International Journal of Animal and Veterinary Advances, V4, P221; Mcgaw LJ, 2008, J ETHNOPHARMACOL, V119, P559, DOI 10.1016/j.jep.2008.06.013; Muhammad F, 2005, TOXICOL PATHOL, V33, P258, DOI 10.1080/01926230590908222; Mussarat S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/616858; Nahed J, 1997, ANIM FEED SCI TECH, V68, P213, DOI 10.1016/S0377-8401(97)00052-7; Nisar M. F., 2014, Middle East Journal of Scientific Research, V21, P1466; Njoroge GN, 2006, J ETHNOPHARMACOL, V108, P332, DOI 10.1016/j.jep.2006.05.031; Noor MJ, 2011, PAK J BOT, V43, P781; Nunes AT, 2015, J ETHNOBIOL ETHNOMED, V11, DOI 10.1186/1746-4269-11-12; Offiah NV, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-36; Okoli IC, 2003, AGR ECOSYST ENVIRON, V96, P147, DOI 10.1016/S0167-8809(02)00172-X; Ong HG, 2014, J ETHNOPHARMACOL, V157, P228, DOI 10.1016/j.jep.2014.09.015; Panwar P, 2013, J BIOL CHEM, V288, P5940, DOI 10.1074/jbc.M112.419689; Parthiban R, 2016, REV BRAS FARMACOGN, V26, P109, DOI 10.1016/j.bjp.2015.07.016; Parvaiz M, 2014, AVICENNA J PHYTOMEDI, V4, P364; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Pieroni A, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-16; Pieroni A, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-22; Prasad SK, 2013, BRIT J PHARM RES, V3, P135, DOI 10.9734/BJPR/2013/2661; Provenza FD, 2003, SMALL RUMINANT RES, V49, P257, DOI 10.1016/S0921-4488(03)00143-3; Qureshi R, 2011, PAK J BOT, V43, P121; Qureshi R, 2009, PAK J BOT, V41, P529; Rahman A, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1632-y; Raziq A, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-16; Rehman MN, 2017, REV BRAS FARMACOGN, V27, P751, DOI 10.1016/j.bjp.2017.09.004; Ritter RA, 2012, J ETHNOPHARMACOL, V144, P346, DOI 10.1016/j.jep.2012.09.018; Saha S, 2013, INT J PHARM SCI RES, V4, P512, DOI 10.13040/IJPSR.0975-8232.4(1).512-15; Sardar AA, 2015, AFR J TRADIT COMPLEM, V12, P9, DOI 10.4314/ajtcam.v12i4.2; Shah A, 2017, J ETHNOPHARMACOL, V200, P84, DOI 10.1016/j.jep.2017.02.005; Shah GM, 2012, J ANIM PLANT SCI, V22, P791; Sharma R, 2012, J ETHNOPHARMACOL, V141, P265, DOI 10.1016/j.jep.2012.02.027; Shen SC, 2010, J ETHNOBIOL ETHNOMED, V6, DOI 10.1186/1746-4269-6-24; Sher H., 2004, PAK J PLANT SCI, V10, P35; Shosan L. O., 2014, American Journal of Plant Sciences, V5, P3258, DOI 10.4236/ajps.2014.521340; Sindhu ZUD, 2012, INT J AGRIC BIOL, V14, P922; Sindhu ZUD, 2010, INT J AGRIC BIOL, V12, P353; Singh AG, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-19; Singh A, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0178-3; Somvanshi R., 2006, ASIAN AGRIHISTORY, V10, P133; Souto WMS, 2011, J ETHNOBIOL ETHNOMED, V7, DOI 10.1186/1746-4269-7-30; Stur W. W., 2000, Working with farmers: the key to adoption of forage technologies. Proceedings of an International Workshop held in Cagayan de Oro City, Mindanao, Philippines from 12-15 October 1999, P112; Sushama B., 2014, International Journal of Ayurvedic and Herbal Medicine, V4, P1480; Tariq A, 2014, SCI WORLD J, DOI [10.1155/2014/748490, 10.1155/2014/127526]; Tefera BN, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0302-7; Tipu M. A., 2006, Pakistan Veterinary Journal, V26, P144; Tomar A, 2009, INDIAN J TRADIT KNOW, V8, P298; TURNER NJ, 1988, AM ANTHROPOL, V90, P272, DOI 10.1525/aa.1988.90.2.02a00020; Ullah S, 2014, J ETHNOPHARMACOL, V158, P412, DOI 10.1016/j.jep.2014.09.048; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Vendruscolo Giovana Secretti, 2006, Iheringia Serie Botanica, V61, P83; Vitalini S, 2013, J ETHNOPHARMACOL, V145, P517, DOI 10.1016/j.jep.2012.11.024; Winter K, 2008, FUNC ECOSYST COMMUN, V2, P1; Wong JL, 2000, BIOMETRICS NONTIMBER; Zafar Iqbal, 2005, Journal of Agriculture and Social Sciences, V1, P187; Zereen A., 2012, BIOL PAKISTAN, V58, P21; Zereen A, 2013, BIOL PAKISTAN, V59, P139	139	16	16	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2020	15	11							e0241705	10.1371/journal.pone.0241705	http://dx.doi.org/10.1371/journal.pone.0241705			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8YL	33142315	gold, Green Published			2023-01-03	WOS:000588376700047
J	Chan, GCK; Dor, FJ; Kit-Chung, NGJ; Chow, KM; Kwong, VWK; Pang, WF; Cheng, PMS; Law, MC; Leung, CB; Kam-Tao, LIP; Szeto, CC				Chan, Gordon Chun-Kau; Dor, Frank Jmf; Kit-Chung, Jack N. G.; Chow, Kai-Ming; Kwong, Vickie Wai-Ki; Pang, Wing-Fai; Cheng, Phyllis Mei-Shan; Law, Man-Ching; Leung, Chi-Bon; Kam-Tao, Philip L., I; Szeto, Cheuk Chun			Interaction between central obesity and frailty on the clinical outcome of peritoneal dialysis patients	PLOS ONE			English	Article							BODY-MASS INDEX; QUALITY-OF-LIFE; BIOIMPEDANCE SPECTROSCOPY; WAIST CIRCUMFERENCE; ABDOMINAL OBESITY; HEMODIALYSIS; ASSOCIATION; PREDICTOR; MORTALITY; SURVIVAL	Background Frailty and obesity contribute to the adverse clinical outcome of peritoneal dialysis (PD) patients, but the interaction between frailty and obesity remains uncertain. Objective To examine the interaction between frailty and obesity on the clinical outcome of PD patients. Design Single centre prospective observational cohort study. Patients 267 prevalent Chinese PD patients were recruited. Measurements Frailty was identified by a standard score. General and central obesity were determined by body mass index (BMI) and waist-hip ratio (WHR), respectively. Body composition was assessed by bioimpedance spectroscopy. All patients were followed for two years. Outcome measures included all-cause as well as cardiovascular mortality and hospitalization. Results Of the 267 patients, 120 (44.9%) were frail. Frail individuals were more likely to have central obesity (p < 0.001) but not general obesity. Although WHR did not predict patient survival, there was a significant interaction between WHR and frailty on patient survival and cardiovascular survival (p = 0.002 and p = 0.038, respectively). For patients without frailty, the two-year cardiovascular survival was 91.3% and 74.4% for those with and without central obesity, respectively (p = 0.002). For patients with frailty, however, the two-year cardiovascular survival was 64.6% and 66.7% for those with and without central obesity, respectively (p = 0.6). For patients without frailty, the number of hospital admission for cardiovascular disease over 2 years were 0.12 +/- 0.37 and 0.34 +/- 0.72 for those with and without central obesity, respectively (p = 0.03). For frail patients, however, the number of hospital admission was similar between those with and without central obesity. Conclusion There is a significant interaction between frailty and central obesity on the outcome of PD patients. The protective role of central obesity is only apparent in PD patients without frailty but not the frail ones, and there is a little prognostic value of general (non-central) obesity.	[Chan, Gordon Chun-Kau; Dor, Frank Jmf; Kit-Chung, Jack N. G.; Chow, Kai-Ming; Kwong, Vickie Wai-Ki; Pang, Wing-Fai; Cheng, Phyllis Mei-Shan; Law, Man-Ching; Leung, Chi-Bon; Kam-Tao, Philip L., I; Szeto, Cheuk Chun] Chinese Univ Hong Kong, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Szeto, CC (corresponding author), Chinese Univ Hong Kong, Carol & Richard Yu Peritoneal Dialysis Res Ctr, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	ccszeto@cuhk.edu.hk	Ming, Chow Kai/Y-5568-2019; Chan, Gordon Chun Kau/AHA-4072-2022	Ming, Chow Kai/0000-0001-5310-5197; Chan, Gordon Chun Kau/0000-0003-4681-7326	Chinese University of Hong Kong (CUHK) research	Chinese University of Hong Kong (CUHK) research	This study was supported by the Chinese University of Hong Kong (CUHK) research	Afsar B, 2006, PERITON DIALYSIS INT, V26, P705; Alfaadhel TA, 2015, CLIN J AM SOC NEPHRO, V10, P832, DOI 10.2215/CJN.07760814; [Anonymous], 2007, NEFROLOGIA, V27, pN3; [Anonymous], 2014, REV PRESCRIRE, V34, P171; [Anonymous], 2016, INT J SPECIALEDUCATI, V31, P1; [Anonymous], 2015, M2 PRESSWIRE, V32, P41; Avila-Carrasco L, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00630; Brown EA, 2020, PERITON DIALYSIS INT, V40, P327, DOI 10.1177/0896860819893558; Brown EA, 2017, KIDNEY INT, V91, P294, DOI 10.1016/j.kint.2016.08.026; Brown EA, 2010, NEPHROL DIAL TRANSPL, V25, P3755, DOI 10.1093/ndt/gfq212; Buch A, 2016, EXP GERONTOL, V76, P25, DOI 10.1016/j.exger.2016.01.008; Castro ACM, 2017, BRIT J NUTR, V117, P1299, DOI 10.1017/S0007114517001179; Chan GCK, 2020, BMC NEPHROL, V21, DOI 10.1186/s12882-020-01994-4; Choi SJ, 2011, PERITON DIALYSIS INT, V31, P67, DOI 10.3747/pdi.2009.00131; Clark AL, 2011, J CARD FAIL, V17, P374, DOI 10.1016/j.cardfail.2011.01.009; Cobo G, 2018, NEPHROL DIAL TRANSPL, V33, P35, DOI 10.1093/ndt/gfy175; Crow RS, 2019, J NUTR HEALTH AGING, V23, P138, DOI 10.1007/s12603-018-1138-x; Fitzpatrick J, 2019, NEPHROL DIAL TRANSPL, V34, P346, DOI 10.1093/ndt/gfy124; Franco Marcia Regina Gianotti, 2013, Braz. J. Nephrol., V35, P132, DOI 10.5935/0101-2800.20130022; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Guedes AM, 2019, PERITON DIALYSIS INT, V39, P201, DOI 10.3747/pdi.2018.00138; Horwich TB, 2018, PROG CARDIOVASC DIS, V61, P151, DOI 10.1016/j.pcad.2018.05.005; Hubbard RE, 2010, J GERONTOL A-BIOL, V65, P377, DOI 10.1093/gerona/glp186; Iyasere O, 2019, CLIN KIDNEY J, V12, P262, DOI 10.1093/ckj/sfy059; Iyasere O, 2019, PERITON DIALYSIS INT, V39, P112, DOI 10.3747/pdi.2018.00086; Jin Haifeng, 2015, Electrolyte Blood Press, V13, P22, DOI 10.5049/EBP.2015.13.1.22; Johansen KL, 2007, J AM SOC NEPHROL, V18, P2960, DOI 10.1681/ASN.2007020221; Johansen KL, 2015, CURR OPIN NEPHROL HY, V24, P268, DOI 10.1097/MNH.0000000000000120; Johansen KL, 2014, J AM SOC NEPHROL, V25, P381, DOI 10.1681/ASN.2013040431; Kiebalo T, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061715; Kim JK, 2019, PERITON DIALYSIS INT, V39, P268, DOI 10.3747/pdi.2018.00164; Kwan BCH, 2014, PERITON DIALYSIS INT, V34, P409, DOI 10.3747/pdi.2013.00066; Kwong VWK, 2015, KIDNEY DIS-BASEL, V1, P147, DOI 10.1159/000439193; Lavie CJ, 2012, J AM COLL CARDIOL, V60, P1374, DOI 10.1016/j.jacc.2012.05.037; Lee MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077082; Lee SY, 2017, J RENAL NUTR, V27, P106, DOI 10.1053/j.jrn.2016.11.003; Li HF, 2011, AGING DIS, V2, P466; Li PKT, 2017, SEMIN NEPHROL, V37, P54, DOI 10.1016/j.semnephrol.2016.10.007; Lu JL, 2014, J AM SOC NEPHROL, V25, P2088, DOI 10.1681/ASN.2013070754; Lyasere OU, 2016, CLIN J AM SOC NEPHRO, V11, P423, DOI 10.2215/CJN.01050115; McAdams-DeMarco MA, 2013, J AM GERIATR SOC, V61, P896, DOI 10.1111/jgs.12266; Ng JKC, 2016, KIDNEY BLOOD PRESS R, V41, P736, DOI 10.1159/000450563; O'Lone EL, 2014, NEPHROL DIAL TRANSPL, V29, P1430, DOI 10.1093/ndt/gfu049; Obi Y, 2018, AM J KIDNEY DIS, V71, P802, DOI 10.1053/j.ajkd.2017.09.010; Pugh J, 2016, CLIN KIDNEY J, V9, P324, DOI 10.1093/ckj/sfv150; Sabatino A, 2017, CLIN NUTR, V36, P663, DOI 10.1016/j.clnu.2016.06.007; Su WS, 2010, INT J NEPHROL, V2010, DOI 10.4061/2010/831243; Szeto CC, 2001, J AM SOC NEPHROL, V12, P355, DOI 10.1681/ASN.V122355; Szeto CC, 2012, AM J NEPHROL, V35, P127, DOI 10.1159/000335580; Tang SCW, 2020, AM J KIDNEY DIS, V75, P772, DOI 10.1053/j.ajkd.2019.08.005; Townsend RR, 2015, HYPERTENSION, V66, P698, DOI 10.1161/HYP.0000000000000033; Wang ZX, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/535918; Wu CC, 2011, NEPHROL DIAL TRANSPL, V26, P3689, DOI 10.1093/ndt/gfr057	53	6	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2020	15	10							e0241242	10.1371/journal.pone.0241242	http://dx.doi.org/10.1371/journal.pone.0241242			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8VY	33104712	Green Published, gold			2023-01-03	WOS:000588370000001
J	Adigbli, G				Adigbli, George			Race, science and (im)precision medicine	NATURE MEDICINE			English	Editorial Material							VAGINAL BIRTH; PREDICTION; ETHNICITY; COHORT; HEALTH	The limitations of using race in biomedicine are important to recognize because race is often afforded more biological value than can be scientifically justified - and less social value than it commands.	[Adigbli, George] Univ Oxford, Nuffield Dept Surg Sci, Transplantat Res & Immunol Grp, Oxford, England	University of Oxford	Adigbli, G (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Transplantat Res & Immunol Grp, Oxford, England.	george.adigbli@nhs.net		Adigbli, George/0000-0003-3790-927X				Attanasio LB, 2019, J WOMENS HEALTH, V28, P1302, DOI 10.1089/jwh.2018.7270; Bentley AR, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-019-0111-x; Collins FS, 2004, NAT GENET, V36, pS13, DOI 10.1038/ng1436; Costa DL, 2018, P NATL ACAD SCI USA, V115, P11215, DOI 10.1073/pnas.1803630115; Delanaye P, 2011, CLIN J AM SOC NEPHRO, V6, P906, DOI 10.2215/CJN.10931210; Duncan L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11112-0; Gianfrancesco MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/jamainternmed.2018.3763; Joyner MJ, 2019, J CLIN INVEST, V129, P946, DOI 10.1172/JCI126119; Kalewold KH, 2020, BIOL PHILOS, V35, DOI 10.1007/s10539-020-09759-x; Knight HE, 2014, BJOG-INT J OBSTET GY, V121, P183, DOI 10.1111/1471-0528.12508; Manrai AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMsa1507092; Marigorta UM, 2018, TRENDS GENET, V34, P504, DOI 10.1016/j.tig.2018.03.005; McDade TW, 2019, AM J PHYS ANTHROPOL, V169, P3, DOI 10.1002/ajpa.23800; Murphy SA, 2019, JAMA CARDIOL, V4, P613, DOI 10.1001/jamacardio.2019.0886; Oh SS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001918; Rutherford A., 2020, ARGUE RACIST WHAT OU; Saini A, 2019, SUPERIOR RETURN RACE; Sehgal AR, 2020, ANN INTERN MED, V173, P1008, DOI 10.7326/M20-4951; Sheffet AJ, 2018, STROKE, V49, P84, DOI 10.1161/STROKEAHA.117.018063; Snyder-Mackler N, 2020, SCIENCE, V368, P843, DOI 10.1126/science.aax9553; Tillin T, 2014, HEART, V100, P60, DOI 10.1136/heartjnl-2013-304474; Udler MS, 2015, J AM SOC NEPHROL, V26, P1682, DOI 10.1681/ASN.2014050474; Vyas DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMms2004740; Wang C, 2019, BRIT J CLIN PHARMACO, V85, P114, DOI 10.1111/bcp.13767; Witherspoon DJ, 2007, GENETICS, V176, P351, DOI 10.1534/genetics.106.067355; Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109	27	7	7	4	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2020	26	11					1675	1676		10.1038/s41591-020-1115-x	http://dx.doi.org/10.1038/s41591-020-1115-x		OCT 2020	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	OT0SR	33093683				2023-01-03	WOS:000582377100001
J	Wolday, D; Legesse, D; Kebede, Y; Siraj, DS; McBride, JA; Striker, R				Wolday, Dawit; Legesse, Dorsisa; Kebede, Yazezew; Siraj, Dawd S.; McBride, Joseph A.; Striker, Robert			Immune recovery in HIV-1 infected patients with sustained viral suppression under long-term antiretroviral therapy in Ethiopia	PLOS ONE			English	Article							T-CELL-ACTIVATION; CD4/CD8 RATIO; INFECTED PATIENTS; CD4 COUNTS; HIV; NORMALIZATION; INDIVIDUALS; DETERMINANTS; PERCENTAGE; INITIATION	Background There is very little data on long-term immune recovery responses in patients on suppressive antiretroviral therapy (ART) in the setting of sub-Saharan Africa (SSA). Thus, we sought to determine CD4+ T-cell, CD8+ T-cell and CD4/CD8 ratio responses in a cohort of HIV infected individuals on sustained suppressive ART followed up for more than a decade. Methods The cohort comprised adult patients who started ART between 2001 and 2007 and followed for up to 14 years. Trends in median CD4+ T-cells, CD8+ T-cells and CD4/CD8 ratio were reviewed retrospectively. Poisson regression models were used to identify factors associated with achieving normalized T-cell biomarkers. Kaplan-Meier curves were used to estimate the probability of attaining normalized counts while on suppressive ART. Results A total of 227 patients with a median duration of follow-up on ART of 12 (IQR: 10.5-13.0) years were included. CD4 cell count increased from baseline median of 138 cells (IQR: 70-202) to 555 cells (IQR: 417-830). CD4 cell increased continuously up until 5 years, after which it plateaued up until 14 years of follow up. Only 69.6% normalized their CD4 cell count within a median of 6.5 (IQR: 3.0-10.5) years. In addition, only 15.9% of the cohort were able to achieve the median reference CD4+ T-cell threshold count in Ethiopians (approximate to 760 cells/mu L). CD8+ T-cell counts increased initially until year 1, after which continuous decrease was ascertained. CD4/CD8 ratio trend revealed continuous increase throughout the course of ART, and increased from a median baseline of 0.14 (IQR: 0.09-0.22) to a median of 0.70 (IQR: 0.42-0.95). However, only 12.3% normalized their ratio (>= 1.0) after a median of 11.5 years. In addition, only 8.8% of the cohort were able to achieve the median reference ratio of healthy Ethiopians. Conclusion Determination of both CD4+ and CD8+ T-cells, along with CD4/CD8 ratio is highly relevant in long-term follow-up of patients to assess immune recovery. Monitoring ratio levels may serve as a better biomarker risk for disease progression among patients on long-term ART. In addition, the findings emphasize the relevance of initiation of ART at the early stage of HIV-1 infection.	[Wolday, Dawit; Kebede, Yazezew] Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia; [Legesse, Dorsisa] Hayat Gen Hosp, Addis Ababa, Ethiopia; [Siraj, Dawd S.; McBride, Joseph A.; Striker, Robert] Univ Wisconsin, Div Infect Dis, Dept Med, Madison, WI USA	Mekelle University; University of Wisconsin System; University of Wisconsin Madison	Wolday, D (corresponding author), Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia.	dawwol@gmail.com			Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA	Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA	The project was supported by the Division of Infectious Diseases, Department of Medicine, University of Wisconsin, Madison, USA.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Abuye C, 2005, J CLIN IMMUNOL, V25, P127, DOI 10.1007/s10875-005-2818-y; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; [Anonymous], 2016, MEDICINE BALTIMORE, V95, pe3187; [Anonymous], 2012, DRUG DISCOV TODAY TE; [Anonymous], 2014, ALZHEIMERS DEMENT J, V10, pe47; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Battegay M, 2006, LANCET INFECT DIS, V6, P280, DOI 10.1016/S1473-3099(06)70463-7; Caby F, 2016, CLIN INFECT DIS, V62, P1297, DOI 10.1093/cid/ciw076; Geltzeiler CB, 2020, DIS COLON RECTUM; Geng EH, 2015, INT J EPIDEMIOL, V44, P251, DOI 10.1093/ije/dyu271; Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669; Hughes RA, 2018, AIDS, V32, P1361, DOI [10.1097/QAD.0000000000001848, 10.1097/qad.0000000000001848]; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Kassu A, 2003, CLIN EXP IMMUNOL, V132, P113, DOI 10.1046/j.1365-2249.2003.02106.x; Kassu A, 2001, CLIN DIAGN LAB IMMUN, V8, P1171, DOI 10.1128/CDLI.8.6.1171-1176.2001; Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484; Khanna N, 2008, CLIN INFECT DIS, V47, P1093, DOI 10.1086/592113; Kroeze S, 2019, J INFECT DIS, V220, P1029, DOI 10.1093/infdis/jiz252; Kroeze S, 2018, AIDS, V32, P1043, DOI [10.1097/qad.0000000000001801, 10.1097/QAD.0000000000001801]; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f; Le T, 2013, NEW ENGL J MED, V368, P218, DOI 10.1056/NEJMoa1110187; Leung V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077665; Loutfy MR, 2010, JAIDS-J ACQ IMM DEF, V55, P451, DOI 10.1097/QAI.0b013e3181ec28ff; Lu W, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20052; Massanella M, 2010, AIDS, V24, P959, DOI 10.1097/QAD.0b013e328337b957; Mekonnen Y, 2005, J INFECT DIS, V192, P739, DOI 10.1086/432545; Ministry of Health (MoH). HIV/AIDS Prevention and Control Office, 2001, NAT GUID US ANT DRUG; Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Mussini C, 2015, LANCET HIV, V2, pE98, DOI 10.1016/S2352-3018(15)00006-5; Mutoh Y, 2018, CLIN INFECT DIS, V67, P927, DOI 10.1093/cid/ciy176; Nakanjako D, 2016, AIDS, V30, P1913, DOI 10.1097/QAD.0000000000001085; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; Plana M, 2000, AIDS, V14, P1921, DOI 10.1097/00002030-200009080-00007; Ronsholt FF, 2012, JAIDS-J ACQ IMM DEF, V61, P270, DOI 10.1097/QAI.0b013e31825e7ac1; Sainz T, 2013, AIDS, V27, P1513, DOI 10.1097/QAD.0b013e32835faa72; Sempa JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073190; Seng R, 2017, AIDS, V31, P1323, DOI 10.1097/QAD.0000000000001482; Serrano-Villar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085798; Serrano-Villar S, 2013, J INFECTION, V66, P57, DOI 10.1016/j.jinf.2012.09.013; Takuva S, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18651; Thornhill J, 2016, JAIDS-J ACQ IMM DEF, V73, P69, DOI 10.1097/QAI.0000000000001013; Tinago W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097011; Torti C, 2012, CLIN MICROBIOL INFEC, V18, P449, DOI 10.1111/j.1469-0691.2011.03650.x; Trickey A, 2017, CLIN INFECT DIS, V65, P959, DOI 10.1093/cid/cix466; Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410, DOI 10.1128/CDLI.6.3.410-414.1999; WHO, 2017, CONGUID UANT DRU; Wolday D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233049; Zhang XY, 2013, HIV CLIN TRIALS, V14, P61, DOI 10.1310/hct1402-61; 2014, REG ANESTH PAIN MED, V0009	53	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2020	15	10							e0240880	10.1371/journal.pone.0240880	http://dx.doi.org/10.1371/journal.pone.0240880			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ON4AZ	33091053	Green Published, gold			2023-01-03	WOS:000586647200030
J	Sorrie, MB; Amaje, E; Gebremeskel, F				Sorrie, Muluken Bekele; Amaje, Elias; Gebremeskel, Feleke			Pre-lacteal feeding practices and associated factors among mothers of children aged less than 12 months in Jinka Town, South Ethiopia, 2018/19	PLOS ONE			English	Article								Background Pre-lacteal feeding is one of the major harmful practices being faced while feeding the newborns. Although it affects child health, little is known about the extent of the problem and its contributing factors in the study area. Therefore, this study aimed to figure the prevalence of pre-lacteal feeding practices and associated factors among mothers of children aged less than 12 months in Jinka Town. Methods A community-based cross-sectional study was conducted at Jinka Town from March 1 to 30, 2019. A total of 430 mothers, having children less than 12 months of age, were selected by systematic sampling technique. The data were collected by using pretested and interviewer-administered structured questionnaires. The data were entered using epidata 4.2.1 and exported to SPSS version 23 for analysis. Adjusted odds ratios, 95% confidence intervals and p-values were reported. Results The prevalence of pre-lacteal feeding practice was 12.6% [95% CI (9.5-15.7)]. Having no maternal education [AOR = 4.82(95%CI 1.60-14.24)], colostrum avoidance [AOR = 4.09(95% CI 1.62-7.67)], lack of breast feeding counseling [AOR: = 2.51(95% CI 1.20-5.25)], home delivery [AOR = 3.34 (95% CI 1.52-7.33)], lack of knowledge about risks of pre-lacteal feeding [AOR = 2.86 (95% CI 1.30-6.29] and poor knowledge on breast feeding practices [AOR = 3.63(95% CI 1.62-8.11)] were factors associated with pre-lacteal feeding practices. Conclusion Pre-lacteal feeding practice among mothers of children aged less than 12 months in Jinka town was found to be higher than the national prevalence. Illiterate, colostrum avoidance, lack of breastfeeding counseling, home delivery, lack of knowledge on the risk of pre-lacteal feeding, and poor knowledge on breastfeeding practice were factors associated with pre-lacteal feeding practices.	[Sorrie, Muluken Bekele; Gebremeskel, Feleke] Arba Minch Univ, Sch Publ Hlth, Coll Med & Hlth Sci, Arba Minch, Ethiopia; [Amaje, Elias] Bule Hora Univ, Dept Publ Hlth, Hagere Maryam, Ethiopia	Arba Minch University	Sorrie, MB (corresponding author), Arba Minch Univ, Sch Publ Hlth, Coll Med & Hlth Sci, Arba Minch, Ethiopia.	mulukenbekele51@gmail.com	Amaje, Elias/AAA-7536-2022	Amaje, Elias/0000-0002-8991-9579; Bekele, Muluken/0000-0002-3464-2584				[Anonymous], 2011, ANNU REV NUCL PART S, V61, P99; [Anonymous], 2018, BNJ M; Anupam Parashar, 2017, International Journal of Health and Allied Sciences, V6, P30; Argaw MD, 2019, BMC NUTR, V5, DOI 10.1186/s40795-019-0277-8; Bililign N, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0073-x; Central Statistical Agency [Ethiopia] and ICF, 2016, NAT AD YOUTH REPR HL; El-Gilany AH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/258470; Federal Ministry of Health FHD, 2004, NAT STRAT INF YOUNG; Fetene N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156438; Goldman AS, 2000, J NUTR, V130, p426S, DOI 10.1093/jn/130.2.426S; Gualu T, 2017, NUTR DIET SUPPL, V9, P97, DOI 10.2147/NDS.S146188; Hailemariam TW, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2420-z; Horta BL, 2015, ACTA PAEDIATR, V104, P30, DOI 10.1111/apa.13133; Ibadin O, 2013, NIGER J PAEDIAT, V40, P139; Jayarama S., 2017, INT J COMMUNITY MED, V4, P2919; Khanal V, 2014, J PEDIATR GASTR NUTR, V59, P162, DOI 10.1097/MPG.0000000000000429; Khanal V, 2013, INT BREASTFEED J, V8, DOI 10.1186/1746-4358-8-9; Laroia N, 2006, BREASTFEED MED, V1, P94, DOI 10.1089/bfm.2006.1.94; Legesse M, 2014, INT BREASTFEED J, V9, DOI 10.1186/s13006-014-0025-2; Lenja A, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0091-8; Liben ML, 2015, FACTORS ASS PRELACTE; Nguyen PH, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-932; Ogah A, 2012, ASIAN J MED SCI, V4, P79; Organization WH, 2009, GLOB HLTH RISKS MORT; Rogers NL, 2011, PUBLIC HEALTH NUTR, V14, P2029, DOI 10.1017/S1368980011000073; Salve Dawal, 2014, Scholars Journal of Applied Medical Sciences, V2, P1422; Shankar Kanagasabapathy, 2015, International Journal of Biomedical and Advance Research, V6, P484; Singh B., 2010, EUR J SCI RES, V40, P404; SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01; Tariku A, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0074-9; Tekaly G, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1284-7; Tongun JB, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1523304; WHO U, 2018, CAPT MOM ERL IN BREA; WHO-WORLD HEALTH ORGANIZATION, 2009, INF YOUNG CHILD FEED; Wolde TF, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4044-3; World Health Organization, 2017, DEPR OTH COMM MENT D; Yoseph Bekele, 2014, Open Journal of Preventive Medicine, V4, P529, DOI 10.4236/ojpm.2014.47063	37	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2020	15	10							e0240583	10.1371/journal.pone.0240583	http://dx.doi.org/10.1371/journal.pone.0240583			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3UK	33048981	gold, Green Published			2023-01-03	WOS:000581813300055
J	Smith, ST; Meiler, J				Smith, Shannon T.; Meiler, Jens			Assessing multiple score functions in Rosetta for drug discovery	PLOS ONE			English	Article							PROTEIN-LIGAND DOCKING; ENERGY FUNCTION; DESIGN; OPTIMIZATION; MODEL; LEAD	Rosetta is a computational software suite containing algorithms for a wide variety of macromolecular structure prediction and design tasks including small molecule protocols commonly used in drug discovery or enzyme design. Here, we benchmark RosettaLigand score functions and protocols in comparison to results of other software recently published in the Comparative Assessment of Score Functions (CASF-2016). The CASF-2016 benchmark covers a wide variety of tests including scoring and ranking multiple compounds against a target, ligand docking of a small molecule to a target, and virtual screening to extract binders from a compound library. Direct comparison to the score functions provided by CASF-2016 results shows that the original RosettaLigand score function ranks among the top software for scoring, ranking, docking and screening tests. Most notably, the RosettaLigand score function ranked 2/34 among other report score functions in CASF-2016. We additionally perform a ligand docking test with full sampling to mimic typical use cases. Despite improved performance of newer score functions in canonical protein structure prediction and design, we demonstrate here that more recent Rosetta score functions have reduced performance across all small molecule benchmarks. The tests described here have also been uploaded to the Rosetta scientific benchmarking server and will be run weekly to track performance as the code is continually being developed.	[Smith, Shannon T.] Vanderbilt Univ, Chem & Phys Biol Program, 221 Kirkland Hall, Nashville, TN 37235 USA; [Smith, Shannon T.; Meiler, Jens] Vanderbilt Univ, Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Meiler, Jens] Ctr Struct Biol, Dept Chem, Nashville, TN 37240 USA; [Meiler, Jens] Ctr Struct Biol, Dept Pharmacol, Nashville, TN 37240 USA; [Meiler, Jens] Ctr Struct Biol, Dept Biomed Informat, Nashville, TN 37240 USA; [Meiler, Jens] Inst Chem Biol, Nashville, TN 37240 USA; [Meiler, Jens] Univ Leipzig, Inst Drug Discovery, Med Sch, Leipzig, Stadelschule, Germany	Vanderbilt University; Vanderbilt University; Leipzig University	Meiler, J (corresponding author), Vanderbilt Univ, Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.; Meiler, J (corresponding author), Ctr Struct Biol, Dept Chem, Nashville, TN 37240 USA.; Meiler, J (corresponding author), Ctr Struct Biol, Dept Pharmacol, Nashville, TN 37240 USA.; Meiler, J (corresponding author), Ctr Struct Biol, Dept Biomed Informat, Nashville, TN 37240 USA.; Meiler, J (corresponding author), Inst Chem Biol, Nashville, TN 37240 USA.; Meiler, J (corresponding author), Univ Leipzig, Inst Drug Discovery, Med Sch, Leipzig, Stadelschule, Germany.	jens@meilerlab.org		Smith, Shannon/0000-0002-1225-8928; Meiler, Jens/0000-0001-8945-193X	National Cancer Institute of the National Institutes of Health [F31 CA243353]; STS also received funding through the PhRMA Foundation	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); STS also received funding through the PhRMA Foundation	STS received funding for this work through the National Cancer Institute of the National Institutes of Health (F31 CA243353). STS also received funding through the PhRMA Foundation's Pre-Doctoral Fellowship in Informatics (phrmafoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alford RF, 2017, J CHEM THEORY COMPUT, V13, P3031, DOI 10.1021/acs.jctc.7b00125; Aucar MG, 2020, METHODS MOL BIOL, V2114, P269, DOI 10.1007/978-1-0716-0282-9_17; Ballante F, 2018, METHODS MOL BIOL, V1824, P67, DOI 10.1007/978-1-4939-8630-9_5; Baumgartner MP, 2018, J COMPUT AID MOL DES, V32, P45, DOI 10.1007/s10822-017-0081-y; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhardwaj G, 2016, NATURE, V538, P329, DOI 10.1038/nature19791; Cavasotto CN, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00188; Cheng TJ, 2009, J CHEM INF MODEL, V49, P1079, DOI 10.1021/ci9000053; Cole DJ, 2019, FUTURE MED CHEM, V11, P2359, DOI 10.4155/fmc-2019-0196; Davis IW, 2009, J MOL BIOL, V385, P381, DOI 10.1016/j.jmb.2008.11.010; DeLuca S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132508; dos Santos RN, 2018, METHODS MOL BIOL, V1762, P31, DOI 10.1007/978-1-4939-7756-7_3; Eldridge MD, 1997, J COMPUT AID MOL DES, V11, P425, DOI 10.1023/A:1007996124545; Fleishman SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020161; Heifetz A, 2018, METHODS MOL BIOL, V1705, P375, DOI 10.1007/978-1-4939-7465-8_19; Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128; Kothiwale S, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0095-1; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Leaver-Fay A, 2013, METHOD ENZYMOL, V523, P109, DOI [10.1016/B978-0-12:394292-0.00006-0, 10.1016/B978-0-12-394292-0.00006-0]; Lemmon G, 2012, METHODS MOL BIOL, V819, P143, DOI 10.1007/978-1-61779-465-0_10; Lewis SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020872; Li Y, 2018, NAT PROTOC, V13, P666, DOI 10.1038/nprot.2017.114; Macalino SJY, 2015, ARCH PHARM RES, V38, P1686, DOI 10.1007/s12272-015-0640-5; Marze NA, 2018, BIOINFORMATICS, V34, P3461, DOI 10.1093/bioinformatics/bty355; Meiler J, 2006, PROTEINS, V65, P538, DOI 10.1002/prot.21086; Muegge I, 2006, J MED CHEM, V49, P5895, DOI 10.1021/jm050038s; Nivon LG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059004; O'Meara MJ, 2015, J CHEM THEORY COMPUT, V11, P609, DOI 10.1021/ct500864r; Park H, 2016, J CHEM THEORY COMPUT, V12, P6201, DOI 10.1021/acs.jctc.6b00819; Pavlovicz RE, 2019, EFFICIENT CONSIDERAT, DOI [10.1101/618603, DOI 10.1101/618603]; Perez-Sianes J, 2019, CURR COMPUT-AID DRUG, V15, P6, DOI 10.2174/1573409914666181018141602; Schulz-Gasch Tanja, 2004, Drug Discov Today Technol, V1, P231, DOI 10.1016/j.ddtec.2004.08.004; Shaikh SA, 2007, CURR PHARM DESIGN, V13, P3454, DOI 10.2174/138161207782794220; Shapovalov MV, 2011, STRUCTURE, V19, P844, DOI 10.1016/j.str.2011.03.019; Sliwoski G, 2014, PHARMACOL REV, V66, P334, DOI 10.1124/pr.112.007336; Sousa SF, 2006, PROTEINS, V65, P15, DOI 10.1002/prot.21082; Stranges PB, 2013, PROTEIN SCI, V22, P74, DOI 10.1002/pro.2187; Su MY, 2019, J CHEM INF MODEL, V59, P895, DOI 10.1021/acs.jcim.8b00545; Tropsha A, 2000, Curr Opin Drug Discov Devel, V3, P310; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035	41	11	11	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2020	15	10							e0240450	10.1371/journal.pone.0240450	http://dx.doi.org/10.1371/journal.pone.0240450			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TU	33044994	Green Published, gold			2023-01-03	WOS:000581811700037
J	Qaseem, A; Yost, J; Etxeandia-Ikobaltzeta, I; Abraham, GM; Jokela, JA; Forciea, MA; Miller, MC; Humphrey, LL				Qaseem, Amir; Yost, Jennifer; Etxeandia-Ikobaltzeta, Itziar; Abraham, George M.; Jokela, Janet A.; Forciea, Mary Ann; Miller, Matthew C.; Humphrey, Linda L.		Sci Med Policy Comm Amer Coll Phys	Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1)	ANNALS OF INTERNAL MEDICINE			English	Article							GS-5734		[Qaseem, Amir; Etxeandia-Ikobaltzeta, Itziar] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA; [Yost, Jennifer] Amer Coll Physicians, Villanova, PA USA; [Yost, Jennifer] Villanova Univ, Villanova, PA 19085 USA; [Abraham, George M.] Univ Massachusetts, Med Sch, Worcester, MA USA; [Abraham, George M.] St Vincent Hosp, Worcester, MA 01604 USA; [Jokela, Janet A.] Univ Illinois, Coll Med Urbana Champaign, Champaign, IL 61820 USA; [Forciea, Mary Ann; Miller, Matthew C.] Penn Med, Philadelphia, PA USA; [Humphrey, Linda L.] Portland VA Med Ctr, Portland, OR USA; [Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Yost, Jennifer] 800 Lancaster Ave, Villanova, PA 19085 USA; [Etxeandia-Ikobaltzeta, Itziar] 1 Santa Margarita Hosp St,Ground Floor 2,Off 1, Irun 20303, Gipuzkoa, Spain; [Abraham, George M.] 123 Summer St,Suite 370, North Worcester, MA 01608 USA; [Jokela, Janet A.] Carle Forum, 611 West Pk, Urbana, IL 61801 USA; [Forciea, Mary Ann; Miller, Matthew C.] 3615 Chestnut St, Philadelphia, PA 19104 USA; [Forciea, Mary Ann; Miller, Matthew C.] Penn Med Radnor, 145 King Prussia Rd, Radnor, PA 19087 USA; [Humphrey, Linda L.] 12310 Northwest Tualatin Ave, Portland, OR 97229 USA	American College of Physicians; American College of Physicians; Villanova University; University of Massachusetts System; University of Massachusetts Worcester; University of Illinois System; University of Illinois Urbana-Champaign; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org	ETXEANDIA-IKOBALTZETA, ITZIAR/AFK-4845-2022; ETXEANDIA-IKOBALTZETA, ITZIAR/AAG-3519-2022	ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; ETXEANDIA-IKOBALTZETA, ITZIAR/0000-0001-6606-649X; Qaseem, Amir/0000-0001-6866-7985; Yost, Jennifer/0000-0002-3170-1956; Abraham, George/0000-0003-4296-8362; Miller, Matthew/0000-0001-7267-4897; Forciea, Mary Ann/0000-0002-1999-1145	ACP operating budget	ACP operating budget	Financial support for the development of the Practice Points comes exclusively from the ACP operating budget.	Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18; [Anonymous], 2020, TIMES INDIA; [Anonymous], 2020, THE ASAHI SHIMBUN; Beigel JH, 2020, N ENGL J MED, DOI [10.1056/NEJMoa 2007764, DOI 10.1056/NEJMOA 2007764]; Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541; de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117; FDA, 2020, FACT SHEET HLTH CAR; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Madelain V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06215-z; O'Day D., OPEN LETT DANIEL ODA; Reuters Staff, 2020, SINGAPORE APPROVES R; Roberts M, 2020, BBC NEWS; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Varga A, 2016, CURR DRUG METAB, V17, P237, DOI 10.2174/1389200217666151210141903; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180; Wilt TJ, 2020, RAPID RESPONSE COVID	19	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2021	174	2					229	+		10.7326/M20-5831	http://dx.doi.org/10.7326/M20-5831			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ2CK	33017175	Green Published			2023-01-03	WOS:000619497100025
J	Hung, SH; Hwang, CY; Chang, CY				Hung, Shih-Han; Hwang, Ching-Yung; Chang, Chun-Yen			Is the Qi experience related to the flow experience? Practicing qigong in urban green spaces	PLOS ONE			English	Article							VALIDATION; BRAIN; STATE	People experience a healthy energy gained from the environment and an inner feeling, called the Qi experience. The flow experience has been a popular topic in Western studies, especially within the fields of psychology and health, and in all kinds of activities. Our current study used quantitative and qualitative methods to analyze the relationship between the Qi experience and the flow experience. After collecting data using open-ended questions, we integrated and connected the Qi experience into five orientations: (1) the feeling of Qi; (2) the mind; (3) Qi and consciousness; (4) physical, mental, and spiritual benefits; and (5) the feeling of Tao. The results revealed a high level of consistency between the flow experience and the Qi experience (r = 0.90, p<0.00, which supports the conclusion that the concept of the flow experience in Qigong activity seems to be the same as that in East Asian disciplines, called the Qi experience.	[Hung, Shih-Han; Chang, Chun-Yen] Natl Taiwan Univ, Dept Hort & Landscape Architecture, Taipei, Taiwan; [Hwang, Ching-Yung] Natl Taiwan Univ, Dept Athlet, Taipei, Taiwan	National Taiwan University; National Taiwan University	Chang, CY (corresponding author), Natl Taiwan Univ, Dept Hort & Landscape Architecture, Taipei, Taiwan.	cycmail@ntu.edu.tw		Hung, Shih-Han/0000-0002-2937-4255; Chang, Chun-Yen/0000-0001-6244-1977	National Taiwan University of Cutting-Edge Steering Research Project [10R70613]	National Taiwan University of Cutting-Edge Steering Research Project	Funding was received by Dr. Chun-Yen Chang to support this study from National Taiwan University of Cutting-Edge Steering Research Project [Grant Number 10R70613,http://research.ord.ntu.edu.tw/en/DivisionStrategic.aspx]. The funder play no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ai AL, 2003, SEMIN INTEG MED, V1, P112, DOI 10.1016/S1543-1150(03)00022-X; Butzer B, 2016, APPL PSYCHOPHYS BIOF, V41, P191, DOI 10.1007/s10484-015-9321-x; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Chen N.N., 2003, BREATHING SPACES QIG; Csikszentmihalyi M., 1990, ART SEEING INTERPRET; Csikszentmihalyi M., 1992, FLOW PSYCHOL HAPPINE; Enz Gideon, 2011, ENERGY MED E W NATUR, P73; Fruehauf H, 1993, CULTIVATING FLOW CON; Henz D, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00154; Hung SH, 2018, GUIDE BETTER LIFE LE, P123; Hung SH, 2019, URBAN LANDSCAPES IN HIGH-DENSITY CITIES: PARKS, STREETSCAPES, ECOSYSTEMS, P216; Jackson SA, 1996, J SPORT EXERCISE PSY, V18, P17, DOI 10.1123/jsep.18.1.17; Jahnke Roger, 2010, Am J Health Promot, V24, pe1, DOI 10.4278/ajhp.081013-LIT-248; Kaselionyte J, 2019, TRANSCULT PSYCHIATRY, V56, P1094, DOI 10.1177/1363461519861842; Kawabata M, 2011, MOTIV EMOTION, V35, P393, DOI 10.1007/s11031-011-9221-1; Kendall DE, 2002, DAO CHINESE MED UNDE; Klein Penelope, 2017, Medicines (Basel), V4, DOI 10.3390/medicines4040069; Liu Kuo Nian, 2009, BIZARRE JOURNEY QI; Liu T, 2010, CHINESE MED QIGONG S; Nakamura J., 2014, FLOW FDN POSITIVE PS, P239, DOI [DOI 10.1007/978-94-017-9088-8_16, 10.1007/978-94-017-9088-8_16]; Ospina Maria B, 2007, Evid Rep Technol Assess (Full Rep), P1; Peifer C, 2012, ADVANCES IN FLOW RESEARCH, P139, DOI 10.1007/978-1-4614-2359-1_8; Phillips L. L., 2005, THESIS, P336; Polonen P, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02375; Posadzki P, 2010, J EVID-BASED INTEGR, V15, P84, DOI 10.1177/1533210110387019; Posadzki P, 2010, J BODYW MOV THER, V14, P73, DOI 10.1016/j.jbmt.2008.11.002; Posadzki P, 2009, J HOLIST NURS, V27, P103, DOI 10.1177/0898010108330807; Shinnick P, 2004, SCI WHOLE PERSON HEA, P87; Shinnick P, 2006, J ALTERN COMPLEM MED, V12, P351, DOI 10.1089/acm.2006.12.351; Steinborn MB, 2018, PSYCHOL ASSESSMENT, V30, P339, DOI 10.1037/pas0000482; Tenenbaum G, 1999, J Outcome Meas, V3, P278; Wang F, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/152738; Wilson E.O, 1984, BIOPHILIA, DOI DOI 10.2307/J.CTVK12S6H; Yn WL, 2007, AM J CHINESE MED, V35, P937, DOI 10.1142/S0192415X07005405	34	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2021	16	1							e0240180	10.1371/journal.pone.0240180	http://dx.doi.org/10.1371/journal.pone.0240180			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PR2KB	33395692	Green Published, gold			2023-01-03	WOS:000607069100039
J	Gantzer, HE				Gantzer, Heather E.			When Patients Read Their Story in Clinical Notes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Gantzer, Heather E.] Pk Nicollet Clin, St Louis Pk, MN USA		Gantzer, HE (corresponding author), 3800 Pk Nicollet Blvd, St Louis Pk, MN 55416 USA.	hgantzer@mac.com		Gantzer, Heather/0000-0003-0436-0284				Blease C, 2021, ANN INTERN MED, V174, P101, DOI 10.7326/M20-5370; Delbanco T, 2012, ANN INTERN MED, V157, P461, DOI 10.7326/0003-4819-157-7-201210020-00002; Gantzer HE, 2020, ANN INTERN MED, V173, P380, DOI 10.7326/M20-0934; Sweeney Anthony E., 2020, HEALTHITBUZZ BL 0309	4	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					115	115		10.7326/M20-6632	http://dx.doi.org/10.7326/M20-6632			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33045181				2023-01-03	WOS:000619485200036
J	Sancar, A; Van Gelder, RN				Sancar, Aziz; Van Gelder, Russell N.			Clocks, cancer, and chronochemotherapy	SCIENCE			English	Review							METASTATIC COLORECTAL-CANCER; CISPLATIN-DNA-DAMAGE; CORE CIRCADIAN CLOCK; NIGHT-SHIFT WORK; TRANSCRIPTIONAL ARCHITECTURE; CELL-CYCLE; CRYPTOCHROME; REPAIR; CHEMOTHERAPY; RHYTHMS	The circadian clock coordinates daily rhythmicity of biochemical, physiologic, and behavioral functions in humans. Gene expression, cell division, and DNA repair are modulated by the clock, which gives rise to the hypothesis that clock dysfunction may predispose individuals to cancer. Although the results of many epidemiologic and animal studies are consistent with there being a role for the clock in the genesis and progression of tumors, available data are insufficient to conclude that clock disruption is generally carcinogenic. Similarly, studies have suggested a circadian time-dependent efficacy of chemotherapy, but clinical trials of chronochemotherapy have not demonstrated improved outcomes compared with conventional regimens. Future hypothesis-driven and discovery-oriented research should focus on specific interactions between clock components and carcinogenic mechanisms to realize the full clinical potential of the relationship between clocks and cancer.	[Sancar, Aziz] Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; [Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98104 USA; [Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98104 USA; [Van Gelder, Russell N.] Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA 98104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sancar, A (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA.; Van Gelder, RN (corresponding author), Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98104 USA.; Van Gelder, RN (corresponding author), Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98104 USA.; Van Gelder, RN (corresponding author), Univ Washington, Sch Med, Dept Lab Med & Pathol, Seattle, WA 98104 USA.	aziz_sancar@med.unc.edu; russvg@uw.edu	Van Gelder, Russell/ABB-4225-2021	Van Gelder, Russell/0000-0001-5368-3659	National Institutes of Health [GM118102, ES027255, EY023937, EY026921]; Research to Prevent Blindness; Mark J. Daily, MD, Research Fund	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Mark J. Daily, MD, Research Fund	This work was supported by National Institutes of Health grants GM118102 (A.S.), ES027255 (A.S.), EY023937 (R.N.V.G.), and EY026921 (R.N.V.G.); Research to Prevent Blindness (R.N.V.G.); and the Mark J. Daily, MD, Research Fund (R.N.V.G.).	Abbott SM, 2019, NEUROL CLIN, V37, P601, DOI 10.1016/j.ncl.2019.04.004; Antoch MP, 2008, CELL CYCLE, V7, P1197, DOI 10.4161/cc.7.9.5886; Antoch MP, 2013, CELL CYCLE, V12, P3673, DOI 10.4161/cc.26614; Antoch MP, 2005, CELL CYCLE, V4, P901, DOI 10.4161/cc.4.7.1792; Ashbrook LH, 2020, NEUROPSYCHOPHARMACOL, V45, P45, DOI 10.1038/s41386-019-0476-7; Ballesta A, 2017, PHARMACOL REV, V69, P161, DOI 10.1124/pr.116.013441; Barclay JL, 2013, AM J PHYSIOL-ENDOC M, V304, pE1053, DOI 10.1152/ajpendo.00512.2012; Benna C, 2017, ONCOTARGET, V8, P23978, DOI 10.18632/oncotarget.15074; Burki TK, 2019, LANCET ONCOL, V20, pE352, DOI 10.1016/S1470-2045(19)30383-3; Cavga AD, 2019, FUNCT INTEGR GENOMIC, V19, P729, DOI 10.1007/s10142-019-00680-5; Cederroth CR, 2019, CELL METAB, V30, P238, DOI 10.1016/j.cmet.2019.06.019; Cheng P, 2019, NEUROL CLIN, V37, P563, DOI 10.1016/j.ncl.2019.03.003; Comas M, 2014, CHRONOBIOL INT, V31, P901, DOI 10.3109/07420528.2014.925469; Dakup Panshak P, 2018, Oncotarget, V9, P14524, DOI 10.18632/oncotarget.24539; Dallmann R, 2016, TRENDS MOL MED, V22, P430, DOI 10.1016/j.molmed.2016.03.004; DeCoursey PJ, 2000, J COMP PHYSIOL A, V186, P169, DOI 10.1007/s003590050017; Dubrovsky YV, 2010, AGING-US, V2, P936, DOI 10.18632/aging.100241; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; Erren TC, 2017, J OCCUP MED TOXICOL, V12, DOI 10.1186/s12995-017-0175-4; Filipski E, 2004, CANCER RES, V64, P7879, DOI 10.1158/0008-5472.CAN-04-0674; Filipski E, 2002, J NATL CANCER I, V94, P690; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gaddameedhi S, 2012, CELL CYCLE, V11, P3481, DOI 10.4161/cc.21771; Gaddameedhi S, 2011, P NATL ACAD SCI USA, V108, P18790, DOI 10.1073/pnas.1115249108; Gaucher J, 2018, TRENDS CELL BIOL, V28, P368, DOI 10.1016/j.tcb.2018.01.006; Gauger MA, 2005, CANCER RES, V65, P6828, DOI 10.1158/0008-5472.CAN-05-1119; Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038; Giacchetti S, 2012, ANN ONCOL, V23, P3110, DOI 10.1093/annonc/mds148; Giacchetti S, 2006, J CLIN ONCOL, V24, P3562, DOI 10.1200/JCO.2006.06.1440; Hamada T, 2014, GENES CELLS, V19, P441, DOI 10.1111/gtc.12144; Hanawalt PC, 2008, NAT REV MOL CELL BIO, V9, P958, DOI 10.1038/nrm2549; Hanoun M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034347; Hansen AB, 2016, OCCUP ENVIRON MED, V73, P262, DOI 10.1136/oemed-2015-103342; Hashikawa K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10599-1; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Hatori M, 2012, CELL METAB, V15, P848, DOI 10.1016/j.cmet.2012.04.019; Horn M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01374; HRUSHESKY WJM, 1993, J CLIN ONCOL, V11, P1403, DOI 10.1200/JCO.1993.11.7.1403; HRUSHESKY WJM, 1985, SCIENCE, V228, P73, DOI 10.1126/science.3883493; Hu JC, 2016, P NATL ACAD SCI USA, V113, P11507, DOI 10.1073/pnas.1614430113; Huber AL, 2016, MOL CELL, V64, P774, DOI 10.1016/j.molcel.2016.10.012; Huisman SA, 2015, INT J CANCER, V136, P1024, DOI 10.1002/ijc.29089; Jones ME, 2019, BRIT J CANCER, V121, P172, DOI 10.1038/s41416-019-0485-7; Kang TH, 2014, NUCLEIC ACIDS RES, V42, P4427, DOI 10.1093/nar/gku094; Kang TH, 2010, P NATL ACAD SCI USA, V107, P4890, DOI 10.1073/pnas.0915085107; Kettner NM, 2016, CANCER CELL, V30, P909, DOI 10.1016/j.ccell.2016.10.007; Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Korkmaz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34433-4; Lee JH, 2013, CANCER RES, V73, P785, DOI 10.1158/0008-5472.CAN-12-1994; Lee Y, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000228; LEVI F, 1990, J CLIN ONCOL, V8, P705, DOI 10.1200/JCO.1990.8.4.705; Levi F, 2007, ANNU REV PHARMACOL, V47, P593, DOI 10.1146/annurev.pharmtox.47.120505.105208; Lim YC, 2018, OCCUP ENVIRON MED, V75, P716, DOI 10.1136/oemed-2018-105104; Miki T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3444; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Mocellin S, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1010-1; Molzof HE, 2017, CHRONOBIOL INT, V34, P337, DOI 10.1080/07420528.2016.1259242; Mteyrek A, 2017, INT J CANCER, V140, P2473, DOI 10.1002/ijc.30663; Okawa M, 2007, SLEEP MED REV, V11, P485, DOI 10.1016/j.smrv.2007.08.001; Ozturk N, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102168; Ozturk N, 2009, P NATL ACAD SCI USA, V106, P2841, DOI 10.1073/pnas.0813028106; Pan A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001141; Panda S, 2016, SCIENCE, V354, P1008, DOI 10.1126/science.aah4967; Papagiannakopoulos T, 2016, CELL METAB, V24, P324, DOI 10.1016/j.cmet.2016.07.001; Partch CL, 2014, TRENDS CELL BIOL, V24, P90, DOI 10.1016/j.tcb.2013.07.002; Patke A, 2020, NAT REV MOL CELL BIO, V21, P67, DOI 10.1038/s41580-019-0179-2; Puram RV, 2016, CELL, V165, P303, DOI 10.1016/j.cell.2016.03.015; Reddy AB, 2002, J NEUROSCI, V22, P7326; Relogio A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004338; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Sancar A, 2016, ANGEW CHEM INT EDIT, V55, P8502, DOI 10.1002/anie.201601524; Sancar A, 2015, BIOCHEMISTRY-US, V54, P110, DOI 10.1021/bi5007354; Sato F, 2009, J BIOCHEM, V146, P833, DOI 10.1093/jb/mvp126; Shostak A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11807; Spoelstra K, 2016, P NATL ACAD SCI USA, V113, P686, DOI 10.1073/pnas.1516442113; Stevens RG, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw342; Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X; Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150; Travis RC, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx008; Travis RC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw169; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Van Dycke KCG, 2015, CURR BIOL, V25, P1932, DOI 10.1016/j.cub.2015.06.012; Vistisen HT, 2017, SCAND J WORK ENV HEA, V43, P59, DOI 10.5271/sjweh.3603; Walton ZE, 2018, ANNU REV CANC BIOL, V2, P133, DOI 10.1146/annurev-cancerbio-030617-050216; Yang YY, 2019, J BIOL CHEM, V294, P11960, DOI 10.1074/jbc.RA119.009579; Yang YY, 2018, P NATL ACAD SCI USA, V115, pE4777, DOI 10.1073/pnas.1804493115; Ye R, 2014, GENE DEV, V28, P1989, DOI 10.1101/gad.249417.114; Ye YQ, 2018, CELL SYST, V6, P314, DOI 10.1016/j.cels.2018.01.013; Yimit A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08290-2; Yu EA, 2011, AGING-US, V3, P479, DOI 10.18632/aging.100323	92	61	63	25	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	2021	371	6524					42	+	eabb0738	10.1126/science.abb0738	http://dx.doi.org/10.1126/science.abb0738			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PO1XP	33384351				2023-01-03	WOS:000604963800051
J	Zheng, SZ; Zhang, WR; Liu, SR				Zheng, Shizhong; Zhang, Weirui; Liu, Shengrong			Optimization of ultrasonic-assisted extraction of polysaccharides and triterpenoids from the medicinal mushroom Ganoderma lucidum and evaluation of their in vitro antioxidant capacities	PLOS ONE			English	Article							ANTITUMOR; ACID	Ganoderma lucidum (Fr.) Krast, commonly known as "Lingzhi" in Chinese, is a medicinal mushroom that is rich in biologically active substances. Polysaccharides and triterpenoids are the two major components responsible for the bioactivity of this fungus. In the present study, the ultrasonic-assisted co-extraction (UACE) of polysaccharides and triterpenoids from G. lucidum was optimized using response surface methodology with a desirability function, with the equal importance for the two components. Following single factor experiments, the optimal conditions were determine as ultrasonic power of 210 W, extraction temperature of 80C, ratio of liquid to solid of 50 mL/g, and 100 min extraction time, using aqueous ethanol (50%, v/v) as the extracting solvent. Under the optimal conditions, the extraction yields of polysaccharides and triterpenoids reached 0.63% and 0.38%, respectively. On the basis of the scavenging capacity of 2,2-diphenyl-1-picrylhydrazyl and evaluation of reducing power, the antioxidant capacities of the polysaccharides obtained by optimal UACE process were higher than those of polysaccharides extracted using traditional hot water extraction, whereas the triterpenoid-rich extracts showed antioxidant activities similar to those obtained using the ethanol maceration method. The present study is the first report on the simultaneous extraction of polysaccharides and triterpenoids from G. lucidum. The developed UACE process could be useful in preparation of a polysaccharide- and triterpenoid-rich ingredient that holds great promise for application in the Ganoderma industry.	[Zheng, Shizhong; Zhang, Weirui; Liu, Shengrong] Ningde Normal Univ, Coll Life Sci, Ningde City, Fujian, Peoples R China; [Zhang, Weirui] Fujian Higher Educ Res Ctr Local Biol Resources N, Ningde City, Fujian, Peoples R China	Ningde Normal University	Liu, SR (corresponding author), Ningde Normal Univ, Coll Life Sci, Ningde City, Fujian, Peoples R China.	fjhost@163.com		zheng, shizhong/0000-0003-1248-7787	Key Cultivating Program of Ningde Normal University [2018ZDK01]; Ningde Science and Technology Plan Project [20190013]	Key Cultivating Program of Ningde Normal University; Ningde Science and Technology Plan Project	The research was supported by the Key Cultivating Program (No. 2018ZDK01) of Ningde Normal University and Ningde Science and Technology Plan Project (20190013).	Abuduwaili A, 2019, PROCESS BIOCHEM, V83, P189, DOI 10.1016/j.procbio.2019.05.020; Ahmadi F, 2007, FOOD CHEM, V105, P57, DOI 10.1016/j.foodchem.2007.03.056; Askin R, 2010, FOOD BIOPROD PROCESS, V88, P291, DOI 10.1016/j.fbp.2009.07.002; Babamoradi N, 2018, J FOOD PROCESS ENG, V41, DOI 10.1111/jfpe.12851; BLOIS MS, 1958, NATURE, V181, P1199, DOI 10.1038/1811199a0; Box G.E.P., 1960, TECHNOMETRICS, V2, P455, DOI [10.2307/1266454, DOI 10.2307/1266454, 10.1080/00401706.1960.10489912, DOI 10.1080/00401706.1960.10489912]; Cai CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43886-0; Chen TQ, 2014, J TAIWAN INST CHEM E, V45, P57, DOI 10.1016/j.jtice.2013.05.010; Chen W, 2012, CARBOHYD POLYM, V87, P614, DOI 10.1016/j.carbpol.2011.08.029; Chen XY, 2020, J FOOD MEAS CHARACT, V14, P194, DOI 10.1007/s11694-019-00281-7; Chen Y, 2007, J FOOD ENG, V81, P162, DOI 10.1016/j.jfoodeng.2006.10.018; Chen YY, 2010, INT J BIOL MACROMOL, V46, P429, DOI 10.1016/j.ijbiomac.2010.02.003; Chien CA, 2004, BIOORGAN MED CHEM, V12, P5603, DOI 10.1016/j.bmc.2004.08.004; Cor D, 2018, MOLECULES, V23, DOI 10.3390/molecules23030649; DERRINGER G, 1980, J QUAL TECHNOL, V12, P214, DOI 10.1080/00224065.1980.11980968; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Feng J, 2019, APPL BIOCHEM BIOTECH, V189, P972, DOI 10.1007/s12010-019-02968-5; Gharibzahedi SMT, 2013, IND CROP PROD, V49, P10, DOI 10.1016/j.indcrop.2013.03.019; Hu Z, 2008, SEP PURIF TECHNOL, V61, P266, DOI 10.1016/j.seppur.2007.10.016; JONG SC, 1992, ADV APPL MICROBIOL, V37, P101, DOI 10.1016/S0065-2164(08)70253-3; Kan YJ, 2015, INT J BIOL MACROMOL, V72, P151, DOI 10.1016/j.ijbiomac.2014.07.056; Kimura Y, 2002, ANTICANCER RES, V22, P3309; Liu TT, 2011, J CHROMATOGR A, V1218, P8480, DOI 10.1016/j.chroma.2011.09.073; Liu Y, 2014, CARBOHYD POLYM, V110, P278, DOI 10.1016/j.carbpol.2014.03.040; Ma CW, 2013, J TAIWAN INST CHEM E, V44, P886, DOI 10.1016/j.jtice.2013.01.032; Ma YQ, 2009, ULTRASON SONOCHEM, V16, P57, DOI 10.1016/j.ultsonch.2008.04.012; Mtetwa MD, 2020, J FOOD MEAS CHARACT, V14, P1223, DOI 10.1007/s11694-019-00371-6; Rosello-Soto E, 2016, FOOD ENG REV, V8, P214, DOI 10.1007/s12393-015-9131-1; Ruan WM, 2014, NAT PROD RES, V28, P2264, DOI 10.1080/14786419.2014.938337; Russell R, 2006, PHYTOCHEMISTRY, V67, P1985, DOI 10.1016/j.phytochem.2006.07.004; Ryu DH, 2021, FOOD CHEM, V335, DOI 10.1016/j.foodchem.2020.127645; Smiderle FR, 2017, CARBOHYD POLYM, V156, P165, DOI 10.1016/j.carbpol.2016.09.029; Wang N, 2016, INT J BIOL MACROMOL, V83, P103, DOI 10.1016/j.ijbiomac.2015.11.032; Xu JW, 2010, APPL MICROBIOL BIOT, V87, P457, DOI 10.1007/s00253-010-2576-5; Yang B, 2008, FOOD CHEM, V106, P685, DOI 10.1016/j.foodchem.2007.06.031; Yang FC, 2000, ENZYME MICROB TECH, V27, P295, DOI 10.1016/S0141-0229(00)00213-1; Yang S, 2014, J FOOD DRUG ANAL, V22, P468, DOI 10.1016/j.jfda.2014.01.028; Ye CL, 2011, CARBOHYD POLYM, V84, P495, DOI 10.1016/j.carbpol.2010.12.014; Zhou GF, 2004, PHARMACOL RES, V50, P47, DOI 10.1016/j.phrs.2003.12.002; Zhou XW, 2012, APPL MICROBIOL BIOT, V93, P941, DOI 10.1007/s00253-011-3780-7; Zhu LW, 2008, PROCESS BIOCHEM, V43, P1359, DOI 10.1016/j.procbio.2008.08.003	41	12	12	13	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244749	10.1371/journal.pone.0244749	http://dx.doi.org/10.1371/journal.pone.0244749			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382761	Green Published, gold			2023-01-03	WOS:000605651900017
J	Park, JM; Choi, CH; Wu, HG; Kim, JI				Park, Jong Min; Choi, Chang Heon; Wu, Hong-Gyun; Kim, Jung-in			Correlation of the gamma passing rates with the differences in the dose-volumetric parameters between the original VMAT plans and actual deliveries of the VMAT plans	PLOS ONE			English	Article							IMRT; IMPLEMENTATION; INDEX; DOSIMETRY	Purpose The aim of this study was to investigate the correlations of the gamma passing rates (GPR) with the dose-volumetric parameter changes between the original volumetric modulated arc therapy (VMAT) plans and the actual deliveries of the VMAT plans (DV errors). We compared the correlations of the TrueBeam STx system to those of a C-series linac. Methods A total of 20 patients with head and neck (H&N) cancer were retrospectively selected for this study. For each patient, two VMAT plans with the TrueBeam STx and Trilogy (C-series linac) systems were generated under similar modulation degrees. Both the global and local GPRs with various gamma criteria (3%/3 mm, 2%/2 mm, 2%/1 mm, 1%/2 mm, and 1%/1 mm) were acquired with the 2D dose distributions measured using the MapCHECK2 detector array. During VMAT deliveries, the linac log files of the multi-leaf collimator positions, gantry angles, and delivered monitor units were acquired. The DV errors were calculated with the 3D dose distributions reconstructed using the log files. Subsequently, Spearman's rank correlation coefficients (r(s)) and the corresponding p values were calculated between the GPRs and the DV errors. Results For the Trilogy system, the r(s) values with p < 0.05 showed weak correlations between the GPRs and the DV errors (r(s)<0.4) whereas for the TrueBeam STx system, moderate or strong correlations were observed (r(s)>= 0.4). The DV errors in the V-20Gy of the left parotid gland and those in the mean dose of the right parotid gland showed strong correlations (always with r(s) > 0.6) with the GPRs with gamma criteria except 3%/3 mm. As the GPRs increased, the DV errors decreased. Conclusion The GPRs showed strong correlations with some of the DV errors for the VMAT plans for H&N cancer with the TrueBeam STx system.	[Park, Jong Min; Choi, Chang Heon; Wu, Hong-Gyun; Kim, Jung-in] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; [Park, Jong Min; Choi, Chang Heon; Wu, Hong-Gyun; Kim, Jung-in] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea; [Park, Jong Min; Choi, Chang Heon; Wu, Hong-Gyun; Kim, Jung-in] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul, South Korea; [Park, Jong Min; Wu, Hong-Gyun] Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Kim, JI (corresponding author), Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea.; Kim, JI (corresponding author), Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea.; Kim, JI (corresponding author), Seoul Natl Univ Hosp, Biomed Res Inst, Seoul, South Korea.	madangin@gmail.com		Kim, Jung-in/0000-0002-0305-5969	National Research Foundation of Korea - Ministry of Science and ICT [2019M2A2B4095126, 2019M2A2B4096540, 0411-20190090]	National Research Foundation of Korea - Ministry of Science and ICT	This work was supported by the National Research Foundation of Korea funded by the Ministry of Science and ICT (No. 2019M2A2B4095126, 2019M2A2B4096540, and 0411-20190090).	Agnew CE, 2012, PHYS MED BIOL, V57, P6761, DOI 10.1088/0031-9155/57/21/6761; Almond PR, 1999, MED PHYS, V26, P1847, DOI 10.1118/1.598691; Bentzen SM, 2010, INT J RADIAT ONCOL, V76, pS3, DOI 10.1016/j.ijrobp.2009.09.040; Du WL, 2014, MED PHYS, V41, DOI 10.1118/1.4861821; Evans JD, 1996, STRAIGHTFORWARD STAT, pxxii; Ezzell GA, 2003, MED PHYS, V30, P2089, DOI 10.1118/1.1591194; Ezzell GA, 2009, MED PHYS, V36, P5359, DOI 10.1118/1.3238104; Fredh A, 2013, MED PHYS, V40, DOI 10.1118/1.4788645; Heilemann G, 2013, MED PHYS, V40, DOI 10.1118/1.4789580; Kim JI, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-167; LoSasso T, 1998, MED PHYS, V25, P1919, DOI 10.1118/1.598381; Low DA, 1998, MED PHYS, V25, P656, DOI 10.1118/1.598248; Masi L, 2013, MED PHYS, V40, DOI 10.1118/1.4810969; Miften M, 2018, MED PHYS, V45, pE53, DOI 10.1002/mp.12810; Nelms BE, 2011, MED PHYS, V38, P1037, DOI 10.1118/1.3544657; Nicolini G, 2011, MED PHYS, V38, P264, DOI 10.1118/1.3528214; Park JM, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140698; Park JI, 2015, PHYS MEDICA, V31, P1118, DOI 10.1016/j.ejmp.2015.08.005; Park JM, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1123-x; Park JM, 2015, PHYS MED BIOL, V60, P7101, DOI 10.1088/0031-9155/60/18/7101; Park JM, 2014, PHYS MED BIOL, V59, P7315, DOI 10.1088/0031-9155/59/23/7315; Park SY, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0382-z; Stasi M, 2012, MED PHYS, V39, P7626, DOI 10.1118/1.4767763; Sun BZ, 2013, PRACT RADIAT ONCOL, V3, pE199, DOI 10.1016/j.prro.2012.11.013; Teke T, 2010, MED PHYS, V37, P116, DOI 10.1118/1.3266821	25	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0244690	10.1371/journal.pone.0244690	http://dx.doi.org/10.1371/journal.pone.0244690			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BU	33373394	Green Published, gold			2023-01-03	WOS:000603612300041
J	Li, XY; Si, HY; Chen, YM; Li, SH; Yin, NN; Wang, ZL				Li, Xiaoyuan; Si, Hongyu; Chen, Yamin; Li, Shouhao; Yin, Ningning; Wang, Zhenlong			Effects of fitness qigong and tai chi on middle-aged and elderly patients with type 2 diabetes mellitus	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; DIAGNOSTIC-CRITERIA; PREVENTION PROGRAM; ASIAN INDIANS; C-PEPTIDE; PATHOPHYSIOLOGY; POPULATION; INCREASE; OBESITY; TRIAL	Currently, qigong and tai chi exercises are the two most common preventive as well as therapeutic interventions for chronic metabolic diseases such as type 2 diabetes mellitus (T2DM). However, the quantitative evaluation of these interventions is limited. This study aimed to evaluate the therapeutic efficacy of qigong and tai chi intervention in middle-aged and older adults with T2DM. The study included 103 eligible participants, who were randomized to participate for 12 weeks, in one of the following intervention groups for the treatment of T2DM: fitness qigong, tai chi, and control group. Three biochemical measures, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1C), and C-peptide (C-P) levels, assessed at baseline and 12 weeks, served as the primary outcome measures. During the training process, 16 of the 103 participants dropped out. After the 12-week intervention, there were significant influences on HbA1C (F-2,F-83 = 4.88, p = 0.010) and C-P levels (F-2,F-83 = 3.64, p = 0.031). Moreover, significant reduction in C-P levels was observed after 12-week tai chi practice (p = 0.004). Furthermore, there was a significant negative correlation between the duration of T2DM and the relative changes in FPG levels after qigong intervention, and the relative changes in HbA1C levels were positively correlated with waist-to-height ratio after tai chi practice. Our study suggests that targeted qigong exercise might have a better interventional effect on patients with a longer duration of T2DM, while tai chi might be risky for people with central obesity.	[Li, Xiaoyuan; Chen, Yamin; Li, Shouhao] Zhengzhou Univ, Sch Elect Engn, Zhengzhou, Peoples R China; [Li, Xiaoyuan; Si, Hongyu; Yin, Ningning] Zhengzhou Univ, Coll Phys Educ, Zhengzhou, Peoples R China; [Li, Xiaoyuan; Si, Hongyu] Fitness Qigong Sci Res Ctr China, Zhengzhou, Peoples R China; [Wang, Zhenlong] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University	Wang, ZL (corresponding author), Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China.	wzl@zzu.edu.cn			Management Center of Health-care Qigong of the National Sports Bureau [QG2017019]; Key R&D and Promotion Projects from the Science and Technology Department of Henan Province [192102310026]; Open Foundation of Henan Key laboratory of Brain Science and Brain-Computer Interface Technology [HNBBL17006]	Management Center of Health-care Qigong of the National Sports Bureau; Key R&D and Promotion Projects from the Science and Technology Department of Henan Province; Open Foundation of Henan Key laboratory of Brain Science and Brain-Computer Interface Technology	This research was supported by a grant (QG2017019) from the Management Center of Health-care Qigong of the National Sports Bureau, the Key R&D and Promotion Projects (192102310026) from the Science and Technology Department of Henan Province, and Open Foundation of Henan Key laboratory of Brain Science and Brain-Computer Interface Technology (No.HNBBL17006).	Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S062]; [Anonymous], 2014, HAEMOPHILIA, V20, P79; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; [Anonymous], 2009, S AFR CRIME Q, V30, P45; Bhardwaj S, 2008, ASIA PAC J CLIN NUTR, V17, P172; Cash JC, 2017, FAMILY PRACTICE GUID; Charles MA, 1996, LANCET, V348, P1657, DOI 10.1016/S0140-6736(05)65719-4; Chen Z, 2009, CHEN STYLE TAI CHI Q; Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653; Galalain A.M., 2019, EUR J BIOL, Vl4, P1; Gavin JR, 1997, DIABETES CARE, V20, P1183; Geng T, 2008, GANSU CHIN MED, P10; Gomez-Marcos MA, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-90; Huffman FG, 2013, AM J LIFESTYLE MED, V7, P104, DOI 10.1177/1559827612469337; Imperatore G, 2012, DIABETES CARE, V35, P2515, DOI 10.2337/dc12-0669; Johnson RJ, 2013, DIABETES, V62, P3307, DOI 10.2337/db12-1814; Kan Y, 2004, JILIN J TRADIT CHIN, V24, P11; Kitabchi AE, 2009, DIABETES CARE, V32, P1335, DOI 10.2337/dc09-9032; Kramer MK, 2009, AM J PREV MED, V37, P505, DOI 10.1016/j.amepre.2009.07.020; Krentz AJ, 2005, DRUGS, V65, P385, DOI 10.2165/00003495-200565030-00005; Labocha MK, 2014, OIKOS, V123, P111, DOI 10.1111/j.1600-0706.2013.00755.x; Jorge AJL, 2013, REV PORT CARDIOL, V32, P647, DOI 10.1016/j.repc.2012.10.019; LANDINOLSSON M, 1990, DIABETOLOGIA, V33, P561, DOI 10.1007/BF00404145; Lee MS, 2015, MATURITAS, V80, P14, DOI 10.1016/j.maturitas.2014.09.008; Lee MS, 2009, COMPLEMENT THER MED, V17, P236, DOI 10.1016/j.ctim.2009.05.001; Leutholtz B. C., 2011, EXERCISE DIS MANAGEM; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; Li Hongchen, 2015, CHIN J GERONTOL, V35, P1293; Lin Chia-Ling, 2013, Hu Li Za Zhi, V60, P69, DOI 10.6224/JN.60.1.69; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Liu T., 2010, CHINESE MEDICAL QIGO; Maruthur NM, 2016, ANN INTERN MED, V164, P740, DOI 10.7326/M15-2650; Misra A, 2009, J Assoc Physicians India, V57, P163; Moon JS, 2014, ACTA DIABETOL, V51, P277, DOI 10.1007/s00592-013-0553-z; Ohkura T, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-21; Perera DP, 2013, E MEDITERR HEALTH J, V19, P644; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; RENDELL M, 1981, ARCH INTERN MED, V141, P1617, DOI 10.1001/archinte.141.12.1617; Resnick HE, 1999, BRIT MED J, V318, P531, DOI 10.1136/bmj.318.7182.531; Ruchat SM, 2013, DIABETES-METAB RES, V29, P334, DOI 10.1002/dmrr.2402; Saenz A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002966.pub3; Shoback DM, 2017, GREENSPANS BASIC CLI; 송민선, 2005, Diabetes and Metabolism Journal, V29, P140; Stefan N, 2011, LANCET, V377, P1917, DOI 10.1016/S0140-6736(11)60805-2; Sterelny K, 2003, M M COG SCI, P1; TAHARA Y, 1995, DIABETES CARE, V18, P440, DOI 10.2337/diacare.18.4.440; Tfayli H, 2009, ARQ BRAS ENDOCRINOL, V53, P165, DOI 10.1590/S0004-27302009000200008; Tripathy HB., 2012, RSSDI TXB DIABETES M, DOI 10.5005/jp/books/11487; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wasserman DH, 2009, AM J PHYSIOL-ENDOC M, V296, pE11, DOI 10.1152/ajpendo.90563.2008; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Williams LB, 2013, CONTEMP CLIN TRIALS, V34, P336, DOI 10.1016/j.cct.2013.01.002; Williamson R T, 2009, Practitioner, V253, P37; Wu YM, 2008, CHIN PRIM HLTH CARE, V02, P80; Yang K, 2017, INNOV AGING, V1, P256; Yeh SH, 2009, BRIT J SPORT MED, V43, P845, DOI 10.1136/bjsm.2007.043562; Yeh SH, 2007, DIABETES CARE, V30, P716, DOI 10.2337/dc06-1507; Youngwanichsetha S., 2013, Focus on Alternative and Complementary Therapies, V18, P182, DOI 10.1111/fct.12064; Zaccardi F, 2016, POSTGRAD MED J, V92, P63, DOI 10.1136/postgradmedj-2015-133281; 吴云川, 2015, [中国老年学杂志, Chinese Journal of Gerontology], V35, P5218	61	6	6	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2020	15	12							e0243989	10.1371/journal.pone.0243989	http://dx.doi.org/10.1371/journal.pone.0243989			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8BZ	33332396	Green Published, gold			2023-01-03	WOS:000601310900067
J	Sohn, W; Ham, CB; Kim, NH; Kim, HJ; Cho, YK; Jeon, WK; Kim, BI				Sohn, Won; Ham, Cheol Bae; Kim, Nam Hee; Kim, Hong Joo; Cho, Yong Kyun; Jeon, Woo Kyu; Kim, Byung Ik			Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; CIRRHOTIC-PATIENTS; DEFINITION; DIAGNOSIS; MORTALITY; RISK	The purpose of this study was to investigate the effect of acute kidney injury (AKI) on the prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). A total of 347 HCC patients with Child-Pugh class A and pre-TACE serum creatinine (SCr) <= 1.5 mg/dL undergoing TACE as an initial therapy 2000-2014 were analyzed. Overall survival with related risk factors including AKI was investigated. We assessed AKI based on the International Club of Ascites (ICA)-AKI criteria. The mean age was 60.9 years. Of 347 patients, death was observed in 109 patients (31.4%). The mean SCr levels at pre-TACE, one day, two months, and four months after TACE were 0.9, 0.9, 0.9, and 1.1 mg/dL, respectively. The AKI within four months after TACE developed in 37 patients (11%). The AKI stages were non-AKI in 310 (89%), stage 1 in 10 (3%), stage 2 in 10 (3%), and stage 3 in 17 patients (5%). Multivariable analysis showed that the risk factors for overall survival were serum albumin <= 3.5 g/dL (hazard ratio [HR] 1.58, p = 0.027), BCLC stage B (HR 2.07, p = 0.008), BCLC stage C (HR 3.96, p<0.001), bilobar tumor location (HR 1.66, p = 0.022), AKI stage 1 (HR 6.09, p<0.001), AKI stage 2 (HR 8.51, p<0.001), and AKI stage 3 (HR 17.64, p<0.001). AKI is a crucial prognostic factor for overall survival in HCC patients undergoing TACE. The assessment of AKI based on the ICA-AKI criteria can facilitate evaluation of the prognosis of HCC patients undergoing TACE.	[Sohn, Won; Ham, Cheol Bae; Kim, Nam Hee; Kim, Hong Joo; Cho, Yong Kyun; Jeon, Woo Kyu; Kim, Byung Ik] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Gastroenterol, Dept Internal Med,Sch Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, BI (corresponding author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Gastroenterol, Dept Internal Med,Sch Med, Seoul, South Korea.	bik.kim@samsung.com		Sohn, Won/0000-0003-3284-2715; Kim, Hong Joo/0000-0003-4121-6329				Angeli P, 2015, J HEPATOL, V62, P968, DOI 10.1016/j.jhep.2014.12.029; [Anonymous], 2015, ARCH BRONCONEUMOL S, V51, pS1; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bucsics T, 2017, GASTROENTEROL REP, V5, P127, DOI 10.1093/gastro/gox009; de Carvalho JR, 2012, J CLIN GASTROENTEROL, V46, pE21, DOI 10.1097/MCG.0b013e31822e8e12; Desai AP, 2020, J HEPATOL, V73, P1092, DOI 10.1016/j.jhep.2020.04.043; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; de Paredes AGG, 2018, LIVER INT, V38, P285, DOI 10.1111/liv.13515; Garcia-Tsao G, 2008, HEPATOLOGY, V48, P2064, DOI 10.1002/hep.22605; Hayashi M, 2020, JPN J CLIN ONCOL, V50, P36, DOI 10.1093/jjco/hyz129; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Hoste EAJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4915; Hsieh YC, 2017, J GASTROEN HEPATOL, V32, P1859, DOI 10.1111/jgh.13777; Hsu CY, 2010, LIVER INT, V30, P77, DOI 10.1111/j.1478-3231.2009.02128.x; Huo TI, 2004, ALIMENT PHARM THER, V19, P999, DOI 10.1111/j.1365-2036.2004.01936.x; Kim NH, 2018, J GASTROEN HEPATOL, V33, P1397, DOI 10.1111/jgh.14083; Lee BC, 2017, EUR RADIOL, V27, P4482, DOI 10.1007/s00330-017-4893-x; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.19, 10.1038/nrdp.2016.18]; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Mehran R, 2019, NEW ENGL J MED, V380, P2146, DOI 10.1056/NEJMra1805256; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Russ KB, 2015, J CLIN TRANSL HEPATO, V3, P195, DOI 10.14218/JCTH.2015.00015; Salerno F, 2007, GUT, V56, P1310, DOI 10.1136/gut.2006.107789; Sieghart W, 2015, J HEPATOL, V62, P1187, DOI 10.1016/j.jhep.2015.02.010; Sohn W, 2020, J GASTROEN HEPATOL, V35, P870, DOI 10.1111/jgh.14871; Wong F, 2016, CLIN MOL HEPATOL, V22, P415, DOI 10.3350/cmh.2016.0056; Xiong J, 2018, SCAND J GASTROENTERO, V53, P1590, DOI 10.1080/00365521.2018.1545423; Zhou CZ, 2014, INT J CLIN EXP PATHO, V7, P2579	32	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243780	10.1371/journal.pone.0243780	http://dx.doi.org/10.1371/journal.pone.0243780			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315944	Green Published, gold			2023-01-03	WOS:000600186100005
J	Verbiest, S; Ferrari, R; Tucker, C; McClain, EK; Charles, N; Stuebe, AM				Verbiest, Sarah; Ferrari, Renee; Tucker, Christine; McClain, Erin K.; Charles, Nkechi; Stuebe, Alison M.			Health Needs of Mothers of Infants in a Neonatal Intensive Care Unit A Mixed-Methods Study	ANNALS OF INTERNAL MEDICINE			English	Article							POSTPARTUM DEPRESSION; BIRTH; MORTALITY; RISK	Background: Mothers with babies in the neonatal intensive care unit (NICU) face a host of challenges following childbirth. Limited information is available on these mothers' postpartum health needs and access to services. Objective: To identify health needs of NICU mothers, access to services, and potential service improvements. Design: A mixed-methods study including a retrospective cohort study, in-depth interviews, and focus groups. Setting: Large, Level IV, regional referral, university-affiliated hospital in the United States. Participants: Mothers of live-born infants born from 1 July 2014 to 30 June 2016 (n = 6849). Interviews included 50 NICU mothers and 59 stakeholders who provide services to these mothers or their infants. Measurements: Severe maternal morbidity, chronic health conditions, health care encounters from discharge through 12 weeks postpartum, maternal health needs, care access, and system improvements. Results: Compared with mothers of well babies, NICU mothers had more chronic diseases, experienced more perinatal complications, and utilized more acute care postpartum. Qualitative analyses revealed the desire to be at the baby's bedside as a driver of maternal health-seeking behaviors, with women not seeking or delaying medical care so as to stay by their infant. Stakeholders acknowledged the unique needs of NICU mothers and cited system challenges, lack of clarity about provider roles, and reimbursement policies as barriers to meeting needs. Limitations: The study was conducted within a single health care system, which may limit generalizability. Qualitative analyses did not explore the influence of fathers, other children in the home, or length of NICU stay. Conclusion: Universal screening and convenient access to maternal health services for NICU mothers should be explored to reduce adverse maternal health outcomes. Primary Funding Source: Maternal and Child Health Bureau, Health Resources and Services Administration, U.S. Department of Health and Human Services.	[Verbiest, Sarah; McClain, Erin K.] Univ North Carolina Chapel Hill, Sch Med, CB 7181, Chapel Hill, NC 27599 USA; [Verbiest, Sarah; Charles, Nkechi] Univ North Carolina Chapel Hill, Sch Social Work, CB 3550, Chapel Hill, NC 27599 USA; [Ferrari, Renee] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, CB 7293, Chapel Hill, NC 27599 USA; [Tucker, Christine; Charles, Nkechi; Stuebe, Alison M.] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, CB 7400, Chapel Hill, NC 27599 USA; [Stuebe, Alison M.] Univ North Carolina Chapel Hill, Sch Med, CB 7516, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Verbiest, S (corresponding author), Univ North Carolina Chapel Hill, Sch Social Work, CB 3550, Chapel Hill, NC 27599 USA.	sarah_verbiest@med.unc.edu		Ferrari, Renee/0000-0001-6207-9824; Tucker, Christine/0000-0002-8676-5359	Maternal and Child Health Bureau, Health Resources and Services Administration of the U.S. Department of Health and Human Services [R40MC29455]	Maternal and Child Health Bureau, Health Resources and Services Administration of the U.S. Department of Health and Human Services	By grant R40MC29455 from the Maternal and Child Health Bureau, Health Resources and Services Administration of the U.S. Department of Health and Human Services to Care4Moms.	Albers LL, 2000, J MIDWIFERY WOM HEAL, V45, P55, DOI 10.1016/S1526-9523(99)00003-3; Alliance for Innovation on Maternal Health, AIM SMM COD LIST; Antonacci G, 2018, HEALTH SERV MANAG RE, V31, P74, DOI 10.1177/0951484818770411; Association of Women's Health, POST BIRTH WARN SIGN; Bakewell-Sachs Susan, 2004, MCN Am J Matern Child Nurs, V29, P398, DOI 10.1097/00005721-200411000-00011; Bialoskurski MM, 2002, J ADV NURS, V37, P62, DOI 10.1046/j.1365-2648.2002.02057.x; Charmaz K., 2004, APPROACHES QUALITATI, P441; Creanga AA, 2017, OBSTET GYNECOL, V130, P366, DOI 10.1097/AOG.0000000000002114; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Firoz T, 2013, B WORLD HEALTH ORGAN, V91, P794, DOI 10.2471/BLT.13.117564; Gennaro S, 1996, Health Care Women Int, V17, P35; Harrison WN, 2018, J PEDIATR-US, V192, P73, DOI 10.1016/j.jpeds.2017.08.028; Hynan MT, 2015, J PERINATOL, V35, pS14, DOI 10.1038/jp.2015.144; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31470-2; Lee SY, 2009, JOGNN-J OBST GYN NEO, V38, P676, DOI 10.1111/j.1552-6909.2009.01064.x; Maher J, 2006, HLTH SOCIOLOGY REV, V15, P104, DOI [10.5172/hesr.2006.15.1.104, DOI 10.5172/HESR.2006.15.1.104]; March of Dimes Perinatal Data Center, 2011, SPEC CAR NURS ADM; Miles M.B., 1994, QUALITATIVE DATA ANA, V2nd; OHara MW, 1996, INT REV PSYCHIATR, V8, P37, DOI 10.3109/09540269609037816; Pacagnella RC, 2010, J OBSTET GYNAECOL CA, V32, P730, DOI 10.1016/S1701-2163(16)34612-6; Phillips RM, 2012, J PERINATOL, V32, P374, DOI 10.1038/jp.2011.106; Reddy UM, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.06.064; ResearchTalk, 2019, QUAL INQ CAMP; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Singer LT, 1999, JAMA-J AM MED ASSOC, V281, P799, DOI 10.1001/jama.281.9.799; Society for Maternal-Fetal Medicine, 2018, PAID FAM MED LEAV OF; Stuebe A, 2018, OBSTET GYNECOL, V131, pE140, DOI 10.1097/AOG.0000000000002633; Tully KP, 2017, AM J OBSTET GYNECOL, V217, P37, DOI 10.1016/j.ajog.2017.03.032; Verbiest S, 2018, J BEHAV MED, V41, P577, DOI 10.1007/s10865-018-9961-4; Verbiest S, 2016, MATERN CHILD HLTH J, V20, pS125, DOI 10.1007/s10995-016-2045-6; VERBIEST SB, 2017, ZERO 3, V37, P34; Vigod SN, 2010, BJOG-INT J OBSTET GY, V117, P540, DOI 10.1111/j.1471-0528.2009.02493.x	32	5	5	2	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2020	173			11			S37	S44		10.7326/M19-3252	http://dx.doi.org/10.7326/M19-3252			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QI2TF	33253024				2023-01-03	WOS:000618828900006
J	Lyu, Q; Bai, YG; Cheng, JH; Liu, H; Li, SH; Yang, J; Wang, ZC; Ma, Y; Jiang, M; Dong, D; Yan, YQ; Shi, QX; Ren, XL; Ma, J				Lyu, Qiang; Bai, Yungang; Cheng, Jiuhua; Liu, Huan; Li, Shaohua; Yang, Jing; Wang, Zhongchao; Ma, Yan; Jiang, Min; Dong, Dong; Yan, Yiquan; Shi, Qixin; Ren, Xinling; Ma, Jin			Intermittent short-duration reoxygenation protects against simulated high altitude-induced pulmonary hypertension in rats	FASEB JOURNAL			English	Article						artery remodeling; high&#8208; altitude pulmonary hypertension; human pulmonary artery smooth muscle cells; intermittent reoxygenation	OXIDE-MEDIATED RELAXATION; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA; RESISTANCE; ARTERIES; VASOCONSTRICTION; PROLIFERATION; DYSFUNCTION; EXPRESSION; APOPTOSIS	High-altitude pulmonary hypertension (HAPH) is a severe and progressive disease caused by chronic hypoxia and subsequent pulmonary vascular remodeling. No cure is currently available owing to an incomplete understanding about vascular remodeling. It is believed that hypoxia-induced diseases can be prevented by treating hypoxia. Thus, this study aimed to determine whether daily short-duration reoxygenation at sea level attenuates pulmonary hypertension under high-altitude hypoxia. To this end, a simulated 5000-m hypoxia rat model and hypoxic cultured human pulmonary artery smooth muscle cells were used to evaluate the effect of short-duration reoxygenation. Results show that intermittent, not continuous, short-duration reoxygenation effectively attenuates hypoxia-induced pulmonary hypertension. The mechanisms underlining the protective effects involved that intermittent, short-duration reoxygenation prevented functional and structural remodeling of pulmonary arteries and proliferation, migration, and phenotypic conversion of pulmonary artery smooth muscle cells under hypoxia. The specific genes or potential molecular pathways responsible for mediating the protective effects were also characterised by RNA sequencing. Further, the frequency and the total time of intermittent reoxygenation affected its preventive effect of HAPH, which was likely attributable to augmented oxidative stress. Hence, daily intermittent, not continuous, short-duration reoxygenation partially prevented pulmonary hypertension induced by 5000-m hypoxia in rats. This study is novel in revealing a new potential method in preventing HAPH. It gives insights into the selection and optimisation of oxygen supply schemes in high-altitude areas.	[Lyu, Qiang; Bai, Yungang; Cheng, Jiuhua; Liu, Huan; Li, Shaohua; Yang, Jing; Wang, Zhongchao; Ma, Yan; Jiang, Min; Dong, Dong; Yan, Yiquan; Shi, Qixin; Ma, Jin] Fourth Mil Med Univ, Dept Aerosp Physiol, Xian, Peoples R China; [Ren, Xinling] Dept Resp Dis, Xian, Peoples R China	Air Force Military Medical University	Ma, J (corresponding author), Fourth Mil Med Univ, Dept Aerosp Physiol, Xian, Peoples R China.; Ren, XL (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Resp Dis, Xian, Peoples R China.	majrenxl@fmmu.edu.cn; jin-ma@fmmu.edu.cn		Jiang, Min/0000-0002-4952-1283	National Natural Science Foundation of China [31571230]; Fourth Military Medical University [2018HKTS03, 2017D07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fourth Military Medical University	The work was supported by grants from the National Natural Science Foundation of China (No. 31571230 to Jin Ma) and Fourth Military Medical University (No. 2018HKTS03 to Jin Ma and No. 2017D07 to Qiang Lyu). The funders had no role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication	Aggarwal S, 2013, COMPR PHYSIOL, V3, P1011, DOI 10.1002/cphy.c120024; Aldashev AA, 2005, THORAX, V60, P683, DOI 10.1136/thx.2005.041954; Austin ED, 2014, CIRC RES, V115, P189, DOI 10.1161/CIRCRESAHA.115.303404; Bartoszewski R, 2019, FASEB J, V33, P7929, DOI 10.1096/fj.201802650RR; Bonnet S, 2001, AM J PHYSIOL-LUNG C, V281, pL193, DOI 10.1152/ajplung.2001.281.1.L193; Christou H, 2018, J PHARMACOL EXP THER, V364, P258, DOI 10.1124/jpet.117.244798; Crawford JE, 2017, AM J HUM GENET, V101, P752, DOI 10.1016/j.ajhg.2017.09.023; Cui Jian-Hua, 2013, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V29, P391; Feng B, 2016, CHINESE MED J-PEKING, V129, P1322, DOI 10.4103/0366-6999.182831; Granger DN, 2015, REDOX BIOL, V6, P524, DOI 10.1016/j.redox.2015.08.020; Grimminger J, 2017, CAN RESPIR J, V2017, DOI 10.1155/2017/8381653; GROVES BM, 1993, J APPL PHYSIOL, V74, P312, DOI 10.1152/jappl.1993.74.1.312; Hansen T, 2016, PHARMACOL THERAPEUT, V165, P50, DOI 10.1016/j.pharmthera.2016.05.005; Herrera EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009250; Hirose S, 2000, PATHOL INT, V50, P472, DOI 10.1046/j.1440-1827.2000.01068.x; HISLOP A, 1976, BRIT J EXP PATHOL, V57, P542; Hoffmann J, 2016, EUR RESPIR J, V48, P229, DOI 10.1183/13993003.02030-2015; Holland M, 1996, BRIT J PHARMACOL, V117, P119, DOI 10.1111/j.1476-5381.1996.tb15163.x; Jiang CH, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-701; Jiang M, 2018, CAN J PHYSIOL PHARM, V96, P772, DOI 10.1139/cjpp-2017-0665; JIANG MJ, 1994, LIFE SCI, V54, P2005, DOI 10.1016/0024-3205(94)90135-X; Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004; Kojonazarov B, 2012, EUR RESPIR J, V39, P496, DOI 10.1183/09031936.00095211; Mam V, 2010, J PHARMACOL EXP THER, V332, P455, DOI 10.1124/jpet.109.160119; Minutoli L, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2183026; Naeije R, 2013, HIGH ALT MED BIOL, V14, P117, DOI 10.1089/ham.2012.1124; Omura J, 2016, CIRC RES, V119, P197, DOI 10.1161/CIRCRESAHA.115.308178; Papaioannou Andriana I, 2009, BMC Pulm Med, V9, P18, DOI 10.1186/1471-2466-9-18; Perros F, 2015, J AM COLL CARDIOL, V65, P668, DOI 10.1016/j.jacc.2014.11.050; Ponnuchamy B, 2009, AM J PHYSIOL-REG I, V296, pR1001, DOI 10.1152/ajpregu.90960.2008; Ren XL, 2011, CLIN EXP PHARMACOL P, V38, P683, DOI 10.1111/j.1440-1681.2011.05565.x; Richalet JP, 2008, AM J RESP CRIT CARE, V177, P1370, DOI 10.1164/rccm.200802-196OC; Shaw L, 2004, BRIT J PHARMACOL, V141, P678, DOI 10.1038/sj.bjp.0705647; Shimoda LA, 2014, J APPL PHYSIOL, V116, P867, DOI 10.1152/japplphysiol.00643.2013; Shimoda LA, 2013, J MOL MED, V91, P297, DOI 10.1007/s00109-013-0998-0; Sylvester JT, 2012, PHYSIOL REV, V92, P367, DOI 10.1152/physrev.00041.2010; Tajsic T, 2011, COMPR PHYSIOL, V1, P295, DOI 10.1002/cphy.c100026; Tykocki NR, 2017, COMPR PHYSIOL, V7, P485, DOI 10.1002/cphy.c160011; Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005; Wang ZC, 2015, J PHYSIOL BIOCHEM, V71, P205, DOI 10.1007/s13105-015-0398-8; Waypa GB, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01929-2019; Weisel FC, 2014, CIRCULATION, V129, P1510, DOI 10.1161/CIRCULATIONAHA.113.006402; West JB, 2017, NEW ENGL J MED, V376, P1965, DOI 10.1056/NEJMra1612008; West JB, 2012, AM J RESP CRIT CARE, V186, P1229, DOI 10.1164/rccm.201207-1323CI; Wilkins MR, 2015, CIRCULATION, V131, P582, DOI 10.1161/CIRCULATIONAHA.114.006977; You BY, 2018, CARDIOVASC RES, V114, P188, DOI 10.1093/cvr/cvx234; Zhang LF, 2003, J APPL PHYSIOL, V95, P207, DOI 10.1152/japplphysiol.00969.2002; Zhang LF, 2013, EUR J APPL PHYSIOL, V113, P2873, DOI 10.1007/s00421-013-2597-8	48	5	5	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2021	35	2								10.1096/fj.202000533RR	http://dx.doi.org/10.1096/fj.202000533RR		NOV 2020	18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RY3BC	33230951	hybrid			2023-01-03	WOS:000592381900001
J	Perry, KE; Taylor, J; Patel, H; Javadi, SS; Mathur, K; Kaytes, A; Concha-Garcia, S; Little, S; Smith, D; Gianella, S; Dube, K				Perry, Kelly E.; Taylor, Jeff; Patel, Hursch; Javadi, Sogol Stephanie; Mathur, Kushagra; Kaytes, Andy; Concha-Garcia, Susanna; Little, Susan; Smith, Davey; Gianella, Sara; Dube, Karine			"[It] is now my responsibility to fulfill that wish:" Clinical and rapid autopsy staff members' experiences and perceptions of HIV reservoir research at the end of life	PLOS ONE			English	Article							ETHICS; CARE; CHALLENGES; PHYSICIANS; ALTRUISM; DONATION; ERA	Introduction Little is known about the effects of HIV reservoir research at the end of life on staff members involved. Staff members' perceptions and experiences were assessed related to their involvement in the Last Gift, a rapid autopsy study at the University of California San Diego enrolling people living with HIV who are terminally ill and have a desire to contribute to HIV cure-related research. Methods Two focus group discussions consisting of clinical (n = 7) and rapid research autopsy (n = 8) staff members were conducted to understand the perspectives of staff members and the impact the Last Gift rapid autopsy study had on them. The total sample consisted of 66.7% females and 33.3% males and was ethnically diverse (66.7% Caucasian, 6.7% African American, 20.0% Asian descent, 6.7% Hispanic descent and American Indian) with a range of experience in the HIV field from 1 year to 30 years. Results Qualitative focus group data revealed five major themes underlying study staff members' multilayered mental and practical involvement: 1) positive perceptions of the Last Gift study, with sub-themes including Last Gift study participants' altruism, fulfillment, and control at the end of life, 2) perceptions of staff members' close involvement in the Last Gift study, with sub-themes related to staff members' cognitive processing, self-actualization and fulfillment, stress management and resilience, coping mechanisms, and gratitude toward Last Gift participants and toward the study itself, 3) considerations for successful and sustainable study implementation, such as ethical awareness and sustained community and patient engagement, 4) collaborative learning and organizational processes and the value of interdependence between staff members, and 5) considerations for potential study scale-up at other clinical research sites. Discussion Understanding staff members' nuanced emotional and procedural experiences is crucial to the Last Gift study's sustainability and will inform similar cure research studies conducted with people living with HIV at the end of life. The study's potential reproducibility depends on a robust research infrastructure with established, interdependent clinical and rapid autopsy teams, continuous community engagement, and an ethical and well-informed engagement process with people living with HIV.	[Perry, Kelly E.; Patel, Hursch; Dube, Karine] UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA; [Taylor, Jeff; Kaytes, Andy] AntiViral Res Ctr Community Advisory Board, San Diego, CA USA; [Taylor, Jeff] HIV Aging Res Project Palm Springs HARP PS, Palm Springs, CA USA; [Javadi, Sogol Stephanie; Mathur, Kushagra; Concha-Garcia, Susanna; Little, Susan; Smith, Davey; Gianella, Sara] Univ Calif San Diego, AntiViral Res Ctr AVRC, San Diego, CA 92103 USA; [Concha-Garcia, Susanna] Univ Calif San Diego, HIV Neurobehav Res Ctr, San Diego, CA 92103 USA; [Little, Susan; Smith, Davey; Gianella, Sara] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, San Diego, CA 92103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Perry, KE (corresponding author), UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.	perryke@email.unc.edu		Patel, Hursch/0000-0002-0725-4922; E. Perry, Kelly/0000-0002-8637-4729; Gianella, Sara/0000-0002-9927-0849; Little, Susan/0000-0002-7645-9737	Department of Veterans Affairs; National Institutes of Health [AI120009, AI131385, AI100665, P30 AI036214, AI134295, HD094646];  [R21MH118120]	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 	This work was supported by R21MH118120 to K.D. We also acknowledge support received from the Department of Veterans Affairs and grants from the National Institutes of Health: AI120009, AI131385, AI100665, P30 AI036214, AI134295, and HD094646.	Abt PL, 2013, AM J TRANSPLANT, V13, P1400, DOI 10.1111/ajt.12243; Alsop K, 2016, NAT BIOTECHNOL, V34, P1010, DOI 10.1038/nbt.3674; [Anonymous], 2018, NAT REV GENET, V19, P1, DOI 10.1038/nrg.2017.141; Beaver K., 1999, INT J PALLIAT NURS, V5, P13, DOI [10.12968/ijpn.1999.5.1.9926, DOI 10.12968/IJPN.1999.5.1.9926]; Cresswell J, 2013, QUALITATIVE QUANTITA, V4th; Danielson Michael M, 2018, Ann Intern Med, V169, P349, DOI 10.7326/M18-1719; De Cock KM, 2019, NEW ENGL J MED, V381, P1889, DOI 10.1056/NEJMp1909017; DUBE K, 2015, J VIRUS ERAD, V1, pE14; Dube K, J VIRUS ERAD; Dube K, 2020, AIDS RES HUM RETROV, V36, P1033, DOI [10.1089/aid.2020.0025, 10.1089/AID.2020.0025]; Evans D, 2017, J MED ETHICS, V43, P100, DOI 10.1136/medethics-2015-103120; FDA, 2014, VOICE PATIENT; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gianella S, 2017, AIDS, V31, P1, DOI 10.1097/QAD.0000000000001300; Gilbertson A, 2019, AIDS RES HUM RETROV, V35, P100, DOI [10.1089/AID.2017.0224, 10.1089/aid.2017.0224]; Goodkin K, 2003, PUTTING FACE HIV INF, pS171; Goodkin K, 2018, NURS CLIN N AM, V53, P123, DOI 10.1016/j.cnur.2017.10.010; Greenberg B, 2000, J URBAN HEALTH, V77, P150, DOI 10.1007/BF02390527; Hold JL, 2017, J ASSOC NURSE AIDS C, V28, P752, DOI 10.1016/j.jana.2017.03.011; Karasz A, 2003, SOC SCI MED, V57, P1609, DOI 10.1016/S0277-9536(03)00013-3; Karnik S, 2016, HEALTHCARE, V4, P1; Lindell KO, 2006, PLOS MED, V3, P953, DOI 10.1371/journal.pmed.0030234; Lo B, 2013, CURR OPIN HIV AIDS, V8, P243, DOI 10.1097/COH.0b013e32835ea1c5; Pentz RD, 2005, NAT MED, V11, P1145, DOI 10.1038/nm1105-1145; Prakash K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199670; Protiere C, 2018, HIV MED, V19, pE56, DOI 10.1111/hiv.12526; Quinn GP, 2013, MED HEALTH CARE PHIL, V16, P857, DOI 10.1007/s11019-013-9480-6; Rosenbaum L, 2020, NEW ENGL J MED, V382, P493, DOI 10.1056/NEJMp2000048; Sandstrom TS, 2019, CLIN INFECT DIS, V69, P1063, DOI 10.1093/cid/ciz068; Seppet E, 2011, BIOGERONTOLOGY, V12, P491, DOI 10.1007/s10522-011-9340-9; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Surman OS, 2005, PSYCHOSOMATICS, V46, P1, DOI 10.1176/appi.psy.46.1.1; Taylor J, 2020, AIDS RES HUM RETROVI; UCSD, 2018, LAST GIFT U CAL SAN; Vasquez JJ, 2019, CLIN INFECT DIS, V69, P1068, DOI 10.1093/cid/ciz070; Wicclair MR, 2008, CAMB Q HEALTHC ETHIC, V17, P87, DOI 10.1017/S0963180108080092	36	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0242420	10.1371/journal.pone.0242420	http://dx.doi.org/10.1371/journal.pone.0242420			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ9VG	33206710	gold, Green Published			2023-01-03	WOS:000595265900031
J	Freund, Y; Cachanado, M; Delannoy, Q; Laribi, S; Yordanov, Y; Gorlicki, J; Chouihed, T; Feral-Pierssens, AL; Truchot, J; Desmettre, T; Occelli, C; Bobbia, X; Khellaf, M; Ganansia, O; Bokobza, JM; Balen, F; Beaune, S; Bloom, B; Simon, T; Mebazaa, A				Freund, Yonathan; Cachanado, Marine; Delannoy, Quentin; Laribi, Said; Yordanov, Youri; Gorlicki, Judith; Chouihed, Tahar; Feral-Pierssens, Anne-Laure; Truchot, Jennifer; Desmettre, Thibaut; Occelli, Celine; Bobbia, Xavier; Khellaf, Mehdi; Ganansia, Olivier; Bokobza, Jerome; Balen, Frederic; Beaune, Sebastien; Bloom, Ben; Simon, Tabassome; Mebazaa, Alexandre			Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure The ELISABETH Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ISOSORBIDE-DINITRATE; EUROPEAN-SOCIETY; MANAGEMENT; MORTALITY; ASSOCIATION; GUIDELINES; FUROSEMIDE; CARDIOLOGY; OUTCOMES	This unblinded cluster randomized trial compares the effects of an emergency department (ED)-based comprehensive, guideline-recommended care bundle vs usual care on the number of days alive and out of the hospital at 30 days in older patients with acute heart failure cared for at French hospitals. Importance Clinical guidelines for the early management of acute heart failure in the emergency department (ED) setting are based on only moderate levels of evidence, with subsequent low adherence to these guidelines. Objective To test the effect of an early guideline-recommended care bundle on short-term prognosis in older patients with acute heart failure in the ED. Design, Setting, and Participants Stepped-wedge cluster randomized trial in 15 EDs in France of 503 patients 75 years and older with a diagnosis of acute heart failure in the ED from December 2018 to September 2019 and followed up for 30 days until October 2019. Interventions A care bundle that included early intravenous nitrate boluses; management of precipitating factors, such as acute coronary syndrome, infection, or atrial fibrillation; and moderate dose of intravenous diuretics (n = 200). In the control group, patient care was left to the discretion of the treating emergency physician (n = 303). Each center was randomized to the order in which they switched to the "intervention period." After the initial 4-week control period for all centers, 1 center entered in the intervention period every 2 weeks. Main Outcomes and Measures The primary end point was the number of days alive and out of hospital at 30 days. Secondary outcomes included 30-day all-cause mortality, 30-day cardiovascular mortality, unscheduled readmission, length of hospital stay, and kidney impairment. Results Among 503 patients who were randomized (median age, 87 years; 298 [59%] women), 502 were analyzed. In the intervention group, patients received a median (interquartile range) of 27.0 (9-54) mg of intravenous nitrates in the first 4 hours vs 4.0 (2.0-6.0) mg in the control group (adjusted difference, 23.8 [95% CI, 13.5-34.1]). There was a significantly higher percentage of patients in the intervention group treated for their precipitating factors than in the control group (58.8% vs 31.9%; adjusted difference, 31.1% [95% CI, 14.3%-47.9%]). There was no statistically significant difference in the primary end point of the number of days alive and out of hospital at 30 days (median [interquartile range], 19 [0- 24] d in both groups; adjusted difference, -1.9 [95% CI, -6.6 to 2.8]; adjusted ratio, 0.88 [95% CI, 0.64-1.21]). At 30 days, there was no significant difference between the intervention and control groups in mortality (8.0% vs 9.7%; adjusted difference, 4.1% [95% CI, -17.2% to 25.3%]), cardiovascular mortality (5.0% vs 7.4%; adjusted difference, 2.1% [95% CI, -15.5% to 19.8%]), unscheduled readmission (14.3% vs 15.7%; adjusted difference, -1.3% [95% CI, -26.3% to 23.7%]), median length of hospital stay (8 d in both groups; adjusted difference, 2.5 [95% CI, -0.9 to 5.8]), and kidney impairment (1% in both groups). Conclusions and Relevance Among older patients with acute heart failure, use of a guideline-based comprehensive care bundle in the ED compared with usual care did not result in a statistically significant difference in the number of days alive and out of the hospital at 30 days. Further research is needed to identify effective treatments for acute heart failure in older patients. Question Does an intervention aimed at improving guideline adherence for the management of acute heart failure, including intensive intravenous nitrate therapy and management of precipitating factors, improve hospital discharge and survival at 30 days? Findings In this stepped-wedge cluster randomized trial that included 503 patients 75 years and older who presented to the emergency department with acute heart failure, implementation of an early and comprehensive care bundle compared with usual care improved guideline adherence, but had no significant effect on number of days alive and out of hospital at 30 days (median of 19 d in both groups). Meanings This emergency department care bundle did not improve 30-day outcomes among older patients with acute heart failure.	[Freund, Yonathan; Yordanov, Youri; Simon, Tabassome] Sorbonne Univ, Improving Emergency Care FHU, Paris, France; [Freund, Yonathan; Delannoy, Quentin] Hop La Pitie Salpetriere, AP HP, Emergency Dept, Paris, France; [Cachanado, Marine; Simon, Tabassome] Hop St Antoine, AP HP, Clin Res Platform URC CRC CRB, Paris, France; [Laribi, Said] Hop Bretonneau, Emergency Dept, Tours, France; [Yordanov, Youri] Hop St Antoine, AP HP, Inst Pierre Louis Epidemiol & Sante Publ, Emergency Dept,INSERM,UMR S 1136, Paris, France; [Gorlicki, Judith] Hop Avicenne, AP HP, Emergency Dept, Bobigny, France; [Chouihed, Tahar] Univ Lorraine, Hop CHRU Nancy, INSERM, U1116,Emergency Dept, Vandoeuvre Les Nancy, France; [Feral-Pierssens, Anne-Laure] Hop Europeen Georges Pompidou, AP HP, Emergency Dept, Paris, France; [Truchot, Jennifer] Hop Lariboisiere, AP HP, Emergency Dept, Paris, France; [Desmettre, Thibaut] CHRU Besancon, Emergency Dept, Besancon, France; [Occelli, Celine] CHU Nice, Emergency Dept, Nice, France; [Bobbia, Xavier] CHU Nimes, Emergency Dept, Nimes, France; [Khellaf, Mehdi] Univ Paris Est, Hop Henri Mondor, AP HP, Emergency Dept,INSERM,U955, Creteil, France; [Ganansia, Olivier] Hop Paris St Joseph, Grp Hosp Paris St Joseph, Emergency Dept, Paris, France; [Bokobza, Jerome] Hop Cochin, AP HP, Emergency Dept, Paris, France; [Balen, Frederic] CHU Toulouse, Emergency Dept, Toulouse, France; [Beaune, Sebastien] Univ Paris, Hop Ambroise Pare, AP HP, Emergency Dept,Inserm,U1144, Paris, France; [Bloom, Ben] Barts Hlth NHS Trust, Royal London Hosp, Emergency Dept, London, England; [Mebazaa, Alexandre] Hop Univ St Louis Lariboisiere, Dept Anesthesia Burn & Crit Care, AP HP, FHU PROMICE INI CRCT, Paris, France; [Mebazaa, Alexandre] Univ Paris, Paris, France; [Mebazaa, Alexandre] INSERM, U942, MASCOT, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Nice; Universite de Montpellier; CHU de Nimes; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Barts Health NHS Trust; Royal London Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Freund, Y (corresponding author), Sorbonne Univ, Improving Emergency Care FHU, Paris, France.; Freund, Y (corresponding author), Hop La Pitie Salpetriere, AP HP, Emergency Dept, Paris, France.; Freund, Y (corresponding author), Serv Accueil Urgences, 47-83 Bd Hop, F-75013 Paris, France.	yonathan.freund@aphp.fr	DESMETTRE, Thibaut/GLT-4326-2022; Laribi, Said/S-3693-2016	DESMETTRE, Thibaut/0000-0003-4585-5494; Laribi, Said/0000-0003-4648-4672; Bloom, Ben/0000-0002-3016-4925				Arrigo M, 2016, ESC HEART FAIL, V3, P115, DOI 10.1002/ehf2.12083; Barnett AG, 2008, AUST NZ J PUBL HEAL, V32, P408, DOI 10.1111/j.1753-6405.2008.00270.x; Chioncel O, 2019, EUR J HEART FAIL, V21, P1338, DOI 10.1002/ejhf.1492; Collins SP, 2015, ACAD EMERG MED, V22, P94, DOI 10.1111/acem.12538; Cotter G, 1998, LANCET, V351, P389, DOI 10.1016/S0140-6736(97)08417-1; Ezekowitz JA, 2008, EUR J HEART FAIL, V10, P308, DOI 10.1016/j.ejheart.2008.01.014; Felker GM, 2011, NEW ENGL J MED, V364, P797, DOI 10.1056/NEJMoa1005419; Freund Y, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3188-8; Gorlicki J, 2020, IJC HEART VASC, V26, DOI 10.1016/j.ijcha.2019.100448; Gorlicki J, 2019, EUR J EMERG MED, V26, P379, DOI 10.1097/MEJ.0000000000000593; Hemming K, 2019, TRIALS, V20, DOI 10.1186/s13063-018-3116-3; Hemming K, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k1614; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; Kaneko H, 2014, J CARDIOL, V64, P470, DOI 10.1016/j.jjcc.2014.03.004; Kozhuharov N, 2019, JAMA-J AM MED ASSOC, V322, P2292, DOI 10.1001/jama.2019.18598; Lemachatti N, 2016, ARCH CARDIOVASC DIS, V109, P449, DOI 10.1016/j.acvd.2016.01.014; Machado J., 2020, QREG2 STATA MODULE P; Matsue Y, 2017, J AM COLL CARDIOL, V69, P3042, DOI 10.1016/j.jacc.2017.04.042; McMurray JJV, 2012, TURK KARDIYOL DERN A, V40, P77, DOI 10.1093/eurheartj/ehs104; Mebazaa A, 2015, EUR J HEART FAIL, V17, P544, DOI 10.1002/ejhf.289; Packer M, 2017, NEW ENGL J MED, V376, P1956, DOI 10.1056/NEJMoa1601895; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Sharon A, 2000, J AM COLL CARDIOL, V36, P832, DOI 10.1016/S0735-1097(00)00785-3; Teixeira A, 2016, ARCH CARDIOVASC DIS, V109, P422, DOI 10.1016/j.acvd.2016.02.002; Teixeira A, 2015, EUR J HEART FAIL, V17, P1114, DOI 10.1002/ejhf.330; Zannad F, 2013, EUR J HEART FAIL, V15, P1082, DOI 10.1093/eurjhf/hft095	26	29	32	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2020	324	19					1948	1956		10.1001/jama.2020.19378	http://dx.doi.org/10.1001/jama.2020.19378			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB0RP	33201202	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000596035800015
J	Biondi, S; Mazza, C; Orru, G; Monaro, M; Ferracuti, S; Ricci, E; Di Domenico, A; Roma, P				Biondi, Silvia; Mazza, Cristina; Orru, Graziella; Monaro, Merylin; Ferracuti, Stefano; Ricci, Eleonora; Di Domenico, Alberto; Roma, Paolo			Interrogative suggestibility in the elderly	PLOS ONE			English	Article							MINI-MENTAL-STATE; MEMORY FUNCTIONING QUESTIONNAIRE; GUDJONSSON SUGGESTIBILITY; SELF-ESTEEM; SOCIAL DESIRABILITY; WORRY QUESTIONNAIRE; AGE-DIFFERENCES; OLDER-ADULTS; SCALE; ANXIETY	Interrogative suggestibility (IS) describes the extent to which an individual behavioral response is affected by messages communicated during formal questioning within a closed social interaction. The present study aimed at improving knowledge about IS in the elderly (aged 65 years and older), in particular about its association with both emotive/affective and cognitive variables. The sample (N = 172) was divided into three groups on the basis of age: late adult (aged 55-64, N = 59), young elderly (aged 65-74, N = 63), and elderly (aged 75 and older, N = 50). Cognitive (i.e., Kaufman Brief Intelligence Test-2, Rey Auditory Verbal Learning Test), emotive/affective (i.e., Rosenberg Self-Esteem Scale, Marlowe-Crowne Social Desirability Scale, Penn State Worry Questionnaire) and suggestibility measures (i.e., Gudjonsson Suggestibility Scale-2) were administered. In order to identify differences and associations between groups in IS, cognitive and emotive/affective variables, ANOVAs tests and Pearson's correlations were run. Furthermore, moderation analyses and hierarchical regression were set to determine whether age, cognitive and emotive/affective variables predicted IS components (i.e., Yield and Shift). Finally, machine learning models were developed to highlight the best strategy for classifying elderly subjects with high suggestibility. The results corroborated the significant link between IS and age, showing that elderly participants had the worst performance on all suggestibility indexes. Age was also the most important predictor of both Yield and Shift. Results also confirmed the important role of non-verbal intelligence and memory impairment in explaining IS dimensions, showing that these associations were stronger in young elderly and elderly groups. Implications about interrogative procedures with older adults were discussed.	[Biondi, Silvia; Ferracuti, Stefano; Ricci, Eleonora; Roma, Paolo] Sapienza Univ Rome, Fac Med & Dent, Dept Human Neurosci, Rome, Italy; [Mazza, Cristina] G dAnnunzio Univ Chieti Pescara, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Orru, Graziella] Univ Pisa, Dept Surg Med Mol & Crit Area Pathol, Pisa, Italy; [Monaro, Merylin] Univ Padua, Dept Gen Psychol, Padua, Italy; [Di Domenico, Alberto] G dAnnunzio Univ Chieti Pescara, Dept Psychol Hlth & Terr Sci, Chieti, Italy	Sapienza University Rome; G d'Annunzio University of Chieti-Pescara; University of Pisa; University of Padua; G d'Annunzio University of Chieti-Pescara	Roma, P (corresponding author), Sapienza Univ Rome, Fac Med & Dent, Dept Human Neurosci, Rome, Italy.	paolo.roma@uniroma1.it	Di Domenico, Alberto/AIB-7965-2022; Ricci, Eleonora/HJG-5726-2022; Monaro, Merylin/AAM-3066-2021; Ferracuti, Stefano/K-8437-2012	Di Domenico, Alberto/0000-0002-9962-2891; Monaro, Merylin/0000-0001-5598-691X; Ricci, Eleonora/0000-0003-0591-3389; Biondi, Silvia/0000-0001-5862-1799; Ferracuti, Stefano/0000-0003-1150-1460				Bain S. A., 2000, LEGAL CRIMINOL PSYCH, V5, P123, DOI DOI 10.1348/135532500168029; Balota D.A., 2000, OXFORD HDB MEMORY, P395; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bartlett JC, 2007, HDB EYEWITNESS PSYCH, P309; Baxter JS, 2003, PERS INDIV DIFFER, V35, P1285, DOI 10.1016/S0191-8869(02)00349-5; Behar E, 2003, J BEHAV THER EXP PSY, V34, P25, DOI 10.1016/S0005-7916(03)00004-1; Bonifacci P., 2016, KAUFMAN BRIEF INTELL, V2nd; Brown TA, 2003, BEHAV RES THER, V41, P1411, DOI 10.1016/S0005-7967(03)00059-7; Bruck M, 1999, ANNU REV PSYCHOL, V50, P419, DOI 10.1146/annurev.psych.50.1.419; Buddhinath G., 2006, SIMPLE ENHANCEMENT O; Caltagirone C, 1995, ARCH PSICOL NEUROL P, V55, P61; CECI SJ, 1993, PSYCHOL BULL, V113, P403, DOI 10.1037/0033-2909.113.3.403; CLARE ICH, 1994, BRIT J CLIN PSYCHOL, V33, P357, DOI 10.1111/j.2044-8260.1994.tb01132.x; Clark N. K., 1986, SOCIAL BEHAVIOUR, V1, P83; COHEN G, 1989, PSYCHOL AGING, V4, P10, DOI 10.1037/0882-7974.4.1.10; Coin A, 2009, ARCH GERONTOL GERIAT, V49, P35, DOI 10.1016/j.archger.2009.09.010; Corwyn RF, 2000, J RES PERS, V34, P357, DOI 10.1006/jrpe.2000.2291; Costa, 1989, NEO PI NEO FFI MANUA; Costa PT, 1992, REVISED NEO PERSONAL; Coxon P, 1997, APPL COGNITIVE PSYCH, V11, P415, DOI 10.1002/(SICI)1099-0720(199710)11:5<415::AID-ACP469>3.0.CO;2-A; CROOK TH, 1990, PSYCHOL AGING, V5, P48, DOI 10.1037/0882-7974.5.1.48; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Curci A, 2014, MANUALE USO; DANIELSDOTTIR G, 1993, PERS INDIV DIFFER, V14, P499, DOI 10.1016/0191-8869(93)90323-U; Drake K, 2011, PSYCHOL CRIME LAW, V17, P677, DOI 10.1080/10683160903511967; Drake KE, 2008, LEGAL CRIMINOL PSYCH, V13, P299, DOI 10.1348/135532507X209981; DUKALA K, 2013, J GERONTOL B-PSYCHOL, V69, P348; Fastame MC, 2012, CLIN GERONTOLOGIST, V35, P239, DOI 10.1080/07317115.2012.660411; Fastame MC, 2015, QUAL LIFE RES, V24, P241, DOI 10.1007/s11136-014-0750-4; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gignac GE, 2006, APPL COGNITIVE PSYCH, V20, P617, DOI 10.1002/acp.1213; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GILEWSKI MJ, 1988, PSYCHOPHARMACOL BULL, V24, P665; Gudjonsson G., 2018, PSYCHOL FALSE CONFES, DOI [10.1002/9781119315636, DOI 10.1002/9781119315636]; Gudjonsson G.H., 2003, PSYCHOL INTERROGATIO; Gudjonsson G.H., 1997, GUDJONSSON SUGGESTIB; GUDJONSSON GH, 1983, BRIT J PSYCHIAT, V142, P35, DOI 10.1192/bjp.142.1.35; GUDJONSSON GH, 1984, PERS INDIV DIFFER, V5, P425, DOI 10.1016/0191-8869(84)90007-2; Gudjonsson GH, 2003, LEGAL CRIMINOL PSYCH, V8, P241, DOI 10.1348/135532503322363013; GUDJONSSON GH, 1984, PERS INDIV DIFFER, V5, P303, DOI 10.1016/0191-8869(84)90069-2; GUDJONSSON GH, 1987, BRIT J CLIN PSYCHOL, V26, P215, DOI 10.1111/j.2044-8260.1987.tb01348.x; GUDJONSSON GH, 1987, SOC BEHAV, V2, P29; GUDJONSSON GH, 1992, PERS INDIV DIFFER, V13, P479, DOI 10.1016/0191-8869(92)90077-3; GUDJONSSON GH, 1988, BRIT J CLIN PSYCHOL, V27, P159, DOI 10.1111/j.2044-8260.1988.tb00764.x; GUDJONSSON GH, 1984, J FORENSIC SCI SOC, V24, P99, DOI 10.1016/S0015-7368(84)72302-4; GUDJONSSON GH, 1989, PERS INDIV DIFFER, V10, P535, DOI 10.1016/0191-8869(89)90035-4; Gudjonsson GH, 2014, GSS GUDJONSSON SUGGE; Hall M. A., 1999, Proceedings of the Twelfth International Florida AI Research Society Conference, P235; Hayes A. F., 2013, INTRO MEDIATION MODE; Hayes AF, 2018, COMMUN MONOGR, V85, P4, DOI 10.1080/03637751.2017.1352100; Hilgard ER, 1991, HUMAN SUGGESTIBILITY, P37; Holliday RE, 2012, PSYCHOL AGING, V27, P1191, DOI 10.1037/a0022031; Kaufman A., 2004, KAUFMAN BRIEF INTELL, V2nd ed; Loftus Elizabeth F, 1996, EYEWITNESS TESTIMONY; Luo L, 2008, CAN J PSYCHIAT, V53, P346, DOI 10.1177/070674370805300603; Martino GD, 2018, IEEE T NEUR NET LEAR, V29, P3270, DOI 10.1109/TNNLS.2017.2705694; Mazza C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61636-5; Mazza C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0227113; Mazza C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00389; McDougall W, 2001, INTRO SOCIAL PSYCHOL, P74; McGroarty A, 2013, LEGAL CRIMINOL PSYCH, V18, P287, DOI 10.1111/j.2044-8333.2012.02046.x; McGroarty A, 2009, PERS INDIV DIFFER, V47, P642, DOI 10.1016/j.paid.2009.05.024; MEYER TJ, 1990, BEHAV RES THER, V28, P487, DOI 10.1016/0005-7967(90)90135-6; Mitchell KJ, 2003, APPL COGNITIVE PSYCH, V17, P107, DOI 10.1002/acp.857; Morani S., 1999, PSICOTERAPIA COGNITI, V5, P195; Mueller-Johnson K, 2004, APPL COGNITIVE PSYCH, V18, P1109, DOI 10.1002/acp.1078; Mueller-Johnson K, 2007, BEHAV SCI LAW, V25, P355, DOI 10.1002/bsl.765; Navarin N, 2017, BIOINFORMATICS, V33, P2642, DOI 10.1093/bioinformatics/btx295; Orru G, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02970; Pace G, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01650; Pangman VC, 2000, APPL NURS RES, V13, P209, DOI 10.1053/apnr.2000.9231; Phillips LH, 2006, AGING MENT HEALTH, V10, P250, DOI 10.1080/13607860500310385; Piernik M, 2016, KNOWL INF SYST, V46, P185, DOI 10.1007/s10115-015-0820-0; Polak M, 2016, CURR PSYCHOL, V35, P1, DOI 10.1007/s12144-015-9352-8; Polczyk R, 2004, APPL COGNITIVE PSYCH, V18, P1097, DOI 10.1002/acp.1073; Polczyk R, 2005, PERS INDIV DIFFER, V38, P177, DOI 10.1016/j.paid.2004.03.018; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Prezza M., 1997, BPA APPL PSICOL B, V223, P35; Rey A., 1964, EXAMEN CLINIQUE PSYC; Richardson G, 2004, PERS INDIV DIFFER, V36, P485, DOI 10.1016/S0191-8869(03)00263-0; RICHARDSON G, 1995, J ADOLESCENCE, V18, P211, DOI 10.1006/jado.1995.1014; Ridley AM, 2006, MEMORY, V14, P37, DOI 10.1080/09658210444000494; Ridley AM, 2002, APPL COGNITIVE PSYCH, V16, P547, DOI 10.1002/acp.813; Ridley AM, 2013, SUGGESTIBILITY LEGAL, P85, DOI [10.1002/9781118432907, DOI 10.1002/9781118432907]; Ridley AM, 2013, SUGGESTIBILITY LEGAL; Roma P, 2011, PERS INDIV DIFFER, V51, P488, DOI 10.1016/j.paid.2011.05.003; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1515/9781400876136; Sarason I.G., 1988, ANXIETY RES, V1, P3, DOI [https://doi.org/10.1080/10615808808248215, DOI 10.1080/10615808808248215]; Sartori, 2016, P5 MED JUSTICE, P330, DOI [10.1007/978-3-319-67092-8_21, DOI 10.1007/978-3-319-67092-8_21]; Sidis B, 1998, PSYCHOL SUGGESTION, P15, DOI [10.1095/biolreprod59.4.807, DOI 10.1095/BIOLREPROD59.4.807]; SIGURDSSON E, 1994, NORD J PSYCHIAT, V48, P443, DOI 10.3109/08039489409078163; SINGH KK, 1992, J ADOLESCENCE, V15, P155, DOI 10.1016/0140-1971(92)90044-6; SINGH KK, 1984, PERS INDIV DIFFER, V5, P203, DOI 10.1016/0191-8869(84)90052-7; SMITH P, 1995, PERS INDIV DIFFER, V19, P517, DOI 10.1016/0191-8869(95)00085-K; Tuijl JP, 2012, INT J GERIATR PSYCH, V27, P755, DOI 10.1002/gps.2776; Tully B., 1984, POLICE INTERVIEWING; United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POPULATION PRO, P1; WARREN A, 1991, LAW HUMAN BEHAV, V15, P273, DOI 10.1007/BF01061713; Wechsler D., 1981, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wells Gary L, 2006, Psychol Sci Public Interest, V7, P45, DOI 10.1111/j.1529-1006.2006.00027.x; Winterling D, 1986, SENILE DEMENTIAS EAR, P482; Wolfradt U, 1998, PERS INDIV DIFFER, V25, P425, DOI 10.1016/S0191-8869(98)00023-3; Yarkoni T, 2017, PERSPECT PSYCHOL SCI, V12, P1100, DOI 10.1177/1745691617693393; Young K, 2003, PERS INDIV DIFFER, V35, P31, DOI 10.1016/S0191-8869(02)00138-1	105	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2020	15	11							e0241353	10.1371/journal.pone.0241353	http://dx.doi.org/10.1371/journal.pone.0241353			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ9VP	33196666	Green Published, gold			2023-01-03	WOS:000595266800037
J	Self, WH; Semler, MW; Leither, LM; Casey, JD; Angus, DC; Brower, RG; Chang, SY; Collins, SP; Eppensteiner, JC; Filbin, MR; Files, DC; Gibbs, KW; Ginde, AA; Gong, MN; Harrell, FE; Hayden, DL; Hough, CL; Johnson, NJ; Khan, A; Lindsell, CJ; Matthay, MA; Moss, M; Park, PK; Rice, TW; Robinson, BRH; Schoenfeld, DA; Shapiro, NI; Steingrub, JS; Ulysse, CA; Weissman, A; Yealy, DM; Thompson, BT; Brown, SM				Self, Wesley H.; Semler, Matthew W.; Leither, Lindsay M.; Casey, Jonathan D.; Angus, Derek C.; Brower, Roy G.; Chang, Steven Y.; Collins, Sean P.; Eppensteiner, John C.; Filbin, Michael R.; Files, D. Clark; Gibbs, Kevin W.; Ginde, Adit A.; Gong, Michelle N.; Harrell, Frank E.; Hayden, Douglas L.; Hough, Catherine L.; Johnson, Nicholas J.; Khan, Akram; Lindsell, Christopher J.; Matthay, Michael A.; Moss, Marc; Park, Pauline K.; Rice, Todd W.; Robinson, Bryce R. H.; Schoenfeld, David A.; Shapiro, Nathan, I; Steingrub, Jay S.; Ulysse, Christine A.; Weissman, Alexandra; Yealy, Donald M.; Thompson, B. Taylor; Brown, Samuel M.		Natl Heart Lung Blood Inst PETAL C	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHLOROQUINE	Importance Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. Objective To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. Design, Setting, and Participants This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. Interventions Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237). Main Outcomes and Measures The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality. Results Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). Conclusions and Relevance Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.	[Self, Wesley H.; Collins, Sean P.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,Oxford House 312, Nashville, TN 37232 USA; [Semler, Matthew W.; Casey, Jonathan D.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Leither, Lindsay M.; Brown, Samuel M.] Intermt Med Ctr, Div Pulm & Crit Care Med, Murray, KY USA; [Leither, Lindsay M.; Brown, Samuel M.] Univ Utah, Salt Lake City, UT USA; [Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Brower, Roy G.] Johns Hopkins Univ, Sch Med, Dept Med, Pulm & Crit Care Med, Baltimore, MD 21205 USA; [Chang, Steven Y.] Univ Calif Los Angeles, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Div Pulm & Crit Care Med,Dept Med, Los Angeles, CA 90095 USA; [Eppensteiner, John C.] Duke Univ, Dept Surg, Durham, NC USA; [Filbin, Michael R.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Files, D. Clark; Gibbs, Kevin W.] Wake Forest Sch Med, Dept Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27101 USA; [Ginde, Adit A.] Univ Colorado, Dept Emergency Med, Sch Med, Aurora, CO USA; [Gong, Michelle N.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Epidemiol & Populat Hlth, Bronx, NY 10467 USA; [Harrell, Frank E.; Lindsell, Christopher J.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Hayden, Douglas L.; Schoenfeld, David A.; Ulysse, Christine A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Hough, Catherine L.; Khan, Akram] Oregon Hlth & Sci Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA; [Johnson, Nicholas J.] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA; [Johnson, Nicholas J.] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; [Matthay, Michael A.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA USA; [Moss, Marc] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Park, Pauline K.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Robinson, Bryce R. H.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Shapiro, Nathan, I] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Shapiro, Nathan, I] Harvard Med Sch, Boston, MA 02115 USA; [Steingrub, Jay S.] Univ Massachusetts, Med Sch Baystate, Dept Med, Springfield, MA USA; [Weissman, Alexandra; Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02114 USA	Vanderbilt University; Vanderbilt University; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ronald Reagan UCLA Medical Center; Duke University; Harvard University; Massachusetts General Hospital; Wake Forest University; University of Colorado System; University of Colorado Anschutz Medical Campus; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Vanderbilt University; Harvard University; Massachusetts General Hospital; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Massachusetts System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital	Self, WH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Emergency Med, 1313 21st Ave S,Oxford House 312, Nashville, TN 37232 USA.	wesley.self@vumc.org	Chenoweth, James/AAN-9965-2021; Casey, Jonathan/AAG-1211-2020; Leither, Lindsay/ABG-4892-2020; Khan, Akram/AAB-6446-2022; Brown, Samuel/E-6846-2015	Casey, Jonathan/0000-0002-0977-290X; Khan, Akram/0000-0003-3091-632X; Yee, Kimberly/0000-0002-3703-1367; Douglas, Ivor/0000-0002-4541-1431; Morse, Caryn/0000-0002-1177-4365; Borg, Bryan/0000-0001-7353-2217; Brown, Samuel/0000-0003-1206-6261; Files, Daniel Clark/0000-0002-1595-4080; O'Mara, Thomas/0000-0002-5310-0254; Huebinger, Ryan/0000-0002-9448-5744; , Neil/0000-0002-0922-8824; Gibbs, Kevin/0000-0002-5272-2289; Rogers, Angela/0000-0001-6969-6200; Collins, Sean/0000-0002-2305-9836	NHLBI [3U01HL123009-06S1, U01HL123009, U01HL122998, U01HL123018, U01HL123023, U01HL123008, U01HL123031, U01HL123004, U01HL123027, U01HL123010, U01HL123033, U01HL122989, U01HL123022, U01HL123020]; NCATS [5UL1TR002243]; Harvard Catalyst/Harvard Clinical and Translational Science Center (NCATS, NIH) [UL1TR001102, UL1TR002541-01]	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Harvard Catalyst/Harvard Clinical and Translational Science Center (NCATS, NIH)	This study was supported by grants from the NHLBI (3U01HL123009-06S1, U01HL123009, U01HL122998, U01HL123018, U01HL123023, U01HL123008, U01HL123031, U01HL123004, U01HL123027, U01HL123010, U01HL123033, U01HL122989, U01HL123022, and U01HL123020). The REDCap data tools used for this study were supported by a grant from NCATS (5UL1TR002243). The work at Massachusetts General Hospital was supported in part by the Harvard Catalyst/Harvard Clinical and Translational Science Center (NCATS, NIH awards UL1TR001102 and UL1TR002541-01). Sandoz, a Novartis division, supplied the hydroxychloroquine and placebo used in this trial.	Azoulay E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03194-w; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478; Casey JD, 2020, ANN AM THORAC SOC, V17, P1144, DOI 10.1513/AnnalsATS.202005-478SD; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; COVID-19 Treatment Guidelines Panel, COR DIS 2019 COVID 1; Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815; FDA, FACT SHEET HEALTHC P; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Food and Drug Administration (FDA), LETT REV EUA CHLOR P; Food and Drug Administration (FDA), REQ EM US AUTH US CH; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3; Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2022926, DOI 10.1056/NEJM0A2022926]; Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8; Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4; Massachusetts General Hospital, MASS GEN HOSP COVID; Medicines and Healthcare Products Regulatory Agency, MHRA SUSP RECR COVID; Mercuro Nicholas J, 2020, JAMA Cardiol, V5, P1036, DOI 10.1001/jamacardio.2020.1834; RECOVERY Investigators, 2020, NO CLIN BEN US HYDR; Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521; Rubin EJ, 2020, NEW ENGL J MED, V382, P2461, DOI 10.1056/NEJMe2015903; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Vanderbilt University Medical Center, CLIN REC TREATM COVI; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WHO, WHO R D BLUEPR NOV C; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; World Health Organisation (WHO), WHO COR DIS COVID 19; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP; Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982	36	204	208	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2020	324	21					2165	2176		10.1001/jama.2020.22240	http://dx.doi.org/10.1001/jama.2020.22240		NOV 2020	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA4NB	33165621	Bronze, Green Published			2023-01-03	WOS:000592279600002
J	Ogura, Y; Kakehashi, C; Yoshihara, T; Kurosaka, M; Kakigi, R; Higashida, K; Fujiwara, SE; Akema, T; Funabashi, T				Ogura, Yuji; Kakehashi, Chiaki; Yoshihara, Toshinori; Kurosaka, Mitsutoshi; Kakigi, Ryo; Higashida, Kazuhiko; Fujiwara, Sei-Etsu; Akema, Tatsuo; Funabashi, Toshiya			Ketogenic diet feeding improves aerobic metabolism property in extensor digitorum longus muscle of sedentary male rats	PLOS ONE			English	Article							SKELETAL-MUSCLE; LOW-CARBOHYDRATE; GENE-EXPRESSION; EXERCISE; MITOCHONDRIAL; ADAPTATIONS; PERFORMANCE; INDUCTION; ALPHA; FAT	Recent studies of the ketogenic diet, an extremely high-fat diet with extremely low carbohydrates, suggest that it changes the energy metabolism properties of skeletal muscle. However, ketogenic diet effects on muscle metabolic characteristics are diverse and sometimes countervailing. Furthermore, ketogenic diet effects on skeletal muscle performance are unknown. After male Wistar rats (8 weeks of age) were assigned randomly to a control group (CON) and a ketogenic diet group (KD), they were fed for 4 weeks respectively with a control diet (10% fat, 10% protein, 80% carbohydrate) and a ketogenic diet (90% fat, 10% protein, 0% carbohydrate). After the 4-week feeding period, the extensor digitorum longus (EDL) muscle was evaluated ex vivo for twitch force, tetanic force, and fatigue. We also analyzed the myosin heavy chain composition, protein expression of metabolic enzymes and regulatory factors, and citrate synthase activity. No significant difference was found between CON and KD in twitch or tetanic forces or muscle fatigue. However, the KD citrate synthase activity and the protein expression of Sema3A, citrate synthase, succinate dehydrogenase, cytochrome c oxidase subunit 4, and 3-hydroxyacyl-CoA dehydrogenase were significantly higher than those of CON. Moreover, a myosin heavy chain shift occurred from type IIb to IIx in KD. These results demonstrated that the 4-week ketogenic diet improves skeletal muscle aerobic capacity without obstructing muscle contractile function in sedentary male rats and suggest involvement of Sema3A in the myosin heavy chain shift of EDL muscle.	[Ogura, Yuji; Kakehashi, Chiaki; Kurosaka, Mitsutoshi; Fujiwara, Sei-Etsu; Akema, Tatsuo; Funabashi, Toshiya] St Marianna Univ, Dept Physiol, Sch Med, Miyamae Ku, Kawasaki, Kanagawa, Japan; [Yoshihara, Toshinori] Juntendo Univ, Grad Sch Hlth & Sports Sci, Inzai, Chiba, Japan; [Kakigi, Ryo] Josai Int Univ, Fac Management & Informat Sci, Togane, Chiba, Japan; [Higashida, Kazuhiko] Univ Shiga Prefecture, Dept Nutr, Hikone, Shiga, Japan	Saint Marianna University; Juntendo University; University Shiga Prefecture	Ogura, Y (corresponding author), St Marianna Univ, Dept Physiol, Sch Med, Miyamae Ku, Kawasaki, Kanagawa, Japan.	yuji_ogura@marianna-u.ac.jp		Ogura, Yuji/0000-0002-3711-4947	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) [24650334, 18K17767]	Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a Grant-in-Aid for Exploratory Research (24650334 to CK) and by a Grant-in-Aid for Scientific Research (18K17767 to CK) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT).	Al-Khalifa A, 2011, EXP TOXICOL PATHOL, V63, P663, DOI 10.1016/j.etp.2010.05.008; Al-Khalifa A, 2009, NUTRITION, V25, P1177, DOI 10.1016/j.nut.2009.04.004; [Anonymous], 2014, REG ANESTH PAIN MED; [Anonymous], 1986, AM J PHYSL, V250, pH822; Baranano Kristin W, 2008, Curr Treat Options Neurol, V10, P410, DOI 10.1007/s11940-008-0043-8; Beckett TL, 2013, BRAIN RES, V1505, P61, DOI 10.1016/j.brainres.2013.01.046; Bielohuby M, 2011, ENDOCRINOLOGY, V152, P1948, DOI 10.1210/en.2010-1423; Bielohuby M, 2011, AM J PHYSIOL-ENDOC M, V300, pE65, DOI 10.1152/ajpendo.00478.2010; Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273; Brambilla A, 2014, JIMD REP, V17, P91, DOI 10.1007/8904_2014_343; Branco AF, 2016, EUR J CLIN INVEST, V46, P285, DOI 10.1111/eci.12591; Crumbley C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033804; Dashti HM, 2007, MOL CELL BIOCHEM, V302, P249, DOI 10.1007/s11010-007-9448-z; Demirel HA, 1999, J APPL PHYSIOL, V86, P1002, DOI 10.1152/jappl.1999.86.3.1002; Egawa T, 2011, ACTA PHYSIOL, V201, P227, DOI 10.1111/j.1748-1716.2010.02169.x; Ellenbroek JH, 2014, AM J PHYSIOL-ENDOC M, V306, pE552, DOI 10.1152/ajpendo.00453.2013; Francini-Pesenti Francesco, 2019, Acta Myol, V38, P17; Freeman John M, 2010, Adv Pediatr, V57, P315, DOI 10.1016/j.yapd.2010.08.003; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Fukushima A, 2015, BRAIN RES, V1622, P36, DOI 10.1016/j.brainres.2015.06.016; Hennebry A, 2009, AM J PHYSIOL-CELL PH, V296, pC525, DOI 10.1152/ajpcell.00259.2007; Hussain TA, 2012, NUTRITION, V28, P1016, DOI 10.1016/j.nut.2012.01.016; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; Kephart WC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091019; Kramer DK, 2006, ACTA PHYSIOL, V188, P207, DOI 10.1111/j.1748-1716.2006.01620.x; Krysciak K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195704; Kurosaka M, 2017, J CELL PHYSIOL, V232, P1114, DOI 10.1002/jcp.25574; Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; MacDougall JD, 1998, J APPL PHYSIOL, V84, P2138, DOI 10.1152/jappl.1998.84.6.2138; McAinch AJ, 2003, OBES RES, V11, P1471, DOI 10.1038/oby.2003.197; McClelland GB, 2004, BBA-MOL BASIS DIS, V1688, P86, DOI 10.1016/j.bbadis.2003.10.006; Meira ID, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00005; Miotto PM, 2018, DIABETES, V67, P2199, DOI 10.2337/db18-0417; Miyamoto-Mikami E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35115-x; Moreno CL, 2017, MOL CELL ENDOCRINOL, V455, P33, DOI 10.1016/j.mce.2016.11.013; Mortensen OH, 2006, AM J PHYSIOL-ENDOC M, V291, pE807, DOI 10.1152/ajpendo.00591.2005; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Ogura Y, 2009, ACTA PHYSIOL, V196, P341, DOI 10.1111/j.1748-1716.2008.01945.x; Ogura Y, 2008, BIOCHEM BIOPH RES CO, V372, P584, DOI 10.1016/j.bbrc.2008.05.059; Parker BA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082247; Parry HA, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00975; Poplawski MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018604; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Rivero JLL, 1999, HISTOCHEM CELL BIOL, V111, P277, DOI 10.1007/s004180050358; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Romero-Calvo I, 2010, ANAL BIOCHEM, V401, P318, DOI 10.1016/j.ab.2010.02.036; Shimizu K, 2018, NUTR RES, V60, P77, DOI 10.1016/j.nutres.2018.09.004; Skripnikova E., 2017, AM J PHYSL REGUL INT, V312, pR412; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Stump CS, 2006, ANN MED, V38, P389, DOI 10.1080/07853890600888413; Tanner CB, 2013, AM J PHYSIOL-ENDOC M, V305, pE1018, DOI 10.1152/ajpendo.00227.2013; Tatsumi R, 2017, STEM CELLS, V35, P1815, DOI 10.1002/stem.2639; Vamecq J, 2005, PROG NEUROBIOL, V75, P1, DOI 10.1016/j.pneurobio.2004.11.003; Volek JS, 2016, METABOLISM, V65, P100, DOI 10.1016/j.metabol.2015.10.028; Wheless JW, 2008, EPILEPSIA, V49, P3, DOI 10.1111/j.1528-1167.2008.01821.x; Yamakuchi M, 2000, FEBS LETT, V477, P135, DOI 10.1016/S0014-5793(00)01715-4; Yang HJ, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00585; 2016, AM J PHYSL LUNG CELL, V311, pL970	60	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2020	15	10							e0241382	10.1371/journal.pone.0241382	http://dx.doi.org/10.1371/journal.pone.0241382			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8VN	33125406	Green Published, gold			2023-01-03	WOS:000588368900038
J	Romero, MM; Cespedes, AA; Sahuquillo, MTT; Zamora, EBC; Ballesteros, CG; Alfaro, VSF; Bru, RL; Utiel, ML; Cifuentes, SC; Longobardo, LMP; Romero, AM; Carmona, LP; Garcia, BG; Fernandez-Rius, AP; Corcoles, RA; Garcia, BR; Rizos, LR; Jurado, PMS; Ortiz, ML; Nunez, PA; Garcia, AN; Garcia, MFR; Molina, RG; Cazalla, JDE; Moreno, JO; Abizanda, P				Mas Romero, Marta; Avendano Cespedes, Almudena; Tabernero Sahuquillo, Maria Teresa; Cortes Zamora, Elisa Belen; Gomez Ballesteros, Cristina; Sanchez-Flor Alfaro, Victoria; Lopez Bru, Rita; Lopez Utiel, Melisa; Celaya Cifuentes, Sara; Pena Longobardo, Luz Maria; Murillo Romero, Antonio; Plaza Carmona, Laura; Gil Garcia, Borja; Perez Fernandez-Rius, Ana; Alcantud Corcoles, Ruben; Roldan Garcia, Belen; Romero Rizos, Luis; Sanchez Jurado, Pedro Manuel; Leon Ortiz, Matilde; Atienzar Nunez, Pilar; Nogueron Garcia, Alicia; Ruiz Garcia, Maria Fe; Garcia Molina, Rafael; Estrella Cazalla, Juan de Dios; Oliva Moreno, Juan; Abizanda, Pedro			COVID-19 outbreak in long-term care facilities from Spain. Many lessons to learn	PLOS ONE			English	Article							FRAILTY; MULTIMORBIDITY; DISABILITY; VALIDATION; MORTALITY; PEOPLE	Background/Objectives To analyze mortality, costs, residents and personnel characteristics, in six long-term care facilities (LTCF) during the outbreak of COVID-19 in Spain. Design Epidemiological study. Setting Six open LTCFs in Albacete (Spain). Participants 198 residents and 190 workers from LTCF A were included, between 2020 March 6 and April 5. Epidemiological data were also collected from six LTCFs of Albacete for the same period of time, including 1,084 residents. Measurements Baseline demographic, clinical, functional, cognitive and nutritional variables were collected. 1-month and 3-month mortality was determined, excess mortality was calculated, and costs associated with the pandemics were analyzed. Results The pooled mortality rate for the first month and first three months of the outbreak were 15.3% and 28.0%, and the pooled excess mortality for these periods were 564% and 315% respectively. In facility A, the percentage of probable COVID-19 infected residents were 33.6%. Probable infected patients were older, frail, and with a worse functional situation than those without COVID-19. The most common symptoms were fever, cough and dyspnea. 25 residents were transferred to the emergency department, 21 were hospitalized, and 54 were moved to the facility medical unit. Mortality was higher upon male older residents, with worse functionality, and higher comorbidity. During the first month of the outbreak, 65 (24.6%) workers leaved, mainly with COVID-19 symptoms, and 69 new workers were contracted. The mean number of days of leave was 19.2. Costs associated with the COVID-19 in facility A were estimated at euro 276,281/month, mostly caused by resident hospitalizations, leaves of workers, staff replacement, and interventions of healthcare professionals. Conclusion The COVID-19 pandemic posed residents at high mortality risk, mainly in those older, frail and with worse functional status. Personal and economic costs were high.	[Mas Romero, Marta; Avendano Cespedes, Almudena; Tabernero Sahuquillo, Maria Teresa; Cortes Zamora, Elisa Belen; Gomez Ballesteros, Cristina; Sanchez-Flor Alfaro, Victoria; Lopez Bru, Rita; Lopez Utiel, Melisa; Celaya Cifuentes, Sara; Plaza Carmona, Laura; Gil Garcia, Borja; Perez Fernandez-Rius, Ana; Alcantud Corcoles, Ruben; Roldan Garcia, Belen; Romero Rizos, Luis; Sanchez Jurado, Pedro Manuel; Leon Ortiz, Matilde; Atienzar Nunez, Pilar; Nogueron Garcia, Alicia; Garcia Molina, Rafael; Estrella Cazalla, Juan de Dios; Abizanda, Pedro] Complejo Hosp Univ Albacete, Dept Geriatr, Albacete, Spain; [Avendano Cespedes, Almudena; Romero Rizos, Luis; Sanchez Jurado, Pedro Manuel; Estrella Cazalla, Juan de Dios; Abizanda, Pedro] Minist Econ & Competitividad, CIBERFES, Madrid, Spain; [Pena Longobardo, Luz Maria; Oliva Moreno, Juan] Univ Castilla La Mancha, Dept Econ Anal & Finance, Toledo, Spain; [Murillo Romero, Antonio] Complejo Hosp Univ Albacete, Long Term Care Facil Coordinat, Albacete, Spain; [Ruiz Garcia, Maria Fe; Estrella Cazalla, Juan de Dios] Vasco Nunez de Balboa Facil, Albacete, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERFES; Spanish Ministry of Economy & Competitiveness; Universidad de Castilla-La Mancha	Abizanda, P (corresponding author), Complejo Hosp Univ Albacete, Dept Geriatr, Albacete, Spain.; Abizanda, P (corresponding author), Minist Econ & Competitividad, CIBERFES, Madrid, Spain.	pabinzanda@sescam.jccm.es	Alcantud Córcoles, Rubén/AAG-5376-2021	Alcantud Córcoles, Rubén/0000-0002-5773-0835; Ariza-Zafra, Gabriel/0000-0001-9171-5535; Gil Garcia, Borja/0000-0003-2959-1425; MAS ROMERO, MARTA/0000-0003-0553-9278; Abizanda Soler, Pedro/0000-0002-4707-2963; Roldan, Belen/0000-0002-9634-2958; Leon Ortiz, Matilde/0000-0002-2180-3641; Gomez Ballesteros, Cristina/0000-0003-4639-2882	CIBERFES, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana; Una Manera de hacer Europa [CB16/10/00408]; Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana [COV20/00004]; Fondo Europeo de Desarrollo Regional FEDER	CIBERFES, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana; Una Manera de hacer Europa; Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana; Fondo Europeo de Desarrollo Regional FEDER(European CommissionSpanish Government)	We declare that this work was supported by CIBERFES, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana. Ayuda cofinanciada por el Fondo Europeo de Desarrollo Regional FEDER. Una Manera de hacer Europa (Grant number CB16/10/00408), Grant received by PA, and by Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Espana (Grant number COV20/00004), Grant received by PA. The sponsor did not have any role in the study. There was no additional external funding received for this study.	Abbatecola AM, 2020, J NUTR HEALTH AGING, V24, P453, DOI 10.1007/s12603-020-1357-9; Abizanda P, 2014, J Nutr Health Aging, V18, P622, DOI 10.1007/s12603-014-0033-3; Abizanda P, 2017, J AM GERIATR SOC, V65, P2333, DOI 10.1111/jgs.15021; Abizanda P, 2013, MATURITAS, V74, P54, DOI 10.1016/j.maturitas.2012.09.018; Abrams HR, 2020, J AM GERIATR SOC, V68, P1653, DOI 10.1111/jgs.16661; Amer Geriatrics Soc, 2020, J AM GERIATR SOC, V68, P908, DOI 10.1111/jgs.16477; Centers for Disease Control and Prevent ion, COR DIS 2019 COVID 1; Centers for Medicare & Medicaid Services, GUID INF CONTR PREV; Cesari M, 2020, J NUTR HEALTH AGING, V24, P459, DOI 10.1007/s12603-020-1354-z; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chidambaram P, KAISER FAMILY FDN IS; CIOMS, 2016, INT ETH GUID HLTH RE; Comas-Herrera A., 2020, MORTALITY ASS COVID, P1; Grabowski DC, 2020, JAMA-J AM MED ASSOC, V324, P23, DOI 10.1001/jama.2020.8524; Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Hoogendijk EO, 2019, J AM MED DIR ASSOC, V20, P1105, DOI 10.1016/j.jamda.2019.01.129; Instituto Nacional de Estadistica (INE), ENC ESTR SAL; Kaiser MJ, 2009, J NUTR HEALTH AGING, V13, P782, DOI 10.1007/s12603-009-0214-7; Kunz R, 2020, SWISS MED WEEKLY, V150, DOI [10.4414/smw.2020.20235.eCollection2020Mar23, DOI 10.4414/SMW.2020.20235]; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125; Lloyd-Sherlock PG, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1164; MAHONEY F I, 1965, Md State Med J, V14, P61; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Ministry of Health Consumption and Social Welfare, 2017, EST WEIGHTS COSTS HO; Ministry of Health Government of Spain, 2020, COVID 19 ACT NUMB 18; Ministry of Health Government of Spain, 2020, B OF EST, V81, P26758; Morley JE, 2012, J NUTR HEALTH AGING, V16, P601, DOI 10.1007/s12603-012-0084-2; National Institute of Statistics, CONS PRIC IND; Stall NM, 2020, J AM GERIATR SOC, V68, P1376, DOI 10.1111/jgs.16625; Stineman MG, 2012, J AM GERIATR SOC, V60, P485, DOI 10.1111/j.1532-5415.2011.03867.x; Tan LF, 2020, J AM GERIATR SOC, V68, P942, DOI 10.1111/jgs.16447; WHO, COR DIS COVID 19 TEC; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	36	32	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0241030	10.1371/journal.pone.0241030	http://dx.doi.org/10.1371/journal.pone.0241030			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8WV	33108381	Green Published, gold			2023-01-03	WOS:000588372400025
J	Anbesse, ZK; Mega, TA; Tesfaye, BT; Negera, GZ				Anbesse, Zenebe Kano; Mega, Teshale Ayele; Tesfaye, Behailu Terefe; Negera, Getandale Zeleke			Early readmission and its predictors among patients treated for acute exacerbations of chronic obstructive respiratory disease in Ethiopia: A prospective cohort study	PLOS ONE			English	Article							RISK-FACTORS; PULMONARY-DISEASE; MANAGEMENT PROGRAM; ASTHMA; COPD; PREVALENCE; FREQUENCY; THERAPY; DECLINE; AFRICA	Background Significant numbers of chronic obstructive respiratory disease patients are readmitted for Acute Exacerbation (AE) within 30 days of discharge. And these early readmissions have serious clinical and socioeconomic consequences. The objective of our study was to determine the rate of readmission within 30 days of discharge and it's predictors among patients treated for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Methods A prospective cohort study involving 130 patients (asthma = 59, COPD = 71) was conducted from April-September, 2019, in Jimma Medical Center (JMC), South-West Ethiopia. Socio-demographic, clinical, laboratory, and drug-related data were recorded at admission and during hospital stay. Cox regression analysis was performed to identify risk factors for readmissions following an AE of asthma and COPD. Results During the study period, 130 (male, 78(60%)) patients were admitted with AE of asthma and COPD. The median age was 59(IQR, 50-70) years. Of 130 patients, 21(18.10%) had a new AE of asthma and COPD that required hospitalization in the 30 days after discharge. The overall median survival time to 30-day readmission was 20 days (IQR, 16-29). Multivariate analysis revealed prolonged use of oxygen therapy (AHR = 4.972, 95% CI [1.041-23.736] and frequent hospital admissions (AHR = 11.482 [1.308-100.793]) to be independent risk factors for early readmissions. Conclusion Early hospital readmission rates for AE of asthma and COPD were alarmingly high. Frequent hospital admission and long-term oxygen therapy during hospital stay were independent predictors of 30-day readmission.	[Anbesse, Zenebe Kano] Haramaya Univ, Coll Hlth & Med Sci, Sch Pharm, Clin Pharm Unit, Harar, Ethiopia; [Mega, Teshale Ayele; Tesfaye, Behailu Terefe; Negera, Getandale Zeleke] Jimma Univ, Sch Pharm, Inst Hlth, Dept Clin Pharm, Jimma, Ethiopia	Haramaya University; Jimma University	Negera, GZ (corresponding author), Jimma Univ, Sch Pharm, Inst Hlth, Dept Clin Pharm, Jimma, Ethiopia.	getandale@gmail.com	MEGA, TESHALE AYELE/AAE-6330-2022; Negera, Getandale/AAD-6841-2021; Tesfaye, Behailu Terefe/AAL-6003-2020	Tesfaye, Behailu Terefe/0000-0002-4512-2111; Negera, Getandale/0000-0002-0178-5888				Adeloye D, 2015, COPD, V12, P71, DOI 10.3109/15412555.2014.908834; Adeloye D, 2013, CROAT MED J, V54, P519, DOI 10.3325/cmj.2013.54.519; AL-Jahdali H, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-8; Almagro P, 2006, RESPIRATION, V73, P311, DOI 10.1159/000088092; [Anonymous], 2019, PROG RETIN EYE RES; [Anonymous], 2009, LUSOTOPIE, V16, pxiii; [Anonymous], 2017, QUAESTIO INSULARIS, V17, P74; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Boulet LP, 2011, EXPERT REV RESP MED, V5, P377, DOI [10.1586/ERS.11.34, 10.1586/ers.11.34]; Buyantseva LV, 2016, J ASTHMA, V53, P684, DOI 10.3109/02770903.2016.1140773; Cao ZY, 2006, RESPIROLOGY, V11, P188, DOI 10.1111/j.1440-1843.2006.00819.x; Capanoglu M, 2015, J ASTHMA, V52, P838, DOI 10.3109/02770903.2015.1028075; Castro-Rodriguez JA, 2016, J ALLER CL IMM-PRACT, V4, P1111, DOI 10.1016/j.jaip.2016.05.003; Crisafulli E, 2015, COPD, V12, P306, DOI 10.3109/15412555.2014.933954; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Donaldson GC, 2003, EUR RESPIR J, V22, P931, DOI 10.1183/09031936.03.00038303; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Fingar K WR, 2015, TRENDS HOSP READMISS; GA N, 2018, GLOBAL ASTHMA REPORT; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Goto T, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1136-8; Guerrero M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150737; Hammerlein A, 2011, J EVAL CLIN PRACT, V17, P61, DOI 10.1111/j.1365-2753.2010.01369.x; Hijjawi SB, 2015, POSTGRAD MED, V127, P343, DOI 10.1080/00325481.2015.1015394; Jain VV, 2014, RESP MED, V108, P1794, DOI 10.1016/j.rmed.2014.09.010; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Kirenga JB, 2012, AFR HEALTH SCI, V12, P48; Magitta NF, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00182-2017; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Meservey AJ, 2019, LUNG, V198, P1, DOI DOI 10.1007/S00408-018-0171-1; Miller Jeffrey D, 2005, COPD, V2, P311, DOI 10.1080/15412550500218221; Miravitlles M, 2000, RESPIRATION, V67, P495, DOI 10.1159/000067462; Misganaw A, 2014, J HEALTH POPUL NUTR, V32, P1; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Russo AN, 2017, RESP CARE, V62, P1396, DOI 10.4187/respcare.05547; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Sharma S., 2019, TIMES INDIA; Shine S, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4670-9; Singh U, 2019, J ALLER CL IMM-PRACT, V7, P279, DOI 10.1016/j.jaip.2018.06.029; Soriano JB, 2017, LANCET RESP MED, V5, P691, DOI 10.1016/S2213-2600(17)30293-X; Tageldin MA, 2015, EGYPT J CHEST DIS TU, V64, P313, DOI 10.1016/j.ejcdt.2014.11.023; van Gemert F, 2015, LANCET GLOB HEALTH, V3, pE44, DOI 10.1016/S2214-109X(14)70337-7; Vestbo J, 2009, THORAX, V64, P939, DOI 10.1136/thx.2009.113662; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Woldeamanuel GG, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0946-z; Zielinska-Danch W, 2007, BIOMARKERS, V12, P484, DOI 10.1080/13547500701421341	47	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2020	15	10							e0239665	10.1371/journal.pone.0239665	http://dx.doi.org/10.1371/journal.pone.0239665			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OB4WW	33022006	gold, Green Published			2023-01-03	WOS:000578473000035
J	van der Vlist, AC; van Oosterom, RF; van Veldhoven, PLJ; Bierma-Zeinstra, SMA; Waarsing, JH; Verhaar, JAN; de Vos, RJ				van der Vlist, Arco C.; van Oosterom, Robert F.; van Veldhoven, Peter L. J.; Bierma-Zeinstra, Sita M. A.; Waarsing, Jan H.; Verhaar, Jan A. N.; de Vos, Robert-Jan			Effectiveness of a high volume injection as treatment for chronic Achilles tendinopathy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POWER DOPPLER ULTRASONOGRAPHY; IMAGE-GUIDED INJECTIONS; PLATELET-RICH PLASMA; CLINICAL SEVERITY; TENDON RUPTURE; NEOVASCULARIZATION; MANAGEMENT; PAIN	OBJECTIVE To study whether a high volume injection without corticosteroids improves clinical outcome in addition to usual care for adults with chronic midportion Achilles tendinopathy. DESIGN Patient and assessor blinded, placebo controlled randomised clinical trial. SETTING Sports medicine department of a large district general hospital, the Netherlands. PARTICIPANTS 80 adults (aged 18-70 years) with clinically diagnosed chronic midportion Achilles tendinopathy and neovascularisation on ultrasonography. 39 were randomised to a high volume injection without corticosteroids and 41 to placebo. INTERVENTIONS Participants were instructed to perform an exercise programme for 24 weeks (usual care) combined with one 50 mL high volume injection of saline and lidocaine (intervention group) or one 2 mL placebo injection of saline and lidocaine (placebo group) at baseline. MAIN OUTCOME MEASURES Primary outcome was pain and function assessed using the validated Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire at 24 weeks (analysed using a generalised estimation equations model). Secondary outcomes were patient satisfaction, return to sport, degree of ultrasonographic Doppler flow, visual analogue scale on 10 hop test, power and flexibility of the gastrocnemius and soleus muscles, pain detect questionnaire for neuropathic pain, and pain coping inventory. Participants were evaluated at baseline and at 2, 6, 12, and 24 weeks. RESULTS Only one participant (1%) was lost to follow-up. The estimated mean VISA-A score improved significantly, from 40.4 (95% confidence interval 32.0 to 48.7) at baseline to 59.1 (50.4 to 67.8) at 24 weeks in the high volume injection group and from 36.9 (27.1 to 46.8) to 58.5 (47.9 to 69.1) in the placebo group. The VISA-A score over time did not differ between the groups (adjusted between group difference at 24 weeks 0.5 points, 95% confidence interval-17.8 to 18.8). No significant between group differences were found for patient satisfaction (21/37 (57%) v 19/39 (49%) patients, P=0.50) and return to desired sport (15/29 (52%) v 19/31 (61%) patients active in sports, P=0.65) at 24 weeks. None of the other secondary outcomes differed between the two groups. CONCLUSIONS A high volume injection without corticosteroids in addition to usual care is not effective for symptom reduction in patients with chronic midportion Achilles tendinopathy. On the basis of our findings, we cannot recommend the use of a high volume injection in this patient group. TRIAL REGISTRATION ClinicalTrials.gov NCT02996409	[van der Vlist, Arco C.; Waarsing, Jan H.; Verhaar, Jan A. N.; de Vos, Robert-Jan] Univ Med Ctr, Erasmus MC, Dept Orthopaed & Sports Med, POB 2040, NL-3000 CA Rotterdam, Netherlands; [van Oosterom, Robert F.; van Veldhoven, Peter L. J.] Haaglanden Med Centre, Dept Sports Med, NL-2262 BA Leidschendam, Netherlands; [Bierma-Zeinstra, Sita M. A.] Univ Med Ctr, Erasmus MC, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Vos, RJ (corresponding author), Univ Med Ctr, Erasmus MC, Dept Orthopaed & Sports Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	r.devos@erasmusmc.nl		van der Vlist, Arco/0000-0003-4238-3540; de Vos, Robert-Jan/0000-0003-0372-0188	Dutch Arthritis Association; Anna Foundation	Dutch Arthritis Association; Anna Foundation	This study was supported by the Dutch Arthritis Association and the Anna Foundation. Both are non-commercial organisations and were not involved in the design, analysis, and content of this publication.	Alfredson H, 2003, CLIN SPORT MED, V22, P727, DOI 10.1016/S0278-5919(03)00010-3; Beyer R, 2015, AM J SPORT MED, V43, P1704, DOI 10.1177/0363546515584760; Boesen AP, 2019, SCAND J MED SCI SPOR, V29, P1223, DOI 10.1111/sms.13450; Boesen AP, 2017, AM J SPORT MED, V45, P2034, DOI 10.1177/0363546517702862; Brant R., INFERENCE MEANS COMP; Brown R, 2006, BRIT J SPORT MED, V40, P275, DOI 10.1136/bjsm.2005.021931; Chan O, 2008, DISABIL REHABIL, V30, P1697, DOI 10.1080/09638280701788225; Coombes BK, 2013, JAMA-J AM MED ASSOC, V309, P461, DOI 10.1001/jama.2013.129; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; De Jonge S, 2014, SCAND J MED SCI SPOR, V24, P773, DOI 10.1111/sms.12072; de Jonge S, 2011, BRIT J SPORT MED, V45, P1026, DOI 10.1136/bjsports-2011-090342; de Jonge S, 2010, BRIT J SPORT MED, V44, P673, DOI 10.1136/bjsm.2008.052142; de Vos RJ, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.032532; de Vos RJ, 2010, JAMA-J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986; de Vos RJ, 2007, AM J SPORT MED, V35, P1696, DOI 10.1177/0363546507303116; Halasi T, 2004, AM J SPORT MED, V32, P899, DOI 10.1177/0363546503262181; Humphrey J, 2010, J SCI MED SPORT, V13, P295, DOI 10.1016/j.jsams.2009.09.007; Johannsen F, 2018, BMJ OPEN SPORT EXERC, V4, DOI 10.1136/bmjsem-2018-000415; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kujala UM, 2005, CLIN J SPORT MED, V15, P133, DOI 10.1097/01.jsm.0000165347.55638.23; KVIST M, 1991, ANN CHIR GYNAECOL FE, V80, P188; Lagas IF, 2019, VSG C ERM NETH; Leung JL, 2008, J CLIN ULTRASOUND, V36, P27, DOI 10.1002/jcu.20388; Maffulli N, 2004, J ROY SOC MED, V97, P472, DOI 10.1258/jrsm.97.10.472; Maffulli N, 2013, PHYS THER SPORT, V14, P163, DOI 10.1016/j.ptsp.2012.07.002; Murphy MC, 2019, BRIT J SPORT MED, V53, P1070, DOI 10.1136/bjsports-2018-099934; NEWNHAM DM, 1991, THORAX, V46, P853, DOI 10.1136/thx.46.11.853; Ohberg L, 2001, KNEE SURG SPORT TR A, V9, P233, DOI 10.1007/s001670000189; Peers KHE, 2003, INT ORTHOP, V27, P180, DOI 10.1007/s00264-002-0426-5; Robinson JM, 2001, BRIT J SPORT MED, V35, P335, DOI 10.1136/bjsm.35.5.335; Sayana MK, 2007, J SCI MED SPORT, V10, P52, DOI 10.1016/j.jsams.2006.05.008; Sierevelt I, 2018, WORLD J ORTHOP, V9, P1, DOI 10.5312/wjo.v9.i1.1; Silbernagel KG, 2007, AM J SPORT MED, V35, P897, DOI 10.1177/0363546506298279; Silbernagel KG, 2001, SCAND J MED SCI SPOR, V11, P197; Tumilty S, 2012, ARCH PHYS MED REHAB, V93, P733, DOI 10.1016/j.apmr.2011.08.049; Vallone G, 2014, J ULTRASOUND, V17, P165, DOI 10.1007/s40477-014-0066-9; Wheeler PC, 2020, CLIN J SPORT MED, V30, P14, DOI 10.1097/JSM.0000000000000580; Wheeler PC, 2016, J FOOT ANKLE SURG, V55, P976, DOI 10.1053/j.jfas.2016.04.017; Wilson F, 2018, BRIT J SPORT MED, V52, P1564, DOI 10.1136/bjsports-2017-098913; Yang X., 2010, Journal of Medical Engineering & Technology, V34, P365, DOI 10.3109/03091902.2010.497892; Yelland MJ, 2011, BRIT J SPORT MED, V45, P421, DOI 10.1136/bjsm.2009.057968; Zanetti M, 2003, RADIOLOGY, V227, P556, DOI 10.1148/radiol.2272012069	42	12	12	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2020	370								m3027	10.1136/bmj.m3027	http://dx.doi.org/10.1136/bmj.m3027			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP5VZ	33315586	Green Published, hybrid			2023-01-03	WOS:000570245200012
J							ACTIV-3 TICO LY-CoV555 Study Grp	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19. MethodsIn this platform trial of therapeutic agents, we randomly assigned hospitalized patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either LY-CoV555 or matching placebo. In addition, all the patients received high-quality supportive care as background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of 7000 mg) or placebo was administered as a single intravenous infusion over a 1-hour period. The primary outcome was a sustained recovery during a 90-day period, as assessed in a time-to-event analysis. An interim futility assessment was performed on the basis of a seven-category ordinal scale for pulmonary function on day 5. ResultsOn October 26, 2020, the data and safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the LY-CoV555 group and 151 in the placebo group) had undergone randomization and infusion. The median interval since the onset of symptoms was 7 days (interquartile range, 5 to 9). At day 5, a total of 81 patients (50%) in the LY-CoV555 group and 81 (54%) in the placebo group were in one of the two most favorable categories of the pulmonary outcome. Across the seven categories, the odds ratio of being in a more favorable category in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.56 to 1.29; P=0.45). The percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.56; 95% CI, 0.78 to 3.10; P=0.20). The rate ratio for a sustained recovery was 1.06 (95% CI, 0.77 to 1.47). ConclusionsMonoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure. (Funded by Operation Warp Speed and others; TICO ClinicalTrials.gov number, NCT04501978.) In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.					Gottlieb, Robert/AAM-8310-2020; Khan, Akram/AAB-6446-2022; Ferrer, Daniel/AFQ-6435-2022; Holland, Thomas/AAA-6096-2022; Casey, Jonathan/AAG-1211-2020; Jensen, Tomas/AFN-5759-2022; Lundgren, Jens/AAE-6876-2019; Chia, Po Ying/GSD-9737-2022; Sturek, Jeffrey/AFO-7641-2022; Chia, Po Ying/AAN-9657-2020; Brown, Samuel/E-6846-2015; Mora-Rillo, Marta/E-8211-2015	Gottlieb, Robert/0000-0001-8376-8709; Khan, Akram/0000-0003-3091-632X; Ferrer, Daniel/0000-0003-4215-6030; Casey, Jonathan/0000-0002-0977-290X; Jensen, Tomas/0000-0003-0398-4431; Chia, Po Ying/0000-0002-8797-9527; Sturek, Jeffrey/0000-0002-2731-3299; Chia, Po Ying/0000-0002-8797-9527; Sendra Alvarez de Cienfuegos, Elena/0000-0002-4374-2173; Brown, Samuel/0000-0003-1206-6261; Jia, Shijing/0000-0002-3467-8149; Douglas, Ivor/0000-0002-4541-1431; Jain, Mamta/0000-0003-2292-6544; Holland, Thomas/0000-0001-7745-9010; Lindegaard, Birgitte/0000-0002-5236-8427; Benfield, Thomas/0000-0003-0698-9385; Staerke, Nina Breinholt/0000-0002-5834-2033; Mateu, Lourdes/0000-0001-7223-7611; Goodman, Anna/0000-0003-0643-9017; Yee, Kimberly/0000-0002-3703-1367; Ostergaard, Lars/0000-0003-2459-0511; Ong, Sean/0000-0002-8570-436X; Files, Daniel Clark/0000-0002-1595-4080; Mayer, Kirby/0000-0003-3844-3846; Jensen, Jens Ulrik/0000-0003-4036-0521; Murray, Daniel/0000-0001-8501-8661; Paredes, Roger/0000-0002-6553-691X; HELLEBERG, MARIE/0000-0002-2370-1657; Mora-Rillo, Marta/0000-0002-2735-5931; johansen, isik somuncu/0000-0002-2189-9823; Legarda, Almudena/0000-0001-5088-6872; Chang, Christina Catherine/0000-0003-0109-0725; Clariday, Laura/0000-0001-5291-2982; Young, Barnaby/0000-0003-1010-2230; Rogers, Angela/0000-0001-6969-6200; Chen, Peter/0000-0002-5330-1718; Gibbs, Kevin/0000-0002-5272-2289	U.S. Operation Warp Speed program; National Institute of Allergy and Infectious Diseases; Leidos Biomedical Research for the INSIGHT Network; National Heart, Lung, and Blood Institute; Research Triangle Institute for the PETAL (Prevention and Early Treatment of Acute Lung Injury) Network; Cardiothoracic Surgical Trials Network; U.S. Department of Veterans Affairs; government of Denmark (National Research Foundation) [126]; government of Australia (National Health and Medical Research Council); government of United Kingdom (Medical Research Council) [MRC_UU_12023/23]; MRC [MC_UU_12023/22] Funding Source: UKRI	U.S. Operation Warp Speed program; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Leidos Biomedical Research for the INSIGHT Network; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Research Triangle Institute for the PETAL (Prevention and Early Treatment of Acute Lung Injury) Network; Cardiothoracic Surgical Trials Network; U.S. Department of Veterans Affairs(US Department of Veterans Affairs); government of Denmark (National Research Foundation); government of Australia (National Health and Medical Research Council); government of United Kingdom (Medical Research Council); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the U.S. Operation Warp Speed program; the National Institute of Allergy and Infectious Diseases and Leidos Biomedical Research for the INSIGHT Network; the National Heart, Lung, and Blood Institute and the Research Triangle Institute for the PETAL (Prevention and Early Treatment of Acute Lung Injury) Network and the Cardiothoracic Surgical Trials Network; and the U.S. Department of Veterans Affairs and grants from the governments of Denmark (no. 126 from the National Research Foundation), Australia (from the National Health and Medical Research Council), and the United Kingdom (MRC_UU_12023/23 from the Medical Research Council). Trial medications were donated by Gilead Sciences and Eli Lilly.	[Anonymous], 2017, DIVISION AIDS DAIDS; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Jones Bryan E, 2020, bioRxiv, DOI 10.1101/2020.09.30.318972; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; Murray DD, 2020, DESIGN IMPLEMENTATIO, DOI [10.1101/2020.11.08.20227876v2, DOI 10.1101/2020.11.08.20227876V2]; National Institutes of Health, 2020, ACC COVID 19 THER IN; R Core Team, 2017, R LANG STAT COMP; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; World Health Organization, 2020, NOV COR COVID 19 THE	15	211	214	7	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	2021	384	10					905	914		10.1056/NEJMoa2033130	http://dx.doi.org/10.1056/NEJMoa2033130			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD5XO	33356051	Green Published, Bronze			2023-01-03	WOS:000687279800010
J	Kalil, AC; Patterson, TF; Mehta, AK; Tomashek, KM; Wolfe, CR; Ghazaryan, V; Marconi, VC; Ruiz-Palacios, GM; Hsieh, L; Kline, S; Tapson, V; Iovine, NM; Jain, MK; Sweeney, DA; El Sahly, HM; Branche, AR; Pineda, JR; Lye, DC; Sandkovsky, U; Luetkemeyer, AF; Cohen, SH; Finberg, RW; Jackson, PEH; Taiwo, B; Paules, CI; Arguinchona, H; Erdmann, N; Ahuja, N; Frank, M; Oh, M; Kim, ES; Tan, SY; Mularski, RA; Nielsen, H; Ponce, PO; Taylor, BS; Larson, LA; Rouphael, NG; Saklawi, Y; Cantos, VD; Ko, ER; Engemann, JJ; Amin, AN; Watanabe, M; Billings, J; Elie, MC; Davey, RT; Burgess, TH; Ferreira, J; Green, M; Makowski, M; Cardoso, A; de Bono, S; Bonnett, T; Proschan, M; Deye, GA; Dempsey, W; Nayak, SU; Dodd, LE; Beigel, JH				Kalil, A. C.; Patterson, T. F.; Mehta, A. K.; Tomashek, K. M.; Wolfe, C. R.; Ghazaryan, V.; Marconi, V. C.; Ruiz-Palacios, G. M.; Hsieh, L.; Kline, S.; Tapson, V.; Iovine, N. M.; Jain, M. K.; Sweeney, D. A.; El Sahly, H. M.; Branche, A. R.; Pineda, J. Regalado; Lye, D. C.; Sandkovsky, U.; Luetkemeyer, A. F.; Cohen, S. H.; Finberg, R. W.; Jackson, P. E. H.; Taiwo, B.; Paules, C. I.; Arguinchona, H.; Erdmann, N.; Ahuja, N.; Frank, M.; Oh, M.; Kim, E. -S.; Tan, S. Y.; Mularski, R. A.; Nielsen, H.; Ponce, P. O.; Taylor, B. S.; Larson, L. A.; Rouphael, N. G.; Saklawi, Y.; Cantos, V. D.; Ko, E. R.; Engemann, J. J.; Amin, A. N.; Watanabe, M.; Billings, J.; Elie, M. -C.; Davey, R. T.; Burgess, T. H.; Ferreira, J.; Green, M.; Makowski, M.; Cardoso, A.; de Bono, S.; Bonnett, T.; Proschan, M.; Deye, G. A.; Dempsey, W.; Nayak, S. U.; Dodd, L. E.; Beigel, J. H.		ACTT-2 Study Grp Members	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known. METHODS We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (<= 10 days) and either baricitinib (<= 14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15. RESULTS A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P=0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P=0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P=0.003). CONCLUSIONS Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.)	[Kalil, A. C.; Larson, L. A.] Univ Nebraska Med Ctr, 985400 Nebraska Med, Omaha, NE 68198 USA; [Patterson, T. F.; Ponce, P. O.; Taylor, B. S.] Univ Texas Hlth San Antonio, Univ Hlth, San Antonio, TX USA; [Patterson, T. F.; Ponce, P. O.; Taylor, B. S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA; [Jain, M. K.] UT Southwestern Med Ctr, Parkland Hlth & Hosp Syst, Dallas, TX USA; [Sandkovsky, U.] Baylor Scott & White Hlth, Dallas, TX USA; [El Sahly, H. M.] Baylor Coll Med, Houston, TX 77030 USA; [Mehta, A. K.; Marconi, V. C.; Rouphael, N. G.; Saklawi, Y.; Cantos, V. D.] Emory Univ, Atlanta, GA 30322 USA; [Cantos, V. D.] Grady Mem Hosp, Atlanta, GA USA; [Marconi, V. C.] Atlanta Vet Affairs Med Ctr, Decatur, GA USA; [Tomashek, K. M.; Ghazaryan, V.; Davey, R. T.; Proschan, M.; Deye, G. A.; Dempsey, W.; Nayak, S. U.; Dodd, L. E.; Beigel, J. H.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Burgess, T. H.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA; [Ferreira, J.; Green, M.; Makowski, M.] Emmes & Clin Monitoring Res Program Directorate, Rockville, MD USA; [Bonnett, T.] Frederick Natl Lab, Rockville, MD USA; [Wolfe, C. R.; Ko, E. R.; Engemann, J. J.] Duke Univ, Durham, NC USA; [Ruiz-Palacios, G. M.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Pineda, J. Regalado] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico; [Hsieh, L.; Amin, A. N.; Watanabe, M.] Univ Calif Irvine, Irvine, CA USA; [Tapson, V.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Sweeney, D. A.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Luetkemeyer, A. F.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cohen, S. H.] Univ Calif Davis, Davis, CA 95616 USA; [Ahuja, N.] Stanford Univ, Stanford, CA 94305 USA; [Kline, S.; Billings, J.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Iovine, N. M.; Elie, M. -C.] Univ Florida, Gainesville, FL USA; [Branche, A. R.] Univ Rochester, Rochester, NY USA; [Lye, D. C.] Tan Tock Seng Hosp, Natl Ctr Infect Dis, Lee Kong Chian Sch Med, Singapore, Singapore; [Lye, D. C.] Yong Loo Lin Sch Med, Singapore, Singapore; [Tan, S. Y.] Changi Gen Hosp, Singapore, Singapore; [Finberg, R. W.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Jackson, P. E. H.] Univ Virginia, Charlottesville, VA USA; [Taiwo, B.] Northwestern Univ, Chicago, IL 60611 USA; [Paules, C. I.] Penn State Hlth Milton S Hershey Med Ctr, Hershey, PA USA; [Arguinchona, H.] Providence Sacred Heart Med Ctr, Spokane, WA USA; [Erdmann, N.] Univ Alabama Birmingham, Birmingham, AL USA; [Frank, M.] Denver Hlth & Hosp Author, Denver, CO USA; [Oh, M.] Seoul Natl Univ Hosp, Seoul, South Korea; [Kim, E. -S.] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea; [Mularski, R. A.] Kaiser Permanente Northwest, Portland, OR USA; [Nielsen, H.] Aalborg Univ Hosp, Aalborg, Denmark; [Cardoso, A.; de Bono, S.] Eli Lilly, Indianapolis, IN USA	University of Nebraska System; University of Nebraska Medical Center; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; Baylor Health Care System; Baylor College of Medicine; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; University of California System; University of California Irvine; Cedars Sinai Medical Center; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California Davis; Stanford University; University of Minnesota System; University of Minnesota Twin Cities; State University System of Florida; University of Florida; University of Rochester; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Centre for Infectious Diseases Singapore; Tan Tock Seng Hospital; National University of Singapore; Changi General Hospital; University of Massachusetts System; University of Massachusetts Worcester; University of Virginia; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Alabama System; University of Alabama Birmingham; Denver Health Medical Center; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Kaiser Permanente; Aalborg University; Aalborg University Hospital; Eli Lilly	Kalil, AC (corresponding author), Univ Nebraska Med Ctr, 985400 Nebraska Med, Omaha, NE 68198 USA.	akalil@unmc.edu	Jensen, Tomas/AFN-5759-2022; Marconi, Vincent/GRJ-4553-2022; Beigel, John H/GNP-2628-2022; Ruiz-Palacios, Guillermo/GYQ-5462-2022; Chia, Po Ying/AAN-9657-2020; Frank, Maria (Gaby)/AHA-0816-2022; Beigel, John/AAQ-4289-2021; Chia, Po Ying/GSD-9737-2022; Lye, David/ABF-4402-2021; Marconi, Vincent/N-3210-2014; Marconi, Vincent/AFK-5812-2022; Deye, Gregory/AAL-7961-2021; Elie-Turenne, Marie-Carmelle/G-6895-2013	Jensen, Tomas/0000-0003-0398-4431; Marconi, Vincent/0000-0001-8409-4689; Chia, Po Ying/0000-0002-8797-9527; Beigel, John/0000-0002-4879-4941; Chia, Po Ying/0000-0002-8797-9527; Marconi, Vincent/0000-0001-8409-4689; Lindholm, David/0000-0001-5428-7404; Rajme-Lopez, Sandra/0000-0001-7809-9619; wang, jennifer/0000-0002-2556-9100; Lye, David/0000-0003-0324-0205; Young, Barnaby/0000-0003-1010-2230; Holodniy, Mark/0000-0002-6655-7982; Jain, Mamta/0000-0003-2292-6544; Paules, Catharine/0000-0002-9064-6678; Song, Kyoung-Ho/0000-0002-4517-3840; Ahmad, Danish/0000-0001-5381-1243; Ponce-de-Leon, Alfredo/0000-0003-2640-2916; Goodman, Anna/0000-0003-0643-9017; Bonnett, Tyler/0000-0001-5545-6433; Elie-Turenne, Marie-Carmelle/0000-0002-4807-9403; George, Sarah/0000-0002-9699-1042; Mateu, Lourdes/0000-0001-7223-7611; Thomsen, Isaac/0000-0001-9240-0164; Jackson, Patrick/0000-0002-7003-018X; Ghazaryan, Varduhi/0000-0002-6649-7342; /0000-0002-9808-063X; Rapaka, Rekha/0000-0002-4770-4422; Yan, Gabriel/0000-0003-3513-428X; Colombo, Christopher/0000-0001-5499-3368; Ong, Sean/0000-0002-8570-436X; Murray, Daniel/0000-0001-8501-8661	NIAID, National Institutes of Health (NIH), Bethesda, MD; NIAID; National Cancer Institute, NIH [HHSN261200800001E 75N910D00024, 75N91019F00130/75N91020F00010]; Department of Defense, Defense Health Program; NIAID of the NIH [UM1AI148684, UM1AI148576, UM1AI148573, UM1AI148575, UM1AI148452, UM1AI148685, UM1AI148450, UM1AI148689]; NIH Stimulating Access to Research in Residency grant [5R38AI140299-02]; government of Japan; government of Mexico; government of Denmark; government of Singapore; Seoul National University Hospital; United Kingdom Medical Research Council [MRC_UU_12023/23]; MRC [MC_UU_12023/22] Funding Source: UKRI	NIAID, National Institutes of Health (NIH), Bethesda, MD; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense, Defense Health Program; NIAID of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Stimulating Access to Research in Residency grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); government of Japan; government of Mexico; government of Denmark; government of Singapore; Seoul National University Hospital; United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, the Departments of the Army, Navy, or Air Force, the Department of Defense, or the Department of Veterans Affairs, nor does any mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Gilead Sciences provided remdesivir for use in this trial but did not provide any financial support. Eli Lilly provided baricitinib for use in this trial but did not provide any financial support. Employees of Gilead Sciences and Eli Lilly participated in discussions about protocol development and in weekly protocol team calls. The National Institute of Allergy and Infectious Diseases (NIAID) ultimately made all decisions regarding trial design and implementation.; The trial was sponsored and primarily funded by the NIAID, National Institutes of Health (NIH), Bethesda, MD. This trial has been funded in part with federal funds from the NIAID and the National Cancer Institute, NIH, under contract -HHSN261200800001E 75N910D00024, task order number 75N91019F00130/75N91020F00010, and by the Department of Defense, Defense Health Program. This trial has been supported in part by the NIAID of the NIH under award numbers UM1AI148684, UM1AI148576, UM1AI148573, UM1AI148575, UM1AI148452, UM1AI148685, UM1AI148450, and UM1AI148689 and by NIH Stimulating Access to Research in Residency grant 5R38AI140299-02. The trial has also been funded in part by the governments of Japan, Mexico, Denmark, and Singapore. The trial site in South Korea received funding from the Seoul National University Hospital. Support for the London International Coordinating Centre was also provided by the United Kingdom Medical Research Council (MRC_UU_12023/23).; Dr. Marconi reports receiving grant support from Bayer, grant support and lecture fees from ViiV Healthcare and Gilead Sciences, and grant support and consulting fees from Eli Lilly; Dr. Hsieh, receiving grant support from NeuroRx, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, Octapharma, Fulcrum Therapeutics, and Alexion Pharmaceuticals; Dr. Jain, receiving grant support and advisory board fees from Gilead Sciences and grant support from Regeneron Pharmaceuticals; Dr. Lye, serving on an advisory board for Gilead Sciences; Dr. Sandkovsky, receiving grant support from CytoDyn; Dr. Luetkemeyer, receiving grant support, paid to the University of California, San Francisco, from AstraZeneca and Novartis; Dr. Amin, receiving grant support from Pulmotect, Blade Therapeutics, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, Octapharma, Fulcrum Therapeutics, and NeuroRx, grant support and consulting fees from Novartis, grant support, consulting fees, and lecture fees from Alexion Pharmaceuticals, consulting fees and lecture fees from Bristol Myers Squibb, Pfizer, Portola Pharmaceuticals, Sunovion, and AstraZeneca, and consulting fees from Boehringer Ingelheim, Mylan, Salix Pharmaceuticals, Nabriva Therapeutics, Paratek Pharmaceuticals, Bayer, Tetraphase Pharmaceuticals, Achaogen, La Jolla Pharmaceutical, Millenium Pharmaceuticals, Ferring Pharmaceuticals, PeraHealth, AseptiScope, Heartrite, and Sprightly; Dr. Watanabe, receiving grant support from Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, Octapharma, Fulcrum Therapeutics, and Alexion Pharmaceuticals; and Drs. Cardoso and de Bono, being employed by Eli Lilly. No other potential conflict of interest relevant to this article was reported.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Boddapati AK, 2020, PREPRINT, DOI [10.1101/2020.09.16.300277v1, DOI 10.1101/2020.09.16.300277V1]; Cantini F, 2020, J INFECTION, V81, P673, DOI 10.1016/j.jinf.2020.06.052; Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017; Dodd LE, 2020, CLIN TRIALS, V17, P472, DOI 10.1177/1740774520939938; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Rodriguez-Garcia JL, 2021, RHEUMATOLOGY, V60, P399, DOI 10.1093/rheumatology/keaa587; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Sims JT, 2021, J ALLERGY CLIN IMMUN, V147, P107, DOI 10.1016/j.jaci.2020.08.031; Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697; Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8; Titanji BK, 2021, CLIN INFECT DIS, V72, P1247, DOI 10.1093/cid/ciaa879; Yao TC, 2020, ANN INTERN MED, V173, P325, DOI 10.7326/M20-0432	16	785	802	13	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	2021	384	9					795	807		10.1056/NEJMoa2031994	http://dx.doi.org/10.1056/NEJMoa2031994			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QS8DS	33306283	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000626124800015
J	Allen, KD; Woolson, S; Hoenig, HM; Bongiorni, D; Byrd, J; Caves, K; Hall, KS; Heiderscheit, B; Hodges, NJ; Huffman, KM; Morey, MC; Ramasunder, S; Severson, H; Van Houtven, C; Abbate, LM; Coffman, CJ				Allen, Kelli D.; Woolson, Sandra; Hoenig, Helen M.; Bongiorni, Dennis; Byrd, James; Caves, Kevin; Hall, Katherine S.; Heiderscheit, Bryan; Hodges, Nancy Jo; Huffman, Kim M.; Morey, Miriam C.; Ramasunder, Shalini; Severson, Herbert; Van Houtven, Courtney; Abbate, Lauren M.; Coffman, Cynthia J.			Stepped Exercise Program for Patients With Knee Osteoarthritis A Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-THERAPY; SELF-MANAGEMENT; PRIMARY-CARE; CHRONIC PAIN; HIP; ADULTS; GUIDELINES; SAMPLE; INTERVENTION; TELEPHONE	Background: Evidence-based models are needed to deliver exercise-related services for knee osteoarthritis efficiently and according to patient needs. Objective: To examine a stepped exercise program for patients with knee osteoarthritis (STEP-KOA). Design: Randomized controlled trial. (ClinicalTrials.gov: NCT02653768) Setting: 2 U.S. Department of Veterans Affairs sites. Participants: 345 patients (mean age, 60 years; 15% female; 67% people of color) with symptomatic knee osteoarthritis. Intervention: Participants were randomly assigned in a 2:1 ratio to STEP-KOA or an arthritis education (AE) control group, respectively. The STEP-KOA intervention began with 3 months of an internet-based exercise program (step 1). Participants who did not meet response criteria for improvement in pain and function after step 1 progressed to step 2, which involved 3 months of biweekly physical activity coaching calls. Participants who did not meet response criteria after step 2 went on to in-person physical therapy visits (step 3). The AE group received educational materials via mail every 2 weeks. Measurements: Primary outcome was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Scores for the STEP-KOA and AE groups at 9 months were compared by using linear mixed models. Results: In the STEP-KOA group, 65% of participants (150 of 230) progressed to step 2 and 35% (81 of 230) to step 3. The estimated baseline WOMAC score for the full sample was 47.5 (95% CI, 45.7 to 49.2). At 9-month follow-up, the estimated mean WOMAC score was 6.8 points (CI, -10.5 to -3.2 points) lower in the STEP-KOA than the AE group, indicating greater improvement. Limitation: Participants were mostly male veterans, and follow-up was limited. Conclusion: Veterans in STEP-KOA reported modest improvements in knee osteoarthritis symptoms compared with the control group. The STEP-KOA strategy may be efficient for delivering exercise therapies for knee osteoarthritis.	[Allen, Kelli D.; Woolson, Sandra; Van Houtven, Courtney; Coffman, Cynthia J.] Durham VA Hlth Care Syst, Ctr Innovat Accelerate Discovery & Practice Trans, HSRD 152,508 Fulton St, Durham, NC 27705 USA; [Allen, Kelli D.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Woolson, Sandra; Hoenig, Helen M.; Hodges, Nancy Jo; Huffman, Kim M.] Durham VA Hlth Care Syst, Durham, NC 27705 USA; [Hoenig, Helen M.; Bongiorni, Dennis] Durham VA Hlth Care Syst, Phys Med & Rehabil Serv, HSRD, 508 Fulton St, Durham, NC 27705 USA; [Hall, Katherine S.; Morey, Miriam C.] Durham VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, HSRD 152,508 Fulton St, Durham, NC 27705 USA; [Ramasunder, Shalini] Durham VA Hlth Care Syst, Orthoped Serv, HSRD 152,508 Fulton St, Durham, NC 27705 USA; [Hoenig, Helen M.; Caves, Kevin; Hall, Katherine S.; Huffman, Kim M.; Morey, Miriam C.; Ramasunder, Shalini] Duke Univ, Durham, NC 27706 USA; [Byrd, James; Caves, Kevin; Hodges, Nancy Jo] Greenville VA Hlth Care Ctr, 401 Moye Blvd, Greenville, NC 27834 USA; [Heiderscheit, Bryan] Univ Wisconsin, Madison, WI USA; [Severson, Herbert] Oregon Res Inst, 1715 Franklin Blvd, Eugene, OR 97403 USA; [Van Houtven, Courtney] Duke Univ, Sch Med, Durham, NC USA; [Abbate, Lauren M.] VA Eastern Colorado Hlth Care Syst, Aurora, CO USA; [Abbate, Lauren M.] Univ Colorado, Sch Med, Aurora, CO USA; [Coffman, Cynthia J.] Duke Univ, Med Ctr, Durham, NC USA; [Caves, Kevin] 40 Duke Med Circle,Clin 1l, Durham, NC 27710 USA; [Heiderscheit, Bryan] 621 Sci Dr,1114, Madison, WI 53711 USA; [Huffman, Kim M.] 3475 Erwin Rd, Durham, NC 27705 USA; [Abbate, Lauren M.] Educ & Clin Ctr, Eastern Colorado Geriatr Res, 1700 Wheeling St, Aurora, CO 80045 USA	University of North Carolina; University of North Carolina Chapel Hill; Geriatric Research Education & Clinical Center; Duke University; University of Wisconsin System; University of Wisconsin Madison; Oregon Research Institute; Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus; Duke University	Allen, KD (corresponding author), Durham VA Hlth Care Syst, Ctr Innovat Accelerate Discovery & Practice Trans, HSRD 152,508 Fulton St, Durham, NC 27705 USA.	kelli.allen@va.gov		Van Houtven, Courtney/0000-0002-0783-1611; Allen, Kelli/0000-0002-3886-0677	National Institute of Arthritis and Musculoskeletal and Skin Diseases Core Center for Clinical Research [P30AR072580]; VA HSRD [19-332, IIR 14-091]; Center of Innovation to Accelerate Discovery and Practice Transformation [CIN 13-410]; National Institutes of Health/National Institute on Aging Claude D. Pepper Older Americans Independence Centers [AG028716]	National Institute of Arthritis and Musculoskeletal and Skin Diseases Core Center for Clinical Research; VA HSRD; Center of Innovation to Accelerate Discovery and Practice Transformation; National Institutes of Health/National Institute on Aging Claude D. Pepper Older Americans Independence Centers	Research reported in this manuscript was funded through Investigator-Initiated Research Award IIR 14-091 from the VA HSRD. Dr. Allen receives support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Core Center for Clinical Research (grant P30AR072580) and VA HSRD (Career Scientist Award 19-332). Drs. Allen, Coffman, and Van Houtven and Ms. Woolson receive support from the Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410) at the Durham VA Health Care System. Mr. Caves and Drs. Hall, Hoenig, and Morey receive support from the National Institutes of Health/National Institute on Aging Claude D. Pepper Older Americans Independence Centers (grant AG028716).	Abbate LM, 2018, ARTHRIT CARE RES, V70, P1141, DOI 10.1002/acr.23466; Allen KD, 2018, OSTEOARTHR CARTILAGE, V26, P383, DOI 10.1016/j.joca.2017.12.008; Allen KD, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2627-8; Allen KD, 2016, PHYS THER, V96, P597, DOI 10.2522/ptj.20150194; Allen KD, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-60; Allen KD, 2010, ANN INTERN MED, V153, P570, DOI 10.7326/0003-4819-153-9-201011020-00006; American Physical Therapy Association Workforce Task Force, 2010, MOD PROJ SUPPL DEM P; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Angst F, 2002, J RHEUMATOL, V29, P131; [Anonymous], 1999, STAT MED, V18, P1905; Bair MJ, 2015, JAMA INTERN MED, V175, P682, DOI 10.1001/jamainternmed.2015.97; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Bellamy N, 2002, J RHEUMATOL, V29, P783; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Blissmer B, 2013, ACSMS GUIDELINES EXE; Borm GF, 2007, J CLIN EPIDEMIOL, V60, P1234, DOI 10.1016/j.jclinepi.2007.02.006; Brooks MA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-158; Cisternas MG, 2009, ARTHRIT RHEUM-ARTHR, V61, P1694, DOI 10.1002/art.24897; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Davison GC, 2000, J CONSULT CLIN PSYCH, V68, P580, DOI 10.1037/0022-006X.68.4.580; Dhawan A, 2014, ARTHROSCOPY, V30, P65, DOI 10.1016/j.arthro.2013.09.002; Dobson F, 2013, OSTEOARTHR CARTILAGE, V21, P1042, DOI 10.1016/j.joca.2013.05.002; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; Fransen M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-095424; Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596; Hootman JM, 2016, ARTHRITIS RHEUMATOL, V68, P1582, DOI 10.1002/art.39692; Jakicic JM, 2012, JAMA-J AM MED ASSOC, V307, P2617, DOI 10.1001/jama.2012.6866; Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Kroenke K, 2014, JAMA-J AM MED ASSOC, V312, P240, DOI 10.1001/jama.2014.7689; Kroenke K, 2009, JAMA-J AM MED ASSOC, V301, P2099, DOI 10.1001/jama.2009.723; Little R.J.A., 2002, STAT ANAL MISSING DA, Vsecond; Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639; Mattsson S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-414; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Meneses SRF, 2016, OSTEOARTHR CARTILAGE, V24, P1487, DOI 10.1016/j.joca.2016.04.004; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Miller WR, 2002, MOTIVATIONAL INTERVI, V2nd, DOI DOI 10.1097/01445442-200305000-00013; OKelly M, 2014, STAT PRACT, P1, DOI 10.1002/9781118762516; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Sangha O, 2003, ARTHRIT RHEUM-ARTHR, V49, P156, DOI 10.1002/art.10993; Song J, 2013, ARTHRIT CARE RES, V65, P195, DOI 10.1002/acr.21803; United States Bone and Joint Initiative, BURD MUSC DIS US BMU; Uthman OA, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5555; Verhagen AP, 2019, OSTEOARTHR CARTILAGE, V27, P1266, DOI 10.1016/j.joca.2019.04.020; Von Korff M, 2000, WESTERN J MED, V172, P133, DOI 10.1136/ewjm.172.2.133; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wright AA, 2011, J ORTHOP SPORT PHYS, V41, P319, DOI 10.2519/jospt.2011.3515	48	10	11	4	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					298	+		10.7326/M20-4447	http://dx.doi.org/10.7326/M20-4447			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33370174				2023-01-03	WOS:000629294000012
J	Zeinomar, N; Chung, WK				Zeinomar, Nur; Chung, Wendy K.			Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PREDICTION; WOMEN; VALIDATION; DENSITY; MODELS; SNPS	Polygenic risk scores (PRSs) have been consistently associated with elevated breast cancer risk in cohort studies and are associated with risk in both women with and those without a family history of breast cancer. However, before clinical implementation, several issues must be addressed, including understanding the potential clinical utility and optimal method to communicate personalized screening recommendations that incorporate the PRS. Several trials are under way to answer some of these questions and facilitate clinical implementation. Because these PRSs have been developed in women of European ancestry, it is important to understand the limitations of their predictive ability in other ancestral groups. Finally, the value of the PRS will lie in considering it along with other clinical, familial, and rare genetic factors that are currently used in personalized risk assessment of breast cancer.	[Chung, Wendy K.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, 1150 St Nicholas Ave,Room 620, New York, NY 10032 USA; [Zeinomar, Nur] Columbia Univ, Mailman Sch Publ Hlth, 722 West 168th St,Room 1605, New York, NY 10032 USA	Columbia University; Columbia University	Chung, WK (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, 1150 St Nicholas Ave,Room 620, New York, NY 10032 USA.	wkc15@cumc.columbia.edu			National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR001875, UL1TR001873]	National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	By grants TL1TR001875 (Dr. Zeinomar) and UL1TR001873 (Dr. Chung) from the National Center for Advancing Translational Sciences of the National Institutes of Health.	Allman R, 2015, BREAST CANCER RES TR, V154, P583, DOI 10.1007/s10549-015-3641-7; Barnes DR, 2020, GENET MED, V22, P1653, DOI 10.1038/s41436-020-0862-x; Black MH, 2018, VALIDATION POLYGENIC; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Costantino JP, 1999, J NATL CANCER I, V91, P1541, DOI 10.1093/jnci/91.18.1541; Cuzick J, 2017, J CLIN ONCOL, V35, P743, DOI 10.1200/JCO.2016.69.8944; Dite GS, 2016, CANCER EPIDEM BIOMAR, V25, P359, DOI 10.1158/1055-9965.EPI-15-0838; Fung SM, 2019, CANCER EPIDEM BIOMAR, V28, P506, DOI 10.1158/1055-9965.EPI-18-0810; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Gallagher S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8501; Ho WK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17680-w; Jia GC, 2020, JNCI CANCER SPECT, V4, DOI 10.1093/jncics/pkaa021; Kapoor PM, 2021, JNCI-J NATL CANCER I, V113, P329, DOI 10.1093/jnci/djaa056; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kuchenbaecker KB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw302; Lambert SA, 2019, HUM MOL GENET, V28, pR133, DOI 10.1093/hmg/ddz187; Lee A, 2019, GENET MED, V21, P1708, DOI 10.1038/s41436-018-0406-9; Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002; Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036; National Comprehensive Cancer Network, GEN FAM HIGH RISK AS; Shieh Y, 2020, JNCI-J NATL CANCER I, V112, P590, DOI 10.1093/jnci/djz174; Tice JA, 2008, ANN INTERN MED, V148, P337, DOI 10.7326/0003-4819-148-5-200803040-00004; Tice JA, 2015, J CLIN ONCOL, V33, P3137, DOI 10.1200/JCO.2015.60.8869; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; Vachon CM, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju397; Wang SF, 2018, BREAST CANCER RES TR, V168, P703, DOI 10.1007/s10549-017-4638-1	26	2	2	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					408	+		10.7326/M20-5874	http://dx.doi.org/10.7326/M20-5874			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33253037	Green Accepted			2023-01-03	WOS:000629294000024
J	Ang, SH; Hwong, WY; Bots, ML; Sivasampu, S; Aziz, AFA; Hoo, FK; Vaartjes, I				Ang, Swee Hung; Hwong, Wen Yea; Bots, Michiel L.; Sivasampu, Sheamini; Aziz, Aznida Firzah Abdul; Hoo, Fan Kee; Vaartjes, Ilonca			Risk of 28-day readmissions among stroke patients in Malaysia (2008-2015): Trends, causes and its associated factors	PLOS ONE			English	Article							TRANSIENT ISCHEMIC ATTACK; PREVENTABLE READMISSIONS; HOSPITAL READMISSION; 30-DAY READMISSION; GLOBAL BURDEN; HEALTH-CARE; PREDICTORS; EDUCATION; DISEASE	Background and objectives Risk of readmissions is an important quality indicator for stroke care. Such information is limited among low- and middle-income countries. We assessed the trends for 28-day readmissions after a stroke in Malaysia from 2008 to 2015 and evaluated the causes and factors associated with readmissions in 2015. Methods Using the national hospital admission records database, we included all stroke patients who were discharged alive between 2008 and 2015 for this secondary data analysis. The risk of readmissions was described in proportion and trends. Reasons were coded according to the International Classification of Diseases, 10(th) Edition. Multivariable logistic regression was performed to identify factors associated with readmissions. Results Among 151729 patients, 11 to 13% were readmitted within 28 days post-discharge from their stroke events each year. The trend was constant for ischemic stroke but decreasing for hemorrhagic stroke. The leading causes for readmissions were recurrent stroke (32.1%), pneumonia (13.0%) and sepsis (4.8%). The risk of 28-day readmission was higher among those with stroke of hemorrhagic (adjusted odds ratio (AOR): 1.52) and subarachnoid hemorrhage (AOR: 2.56) subtypes, and length of index admission >3 days (AOR: 1.48), but lower among younger age groups of 35-64 (AORs: 0.61-0.75), p values Conclusion The risk of 28-day readmission remained constant from 2008 to 2015, where one in eight stroke patients required readmission, mainly attributable to preventable causes. Age, ethnicity, stroke subtypes and duration of the index admission influenced the risk of readmission. Efforts should focus on minimizing potentially preventable admissions, especially among those at higher risk.	[Ang, Swee Hung; Hwong, Wen Yea; Sivasampu, Sheamini] Minist Hlth, Natl Inst Hlth, Inst Clin Res, Petaling Jaya, Selangor, Malaysia; [Hwong, Wen Yea; Bots, Michiel L.; Vaartjes, Ilonca] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Aziz, Aznida Firzah Abdul] Univ Kebangsaan Malaysia, Fac Med, Dept Family Med, Med Ctr, Bangi, Selangor, Malaysia; [Hoo, Fan Kee] Univ Putra Malaysia, Fac Med, Dept Med, Neurol Unit, Serdang, Selangor, Malaysia; [Ang, Swee Hung] Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia	Kementerian Kesihatan Malaysia; Utrecht University; Utrecht University Medical Center; Universiti Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti Malaya	Ang, SH (corresponding author), Minist Hlth, Natl Inst Hlth, Inst Clin Res, Petaling Jaya, Selangor, Malaysia.; Ang, SH (corresponding author), Univ Malaya, Fac Med, Dept Social & Prevent Med, Kuala Lumpur, Malaysia.	angsh.crc@gmail.com	; Hoo, Fan Kee/J-2591-2013	Ang, SweeHung/0000-0001-6676-6269; Hoo, Fan Kee/0000-0003-1687-627X; Sivasampu, Sheamini/0000-0003-2314-6048	Ministry of Health Malaysia - National Institute of Health grant under the project "Monitoring Stroke Burden in Malaysia: the use of linked national data sources" [NMRR-18-100-39847]; Honours Track of MSc Epidemiology, University Medical Center Utrecht; Netherlands Organization for Scientific Research [022.005.021]; Dutch Heart Foundation	Ministry of Health Malaysia - National Institute of Health grant under the project "Monitoring Stroke Burden in Malaysia: the use of linked national data sources"; Honours Track of MSc Epidemiology, University Medical Center Utrecht; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Heart Foundation(Netherlands Heart Foundation)	This study was funded by a grant from the Ministry of Health Malaysia - National Institute of Health grant under the project "Monitoring Stroke Burden in Malaysia: the use of linked national data sources" (NMRR-18-100-39847). WYH is supported by the Honours Track of MSc Epidemiology, University Medical Center Utrecht with a grant from the Netherlands Organization for Scientific Research (Grant number: 022.005.021). IV is funded by the Dutch Heart Foundation for project Facts and Figures. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang SH, 2019, MED J MALAYSIA S2, V74, P135; [Anonymous], 2012, CLIN PRACT GUID MAN, DOI [10.1161/STR.0b013e3182587839, DOI 10.1161/STR.0B013E3182587839]; [Anonymous], 2016, FACTS HLTH 2016; Aziz AFA, 2014, VALUE HEALTH, V17, pA761, DOI 10.1016/j.jval.2014.08.259; Aziz AFA, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-40; Bambhroliya AB, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1190; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Basu J, 2018, INQUIRY-J HEALTH CAR, V55, DOI 10.1177/0046958018774180; Berry JG, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k497; Bhattacharya P, 2011, J NEUROL SCI, V307, P50, DOI 10.1016/j.jns.2011.05.022; Bjerkreim AT, 2015, J STROKE CEREBROVASC, V24, P2095, DOI 10.1016/j.jstrokecerebrovasdis.2015.05.019; Bjerkreim AT, 2018, STROKE RES TREAT, V2018, DOI 10.1155/2018/7195369; Boden-Albala B, 2013, STROKE, V44, pS48, DOI 10.1161/STROKEAHA.111.000396; Chapman C, 2020, INT J STROKE, V15, P390, DOI 10.1177/1747493019833008; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; Chuang Kun-Yang, 2005, J Nurs Res, V13, P117; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI [10.1016/S1474-4422(18)30499-X, 10.1136/bmj.l94, 10.1016/S1474-4422(19)30034-1]; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Hwong WY, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0984-1; Johnson BH, 2016, CLINICOECONOMIC OUTC, V8, P53, DOI 10.2147/CEOR.S95662; Kilkenny MF, 2013, STROKE, V44, P2260, DOI 10.1161/STROKEAHA.111.000531; Klehmet J, 2009, NEUROSCIENCE, V158, P1184, DOI 10.1016/j.neuroscience.2008.07.044; Lee SA, 2019, J INVEST MED, V67, P52, DOI 10.1136/jim-2018-000748; Li HW, 2011, J FORMOS MED ASSOC, V110, P627, DOI 10.1016/j.jfma.2011.08.004; Lichtman JH, 2013, STROKE, V44, P3429, DOI 10.1161/STROKEAHA.113.003165; Lin HJ, 2011, NEUROLOGY, V76, P438, DOI 10.1212/WNL.0b013e31820a0cd8; Marschner IC, 2011, R J, V3, P12; Michael E, 2012, ARPN J SCI TECHNOLOG, V2; Nakagawa K, 2016, STROKE, V47, P2611, DOI 10.1161/STROKEAHA.116.013669; Noh NA, 2016, SOC WORK PUBLIC HLTH, V31, P419, DOI 10.1080/19371918.2015.1125321; R Core Team, 2021, R LANG ENV STAT COMP; Rao A, 2016, STROKE RES TREAT, V2016, DOI 10.1155/2016/9325368; Shah SV, 2015, J STROKE CEREBROVASC, V24, P1969, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.037; Team RStudio, 2018, RSTUDIO INT DEV R; Vahidy FS, 2017, STROKE, V48, P1386, DOI 10.1161/STROKEAHA.116.016085; Wen TC, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1209-y; Zhong WB, 2016, NEUROL SCI, V37, P1195, DOI 10.1007/s10072-016-2570-5	37	2	2	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0245448	10.1371/journal.pone.0245448	http://dx.doi.org/10.1371/journal.pone.0245448			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY3TH	33465103	Green Published, gold			2023-01-03	WOS:000611969200002
J	Elliot, V; Morgan, D; Kosteniuk, J; Bayly, M; Chow, AF; Cammer, A; O'Connell, ME				Elliot, Valerie; Morgan, Debra; Kosteniuk, Julie; Bayly, Melanie; Froehlich Chow, Amanda; Cammer, Allison; O'Connell, Megan E.			Palliative and end-of-life care for people living with dementia in rural areas: A scoping review	PLOS ONE			English	Review							NURSING-HOME RESIDENTS; URBAN DIFFERENCES; HOSPICE CARE; TELEMEDICINE; NUTRITION	Background and objectives People living with dementia deserve to experience the benefits of receiving palliative care and end-of-life services and supports, yet they often do not receive this care compared to those with other terminal diseases. People living with dementia in rural areas often face additional challenges to accessing such care. The purpose of this scoping review was to systematically review and synthesize the literature on palliative and end-of-life care for people with dementia living in rural areas, and to identify and describe key findings and gaps in the literature. Methods A collaborative research team approach was used in an iterative process across all stages of this review. Systematic, comprehensive searches were conducted across ten databases and eight targeted websites for relevant peer-reviewed, original research and other less formal literature, published in English, which yielded a total of 4476 results. After duplicate removal, screening, and review, 24 items were included for synthesis. Results All items were described and illustrated by frequency distribution, findings were grouped thematically, and five key themes emerged, including: 1) Knowledge about dementia, 2) Availability, accessibility, and utilization of palliative and end-of-life care services and supports, 3) Decision-making about care, the value of a person-centered approach and collaborative support, 4) Perspectives on artificial nutrition, hydration, and comfort care, and 5) Quality of life and death. The main gap identified was literature pertaining to rural populations, especially from locations other than the United States. The influence of rurality on relevant findings was mixed across rural-urban comparison studies, as was the effect of sex and gender across the literature. Conclusions Several areas were highlighted including the importance of increasing knowledge about dementia, having early conversations about advanced care and treatment options, providing a person-centered approach, and the potential for using technology to address rural access issues. These findings can be used to inform future research and policy and the development of services, supports, and strategies for rural people living with dementia. Further research is recommended.	[Elliot, Valerie; Morgan, Debra; Kosteniuk, Julie; Bayly, Melanie] Univ Saskatchewan, Canadian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada; [Froehlich Chow, Amanda] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, Canada; [Cammer, Allison] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada; [O'Connell, Megan E.] Univ Saskatchewan, Dept Psychol, Saskatoon, SK, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Elliot, V (corresponding author), Univ Saskatchewan, Canadian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada.	v.elliot@usask.ca		Elliot, Valerie/0000-0002-6333-9744; morgan, danison/0000-0003-2418-9592	Canadian Consortium on Neurodegeneration in Aging (CCNA); Canadian Institutes of Health Research (CIHR) Foundation [148444]; Canadian Institutes of Health Research [CAN 137794]; Alzheimer Society of Canada; Centre for Aging and Brain Health Innovation; Saskatchewan Health Research Foundation	Canadian Consortium on Neurodegeneration in Aging (CCNA); Canadian Institutes of Health Research (CIHR) Foundation(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alzheimer Society of Canada; Centre for Aging and Brain Health Innovation; Saskatchewan Health Research Foundation	Study funding was provided by the Canadian Consortium on Neurodegeneration in Aging (CCNA) and a Canadian Institutes of Health Research (CIHR) Foundation Grant to DGM (grant number 148444). The CCNA is supported by a grant from the Canadian Institutes of Health Research (CAN 137794) with funding from several partners including the Alzheimer Society of Canada, the Centre for Aging and Brain Health Innovation, and the Saskatchewan Health Research Foundation.	Adsf Scheil-Adlung X, 2015, 47 ESS, P1; African Hunter, 2010, AFRICAN HUNTER, V13, pXI; Alzheimer Society of Canada, 2016, DEM END OF LIF CAR 2; Alzheimer's Society, 2016, RISK FACT DEM FACTSH; [Anonymous], 2019, WORLD ALZH REP 2019; [Anonymous], 2012, J AM COLL CARDIOL, V60, pe44; [Anonymous], 2016, SENSORS, V16, pC1, DOI 10.1109/JSEN.2016.2517933; [Anonymous], 2018, J BONE MINER RES, V33; Aparanji KP, 2010, J AM MED DIR ASSOC, V11, P453, DOI 10.1016/j.jamda.2009.11.016; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Bayly M, 2020, CAN J AGING, P1; Bramha S, 2019, SN APPL SCI, V1, DOI 10.1007/s42452-019-0716-9; Brundisini F, 2013, Ont Health Technol Assess Ser, V13, P1; Corbett T, 2015, J PAIN SYMPTOM MANAG, V49, P417, DOI 10.1016/j.jpainsymman.2014.11.201; Crouch E, 2017, RURAL REMOTE HEALTH, V17, DOI 10.22605/RRH4351; De Vleminck A, 2018, J AM MED DIR ASSOC, V19, P633, DOI 10.1016/j.jamda.2017.10.003; Dicharry J, 2010, CLIN SPORT MED, V29, P347, DOI 10.1016/j.csm.2010.03.013; Druml C, 2016, CLIN NUTR, V35, P545, DOI 10.1016/j.clnu.2016.02.006; Erel M, 2017, ANN PALLIAT MED, V6, P365, DOI 10.21037/apm.2017.06.13; Forbes DA, 2012, RURAL REMOTE HEALTH, V12; Franklin J, 2018, J PAIN SYMPTOM MANAG, V55, P603, DOI 10.1016/j.jpainsymman.2017.12.099; Gamiz B, 2019, AGRONOMY-BASEL, V9, DOI 10.3390/agronomy9100588; Gessert CE, 2006, J RURAL HEALTH, V22, P1, DOI 10.1111/j.1748-0361.2006.00013.x; Gessert CE, 2001, J RURAL HEALTH, V17, P16, DOI 10.1111/j.1748-0361.2001.tb00250.x; Gessert C, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1658-9; Gessert CE, 2006, J AM GERIATR SOC, V54, P1199, DOI 10.1111/j.1532-5415.2006.00824.x; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Hanlon N, 2016, ROUTL STUD HUM GEOGR, V56, P11; Harwood RH, 2014, J ROY COLL PHYS EDIN, V44, P232, DOI 10.4997/JRCPE.2014.310; Health Canada, 2002, CAN STRAT PALL END O; Herman C, 2013, AUSTRALAS J AGEING, V32, P26; Huff C, 2019, HEALTH AFFAIR, V38, P1971, DOI 10.1377/hlthaff.2019.01470; Johnston J, MEMORIES PROJECT PER; Kehl Karen A, 2006, Am J Hosp Palliat Care, V23, P277, DOI 10.1177/1049909106290380; Keyworth C, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0661-3; Kvedar J, 2014, HEALTH AFFAIR, V33, P194, DOI 10.1377/hlthaff.2013.0992; Lethin C, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3592-x; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Mackie SD, 2011, J THEOL STUD, V62, P77, DOI 10.1093/jts/flr026; Menon PR, 2011, AM J RESP CRIT CARE, pA1670, DOI [10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A1670, DOI 10.1164/AJRCCM-CONFERENCE.2011.183.1_MEETINGABSTRACTS.A1670]; Miller SC, 2010, AM J ALZHEIMERS DIS, V25, P666, DOI 10.1177/1533317510385809; Mitchell SL, 2007, J PAIN SYMPTOM MANAG, V34, P7, DOI 10.1016/j.jpainsymman.2007.01.003; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Noel MA, 2017, J APPL GERONTOL, V36, P195, DOI 10.1177/0733464815589986; O'Connell M. E., 2018, GERONTECHNOLOGY, V17, P126, DOI DOI 10.4017/GT.2018.17.3.001.00; O'Connell ME, 2014, DEMENTIA-LONDON, V13, P382, DOI 10.1177/1471301212474143; Peters M. D. J., 2020, JBI MANUAL EVIDENCE, DOI [DOI 10.46658/JBIMES-20-01, 10.46658/JBIMES-20-12]; Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; Salomon ALR, 2015, J NUTR HEALTH AGING, V19, P169, DOI 10.1007/s12603-014-0517-1; Scerbe A, 2019, EDUC GERONTOL, V45, P681, DOI 10.1080/03601277.2019.1687149; Schulze J, 2016, AM J ALZHEIMERS DIS, V31, P27, DOI 10.1177/1533317515588180; Smith Lenora, 2016, Home Healthc Now, V34, P478, DOI 10.1097/NHH.0000000000000459; Smoliner C, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-52; The Lancet Global Health, 2018, LANCET GLOB HLTH, V6, pE593; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; United Nations, 2019, WORLD URBANIZATION P; Volandes AE, 2011, J PALLIAT MED, V14, P169, DOI 10.1089/jpm.2010.0299; World Health Organization, 2017, GLOB ACT PLAN REP HL; World Health Organization (WHO), COMM BAS SERV DEM PA; World Health Organization (WHO), 2018, IND MET REG INT LIF; Worldwide Hospice Palliative Care Alliance, 2015, 1 WHO MIN C GLOB ACT; Worldwide Palliative Care Alliance and World Health Organization, 2014, GLOB ATL PALL CAR EN	62	2	2	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0244976	10.1371/journal.pone.0244976	http://dx.doi.org/10.1371/journal.pone.0244976			39	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PV4VV	33444351	Green Published, gold			2023-01-03	WOS:000609988100030
J	Lacy, BE; Shea, EP; Manuel, M; Abel, JL; Jiang, HC; Taylor, DCA				Lacy, Brian E.; Shea, Elizabeth P.; Manuel, Machelle; Abel, Jessica L.; Jiang, Hancheng; Taylor, Douglas C. A.			Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medications	PLOS ONE			English	Article								Introduction Chronic idiopathic constipation (CIC) is a prevalent functional gastrointestinal disorder diagnosed based on patient-reported symptoms and the absence of structural gastrointestinal abnormalities. Individuals with CIC typically institute dietary changes and use stool softeners or over-the-counter (OTC) laxatives, possibly at the direction of a healthcare provider, before prescription medications for CIC are initiated. Although highly prevalent, there is limited information regarding CIC patient experiences with OTC medications. Methods This post-hoc analysis used patient-reported data from a questionnaire administered during patient screening for a prospective linaclotide Phase 3b clinical trial in patients with CIC (N = 1482 screened). The questionnaire asked patients to report their experiences with OTC CIC medications over the preceding 6 months. Results Among patients with screening responses (N = 1423), most were female (85%) and white (66%), with a mean age of 48.9 years. A high proportion of patients had used one or more OTC medications (70% had >= 1 OTC; 19% had >= 3 OTCs), with the majority being bisacodyl (33%) and polyethylene glycol (30%). The most commonly cited reason for stopping an OTC medication was insufficient symptom relief (17-40%). The majority of patients taking OTC medications reported no or little satisfaction with the medication's effect on their constipation (62%) and CIC-specific abdominal symptoms (78%). Many patients had little to no confidence in bowel movement (BM) frequency after taking OTC medications and their confidence in their ability to predict BM timing was also low (49-81% not at all confident). Conclusions Treatment effects on individual CIC symptoms, predictability of bowel habits, and satisfaction with treatment are all important factors for healthcare providers and patients to consider when establishing an effective treatment regimen for CIC.	[Lacy, Brian E.] Mayo Clin, Gastroenterol & Hepatol, Jacksonville, FL 32224 USA; [Shea, Elizabeth P.] Ironwood Pharmaceut Inc, Med Writing & Publicat, Boston, MA USA; [Manuel, Machelle; Jiang, Hancheng] Ironwood Pharmaceut Inc, Boston, MA USA; [Abel, Jessica L.] AbbVie Inc, Global Hlth Econ & Outcomes Res, Madison, NJ USA; [Taylor, Douglas C. A.] Ironwood Pharmaceut Inc, Hlth Econ & Outcomes Res, Boston, MA USA	Mayo Clinic; Ironwood Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; AbbVie; Ironwood Pharmaceuticals, Inc.	Lacy, BE (corresponding author), Mayo Clin, Gastroenterol & Hepatol, Jacksonville, FL 32224 USA.	Lacy.Brian@mayo.edu			Allergan plc; AbbVie Inc.; Ironwood Pharmaceuticals, Inc., Boston, MA, USA; Ironwood Pharmaceuticals, Inc.	Allergan plc(AbbVieAllergan); AbbVie Inc.(AbbVie); Ironwood Pharmaceuticals, Inc., Boston, MA, USA; Ironwood Pharmaceuticals, Inc.	This analysis was sponsored by Allergan plc (prior to acquisition by AbbVie Inc.) and/or AbbVie Inc. and Ironwood Pharmaceuticals, Inc., Boston, MA, USA. The funders provided support in the form of salaries for authors [EPS, MM, JLA, HJ, and DCAT] who had a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. The specific roles of these authors are articulated in the "Author Contributions" section." Support for writing assistance was funded by Allergan plc (prior to acquisition by AbbVie, Inc.) and/or AbbVie, Inc. and Ironwood Pharmaceuticals, Inc.	American Gastroenterological Association, 2013, Gastroenterology, V144, P211, DOI 10.1053/j.gastro.2012.10.029; Bellini M, 2015, WORLD J GASTROENTERO, V21, P11362, DOI 10.3748/wjg.v21.i40.11362; Chang L, 2014, ALIMENT PHARM THER, V40, P1302, DOI 10.1111/apt.12985; Drossman DA, 1999, ROME 2 MULTINATIONAL; Emmanuel A, 2013, UNITED EUR GASTROENT, V1, P375, DOI 10.1177/2050640613494200; Eoff JC, 2008, J MANAGE CARE PHARM, V14, pS3; Ervin Claire M, 2014, Clin Exp Gastroenterol, V7, P191, DOI 10.2147/CEG.S58321; Ford AC, 2014, AM J GASTROENTEROL, V109, pS2, DOI 10.1038/ajg.2014.187; Harris LA, 2017, ADV THER, V34, P2661, DOI 10.1007/s12325-017-0633-5; Heidelbaugh JJ, 2015, AM J GASTROENTEROL, V110, P580, DOI 10.1038/ajg.2015.67; Higgins PDR, 2004, AM J GASTROENTEROL, V99, P750, DOI 10.1111/j.1572-0241.2004.04114.x; Johanson JF, 2007, ALIMENT PHARM THER, V25, P599, DOI 10.1111/j.1365-2036.2006.03238.x; Kamm MA, 2011, CLIN GASTROENTEROL H, V9, P577, DOI 10.1016/j.cgh.2011.03.026; Lacy BE, 2016, GASTROENTEROLOGY, V150, P1393, DOI 10.1053/j.gastro.2016.02.031; Lacy BE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134349; Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208; McCormick D, 2019, AM J MANAG CARE, V25, pS63; Menees SB, 2015, AM J GASTROENTEROL, V110, P1516, DOI 10.1038/ajg.2015.156; Muller-Lissner S, 2013, ALIMENT PHARM THER, V37, P137, DOI 10.1111/apt.12124; Norton NJ, 2016, AM J GASTROENTEROL, V111, P451, DOI 10.1038/ajg.2016.81; Sbahi Hani, 2015, Curr Gastroenterol Rep, V17, P47, DOI 10.1007/s11894-015-0471-z; Thompson WG, 1999, GUT, V45, P43	22	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2021	16	1							e0243318	10.1371/journal.pone.0243318	http://dx.doi.org/10.1371/journal.pone.0243318			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY4UJ	33428631	Green Published, gold			2023-01-03	WOS:000630036100010
J	Hamilton, MA; Calzavara, A; Emerson, SD; Djebli, M; Sundaram, ME; Chan, AK; Kustra, R; Baral, SD; Mishra, S; Kwong, JC				Hamilton, Mackenzie A.; Calzavara, Andrew; Emerson, Scott D.; Djebli, Mohamed; Sundaram, Maria E.; Chan, Adrienne K.; Kustra, Rafal; Baral, Stefan D.; Mishra, Sharmistha; Kwong, Jeffrey C.			Validating International Classification of Disease 10(th) Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations	PLOS ONE			English	Article							DIAGNOSIS; CODES	Objective Routinely collected health administrative data can be used to efficiently assess disease burden in large populations, but it is important to evaluate the validity of these data. The objective of this study was to develop and validate International Classification of Disease 10(th) revision (ICD -10) algorithms that identify laboratory-confirmed influenza or laboratory-confirmed respiratory syncytial virus (RSV) hospitalizations using population-based health administrative data from Ontario, Canada. Study design and setting Influenza and RSV laboratory data from the 2014-15, 2015-16, 2016-17 and 2017-18 respiratory virus seasons were obtained from the Ontario Laboratories Information System (OLIS) and were linked to hospital discharge abstract data to generate influenza and RSV reference cohorts. These reference cohorts were used to assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the ICD-10 algorithms. To minimize misclassification in future studies, we prioritized specificity and PPV in selecting top-performing algorithms. Results 83,638 and 61,117 hospitalized patients were included in the influenza and RSV reference cohorts, respectively. The best influenza algorithm had a sensitivity of 73% (95% CI 72% to 74%), specificity of 99% (95% CI 99% to 99%), PPV of 94% (95% CI 94% to 95%), and NPV of 94% (95% CI 94% to 95%). The best RSV algorithm had a sensitivity of 69% (95% CI 68% to 70%), specificity of 99% (95% CI 99% to 99%), PPV of 91% (95% CI 90% to 91%) and NPV of 97% (95% CI 97% to 97%). Conclusion We identified two highly specific algorithms that best ascertain patients hospitalized with influenza or RSV. These algorithms may be applied to hospitalized patients if data on laboratory tests are not available, and will thereby improve the power of future epidemiologic studies of influenza, RSV, and potentially other severe acute respiratory infections.	[Hamilton, Mackenzie A.; Calzavara, Andrew; Emerson, Scott D.; Djebli, Mohamed; Sundaram, Maria E.; Kwong, Jeffrey C.] ICES, Toronto, ON, Canada; [Hamilton, Mackenzie A.; Djebli, Mohamed; Chan, Adrienne K.; Kustra, Rafal; Kwong, Jeffrey C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Chan, Adrienne K.; Mishra, Sharmistha] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Chan, Adrienne K.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Infect Dis, Toronto, ON, Canada; [Baral, Stefan D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Mishra, Sharmistha] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON, Canada; [Mishra, Sharmistha] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Kwong, Jeffrey C.] St Michaels Hosp, MAP Ctr Urban Hlth Solut, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Kwong, Jeffrey C.] Publ Hlth Ontario, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Hlth Network, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Toronto, Ctr Vaccine Preventable Dis, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Kwong, JC (corresponding author), ICES, Toronto, ON, Canada.; Kwong, JC (corresponding author), Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.; Kwong, JC (corresponding author), Publ Hlth Ontario, Toronto, ON, Canada.; Kwong, JC (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.; Kwong, JC (corresponding author), Univ Hlth Network, Toronto, ON, Canada.; Kwong, JC (corresponding author), Univ Toronto, Ctr Vaccine Preventable Dis, Toronto, ON, Canada.	jeff.kwong@utoronto.ca	Baral, Stefan/AAG-4818-2020	Baral, Stefan/0000-0002-5482-2419; Mishra, Sharmistha/0000-0001-8492-5470; Hamilton, Mackenzie A./0000-0003-2423-3629	Canadian Institutes of Health Research [PJT 159516, VR5 172683]; St. Michael's Hospital Foundation Research Innovation Council; Tier 2 Canada Research Chair in Mathematical Modelling and Program Science (CRC) [950-232643]; University of Toronto Department of Family and Community Medicine; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); St. Michael's Hospital Foundation Research Innovation Council; Tier 2 Canada Research Chair in Mathematical Modelling and Program Science (CRC); University of Toronto Department of Family and Community Medicine; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	This study was funded by the Canadian Institutes of Health Research (JCK, PJT 159516, https://cihr-irsc.gc.ca/e/193.html; SM, VR5 172683; https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=430319&lang=en) and a St. Michael's Hospital Foundation Research Innovation Council's 2020 COVID-19 Research Award (SM; https://secure3.convio.net/smh/site/SPageNavigator/RIC2019.html). SM is supported by a Tier 2 Canada Research Chair in Mathematical Modelling and Program Science (CRC number 950-232643). JCK is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amodio E, 2014, MED PRIN PRACT, V23, P568, DOI 10.1159/000364780; BRENNER H, 1993, AM J EPIDEMIOL, V138, P1007, DOI 10.1093/oxfordjournals.aje.a116805; Buda S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4515-1; Cai W, 2020, INFLUENZA OTHER RESP, V14, P630, DOI 10.1111/irv.12665; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Feemster KA, 2013, J PEDIATR INFECT DIS, V2, P63, DOI 10.1093/jpids/pis052; Keren R, 2006, EMERG INFECT DIS, V12, P1603, DOI 10.3201/eid1210.051525; Kwong JC, 2019, VACCINE, V37, P4392, DOI 10.1016/j.vaccine.2019.06.011; Marsden-Haug N, 2007, EMERG INFECT DIS, V13, P207, DOI 10.3201/eid1302.060557; Moore HC, 2014, J PEDIATR INFECT DIS, V3, P255, DOI 10.1093/jpids/pit036; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595; Pisesky A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150416; Public Health Ontario, ONT RESP PATH B; Sivashankaran S, 2020, AMIA ANN S P, V2019, P804; Varela LO, 2019, 2019 IEEE WORKSHOP ON VISUAL ANALYTICS IN HEALTHCARE (VAHC), P60, DOI 10.1109/VAHC47919.2019.8945033	16	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244746	10.1371/journal.pone.0244746	http://dx.doi.org/10.1371/journal.pone.0244746			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411792	gold, Green Published			2023-01-03	WOS:000608044300058
J	Singh, H; Carayon, P				Singh, Hardeep; Carayon, Pascale			A Roadmap to Advance Patient Safety in Ambulatory Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint emphasizes the need for research and initiatives related to patient safety in outpatient settings and proposes practice, policy, and patient and caregiver milestones to give patient harm reduction in ambulatory care settings the same priority as in inpatient settings.	[Singh, Hardeep] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA; [Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA; [Carayon, Pascale] Univ Wisconsin, Wisconsin Inst Healthcare Syst Engn, Dept Ind & Syst Engn, Madison, WI USA	Baylor College of Medicine; Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison	Singh, H (corresponding author), 2002 Holcombe Blvd,Ste 152, Houston, TX 77030 USA.	hardeeps@bcm.edu			Houston Veterans Administration (VA) Health Services Research and Development (HSR&D) Center for Innovations in Quality, Effectiveness, and Safety [CIN13-413]; VA HSRD Service [CRE17-127, USA 14-274]; VA National Center for Patient Safety; Agency for Healthcare Research and Quality (AHRQ) [R01HS27363]; CanTest Research Collaborative - Cancer Research UK Population Research Catalyst award [C8640/A23385]; Gordon and Betty Moore Foundation; AHRQ [R01HS022086, R18HS026624]; Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences [UL1TR002373]	Houston Veterans Administration (VA) Health Services Research and Development (HSR&D) Center for Innovations in Quality, Effectiveness, and Safety; VA HSRD Service; VA National Center for Patient Safety; Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); CanTest Research Collaborative - Cancer Research UK Population Research Catalyst award; Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences	Dr Singh is funded in part by the Houston Veterans Administration (VA) Health Services Research and Development (HSR&D) Center for Innovations in Quality, Effectiveness, and Safety (CIN13-413), the VA HSR&D Service (CRE17-127 and the Presidential Early Career Award for Scientists and Engineers USA 14-274), the VA National Center for Patient Safety, the Agency for Healthcare Research and Quality (AHRQ) (R01HS27363), the CanTest Research Collaborative funded by a Cancer Research UK Population Research Catalyst award (C8640/A23385), and the Gordon and Betty Moore Foundation. Dr Carayon is funded in part by AHRQ (R01HS022086; R18HS026624) and the Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences (UL1TR002373).	Bates DW, 2018, HEALTH AFFAIR, V37, P1736, DOI 10.1377/hlthaff.2018.0738; Carayon P, 2020, APPL ERGON, V84, DOI 10.1016/j.apergo.2019.103033; Famolaro T, 2020, AHRQ PUBLICATION; Millenson ML, 2018, DIAGNOSIS, V5, P95, DOI 10.1515/dx-2018-0009; Panesar SS, 2016, BMJ QUAL SAF, V25, P544, DOI 10.1136/bmjqs-2015-004178; Powell L, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.6752; Sarkar U, 2011, HEALTH SERV RES, V46, P1517, DOI 10.1111/j.1475-6773.2011.01269.x; Sharma A, 2020, JT COMM J QUAL PATIE; Singh H, 2014, BMJ QUAL SAF, V23, P727, DOI 10.1136/bmjqs-2013-002627	9	6	6	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	2020	324	24					2481	2482		10.1001/jama.2020.18551	http://dx.doi.org/10.1001/jama.2020.18551			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PO2FZ	33351052	Green Accepted			2023-01-03	WOS:000604986900014
J	Friedrich, MS; Studt, JD; Braun, J; Spahn, DR; Kaserer, A				Friedrich, Marie Sophie; Studt, Jan-Dirk; Braun, Julia; Spahn, Donat R.; Kaserer, Alexander			Coronavirus-induced coagulopathy during the course of disease	PLOS ONE			English	Article							FIBRINOGEN	Background A significant proportion of patients with coronavirus disease 19 (COVID-19) suffer from excessive coagulation activation and coagulopathy which is associated with an increased risk of venous and arterial thromboembolism and adverse outcome. Our study investigates coagulation markers and the incidence of thromboembolic events in COVID-19 patients receiving recommended anticoagulation strategies. Methods In a retrospective single-center analysis at the University Hospital Zurich, Switzerland, we investigated 31 adult COVID-19 patients between April 6(th) and May 13(th), 2020 and with at least one laboratory assessment of the coagulation markers prothrombin time/Quick, thrombin time, fibrinogen and D-dimers. For antithrombotic prophylaxis low-molecular-weight-heparin or unfractionated heparin was administered and two patients with heparin-induced thrombocytopenia received argatroban. Results We analyzed 31 patients (68% male, mean age 60 +/- SD 15 years). 22 (71%) of these required intensive care unit treatment, 5 (16%) were hospitalized in a ward, and 4 (13%) were outpatients. Mean fibrinogen levels were markedly elevated to 6.4 +/- SD 1.8g/l, with a peak in the third week of the disease and no significant decrease over time. D-dimers were elevated to a mean value of 5.1 +/- 4.4mg/l with peak levels of 6.8 +/- 5.3mg/l in the fourth week of disease, and a subsequent decrease. Platelet count (308 +/- 136G/l) and PT/Quick (85 +/- 22%) showed no significant changes over time. Sensitivity analyses for patients treated in the ICU showed that D-dimer levels were higher in this group. The results of other sensitivity analyses were comparable. Thromboembolic events were diagnosed in 4 (13%) patients and 5 (16%) patients died during the observation period. Conclusion We find coagulation alterations in COVID-19 patients indicating significant hypercoagulability. These alterations are visible despite antithrombotic treatment, and peak around week 3-4 of the disease.	[Friedrich, Marie Sophie; Spahn, Donat R.; Kaserer, Alexander] Univ Zurich, Inst Anesthesiol, Zurich, Switzerland; [Friedrich, Marie Sophie; Studt, Jan-Dirk; Spahn, Donat R.; Kaserer, Alexander] Univ Hosp Zurich, Zurich, Switzerland; [Studt, Jan-Dirk] Univ Zurich, Div Med Oncol & Hematol, Zurich, Switzerland; [Braun, Julia] Univ Zurich, Biostat & Prevent Inst, Dept Epidemiol & Biostat, Zurich, Switzerland; [Braun, Julia] Univ Zurich, Biostat & Prevent Inst, Dept Epidemiol, Zurich, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University of Zurich; University of Zurich	Kaserer, A (corresponding author), Univ Zurich, Inst Anesthesiol, Zurich, Switzerland.; Kaserer, A (corresponding author), Univ Hosp Zurich, Zurich, Switzerland.	alexander.kaserer@usz.ch		Kaserer, Alexander/0000-0001-9105-8328				Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520; Atallah B, 2021, ANAESTHESIA, V76, P327, DOI 10.1111/anae.15300; BAUMANN H, 1990, MOL BIOL MED, V7, P147; Casini Alessandro, 2020, Swiss Med Wkly, V150, pw20247, DOI 10.4414/smw.2020.20247; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Franchini M, 2020, DIAGNOSIS, V7, P357, DOI 10.1515/dx-2020-0078; Gesellschaft fur Thrombose und Hamostaseforschung, AKT EMPF ZUR THROMB; Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975; Ikewaki N, 2020, THROMB J, V18, DOI 10.1186/s12959-020-00239-6; Kattula S, 2017, ARTERIOSCL THROM VAS, V37, pE13, DOI 10.1161/ATVBAHA.117.308564; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Liao S, 2014, J THROMB HAEMOST, V12, P214, DOI 10.1111/jth.12464; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Maatman TK, 2020, CRIT CARE MED, V48, pE783, DOI 10.1097/CCM.0000000000004466; Machlus KR, 2011, BLOOD, V117, P4953, DOI 10.1182/blood-2010-11-316885; Poterucha TJ, 2017, THROMB HAEMOSTASIS, V117, P437, DOI 10.1160/TH16-08-0620; Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Susen S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03000-7; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Thachil J, 2020, J THROMB HAEMOST, V18, P1849, DOI 10.1111/jth.14942; Thachil J, 2020, J THROMB HAEMOST, V18, P1795, DOI 10.1111/jth.14841; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Walton BL, 2015, J THROMB HAEMOST, V13, pS208, DOI 10.1111/jth.12918; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wool GD, 2021, PATHOBIOLOGY, V88, P15, DOI 10.1159/000512007; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	33	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2020	15	12							e0243409	10.1371/journal.pone.0243409	http://dx.doi.org/10.1371/journal.pone.0243409			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8BZ	33332362	Green Accepted, Green Published, gold			2023-01-03	WOS:000601310900061
J	Yu, HL; Gu, DY; Qian, PD				Yu, Hongliang; Gu, Dayong; Qian, Pudong			Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-BETA; CELL LUNG-CANCER; VINORELBINE PLUS CISPLATIN; MESSENGER-RNA EXPRESSION; SURVIVAL; IDENTIFICATION; ASSOCIATION; SIGNATURES; GENES	Background Prognostic biomarker, which can inform the treatment outcome of adjuvant chemotherapy (ACT) after complete resection of early-stage non-small cell lung cancer (NSCLC), is urgently needed for the personalized treatment of these patients. Patients and methods The prognostic value of gene expression of the estrogen receptor (ER) on the effect of ACT in completely resected NSCLC was investigated in the present study. Two independent datasets from Gene Expression Omnibus (GEO) with a total of 309 patients were included in this study. The prognostic value of ER gene expression on ACT's efficacy was evaluated by survival analysis and Cox hazards models. Results We found a consistent and significant prognostic value of ER beta (ESR2) expression for ACT's efficacy in completely resected NSCLC in both of the two independent cohorts. After multivariate adjustment, a significant survival benefit of ACT was observed in patients with low expression of ESR2, with a hazard ratio (HR) of 0.19 (95%CI 0.05-0.82, p = 0.026) in the discovery cohort and an HR of 0.27 (95%CI 0.10-0.76, p = 0.012) in the validation group. No significant benefit of ACT in the subgroup of patients with high expression of ESR2 was observed, with an HR of 0.80 (95%CI 0.31-2.09, p = 0.644) in the discovery cohort and an HR of 1.05 (95%CI 0.48-2.29, p = 0.896) in the validation group. Conclusion A significant survival benefit from ACT was observed in patients with low ESR2 expression. No significant survival benefit was observed in patients with high ESR2 expression. Detection of ESR2 expression in NSCLC may help personalize its treatment after complete resection.	[Qian, Pudong] Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Qian, PD (corresponding author), Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China.	qpd201210@163.com	Qian, Pu/GZM-2400-2022	Yu, Hongliang/0000-0003-2404-4158	fund of key project of Jiangsu Cancer Hospital [ZK201607]; Natural Science Foundation of China [81701722]	fund of key project of Jiangsu Cancer Hospital; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was partially supported by the fund of key project of Jiangsu Cancer Hospital (No. ZK201607), and the Natural Science Foundation of China (No.81701722).	Atmaca A, 2014, INT J CANCER, V134, P2314, DOI 10.1002/ijc.28571; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583; Fan S, 2017, ONCOTARGET, V8, P56443, DOI 10.18632/oncotarget.16992; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Lee ES, 2008, CLIN CANCER RES, V14, P7397, DOI 10.1158/1078-0432.CCR-07-4937; Li WT, 2015, STEROIDS, V104, P129, DOI 10.1016/j.steroids.2015.09.005; Liu ZG, 2013, ENDOCRINE, V44, P517, DOI 10.1007/s12020-013-9916-z; Luo Z, 2015, INT J CLIN EXP MED, V8, P8686; Nose N, 2009, J CLIN ONCOL, V27, P411, DOI 10.1200/JCO.2008.18.3251; Pignon JP, 2008, J CLIN ONCOL, V26, P3552, DOI 10.1200/JCO.2007.13.9030; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; Sainz J, 2011, ENDOCR-RELAT CANCER, V18, P265, DOI 10.1530/ERC-10-0264; Schwartz AG, 2005, CLIN CANCER RES, V11, P7280, DOI 10.1158/1078-0432.CCR-05-0498; Siegfried JM, 2009, SEMIN ONCOL, V36, P524, DOI 10.1053/j.seminoncol.2009.10.004; Smida T, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00137; Stabile LP, 2011, CLIN CANCER RES, V17, P154, DOI 10.1158/1078-0432.CCR-10-0992; Stabile LP, 2002, CANCER RES, V62, P2141; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Tang H, 2013, CLIN CANCER RES, V19, P1577, DOI 10.1158/1078-0432.CCR-12-2321; Verma MK, 2012, LIFE SCI, V91, P800, DOI 10.1016/j.lfs.2012.08.029; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Wu CT, 2005, J THORAC CARDIOV SUR, V130, P979, DOI 10.1016/j.jtcvs.2005.06.012; Yu HL, 2017, ONCOTARGETS THER, V10, P3017, DOI 10.2147/OTT.S132071; Zhang GF, 2010, MOL ENDOCRINOL, V24, P1737, DOI 10.1210/me.2010-0125; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; Zhu CQ, 2010, J CLIN ONCOL, V28, P4417, DOI 10.1200/JCO.2009.26.4325; Zhu CQ, 2009, CLIN LUNG CANCER, V10, P331, DOI 10.3816/CLC.2009.n.045	28	0	0	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2020	15	12							e0243891	10.1371/journal.pone.0243891	http://dx.doi.org/10.1371/journal.pone.0243891			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8BZ	33332474	Green Published, gold			2023-01-03	WOS:000601310900054
J	Chibi, B; Yende-Zuma, N; Mashamba-Thompson, TP				Chibi, Buyisile; Yende-Zuma, Nonhlanhla; Mashamba-Thompson, Tivani P.			Prevalence and correlates of prescription drug diversion and misuse among people living with HIV in the eThekwini district, KwaZulu-Natal, South Africa	PLOS ONE			English	Article							COMMUNITY-BASED COHORT; POSITIVE SUBSTANCE-ABUSERS; OPIOID ANALGESIC MISUSE; MEDICATION ADHERENCE; USE HISTORY; POPULATIONS; DEPENDENCE; BEHAVIORS; MODEL; PAIN	Background Prescription drug diversion, and misuse has increased over the past decade and is notably in high-income-countries and significantly contributes to the opioid epidemic. People living with HIV (PLWH) are particularly vulnerable to prescription drug diversion, and misuse as most experience chronic pain, mental health problems and HIV-related illnesses. The researchers investigated the prevalence and correlates of prescription drug diversion, and misuse among PLWH in the eThekwini district, KwaZulu-Natal. Methods A cross-sectional study was conducted among 392 PLWH, conveniently recruited from the public healthcare facilities located in rural, semi-urban and urban areas of the eThekwini district. Participants answered questions about their background, prescription medications, substance use, and prescription drug diversion, and misuse. Descriptive analysis was performed to estimate the prevalence of prescription drug diversion, and misuse. Multivariable logistic regression was used to identify predictors of prescription drug diversion, and misuse. Findings Overall, 13% of the participants reported lifetime prescription drug diversion. The most common type of diversion was using prescription medication not prescribed by a healthcare provider (11%), followed by sharing of prescription medication (9%) and buying prescription medication without a medical script (5%). Twenty-three per cent of the participants reported prescription drug misuse in the past 90 days, with using prescription medication without a healthcare providers' guidance (9%) and not following the scheduled time periods (8%) being the most common reported types of misuse. Self-medicating was identified as a risk factor for prescription drug misuse. There was no association between ART adherence and prescription drug diversion, and misuse. Conclusion The study findings contribute to improving the limited data available on prescription drug diversion, and misuse among PLWH in South Africa. The prevalence underscores a need for urgent interventions when prescribing medications with potential risks. Addressing the risk of self-medicating is imperative for HIV care outcomes and to avert death.	[Chibi, Buyisile; Mashamba-Thompson, Tivani P.] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa; [Chibi, Buyisile; Yende-Zuma, Nonhlanhla] Doris Duke Med Res Inst, Ctr AIDS Programme Res South Africa, Durban, South Africa; [Mashamba-Thompson, Tivani P.] Univ Limpopo, Dept Publ Hlth, Fac Hlth Sci, Mankweng, Limpopo Provinc, South Africa	University of Kwazulu Natal; University of Limpopo	Chibi, B (corresponding author), Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa.; Chibi, B (corresponding author), Doris Duke Med Res Inst, Ctr AIDS Programme Res South Africa, Durban, South Africa.	chibuyi@gmail.com	Mashamba-Thompson, Tivani/GRO-3709-2022	Mashamba-Thompson, Tivani/0000-0002-4193-2416; Chibi, Buyisile/0000-0003-1912-8402	Buyisile Chibi Grant [107620]; National Research Foundation Buyisile Chibi Grant	Buyisile Chibi Grant; National Research Foundation Buyisile Chibi Grant	Buyisile Chibi Grant no. 107620 National Research Foundation Buyisile Chibi Grant no. N/A University of KwaZulu-Natal, College of Health Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdool Karim SS, 2015, OVERCOMING IMPEDIMEN; [Anonymous], 2018, BRIEF REPORTS REV, V13, P12, DOI [10.1142/S1793292018500704, DOI 10.1142/S17932920185007041850070]; Assembly UN General, 2016, POL DECL HIV AIDS FA; Bulbul F, 2014, KLIN PSIKOFARMAKOL B, V24, P135, DOI 10.5455/bcp.20130925022443; Casati A, 2012, EUR ADDICT RES, V18, P228, DOI 10.1159/000337028; Centers for Disease Control and Prevention (CDC), 2012, MMWR MORB MORTAL WKL, V61, P10; Chibi B, 2019, PUBLIC HEALTH, V177, P26, DOI 10.1016/j.puhe.2019.07.017; Chibi B, 2020, INT J EVID-BASED HEA, V18, P5, DOI 10.1097/XEB.0000000000000167; Council HSR, 2018, 5 S AFR NAT HIV PREV; Dada S, 2015, SAMJ, S. Afr. med. j., V105, P776, DOI [10.7196/SAMJNEW.8172, 10.7196/SAMJnew.8172]; Daniel W. W., 2009, BIOSTATISTICS FDN AN; Deeks A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-213; Deiss R, 2018, OPEN FORUM INFECT DI, P5; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Flores J, 2018, AIDS BEHAV, V22, P1323, DOI 10.1007/s10461-017-1842-2; Foley M, 2018, SAJP-S AFR J PSYCHI, V24, DOI 10.4102/sajpsychiatry.v24.i0.1162; Ford J, 2017, SUBST USE MISUSE, V52, P1772, DOI 10.1080/10826084.2017.1311348; Gelberg L, 2000, HEALTH SERV RES, V34, P1273; Genberg BL, 2013, ADDICT BEHAV, V38, P2868, DOI 10.1016/j.addbeh.2013.08.008; Gumede-Moyo S, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008055; Haddad M, 2017, J PUBLIC HEALTH RES, V6, P24, DOI 10.4081/jphr.2017.818; Hansen L, 2011, J PAIN SYMPTOM MANAG, V42, P893, DOI 10.1016/j.jpainsymman.2011.02.026; Inciardi JA, 2006, SUBST USE MISUSE, V41, P255, DOI 10.1080/10826080500391829; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; Jeevanjee S, 2014, AIDS BEHAV, V18, P1352, DOI 10.1007/s10461-013-0619-5; Kamangar F, 2012, ARCH IRAN MED, V15, P508, DOI 012158/AIM.0014; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kurtz SP, 2014, AIDS CARE, V26, P411, DOI 10.1080/09540121.2013.837139; National Department of Health (NDoH) SSASS South African Medical Research Council (SAMRC) and ICF, 2019, S AFR DEM HLTH SURV; Newville H, 2015, J SUBST ABUSE TREAT, V48, P56, DOI 10.1016/j.jsat.2014.07.013; NIDA, 2020, GLOSSARY; OGRADY CL, 2014, DRUG ALCOHOL DEPEN, V140, pE164; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Parry CDH, 2017, SAMJ S AFR MED J, V107, P451, DOI [10.7196/SAMJ.2017.v107i5.12242, 10.7196/samj.2017.v107i5.12242]; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peng DD, 2018, GLOBAL HEALTH ACTION, V11, DOI 10.1080/16549716.2018.1496973; Prejean J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017502; Robinson-Papp J, 2012, JAIDS-J ACQ IMM DEF, V61, P187, DOI 10.1097/QAI.0b013e3182683c98; Rough K, 2014, AIDS BEHAV, V18, P1378, DOI 10.1007/s10461-013-0683-x; Roux P, 2011, HARM REDUCT J, V8, DOI 10.1186/1477-7517-8-31; Shirzadeh E, 2016, ACTA FAC MEDICAE NAI, V33, P287, DOI 10.1515/afmnai-2016-0030; Substance Abuse and Mental Health Services Administration, 2019, KEY SUBSTANCE USE ME, VH-54; Surratt HL, 2015, AM J PUBLIC HEALTH, V105, P1660, DOI 10.2105/AJPH.2015.302612; Surratt HL, 2015, AIDS CARE, V27, P307, DOI 10.1080/09540121.2014.967656; Surratt HL, 2013, AM J PUBLIC HEALTH, V103, P1026, DOI 10.2105/AJPH.2012.301092; Tsao JCI, 2007, PAIN, V133, P128, DOI 10.1016/j.pain.2007.03.016; Tsao Jennie C I, 2012, J Pain Manag, V5, P111; Tsao JCI, 2010, PAIN MED, V11, P815, DOI 10.1111/j.1526-4637.2010.00858.x; Tsuyuki K, 2015, AIDS BEHAV, V19, P869, DOI 10.1007/s10461-014-0969-7; Tsuyuki K, 2015, AIDS BEHAV, V19, P857, DOI 10.1007/s10461-014-0856-2; Turner AN, 2016, AIDS CARE, V28, P1559, DOI 10.1080/09540121.2016.1198746; United Nations Joint Programme on HIV/AIDS (UNAIDS), GLOB AIDS UPD 2019 C; Van Hout MC, 2017, BEHAV COGN PSYCHOTH, V45, P238, DOI 10.1017/S1352465817000030; Van Hout MC, 2017, QUAL HEALTH RES, V27, P341, DOI 10.1177/1049732315613764; Venables W, 1997, INTRO R NOTES R PROG; Vijayaraghavan M, 2014, DRUG ALCOHOL DEPEN, V143, P263, DOI 10.1016/j.drugalcdep.2014.06.044; Vijayaraghavan M, 2013, JAMA INTERN MED, V173, P235, DOI 10.1001/jamainternmed.2013.1576; Vijayaraghavan M, 2011, J GEN INTERN MED, V26, P412, DOI 10.1007/s11606-010-1555-y; Wang XM, 2017, INT J ANTIMICROB AG, V50, P441, DOI 10.1016/j.ijantimicag.2017.04.009; Wazaify M, 2014, SUBST USE MISUSE, V49, P1296, DOI 10.3109/10826084.2014.891625; Wells JSG, 2018, J PHARM PHARM SCI, V21, P286, DOI 10.18433/jpps30049; Wixson SE, 2015, MEDICATION MISADVENT; Yaylaci S, 2017, BIOMED RES-INDIA, V28, P2661	63	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2020	15	12							e0243718	10.1371/journal.pone.0243718	http://dx.doi.org/10.1371/journal.pone.0243718			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH1IW	33326499	Green Published, gold			2023-01-03	WOS:000600176400072
J	Campo, DS; Gussler, JW; Sue, A; Skums, P; Khudyakov, Y				Campo, David S.; Gussler, Joseph W.; Sue, Amanda; Skums, Pavel; Khudyakov, Yury			Accurate spatiotemporal mapping of drug overdose deaths by machine learning of drug-related web-searches	PLOS ONE			English	Article							HIV-INFECTION; INTERNET SEARCHES; OXYMORPHONE; OUTBREAK; INDIANA	Persons who inject drugs (PWID) are at increased risk for overdose death (ODD), infections with HIV, hepatitis B (HBV) and hepatitis C virus (HCV), and noninfectious health conditions. Spatiotemporal identification of PWID communities is essential for developing efficient and cost-effective public health interventions for reducing morbidity and mortality associated with injection-drug use (IDU). Reported ODDs are a strong indicator of the extent of IDU in different geographic regions. However, ODD quantification can take time, with delays in ODD reporting occurring due to a range of factors including death investigation and drug testing. This delayed ODD reporting may affect efficient early interventions for infectious diseases. We present a novel model, Dynamic Overdose Vulnerability Estimator (DOVE), for assessment and spatiotemporal mapping of ODDs in different U.S. jurisdictions. Using Google(R) Web-search volumes (i.e., the fraction of all searches that include certain words), we identified a strong association between the reported ODD rates and drug-related search terms for 2004-2017. A machine learning model (Extremely Random Forest) was developed to produce yearly ODD estimates at state and county levels, as well as monthly estimates at state level. Regarding the total number of ODDs per year, DOVE's error was only 3.52% (Median Absolute Error, MAE) in the United States for 2005-2017. DOVE estimated 66,463 ODDs out of the reported 70,237 (94.48%) during 2017. For that year, the MAE of the individual ODD rates was 4.43%, 7.34%, and 12.75% among yearly estimates for states, yearly estimates for counties, and monthly estimates for states, respectively. These results indicate suitability of the DOVE ODD estimates for dynamic IDU assessment in most states, which may alert for possible increased morbidity and mortality associated with IDU. ODD estimates produced by DOVE offer an opportunity for a spatiotemporal ODD mapping. Timely identification of potential mortality trends among PWID might assist in developing efficient ODD prevention and HBV, HCV, and HIV infection elimination programs by targeting public health interventions to the most vulnerable PWID communities.	[Campo, David S.; Gussler, Joseph W.; Sue, Amanda; Khudyakov, Yury] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA; [Gussler, Joseph W.; Skums, Pavel] Georgia State Univ, Atlanta, GA 30303 USA; [Sue, Amanda] SUNY Albany, Albany, NY 12222 USA	Centers for Disease Control & Prevention - USA; University System of Georgia; Georgia State University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Campo, DS (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.	fyv6@cdc.gov		Campo, David S./0000-0002-8970-3436				[Anonymous], 2017, MMWR-MORBID MORTAL W, V66, P465; [Anonymous], 2013, CLIN INFECT DIS, V57, pi; Bowen DA, 2019, J GEN INTERN MED, V34, P2702, DOI 10.1007/s11606-019-05255-5; Brownstein JS, 2009, NEW ENGL J MED, V360, P2153, DOI [10.1056/NEJMp0900702, 10.1056/NEJMp0904012]; Campbell EM, 2017, J INFECT DIS, V216, P1053, DOI 10.1093/infdis/jix307; Conrad C, 2015, MMWR-MORBID MORTAL W, V64, P443; Domnich A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127754; Geurts P, 2006, MACH LEARN, V63, P3, DOI 10.1007/s10994-006-6226-1; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Kandula S, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007258; Lippi G, 2019, J EPIDEMIOL GLOB HEA, V9, P146, DOI 10.2991/jegh.k.190314.003; Lippi G, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2018.11.55; Longmire AG, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4268-3; Maree R, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-S1-S2; NCHS, 2020, PROV DRUG OV DEATH C; NCHS, 2019, ICD 10 CM INT CLASS; NCHS, 2019, UND CAUS DEATH 1999; Okolie C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008981; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Perlman DC, 2018, CURR HIV-AIDS REP, V15, P96, DOI 10.1007/s11904-018-0390-3; Peters PJ, 2016, NEW ENGL J MED, V375, P229, DOI 10.1056/NEJMoa1515195; Polgreen PM, 2008, CLIN INFECT DIS, V47, P1443, DOI 10.1086/593098; Ramachandran S, 2016, NETWORKS HCV TRANSMI; Saab S, 2018, HEPATOLOGY, V67, P2449, DOI 10.1002/hep.29685; Salathe M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002616; Sandahl M, 2016, STAT ANAL GOOGLE FLU; Teng Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0165085; Urbanowicz RJ, 2018, J BIOMED INFORM, V85, P168, DOI 10.1016/j.jbi.2018.07.015; Van Handel MM, 2016, JAIDS-J ACQ IMM DEF, V73, P323, DOI 10.1097/QAI.0000000000001098; Varian, 2009, PREDICTING PRESENT G; Wilson K, 2009, CAN MED ASSOC J, V180, P829, DOI [10.1503/cmaj.1090215, 10.1503/cmaj.090215]; Young SD, 2018, DRUG ALCOHOL DEPEN, V190, P166, DOI 10.1016/j.drugalcdep.2018.05.009	33	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243622	10.1371/journal.pone.0243622	http://dx.doi.org/10.1371/journal.pone.0243622			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD8LW	33284864	Green Published, gold			2023-01-03	WOS:000597930500005
J	Wong, J; Horwitz, MM; Bertisch, SM; Herzig, SJ; Buysse, DJ; Toh, S				Wong, Jenna; Murray Horwitz, Mara; Bertisch, Suzanne M.; Herzig, Shoshana J.; Buysse, Daniel J.; Toh, Sengwee			Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PHARMACOLOGICAL-TREATMENT; INSOMNIA	This study uses IBM MarketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, before and after a 2017 clinical practice guideline discouraged trazodone use for insomnia.	[Wong, Jenna; Toh, Sengwee] Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Ste 401 E, Boston, MA 02215 USA; [Murray Horwitz, Mara] Boston Med Ctr, Dept Med, Boston, MA USA; [Bertisch, Suzanne M.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, 75 Francis St, Boston, MA 02115 USA; [Herzig, Shoshana J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Buysse, Daniel J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA	Harvard University; Harvard Medical School; Boston Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wong, J (corresponding author), Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Ste 401 E, Boston, MA 02215 USA.; Wong, J (corresponding author), Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Ste 401 E, Boston, MA 02215 USA.	jenna_wong@harvardpilgrim.org	Buysse, Daniel/AAJ-1608-2021; Bertisch, Suzanne/AFP-3293-2022; Toh, Sengwee/D-7567-2017	Buysse, Daniel/0000-0002-3288-1864; Toh, Sengwee/0000-0002-5160-0810; Murray Horwitz, Mara/0000-0001-6142-0285; Bertisch, Suzanne/0000-0002-4627-8871	Harvard Medical School; Harvard Pilgrim Health Care Institute through the Thomas O. Pyle Fellowship Fund; Robert H. Ebert Career Development Award	Harvard Medical School; Harvard Pilgrim Health Care Institute through the Thomas O. Pyle Fellowship Fund; Robert H. Ebert Career Development Award	This study was funded by Harvard Medical School and the Harvard Pilgrim Health Care Institute through the Thomas O. Pyle Fellowship Fund (to DrsWong and Murray Horwitz) and by a Robert H. Ebert Career Development Award (to Dr Toh).	Bertisch SM, 2014, SLEEP, V37, P343, DOI 10.5665/sleep.3410; FDA, 2005, ROS CLIN REV BPCA; Ford ES, 2015, SLEEP MED, V16, P372, DOI 10.1016/j.sleep.2014.12.008; Sateia MJ, 2017, J CLIN SLEEP MED, V13, P307, DOI 10.5664/jcsm.6470; US Food and Drug Administration, 2019, FDA ADDS BOX WARN RI; Walsh JK, 1999, SLEEP, V22, P371	6	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2020	324	21					2211	2213		10.1001/jama.2020.19224	http://dx.doi.org/10.1001/jama.2020.19224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA4NB	33258882	Green Published, Bronze			2023-01-03	WOS:000595613500021
J	Gandhi, GY				Gandhi, Gunjan Y.			In type 2 diabetes, some glucose-lowering drugs reduce HbA(1c) more than others; drugs do not differ for mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Gandhi, Gunjan Y.] Univ Florida, Coll Med, Jacksonville, FL 32209 USA	State University System of Florida; University of Florida	Gandhi, GY (corresponding author), Univ Florida, Coll Med, Jacksonville, FL 32209 USA.							American Diabetes Association, 2020, Diabetes Care, V43, pS98, DOI 10.2337/dc20-S009; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470	2	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					JC53	JC53		10.7326/ACPJ202011170-053	http://dx.doi.org/10.7326/ACPJ202011170-053			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OU5XD	33197350				2023-01-03	WOS:000591600700006
J	Brophy, J				Brophy, James			In adults with chest pain, a troponin limit of detection strategy did not increase early discharge rate	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Brophy, James] McGill Univ, Hlth Ctr, Montreal, PQ, Canada	McGill University	Brophy, J (corresponding author), McGill Univ, Hlth Ctr, Montreal, PQ, Canada.							El Dib R, 2017, J CLIN EPIDEMIOL, V84, P61, DOI 10.1016/j.jclinepi.2016.12.009; Kennedy-Martin T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1023-4	2	0	0	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2020	173	8					JC45	JC45		10.7326/ACPJ202010200-045	http://dx.doi.org/10.7326/ACPJ202010200-045			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH7WZ	33075263				2023-01-03	WOS:000582805500009
J	Clark, J; Sweet, L; Nyoni, S; Ward, PR				Clark, Jacinta; Sweet, Linda; Nyoni, Simangaliso; Ward, Paul R.			Improving male involvement in antenatal care in low and middle-income countries to prevent mother to child transmission of HIV: A realist review	PLOS ONE			English	Review							PREGNANT-WOMEN; MALE PARTNERS; SERVICES; PARTICIPATION; PMTCT; BARRIERS; SUPPORT; TRIAL; KENYA	Background Childhood Human Immunodeficiency Virus (HIV) infection occurs almost exclusively via mother to child transmission (MTCT) during pregnancy, birth, or through breastfeeding. Recent studies have shown that male involvement (MI) in antenatal care (ANC) and HIV testing, including couples voluntary counselling and testing (CVCT), increases the likelihood that women will adhere to prevention advice and comply with HIV treatment if required during their pregnancy; hence reducing the rates of MTCT of HIV. This realist review investigates how, why, when, and for whom MI in ANC works best to provide contextual advice on how MI in ANC can be best used for prevention of mother to child transmission (PMTCT) of HIV. Methods A realist review of existing evidence was conducted. Realist review seeks to explain how and why an intervention works, or does not work, in a given context. This was completed through the five stages of realist synthesis; Eliciting the program theory, search strategy, study selection criteria, data extraction, and data analysis and synthesis. Findings are presented as context-mechanism-outcome (CMO) configurations outlining the mechanisms that work in given contexts to give an outcome. Results Three CMO configurations were developed. These describe that 1) Couples in monogamous relationships have higher levels of trust, commitment and security leading to increased uptake of PMTCT programs together; 2) ANC spaces that make 'male friendly' adaptions promote normalisation of MI in PMTCT and are more welcoming, leading to increased willingness of male partners to participate in ANC; and 3) couples and communities with higher health literacy encourage increased informed decision making, ownership, and responsibility and thus increased participation in PMTCT of HIV. Conclusions The CMOs developed in this review give contextual advice on how one might improve ANC services to increase MI and help reduce MTCT of HIV. We propose that MI in ANC works best where couples are monogamous and trusting, where ANC spaces actively promote being a 'male friendly space' and where there are high levels of community education programs around MTCT.	[Clark, Jacinta; Nyoni, Simangaliso; Ward, Paul R.] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Sweet, Linda] Deakin Univ & Western Hlth Partnership, Sch Nursing & Midwifery, Burwood, Australia; [Sweet, Linda] Flinders Univ S Australia, Coll Nursing & Hlth Sci, Adelaide, SA, Australia	Flinders University South Australia; Flinders University South Australia	Sweet, L (corresponding author), Deakin Univ & Western Hlth Partnership, Sch Nursing & Midwifery, Burwood, Australia.; Sweet, L (corresponding author), Flinders Univ S Australia, Coll Nursing & Hlth Sci, Adelaide, SA, Australia.	l.sweet@deakin.edu.au		Sweet, Linda/0000-0003-0605-1186; Ward, Paul/0000-0002-5559-9714				Aluisio AR, 2016, JAIDS-J ACQ IMM DEF, V73, P169, DOI 10.1097/QAI.0000000000001038; [Anonymous], 2018, AM J TRANSPLANT, V18, P10, DOI 10.1111/ajt.14556; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Audet CM, 2016, QUAL HEALTH RES, V26, P1721, DOI 10.1177/1049732315580302; Audet CM, 2016, AIDS BEHAV, V20, P2090, DOI 10.1007/s10461-016-1341-x; Auvinen J, 2014, MIDWIFERY, V30, P17, DOI 10.1016/j.midw.2013.01.010; Byamugisha R, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-12; Cuco RMM, 2015, SAHARA J-J SOC ASP H, V12, P87, DOI 10.1080/17290376.2015.1123643; Davis J, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1759-4; Ditekemena J, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-32; Duff P, 2012, INT J WOMENS HEALTH, V4, P227, DOI 10.2147/IJWH.S31807; Eastwood JG, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-12; Elias M, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.90.8901; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Falnes EF, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-21; Family Planning NSW, 2016, REPR SEX HLTH AUSTR; Galle A, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2530-1; Gill MM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1587-y; Haile F, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-65; Hamilton E, 2017, JAIDS-J ACQ IMM DEF, V75, pS27, DOI 10.1097/QAI.0000000000001325; J.U.N.P. on H. (UNAIDS), 2014, GAP REP; John Kuumuori G, 2015, REPROD HLTH, P12, DOI [10.1186/1742-4755-12-12, DOI 10.1186/1742-4755-12-12]; Kalembo FW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066517; Ladur AN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133239; Larsson EC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-769; Maman S, 2011, J MIDWIFERY WOM HEAL, V56, P325, DOI 10.1111/j.1542-2011.2011.00029.x; Meyer SB, 2013, SOCIOL RES ONLINE, V18, DOI 10.5153/sro.2819; Middelkoop K, 2008, J ADOLESCENT HEALTH, V43, P8, DOI 10.1016/j.jadohealth.2007.11.144; Mohlala BKF, 2011, AIDS, V25, P1535, DOI 10.1097/QAD.0b013e328348fb85; Morfaw F, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-5; Musheke M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-97; Natoli L, 2012, GLOB PUBLIC HEALTH, V7, P299, DOI 10.1080/17441692.2011.641987; Nyondo AL, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.22780; Nyondo AL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-691; Nyondo AL, 2014, BMC INT HEALTH HUM R, V14, DOI 10.1186/s12914-014-0030-y; Orne-Gliemann J, 2013, AIDS, V27, P1167, DOI 10.1097/QAD.0b013e32835f1d8c; Orne-Gliemann J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-197; Osoti AO, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1053-2; Osoti AO, 2014, AIDS, V28, P95, DOI 10.1097/QAD.0000000000000023; Oyugi Elvis, 2017, Pan Afr Med J, V28, P6, DOI 10.11604/pamj.supp.2017.28.1.9283; Pawson R., 2006, EVIDENCE BASED POLIC, DOI DOI 10.4135/9781849209120; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Ramirez-Ferrero E, 2012, MALE INVOLVEMENT PRE; Rogers AJ, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21224; Rycroft-Malone J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-33; Saul JE, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-103; Sileo KM, 2016, J HEALTH PSYCHOL, V29, P29; The Lancet Haematology, 2018, LANCET HAEMATOL, V5, pe127; Theuring S, 2010, AIDS CARE, V22, P1562, DOI 10.1080/09540121003758572; Tweheyo R, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-53; UNAIDS, 2016, PREV GAP REP; UNAIDS, 2016, FAST TRACK AIDS FREE; UNAIDS, 2016, CHILDR HIV FACTSH; UNAIDS, 2020, GLOB AIDS UPD; UNAIDS, 2020, FACTSH GLOB HIV STAT; Villar-Loubet OM, 2013, CULT HEALTH SEX, V15, P253, DOI 10.1080/13691058.2012.716166; Wariki WMV, 2013, COCHRANE DATABASE SY; Wong G, 2013, J ADV NURS, V69, P1005, DOI 10.1111/jan.12095; World Health Organization, 2017, GLOB GUID CRIT PROC; Yeganeh N, 2014, AIDS CARE, V26, P790, DOI 10.1080/09540121.2013.855297; Yende N, 2017, J PREGNANCY, V2017, DOI 10.1155/2017/4758017; Zenebe A, 2016, J PREGNANCY, V2016, DOI 10.1155/2016/3073908	63	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2020	15	10							e0240087	10.1371/journal.pone.0240087	http://dx.doi.org/10.1371/journal.pone.0240087			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3UY	33057353	gold, Green Published			2023-01-03	WOS:000581814700062
J	de Medeiros, OL; Barreto, JOM; Harris, M; Russo, LX; da Silva, EN				de Medeiros, Olivia Lucena; Barreto, Jorge Otavio Maia; Harris, Matthew; Russo, Leticia Xander; da Silva, Everton Nunes			Delivering maternal and childcare at primary healthcare level: The role of PMAQ as a pay for performance strategy in Brazil	PLOS ONE			English	Article							SYSTEM; PROGRAMS; PAYMENT; POLICY	Background Improving access and quality in health care is a pressing issue worldwide and pay for performance (P4P) strategies have emerged as an alternative to enhance structure, process and outcomes in health. In 2011, Brazil adopted its first P4P scheme at national level, the National Programme for Improving Primary Care Access and Quality (PMAQ). The contribution of PMAQ in achieving the Sustainable Development Goals related to maternal and childcare remains under investigated in Brazil. Objective To estimate the association of PMAQ with the provision of maternal and childcare in Brazil, controlling for socioeconomic, geographic and family health team characteristics. Method We used cross-sectional quantile regression (QR) models for two periods, corresponding to 33,368 Family Health Teams (FHTs) in the first cycle and 39,211 FHTs in the second cycle of PMAQ. FHTs were analysed using data from the Brazilian Ministry of Health (SIAB and CNES) and the Brazilian Institute for Geography and Statistics (IBGE). Results The average number of antenatal consultations per month were positively associated with PMAQ participating teams, with larger effect in the lower tail (10th and 25th quantiles) of the conditional distribution of the response variable. There was a positive association between PMAQ and the average number of consultations under 2 years old per month in the 10th and 25th quantiles, but a negative association in the upper tail (75th and 90th quantiles). For the average number of physician consultations for children under 1 year old per month, PMAQ participating teams were positively associated with the response variable in the lower tail, but different from the previous models, there is no clear evidence that the second cycle gives larger coefficients compared with first cycle. Conclusion PMAQ has contributed to increase the provision of care to pregnant women and children under 2 years at primary healthcare level. Teams with lower average number of antenatal or child consultations benefited the most by participating in PMAQ, which suggests that PMAQ might motivate worse performing health providers to catch up.	[de Medeiros, Olivia Lucena; Barreto, Jorge Otavio Maia; da Silva, Everton Nunes] Univ Brasilia, Grad Program Publ Hlth, Brasilia, DF, Brazil; [de Medeiros, Olivia Lucena] Minist Hlth, Brasilia, DF, Brazil; [Barreto, Jorge Otavio Maia] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil; [Harris, Matthew] Imperial Coll, Fac Med, Sch Publ Hlth, London, England; [Russo, Leticia Xander] Univ Estadual Maringa, Dept Econ, Maringa, Parana, Brazil	Universidade de Brasilia; Fundacao Oswaldo Cruz; Imperial College London; Universidade Estadual de Maringa	da Silva, EN (corresponding author), Univ Brasilia, Grad Program Publ Hlth, Brasilia, DF, Brazil.	evertonsilva@unb.br	; Barreto, Jorge/P-5738-2018	Harris, Matthew/0000-0002-0005-9710; Russo, Leticia Xander/0000-0001-9592-8212; Silva, Everton/0000-0001-8747-4185; Barreto, Jorge/0000-0002-7648-0472	NW London NIHR Applied Research Collaboration; Imperial NIHR Biomedical Research Centre; MRC [MR/R022828/1] Funding Source: UKRI	NW London NIHR Applied Research Collaboration; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	MH is supported in part by the NW London NIHR Applied Research Collaboration. Imperial College London is grateful for support from the NW London NIHR Applied Research Collaboration and the Imperial NIHR Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. No additional external funding received for this study.	[Anonymous], 2017, ARTIFICIAL ORGANS, V41, pE141; [Anonymous], 2017, CLIN GENITOURIN CANC; [Anonymous], 2018, CAN J DIABETES S1; [Anonymous], 2016, BIRDS NZ, V9, P8; [Anonymous], 2008, MEDWAVE, V8, pe1717, DOI 10.5867/medwave.2008.09.1717; [Anonymous], 2017, EPLASTY, V17, pic25; [Anonymous], 2007, SPINE J S, V7, p1S; Barros AJD, 2016, LANCET GLOB HEALTH, V4, pE873, DOI 10.1016/S2214-109X(16)30298-4; Brasil, 2015, MAN INSTR PMAQ EQ AT; Brazi, 2012, HLTH CLOS YOU ACC QU, P60; Brazil, 2012, CHILD HLTH GROWTH DE, V33; Brazil, SUPP ROOM STRAT MAN; Brazil, 2015, NOT MET CERT PMAQ EQ; Brazil, HIST REP COV PRIM CA; Brazil, PMAQ PAYM REP; Collaborative Study Group on Perioperative ScvO2 Monitoring, 2006, CRIT CARE, V10, pR158; da Silva EN, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000242; Damberg Cheryl L, 2014, Rand Health Q, V4, P9; Alonso CMD, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000395, 10.11606/s1518-8787.2018052000395]; dos Santos AS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000186, 10.11606/s1518-8787.2018052000186]; dos Santos EP, 2016, REV ESC ENFERM USP, V50, P390, DOI 10.1590/S0080-623420160000400003; Engineer CY, 2016, INT J EPIDEMIOL, V45, P451, DOI 10.1093/ije/dyv362; Franca GVA, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0445-2; Harrison SE, 2018, SOUTH MED J, V111, P12, DOI 10.14423/SMJ.0000000000000754; Hequet D, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1658-0; Josephson E, 2017, HEALTH POLICY PLANN, V32, P1120, DOI 10.1093/heapol/czx053; Koenker R, 2001, J ECON PERSPECT, V15, P143, DOI 10.1038/s41592-019-0406-y; KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643; Landrine H, 2016, TOB CONTROL, V25, pe142; Lansky S, 2014, CAD SAUDE PUBLICA, V30, DOI 10.1590/0102-311X00133213; Leal MD, 2018, CIENC SAUDE COLETIVA, V23, P1915, DOI [10.1590/1413-81232018236.03942018, 10.1590/1413-81232018236.039420181]; Macinko J, 2017, J AMBUL CARE MANAG, V40, pS4, DOI 10.1097/JAC.0000000000000189; Malta DC, 2017, CIENC SAUDE COLETIVA, V22, P179, DOI 10.1590/1413-81232017221.16782015; Mendelson A, 2017, ANN INTERN MED, V166, P341, DOI 10.7326/M16-1881; OCDE, 2010, HLTH CAR SYST GETT M; Oxman AD, 2008, 162008 NOKC; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Paul E, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000664; Rasella D, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002570; Ribeiro JM, 2018, CIENC SAUDE COLETIVA, V23, P1777, DOI 10.1590/1413-81232018236.07932018; Saddi FC, 2018, J AMBUL CARE MANAG, V41, P25, DOI 10.1097/JAC.0000000000000220; Saddi FD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00202417, 10.1590/0102-311X00202417]; Scott A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008451.pub2; Shorey S, 2018, J PSYCHIATR RES, V104, P235, DOI 10.1016/j.jpsychires.2018.08.001; SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01; Domingues RMSM, 2015, REV PANAM SALUD PUBL, V37, P140; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222566; The editors of Pharmaceutical Technology, 2015, PHARM TECHNOL S, V39, ps24; Tomasi Elaine, 2017, Cad. Saúde Pública, V33, pe00195815, DOI 10.1590/0102-311x00195815; Van Herck P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-247; Victora CG, 2011, LANCET, V377, P85, DOI 10.1016/S0140-6736(10)60810-0; WHO, 2016, WHO TECH REP SER, V997, P1; Yuan BB, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011153.pub2; 2003, DIABETES CARE S1, V1	54	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2020	15	10							e0240631	10.1371/journal.pone.0240631	http://dx.doi.org/10.1371/journal.pone.0240631			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3UY	33057414	gold, Green Published			2023-01-03	WOS:000581814700053
J	Kallianpur, AR; Wen, WQ; Erwin, AL; Clifford, DB; Hulgan, T; Robbins, GK				Kallianpur, Asha R.; Wen, Wanqing; Erwin, Angelika L.; Clifford, David B.; Hulgan, Todd; Robbins, Gregory K.			Higher iron stores and theHFE187C > G variant delay onset of peripheral neuropathy during combination antiretroviral therapy	PLOS ONE			English	Article							HEMOCHROMATOSIS PROTEIN HFE; SEQUENTIAL 3-DRUG REGIMENS; SUB-SAHARAN AFRICA; TRANSFERRIN RECEPTOR; SENSORY NEUROPATHY; INITIAL THERAPY; GENE; FERRITIN; ANEMIA; INFLAMMATION	Objective People with HIV (PWH) continue to experience sensory neuropathy and neuropathic pain in the combination antiretroviral therapy (cART) era for unclear reasons. This study evaluated the role of iron in a previously reported association of iron-loading hemochromatosis (HFE) gene variants with reduced risk of neuropathy in PWH who received more neurotoxic cART, since an iron-related mechanism also might be relevant to neuropathic symptoms in PWH living in low-resource settings today. Design This time-to-event analysis addressed the impact of systemic iron levels on the rapidity of neuropathy onset in PWH who initiated cART. Methods Soluble transferrin receptor (sTFR), the sTFR-ferritin index of iron stores, and high-sensitivity C-reactive protein (hsCRP) levels were determined in stored baseline sera from participants of knownHFEgenotype from AIDS Clinical Trials Group (ACTG) Study 384, a multicenter randomized clinical trial that evaluated cART strategies. Associations with incident neuropathy were evaluated in proportional-hazards, time-to-event regression models, adjusting for potential confounders. Results Of 151 eligible participants with stored serum who were included in the original genetic study, 43 had cART-associated neuropathy; 108 had sufficient serum for analysis, including 30 neuropathy cases. Carriers ofHFEvariants had higher systemic iron (lower sTFR and sTFR-ferritin index) and lower hsCRP levels than non-carriers (allp<0.05). Higher sTFR or iron stores, theHFE187C>G variant, and lower baseline hsCRP were associated with significantly delayed neuropathy in self-reported whites (n = 28; allp-values<0.05), independent of age, CD4+ T-cell count, plasma HIV RNA, and cART regimen. Conclusions Higher iron stores, theHFE187C>G variant, and lower hsCRP predicted delayed onset of neuropathy among self-reported white individuals initating cART. These findings require confirmation but may have implications for cART in HIV+ populations in areas with high endemic iron deficiency, especially those PWH in whom older, more neurotoxic antiretroviral drugs are occasionally still used.	[Kallianpur, Asha R.; Erwin, Angelika L.] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA; [Kallianpur, Asha R.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Kallianpur, Asha R.] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Wen, Wanqing] Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN USA; [Clifford, David B.] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA; [Clifford, David B.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Hulgan, Todd] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA; [Robbins, Gregory K.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Vanderbilt University; Washington University (WUSTL); Washington University (WUSTL); Vanderbilt University; Harvard University; Massachusetts General Hospital	Kallianpur, AR (corresponding author), Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44106 USA.; Kallianpur, AR (corresponding author), Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA.; Kallianpur, AR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.	kalliaa@ccf.org		Robbins, Gregory/0000-0001-7545-5817; Kallianpur, Asha/0000-0002-6483-523X; Clifford, David/0000-0001-5719-1555	National Heart, Lung, and Blood Institute [R21HL087726, R21NS059330]; Vanderbilt Center for AIDS Research (CFAR) Interdisciplinary HIV/AIDS Developmental Core Award	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Vanderbilt Center for AIDS Research (CFAR) Interdisciplinary HIV/AIDS Developmental Core Award	Funding support for this work was provided by National Heart, Lung, and Blood Institute R21HL087726 (to AK) and R21NS059330 (to TH) and a Vanderbilt Center for AIDS Research (CFAR) Interdisciplinary HIV/AIDS Developmental Core Award (to AK). The funders (https://www.nimh.nih.gov/index.shtml and https://www.nih. gov) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534; Agoro R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196921; Arenas-Pinto A, 2016, J NEUROVIROL, V22, P104, DOI 10.1007/s13365-015-0374-7; Aziz-Donnelly A, 2017, CURR TREAT OPTION NE, V19, DOI 10.1007/s11940-017-0472-3; Banjoko SO, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-26; Brissot P, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.16; Canter JA, 2008, PHARMACOGENOMICS J, V8, P71, DOI 10.1038/sj.tpj.6500470; Canter JA, 2010, J INFECT DIS, V201, P1703, DOI 10.1086/652419; Cherry CL, 2016, PAIN MANAG, V6, P191, DOI 10.2217/pmt.15.65; Cherry CL, 2006, NEUROLOGY, V66, P867, DOI 10.1212/01.wnl.0000203336.12114.09; Cook JD, 1999, P NUTR SOC, V58, P489, DOI 10.1017/S0029665199000634; Costantini A, 2009, JAIDS-J ACQ IMM DEF, V52, P70, DOI 10.1097/QAI.0b013e3181af65c5; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Drakesmith H, 2005, P NATL ACAD SCI USA, V102, P11017, DOI 10.1073/pnas.0504823102; Ekblom K, 2011, INT J CARDIOL, V150, P169, DOI 10.1016/j.ijcard.2010.04.001; Ellis RJ, 2010, ARCH NEUROL-CHICAGO, V67, P552, DOI 10.1001/archneurol.2010.76; Erlandson KM, 2019, JAIDS-J ACQ IMM DEF, V81, pE117, DOI 10.1097/QAI.0000000000002074; Evans SR, 2011, AIDS, V25, P919, DOI 10.1097/QAD.0b013e328345889d; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Ganz T, 2015, NAT REV IMMUNOL, V15, P500, DOI 10.1038/nri3863; Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467; Gao J, 2008, J BIOL CHEM, V283, P21462, DOI 10.1074/jbc.M803150200; Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0; Gordeuk VR, 2006, HAEMATOLOGICA, V91, P739; Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200; Huang WL, 2017, PAIN, V158, P75, DOI 10.1097/j.pain.0000000000000727; Hulgan T, 2005, AIDS, V19, P1341, DOI 10.1097/01.aids.0000180786.02930.a1; Johnson EE, 2012, MICROBES INFECT, V14, P207, DOI 10.1016/j.micinf.2011.10.001; Kaku Michelle, 2018, Handb Clin Neurol, V152, P201, DOI 10.1016/B978-0-444-63849-6.00016-5; Kallianpur AR, 2006, AIDS, V20, P1503, DOI 10.1097/01.aids.0000237366.56864.3c; Kallianpur AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103123; Kallianpur AR, 2009, PHARMACOGENOMICS, V10, P623, DOI [10.2217/pgs.09.14, 10.2217/PGS.09.14]; Keswani SC, 2002, AIDS, V16, P2105, DOI 10.1097/00002030-200211080-00002; Lawless MW, 2007, TISSUE ANTIGENS, V70, P294, DOI 10.1111/j.1399-0039.2007.00895.x; Lee SY, 2007, FASEB J, V21, P564, DOI 10.1096/fj.06-6397com; Lehmann HC, 2011, ANN NEUROL, V69, P100, DOI 10.1002/ana.22150; Levi S, 2009, BBA-GEN SUBJECTS, V1790, P629, DOI 10.1016/j.bbagen.2008.09.008; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; Malvar J, 2015, PAIN, V156, P731, DOI 10.1097/01.j.pain.0000461252.75089.bf; Maskew M, 2012, J INT AIDS SOC, V15, DOI 10.1186/1758-2652-15-13; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; McDermid JM, 2009, AM J CLIN NUTR, V90, P225, DOI 10.3945/ajcn.2009.27709; Mehta SA, 2011, CLIN INFECT DIS, V53, P490, DOI 10.1093/cid/cir432; Mitchell RM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-6; Moketla MB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204111; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Morgello Susan, 2018, Handb Clin Neurol, V152, P3, DOI 10.1016/B978-0-444-63849-6.00002-5; Musallam KM, 2018, CURR MED RES OPIN, V34, P81, DOI 10.1080/03007995.2017.1394833; Northrop-Clewes CA, 2013, J BLOOD MED, V4, P11, DOI 10.2147/JBM.S29212; Pantopoulos K, 2008, WORLD J GASTROENTERO, V14, P6893, DOI 10.3748/wjg.14.6893; Pereira M, 2019, CELL REP, V28, P498, DOI 10.1016/j.celrep.2019.06.039; Persad GC, 2016, LANCET, V388, P932, DOI 10.1016/S0140-6736(15)01025-9; Peters RPH, 2014, EUR J PEDIATR, V173, P1245, DOI 10.1007/s00431-014-2303-9; Pietrangelo A, 2006, BBA-MOL CELL RES, V1763, P700, DOI 10.1016/j.bbamcr.2006.05.013; Pillay P, 2019, J PERIPHER NERV SYST, DOI 10.1111/jns.12349; Puplampu P, 2019, J NEUROVIROL, V25, P464, DOI 10.1007/s13365-019-00743-0; Redig AJ, 2013, HEMATOL-AM SOC HEMAT, P377, DOI 10.1182/asheducation-2013.1.377; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Roda RH, 2019, INT REV NEUROBIOL, V145, P67, DOI 10.1016/bs.irn.2019.04.001; Roy CN, 2004, NAT GENET, V36, P481, DOI 10.1038/ng1350; Sakabumi DZ, 2019, JAIDS-J ACQ IMM DEF, V80, P568, DOI 10.1097/QAI.0000000000001953; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; Shrestha P, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1360-8; Skikne BS, 2011, AM J HEMATOL, V86, P923, DOI 10.1002/ajh.22108; Steinberg KK, 2001, JAMA-J AM MED ASSOC, V285, P2216, DOI 10.1001/jama.285.17.2216; Takou D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3871-0; Technau KG, 2014, PEDIATR INFECT DIS J, V33, P617, DOI 10.1097/INF.0000000000000222; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Vieira J, 2007, INT J IMMUNOGENET, V34, P359, DOI 10.1111/j.1744-313X.2007.00700.x; Wang LJ, 2008, J IMMUNOL, V181, P2723, DOI 10.4049/jimmunol.181.4.2723	70	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2020	15	10							e0239758	10.1371/journal.pone.0239758	http://dx.doi.org/10.1371/journal.pone.0239758			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3UY	33057367	Green Published, gold			2023-01-03	WOS:000581814700101
J	Willyard, C				Willyard, Cassandra			AGEING AND COVID VACCINES	NATURE			English	News Item																		Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Bramante C, 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.06.19.20135095, DOI 10.1101/2020.06.19.20135095]; Helfand BKI, 2020, JAMA INTERN MED, V180, P1546, DOI 10.1001/jamainternmed.2020.5084; Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375; Mannick J. B, 2020, SCI TRANSL MED, V10; Vukmanovic-Stejic M, 2018, J ALLERGY CLIN IMMUN, V142, P844, DOI 10.1016/j.jaci.2017.10.032; Walsh E. E, 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.08.17.20176651, DOI 10.1101/2020.08.17.20176651]	7	7	8	0	3	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 15	2020	586	7829					352	354		10.1038/d41586-020-02856-7	http://dx.doi.org/10.1038/d41586-020-02856-7			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OB2NY	33057226				2023-01-03	WOS:000578311600034
J	Chen, CY; Huang, WS; Chen, HC; Chang, CH; Lee, LT; Chen, HS; Kang, YD; Chie, WC; Jan, CF; Wang, WD; Tsai, JS				Chen, Chin-Ying; Huang, Wei-Sheng; Chen, Hui-Chuen; Chang, Chin-Hao; Lee, Long-Teng; Chen, Heng-Shuen; Kang, Yow-Der; Chie, Wei-Chu; Jan, Chyi-Feng; Wang, Wei-Dean; Tsai, Jaw-Shiun			Effect of a 90 g/day low-carbohydrate diet on glycaemic control, small, dense low-density lipoprotein and carotid intima-media thickness in type 2 diabetic patients: An 18-month randomised controlled trial	PLOS ONE			English	Article							SATURATED FAT; WEIGHT-LOSS; MANAGEMENT; RESTRICTION; HEMOGLOBIN; THERAPY; PEOPLE	Aim This study explored the effect of a moderate (90 g/d) low-carbohydrate diet (LCD) in type 2 diabetes patients over 18 months. Methods Ninety-two poorly controlled type 2 diabetes patients aged 20-80 years with HbA1c >= 7.5% (58 mmol/mol) in the previous three months were randomly assigned to a 90 g/d LCD r traditional diabetic diet (TDD). The primary outcomes were glycaemic control status and change in medication effect score (MES). The secondary outcomes were lipid profiles, small, dense low-density lipoprotein (sdLDL), serum creatinine, microalbuminuria and carotid intima-media thickness (IMT). Results A total of 85 (92.4%) patients completed 18 months of the trial. At the end of the study, the LCD and TDD group consumed 88.0 +/- 29.9 g and 151.1 +/- 29.8 g of carbohydrates, respectively (p < 0.05). The 18-month mean change from baseline was statistically significant for the HbA1c (-1.6 +/- 0.3 vs. -1.0 +/- 0.3%), 2-h glucose (-94.4 +/- 20.8 vs. -18.7 +/- 25.7 mg/dl), MES (-0.42 +/- 0.32 vs. -0.05 +/- 0.24), weight (-2.8 +/- 1.8 vs. -0.7 +/- 0.7 kg), waist circumference (-5.7 +/- 2.7 vs. -1.9 +/- 1.4 cm), hip circumference (-6.1 +/- 1.8 vs. -2.9 +/- 1.7 cm) and blood pressure (-8.3 +/- 4.6/-5.0 +/- 3 vs. 1.6 +/- 0.5/2.5 +/- 1.6 mmHg) between the LCD and TDD groups (p<0.05). The 18-month mean change from baseline was not significantly different in lipid profiles, sdLDL, serum creatinine, microalbuminuria, alanine aminotransferase (ALT) and carotid IMT between the groups. Conclusions A moderate (90 g/d) LCD showed better glycaemic control with decreasing MES, lowering blood pressure, decreasing weight, waist and hip circumference without adverse effects on lipid profiles, sdLDL, serum creatinine, microalbuminuria, ALT and carotid IMT than TDD for type 2 diabetic patients.	[Chen, Chin-Ying; Huang, Wei-Sheng; Lee, Long-Teng; Chen, Heng-Shuen; Kang, Yow-Der; Jan, Chyi-Feng; Wang, Wei-Dean; Tsai, Jaw-Shiun] Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan; [Chen, Chin-Ying; Huang, Wei-Sheng; Chen, Hui-Chuen; Chang, Chin-Hao; Lee, Long-Teng; Chen, Heng-Shuen; Kang, Yow-Der; Jan, Chyi-Feng; Wang, Wei-Dean; Tsai, Jaw-Shiun] Natl Taiwan Univ, Taipei, Taiwan; [Chen, Hui-Chuen] Natl Taiwan Univ Hosp, Dept Dietet, Taipei, Taiwan; [Chang, Chin-Hao] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Chie, Wei-Chu] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Dept Publ Hlth, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Huang, WS (corresponding author), Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan.; Huang, WS (corresponding author), Natl Taiwan Univ, Taipei, Taiwan.	starsambora@gmail.com	; JAN, CHYI-FENG/E-6665-2012	Chie, Wei-Chu/0000-0001-5584-6554; JAN, CHYI-FENG/0000-0003-2893-2187; CHEN, CHIN-YING/0000-0001-7827-8764; Tsai, Jaw-Shiun/0000-0002-5227-8894	National Taiwan University Hospital [106-37]	National Taiwan University Hospital(National Taiwan University)	The project was funded by the National Taiwan University Hospital project number 106-37. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457; Cochran E, 2005, DIABETES CARE, V28, P1240, DOI 10.2337/diacare.28.5.1240; Dyson P, 2015, DIABETES THER, V6, P411, DOI 10.1007/s13300-015-0136-9; Evert AB, 2013, DIABETES CARE, V36, P3821, DOI 10.2337/dc13-2042; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; FoodCorps, 2013, CHILDHOOD OBESITY, V9, P7, DOI [10.1089/chi.2013.9107, DOI 10.1089/CHI.2013.9107]; Forsythe CE, 2010, LIPIDS, V45, P947, DOI 10.1007/s11745-010-3467-3; Gerber PA, 2012, CURR OPIN CLIN NUTR, V15, P381, DOI 10.1097/MCO.0b013e3283545a6d; Goday A, 2016, NUTR DIABETES, V6, DOI 10.1038/nutd.2016.36; Guldbrand H, 2012, DIABETOLOGIA, V55, P2118, DOI 10.1007/s00125-012-2567-4; Alcantara GH, 2015, NUTR HOSP, V32, P1960, DOI 10.3305/nh.2015.32.5.9695; Huang Ya-Ching, 2014, Biomed J, V37, P375, DOI 10.4103/2319-4170.132883; Kang M, 2008, J ATHL TRAINING, V43, P215, DOI 10.4085/1062-6050-43.2.215; Larsen RN, 2011, DIABETOLOGIA, V54, P731, DOI 10.1007/s00125-010-2027-y; Liu Y., 2004, THESIS TSINGHUA U BE; Mayer SB, 2014, DIABETES OBES METAB, V16, P90, DOI 10.1111/dom.12191; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Naude CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100652; Noakes TD, 2017, BRIT J SPORT MED, V51, P133, DOI 10.1136/bjsports-2016-096491; Saslow LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091027; Sato J, 2017, CLIN NUTR, V36, P992, DOI 10.1016/j.clnu.2016.07.003; Shai I, 2010, CIRCULATION, V121, P1200, DOI 10.1161/CIRCULATIONAHA.109.879254; Tay J, 2015, AM J CLIN NUTR, V102, P780, DOI 10.3945/ajcn.115.112581; Tay J, 2014, DIABETES CARE, V37, P2909, DOI 10.2337/dc14-0845; van Wyk HJ, 2016, DIABETIC MED, V33, P148, DOI 10.1111/dme.12964; Vasilakou D, 2013, ANN INTERN MED, V159, P262, DOI 10.7326/0003-4819-159-4-201308200-00007; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Wheeler ML, 2012, DIABETES CARE, V35, P434, DOI 10.2337/dc11-2216; Wood RJ, 2006, J NUTR, V136, P384, DOI 10.1093/jn/136.2.384	29	16	16	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2020	15	10							e0240158	10.1371/journal.pone.0240158	http://dx.doi.org/10.1371/journal.pone.0240158			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OB4VZ	33017456	Green Published, gold			2023-01-03	WOS:000578470500006
J	Awuviry-Newton, K; Ofori-Dua, K; Newton, A				Awuviry-Newton, Kofi; Ofori-Dua, Kwadwo; Newton, Abraham			Correlates of older adult inpatients' personal care provision to people with functional difficulties in Ghana	PLOS ONE			English	Article							CHILDREN	Introduction Most research depicts older adults as needing personal care, with limited research on older adults' contributions in the lives of others in developing countries like Ghana. The purpose of the study was to examine the personal care provision and socio-demographic correlates of personal care provision by older adult inpatients in Ghana. Materials and methods A hospital-based survey was conducted among 400 consecutively surveyed older adult inpatients at Komfo Anokye Teaching Hospital in southern Ghana. Stata 15 was used to analyse the data. The relationship between personal care and older adult inpatients' socio-demographic characteristics were analysed using the chi-square test. Multivariate logistic regression analysis was employed. Results Overall, 28% of older adult inpatients provided personal care. Participants were mostly females, married or cohabiting, completed at most junior high school, Christians, urban residents, not working and living with their immediate family. Primarily, most participants provided personal care to one person, once a week, and one-hour duration. Nearly three-quarters of participants provided personal care to someone who lives with them. After adjustment, male older adults were 50% less likely to and urban residents were 83% more likely to provide personal care. Being single, separated or divorced was statistically significantly associated with personal care provision, however, were not statistically significant after adjusting for sex and residence. A post hoc analysis testing for interaction revealed no relationship existing between sex and marital status concerning personal care provision (p = 0.106). Conclusion Female and urban resident older adult inpatients in Ghana are not just passive receivers of care but also provide personal care to others with functional difficulties, independent on age. It further draws attention to the need for policies and programs that can support older adults, particularly females and urban residents, to be productive in the later life.	[Awuviry-Newton, Kofi] Univ Newcastle, Prior Res Ctr Generat Hlth & Ageing, Sch Med & Hlth, Newcastle, NSW, Australia; [Ofori-Dua, Kwadwo] Kwame Nkrumah Univ Sci & Technol, Dept Sociol & Social Work, Kumasi, Ghana; [Newton, Abraham] Univ Educ, Dept Social Studies & Educ, Winneba, Ghana	University of Newcastle; Kwame Nkrumah University Science & Technology	Awuviry-Newton, K (corresponding author), Univ Newcastle, Prior Res Ctr Generat Hlth & Ageing, Sch Med & Hlth, Newcastle, NSW, Australia.	newscous@gmail.com	Awuviry-Newton, Kofi/O-7488-2016	Awuviry-Newton, Kofi/0000-0001-9109-0694	University of Newcastle International Postgraduate Research Scholarship (UNIPRS); University of Newcastle Research Scholarship Central 50:50 (UNRSC50:50); Australian Research Council Centre of Excellence in Population Ageing Research [CE170100005]	University of Newcastle International Postgraduate Research Scholarship (UNIPRS); University of Newcastle Research Scholarship Central 50:50 (UNRSC50:50); Australian Research Council Centre of Excellence in Population Ageing Research(Australian Research Council)	This study was funded by The University of Newcastle International Postgraduate Research Scholarship (UNIPRS) and The University of Newcastle Research Scholarship Central 50:50 (UNRSC50:50). This research was supported by the Australian Research Council Centre of Excellence in Population Ageing Research (project number CE170100005).	Amosun SL, 2013, AFR HEALTH SCI, V13, P24, DOI 10.4314/ahs.v13i1.4; [Anonymous], 2015, GLOBAL AGEWATCH INDE; [Anonymous], 1992, B FUNDACION FEDERICO, V4, p[125, 132]; Awuviry-Newton K., 2019, INNOV AGING, V3, pS520, DOI [10.1093/geroni/igz038.1916, DOI 10.1093/GERONI/IGZ038.1916]; Awuviry-Newton K, 2020, HLTH SOC CARE COMMUN; Awuviry-Newton K, 2020, J PRIM CARE COMMUNIT, V11, DOI 10.1177/2150132720931110; Awuviry-Newton K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233541; Bass S. A., 2001, PRODUCTIVE AGING CON, P38; Biritwum RB, 2016, MATURITAS, V91, P8, DOI 10.1016/j.maturitas.2016.05.012; Biritwum RB, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.20096; Brown CK, 1999, CARING ELDERLY PERSP; Butler RN, 1985, PRODUCTIVE AGING; Debpuur C, 2010, GLOBAL HEALTH ACTION, V3, P54, DOI 10.3402/gha.v3i0.2151; Fenton S-J, 2014, SOME COMMUNITIES FAI; Geurts T, 2012, J MARRIAGE FAM, V74, P239, DOI 10.1111/j.1741-3737.2011.00952.x; Ghana Statistical Service, 2013, POPULATION HOUSING C; Ghana Statistical Services, 2014, 2010 POP HOUS CENS D; Government of Ghana, 2010, GHAN NAT AG POL AG S; Kincade JE, 1996, GERONTOLOGIST, V36, P474, DOI 10.1093/geront/36.4.474; Mui A.C., 2008, ASIAN AM ELDERS 21 C; Mui AC., 2010, CHINA J SOCIAL WORK, V3, P111, DOI [10.1080/17525098.2010.492634, DOI 10.1080/17525098.2010.492634]; Noddings N., 1984, CARING FEMININE APPR; Nukunya G.K., 2003, TRADITION CHANGE GHA; Ofori-Dua K, 2014, EXTENDED FAMILY SUPP; Roberts CE, 2017, J AGING PHYS ACTIV, V25, P653, DOI 10.1123/japa.2016-0201; Sackey H. A., 2005, FEMALE LABOUR FORCE; Sanuade OA, 2015, PUBLIC HEALTH, V129, P941, DOI 10.1016/j.puhe.2015.05.016; Schulz R., 1990, THEORETICAL PERSPECT; Shiel W., 2018, COMMON MED ABBREVIAT; Sun JJ, 2013, AGEING INT, V38, P58, DOI 10.1007/s12126-012-9161-4; World Health Organization, 2017, DEPR OTH COMM MENT D; Zhang K. T., 2009, STUDY SOCIAL ACTIVIT; Zimmer Z, 2005, POP STUD-J DEMOG, V59, P295, DOI 10.1080/00324720500212255	33	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2020	15	10							e0238693	10.1371/journal.pone.0238693	http://dx.doi.org/10.1371/journal.pone.0238693			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ4YX	33007005	Green Published, gold			2023-01-03	WOS:000577103500044
J	Tesfay, W; Abay, M; Hintsa, S; Zafu, T				Tesfay, Wagnew; Abay, Mebrahtu; Hintsa, Solomon; Zafu, Tekia			Length of stay to recover from severe acute malnutrition and associated factors among under-five years children admitted to public hospitals in Aksum, Ethiopia	PLOS ONE			English	Article							MANAGEMENT	Background Severe acute malnutrition is defined by <70% weight for length/height, by visible severe wasting, by the presence of pitting edema, and in children 6 to 59 months of age, mid upper arm circumference <110 mm. Severe acute malnutrition remains to be a worldwide problem, claiming lives of millions of children, especially in sub-Saharan Africa and south Asia. Though the Ethiopian national guideline states the total length of stay in therapeutic feeding units should not be more than four weeks, there is huge difference, varying from 8 to 47 days of stay. Therefore, the objective of this study was to assess length of stay to recover from severe acute malnutrition and associated factors among under five children hospitalized to the public hospitals in Aksum Town. Methods Sample size was calculated using STATA version 12.0. A retrospective cohort study was conducted using pretested questionnaire in the public hospitals in Aksum on children aged 0-59 months. Cleaned data was entered to Epi info version 7.1.4 and then exported into SPSS version 21 for analysis. Bivariable and multivariable analyses were performed using Kaplan Meier and Cox regression models. During bivariable analysis, variables with p-value < 0.05 were selected for multivariable analysis to identify independent factors associated with length of stay. Results A total of 564 participants enrolled to the study. The rate of recovery was 56% with median length of stay of 15 days (95% CI: 14.1, 15.9). The independent predictors of length of stay to recovery were presence of diarrhea at admission (AHR = 0.573, 95% CI: 0.415-0.793), being HIV positive (AHR = 0.391, 95% CI: 0.194-0.788), palmar pallor (AHR = 0.575, 95% CI: 0.416-0.794), presence of other co-morbidities at admission (AHR = 0.415, 95% CI: 0.302-0.570) and not being treated with plumpy nut (AHR = 0.368, 95% CI: 0.262-0.518). Conclusions Length of stay is in the acceptable range of the international and national set of standards. Nevertheless, the recovery rate was lower compared to the Sphere standard. Presence of diarrhea, palmar pallor, HIV other co-morbidities and not treated with plumpy nut were found independent protective factors for recovery from sever acute malnutrition.	[Tesfay, Wagnew] Ethiopia Mission, Tigray Project, Med Sans Frontieres Holland, Addis Ababa, Ethiopia; [Abay, Mebrahtu; Hintsa, Solomon; Zafu, Tekia] Aksum Univ, Coll Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Aksum, Ethiopia		Zafu, T (corresponding author), Aksum Univ, Coll Hlth Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Aksum, Ethiopia.	tekish2014@gmail.com		Hintsa, Solomon/0000-0003-1270-4817	Aksum University comprehensive specialized hospital	Aksum University comprehensive specialized hospital	We are cordially thankful for the data collectors, the supervisor and staffs of St. Mary general hospital and Aksum University comprehensive specialized hospital for their support during data collection.	Alemneh Kabeta, 2017, Clinics in Mother and Child Health, V14, P261; Anil Kumar Jaiswal., 2018, INT J CONT PEDIAT, V5, P1497; [Anonymous], 2017, LANCET HIV, V2017, pPE475; [Anonymous], 2017, J19 J 19 CENTURY AM, V5, P55; [Anonymous], 2015, BMJ, V2015, ph1887; Ashworth A., 2003, GUIDELINES INPATIENT; Asres DT, 2018, BMC NUTR, V4, DOI 10.1186/s40795-018-0224-0; Awoke A, 2018, BMC NUTR, V4, DOI 10.1186/s40795-018-0211-5; Case P. C., 2012, EVALUATION COMMUNITY; Collins S, 2006, LANCET, V368, P1992, DOI 10.1016/S0140-6736(06)69443-9; Derseh B, 2018, NUTR J, V17, DOI 10.1186/s12937-018-0423-1; Desyibelew HD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171020; Eicher S, 2019, J CHINESE HIST, V3, P1, DOI 10.1017/jch.2017.39; Fikrie A, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0642-x; Frontieres MS, 2006, CLIN HIV AIDS CARE G; Gachau S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197607; Gebremichael DY, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2593-5; Girum T, 2018, OPEN PUBLIC HLTH J, V11; Hassen SL, 2019, J NUTR METAB, V2019, DOI 10.1155/2019/2643531; Jarso H, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0398-4; John C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196971; Mekuria Getnet, 2017, BMC Nutr, V3, P42, DOI 10.1186/s40795-017-0161-3; Mena MB, 2018, INT J PEDIAT, V2018, DOI 10.1155/2018/8686501; Mengesha MM, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30704; Mitiku M, 2019, RES REV J MED, V8, P47; Muftah S., 2016, INT J CONT PEDIAT, V3, DOI [10.18203/2349-3291.ijcp20161026, DOI 10.18203/2349-3291.IJCP20161026]; Nyeko R., 2016, BMC NUTR, V2, P19, DOI DOI 10.1186/s40795-016-0058-6; Project TS, 2011, HUM CHART MIN STAND; SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01; Teshome G, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1407-9; Tirore Mengistu Girma, 2017, BMC Nutr, V3, P66, DOI 10.1186/s40795-017-0186-7; Trehan I, 2016, MALAWI MED J, V28, P123, DOI 10.1056/NEJMoa1202851; Trehan I, 2015, ARCH DIS CHILD, V100, P283, DOI 10.1136/archdischild-2014-306026; UNICEF W. World Bank Group, 2018, WORLD BANK GROUP LEV; Wagnew F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211628; Wang H., 2016, ETHIOPIA HLTH EXTENS; Williams P.C.M., 2016, SEVER ACUTE MALNUTRI, P1; World Health Organization, 1999, MAN SEV MALN MAN PHY; Yohannes Tadele, 2017, BMC Nutr, V3, P18, DOI 10.1186/s40795-017-0135-5	39	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2020	15	9							e0238311	10.1371/journal.pone.0238311	http://dx.doi.org/10.1371/journal.pone.0238311			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY8KQ	32991575	Green Published, gold			2023-01-03	WOS:000576632300013
J	Grover, S; Nguyen, JA; Viswanathan, V; Reinhart, RMG				Grover, Shrey; Nguyen, John A.; Viswanathan, Vighnesh; Reinhart, Robert M. G.			High-frequency neuromodulation improves obsessive-compulsive behavior	NATURE MEDICINE			English	Article							DIRECT-CURRENT STIMULATION; ALTERNATING-CURRENT STIMULATION; OSCILLATORY ACTIVITY; BRAIN-STIMULATION; NETWORK DYNAMICS; OCI-R; DISORDER; EEG; VALIDATION; CORTEX	Nearly one billion people worldwide suffer from obsessive-compulsive behaviors(1,2), yet our mechanistic understanding of these behaviors is incomplete, and effective therapeutics are unavailable. An emerging perspective characterizes obsessive-compulsive behaviors as maladaptive habit learning(3,4), which may be associated with abnormal beta-gamma neurophysiology of the orbitofrontal-striatal circuitry during reward processing(5,6). We target the orbitofrontal cortex with alternating current, personalized to the intrinsic beta-gamma frequency of the reward network, and show rapid, reversible, frequency-specific modulation of reward- but not punishment-guided choice behavior and learning, driven by increased exploration in the setting of an actor-critic architecture. Next, we demonstrate that chronic application of the procedure over 5 days robustly attenuates obsessive-compulsive behavior in a non-clinical population for 3 months, with the largest benefits for individuals with more severe symptoms. Finally, we show that convergent mechanisms underlie modulation of reward learning and reduction of obsessive-compulsive symptoms. The results contribute to neurophysiological theories of reward, learning and obsessive-compulsive behavior, suggest a unifying functional role of rhythms in the beta-gamma range, and set the groundwork for the development of personalized circuit-based therapeutics for related disorders.	[Grover, Shrey; Nguyen, John A.; Viswanathan, Vighnesh; Reinhart, Robert M. G.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA; [Reinhart, Robert M. G.] Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA	Boston University; Boston University; Boston University; Boston University	Reinhart, RMG (corresponding author), Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Syst Neurosci, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Cognit Neuroimaging Ctr, Boston, MA 02215 USA.; Reinhart, RMG (corresponding author), Boston Univ, Ctr Res Sensory Commun & Emerging Neural Technol, Boston, MA 02215 USA.	rmgr@bu.edu		Viswanathan, Vighnesh/0000-0002-6717-8829; Grover, Shrey/0000-0003-3168-5543	National Institutes of Health [R01-MH114877]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the National Institutes of Health (R01-MH114877) and a generous gift from an individual philanthropist awarded to R.M.G.R.	Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; Andersson E, 2012, PSYCHOL MED, V42, P2193, DOI 10.1017/S0033291712000244; Axmacher N, 2010, NEURON, V65, P541, DOI 10.1016/j.neuron.2010.02.006; Bloch MH, 2010, MOL PSYCHIATR, V15, P850, DOI 10.1038/mp.2009.50; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Burguiere E, 2015, CURR OPIN NEUROBIOL, V30, P59, DOI 10.1016/j.conb.2014.08.008; Camara E, 2009, FRONT NEUROSCI-SWITZ, V3, P350, DOI 10.3389/neuro.01.034.2009; Chasson GS, 2013, BEHAV COGN PSYCHOTH, V41, P249, DOI 10.1017/S1352465812000379; Clarke HF, 2014, J NEUROSCI, V34, P7663, DOI 10.1523/JNEUROSCI.0718-14.2014; Cocchi L, 2018, NEUROIMAGE-CLIN, V19, P661, DOI 10.1016/j.nicl.2018.05.029; Cohen JD, 2007, PHILOS T R SOC B, V362, P933, DOI 10.1098/rstb.2007.2098; Cohen MX, 2007, NEUROIMAGE, V35, P968, DOI 10.1016/j.neuroimage.2006.11.056; Cohen MX, 2011, TRENDS COGN SCI, V15, P558, DOI 10.1016/j.tics.2011.10.004; Dayan E, 2013, NAT NEUROSCI, V16, P838, DOI 10.1038/nn.3422; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Edwards D, 2013, NEUROIMAGE, V74, P266, DOI 10.1016/j.neuroimage.2013.01.042; Foa EB, 2002, PSYCHOL ASSESSMENT, V14, P485, DOI 10.1037//1040-3590.14.4.485; Frane JW, 1998, DRUG INF J, V32, P423, DOI 10.1177/009286159803200213; Fullana MA, 2009, AM J PSYCHIAT, V166, P329, DOI 10.1176/appi.ajp.2008.08071006; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gillan CM, 2017, PSYCHOL MED, V47, P1528, DOI 10.1017/S0033291716002786; Gold JM, 2012, ARCH GEN PSYCHIAT, V69, P129, DOI 10.1001/archgenpsychiatry.2011.1269; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024; Hajcak G, 2004, BEHAV RES THER, V42, P115, DOI 10.1016/j.brat.2003.08.002; Hernaus D, 2018, BIOL PSYCHIAT-COGN N, V3, P916, DOI 10.1016/j.bpsc.2018.03.014; Hollander E, 2000, PSYCHIAT CLIN N AM, V23, P643, DOI 10.1016/S0193-953X(05)70186-6; Howe MW, 2011, P NATL ACAD SCI USA, V108, P16801, DOI 10.1073/pnas.1113158108; Huppert JD, 2007, J ANXIETY DISORD, V21, P394, DOI 10.1016/j.janxdis.2006.05.006; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Karabanov AN, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00213; Kayser J, 2006, CLIN NEUROPHYSIOL, V117, P348, DOI 10.1016/j.clinph.2005.08.034; Kubota Y, 2019, PSYCHIAT RES-NEUROIM, V285, P40, DOI 10.1016/j.pscychresns.2019.01.012; Marco-Pallares J, 2008, NEUROPSYCHOLOGIA, V46, P241, DOI 10.1016/j.neuropsychologia.2007.07.016; Marco-Pallares J, 2015, NEUROSCI BIOBEHAV R, V49, P1, DOI 10.1016/j.neubiorev.2014.11.014; Marco-Pallares J, 2009, BIOL PSYCHIAT, V66, P154, DOI 10.1016/j.biopsych.2009.01.006; Mas-Herrero E, 2015, NEUROIMAGE, V119, P13, DOI 10.1016/j.neuroimage.2015.05.095; McClure S. M., 2006, ADV NEURAL INFORM PR, V18, P867, DOI DOI 10.1080/026999399379069; McDannald MA, 2011, J NEUROSCI, V31, P2700, DOI 10.1523/JNEUROSCI.5499-10.2011; Morris LS, 2016, NEUROPSYCHOPHARMACOL, V41, P940, DOI 10.1038/npp.2015.208; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Pessiglione M, 2006, NATURE, V442, P1042, DOI 10.1038/nature05051; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Reinhart RMG, 2019, NAT NEUROSCI, V22, P820, DOI 10.1038/s41593-019-0371-x; Reinhart RMG, 2017, P NATL ACAD SCI USA, V114, P11542, DOI 10.1073/pnas.1710257114; Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414-016-1224-2; Reinhart RMG, 2016, CURR BIOL, V26, P1867, DOI 10.1016/j.cub.2016.05.019; Remijnse PL, 2006, ARCH GEN PSYCHIAT, V63, P1225, DOI 10.1001/archpsyc.63.11.1225; Robbins TW, 2019, NEURON, V102, P27, DOI 10.1016/j.neuron.2019.01.046; Ruscio AM, 2010, MOL PSYCHIATR, V15, P53, DOI 10.1038/mp.2008.94; Schreiner DC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29285-x; Simpson HB, 2008, AM J PSYCHIAT, V165, P621, DOI 10.1176/appi.ajp.2007.07091440; Srinivasan R, 2007, J NEUROSCI METH, V166, P41, DOI 10.1016/j.jneumeth.2007.06.026; Sutton R.S., 1998, INTRO REINFORCEMENT, V135; Thompson SL, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0558-7; Toffolo MBJ, 2014, J OBSESS-COMPULS REL, V3, P338, DOI 10.1016/j.jocrd.2014.08.004; Villamar MF, 2013, J PAIN, V14, P371, DOI 10.1016/j.jpain.2012.12.007; VOON V, 2015, TRANSL PSYCHIAT, V5; Vossen A, 2015, BRAIN STIMUL, V8, P499, DOI 10.1016/j.brs.2014.12.004	60	39	40	7	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					232	+		10.1038/s41591-020-01173-w	http://dx.doi.org/10.1038/s41591-020-01173-w		JAN 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462447	Green Accepted			2023-01-03	WOS:000608674100002
J	Rago, M; Placidi, L; Polsoni, M; Rambaldi, G; Cusumano, D; Greco, F; Indovina, L; Menna, S; Placidi, E; Stimato, G; Teodoli, S; Mattiucci, GC; Chiesa, S; Marazzi, F; Masiello, V; Valentini, V; De Spirito, M; Azario, L				Rago, Maria; Placidi, Lorenzo; Polsoni, Mattia; Rambaldi, Giulia; Cusumano, Davide; Greco, Francesca; Indovina, Luca; Menna, Sebastiano; Placidi, Elisa; Stimato, Gerardina; Teodoli, Stefania; Mattiucci, Gian Carlo; Chiesa, Silvia; Marazzi, Fabio; Masiello, Valeria; Valentini, Vincenzo; De Spirito, Marco; Azario, Luigi			Evaluation of a generalized knowledge-based planning performance for VMAT irradiation of breast and locoregional lymph nodes-Internal mammary and/or supraclavicular regions	PLOS ONE			English	Article							MODULATED ARC THERAPY; RESOLUTION OPTIMIZER PRO; RADIATION-THERAPY; LUNG-CANCER; AT-RISK; RADIOTHERAPY; VALIDATION; QUALITY; IMRT; IMPACT	Purpose To evaluate the performance of eleven Knowledge-Based (KB) models for planning optimization (RapidPlan(TM) (RP), Varian) of Volumetric Modulated Arc Therapy (VMAT) applied to whole breast comprehensive of nodal stations, internal mammary and/or supraclavicular regions. Methods and materials Six RP models have been generated and trained based on 120 VMAT plans data set with different criteria. Two extra-structures were delineated: a PTV for the optimization and a ring structure. Five more models, twins of the previous models, have been created without the need of these structures. Results All models were successfully validated on an independent cohort of 40 patients, 30 from the same institute that provided the training patients and 10 from an additional institute, with the resulting plans being of equal or better quality compared with the clinical plans. The internal validation shows that the models reduce the heart maximum dose of about 2 Gy, the mean dose of about 1 Gy and the V-20Gy of 1.5 Gy on average. Model R and L together with model B without optimization structures ensured the best outcomes in the 20% of the values compared to other models. The external validation observed an average improvement of at least 16% for the V-5Gy of lungs in RP plans. The mean heart dose and for the V-20Gy for lung IPSI were almost halved. The models reduce the maximum dose for the spinal canal of more than 2 Gy on average Conclusions All KB models allow a homogeneous plan quality and some dosimetric gains, as we saw in both internal and external validation. Sub-KB models, developed by splitting right and left breast cases or including only whole breast with locoregional lymph nodes, have shown good performances, comparable but slightly worse than the general model. Finally, models generated without the optimization structures, performed better than the original ones.	[Rago, Maria; Placidi, Lorenzo; Valentini, Vincenzo; De Spirito, Marco; Azario, Luigi] Univ Cattolica Sacro Cuore, Rome, Italy; [Placidi, Lorenzo; Cusumano, Davide; Greco, Francesca; Indovina, Luca; Menna, Sebastiano; Placidi, Elisa; Stimato, Gerardina; Teodoli, Stefania; Mattiucci, Gian Carlo; Chiesa, Silvia; Marazzi, Fabio; Masiello, Valeria; Valentini, Vincenzo; De Spirito, Marco; Azario, Luigi] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy; [Polsoni, Mattia; Rambaldi, Giulia] Osped San Giovanni Calibita, Fatebenefratelli Isola Tiberina, Rome, Italy; [Polsoni, Mattia; Rambaldi, Giulia] Amethyst Radioterapia Italia, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Placidi, L (corresponding author), Univ Cattolica Sacro Cuore, Rome, Italy.; Placidi, L (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.	lorenzo.placidi@policlinicogemelli.it	Placidi, Lorenzo/AAB-5254-2022; indovina, luca/ABF-4641-2021; Chiesa, Silvia/Q-7291-2016	Placidi, Lorenzo/0000-0003-0058-9145; indovina, luca/0000-0001-8073-9005; Masiello, Valeria/0000-0001-7589-7623; Chiesa, Silvia/0000-0003-0168-3459; Azario, Luigi/0000-0001-8575-8627; Marazzi, Fabio/0000-0003-0977-0143				[Anonymous], 2014, PHAS 3 TRIAL ACC WHO; Appenzoller LM, 2012, MED PHYS, V39, P7446, DOI 10.1118/1.4761864; Berry SL, 2016, RADIOTHER ONCOL, V120, P349, DOI 10.1016/j.radonc.2016.06.010; Binny D, 2018, MED DOSIM, V43, P267, DOI 10.1016/j.meddos.2017.10.003; Boman E, 2016, PHYS MEDICA, V32, P1428, DOI 10.1016/j.ejmp.2016.10.012; Borst GR, 2010, INT J RADIAT ONCOL, V78, P1345, DOI 10.1016/j.ijrobp.2009.10.006; Buschmann M, 2018, STRAHLENTHER ONKOL, V194, P333, DOI 10.1007/s00066-017-1246-2; Cagni E, 2018, PHYS MEDICA, V55, P98, DOI 10.1016/j.ejmp.2018.11.002; Castriconi R, 2019, PHYS MEDICA, V57, P231, DOI 10.1016/j.ejmp.2018.12.002; Chang ATY, 2016, INT J RADIAT ONCOL, V95, P981, DOI 10.1016/j.ijrobp.2016.02.017; Chatterjee A, 2017, INT J RADIAT ONCOL, V99, P1021, DOI 10.1016/j.ijrobp.2017.07.012; Clark CH, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20150251; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Das IJ, 2008, JNCI-J NATL CANCER I, V100, P300, DOI 10.1093/jnci/djn020; Fogliata A, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0808-x; Fogliata A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145137; Fogliata A, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0530-5; Fogliata A, 2014, RADIOTHER ONCOL, V113, P385, DOI 10.1016/j.radonc.2014.11.009; Fogliata A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-82; Foy JJ, 2017, PRACT RADIAT ONCOL, V7, pE355, DOI 10.1016/j.prro.2017.02.007; Fusella M, 2018, MED PHYS, V45, P2611, DOI 10.1002/mp.12896; Good D, 2013, INT J RADIAT ONCOL, V87, P176, DOI 10.1016/j.ijrobp.2013.03.015; Hansen Christian Ronn, 2016, Clin Transl Radiat Oncol, V1, P2, DOI 10.1016/j.ctro.2016.08.001; Hjelstuen MHB, 2012, ACTA ONCOL, V51, P333, DOI 10.3109/0284186X.2011.618510; Hussein M, 2016, RADIOTHER ONCOL, V120, P473, DOI 10.1016/j.radonc.2016.06.022; Jiang F, 2017, J APPL CLIN MED PHYS, V18, P9, DOI 10.1002/acm2.12038; Johansen S, 2009, ACTA ONCOL, V48, P495, DOI 10.1080/02841860802657227; Kachnic LA, 2011, J NATL CANCER I, V103, P777, DOI 10.1093/jnci/djr136; Kamima T, 2019, PHYS MEDICA, V64, P174, DOI 10.1016/j.ejmp.2019.07.004; Kan MWK, 2013, INT J RADIAT ONCOL, V85, pE73, DOI 10.1016/j.ijrobp.2012.08.031; Krayenbuehl J, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1113-z; Krayenbuehl J, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0896-7; Kubo K, 2019, PHYS MEDICA, V67, P132, DOI 10.1016/j.ejmp.2019.10.032; Kubo K, 2017, PHYS MEDICA, V44, P199, DOI 10.1016/j.ejmp.2017.06.026; Li N, 2017, INT J RADIAT ONCOL, V97, P164, DOI 10.1016/j.ijrobp.2016.10.005; Michalski A, 2012, J MED IMAG RADIAT ON, V56, P499, DOI 10.1111/j.1754-9485.2012.02434.x; Miles EA, 2005, RADIOTHER ONCOL, V77, P241, DOI 10.1016/j.radonc.2005.10.011; Moore KL, 2015, INT J RADIAT ONCOL, V92, P228, DOI 10.1016/j.ijrobp.2015.01.046; Nelms BE, 2012, PRACT RADIAT ONCOL, V2, P296, DOI 10.1016/j.prro.2011.11.012; Nichols GP, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-66; Nicolini G, 2010, PHYS MED BIOL, V55, pN347, DOI 10.1088/0031-9155/55/12/N01; Nicolini G, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-27; Nissen HD, 2013, RADIOTHER ONCOL, V106, P28, DOI 10.1016/j.radonc.2012.10.016; Offersen BV, 2015, RADIOTHER ONCOL, V114, P3, DOI 10.1016/j.radonc.2014.11.030; Osman SOS, 2014, RADIOTHER ONCOL, V112, P17, DOI 10.1016/j.radonc.2014.04.004; Peters LJ, 2010, J CLIN ONCOL, V28, P2996, DOI 10.1200/JCO.2009.27.4498; Popescu CC, 2010, INT J RADIAT ONCOL, V76, P287, DOI 10.1016/j.ijrobp.2009.05.038; Qiu JJ, 2010, INT J RADIAT ONCOL, V78, P288, DOI 10.1016/j.ijrobp.2009.10.036; Quan EM, 2012, INT J RADIAT ONCOL, V84, pE69, DOI 10.1016/j.ijrobp.2012.02.017; Remouchamps VM, 2003, INT J RADIAT ONCOL, V55, P392, DOI 10.1016/S0360-3016(02)04143-3; Roach D, 2019, PHYS IMAG RADIAT ONC, V10, P7, DOI 10.1016/j.phro.2019.04.007; Scaggion A, 2018, PHYS MEDICA, V53, P86, DOI 10.1016/j.ejmp.2018.08.016; Schubert C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178034; Scorsetti M, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-145; Sharfo AWM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169202; Sheng Y, 2017, MED PHYS, V44, P5617, DOI 10.1002/mp.12556; Smith A, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819851763; Snyder KC, 2016, J APPL CLIN MED PHYS, V17, P263, DOI 10.1120/jacmp.v17i6.6429; Spruijt KH, 2013, INT J RADIAT ONCOL, V85, P506, DOI 10.1016/j.ijrobp.2012.03.040; Stranzl H, 2009, STRAHLENTHER ONKOL, V185, P155, DOI 10.1007/s00066-009-1939-2; Subramaniam S, 2012, STRAHLENTHER ONKOL, V188, P484, DOI 10.1007/s00066-012-0075-6; Symonds P., 2012, TXB RADIOTHERAPY, V7th; Teoh M, 2011, BRIT J RADIOL, V84, P967, DOI 10.1259/bjr/22373346; Tol JP, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0542-1; Tol JP, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0388-6; Tol JP, 2015, INT J RADIAT ONCOL, V91, P612, DOI 10.1016/j.ijrobp.2014.11.014; Toscas JI, 2010, RADIOTHER ONCOL, V96, P192, DOI 10.1016/j.radonc.2010.05.007; Tsai PF, 2012, J APPL CLIN MED PHYS, V13, P62, DOI 10.1120/jacmp.v13i5.3806; Ueda Y, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-0994-1; van Duren-Koopman MJ, 2018, PRACT RADIAT ONCOL, V8, P332, DOI 10.1016/j.prro.2018.03.008; Voet PWJ, 2014, INT J RADIAT ONCOL, V88, P1175, DOI 10.1016/j.ijrobp.2013.12.046; Wang JZ, 2013, PHYS MED BIOL, V58, pN181, DOI 10.1088/0031-9155/58/13/N181; Wang JQ, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0822-z; Wu BB, 2017, RADIOTHER ONCOL, V123, P57, DOI 10.1016/j.radonc.2017.01.012; Yin Y, 2012, MED DOSIM, V37, P287, DOI 10.1016/j.meddos.2011.11.001; Yuan LL, 2012, MED PHYS, V39, P6868, DOI 10.1118/1.4757927; Zhang XD, 2011, PHYS MED BIOL, V56, P3873, DOI 10.1088/0031-9155/56/13/009	77	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2021	16	1							e0245305	10.1371/journal.pone.0245305	http://dx.doi.org/10.1371/journal.pone.0245305			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4XD	33449952	Green Published, gold			2023-01-03	WOS:000609991600030
J	Case, GV; Storey, KM; Parmeley, LE; Schulz, LC				Van Gronigen Case, Gerialisa; Storey, Kathryn M.; Parmeley, Lauren E.; Schulz, Laura C.			Effects of maternal nutrient restriction during the periconceptional period on placental development in the mouse	PLOS ONE			English	Article							AMINO-ACID-TRANSPORT; PITUITARY-ADRENAL AXIS; FETAL-GROWTH; GENE-EXPRESSION; BIRTH-WEIGHT; WILD-TYPE; NUTRITIONAL MANIPULATION; CARDIOVASCULAR-DISEASE; GLUCOSE-TRANSPORTER; DNA METHYLATION	Maternal undernutrition has detrimental effects on fetal development and adult health. Total caloric restriction during early pregnancy followed by adequate nutrition for the remainder of gestation, is particularly linked to cardiovascular and metabolic disease risks during adulthood. The placenta is responsible for transport of nutrients from the maternal to fetal circulation, and the efficiency with which it does so can be adjusted to the maternal nutrient supply. There is evidence that placental adaptations to nutrient restriction in early pregnancy may be retained even when adequate nutrition is restored later in pregnancy, leading to a potential mismatch between placental efficiency and maternal nutrient supplies. However, in the mouse, 50% caloric restriction from days 1.5-11.5 of gestation, while temporarily altering placental structure and gene expression, had no significant effect on day 18.5. The periconceptional period, during which oocyte maturation, fertilization, and preimplantation development occur may be especially critical in creating lasting impact on the placenta. Here, mice were subjected to 50% caloric restriction from 3 weeks prior to pregnancy through d11.5, and then placental structure, the expression of key nutrient transporters, and global DNA methylation levels were examined at gestation d18.5. Prior exposure to caloric restriction increased maternal blood space area, but decreased expression of the key System A amino acid transporter Slc38a4 at d18.5. Neither placental and fetal weights, nor placental DNA methylation levels were affected. Thus, total caloric restriction beginning in the periconceptional period does have a lasting impact on placental development in the mouse, but without changing placental efficiency.	[Van Gronigen Case, Gerialisa; Storey, Kathryn M.; Parmeley, Lauren E.; Schulz, Laura C.] Univ Missouri, Dept Obstet Gynecol & Womens Hlth, Columbia, MO 65211 USA; [Van Gronigen Case, Gerialisa; Storey, Kathryn M.; Parmeley, Lauren E.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Schulz, LC (corresponding author), Univ Missouri, Dept Obstet Gynecol & Womens Hlth, Columbia, MO 65211 USA.	schulzl@missouri.edu		Schulz, Laura/0000-0001-8722-6616; Storey, Kathryn/0000-0002-2158-4784	National Institutes of Health [IMSD R25GM056901]; University of Missouri Mission Enhancement	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Missouri Mission Enhancement	This work was funded by the National Institutes of Health IMSD R25GM056901 to GVGC, and University of Missouri Mission Enhancement to LCS. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Barker DJP, 2004, ACTA PAEDIATR, V93, P26, DOI 10.1080/08035320410022730; Belkacemi L, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-105; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Bispham J, 2003, ENDOCRINOLOGY, V144, P3575, DOI 10.1210/en.2003-0320; Bleker OP, 2005, NESTLE NUTR WORKS SE, V55, P183; Bloise E, 2012, ENDOCRINOLOGY, V153, P3457, DOI 10.1210/en.2011-1921; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; Carter MG, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r61; Chen PY, 2013, PHYSIOL GENOMICS, V45, P565, DOI 10.1152/physiolgenomics.00034.2013; Cleal JK, 2008, J NEUROENDOCRINOL, V20, P419, DOI 10.1111/j.1365-2826.2008.01662.x; Coan PM, 2008, J PHYSIOL-LONDON, V586, P4567, DOI 10.1113/jphysiol.2008.156133; Coan PM, 2011, J PHYSIOL-LONDON, V589, P3659, DOI 10.1113/jphysiol.2011.208629; Coan PM, 2010, J PHYSIOL-LONDON, V588, P527, DOI 10.1113/jphysiol.2009.181214; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Dahl KDC, 2005, MOL CELL BIOL, V25, P10479, DOI 10.1128/MCB.25.23.10479-10491.2005; Dandrea J, 2001, REPRODUCTION, V122, P793, DOI 10.1530/rep.0.1220793; de Waal E, 2015, HUM MOL GENET, V24, P6975, DOI 10.1093/hmg/ddv400; Dimasuay KG, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00012; Dong F, 2005, GROWTH HORM IGF RES, V15, P291, DOI 10.1016/j.ghir.2005.05.003; Duttaroy AK, 2009, PROG LIPID RES, V48, P52, DOI 10.1016/j.plipres.2008.11.001; Edwards LJ, 2002, AM J PHYSIOL-REG I, V283, pR669, DOI 10.1152/ajpregu.00736.2001; El-Hashash AHK, 2010, MECH DEVELOP, V127, P1, DOI 10.1016/j.mod.2009.09.004; Feil D, 2006, J PHYSIOL-LONDON, V572, P87, DOI 10.1113/jphysiol.2005.102681; Feuer SK, 2017, J DEV ORIG HLTH DIS, V8, P403, DOI 10.1017/S204017441700023X; FIELDER PJ, 1987, AM J PHYSIOL, V253, pE40, DOI 10.1152/ajpendo.1987.253.1.E40; Fleming TP, 2004, BIOL REPROD, V71, P1046, DOI 10.1095/biolreprod.104.030957; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; Ganguly A, 2018, J NUTR BIOCHEM, V62, P192, DOI 10.1016/j.jnutbio.2018.09.001; Ganguly A, 2016, ENDOCRINOLOGY, V157, P4041, DOI 10.1210/en.2016-1259; Ganguly A, 2012, ENDOCRINOLOGY, V153, P3995, DOI 10.1210/en.2011-1973; Gardner DS, 2006, J ENDOCRINOL, V190, P203, DOI 10.1677/joe.1.06751; Gardner DS, 2004, HYPERTENSION, V43, P1290, DOI 10.1161/01.HYP.0000126991.67203.7b; Gluckman PD, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0109; Gopalakrishnan GS, 2004, AM J PHYSIOL-REG I, V287, pR12, DOI 10.1152/ajpregu.00687.2003; Harper JL, 2015, REPRODUCTION, V150, P165, DOI 10.1530/REP-15-0010; Heasman L, 1999, P NUTR SOC, V58, P283, DOI 10.1017/S0029665199000397; Jansson T, 2007, CLIN SCI, V113, P1, DOI 10.1042/CS20060339; Kaiser S, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.114.126474; Kalisch-Smith JI, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172205; Kavitha JV, 2014, FASEB J, V28, P1294, DOI 10.1096/fj.13-242271; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Li JH, 2009, AM J PATHOL, V175, P1380, DOI 10.2353/ajpath.2009.090096; Li YH, 2019, EPIGENETICS-US, V14, P850, DOI 10.1080/15592294.2019.1615357; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lumey LH, 1998, PLACENTA, V19, P105; Malandro MS, 1996, AM J PHYSIOL-CELL PH, V271, pC295, DOI 10.1152/ajpcell.1996.271.1.C295; Matoba S, 2019, P NATL ACAD SCI USA, V116, P21047, DOI 10.1073/pnas.1907884116; MCCRABB GJ, 1991, BRIT J NUTR, V65, P157, DOI 10.1079/BJN19910077; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Natale DRC, 2006, METH MOLEC MED, V121, P275; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Ojha S, 2015, REPROD FERT DEVELOP, V27, P1205, DOI 10.1071/RD14007; Oliver MH, 2005, PEDIATR RES, V57, P591, DOI 10.1203/01.PDR.0000155942.18096.9C; Outhwaite JE, 2015, PLACENTA, V36, P951, DOI 10.1016/j.placenta.2015.05.013; Pangas SA, 2014, KNOBIL NEILLS PHYSL; Pankevich DE, 2010, J NEUROSCI, V30, P16399, DOI 10.1523/JNEUROSCI.1955-10.2010; Poore KR, 2010, J PHYSIOL-LONDON, V588, P2219, DOI 10.1113/jphysiol.2010.187682; Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811; Rawn SM, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.132431; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Roberts CT, 2001, PLACENTA, V22, P177, DOI 10.1053/plac.2000.0602; Rooke JA, 2007, THERIOGENOLOGY, V67, P639, DOI 10.1016/j.theriogenology.2006.09.040; Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001; Schaiff WT, 2007, ENDOCRINOLOGY, V148, P3625, DOI 10.1210/en.2007-0211; Schulz LC, 2010, P NATL ACAD SCI USA, V107, P16757, DOI 10.1073/pnas.1012911107; Schulz LC, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.103218; Sferruzzi-Perri AN, 2009, BIOL REPROD, V81, P207, DOI 10.1095/biolreprod.108.073312; Shafiee A, 2018, STEM CELL REP, V10, P890, DOI 10.1016/j.stemcr.2018.01.011; Simmons DG, 2007, DEV BIOL, V304, P567, DOI 10.1016/j.ydbio.2007.01.009; Simmons DG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-352; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Symonds M. E., 2003, Archives of Physiology and Biochemistry, V111, P45, DOI 10.1076/apab.111.1.45.15141; Talton OO, 2016, ENDOCRINOLOGY, V157, P2636, DOI 10.1210/en.2016-1039; Tobi EW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6592; Townsend KL, 2008, ENDOCRINE, V33, P176, DOI 10.1007/s12020-008-9070-1; Tunster SJ, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0154-6; Van Baak TE, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1374-0; Vaughan OR, 2017, PROG MOL BIOL TRANSL, V145, P217, DOI 10.1016/bs.pmbts.2016.12.008; Velazquez MA, 2019, J ENDOCRINOL, V242, pT33, DOI 10.1530/JOE-18-0676; Wang PX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049720; Watkins AJ, 2015, REPRODUCTION, V149, P563, DOI 10.1530/REP-14-0667; Yang Y, 2017, CELL, V169, P243, DOI 10.1016/j.cell.2017.02.005; Yu KF, 2020, MOL METAB, V42, DOI 10.1016/j.molmet.2020.101053; Zhu MJ, 2007, PLACENTA, V28, P1192, DOI 10.1016/j.placenta.2007.05.004	84	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0244971	10.1371/journal.pone.0244971	http://dx.doi.org/10.1371/journal.pone.0244971			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4VV	33444393	Green Published, gold			2023-01-03	WOS:000609988100037
J	Ben Lagha, A; Azelmat, J; Vaillancourt, K; Grenier, D				Ben Lagha, Amel; Azelmat, Jabrane; Vaillancourt, Katy; Grenier, Daniel			A polyphenolic cinnamon fraction exhibits anti-inflammatory properties in a monocyte/macrophage model	PLOS ONE			English	Article							GINGIVAL CREVICULAR FLUID; NF-KAPPA-B; PPAR-GAMMA; PORPHYROMONAS-GINGIVALIS; ESSENTIAL OIL; PERIODONTITIS; MODULATION; LIPOPOLYSACCHARIDE; CONSTITUENTS; INFLAMMATION	Periodontal diseases are bacteria-induced inflammatory disorders that lead to the destruction of the tooth-supporting tissues. Active compounds endowed with a capacity to regulate the inflammatory response are regarded as potential therapeutic agents for the treatment of periodontal diseases. The aim of this study was to characterize the anti-inflammatory properties of a polyphenolic cinnamon fraction. Chromatographic and mass spectrometry analyses of the polyphenolic composition of the cinnamon fraction revealed that phenolic acids, flavonoids (flavonols, anthocyanins, flavan-3-ols), and procyanidins make up 9.22%, 0.72%, and 10.63% of the cinnamon fraction, respectively. We used a macrophage model stimulated with lipopolysaccharides (LPS) from either Aggregatibacter actinomycetemcomitans or Escherichia coli to show that the cinnamon fraction dose-dependently reduced IL-6, IL-8, and TNF-alpha secretion. Evidence was brought that this inhibition of cytokine secretion may result from the ability of the fraction to prevent LPS-induced NF-kappa B activation. We also showed that the cinnamon fraction reduces LPS binding to monocytes, which may contribute to its anti-inflammatory properties. Lastly, using a competitor assay, it was found that the cinnamon fraction may represent a natural PPAR-gamma ligand. Within the limitations of this in vitro study, the cinnamon fraction was shown to exhibit a therapeutic potential for the treatment of periodontal diseases due to its anti-inflammatory properties.	[Ben Lagha, Amel; Azelmat, Jabrane; Vaillancourt, Katy; Grenier, Daniel] Univ Laval, Fac Dent, Oral Ecol Res Grp, Quebec City, PQ, Canada	Laval University	Grenier, D (corresponding author), Univ Laval, Fac Dent, Oral Ecol Res Grp, Quebec City, PQ, Canada.	Daniel.Grenier@greb.ulaval.ca	Grenier, Daniel/E-5557-2015	Grenier, Daniel/0000-0003-0878-4674	Laboratoire de Controle Microbiologique de l'Universite Laval [2019-03-12]	Laboratoire de Controle Microbiologique de l'Universite Laval	The present study was supported by the Laboratoire de Controle Microbiologique de l'Universite Laval (#2019-03-12).	AlJehani YA, 2014, INT J DENT, V2014, DOI 10.1155/2014/182513; Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b; [Anonymous], 2017, J SAFETY ENV, V2017, P15; Ben Lagha A, 2019, CYTOKINE, V115, P64, DOI 10.1016/j.cyto.2018.12.009; Ben Lagha A, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-017-2072-x; Ben Lagha A, 2015, J AGR FOOD CHEM, V63, P6999, DOI 10.1021/acs.jafc.5b01525; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Chao LK, 2005, J AGR FOOD CHEM, V53, P7274, DOI 10.1021/jf051151u; de Souza JAC, 2012, J APPL ORAL SCI, V20, P128, DOI 10.1590/S1678-77572012000200002; Curtis MA, 2020, PERIODONTOL 2000, V83, P14, DOI 10.1111/prd.12296; Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; Dudonne S, 2014, J AGR FOOD CHEM, V62, P3244, DOI 10.1021/jf404965z; Golan-Goldhirsh A, 2014, PHYTOCHEM REV, V13, P107, DOI 10.1007/s11101-013-9293-5; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Hajishengallis G, 2020, PERIODONTOL 2000, V84, P14, DOI 10.1111/prd.12331; Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785; Hasturk H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00118; Hong JW, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-237; Jain S, 2010, PERIODONTOL 2000, V54, P53, DOI 10.1111/j.1600-0757.2009.00333.x; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kumar PS, 2017, J PHYSIOL-LONDON, V595, P465, DOI 10.1113/JP272427; La VD, 2010, ANTIMICROB AGENTS CH, V54, P1778, DOI 10.1128/AAC.01432-09; Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600-0757.2009.00321.x; Loos BG, 2020, PERIODONTOL 2000, V83, P26, DOI 10.1111/prd.12297; Mateos-Martin ML, 2012, ANAL BIOANAL CHEM, V402, P1327, DOI 10.1007/s00216-011-5557-3; Madureira DF, 2018, J EVID-BASED DENT PR, V18, P315, DOI 10.1016/j.jebdp.2018.04.001; Marciano DP, 2014, CELL METAB, V19, P193, DOI 10.1016/j.cmet.2013.12.009; Martin H, 2010, MUTAT RES-FUND MOL M, V690, P57, DOI 10.1016/j.mrfmmm.2009.09.009; Ranasinghe P, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-275; Rao PV, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/642942; Reynolds MA, 2014, PERIODONTOL 2000, V64, P7, DOI 10.1111/prd.12047; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; Stadler AF, 2016, J CLIN PERIODONTOL, V43, P727, DOI 10.1111/jcpe.12557; Sulijaya B, 2019, ARCH ORAL BIOL, V105, P72, DOI 10.1016/j.archoralbio.2019.07.002; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tanaka T, 2008, J AGR FOOD CHEM, V56, P5864, DOI 10.1021/jf800921r; Triantafilou K, 2000, CYTOMETRY, V41, P316, DOI 10.1002/1097-0320(20001201)41:4<316::AID-CYTO10>3.3.CO;2-Q; Tung YT, 2008, BIORESOURCE TECHNOL, V99, P3908, DOI 10.1016/j.biortech.2007.07.050; Tung YT, 2010, PHARM BIOL, V48, P1130, DOI 10.3109/13880200903527728; Veilleux MP, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2730-2; Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455; Yanakiev S, 2020, MOLECULES, V25, DOI 10.3390/molecules25184184; Yucel-Lindberg T, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.8; ZAPPA U, 1991, J CLIN PERIODONTOL, V18, P508, DOI 10.1111/j.1600-051X.1991.tb00082.x	45	2	2	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0244805	10.1371/journal.pone.0244805	http://dx.doi.org/10.1371/journal.pone.0244805			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4UT	33439867	Green Published, gold			2023-01-03	WOS:000609985300034
J	Longman, J; Johnston, J; Ewald, D; Gilliland, A; Burke, M; Mutonga, T; Passey, M				Longman, Jo; Johnston, Jennifer; Ewald, Dan; Gilliland, Adrian; Burke, Michael; Mutonga, Tabeth; Passey, Megan			What could prevent chronic condition admissions assessed as preventable in rural and metropolitan contexts? An analysis of clinicians' perspectives from the DaPPHne study	PLOS ONE			English	Article							CARE; READMISSIONS; HEALTH	Introduction Reducing potentially preventable hospitalisations (PPH) is a priority for health services. This paper describes the factors that clinicians perceived contributed to preventable admissions for angina, diabetes, congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD), and what they considered might have been done in the three months leading up to an admission to prevent it. Methods The study was conducted in a rural and a metropolitan health district in NSW, Australia. Expert Panels reviewed detailed case reports to assess preventability. For those admissions identified as preventable, comments from clinicians indicating what they perceived could have made a difference and/or been done differently to prevent each of the preventable admissions were analysed qualitatively. Results 148 (46%) of 323 admissions were assessed as preventable. Across the two districts, the most commonly identified groups of contributing factors to preventable admissions were: 'Systems issues: Community based services missing or inadequate or not referred to'; 'Patient issues: Problems with adherence/self-management'; and 'Clinician issues: GP care inadequate'. In some instances, important differences drove these groups of factors. For example, in the rural district 'Systems issues: Community based services missing or inadequate or not referred to' was largely driven by social and welfare support services missing/inadequate/not referred to, whereas in the metropolitan district it was largely driven by community nursing, allied health, care coordination or integrated care services missing/inadequate/not referred to. Analyses revealed the complexity of system, clinician and patient factors contributing to each admission. Admissions for COPD (rural) and CHF (metropolitan) admissions showed greatest complexity. Discussion and conclusion These findings suggest preventability of individual admissions is complex and context specific. There is no single, simple solution likely to reduce PPH. Rather, an approach addressing multiple factors is required. This need for comprehensiveness may explain why many programs seeking to reduce PPH have been unsuccessful.	[Longman, Jo; Johnston, Jennifer; Ewald, Dan; Passey, Megan] Univ Sydney, Univ Ctr Rural Hlth, Lismore, NSW, Australia; [Ewald, Dan] North Coast Primary Hlth Network, Ballina, NSW, Australia; [Gilliland, Adrian] Coffs Med Ctr, Coffs Harbour, NSW, Australia; [Burke, Michael] Univ Sydney, Sch Med, Sydney, NSW, Australia; [Burke, Michael] Western Sydney Univ, Sch Med, Sydney, NSW, Australia; [Mutonga, Tabeth] Western Sydney Local Hlth Dist, Mt Druitt Community Hlth Ctr, Mt Druitt, NSW, Australia	University of Sydney; University of Sydney; Western Sydney University	Longman, J (corresponding author), Univ Sydney, Univ Ctr Rural Hlth, Lismore, NSW, Australia.	jo.longman@sydney.edu.au		Longman, Jo/0000-0002-8257-7772	Western Sydney Local Health District; Mid North Coast Local Health District; North Coast Primary Health Network; New South Wales Agency for Clinical Innovation; University Centre for Rural Health, University of Sydney	Western Sydney Local Health District; Mid North Coast Local Health District; North Coast Primary Health Network; New South Wales Agency for Clinical Innovation; University Centre for Rural Health, University of Sydney	The University Centre for Rural Health received funding for the DaPPHne study from the partner organisations: Western Sydney Local Health District, Mid North Coast Local Health District, North Coast Primary Health Network, New South Wales Agency for Clinical Innovation and University Centre for Rural Health, University of Sydney. The University Centre for Rural Health designed and executed the study, data collection was facilitated by Western Sydney Local Health District and Mid North Coast Local Health District.	Ahn S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1141; Arozullah AM, 2006, J GEN INTERN MED, V21, P140, DOI 10.1111/j.1525-1497.2005.00300.x; Australian Institute of Health and Welfare, 2019, ADMITTED PATIENT CAR; Australian Institute of Health and Welfare, 2014, AUSTR I HLTH WELF HL, V50; Australian Medical Association, 2016, PLAN BETTER HEALTHCA; Barker I, 2018, BMJ QUAL SAF, V27, P989, DOI 10.1136/bmjqs-2017-007635; Barker I, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j84; Council of Australian Governments, 2012, NATL HEALTHCARE AGRE; Cresswell J.W., 2017, DESIGNING CONDUCTING; Cui XN, 2019, RURAL REMOTE HEALTH, V19, DOI [10.22605/RRH5270, 10.22605/rrh5270]; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Erny-Albrecht K, 2016, PHCRIS POLICY ISSUE; Fischer C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112282; Health Workforce Australia, 2013, NATL RURAL REMOTE HE; Hodgson K, 2019, BMJ QUAL SAF, V28, P429, DOI 10.1136/bmjqs-2018-008820; Howcroft M, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005074.pub4; Johnston J, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038415; Johnston JJ, 2019, FAM PRACT, P1, DOI [10.1093/fampra/cmz001, DOI 10.1093/FAMPRA/CMZ001]; Katterl R., 2012, POTENTIALLY AVOIDABL; Lenferink A, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011682.pub2; Leppin AL, 2014, JAMA INTERN MED, V174, P1095, DOI 10.1001/jamainternmed.2014.1608; Longman J, 2013, AUST HEALTH REV, V37, P223, DOI 10.1071/AH12152; Longman JM, 2018, AUST J PRIM HEALTH, V24, P304, DOI 10.1071/PY17191; Longman JM, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1137-0; Longman JM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-373; Longman JM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-265; National Health Performance Authority, 2012, PERFORMANCE ACCOUNTA; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; Oyanguren J, 2016, REV ESP CARDIOL, V69, P900, DOI 10.1016/j.rec.2016.05.012; Parry W, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026470; Passey ME, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009879; Peters DH, 2014, HEALTH RES POLICY SY, V12, DOI 10.1186/1478-4505-12-51; Purdy S, 2012, INTERVENTIONS REDUCE; Purdy S., 2010, AVOIDING HOSP ADMISS; Raven MC, 2009, J URBAN HEALTH, V86, P230, DOI 10.1007/s11524-008-9336-1; Roberts R, 2018, AUST J RURAL HEALTH, V26, P144, DOI 10.1111/ajr.12443; San Ko FW, 2019, J THORAC DIS, V11, pS2181, DOI 10.21037/jtd.2019.09.81; Smith SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006560.pub2; Steventon A, 2018, BRIEFING EMERGENCY H; Steventon A, 2017, BMJ QUAL SAF, V26, P782, DOI 10.1136/bmjqs-2017-006629; Trivedi RB, 2012, ANN BEHAV MED, V44, P66, DOI 10.1007/s12160-012-9355-8; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	42	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244313	10.1371/journal.pone.0244313	http://dx.doi.org/10.1371/journal.pone.0244313			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411717	gold, Green Published			2023-01-03	WOS:000608044300073
J	Sharma, L				Sharma, Leena			Osteoarthritis of the Knee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIP OSTEOARTHRITIS; SELF-EFFICACY; OLDER-ADULTS; DOUBLE-BLIND; CHRONIC PAIN; MANAGEMENT; PLACEBO; INTERVENTIONS; METAANALYSIS; PREVALENCE	Knee osteoarthritis is highly prevalent among older adults. Treatments include exercise, weight management, training in self-efficacy and pain-coping skills, and medications (commonly topical or oral NSAIDs, the latter often with a proton-pump inhibitor).	[Sharma, Leena] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Sharma, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, 633 N St Clair St,Suite 18-097, Chicago, IL 60611 USA.	l-sharma@northwestern.edu		Sharma, Leena/0000-0002-5571-1622				Bally M, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1909; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14-1231; Barbour KE, 2014, ARTHRIT CARE RES, V66, P139, DOI 10.1002/acr.22120; Barcella CA, 2019, BASIC CLIN PHARMACOL, V124, P629, DOI 10.1111/bcpt.13182; Bennell KL, 2017, ANN INTERN MED, V166, P453, DOI 10.7326/M16-1714; Brand E, 2013, J ORTHOP SPORT PHYS, V43, P895, DOI 10.2519/jospt.2013.4471; Brignardello-Petersen R, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016114; Broderick JE, 2014, PAIN, V155, P1743, DOI 10.1016/j.pain.2014.05.024; Carlesso LC, 2019, ARTHRITIS RHEUMATOL, V71, P542, DOI 10.1002/art.40752; Chappell AS, 2011, PAIN PRACT, V11, P33, DOI 10.1111/j.1533-2500.2010.00401.x; Collins JE, 2014, OSTEOARTHR CARTILAGE, V22, P622, DOI 10.1016/j.joca.2014.03.009; Conaghan PG, 2020, ANN INTERN MED, V172, P86, DOI 10.7326/M19-0675; da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140-6736(17)31744-0; Deyle GD, 2020, NEW ENGL J MED, V382, P1420, DOI 10.1056/NEJMoa1905877; Dillon CF, 2006, J RHEUMATOL, V33, P2271; Dixon KE, 2007, HEALTH PSYCHOL, V26, P241, DOI 10.1037/0278-6133.26.3.241; Dunlop DD, 2019, AM J PREV MED, V56, P664, DOI 10.1016/j.amepre.2018.12.017; Dunlop DD, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2472; Dunlop DD, 2011, ARTHRITIS RHEUM-US, V63, P3372, DOI 10.1002/art.30562; Edwards RR, 2011, NAT REV RHEUMATOL, V7, P216, DOI 10.1038/nrrheum.2011.2; Felson DT, 2007, ARTHRIT RHEUM-ARTHR, V57, P6, DOI 10.1002/art.22464; Fransen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub3; Gersing AS, 2016, OSTEOARTHR CARTILAGE, V24, P1126, DOI 10.1016/j.joca.2016.01.984; Ghazi C, 2018, PHYSIOTHER THEOR PR, V34, P495, DOI 10.1080/09593985.2017.1422204; Gill TM, 2017, ANN INTERN MED, V167, P818, DOI 10.7326/M17-2550; Gunter BR, 2017, J CLIN PHARM THER, V42, P27, DOI 10.1111/jcpt.12484; Hall M, 2019, SEMIN ARTHRITIS RHEU, V48, P765, DOI 10.1016/j.semarthrit.2018.06.005; Hawker GA, 2008, OSTEOARTHR CARTILAGE, V16, P415, DOI 10.1016/j.joca.2007.12.017; Hochberg MC, 2019, JAMA-J AM MED ASSOC, V322, P1360, DOI 10.1001/jama.2019.14735; Holla JFM, 2015, ARTHRIT CARE RES, V67, P48, DOI 10.1002/acr.22381; Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9; Juhl C, 2014, ARTHRITIS RHEUMATOL, V66, P622, DOI 10.1002/art.38290; Keefe FJ, 1996, ARTHRIT CARE RES, V9, P279, DOI 10.1002/1529-0131(199608)9:4<279::AID-ANR1790090413>3.0.CO;2-6; Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI [10.1002/art.41142, 10.1002/acr.24131]; Lawford BJ, 2018, J MED INTERNET RES, V20, DOI 10.2196/10021; Leopoldino AO, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013273; McAlindon TE, 2017, JAMA-J AM MED ASSOC, V317, P1967, DOI 10.1001/jama.2017.5283; Messier SP, 2018, ARTHRIT CARE RES, V70, P1569, DOI 10.1002/acr.23608; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Nguyen USDT, 2011, ANN INTERN MED, V155, P725, DOI 10.7326/0003-4819-155-11-201112060-00004; Osthoff AKR, 2018, ANN RHEUM DIS, V77, P1251, DOI 10.1136/annrheumdis-2018-213585; Quicke JG, 2015, OSTEOARTHR CARTILAGE, V23, P1445, DOI 10.1016/j.joca.2015.05.002; Rini C, 2015, PAIN, V156, P837, DOI 10.1097/j.pain.0000000000000121; Roemer FW, 2015, ARTHRITIS RHEUMATOL, V67, P2085, DOI 10.1002/art.39176; Runhaar J, 2017, ANN RHEUM DIS, V76, P1862, DOI 10.1136/annrheumdis-2017-211149; Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003-4819-157-3-201208070-00473; Shan L, 2015, J BONE JOINT SURG AM, V97A, P156, DOI 10.2106/JBJS.M.00372; Sharma L, 2017, OSTEOARTHR CARTILAGE, V25, P1068, DOI 10.1016/j.joca.2017.02.788; Sharma L, 2019, ANN RHEUM DIS, V78, P1412, DOI 10.1136/annrheumdis-2019-215353; Siemieniuk RAC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1982; Thorlund JB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2747; Uchio Y, 2018, J PAIN RES, V11, P809, DOI 10.2147/JPR.S164128; Wandel S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4675; Wang CC, 2016, ANN INTERN MED, V165, P77, DOI 10.7326/M15-2143; Zeng C, 2019, JAMA-J AM MED ASSOC, V321, P969, DOI 10.1001/jama.2019.1347	56	144	155	97	258	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	2021	384	1					51	59		10.1056/NEJMcp1903768	http://dx.doi.org/10.1056/NEJMcp1903768			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PS6FK	33406330				2023-01-03	WOS:000608021500010
J	Kruik-Kolloffel, WJ; van der Palen, J; Doggen, CJM; van Maaren, MC; Kruik, HJ; Heintjes, EM; Movig, KLL; Linssen, GCM				Kruik-Kolloffel, Willemien J.; van der Palen, Job; Doggen, Carine J. M.; van Maaren, Marissa C.; Kruik, H. Joost; Heintjes, Edith M.; Movig, Kris L. L.; Linssen, Gerard C. M.			Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases	PLOS ONE			English	Article							INITIATE LIFESAVING TREATMENT; ORGANIZED PROGRAM; MORTALITY; CARVEDILOL; ASSOCIATION; METOPROLOL; MORBIDITY; COMET; REHOSPITALIZATION; MANAGEMENT	Background This study assessed the association between heart failure (HF) medication (angiotensin-converting-enzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB), beta-blockers (BB), mineralocorticoid-receptor antagonists (MRA) and diuretics) and HF readmissions in a real-world unselected group of patients after a first hospital admission for HF. Furthermore we analysed readmission rates for ACEI versus ARB and for carvedilol versus beta 1-selective BB and we investigated the effect of HF medication in relation to time since discharge. Methods and findings Medication at discharge was determined with dispensing data from the Dutch PHARMO Database Network including 22,476 patients with HF between 2001 and 2015. After adjustment for age, gender, number of medications and year of admission no associations were found for users versus non-users of ACEI/ARB (hazard ratio, HR = 1.01; 95%CI 0.96-1.06), BB (HR = 1.00; 95%CI 0.95-1.05) and readmissions. The risk of readmission for patients prescribed MRA (HR = 1.11; 95%CI 1.05-1.16) or diuretics (HR = 1.17; 95%CI 1.09-1.25) was higher than for non-users. The HR for ARB relative to ACEI was 1.04 (95%CI 0.97-1.12) and for carvedilol relative to beta 1-selective BB 1.33 (95%CI 1.20-1.46). Post-hoc analyses showed a protective effect shortly after discharge for most medications. For example one month post discharge the HR for ACEI/ARB was 0.77 (95%CI 0.69-0.86). Although we did try to adjust for confounding by indication, probably residual confounding is still present. Conclusions Patients who were prescribed carvedilol have a higher or at least a similar risk of HF readmission compared to beta 1-selective BB. This study showed that all groups of HF medication -some more pronounced than others- were more effective immediately following discharge.	[Kruik-Kolloffel, Willemien J.] Ziekenhuisgrp Twente Hosp Grp Twente, Dept Clin Pharm, Almelo, Netherlands; [Kruik-Kolloffel, Willemien J.] Ziekenhuisgrp Twente Hosp Grp Twente, Dept Clin Pharm, Hengelo, Netherlands; [van der Palen, Job] Med Spectrum Twente, Med Sch Twente, Enschede, Netherlands; [van der Palen, Job] Univ Twente, Dept Res Methodol Measurement & Data Anal, Enschede, Netherlands; [Doggen, Carine J. M.; van Maaren, Marissa C.] Univ Twente, Dept Hlth Technol & Serv Res, Tech Med Ctr, Enschede, Netherlands; [van Maaren, Marissa C.] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands; [Kruik, H. Joost; Linssen, Gerard C. M.] Ziekenhuisgrp Twente Hosp Grp Twente, Dept Cardiol, Almelo, Netherlands; [Kruik, H. Joost; Linssen, Gerard C. M.] Ziekenhuisgrp Twente Hosp Grp Twente, Dept Cardiol, Hengelo, Netherlands; [Heintjes, Edith M.] PHARMO Inst, Utrecht, Netherlands; [Movig, Kris L. L.] Med Spectrum Twente, Dept Clin Pharm, Enschede, Netherlands	Medical Spectrum Twente; University of Twente; University of Twente; Medical Spectrum Twente	Kruik-Kolloffel, WJ (corresponding author), Ziekenhuisgrp Twente Hosp Grp Twente, Dept Clin Pharm, Almelo, Netherlands.; Kruik-Kolloffel, WJ (corresponding author), Ziekenhuisgrp Twente Hosp Grp Twente, Dept Clin Pharm, Hengelo, Netherlands.	w.kruik@sxb.nl		van der Palen, Job/0000-0003-1071-6769; Heintjes, Edith/0000-0002-2617-3845				[Anonymous], 2019, DIABETES CARE, V40, pS13; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bolling R, 2014, EUR J HEART FAIL, V16, P678, DOI 10.1002/ejhf.81; Bowman L, 2020, EUR HEART J, V41, P2571, DOI 10.1093/eurheartj/ehaa020; Bristow MR, 2003, J CARD FAIL, V9, P444, DOI 10.1016/j.cardfail.2003.10.009; Camm AJ, 2018, OPEN HEART, V5, DOI 10.1136/openhrt-2018-000788; Chatterjee S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f55; Cleland JGF, 2018, EUR HEART J, V39, P26, DOI 10.1093/eurheartj/ehx564; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Crespo-Leiro MG, 2016, EUR J HEART FAIL, V18, P613, DOI 10.1002/ejhf.566; Dargie HJ, 2003, LANCET, V362, P2, DOI 10.1016/S0140-6736(03)13842-1; Desai AS, 2012, CIRCULATION, V126, P501, DOI 10.1161/CIRCULATIONAHA.112.125435; Eschalier R, 2015, CARDIOVASC DRUG THER, V29, P89, DOI 10.1007/s10557-015-6572-y; Freemantle N, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6409; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Go AS, 2007, AM J CARDIOL, V100, P690, DOI 10.1016/j.amjcard.2007.03.084; Goldgrab D, 2019, HEART FAIL REV, V24, P177, DOI 10.1007/s10741-018-9754-4; Herings RMC, 2012, PHARMACOEPIDEM DR S; Hernandez AF, 2009, J AM COLL CARDIOL, V53, P184, DOI 10.1016/j.jacc.2008.09.031; Jhund PS, 2020, EUR J HEART FAIL, V22, P249, DOI 10.1002/ejhf.1721; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Kapelios CJ, 2018, EUR HEART J-CARD PHA, V4, P54, DOI 10.1093/ehjcvp/pvx020; KOTECHA D, 2016, BMJ-BRIT MED J, V353, DOI DOI 10.1136/BMJ.I1855; Kruik-Kolloffel WJ, 2019, HEART FAIL REV, V24, P499, DOI 10.1007/s10741-019-09777-2; Kruik-Kolloffel WJ, 2019, THESIS; Lazarus DL, 2011, AM J CARDIOL, V107, P1196, DOI 10.1016/j.amjcard.2010.12.017; Lund LH, 2018, EUR J HEART FAIL, V20, P511, DOI 10.1002/ejhf.1107; Mullens W, 2019, EUR J HEART FAIL, V21, P137, DOI 10.1002/ejhf.1369; Network Equator, 2019, REPORTING STUD COND; O'Connor CM, 2008, AM HEART J, V156, P662, DOI 10.1016/j.ahj.2008.04.030; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Packer M, 2003, J CARD FAIL, V9, P429, DOI 10.1016/j.cardfail.2003.08.003; Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426; Paolillo S, 2017, EUR J HEART FAIL, V19, P904, DOI 10.1002/ejhf.775; Pasternak B, 2014, JAMA INTERN MED, V174, P1597, DOI 10.1001/jamainternmed.2014.3258; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Rush CJ, 2018, EUR HEART J, V39, P3417, DOI 10.1093/eurheartj/ehy407; Sanam K, 2016, AM J MED, V129, P1067, DOI 10.1016/j.amjmed.2016.05.008; Schmidt M, 2016, EUR J HEART FAIL, V18, P490, DOI 10.1002/ejhf.486; Solomon SD, 2007, CIRCULATION, V116, P1482, DOI 10.1161/CIRCULATIONAHA.107.696906; Stolfo D, 2020, EUR J HEART FAIL, V22, P103, DOI 10.1002/ejhf.1615; Sulo G, 2020, EUR J HEART FAIL, V22, P241, DOI 10.1002/ejhf.1609; van Herk-Sukel MPP, 2010, EUR J CANCER, V46, P395, DOI 10.1016/j.ejca.2009.09.010; Wolsk E, 2018, EUR J HEART FAIL, V20, P1267, DOI 10.1002/ejhf.1225; Yamaguchi T, 2018, AM J CARDIOL, V121, P969, DOI 10.1016/j.amjcard.2018.01.006; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019	48	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2020	15	12							e0244231	10.1371/journal.pone.0244231	http://dx.doi.org/10.1371/journal.pone.0244231			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CG	33351823	Green Published, gold			2023-01-03	WOS:000603071400011
J	Lopes, LC; Bomfim, E; Olson, K; Neves, ET; Silveira, DSC; Nunes, MDR; Nascimento, LC; Pereira-da-Silva, G; Lima, RAG				Lopes-Junior, Luis Carlos; Bomfim, Emiliana; Olson, Karin; Neves, Eliane Tatsch; Calheiros Silveira, Denise Sayuri; Rodrigues Nunes, Michelle Darezzo; Nascimento, Lucila Castanheira; Pereira-da-Silva, Gabriela; Garcia Lima, Regina Aparecida			Effectiveness of hospital clowns for symptom management in paediatrics: systematic review of randomised and non-randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							REDUCE PREOPERATIVE ANXIETY; QUALITY-OF-LIFE; MEDICAL CLOWNS; PSYCHOLOGICAL DISTRESS; EMERGENCY-DEPARTMENT; EMOTIONAL RESPONSES; THERAPEUTIC CLOWNS; CHILDREN; PAIN; INTERVENTION	OBJECTIVE To evaluate evidence from randomised controlled trials and non-randomised controlled trials on the effectiveness of hospital clowns for a range of symptom clusters in children and adolescents admitted to hospital with acute and chronic conditions. DESIGN Systematic review of randomised and non-randomised controlled trials. DATA SOURCES Medline, ISI of Knowledge, Cochrane Central Register of Controlled Trials, Science Direct, Scopus, American Psychological Association PsycINFO, Cumulative Index to Nursing and Allied Health Literature, and Latin American and Caribbean Health Sciences Literature. STUDY SELECTION Randomised and non-randomised controlled trials were peer reviewed using the following eligibility criteria: children and adolescents who were admitted to hospital for acute conditions or chronic disorders, studies comparing use of hospital clowns with standard care, and studies evaluating the effect of hospital clowns on symptom management of inpatient children and adolescents as a primary outcome. DATA EXTRACTION AND SYNTHESIS Two investigators independently screened studies, extracted data, and appraised the risk of bias. Methodological appraisal was assessed by two investigators independently using the Jadad scale, the revised Cochrane risk-of-bias tool for randomised controlled trials (RoB 2), and the risk of bias in non-randomised studies (ROBINS-I) tool for non-randomised controlled trials. RESULTS 24 studies (n=1612) met the inclusion criteria for data extraction and analysis. Most studies were randomised controlled trials (n=13). Anxiety was the most frequently analysed symptom (n=13), followed by pain (n=9), psychological and emotional responses and perceived wellbeing (n=4), stress (n=4), cancer related fatigue (n=3), and crying (n=2). Five studies used biomarkers, mainly cortisol, to assess stress or fatigue outcome following hospital clowns. Most of the randomised controlled trials (n=11; 85%) were rated as showing some concerns, and two trials were rated with a high risk of bias. Most non-randomised controlled trials (n=6; 55%) were rated with a moderate risk of bias according to ROBINS-I tool. Studies showed that children and adolescents who were in the presence of hospital clowns, either with or without a parent present, reported significantly less anxiety during a range of medical procedures, as well as improved psychological adjustment (P<0.05). Three studies that evaluated chronic conditions showed favourable results for the intervention of hospital clowns with significant reduction in stress, fatigue, pain, and distress (P<0.05). CONCLUSIONS These findings suggest that the presence of hospital clowns during medical procedures, induction of anaesthesia in the preoperative room, and as part of routine care for chronic conditions might be a beneficial strategy to manage some symptom clusters. Furthermore, hospital clowns might help improve psychological wellbeing in admitted children and adolescents with acute and chronic disorders, compared with those who received only standard care. Systematic review registration PROSPERO CRD42018107099.	[Lopes-Junior, Luis Carlos] Univ Fed Espirito Santo, Ave Marechal Campus,1468 Maruipe, BR-29043900 Vitoria, ES, Brazil; [Bomfim, Emiliana] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada; [Olson, Karin] Univ Alberta, Edmonton, AB, Canada; [Neves, Eliane Tatsch] Univ Fed Santa Maria, Santa Maria, RS, Brazil; [Calheiros Silveira, Denise Sayuri] Fed Inst Espirito Santo, Linhares, ES, Brazil; [Rodrigues Nunes, Michelle Darezzo] Univ Estado Rio De Janeiro, Rio De Janeiro, RJ, Brazil; [Nascimento, Lucila Castanheira; Pereira-da-Silva, Gabriela; Garcia Lima, Regina Aparecida] Univ Sao Paulo Ribeirao Preto, Coll Nursing, Ribeirao Preto, SP, Brazil	Universidade Federal do Espirito Santo; University of Saskatchewan; University of Alberta; Universidade Federal de Santa Maria (UFSM); Instituto Federal do Espirito Santo (IFES); Universidade do Estado do Rio de Janeiro; Universidade de Sao Paulo	Lopes, LC (corresponding author), Univ Fed Espirito Santo, Ave Marechal Campus,1468 Maruipe, BR-29043900 Vitoria, ES, Brazil.	lopesjr.lc@gmail.com	Lopes-Júnior, Luís Carlos/B-8540-2015; Bomfim, Emiliana/N-1874-2019	Lopes-Júnior, Luís Carlos/0000-0002-2424-6510; Bomfim, Emiliana/0000-0001-7759-8459	CAPES	CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Support from CAPES has been granted for this work. The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Abrahao CA, 2019, J EVID-BASED INTEGR, V24, DOI 10.1177/2515690X19834169; Agostini F, 2014, J HEALTH PSYCHOL, V19, P587, DOI 10.1177/1359105313475900; Aktas A, 2010, PALLIATIVE MED, V24, P373, DOI 10.1177/0269216310367842; Amorim MHC, ACTA PAUL ENFERM, V34, P1; Aquino R. G., 2004, ONLINE BRAZILIAN J N, V3, P41, DOI [10.17665/1676-4285.20044909, DOI 10.17665/1676-4285.20044909]; Arriaga P, 2020, CHILD YOUTH CARE FOR, V49, P365, DOI 10.1007/s10566-019-09532-6; Arriaga P, 2016, INT J EMOT EDUC, V8, P19; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Barkmann C, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-166; Barsevick AM, 2006, J PAIN SYMPTOM MANAG, V31, P85, DOI 10.1016/j.jpainsymman.2005.05.015; Battrick C., 2007, J CHILDRENS YOUNG PE, V1, P174, DOI [10.12968/jcyn.2007.1.4.24403, DOI 10.12968/JCYN.2007.1.4.24403]; Ben-Pazi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175028; Bertini M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq064; Bilandzic A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001987; Black N, 1996, BRIT MED J, V312, P1215; Bomfim ED, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.29_suppl.95; Brown EA, 2018, CLIN CHILD FAM PSYCH, V21, P224, DOI 10.1007/s10567-017-0252-3; Canto M A Gutierrez, 2008, Cir Pediatr, V21, P195; Caserta MT, 2008, BRAIN BEHAV IMMUN, V22, P933, DOI 10.1016/j.bbi.2008.01.007; Dionigi A., 2019, EUROPEAN J HUMOUR RE, V7, P1, DOI [10.7592/EJHR2019.7.4.dionigi, DOI 10.7592/EJHR2019.7.4.DIONIGI]; Dionigi A, 2017, J CLIN NURS, V26, P632, DOI 10.1111/jocn.13578; Dionigi A, 2014, J HEALTH PSYCHOL, V19, P369, DOI 10.1177/1359105312471567; Dodd Marylin J, 2004, J Natl Cancer Inst Monogr, P76; Felluga M, 2016, EUR J PEDIATR, V175, P645, DOI 10.1007/s00431-015-2688-0; Fernandes SC, 2010, J HEALTH PSYCHOL, V15, P405, DOI 10.1177/1359105309350231; de Lima RAG, 2009, REV ESC ENFERM USP, V43, P178; Goh XTW, 2017, J CLIN PHARM THER, V42, P1, DOI 10.1111/jcpt.12441; Golan G, 2009, PEDIATR ANESTH, V19, P262, DOI 10.1111/j.1460-9592.2008.02903.x; Golan G, 2007, ANAESTHESIA, V107, pA1394; Goldberg A, 2014, ALLERGY, V69, P1372, DOI 10.1111/all.12463; Goncalves CA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026975; Gorfinkle KS, 1998, PEDIATR RES, V43, P12, DOI DOI 10.1203/00006450-199804001-00076; da Silva FJG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039426; Hansen Lars Kjaersgaard, 2011, J Pain Res, V4, P297, DOI 10.2147/JPR.S23199; Heilbrunn BR, 2014, J EMERG MED, V47, P623, DOI 10.1016/j.jemermed.2014.06.052; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hyacinth O, 2020, J PAIN SYMPTOM MANAG, V60, P1079, DOI 10.1016/j.jpainsymman.2020.07.006; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Kingsnorth S, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq008; Kocherov S, 2016, J PAEDIATR CHILD H, V52, P877, DOI 10.1111/jpc.13242; Konsgen N, 2019, SYST REV-LONDON, V8, DOI 10.1186/s13643-019-1095-4; Koller D, 2008, EVID-BASED COMPL ALT, V5, P17, DOI 10.1093/ecam/nem033; Kristensen Helle Nygaard, 2019, Paediatr Neonatal Pain, V1, P5, DOI 10.1002/pne2.12005; Kristensen HN, 2019, J PEDIATR NURS, V46, pE77, DOI 10.1016/j.pedn.2019.03.013; LEBARON S, 1988, MED PEDIATR ONCOL, V16, P263, DOI 10.1002/mpo.2950160408; Linge L, 2013, INT J QUAL STUD HEAL, V8, DOI 10.3402/qhw.v8i0.18907; Lopes LC, 2016, EUR J CANCER CARE, V25, P921, DOI 10.1111/ecc.12381; Lopes-Junior LC, 2015, REV ENFERM UFPE, V9, P1, DOI [10.5205/1981-8963.2015.10806, DOI 10.5205/1981-8963.2015.10806]; Lopes-Junior LC, 2016, BR J NURS, V25, pS16, DOI [10.12968/bjon.2016.25.10.S12, DOI 10.12968/BJON.2016.25.10.S12]; Lopes LC, 2020, CANCER NURS, V43, P290, DOI 10.1097/NCC.0000000000000690; Lopes LC, 2018, INTEGR CANCER THER, V17, P928, DOI 10.1177/1534735418781725; Lopes LC, 2020, REV LAT-AM ENFERM, V28, DOI 10.1590/1518-8345.4213.3377; Lopes LC, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026524; Lopes LC, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311x00193218, 10.1590/0102-311X00193218]; Lopes LC, 2018, PEDIATR CRIT CARE ME, V19, pE58, DOI [10.1097/PCC.0000000000001390, 10.1097/PCC.0000000000001378]; Lopes LC, 2016, REV LAT-AM ENFERM, V24, DOI 10.1590/1518-8345.0647.2762; Lopes-Júnior Luís Carlos, 2015, Rev. Gaúcha Enferm., V36, P109, DOI 10.1590/1983-1447.2015.03.51465; Manyande A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006447.pub3; Mavrides N, 2014, INT REV PSYCHIATR, V26, P63, DOI 10.3109/09540261.2013.870537; Meiri N, 2016, EUR J PEDIATR, V175, P373, DOI 10.1007/s00431-015-2652-z; Meiri N, 2017, EUR J PEDIATR, V176, P269, DOI 10.1007/s00431-016-2826-3; Meisel V, 2009, PSICOTHEMA, V21, P604; Methley AM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0579-0; Miaskowski Christine, 2007, J Natl Cancer Inst Monogr, P39, DOI 10.1093/jncimonographs/lgm003; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Nassau JH, 2008, J PEDIATR PSYCHOL, V33, P195, DOI 10.1093/jpepsy/jsm076; New Zealand Nurses' Organization, 2017, KAI TIAKI NURSING NZ, V238, P9; Newman N, 2019, PEDIATRIC REP, V11, P44, DOI 10.4081/pr.2019.8165; Nóia Tainan de Cerqueira, 2015, Invest. educ. enferm, V33, P465, DOI 10.17533/udea.iee.v33n3a10; Parsons SK, 2012, QUAL LIFE RES, V21, P915, DOI 10.1007/s11136-011-9986-4; Petrangeli F, 2012, ARCH DIS CHILD, V97, pA537, DOI [10.1136/archdischild-2012-302724.1904, DOI 10.1136/ARCHDISCHILD-2012-302724.1904]; Pinquart M, 2011, KLIN PADIATR, V223, P74, DOI 10.1055/s-0030-1267932; Raviv A, 2014, SOC SEMIOT, V24, P599, DOI 10.1080/10350330.2014.943460; Rodgers C, 2016, SEMIN ONCOL NURS, V32, P394, DOI 10.1016/j.soncn.2016.08.005; Rodgers CC, 2013, CURR OPIN SUPPORT PA, V7, P67, DOI 10.1097/SPC.0b013e32835ad551; Nunes MDR, 2018, J CHILD HEALTH CARE, V22, P186, DOI 10.1177/1367493517752498; Nunes MDR, 2017, EUR J ONCOL NURS, V29, P39, DOI 10.1016/j.ejon.2017.05.001; Saliba FG, 2016, PEDIATRIC REP, V8, P12, DOI 10.4081/pr.2016.6188; Sanchez Julio C, 2017, Hosp Pediatr, V7, P46, DOI 10.1542/hpeds.2016-0128; Sato M, 2016, INTERFACE-BOTUCATU, V20, P123, DOI 10.1590/1807-57622015.0178; Scheyer Rachel, 2008, Harefuah, V147, P25; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Schunemann HJ, 2013, RES SYNTH METHODS, V4, P49, DOI 10.1002/jrsm.1078; Silva MC, 2016, REV LAT-AM ENFERM, V24, pe2784, DOI [10.1590/1518-110 8345.1159.2784, DOI 10.1590/1518-1108345.1159.2784]; Slater J, 1998, PSYCHOSOM MED, V60, P92, DOI 10.1097/00006842-199801000-00022; SMERLING AJ, 1999, ANESTHESIA ANALGESIA, V88, P243, DOI DOI 10.1097/00000539-199902001-00303; Souza AR, ACTA PAUL ENFERM, V34, P1; Spitzer P, 2001, Aust Fam Physician, V30, P12; Spitzer P, 2006, LANCET, V368, pS34, DOI 10.1016/S0140-6736(06)69919-4; Sridharan K, 2017, EUR J PEDIATR, V176, P681, DOI 10.1007/s00431-017-2889-9; Sridharan K, 2016, EUR J PEDIATR, V175, P1353, DOI 10.1007/s00431-016-2764-0; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Tener D, 2012, J LOSS TRAUMA, V17, P12, DOI 10.1080/15325024.2011.578025; Theodora Foundation, 2018, WHATS CLOWN DOCT; Vagnoli L, 2005, PEDIATRICS, V116, pE563, DOI 10.1542/peds.2005-0466; Vagnoli L, 2019, RIV ITALIANA STUDI U, V2, P7; Vagnoli L, 2007, ALGIA HOSP, V2, P114, DOI DOI 10.1177/1359105312471567; Vagnoli L, 2010, PEDIATR ANESTH, V20, P937, DOI 10.1111/j.1460-9592.2010.03403.x; Van Schoors M, 2017, J PEDIATR PSYCHOL, V42, P6, DOI 10.1093/jpepsy/jsw070; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; van Venrooij LT, 2017, EUR J PEDIATR, V176, P191, DOI 10.1007/s00431-016-2821-8; Vaz M, 2016, INDIAN J MED ETHICS, V1, P126; Vitorino LM, 2018, PSYCHO-ONCOLOGY, V27, P1900, DOI 10.1002/pon.4739; Von Essen L, 2000, ACTA PAEDIATR, V89, P229, DOI 10.1080/080352500750028889; Weaver K., 2007, J CHILDRENS YOUNG PE, V01, P359, DOI [DOI 10.12968/JCYN.2007.1.8.27777, 10.12968/jcyn.2007.1.8.27777]; Wolyniez I, 2013, CLIN PEDIATR, V52, P1168, DOI 10.1177/0009922813502257; Xavier WD, 2020, ACTA PAUL ENFERM, V33, DOI 10.37689/acta-ape/2020AR0022; Yun OB, 2015, J PEDIATR NURS, V30, pE89, DOI 10.1016/j.pedn.2015.03.003; Zhang YF, 2017, J PAEDIATR CHILD H, V53, P237, DOI 10.1111/jpc.13369	112	23	25	5	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 16	2020	371								m4290	10.1136/bmj.m4290	http://dx.doi.org/10.1136/bmj.m4290			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PI0XW	33328164	hybrid, Green Published			2023-01-03	WOS:000600824600002
J	Dusetzina, SB; Muluneh, B; Keating, NL; Huskamp, HA				Dusetzina, Stacie B.; Muluneh, Benyam; Keating, Nancy L.; Huskamp, Haiden A.			Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								For expensive specialty drugs, it's unclear how quickly substantial price competition among generics manufacturers can be achieved. Even if generic specialty drugs have far lower list prices than brand-name versions, savings may not accrue to Medicare beneficiaries.	[Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Dusetzina, Stacie B.] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [Muluneh, Benyam] Univ N Carolina, Chapel Hill, NC 27515 USA; [Keating, Nancy L.; Huskamp, Haiden A.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA	Vanderbilt University; Vanderbilt University; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Dusetzina, SB (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA.; Dusetzina, SB (corresponding author), Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA.			Muluneh, Benyam/0000-0002-2387-6676				Anderson-Cook A, 2019, 201902 C BUDG OFF; Dusetzina SB, 2019, HEALTH AFFAIR, V38, P1188, DOI 10.1377/hlthaff.2018.05476; Gupta R, 2016, JAMA INTERN MED, V176, P1391, DOI 10.1001/jamainternmed.2016.3411; Kang SY, 2019, JAMA-J AM MED ASSOC, V322, P422, DOI 10.1001/jama.2019.9943; Medicare Payment Advisory Commission, 2018, REP C MED PAYM POL	5	5	5	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2020	383	24					2299	2301		10.1056/NEJMp2027580	http://dx.doi.org/10.1056/NEJMp2027580			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU3ER	33283988				2023-01-03	WOS:000627165900007
J	Katsura, H; Sontake, V; Tata, A; Kobayashi, Y; Edwards, CE; Heaton, BE; Konkimalla, A; Asakura, T; Mikami, Y; Fritch, EJ; Lee, PJ; Heaton, NS; Boucher, RC; Randell, SH; Baric, RS; Tata, PR				Katsura, Hiroaki; Sontake, Vishwaraj; Tata, Aleksandra; Kobayashi, Yoshihiko; Edwards, Caitlin E.; Heaton, Brook E.; Konkimalla, Arvind; Asakura, Takanori; Mikami, Yu; Fritch, Ethan J.; Lee, Patty J.; Heaton, Nicholas S.; Boucher, Richard C.; Randell, Scott H.; Baric, Ralph S.; Tata, Purushothama Rao			Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction	CELL STEM CELL			English	Article							LONG-TERM EXPANSION; IN-VITRO; HEPATOCYTES; IMMUNITY; MOUSE	Coronavirus infection causes diffuse alveolar damage leading to acute respiratory distress syndrome. The absence of ex vivo models of human alveolar epithelium is hindering an understanding of coronavirus disease 2019 (COVID-19) pathogenesis. Here, we report a feeder-free, scalable, chemically defined, and modular alveolosphere culture system for the propagation and differentiation of human alveolar type 2 cells/pneumocytes derived from primary lung tissue. Cultured pneunocytes express the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor angiotensin-converting enzyme receptor type-2 (ACE2) and can be infected with virus. Transcriptome and histological analysis of infected alveolospheres mirror features of COVID-19 lungs, including emergence of interferon (IFN)-mediated inflammatory responses, loss of surfactant proteins, and apoptosis. Treatment of alveolospheres with IFNs recapitulates features of virus infection, including cell death. In contrast, alveolospheres pretreated with low-dose IFNs show a reduction in viral replication, suggesting the prophylactic effectiveness of IFNs against SARS-CoV-2. Human stem cell-based alveolospheres, thus, provide novel insights into COVID-19 pathogenesis and can serve as a model for understanding human respiratory diseases.	[Katsura, Hiroaki; Sontake, Vishwaraj; Tata, Aleksandra; Kobayashi, Yoshihiko; Konkimalla, Arvind; Tata, Purushothama Rao] Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27710 USA; [Edwards, Caitlin E.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Heaton, Brook E.; Heaton, Nicholas S.] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Konkimalla, Arvind] Duke Univ, Sch Med, Med Scientist Training Program, Durham, NC 27710 USA; [Asakura, Takanori; Mikami, Yu; Boucher, Richard C.] Univ N Carolina, Mars Lung Inst, Chapel Hill, NC 27515 USA; [Fritch, Ethan J.; Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA; [Lee, Patty J.] Duke Univ, Med Sch, Dept Med, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; [Randell, Scott H.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA; [Tata, Purushothama Rao] Duke Univ, Sch Med, Duke Canc Inst, Durham, NC 27710 USA; [Tata, Purushothama Rao] Duke Univ, Regenerat Next, Durham, NC 27710 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University	Tata, PR (corresponding author), Duke Univ, Sch Med, Dept Cell Biol, Durham, NC 27710 USA.; Tata, PR (corresponding author), Duke Univ, Sch Med, Duke Canc Inst, Durham, NC 27710 USA.; Tata, PR (corresponding author), Duke Univ, Regenerat Next, Durham, NC 27710 USA.	purushothamarao.tata@duke.edu	Sontake, Vishwaraj/ABD-7278-2020; Asakura, Takanori/AAF-2785-2020; Kobayashi, Yoshihiko/AAH-7324-2019	Sontake, Vishwaraj/0000-0002-8532-7680; Asakura, Takanori/0000-0003-3122-6937; Kobayashi, Yoshihiko/0000-0001-7031-1478; Fritch, Ethan/0000-0003-1096-8958; Konkimalla, Arvind/0000-0002-9639-8142; Tata, Purushothama Rao/0000-0003-4837-0337; MIKAMI, YU/0000-0003-3262-2958	National Science Foundation [ECCS-1542015]; National Institutes of Health, National Institute of Allergy and Infectious Diseases [UC6-AI058607]; Regeneration Next Initiative at Duke University; NHLBI/NIH [F30HL143911, R00HL127181, R01HL146557, R01HL153375]; Cystic Fibrosis Foundation [BOUCHE15R0]; NIH [DK065988, AI132178, AI149644]; NIGMS [R21GM1311279]; Regeneration NeXT and Kaganov-MEDx Pulmonary Research Initiative at Duke University; United Therapeutics Corporation	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Regeneration Next Initiative at Duke University; NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Regeneration NeXT and Kaganov-MEDx Pulmonary Research Initiative at Duke University; United Therapeutics Corporation	We thank Brigid Hogan for advice and critical reading of the manuscript. We thank Peiying Shan (Yale University) and Randell lab members (University of North Carolina at Chapel Hill) for human lung preparation, the Duke Cancer Institute Flow Cytometry Shared Resource for cell sorting, the Duke University Light Microscopy Core Facility for imaging equipment and consultation, and the Duke Compute Cluster for help with computing sequencing data. This work was performed in part at the Duke University Shared Materials Instrumentation Facility, a member of the North Carolina Research Triangle Nanotechnology Network, which is supported by the National Science Foundation (grant ECCS-1542015) as part of the National Nanotechnology Coordinated Infrastructure. SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281 was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. Biocontainment work was performed in the Duke Regional Biocontainment Laboratory, which received partial support for construction from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (UC6-AI058607). Y.K. is a fellow of the Japan Society for the Promotion of Science Overseas Research. V.S. is supported by a fellowship from Regeneration Next Initiative at Duke University. A.K. is supported by a medical scientist training program fellowship from NHLBI/NIH (F30HL143911). S.H.R. is supported by Cystic Fibrosis Foundation grant BOUCHE15R0 and NIH grant DK065988. This work was supported by a generous gift from the Chan Zuckerberg Foundation and NIH grants AI132178 and AI149644 to R.S.B. This work was supported by NHLBI/NIH (R00HL127181, R01HL146557, and R01HL153375), NIGMS (R21GM1311279), and funds from Regeneration NeXT and Kaganov-MEDx Pulmonary Research Initiative at Duke University to P.R.T. This work was partially supported by a grant from the United Therapeutics Corporation (to P.R.T.). P.R.T. is a Whitehead Scholar at Duke University.	Arenkiel BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029423; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Barkauskas CE, 2013, J CLIN INVEST, V123, P3025, DOI 10.1172/JCI68782; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Bartee E, 2008, CURR OPIN MICROBIOL, V11, P378, DOI 10.1016/j.mib.2008.05.015; Blanco-Melo D., 2020, BIORXIV, DOI [10.1101/2020.03.24.004655, DOI 10.1101/2020.03.24.004655]; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Chung MI, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163014; Clementi N, 2020, J INFECT DIS, V222, P722, DOI 10.1093/infdis/jiaa350; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DESMYTER J, 1968, J VIROL, V2, P955, DOI 10.1128/JVI.2.10.955-961.1968; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Dye BR, 2015, ELIFE, V4, DOI 10.7554/eLife.05098; Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788; Gonzalez RF, 2010, J HISTOCHEM CYTOCHEM, V58, P891, DOI 10.1369/jhc.2010.956433; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hafemeister C., 2019, NORMALIZATION VARIAN, DOI [10.1101/576827, DOI 10.1101/576827]; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hogan Brigid, 2019, Nat Cell Biol, DOI 10.1038/s41556-019-0357-7; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Hu HL, 2018, CELL, V175, P1591, DOI 10.1016/j.cell.2018.11.013; Huang Jessie, 2020, bioRxiv, DOI [10.1016/j.stem.2020.09.013, 10.1101/2020.06.30.175695]; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Jacob A, 2017, CELL STEM CELL, V21, P472, DOI 10.1016/j.stem.2017.08.014; Jacob F, 2020, CELL STEM CELL, V27, P937, DOI 10.1016/j.stem.2020.09.016; Katsura H, 2019, STEM CELL REP, V12, P657, DOI 10.1016/j.stemcr.2019.02.013; Kebaabetswe LP, 2015, VIROLOGY, V483, P96, DOI 10.1016/j.virol.2015.03.045; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Koerner I, 2007, J VIROL, V81, P2025, DOI 10.1128/JVI.01718-06; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Lancaster MA, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039347; Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125; Lee JH, 2013, AM J RESP CELL MOL, V48, P288, DOI 10.1165/rcmb.2011-0403OC; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marshall D., 2020, MEDRXIV, DOI [10.1101/2020.04.17.20058545, DOI 10.1101/2020.04.17.20058545, 10.1101/2020.04.17.20058545.]; MASON RJ, 1980, BIOCHIM BIOPHYS ACTA, V617, P36, DOI 10.1016/0005-2760(80)90222-2; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; McQualter JL, 2010, P NATL ACAD SCI USA, V107, P1414, DOI 10.1073/pnas.0909207107; Menachery VD, 2014, MBIO, V5, DOI 10.1128/mBio.01174-14; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Nikolic MZ, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163485; Osada N, 2014, DNA RES, V21, P673, DOI 10.1093/dnares/dsu029; Peng WC, 2018, CELL, V175, P1607, DOI 10.1016/j.cell.2018.11.012; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230; Rock JR, 2011, P NATL ACAD SCI USA, V108, pE1475, DOI 10.1073/pnas.1117988108; Shiraishi K, 2019, BIOCHEM BIOPH RES CO, V515, P579, DOI 10.1016/j.bbrc.2019.05.187; Shiraishi K, 2019, ISCIENCE, V11, P318, DOI 10.1016/j.isci.2018.12.022; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Syedbasha M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00119; Takashima S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay8556; Ujie M, 2019, J GEN VIROL, V100, P1345, DOI 10.1099/jgv.0.001314; Velasco S, 2019, NATURE, V570, P523, DOI 10.1038/s41586-019-1289-x; Weiner AI, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0080-9; Winters N.I., 2019, SINGLE CELL RNA SEQU, DOI [10.1101/ 753806, DOI 10.1101/753806]; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yamamoto Y, 2017, NAT METHODS, V14, P1097, DOI [10.1038/nmeth.4448, 10.1038/NMETH.4448]; Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015; Zacharias WJ, 2018, NATURE, V555, P251, DOI 10.1038/nature25786; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	69	131	133	6	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	DEC 3	2020	27	6					890	+		10.1016/j.stem.2020.10.005	http://dx.doi.org/10.1016/j.stem.2020.10.005			23	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	PB1JR	33128895	Bronze, Green Submitted, Green Published			2023-01-03	WOS:000596086200006
J	Ramirez, GA; Richardson, E; Clark, J; Keshri, J; Drechsler, Y; Berrang, ME; Meinersmann, RJ; Cox, NA; Oakley, BB				Ramirez, Gustavo A.; Richardson, Ella; Clark, Jory; Keshri, Jitendra; Drechsler, Yvonne; Berrang, Mark E.; Meinersmann, Richard J.; Cox, Nelson A.; Oakley, Brian B.			Broiler chickens and early life programming: Microbiome transplant-induced cecal community dynamics and phenotypic effects	PLOS ONE			English	Article							ANTIMICROBIAL GROWTH PROMOTERS; SALMONELLA-TYPHIMURIUM; BACTERIAL COMMUNITY; PERFORMANCE; ALTERNATIVES; MODE; COLONIZATION; ANTIBIOTICS; SUCCESSION; DIVERSITY	The concept of successional trajectories describes how small differences in initial community composition can magnify through time and lead to significant differences in mature communities. For many animals, the types and sources of early-life exposures to microbes have been shown to have significant and long-lasting effects on the community structure and/or function of the microbiome. In modern commercial poultry production, chicks are reared as a single age cohort and do not directly encounter adult birds. This scenario is likely to initiate a trajectory of microbial community development that is significantly different than non-industrial settings where chicks are exposed to a much broader range of environmental and fecal inocula; however, the comparative effects of these two scenarios on microbiome development and function remain largely unknown. In this work, we performed serial transfers of cecal material through multiple generations of birds to first determine if serial transfers exploiting the ceca in vivo, rather than the external environment or artificial incubations, can produce a stable microbial community. Subsequently, we compared microbiome development between chicks receiving this passaged, i.e. host-selected, cecal material orally, versus an environmental inoculum, to test the hypothesis that the first exposure of newly hatched chicks to microbes determines early GI microbiome structure and may have longer-lasting effects on bird health and development. Cecal microbiome dynamics and bird weights were tracked for a two-week period, with half of the birds in each treatment group exposed to a pathogen challenge at 7 days of age. We report that: i) a relatively stable community was derived after a single passage of transplanted cecal material, ii) this cecal inoculum significantly but ephemerally altered community structure relative to the environmental inoculum and PBS controls, and iii) either microbiome transplant administered at day-of-hatch appeared to have some protective effects against pathogen challenge relative to uninoculated controls. Differentially abundant taxa identified across treatment types may inform future studies aimed at identifying strains associated with beneficial phenotypes.	[Ramirez, Gustavo A.; Richardson, Ella; Clark, Jory; Keshri, Jitendra; Drechsler, Yvonne; Oakley, Brian B.] Western Univ Hlth Sci, Coll Vet Med, Pomona, CA 91766 USA; [Ramirez, Gustavo A.] Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27515 USA; [Berrang, Mark E.; Meinersmann, Richard J.; Cox, Nelson A.] USDA ARS, Natl Poultry Ctr, Athens, GA 30613 USA	Western University of Health Sciences; University of North Carolina; University of North Carolina Chapel Hill; United States Department of Agriculture (USDA)	Oakley, BB (corresponding author), Western Univ Hlth Sci, Coll Vet Med, Pomona, CA 91766 USA.	boakley@westernu.edu	Oakley, Brian Oakley B/AAG-4015-2019	Oakley, Brian/0000-0003-2098-6439	U.S. Poultry & Egg Association; Western University of Health Sciences College of Veterinary Medicine; Office of the Vice-President for Research and Biotechnology; USDA NIFA grants [1015210, 1011327]	U.S. Poultry & Egg Association; Western University of Health Sciences College of Veterinary Medicine; Office of the Vice-President for Research and Biotechnology; USDA NIFA grants	Support was provided by the U.S. Poultry & Egg Association, the Western University of Health Sciences College of Veterinary Medicine, and the Office of the Vice-President for Research and Biotechnology. Additional funding was provided by USDA NIFA grants (Accession numbers 1015210 and 1011327) to Western University of Health Sciences College of Veterinary Medicine and BBO.	Aidara-Kane A, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-017-0294-9; Allen HK, 2013, TRENDS MICROBIOL, V21, P114, DOI 10.1016/j.tim.2012.11.001; Apajalahti J, 2004, WORLD POULTRY SCI J, V60, P223, DOI [10.1079/WPS200415, 10.1079/WPS20040017]; Bai SP, 2013, POULTRY SCI, V92, P663, DOI 10.3382/ps.2012-02813; Batte MT, 2007, FOOD POLICY, V32, P145, DOI 10.1016/j.foodpol.2006.05.003; Blankenberg D, 2010, BIOINFORMATICS, V26, P1783, DOI 10.1093/bioinformatics/btq281; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bortoluzzi C, 2017, POULTRY SCI, V96, P3981, DOI 10.3382/ps/pex218; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Canani RB, 2011, NUTR RES REV, V24, P198, DOI 10.1017/S0954422411000102; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Choi JH, 2014, POULTRY SCI, V93, P1942, DOI 10.3382/ps.2014-03974; Clavijo V, 2018, POULTRY SCI, V97, P1006, DOI 10.3382/ps/pex359; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; CORRIER DE, 1995, POULTRY SCI, V74, P916, DOI 10.3382/ps.0740916; Costa MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171642; Danzeisen JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027949; De Maesschalck C, 2015, APPL ENVIRON MICROB, V81, P5880, DOI 10.1128/AEM.01616-15; Diaz-Sanchez S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216080; Dibner JJ, 2005, POULTRY SCI, V84, P634, DOI 10.1093/ps/84.4.634; Dunkley KD, 2007, POULTRY SCI, V86, P801, DOI 10.1093/ps/86.5.801; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Eeckhaut V, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01416; Faircloth BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042543; FASTIE CL, 1995, ECOLOGY, V76, P1899, DOI 10.2307/1940722; Gadde UD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22004-6; Gaskins HR, 2002, ANIM BIOTECHNOL, V13, P29, DOI 10.1081/ABIO-120005768; LeBlanc JG, 2013, CURR OPIN BIOTECH, V24, P160, DOI 10.1016/j.copbio.2012.08.005; Huyghebaert G, 2011, VET J, V187, P182, DOI 10.1016/j.tvjl.2010.03.003; Landers TF, 2012, PUBLIC HEALTH REP, V127, P4, DOI 10.1177/003335491212700103; Liljebjelke KA, 2005, FOODBORNE PATHOG DIS, V2, P90, DOI 10.1089/fpd.2005.2.90; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu JR, 2003, APPL ENVIRON MICROB, V69, P6816, DOI 10.1128/AEM.69.11.6816-6824.2003; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Malorny B, 2003, APPL ENVIRON MICROB, V69, P290, DOI 10.1128/AEM.69.1.290-296.2003; McEwen SA, 2002, CLIN INFECT DIS, V34, pS93, DOI 10.1086/340246; McMurdie PJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003531; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Mende M, 2009, ITAL J ANIM SCI, P8; Milani C, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00036-17; Miquel S, 2013, CURR OPIN MICROBIOL, V16, P255, DOI 10.1016/j.mib.2013.06.003; Muller SC, 2018, IEEE T SMART GRID, V9, P14, DOI 10.1109/TSG.2016.2542824; Namkung H, 2011, POULTRY SCI, V90, P2217, DOI 10.3382/ps.2011-01498; Neal-McKinney JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043928; Neu J, 2011, CLIN PERINATOL, V38, P321, DOI 10.1016/j.clp.2011.03.008; Niewold TA, 2007, POULTRY SCI, V86, P605, DOI 10.1093/ps/86.4.605; Oakley BB, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00011; Oakley BB, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0282-8; Oakley BB, 2014, FEMS MICROBIOL LETT, V360, P100, DOI 10.1111/1574-6968.12608; Oakley BB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057190; Oakley BB, 2012, FEMS MICROBIOL ECOL, V79, P327, DOI 10.1111/j.1574-6941.2011.01219.x; Oksanen J, 2015, VEGAN COMMUNITY ECOL, V2, P2; Pryde SE, 2002, FEMS MICROBIOL LETT, V217, P133, DOI 10.1111/j.1574-6968.2002.tb11467.x; Racine JS, 2012, J APPL ECONOMET, V27, P167, DOI 10.1002/jae.1278; RANTALA M, 1973, BRIT POULTRY SCI, V14, P627, DOI 10.1080/00071667308416073; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rubio LA, 2019, POULTRY SCI, V98, P695, DOI 10.3382/ps/pey416; Sarmah AK, 2006, CHEMOSPHERE, V65, P725, DOI 10.1016/j.chemosphere.2006.03.026; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schokker D, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1646-6; Seal BS, 2013, ANIM HEALTH RES REV, V14, P78, DOI 10.1017/S1466252313000030; Sergeant MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091941; SHAPIRO SK, 1949, J BACTERIOL, V58, P531, DOI 10.1128/JB.58.4.531-544.1949; Siegerstetter SC, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02330-17; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; STAVRIC S, 1985, J FOOD PROTECT, V48, P778, DOI 10.4315/0362-028X-48.9.778; Sunkara LT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027225; Szekely AJ, 2014, FEMS MICROBIOL ECOL, V87, P102, DOI 10.1111/1574-6941.12195; Timmerman HM, 2006, POULTRY SCI, V85, P1383, DOI 10.1093/ps/85.8.1383; Torok VA, 2011, APPL ENVIRON MICROB, V77, P5868, DOI 10.1128/AEM.00165-11; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; van der Wielen PWJJ, 2000, APPL ENVIRON MICROB, V66, P2536, DOI 10.1128/AEM.66.6.2536-2540.2000; Van Loo E, 2010, J FOOD SCI, V75, pS384, DOI 10.1111/j.1750-3841.2010.01775.x; Wang WC, 2018, J ANIM SCI, V96, P1654, DOI 10.1093/jas/sky092; Yadav S, 2019, J ANIM SCI BIOTECHNO, V10, DOI 10.1186/s40104-018-0310-9; Yarza P, 2010, SYST APPL MICROBIOL, V33, P291, DOI 10.1016/j.syapm.2010.08.001	76	6	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2020	15	11							e0242108	10.1371/journal.pone.0242108	http://dx.doi.org/10.1371/journal.pone.0242108			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0NB	33186366	gold, Green Submitted, Green Published			2023-01-03	WOS:000593949800022
J	Wang, SJ; Chen, ZS; Lin, YJ; Lin, L; Lin, QY; Fang, SF; Shi, YH; Zhuang, XB; Ye, YM; Wang, T; Zhang, HY; Shao, CZ				Wang, Sijiao; Chen, Zhisheng; Lin, Yijian; Lin, Li; Lin, Qunying; Fang, Sufang; Shi, Yonghong; Zhuang, Xibin; Ye, Yuming; Wang, Ting; Zhang, Hongying; Shao, Changzhou			Clinical characteristics of 199 discharged patients with COVID-19 in Fujian Province: A multicenter retrospective study between January 22nd and February 27th, 2020	PLOS ONE			English	Article							CORONAVIRUS; WUHAN	Background Coronavirus disease 2019 (COVID-19) has quickly spread throughout the country and the world since first broke out in Wuhan, China. The outbreak that started from January 22, 2020, in Fujian Province has been controlled as the number of indigenous cases has not increased since March. We aimed to describe the clinical characteristics of patients with COVID-19 in Fujian Province, China. Methods In this retrospective, multicenter study, we collected and analyzed the epidemiological, clinical, and laboratory data of all cases confirmed by nucleic acid tests in five designated hospitals in Fujian Province between January 22 and February 27, 2020. All patients were followed up until discharge. COVID-19 severity was classified as mild, moderate, severe, or critical. Results Of 199 discharged patients with COVID-19, 105 patients were male, with a median age of 46.3 years, and 17 patients were severe, and 5 patients were critical on admission. Hypertension and diabetes were the most common comorbidities. The symptoms at illness onset were mainly fever (76.4%), cough (60.8%), and myalgia or fatigue (27.6%). A total of 96.5% of patients had abnormal imaging findings on chest computed tomography. Lymphopenia (37.2%) and hypoxemia (13.6%) were observed. Acute respiratory distress syndrome and respiratory failure occurred in 9 patients (4.5%) and 8 patients (4.0%) respectively. One patient died and the others were cured and discharged with the median hospital stay of 19 days. Old age was negatively correlated with lymphocyte count (r = - 0.296, p < 0.001) and oxygenation index (r = - 0.263, p = 0.001). Bivariate regression analysis revealed that old age (>= 75 years), hypertension, diabetes, and lymphopenia were correlated with the severity of COVID-19. Conclusions Patients in Fujian Province were mostly nonsevere cases with mild or moderate symptoms, and had a lower mortality than patients in Wuhan (4.3%-15%). Older age, hypertension, diabetes, and lymphopenia were risk factors for severity of COVID-19.	[Wang, Sijiao; Chen, Zhisheng; Shao, Changzhou] Fudan Univ, Dept Pulm Med, Xiamen Branch, Zhongshan Hosp, Xiamen, Fujian, Peoples R China; [Wang, Sijiao; Shao, Changzhou] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China; [Lin, Yijian; Zhuang, Xibin] Fujian Med Univ, Dept Pulm & Crit Care Med, Quanzhou First Hosp, Quanzhou, Fujian, Peoples R China; [Lin, Li; Ye, Yuming] Fujian Med Univ, Dept Pulm & Crit Care Med, Zhangzhou Affiliated Hosp, Zhangzhou, Fujian, Peoples R China; [Lin, Qunying] Putian Univ, Dept Pulm & Crit Care Med, Affiliated Hosp, Putian, Fujian, Peoples R China; [Fang, Sufang; Wang, Ting; Zhang, Hongying] Fuzhou Pulm Hosp, Dept Resp Med, Fuzhou, Fujian, Peoples R China; [Shi, Yonghong] Xiamen Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China	Fudan University; Fudan University; Fujian Medical University; Fujian Medical University; Putian University; Xiamen University	Shao, CZ (corresponding author), Fudan Univ, Dept Pulm Med, Xiamen Branch, Zhongshan Hosp, Xiamen, Fujian, Peoples R China.; Shao, CZ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China.; Zhang, HY (corresponding author), Fuzhou Pulm Hosp, Dept Resp Med, Fuzhou, Fujian, Peoples R China.	290923206@qq.com; sczzhongshan@126.com			Fujian Provincial Department of Science and Technology [2020Y01090006]	Fujian Provincial Department of Science and Technology	This work is funded by Fujian Provincial Department of Science and Technology (2020Y01090006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457; Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Bao JF, 2020, CLIN CHIM ACTA, V509, P180, DOI 10.1016/j.cca.2020.06.009; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; Gong Y, 2020, J MED VIROL, V92, P2551, DOI 10.1002/jmv.26052; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Li Diangeng, 2020, JAMA Netw Open, V3, pe208292, DOI 10.1001/jamanetworkopen.2020.8292; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; M C W., 2020, BMJ-BRIT MED J, V368, pm544, DOI 10.1136/bmj.l6968; Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929; Organization WH, 2020, 1932020 ORG WH; Organization WH, 2020, CLIN MAN COVID 19 20; Pan XF, 2020, LANCET INFECT DIS, V20, P410, DOI 10.1016/S1473-3099(20)30114-6; Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468; Shi HB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2636-4; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Tang A, 2020, EMERG INFECT DIS, V26, P1337, DOI 10.3201/eid2606.200301; Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu Jianmin, 2022, Crit Rev Food Sci Nutr, V62, P783, DOI 10.1080/10408398.2020.1828813; Xu Zhe, 2020, Lancet Respir Med, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743; Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	38	5	5	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2020	15	11							e0242307	10.1371/journal.pone.0242307	http://dx.doi.org/10.1371/journal.pone.0242307			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0MJ	33180862	gold, Green Published			2023-01-03	WOS:000593948000033
J	Bernhardt, J; Urimubenshi, G; Gandhi, DBC; Eng, JJ				Bernhardt, Julie; Urimubenshi, Gerard; Gandhi, Dorcas B. C.; Eng, Janice J.			Stroke rehabilitation in low-income and middle-income countries: a call to action	LANCET			English	Review							SURVIVORS; GUIDELINES; MANAGEMENT; OUTCOMES; INTERVENTION; FEASIBILITY; MEDICINE; SERVICES; PROGRAM; TRIAL	The WHO Rehabilitation 2030 agenda recognises the importance of rehabilitation in the value chain of quality health care. Developing and delivering cost-effective, equitable-access rehabilitation services to the right people at the right time is a challenge for health services globally. These challenges are amplified in low-income and middle-income countries (LMICs), in which the unmet need for rehabilitation and recovery treatments is high. In this Series paper, we outline what is happening more broadly as part of the WHO Rehabilitation 2030 agenda, then focus on the specific challenges to development and implementation of effective stroke rehabilitation services in LMICs. We use stroke rehabilitation clinical practice guidelines from both high-income countries and LMICs to highlight opportunities for rapid uptake of evidence-based practice. Finally, we call on educators and the stroke rehabilitation clinical, research, and not-for-profit communities to work in partnership for greater effect and to accelerate progress.	[Bernhardt, Julie] Univ Melbourne, Stroke Theme, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Bernhardt, Julie] Univ Melbourne, Natl Hlth & Med Res Council Ctr, Melbourne, Vic, Australia; [Urimubenshi, Gerard] Univ Rwanda, Dept Physiotherapy, Coll Med & Hlth Sci, Kigali, Rwanda; [Gandhi, Dorcas B. C.] Christian Med Coll & Hosp, Coll Physiotherapy, Ludhiana, Punjab, India; [Gandhi, Dorcas B. C.] DBT Wellcome Trust India Alliance, Hyderabad, Telangana, India; [Eng, Janice J.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada; [Eng, Janice J.] GF Strong Rehab Ctr, Rehab Res Program, Vancouver, BC, Canada	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; University of Rwanda; Wellcome Trust DBT India Alliance; University of British Columbia; University of British Columbia	Bernhardt, J (corresponding author), Univ Melbourne, Stroke Theme Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic 3084, Australia.	julie.bernhardt@florey.edu.au	Urimubenshi, Gerard/AAU-6599-2020; Gandhi, Dorcas/AAO-3740-2021	Urimubenshi, Gerard/0000-0002-0319-2912; 				Agho AO, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0212-5; Alochi V., 2018, OCCUPATIONAL THERAPY; [Anonymous], SOUTH AFR J PHYSIOTH; [Anonymous], 2019, GUID PREV MAN STROK; Aziz AFA, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-016-1963-8; Baatiema L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0599-3; Bernhardt J, 2019, INT J STROKE, V14, P450, DOI 10.1177/1747493019851287; Bernhardt J, 2017, INT J STROKE, V12, P444, DOI 10.1177/1747493017711816; Bettger JP, 2019, STROKE, V50, P3307, DOI 10.1161/STROKEAHA.119.023565; Brady MC, 2014, APHASIOLOGY, V28, P1385, DOI 10.1080/02687038.2014.930261; Bryer A, 2010, SAMJ S AFR MED J, V100, P750; Chimatiro GL, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4654-4; Dee M, 2020, DISABIL REHABIL, V42, P473, DOI 10.1080/09638288.2018.1501617; Eldar R, 2008, DISABIL REHABIL, V30, P134, DOI 10.1080/09638280701191776; Eng JJ, 2019, INT J STROKE, V14, P766, DOI 10.1177/1747493019873597; Gimigliano F, 2017, EUR J PHYS REHAB MED, V53, P155, DOI 10.23736/S1973-9087.17.04746-3; Gupta S, 2016, CAN MED ASSOC J, V188, pE362, DOI 10.1503/cmaj.151102; Harini JA, 2019, GLOB ADV HLTH MED, V8; Harrison MB, 2010, CAN MED ASSOC J, V182, pE78, DOI 10.1503/cmaj.081232; Harvey LA, 2014, SPINAL CORD, V52, P911, DOI 10.1038/sc.2014.174; Harvey Lisa A, 2017, Spinal Cord Ser Cases, V3, P17005, DOI 10.1038/scsandc.2017.5; Hassett L, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012074; Hubbard IJ, 2012, ARCH PHYS MED REHAB, V93, P965, DOI 10.1016/j.apmr.2012.01.011; Im H, 2019, PREVALENCE WORSENING; Jesus TS, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16060980; Johnson C.O., 2019, LANCET NEUROL, V18, P439, DOI [10.1016/s1474-4422(19)30034-1, 10.1016/S1474-4422(19)30034-1]; Jolliffe L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213525; Jolliffe L, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018791; Joubert J, 2015, J NEUROL SCI, V348, P3, DOI 10.1016/j.jns.2014.11.021; Kamalakannan S, 2016, ARCH PHYS MED REHAB, V97, P1526, DOI 10.1016/j.apmr.2016.02.008; Kamwesiga JT, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0400-7; Khan F, 2018, J REHABIL MED, V50, P472, DOI 10.2340/16501977-2313; Khan F, 2018, J REHABIL MED, V50, P367, DOI 10.2340/16501977-2276; Khatib R, 2018, NEUROEPIDEMIOLOGY, V51, P104, DOI 10.1159/000491442; Kjork EK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028218; Koehring M., 2016, ECONOMIST; Krug E, 2017, B WORLD HEALTH ORGAN, V95, P167, DOI 10.2471/BLT.17.191809; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lindley RI, 2017, LANCET, V390, P588, DOI [10.1016/S0140-6736(17)31447-2, 10.1016/s0140-6736(17)31447-2]; Lindsay MP, 2019, GLOBAL STROKE GUIDEL; Lindsay P, 2014, INT J STROKE, V9, P4, DOI 10.1111/ijs.12371; Liu HM, 2019, INT J STROKE, V14, P53, DOI 10.1177/1747493018790076; Lynch EA, 2017, TOP STROKE REHABIL, V24, P619, DOI 10.1080/10749357.2017.1366010; Melifonwu R, 2019, INT J STROKE, V14, pNP13, DOI 10.1177/1747493019858773; Mendis S, 2010, INT J STROKE, V5, P86, DOI 10.1111/j.1747-4949.2010.00406.x; Ministry of Health Brazil, 2013, REH GUID PEOPL STROK; Ministry of Health Ukraine, 2012, ORD MIN HLTH CLIN GU; Mohammadi Dara, 2011, Lancet Neurol, V10, P953, DOI 10.1016/S1474-4422(11)70235-6; Ochieng BM, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-S1-S4; Olaleye OA, 2017, PHYSIOTHER THEOR PR, V33, P41, DOI 10.1080/09593985.2016.1247931; Onwujekwe O, 2019, HEALTH POLICY PLANN, V34, P529, DOI 10.1093/heapol/czz070; Pandian JD, 2012, TOP STROKE REHABIL, V19, P384, DOI 10.1310/tsr1905-384; Patel V, 2009, INT HEALTH, V1, P37, DOI 10.1016/j.inhe.2009.02.002; Peters GO, 2013, DISABIL REHABIL, V35, P455, DOI 10.3109/09638288.2012.697251; Pitthayapong S, 2017, ASIAN NURS RES, V11, P150, DOI 10.1016/j.anr.2017.05.009; Reistetter TA, 2015, ARCH PHYS MED REHAB, V96, P1248, DOI 10.1016/j.apmr.2015.02.020; Rhoda A, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1057-z; Sankaran R, 2019, J AYURVEDA INTEGR ME, V10, P126, DOI 10.1016/j.jaim.2018.02.137; Sarfo FS, 2018, J NEUROL SCI, V387, P94, DOI 10.1016/j.jns.2018.01.039; Sarfo FS, 2017, J NEUROL SCI, V381, P203, DOI 10.1016/j.jns.2017.08.3265; Simpson LA, 2017, DISABIL REHABIL, V39, P874, DOI 10.3109/09638288.2016.1162853; Song HY, 2015, ASIAN NURS RES, V9, P328, DOI 10.1016/j.anr.2015.10.002; Stroke Foundation, 2019, CLIN GUID STROK MAN; Sureshkumar K, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009243; Swaine B, 2018, J HEAD TRAUMA REHAB, V33, P285, DOI 10.1097/HTR.0000000000000427; The Chinese Medical Association Neurology Branch Neurological Rehabilitation Group and Cerebrovascular Disease Group, 2017, CHIN STROK EARL REH; The Stroke Society of the Philippines, 2011, GUID PREV TREATM REH, V5th; The World Bank, 2019, TCDATA360 INT ACC HO; Urimubenshi G, 2018, INT J STROKE, V13, P797, DOI 10.1177/1747493018772747; Vloothuis JDM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214241; Vloothuis JDM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011058.pub2; Whitehead S, 2019, SAMJ S AFR MED J, V109, P81, DOI [10.7196/SAMJ.2019.v109i2.00011, 10.7196/samj.2019.v109i2.00011]; WHO, 2011, WORLD REPORT ON DISABILITY, P1; WHO, TASK SHIFT GLOB REC; WHO, 2018, WHO TECHN WORK GROUP; WHO, 2019, TEMPL REH INF COLL T; World Health Organisation, 2017, REH 2030 CALL ACT; World Health Organization, 2017, REH 2030 CALL ACT NE; World Health Organization, 2017, REH HLTH SYST; Wylie K, 2016, AFR J DISABIL, V5, DOI 10.4102/ajod.v5i1.227; Yan Lijing L, 2016, eNeurologicalSci, V2, P21, DOI 10.1016/j.ensci.2016.02.011; Yan LJL, 2016, INT J STROKE, V11, P823, DOI 10.1177/1747493016654290	82	26	27	1	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	2020	396	10260					1452	1462						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OI1EY	33129396				2023-01-03	WOS:000583031700034
J	Mohammed, S; Larsen-Reindorf, RE				Mohammed, Shamsudeen; Larsen-Reindorf, Roderick Emil			Menstrual knowledge, sociocultural restrictions, and barriers to menstrual hygiene management in Ghana: Evidence from a multi-method survey among adolescent schoolgirls and schoolboys	PLOS ONE			English	Article							GIRLS	On a daily basis, schoolgirls in low and middle-income countries discover blood on their clothing for the first time in school environments without toilets, water, or a supportive teacher, mentor, or role model to help them understand the changes happening in their bodies. This study aimed to examine the menstrual knowledge, sociocultural restrictions, and barriers to menstrual hygiene management in school environment among adolescent schoolgirls in a rural community. We collected quantitative data from 250 adolescent schoolgirls and qualitative data from thirty schoolboys and five schoolteachers in five Junior High Schools in the Kumbungu district of northern Ghana. Binary logistic regression models were fitted to determine the predictors of poor menstrual knowledge. Qualitative data were transcribed verbatim, coded, and organized into themes. Overall, 53.6% of the girls had poor knowledge about menstruation. Most of the boys had heard about menstruation and had an idea about what menstruation is with most of them describing it as "the flow of blood through the vagina of a female." The boys revealed that terms such as "Vodafone," "Red card," and "Palm oil" are used to describe menstruation in the schools and within the community. After adjusting for the effect of other sociodemographic factors, we found evidence that girls in their late adolescents were less likely to have poor menstrual knowledge compared to those aged 10-14 years (aOR 0.20, 95%CI 0.08-0.48). Maternal education was protective against poor menstrual knowledge. When compared to adolescents whose mothers were illiterates, those whose mothers had basic education (aOR 0.62, 95%CI 0.28-1.40) and those whose mothers had secondary or higher education (AOR 0.22, 95%CI 0.06-0.76) were less likely to have poor knowledge about menstruation. Adolescents from homes with no television and radio sets were more likely to have poor menstrual knowledge compared to those from homes with television and radio sets (aOR 2.42, 95%CI 1.41-4.15). Comfort, safety, and cost were the major factors that influenced their choice of sanitary products. Most of the teachers said the schools do not provide students with sanitary products, even in emergencies. We found that girls were not to prepare some local dishes (e.g.Wasawasa) during their periods and are forbidden from participating in religious activities (i.e. read the Holy Quran or pray in the mosque) during the period of menstruation. Open discussions about menstruation and its management are not encouraged and girls are considered unclean and impure during the period of menstruation. None of the schools had a regular supply of water in WASH facilities, a mirror for girls to check their uniforms for bloodstains or soap in the toilet facilities for handwashing. Menstrual education through the standard school curriculum, starting from primary school, could prepare girls for menarche, improve their knowledge on menstruation, and teach boys how to support girls and women during the period of menstruation. This could also eliminate the sociocultural misconceptions surrounding menstruation.	[Mohammed, Shamsudeen] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Kumasi, Ghana; [Mohammed, Shamsudeen] Coll Nursing & Midwifery, Populat & Reprod Hlth Resident, Nalerigu, Ghana; [Larsen-Reindorf, Roderick Emil] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Dept Obstet & Gynaecol, Kumasi, Ghana	Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology	Mohammed, S (corresponding author), Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Kumasi, Ghana.; Mohammed, S (corresponding author), Coll Nursing & Midwifery, Populat & Reprod Hlth Resident, Nalerigu, Ghana.	deen0233@gmail.com		Mohammed, Shamsudeen/0000-0002-3771-8425				Abanyie SK, 2016, ENSURING AVAILABILIT, P1; Alberda H, 2018, MENSTRUAL HLTH TRAIN; Ameade Evans Paul Kwame, 2016, Adv Prev Med, V2016, P1056235, DOI 10.1155/2016/1056235; [Anonymous], 2019, PREV TREAT CARDIO CE, V19, P1, DOI [DOI 10.5230/jgc.2019.19.e8, DOI 10.1186/s12877-019-1185-0]; [Anonymous], 2017, JAP CLASS ES CANC, V14, P1, DOI [DOI 10.1007/s10388-016-0551-7, DOI 10.1093/GERONT/GNY014]; [Anonymous], 2013, C M L R, V2, P2; [Anonymous], 2015, GAIKO; Baumgarten N, 2012, STUD PRAGMAT, P1; Boosey R, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.253.5313; Chandra-Mouli V, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0293-6; Chang YT, 2012, J CLIN NURS, V21, P513, DOI 10.1111/j.1365-2702.2011.03700.x; Coast E, 2019, INT J PUBLIC HEALTH, V64, P293, DOI 10.1007/s00038-019-01209-0; Crofts T, 2012, FACT SHEET; Ghana Statistical Service (GSS), 2014, DISTR AN REP; Johnson L, 2016, SCH EXPERIENCE BOLIV; Kasiulevicius V., 2006, GERONTOLOGIJA, V7, P225, DOI DOI 10.1080/14636200601084014; Kennedy E, 2015, MENSTRUAL HYGIENE MA; Kgware M, 2016, MENSTRUATION MENSTRU; Kumar A, 2011, SOC WORK PUBLIC HLTH, V26, P594, DOI 10.1080/19371918.2010.525144; Lawan U M, 2010, Afr J Reprod Health, V14, P201; Mathiaud C, 2014, MENSTRUAL HYGIENE MA; Morrison J, 2018, ANAL MENSTRUAL HYGIE; Nanda G, 2016, MENSTRUAL HYGIENE MA; Sommer M, 2015, COMPARE, V45, P589, DOI 10.1080/03057925.2013.871399; Sommer M, 2013, AM J PUBLIC HEALTH, V103, P1556, DOI 10.2105/AJPH.2013.301374; Swedish International Development Cooperation Agency [Sida], 2016, HLTH BOTH PREREQUISI, P1; Tegegne TK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1118; Ten VTA, 2007, MENSTRUAL HYGIENE NE, P1; Thakre SB, 2011, J CLIN DIAGN RES, V5, P1027; The World Bank, 2018, MENSTR HYG MAN EN WO; UNESCO, 2014, PUB ED MENSTR HYG MA; UNICEF, 2012, WAT SAN HYG WASH SCH, P3; UNICEF, 2008, MAIL GUARDIAN; UNICEF, 2016, SUPP RIGHTS GIRLS WO, P1; Upashe SP, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0245-7; WaterAid, 2009, EC GYNAECOL; World Anti-Doping Agency, 2020, WAST WAST RES CAS NA, P1; WSSCC and UN Women, 2014, MENSTR HYG MAN BEH P	38	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2020	15	10							e0241106	10.1371/journal.pone.0241106	http://dx.doi.org/10.1371/journal.pone.0241106			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ON4AZ	33091080	Green Accepted, Green Published, gold			2023-01-03	WOS:000586647200040
J	Holbrook, AM				Holbrook, Anne M.			USPSTF recommends asking adults screening questions about unhealthy drug use	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Holbrook, Anne M.] McMaster Univ, Hamilton, ON, Canada	McMaster University	Holbrook, AM (corresponding author), McMaster Univ, Hamilton, ON, Canada.							[Anonymous], 2016, FAC ADD AM SURG GEN; Canadian Substance Use Costs and Harms Scientific Working Group, 2020, CAN SUBST US COSTS H	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2020	173	8					JC38	JC38		10.7326/ACPJ202010200-038	http://dx.doi.org/10.7326/ACPJ202010200-038			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH7WZ	33075271				2023-01-03	WOS:000582805500002
J	Uuskula, A; Vickerman, P; Raag, M; Walker, J; Paraskevis, D; Eritsyan, K; Sypsa, V; Lioznov, D; Avi, R; Des Jarlais, D				Uuskula, Anneli; Vickerman, Peter; Raag, Mait; Walker, Josephine; Paraskevis, Dimitrios; Eritsyan, Ksenia; Sypsa, Vana; Lioznov, Dmitry; Avi, Radko; Des Jarlais, Don			Presenting a conceptual framework for an HIV prevention and care continuum and assessing the feasibility of empirical measurement in Estonia: A case study	PLOS ONE			English	Article							OPIOID SUBSTITUTION THERAPY; ANTIRETROVIRAL THERAPY; INJECT DRUGS; VIRAL LOAD; PEOPLE; TRANSMISSION; ADHERENCE; IMPACT	Objective We aim to show the feasibility of using an integrated prevention and care continuum (PCC) model as a complete and improved tool for HIV control measurement and programming. Alignment of prevention and care continua is essential to further improve health outcomes and minimize HIV transmission risk. Design Cross-sectional study. Methods Data from 977 persons who inject drugs (PWID) collected in 2011-2016 in Tallinn, Estonia, were used to construct an HIV PCC for PWID, stratified by risk for acquiring or transmitting HIV infection and by coverage of combined interventions. We also estimated the average protective effect of current levels of intervention provision. Results 74.4%, 20.3% and 35.2% of PWID were currently using needle and syringe programmes (NSP), drug treatment and HIV testing, respectively. 51.1% of current PWID were HIV seropositive and of those 62.5% were currently on ART and 19.0% were virally suppressed. Across the PCC, individuals moved between categories of being aware and ever using drug treatment (resulting in -50% "leakage"); from ever having used to currently using drug treatment (-59%); between "ever testing" and "current (continuous) testing" (-62%); and from self-reported antiretroviral therapy (ART) adherence to viral suppression (-70%). Use of prevention services was higher among those at risk of transmission (HIV positive). The overall reduction in acquisition risk among HIV-negative PWID was 77.7% (95% CrI 67.8-84.5%), estimated by the modelled protective effects of current levels of NSP, drug treatment and ART compared to none of these services. Conclusions Our findings suggest that developing a cohesive model for HIV prevention and treatment is feasible and reflects the bi-directional relationships between prevention and care. The integrated continuum model indicates the major factors which may predict the epidemic course and control response.	[Uuskula, Anneli; Raag, Mait] Univ Tartu, Dept Family Med & Publ Hlth, Tartu, Estonia; [Vickerman, Peter; Walker, Josephine] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Paraskevis, Dimitrios; Sypsa, Vana] Natl & Kapodistrian Univ Athens, Med Sch, Athens, Greece; [Eritsyan, Ksenia] Natl Res Univ Higher Sch Econ, St Petersburg, Russia; [Lioznov, Dmitry] Smorodintsev Res Inst Influenza, St Petersburg, Russia; [Lioznov, Dmitry] First Pavlov State Med Univ, St Petersburg, Russia; [Avi, Radko] Univ Tartu, Dept Microbiol, Tartu, Estonia; [Des Jarlais, Don] NYU, Coll Global Publ Hlth, New York, NY USA	University of Tartu; University of Bristol; National & Kapodistrian University of Athens; HSE University (National Research University Higher School of Economics); Pavlov First Saint Petersburg State Medical University; University of Tartu; New York University	Uuskula, A (corresponding author), Univ Tartu, Dept Family Med & Publ Hlth, Tartu, Estonia.	anneli.uuskula@ut.ee	Eritsyan, Ksenia/K-7144-2013	Eritsyan, Ksenia/0000-0002-4400-0593; SYPSA, VANA/0000-0002-9430-7614; Paraskevis, Dimitrios/0000-0001-6167-7152	Ministry of Education and Research [IUT34-17, IUT34-24]; Estonian Research Council [PUT 1580]; National Institute on Drug Abuse, USA [1DP1DA039542]	Ministry of Education and Research; Estonian Research Council(Estonian Research Council); National Institute on Drug Abuse, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	AU - Ministry of Education and Research grant IUT34-17; RA - Estonian Research Council (grant PUT 1580) and Ministry of Education and Research grant IUT34-24; DDS and AU - grant 1DP1DA039542 from the National Institute on Drug Abuse, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aspinall EJ, 2014, INT J EPIDEMIOL, V43, P235, DOI 10.1093/ije/dyt243; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Bezabhe WM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003361; Centers for Disease Control and Prevention, 2015, NAT HIV BEH SURV SYS; Desai M, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5011; European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2019, HIV AIDS SURV EUR 20; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2010, GUID TEST HIV VIR HE; Garnett GP, 2016, LANCET HIV, V3, pE297, DOI 10.1016/S2352-3018(16)30039-X; Giordano TP, 2004, HIV CLIN TRIALS, V5, P74, DOI 10.1310/JFXH-G3X2-EYM6-D6UG; Gowing L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub4; Grebely J, 2013, CLIN INFECT DIS, V57, P1014, DOI 10.1093/cid/cit377; Handcock M.S., 2012, RDS RESPONDENT DRIVE; Hargreaves JR, 2016, LANCET HIV, V3, pE318, DOI 10.1016/S2352-3018(16)30063-7; HIV nakkuse ja kaasuvate infektsioonide epidemioloogiline olukord Eestis 2000-2016, 2017, HIV NAKK JA KAAS INF; Horn T, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21263; Jose S, 2018, LANCET HIV, V5, pE301, DOI 10.1016/S2352-3018(18)30048-1; Karnite A, 2014, ASSESSMENT HIV TB KN; Kelley CF, 2015, CLIN INFECT DIS, V61, P1590, DOI 10.1093/cid/civ664; Low AJ, 2016, CLIN INFECT DIS, V63, P1094, DOI 10.1093/cid/ciw416; MacArthur GJ, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5945; McNairy ML, 2014, CLIN INFECT DIS, V59, pS12, DOI 10.1093/cid/ciu251; Moorhouse L, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25309; Mukandavire C, 2017, AIDS, V31, P1181, DOI 10.1097/QAD.0000000000001458; Murray M, 2012, HIV MED, V13, P89, DOI 10.1111/j.1468-1293.2011.00940.x; Nosyk B, 2013, AIDS, V27, P1159, DOI 10.1097/QAD.0b013e32835f1d68; Platt L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012021.pub2; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; R-Core-Team, 2016, LANG ENV STAT COMP; Raben D, 2014, HIV AIDS TREATMENT C; UNAIDS, 2010, COMB HIV PREV TAIL C; UNAIDS, 2014, 90 90 90 AMB TREATM; United States Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, GUID US ANT AG AD AD; Uuskula A, 2015, AIDS CARE, V27, P105, DOI 10.1080/09540121.2014.940271; Uuskula A, 2018, AIDS BEHAV, V22, P224, DOI 10.1007/s10461-017-1859-6; Vickerman P, 2014, INT J DRUG POLICY, V25, P1163, DOI 10.1016/j.drugpo.2014.09.013; WHO, 2003, WHO DRUG INJ STUD PH; World Health Organization, 2016, GLOB HLTH SECT STRAT	37	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2020	15	10							e0240224	10.1371/journal.pone.0240224	http://dx.doi.org/10.1371/journal.pone.0240224			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3WA	33035238	gold, Green Published			2023-01-03	WOS:000581817500050
J	Vickers, H				Vickers, Hannah			WHAT YOUR PATIENT IS THINKING	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												hannah.vickers.15@ucl.ac.uk							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 7	2020	371								m3571	10.1136/bmj.m3571	http://dx.doi.org/10.1136/bmj.m3571			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC8ZV	33028541	Bronze			2023-01-03	WOS:000579445600005
J	Wilt, TJ; Kaka, AS; MacDonald, R; Greer, N; Obley, A; Duan-Porter, W				Wilt, Timothy J.; Kaka, Anjum S.; MacDonald, Roderick; Greer, Nancy; Obley, Adam; Duan-Porter, Wei			Remdesivir for Adults With COVID-19 A Living Systematic Review for American College of Physicians Practice Points	ANNALS OF INTERNAL MEDICINE			English	Review								Background: Few treatments exist for coronavirus disease 2019 (COVID-19). Purpose: To evaluate the effectiveness and harms of remdesivir for COVID-19. Data Sources: Several databases, tables of contents of journals, and U.S. Food and Drug Administration and company websites were searched from 1 January through 31 August 2020. Study Selection: English-language, randomized trials of remdesivir treatments for adults with suspected or confirmed COVID-19. New evidence will be incorporated using living review methods. Data Extraction: Single-reviewer abstraction and risk-of-bias assessment verified by a second reviewer; GRADE (Grading of Recommendations Assessment, Development and Evaluation) methods used for certainty-of-evidence assessments. Data Synthesis: Four randomized trials were included. In adults with severe COVID-19, remdesivir compared with placebo probably improves recovery by a large amount (absolute risk difference [ARD] range, 7% to 10%) and may result in a small reduction in mortality (ARD range, -4% to 1%) and a shorter time to recovery or clinical improvement. Remdesivir may have little to no effect on hospital length of stay. Remdesivir probably reduces serious adverse events by a moderate amount (ARD range, -6% to -8%). Compared with a 10-day remdesivir course, a 5-day course may reduce mortality, increase recovery or clinical improvement by small to moderate amounts, reduce time to recovery, and reduce serious adverse events among hospitalized patients not requiring mechanical ventilation. Recovery due to remdesivir may not vary by age, sex, symptom duration, or disease severity. Limitations: Low-certainty evidence with few published trials, including 1 preliminary report and 2 open-label trials. Trials excluded pregnant women and adults with severe kidney or liver disease. Conclusion: In hospitalized adults with COVID-19, remdesivir probably improves recovery and reduces serious adverse events and may reduce mortality and time to clinical improvement. For adults not receiving mechanical ventilation or extracorporeal membrane oxygenation, a 5-day course of remdesivir may provide similar benefits to and fewer harms than a 10-day course.	[Wilt, Timothy J.; MacDonald, Roderick; Greer, Nancy; Duan-Porter, Wei] Ctr Care Delivery & Outcomes Res, Minneapolis VA Evidence Synth Program, Minneapolis, MN USA; [Wilt, Timothy J.] Univ Minnesota, Sch Med, Minneapolis, MN USA; [Kaka, Anjum S.] Minneapolis VA Sect Infect Dis, Minneapolis, MN USA; [Obley, Adam] VA Portland Hlth Care Syst, Portland, OR USA; [Obley, Adam] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA; [Wilt, Timothy J.; Kaka, Anjum S.; MacDonald, Roderick; Greer, Nancy; Duan-Porter, Wei] Minneapolis VA Hlth Care Syst, One Vet Dr,111-0, Minneapolis, MN 55417 USA; [Obley, Adam] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center	Wilt, TJ (corresponding author), Minneapolis VA Hlth Care Syst, One Vet Dr,111-0, Minneapolis, MN 55417 USA.	Tim.wilt@va.gov			Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Evidence Synthesis Program	Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Evidence Synthesis Program(US Department of Veterans Affairs)	By the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service, Evidence Synthesis Program.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhimraj A., 2020, INFECT DIS SOC AM GU; Duan-Porter W., 2020, 09009 VA ESP HLTH SE; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Jiang YW, 2021, J MED VIROL, V93, P1171, DOI 10.1002/jmv.26443; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mccaw ZR, 2020, ANN INTERN MED, V173, P632, DOI 10.7326/M20-4044; Misra S, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13383; Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993; O'Day D., 2020, STORIES GILEAD 0629; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI 10.1001/jama.2020.7681; Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457; Schunemann H, GRADE HDB; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Simmonds M, 2017, J CLIN EPIDEMIOL, V91, P38, DOI 10.1016/j.jclinepi.2017.08.008; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Yokoyama Y, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198137	19	43	43	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	2021	174	2					209	+		10.7326/M20-5752	http://dx.doi.org/10.7326/M20-5752			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ2CK	33017170	Green Published			2023-01-03	WOS:000619497100023
J	Lewis, K; Chaudhuri, D; Alshamsi, F; Carayannopoulos, L; Dearness, K; Chagla, Z; Alhazzani, W				Lewis, Kimberley; Chaudhuri, Dipayan; Alshamsi, Fayez; Carayannopoulos, Laiya; Dearness, Karin; Chagla, Zain; Alhazzani, Waleed		GUIDE Grp	The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials	PLOS ONE			English	Review								Background Populations such as healthcare workers (HCW) that are unable to practice physical distancing are at high risk of acquiring Coronavirus disease-2019 (COVID-19). In these cases pharmacological prophylaxis would be a solution to reduce severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) transmission. Hydroxychloroquine has in vitro antiviral properties against SARS CoV-2. We therefore sought to determine the efficacy and safety of hydroxychloroquine as prophylaxis for COVID-19. Methods and findings We electronically searched EMBASE, MEDLINE, the Cochrane COVID-19 Register of Controlled Trials, Epistemonikos COVID-19, clinicaltrials.gov, and the World Health Organization International Clinical Trials Registry Platform up to September 28(th), 2020 for randomized controlled trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes with the corresponding 95% confidence intervals (CIs) using a random-effect model. We identified four RCTs (n = 4921) that met our eligibility criteria. The use of hydroxychloroquine, compared to placebo, did not reduce the risks of developing COVID-19 (RR 0.82, 95% CI 0.65 to 1.04, moderate certainty), hospitalization (RR 0.72, 95% CI 0.34 to 1.50, moderate certainty), or mortality (RR 3.26, 95% CI 0.13 to 79.74, low certainty), however, hydroxychloroquine use increased the risk of adverse events (RR 2.76, 95% CI 1.38 to 5.55, moderate certainty). Conclusion Although pharmacologic prophylaxis is an attractive preventive strategy against COVID-19, the current body of evidence failed to show clinical benefit for prophylactic hydroxychloroquine and showed a higher risk of adverse events when compared to placebo or no prophylaxis.	[Lewis, Kimberley; Chaudhuri, Dipayan; Carayannopoulos, Laiya; Chagla, Zain; Alhazzani, Waleed] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Lewis, Kimberley; Chaudhuri, Dipayan; Alhazzani, Waleed] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Alshamsi, Fayez] United Arab Emirates Univ, Coll Med & Hlth Sci, Dept Internal Med, Al Ain, U Arab Emirates; [Dearness, Karin] St Josephs Healthcare Hamilton, Hamilton, ON, Canada	McMaster University; McMaster University; United Arab Emirates University; McMaster University	Lewis, K (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.; Lewis, K (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.	kimberley.lewis@medportal.ca	Alshamsi, Fayez/AAZ-5713-2021; Chaudhuri, Dipayan/AAP-9027-2021	Alshamsi, Fayez/0000-0002-9121-4279; Chaudhuri, Dipayan/0000-0002-8305-1481; Junek, Mats/0000-0001-8416-3955; Sharma, Sunjay/0000-0001-7826-9075; Carayannopoulos, Kallirroi Laiya/0000-0001-9041-9216				Abella BS, 2021, JAMA INTERN MED, V181, P195, DOI 10.1001/jamainternmed.2020.6319; Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293; Al-Rawi H, 2018, LUPUS, V27, P847, DOI 10.1177/0961203317727601; [Anonymous], STRINGS ATT CADTHS D; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; COVID-19 Map, COVID 19 MAP; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horby P., 2020, MEDRXIV, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]; Jorge A, 2018, NAT REV RHEUMATOL, V14, P693, DOI 10.1038/s41584-018-0111-8; Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8; Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085; Kuhar DT, 2013, INFECT CONT HOSP EP, V34, P875, DOI 10.1086/672271; Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988; Li W, 2020, CLIN INFECT DIS, V71, P1943, DOI 10.1093/cid/ciaa450; Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McMaster University, 2020, GRADEPRO GUID DEV TO; Mitja O, 2021, NEW ENGL J MED, V384, P417, DOI 10.1056/NEJMoa2021801; Rajasingham Radha, 2021, Clin Infect Dis, V72, pe835, DOI [10.1093/cid/ciaa1571, 10.1101/2020.09.18.20197327]; Richardson M, 2019, CLIN EPIDEMIOL GLOB, V7, P192, DOI 10.1016/j.cegh.2018.05.005; Rodrigo C, 2020, CLIN MICROBIOL INFEC, V26, P979, DOI 10.1016/j.cmi.2020.05.016; Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x; Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69; Walter SD, 2020, BMC MED RES METHODOL, V20, DOI 10.1186/s12874-020-0899-1; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2; Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114	35	23	23	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2021	16	1							e0244778	10.1371/journal.pone.0244778	http://dx.doi.org/10.1371/journal.pone.0244778			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS4TL	33406138	gold, Green Published			2023-01-03	WOS:000607915500067
J	Walker, J; Dolly, S; Ng, L; Prior-Ong, M; Sabapathy, K				Walker, Jonathan; Dolly, Shaman; Ng, Liji; Prior-Ong, Melissa; Sabapathy, Kalpana			The role of CPAP as a potential bridge to invasive ventilation and as a ceiling-of-care for patients hospitalized with Covid-19-An observational study	PLOS ONE			English	Article								Background Continuous positive airway pressure (CPAP) ventilation may be used as a potential bridge to invasive mechanical ventilation (IMV), or as a ceiling-of-care for persistent hypoxaemia despite standard oxygen therapy, according to UK guidelines. We examined the association of mode of respiratory support and ceiling-of-care on mortality. Methods We conducted a retrospective cohort analysis of routinely collected de-identified data of adults with nasal/throat SARs-CoV-2 swab-positive results, at the Calderdale and Huddersfield NHS Foundation Trust between 10th March-19th April 2020 (outcomes determined on 22nd May). Findings Of 347 patients with SARs-CoV-2 swab-positive results, 294 (84.7%) patients admitted for Covid-19 were included in the study. Sixty-nine patients were trialled on CPAP, mostly delivered by face mask, either as an early ceiling of care instituted within 24 hours of admission (N = 19), or as a potential bridge to IMV (N = 44). Patients receiving a ceiling of care more than 24 hours after admission (N = 6) were excluded from the analysis. Two hundred and fifteen patients (73.1%) maximally received air/standard oxygen therapy, and 45 (15.3%) patients maximally received CPAP. Thirty-four patients (11.6%) required IMV, of which 24 had received prior CPAP. There were 138 patients with an early ceiling-of-care plan (pre-admission/within 24h). Overall, 103(35.0%) patients died and 191(65.0%) were alive at study end. Among all patients trialled on CPAP either as a potential bridge to IMV (N = 44) or as a ceiling-of-care (N = 19) mortality was 25% and 84%, respectively. Overall, there was strong evidence for higher mortality among patients who required CPAP or IMV, compared to those who required only air/oxygen (aOR 5.24 95%CI: 1.38, 19.81 and aOR 46.47 95%CI: 7.52, 287.08, respectively; p<0.001), and among patients with early ceiling-of-care compared to those without a ceiling (aOR 41.81 95%CI: 8.28, 211.17; p<0.001). Among patients without a ceiling of care (N = 137), 10 patients required prompt intubation following failed oxygen therapy, but 44 patients received CPAP. CPAP failure, defined as death (N = 1) or intubation (N = 24), occurred in 57% (N = 25) of patients. But in total, 75% (N = 33) of those started on CPAP with no ceiling of care recovered to discharge-19 without the need for IMV, and 14 following IMV. Conclusion Our data suggest that among patients with no ceiling-of-care, an initial trial of CPAP as a potential bridge to IMV offers a favourable therapeutic alternative to early intubation. In contrast, among patients with a ceiling-of care, CPAP seems to offer little additional survival benefit beyond oxygen therapy alone. Information on ceilings of respiratory support is vital to interpreting mortality from Covid-19. Strengths and limitations of this study Sample size relatively small. Study sample representative of hospitalised Covid-19 patients in UK. Previously unreported data on role of ceilings-of-care in hospitalised Covid-19 patients. Novel data on use of CPAP separated by indication.	[Walker, Jonathan; Dolly, Shaman; Ng, Liji; Prior-Ong, Melissa] Calderdale Royal Hosp, Calderdale & Huddersfield NHS Fdn Trust, Halifax, NS, Canada; [Sabapathy, Kalpana] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England	University of London; London School of Hygiene & Tropical Medicine	Walker, J (corresponding author), Calderdale Royal Hosp, Calderdale & Huddersfield NHS Fdn Trust, Halifax, NS, Canada.	johnniewalker@doctors.org.uk			UK Medical Research Council (MRC); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement; European Union [MR/R010161/1]; MRC [MR/R010161/1] Funding Source: UKRI	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development (DFID) under the MRC/DFID Concordat agreement(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The senior author, Kalpana Sabapathy, received funding from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement; part of the EDCTP2 programme supported by the European Union. Grant Ref: MR/R010161/1 URL: https://mrc.ukri.org The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alraddadi BM, 2019, INFLUENZA OTHER RESP, V13, P382, DOI 10.1111/irv.12635; [Anonymous], [No title captured]; Arulkumaran N, 2020, LANCET RESP MED, V8, pE45, DOI 10.1016/S2213-2600(20)30181-8; British Thoracic Society, 2020, BTS GUID RESP SUPP P; Cheung TMT, 2004, CHEST, V126, P845, DOI 10.1378/chest.126.3.845; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Franco C, 2020, PHYS REV MATER, V4, DOI 10.1103/PhysRevMaterials.4.045404; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Intensive Care National Research and Audit Centre, 2020, ICNARC REP COVID 19; John B, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00320; Johns Hopkins University, 2020, COR RES CTR MAPS TRE; Mario Negri Institute for Pharmacological Research, 2020, EARLY CPAP COVID PAT; Myers LC, 2020, JAMA; National Health Service, 2020, NHS SPEC GUID PAT MA; National Institute for Clinical Excellence, 2019, END LIF CAR AD SERV; National Institute of Clinical Excellence, 2020, COVID 19 RAP GUID CA; Nightingale R, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000639; Office for National Statistics, 2020, PEDIATRICS; Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338; RECOVERY Respiratory Support Trial Team, 2020, RECOVERY RESP SUPPOR; RECOVERY Trial Team, 2020, RANDOMISED EVALUTAIO; Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9; Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689; Whittle Jessica S, 2020, J Am Coll Emerg Physicians Open, V1, P95, DOI 10.1002/emp2.12071; World Health Organization, 2020, CLIN MAN COVID 19 WH; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	33	13	13	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244857	10.1371/journal.pone.0244857	http://dx.doi.org/10.1371/journal.pone.0244857			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382796	Green Published, gold			2023-01-03	WOS:000605651900053
J	Fyfe, C; Telfar-Barnard, L; Howden-Chapman, P; Douwes, J				Fyfe, Caroline; Telfar-Barnard, Lucy; Howden-Chapman, Philippa; Douwes, Jeroen			Association between home insulation and hospital admission rates: retrospective cohort study using linked data from a national intervention programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY HEALTH; MORTALITY; MOLD	OBJECTIVES To investigate whether retrofitting insulation into homes can reduce cold associated hospital admission rates among residents and to identify whether the effect varies between different groups within the population and by type of insulation. DESIGN A quasi-experimental retrospective cohort study using linked datasets to evaluate a national intervention programme. PARTICIPANTS 994 317 residents of 204 405 houses who received an insulation subsidy through the Energy Efficiency and Conservation Authority Warm-up New Zealand: Heat Smart retrofit programme between July 2009 and June 2014. MAIN OUTCOME MEASURE A difference-in-difference approach was used to compare the change in hospital admissions of the study population post-insulation with the change in hospital admissions of the control population that did not receive the intervention over the same two timeframes. Relative rate ratios were used to compare the two groups. RESULTS 234 873 hospital admissions occurred during the study period. Hospital admission rates after the intervention increased in the intervention and control groups for all population categories and conditions with the exception of acute hospital admissions among Pacific Peoples (rate ratio 0.94, 95% confidence interval 0.90 to 0.98), asthma (0.92, 0.86 to 0.99), cardiovascular disease (0.90, 0.88 to 0.93), and ischaemic heart disease for adults older than 65 years (0.79, 0.74 to 0.84). Post-intervention increases were, however, significantly lower (11%) in the intervention group compared with the control group (relative rate ratio 0.89, 95% confidence interval 0.88 to 0.90), representing 9.26 (95% confidence interval 9.05 to 9.47) fewer hospital admissions per 1000 in the intervention population. Effects were more pronounced for respiratory disease (0.85, 0.81 to 0.90), asthma in all age groups (0.80, 0.70 to 0.90), and ischaemic heart disease in those older than 65 years (0.75, 0.66 to 0.83). CONCLUSION This study showed that a national home insulation intervention was associated with reduced hospital admissions, supporting previous research, which found an improvement in self-reported health.	[Fyfe, Caroline; Telfar-Barnard, Lucy; Howden-Chapman, Philippa] Univ Otago Wellington, Dept Publ Hlth, He Kianga Oranga, POB 7343, Wellington 6242, New Zealand; [Douwes, Jeroen] Massey Univ Wellington, Ctr Publ Hlth Res, Wellington, New Zealand	University of Otago; Massey University	Fyfe, C (corresponding author), Univ Otago Wellington, Dept Publ Hlth, He Kianga Oranga, POB 7343, Wellington 6242, New Zealand.	fyfca725@student.otago.ac.nz						Amitrano L., 2006, PR106 BRANZ; Anderson P, 2012, NEW ZEAL MED J, V125, P25; Atkinson J., 2014, NZDEP2013 INDEX DEPR; Barnard LFT, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1580-1; Curl A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2524-5; Davie GS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-263; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Fung, 2008, EN65708 BEAC PATHW; Grey CNB, 2017, INDOOR BUILT ENVIRON, V26, P902, DOI 10.1177/1420326X17703450; Grimes A., 2012, COST BENEFIT ANAL WA; Hales S, 2012, J EPIDEMIOL COMMUN H, V66, P379, DOI 10.1136/jech.2010.111864; Hamilton IG, 2017, ENERG BUILDINGS, V141, P142, DOI 10.1016/j.enbuild.2017.02.014; Handley MA, 2018, ANNU REV PUBL HEALTH, V39, P5, DOI 10.1146/annurev-publhealth-040617-014128; Healy JD, 2003, J EPIDEMIOL COMMUN H, V57, P784, DOI 10.1136/jech.57.10.784; Heyman B, 2005, HOUSING STUD, V20, P649, DOI 10.1080/02673030500114656; Howden-Chapman P., 2013, INFECT DIS ATTRIBUTE; Howden-Chapman P, 2011, INT J PUBLIC HEALTH, V56, P583, DOI 10.1007/s00038-011-0287-z; Howden-Chapman P, 2007, BMJ-BRIT MED J, V334, P460, DOI 10.1136/bmj.39070.573032.80; Howden-Chapman P, 2009, ENERG POLICY, V37, P3387, DOI 10.1016/j.enpol.2008.12.023; HUNT DRG, 1982, BUILD ENVIRON, V17, P107, DOI 10.1016/0360-1323(82)90048-8; Isaacs N, 2015, 221 BRANZ; Jackson G, 2011, J EPIDEMIOL COMMUN H, V65, P588, DOI 10.1136/jech.2009.107441; Maidment CD, 2014, ENERG POLICY, V65, P583, DOI 10.1016/j.enpol.2013.10.054; NICE, 2015, EXC WINT DEATHS ILLN; Pollard A., 2018, SR389 BRANZ; Preval N., 2015, THESIS; Preval N, 2019, AGENDA-J POLICY ANAL, V26, P51, DOI 10.22459/AG.26.01.2019.03; Preval N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018079; Shorter C, 2018, INDOOR AIR, V28, P6, DOI 10.1111/ina.12413; Taylor B, 2005, WOMEN, GENDER AND ENLIGHTENMENT, P1, DOI 10.1057/9780230554801; Telfar Barnard L, 2015, IMPACT RESP DIS NZ 2; Telfar Barnard L., 2011, IMPACT RETROFITTING; Webb E, 2013, J EPIDEMIOL COMMUN H, V67, P280, DOI 10.1136/jech-2012-201458; White H., 2014, QUASI EXPT DESIGN ME; World Health Organization, 2018, HOUS HLTH GUID; World Health Organization, 1987, HLTH IMP LOW IND TEM	36	16	16	3	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 29	2020	371								m4571	10.1136/bmj.m4571	http://dx.doi.org/10.1136/bmj.m4571			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PO1QW	33376083	Green Published, hybrid			2023-01-03	WOS:000604946300001
J	Sagbakken, M; Ingebretsen, R; Spilker, RS				Sagbakken, Mette; Ingebretsen, Reidun; Spilker, Ragnhild Storstein			How to adapt caring services to migration-driven diversity? A qualitative study exploring challenges and possible adjustments in the care of people living with dementia	PLOS ONE			English	Article							RESIDENTIAL CARE; FAMILY CARE; CULTURE; COMMUNICATION; IMMIGRANTS; ETHNICITY; SWEDEN; MAINSTREAM; PROVISION; COMMUNITY	Background Research on how services can be adapted to meet the needs of people with dementia with an immigrant or minority ethnic background is scarce. Several approaches have been discussed: offering services adapted to language and culture, adding bilingual staff to mainstream services, and providing cultural awareness and sensitivity training to health personnel in mainstream services. This study seeks to develop more knowledge of challenges and possible adjustments related to receive and provide public care for people living with dementia with an immigrant or minority ethnic background. Methods and materials Through a qualitative design, including 19 single interviews, 3 dyad interviews and 16 focus groups with older immigrants, relatives of immigrants with dementia, and health personnel, we explored experiences and perceptions related to receive and provide care for people with immigrant backgrounds living with dementia in Norway. The analysis were conducted inspired by Kvale and Brinkmann's three contexts of interpretations. Results Challenges related to language and communication were emphasized as the most fundamental barrier to provide adjusted care; exemplified through cases of isolation and agitation among patients not able to communicate. Care services framed by the majority culture creates feelings of alienation and exclusion. Not having access to specific types of food and the possibility to listen to songs, music, literature or TV programs representing a familiar and homely context may prevent use of public dementia care. Findings also point to differences in moral views regarding life-prolonging treatment in advanced stages of dementia. Conclusion This study argues that to be able to address challenges related to migration-driven diversity one needs holistic care services that addresses individual as well as socio-cultural needs. A linguistically and culturally diverse workforce may represent an important resource, potentially reducing some of the problems related to communication. On a structural level, it seems necessary to allocate more time and resources, including the use of interpreters, when assessing and getting to know persons with dementia with another linguistic and cultural background. However, shared language does not guarantee understanding. Rather, one needs to become familiar with each person's way of being ill, on a cultural and individual level, including changes occurring living with progressive dementia. Getting to know a person and his/her family will also facilitate the possibility to ensure a more familiar and homely context. Thus, continuity in relation to language and culture is important, but continuity in relations may be equally important ensuring that people with dementia receive equitable care.	[Sagbakken, Mette] OsloMet Oslo Metropolitan Univ, Dept Nursing & Hlth Promot, Fac Hlth Sci, Oslo, Norway; [Ingebretsen, Reidun] OsloMet Oslo Metropolitan Univ, Norwegian Social Res NOVA, Oslo, Norway; [Spilker, Ragnhild Storstein] Norwegian Inst Publ Hlth, Unit Migrat & Hlth, Oslo, Norway	Oslo Metropolitan University (OsloMet); Oslo Metropolitan University (OsloMet); Norwegian Institute of Public Health (NIPH)	Sagbakken, M (corresponding author), OsloMet Oslo Metropolitan Univ, Dept Nursing & Hlth Promot, Fac Hlth Sci, Oslo, Norway.	metsa@oslomet.no	Giacalone, Laura/AHD-0203-2022		Norwegian Directorate of Health	Norwegian Directorate of Health	The study was supported by the Norwegian Directorate of Health. The financial sponsor played no role in the design, execution, analysis and interpretation of data.	Agotnes G., 2017, I PRACTICE NURSING H; [Anonymous], 2014, 20148 NOU MIN CHILDR; [Anonymous], 2002, 200229 SOU SWED GOV; Antelius E, 2016, ANTHROPOL AGING, V37, P9, DOI 10.5195/aa.2016.107; Antelius Eleonor, 2015, Care Manag J, V16, P79; Barrett AE, 2003, J GERONTOL B-PSYCHOL, V58, pS101, DOI 10.1093/geronb/58.2.S101; BAUM SK, 1983, GERONTOLOGIST, V23, P532, DOI 10.1093/geront/23.5.532; Botsford J, 2011, J RES NURS, V16, P437, DOI 10.1177/1744987111414531; Bowes A, 2003, HEALTH SOC CARE COMM, V11, P387, DOI 10.1046/j.1365-2524.2003.00440.x; Collins P. H., 1990, BLACK FEMINIST THOUG; Connolly A, 2012, J AM GERIATR SOC, V60, P351, DOI 10.1111/j.1532-5415.2011.03754.x; Cooper C, 2018, INT J GERIATR PSYCH, V33, P504, DOI 10.1002/gps.4786; Cooper C, 2010, AM J GERIAT PSYCHIAT, V18, P193, DOI 10.1097/JGP.0b013e3181bf9caf; Daker-White G, 2002, AGING MENT HEALTH, V6, P101, DOI 10.1080/13607860220126835; Davies AA, 2014, MIGRATION SOCIAL DET; Debesay J, 2014, J ADV NURS, V70, P2107, DOI 10.1111/jan.12369; Diaz E, 2015, DEMENT GERIATR COGN, V39, P321, DOI 10.1159/000375526; Ekman S L, 1994, Int Psychogeriatr, V6, P105, DOI 10.1017/S1041610294001675; EKMAN SL, 1993, INT J AGING HUM DEV, V37, P37, DOI 10.2190/NU87-FGP0-CNEU-DCH5; Erikson E, 1986, VITAL INVOLVEMENT OL; European Parliament and Council of the European Union, 2002, OFF J EUR UNION L, V037, P19; Folkehelseinstituttet [Norwegian Institute of Public Health], 2018, FOLK; Goral M, 2013, ANNU REV APPL LINGUI, V33, P128, DOI 10.1017/S026719051300010X; Harper S, 2005, SOC POLICY SOC, V4, P157, DOI 10.1017/S1474746404002295; Heikkila K, 2007, SCAND J CARING SCI, V21, P354, DOI 10.1111/j.1471-6712.2007.00480.x; Hossain M, 2020, DEMENTIA-LONDON, V19, P1441, DOI 10.1177/1471301218800641; Hossain MZ, 2020, J EVAL CLIN PRACT, V26, P1629, DOI 10.1111/jep.13361; Hossain MZ, 2019, J EVAL CLIN PRACT, V25, P769, DOI 10.1111/jep.13117; Hyden LC, 2013, J INTERACT RES COM D, V4, P211, DOI 10.1558/jircd.v4i2.211; Iliffe S, 2004, AGING MENT HEALTH, V8, P283, DOI 10.1080/13607860410001709656; IMDi, 2020, INNV ARB; JONES DC, 1986, J ADV NURS, V11, P265, DOI 10.1111/j.1365-2648.1986.tb01247.x; Jonson H, 2018, EUR J SOC WORK, V21, P235, DOI 10.1080/13691457.2017.1288087; Jutlla K., 2013, J DEMENTIA CARE, V21, P33; Kiwi M, 2018, J CROSS-CULT GERONTO, V33, P21, DOI 10.1007/s10823-017-9337-1; KOENIG BA, 1995, WESTERN J MED, V163, P244; Kvale S., 2015, INTERVIEW LEARNING C, V3rd; Leininger M, 1991, J Transcult Nurs, V2, P32, DOI 10.1177/104365969100200205; Leininger M, 2007, NURS SCI QUART, V20, P9, DOI 10.1177/0894318406296784; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Lucy JA, 1997, ANNU REV ANTHROPOL, V26, P291, DOI 10.1146/annurev.anthro.26.1.291; Mackenzie J., 2006, DEMENTIA, V5, P233, DOI [DOI 10.1177/1471301206062252, 10.1177/1471301206062252]; MacLean MJ, 1986, INT SOCIAL WORK, V29, P227; McCleary L., 2013, INDIAN J GERONTOL, V27, P178; McFarland MR, 1997, NURS SCI QUART, V10, P186, DOI 10.1177/089431849701000412; Mold F, 2005, AGE AGEING, V34, P107, DOI 10.1093/ageing/afi009; Moriarty J., 2011, BLACK MINORITY ETHNI; Mukadam N, 2011, INT J GERIATR PSYCH, V26, P12, DOI 10.1002/gps.2484; Nielsen TR, 2011, DEMENT GERIATR COGN, V31, P388, DOI 10.1159/000327362; Norwegian Directorate of Health, 2015, ALZH ANDR DEM; Norwegian Directorate of Health, 2017, NASJ FAGL RETN DEM; Norwegian Institute of Public Health, 2016, DEM NORW PUBL HLTH R; Patton MQ, 2002, QUALITATIVE RES EVAL; Phillimore J, 2016, IRIS WORKING PAPER S, V15; Plejert C, 2014, J CROSS-CULT GERONTO, V29, P1, DOI 10.1007/s10823-013-9217-2; Prince R, 2017, DEMENTIA ETHNIC MINO; Ringard A, 2013, HEALT SYST TRANSIT, V15, P1; Rosendahl SP, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0200-y; Runci S, 1999, Int Psychogeriatr, V11, P301, DOI 10.1017/S1041610299005864; Runci SJ, 2005, INT PSYCHOGERIATR, V17, P699, DOI 10.1017/S1041610205002309; Runci SJ, 2005, AUSTRALAS J AGEING, V24, P157, DOI 10.1111/j.1741-6612.2005.00106.x; Runci SJ, 2012, INT PSYCHOGERIATR, V24, P733, DOI 10.1017/S1041610211002134; Sagbakken M, 2019, AGEING SOC, P1; Sagbakken M, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3720-7; Sagbakken M, 2018, QUAL HEALTH RES, V28, P16, DOI 10.1177/1049732317730818; Seeberg ML, 2012, EUR J WOMENS STUD, V19, P173, DOI 10.1177/1350506811434665; Sjogren K, 2013, J ADV NURS, V69, P2196, DOI 10.1111/jan.12085; Strandroos L, 2017, HEALTH-LONDON, V21, P538, DOI 10.1177/1363459316677626; TOnnessen M, OKONOMISKE ANAL 3 20; Torres S, 2006, J ETHN MIGR STUD, V32, P1341, DOI 10.1080/13691830600928730; Uppal G, 2014, MENT HEALTH RELIG CU, V17, P143, DOI 10.1080/13674676.2013.764515; Viruell-Fuentes EA, 2012, SOC SCI MED, V75, P2099, DOI 10.1016/j.socscimed.2011.12.037; Yee D L, 1992, J Health Care Poor Underserved, V2, P448	73	0	0	6	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2020	15	12							e0243803	10.1371/journal.pone.0243803	http://dx.doi.org/10.1371/journal.pone.0243803			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PL4CG	33351820	Green Published, gold			2023-01-03	WOS:000603071400054
J	Kehali, H; Berhane, Y; Gize, A				Kehali, Habtamu; Berhane, Yemane; Gize, Addisu			A phenomenological study on the lived experiences of families of ICU patients, Addis Ababa, Ethiopia	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; DECISION-MAKING; COMMUNICATION; MEMBERS; NEEDS	Background Family-centered care of ICU patients is increasingly recommended as it is believed to have effect on family members' psychosocial status and patient outcomes. Defining the nature and extent of families' involvement in a given health care environment for different stakeholders is a challenge. Understanding the lived experiences of families of ICU patients would help strategize on how to better engage family members for improved ICU care processes and outcomes. Objectives The aim of this study is to explore the lived experiences of families of patients in the ICUs of hospitals in Addis Ababa, Ethiopia. Methods The study adopted a qualitative approach and a phenomenological research design. In-depth interviews were conducted with twelve (12) family members who were purposively sampled from two government hospitals and four private hospitals. Thematic approach with the application of hermeneutic circle of interpretation was applied to understand the meanings of their experiences. Results The study revealed the following major themes: financial burden, challenge in decision making, shattered family integrity and expectations, information and communication gap between family members and health professionals, lack of confidence in the service delivery of hospitals, social pressure against patient families, and families being immersed in an unfriendly environment. Though they do not explicitly mention it to the health care tram, further interpretation of the main themes elucidated that family's need the intensive care process be cut shorter irrespective of the outcome of the patient condition. Conclusion The study gave an insight on the multiple and interrelated challenges faced by families of ICU patients admitted in the hospitals of Addis Ababa. Further contextualized interpretation of their experiences revealed that families were somehow in a state of despair and they implicitly need the ICU care for their family member be ended irrespective of the potential clinical consequences on the patient. The philosophy of family-centered care be advocated in hospitals. The study result affirms the need to include family members during nursing assessment of patients in ICUs and also offers the basis for guidelines development on informational support to the families of the patients hospitalized in ICUs.	[Kehali, Habtamu; Gize, Addisu] St Pauls Hosp, Millennium Med Coll, Addis Ababa, Ethiopia; [Berhane, Yemane] Addis Continental Inst Publ Hlth, Addis Ababa, Ethiopia	Addis Continental Institute of Public Health	Gize, A (corresponding author), St Pauls Hosp, Millennium Med Coll, Addis Ababa, Ethiopia.	addisu.gize@sphmmc.edu.et						[Anonymous], 2012, Manag Care, V21, P43; [Anonymous], 2012, CHALLENGES CRITICAL; Asrat A, 2014, INT J MED MED SCI, V6, P195, DOI [10.5897/IJMMS2013.0883, DOI 10.5897/IJMMS2013.0883]; Auerbach SM, 2005, AM J CRIT CARE, V14, P202, DOI 10.4037/ajcc2005.14.3.202; Azoulay E, 2004, CRIT CARE MED, V32, P1832, DOI 10.1097/01.CCM.0000139693.88931.59; Birhanu Z, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-78; Curtis JR, 2006, CRIT CARE MED, V34, P211, DOI 10.1097/01.CCM.0000190617.76104.AC; Dahlgren Lars, 2007, QUALITATIVE METHODOL; Epstein EG, 2016, APPL NURS RES, V32, P286, DOI 10.1016/j.apnr.2016.08.011; Eriksson Thomas, 2011, Intensive Crit Care Nurs, V27, P60, DOI 10.1016/j.iccn.2011.01.001; Fritsch Jenna, 2013, J Clin Ethics, V24, P125; Hashim F, 2012, PROCD SOC BEHV, V36, P103, DOI 10.1016/j.sbspro.2012.03.012; Heyland DK, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2379-4; Hickman RL, 2010, AACN ADV CRIT CARE, V21, P80, DOI 10.1097/NCI.0b013e3181c930a3; Hinkle Janice L, 2011, Intensive Crit Care Nurs, V27, P218, DOI 10.1016/j.iccn.2011.04.003; Hoye Sevald, 2010, Intensive Crit Care Nurs, V26, P24, DOI 10.1016/j.iccn.2009.10.003; Iverson E, 2014, INTENS CRIT CARE NUR, V30, P77, DOI 10.1016/j.iccn.2013.08.008; Kruisselbrink R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151408; McKiernan Margaret, 2010, Intensive Crit Care Nurs, V26, P254, DOI 10.1016/j.iccn.2010.06.004; Nguyen MN, 2010, PLOS ONE, V5, pe9907; Olding M, 2016, HEALTH EXPECT, V19, P1183, DOI 10.1111/hex.12402; Osborn TR, 2012, CHEST, V142, P1185, DOI 10.1378/chest.11-3277; Fortunatti CP, 2018, AUST CRIT CARE, V31, P318, DOI 10.1016/j.aucc.2017.08.003; Petty NJ, 2012, MANUAL THER, V17, P378, DOI 10.1016/j.math.2012.03.004; Prevett M, 2012, ETHIOP J HEALTH SCI, V22, P1; Roche SD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214918; To WS, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-21; Torke AM, 2012, PATIENT EDUC COUNS, V87, P54, DOI 10.1016/j.pec.2011.07.027; Wall JM, 2017, PSYCHOTHER RES, V27, P539, DOI 10.1080/10503307.2015.1136441; Woldemichael A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213896; Zewdneh D, 2011, ETHIOP J HEALTH DEV, V25, P3	31	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2020	15	12							e0244073	10.1371/journal.pone.0244073	http://dx.doi.org/10.1371/journal.pone.0244073			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PI8CZ	33338068	gold, Green Published			2023-01-03	WOS:000601313500002
J	Makata, K; Kinung'hi, S; Hansen, C; Ayieko, P; Sichalwe, S; Mcharo, O; Ensink, J; Dreibelbis, R; Rockowitz, S; Okello, E; Grosskurth, H; Kapiga, S				Makata, Kenneth; Kinung'hi, Safari; Hansen, Christian; Ayieko, Philip; Sichalwe, Simon; Mcharo, Onike; Ensink, Jeroen; Dreibelbis, Robert; Rockowitz, Sarah; Okello, Elialilia; Grosskurth, Heiner; Kapiga, Saidi			Hand hygiene intervention to optimize helminth infection control: Design and baseline results of Mikono Safi-An ongoing school-based cluster-randomised controlled trial in NW Tanzania	PLOS ONE			English	Article							TRICHURIS-TRICHIURA; ETHER SEDIMENTATION; ALBENDAZOLE; EFFICACY; CHILDREN; REINFECTION; REGION; IMPACT; SOAP	Introduction Soil transmitted helminths (STH) can affect over 50% of children in some parts of Tanzania. Control measures involve annual deworming campaigns in schools, but re-infection is rapid. This paper presents the design and baseline survey results of an ongoing school-based cluster-randomised controlled trial in Kagera region, NW Tanzania. The trial aims to determine whether the effect of routine deworming on the prevalence of Ascaris lumbricoides and Trichuris trichiura infections among school aged children can be sustained when combined with a behaviour change intervention promoting handwashing with water and soap. Methods As part of the trial, a total of 16 schools were randomised to receive the intervention (N = 8) or as controls (N = 8). Randomisation was stratified per district and restricted to ensure pre-trial STH prevalence was balanced between study arms. The combination intervention to be tested comprises class-room based teacher-led health education, improvement of handwash stations, coloured nudges to facilitate handwashing and parental engagement sessions. The impact evaluation involves two cross-sectional surveys conducted at baseline and endline. The objectives of the baseline survey were: (i) to confirm whether the deworming campaign was successful, and identify and treat students still infected about 2 weeks after deworming, (ii) to document any baseline differences in STH prevalence between trial arms, and (iii) to assess handwashing behaviours, and access to water and sanitation at school and home. We randomly sampled 35 students per class in Grades 1-6 (an average of 200 children per school), stratified to ensure equal representation between genders. Assenting students were interviewed using a structured questionnaire and asked to provide a stool specimen. Results Results of the baseline survey conducted about 2 weeks after deworming shows balanced demographic and STH prevalence data across trial arms. We observed a low prevalence of ascariasis (< 5%) as expected; however, the prevalence of trichuriasis was still about 35% in both arms. Conclusion The randomisation procedure was successful in achieving a balanced distribution of demographic characteristics and helminth infections between trial arms. The intervention is being rolled out. The current deworming treatment regimen may need to be revised with regards to the treatment of trichuriasis.	[Makata, Kenneth; Ayieko, Philip; Sichalwe, Simon; Mcharo, Onike; Okello, Elialilia; Grosskurth, Heiner; Kapiga, Saidi] Mwanza Intervent Trials Unit, Mwanza, Tanzania; [Kinung'hi, Safari; Grosskurth, Heiner; Kapiga, Saidi] Natl Inst Med Res, Mwanza, Tanzania; [Hansen, Christian; Ayieko, Philip; Grosskurth, Heiner; Kapiga, Saidi] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England; [Ensink, Jeroen; Dreibelbis, Robert] London Sch Hyg & Trop Med, Dept Dis Control, London, England; [Rockowitz, Sarah] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	National Institute of Medical Research; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kapiga, S (corresponding author), Mwanza Intervent Trials Unit, Mwanza, Tanzania.; Kapiga, S (corresponding author), Natl Inst Med Res, Mwanza, Tanzania.; Kapiga, S (corresponding author), London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London, England.	saidi.kapiga@lshtm.ac.uk		Kapiga, Saidi/0000-0003-1753-4060; Hansen, Christian/0000-0002-5949-0097; Grosskurth, Heiner/0000-0001-9960-7280; Makata, Kenneth/0000-0001-5209-2347	UK Department for International Development (DFID) through the SHARE Consortium based at LSHTM; MRC [MR/R010161/1, MR/R00255X/1, G0901756] Funding Source: UKRI	UK Department for International Development (DFID) through the SHARE Consortium based at LSHTM; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study is funded by the UK Department for International Development (DFID) through the SHARE Consortium based at LSHTM.	[Anonymous], 2018, FAMILY HLTH INT 360; Bieri FA, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-29; Biran A, 2014, LANCET GLOB HEALTH, V2, pE145, DOI 10.1016/S2214-109X(13)70160-8; Brooker S, 2008, MANSONS TROPICAL DIS, P848; Brooker S, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-42; Campbell SJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005393; Clements ACA, 2010, TROP MED INT HEALTH, V15, P198, DOI 10.1111/j.1365-3156.2009.02440.x; Dreibelbis R, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010129; Ercumen A, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007323; Freeman MC, 2013, AM J TROP MED HYG, V89, P875, DOI 10.4269/ajtmh.13-0237; Geissler PW, 1998, TROP MED INT HEALTH, V3, P529, DOI 10.1046/j.1365-3156.1998.00272.x; Grover E, 2018, TROP MED INT HEALTH, V23, P10, DOI 10.1111/tmi.12999; Harrington D, 2019, NEW ENGL J MED, V381, P285, DOI 10.1056/NEJMe1906559; Hayes RJ, CLUSTER RANDOMISED T; Hotez PJ, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P467; Hussein AH, 2017, AM J TROP MED HYG, V96, P589, DOI 10.4269/ajtmh.16-0436; Ismail MM, 1999, ANN TROP MED PARASIT, V93, P501, DOI 10.1080/00034989958230; Jeandron A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096731; Muller I, 2016, T ROY SOC TROP MED H, V110, P676, DOI 10.1093/trstmh/trw075; Naluonde T, 2019, HEALTH PROMOT INT, V34, pE119, DOI 10.1093/heapro/day080; Namwanje H, 2011, T ROY SOC TROP MED H, V105, P586, DOI 10.1016/j.trstmh.2011.07.009; NBS, 2012, NAT BUR STAT TANZ 20; Nery SV, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3532-6; Nery SV, 2019, INT J PARASITOL, V49, P389, DOI 10.1016/j.ijpara.2018.12.006; RIDLEY DS, 1956, J CLIN PATHOL, V9, P74, DOI 10.1136/jcp.9.1.74; Saboori S, 2013, AM J TROP MED HYG, V89, P698, DOI 10.4269/ajtmh.12-0387; Sara S, 2014, INT J ENV RES PUB HE, V11, P9854, DOI 10.3390/ijerph110909854; Sirivichayakul C, 2003, ANN TROP MED PARASIT, V97, P847, DOI 10.1179/000349803225002480; Strunz EC, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001620; WHO, 2019, SCH DEW GLANC POL GU; WHO, 2019, SOIL TRANSM HELM FAC; Yap P, 2013, AM J TROP MED HYG, V89, P23, DOI 10.4269/ajtmh.13-0009; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852, DOI 10.1128/JCM.10.6.852-853.1979; Ziegelbauer K, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001162	34	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2020	15	12							e0242240	10.1371/journal.pone.0242240	http://dx.doi.org/10.1371/journal.pone.0242240			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE8QN	33296365	Green Published, gold			2023-01-03	WOS:000598626100059
J	Perichou, J; Ranchon, F; Herledan, C; Huot, L; Larbre, V; Carpentier, I; Lazareth, A; Karlin, L; Beny, K; Vantard, N; Schwiertz, V; Caffin, AG; Baudouin, A; Sesques, P; Brisou, G; Ghesquieres, H; Salles, G; Rioufol, C				Perichou, Juliette; Ranchon, Florence; Herledan, Chloe; Huot, Laure; Larbre, Virginie; Carpentier, Isabelle; Lazareth, Anne; Karlin, Lionel; Beny, Karen; Vantard, Nicolas; Schwiertz, Verane; Caffin, Anne Gaelle; Baudouin, Amandine; Sesques, Pierre; Brisou, Gabriel; Ghesquieres, Herve; Salles, Gilles; Rioufol, Catherine			Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects	PLOS ONE			English	Article							ORAL CHEMOTHERAPY; TREATMENT SATISFACTION; OLDER-ADULTS; ADHERENCE; CANCER; PERSISTENCE; NEUTROPENIA; VALIDATION; SURVIVORS; THERAPY	Long-term multiple myeloma therapy by immunomodulatory drugs (IMiDs) raises the question of management of adverse effects. The aim of this study is to assess the impact of an educational session for patients on the acquisition of knowledge to manage hematologic and thromboembolic adverse effects of IMiDs. In this prospective single-center study, patients attended an educational session with a hospital clinical pharmacist and a nurse. The primary endpoint was the patient's level of knowledge for the management of IMiDs adverse effects, assess with a dedicated questionnaire administered before the session then 1 and 6 months after. Assessment of knowledge was combined with self-assessment of certainty. The secondary endpoints were adherence and IMiD treatment satisfaction. 50 patients were included. Patient knowledge increased at 1 month (p<0.001) despite a loss of knowledge at 6 months (p<0.05). Six months after the educational intervention, the number of patients with skills considered satisfactory by the pharmacist and nurse increased (p<0.01). Most patients showed satisfactory adherence, with medication possession ratio >= 80%. The Self CARe and MEdication Toxicity (SCARMET) study highlighted the impact of multidisciplinary follow-up in multiple myeloma patients to improve knowledge of toxicity self-management.	[Perichou, Juliette; Ranchon, Florence; Herledan, Chloe; Larbre, Virginie; Vantard, Nicolas; Schwiertz, Verane; Caffin, Anne Gaelle; Baudouin, Amandine; Rioufol, Catherine] Hosp Civils Lyon, Grp Hosp Sud, Unite Pharm Clin Oncol, Pierre Benite, France; [Perichou, Juliette; Ranchon, Florence; Herledan, Chloe; Larbre, Virginie; Vantard, Nicolas; Schwiertz, Verane; Caffin, Anne Gaelle; Baudouin, Amandine; Rioufol, Catherine] Univ Lyon 1, EMR 3738, Lyon, France; [Huot, Laure] Hosp Civils Lyon, Dept Rech Clin & Innovat, Cellule Innovat, Lyon, France; [Carpentier, Isabelle; Beny, Karen] Hosp Civils Lyon, Pharm Cent, Pierre Benite, France; [Lazareth, Anne; Karlin, Lionel; Sesques, Pierre; Brisou, Gabriel; Ghesquieres, Herve; Salles, Gilles] Hosp Civils Lyon, Grp Hosp Sud, Hematol Dept, Pierre Benite, France; [Salles, Gilles] Univ Lyon 1, INSERM CNRS 1052 5286, Ctr Rech Cancerol Lyon, Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Rioufol, C (corresponding author), Hosp Civils Lyon, Grp Hosp Sud, Unite Pharm Clin Oncol, Pierre Benite, France.; Rioufol, C (corresponding author), Univ Lyon 1, EMR 3738, Lyon, France.	catherine.rioufol@chu-lyon.fr	Huot, Laure/GLS-5988-2022; Salles, Gilles/Z-2336-2019; Ranchon, Florence/AAF-6943-2021	Huot, Laure/0000-0002-7870-9912; Salles, Gilles/0000-0002-9541-8666; Ranchon, Florence/0000-0002-9181-4231				Anghel Laura Alexandra, 2019, Med Pharm Rep, V92, P117, DOI 10.15386/mpr-1201; [Anonymous], 2013, ED THERAPEUTIQUE PAT; [Anonymous], 2009, PHARM HOSP; [Anonymous], 2009, SHADOW PHENOMENOLOGY; Barthelemy P, 2015, ONCOLOGY-BASEL, V88, P1, DOI 10.1159/000366226; Basch E, 2017, JAMA-J AM MED ASSOC, V318, P197, DOI 10.1001/jama.2017.7156; Blumel Susan, 2014, J Adv Pract Oncol, V5, P269; Bruttomesso D, 2003, PATIENT EDUC COUNS, V51, P29, DOI 10.1016/S0738-3991(02)00226-4; Campbell LC, 2007, CANCER-AM CANCER SOC, V109, P414, DOI 10.1002/cncr.22355; Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x; Cransac A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214446; Delestras S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056247; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Eek D, 2016, PATIENT PREFER ADHER, V10, P1609, DOI 10.2147/PPA.S106629; Eliasson L, 2011, LEUKEMIA RES, V35, P626, DOI 10.1016/j.leukres.2010.10.017; Feiten S, 2019, SUPPORT CARE CANCER, V27, P4265, DOI 10.1007/s00520-019-04721-4; Green J, 2018, J CLIN NURS, V27, pE1485, DOI 10.1111/jocn.14270; Jacobs JM, 2017, J ONCOL PRACT, V13, pE474, DOI 10.1200/JOP.2016.019729; Karve S, 2009, CURR MED RES OPIN, V25, P2303, DOI 10.1185/03007990903126833; Kav S, 2010, SUPPORT CARE CANCER, V18, P583, DOI 10.1007/s00520-009-0692-5; Krueger KP, 2005, ADV THER, V22, P313, DOI 10.1007/BF02850081; Kunin-Batson A, 2016, PSYCHO-ONCOLOGY, V25, P1308, DOI 10.1002/pon.3956; Laugueux Aurore, 2016, Journal de Pharmacie Clinique, V35, P140, DOI 10.1684/jpc.2016.0337; Lee C, 2016, J MED ECON, V19, P397, DOI 10.3111/13696998.2015.1130710; Leleu X, 2018, ANN HEMATOL, V97, P387, DOI 10.1007/s00277-017-3191-7; Li G, 2014, ASIA-PAC J ONCOL NUR, V1, P46, DOI 10.4103/2347-5625.135820; Molassiotis A, 2009, J CLIN ONCOL, V27, P6191, DOI 10.1200/JCO.2008.20.6755; Morrow DG, 2005, GERONTOLOGIST, V45, P545, DOI 10.1093/geront/45.4.545; Nicolucci A, 2000, DIABETES NUTR METAB, V13, P276; Nightingale G, 2017, J GERIATR ONCOL, V8, P296, DOI 10.1016/j.jgo.2017.04.005; Noens L, 2009, BLOOD, V113, P5401, DOI 10.1182/blood-2008-12-196543; Olszewski AJ, 2017, J CLIN ONCOL, V35, P3306, DOI 10.1200/JCO.2017.72.2447; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Reach G, 2005, PATIENT EDUC COUNS, V56, P98, DOI 10.1016/j.pec.2004.01.001; Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004; Ruiz MA, 2008, VALUE HEALTH, V11, P913, DOI 10.1111/j.1524-4733.2008.00323.x; seer, MYEL CANC STAT FACTS; Sitzia J, 1997, SOC SCI MED, V45, P1829, DOI 10.1016/S0277-9536(97)00128-7; Spoelstra SL, 2013, CANCER NURS, V36, P18, DOI 10.1097/NCC.0b013e3182551587; Sun HW, 2015, LEUKEMIA LYMPHOMA, V56, P407, DOI 10.3109/10428194.2014.915544; Videau S, 2010, THER PATIENT ED, V2, P15; Yardley SJ, 2001, PALLIATIVE MED, V15, P379, DOI 10.1191/026921601680419429	43	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2020	15	12							e0243309	10.1371/journal.pone.0243309	http://dx.doi.org/10.1371/journal.pone.0243309			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PC7AS	33275634	Green Published, gold			2023-01-03	WOS:000597150200039
J	King, CS; Sahjwani, D; Brown, AW; Feroz, S; Cameron, P; Osborn, E; Desai, M; Djurkovic, S; Kasarabada, A; Hinerman, R; Lantry, J; Shlobin, OA; Ahmad, K; Khangoora, V; Aryal, S; Collins, AC; Speir, A; Nathan, S				King, Christopher S.; Sahjwani, Dhwani; Brown, A. Whitney; Feroz, Saad; Cameron, Paula; Osborn, Erik; Desai, Mehul; Djurkovic, Svetolik; Kasarabada, Aditya; Hinerman, Rachel; Lantry, James; Shlobin, Oksana A.; Ahmad, Kareem; Khangoora, Vikramjit; Aryal, Shambhu; Collins, A. Claire; Speir, Alan; Nathan, Steven			Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure	PLOS ONE			English	Article								Purpose The outcomes of patients requiring invasive mechanical ventilation for COVID-19 remain poorly defined. We sought to determine clinical characteristics and outcomes of patients with COVID-19 managed with invasive mechanical ventilation in an appropriately resourced US health care system. Methods Outcomes of COVID-19 infected patients requiring mechanical ventilation treated within the Inova Health System between March 5, 2020 and April 26, 2020 were evaluated through an electronic medical record review. Results 1023 COVID-19 positive patients were admitted to the Inova Health System during the study period. Of these, 164 (16.0%) were managed with invasive mechanical ventilation. All patients were followed to definitive disposition. 70/164 patients (42.7%) had died and 94/164 (57.3%) were still alive. Deceased patients were older (median age of 66 vs. 55, p <0.0001) and had a higher initial d-dimer (2.22 vs. 1.31, p = 0.005) and peak ferritin levels (2998 vs. 2077, p = 0.016) compared to survivors. 84.3% of patients over 70 years old died in the hospital. Conversely, 67.4% of patients age 70 or younger survived to hospital discharge. Younger age, non-Caucasian race and treatment at a tertiary care center were all associated with survivor status. Conclusion Mortality of patients with COVID-19 requiring invasive mechanical ventilation is high, with particularly daunting mortality seen in patients of advanced age, even in a well-resourced health care system. A substantial proportion of patients requiring invasive mechanical ventilation were not of advanced age, and this group had a reasonable chance for recovery.	[King, Christopher S.; Brown, A. Whitney; Shlobin, Oksana A.; Ahmad, Kareem; Khangoora, Vikramjit; Aryal, Shambhu; Nathan, Steven] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, Falls Church, VA 22042 USA; [Sahjwani, Dhwani; Feroz, Saad] Inova Fairfax Hosp, Dept Pediat, Falls Church, VA USA; [Cameron, Paula] Inova Fairfax Hosp, Resp Therapy Dept, Falls Church, VA USA; [Osborn, Erik; Desai, Mehul; Djurkovic, Svetolik; Kasarabada, Aditya; Hinerman, Rachel; Lantry, James] Inova Fairfax Hosp, Med Crit Care Serv, Falls Church, VA USA; [Collins, A. Claire] Inova Fairfax Hosp, Adv Lung Dis Res, Falls Church, VA USA; [Speir, Alan] Inova Fairfax Hosp, Dept Cardiothorac Surg, Falls Church, VA USA	Inova Fairfax Hospital; Inova Fairfax Hospital; Inova Fairfax Hospital; Inova Fairfax Hospital; Inova Fairfax Hospital; Inova Fairfax Hospital	King, CS (corresponding author), Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, Falls Church, VA 22042 USA.	Christopher.king@inova.org	Aryal, Shambhu/AAM-5534-2021					Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Richardson S., 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775, 10.1001/jama.2020.7681]; Ying LY, 2021, NURS CRIT CARE, V26, P432, DOI 10.1111/nicc.12551; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	6	46	46	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2020	15	11							e0242651	10.1371/journal.pone.0242651	http://dx.doi.org/10.1371/journal.pone.0242651			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5BU	33227024	Green Submitted, Green Published, gold			2023-01-03	WOS:000595651800014
J	Kim, D; Xue, JYH; Lito, P				Kim, Dongsung; Xue, Jenny Yaohua; Lito, Piro			Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients	CELL			English	Review								KRAS mutations are among the most common genetic alterations in lung, colorectal, and pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit in precision oncology, one established shortly after the discovery of RAS mutations in human cancer cells nearly 40 years ago. Recent advances in medicinal chemistry have established inhibitors targeting KRAS(G12C), a mutation found in similar to 13% of lung adenocarcinomas and, at a lower frequency, in other cancers. Preclinical studies describing their discovery and mechanism of action, coupled with emerging clinical data from patients treated with these drugs, have sparked a renewed enthusiasm in the study of KRAS and its therapeutic potential. Here, we discuss how these advances are reshaping the fundamental aspects of KRAS oncoprotein biology and the strides being made toward improving patient outcomes in the clinic.	[Kim, Dongsung; Xue, Jenny Yaohua; Lito, Piro] Mem Sloan Kettering Canc, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Xue, Jenny Yaohua; Lito, Piro] Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY 10065 USA; [Lito, Piro] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Lito, Piro] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Lito, P (corresponding author), Mem Sloan Kettering Canc, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Lito, P (corresponding author), Weill Cornell Rockefeller Sloan Kettering Triinst, New York, NY 10065 USA.; Lito, P (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.; Lito, P (corresponding author), Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.	litop@mskcc.org			NIH/NCI [1R01CA23074501, 1R01CA23026701A1, K08CA191082-01A1, F30CA232549]; Pew Charitable Trusts; Damon Runyon Cancer Research Foundation; American Lung Association; Medical Scientist Training Program [T32GM007739]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pew Charitable Trusts; Damon Runyon Cancer Research Foundation; American Lung Association; Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Megan Mroczkowski for discussing the manuscript. P.L. is supported in part by the NIH/NCI (1R01CA23074501, 1R01CA23026701A1, and K08CA191082-01A1), the Pew Charitable Trusts, the Damon Runyon Cancer Research Foundation, and the American Lung Association. J.Y.X. is supported in part by the NIH/NCI (F30CA232549) and a Medical Scientist Training Program grant to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program (T32GM007739).		0	76	78	13	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2020	183	4					850	859		10.1016/j.cell.2020.09.044	http://dx.doi.org/10.1016/j.cell.2020.09.044			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	OQ2TD	33065029	Bronze, Green Accepted			2023-01-03	WOS:000588640900005
J	Morais, LS; Dusi, RG; Demarque, DP; Silva, RL; Albernaz, LC; Bao, SN; Merten, C; Antinarelli, LMR; Coimbra, ES; Espindola, LS				Morais, Lais S.; Dusi, Renata G.; Demarque, Daniel P.; Silva, Raquel L.; Albernaz, Lorena C.; Bao, Sonia N.; Merten, Christian; Antinarelli, Luciana M. R.; Coimbra, Elaine S.; Espindola, Laila S.			Antileishmanial compounds from Connarus suberosus: Metabolomics, isolation and mechanism of action	PLOS ONE			English	Article							LEISHMANIA-AMAZONENSIS; DERIVATIVES; CONSTITUENTS; MITOCHONDRIA; ROOTS; DEATH	Leishmaniasis is a disease impacting public health worldwide due to its high incidence, morbidity and mortality. Available treatments are costly, lengthy and toxic, not to mention the problem of parasite resistance. The development of alternative treatments is warranted and natural products demonstrate promising activity. This study investigated the activity of Connarus suberosus extracts and compounds against Leishmania species. Several C. suberosus extracts were tested against L. amazonensis promastigotes. Active and inactive extracts were analyzed by UHPLC-MS and data evaluated using a metabolomics platform, revealing an unknown neoflavonoid (connarin, 3), isolated together with the pterocarpans: hemileiocarpin (1) and leiocarpin (2). The aforementioned compounds (1-3), together with the benzoquinones: rapanone (4), embelin (5) and suberonone (6) previously isolated by our group from the same species, were tested against: (i) L. amazonensis and L. infantum promastigotes, and (ii) L. amazonensis intracellular amastigotes, with the most active compound (3) also tested against L. infantum amastigotes. Cytotoxicity against murine peritoneal macrophages was also investigated. Compounds 2 and 3 presented an IC50 33.8 mu M and 11.4 mu M for L. amazonensis promastigotes; and 44.3 mu M and 13.3 mu M for L. infantum promastigotes, respectively. For L. amazonensis amastigotes, the IC50 of 2 was 20.4 mu M with a selectivity index (SI) of 5.7, while the IC50 of 3 was 2.9 mu M with an SI of 6.3. For L. infantum amastigotes, the IC50 of 3 was 7.7 mu M. Compounds 2 and 3 presented activity comparable with the miltefosine positive control, with compound 3 found to be 2-4 times more active than the positive control, depending on the Leishmania species and form. The extracts and isolated compounds showed moderate toxicity against macrophages. Compounds 2 and 3 altered the mitochondrial membrane potential (Delta psi m) and neutral lipid body accumulation, while 2 also impacted plasma membrane permeabilization, culminating in cellular disorder and parasite death. Transmission electron microscopy of L. amazonensis promastigotes treated with compound 3 confirmed the presence of lipid bodies. Leiocarpin (2) and connarin (3) demonstrated antileishmanial activity. This study provides knowledge of natural products with antileishmanial activity, paving the way for prototype development to fight this neglected tropical disease.	[Morais, Lais S.; Dusi, Renata G.; Demarque, Daniel P.; Silva, Raquel L.; Albernaz, Lorena C.; Espindola, Laila S.] Univ Brasilia, Lab Farmacognosia, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil; [Demarque, Daniel P.; Merten, Christian] Ruhr Univ Bochum, Fak Chem & Biochem, Organ Chem 2, Bochum, Germany; [Bao, Sonia N.] Univ Brasilia, Lab Microscopia & Microanal, Inst Ciencias Biol, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil; [Antinarelli, Luciana M. R.; Coimbra, Elaine S.] Univ Fed Juiz De Fora, Dept Parasitol Microbiol & Imunol, ICB, Campus Univ Juiz De Fora, Juiz De Fora, MG, Brazil	Universidade de Brasilia; Ruhr University Bochum; Universidade de Brasilia; Universidade Federal de Juiz de Fora	Espindola, LS (corresponding author), Univ Brasilia, Lab Farmacognosia, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil.	darvenne@unb.br	Demarque, Daniel Pecoraro/K-7325-2014; Merten, Christian/I-2811-2012; Espindola, Laila Salmen/U-3378-2019	Demarque, Daniel Pecoraro/0000-0002-3576-5148; Merten, Christian/0000-0002-4106-1905; Espindola, Laila Salmen/0000-0002-1886-868X; Morais, Lais/0000-0002-1340-7681	Ministry of Health [TED74/2016, TED 42/2017]; FAPDF [0193.001482/2016, 0193.001219/2016]; CNPq; CAPES/Alexander von Humboldt Foundation; Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) [ME 4267/5-1, 418661145]; Boehringer Ingelheim Foundation (BIS)	Ministry of Health; FAPDF(Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES/Alexander von Humboldt Foundation; Deutsche Forschungsgemeinschaft (German Research Foundation, DFG)(German Research Foundation (DFG)); Boehringer Ingelheim Foundation (BIS)	The authors wish to thank the ArboControlBrasil Project funded by the Ministry of Health (Process no. TED74/2016 and TED 42/2017) and FAPDF (Process no. 0193.001482/2016 and 0193.001219/2016) for financial support. We also express our gratitude to CNPq for the fellowships (E.S. Coimbra and L.M.R. Antinarelli), and CAPES/Alexander von Humboldt Foundation for co-funding the post-doctoral fellowship (D. P. Demarque). CM acknowledges support by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) through the Heisenberg programme (ME 4267/5-1/ project number 418661145) and the Boehringer Ingelheim Foundation (BIS) through the Plus 3-programme.	Antinarelli LMR, 2015, CHEM BIOL DRUG DES, V86, P704, DOI 10.1111/cbdd.12540; Araujo MV, 2019, ANALYST, V144, P5232, DOI 10.1039/c9an00948e; Aureliano DP, 2018, PHOTODIAGN PHOTODYN, V23, P1, DOI 10.1016/j.pdpdt.2018.05.005; Batista JM, 2015, NAT PROD REP, V32, P1280, DOI 10.1039/c5np00027k; Bekhit AA, 2018, EUR J MED CHEM, V160, P229, DOI 10.1016/j.ejmech.2018.10.022; Borges RM, 2018, PHYTOCHEM ANALYSIS, V29, P601, DOI 10.1002/pca.2773; BRAZ FILHO R, 1971, PHYTOCHEMISTRY, V10, P2433, DOI 10.1016/S0031-9422(00)89891-X; Brenzan MA, 2008, BIOMED PHARMACOTHER, V62, P651, DOI 10.1016/j.biopha.2008.08.024; Charneau S, 2016, NAT PROD RES, V30, P1320, DOI 10.1080/14786419.2015.1055264; Chin YW, 2007, J AGR FOOD CHEM, V55, P4691, DOI 10.1021/jf0703553; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Cortes S, 2020, PATHOG GLOB HEALTH, V114, P170, DOI 10.1080/20477724.2020.1754655; da Costa RC, 2014, BIOORGAN MED CHEM, V22, P135, DOI 10.1016/j.bmc.2013.11.044; de Araujo Cintia F, 2014, BMC Res Notes, V7, P70, DOI 10.1186/1756-0500-7-70; de Oliveira GG, 2017, PLANTA MED, V83, P636, DOI 10.1055/s-0042-118712; de Souza W, 2009, INT J BIOCHEM CELL B, V41, P2069, DOI 10.1016/j.biocel.2009.04.007; Demarque DP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58046-y; Cataneo AHD, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108745; Feresin GE, 2003, J ETHNOPHARMACOL, V88, P241, DOI 10.1016/S0378-8741(03)00258-7; Flora do Brasil, 2018, FLOR BRAS CONN SUB P; Fonseca-Silva F, 2015, J NAT PROD, V78, P880, DOI 10.1021/acs.jnatprod.5b00011; Frisch M, 2016, GAUSSIAN 16 REVISION; Gasparotto A, 2005, QUIM NOVA, V28, P575, DOI 10.1590/S0100-40422005000400003; Ghorbani M, 2018, DRUG DES DEV THER, V12, P25, DOI 10.2147/DDDT.S146521; Inacio JDF, 2012, EXP PARASITOL, V132, P151, DOI 10.1016/j.exppara.2012.06.008; Kulshrestha A, 2013, PARASITOL RES, V112, P825, DOI 10.1007/s00436-012-3212-3; Lage PS, 2015, PARASITOL RES, V114, P4625, DOI 10.1007/s00436-015-4708-4; Mendes EA, 2016, CHEM-BIOL INTERACT, V256, P16, DOI 10.1016/j.cbi.2016.06.018; Merten C, 2019, J ORG CHEM, V84, P8797, DOI 10.1021/acs.joc.9b00466; Militao GCG, 2007, BIOORGAN MED CHEM, V15, P6687, DOI 10.1016/j.bmc.2007.08.011; Fidalgo LM, 2011, PHARM RES-DORDR, V28, P2758, DOI 10.1007/s11095-011-0586-3; Morimoto M, 2017, CHEM BIODIVERS, V14, DOI 10.1002/cbdv.201700324; Nafie LA, 2006, HDB VIBRATIONAL SPEC, DOI [10.1002/0470027320.s0503, DOI 10.1002/0470027320.S0503]; Pan American Health Organization, 2019, LEISHM EP REP AM DEC; Antinarelli LMR, 2019, J PHARM PHARMACOL, V71, P1854, DOI 10.1111/jphp.13177; Antinarelli LMR, 2016, EXP PARASITOL, V171, P10, DOI 10.1016/j.exppara.2016.10.009; Menna-Barreto RFS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/614014; Sangenito LS, 2018, INT J ANTIMICROB AG, V52, P185, DOI 10.1016/j.ijantimicag.2018.03.021; Selvaraj S, 2015, PROG LIPID RES, V58, P1, DOI 10.1016/j.plipres.2014.11.002; Silva RL, 2020, MOLECULES, V25, DOI 10.3390/molecules25173978; Soyer TG, 2019, EXP PARASITOL, V199, P30, DOI 10.1016/j.exppara.2019.02.019; Takahashi M, 2006, CHEM PHARM BULL, V54, P915, DOI 10.1248/cpb.54.915; Tokunaga E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35457-6; Tomas AM, 2013, ANTIOXID REDOX SIGN, V19, P696, DOI 10.1089/ars.2012.4948; Torres-Guerrero Edoardo, 2017, F1000Res, V6, P750, DOI 10.12688/f1000research.11120.1; Uliana SRB, 2018, PARASITOLOGY, V145, P464, DOI 10.1017/S0031182016002523; WHO, 2020, LEISHM OV; World Health Organization, 2020, LEISHMANIASIS; Wu SF, 2011, J NAT PROD, V74, P989, DOI 10.1021/np100871g	49	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241855	10.1371/journal.pone.0241855	http://dx.doi.org/10.1371/journal.pone.0241855			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PV	33156835	gold, Green Published			2023-01-03	WOS:000591376400018
J	Alviset, S; Riller, Q; Aboab, JM; Dilworth, K; Billy, PA; Lombardi, Y; Azzi, M; Vargas, LF; Laine, L; Lermuzeaux, M; Memain, N; Silva, D; Tchoubou, T; Ushmorova, D; Dabbagh, H; Escoda, S; Lefrancois, R; Nardi, A; Ngima, A; Ioos, V				Alviset, Sophie; Riller, Quentin; Aboab, Jerome; Dilworth, Kelly; Billy, Pierre-Antoine; Lombardi, Yannis; Azzi, Mathilde; Ferreira Vargas, Luis; Laine, Laurent; Lermuzeaux, Mathilde; Memain, Nathalie; Silva, Daniel; Tchoubou, Tona; Ushmorova, Daria; Dabbagh, Hanane; Escoda, Simon; Lefrancois, Remi; Nardi, Annelyse; Ngima, Armand; Ioos, Vincent			Continuous Positive Airway Pressure (CPAP) face-mask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: A retrospective cohort study	PLOS ONE			English	Article							NONINVASIVE VENTILATION; MECHANICAL VENTILATION; CLINICAL-PRACTICE; DISTRESS-SYNDROME; DISPERSION	Introduction Because of the COVID-19 pandemic, intensive care units (ICU) can be overwhelmed by the number of hypoxemic patients. Material and methods This single centre retrospective observational cohort study took place in a French hospital where the number of patients exceeded the ICU capacity despite an increase from 18 to 32 beds. Because of this, 59 (37%) of the 159 patients requiring ICU care were referred to other hospitals. From 27th March to 23rd April, consecutive patients who had respiratory failure or were unable to maintain an SpO2 > 90%, despite receiving 10-15 l/min of oxygen with a non-rebreather mask, were treated by continuous positive airway pressure (CPAP) unless the ICU physician judged that immediate intubation was indicated. We describe the characteristics, clinical course, and outcomes of these patients. The main outcome under study was CPAP discontinuation. Results CPAP was initiated in 49 patients and performed out of ICU in 41 (84%). Median age was 65 years (IQR = 54-71) and 36 (73%) were men. Median respiratory rate before CPAP was 36 (30-40) and median SpO2 was 92% (90-95) under 10 to 15 L/min oxygen flow. Median duration of CPAP was 3 days (IQR = 1-5). Reasons for discontinuation of CPAP were: intubation in 25 (51%), improvement in 16 (33%), poor tolerance in 6 (12%) and death in 2 (4%) patients. A decision not to intubate had been taken for 8 patients, including the 2 who died while on CPAP. Two patients underwent less than one hour CPAP for poor tolerance. In the end, 15 (38%) out of 39 evaluable patients recovered with only CPAP whereas 24 (62%) were intubated. Conclusions CPAP is feasible in a non-ICU environment in the context of massive influx of patients. In our cohort up to 1/3 of the patients presenting with acute respiratory failure recovered without intubation.	[Alviset, Sophie; Riller, Quentin; Aboab, Jerome; Lombardi, Yannis; Azzi, Mathilde; Ferreira Vargas, Luis; Laine, Laurent; Lermuzeaux, Mathilde; Memain, Nathalie; Silva, Daniel; Tchoubou, Tona; Ushmorova, Daria; Ioos, Vincent] Hop Delafontaine, Serv Med Intens Reanimat, St Denis, France; [Dilworth, Kelly] Ctr Hosp Univ Grenoble, Serv Anesthesie, La Tronche, France; [Billy, Pierre-Antoine] Hop Delafontaine, Lab Microbiol, St Denis, France; [Dabbagh, Hanane] Hop Delafontaine, Serv Anesthesie, St Denis, France; [Escoda, Simon] Hop Delafontaine, Serv Pediatrie, St Denis, France; [Lefrancois, Remi] Hop Delafontaine, Serv Malad Infect, St Denis, France; [Nardi, Annelyse] Hop Delafontaine, Serv Pneumol, St Denis, France; [Ngima, Armand] Hop Delafontaine, Serv Urgences, St Denis, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Ioos, V (corresponding author), Hop Delafontaine, Serv Med Intens Reanimat, St Denis, France.	vincent.ioos@ch-stdenis.fr	Lombardi, Yannis/AAR-6427-2021	Lombardi, Yannis/0000-0001-9031-1862; RILLER, Quentin/0000-0003-3323-0235; Ioos, Vincent/0000-0001-6959-5602; Dabbagh, Hooshang/0000-0003-2176-4598				Agarwal R, 2006, RESP MED, V100, P2235, DOI 10.1016/j.rmed.2006.03.018; Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Aliberti S, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01935-2020; Antonelli M, 2001, INTENS CARE MED, V27, P1718, DOI 10.1007/s00134-001-1114-4; Antonelli M, 2007, CRIT CARE MED, V35, P18, DOI 10.1097/01.CCM.0000251821.44259.F3; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Caputo ND, 2020, ACAD EMERG MED, V27, P375, DOI 10.1111/acem.13994; Copin MC, 2020, INTENS CARE MED, V46, P1124, DOI 10.1007/s00134-020-06057-8; Crimi C, 2020, MINERVA ANESTESIOL, V86, P1190, DOI 10.23736/S0375-9393.20.14785-0; Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352; Dessap AM, 2019, INTENS CARE MED, V45, P252, DOI 10.1007/s00134-018-5391-6; Ding L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2738-5; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Duca A, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100419; Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255; Esquinas AM, 2014, EUR RESPIR REV, V23, P427, DOI 10.1183/09059180.00009413; Ferreyro BL, 2020, JAMA-J AM MED ASSOC, V324, P57, DOI 10.1001/jama.2020.9524; Frat JP, 2019, LANCET RESP MED, V7, P303, DOI 10.1016/S2213-2600(19)30048-7; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Geng SK, 2020, HEART LUNG, V49, P444, DOI 10.1016/j.hrtlng.2020.03.018; He JL, 2020, RESP MED, V168, DOI 10.1016/j.rmed.2020.105980; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018; Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434; Lawton T, 2020, REDUCED ICU DEMAND E, P2020, DOI [10.1101/2020.06.05.20123307, DOI 10.1101/2020.06.05.20123307]; Leisman DE, 2020, INTENS CARE MED, V46, P1105, DOI 10.1007/s00134-020-06059-6; Luo J, 2014, RESPIROLOGY, V19, P1149, DOI 10.1111/resp.12383; Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825; Nightingale R, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000639; Observatoire Regional de Sante, SURM DUR EP COV 19 D; Oranger M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01692-2020; Radovanovic D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041191; Sarma A, 2020, JAMA INTERN MED, V180, P1539, DOI 10.1001/jamainternmed.2020.3027; Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861; Schunemann HJ, 2020, ANN INTERN MED, V173, P204, DOI 10.7326/M20-2306; Simonds AK, 2010, HEALTH TECHNOL ASSES, V14, P131, DOI 10.3310/hta14460-02; Telias I, 2020, JAMA-J AM MED ASSOC, V323, P2265, DOI 10.1001/jama.2020.8539; Thompson AE, 2020, JAMA INTERN MED, V180, P1537, DOI 10.1001/jamainternmed.2020.3030; Villarreal-Fernandez E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03063-6; Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z; Williamson E., 2020, MEDRXIV, P1, DOI [10.1101/2020.05.06.20092999, 10.1101/2020.05.06.20092999v1]; Winck JC, 2020, PULMONOLOGY, V26, P213, DOI 10.1016/j.pulmoe.2020.04.013; Xu QH, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02991-7	44	34	34	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240645	10.1371/journal.pone.0240645	http://dx.doi.org/10.1371/journal.pone.0240645			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052968	Green Published, gold			2023-01-03	WOS:000581820200018
J	Moreno-Barbosa, F; de Celis-Alonso, B; Moreno-Barbosa, E; Hernandez-Lopez, JM; Geoghegan, T; Ramos-Mendez, J				Moreno-Barbosa, Fernando; de Celis-Alonso, Benito; Moreno-Barbosa, Eduardo; Hernandez-Lopez, Javier Miguel; Geoghegan, Theodore; Ramos-Mendez, Jose			Monte Carlo simulation of the effect of magnetic fields on brachytherapy dose distributions in lung tissue material	PLOS ONE			English	Article							MV RADIOTHERAPY ACCELERATOR; MRI SCANNER; ELECTRON; DOSIMETRY; ALGORITHM; TOMOGRAPHY; DEPOSITION; GEANT4; TOPAS	The aim of this work was to use TOPAS Monte Carlo simulations to model the effect of magnetic fields on dose distributions in brachytherapy lung treatments, under ideal and clinical conditions. Idealistic studies were modeled consisting of either a monoenergetic electron source of 432 keV, or a polyenergetic electron source using the spectrum of secondary electrons produced by(192)Ir gamma-ray irradiation. The electron source was positioned in the center of a homogeneous, lung tissue phantom (rho = 0.26 g/cm(3)). Conversely, the clinical study was simulated using the VariSource VS2000 Ir-192 source in a patient with a lung tumor. Three contoured volumes were considered: the tumor, the planning tumor volume (PTV), and the lung. In all studies, dose distributions were calculated in the presence or absence of a constant magnetic field of 3T. Also, TG-43 parameters were calculated for the VariSource and compared with published data from EGS-brachy (EGSnrc) and PENELOPE. The magnetic field affected the dose distributions in the idealistic studies. For the monoenergetic and poly-energetic studies, the radial distance of the 10% iso-dose line was reduced in the presence of the magnetic field by 64.9% and 24.6%, respectively. For the clinical study, the magnetic field caused differences of 10% on average in the patient dose distributions. Nevertheless, differences in dose-volume histograms were below 2%. Finally, for TG-43 parameters, the dose-rate constant from TOPAS differed by 0.09% +/- 0.33% and 0.18% +/- 0.33% with respect to EGS-brachy and PENELOPE, respectively. The geometry and anisotropy functions differed within 1.2% +/- 1.1%, and within 0.0% +/- 0.3%, respectively. The Lorentz forces inside a 3T magnetic resonance machine during(192)Ir brachytherapy treatment of the lung are not large enough to affect the tumor dose distributions significantly, as expected. Nevertheless, large local differences were found in the lung tissue. Applications of this effect are therefore limited by the fact that meaningful differences appeared only in regions containing air, which is not abundant inside the human.	[Moreno-Barbosa, Fernando; de Celis-Alonso, Benito; Moreno-Barbosa, Eduardo; Hernandez-Lopez, Javier Miguel] Benemerita Univ Autonoma Puebla, Fac Math & Phys Sci, Mexico City, DF, Mexico; [Geoghegan, Theodore] Univ Iowa Hosp & Clin, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Ramos-Mendez, Jose] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA	Benemerita Universidad Autonoma de Puebla; University of Iowa; University of California System; University of California San Francisco	Moreno-Barbosa, E (corresponding author), Benemerita Univ Autonoma Puebla, Fac Math & Phys Sci, Mexico City, DF, Mexico.	emoreno@fcfm.buap.mx	Moreno-Barbosa, Eduardo/AAX-6669-2020; Mendez, Jose Ramos/J-8491-2019; Moreno-Barbosa, Fernando/GYU-2935-2022; , de Celis Alonso Benito/AAP-4512-2021; , db/GRS-6835-2022	Moreno-Barbosa, Eduardo/0000-0002-1114-2640; Mendez, Jose Ramos/0000-0002-8106-5142; , de Celis Alonso Benito/0000-0003-2124-1084; Moreno-Barbosa, Fernando/0000-0003-4001-1671	CONACyT; UCSF School of Medicine; National Cancer Institute [U24 CA215123]; Laboratorio Nacional de Supercomputo del Sureste de Mexico (LNS), a member of the CONACYT national laboratories	CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); UCSF School of Medicine; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Laboratorio Nacional de Supercomputo del Sureste de Mexico (LNS), a member of the CONACYT national laboratories	Authors would like to thank CONACyT for the support of Ph.D. student FMB. JRM was partially funded by UCSF School of Medicine bridge fundingand National Cancer Institute under U24 CA215123 (The TOPAS Tool for Particle Simulation, a Monte Carlo Simulation Tool for Physics, Biology and Clinical Research). The authors thankfully acknowledge computer resources, technical advice and support provided by the Laboratorio Nacional de Supercomputo del Sureste de Mexico (LNS), a member of the CONACYT national laboratories. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afsharpour H, 2012, PHYS MED BIOL, V57, P3273, DOI 10.1088/0031-9155/57/11/3273; Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8; Angelopoulos A, 2000, MED PHYS, V27, P2521, DOI 10.1118/1.1315316; [Anonymous], 2007, ANN THORAC SURG, V83, pS27; BARO J, 1995, NUCL INSTRUM METH B, V100, P31, DOI 10.1016/0168-583X(95)00349-5; Belanger C, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/ab1817; Beld E, 2016, PHYS MED BIOL, V61, P6791, DOI 10.1088/0031-9155/61/18/6791; Berger M.J., 2018, ESTAR PSTAR ASTAR CO; BIELAJEW AF, 1993, MED PHYS, V20, P1171, DOI 10.1118/1.597149; Brown JMC, 2014, NUCL INSTRUM METH B, V338, P77, DOI 10.1016/j.nimb.2014.07.042; Chamberland MJP, 2016, PHYS MED BIOL, V61, P8214, DOI 10.1088/0031-9155/61/23/8214; Chen Y, 2005, MED PHYS, V32, P3810, DOI 10.1118/1.2011091; Earl MA, 2002, MED PHYS, V29, P484, DOI 10.1118/1.1461374; Enger SA, 2012, PHYS MED BIOL, V57, P6269, DOI 10.1088/0031-9155/57/19/6269; FROMSON BH, 1988, THORAX, V43, P120, DOI 10.1136/thx.43.2.120; GBD 2015 Eastern Mediterranean Region Collaborators, 2018, INT J PUBLIC HLTH S1, V63, pS11; Grove O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118261; Hauf S, 2013, IEEE T NUCL SCI, V60, P2966, DOI 10.1109/TNS.2013.2270894; Kirisits C, 2014, RADIOTHER ONCOL, V110, P199, DOI 10.1016/j.radonc.2013.11.002; National Toxicology Program, 2011, Rep Carcinog, V12, P159; O'Brien DJ, 2016, MED PHYS, V43, P4915, DOI 10.1118/1.4959785; Oborn BM, 2014, MED PHYS, V41, DOI 10.1118/1.4871618; Padilla-Cabal F, 2020, MED PHYS, V47, P223, DOI 10.1002/mp.13883; Perl J, 2012, MED PHYS, V39, P6818, DOI 10.1118/1.4758060; Piersimoni P, 2017, MED PHYS, V44, P284, DOI 10.1002/mp.12013; Piersimoni P, 2018, MED PHYS, V45, P3264, DOI 10.1002/mp.12942; Raaijmakers AJE, 2007, PHYS MED BIOL, V52, P4283, DOI 10.1088/0031-9155/52/14/017; Raaijmakers AJE, 2005, PHYS MED BIOL, V50, P1363, DOI 10.1088/0031-9155/50/7/002; Raaymakers BW, 2004, PHYS MED BIOL, V49, P4109, DOI 10.1088/0031-9155/49/17/019; Ricke J, 2005, CHEST, V127, P2237, DOI 10.1378/chest.127.6.2237; Rivard MJ, 2004, MED PHYS, V31, P633, DOI 10.1118/1.1646040; Schneider W, 2013, PHYS MED BIOL, V58, P4255; Schumann J, 2012, PHYS MED BIOL, V57, P3281, DOI 10.1088/0031-9155/57/11/3281; Sempau J, 1997, NUCL INSTRUM METH B, V132, P377, DOI 10.1016/S0168-583X(97)00414-X; Sharma DN, 2011, J CANCER RES THER, V7, P174, DOI 10.4103/0973-1482.82914; Simiele E, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aaedc9; Suntharalingam N., 2005, RAD ONCOLOGY PHYS; Taylor REP, 2007, MED PHYS, V34, P445, DOI 10.1118/1.2400843	38	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2020	15	10							e0238704	10.1371/journal.pone.0238704	http://dx.doi.org/10.1371/journal.pone.0238704			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3WA	33035214	Green Published, gold			2023-01-03	WOS:000581817500058
J	Sadozai, L; Sable, S; Le Roux, E; Coste, P; Guillot, C; Boizeau, P; Berthe-Aucejo, A; Angoulvant, F; Lorrot, M; Bourdon, O; Prot-Labarthe, S				Sadozai, Laily; Sable, Shaya; Le Roux, Enora; Coste, Pierre; Guillot, Clemence; Boizeau, Priscilla; Berthe-Aucejo, Aurore; Angoulvant, Francois; Lorrot, Mathie; Bourdon, Olivier; Prot-Labarthe, Sonia			International consensus validation of the POPI tool (Pediatrics: Omission of Prescriptions and Inappropriate prescriptions) to identify inappropriate prescribing in pediatrics	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; STOPP SCREENING TOOL; ELDERLY-PATIENTS; METOCLOPRAMIDE; CRITERIA	Introduction While drug prescription should be based on established recommendations stemming from clinical trials but in pediatrics, many drugs are used without marketing authorization. Consequently recommendations are often based on clinical experience and the risk of inappropriate prescription (IP) is high. A tool for detecting IP in pediatrics-called POPI (Pediatrics: Omission of Prescriptions and Inappropriate prescriptions)-has been developed in France. However the relevance of its use at an international level is not known. Our aim has been to adapt POPI for a worldwide use. Material and method A two-round Delphi online questionnaire was completed and validated by international experts to identify consensual items. They were asked to rate the validity of each items taking into account the recommendations and practices in their countries. Only propositions obtaining a median score in the upper tertile with an agreement of more than 75% of the panel-for the first round-and 85%-for the second round-were retained. Results Our panel included 11 pharmacists (55%) and 9 physicians (45%). The panelists came from 12 different countries: England, Belgium, Brazil, Canada, China, Ivory Coast, Ireland, Malaysia, Portugal, Switzerland, Turkey and Vietnam. At the end of the first round, of the 105 items of the original POPI tool, 80 items were retained including 16 items reworded and 25 items were deleted. In the second round, 14 experts participated in the study. This final international POPI tool is composed of 73 IP and omissions of prescriptions in the fields of neuropsychiatry, dermatology, infectiology, pneumology, gastroenterology, pain and fever. Discussion and conclusion This study highlights international consensus on prescription practice in pediatrics. The use of this tool in everyday practice could reduce the risk of inappropriate prescription. The impact of the diffusion of POPI tool will be assessed in a prospective multicentric study.	[Sadozai, Laily; Sable, Shaya; Guillot, Clemence; Berthe-Aucejo, Aurore; Bourdon, Olivier; Prot-Labarthe, Sonia] Robert Debre Hosp, AP HP, Pharm Dept, Paris, France; [Le Roux, Enora; Coste, Pierre; Boizeau, Priscilla] Nord Univ Paris, AP HP, Hop Univ Robert Debre, INSERM,CIC 1426,Unite Epidemiol Clin, Paris, France; [Le Roux, Enora; Coste, Pierre; Boizeau, Priscilla; Berthe-Aucejo, Aurore; Prot-Labarthe, Sonia] Univ Paris, INSERM, ECEVE, UMR 1123, Paris, France; [Angoulvant, Francois] Hop Necker Enfants Malad, AP HP, Paris, France; [Lorrot, Mathie] Trousseau Hosp, AP HP, Paris, France; [Bourdon, Olivier] Paris Descartes Univ, Clin Pharm, Paris, France; [Bourdon, Olivier] Paris XIII Univ, Educ & Hlth Practices, Bobigny, France; [Prot-Labarthe, Sonia] Soc Francaise Pharm Clin, Pediat Grp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Sadozai, L (corresponding author), Robert Debre Hosp, AP HP, Pharm Dept, Paris, France.	sadozai.laily@gmail.com	Bourdon, Olivier/AHA-7107-2022	Sadozai, Laily/0000-0001-6844-4503; Le Roux, Enora/0000-0002-2238-7133; Berthe-Aucejo, Aurore/0000-0002-9457-6996				Angoulvant F, 2010, EUR J EPIDEMIOL, V25, P593, DOI 10.1007/s10654-010-9480-2; [Anonymous], INDICATION SPECIALIT; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2019, RECOMMANDATIONS VACC; [Anonymous], NOUVELLES RECOMMANDA; Barry E, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012079; Benjamin L, 2018, PEDIATRIC MEDICATION, V141, P10; Berthe-Aucejo A, 2019, INT J CLIN PHARM-NET, V41, P734, DOI 10.1007/s11096-019-00819-1; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Gallagher P, 2009, AGE AGEING, V38, P603, DOI 10.1093/ageing/afp058; Hondeghem LM, 2013, J CARDIOVASC PHARM, V61, P218, DOI 10.1097/FJC.0b013e31827afd0d; Impicciatore P, 2001, BRIT J CLIN PHARMACO, V52, P77, DOI 10.1046/j.0306-5251.2001.01407.x; Karpman E, 2004, J UROLOGY, V172, P448, DOI 10.1097/01.ju.0000130653.74548.d6; Kenney C, 2008, J CLIN PHARMACOL, V48, P379, DOI 10.1177/0091270007312258; Kurian J, 2016, INDIAN J PEDIATR, V83, P414, DOI 10.1007/s12098-015-2002-1; Lancet Global Health, 2019, LANCET GLOBAL HLTH, V7, pe1; McMahon AW, 2020, PEDIAT INTERNET, P145; MILLER LG, 1989, ARCH INTERN MED, V149, P2486, DOI 10.1001/archinte.149.11.2486; Morris AD, 2016, CAN J HOSP PHARM, V69, P224; pediatrie S canadienne de, PEDIATRIE S CANADIEN; Prot-Labarthe S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101171; Shah SS, 2007, ARCH PEDIAT ADOL MED, V161, P282, DOI 10.1001/archpedi.161.3.282; Svendsen K, 2018, EUR J CLIN PHARMACOL, V74, P627, DOI 10.1007/s00228-017-2407-z; Thiesen S, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-237; Yis U, 2005, EUR J EMERG MED, V12, P117, DOI 10.1097/00063110-200506000-00004	30	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2020	15	10							e0240105	10.1371/journal.pone.0240105	http://dx.doi.org/10.1371/journal.pone.0240105			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OB4VZ	33017423	Green Published, gold			2023-01-03	WOS:000578470500031
J	Hoang, TN; Pino, M; Boddapati, AK; Viox, EG; Starke, CE; Upadhyay, AA; Gumber, S; Nekorchuk, M; Busman-Sahay, K; Strongin, Z; Harper, JL; Tharp, GK; Pellegrini, KL; Kirejczyk, S; Zandi, K; Tao, SJ; Horton, TR; Beagle, EN; Mahar, EA; Lee, MYH; Cohen, J; Jean, SM; Wood, JS; Connor-Stroud, F; Stammen, RL; Delmas, OM; Wang, S; Cooney, KA; Sayegh, MN; Wang, LF; Filev, PD; Weiskopf, D; Silvestri, G; Waggoner, J; Piantadosi, A; Kasturi, SP; Al-Shakhshir, H; Ribeiro, SP; Sekaly, RP; Levit, RD; Estes, JD; Vanderford, TH; Schinazi, RF; Bosinger, SE; Paiardini, M				Hoang, Timothy N.; Pino, Maria; Boddapati, Arun K.; Viox, Elise G.; Starke, Carly E.; Upadhyay, Amit A.; Gumber, Sanjeev; Nekorchuk, Michael; Busman-Sahay, Kathleen; Strongin, Zachary; Harper, Justin L.; Tharp, Gregory K.; Pellegrini, Kathryn L.; Kirejczyk, Shannon; Zandi, Keivan; Tao, Sijia; Horton, Tristan R.; Beagle, Elizabeth N.; Mahar, Ernestine A.; Lee, Michelle Y. H.; Cohen, Joyce; Jean, Sherrie M.; Wood, Jennifer S.; Connor-Stroud, Fawn; Stammen, Rachelle L.; Delmas, Olivia M.; Wang, Shelly; Cooney, Kimberly A.; Sayegh, Michael N.; Wang, Lanfang; Filev, Peter D.; Weiskopf, Daniela; Silvestri, Guido; Waggoner, Jesse; Piantadosi, Anne; Kasturi, Sudhir P.; Al-Shakhshir, Hilmi; Ribeiro, Susan P.; Sekaly, Rafick P.; Levit, Rebecca D.; Estes, Jacob D.; Vanderford, Thomas H.; Schinazi, Raymond F.; Bosinger, Steven E.; Paiardini, Mirko			Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques	CELL			English	Article							RIG-I; EXPRESSION; INFECTION; COVID-19; MILD; SARS	SARS-CoV-2-induced hypercytokinemia and inflammation are critically associated with COVID-19 severity. Baricitinib, a clinically approved JAK1/JAK2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages, and tissues was not reduced with baricitinib. Type I interferon (IFN) antiviral responses and SARS-CoV-2-specific T cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib-treated animals had a rapid and remarkably potent suppression of lung macrophage production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.	[Hoang, Timothy N.; Pino, Maria; Viox, Elise G.; Strongin, Zachary; Harper, Justin L.; Mahar, Ernestine A.; Lee, Michelle Y. H.; Delmas, Olivia M.; Wang, Shelly; Silvestri, Guido; Kasturi, Sudhir P.; Vanderford, Thomas H.; Bosinger, Steven E.; Paiardini, Mirko] Emory Univ, Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30329 USA; [Boddapati, Arun K.; Upadhyay, Amit A.; Tharp, Gregory K.; Pellegrini, Kathryn L.; Horton, Tristan R.; Beagle, Elizabeth N.; Bosinger, Steven E.] Emory Univ, Yerkes Natl Primate Res Ctr, Yerkes Genom Core Lab, Atlanta, GA 30329 USA; [Starke, Carly E.; Nekorchuk, Michael; Busman-Sahay, Kathleen; Estes, Jacob D.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; [Gumber, Sanjeev; Silvestri, Guido; Piantadosi, Anne; Ribeiro, Susan P.; Sekaly, Rafick P.; Schinazi, Raymond F.; Bosinger, Steven E.; Paiardini, Mirko] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Gumber, Sanjeev; Kirejczyk, Shannon] Emory Univ, Yerkes Natl Primate Res Ctr, Div Pathol, Atlanta, GA 30329 USA; [Zandi, Keivan; Tao, Sijia; Schinazi, Raymond F.] Emory Univ, Ctr AIDS Res, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Cohen, Joyce; Jean, Sherrie M.; Wood, Jennifer S.; Connor-Stroud, Fawn; Stammen, Rachelle L.] Emory Univ, Yerkes Natl Primate Res Ctr, Div Anim Resources, Atlanta, GA 30329 USA; [Cooney, Kimberly A.; Sayegh, Michael N.; Wang, Lanfang; Waggoner, Jesse; Piantadosi, Anne; Levit, Rebecca D.] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; [Filev, Peter D.] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA; [Weiskopf, Daniela] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA; [Al-Shakhshir, Hilmi; Ribeiro, Susan P.; Sekaly, Rafick P.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Estes, Jacob D.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA	Emory University; Emory University; Oregon Health & Science University; Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; La Jolla Institute for Immunology; Case Western Reserve University; Oregon Health & Science University; Oregon National Primate Research Center	Bosinger, SE; Paiardini, M (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Div Microbiol & Immunol, Atlanta, GA 30329 USA.; Bosinger, SE (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Yerkes Genom Core Lab, Atlanta, GA 30329 USA.; Schinazi, RF; Bosinger, SE; Paiardini, M (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.; Schinazi, RF (corresponding author), Emory Univ, Ctr AIDS Res, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.	rschina@emory.edu; steven.bosinger@emory.edu; mirko.paiardini@emory.edu	Upadhyay, Amit/R-5056-2019; Boddapati, Arun/AIA-0658-2022	Upadhyay, Amit/0000-0002-0952-4164; Boddapati, Arun Kumar/0000-0002-7661-8443; Cohen, Joyce/0000-0001-9194-6640; Starke, Carly Elizabeth/0000-0002-9548-9368; Sayegh, Michael/0000-0002-6280-101X; Hoang, Timothy/0000-0002-7781-1130; Pino Claveria, Maria/0000-0003-4954-5215; Gumber, Sanjeev/0000-0001-9048-2717	Emory University COVID-19 Molecules and Pathogens to Populations and Pandemics Initiative Seed Grant; YNPRC Coronavirus Pilot Research Project [P51 OD11132]; National Institute of Allergy and Infectious Diseases (NIAID, NIH) [R37AI141258, R01AI116379, R01MH116695, R01AI143411, R01HL140223, R01AI149672, U24AI120134]; NIH Office of Research Infrastructure Programs (ORIP) [P51OD11132, P51OD011092, 1S10OD025002-01, P30 AI050409, 75N9301900065]; NIH [P51OD011132, S10OD026799]; Fast Grants Award [2144]	Emory University COVID-19 Molecules and Pathogens to Populations and Pandemics Initiative Seed Grant; YNPRC Coronavirus Pilot Research Project; National Institute of Allergy and Infectious Diseases (NIAID, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH Office of Research Infrastructure Programs (ORIP)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fast Grants Award	We thank the Yerkes National Primate Research Center (YNPRC) Division of Animal Resources, especially Stephanie Ehnert, Stacey Weissman, Denise Bonenberger, John M. Wambua, Dominic M. D'Urso, Racquel Sampson-Harley, and Kalpana Patel in Research Resources for providing support in animal care. We thank Nichole Arnett for assistance with clinical pathology assays and Kevin Nguyen for additional laboratory processing. We thank Dr. Vincent Marconi for discussions and critical reading of the manuscript. Pharmaceutical-grade baricitinib was commercially obtained, provided free of charge by Dr. Schinazi, and it was found to be >99% pure by LC-MS-MS. This study was supported by an Emory University COVID-19 Molecules and Pathogens to Populations and Pandemics Initiative Seed Grant to M. Paiardini, A.P., and R.F.S.; by YNPRC Coronavirus Pilot Research Project Program grant to M. Paiardini under award P51 OD11132; and by Fast Grants Award #2144 to M. Paiardini. This work was additionally funded by the National Institute of Allergy and Infectious Diseases (NIAID, NIH) under awards R37AI141258 and R01AI116379 to M. Paiardini, R01MH116695 to R.F.S, R01AI143411, R01HL140223 to R.D.L., and R01AI149672 to J.D.E., and U24AI120134 to S.E.B. Support for this work was also provided by award NIH Office of Research Infrastructure Programs (ORIP) P51OD11132 to YNPRC, P51OD011092 to ONPRC, 1S10OD025002-01 to the Integrated Pathology Core/ONPRC, NIAID award P30 AI050409 to the Center for AIDS Research (CFAR) at Emory University, and contract Nr. 75N9301900065 (to D.W.). Next-generation sequencing services were provided by the Yerkes NHP Genomics Core, which is supported in part by NIH P51OD011132. Sequencing data were acquired on an Illumina NovaSeq6000 funded by NIH S10OD026799 to S.E.B. Pictorial illustrations were created with BioRender. com. The content of this publication does not necessarily reflect the views or policies of the U.S. Department of Health and Human Services nor does it imply endorsement of organizations or commercial products.	Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006; Bronte V, 2020, J CLIN INVEST, V130, P6409, DOI 10.1172/JCI141772; Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Chertow DS, 2016, ANTIVIR RES, V129, P120, DOI 10.1016/j.antiviral.2016.02.013; Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4; Coronavirus Disease, 2019, CORONAVIRUS DIS 2019; Davidson AD, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00763-0; De Lang A, 2007, PLOS PATHOG, V3, P1129, DOI 10.1371/journal.ppat.0030112; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Estes JD, 2018, NAT REV IMMUNOL, V18, P390, DOI 10.1038/s41577-018-0005-7; Finak G, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0844-5; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Harper J, 2020, NAT MED, V26, P519, DOI 10.1038/s41591-020-0782-y; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Kasturi SP, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1025; Keystone EC, 2015, ANN RHEUM DIS, V74, P333, DOI 10.1136/annrheumdis-2014-206478; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Love M.I., 2014, GENOME BIOL, V15, P550, DOI [10.1186/s13059-014-0550-8, DOI 10.1186/S13059-014-0550-8]; McGary CS, 2017, IMMUNITY, V47, P776, DOI 10.1016/j.immuni.2017.09.018; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Micci L, 2015, J CLIN INVEST, V125, P4497, DOI 10.1172/JCI81400; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Munster VJ, 2020, NATURE, V585, P268, DOI [10.1038/s41586-020-2324-7, 10.1101/2020.03.21.001628]; Nganou-Makamdop K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007246; Palesch D, 2018, NATURE, V553, P77, DOI 10.1038/nature25140; Pino M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008081; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Satija R., 2018, R PACKAGE VERSION 2; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Sievert C, 2020, INTERACTIVE WEBBASED; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Skendros P, 2020, J CLIN INVEST, V130, P6151, DOI 10.1172/JCI141374; Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang NLS, 2005, CLIN CHEM, V51, P2333, DOI 10.1373/clinchem.2005.054460; Titanji BK, 2021, CLIN INFECT DIS, V72, P1247, DOI 10.1093/cid/ciaa879; Waggoner JJ, 2020, EMERG INFECT DIS, V26, P1633, DOI 10.3201/eid2607.201285; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4; Williamson BN, 2020, NATURE, V585, P273, DOI 10.1038/s41586-020-2423-5; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zevini A, 2017, TRENDS IMMUNOL, V38, P194, DOI 10.1016/j.it.2016.12.004; ZHENG GX, 2017, NATURE, V0008	56	92	92	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2021	184	2					460	+		10.1016/j.cell.2020.11.007	http://dx.doi.org/10.1016/j.cell.2020.11.007		JAN 2021	37	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY8KT	33278358	Bronze, Green Published			2023-01-03	WOS:000612290800017
J	Zivich, PN; Huang, W; Walsh, A; Dutta, P; Eisenberg, M; Aiello, AE				Zivich, Paul N.; Huang, Will; Walsh, Ali; Dutta, Prabal; Eisenberg, Marisa; Aiello, Allison E.			Measuring office workplace interactions and hand hygiene behaviors through electronic sensors: A feasibility study	PLOS ONE			English	Article							INFECTIOUS-DISEASES; CONTACT DIARIES; TRANSMISSION	Office-based workplaces are an important but understudied context for infectious disease transmission. We examined the feasibility of two different sensors (Opos and Bluetooth beacons) for collecting person-to-person contacts and hand hygiene in office-based workplaces. Opo is an interaction sensor that captures sensor-to-sensor interactions through ultrasonic frequencies, which correspond to face-to-face contacts between study participants. Opos were additionally used to measure hand hygiene events by affixing sensors to soap and alcohol-based hand sanitizer dispensers. Bluetooth beacons were used in conjunction with a smartphone application and recorded proximity contacts between study participants. Participants in two office sites were followed for one-week in their workplace in March 2018. Contact patterns varied by time of day and day of the week. Face-to-face contacts were of shorter mean duration than proximity contacts. Supervisors had fewer proximity contacts but more face-to-face contacts than non-supervisors. Self-reported hand hygiene was substantively higher than sensor-collected hand hygiene events and duration of hand washing events was short (median: 9 seconds, range: 2.5-33 seconds). Given that office settings are key environments in which working age populations spend a large proportion of their time and interactions, a better characterization of empirical social networks and hand hygiene behaviors for workplace interactions are needed to mitigate outbreaks and prepare for pandemics. Our study demonstrates that implementing sensor technologies for tracking interactions and behaviors in offices is feasible and can provide new insights into real-world social networks and hygiene practices. We identified key social interactions, variability in hand hygiene, and differences in interactions by workplace roles. High-resolution network data will be essential for identifying the most effective ways to mitigate infectious disease transmission and develop pandemic preparedness plans for the workplace setting.	[Zivich, Paul N.; Aiello, Allison E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Zivich, Paul N.; Aiello, Allison E.] Carolina Populat Ctr, Chapel Hill, NC 27516 USA; [Huang, Will; Dutta, Prabal] Univ Calif Berkley, Coll Engn, Berkeley, CA USA; [Walsh, Ali] Univ Michigan, Sch Nursing, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA; [Eisenberg, Marisa] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Aiello, AE (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Aiello, AE (corresponding author), Carolina Populat Ctr, Chapel Hill, NC 27516 USA.	aaiello@unc.edu	Walsh, Alison (Ali) R./ABF-3163-2021	Walsh, Alison (Ali) R./0000-0002-6123-5730	GOJO Industries Incorporated; National Institute of Child Health and Human Development [T32HD091058]	GOJO Industries Incorporated; National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This study was funded by a financial gift from GOJO Industries Incorporated (http://gojo.com/en?sc_lang=en) awarded to Allison E Aiello. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. National Institute of Child Health and Human Development, T32HD091058, Paul N Zivich.	[Anonymous], 2019, AM TIM US SURV SUMM; BROUGHALL JM, 1984, J HOSP INFECT, V5, P447, DOI 10.1016/0195-6701(84)90016-1; Contzen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136445; Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P751, DOI 10.15585/mmwr.mm6924e1; DeMaio T., 1984, SURVEYING SUBJECTIVE, P257, DOI 10.2458/v7i2.20321; Ellingson K, 2014, INFECT CONT HOSP EP, V35, P937, DOI [10.1086/677145, 10.1017/S0899823X00193900]; Ferguson N, 2007, NATURE, V446, P733, DOI 10.1038/446733a; Funk S, 2015, EPIDEMICS-NETH, V10, P21, DOI 10.1016/j.epidem.2014.09.005; Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460; Hovi T, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0691-4; Jenner EA, 2006, J HOSP INFECT, V63, P418, DOI 10.1016/j.jhin.2006.03.012; Larson EL, 2004, ASSESSING NURSES HAN; Leecaster M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153690; Machinery AfC, 2014; Mastrandrea Rossana, 2015, BMC Res Notes, V8, P426, DOI 10.1186/s13104-015-1409-0; Mastrandrea R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136497; Nematian SSS, 2017, AM J INFECT CONTROL, V45, pE65, DOI 10.1016/j.ajic.2017.03.007; Read JM, 2012, EPIDEMIOL INFECT, V140, P2117, DOI 10.1017/S0950268812000842; Smieszek T, 2012, EPIDEMIOL INFECT, V140, P744, DOI 10.1017/S0950268811001130; Smieszek T, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1676-y; Smieszek T, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-136; Surgeoner BV, 2009, J ENVIRON HEALTH, V72, P24; Swoboda SM, 2004, CRIT CARE MED, V32, P358, DOI 10.1097/01.CCm.0000108866.48795.0F; Thumma J, 2009, AM J INFECT CONTROL, V37, P70, DOI 10.1016/j.ajic.2007.12.008; VanderWeele TJ, 2019, INT J EPIDEMIOL, V48, P1032, DOI 10.1093/ije/dyz010; Venkatesh AK, 2008, AM J INFECT CONTROL, V36, P199, DOI 10.1016/j.ajic.2007.11.005; Zivich PN, 2018, AM J INFECT CONTROL, V46, P448, DOI 10.1016/j.ajic.2017.10.006	27	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0243358	10.1371/journal.pone.0243358	http://dx.doi.org/10.1371/journal.pone.0243358			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY3TH	33465139	Green Published, gold			2023-01-03	WOS:000611969200043
J	Vega-Solano, J; Blanco-Metzler, A; Madriz-Morales, K; Fernandes-Nilson, EA; Labonte, ME				Vega-Solano, Jaritza; Blanco-Metzler, Adriana; Madriz-Morales, Karol; Fernandes-Nilson, Eduardo-Augusto; Labonte, Marie Eve			Impact of salt intake reduction on CVD mortality in Costa Rica: A scenario modelling study	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE; CANCER; DIET	Cardiovascular diseases (CVD) represent the leading cause of death in Costa Rica and high blood pressure was associated with a mortality rate of 29% in 2018. The average household sodium intake in the country is also two times higher than the World Health Organization recommendation. The objective of this study was to estimate the impact of reducing salt intake on CVD mortality in Costa Rica using a scenario simulation model. The Preventable Risk Integrated ModEl (PRIME) was used to estimate the number of deaths that would be averted or delayed in the Costa Rican population by following the national and the international guidelines to reduce salt consumption, according to two scenarios: A) 46% reduction and B) 15% reduction, both at an energy intake of 2171 kcal. The scenarios estimated that between 4% and 13%, respectively, of deaths due to CVD would be prevented or postponed. The highest percentages of deaths prevented or postponed by type of CVD would be related to Coronary heart disease (39% and 38%, respectively), Hypertensive disease (32% and 33%, respectively), and Stroke (22% in both). The results demonstrate that reducing salt consumption could prevent or postpone an important number of deaths in Costa Rica. More support for existing policies and programs urges.	[Vega-Solano, Jaritza; Blanco-Metzler, Adriana; Madriz-Morales, Karol] Costa Rican Inst Res & Teaching Nutr & Hlth INCIE, Tres Rios, Cartago, Costa Rica; [Fernandes-Nilson, Eduardo-Augusto] Univ Sao Paulo, Ctr Epidemiol Res Hlth & Nutr, Sao Paulo, SP, Brazil; [Labonte, Marie Eve] Univ Laval, Ctr Nutr Sante & Soc NUTRISS, Inst Nutr & Funct Foods INAF, Quebec City, PQ, Canada	Universidade de Sao Paulo; Laval University	Blanco-Metzler, A (corresponding author), Costa Rican Inst Res & Teaching Nutr & Hlth INCIE, Tres Rios, Cartago, Costa Rica.	ablanco@inciensa.sa.cr		Labonte, Marie-Eve/0000-0001-9745-0443	IDRC PROJECT [108167]; International Development Reserch Center of Canada	IDRC PROJECT; International Development Reserch Center of Canada	A.B.M. awarded IDRC PROJECT 108167, from "The International Development Reserch Center of Canada". Website: https://www.idrc.ca/en The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshin A, 2019, LANCET, V393, P1958, DOI 10.1016/S0140-6736(19)30041-8; Belanger M, 2014, PUBLIC HEALTH, V128, P222, DOI 10.1016/j.puhe.2013.11.003; Blanco-Metzler A, 2016, IMPLEMENTACION PROGR; Blanco-Metzler A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9091020; Brouillard AM, 2019, AM J MED, V132, P1199, DOI 10.1016/j.amjmed.2019.04.040; Caja Costarricense del Seguro Social, 2011, VIG FACT RIESG CARD, P41; Castro B.V., 2017, THESIS; Colin-Ramirez Eloisa, 2017, Nutrients, V9, DOI 10.3390/nu9080810; Egnell M, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0817-2; He FJ, 2009, J HUM HYPERTENS, V23, P363, DOI 10.1038/jhh.2008.144; Laatikainen T, 2006, EUR J CLIN NUTR, V60, P965, DOI 10.1038/sj.ejcn.1602406; Laatikainen T, 2005, AM J EPIDEMIOL, V162, P764, DOI 10.1093/aje/kwi274; Labonte ME, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226975; Mill José Geraldo, 2019, Rev. bras. epidemiol., V22, pE190009.SUPL.2, DOI 10.1590/1980-549720190009.supl.2; Ministerio de Salud Costa, 2011, PLAN NAT DEV SAN, P3; Moreira PVL, 2018, PUBLIC HEALTH NUTR, V21, P181, DOI 10.1017/S1368980017002063; Neupane D, 2020, J CLIN HYPERTENS, V22, P273, DOI 10.1111/jch.13813; Nilson EAF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235514; Organizacion Panamericana de la Salud, 2018, SHAKE MEN SAL MAS SA; Organization W. H, 2020, H DEMENTIA; Pan American Health Organization (PAHO), 2013, SALT SMART AM GUID C, P91; Pietinen P, 2010, PUBLIC HEALTH NUTR, V13, P901, DOI 10.1017/S1368980010001072; Saha S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061434; Saha S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16050890; Sarno F, 2013, REV SAUDE PUBL, V47, P571, DOI 10.1590/S0034-8910.2013047004418; Scarborough P, 2014, SCIENTIFICA, V2014, DOI 10.1155/2014/748750; Scarborough P, 2012, J EPIDEMIOL COMMUN H, V66, P420, DOI 10.1136/jech.2010.114520; Webb M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6699; WHO, 2017, TACKLING NCDS BEST B; WHO, ICD 11 MORT MORB STA; World Health Organization, 2012, GUID SOD INT AD CHIL; World Health Organization, 2018, NONCOMMUNICABLE DIS	33	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2021	16	1							e0245388	10.1371/journal.pone.0245388	http://dx.doi.org/10.1371/journal.pone.0245388			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4SP	33434241	Green Published, gold			2023-01-03	WOS:000609979700032
J	Shin, JH; Takada, D; Morishita, T; Lin, HR; Bun, S; Teraoka, E; Okuno, T; Itoshima, H; Nagano, H; Kishimoto, K; Segawa, H; Asami, Y; Higuchi, T; Minato, K; Kunisawa, S; Imanaka, Y				Shin, Jung-ho; Takada, Daisuke; Morishita, Tetsuji; Lin, Hueiru; Bun, Seiko; Teraoka, Emi; Okuno, Takuya; Itoshima, Hisashi; Nagano, Hiroyuki; Kishimoto, Kenji; Segawa, Hiromi; Asami, Yuka; Higuchi, Takuya; Minato, Kenta; Kunisawa, Susumu; Imanaka, Yuichi			Economic impact of the first wave of the COVID-19 pandemic on acute care hospitals in Japan	PLOS ONE			English	Article								Background In response to the coronavirus diseases 2019 (COVID-19) pandemic, the Japanese government declared a state of emergency on April 7, 2020. Six days earlier, the Japan Surgical Society had recommended postponing elective surgical procedures. Along with the growing public fear of COVID-19, hospital visits in Japan decreased. Methods Using claims data from the Quality Indicator/Improvement Project (QIP) database, this study aimed to clarify the impact of the first wave of the pandemic, considered to be from March to May 2020, on case volume and claimed hospital charges in acute care hospitals during this period. To make year-over-year comparisons, we considered cases from July 2018 to June 2020. Results A total of 2,739,878 inpatient and 53,479,658 outpatient cases from 195 hospitals were included. In the year-over-year comparisons, total claimed hospital charges decreased in April, May, June 2020 by 7%, 14%, and 5%, respectively, compared to the same months in 2019. Our results also showed that per-case hospital charges increased during this period, possibly to compensate for the reduced case volumes. Regression results indicated that the hospital charges in April and May 2020 decreased by 6.3% for hospitals without COVID-19 patients. For hospitals with COVID-19 patients, there was an additional decrease in proportion with the length of hospital stay of COVID-19 patients including suspected cases. The mean additional decrease per COVID-19 patient was estimated to 5.5 million JPY. Conclusion It is suggested that the hospitals treating COVID-19 patients were negatively incentivized.	[Shin, Jung-ho; Takada, Daisuke; Morishita, Tetsuji; Lin, Hueiru; Bun, Seiko; Teraoka, Emi; Okuno, Takuya; Itoshima, Hisashi; Nagano, Hiroyuki; Kishimoto, Kenji; Segawa, Hiromi; Asami, Yuka; Higuchi, Takuya; Minato, Kenta; Kunisawa, Susumu; Imanaka, Yuichi] Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan; [Bun, Seiko] Natl Ctr Child Hlth & Dev Hosp, Dept Pharm, Tokyo, Japan	Kyoto University	Imanaka, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Healthcare Econ & Qual Management, Kyoto, Japan.	imanaka-y@umin.net	Yuichi, Imanaka/GYR-2098-2022; KUNISAWA, Susumu/HCH-1094-2022; SHIN, Jung-ho/HCH-1481-2022	Yuichi, Imanaka/0000-0003-4613-2159; Higuchi, Takuya/0000-0003-0757-1650; Segawa, Hiromi/0000-0003-4038-1189; Lin, Huei-Ru/0000-0001-7149-208X	JSPS KAKENHI from the Japan Society for the Promotion of Science [JP19H01075]; Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan [20HA2003]; GAP Fund Program of Kyoto University, GAP Fund Program Type B	JSPS KAKENHI from the Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); GAP Fund Program of Kyoto University, GAP Fund Program Type B	This study was supported by JSPS KAKENHI Grant Numbers JP19H01075 from the Japan Society for the Promotion of Science (https://www.jsps.go.jp/english/e-grants/), Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan, Grant Numbers 20HA2003 (https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hokabunya/kenkyujigyou/index.html), and by GAP Fund Program of Kyoto University, GAP Fund Program Type B (http://www.venture.saci.kyoto-u.ac.jp/? page_id=83#gp) to Y. I. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Surgeons, 2020, COVID 19 GUID TRIAG; American Hospital Association, 2020, HOSP HLTH SYST FAC U; [Anonymous], 2020, LANCET MICROBE, V1, pe99, DOI 10.1016/S2666-5247(20)30054-9; Best MJ, 2020, SURGERY, V168, P962, DOI 10.1016/j.surg.2020.07.014; Boserup B, 2021, AM J EMERG MED, V45, P530, DOI 10.1016/j.ajem.2020.07.007; California Health Care Foundation, 2020, FIN IMP COVID 19 CAL; Japan Surgical Society, 2020, REC SURG PAT COVID 1; Japanese Association of Medical Care Corporations, 2020, REP SURV STAT HOSP M; Khullar D, 2020, JAMA-J AM MED ASSOC, V323, P2127, DOI 10.1001/jama.2020.6269; Ministry of Health Labour and Welfare, 2018, DYN SURV MED I HOSP; Ministry of Health Labour and Welfare, 2020, DES HOSP PAT NOV COR; Ministry of Health Labour and Welfare, 2020, CURR SIT JAP; Ministry of Health Labour and Welfare, 2020, REP SURV DISCH PAT S; Ministry of Health Labour and Welfare, 2020, GUID SURV ASS EFF IN; Ministry of Health Labour and Welfare, 2020, TEMP REV NAT FEE SCH; Ministry of Health Labour and Welfare, 2020, TEMP REV NAT FEE SCH; Prime Minister of Japan and His Cabinet, 2020, DECL STAT EM RESP NO; Prime Minister of Japan and His Cabinet, 2020, DECL LIFT STAT EM RE; Prime Minister of Japan and His Cabinet, 2020, DECL STAT EM RESP NO; Sakamoto H, 2018, JAPAN HLTH SYSTEM RE, P121; Shimizu K, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3221; U.S. Department of Health & Human Services, 2020, CAR ACT REL FUND	22	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244852	10.1371/journal.pone.0244852	http://dx.doi.org/10.1371/journal.pone.0244852			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382838	Green Published, Green Submitted, gold			2023-01-03	WOS:000605651900043
J	Methangkool, E; Cole, DJ; Cannesson, M				Methangkool, Emily; Cole, Daniel J.; Cannesson, Maxime			Progress in Patient Safety in Anesthesia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint describes the history of patient safety improvements in the practice of anesthesiology, with a shift in focus from reducing procedural mortality to improving systems, including optimization of teamwork, communication, interdisciplinary care, and standards for new technologies.	[Methangkool, Emily; Cole, Daniel J.; Cannesson, Maxime] Univ Calif Los Angeles, Dept Anesthesiol & Perioperat Med, Los Angeles, CA USA	University of California System; University of California Los Angeles	Cannesson, M (corresponding author), UCLA, Dept Anesthesiol & Perioperat Med, David Geffen Sch Med, 757Westwood Plaza, Los Angeles, CA 90095 USA.	mcannesson@mednet.ucla.edu			National Institutes of Health [R01 HL144692, R01 EB029751]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work is supported by grants R01 HL144692 and R01 EB029751 from the National Institutes of Health.	BEECHER HK, 1954, ANN SURG, V140, P2, DOI 10.1097/00000658-195407000-00001; Cline KM, 2020, J CLIN ANESTH, V63, DOI 10.1016/j.jclinane.2020.109760; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Li G, 2009, ANESTHESIOLOGY, V110, P759, DOI 10.1097/ALN.0b013e31819b5bdc; Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952; Muller M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022202; Pollard RJ, 2018, ANESTH ANALG, V127, P730, DOI 10.1213/ANE.0000000000003483; Ramsingh D, 2015, ANESTHESIOLOGY, V123, P670, DOI 10.1097/ALN.0000000000000776; World Health Organization, 2019, PATIENT SAFETY	9	3	3	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	2020	324	24					2485	2486		10.1001/jama.2020.23205	http://dx.doi.org/10.1001/jama.2020.23205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PO2FZ	33351053				2023-01-03	WOS:000604986900016
J	Helgoy, KV; Smeby, JC; Bonsaksen, T; Olsen, NR				Helgoy, Kjersti Velde; Smeby, Jens-Christian; Bonsaksen, Tore; Rydland Olsen, Nina			Research-based occupational therapy education: An exploration of students' and faculty members' experiences and perceptions	PLOS ONE			English	Article							UNDERGRADUATE RESEARCH EXPERIENCES; ACADEMICS PERCEPTIONS; ATTITUDES; KNOWLEDGE; ENVIRONMENT; BARRIERS	Introduction One argument for introducing research in bachelor`s degree in health care is to ensure the quality of future health care delivery. The requirements for research-based education have increased, and research on how research-based education is experienced is limited, especially in bachelor health care education programmes. The aim of this study was to explore how occupational therapy students and faculty members experienced and perceived research-based education. Methods This qualitative, interpretative description consisted of three focus group interviews with occupational therapy students in their final year (n = 8, 6 and 4), and three focus group interviews with faculty members affiliated with occupational therapy programmes in Norway (n = 5, 2 and 5). Interviewing both students and faculty members enabled us to explore the differences in their experiences and perceptions. Results Five integrative themes emerged from the analysis: "introducing research early", "setting higher expectations", "ensuring competence in research methods", "having role models" and "providing future best practice". Research was described as an important aspect of the occupational therapy bachelor program as it helps ensure that students achieve the necessary competence for offering future best practice. Students expressed a need to be introduced to research early in the program, and they preferred to have higher expectations regarding use of research. Competence in research methods and the importance of role models were also highlighted. Conclusions Undergraduate health care students are expected to be competent in using research. Findings from our study demonstrated that the participants perceived the use of research during training as important to ensure future best practice. Increasing the focus on research in the programme's curricula and efforts to improve students' formal training in research-specific skills could be a starting point towards increased use of research in the occupational therapy profession.	[Helgoy, Kjersti Velde] VID Specialized Univ, Ctr Diakonia & Profess Practice, Stavanger, Norway; [Smeby, Jens-Christian] OsloMet Oslo Metropolitan Univ, Ctr Study Profess, Oslo, Norway; [Bonsaksen, Tore] Inland Norway Univ Appl Sci, Fac Social & Hlth Sci, Dept Hlth & Nursing Sci, Elverum, Norway; [Bonsaksen, Tore] VID Specialized Univ, Fac Hlth Studies, Sandnes, Norway; [Rydland Olsen, Nina] Western Norway Univ Appl Sci, Fac Hlth & Social Sci, Dept Hlth & Functioning, Bergen, Norway	VID Specialised University; Oslo Metropolitan University (OsloMet); Inland Norway University of Applied Sciences; VID Specialised University; Western Norway University of Applied Sciences	Helgoy, KV (corresponding author), VID Specialized Univ, Ctr Diakonia & Profess Practice, Stavanger, Norway.	kjersti.velde.helgoy@vid.no	Bonsaksen, Tore/U-5148-2018	Bonsaksen, Tore/0000-0001-6315-1111; Olsen, Nina Rydland/0000-0002-5173-1597; Helgoy, Kjersti Velde/0000-0001-9615-9881				[Anonymous], 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14123; [Anonymous], 2015, JMIR MED INFORM, V3, pe22; [Anonymous], 2017, FORSKRIFT TILSYN MED, V2-3; [Anonymous], 2018, 7 SER FPGAS DAT SHEE, V2, P1; [Anonymous], 2016, EVIDENCE, V8, pe1000; Auchincloss LC, 2014, CBE-LIFE SCI EDUC, V13, P29, DOI 10.1187/cbe.14-01-0004; Brew A, 2017, TEACH HIGH EDUC, V22, P551, DOI 10.1080/13562517.2016.1273216; Chang YJ, 2015, ACAD MED, V90, P1162, DOI 10.1097/ACM.0000000000000702; Deicke W., 2014, CUR Q, V35, P27; Griffiths R, 2004, STUD HIGH EDUC, V29, P709, DOI 10.1080/0307507042000287212; Halabi JO., 2016, SAUDI J HLTH SCI, V5, P118, DOI [10. 4103/2278-0521. 195813, DOI 10.4103/2278-0521.195813, 10.4103/2278-0521.195813]; Healey Mick, 2005, RESHAPING U NEW RELA, P67, DOI DOI 10.1371/JOURNAL.PMED.0020124; Healey Mick., 2009, HIGH EDUC; Huet I, 2018, EUR J ENG EDUC, V43, P725, DOI 10.1080/03043797.2017.1415299; Jackson L, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.72S1-PO8029; Jenkins A., 2015, COUNC UNDERGRAD RES, V35, P31; Jenkins A., 2007, LINKING RES TEACHING; Jenkins A, 2013, UNIVERSITY TEACHING IN FOCUS: A LEARNING-CENTRED APPROACH, P128; Johansson B, 2010, J NURS MANAGE, V18, P70, DOI 10.1111/j.1365-2834.2009.01060.x; Kamwendo K, 2001, SCAND J CARING SCI, V15, P295, DOI 10.1046/j.1471-6712.2001.00041.x; Kandell GV, 2019, MED STUDENTS UNDERST, P1; Keib CN, 2017, NURS EDUC TODAY, V54, P37, DOI 10.1016/j.nedt.2017.04.007; Krueger R., 2014, PRACTICAL GUIDE APPL; Kunnskapsdepartementet, 2017, KULT KVAL HOYER UTD, P130; Kyvik S., 2014, FORSKNINGSBASERT UTD; Kyvik S, 2015, VOCATIONAL PROFESSIO, P105; Leach MJ, 2016, J CLIN NURS, V25, P194, DOI 10.1111/jocn.13103; Lomborg K., 2010, KLIN SYGEPLEJE, V24, P7; Lopatto D., 2010, SCI SOLUTION IMPACT; Malterud K., 2018, FOKUSGRUPPER SOM FOR; McCluskey A., 2003, AUST OCCUP THER J, V50, P3, DOI [10.1046/j.1440-1630.2003.00303.x, DOI 10.1046/J.1440-1630.2003.00303.X]; Ofsted, 2016, UNKN CHILDR DEST DIS; Olsen NR, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-52; Ordinetz SA., 2009, THESIS; Ozay SB, 2012, TEACH HIGH EDUC, V17, P453, DOI 10.1080/13562517.2011.641009; Paudel S, 2019, MED STUDENTS KNOWLED, P162; Rodenbusch SE, 2016, CBE-LIFE SCI EDUC, V15, DOI 10.1187/cbe.16-03-0117; Ross JG, 2019, NURS EDUC TODAY, V82, P79, DOI 10.1016/j.nedt.2019.08.006; Ryan EJ, 2016, J CLIN NURS, V25, P1548, DOI 10.1111/jocn.13229; Sabzwari S, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-68; Samuelsson K, 2015, BRIT J OCCUP THER, V78, P175, DOI 10.1177/0308022615569511; Smyth L, 2016, HIGH EDUC, V72, P191, DOI 10.1007/s10734-015-9945-z; Stronge M, 2012, OCCUP THER INT, V19, P7, DOI 10.1002/oti.328; Stube JE, 2007, AM J OCCUP THER, V61, P53, DOI 10.5014/ajot.61.1.53; Thorne S, 2016, DEV QUAL INQ, V2; Trowler P., 2007, TRIBES TERRITORIES R; Upton D, 2014, BRIT J OCCUP THER, V77, P24, DOI 10.4276/030802214X13887685335544; Utdannings- og forskningsdepartementet, 2005, RAMM ERG, P1; Utdanningsforbundet, 2020, TID FORSK UTV KARTL; Vereijken MWC, 2018, ADV HEALTH SCI EDUC, V23, P371, DOI 10.1007/s10459-017-9803-0; VID Specialized University, 2012, FAGPL BACH ERG 180 S; Visser-Wijnveen G., 2013, INTEGRATIE ONDERZOEK; Walkington H, 2011, J GEOGR HIGHER EDUC, V35, P315, DOI 10.1080/03098265.2011.563377; Wilson A, 2012, STUD HIGH EDUC, V37, P513, DOI 10.1080/03075079.2010.527933	54	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2020	15	12							e0243544	10.1371/journal.pone.0243544	http://dx.doi.org/10.1371/journal.pone.0243544			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PL4CD	33347466	Green Published, gold			2023-01-03	WOS:000603071100004
J	Bajcar, EA; Wiercioch-Kuzianik, K; Farley, D; Adamczyk, WM; Buglewicz, E; Babel, P				Bajcar, Elzbieta A.; Wiercioch-Kuzianik, Karolina; Farley, Dominika; Adamczyk, Waclaw M.; Buglewicz, Ewa; Babel, Przemyslaw			One of us or one of them? The effects of the model's and observer's characteristics on placebo analgesia induced by observational learning	PLOS ONE			English	Article							PEER MODELS; PAIN; CONFORMITY; SEX; POWER; RACE; FEAR; IMITATION; PRESSURE; GENDER	Previous studies have proved that observational learning can induce placebo analgesia, but the factors that influence observationally induced placebo analgesia have not yet been extensively examined. The primary goal of this study was to investigate the effect of information about the role that the observed person (model) plays in the experiment on the magnitude of the observationally induced placebo effect. This study also examined the contribution of the observer's empathy, conformity and fear of pain to the placebo analgesia induced by observational learning. The effects induced in two experimental groups and one control group were compared. Participants in the experimental groups observed a model introduced as either another participant taking part in the study or a coworker of the experimenter. The model rated the intensity of pain induced by electrocutaneous stimuli preceded by color stimuli. One-half of all participants watched a model rating pain stimuli preceded by the color orange as higher than stimuli preceded by the color blue; for the other half, the ratings were the opposite. There was no observation in the control group. Subsequently, all participants received pain stimuli of the same intensity preceded by orange and blue stimuli and rated the intensity of the experienced pain. Placebo analgesia was found in both experimental groups. However, the way the observed model was introduced to participants did not affect the magnitude of placebo analgesia. Thus, the study showed that the role played by the model is not crucial for observationally induced placebo analgesia. The examined observer's individual characteristics did not predict the magnitude of placebo effect.	[Bajcar, Elzbieta A.; Wiercioch-Kuzianik, Karolina; Farley, Dominika; Buglewicz, Ewa; Babel, Przemyslaw] Jagiellonian Univ, Inst Psychol, Pain Res Grp, Krakow, Poland; [Adamczyk, Waclaw M.] Jerzy Kukuczka Acad Phys Educ, Dept Kinesiotherapy & Special Methods Physiothera, Katowice, Poland	Jagiellonian University; Akademia Wychowania Fizycznego im. Jerzego Kukuczki w Katowicach	Bajcar, EA (corresponding author), Jagiellonian Univ, Inst Psychol, Pain Res Grp, Krakow, Poland.	elzbieta.bajcar@uj.edu.pl	Adamczyk, Waclaw M./X-5590-2018	Adamczyk, Waclaw M./0000-0001-8941-8355; Wiercioch-Kuzianik, Karolina/0000-0003-1480-6569; Farley, Dominika/0000-0001-9173-324X	National Science Centre in Poland [2016/23/B/HS6/03890]	National Science Centre in Poland(National Science Centre, Poland)	The study was funded by the National Science Centre in Poland (www.ncn.gov.pl) under the grant no. 2016/23/B/HS6/03890 obtained by PB.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASCH SE, 1956, PSYCHOL MONOGR, V70, P1, DOI 10.1037/h0093718; Bajcar EA, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02041; Bandura A., 1994, ENCY HUMAN BEHAV, V4, P71; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bandura A., 1971, SOCIAL LEARNING THEO; Berger S. M., 1977, SOCIAL COMP PROCESSE, P209; Bobier DM, 2002, EASURE SUSCEPTIBILIT; BREYER NL, 1970, PSYCHOL REP, V27, P639, DOI 10.2466/pr0.1970.27.2.639; BRODY GH, 1985, J GENET PSYCHOL, V146, P161, DOI 10.1080/00221325.1985.9914443; BUSSEY K, 1984, J PERS SOC PSYCHOL, V47, P1292, DOI 10.1037/0022-3514.47.6.1292; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033; Davis M. H., 1980, JSAS CATALOG SELECTE, V10, P1, DOI DOI 10.1037/0022-3514.44.1.113; Egorova N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16809; Epley N, 1999, J EXP SOC PSYCHOL, V35, P578, DOI 10.1006/jesp.1999.1390; Faasse K, 2016, CURR DIR PSYCHOL SCI, V25, P438, DOI 10.1177/0963721416657316; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gibson SJ, 2001, CLIN GERIATR MED, V17, P433, DOI 10.1016/S0749-0690(05)70079-3; Gierthmuhlen J, 2015, PAIN, V156, P2203, DOI 10.1097/j.pain.0000000000000227; GUDJONSSON GH, 1989, PERS INDIV DIFFER, V10, P535, DOI 10.1016/0191-8869(89)90035-4; Haun DBM, 2011, CHILD DEV, V82, P1759, DOI 10.1111/j.1467-8624.2011.01666.x; Hunter T, 2014, EUR J PAIN, V18, P914, DOI 10.1002/j.1532-2149.2013.00436.x; Kamierczak Maria., 2007, PRZEGLAD PSYCHOLOGIC, V50, P9; Karunanayake D, 2004, CAREER DEV Q, V52, P225, DOI 10.1002/j.2161-0045.2004.tb00644.x; Koban L, 2016, EMOTION, V16, P24, DOI 10.1037/emo0000087; Lamm C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001292; Lautenbacher S, 2005, PAIN, V115, P410, DOI 10.1016/j.pain.2005.03.025; LIRGG CD, 1991, RES Q EXERCISE SPORT, V62, P217, DOI 10.1080/02701367.1991.10608713; Lyby PS, 2011, PAIN, V152, P2405, DOI 10.1016/j.pain.2011.07.010; Lyby PS, 2010, J PSYCHOSOM RES, V68, P369, DOI 10.1016/j.jpsychores.2009.10.009; MCCULLAGH P, 1986, J SPORT PSYCHOL, V8, P319, DOI 10.1123/jsp.8.4.319; McNeil DW, 1998, J BEHAV MED, V21, P389, DOI 10.1023/A:1018782831217; Miller FG, 2008, J ROY SOC MED, V101, P222, DOI 10.1258/jrsm.2008.070466; MISCHEL W, 1966, J PERS SOC PSYCHOL, V3, P197, DOI 10.1037/h0022883; Mitsikostas DD, 2020, J HEADACHE PAIN, V21, DOI 10.1186/s10194-020-01178-3; Morrison I, 2013, HUM BRAIN MAPP, V34, P1982, DOI 10.1002/hbm.22040; Osborn Jody, 2010, Pain, V148, P268, DOI 10.1016/j.pain.2009.11.007; PARADISE LV, 1986, J COUNS PSYCHOL, V33, P16; Peirce J, 2019, BEHAV RES METHODS, V51, P195, DOI 10.3758/s13428-018-01193-y; PERRY DG, 1975, J PERS SOC PSYCHOL, V31, P1083, DOI 10.1037/h0076944; Polczyk R, 2007, MECH EFEKTU DEZINFOR, DOI [10.1080/02770900701209772, DOI 10.1080/02770900701209772]; SCHUNK DH, 1987, REV EDUC RES, V57, P149, DOI 10.3102/00346543057002149; SIMON B, 1990, EUR J SOC PSYCHOL, V20, P269; SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01; Swider K, 2013, PAIN, V154, P1312, DOI 10.1016/j.pain.2013.04.001; THELEN MH, 1971, CHILD DEV, V42, P972, DOI 10.1111/j.1467-8624.1971.tb03717.x; Turner J.C., 1991, MAPPING SOCIAL PSYCH; Vandenbroucke S, 2014, FRONT HUM NEUROSCI, P8, DOI [10.3389/fnhum.2014.00008, DOI 10.3389/FNHUM.2014.00008]; Vogtle E, 2016, J PAIN RES, V9, P241, DOI 10.2147/JPR.S96228; Vogtle E, 2013, PAIN, V154, P1427, DOI 10.1016/j.pain.2013.04.041; Wheeler L, 2005, HDB COMPETENCE MOTIV, P566; Wiercioch-Kuzianik K, 2019, PAIN MED, V20, P1955, DOI 10.1093/pm/pny285; WOODROW KM, 1972, PSYCHOSOM MED, V34, P548, DOI 10.1097/00006842-197211000-00007; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2020	15	12							e0243996	10.1371/journal.pone.0243996	http://dx.doi.org/10.1371/journal.pone.0243996			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH1IW	33326481	Green Published, gold			2023-01-03	WOS:000600176400059
J	Melkie, G; Azage, M; Gedamu, G				Melkie, Gashaw; Azage, Muluken; Gedamu, Genet			Prevalence and associated factors of active trachoma among children aged 1-9 years old in mass drug administration graduated and non-graduated districts in Northwest Amhara region, Ethiopia: A comparative cross-sectional study	PLOS ONE			English	Article							FACIAL CLEANLINESS; WATER; ZONE; RISK	Background Mass drug administration has implemented to reduce trachoma since 2001, however, trachoma is still the major public health problem in Amhara Region, Ethiopia. However, credible evidence on the prevalence of trachoma and its associated factors after the implementation of mass drug administration is limited. Objective To assess the prevalence and associated factors of active trachoma among children aged 1-9 years old in mass drug administration graduated and non-graduated districts in the Northwest Amhara Region. Methods A comparative cross-sectional study was conducted from October to November, 2019. A stratified multistage random sampling was used to select 690 households having children aged 1-9 years. Data were collected using a pretested structured questionnaire. Data were entered into Epi-data version 3.1 and exported to SPSS version 20.0 for analysis. Bivariate and multivariable logistic regressions were employed to identify factors associated with active trachoma. Crude and adjusted odds ratios with 95% confidence interval were computed to assess the degree of association between the independent variables and active trachoma. Results The overall prevalence of active trachoma was 8.3% (95% CI: 6.2% -10.5%) and showed a significant variation between graduated [3.5% (95% CI: 1.8% -5.6%)] and non-graduated [13% (95% CI: 9.7%-16.8%)] districts. Living in graduated districts (AOR = 7.39, 95% CI: 3.19, 17.09), fly presence in the house (AOR = 3.14, 95% CI: 1.43, 6.89), presence of more than two children in the family (AOR = 3.78, 95%CI: 1.79, 7.98), did not wash face daily (AOR = 6.31, 95% CI: 1.81, 21.98), did not use soap during face washing (AOR = 3.34, 95% CI: 1.37, 8.15), presence of sleep in eyes (AOR = 3.16, 95% CI: 1.42, 7.02) and presence of dirt on child face (AOR = 2.44, 95% CI: 1.08, 5.50) increased the odds of having active trachoma. Conclusion The prevalence of active trachoma was high in the study area and showed a significant variation between graduated and non-graduated districts with mass drug administration. Living in non-graduated districts, fly presence in the house, more than two children in a household, did not wash the face daily, did not use soap during face washing, presence of sleep in eyes, and dirt on the child's face were the significant predictors of active trachoma. Therefore, the identified modifiable factors are the area of intervention to reduce the burden of active trachoma.	[Melkie, Gashaw; Gedamu, Genet] Teda Hlth Sci Coll, Sch Publ Hlth, Dept Environm Hlth, Gondar, Ethiopia; [Azage, Muluken; Gedamu, Genet] Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Environm Hlth, Bahir Dar, Ethiopia	Bahir Dar University	Gedamu, G (corresponding author), Bahir Dar Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Dept Environm Hlth, Bahir Dar, Ethiopia.	geni_31280@yahoo.com	Azage, Muluken/AAF-6515-2020	Azage, Muluken/0000-0003-3222-0158	Bahir Dar University; Amhara Regional Health Bureau	Bahir Dar University; Amhara Regional Health Bureau	This research work is funded by Bahir Dar University and Amhara Regional Health Bureau.	Alemayehu M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/570898; Miller HA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229297; [Anonymous], 2014, Wkly Epidemiol Rec, V89, P421; [Anonymous], 2007, J ORTHOP TRAUMA, V21, pS39; [Anonymous], 2018, J ORTHOP TRAUMA, V32, pS141; Anteneh Zelalem Alamrew, 2016, Trop Dis Travel Med Vaccines, V2, P5, DOI 10.1186/s40794-016-0022-0; Asres M, 2016, PREV MED, V1, P5; Astale T, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006270; BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J; Bamani S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000734; BRECHNER RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P687, DOI 10.1001/archopht.1992.01080170109035; Burton MJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000460; Central Gondar Zonal Health Department, 2018, CENTR GOND ZON DISTR; Delea MG, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006178; Frick KD, 2003, OPHTHAL EPIDEMIOL, V10, P121, DOI 10.1076/opep.10.2.121.13899; Golovaty I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006702; Kalua K., 2014, Health, V6, P57, DOI 10.4236/health.2014.61009; Kassim K, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3992-5; Ketema K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1105; Lakew T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000507; Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494; Mengistu K, 2016, CLIN OPHTHALMOL, V10, P1663, DOI 10.2147/OPTH.S107619; Missamou F, 2018, OPHTHAL EPIDEMIOL, V25, P155, DOI 10.1080/09286586.2018.1546878; Mpyet C, 2018, OPHTHAL EPIDEMIOL, V25, P79, DOI 10.1080/09286586.2018.1467466; Mpyet C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040421; Nigusie Adane, 2015, BMC Res Notes, V8, P641, DOI 10.1186/s13104-015-1529-6; Oswald .WE, 2017, B WORLD HEALTH ORGAN, V95, P250, DOI [10.2471/BLT.16.177758, 10.2471/blt.16.177758]; Roba AA, 2011, J EPIDEMIOL COMMUN H, V65, P626, DOI 10.1136/jech.2009.094763; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; Stewart AEP, 2019, AM J TROP MED HYG, V101, P1286, DOI 10.4269/ajtmh.19-0450; Tadesse B, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0358-3; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855, DOI 10.1001/archopht.1991.01080060119038; WHO, TRACHOMA; WHO, 2016, VAL EL TRACH PUBL HL; WoldeKidan E, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4495-0; World Health Organization, 1998, WHA51 11 GLOB EL BLI; World Health Organization, 2015, PROGR SAN DRINK WAT; Yemane Berhane, 2007, Ethiopian Journal of Health Development, V21, P204; Zack R, 2008, T ROY SOC TROP MED H, V102, P426, DOI 10.1016/j.trstmh.2008.02.001	40	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2020	15	12							e0243863	10.1371/journal.pone.0243863	http://dx.doi.org/10.1371/journal.pone.0243863			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH3TP	33320864	Green Published, gold			2023-01-03	WOS:000600339800039
J	Irons, JY; Garip, G; Cross, AJ; Sheffield, D; Bird, J				Irons, J. Yoon; Garip, Gulcan; Cross, Ainslea J.; Sheffield, David; Bird, Jamie			An integrative systematic review of creative arts interventions for older informal caregivers of people with neurological conditions	PLOS ONE			English	Review							DEMENTIA; HEALTH; EXPERIENCES; QUALITY; DISEASE; CARERS	Objective We aimed to assess and synthesise the current state of quantitative and qualitative research concerning creative arts interventions for older informal caregivers of people with neurological conditions. Methods A systematic search was employed to identify studies that examined creative arts interventions for older informal caregivers, which were synthesised in this integrative review. We searched the following databases: MEDLINE, PubMed, EBSCO, CINAHL, EMBASE, PsycINFO, Cochrane Library, Scopus, Web of Science, and Google Scholar. We also backwards searched references of all relevant studies and inspected trials registers. Results Of the 516 studies identified, 17 were included: one was quantitative, nine were qualitative and seven used mixed methods. All included quantitative studies were pilot or feasibility studies employing pre- and post-test design with small sample sizes. Studies varied in relation to the type of creative intervention and evaluation methods, which precluded meta-analysis. Large effect sizes were detected in wellbeing measures following singing and art interventions. The qualitative synthesis highlighted that interventions created space for caregivers to make sense of, accept and adapt to their identity as a caregiver. Personal developments, such as learning new skills, were viewed positively by caregivers as well as welcoming the opportunity to gain cognitive and behavioural skills, and having opportunities to unload emotions in a safe space were important to caregivers. Group creative interventions were particularly helpful in creating social connections with their care-recipients and other caregivers. Conclusions The current review revealed all creative interventions focused on caregivers of people living with dementia; subsequently, this identified gaps in the evidence of creative interventions for informal caregivers of other neurological conditions. There are encouraging preliminary data on music and art interventions, however, little data exists on other art forms, e.g., drama, dance. Creative interventions may appeal to many caregivers, offering a range of psycho-social benefits. The findings of the current review open the way for future research to develop appropriate and creative arts programmes and to test their efficacy with robust tools.	[Irons, J. Yoon; Garip, Gulcan; Cross, Ainslea J.; Sheffield, David; Bird, Jamie] Univ Derby, Coll Hlth Psychol & Social Care, Derby, England	University of Derby	Irons, JY (corresponding author), Univ Derby, Coll Hlth Psychol & Social Care, Derby, England.	y.irons@derby.ac.uk	Bird, Jamie/AAA-2794-2019	Cross, Ainslea/0000-0001-5465-3283; Garip, Gulcan/0000-0002-7887-3798; Irons, Jung Yoon/0000-0003-4806-5885; Bird, Jamie/0000-0002-2481-1583; Sheffield, David/0000-0001-9121-1783	University of Derby Library service	University of Derby Library service	The authors have received no funding for undertaking this review. We wish to thank the University of Derby Library service for their support with the searches.	Abraham C, 2014, JAIDS-J ACQ IMM DEF, V66, pS293, DOI 10.1097/QAI.0000000000000231; All-Party Parliamentary Group on Arts Health Wellbeing, 2017, CREAT HLTH ARTS HLTH; [Anonymous], 2018, J NUCL MED, V59, p9N; Baker F., 2012, AUSTR J MUSIC THERAP, V23, P4; Baker FA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00151; Baker FA, 2018, BRIT J MUSIC THER, V32, P8, DOI 10.1177/1359457517728914; Barron F., 1969, CREATIVE PERSON CREA; Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443; Boivin A, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k5147; Bourne P., 2019, J AGING STUDIES THER, P1; Boyatzis RE, 1998, TRANSFORMING QUALITA, DOI [10.1080/00221329809596155, DOI 10.1080/00221329809596155]; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Burnside LD, 2015, DEMENTIA, V16, P29; Cameron M, 2013, PERSPECT PUBLIC HEAL, V133, P52, DOI 10.1177/1757913912466951; Camic P. M., 2011, DEMENTIA, V12, P157, DOI DOI 10.1177/1471301211422761; Camic PM, 2016, GERONTOLOGIST, V56, P1033, DOI 10.1093/geront/gnv063; Camic PM, 2014, AGING MENT HEALTH, V18, P161, DOI 10.1080/13607863.2013.818101; Carers UK, 2016, STATE OF CARING; Cash Therese Verkerke, 2015, BMC Psychol, V3, P44, DOI 10.1186/s40359-015-0101-4; Clark IN, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01332; Cohen J., 2013, STAT POWER ANAL BEHA; Cohn MA, 2009, EMOTION, V9, P361, DOI 10.1037/a0015952; Corbin J., 1996, QUAL INQ, V2, P139, DOI DOI 10.1177/107780049600200201; Cross AJ, 2018, PSYCHOL HEALTH, V33, P1321, DOI 10.1080/08870446.2018.1496250; Csikszentmihalyi M., 1996, CREATIVITY FLOW PSYC; Dassa A, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00215; Davidson JW, 2014, PSYCHOL WELL-BEING, V4, DOI 10.1186/s13612-014-0024-5; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Fels DI, 2011, AM J ALZHEIMERS DIS, V26, P535, DOI 10.1177/1533317511429324; Flatt JD, 2015, AM J ALZHEIMERS DIS, V30, P380, DOI 10.1177/1533317514549953; Glaser B. G., 1967, DISCOVERY GROUNDED T; Greenwood N, 2019, MATURITAS, V124, P1, DOI 10.1016/j.maturitas.2019.03.006; Hanser SB, 2011, J MUSIC THER, V48, P2, DOI 10.1093/jmt/48.1.2; Hootman JM, 2011, RES SYNTH METHODS, V2, P110, DOI 10.1002/jrsm.41; Houston E, 2020, 11 ACTIVITIES EXERCI; Kohlbacher F., 2006, QUALITATIVE SOCIAL R, V7, P1, DOI DOI 10.17169/FQS-7.1.75; Lepp M, 2003, J CLIN NURS, V12, P873, DOI 10.1046/j.1365-2702.2003.00801.x; Lewis V, 2015, INT PSYCHOGERIATR, V27, P471, DOI 10.1017/S1041610214001999; Noblit G.W., 1988, METAETHNOGRAPHY SYNT; O'Cathain A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029954; Osman SE, 2016, DEMENTIA-LONDON, V15, P1326, DOI 10.1177/1471301214556291; Richardson M, 2018, ENVIRON HUMANITIES, V10, P1, DOI 10.1215/22011919-4385444; Sarkamo T, 2018, DEMENTIA-LONDON, V17, P670, DOI 10.1177/1471301217729237; Seligman M, 2018, J POSIT PSYCHOL, V13, P333, DOI 10.1080/17439760.2018.1437466; Shaw RL, 2010, DOING QUALITATIVE RE, P39, DOI DOI 10.4135/9781473914209.N5; Singh J, 2013, J PHARMACOL PHARMACO, V4, P76, DOI 10.4103/0976-500X.107697; Smith J. A., 2009, INTERPRETATIVE PHENO; Tamplin J, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00245; Tarr J, 2018, QUAL RES, V18, P36, DOI 10.1177/1468794117694219; Torrance E. P, 1995, WHY FLY PHILOS CREAT; Tyack C, 2017, J APPL GERONTOL, V36, P864, DOI 10.1177/0733464815617287; Unadkat S, 2017, GERONTOLOGIST, V57, P469, DOI 10.1093/geront/gnv698; Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x; WHO, 2006, NEUR DIS PUBL HLTH C; World Health Organization, 2017, GLOB ACT PLAN PUBL H; Zhang Y., 2008, PLOS ONE, V3, pe3933	57	4	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243461	10.1371/journal.pone.0243461	http://dx.doi.org/10.1371/journal.pone.0243461			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PD8LW	33284840	gold, Green Published			2023-01-03	WOS:000597930500012
J	Sampath, R				Sampath, Ramya			Always More to Be Done	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								In this narrative medicine essay a medical student recalls discovering the power of meaningful palliative care, contrasting patients' relief from suffering through caring and comfort with her father's awful experience of pain and neglect in his closing days.	[Sampath, Ramya] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA	University of Rochester	Sampath, R (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.	ramya_sampath@urmc.rochester.edu							0	0	0	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2020	324	21					2159	2160		10.1001/jama.2020.22783	http://dx.doi.org/10.1001/jama.2020.22783			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA4NB	33258893				2023-01-03	WOS:000595613500012
J	Tang, QS; Huang, ZH; Zhou, H; Ye, PJ				Tang, Qishou; Huang, Zhaohui; Zhou, Huan; Ye, Peijie			Effects of music therapy on depression: A meta-analysis of randomized controlled trials	PLOS ONE			English	Article							CANCER-PATIENTS; OLDER-PEOPLE; ANXIETY; SYMPTOMS; IMPACT; INTERVENTIONS; DISORDERS; COGNITION; DEMENTIA; MEDICINE	Background We aimed to determine and compare the effects of music therapy and music medicine on depression, and explore the potential factors associated with the effect. Methods PubMed (MEDLINE), Ovid-Embase, the Cochrane Central Register of Controlled Trials, EMBASE, Web of Science, and Clinical Evidence were searched to identify studies evaluating the effectiveness of music-based intervention on from inception to May 2020. Standardized mean differences (SMDs) were estimated with random-effect model and fixed-effect model. Results A total of 55 RCTs were included in our meta-analysis. Music therapy exhibited a significant reduction in depressive symptom (SMD = -0.66; 95% CI = -0.86 to -0.46; P<0.001) compared with the control group; while, music medicine exhibited a stronger effect in reducing depressive symptom (SMD = -1.33; 95% CI = -1.96 to -0.70; P<0.001). Among the specific music therapy methods, recreative music therapy (SMD = -1.41; 95% CI = -2.63 to -0.20; P<0.001), guided imagery and music (SMD = -1.08; 95% CI = -1.72 to -0.43; P<0.001), music-assisted relaxation (SMD = -0.81; 95% CI = -1.24 to -0.38; P<0.001), music and imagery (SMD = -0.38; 95% CI = -0.81 to 0.06; P = 0.312), improvisational music therapy (SMD = -0.27; 95% CI = -0.49 to -0.05; P = 0.001), music and discuss (SMD = -0.26; 95% CI = -1.12 to 0.60; P = 0.225) exhibited a different effect respectively. Music therapy and music medicine both exhibited a stronger effects of short and medium length compared with long intervention periods. Conclusions A different effect of music therapy and music medicine on depression was observed in our present meta-analysis, and the effect might be affected by the therapy process.	[Tang, Qishou; Zhou, Huan; Ye, Peijie] Bengbu Med Univ, Bengbu, Anhui, Peoples R China; [Huang, Zhaohui] Anhui Prov Ctr Women & Child Hlth, Hefei, Anhui, Peoples R China; [Zhou, Huan] Bengbu Med Univ, Natl Drug Clin Trial Inst, Affiliated Hosp 1, Bengbu, Anhui, Peoples R China	Bengbu Medical College; Bengbu Medical College	Ye, PJ (corresponding author), Bengbu Med Univ, Bengbu, Anhui, Peoples R China.	459695783@qq.com			Education Department of Anhui Province [SK2017A0191]; Anhui Provincial Federation of Social Sciences [2018XF155]; Ministry of Education of the People's Republic of China [17YJC840033]	Education Department of Anhui Province; Anhui Provincial Federation of Social Sciences; Ministry of Education of the People's Republic of China(Ministry of Education, China)	The Key Project of University Humanities and Social Science Research in Anhui Province (SK2017A0191) was granted by Education Department of Anhui Province; the Research Project of Anhui Province Social Science Innovation Development (2018XF155) was granted by Anhui Provincial Federation of Social Sciences; the Ministry of Education Humanities and Social Sciences Research Youth fund Project (17YJC840033) was granted by Ministry of Education of the People's Republic of China. These funders had a role in study design, text editing, interpretation of results, decision to publish and preparation of the manuscript.	Albornoz Y, 2011, NORD J MUSIC THER, V20, P208, DOI 10.1080/08098131.2010.522717; American Music Therapy Association, 2020, DEF QUOT MUS THER; Biasutti M, 2021, INT J AGING HUM DEV, V92, P115, DOI 10.1177/0091415019893988; Bradt J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006911.pub3; Bradt J, 2015, SUPPORT CARE CANCER, V23, P1261, DOI 10.1007/s00520-014-2478-7; Bruscia KE, 2014, DEFINING MUSIC THERA, DOI [10.1182/blood-2013-06-507582, DOI 10.1182/BLOOD-2013-06-507582]; Burrai F, 2020, J CARD FAIL, V26, P541, DOI 10.1016/j.cardfail.2019.12.005; Burrai F, 2019, BIOL RES NURS, V21, P30, DOI 10.1177/1099800418802638; Chan MF, 2012, J CLIN NURS, V21, P776, DOI 10.1111/j.1365-2702.2011.03954.x; Chan MF, 2010, COMPLEMENT THER MED, V18, P150, DOI 10.1016/j.ctim.2010.02.004; Chan MF, 2009, INT J MENT HEALTH NU, V18, P285, DOI 10.1111/j.1447-0349.2009.00614.x; Chang MY, 2008, J CLIN NURS, V17, P2580, DOI 10.1111/j.1365-2702.2007.02064.x; Chen CJ, 2019, J ADV NURS, V75, P1911, DOI 10.1111/jan.13975; Chen CJ, 2015, INT J NURS PRACT, V21, P192, DOI 10.1111/ijn.12236; Chen SC, 2020, SUPPORT CARE CANCER, V28, P351, DOI 10.1007/s00520-019-04817-x; Chen SC, 2018, SUPPORT CARE CANCER, V26, P461, DOI 10.1007/s00520-017-3850-1; Chen XJ, 2016, INT J OFFENDER THER, V60, P1064, DOI 10.1177/0306624X15572795; Chen YJ, 2021, AGING MENT HEALTH, V25, P773, DOI 10.1080/13607863.2019.1704219; Cheung AT, 2019, PSYCHO-ONCOLOGY, V28, P174, DOI 10.1002/pon.4929; Chirico A, 2020, J CELL PHYSIOL, V235, P5353, DOI 10.1002/jcp.29422; Choi AN, 2008, J ALTERN COMPLEM MED, V14, P567, DOI 10.1089/acm.2008.0006; Chu H, 2014, BIOL RES NURS, V16, P209, DOI 10.1177/1099800413485410; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Cooke M, 2010, J HEALTH PSYCHOL, V15, P765, DOI 10.1177/1359105310368188; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Erkkila J, 2011, BRIT J PSYCHIAT, V199, P132, DOI 10.1192/bjp.bp.110.085431; Esfandiari N, 2014, ART PSYCHOTHER, V41, P211, DOI 10.1016/j.aip.2014.02.001; Fancourt D, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026995; Fancourt D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151136; Giovagnoli AR, 2017, NEUROL SCI, V38, P1485, DOI 10.1007/s10072-017-3003-9; Gramaglia C, 2019, CRIT REV ONCOL HEMAT, V138, P241, DOI 10.1016/j.critrevonc.2019.04.004; Guetin S, 2009, DEMENT GERIATR COGN, V28, P36, DOI 10.1159/000229024; HANSER SB, 1994, J GERONTOL, V49, pP265, DOI 10.1093/geronj/49.6.P265; Harmat L, 2008, J ADV NURS, V62, P327, DOI 10.1111/j.1365-2648.2008.04602.x; Hars M, 2014, AGE AGEING, V43, P196, DOI 10.1093/ageing/aft163; Hendricks C. B., 2001, DISS ABSTR INT, V62, P472; HENDRICKS C. B., 1999, J HUMANISTIC COUNSEL, V38, P39, DOI [10.1002/j.2164-490X.1999.tb00160.x, DOI 10.1002/J.2164-490X.1999.TB00160.X]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Kishita N, 2020, J GERIATR PSYCH NEUR, V33, P28, DOI 10.1177/0891988719856690; Koelsch S, 2010, MUSIC PERCEPT, V27, P307, DOI 10.1525/MP.2010.27.4.307; Leubner D, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01109; Li HC, 2019, GERIATR NURS, V40, P510, DOI 10.1016/j.gerinurse.2019.03.017; Liao J, 2018, CHIN J INTEGR MED, V24, P343, DOI 10.1007/s11655-017-2956-0; Liao SJ, 2019, GERIATR NURS, V40, P154, DOI 10.1016/j.gerinurse.2018.08.001; Liao SJ, 2018, ISSUES MENT HEALTH N, V39, P398, DOI 10.1080/01612840.2017.1417519; Low MY, 2020, J ALTERN COMPLEM MED, V26, P113, DOI 10.1089/acm.2019.0249; Lu SF, 2013, COMPLEMENT THER MED, V21, P682, DOI 10.1016/j.ctim.2013.09.002; Mahendran R, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2988-6; Mondanaro John F, 2017, Am J Orthop (Belle Mead NJ), V46, pE13; Nwebube C, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1759-3; Park S, 2015, J CHILD NEUROL, V30, P1757, DOI 10.1177/0883073815579710; Perez-Ros P, 2019, J ALZHEIMERS DIS, V70, P431, DOI 10.3233/JAD-190361; Ploukou S, 2018, APPL NURS RES, V39, P77, DOI 10.1016/j.apnr.2017.11.007; Porter S, 2017, J CHILD PSYCHOL PSYC, V58, P586, DOI 10.1111/jcpp.12656; Radulovic R., 1996, THESIS; Raglio A, 2016, INT J REHABIL RES, V39, P365, DOI 10.1097/MRR.0000000000000187; Ribeiro Mayara K A, 2018, BMC Psychol, V6, P57, DOI 10.1186/s40359-018-0271-y; Ruschweyeh Wilder-Smith O, 2011, COCHRANE HANDBOOK FO, V7, P20; Sigurdardottir GA, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1399; Toccafondi A, 2018, PALLIAT SUPPORT CARE, V16, P777, DOI 10.1017/S1478951517000165; Torres E, 2018, J MUSIC THER, V55, P186, DOI 10.1093/jmt/thy005; Trimmer C, 2018, BEHAV COGN PSYCHOTH, V46, P168, DOI 10.1017/S1352465817000480; Ugur HG, 2017, AGING MENT HEALTH, V21, P1280, DOI 10.1080/13607863.2016.1222348; Volpe U, 2018, PSYCHIATRY, V81, P218, DOI 10.1080/00332747.2018.1502559; Wang JinLiang, 2011, Health, V3, P151, DOI 10.4236/health.2011.33028; Wang PS, 2007, LANCET, V370, P841, DOI 10.1016/S0140-6736(07)61414-7; Wheeler BL, 2015, MUSIC THERAPY HDB; Wigram Tony, 2002, INGE NYGGARD PEDERSE, P143, DOI [10.1016/s0387-7604(02)00058-x, DOI 10.1016/S0387-7604(02)00058-X]; Wigram Tony, 2002, INGE NYGGARD PEDERSE, P143, DOI [10.1016/s0387-7604(02)00058-x, DOI 10.1016/S0387-7604(02)00058-X]; World Health Organization (WHO), 2017, DEPRESSION; Wu QY, 2020, SUBST ABUS, V41, P493, DOI 10.1080/08897077.2019.1675117; Yang WJ, 2019, COMPLEMENT THER CLIN, V37, P93, DOI 10.1016/j.ctcp.2019.09.002; Yap AF, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1825-x; Yinger OS, 2014, CHILD ADOL PSYCH CL, V23, P535, DOI 10.1016/j.chc.2013.03.003; Zerhusen J D, 1991, J Psychosoc Nurs Ment Health Serv, V29, P16; Zhao K, 2016, INT J GERIATR PSYCH, V31, P1188, DOI 10.1002/gps.4494	78	13	14	8	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0240862	10.1371/journal.pone.0240862	http://dx.doi.org/10.1371/journal.pone.0240862			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ9VG	33206656	Green Published			2023-01-03	WOS:000595265900069
J	Kupari, J; Ernfors, P				Kupari, Jussi; Ernfors, Patrik			Pricking into Autonomic Reflex Pathways by Electrical Acupuncture	NEURON			English	Editorial Material							NEURONS; SYSTEM	Using electrical acupuncture, Liu et al. show how electrical stimulation of primary somatosensory neurons at different body regions can tap into discreet autonomic circuits and, depending on the parameters, initiate either a proor anti-inflammatory response.	[Kupari, Jussi; Ernfors, Patrik] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, S-17177 Stockholm, Sweden.	patrik.ernfors@ki.se						Binder M.D., 2009, ENCY NEUROSCIENCE, P272; Deuchars SA, 2015, COMPR PHYSIOL, V5, P829, DOI 10.1002/cphy.c140020; Furlan A, 2016, NAT NEUROSCI, V19, P1331, DOI 10.1038/nn.4376; Janig W, 2000, PROG BRAIN RES, V122, P351; Kupari J, 2019, CELL REP, V27, P2508, DOI 10.1016/j.celrep.2019.04.096; Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015; Norrsell U, 1999, BRAIN RES BULL, V48, P457, DOI 10.1016/S0361-9230(98)00067-7; Okusa MD, 2017, NAT REV NEPHROL, V13, P669, DOI 10.1038/nrneph.2017.132; Pacak K, 1998, AM J PHYSIOL-REG I, V275, pR1247, DOI 10.1152/ajpregu.1998.275.4.R1247; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479	10	1	2	5	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	NOV 11	2020	108	3					395	397		10.1016/j.neuron.2020.09.026	http://dx.doi.org/10.1016/j.neuron.2020.09.026			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OT1CW	33181070	Bronze			2023-01-03	WOS:000590592300001
J	Neicun, J; Yang, JC; Shih, H; Nadella, P; van Kessel, R; Negri, A; Czabanowska, K; Brayne, C; Roman-Urrestarazu, A				Neicun, Jessica; Yang, Justin Christopher; Shih, Hueyjong; Nadella, Pranay; van Kessel, Robin; Negri, Attilio; Czabanowska, Kasia; Brayne, Carol; Roman-Urrestarazu, Andres			Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014	PLOS ONE			English	Article							SEXUAL HEALTH; CHEMSEX; GAY	Introduction As Novel psychoactive substances (NPS) are conceived to mimic the effects of common illicit drugs, they represent a serious public health challenge due to the spike in intoxications and fatalities that have been linked to their use. This study aims to provide epidemiological data on NPS use in the USA, determining lifetime prevalence of use and defining demographic, socioeconomic, drug use patterns and mental health correlates. Methods This study uses secondary data from the US National Survey on Drug Use and Health (NSDUH), which is a large cross-sectional population-based survey carried out annually in the USA. We analysed data from 2007-14 (N = 307,935) using bivariate descriptive analysis and binary logistic regression to calculate prevalence and determine factors underlying NPS consumption. Adjusted odds ratios (OR) with 95% CI's were calculated for a set of selected independent variables. Results and discussion Our analysis NSDUH from 2007-14 highlights an increase in NPS use among adults, especially among white young men aged 18 to 25. Although the level of education of NPS users was relatively higher as compared to non-users, NPS users seemed to have a less wealthy situation. However, socioeconomic vulnerability appeared to be less important than mental health issues as a correlate to NPS use. NPS users seem to have followed a pattern of polysubstance use throughout their life, which involves both traditional illicit drugs and classic synthetic drugs. As NPS use seemed to be more prevalent among people having mental health issues, the rise in their use may have a negative impact on population mental health outcomes. Conclusion Further comparative research on trends in NPS use and potential public health responses would be instrumental for developing appropriate health interventions, including drug checking, education for users and training for healthcare professionals working both within emergency wards and in/outpatient addiction and mental health services.	[Neicun, Jessica; van Kessel, Robin; Czabanowska, Kasia; Brayne, Carol; Roman-Urrestarazu, Andres] Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst CAPHRI, Dept Int Hlth, Maastricht, Netherlands; [Neicun, Jessica; Yang, Justin Christopher; Shih, Hueyjong; Nadella, Pranay; Roman-Urrestarazu, Andres] Univ Cambridge, Inst Publ Hlth, Cambridge, England; [Negri, Attilio] Univ Hertfordshire, Ctr Clin & Hlth Res Serv, Novel Psychoact Subst Unit, Hatfield, Herts, England; [Czabanowska, Kasia] Natl Inst Publ Hlth, Warsaw, Poland	Maastricht University; University of Cambridge; University of Hertfordshire; National Institute of Public Health (NIPH)	Neicun, J (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Care & Publ Hlth Res Inst CAPHRI, Dept Int Hlth, Maastricht, Netherlands.; Neicun, J (corresponding author), Univ Cambridge, Inst Publ Hlth, Cambridge, England.	jessica.neicun@maastrichtuniversity.nl	Yang, Justin Christopher/H-1780-2018; van Kessel, Robin/GWV-1883-2022; van Kessel, Robin/GYD-7902-2022	Yang, Justin Christopher/0000-0003-2881-4906; van Kessel, Robin/0000-0001-6309-6343; van Kessel, Robin/0000-0001-6309-6343; NEGRI, ATTILIO/0000-0002-1035-8095; Brayne, Carol/0000-0001-5307-663X; Neicun, Jessica/0000-0002-8710-8238	Gillings Fellowship in Global Public Health [YOG054]	Gillings Fellowship in Global Public Health	AR-U's work received funding from the Gillings Fellowship in Global Public Health (Grant Award YOG054). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulrahim D, 2018, MISUSE SYNTHETIC OPI; AL-Imam A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2548; [Anonymous], 2020, NAT METHODS, V17, P1, DOI 10.1038/s41592-019-0703-5; [Anonymous], 2017, DUBL DRUG POL SUMM R; [Anonymous], 2017, AM J MED GENET C, V175, P1; Armenian P, 2018, NEUROPHARMACOLOGY, V134, P121, DOI 10.1016/j.neuropharm.2017.10.016; Arnold C, 2013, LANCET, V382, P15, DOI 10.1016/S0140-6736(13)61512-3; Baumann MH, 2018, NEUROPHARMACOLOGY, V134, P101, DOI 10.1016/j.neuropharm.2017.08.016; Benschop A, 2020, J PSYCHOPHARMACOL, V34, P600, DOI 10.1177/0269881120904951; Bourne A, 2015, SEX TRANSM INFECT, V91, P564, DOI 10.1136/sextrans-2015-052052; Center for Behavioral Health Statistics and Quality, 2015, NAT SURV DRUG US HLT, DOI [10.1186/1472-6807-9-19, DOI 10.1186/1472-6807-9-19]; Center for Behavioral Health Statistics and Quality, 2015, 2014 NAT SURV DRUGS; Center for Behavioral Health Statistics and Quality, 2013, NSDUH REP DAT SPOTL; Corazza O., 2017, NOVEL PSYCHOACTIVE S, P125, DOI DOI 10.1007/978-3-319-60600-2_9; Corazza O, 2017, NOVEL PSYCHOACTIVE S; Corazza O., 2019, HDB NOVEL PSYCHOACTI; Dart RC, 2015, ANN EMERG MED, V65, P416, DOI 10.1016/j.annemergmed.2014.11.001; Degenhardt L, 2018, ADDICTION, V113, P924, DOI 10.1111/add.14145; European Monitoring Centre for Drugs and Drug Addiction, 2020, EUR DRUG REP 2020 TR; Every-Palmer S, 2011, DRUG ALCOHOL DEPEN, V117, P152, DOI 10.1016/j.drugalcdep.2011.01.012; Fernandez-Calderon F, 2018, ADDICT BEHAV, V78, P85, DOI 10.1016/j.addbeh.2017.11.004; Hunter LJ, 2014, POSTGRAD MED J, V90, P133, DOI 10.1136/postgradmedj-2012-131428; Jann B, 2005, STATA J, V5, P92, DOI 10.1177/1536867X0500500113; Johnson LA, 2013, J EMERG MED, V44, P1108, DOI 10.1016/j.jemermed.2012.09.147; Johnston L.D., 2013, MONITORING FUTURE NA; Karila L, 2019, NEUROSCI BIOBEHAV R, V106, P133, DOI 10.1016/j.neubiorev.2018.06.010; King G, 2003, J STAT SOFTW, V8; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Ma R, 2016, BRIT J GEN PRACT, V66, P4, DOI 10.3399/bjgp16X683029; Marrinan S, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2587; Martinotti G, 2019, HDB NOVEL PSYCHOACTI; Merikangas KR, 2012, HUM GENET, V131, P779, DOI 10.1007/s00439-012-1168-0; Murphy CM, 2013, J MED TOXICOL, V9, P42, DOI 10.1007/s13181-012-0243-1; National Institute on Drug Abuse, 2014, P COMM EP WORK GROUP; Palamar JJ, 2016, AM J ADDICTION, V25, P400, DOI 10.1111/ajad.12403; Palamar JJ, 2016, AM J DRUG ALCOHOL AB, V42, P39, DOI 10.3109/00952990.2015.1106551; Patrick ME, 2016, DRUG ALCOHOL REV, V35, P586, DOI 10.1111/dar.12372; Peacock A, 2019, LANCET, V394, P1668, DOI 10.1016/S0140-6736(19)32231-7; Place C, 2017, ADV DUAL DIAGN, V10, P97, DOI 10.1108/ADD-10-2016-0018; Race K, 2017, SEX HEALTH, V14, P42, DOI 10.1071/SH16080; Riederer AM, 2016, MMWR-MORBID MORTAL W, V65, P692, DOI 10.15585/mmwr.mm6527a2; Schifano F, 2015, WORLD PSYCHIATRY, V14, P15, DOI 10.1002/wps.20174; Schmidt MM, 2011, FORENSIC SCI INT, V206, P92, DOI 10.1016/j.forsciint.2010.06.030; Simonato P, 2013, HUM PSYCHOPHARM CLIN, V28, P324, DOI 10.1002/hup.2300; Soussan C, 2018, INT J DRUG POLICY, V52, P71, DOI 10.1016/j.drugpo.2017.11.003; Soussan C, 2016, INT J DRUG POLICY, V32, P77, DOI 10.1016/j.drugpo.2016.03.007; U.S. Drug Enforcement Administration, 2018, NAT FOR LAB INF SYST; U.S. Drug Enforcement Administration, 2016, NAT FOR LAB INF SYST; U.S. Drug Enforcement Administration, 2014, NAT FOR LAB INF SYST; United Nations Office on Drugs and Crime, 2020, WORLD DRUG REP 2020; United Nations Office on Drugs and Crime, 2015, INT STAND DRUG US PR; United Nations Office on Drugs and Crime, 2018, WORLD DRUG REP 2018; Wilkins C, 2017, NOVEL PSYCHOACTIVE S, P57, DOI DOI 10.1007/978-3-319-60600-2_5; Winstock AR, 2017, 10 INT C NIGHTL SUBS; Wish E.D, 2015, COMMUNITY DRUG EARLY; World Health Organization, 2017, DEPR OTH COMM MENT D; Yang JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199741; Younger-Coleman N., 2016, 2016 NATL DRUG USE P	58	7	7	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2020	15	10							e0241056	10.1371/journal.pone.0241056	http://dx.doi.org/10.1371/journal.pone.0241056			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8VN	33125395	gold, Green Published			2023-01-03	WOS:000588368900031
J	Okuda, M; Fujita, Y; Takada-Takatori, Y; Sugimoto, H; Urakami, K				Okuda, Michiaki; Fujita, Yuki; Takada-Takatori, Yuki; Sugimoto, Hachiro; Urakami, Katsuya			Aromatherapy improves cognitive dysfunction in senescence-accelerated mouse prone 8 by reducing the level of amyloid beta and tau phosphorylation	PLOS ONE			English	Article							ALZHEIMERS-DISEASE; MODEL; DEMENTIA; MEMORY; BRAIN; OIL; THERAPY; ORANGE	Alzheimer's disease (AD) is a progressive neurodegenerative disease and is known to be the most common cause of dementia. We previously described the benefits of aromatherapy on the cognitive function of patients with AD utilizing various aromatic essential oils; however, its mechanism of action remains poorly understood. Consequently, in the present study, this mechanism was thoroughly evaluated employing a dementia mice model, specifically the senescence-accelerated mouse prone 8. The mice were exposed to a mixture of lemon and rosemary oil at nighttime as well as to a mixture of lavender and orange oil in the daytime for 2 months. The cognitive function of the mice was assessed before and after treatment with the aromatic essential oils using the Y-maze test. Moreover, the brain levels of amyloid beta (A beta), abnormally phosphorylated tau, and brain-derived neurotrophic factor (BDNF) were measured following treatment. The benefits of aromatherapy on the cognitive function in mice were confirmed. It was also established that the brain levels of A beta and abnormally phosphorylated tau were considerably lower in the aromatherapy group, while the levels of BDNF were marginally higher. These results suggest that aromatherapy employing these aromatic essential oils is beneficial for the prevention and treatment of AD.	[Okuda, Michiaki; Fujita, Yuki; Sugimoto, Hachiro] Doshisha Univ, Grad Sch Brain Sci, Kizugawa, Kyoto, Japan; [Okuda, Michiaki; Fujita, Yuki] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Kyoto, Kyoto, Japan; [Takada-Takatori, Yuki] Doshisha Womens Coll, Fac Pharmaceut Sci, Kyotanabe, Kyoto, Japan; [Urakami, Katsuya] Tottori Univ, Fac Med, Sch Hlth Sci, Dept Regulat Biol, Yonago, Tottori, Japan; [Okuda, Michiaki; Fujita, Yuki; Sugimoto, Hachiro] Green Tech Co Ltd, Kyoto, Kyoto, Japan; [Sugimoto, Hachiro] Doshisha Univ, Fac Life & Med Sci, Kyotanabe, Kyoto, Japan	Doshisha University; Kyoto University; Tottori University; Doshisha University	Okuda, M (corresponding author), Doshisha Univ, Grad Sch Brain Sci, Kizugawa, Kyoto, Japan.; Okuda, M (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Kyoto, Kyoto, Japan.	okuda.michiaki.33r@st.kyoto-u.ac.jp		Okuda, Michiaki/0000-0002-0211-7144				[Anonymous], 2015, RES ALZH MED SETB ST; Ballard CG, 2002, J CLIN PSYCHIAT, V63, P553, DOI 10.4088/JCP.v63n0703; Bibari O, 2013, CURR ALZHEIMER RES, V10, P688, DOI 10.2174/15672050113109990147; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Camargo EC, 2016, J ALZHEIMERS DIS, V53, P1597, DOI 10.3233/JAD-160229; Chioca LR, 2013, J ETHNOPHARMACOL, V147, P412, DOI 10.1016/j.jep.2013.03.028; Cummings Jeffrey, 2018, Alzheimers Dement (N Y), V4, P195, DOI 10.1016/j.trci.2018.03.009; Farr SA, 2016, PHYSIOL BEHAV, V165, P328, DOI 10.1016/j.physbeh.2016.08.013; Filan SL, 2006, INT PSYCHOGERIATR, V18, P597, DOI 10.1017/S1041610206003322; Grassmann J, 2001, ARZNEIMITTEL-FORSCH, V51, P799; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Hussain Syed Asif, 2002, Anc Sci Life, V22, P13; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jimbo D, 2009, PSYCHOGERIATRICS, V9, P173, DOI 10.1111/j.1479-8301.2009.00299.x; Koger SM, 1999, J MUSIC THER, V36, P2, DOI 10.1093/jmt/36.1.2; Lehrner J, 2005, PHYSIOL BEHAV, V86, P92, DOI 10.1016/j.physbeh.2005.06.031; Lewith GT, 2005, J ALTERN COMPLEM MED, V11, P631, DOI 10.1089/acm.2005.11.631; Maki T, 2014, ANN CLIN TRANSL NEUR, V1, P519, DOI 10.1002/acn3.79; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MIYAMOTO M, 1986, PHYSIOL BEHAV, V38, P399, DOI 10.1016/0031-9384(86)90112-5; Morley JE, 2000, PEPTIDES, V21, P1761, DOI 10.1016/S0196-9781(00)00342-9; Nasermoaddeli Ali, 2005, Environmental Health and Preventive Medicine, V10, P171, DOI 10.1007/BF02897707; Okuda M, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2167-z; Okuda M, 2017, J ALZHEIMERS DIS, V59, P313, DOI 10.3233/JAD-161017; Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x; Pengelly A, 2012, J MED FOOD, V15, P10, DOI 10.1089/jmf.2011.0005; Peters JM, 2003, AM J PSYCHIAT, V160, P1995, DOI 10.1176/appi.ajp.160.11.1995; Roberson Lynn, 2003, Home Healthc Nurse, V21, P16, DOI 10.1097/00004045-200301000-00004; Sakurai H, 2013, GERIATR GERONTOL INT, V13, P90, DOI 10.1111/j.1447-0594.2012.00866.x; Selkoe DJ, 2012, SCIENCE, V337, P1488, DOI 10.1126/science.1228541; Shin BC, 2007, J ALTERN COMPLEM MED, V13, P247, DOI 10.1089/acm.2006.6189; Shinomiya M, 2012, ACTA MED OKAYAMA, V66, P111; Sigdell J E, 1982, Anc Sci Life, V1, P125; Smallwood J, 2001, INT J GERIATR PSYCH, V16, P1010, DOI 10.1002/gps.473; Sureda FX, 2006, EXP GERONTOL, V41, P360, DOI 10.1016/j.exger.2006.01.015; TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047-6374(81)90084-1; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Wu N, 2013, J ALZHEIMERS DIS, V37, P699, DOI 10.3233/JAD-122443; YAGI H, 1988, BRAIN RES, V474, P86, DOI 10.1016/0006-8993(88)90671-3	39	6	6	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240378	10.1371/journal.pone.0240378	http://dx.doi.org/10.1371/journal.pone.0240378			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052945	Green Published, gold			2023-01-03	WOS:000581820200040
J	Abdu, N; Mosazghi, A; Teweldemedhin, S; Asfaha, L; Teshale, M; Kibreab, M; Anand, IS; Tesfamariam, EH; Russom, M				Abdu, Nuru; Mosazghi, Asmerom; Teweldemedhin, Samuel; Asfaha, Luwam; Teshale, Makda; Kibreab, Mikal; Anand, Indermeet Singh; Tesfamariam, Eyasu H.; Russom, Mulugeta			Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Usage and co-prescription with other potentially interacting drugs in elderly: A cross-sectional study	PLOS ONE			English	Article							PRESCRIBERS	Globally, usage of non-steroidal anti-inflammatory drugs (NSAIDs) in elderly with chronic pain has been reported as frequent. Though NSAIDs are fundamental in maintaining their quality of life, the risk of polypharmacy, drug interactions and adverse effects is of paramount importance as the elderly usually require multiple medications for their co-morbidities. If prescriptions are not appropriately monitored and managed, they are likely to expose patients to serious drug interactions and potentially fatal adverse effects. This study was conducted to assess the appropriateness of NSAIDs use and determine the risk of NSAIDs related potential interactions in elderly. An analytical cross-sectional study was conducted among elderly out-patients (aged 60 and above) who visited three hospitals in Asmara, Eritrea, between August 22 and September 29, 2018. A stratified random sampling design was employed and data was collected using an interview-based questionnaire and by abstracting information from patients' prescriptions and medical cards. Descriptive and analytical statistics including chi-square test and logistic regression were employed using IBM SPSS (version 22). A total of 285 respondents were enrolled in the study with similar male to female ratio. One in four of all respondents were chronic NSAIDs users and NSAIDs risk practice was reported in 24%. Using chronic NSAIDs without prophylactic gastro-protective agents, self-medication, polypharmacy and drug-drug interactions were the main problems identified. A total of 322 potential interactions in 205 patients were identified and of which, 97.2% were classified as moderate, 0.6% severe and the rest were mild. Those who involved in self-medication were more likely to be exposed to drug interactions. Diabetes (AOR = 2.39, 95% CI: 1.14, 5.02) and hypertension (AOR = 9.06, 95% CI: 4.00, 20.51) were associated with chronic NSAIDs use and incidence of potential drug interactions (AOR = 3.5, 95%CI: 1.68, 4.3; AOR = 2.81, 95%CI: 1.61, 4.9 respectively), while diabetes AOR = 4.5, 95% CI: 2.43, 8.35) and cardiac problems (AOR = 4.29, 95% CI: 1.17, 15.73) were more likely to be associated with incidence of polypharmacy. In conclusion, chronic use of NSAIDs without gastro-protective agents and therapeutic duplication of NSAIDs were commonly which requires attention from programmers, health facility managers and healthcare professionals to safeguard elderlies from preventable harm.	[Abdu, Nuru; Mosazghi, Asmerom; Teweldemedhin, Samuel; Asfaha, Luwam; Teshale, Makda; Kibreab, Mikal; Anand, Indermeet Singh] Asmara Coll Hlth Sci, Sch Pharm, Asmera, Eritrea; [Tesfamariam, Eyasu H.] Eritrean Inst Technol, Coll Sci, Biostat & Epidemiol Unit, Dept Stat, Mai Nefhi, Eritrea; [Russom, Mulugeta] Natl Medicines & Food Adm, Eritrean Pharmacovigilance Ctr, Asmera, Eritrea		Abdu, N (corresponding author), Asmara Coll Hlth Sci, Sch Pharm, Asmera, Eritrea.	pharmacistnuru@gmail.com	Russom, Mulugeta/ACM-0020-2022	Russom, Mulugeta/0000-0003-1939-5842; Abdu, Nuru/0000-0003-2426-4337				Abdulla A, 2013, AGE AGEING, V42, pI1, DOI 10.1093/ageing/afs200; Amato R, 2016, ELIFE, V5, DOI 10.7554/eLife.08714; [Anonymous], 2014, TRUSTS TRUSTEES, V20, P673; [Anonymous], 2018, 7 SER FPGAS DAT SHEE, V2, P1; Ateshim Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7020-x; Bahta M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228013; Bakhriansyah M, 2019, CLIN J AM SOC NEPHRO, V14, P1355, DOI 10.2215/CJN.14331218; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; Chen YW, 2016, COGN COMPUT, V8, P114, DOI 10.1007/s12559-015-9346-8; Davies EA, 2015, BRIT J CLIN PHARMACO, V80, P796, DOI 10.1111/bcp.12596; Ely Luísa Scheer, 2015, Rev. bras. geriatr. gerontol., V18, P475, DOI 10.1590/1809-9823.2015.14141; Excellence NIfHaC, 2008, OST CAR MAN OST AD; Goudanavar P, 2016, ASIAN J BIOMEDICAL P, P6; Improvement IfCS, 2011, HLTH CAR GUID ASS MA; Ko Y, 2008, DRUG SAFETY, V31, P525, DOI 10.2165/00002018-200831060-00007; Ko Y, 2008, RES SOC ADMIN PHARM, V4, P355, DOI 10.1016/j.sapharm.2007.10.004; Lanas A, 2012, AM J GASTROENTEROL, V107, P707, DOI 10.1038/ajg.2012.13; Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115; Lima Tiago Aparecido Maschio de, 2016, Rev. bras. geriatr. gerontol., V19, P533, DOI 10.1590/1809-98232016019.150062; Raschi E, 2015, BRIT J CLIN PHARMACO, V80, P1411, DOI 10.1111/bcp.12754; Saedder EA, 2015, BRIT J CLIN PHARMACO, V80, P808, DOI 10.1111/bcp.12600; Schneider V, 2006, AM J EPIDEMIOL, V164, P881, DOI 10.1093/aje/kwj331; Stiftung Warentest, 2016, NON TRADITIONAL REF, V6, P54; Straube S, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-41; Suh DC, 2008, RHEUMATOLOGY, V47, P458, DOI [10.1093/rheumatalogy/kem375, 10.1093/rheumatology/kem375]; U.S. Food and Drug Administration (FDA), 2015, FDA STRENGTHENS WARN; Vandraas KF, 2010, EUR J CLIN PHARMACOL, V66, P823, DOI 10.1007/s00228-010-0825-2	27	11	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2020	15	10							e0238868	10.1371/journal.pone.0238868	http://dx.doi.org/10.1371/journal.pone.0238868			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3WA	33035226	gold, Green Published			2023-01-03	WOS:000581817500057
J	Nyamu, GW; Kihara, JH; Oyugi, EO; Omballa, V; El-Busaidy, H; Jeza, VT				Nyamu, Gibson Waweru; Kihara, Jimmy Hussein; Oyugi, Elvis Omondi; Omballa, Victor; El-Busaidy, Hajara; Jeza, Victor Tunje			Prevalence and risk factors associated with asymptomatic Plasmodium falciparum infection and anemia among pregnant women at the first antenatal care visit: A hospital based cross-sectional study in Kwale County, Kenya	PLOS ONE			English	Article							MALARIA; CLINICS	Background Prevalence of Prevalence of malaria in pregnancy (MiP) in Kenya ranges from 9% to 18%. We estimated the prevalence and factors associated with MiP and anemia in pregnancy (AiP) among asymptomatic women attending antenatal care (ANC) visits. Methods We performed a cross-sectional study among pregnant women attending ANC at Msambweni Hospital, between September 2018 and February 2019. Data was collected and analyzed in Epi Info 7. Descriptive statistics were calculated and we compared MiP and AiP in asymptomatic cases to those without either condition. Adjusted prevalence Odds odds ratios (aPOR) and 95% confidence intervals (CI) were calculated to identify factors associated with asymptomatic MiP and AiP. Results We interviewed 308 study participants; their mean age was 26.6 years (+/- 5.8 years), mean gestational age was 21.8 weeks (+/- 6.0 weeks), 173 (56.2%) were in the second trimester of pregnancy, 12.9% (40/308) had MiP and 62.7% had AiP. Women who were aged <= 20 years had three times likelihood of developing MiP (aPOR = 3.1 Cl: 1.3-7.35) compared to those aged >20 years old. The likelihood of AiP was higher among women with gestational age >= 16 weeks (aPOR = 3.9, CI: 1.96-7.75), those with parasitemia (aPOR = 3.3, 95% CI: 1.31-8.18), those in third trimester of pregnancy (aPOR = 2.6, 95% CI:1.40-4.96) and those who reported eating soil as a craving during pregnancy (aPOR = 1.9, 95%CI:1.15-3.29). Conclusions Majority of the women had asymptomatic MiP and AiP. MiP was observed in one tenth of all study participants. Asymptomatic MiP was associated with younger age while AiP was associated with gestational age parasitemia, and soil consumption as a craving during pregnancy.	[Nyamu, Gibson Waweru; Jeza, Victor Tunje] Tech Univ Mombasa, Mombasa, Kenya; [Nyamu, Gibson Waweru; El-Busaidy, Hajara] Kwale Cty, Dept Hlth, Kwale, Kwale County, Kenya; [Kihara, Jimmy Hussein] Kenya Govt Med Res Ctr, Nairobi, Kenya; [Oyugi, Elvis Omondi] Minist Hlth, Kenya Field Epidemiol & Lab Training Program, Nairobi, Kenya; [Omballa, Victor] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Nairobi, Kenya	Technical University of Mombasa; Kenya Medical Research Institute; Kenya Medical Research Institute	Nyamu, GW (corresponding author), Tech Univ Mombasa, Mombasa, Kenya.; Nyamu, GW (corresponding author), Kwale Cty, Dept Hlth, Kwale, Kwale County, Kenya.	wawerugibson2015@gmail.com	Jeza, Victor Tunje/AAX-4300-2021	Jeza, Victor Tunje/0000-0002-4437-1343; Nyamu, Gibson/0000-0002-0991-8040	Technical University of Mombasa, Kenya	Technical University of Mombasa, Kenya	We would like to thank the Technical University of Mombasa, Kenya, for their support during the study. Special thanks go to study participants and to the Kwale County Department of Health authorities for their collaboration. We also thank the many Vector Borne Disease Control Unit (VBDCU) Laboratory officers, including Said Lipi, Joyce Bandika, Peter Siema, Charles Ng'ang'a, and Elton Mzungu for their dedication and meticulous microscopy. We extend a special thank you to nurse Wendy Losier, for her assistance with the consenting process and data collection. We also thank Dr. Robert Perry, Dr. Elizabeth Wanja, and Dr. Shama Cash-Goldwasser for their valuable insight and comments on the manuscript.	Agan TU, 2010, ASIAN PAC J TROP MED, V3, P51, DOI 10.1016/S1995-7645(10)60032-6; Agomo CO, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-19; Alaku I., 2015, DEV COUNTRY STUDIES, V5; Bisanzio D, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-1006-7; Bouyou-Akotet MK, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-18; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Cochran W. G., 2007, SAMPLING TECHNIQUES; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Dicko A, 2003, ACTA TROP, V89, P17, DOI 10.1016/j.actatropica.2003.07.001; Douamba Z., 2012, BIOMED RES INT; Enato EFO, 2009, J OBSTET GYNAECOL, V29, P301, DOI 10.1080/01443610902883320; Gajida A., 2010, ANN AFR MED, V9; Gedefaw L, 2015, ETHIOP J HEALTH SCI, V25, P155, DOI 10.4314/ejhs.v25i2.8; Glover-Amengor Mary, 2005, Ghana Med J, V39, P102; Helmy ME, 2018, MENOUFIA MED J, V31, P7, DOI [10.4103/1110-2098.234258, DOI 10.4103/1110-2098.234258]; Isah AY, 2011, ANN AFR MED, V10, P171, DOI 10.4103/1596-3519.82070; Ivoke N., 2013, INT J SCI ENG RES, V4, P1876; KNBS, 2019, KEN POP HOUS CENS, V1; Matangila JR, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-132; Mathee A, 2014, SAMJ S AFR MED J, V104, P568, DOI [10.7196/samj.7466, 10.7196/SAMJ.7466]; McClure EM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002724; Melku M, 2014, ANEMIA, V2014, DOI 10.1155/2014/108593; MOH, 2020, MAL PREGN; MOH, 2015, KENYA MALARIA INDICA; MOH, 2015, FOC ANT CAR; Mwangi M.N., 2014, SAFETY EFFICACY IRON; Nega Desalegn, 2015, BMC Res Notes, V8, P110, DOI 10.1186/s13104-015-1081-4; Nega D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123630; Okube O.T., 2016, OPEN J OBSTET GYNECO, V6, P16; Olubukola A, 2011, ANN AFR MED, V10, P272, DOI 10.4103/1596-3519.87042; Ouma P, 2007, TROP MED INT HEALTH, V12, P1515, DOI 10.1111/j.1365-3156.2007.01960.x; Saute F, 2002, TROP MED INT HEALTH, V7, P19, DOI 10.1046/j.1365-3156.2002.00831.x; Stephen G, 2018, ANEMIA, V2018, DOI 10.1155/2018/1846280; Tarning J, 2012, ANTIMICROB AGENTS CH, V56, P1997, DOI 10.1128/AAC.05756-11; Tay S.C., 2013, MALARIA ANAEMIA PREG; Uneke CJ, 2007, J HEALTH POPUL NUTR, V25, P328; Waweru M., 2017, CAPITAL NEWS; WHO, 2017, INT PREV TREATM MAL; WHO, 2010, BAS MAL MICR; WHO, 2020, WORLD MAL REP 2019 1; Yakubu D., 2018, NOBLE INT J SCI RES, V2, P19; Zekarias B., 2017, HEAL SCI J, V11, P1, DOI [10.21767/1791-809x.1000529, DOI 10.21767/1791-809X.1000529, 10.21767/1791-8, DOI 10.21767/1791-809X.10005294]	42	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2020	15	10							e0239578	10.1371/journal.pone.0239578	http://dx.doi.org/10.1371/journal.pone.0239578			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TB	33031456	gold, Green Published			2023-01-03	WOS:000581809800020
J	Smith, ML; Asada, N; Malenka, RC				Smith, Monique L.; Asada, Naoyuki; Malenka, Robert C.			Anterior cingulate inputs to nucleus accumbens control the social transfer of pain and analgesia	SCIENCE			English	Article							EMPATHY; COGNITION; CIRCUIT; MOTIVATION; OXYTOCIN; CAGEMATE; BEHAVIOR; NEURONS; CORTEX; REWARD	Empathy is an essential component of social communication that involves experiencing others' sensory and emotional states. We observed that a brief social interaction with a mouse experiencing pain or morphine analgesia resulted in the transfer of these experiences to its social partner. Optogenetic manipulations demonstrated that the anterior cingulate cortex (ACC) and its projections to the nucleus accumbens (NAc) were selectively involved in the social transfer of both pain and analgesia. By contrast, the ACC -> NAc circuit was not necessary for the social transfer of fear, which instead depended on ACC projections to the basolateral amygdala. These findings reveal that the ACC, a brain area strongly implicated in human empathic responses, mediates distinct forms of empathy in mice by influencing different downstream targets.	[Smith, Monique L.; Asada, Naoyuki; Malenka, Robert C.] Stanford Univ, Nancy Pritzker Lab, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Asada, Naoyuki] Daiichi Sankyo Co Ltd, Tokyo, Japan	Stanford University; Daiichi Sankyo Company Limited	Malenka, RC (corresponding author), Stanford Univ, Nancy Pritzker Lab, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.	malenka@stanford.edu		Smith, Monique/0000-0002-2656-0677	UCSF Dolby Family Center for Mood Disorders; National Institute on Drug Abuse [T32DA035165-06]; Stanford University School of Medicine Deans Fellowship	UCSF Dolby Family Center for Mood Disorders; National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Stanford University School of Medicine Deans Fellowship	This work was supported by the UCSF Dolby Family Center for Mood Disorders. M.L.S. was supported by the National Institute on Drug Abuse (T32DA035165-06) and a Stanford University School of Medicine Deans Fellowship.	Allen WE, 2017, SCIENCE, V357, P1149, DOI 10.1126/science.aan6747; Allsop SA, 2018, CELL, V173, P1329, DOI 10.1016/j.cell.2018.04.004; Apps MAJ, 2016, NEURON, V90, P692, DOI 10.1016/j.neuron.2016.04.018; Apps MAJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00251; Baptista-de-Souza D, 2015, BEHAV PHARMACOL, V26, P664, DOI 10.1097/FBP.0000000000000170; Bartal IBA, 2011, SCIENCE, V334, P1427, DOI 10.1126/science.1210789; Beier KT, 2017, NATURE, V549, P345, DOI 10.1038/nature23888; Burkett JP, 2016, SCIENCE, V351, P375, DOI 10.1126/science.aac4785; Callaway EM, 2015, J NEUROSCI, V35, P8979, DOI 10.1523/JNEUROSCI.0409-15.2015; Carrillo M, 2019, CURR BIOL, V29, P1301, DOI 10.1016/j.cub.2019.03.024; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; de Waal FBM, 2008, ANNU REV PSYCHOL, V59, P279, DOI 10.1146/annurev.psych.59.103006.093625; de Waal FBM, 2017, NAT REV NEUROSCI, V18, P498, DOI 10.1038/nrn.2017.72; Ferretti V, 2019, CURR BIOL, V29, P1938, DOI 10.1016/j.cub.2019.04.070; Fillinger C, 2018, BRAIN STRUCT FUNCT, V223, P1747, DOI 10.1007/s00429-017-1585-x; Guenthner CJ, 2013, NEURON, V78, P773, DOI 10.1016/j.neuron.2013.03.025; Harris HN, 2020, NEURAL REGEN RES, V15, P597, DOI 10.4103/1673-5374.266909; HOFFMAN ML, 1975, DEV PSYCHOL, V11, P607, DOI 10.1037/0012-1649.11.5.607; Hung LW, 2017, SCIENCE, V357, P1406, DOI 10.1126/science.aan4994; Jackson PL, 2006, NEUROPSYCHOLOGIA, V44, P752, DOI 10.1016/j.neuropsychologia.2005.07.015; Jackson PL, 2005, NEUROIMAGE, V24, P771, DOI 10.1016/j.neuroimage.2004.09.006; Jeon D, 2010, NAT NEUROSCI, V13, P482, DOI 10.1038/nn.2504; Keum S, 2016, GENES BRAIN BEHAV, V15, P231, DOI 10.1111/gbb.12278; Kim A, 2019, GENES BRAIN BEHAV, V18, DOI 10.1111/gbb.12521; Kim EJ, 2016, CELL REP, V15, P692, DOI 10.1016/j.celrep.2016.03.067; Klawonn AM, 2018, COLD SH Q B, V83, P119, DOI 10.1101/sqb.2018.83.037457; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Langford DJ, 2006, SCIENCE, V312, P1967, DOI 10.1126/science.1128322; LARSON AA, 1986, PHARMACOL BIOCHEM BE, V24, P49, DOI 10.1016/0091-3057(86)90043-2; Li Z, 2014, PAIN, V155, P1253, DOI 10.1016/j.pain.2014.03.019; Lu YF, 2018, NEUROSCI LETT, V662, P385, DOI 10.1016/j.neulet.2017.10.063; Meyza KZ, 2017, NEUROSCI BIOBEHAV R, V76, P216, DOI 10.1016/j.neubiorev.2016.10.028; Panksepp JB, 2011, NEUROSCI BIOBEHAV R, V35, P1864, DOI 10.1016/j.neubiorev.2011.05.013; Paxinos G, 2012, MOUSE BRAIN STEREOTA, Vfourth; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Ren Ke, 1999, ILAR J, V40, P111; Schwartz N, 2014, SCIENCE, V345, P535, DOI 10.1126/science.1253994; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Sivaselvachandran S, 2018, NEUROSCI BIOBEHAV R, V91, P130, DOI 10.1016/j.neubiorev.2016.06.007; Smith ML, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0087-17.2017; Smith ML, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600855; Stevens FL, 2011, J NEUROPSYCH CLIN N, V23, P120, DOI 10.1176/appi.neuropsych.23.2.121; Timmers I, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00289; Ueno H, 2020, BMC NEUROSCI, V21, DOI 10.1186/s12868-020-00566-4; Ueno H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42290-y; Walsh JJ, 2018, NATURE, V560, P589, DOI 10.1038/s41586-018-0416-4; Watanabe M, 2018, ADV EXP MED BIOL, V1099, P201, DOI 10.1007/978-981-13-1756-9_17	47	59	61	23	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	2021	371	6525					153	159	eabe3040	10.1126/science.abe3040	http://dx.doi.org/10.1126/science.abe3040			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PQ4MV	33414216	Green Accepted			2023-01-03	WOS:000606520400031
J	Keyt, H				Keyt, Holly			WHO recommends corticosteroids for patients with severe or critical COVID-19	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Keyt, Holly] UT Hlth San Antonio, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Keyt, H (corresponding author), UT Hlth San Antonio, San Antonio, TX 78229 USA.							Linsell L, 2020, NEW ENGL J MED, DOI DOI 10.1161/CIR.0000000000000745; National Institutes of Health, COR DIS 2019 COVID 1	2	5	6	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					JC2	JC2		10.7326/ACPJ202101190-002	http://dx.doi.org/10.7326/ACPJ202101190-002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33395337				2023-01-03	WOS:000619485200003
J	Mohammed, DY; Koumoulos, LM; Martin, E; Slim, J				Mohammed, Debbie Y.; Koumoulos, Lisa Marie; Martin, Eugene; Slim, Jihad			Annual and durable HIV retention in care and viral suppression among patients of Peter Ho Clinic, 2013-2017	PLOS ONE			English	Article							WHITE HIV/AIDS PROGRAM; ANTIRETROVIRAL THERAPY; TRANSMISSION RISK; INFECTED PATIENTS; UNITED-STATES; CONTINUUM; OUTCOMES; IMPACT; MORTALITY; AGE	Objectives To determine rates of annual and durable retention in medical care and viral suppression among patients enrolled in the Peter Ho Clinic, from 2013-2017. Methods This is a retrospective review of medical record data in an urban clinic, located in Newark, New Jersey, a high prevalence area of persons living with HIV. Viral load data were electronically downloaded, in rolling 1-year intervals, in two-month increments, from January 1, 2013 to December 31, 2019. Three teams were established, and every two months, they were provided with an updated list of patients with virologic failure. Retention and viral suppression rates were first calculated for each calendar-year. After patients were determined to be retained/suppressed annually, the proportion of patients with durable retention and viral suppression were calculated in two, three, four, five and six-year periods. Descriptive statistics were used to summarize sample characteristics by retention in care, virologic failure and viral suppression with Pearson Chi-square; p-value <0.05 was statistically significant. Multiple logistic regression models identified patient characteristics associated with retention in medical care, virologic failure and suppression. Results As of December 31, 2017, 1000 (57%) patients were retained in medical care of whom 870 (87%) were suppressed. Between 2013 and 2016, decreases in annual (85% to 77%) and durable retention in care were noted: two-year (72% to 70%) and three-year (63% to 59%) periods. However, increases were noted for 2017, in annual (89%) and durable retention in the two-year period (79%). In the adjusted model, when compared to current patients, retention in care was less likely among patients reengaging in medical care (adjusted Odds Ratio (aOR): 0.77, 95% CI: 0.61-0.98) but more likely among those newly diagnosed from 2014-2017 (aOR: 1.57, 95% CI: 1.08-2.29), compared to those in care since 2013. A higher proportion of patients re-engaging in medical care had virologic failure than current patients (56% vs. 47%, p < 0.0001). As age decreased, virologic failure was more likely (p<0.0001). Between 2013 and 2017, increases in annual (74% to 87%) and durable viral suppression were noted: two-year (59% to 73%) and three-year (49% to 58%) periods. Viral suppression was more likely among patients retained in medical care up to 2017 versus those who were not (aOR: 5.52, 95% CI: 4.08-7.46). Those less likely to be suppressed were 20-29 vs. 60 years or older (aOR: 0.52, 95% CI: 0.28-0.97), had public vs. private insurance (aOR: 0.29, 95% CI: 0.15-0.55) and public vs. private housing (aOR: 0.59, 95% CI: 0.40-0.87). Conclusions Restructuring clinical services at this urban clinic was associated with improved viral suppression. However, concurrent interventions to ensure retention in medical care were not implemented. Both retention in care and viral suppression interventions should be implemented in tandem to achieve an end to the epidemic. Retention in care and viral suppression should be measured longitudinally, instead of cross-sectional yearly evaluations, to capture dynamic changes in these indicators.	[Mohammed, Debbie Y.; Koumoulos, Lisa Marie] William Paterson Univ, Dept Nursing, Wayne, NJ 07470 USA; [Mohammed, Debbie Y.; Slim, Jihad] St Michaels Hosp, Div Infect Dis, Newark, NJ 07102 USA; [Koumoulos, Lisa Marie] Hackensack Meridian Hlth, Palisades Med Ctr, Dept Qual, North Bergen, NJ USA; [Martin, Eugene] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Somerset, NJ USA; [Slim, Jihad] New York Med Coll, Valhalla, NY 10595 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; New York Medical College	Mohammed, DY (corresponding author), William Paterson Univ, Dept Nursing, Wayne, NJ 07470 USA.; Mohammed, DY (corresponding author), St Michaels Hosp, Div Infect Dis, Newark, NJ 07102 USA.	Mohammedd1@wpunj.edu						Aidala AA, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2015.302905; [Anonymous], 2020, NEW NJ TOP 10 CIT HI; [Anonymous], 2018, NEW NJ COUNT MUN HIV; [Anonymous], 2010, NAT HIV AIDS STRAT U; Beattie CM, 2019, AIDS BEHAV, V23, P784, DOI 10.1007/s10461-019-02399-7; Bello KJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1677-x; Benator DA, 2015, AIDS BEHAV, V19, P594, DOI 10.1007/s10461-014-0917-6; Bradley H, 2016, CLIN INFECT DIS, V62, P90, DOI 10.1093/cid/civ708; Centers for Disease Control and Prevention, 2018, HIV SURV REP, V31; Centers for Disease Control and Prevention, 2016, 4 CDCP; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen S., 2020, AM PUBL HLTH ASS ANN; Colasanti J, 2016, CLIN INFECT DIS, V62, P648, DOI 10.1093/cid/civ941; Crawford Timothy N, 2017, J Int Assoc Provid AIDS Care, V16, P42, DOI 10.1177/2325957416678929; Crepaz N, 2017, AIDS, V31, P2421, DOI [10.1097/QAD.0000000000001660, 10.1097/qad.0000000000001660]; Crepaz N, 2016, CLIN INFECT DIS, V63, P976, DOI 10.1093/cid/ciw418; Dombrowski JC, 2015, AIDS PATIENT CARE ST, V29, P279, DOI 10.1089/apc.2014.0346; Doshi RK, 2015, CLIN INFECT DIS, V60, P117, DOI 10.1093/cid/ciu722; Eaton EF, 2016, CLIN INFECT DIS, V63, P404, DOI 10.1093/cid/ciw280; Enns EA, 2019, AIDS BEHAV, V23, P2532, DOI 10.1007/s10461-019-02450-7; Fauci AS, 2019, JAMA-J AM MED ASSOC, V321, P844, DOI 10.1001/jama.2019.1343; Ghiam MK, 2017, AIDS RES HUM RETROV, V33, P1027, DOI [10.1089/AID.2017.0016, 10.1089/aid.2017.0016]; Health Resources and Services Administration: HIV/AIDS Bureau, 2019, PERF MEAS PORTF COR; Horberg MA, 2015, AIDS PATIENT CARE ST, V29, P582, DOI 10.1089/apc.2015.0139; Kay ES, 2020, AIDS CARE, V32, P89, DOI 10.1080/09540121.2019.1623375; Lee LM, 2003, PUBLIC HEALTH REP, V118, P400, DOI 10.1093/phr/118.5.400; Lesko CR, 2017, AIDS BEHAV, V21, P1016, DOI 10.1007/s10461-016-1585-5; Lesko CR, 2016, INT J EPIDEMIOL, V45, P140, DOI 10.1093/ije/dyv352; Lopez JD, 2018, AIDS BEHAV, V22, P3091, DOI 10.1007/s10461-018-2124-3; Ludema C, 2016, JAIDS-J ACQ IMM DEF, V73, P307, DOI 10.1097/QAI.0000000000001078; Mandsager P, 2018, AM J PUBLIC HEALTH, V108, pS246, DOI [10.2105/AJPH.2018.304689, 10.2105/ajph.2018.304689]; Marconi VC, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-14; Marks G, 2016, JAIDS-J ACQ IMM DEF, V73, P205, DOI 10.1097/QAI.0000000000001036; Monroe AK, 2017, JAIDS-J ACQ IMM DEF, V76, P82, DOI 10.1097/QAI.0000000000001469; Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005; New Jersey Department of Health, 2020, CHAR CAR NEW JERS HO; Ojikutu B, 2014, AIDS CARE, V26, P731, DOI 10.1080/09540121.2013.855299; Powers KA, 2017, JAIDS-J ACQ IMM DEF, V74, pS88, DOI 10.1097/QAI.0000000000001234; Robertson MM, 2019, JAIDS-J ACQ IMM DEF, V80, P46, DOI 10.1097/QAI.0000000000001877; Siddiqi AEA, 2016, JAIDS-J ACQ IMM DEF, V72, P230, DOI 10.1097/QAI.0000000000000960; Terzian AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029679; The White House Office of National AIDS Policy, NAT HIV AIDS STRAT U; United States Department of Health and Human Services, 2019, GUID US ANT THER AD; United States Department of Health and Human Services, 2017, 2017 POV GUID; Watson L, 2019, J RACIAL ETHN HEALTH, V6, P892, DOI 10.1007/s40615-019-00589-6; Yehia BR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129376; Yehia BR, 2015, JAIDS-J ACQ IMM DEF, V68, P413, DOI 10.1097/QAI.0000000000000489; Zhong YY, 2020, AM J PUBLIC HEALTH, V110, P1068, DOI 10.2105/AJPH.2020.305660	48	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0244376	10.1371/journal.pone.0244376	http://dx.doi.org/10.1371/journal.pone.0244376			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM2BU	33373385	Green Published, gold			2023-01-03	WOS:000603612300047
J	Davies, G; Jordan, S; Thayer, D; Tucker, D; Humphreys, I				Davies, Gareth; Jordan, Sue; Thayer, Daniel; Tucker, David; Humphreys, Ioan			Medicines prescribed for asthma, discontinuation and perinatal outcomes, including breastfeeding: A population cohort analysis	PLOS ONE			English	Article							SPONTANEOUS PRETERM BIRTH; GROWTH RESTRICTION; MATERNAL ASTHMA; PREGNANCY; WOMEN; EPIDEMIOLOGY; PREVALENCE; EXPOSURE; IMPACT; RISK	Objectives To explore associations between exposures to medicines prescribed for asthma and their discontinuation in pregnancy and preterm birth [<37 or <32 weeks], SGA [<10th and <3rd centiles], and breastfeeding at 6-8 weeks. Methods Design. A population-based cohort study. Setting. The Secure Anonymised Information Linkage [SAIL] databank in Wales, linking maternal primary care data with infant outcomes. Population. 107,573, 105,331, and 38,725 infants born 2000-2010 with information on premature birth, SGA and breastfeeding respectively, after exclusions. Exposures. maternal prescriptions for asthma medicines or their discontinuation in pregnancy. Methods. Odds ratios for adverse pregnancy outcomes were calculated for the exposed versus the unexposed population, adjusted for smoking, parity, age and socio-economic status. Results Prescriptions for asthma, whether continued or discontinued during pregnancy, were associated with birth at<32 weeks' gestation, SGA <10th centile, and no breastfeeding (aOR 1.33 [1.10-1.61], 1.10 [1.03-1.18], 0.93 [0.87-1.01]). Discontinuation of asthma medicines in pregnancy was associated with birth at<37 weeks' and <32 weeks' gestation (aOR 1.22 [1.06-1.41], 1.53 [1.11-2.10]). All medicines examined, except ICS and SABA prescribed alone, were associated with SGA Conclusions Prescription of asthma medicines before or during pregnancy was associated with higher prevalence of adverse perinatal outcomes, particularly if prescriptions were discontinued during pregnancy. Women discontinuing medicines during pregnancy could be identified from prescription records. The impact of targeting close monitoring and breastfeeding support warrants exploration.	[Davies, Gareth; Jordan, Sue; Thayer, Daniel; Humphreys, Ioan] Swansea Univ, Fac Hlth & Life Sci, Swansea, W Glam, Wales; [Tucker, David] Publ Hlth Wales, Cardiff, Wales	Swansea University	Jordan, S (corresponding author), Swansea Univ, Fac Hlth & Life Sci, Swansea, W Glam, Wales.	s.e.jordan@swansea.ac.uk		jordan, sue/0000-0002-5691-2987; Thayer, Dan/0000-0003-1847-4362	European Union [HEALTH-F5-2011-260598]; UK Research and Innovation funding through an Administrative Data Research Centre grant (2018-2021) [ES/S007393/1]	European Union(European Commission); UK Research and Innovation funding through an Administrative Data Research Centre grant (2018-2021)	This paper was developed from the EUROmediCAT project, and uses the cohort identified in that project. The analyses presented here were completed outside the funded period. Financial support for the EUROmediCAT study was provided by the European Union under the 7th Framework Program [grant agreement HEALTH-F5-2011-260598]. Start date: 1 March 2011. Duration: 48 months. Coordinator: Prof. Helen Dolk, University of Ulster. Further information can be found at www.euromedicat.eu.The paper is based on data in the all-Wales SAIL databank, which is supported by UK Research and Innovation funding to Swansea University through an Administrative Data Research Centre grant (2018-2021), project reference: ES/S007393/1, Principal Investigator: Professor David Ford. The funder played no part in the study or production of the paper.	Ali Z, 2016, RESP MED, V120, P124, DOI 10.1016/j.rmed.2016.10.004; Aljazaf K, 2003, BRIT J CLIN PHARMACO, V56, P18, DOI 10.1046/j.1365-2125.2003.01822.x; [Anonymous], 2017, NHS WALES DATA DICT; [Anonymous], 2015, GUID ATC CLASS DDD A; [Anonymous], 2013, PER TERM BIRTH FACT; [Anonymous], 2008, LANCET, V372, P917; [Anonymous], 2019, JMIR PUBLIC HLTH SUR, V4, pe53, DOI 10.2196/publichealth.9932; Bain E, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010660.pub2; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; Belanger K, 2010, OBSTET GYNECOL, V115, P559, DOI 10.1097/AOG.0b013e3181d06945; BNF, 2019, BRIT NAT FORM 78; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Broekema M, 2011, AM J RESP CRIT CARE, V183, P310, DOI 10.1164/rccm.201003-0494OC; Brozek JL, 2012, ARCH INTERN MED, V172, P1365, DOI 10.1001/archinternmed.2012.3250; BTS 2019, 2003, SIGN 158 BRIT GUID M; Burr ML, 2006, THORAX, V61, P296, DOI 10.1136/thx.2005.045682; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Chamberlain Chervonne, 2014, Open Nurs J, V8, P56, DOI 10.2174/1874434601408010056; Charlton RA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009237; Christiaens I, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0353-0; Clifton VL, 2009, AUST NZ J OBSTET GYN, V49, P619, DOI 10.1111/j.1479-828X.2009.01077.x; Cooper DL, 2013, J EPIDEMIOL COMMUN H, V67, P821, DOI 10.1136/jech-2012-202303; Corp IBM, REL 2011 IBM SPSS ST; Cossette B, 2014, ANN ALLERG ASTHMA IM, V112, P459, DOI 10.1016/j.anai.2014.02.010; Cossette B, 2013, THORAX, V68, P724, DOI 10.1136/thoraxjnl-2012-203122; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Ellfolk M, 2015, DRUGS DURING PREGNANCY AND LACTATION: TREATMENT OPTIONS AND RISK ASSESSMENT, 3RD EDITION, P651; Eltonsy S, 2014, RESP MED, V108, P9, DOI 10.1016/j.rmed.2013.07.009; Enriquez R, 2007, J ALLERGY CLIN IMMUN, V120, P625, DOI 10.1016/j.jaci.2007.05.044; EUROCAT, 2013, EUROCAT EUR SURV CON; EUROmediCAT, 2015, EMC SEL SER REUPT IN; Fewell Z, 2007, AM J EPIDEMIOL, V166, P646, DOI 10.1093/aje/kwm165; Ford DV, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-157; Gage S, 2015, J PEDIAT, V167, P875, DOI [10.1016/j.jpeds.2015.06.048, DOI 10.1016/J.JPEDS.2015.06.04826254835]; Garne E, 2016, BJOG-INT J OBSTET GY, V123, P1609, DOI 10.1111/1471-0528.14026; Global initiative for Asthma, 2020, GLOB STRAT ASTHM MAN; Gluck JC, 2006, IMMUNOL ALLERGY CLIN, V26, P63, DOI 10.1016/j.iac.2005.10.008; Gluck PA, 2005, CURR MED RES OPIN, V21, P1075, DOI 10.1185/030079905X50570; Greenland S, 2016, INT J EPIDEMIOL, V45, P565, DOI 10.1093/ije/dyw040; Grzeskowiak LE, 2016, EUR J OBSTET GYN R B, V197, P48, DOI 10.1016/j.ejogrb.2015.11.038; Hale T., 2010, MEDICATIONS MOTHERS; Harvey SM, 2020, PEDIATR PULM, V55, P1690, DOI 10.1002/ppul.24756; Heffler E, 2015, J ASTHMA, V52, P931, DOI 10.3109/02770903.2015.1026442; Herrera EA, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00149; IFF Research, 2013, INFANT FEEDING SURVE, DOI 10.5255/UKDA-SN-7281-2; Jonathan ACSterne, 2019, COCHRANE; Jordan S., 2015, ARCH WOMEN MENT HLTH, V18, P269, DOI [10.1007/S00737-014-0488-6, DOI 10.1007/S00737-014-0488-6]; Jordan S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225133; Jordan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067912; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Kemppainen M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197593; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Liu XP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11881-8; Makela MJ, 2013, RESP MED, V107, P1481, DOI 10.1016/j.rmed.2013.04.005; Malm H, 2003, EUR J CLIN PHARMACOL, V59, P127, DOI 10.1007/s00228-003-0584-4; Martins ACM, 2014, J CLIN PHARM THER, V39, P609, DOI 10.1111/jcpt.12204; McLaughlin K, 2018, WOMEN BIRTH, V31, pE349, DOI 10.1016/j.wombi.2018.01.008; Mehta N, 2015, BEST PRACT RES CL OB, V29, P598, DOI 10.1016/j.bpobgyn.2015.04.005; Milovanovic I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100337; Miquel-Verges F, 2015, J PERINATOL, V35, P198, DOI 10.1038/jp.2014.180; Mori K, 2016, RESP MED, V119, P1, DOI 10.1016/j.rmed.2016.08.007; Morrow J, 2006, J NEUROL NEUROSUR PS, V77, P193, DOI 10.1136/jnnp.2005.074203; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murphy VE, 2014, BJOG, V121, P812; Namazy JA, 2013, EUR RESPIR J, V41, P1082, DOI 10.1183/09031936.00195111; Nunes V NJ, 2009, CLIN GUIDELINES EVID; Oldereid NB, 2018, HUM REPROD UPDATE, V24, P320, DOI 10.1093/humupd/dmy005; Olesen C, 1999, ACTA OBSTET GYN SCAN, V78, P686, DOI 10.1034/j.1600-0412.1999.780805.x; Ostgard HF, 2014, J PEDIAT, V165, P921, DOI [10.1016/j.jpeds.2014.07.045, DOI 10.1016/J.JPEDS.2014.07.04525217202]; Platt MJ, 2014, PUBLIC HEALTH, V128, P399, DOI 10.1016/j.puhe.2014.03.010; Price T., 2009, ASTHMA SWANSEA; Rejno G, 2017, J ALLERGY CLIN IMMUN, V6, P916; Rejno G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104755; Renfrew M, 2012, PREVENTING DIS SAVIN; Rey E, 2007, BMJ-BRIT MED J, V334, P582, DOI 10.1136/bmj.39112.717674.BE; Robijn AL, 2019, CLIN EXP ALLERGY, V49, P1403, DOI 10.1111/cea.13474; Rollins NC, 2016, LANCET, V387, P491, DOI 10.1016/S0140-6736(15)01044-2; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Royal College of Paediatrics and Child Health, 2015, EARL YEARS UK WHO GR; Royston P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b604; Saha MR, 2015, INT BREASTFEED J, V10, DOI 10.1186/s13006-015-0053-6; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Schatz M, 2006, AM J OBSTET GYNECOL, V194, P120, DOI 10.1016/j.ajog.2005.06.028; Schnitzer ME, 2018, PHARMACOL RES PERSPE, V6, DOI 10.1002/prp2.426; Schulz KF, 2006, LANCET HDB ESSENTIAL; Sharma D, 2016, CLIN MED INSIGHTS-PE, V10, P67, DOI 10.4137/CMPed.S40070; Sillesen M, 2011, EUR J CARDIO-THORAC, V40, P448, DOI 10.1016/j.ejcts.2010.12.011; Stats Wales, 2019, BREASTF Q COUNTS AG; The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), EMA950982010 ENCEPP; Thygesen LC, 2014, EUR J EPIDEMIOL, V29, P551, DOI 10.1007/s10654-013-9873-0; Townsend PP., 1988, HLTH DEPRIVATION INE; Turkeltaub PC, 2017, J ALLER CL IMM-PRACT, V5, P1679, DOI 10.1016/j.jaip.2017.03.036; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Wadhwa PD, 2011, CLIN PERINATOL, V38, P351, DOI 10.1016/j.clp.2011.06.007; Wadhwa PD, 2004, AM J OBSTET GYNECOL, V191, P1063, DOI 10.1016/j.ajog.2004.06.070; Wales Statistics, 2013, BIRTH STAT NAT COMM; Wareing M, 2014, MICROCIRCULATION, V21, P58, DOI 10.1111/micc.12069; York R, 2012, SOC SCI RES, V41, P1379, DOI 10.1016/j.ssresearch.2012.05.014; Zetstra van der Woude AP., 2016, THESIS, P145	101	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2020	15	12							e0242489	10.1371/journal.pone.0242489	http://dx.doi.org/10.1371/journal.pone.0242489			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PE8QN	33296383	gold, Green Published			2023-01-03	WOS:000598626100067
J	Snyder, J; Zenone, M; Caulfield, T				Snyder, Jeremy; Zenone, Marco; Caulfield, Timothy			Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?	PLOS ONE			English	Article							LUNG-CANCER; STIGMA	Background Complementary and alternative medicine (CAM) is increasingly being integrated into conventional medical care for cancer, used to counter the side effects of conventional cancer treatment, and offered as an alternative to conventional cancer care. Our aim is to gain a broader understanding of trends in CAM interventions for cancer and crowdfunding campaigns for these interventions. Methods GoFundMe campaigns fundraising for CAM were retrieved through a database of crowdfunding campaign data. Search terms were drawn from two National Institutes of Health lists of CAM cancer interventions and a previous study. Campaigns were excluded that did not match these or related search terms or were initiated outside of June 4(th), 2018 to June 4(th), 2019. Results 1,396 campaigns were identified from the US (n = 1,037, 73.9%), Canada (n = 165, 11.8%), and the UK (n = 107, 7.7%). Most common cancer types were breast (n = 344, 24.6%), colorectal (n = 131, 9.4%), and brain (n = 98, 7.0%). CAM interventions sought included supplements (n = 422, 30.2%), better nutrition (n = 293, 21.0%), high dose vitamin C (n = 276, 19.8%), naturopathy (n = 226, 16.2%), and cannabis products (n = 211, 15.1%). Mexico (n = 198, 41.9%), and the US (n = 169, 35.7%) were the most common treatment destinations. Conclusions These findings confirm active and ongoing interest in using crowdfunding platforms to finance CAM cancer interventions. They confirm previous findings that CAM users with cancer tend to have late stage cancers, cancers with high mortality rates, and specific diseases such as breast cancer. These findings can inform targeted responses where facilities engage in misleading marketing practices and the efficacy of interventions is unproven.	[Snyder, Jeremy] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Zenone, Marco] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England; [Caulfield, Timothy] Univ Alberta, Hlth Law Inst, Edmonton, AB, Canada	Simon Fraser University; University of London; London School of Hygiene & Tropical Medicine; University of Alberta	Snyder, J (corresponding author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada.	jcs12@sfu.ca		Snyder, Jeremy/0000-0002-8236-2923	Greenwall Foundation	Greenwall Foundation	The authors received funding from the Greenwall Foundation that supported this work.	American Cancer Society, 2019, TRUTH ALT MED TREATM; [Anonymous], 2015, DIABETOL KLIN SA, V4, pA1; Carter-Harris L, 2015, J AM ASSOC NURSE PRA, V27, P240, DOI 10.1002/2327-6924.12227; Chapple A, 2004, BMJ-BRIT MED J, V328, P1470, DOI 10.1136/bmj.38111.639734.7C; Cohen AJ, 2019, JAMA INTERN MED, V179, P1717, DOI 10.1001/jamainternmed.2019.3330; Coulter M., 2019, GOFUNDME BLOCKS CASH; Eisele G, 2019, NEURO-ONCOL PRACT, V6, P237, DOI 10.1093/nop/npy035; Fouladbakhsh Judith M, 2010, Oncol Nurs Forum, V37, pE7, DOI 10.1188/10.ONF.E7-E15; Gorski D.H., 2019, CANC SOC, P95; John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y; Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487; Johnson SB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx145; Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004; Kreidler M., 2017, TIJUANAS ALTERNATIVE; Loquai C, 2017, EUR J CANCER, V71, P70, DOI 10.1016/j.ejca.2016.10.029; Ludmir EB, 2019, JNCI-J NATL CANCER I, V111, P1358, DOI 10.1093/jnci/djz117; Monroe S, ATLANTIC; National Cancer Institute, 2015, COMPL ALT MED CAM PA; National Cancer Institute, CAM THER A Z HLTH IN; National Cancer Institute, 1980, COMPL ALT MED CAM; National Cancer Institute, CAT CAM THER CAM HLT; National Health Service, 2018, COMPLEMENTARY ALTERN; Newman M, 2018, BMJ-BRIT MED J, P362; Shahvisi A, 2019, J BIOETHIC INQ, V16, P99, DOI 10.1007/s11673-018-9890-5; Sidorchuk A, 2009, CANCER CAUSE CONTROL, V20, P459, DOI 10.1007/s10552-009-9300-8; Snyder J, 2019, LANCET ONCOL, V20, P28, DOI 10.1016/S1470-2045(18)30950-1; Snyder J, 2018, REGEN MED, V13, P375, DOI 10.2217/rme-2018-0007; Snyder J, 2018, JAMA-J AM MED ASSOC, V319, P1935, DOI 10.1001/jama.2018.3057; Tanner C, 2019, HEALTH-LONDON, V23, P436, DOI 10.1177/1363459319829194; Unlu A., 2016, J ONCOL SCI, V1, P10, DOI [10.1016/j.jons.2015.11.010, DOI 10.1016/J.JONS.2015.11.010]; Vox F, 2018, JAMA-J AM MED ASSOC, V320, P1705, DOI 10.1001/jama.2018.10264	31	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0242048	10.1371/journal.pone.0242048	http://dx.doi.org/10.1371/journal.pone.0242048			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5CL	33216790	gold, Green Published			2023-01-03	WOS:000595653500064
J	Marston, C; Sowemimo, A				Marston, Cicely; Sowemimo, Annabel			Bridge-It trial-a step towards better contraception services Comment	LANCET			English	Editorial Material									[Marston, Cicely] London Sch Hyg & Trop Med, DEPTH Res Grp, London WC1E 7HT, England; [Sowemimo, Annabel] Haymarket Hlth Leicester Integrated Sexual & Repr, Midlands Partnership NHS Fdn Trust, Leicester, Leics, England	University of London; London School of Hygiene & Tropical Medicine	Marston, C (corresponding author), London Sch Hyg & Trop Med, DEPTH Res Grp, London WC1E 7HT, England.	cicely.marston@lshtm.ac.uk		Marston, Cicely/0000-0002-5529-4646				[Anonymous], 2018, J HLTH DESIGN; Cameron ST, 2020, LANCET, V396, P1585, DOI 10.1016/S0140-6736(20)31785-2; French RS, 2018, BMJ SEX REPROD HEAL, V44, P16, DOI 10.1136/jfprhc-2017-101728; Marston C, 2018, J HEALTH PSYCHOL, V23, P240, DOI 10.1177/1359105317726367; Marston C, 2016, B WORLD HEALTH ORGAN, V94, P376, DOI 10.2471/BLT.15.168492; World Health Organization Department of Reproductive Health and Research, 2018, FAMILY PLANNING GLOB	6	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	2020	396	10262					1536	1537						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OQ4TW	33189163	Green Submitted			2023-01-03	WOS:000588778800006
J	Rub, MA				Abdul Rub, Malik			Investigation of micellar and interfacial phenomenon of amitriptyline hydrochloride with cationic ester-bonded gemini surfactant mixture in different solvent media	PLOS ONE			English	Article							SODIUM DODECYL-SULFATE; CETYLTRIMETHYLAMMONIUM BROMIDE CTAB; DRUG NORTRIPTYLINE HYDROCHLORIDE; MIXED MICELLES; AGGREGATION BEHAVIOR; MOLECULAR-INTERACTIONS; ASSOCIATION BEHAVIOR; NONIONIC SURFACTANTS; PHENOTHIAZINE DRUGS; ANIONIC SURFACTANT	Herein, the interaction among the antidepressant drug amitriptyline hydrochloride (AMT) and a green gemini surfactant, ethane-1, 2-diyl bis(N,N-dimethyl-N-tetradecylammoniumacetoxy) dichloride (14-E2-14), via numerous techniques such as tensiometry, fluorimetry, FT-IR and UV-visible spectroscopy in three different media (aqueous 0.050 mol center dot kg(-1) NaCl, 0.50 and 1.0 mol center dot kg(-1) urea) were investigated. AMT is used to treat mental illness or mood problems, such as depression. The aggregation of biologically active ingredients can enhance the bioavailability of hydrophobic drugs. A significant interaction between AMT and 14-E2-14 was detected by tensiometric study as the critical micelle concentration (cmc) of AMT+14-E2-14 is reduced upon an increase of mole fraction (alpha(1)) of 14-E2-14. The decrease in cmc indicates the nonideality of studied mixtures of different compositions. Although, employed drug AMT is freely soluble in the aqueous and non-aqueous system but is not hydrophobic enough to act as its carrier. Instead, gemini surfactant formed spherical micelles in an aqueous system and their high solubilization capability, as well as their relatively lower cmc value, makes them highly stable in vivo. The cmc values of AMT+14-E-14 mixtures in all cases were further decreased and increased in NaCl and urea solutions respectively as compared with the aqueous system. Numerous micellar, interfacial, and thermodynamic parameters have been measured by applying various theoretical models. The obtained changes in the physicochemical assets of AMT upon adding of 14-E2-14 are likely to enhance the industrial and pharmaceutical applications of gemini surfactants. The negative interaction parameters (beta(m) and beta(sigma)), indicate synergistic attraction is occurring in the mixed systems. The aggregation number (N-agg), Stern-Volmer constant (K-sv), etc. are attained through the fluorescence method, also supporting the attractive interaction behavior of AMT+14-E2-14 mixtures in all solvents. The N-agg was found to increase in the salt solution and decrease in the urea system compared with the aqueous solution. FT-IR and UV-visible analysis also depict the interaction between the constituent alike tensiometry and fluorimetry methods. The results suggested that gemini surfactants may serve as a capable drug delivery agent for antidepressants, improving their bioavailability.	[Abdul Rub, Malik] King Abdulaziz Univ, Fac Sci, Dept Chem, Jeddah, Saudi Arabia	King Abdulaziz University	Rub, MA (corresponding author), King Abdulaziz Univ, Fac Sci, Dept Chem, Jeddah, Saudi Arabia.	malikrub@gmail.com	Rub, Malik Abdul/H-6027-2012	Rub, Malik Abdul/0000-0002-4798-5308	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah [130-015-D1433]; DSR	Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah; DSR	This work was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (130-015-D1433). The authors, therefore, acknowledge with thanks DSR technical and financial support.	Akram M, 2016, J IND ENG CHEM, V40, P161, DOI 10.1016/j.jiec.2016.06.019; Akram M, 2016, COLLOID SURFACE A, V493, P32, DOI 10.1016/j.colsurfa.2016.01.005; Alam MS, 2007, J CHEM ENG DATA, V52, P1326, DOI 10.1021/je700045r; [Anonymous], 2011, Z POLITIKWISSENSCHAF, V21, P93; [Anonymous], 2014, REG ANESTH PAIN MED; [Anonymous], 2017, INT J COMMUN SYST, V30, pe2999; ASAKAWA T, 1995, LANGMUIR, V11, P2376, DOI 10.1021/la00007a010; Attwood D., 1983, SURFACTANT SYSTEMS T; Azum N, 2019, J MOL LIQ, V290, DOI 10.1016/j.molliq.2019.111187; Azum N, 2017, J MOL LIQ, V240, P189, DOI 10.1016/j.molliq.2017.05.066; Azum N, 2017, J DISPER SCI TECHNOL, V38, P96, DOI 10.1080/01932691.2016.1144197; Bagheri A, 2019, J MOL LIQ, V282, P466, DOI 10.1016/j.molliq.2019.03.015; Bagheri A, 2017, RSC ADV, V7, P18151, DOI 10.1039/c6ra27382c; Bagheri A, 2017, J MOL LIQ, V230, P254, DOI 10.1016/j.molliq.2017.01.024; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; Costantino L, 2000, J PHYS CHEM B, V104, P7326, DOI 10.1021/jp0012808; Dar AA, 2008, J COLLOID INTERF SCI, V322, P572, DOI 10.1016/j.jcis.2008.03.022; Das S, 2014, SOFT MATTER, V10, P2863, DOI 10.1039/c3sm52938j; Fatma N, 2015, J MOL LIQ, V211, P247, DOI 10.1016/j.molliq.2015.06.064; Gaikar VG, 2008, J MOL LIQ, V138, P155, DOI 10.1016/j.molliq.2007.10.001; Ghasemi A, 2020, J MOL LIQ, V298, DOI 10.1016/j.molliq.2019.111948; Hierrezuelo JM, 2004, LANGMUIR, V20, P10419, DOI 10.1021/la048278i; Jakubowska A, 2010, J COLLOID INTERF SCI, V346, P398, DOI 10.1016/j.jcis.2010.03.043; Jojart B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102114; KALYANASUNDARAM K, 1977, J AM CHEM SOC, V99, P2039, DOI 10.1021/ja00449a004; Khan F, 2016, J MOL LIQ, V222, P1020, DOI 10.1016/j.molliq.2016.07.104; KUHARSKI RA, 1984, J AM CHEM SOC, V106, P5786, DOI 10.1021/ja00332a005; KUHARSKI RA, 1984, J AM CHEM SOC, V106, P5794, DOI 10.1021/ja00332a006; Kumar D, 2019, J PHYS ORG CHEM, V32, DOI 10.1002/poc.3918; Kumar D, 2019, J MOL LIQ, V274, P639, DOI 10.1016/j.molliq.2018.11.035; Kumar D, 2018, J MOL LIQ, V271, P254, DOI 10.1016/j.molliq.2018.08.147; Kumar D, 2018, J MOL LIQ, V262, P86, DOI 10.1016/j.molliq.2018.04.053; Kumar D, 2017, J MOL LIQ, V238, P389, DOI 10.1016/j.molliq.2017.05.027; Kumar D, 2016, J PHYS ORG CHEM, V29, P394, DOI 10.1002/poc.3546; Kumar H, 2018, J MOL LIQ, V266, P252, DOI 10.1016/j.molliq.2018.06.082; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; MAEDA H, 1995, J COLLOID INTERF SCI, V172, P98, DOI 10.1006/jcis.1995.1230; Mahajan RK, 2012, PHYS CHEM CHEM PHYS, V14, P887, DOI 10.1039/c1cp22448d; Mahajan S, 2013, ADV COLLOID INTERFAC, V199, P1, DOI 10.1016/j.cis.2013.06.008; Mahajan S, 2013, COLLOID SURFACE A, V424, P96, DOI 10.1016/j.colsurfa.2013.02.032; Mahajan S, 2012, J COLLOID INTERF SCI, V387, P194, DOI 10.1016/j.jcis.2012.07.085; MENGER FM, 1991, J AM CHEM SOC, V113, P1451, DOI 10.1021/ja00004a077; Motomura K, 1998, MIXED SURFACTANT SYS; Mukerjee P., 1967, ADV COLLOID INTERFAC, V1, P242, DOI [10.1016/0001-8686(67)80005-8, DOI 10.1016/0001-8686(67)80005-8]; Myers S, 2006, AMER MADE MUSIC SER, P3; Padalkar KV, 2009, J MOL LIQ, V144, P40, DOI 10.1016/j.molliq.2008.09.004; Patel H, 2010, BIOPHYS CHEM, V150, P119, DOI 10.1016/j.bpc.2010.03.015; Patel R, 2015, J SURFACTANTS DETERG, V18, P719, DOI 10.1007/s11743-015-1709-3; Ren ZH, 2017, J MOL LIQ, V236, P101, DOI 10.1016/j.molliq.2017.03.083; ROSEN MJ, 1982, J COLLOID INTERF SCI, V86, P164, DOI 10.1016/0021-9797(82)90052-2; Rosen MJ, 2004, SURFACTANTS INTERFAC, V3, DOI DOI 10.1002/0471670561.CH11; Rosen MJ, 1998, J SURFACTANT DETERG, V1, P547, DOI [10.1007/s11743-998-0057-8, DOI 10.1007/S11743-998-0057-8]; Rub MA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211077; Rub MA, 2018, J CHEM THERMODYN, V121, P199, DOI 10.1016/j.jct.2018.02.019; Rub MA, 2017, J CHEM ENG DATA, V62, P3216, DOI 10.1021/acs.jced.7b00298; Rub MA, 2017, J MOL LIQ, V241, P91, DOI 10.1016/j.molliq.2017.05.143; Rub MA, 2017, J MOL LIQ, V227, P1, DOI 10.1016/j.molliq.2016.11.113; Rub MA, 2016, RUSS J PHYS CHEM B+, V10, P1007, DOI 10.1134/S1990793116060257; Rub MA, 2016, J MOL LIQ, V218, P595, DOI 10.1016/j.molliq.2016.02.049; Rub MA, 2016, J CHEM THERMODYN, V96, P196, DOI 10.1016/j.jct.2016.01.001; Rubingh DN, 1979, MIXED MICELLE SOLUTI; Saha U, 2020, J MOL LIQ, V309, DOI 10.1016/j.molliq.2020.113164; Sharma R, 2017, ADV COLLOID INTERFAC, V248, P35, DOI 10.1016/j.cis.2017.07.032; Srivastava A, 2019, J MOL LIQ, V277, P349, DOI 10.1016/j.molliq.2018.12.070; Sugihara G., 2003, J OLEO SCI, V52, P449, DOI [10.5650/jos.52.449, DOI 10.5650/JOS.52.449]; Sulthana SB, 1998, J PHYS CHEM B, V102, P9653, DOI 10.1021/jp982060l; Taboada P, 2000, PHYS CHEM CHEM PHYS, V2, P5175, DOI 10.1039/b006400i; TACHIYA M, 1975, CHEM PHYS LETT, V33, P289, DOI 10.1016/0009-2614(75)80158-8; Tanford C., 1980, HYDROPHOBIC EFFECT F; Tehrani-Bagha AR, 2007, J COLLOID INTERF SCI, V312, P444, DOI 10.1016/j.jcis.2007.03.044; TURRO NJ, 1978, J AM CHEM SOC, V100, P5951, DOI 10.1021/ja00486a062; TURRO NJ, 1986, J PHYS CHEM-US, V90, P288, DOI 10.1021/j100274a017; Van Hamme JD, 2006, BIOTECHNOL ADV, V24, P604, DOI 10.1016/j.biotechadv.2006.08.001; Xia J, 2004, GEMINI SURFACTANTS S; Yousuf S, 2014, COLLOID SURFACE A, V463, P8, DOI 10.1016/j.colsurfa.2014.09.026; Zhinong G, 2008, J NAT SCI, V13, P227, DOI DOI 10.1007/S11859-008-0219-9; Zhou Q, 2003, LANGMUIR, V19, P4555, DOI 10.1021/la020789m; Zhu S, 2011, J SURFACTANTS DETERG, V14, P221, DOI 10.1007/s11743-010-1226-3; 2018, INT J COMMUN SYST, V0031, pE3812; 2018, INT J COMMUN SYST, V0031, pE3730	81	3	4	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241300	10.1371/journal.pone.0241300	http://dx.doi.org/10.1371/journal.pone.0241300			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PV	33156844	Green Published, gold			2023-01-03	WOS:000591376400036
J	Truche, P; NeMoyer, RE; Patino-Franco, S; Herrera-Escobar, JP; Torres, M; Pino, LF; Peck, GL				Truche, Paul; NeMoyer, Rachel E.; Patino-Franco, Sara; Herrera-Escobar, Juan P.; Torres, Myerlandi; Pino, Luis F.; Peck, Gregory L.			Publicly funded interfacility ambulance transfers for surgical and obstetrical conditions: A cross sectional analysis in an urban middle-income country setting	PLOS ONE			English	Article							PREHOSPITAL EMERGENCY CARE; MATERNAL MORTALITY; MEXICO-CITY; SYSTEMS; HEALTH; ACCESS; DELAYS	Introduction Interfacility transfers may reflect a time delay of definitive surgical care, but few studies have examined the prevalence of interfacility transfers in the urban low- and middle-income (LMIC) setting. The aim of this study was to determine the number of interfacility transfers required for surgical and obstetric conditions in an urban MIC setting to better understand access to definitive surgical care among LMIC patients. Methods A retrospective analysis of public interfacility transfer records was conducted from April 2015 to April 2016 in Cali, Colombia. Data were obtained from the single municipal ambulance agency providing publicly funded ambulance transfers in the city. Interfacility transfers were defined as any patient transfer between two healthcare facilities. We identified the number of transfers for patients with surgical conditions and categorized transfers based on patient ICD-9-CM codes. We compared surgical transfers from public vs. private healthcare facilities by condition type (surgical, obstetric, nonsurgical), transferring physician specialty, and transfer acuity (code blue, emergent, urgent and nonurgent) using logistic regression. Results 31,659 patient transports occurred over the 13-month study period. 22250 (70.2%) of all transfers were interfacility transfers and 7777 (35%) of transfers were for patients with surgical conditions with an additional 2,244 (10.3%) for obstetric conditions. 49% (8660/17675) of interfacility transfers from public hospitals were for surgical and obstetric conditions vs 32% (1466/4580) for private facilities (P<0.001). The most common surgical conditions requiring interfacility transfer were fractures (1,227, 5.4%), appendicitis (913, 4.1%), wounds (871, 3.9%), abdominal pain (818, 3.6%), trauma (652, 2.9%), and acute abdomen (271, 1.2%). Conclusion Surgical and obstetric conditions account for nearly half of all urban interfacility ambulance transfers. The most common reasons for transfer are basic surgical conditions with public healthcare facilities transferring a greater proportion of patient with surgical conditions than private facilities. Timely access to an initial healthcare facility may not be a reliable surrogate of definitive surgical care given the substantial need for interfacility transfers.	[Truche, Paul; NeMoyer, Rachel E.; Peck, Gregory L.] Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08901 USA; [Patino-Franco, Sara] Univ Antioquia, Dept Surg, Medellin, Colombia; [Herrera-Escobar, Juan P.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA; [Torres, Myerlandi] Pool Ambulancias Publ, Red Salud Ctr, Cali, Colombia; [Pino, Luis F.] Univ Valle, Dept Surg, Cali, Colombia; [Peck, Gregory L.] Rutgers Sch Publ Hlth, Dept Hlth Syst & Policy, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidad de Antioquia; Harvard University; Brigham & Women's Hospital; Universidad del Valle	Truche, P (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08901 USA.	Paul.truche@gmail.com	Herrera-Escobar, Juan Pablo/W-4515-2018	Herrera-Escobar, Juan Pablo/0000-0002-3496-1470; NeMoyer, Rachel/0000-0002-8228-2683				Albutt K, 2018, NATL SURG OBSTET ANA; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Arbelaez C, 2015, INT J EMERG MED, V8, DOI 10.1186/s12245-015-0057-4; Arreola-Risa C, 2000, J TRAUMA, V48, P119, DOI 10.1097/00005373-200001000-00020; Barnes-Josiah D, 1998, SOC SCI MED, V46, P981, DOI 10.1016/S0277-9536(97)10018-1; Bickler S.N., 2015, ESSENTIAL SURG DIS C, V1; Callese TE, 2015, J SURG RES, V193, P300, DOI 10.1016/j.jss.2014.09.040; Calvello EJ, 2015, B WORLD HEALTH ORGAN, V93, P417, DOI 10.2471/BLT.14.146571; Vera-Lopez JD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00144916, 10.1590/0102-311X00144916]; Debas HT, 2015, ESSENTIAL SURG DIS C, V1; Giedion U, 2009, HEALTH AFFAIR, V28, P853, DOI 10.1377/hlthaff.28.3.853; Henry JA, 2012, J TRAUMA ACUTE CARE, V73, P261, DOI 10.1097/TA.0b013e31824bde1e; Juran S, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000875; Kim J, 2017, PREHOSP DISASTER MED, V32, P642, DOI [10.1017/S1049023X1700677X, 10.1017/s1049023x1700677x]; Mallon W, 2017, REV MED CLIN LAS CON, V28, P163, DOI [10.1016/j.rmclc.2017.04.002, DOI 10.1016/J.RMCLC.2017.04.002]; Massenburg BB, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000226; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Mehmood A, 2018, INT J EMERG MED, V11, DOI 10.1186/s12245-018-0207-6; Mgawadere F, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1406-5; Mills A, 2014, NEW ENGL J MED, V370, P552, DOI 10.1056/NEJMra1110897; Morgan R, 2016, INT J HEALTH PLAN M, V31, P49, DOI 10.1002/hpm.2257; Nielsen K, 2012, PREHOSP EMERG CARE, V16, P381, DOI 10.3109/10903127.2012.664245; OECD, 2015, POL PRIOR INCL DEV, DOI [10.1787/9789264233393-en, DOI 10.1787/9789264233393-EN]; Peralta LMP, 2006, PREHOSP DISASTER MED, V21, P104, DOI 10.1017/S1049023X00003447; Pinet LM, 2005, SALUD PUBLICA MEXICO, V47, P64, DOI 10.1590/S0036-36342005000100010; Pouramin P, 2020, LANCET GLOB HEALTH, V8, pE711, DOI 10.1016/S2214-109X(20)30067-X; Qian Maowei, 2003, MINGDAI SHIXUE LICHE; Raykar NP, 2015, LANCET, V385, P16, DOI 10.1016/S0140-6736(15)60811-X; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Sorensen MJ, 2013, JAMA SURG, V148, P763, DOI 10.1001/jamasurg.2013.2132; Sriram V, 2016, PUBLIC HEALTH, V137, P169, DOI 10.1016/j.puhe.2016.02.022; Suryanto MN, 2017, PREHOSP DISASTER MED, V32, P64, DOI 10.1017/S1049023X1600114X; Thind A, 2015, ESSENTIAL SURG DIS C, V1; Vargas I, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-297	34	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241553	10.1371/journal.pone.0241553	http://dx.doi.org/10.1371/journal.pone.0241553			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OU2PV	33156837	gold, Green Published			2023-01-03	WOS:000591376400050
J	Mann, JP; Carter, P; Armstrong, MJ; Abdelaziz, HK; Uppal, H; Patel, B; Chandran, S; More, R; Newsome, PN; Potluri, R				Mann, Jake P.; Carter, Paul; Armstrong, Matthew J.; Abdelaziz, Hesham K.; Uppal, Hardeep; Patel, Billal; Chandran, Suresh; More, Ranjit; Newsome, Philip N.; Potluri, Rahul			Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors	PLOS ONE			English	Article							FIBROSIS STAGE; HEART-FAILURE; FOLLOW-UP; NAFLD; CIRRHOSIS; STEATOHEPATITIS; PREDICTOR	Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mortality in NAFLD derives from specialist liver centres. It is not clear if the higher reported mortality rates in individuals with non-cirrhotic NAFLD are entirely accounted for by complications of atherosclerosis and diabetes. Therefore, we aimed to describe the CVD burden and mortality in NAFLD when adjusting for metabolic risk factors using a 'real world' cohort. We performed a retrospective study of patients followed-up after an admission to non-specialist hospitals with a NAFLD-spectrum diagnosis. Non-cirrhotic NAFLD and NAFLD-cirrhosis patients were defined by ICD-10 codes. Cases were age-/sex-matched with non-NAFLD hospitalised patients. All-cause mortality over 14-years follow-up after discharge was compared between groups using Cox proportional hazard models adjusted for demographics, CVD, and metabolic syndrome components. We identified 1,802 patients with NAFLD-diagnoses: 1,091 with non-cirrhotic NAFLD and 711 with NAFLD-cirrhosis, matched to 24,737 controls. There was an increasing burden of CVD with progression of NAFLD: for congestive heart failure 3.5% control, 4.2% non-cirrhotic NAFLD, 6.6% NAFLD-cirrhosis; and for atrial fibrillation 4.7% control, 5.9% non-cirrhotic NAFLD, 12.1% NAFLD-cirrhosis. Over 14-years follow-up, crude mortality rates were 14.7% control, 13.7% non-cirrhotic NAFLD, and 40.5% NAFLD-cirrhosis. However, after adjusting for demographics, non-cirrhotic NAFLD (HR 1.3 (95% CI 1.1-1.5)) as well as NAFLD-cirrhosis (HR 3.7 (95% CI 3.0-4.5)) patients had higher mortality compared to controls. These differences remained after adjusting for CVD and metabolic syndrome components: non-cirrhotic NAFLD (HR 1.2 (95% CI 1.0-1.4)) and NAFLD-cirrhosis (HR 3.4 (95% CI 2.8-4.2)). In conclusion, from a large non-specialist registry of hospitalised patients, those with non-cirrhotic NAFLD had increased overall mortality compared to controls even after adjusting for CVD.	[Mann, Jake P.] Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England; [Mann, Jake P.] Univ Cambridge, Dept Paediat, Cambridge, England; [Mann, Jake P.; Carter, Paul; Uppal, Hardeep; Potluri, Rahul] Aston Univ, ACALM Study Unit Collaborat, Aston Med Sch, Birmingham, W Midlands, England; [Carter, Paul] Univ Cambridge, Dept Med, Div Cardiovasc Med, Cambridge, England; [Armstrong, Matthew J.] Univ Hosp Birmingham NHS Fdn Trust, Liver Unit, Birmingham, W Midlands, England; [Abdelaziz, Hesham K.; Patel, Billal; More, Ranjit] Blackpool Victoria Hosp, Lancashire Cardiac Ctr, Blackpool, England; [Abdelaziz, Hesham K.] Ain Shams Univ Hosp, Dept Cardiovasc Med, Cairo, Egypt; [Chandran, Suresh] Pennine Acute Hosp NHS Trust, Dept Med, Manchester, Lancs, England; [Newsome, Philip N.] Univ Hosp Birmingham NHS Fdn Trust, Res Liver Biomed Res Unit, Natl Inst Hlth, Birmingham, W Midlands, England; [Newsome, Philip N.] Univ Birmingham, Birmingham, W Midlands, England; [Newsome, Philip N.] Univ Birmingham, Ctr Liver Res, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England	University of Cambridge; University of Cambridge; Aston University; University of Cambridge; University of Birmingham; Egyptian Knowledge Bank (EKB); Ain Shams University; University of Birmingham; University of Birmingham; University of Birmingham	Mann, JP (corresponding author), Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England.; Mann, JP (corresponding author), Univ Cambridge, Dept Paediat, Cambridge, England.; Mann, JP (corresponding author), Aston Univ, ACALM Study Unit Collaborat, Aston Med Sch, Birmingham, W Midlands, England.	jm2032@cam.ac.uk	Hesham K Abdelaziz, Abdelaziz HK/I-9302-2019; Newsome, Philip N/D-4495-2018	Hesham K Abdelaziz, Abdelaziz HK/0000-0002-5165-9919; Newsome, Philip N/0000-0001-6085-3652; Mann, Jake/0000-0002-4711-9215	Wellcome Trust Fellowship [216329/Z/19/Z]	Wellcome Trust Fellowship(Wellcome Trust)	JPM is supported by a Wellcome Trust Fellowship (216329/Z/19/Z, https://wellcome.ac.uk).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander KS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194153; Alexander M, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5367; Angelico F, 2017, ATHEROSCLEROSIS, V262, P179, DOI 10.1016/j.atherosclerosis.2017.03.038; Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Anstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41; Athyros VG, 2020, CURR VASC PHARMACOL, V18, P172, DOI 10.2174/1570161117666190405164313; Athyros VG, 2017, METABOLISM, V71, P17, DOI 10.1016/j.metabol.2017.02.014; Athyros VG, 2015, WORLD J GASTROENTERO, V21, P6820, DOI 10.3748/wjg.v21.i22.6820; Baratta F, 2020, CLIN GASTROENTEROL H, V18, P2324, DOI 10.1016/j.cgh.2019.12.026; Carter P, 2014, INT J CARDIOL, V173, P573, DOI 10.1016/j.ijcard.2014.03.116; Colli A, 2010, RADIOLOGY, V257, P872, DOI 10.1148/radiol.10100013; Dixon JB, 2004, HEPATOLOGY, V39, P1647, DOI 10.1002/hep.20251; Dulai PS, 2017, HEPATOLOGY, V65, P1557, DOI 10.1002/hep.29085; Ekstedt M, 2006, HEPATOLOGY, V44, P865, DOI 10.1002/hep.21327; Ekstedt M, 2015, HEPATOLOGY, V61, P1547, DOI 10.1002/hep.27368; Estes C, 2018, HEPATOLOGY, V67, P123, DOI 10.1002/hep.29466; Gokce S, 2013, PEDIATR CARDIOL, V34, P308, DOI 10.1007/s00246-012-0447-9; Hagstrom H, 2019, LIVER INT, V39, P197, DOI 10.1111/liv.13973; Hagstrom H, 2017, J HEPATOL, V67, P1265, DOI 10.1016/j.jhep.2017.07.027; Hamaguchi M, 2007, WORLD J GASTROENTERO, V13, P1579, DOI 10.3748/wjg.v13.i10.1579; Henson JB, 2020, ALIMENT PHARM THER, V51, P728, DOI 10.1111/apt.15660; Katsiki N, 2019, METABOLISM, V98, pIII, DOI 10.1016/j.metabol.2019.07.009; Kilaru SM, 2017, GASTROENTEROLOGY, V152, pS688, DOI 10.1016/S0016-5085(17)32415-0; Kim D, 2013, HEPATOLOGY, V57, P1357, DOI 10.1002/hep.26156; Labenz C, 2018, ALIMENT PHARM THER, V48, P1109, DOI 10.1111/apt.14976; Liu ZP, 2020, J HEPATOL, V73, P263, DOI 10.1016/j.jhep.2020.03.006; Molnar MZ, 2019, LIVER TRANSPLANT, V25, P399, DOI 10.1002/lt.25367; Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623; Noureddin M, 2020, GASTROENTEROLOGY, V159, P422, DOI 10.1053/j.gastro.2020.04.039; O'Leary JG, 2019, GASTROENTEROLOGY, V157, P34, DOI 10.1053/j.gastro.2019.03.070; Paik J, 2019, LIVER INT, V39, P342, DOI 10.1111/liv.13992; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Potluri R, 2014, INT J CARDIOL, V176, P760, DOI 10.1016/j.ijcard.2014.07.097; Properzi C, 2018, HEPATOLOGY, V68, P1741, DOI 10.1002/hep.30076; Ratziu V, 2018, LANCET GASTROENTEROL, V3, P8, DOI 10.1016/S2468-1253(17)30365-5; Rowe IA, 2018, LANCET GASTROENTEROL, V3, P66, DOI 10.1016/S2468-1253(17)30142-5; Samuel VT, 2018, CELL METAB, V27, P22, DOI 10.1016/j.cmet.2017.08.002; Sanders FWB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1439-8; Sangha J, 2015, INT J NEUROSCI, V125, P256, DOI 10.3109/00207454.2014.930463; Sherwood P, 2001, BRIT MED J, V322, P276, DOI 10.1136/bmj.322.7281.276; Stahl EP, 2019, J AM COLL CARDIOL, V73, P948, DOI 10.1016/j.jacc.2018.11.050; Stefan N, 2019, LANCET DIABETES ENDO, V7, P313, DOI 10.1016/S2213-8587(18)30154-2; Sung KC, 2014, J HEPATOL, V60, P1040, DOI 10.1016/j.jhep.2014.01.009; Targher G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057183; Uppal H, 2015, J INTELL DISABIL RES, V59, P873, DOI 10.1111/jir.12196; Valbusa F, 2018, INT J CARDIOL, V265, P162, DOI 10.1016/j.ijcard.2018.04.129; Widmer RJ, 2015, AM J MED, V128, P229, DOI 10.1016/j.amjmed.2014.10.014; Wijarnpreecha K, 2018, DIGEST LIVER DIS, V50, P1166, DOI 10.1016/j.dld.2018.09.004; Wild SH, 2018, DIABETES CARE, V41, P341, DOI 10.2337/dc17-1590; WU SQ, 2016, SCI REP-UK, V6, DOI DOI 10.1038/SREP3338627633274; Younossi ZM, 2019, TRANSPLANTATION, V103, P22, DOI 10.1097/TP.0000000000002484; Younossi ZM, 2016, HEPATOLOGY, V64, P1577, DOI 10.1002/hep.28785; Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431; Ziaei F, 2016, INT J CARDIOL, V214, P411, DOI 10.1016/j.ijcard.2016.03.198; Ziff OJ, 2018, INT J CARDIOL, V252, P117, DOI 10.1016/j.ijcard.2017.06.033	56	2	2	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0241357	10.1371/journal.pone.0241357	http://dx.doi.org/10.1371/journal.pone.0241357			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8WV	33108366	Green Published, Green Submitted, gold			2023-01-03	WOS:000588372400031
J	Kovacs, L; Cabral, P; Chammas, R				Kovacs, Luciana; Cabral, Pablo; Chammas, Roger			Mannose receptor 1 expression does not determine the uptake of high-density mannose dendrimers by activated macrophages populations	PLOS ONE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; PAMAM DENDRIMERS; POOR-PROGNOSIS; NANOPARTICLES; DELIVERY; DRUG; EXOCYTOSIS; RETENTION; MECHANISM; CORRELATE	The presence of a high number of macrophages within solid tumors is often significantly associated with poor prognosis and predict treatment failure for chemotherapy and radiotherapy. Macrophages are innate immune cells capable of performing diverse functions depending on the different signals from the microenvironment. The classically activated macrophage is commonly present during the early stages of tumor development while alternatively activated macrophages are associated with more advanced tumors. The distinction of the antitumoral macrophages from the pro-tumoral macrophages is not absolute. However, they have different cell surface markers such as mannose receptor (MRC1 or CD206) abundantly expressed by macrophages treated with interleukin-4 (IL-4). The important roles of macrophages in cancers suggest that it is important to develop novel therapies that target these cells. In the present study, we designed a probe using Polyamidoamine (PAMAM) fifth-generation (G5) dendrimers conjugated with mannose, Cyanine 7 (Cy7), and hydrazinonicotinamide (HYNIC) for target macrophages with high expression of MRC1 in the tumor. The intracellular uptake of(99m)Tc-HYNIC-dendrimer-mannose-Cy7 through the interaction with MRC1 in bone marrow-derived macrophages (BMDMs) untreated or treated with lipopolysaccharides (LPS) + interferon (IFN)gamma or IL-4 was analyzed. Our results show that high-density mannose dendrimers are preferentially bound by macrophages treated by IFN gamma and LPS that express lower levels of MRC1 than for macrophages treated by IL-4 that express high levels of MRC1. Furthermore, the intracellular(99m)Tc-HYNIC-dendrimer-mannose-Cy7 uptake in BMDMs was not inhibited in the presence of free mannose or glucose. This result suggests that(99m)Tc-HYNIC-dendrimer-mannose-Cy7 is not internalized via macrophage MRC1. Based on these findings, we concluded that MRC1 expression does not determine the uptake of high-density mannose dendrimers.	[Kovacs, Luciana; Chammas, Roger] Univ Sao Paulo, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Fac Med, Sao Paulo, SP, Brazil; [Cabral, Pablo] Univ Republica, Dept Radiofarmacia, Ctr Invest Nucl, Fac Ciencias, Montevideo, Uruguay; [Chammas, Roger] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Sao Paulo, SP, Brazil	Universidade de Sao Paulo; Universidad de la Republica, Uruguay; Universidade de Sao Paulo	Kovacs, L (corresponding author), Univ Sao Paulo, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.	luciana.kovacs@outlook.com	Kovacs, Luciana/N-7378-2013; Chammas, Roger/A-8004-2011; Cabral, Pablo/HDO-1170-2022	Kovacs, Luciana/0000-0002-3139-7528; Chammas, Roger/0000-0003-0342-8726; 	Sao Paulo Research Foundation (FAPESP) [2014/20746-0]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	The work was supported by grant 2014/20746-0, Sao Paulo Research Foundation (FAPESP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedi-Gaballu F, 2018, APPL MATER TODAY, V12, P177, DOI 10.1016/j.apmt.2018.05.002; ABRAMS MJ, 1990, J NUCL MED, V31, P2022; Albertazzi L, 2010, MOL PHARMACEUT, V7, P680, DOI 10.1021/mp9002464; [Anonymous], 2018, NAT REV GENET, V19, P1, DOI 10.1038/nrg.2017.141; [Anonymous], 2018, NAT CLIM CHANGE, V8, P1, DOI 10.1038/s41558-017-0058-9; [Anonymous], 2018, SUSTAINABILITY; [Anonymous], 2016, EBIOMEDICINE, V14, P1, DOI DOI 10.2903/J.EFSA.2016.4418; Azad AK, 2015, J IMMUNOL, V195, P2019, DOI 10.4049/jimmunol.1402005; Bosnjakovic A, 2011, NANOMED-NANOTECHNOL, V7, P284, DOI 10.1016/j.nano.2010.10.008; Cheng Z, 2006, BIOCONJUGATE CHEM, V17, P662, DOI 10.1021/bc050345c; Chowdhury HH, 2018, BIOMATER SCI-UK, V6, P388, DOI 10.1039/c7bm00886d; Epelman S, 2014, IMMUNITY, V41, P21, DOI 10.1016/j.immuni.2014.06.013; Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024; Gopinath T., 2019, SCI REP, V9, P1; He HL, 2018, TRANSL RES, V193, P13, DOI 10.1016/j.trsl.2017.10.008; Hoeffel G, 2018, CELL IMMUNOL, V330, P5, DOI 10.1016/j.cellimm.2018.01.001; Jiang C, 2017, MOL IMAGING, V16, P1, DOI 10.1177/1536012116689499; Klajnert-Maculewicz B, 2019, PHARM RES-DORDR, V36, P1; Kovacs L, 2014, CURR RADIOPHARM, V7, P115, DOI 10.2174/1874471007666140825121615; Kulhari H, 2016, SCI REP-UK, V6, DOI 10.1038/srep23179; Larionova I, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1596004; Li YC, 2020, ACS APPL BIO MATER, V3, P4335, DOI 10.1021/acsabm.0c00368; Lima L, 2014, UROL ONCOL-SEMIN ORI, V32, P449, DOI 10.1016/j.urolonc.2013.10.012; Loyher PL, 2018, J EXP MED, V215, P2536, DOI 10.1084/jem.20180534; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Mukherjee SP, 2013, NANOMED-NANOTECHNOL, V9, P202, DOI 10.1016/j.nano.2012.05.002; Nabeshima A, 2015, BRIT J CANCER, V112, P547, DOI 10.1038/bjc.2014.637; Naha PC, 2010, TOXICOL APPL PHARM, V246, P91, DOI 10.1016/j.taap.2010.04.014; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Petty AJ, 2017, IMMUNOTHERAPY-UK, V9, P289, DOI 10.2217/imt-2016-0135; Sakhtianchi R, 2013, ADV COLLOID INTERFAC, V201, P18, DOI 10.1016/j.cis.2013.10.013; Saovapakhiran A, 2009, BIOCONJUGATE CHEM, V20, P693, DOI 10.1021/bc8002343; Sharma A, 2018, J CONTROL RELEASE, V283, P175, DOI 10.1016/j.jconrel.2018.06.003; Shiao SL, 2015, CANCER IMMUNOL RES, V3, P518, DOI 10.1158/2326-6066.CIR-14-0232; Shigeoka M, 2013, CANCER SCI, V104, P1112, DOI 10.1111/cas.12188; Sugimura K, 2015, J SURG ONCOL, V111, P752, DOI 10.1002/jso.23881; Sun XL, 2015, THERANOSTICS, V5, P597, DOI 10.7150/thno.11546; Tassano MR, 2011, BIOORG MED CHEM LETT, V21, P5598, DOI 10.1016/j.bmcl.2011.06.079; Tiainen S, 2015, HISTOPATHOLOGY, V66, P873, DOI 10.1111/his.12607; Wangpradit O, 2016, ENVIRON SCI POLLUT R, V23, P2128, DOI 10.1007/s11356-015-5022-5; Zhang CR, 2017, THERANOSTICS, V7, P4276, DOI 10.7150/thno.20999; Zhang F, 2015, BIOMATERIALS, V52, P507, DOI 10.1016/j.biomaterials.2015.02.053; Zhang J, 2016, INT J NANOMED, V11, P3677, DOI 10.2147/IJN.S106418; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83	45	1	1	4	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2020	15	10							e0240455	10.1371/journal.pone.0240455	http://dx.doi.org/10.1371/journal.pone.0240455			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3UK	33048944	gold, Green Published			2023-01-03	WOS:000581813300036
J							WHO Solidarity Trial Consortium	Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								The authors report interim results of the WHO Solidarity trial of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with Covid-19. Effects on overall mortality, initiation of ventilation, and duration of hospital stay are compared. Background World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). Methods We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. Results At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. Conclusions These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ; ClinicalTrials.gov number, .)					Mangal, Vishu/AAM-2975-2021; Faure, Emmanuel/AAD-9412-2020; Retamar-Gentil, Pilar/AGN-4012-2022; Portillo, Alexy Inciarte/ACQ-2720-2022; Hormati, Ahmad/D-5032-2018; Meregildo-Rodriguez, Edinson Dante/AAH-5720-2020; Ray, Avik/AAH-1003-2019; Maggioni, Aldo Pietro/AAL-5334-2020; Khodashahi, Rozita/AAN-1727-2021; Shirani, Kiana/C-6433-2018; Revest, Matthieu/L-9533-2015; Zand, Farid/O-2293-2017; Abdel Baki, Amin/AAW-1717-2021; Zaky, Samy/AAB-6469-2021; Portolés, Antonio/AAE-5451-2020; Bounes, Fanny/ABG-6128-2021; Guijarro, Carlos/B-3003-2008; Siami, Zeinab/ABI-3691-2020; Riccardi, Niccolò/ABG-7609-2020; Sima, Ali Reza/AAV-5625-2021; ghomi, seyed yaser foroghi/AAQ-3261-2021; , Felipe/F-4242-2014; Portillo, Alexy Inciarte/AAH-1727-2022; Marwah, Vikas/ABC-4319-2020; PANDA, PRASAN/AAB-5923-2021; Cruz, Ana Fernández/L-2429-2019; van Blydenstein, Sarah Alexandra/AGR-4822-2022; Olsen, Inge Christoffer/R-9128-2019; Villegas-Chiroque, Miguel/AAK-8016-2021; Hulot, Jean-Sébastien/A-2278-2016; Norouzi, Alireza/L-6872-2016; Nel, Jeremy/ABH-2743-2020; Gimeno, Francesc/AAK-5835-2021; Azañero, Johan/AAV-5606-2021; Díaz Pollán, Beatriz/ABA-9452-2021; Amini, Mahnaz/ABC-4027-2020; assiri, abdullah/AAF-5665-2021; Barry, Mazin/AAJ-7615-2020; Danion, Francois/Q-2764-2017; Tikkinen, Kari/L-3632-2018; Blomberg, Bjorn/B-9605-2015; Kalliala, Ilkka/O-6346-2014; Ramos-Martinez, Antonio/G-5535-2016; Martin-Blondel, Guillaume/K-6762-2014	Faure, Emmanuel/0000-0003-2618-2706; Portillo, Alexy Inciarte/0000-0003-1896-3457; Hormati, Ahmad/0000-0002-1322-1318; Meregildo-Rodriguez, Edinson Dante/0000-0003-1814-5593; Ray, Avik/0000-0002-0047-7453; Maggioni, Aldo Pietro/0000-0003-2764-6779; Khodashahi, Rozita/0000-0002-6514-7308; Shirani, Kiana/0000-0002-2960-9624; Zand, Farid/0000-0003-3489-3372; Abdel Baki, Amin/0000-0002-2769-4503; Zaky, Samy/0000-0003-4123-9221; Portolés, Antonio/0000-0002-5646-5275; Guijarro, Carlos/0000-0001-8132-9366; Riccardi, Niccolò/0000-0002-2947-4707; Sima, Ali Reza/0000-0002-1397-4846; ghomi, seyed yaser foroghi/0000-0002-1555-2241; , Felipe/0000-0001-7658-5832; Portillo, Alexy Inciarte/0000-0003-1896-3457; Marwah, Vikas/0000-0002-7033-6090; PANDA, PRASAN/0000-0002-3008-7245; Cruz, Ana Fernández/0000-0003-1189-1120; van Blydenstein, Sarah Alexandra/0000-0003-3388-6218; Olsen, Inge Christoffer/0000-0001-6889-5873; Villegas-Chiroque, Miguel/0000-0002-8090-8224; Hulot, Jean-Sébastien/0000-0001-5463-6117; Norouzi, Alireza/0000-0003-4227-7350; Nel, Jeremy/0000-0003-4115-894X; Gimeno, Francesc/0000-0002-0937-6819; Azañero, Johan/0000-0003-3385-1891; Díaz Pollán, Beatriz/0000-0002-7241-4208; Amini, Mahnaz/0000-0002-5205-4647; assiri, abdullah/0000-0002-5605-2876; Barry, Mazin/0000-0003-2274-007X; Comeche, Belen/0000-0001-5760-8824; Lee, Heng Gee/0000-0002-0963-5075; McCarthy, Cormac/0000-0003-2896-5210; Sierra Torres, Gonzalo/0000-0003-0572-6292; MOURVILLIER, BRUNO/0000-0001-5227-1468; Ascaso, Ana/0000-0002-9159-3520; Connors, William/0000-0003-4109-152X; siami, zeinab/0000-0002-0587-0705; Marinosci, Annalisa/0000-0002-8054-0044; Kildal, Anders Benjamin/0000-0002-1319-6511; Fanjul, Francisco/0000-0003-1852-0330; Alorayyidh, Najla/0000-0003-3092-811X; Varghese, George M/0000-0002-4040-5649; Vizcarra, Pilar/0000-0001-8553-6995; Abdool Karim, Quarraisha/0000-0002-0985-477X; Murthy, Srinivas/0000-0002-9476-839X; Alcantara, Andres Martin/0000-0001-8204-9796; Sterne, Jonathan/0000-0001-8496-6053; Hakamifard, Atousa/0000-0001-9456-2239; Miranda Montoya, Maria Consuelo/0000-0001-5730-0723; Balbuena, Juan Pablo/0000-0003-0108-2813; Danion, Francois/0000-0003-3907-0658; Myllarniemi, L Marjukka/0000-0001-9343-0867; Tikkinen, Kari/0000-0002-1389-8214; Blomberg, Bjorn/0000-0001-5647-4297; Bingi, Thrilok Chander/0000-0002-6151-3868; Sinisalo, Marjatta/0000-0003-2275-2230; Palacios-Baena, Zaira R./0000-0002-1713-6807; Agrawal, Umang/0000-0002-2105-3932; Merino de Lucas, Esperanza/0000-0003-3854-4874; Gaborit, Benjamin/0000-0002-6076-9722; Perez-Macias, Natalia/0000-0002-9216-8438; Munez Rubio, Elena/0000-0002-5256-097X; Soto, Alonso/0000-0001-8648-8032; Kalliala, Ilkka/0000-0002-7664-0587; Lozano Martin, Daniel/0000-0002-2739-9555; BANI-SADR, Firouze/0000-0001-8268-866X; Ramos-Martinez, Antonio/0000-0002-4840-9425; Balachandran, Amith/0000-0001-8978-6086; Ponce Ponte, Oscar Josue/0000-0001-5729-8408; Merle, Corinne/0000-0003-4229-365X; Trelle, Sven/0000-0002-8162-8910; Mesipogu, Rajarao/0000-0002-9205-8343; Martin-Blondel, Guillaume/0000-0002-8363-7028; Guevara Pulido, Fredy Orlando/0000-0002-6256-4130; Lee, Nelson/0000-0002-0783-6607; Alvarez-Moreno, Carlos Arturo/0000-0001-5419-4494; D'Ortenzio, Eric/0000-0002-4527-6209; de Pablo Esteban, Antonio/0000-0001-6017-609X; Binnie, Alexandra/0000-0003-2969-8177; kabil, Mohamed solyman/0000-0003-2172-2216; Cappel-Porter, Heike/0000-0001-6320-4834; Nezvalova-Henriksen, Katerina/0000-0002-8085-4932; , irmansyah/0000-0001-6734-1940; Hueda Zavaleta, Miguel Angel/0000-0002-8049-7787; Barreto Rocchetti, Luis Guillermo/0000-0002-2851-0219; Palanee-Phillips, Thesla/0000-0002-0052-5830; Tholin, Birgitte/0000-0001-6768-541X; wallet, florent/0000-0003-3174-6246; Medina, Marco Tulio/0000-0003-0469-054X; Hassany, Mohamed/0000-0002-6001-8793; Desgranges, Florian/0000-0002-0409-1689; Godbole, Sheela/0000-0001-6537-9064; RIVAS PATERNA, ANA BELEN/0000-0001-5357-4583; Spasovska, Katerina/0000-0002-4614-9842; Fanciulli, Chiara/0000-0003-2175-9027; Hoff, Dag Arne Lihaug/0000-0002-7861-2125; QUENOT, Jean-Pierre/0000-0003-2351-682X; Moorthy, Vasee/0000-0002-6535-2854	World Health Organization [ISRCTN83971151]	World Health Organization(World Health Organization)	Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Axfors C, 2020, PREPRINT, DOI DOI 10.1101/2020.09.16.20194571V2; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Buchwalder PA, 2000, J INTERF CYTOK RES, V20, P857, DOI 10.1089/10799900050163226; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; fda, FDAS APPR VEKL REMD; Flammer JR, 2010, MOL CELL BIOL, V30, P4564, DOI 10.1128/MCB.00146-10; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Gregoire M, 2020, J ANTIMICROB CHEMOTH, V75, P2702, DOI 10.1093/jac/dkaa195; Horby P, 2020, NEW ENGL J MED, V383, P2030, DOI 10.1056/NEJMoa2022926; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Horby PW, 2020, LANCET, V396, P1345, DOI 10.1016/S0140-6736(20)32013-4; Jalkanen J, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03048-5; Jalkanen J, 2020, INTENS CARE MED, V46, P1937, DOI 10.1007/s00134-020-06086-3; Peto R, 2011, BRIT J CANCER, V104, P1057, DOI 10.1038/bjc.2011.79; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Venisse N, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104866; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; White NJ, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003252; World Health Organization, INT RAND TRIAL ADD T; World Health Organization, 2020, CORT COVID 19 LIV GU; World Health Organization, R D BLUEPR COV 19; World Health Organization, 2020, COORD GLOB RES ROADM	23	1435	1459	23	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	2021	384	6					497	511		10.1056/NEJMoa2023184	http://dx.doi.org/10.1056/NEJMoa2023184			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG5JQ	33264556	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000617621800007
J	Lopes, RD; Macedo, AVS; de Barros E Silva, PGM; Moll-Bernardes, RJ; dos Santos, TM; Mazza, L; Feldman, A; D'Andrea Saba Arruda, G; de Albuquerque, DC; Camiletti, AS; de Sousa, AS; de Paula, TC; Giusti, KGD; Domiciano, RAM; Noya-Rabelo, MM; Hamilton, AM; Loures, VA; Dionisio, RM; Furquim, TAB; De Luca, FA; dos Santos Sousa, IB; Bandeira, BS; Zukowski, CN; de Oliveira, RGG; Ribeiro, NB; de Moraes, JL; Petriz, JLF; Pimentel, AM; Miranda, JS; de Jesus Abufaiad, BE; Gibson, CM; Granger, CB; Alexander, JH; de Souza, OF				Lopes, Renato D.; Macedo, Ariane V. S.; de Barros E Silva, Pedro G. M.; Moll-Bernardes, Renata J.; dos Santos, Tiago M.; Mazza, Lilian; Feldman, Andre; D'Andrea Saba Arruda, Guilherme; de Albuquerque, Denilson C.; Camiletti, Angelina S.; de Sousa, Andrea S.; de Paula, Thiago C.; Giusti, Karla G. D.; Domiciano, Rafael A. M.; Noya-Rabelo, Marcia M.; Hamilton, Alan M.; Loures, Vitor A.; Dionisio, Rodrigo M.; Furquim, Thyago A. B.; De Luca, Fabio A.; dos Santos Sousa, Italo B.; Bandeira, Bruno S.; Zukowski, Cleverson N.; de Oliveira, Ricardo G. G.; Ribeiro, Noara B.; de Moraes, Jeffer L.; Petriz, Joao L. F.; Pimentel, Adriana M.; Miranda, Jacqueline S.; de Jesus Abufaiad, Barbara E.; Gibson, C. Michael; Granger, Christopher B.; Alexander, John H.; de Souza, Olga F.			Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; SYSTEM	Key PointsQuestionDoes discontinuation compared with continuation of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) change the number of days alive and out of the hospital through 30 days in patients hospitalized with mild to moderate coronavirus disease 2019 (COVID-19)? FindingsIn this randomized clinical trial that included 659 patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications was 21.9 vs 22.9, respectively, a difference that was not statistically significant. MeaningThese findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19. ImportanceIt is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). ObjectiveTo determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days. Design, Setting, and ParticipantsA randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020). InterventionsDiscontinuation (n=334) or continuation (n=325) of ACEIs or ARBs. Main Outcomes and MeasuresThe primary outcome was the number of days alive and out of the hospital through 30 days. Secondary outcomes included death, cardiovascular death, and COVID-19 progression. ResultsAmong 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial. The median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline. In terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate. There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01). There also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]). The most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%). Conclusions and RelevanceAmong patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment. Trial RegistrationClinicalTrials.gov Identifier: NCT04364893 This randomized clinical trial compares the effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on days alive and out of the hospital at 30 days among patients with COVID-19 taking the drugs prior to hospitalization.	[Lopes, Renato D.; Macedo, Ariane V. S.; Moll-Bernardes, Renata J.; Feldman, Andre; D'Andrea Saba Arruda, Guilherme; de Albuquerque, Denilson C.; Camiletti, Angelina S.; de Sousa, Andrea S.; de Souza, Olga F.] DOr Inst Res & Educ, Rio De Janeiro, Brazil; [Lopes, Renato D.; Granger, Christopher B.; Alexander, John H.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Lopes, Renato D.; de Barros E Silva, Pedro G. M.; dos Santos, Tiago M.; Mazza, Lilian] Brazilian Clin Res Inst, Sao Paulo, Brazil; [Lopes, Renato D.; Camiletti, Angelina S.; de Souza, Olga F.] Rede DOr Sao Luiz, Sao Paulo, Brazil; [Macedo, Ariane V. S.; de Paula, Thiago C.] Hosp Sao Luiz Jabaquara, Sao Paulo, Brazil; [Macedo, Ariane V. S.] Santa Casa Sao Paulo, Sao Paulo, Brazil; [dos Santos, Tiago M.] Insper Inst Educ & Res, Sao Paulo, Brazil; [Feldman, Andre; Domiciano, Rafael A. M.; Loures, Vitor A.] Hosp Sao Luiz Analia Franco, Sao Paulo, Brazil; [D'Andrea Saba Arruda, Guilherme] Hosp Sao Luiz Sao Caetano, Sao Caetano do Sul, Brazil; [de Albuquerque, Denilson C.] Univ Estado Rio de Janeiro, Rio De Janeiro, Brazil; [de Sousa, Andrea S.] Fundacao Oswaldo Cruz, Evandro Chagas Natl Inst Infect Dis, Rio De Janeiro, Brazil; [de Sousa, Andrea S.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil; [Giusti, Karla G. D.] Hosp Villa Lobos, Sao Paulo, Brazil; [Noya-Rabelo, Marcia M.; Hamilton, Alan M.] Hosp Sao Rafael, Salvador, BA, Brazil; [Noya-Rabelo, Marcia M.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil; [Dionisio, Rodrigo M.; Furquim, Thyago A. B.] Hosp SinoBrasileiro, Osasco, Brazil; [De Luca, Fabio A.; dos Santos Sousa, Italo B.] Hosp Sao Luiz Morumbi, Sao Paulo, Brazil; [Bandeira, Bruno S.] Hosp Caxias DOr, Duque De Caxias, RJ, Brazil; [Zukowski, Cleverson N.] Hosp Copa DOr, Rio De Janeiro, Brazil; [de Oliveira, Ricardo G. G.] Hosp Quinta DOr, Rio De Janeiro, Brazil; [Ribeiro, Noara B.] Hosp Santa Brasilia, Brasilia, DF, Brazil; [de Moraes, Jeffer L.] Hosp Assuncao, Sao Bernardo Do Campo, Brazil; [Petriz, Joao L. F.] Hosp Barra DOr, Rio De Janeiro, Brazil; [Pimentel, Adriana M.] Hosp Niteroi DOr, Niteroi, RJ, Brazil; [Miranda, Jacqueline S.; de Souza, Olga F.] Hosp Copa Star, Rio De Janeiro, Brazil; [de Jesus Abufaiad, Barbara E.] Hosp Oeste DOr, Rio De Janeiro, Brazil; [Gibson, C. Michael] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA	IDOR - Instituto D'Or de Ensino e Pesquisa; Duke University; Insper; Universidade do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Escola Bahiana de Medicina e Saude Publica; Harvard University; Harvard Medical School	Lopes, RD (corresponding author), Duke Clin Res Inst, 200 Morris St, Durham, NC 27701 USA.	renato.lopes@dm.duke.edu	Noya-Rabelo, Marcia M/AAG-2270-2019; Alexander, John/GVS-7271-2022	Noya-Rabelo, Marcia M/0000-0002-6800-8100; Alexander, John/0000-0002-1444-2462; Munford Lima Pimentel, Adriana/0000-0002-8870-5130; Macedo, Ariane/0000-0002-3453-8488; Mendonca dos Santos, Tiago/0000-0002-4223-9162				Ah YM, 2015, J KOREAN MED SCI, V30, P1800, DOI 10.3346/jkms.2015.30.12.1800; Bean DM, 2020, EUR J HEART FAIL, V22, P967, DOI 10.1002/ejhf.1924; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bozkurt B, 2020, J CARD FAIL, V26, P370, DOI 10.1016/j.cardfail.2020.04.013; Bravi F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235248; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Chung MK, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102907; de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8; Drager LF, 2020, CURR HYPERTENS REP, V22, DOI 10.1007/s11906-020-01057-x; Elijovich F, 2020, HYPERTENSION, V76, P665, DOI 10.1161/HYPERTENSIONAHA.120.15712; Ellenberg SS, 2018, CLIN INFECT DIS, V66, P1467, DOI 10.1093/cid/cix1032; European Society of Cardiology Council on Hypertension, 2020, POS STAT ACE INH ANG; Fanaroff AC, 2020, J AM COLL CARDIOL, V76, P580, DOI 10.1016/j.jacc.2020.05.069; Fanaroff AC, 2020, J AM COLL CARDIOL, V75, P556, DOI 10.1016/j.jacc.2019.11.043; Fanaroff AC, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.004755; Fonarow GC, 2008, J AM COLL CARDIOL, V52, P190, DOI 10.1016/j.jacc.2008.03.048; Furtado RHM, 2020, LANCET, V396, P959, DOI 10.1016/S0140-6736(20)31862-6; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Huang ZY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.229; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924; Khera Rohan, 2020, medRxiv, DOI 10.1101/2020.05.17.20104943; Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624; Lopes RD, 2020, AM HEART J, V226, P49, DOI 10.1016/j.ahj.2020.05.002; Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923; Mehta N., 2020, JAMA CARDIOL, V5, P1020, DOI [DOI 10.1001/jamacardio.2020.1855, 10.1001/jamacardio.2020.1855]; Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200; Pan W, 2020, HYPERTENSION, V76, P732, DOI 10.1161/HYPERTENSIONAHA.120.15289; Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812; R Development Core Team, 2005, R LANG ENV STAT COMP; Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975; Rigby RA, 2005, J R STAT SOC C-APPL, V54, P507, DOI 10.1111/j.1467-9876.2005.00510.x; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Soler MJ, 2008, CURR HYPERTENS REP, V10, P410, DOI 10.1007/s11906-008-0076-0; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; Varagic J, 2014, CURR HYPERTENS REP, V16, DOI 10.1007/s11906-014-0420-5; Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134	40	179	183	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2021	325	3					254	264		10.1001/jama.2020.25864	http://dx.doi.org/10.1001/jama.2020.25864			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU8HP	33464336	Green Published, Bronze			2023-01-03	WOS:000609540400020
J	Bachelot, T; Filleron, T; Bieche, I; Arnedos, M; Campone, M; Dalenc, F; Coussy, F; Sablin, MP; Debled, M; Lefeuvre-Plesse, C; Goncalves, A; Reynier, MAM; Jacot, W; You, B; Barthelemy, P; Verret, B; Isambert, N; Tchiknavorian, X; Levy, C; Thery, JC; L'Haridon, T; Ferrero, JM; Mege, A; Del Piano, F; Rouleau, E; Tran-Dien, A; Adam, J; Lusque, A; Jimenez, M; Jacquet, A; Garberis, I; Andre, F				Bachelot, Thomas; Filleron, Thomas; Bieche, Ivan; Arnedos, Monica; Campone, Mario; Dalenc, Florence; Coussy, Florence; Sablin, Marie-Paule; Debled, Marc; Lefeuvre-Plesse, Claudia; Goncalves, Anthony; Reynier, Marie-Ange Mouret; Jacot, William; You, Benoit; Barthelemy, Philippe; Verret, Benjamin; Isambert, Nicolas; Tchiknavorian, Xavier; Levy, Christelle; Thery, Jean-Christophe; L'Haridon, Tifenn; Ferrero, Jean-Marc; Mege, Alice; Del Piano, Francesco; Rouleau, Etienne; Tran-Dien, Alicia; Adam, Julien; Lusque, Amelie; Jimenez, Marta; Jacquet, Alexandra; Garberis, Ingrid; Andre, Fabrice			Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial	NATURE MEDICINE			English	Article							HOMOLOGOUS RECOMBINATION DEFICIENCY	The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after six to eight cycles of chemotherapy. Patients (n = 199) were randomized to either durvalumab (10 mg kg(-1) every 2 weeks) or maintenance chemotherapy. In the overall population, durvalumab did not improve progression-free survival (adjusted hazard ratio (HR): 1.40, 95% confidence interval (CI): 1.00-1.96; P = 0.047) or overall survival (OS; adjusted HR: 0.84, 95% CI: 0.54-1.29; P = 0.423). In an exploratory subgroup analysis, durvalumab improved OS in patients with triple-negative breast cancer (TNBC; n = 82; HR: 0.54, 95% CI: 0.30-0.97, P = 0.0377). Exploratory analysis showed that the HR of death was 0.37 (95% CI: 0.12-1.13) for patients with PD-L1(+) TNBC (n = 32) and 0.49 (95% CI: 0.18-1.34) for those with PD-L1(-) TNBC (n = 29). In patients with TNBC, exploratory analyses showed that the HR for durvalumab efficacy (OS) was 0.18 (95% CI: 0.05-0.71; log-rank test, P = 0.0059) in patients with CD274 gain/amplification (n = 23) and 1.12 (95% CI: 0.42-2.99; log-rank test, P = 0.8139) in patients with CD274 normal/loss (n = 32). Tumor infiltration by lymphocytes (CD8, FoxP3 and CD103 expressions) and homologous recombination deficiency did not predict sensitivity to durvalumab in exploratory analyses. This latter finding should be interpreted with caution since only one patient presented a germline BRCA mutation. The present study provides a rationale to evaluate single-agent durvalumab in maintenance therapy in patients with TNBC. Exploratory analyses identified CD274 amplification as a potential biomarker of sensitivity. Maintenance chemotherapy was more effective than durvalumab in patients with hormone receptor-positive and Her2-negative disease.	[Bachelot, Thomas] Ctr Leon Berard, Dept Med Oncol, Lyon, France; [Filleron, Thomas; Lusque, Amelie] Inst Claudius Regaud, Dept Biostat, IUCT Oncopole, Toulouse, France; [Bieche, Ivan] Descartes Univ, Inst Curie, Dept Genet, Paris, France; [Arnedos, Monica; Verret, Benjamin; Andre, Fabrice] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France; [Campone, Mario] Inst Cancerol Ouest, Rene Gauducheau, Angers, France; [Dalenc, Florence] Inst Claudius Regaud, IUCT Oncopole, Dept Med Oncol, Toulouse, France; [Dalenc, Florence] Univ Paul Sabatier, Toulouse, France; [Coussy, Florence; Sablin, Marie-Paule] Institut Curie, Dept Med Oncol, Paris, France; [Debled, Marc] Inst Bergonie, Dept Med Oncol, Bordeaux, France; [Lefeuvre-Plesse, Claudia] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France; [Goncalves, Anthony] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France; [Reynier, Marie-Ange Mouret] Ctr Jean Perrin, Dept Med Oncol, Clermont Ferrand, France; [Jacot, William] INSERM U1194, Inst Cancerol Montpellier, Inst Rech Cancerol Montpellier, Dept Med Oncol,IRCM, Montpellier, France; [Jacot, William] Montpellier Univ, Montpellier, France; [You, Benoit] Univ Lyon, Univ Claude Bernard Lyon 1,GINECO, Inst Cancerol Hosp Civils Lyon,EMR UCBL HCL 3738, Ctr Invest Therapeut Oncol & Hematol Lyon CITOHL, Lyon, France; [You, Benoit] Ctr Hosp Lyon Sud, Pierre Benite, France; [Barthelemy, Philippe] Inst Cancerol Strasbourg, Strasbourg, France; [Barthelemy, Philippe] Hop Univ Strasbourg, Strasbourg, France; [Isambert, Nicolas] Ctr Georges Francois Leclerc, Dept Med Oncol, Dijon, France; [Tchiknavorian, Xavier] Hop St Musse, Ctr Hosp Intercommunal Toulon Seyne, Toulon, France; [Levy, Christelle] Ctr Francois Baclesse, Dept Med Oncol, Caen, France; [Thery, Jean-Christophe] Univ Med Rouen, Ctr Henri Becquerel, Dept Med Oncol, Rouen, France; [L'Haridon, Tifenn] Ctr Hosp Departemental Vendee, Roche, France; [Ferrero, Jean-Marc] Univ Cote d'Azur, Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France; [Mege, Alice] Inst St Catherine, Avignon, France; [Del Piano, Francesco] Hosp Leman, Bains, France; [Rouleau, Etienne] Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Canc Genet Lab, Villejuif, France; [Tran-Dien, Alicia; Garberis, Ingrid; Andre, Fabrice] INSERM UMR981, Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Villejuif, France; [Tran-Dien, Alicia; Garberis, Ingrid; Andre, Fabrice] Univ Paris Saclay, Le Kremlin Bicetre, France; [Adam, Julien] Gustave Roussy Canc Campus, Dept Pathol, Villejuif, France; [Adam, Julien] Gustave Roussy Canc Campus, INSERM U1186, Villejuif, France; [Jimenez, Marta; Jacquet, Alexandra] UniCanc, Paris, France	UNICANCER; Centre Leon Berard; UNICANCER; Institut Claudius Regaud; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Institut Bergonie; UNICANCER; Centre Eugene Marquis; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Georges-Francois Leclerc; UNICANCER; Centre Francois Baclesse; UNICANCER; Centre Henri Becquerel; CHD Vendee; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER	Andre, F (corresponding author), Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France.; Andre, F (corresponding author), INSERM UMR981, Gustave Roussy Canc Campus, Dept Pathol & Med Biol, Villejuif, France.; Andre, F (corresponding author), Univ Paris Saclay, Le Kremlin Bicetre, France.	fabrice.andre@gustaveroussy.fr	ANDRE, Fabrice/AAL-2683-2020; Jimenez, Marta/HCH-7687-2022; filleron, thomas/C-3554-2014	ANDRE, Fabrice/0000-0001-5795-8357; Jimenez, Marta/0000-0001-7940-4945; filleron, thomas/0000-0003-0724-0659; ARNEDOS, MONICA/0000-0001-5269-1251	Fondation ARC; AstraZeneca; Breast Cancer Research Foundation	Fondation ARC; AstraZeneca(AstraZeneca); Breast Cancer Research Foundation	We thank the patients and their families, as well as the investigators and staff involved in SAFIR02-BREAST and especially M.A., M.C., F.D., F.C., M.-P.S., M.D., C.L.-P., A.G., M.-A.M.R., W.J., B.Y., P.B., N.I., X.T., C.L., J.-C. T., T.L'H., J.-M.F., A.M. and F.D.P. We thank I.G. and J.A. for performing IHC analysis, as well as T.F. and A.L. for performing the statistical analyses and A.T.-D. for performing the bioinformatics analyses. We also thank I.B., E. R. and B.V. for valuable discussions on results. We are grateful to UNICANCER for promoting the clinical trial and especially to M.J. and A.J. in charge of the SAFIR02-BREAST clinical trial and all the members of their team that lead the monitoring of the clinical data, samples and genomic analyses. We are also grateful to the members of the Independent Data Monitoring Committee: N. Turner, S. Loibl, S. Novello, E. Felip, S. Litiere and D. Beltram. The study was funded by Fondation ARC, AstraZeneca and the Breast Cancer Research Foundation. AstraZeneca also supported the duvalumab supply to the study sites.	Adams S, 2019, ANN ONCOL, V30, P405, DOI 10.1093/annonc/mdy518; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Commo F, 2016, BIOINFORMATICS, V32, P1402, DOI 10.1093/bioinformatics/btv718; CORTES J, 2020, J CLIN ONCOL S, V38; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; EMENS LA, 2019, CANCER RES, V79; Emens LA, 2019, JAMA ONCOL, V5, P74, DOI 10.1001/jamaoncol.2018.4224; Force J, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0634-5; Goodman AM, 2018, JAMA ONCOL, V4, P1237, DOI 10.1001/jamaoncol.2018.1701; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hui RN, 2019, LANCET ONCOL, V20, P1670, DOI 10.1016/S1470-2045(19)30519-4; Karn T, 2020, ANN ONCOL, V31, P1216, DOI 10.1016/j.annonc.2020.05.015; Lacour M, 2019, CLIN LUNG CANCER, V20, P391, DOI 10.1016/j.cllc.2019.05.013; Lamberti G, 2020, ANN ONCOL, V31, P807, DOI 10.1016/j.annonc.2020.02.017; Loi S, 2017, ANN ONCOL, V28; Nanda R, 2020, JAMA ONCOL, V6, P676, DOI 10.1001/jamaoncol.2019.6650; Pelekanou V, 2018, MOL CANCER THER, V17, P1324, DOI 10.1158/1535-7163.MCT-17-1005; Powles T., 2020, J CLIN ONCOL, V38, pLBA1, DOI 10.1200/JCO.2020.38.18_suppl.LBA1; Rugo HS, 2018, CLIN CANCER RES, V24, P2804, DOI 10.1158/1078-0432.CCR-17-3452; Sakai H, 2019, LUNG CANCER, V127, P59, DOI 10.1016/j.lungcan.2018.11.025; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Takaya H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59671-3; Telli ML, 2016, CLIN CANCER RES, V22, P3764, DOI 10.1158/1078-0432.CCR-15-2477; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4; Winer EP, 2020, J CLIN ONCOL, V38; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Zhao EY, 2017, CLIN CANCER RES, V23, P7521, DOI 10.1158/1078-0432.CCR-17-1941	31	46	46	2	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2021	27	2					250	+		10.1038/s41591-020-01189-2	http://dx.doi.org/10.1038/s41591-020-01189-2		JAN 2021	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QH6OB	33462450				2023-01-03	WOS:000608674100005
J	Leiter, RE				Leiter, Richard E.			Reentry	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Our approach to early Covid cases was as thoughtful as it could have been, but we didn't know enough, and many patients died. Over time, perhaps we'll uncover the toll Covid-19 has taken on clinicians, in terms of anxiety, depression, and post-traumatic stress disorder.	[Leiter, Richard E.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Leiter, Richard E.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Leiter, RE (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Leiter, RE (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.							Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976; Lobb EA, 2010, DEATH STUD, V34, P673, DOI 10.1080/07481187.2010.496686	2	3	3	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2020	383	27							e141	10.1056/NEJMp2027447	http://dx.doi.org/10.1056/NEJMp2027447			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP1SJ	33053276	Bronze			2023-01-03	WOS:000605648000001
J	Birowo, P; Rangganata, E; Rasyid, N; Atmoko, W				Birowo, Ponco; Rangganata, Ervandy; Rasyid, Nur; Atmoko, Widi			Efficacy and safety of extracorporeal shockwave therapy for the treatment of chronic non-bacterial prostatitis: A systematic review and meta-analysis	PLOS ONE			English	Review							PELVIC-PAIN-SYNDROME; WAVE-THERAPY; MANAGEMENT; ESWT	Purpose Chronic pelvic pain syndrome (CPPS) is one of the most common outpatient urological diagnoses, and its incidence is increasing. Extracorporeal shockwave therapy (ESWT) has been suggested for relieving local perineal symptoms associated with chronic prostatitis/CPPS. Despite several treatment methods, no causal or standardized treatment is available for CPPS. This study aimed to investigate the efficacy and safety profile of ESWT for the treatment of chronic non-bacterial prostatitis. Materials and methods Studies were collected using four search engines (Pubmed, Cochrane, ScienceDirect, and EBSCOHost), on May 16, 2020; and assessed based on predetermined inclusion and exclusion criteria. Two reviewers performed study selection. Studies were then analyzed using Review Manager 5.3 for the meta-analysis. Results Seventy-four publications were initially retrieved, and three studies were considered for both qualitative and quantitative analyses. From these studies, we found that the use of ESWT was significantly associated with decreased pain domain (mean difference: -3.93; 95% confidence interval [CI] -5.13, -2.73; p<0.001), improved urinary score (mean difference: -1.79; 95% CI -2.38, -1.21; p<0.001), improved quality of life (mean difference: -1.71; 95% CI -2.12, -1.31; p<0.001), and improved National Institutes of Health chronic prostatitis symptom index (NIH-CPSI) score (mean difference: -5.45; 95% CI -5.74, -5.16; p<0.001) after 12 weeks of treatment. Conclusion ESWT is efficacious and safe in reducing pain and improving urinary condition, NIH-CPSI score, and quality of life in patients with chronic non-bacterial prostatitis.	[Birowo, Ponco; Rangganata, Ervandy; Rasyid, Nur; Atmoko, Widi] Univ Indonesia, Cipto Mangunkusumo Gen Hosp, Fac Med, Dept Urol, Jakarta, Indonesia	University of Indonesia	Birowo, P (corresponding author), Univ Indonesia, Cipto Mangunkusumo Gen Hosp, Fac Med, Dept Urol, Jakarta, Indonesia.	ponco.birowo@gmail.com	Atmoko, Widi/AGD-1105-2022; Atmoko, Widi/GVS-5551-2022	Atmoko, Widi/0000-0002-7793-7083; 	International Publication Research Grant Universitas Indonesia [NKB-1520/UN2.RST/HKP.05.00/2020]	International Publication Research Grant Universitas Indonesia	Ponco Birowo NKB-1520/UN2.RST/HKP.05.00/2020 International Publication Research Grant Universitas Indonesia www.ui.ac.id.	Al Edwan GM, 2017, ANN MED SURG, V14, P12, DOI 10.1016/j.amsu.2016.12.051; Berghuis JP, 1996, J PSYCHOSOM RES, V41, P313, DOI 10.1016/S0022-3999(96)00157-2; Brede CM, 2011, NAT REV UROL, V8, P207, DOI 10.1038/nrurol.2011.22; Collins MM, 2000, ANN INTERN MED, V133, P367, DOI 10.7326/0003-4819-133-5-200009050-00013; Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X; Delavierre D, 2010, PROG UROL, V20, P940, DOI 10.1016/j.purol.2010.09.018; Fall M, 2008, GEN TREATMENT CHRONI, P84; Grabe M, 2008, PROSTATITIS CHRONIC, P79; Habermacher GM, 2006, ANNU REV MED, V57, P195, DOI 10.1146/annurev.med.57.011205.135654; Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236; Le BV, 2009, UROL CLIN N AM, V36, P527, DOI 10.1016/j.ucl.2009.08.005; Letizia P, 2017, J SEX MED, V14, pE150, DOI 10.1016/j.jsxm.2017.03.042; Magri V, 2015, EXP THER MED, V9, P658, DOI 10.3892/etm.2014.2152; Moayednia A, 2014, J RES MED SCI, V19, P293; Murphy AB, 2009, DRUGS, V69, P71, DOI 10.2165/00003495-200969010-00005; Nickel JC, 2004, J UROLOGY, V172, P551, DOI 10.1097/01.ju.0000131592.98562.16; Nickel JC, 2016, Campbell-walsh urology, Veleventh, P304; Schaeffer AJ, 2006, NEW ENGL J MED, V355, P1690, DOI 10.1056/NEJMcp060423; Vahdatpour Babak, 2013, ISRN Urol, V2013, P972601, DOI 10.1155/2013/972601; von Hippel PT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0024-z; Zhang JZ, 2019, AM J MENS HEALTH, V13, P1, DOI 10.1177/1557988319865380; Zimmermann R, 2008, BJU INT, V102, P976, DOI 10.1111/j.1464-410X.2008.07742.x; Zimmermann R, 2009, EUR UROL, V56, P418, DOI 10.1016/j.eururo.2009.03.043	24	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2020	15	12							e0244295	10.1371/journal.pone.0244295	http://dx.doi.org/10.1371/journal.pone.0244295			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BQ	33370372	Green Published, gold			2023-01-03	WOS:000603611900047
J	Barakat, M; Al-Qudah, R; Akour, A; Al-Qudah, N; Bashi, YDH				Barakat, Muna; Al-Qudah, Raja'a; Akour, Amal; Al-Qudah, Najem; Dallal Bashi, Yahya H.			Unforeseen uses of oral contraceptive pills: Exploratory study in Jordanian community pharmacies	PLOS ONE			English	Article							KNOWLEDGE; MISUSE; WOMEN; PRESCRIPTION; ATTITUDE; IMPACT; ABUSE	Background The use of oral contraceptive pills (OCPs) as a birth control method is very common worldwide. OCPs have many other labeled non-contraceptive indications, and as a result there is an associated risk of improper use, as with any other medications. This study was designed to assess the unforeseen improper uses of OCPs observed by community pharmacists in Jordan. Method A cross-sectional study design was conducted using a self-administered survey. A convenience sample (n = 380) of Jordanian community pharmacists, were recruited through social media resources. The survey included multiple-choice and open-ended questions. Descriptive statistics and correlation analyses were completed using SPSS. Results More than half of the recruited pharmacists (55.3%) were female, and the mean age of the participants was 32.58 +/- 9.94. The majority of the pharmacists (85%) had good knowledge about the non-contraceptive indications of OCPs. About 53% of them confirmed their exposure to cases of the improper use of OCPs. About 67.5% of the pharmacists who confirmed exposure to such cases, reported the topical use of OCPs for the enhancement of hair growth. Around 15% of those pharmacists stated that OCPs were used to give negative results for addictive drug screening tests. In the event that the pharmacists suspected improper use, more than 90% suggested they would refrain from dispensing the pills. Conclusion This study has spotlighted many unforeseen uses of OCPs in Jordan and highlighted the need for restricted national regulations on the monitoring of OCP prescription/selling patterns in Jordan by policymakers. Moreover, there is a need for the establishment of national educational programs for the Jordanian community regarding the safe proper use of OCPs.	[Barakat, Muna; Al-Qudah, Raja'a] Appl Sci Private Univ, Fac Pharm, Amman, Jordan; [Akour, Amal] Al Zaytoonah Univ Jordan, Dept Pharm, Fac Pharm, Amman, Jordan; [Akour, Amal] Univ Jordan, Dept Biopharmaceut & Clin Pharm, Sch Pharm, Amman, Jordan; [Al-Qudah, Najem] Al Balqa Appl Univ, Fac Med, Al Salt, Jordan; [Dallal Bashi, Yahya H.] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland	Al-Zaytoonah University of Jordan; University of Jordan; Al-Balqa Applied University; Queens University Belfast	Barakat, M (corresponding author), Appl Sci Private Univ, Fac Pharm, Amman, Jordan.	m_barakat@asu.edu.jo	Barakat, Muna/AAN-8778-2020	Barakat, Muna/0000-0002-7966-1172; Dallal Bashi, Yahya H/0000-0002-8480-9776				Akour A, 2017, EUR J CONTRACEP REPR, V22, P459, DOI 10.1080/13625187.2017.1412425; Albsoul-Younes A, 2010, SUBST USE MISUSE, V45, P1319, DOI 10.3109/10826080802490683; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626; [Anonymous], 2018, GLOBAL NEWS; [Anonymous], 2007, DIABETES CARE S1, V30, pS4; Bardaweel SK, 2019, BMC WOMENS HEALTH, V19, DOI 10.1186/s12905-019-0770-x; Bardaweel SK, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0275-1; Boynton PM, 2004, BRIT MED J, V328, P1312, DOI 10.1136/bmj.328.7451.1312; Cundill Pauline, 2020, Aust J Gen Pract, V49, P385, DOI 10.31128/AJGP-01-20-5197; Daniels Kimberly, 2014, NCHS Data Brief, P1; El-Mowafi IM, 2020, CONTRACEPTION, V101, P261, DOI 10.1016/j.contraception.2019.10.002; Foroutan Nazanin, 2016, Pharmacy Pract (Granada), V14, P745, DOI [10.18549/PharmPract.2016.04.745, 10.18549/pharmpract.2016.04.745]; Francis A, 2018, Womens Midlife Health, V4, P12, DOI 10.1186/s40695-018-0042-1; Fu S, 2016, ADV CLIN CHEM, V76, P123, DOI 10.1016/bs.acc.2016.05.003; Gardner JS, 2008, J AM PHARM ASSOC, V48, P212, DOI 10.1331/JAPhA.2008.07138; GOLDSTUCK N D, 1987, Advances in Contraception, V3, P335, DOI 10.1007/BF01849291; Hajhashemi V, 2007, PHYSIOL PHARMACOL, V11, P68; Health WHOR, 2018, FAM PLANN GLOB HDB P; Huang QL, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016440; Ibrahim OM, 2017, TROP J PHARM RES, V16, P947, DOI 10.4314/tjpr.v16i4.29; Ilardo ML, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17020536; Irwin AN, 2019, RES SOC ADMIN PHARM, V15, P650, DOI 10.1016/j.sapharm.2018.08.003; Jager J, 2017, MONOGR SOC RES CHILD, V82, P13, DOI 10.1111/mono.12296; Jordan Food and Drug Administration (JFDA)., 2018, LIST NONPR MED; Jordanian pharmacist's association (JPA), 2019, JPA STAT NUMB PHARM; Kennedy CE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001402; Kirkpatrick K., 2015, WHAT MAN TAKES BIRTH; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Mahmoud MA, 2018, COMMUNITY PHARM PERS; McIntosh J, 2011, PHARMACOTHERAPY, V31, P424, DOI 10.1592/phco.31.4.424; Mobark DM, 2019, PHARM PRACT-GRANADA, V17, DOI [10.18549/PharmPract.2019.2.1465, 10.18549/pharmpract.2019.2.1465]; Obreli-Neto PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079875; Pazol K, 2018, AM J PREV MED, V55, P703, DOI 10.1016/j.amepre.2018.07.012; Rafie S, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7030096; Ratanajamit C, 2001, PHARMACOEPIDEM DR S, V10, P149, DOI 10.1002/pds.573; ROSENBERG MJ, 1995, CONTRACEPTION, V51, P283, DOI 10.1016/0010-7824(95)00074-K; Saadatnia M, 2012, J RES MED SCI, V17, P344; Sattari M, 2013, E MEDITERR HEALTH J, V19, P547, DOI 10.26719/2013.19.6.547; Schindler AE, 2013, INT J ENDOCRINOL MET, V11, P41, DOI 10.5812/ijem.4158; Skouby SO, 2004, EUR J CONTRACEP REPR, V9, P57, DOI 10.1080/13625180410001715681; Smith SM, 2013, PAIN, V154, P2287, DOI 10.1016/j.pain.2013.05.053; Spooner C., 2005, SOCIAL DETERMINANTS; Tahaineh L, 2020, J PHARM HEALTH SERV, V11, P33, DOI 10.1111/jphs.12337; Taherdoost H., 2017, INT J EC MANAGEMENT, V2, P237, DOI DOI 10.1016/J.JTH.2017.07.005; The United States Agency for International Development (USAID), 2015, JORD PROGR PROF; Weerasinghe M, 2017, J FAM PLAN REPROD H, V43, P147, DOI 10.1136/jfprhc-2015-101171	46	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2020	15	12							e0244373	10.1371/journal.pone.0244373	http://dx.doi.org/10.1371/journal.pone.0244373			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CD	33347511	Green Published, gold			2023-01-03	WOS:000603071100032
J	Jacobs, LG; Paleoudis, EG; Lesky-Di Bari, D; Nyirenda, T; Friedman, T; Gupta, A; Rasouli, L; Zetkulic, M; Balani, B; Ogedegbe, C; Bawa, H; Berrol, L; Qureshi, N; Aschner, JL				Jacobs, Laurie G.; Paleoudis, Elli Gourna; Lesky-Di Bari, Dineen; Nyirenda, Themba; Friedman, Tamara; Gupta, Anjali; Rasouli, Lily; Zetkulic, Marygrace; Balani, Bindu; Ogedegbe, Chinwe; Bawa, Harinder; Berrol, Lauren; Qureshi, Nabiha; Aschner, Judy L.			Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; WOMEN	Background Characterizing the prevalence and persistence of symptoms associated with COVID-19 infection following hospitalization and their impact is essential to planning post-acute community-based clinical services. This study seeks to identify persistent COVID-19 symptoms in patients 35 days post-hospitalization and their impact on quality of life, health, physical, mental, and psychosocial function. Methods and findings This prospective cohort study used the PROMIS (R) Instruments to identify symptoms and quality of life parameters in consecutively enrolled patients between March 22 and April 16, 2020, in New Jersey. The 183 patients (median age 57 years; 61.5% male, 54.1% white) reported persistent symptoms at 35 days, including fatigue (55.0%), dyspnea (45.3%), muscular pain (51%), associated with a lower odds rating general health (41.5%, OR 0.093 [95% CI: 0.026, 0.329], p = 0.0002), quality of life (39.8%; OR 0.116 [95% CI: 0.038, 0.364], p = 0.0002), physical health (38.7%, OR 0.055 [95% CI: 0.016, 0.193], p <0.0001), mental health (43.7%, OR 0.093 [95% CI: 0.021, 0.418], p = 0.0019) and social active role (38.7%, OR 0.095 [95% CI: 0.031, 0.291], p<0.0001), as very good/excellent, particularly adults aged 65 to 75 years (OR 8 center dot 666 [95% CI: 2 center dot 216, 33 center dot 884], p = 0 center dot 0019). Conclusions COVID-19 symptoms commonly persist to 35 days, impacting quality of life, health, physical and mental function. Early post-acute evaluation of symptoms and their impact on function is necessary to plan community-based services.	[Jacobs, Laurie G.; Gupta, Anjali; Zetkulic, Marygrace; Balani, Bindu; Bawa, Harinder] Hackensack Meridian Sch Med, Dept Internal Med, Nutley, NJ 07110 USA; [Jacobs, Laurie G.; Gupta, Anjali; Rasouli, Lily; Zetkulic, Marygrace; Bawa, Harinder; Qureshi, Nabiha] Hackensack Univ, Dept Internal Med, Med Ctr, Hackensack, NJ 07601 USA; [Paleoudis, Elli Gourna; Nyirenda, Themba; Friedman, Tamara] Off Res Adm, Hackensack Meridian Hlth, Edison, NJ USA; [Lesky-Di Bari, Dineen] Hackensack Univ, Dept Res, Joseph M Sanzari Childrens Hosp, Med Ctr, Hackensack, NJ USA; [Balani, Bindu] Hackensack Univ, Dept Internal Med, Div Infect Dis, Med Ctr, Hackensack, NJ USA; [Ogedegbe, Chinwe] Hackensack Meridian Sch Med, Dept Emergency Med, Nutley, NJ USA; [Ogedegbe, Chinwe] Hackensack Univ, Med Ctr, Hackensack, NJ USA; [Bawa, Harinder; Aschner, Judy L.] Hackensack Meridian Sch Med, Dept Pediat, Nutley, NJ USA; [Bawa, Harinder; Aschner, Judy L.] Hackensack Univ, Joseph M Sanzari Childrens Hosp, Med Ctr, Hackensack, NJ USA; [Berrol, Lauren] Hackensack Univ, Dept Anesthesiol, Med Ctr, Hackensack, NJ USA	Hackensack University Medical Center; Hackensack University Medical Center; Hackensack University Medical Center; Hackensack University Medical Center; Hackensack University Medical Center; Hackensack University Medical Center	Jacobs, LG (corresponding author), Hackensack Meridian Sch Med, Dept Internal Med, Nutley, NJ 07110 USA.; Jacobs, LG (corresponding author), Hackensack Univ, Dept Internal Med, Med Ctr, Hackensack, NJ 07601 USA.	Laurie.Jacobs@HackensackMeridian.org	Gupta, Anjali/HCH-5986-2022	Jacobs, Laurie G./0000-0003-3609-2157				Ahmed H, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2694; [Anonymous], 2020, R D BLUEPR NOV COR C, P6; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Centers for Disease Control and Prevention, HLTH WEIGHT ASS YOUR; CMS Learning Network, 2017, MLN BOOKL HOM OX THE, P3; Cydulka RK, 2001, ANN EMERG MED, V38, P123, DOI 10.1067/mem.2001.114305; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; Fugitive Literacies Collective, 2020, ENGLISH ED, V52, pN3; Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9; Gonzalez-Reiche AS, 2020, SCIENCE, V369, P297, DOI 10.1126/science.abc1917; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hendren NS, 2020, CIRCULATION, V141, P1903, DOI 10.1161/CIRCULATIONAHA.120.047349; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152; Keeley P, 2020, BMJ SUPPORT PALLIAT; Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384; Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x; Park SY, 2020, KOREAN J INTERN MED, V35, P793, DOI 10.3904/kjim.2020.203; Potere N, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03022-1; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Simmons RK, 2010, DIABETOLOGIA, V53, P600, DOI 10.1007/s00125-009-1620-4; The Centers for Disease Control and Prevention, 2020, CORONAVIRUS DIS 2019; World Health Organization, 159 WHO	26	110	113	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243882	10.1371/journal.pone.0243882	http://dx.doi.org/10.1371/journal.pone.0243882			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WM	33306721	gold, Green Published			2023-01-03	WOS:000600144200044
J	Ethier, I; Cho, Y; Hawley, C; Pascoe, EM; Viecelli, AK; Campbell, SB; van Eps, C; Isbel, NM; Cooper, BA; Harris, DC; Pollock, CA; Wong, MG; Johnson, DW				Ethier, Isabelle; Cho, Yeoungjee; Hawley, Carmel; Pascoe, Elaine M.; Viecelli, Andrea K.; Campbell, Scott B.; van Eps, Carolyn; Isbel, Nicole M.; Cooper, Bruce A.; Harris, David C.; Pollock, Carol A.; Wong, Muh Geot; Johnson, David W.			Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study	PLOS ONE			English	Article							RENAL-FUNCTION; RELATIVE CONTRIBUTION; PREDICTORS; ADEQUACY; PRESERVATION; CLEARANCE; NUTRITION; SURVIVAL; START	Background Residual kidney function (RKF) is associated with improved survival and quality of life in dialysis patients. Previous studies have suggested that initiation of peritoneal dialysis (PD) may slow RKF decline compared to the pre-dialysis period. We sought to evaluate the association between PD initiation and RKF decline in the Initiating Dialysis Early And Late (IDEAL) trial. Methods In this post hoc analysis of the IDEAL randomized controlled trial, PD participants were included if results from 24-hour urine collections had been recorded within 30 days of dialysis initiation, and at least one value pre- and one value post-dialysis commencement were available. The primary outcome was slope of RKF decline, calculated as mean of urinary creatinine and urea clearances. Secondary outcomes included slope of urine volume decline and time from PD initiation to anuria. Results The study included 151 participants (79 early start, 72 late start). The slope of RKF decline was slower after PD initiation (-2.69 +/- 0.18mL/min/1.73m(2)/yr) compared to before PD (-4.09 +/- 0.33mL/min/1.73m(2)/yr; change in slope +1.19 mL/min/1.73m(2)/yr, 95%CI 0.48-1.90, p<0.001). In contrast, urine volume decline was faster after PD commencement (-0.74 +/- 0.05 L/yr) compared to beforehand (-0.57 +/- 0.06L/yr; change in slope -0.18L/yr, 95%CI -0.34--0.01, p = 0.04). No differences were observed between the early- and late-start groups with respect to RKF decline, urine volume decline or time to anuria. Conclusions Initiation of PD was associated with a slower decline of RKF compared to the pre-dialysis period.	[Ethier, Isabelle] Ctr Hosp Univ Montreal, Div Nephrol, Montreal, PQ, Canada; [Ethier, Isabelle; Cho, Yeoungjee; Hawley, Carmel; Viecelli, Andrea K.; Campbell, Scott B.; van Eps, Carolyn; Isbel, Nicole M.; Johnson, David W.] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia; [Cho, Yeoungjee; Hawley, Carmel; Pascoe, Elaine M.; Viecelli, Andrea K.; Johnson, David W.] Univ Queensland, Australasian Kidney Trials Network, Brisbane, Qld, Australia; [Hawley, Carmel; Johnson, David W.] Translat Res Inst, Brisbane, Qld, Australia; [Hawley, Carmel; Pascoe, Elaine M.; Campbell, Scott B.; van Eps, Carolyn; Isbel, Nicole M.; Johnson, David W.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Cooper, Bruce A.; Pollock, Carol A.; Wong, Muh Geot] Royal North Shore Hosp, Dept Renal Med, St Leonards, NSW, Australia; [Harris, David C.] Westmead Inst Med Res, Ctr Transplantat & Renal Res, Sydney, NSW, Australia; [Harris, David C.; Pollock, Carol A.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia; [Wong, Muh Geot] George Inst Global Hlth, Newtown, Tas, Australia	Universite de Montreal; University of Queensland; University of Queensland; Royal North Shore Hospital; University of Sydney; Westmead Institute for Medical Research; University of Sydney; George Institute for Global Health; University of Sydney	Ethier, I (corresponding author), Ctr Hosp Univ Montreal, Div Nephrol, Montreal, PQ, Canada.; Ethier, I (corresponding author), Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia.	isabelle.ethier@umontreal.ca	; Johnson, David/F-2897-2011	Ethier, Isabelle/0000-0003-4909-0417; Johnson, David/0000-0001-5491-3460	National Health and Medical Research Council of Australia [211146, 465095]; Australian Health Ministers Advisory Council [PDR 2001/10]; Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology (Don and Lorraine Jacquot Fellowship); National Heart Foundation (Australia); National Heart Foundation (New Zealand); Baxter Healthcare; Health Funding Authority New Zealand (Te Mana Putea Hauora O Aotearoa); International Society for Peritoneal Dialysis; Amgen Australia; Janssen-Cilag; Centre Hospitalier de l'Universite de Montreal; Fondation du CHUM; NHMRC; Jacquot Research Establishment Fellowship Award; Princess Alexandra Research Foundation; Diabetes Australian Research Trust Millennium Grant; Australian National Health and Medical Research Council Practitioner Fellowship	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Health Ministers Advisory Council; Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology (Don and Lorraine Jacquot Fellowship); National Heart Foundation (Australia)(National Heart Foundation of Australia); National Heart Foundation (New Zealand); Baxter Healthcare; Health Funding Authority New Zealand (Te Mana Putea Hauora O Aotearoa); International Society for Peritoneal Dialysis; Amgen Australia(Amgen); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Centre Hospitalier de l'Universite de Montreal; Fondation du CHUM; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Jacquot Research Establishment Fellowship Award; Princess Alexandra Research Foundation; Diabetes Australian Research Trust Millennium Grant; Australian National Health and Medical Research Council Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	The IDEAL study was supported by grants from the National Health and Medical Research Council of Australia (211146 and 465095), the Australian Health Ministers Advisory Council (PDR 2001/10), the Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology (Don and Lorraine Jacquot Fellowship), the National Heart Foundation (Australia), and the National Heart Foundation (New Zealand), and by unrestricted grants from Baxter Healthcare, Health Funding Authority New Zealand (Te Mana Putea Hauora O Aotearoa), the International Society for Peritoneal Dialysis, Amgen Australia, and Janssen-Cilag. IE is supported by a fellowship grant from the Centre Hospitalier de l'Universite de Montreal and the Fondation du CHUM. YC is supported by an Early career fellowship grant from the NHMRC. AV received grant support from the Jacquot Research Establishment Fellowship Award and the Princess Alexandra Research Foundation. MGW is supported by Diabetes Australian Research Trust Millennium Grant. DJ is supported by an Australian National Health and Medical Research Council Practitioner Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, NAT NANOTECHNOL, V11, P1, DOI 10.1038/nnano.2015.333; Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Berlanga JR, 2002, PERITON DIALYSIS INT, V22, P239; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; de Jager DJ, 2013, NEPHROL DIAL TRANSPL, V28, P698, DOI 10.1093/ndt/gfs578; DUBOIS D, 1989, NUTRITION, V5, P303; He L, 2016, PERITON DIALYSIS INT, V36, P334, DOI 10.3747/pdi.2016.00024; Janmaat CJ, 2018, CLIN EPIDEMIOL, V10, P613, DOI 10.2147/CLEP.S153367; Jansen MAM, 2002, KIDNEY INT, V62, P1046, DOI 10.1046/j.1523-1755.2002.00505.x; Johnson DW, 2012, J AM SOC NEPHROL, V23, P1097, DOI 10.1681/ASN.2011121201; Johnson DW, 2003, PERITON DIALYSIS INT, V23, P276; Lang SM, 2001, PERITON DIALYSIS INT, V21, P52; Liao CT, 2008, PERITON DIALYSIS INT, V28, pS191; Lysaght M J, 1991, ASAIO Trans, V37, P598; Medcalf JF, 2001, KIDNEY INT, V59, P1128, DOI 10.1046/j.1523-1755.2001.0590031128.x; Moist LM, 2000, J AM SOC NEPHROL, V11, P556, DOI 10.1681/ASN.V113556; Perl J, 2009, AM J KIDNEY DIS, V53, P1068, DOI 10.1053/j.ajkd.2009.02.012; Phisitkul S, 2010, KIDNEY INT, V77, P617, DOI 10.1038/ki.2009.519; Singhal MK, 2000, PERITON DIALYSIS INT, V20, P429; Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93; Termorshuizen F, 2003, AM J KIDNEY DIS, V41, P1293, DOI 10.1016/S0272-6386(03)00362-7; UCLA: Statistical Consulting Group, CAN I RUN PIEC REGR; Ueda Atsushi, 2017, Adv Perit Dial, V33, P18	25	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2020	15	11							e0242254	10.1371/journal.pone.0242254	http://dx.doi.org/10.1371/journal.pone.0242254			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VP	33196667	gold, Green Published			2023-01-03	WOS:000595266800002
J	Sarker, BK; Rahman, M; Rahman, T; Rahman, T; Khalil, JJ; Hasan, M; Rahman, F; Ahmed, A; Mitra, DK; Mridha, MK; Rahman, A				Sarker, Bidhan Krishna; Rahman, Musfikur; Rahman, Tanjina; Rahman, Tawhidur; Khalil, Jubaida Jahan; Hasan, Mehedi; Rahman, Fariya; Ahmed, Anisuddin; Mitra, Dipak Kumar; Mridha, Malay Kanti; Rahman, Anisur			Status of the WHO recommended timing and frequency of antenatal care visits in Northern Bangladesh	PLOS ONE			English	Article							SYSTEMATIC ANALYSIS; MATERNAL MORTALITY; TRENDS; DETERMINANTS	Objective There is dearth of information on the timeliness of antenatal care (ANC) uptake. This study aimed to determine the timely ANC uptake by a medically trained provider (MTP) as per the World Health Organization (WHO) recommendations and the country guideline. Methods Cross-sectional survey was done with 2,731 women having livebirth outcome in last one year in Dinajpur, Nilphamari and Rajshahi districts, Bangladesh from August-November,2016. Results About 82%(2,232) women received at least one ANC from a MTP. Overall, 78%(2,142) women received 4 or more ANCs by any provider and 43%(1168) from a MTP. Only 14%(378) women received their first ANC at the 1(st) trimester by a MTP. As per 4 schedule visits by the WHO FANC model and the country guideline 8%(203) and 20%(543) women respectively received the first 2 timely ANC by a MTP; where only 1%(32) and 3%(72) received the first 3 visits timely and 0.6%(17) and 1%(29) received all the four timely visits. Factors significantly associated with the first two timely visits are: 10 or above years of schooling of women [adj. OR 2.13 (CI: 1.05, 4.30)] and their husbands [adj. OR 2.40 (CI: 1.31, 4.38)], women's employment [adj. OR 2.32 (CI: 1.43, 3.76)], urban residential status [adj. OR 3.49 (CI: 2.46, 4.95)] and exposure to mass media [adj. OR 1.58 (CI: 1.07, 2.34)] at 95% confidence interval. According to the 2016 WHO ANC model, only 1.5%(40) women could comply with the first two ANC contacts timely by a MTP and no one could comply with all the timely 8 contacts. Conclusion Despite high coverage of ANC utilization, timely ANC visit is low as per both the WHO recommendations and the country guideline. For better understanding, further studies on the timeliness of ANC coverage are required to design feasible intervention for improving maternal and child health.	[Sarker, Bidhan Krishna; Rahman, Musfikur; Rahman, Tanjina; Rahman, Tawhidur; Khalil, Jubaida Jahan; Hasan, Mehedi; Rahman, Fariya; Ahmed, Anisuddin; Rahman, Anisur] Icddrb, Maternal & Child Hlth Div, Dhaka, Bangladesh; [Mitra, Dipak Kumar] North South Univ, Dept Publ Hlth, Dhaka, Bangladesh; [Mridha, Malay Kanti] BRAC Univ, James P Grant Sch Publ Hlth, Ctr Excellence Noncommunicable Dis, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); North South University (NSU); Bangladesh Rural Advancement Committee BRAC; BRAC University	Sarker, BK (corresponding author), Icddrb, Maternal & Child Hlth Div, Dhaka, Bangladesh.	bidhan@icddrb.org	Mridha, Malay Kanti/AAJ-5539-2020; Rahman, Tanjina/HHZ-2026-2022; Mitra, Dipak/W-9569-2018	Mridha, Malay Kanti/0000-0001-9226-457X; Hasan, M. Tasdik/0000-0002-3256-093X; Sarker, Bidhan Krishna/0000-0003-1479-158X; Mitra, Dipak/0000-0001-8680-4146	Bill and Melinda Gates Foundation; BMGF [OPP1146943]; Government of Bangladesh; Government of Canada; Government of Sweden; Government of UK	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); BMGF; Government of Bangladesh; Government of Canada(CGIAR); Government of Sweden; Government of UK	This study funded by Bill and Melinda Gates Foundation. The awarded BMGF grant number is OPP1146943. BKS received the funding. URL of funder website is https://www.gatesfoundation.org.The sponsors had no role in the study design, data collection and analysis, decision to publish and preparing manuscript.; icddr,b acknowledges with gratitude the commitment of Bill & Melinda Gates Foundation to its research efforts. We are grateful to our study participants for their spontaneous participation and sincere commitment to fulfill the research endeavor. icddr,b is also grateful to the Government of Bangladesh, Canada, Sweden and the UK for providing core/ unrestricted support.	Ali S., 2018, J PREG NEONATAL MED, V2; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; [Anonymous], 2012, KIDNEY INT, V2, ps1; Arokiasamy P, 2008, J BIOSOC SCI, V40, P183, DOI 10.1017/S0021932007002623; Association of Paediatric Anaesthetists of Great Britain and Ireland, 2012, PAEDIAT ANAESTH S1, V22, pS1; Azimi MW, 2019, NAGOYA J MED SCI, V81, P121, DOI 10.18999/nagjms.81.1.121; Bangladesh Bureau of Statistics (BBS) UNICEF Bangladesh, 2019, BANGL MULT IND CLUST; Bangladesh Bureau of Statistics Statistics and Informatics Division Ministry of Planning, 2015, POP HOUS CENS 2011; Bangladesh Bureau of Statistics Statistics and Informatics Division Ministry of Planning, 2013, POP HOUS CENS COMM R; Banik BK., 2016, S E ASIA J PUBLIC HL, V6, P23, DOI [10.3329/seajph.v6i2.31832, DOI 10.3329/SEAJPH.V6I2.31832]; BBS, 2015, BANGL POP HOUS CENS; BBS, 2014, BANGL POP HOUS CENS; BBS, 2013, DISTR STAT 2011 KHAG; Beeckman K, 2013, EUR J PUBLIC HEALTH, V23, P366, DOI 10.1093/eurpub/cks123; Beeckman K, 2013, EUR J PUBLIC HEALTH, V23, P67, DOI 10.1093/eurpub/cks020; Benova L, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000779; Bobo FT, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0602-2; Bostoen K, 2006, INT J EPIDEMIOL, V35, P751, DOI 10.1093/ije/dyl019; Chaka EE, STUDIES, V13, P20; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Debiec KE, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.03.001; Debiec KE, 2010, IMPR BIRTH OUTC M CH, V203, p122e1, DOI 10.1016/j.ajog.2010.03.001; Farah S, 2015, BANGL MED J, V44, P67; Gupta R, 2017, J NEONATAL BIOL, V6, P263, DOI [DOI 10.4172/2167-0897.1000263, 10.4172/2167-0897.1000263]; Gupta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101893; Halim A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1866-2; Hollowell J, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-13; Human Resource management (HRM) Ministry of Health and Family Welfare (MOHFW), 2014, HRH DAT SHEET 2014; IIPS ICF, 2017, IND NAT FAM HLTH SUR; Jo Y, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4696-7; Kadapatti MG, 2012, ANTENATAL CARE OCCUR, V2; Kamal SMM, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1467, DOI 10.1177/1010539513485786; Keya K, 2013, BARRIER DISTANCE TRA; Mannan M. A., 2013, Bangladesh Development Studies, V36, P25; Ministry of Health and Family Welfare (MOHFW), 2018, HLTH POP NUTR ETOOLK; Ministry of Health Nepal; New ERA; and ICF, 2017, NEP DEM HLTH SURV 20; Mohammad K.A., 2018, BANGLADESH J SCI RES, V30, P23, DOI [10.3329/BJSR.V30I1-2.36117, DOI 10.3329/BJSR.V30I1-2.36117]; Moinuddin M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189365; Moller AB, 2017, UN HLHT FAM WELF CTR, V5, pe977, DOI 10.1016/S2214-109X(17)30325-X; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Mridha MK, 2009, J HEALTH POPUL NUTR, V27, P124; Myatt M., 2012, SHORT GUIDE UNDERTAK; National Institute of Population Research and Training, 2012, BANGL MAT MORT HLTH; National Institute of Population Research and Training Associates for Community and Population Research ICF International, 2016, BANGL HLTH FAC SURV; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2013, BANGL DEM HLTH SURV; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; National Institute of Population Research and Training (NIPORT) Mitra and Associates Macro International, 2009, BANGL DEM HLTH SURV; National Institute of Population Research and Training (NIPORT) Mitra and Associates ORC Macro, 2004, BANGL DEM HLTH SURV; National Institute of Population ResearchTraining International Centre for Diarrhoeal Disease Research Bangladesh MEASURE Evaluation, 2017, BANGL MAT MORT HLTH; National Institute of Population Studies (NIPS) [Pakistan] and ICF, 2019, PAK DEM HLTH SURV 20; NIPORT ICF, 2019, BANGL DEM HLTH SURV; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Patel Y, 2018, MATER RELIG, V14, P1, DOI 10.1080/17432200.2017.1417215; Phommachanh S, 2019, GLOB IND FRAM SUST D, V19, P255, DOI 10.1186/s12884-019-2345-0; Phommachanh S, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2345-0; Ponna Satyendra Nath, 2017, J Family Med Prim Care, V6, P231, DOI 10.4103/2249-4863.220024; Rahman A, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001462; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Siddique AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205149; Souza JP, 2014, BJOG-INT J OBSTET GY, V121, P1, DOI 10.1111/1471-0528.12735; StataCorp, 2013, STATA STAT SOFTW REL; Tesfaye G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208729; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; THE WORLD BANK, 2019, LOW MIDDL INC 2019; Tuncalp O, 2017, BJOG-INT J OBSTET GY, V124, P860, DOI 10.1111/1471-0528.14599; UNDP Bangladesh, 2020, COV 19 REAL CHECK BA; UNFPA-Afghanistan, 2015, SOC EC SURV CHILD MO; United Nations, 2015, GLOBAL STRATEGY WOME; United Nations International Children's Emergency Fund (unicef), 2016, ANT CAR 2016; Victora CG, 2016, LANCET, V387, P2049, DOI 10.1016/S0140-6736(15)00519-X; Walton LM, 2012, J HLTH ETHICS    FAL; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2015, BANGLADESH HLTH SYST; WHO. UNICEF UNFPA World Bank Group Division atUNP, 2015, TRENDS MAT MORT 1990; World Health Organization, 2016, BURN OPP CLEAN HOUS; World Mission Prayer League (LAMB Hospital), 2017, LAMB ANN REP 2017	78	12	12	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2020	15	11							e0241185	10.1371/journal.pone.0241185	http://dx.doi.org/10.1371/journal.pone.0241185			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OU2PT	33151964	Green Published, gold			2023-01-03	WOS:000591376200037
J	Abou Mrad, Z; Saliba, N; Abou Merhi, D; Rahi, A; Nabulsi, M				Abou Mrad, Zaki; Saliba, Nicole; Abou Merhi, Dima; Rahi, Amal; Nabulsi, Mona			Sustaining compliance with hand hygiene when resources are low: A quality improvement report	PLOS ONE			English	Article							HOSPITALS; PROGRAM; SUCCESS	Background Sustainability of hand hygiene is challenging in low resource settings. Adding ownership and goal setting to the WHO-5 multimodal intervention may help sustain high compliance. Aim To increase and sustain compliance of nursing and medical staff with hand hygiene in a tertiary referral center with limited resources. Methods A quality improvement initiative was conducted over two years (2016-2018). After determining baseline compliance rates, the WHO-5 multimodal intervention was implemented with staff education and training, system change, hospital reminders, direct observation and feedback, and hospital safety climate. Additionally, the medical staff was responsible for continuous surveillance of compliance (ownership) until rates above 90% were achieved and sustained (goal setting). Results Of 2987 observations collected between August 2016 and April 2018, 1630 (54.5%) were before, and 1357 (45.5%) were after patient encounters. The average overall compliance with hand hygiene was sustained at 94% for nursing and medical staff. Two instances of drops below 90% were associated with incidence of nosocomial Rotavirus infections. There were no similar infections during intervention periods with compliance rates above the set goal. Analysis using p-charts revealed significant improvement in compliance rates from baseline (chi(2) (1) = 7.94, p = 0.005). Conclusion Adding ownership and goal setting to the WHO-5 multimodal intervention may help achieve, and sustain high rates of compliance with hand hygiene. Involving health care workers in quality improvement initiatives is feasible, durable, reliable, and cheap, especially in settings with limited financial resources.	[Abou Mrad, Zaki] Amer Univ Beirut, Fac Arts & Sci, Med Res Volunteer Program MRVP, Beirut, Lebanon; [Saliba, Nicole; Abou Merhi, Dima; Rahi, Amal; Nabulsi, Mona] Amer Univ Beirut, Dept Pediat & Adolescent Med, Beirut, Lebanon	American University of Beirut; American University of Beirut	Nabulsi, M (corresponding author), Amer Univ Beirut, Dept Pediat & Adolescent Med, Beirut, Lebanon.	mn04@aub.edu.lb	; Nabulsi, Mona/A-8002-2016	Abou Mrad, Zaki/0000-0001-6387-8396; Nabulsi, Mona/0000-0001-7415-6436				Allegranzi B, 2009, J HOSP INFECT, V73, P305, DOI 10.1016/j.jhin.2009.04.019; [Anonymous], 2019, JMIR PUBLIC HLTH SUR, V4, pe53, DOI 10.2196/publichealth.9932; [Anonymous], 2010, EUR J CARDIOTHORA S1, V38, pS1; Beyersmann J, 2009, INFECT CONT HOSP EP, V30, P273, DOI 10.1086/596020; Carey RG, 2003, BASIC ADV SPC METHOD; Crews JD, 2013, INFECT CONT HOSP EP, V34, P751, DOI 10.1086/671002; Ghee L, 2017, AM SURGEON, V83, pE468; Harbarth S, 2002, PEDIATR INFECT DIS J, V21, P489, DOI 10.1097/00006454-200206000-00002; Harris BD, 2011, HEALTH AFFAIR, V30, P1751, DOI 10.1377/hlthaff.2010.1282; Homa Karen, 2011, Qual Manag Health Care, V20, P116, DOI 10.1097/QMH.0b013e318213ae83; Hussain AS, 2020, ARCH DIS CHILD, DOI 10.1136/archdischild-2019-318779; Johnson L, 2014, AM J INFECT CONTROL, V42, P1146, DOI 10.1016/j.ajic.2014.07.003; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; Lacey G, 2020, AM J INFECT CONTROL, V48, P162, DOI 10.1016/j.ajic.2019.06.015; Linam WM, 2016, AM J INFECT CONTROL, V44, P544, DOI 10.1016/j.ajic.2015.12.019; Linam WM, 2011, PEDIATRICS, V128, pE689, DOI 10.1542/peds.2010-3587; Luangasanatip N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3728; McLean Heather S, 2017, Hosp Pediatr, V7, P189, DOI 10.1542/hpeds.2016-0110; Mestre G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047200; Ogrinc Greg, 2016, BMJ Qual Saf, V25, P986, DOI 10.1136/bmjqs-2015-004411; Organization WH, 2009, WHO GUID HAND HYG HL; Pimentel MPT, 2019, J PATIENT SAF, V15, pE44, DOI 10.1097/PTS.0000000000000282; Rees S, 2013, J NURS CARE QUAL, V28, P312, DOI 10.1097/NCQ.0b013e3182902404; Rosenbluth G, 2016, AM J MED QUAL, V31, P577, DOI 10.1177/1062860615596567; Sharma S, 2019, INDIAN J CRIT CARE M, V23, P224, DOI 10.5005/jp-journals-10071-23165; Smiddy Maura P, 2019, J Infect Prev, V20, P164, DOI 10.1177/1757177419833165; Squires JE, 2014, INFECT CONT HOSP EP, V35, P1511, DOI 10.1086/678597; The European Collaborative Study, 2003, PEDIATRICS, V111, pe52; Zoutman DE, 2017, INT J HEALTH CARE Q, V30, P16, DOI 10.1108/IJHCQA-12-2015-0144	29	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2020	15	11							e0241706	10.1371/journal.pone.0241706	http://dx.doi.org/10.1371/journal.pone.0241706			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8YL	33141855	gold, Green Published			2023-01-03	WOS:000588376700045
J	Braz, LG; Braz, JRC; Modolo, MP; Corrente, JE; Sanchez, R; Pacchioni, M; Cury, JB; Soares, IB; Braz, MG				Braz, Leandro G.; Braz, Jose R. C.; Modolo, Marilia P.; Corrente, Jose E.; Sanchez, Rafael; Pacchioni, Mariana; Cury, Julia B.; Soares, Iva B.; Braz, Mariana G.			Perioperative and anesthesia-related cardiac arrest and mortality rates in Brazil: A systematic review and proportion meta-analysis	PLOS ONE			English	Review							SURGERY; OUTCOMES	Introduction Studies have shown that both perioperative and anesthesia-related cardiac arrest (CA) and mortality rates are much higher in developing countries than in developed countries. This review aimed to compare the rates of perioperative and anesthesia-related CA and mortality during 2 time periods in Brazil. Methods A systematic review with meta-analysis of full-text Brazilian observational studies was conducted by searching the Medline, EMBASE, LILACS and SciELO databases up to January 29, 2020. The primary outcomes were perioperative CA and mortality rates and the secondary outcomes included anesthesia-related CA and mortality events rates up to 48 postoperative hours. Results Eleven studies including 719,273 anesthetic procedures, 962 perioperative CAs, 134 anesthesia-related CAs, 1,239 perioperative deaths and 29 anesthesia-related deaths were included. The event rates were evaluated in 2 time periods: pre-1990 and 1990-2020. Perioperative CA rates (per 10,000 anesthetics) decreased from 39.87 (95% confidence interval [CI]: 34.60-45.50) before 1990 to 17.61 (95% CI: 9.21-28.68) in 1990-2020 (P < 0.0001), while the perioperative mortality rate did not alter (from 19.25 [95% CI: 15.64-23.24] pre-1990 to 25.40 [95% CI: 13.01-41.86] in 1990-2020; P = 0.1984). Simultaneously, the anesthesia-related CA rate decreased from 14.39 (95% CI: 11.29-17.86) to 3.90 (95% CI: 2.93-5.01; P < 0.0001), while there was no significant difference in the anesthesia-related mortality rate (from 1.75 [95% CI: 0.76-3.11] to 0.67 [95% CI: 0.09-1.66; P = 0.5404). Conclusions This review demonstrates an important reduction in the perioperative CA rate over time in Brazil, with a large and consistent decrease in the anesthesia-related CA rate; however, there were no significant differences in perioperative and anesthesia-related mortality rates between the assessed time periods.	[Braz, Leandro G.; Braz, Jose R. C.; Modolo, Marilia P.; Sanchez, Rafael; Pacchioni, Mariana; Cury, Julia B.; Soares, Iva B.; Braz, Mariana G.] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Anesthesiol, Sao Paulo, Brazil; [Corrente, Jose E.] Sao Paulo State Univ UNESP, Inst Biosci, Dept Biostat, Sao Paulo, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista	Braz, LG (corresponding author), Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Anesthesiol, Sao Paulo, Brazil.	leandro.braz@unesp.br	Braz, Leandro/AAK-8378-2021; Braz, Leandro Gobbo/W-4445-2019; Braz, Mariana G/E-7639-2012	Braz, Leandro Gobbo/0000-0002-1927-8729; Braz, Mariana G/0000-0003-4413-226X; Pacchioni, Mariana/0000-0003-2006-6018; Soares, Iva/0000-0002-2076-8127	National Council for Scientific and Technological Development (CNPq) [125054/2016-5, 149852/2019-3, 144230/2019-4]; CNPq [304174/2801-1]; Coordination of Improvement for Higher Academic Staff (CAPES); CAPES	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination of Improvement for Higher Academic Staff (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	R.S., M.P. and J.B.C. received a scholarship from The National Council for Scientific and Technological Development (CNPq; 125054/2016-5, 149852/2019-3 and 144230/2019-4, respectively) and L.G.B. received a fellowship from CNPq (304174/2801-1). M.P.M. received a scholarship from Coordination of Improvement for Higher Academic Staff (CAPES). Both CNPq and CAPES supported our study by financial support. We did not receive funding from our institution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1986, REV BRAS ANESTESIOL; [Anonymous], 1999, REV BRAS ANESTESIOL; Bainbridge D, 2012, LANCET, V380, P1075, DOI 10.1016/S0140-6736(12)60990-8; Bharati Sachidanand Jee, 2014, Niger Med J, V55, P1, DOI 10.4103/0300-1652.128146; Braghiroli KS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02745-6; Braz LG, 2020, J CLIN ANESTH, V64, DOI 10.1016/j.jclinane.2020.109813; Braz LG, 2020, REV BRAS ANESTESIOL, V70, P82, DOI [10.1016/j.bjan.2020.02.004, 10.1016/j.bjane.2020.04.014]; Braz LG, 2006, BRIT J ANAESTH, V96, P569, DOI 10.1093/bja/ael065; Carlucci MTO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090125; Chan Raquel Pei Chen, 2002, Rev. Bras. Anestesiol., V52, P719, DOI 10.1590/S0034-70942002000600009; Choi SW, 2017, ANAESTHESIA, V72, P532, DOI 10.1111/anae.13832; CICARELLI DD., 1998, REV BRASILEIRA ANEST, V48, P289; Cooper JB, 2002, ANESTHESIOLOGY, V97, P1335, DOI 10.1097/00000542-200212000-00003; Covre Eduardo Rocha, 2019, Rev Col Bras Cir, V46, pe1979, DOI 10.1590/0100-6991e-20191979; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eichhorn JH, 2013, CAN J ANESTH, V60, P111, DOI 10.1007/s12630-012-9852-z; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; Gurgel SJT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098006; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hinkelbein J, 2017, MINERVA ANESTESIOL, V83, P1190, DOI 10.23736/S0375-9393.17.11802-X; Holmer H, 2015, LANCET GLOB HEALTH, V3, pS9, DOI 10.1016/S2214-109X(14)70349-3; Ivani G, 2012, PEDIATR ANESTH, V22, P947, DOI 10.1111/pan.12009; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Khan FA, 2018, ANESTH ANALG, V126, P1312, DOI 10.1213/ANE.0000000000002728; Kim SH, 2015, YONSEI MED J, V56, P1401, DOI 10.3349/ymj.2015.56.5.1401; Koga FA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001465; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Massenburg BB, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2016-000226; Meara JG, 2014, LANCET, V383, P12, DOI 10.1016/S0140-6736(13)62345-4; Morray JP, 2007, ANESTHESIOLOGY, V106, P207, DOI 10.1097/00000542-200702000-00004; Munn Z, 2015, INT J EVID-BASED HEA, V13, P147, DOI 10.1097/XEB.0000000000000054; Newland MC, 2002, ANESTHESIOLOGY, V97, P108, DOI 10.1097/00000542-200207000-00016; Nunes JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104041; Nunnally ME, 2015, ANESTH ANALG, V120, P364, DOI 10.1213/ANE.0000000000000527; Pearse RM, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5759; Pignaton W, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002208; Pollard RJ, 2018, ANESTH ANALG, V127, P730, DOI 10.1213/ANE.0000000000003483; Sebbag I, 2013, SAO PAULO MED J, V131, P309, DOI 10.1590/1516-3180.2013.1315507; Stefani LC, 2018, J CLIN ANESTH, V49, P79, DOI 10.1016/j.jclinane.2018.06.025; Toledo FO, 2013, RESUSCITATION, V84, P635, DOI 10.1016/j.resuscitation.2012.09.019; Vane MF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51557-3; Vane MF, 2016, REV BRAS ANESTESIOL, V66, P176, DOI [10.1016/j.bjan.2016.01.001, 10.1016/j.bjane.2014.06.007]; Wacker J, 2014, CURR OPIN ANESTHESIO, V27, P649, DOI 10.1097/ACO.0000000000000124; Watters DA, 2015, WORLD J SURG, V39, P856, DOI 10.1007/s00268-014-2638-4; Weiser TG, 2016, B WORLD HEALTH ORGAN, V94, P201, DOI 10.2471/BLT.15.159293	45	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2020	15	11							e0241751	10.1371/journal.pone.0241751	http://dx.doi.org/10.1371/journal.pone.0241751			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8YA	33137159	gold, Green Published			2023-01-03	WOS:000588375500043
J	Feldman, WB; Rome, BN; Avorn, J; Kesselheim, AS				Feldman, William B.; Rome, Benjamin N.; Avorn, Jerry; Kesselheim, Aaron S.			The Future of Drug-Pricing Transparency	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								A federal "Transparency in Coverage" rule requires insurers to disclose list prices and historical net prices for medications and to give patients personalized cost-sharing estimates. Despite industry opposition, the rule may endure under the Biden administration.	[Feldman, William B.; Rome, Benjamin N.; Avorn, Jerry; Kesselheim, Aaron S.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, 75 Francis St, Boston, MA 02115 USA; [Feldman, William B.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Feldman, William B.; Rome, Benjamin N.; Avorn, Jerry; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Feldman, WB (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, 75 Francis St, Boston, MA 02115 USA.; Feldman, WB (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Feldman, WB (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.			Rome, Benjamin/0000-0001-5776-3293				[Anonymous], 2020, BIDEN SANDERS UNITY; Brown ZY, 2019, REV ECON STAT, V101, P699, DOI 10.1162/rest_a_00765; Transparency in coverage: a rule by the Internal Revenue Service the Employee Benefits Security Administration and the Health and Human Services Department on 11/12/2020, 2020, FED REG	3	5	5	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	2021	384	6					489	491		10.1056/NEJMp2033734	http://dx.doi.org/10.1056/NEJMp2033734			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG5JQ	33440087				2023-01-03	WOS:000617621800004
J	Davies, LE; Kingston, A; Todd, A; Hanratty, B				Davies, Laurie E.; Kingston, Andrew; Todd, Adam; Hanratty, Barbara			Characterising polypharmacy in the very old: Findings from the Newcastle 85+Study	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; SEX-DIFFERENCES; HEALTH INEQUALITIES; ADVANCED AGE; PRESCRIPTION; PATTERNS; MEDICATIONS; NATIONWIDE; PEOPLE; LIFE	Background Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged >= 85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study-a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845). Methods The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2-4, 5-9 and >= 10 medicines-so-called 'no polypharmacy', 'monotherapy', 'minor polypharmacy', 'polypharmacy' and 'hyperpolypharmacy.' Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5-90.5). Participant characteristics were examined through descriptive statistics. Results Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4-8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (<25(th) centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD. Conclusion Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.	[Davies, Laurie E.; Kingston, Andrew; Hanratty, Barbara] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Todd, Adam] Newcastle Univ, Sch Pharm, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Davies, LE (corresponding author), Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England.	L.E.Davies2@newcastle.ac.uk		Todd, Adam/0000-0003-1496-9341; Davies, Laurie/0000-0003-4931-3270; Kingston, Andrew/0000-0003-4211-7007; Hanratty, Barbara/0000-0002-3122-7190	National Institute for Health Research School for Primary Care Research (NIHR SPCR) [SPCR-2014-10043]; Medical Research Council; Dunhill Medical Trust; National Institute for Health Research School for Primary Care Research; British Heart Foundation; Unilever Corporate Research; Newcastle University; NHS North of Tyne (Newcastle Primary Care Trust); Biotechnology and Biological Sciences Research Council; MRC [MR/J50001X/1, G0500997] Funding Source: UKRI	National Institute for Health Research School for Primary Care Research (NIHR SPCR); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dunhill Medical Trust(Dunhill Medical Trust); National Institute for Health Research School for Primary Care Research; British Heart Foundation(British Heart Foundation); Unilever Corporate Research(Unilever); Newcastle University; NHS North of Tyne (Newcastle Primary Care Trust); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This paper presents independent research funded by the National Institute for Health Research School for Primary Care Research (NIHR SPCR) [SPCR-2014-10043]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The Newcastle 85+ Study has been funded by the Medical Research Council, Biotechnology and Biological Sciences Research Council, the Dunhill Medical Trust and the National Institute for Health Research School for Primary Care Research. Parts of the work have also been funded by the British Heart Foundation, Unilever Corporate Research, Newcastle University, NHS North of Tyne (Newcastle Primary Care Trust). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARBER N, 1995, BRIT MED J, V310, P923, DOI 10.1136/bmj.310.6984.923; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; Bjerrum L, 1997, EUR J CLIN PHARMACOL, V53, P7, DOI 10.1007/s002280050329; Brannstrom J, 2011, DRUG AGING, V28, P993, DOI 10.2165/11594730-000000000-00000; *BRIT MED ASS, 2009, BRIT NAT FORM; Brittain K, 2017, AGEING SOC, V37, P39, DOI 10.1017/S0144686X15001142; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Cohen A, 2006, ARCH GEN PSYCHIAT, V63, P50, DOI 10.1001/archpsyc.63.1.50; Collerton Joanna, 2007, BMC Geriatr, V7, P14, DOI 10.1186/1471-2318-7-14; Collerton J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8745670; Collerton J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4904; Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364; Dahlgren G., 1991, POLICIES STRATEGIES, V14; Davies K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108370; Davies K, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-64; Davies LE, 2020, J AM MED DIR ASSOC, V21, P181, DOI 10.1016/j.jamda.2019.10.022; Department of Health and Social Security England, 1980, IN HLTH REP RES WORK; Duncan R, 2011, AGE AGEING, V40, P752, DOI 10.1093/ageing/afr105; Eachus J, 1999, J EPIDEMIOL COMMUN H, V53, P603, DOI 10.1136/jech.53.10.603; Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI [10.1146/annurev.pharmtox.44.101802.121453, 10.2165/00003088-200948030-00001]; Giron MST, 1999, CLIN DRUG INVEST, V17, P389; Gnjidic D, 2012, CLIN PHARMACOL THER, V91, P521, DOI 10.1038/clpt.2011.258; GRIFFIN JP, 1993, J ROY COLL PHYS LOND, V27, P121; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hofer-Duckelmann Christina, 2012, Handb Exp Pharmacol, P169, DOI 10.1007/978-3-642-30726-3_9; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Holmes HM, 2013, DRUG AGING, V30, P655, DOI 10.1007/s40266-013-0095-7; Hovstadius Bo, 2010, BMC Clin Pharmacol, V10, P16, DOI 10.1186/1472-6904-10-16; Hughes LD, 2013, AGE AGEING, V42, P62, DOI 10.1093/ageing/afs100; Ilango S, 2017, INTERN MED J, V47, P1019, DOI 10.1111/imj.13526; Johnell K, 2018, EXPERT REV CLIN PHAR, V11, P825, DOI 10.1080/17512433.2018.1510313; Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351; Jyrkka J, 2009, DRUG AGING, V26, P493, DOI 10.2165/00002512-200926060-00006; Kalache A, 1997, WORLD HEALTH, V50, P4, DOI DOI 10.1007/S10534-014-9784-X; Kerse N, 2015, INT J EPIDEMIOL, V44, P1823, DOI 10.1093/ije/dyv103; Kingston A, 2015, ARCH GERONTOL GERIAT, V60, P405, DOI 10.1016/j.archger.2015.02.006; Kingston A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088016; Kingston A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031665; Lagerin A, 2017, SCAND J PUBLIC HLTH; Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0; Lorant V, 2003, AM J EPIDEMIOL, V157, P98, DOI 10.1093/aje/kwf182; Mangin D, 2007, BMJ-BRIT MED J, V335, P285, DOI 10.1136/bmj.39241.630741.BE1; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Martin-Ruiz C, 2011, MECH AGEING DEV, V132, P496, DOI 10.1016/j.mad.2011.08.001; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; Morin L, 2017, AM J MED, V130, P927, DOI [10.1016/amjmed.2017.02.028, 10.1016/j.amjmed.2017.02.028]; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Institute for Health and Care Excellence, 2010, CLOP MOD REL REL DIP; Nobili A, 2011, PHARMACOEPIDEM DR S, V20, P488, DOI 10.1002/pds.2108; O'Rand AM, 2002, CUMULATIVE ADVANTAGE; Office for National Statistics, 2018, LIV LONG OUR POP CHA; Oksuzyan A, 2008, AGING CLIN EXP RES, V20, P91; Onder G, 2016, J AM MED DIR ASSOC, V17, P168, DOI 10.1016/j.jamda.2015.08.009; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Rawle MJ, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0795-2; Royal College of Physicians, 2016, NAT CLIN GUID STROK; Royal College of Physicians, 2014, WHY ASTHM STILL KILL; Teh R, 2014, NEW ZEAL MED J, V127; Teh RO, 2018, AGE AGEING, V47, P261, DOI 10.1093/ageing/afx184; Tsoi Christopher S, 2014, BMC Res Notes, V7, P340, DOI 10.1186/1756-0500-7-340; van Kraaij DJW, 1998, BRIT J CLIN PHARMACO, V46, P403, DOI 10.1046/j.1365-2125.1998.00793.x; VERBRUGGE LM, 1985, J HEALTH SOC BEHAV, V26, P156, DOI 10.2307/2136750; Wagert PV, 2006, AGING CLIN EXP RES, V18, P116; Wastesson JW, 2017, PHARMACOEPIDEM DR S, V26, P152, DOI 10.1002/pds.4120; Wastesson JW, 2012, AGE AGEING, V41, P218, DOI 10.1093/ageing/afr144; WINGARD DL, 1984, ANNU REV PUBL HEALTH, V5, P433, DOI 10.1146/annurev.pu.05.050184.002245; Woodward MC., 2003, J PHARM PRACT RES, V33, P323, DOI DOI 10.1002/jppr2003334323; World Health Organization, SOCIAL DETERMINANTS; Yadegarfar ME, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019218	70	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0245648	10.1371/journal.pone.0245648	http://dx.doi.org/10.1371/journal.pone.0245648			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PY3TH	33465141	Green Published, gold			2023-01-03	WOS:000611969200038
J	Enriquez-Hesles, E; Smith, DL; Maqani, N; Wierman, MB; Sutcliffe, MD; Fine, RD; Kalita, A; Santos, SM; Muehlbauer, MJ; Bain, JR; Janes, KA; Hartman, JL; Hirschey, MD; Smith, JS				Enriquez-Hesles, Elisa; Smith, Daniel L., Jr.; Maqani, Nazif; Wierman, Margaret B.; Sutcliffe, Matthew D.; Fine, Ryan D.; Kalita, Agata; Santos, Sean M.; Muehlbauer, Michael J.; Bain, James R.; Janes, Kevin A.; Hartman, John L.; Hirschey, Matthew D.; Smith, Jeffrey S.			A cell-nonautonomous mechanism of yeast chronological aging regulated by caloric restriction and one-carbon metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; AMINO-ACID; DIETARY RESTRICTION; BUDDING YEAST; SERINE; MITOCHONDRIAL; CONSUMPTION; HOMEOSTASIS; SUPEROXIDE	Caloric restriction (CR) improves health span and life span of organisms ranging from yeast to mammals. Understanding the mechanisms involved will uncover future interventions for aging-associated diseases. In budding yeast, Saccharomyces cerevisiae, CR is commonly defined by reduced glucose in the growth medium, which extends both replicative and chronological life span (CLS). We found that conditioned media collected from stationary-phase CR cultures extended CLS when supplemented into nonrestricted (NR) cultures, suggesting a potential cell-nonautonomous mechanism of CR-induced life span regulation. Chromatography and untargeted metabolomics of the conditioned media, as well as transcriptional responses associated with the longevity effect, pointed to specific amino acids enriched in the CR conditioned media (CRCM) as functional molecules, with L-serine being a particularly strong candidate. Indeed, supplementing L-serine into NR cultures extended CLS through a mechanism dependent on the one-carbon metabolism pathway, thus implicating this conserved and central metabolic hub in life span regulation.	[Enriquez-Hesles, Elisa; Smith, Daniel L., Jr.; Maqani, Nazif; Wierman, Margaret B.; Fine, Ryan D.; Kalita, Agata; Janes, Kevin A.; Smith, Jeffrey S.] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Sutcliffe, Matthew D.; Janes, Kevin A.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA; [Smith, Daniel L., Jr.] Univ Alabama Birmingham, Dept Nutr Sci, Res Ctr, Nathan Shock Ctr Excellence Basic Biol Aging, Birmingham, AL 35294 USA; [Santos, Sean M.; Hartman, John L.] Univ Alabama Birmingham, Dept Genet Nutr & Obes, Res Ctr, Nathan Shock Ctr Excellence Basic Biol Aging, Birmingham, AL USA; [Muehlbauer, Michael J.; Bain, James R.; Hirschey, Matthew D.] Duke Univ, Dept Med, Duke Mol Physiol Inst, Durham, NC USA	University of Virginia; University of Virginia; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University	Smith, JS (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	jss5y@virginia.edu		Fine, Ryan/0000-0002-3165-9110; Bain, James R./0000-0002-8917-9187; Smith Jr, Daniel/0000-0002-1602-2023; Hartman, John/0000-0003-1176-6469; Kalita, Agata Izabela/0000-0002-0231-3428	Medical Scientist Training Program (MSTP) [T32GM007267]; Cell and Molecular Biology (CMB) from NIH [T32GM008136]; CMB training grant; NIH [R21AG053596, RO1GM075240, R56AG059590, RO1AG043076, RO1AG045351, RO1CA214718, P30AG028716]; David and Lucile Packard Foundation [2009-34710]	Medical Scientist Training Program (MSTP); Cell and Molecular Biology (CMB) from NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CMB training grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); David and Lucile Packard Foundation(The David & Lucile Packard Foundation)	E. E. H was supported by the Medical Scientist Training Program (MSTP) training grant T32GM007267, and the Cell and Molecular Biology (CMB) training grant T32GM008136 from the NIH. R. D. F was also supported by the CMB training grant. This work was also supported by NIH grants R21AG053596 and RO1GM075240 to J. S. S., R56AG059590 to J. L. H and J. S. S., RO1AG043076 to J. L. H., RO1AG045351 to M. D. H, and RO1CA214718 to K. A. J., who was also supported by The David and Lucile Packard Foundation (#2009-34710). Additional support was provided by NIH grant P30AG028716 to the Duke Claude Pepper Older Americans Independence Center.	Allen C, 2006, J CELL BIOL, V174, P89, DOI 10.1083/jcb.200604072; Alvers AL, 2009, AGING CELL, V8, P353, DOI 10.1111/j.1474-9726.2009.00469.x; Borten MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18815-8; Burke D., 2000, METHODS YEAST GENETI; Burtner CR, 2009, CELL CYCLE, V8, P1256, DOI 10.4161/cc.8.8.8287; Chen H, 2006, GENE DEV, V20, P1150, DOI 10.1101/gad.1411806; Chew SY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0546-5; Choi JS, 2013, BIOCHEM BIOPH RES CO, V439, P126, DOI 10.1016/j.bbrc.2013.08.014; Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86; Crepin L, 2012, APPL ENVIRON MICROB, V78, P8102, DOI 10.1128/AEM.02294-12; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diaz-Ruiz R, 2011, BBA-BIOENERGETICS, V1807, P568, DOI 10.1016/j.bbabio.2010.08.010; Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Dunlop RA, 2018, NEUROTOX RES, V33, P123, DOI 10.1007/s12640-017-9829-3; Dunlop RA, 2021, NEUROTOX RES, V39, P17, DOI 10.1007/s12640-020-00168-2; Edwards C, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0167-2; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; Fontana L, 2016, CELL REP, V16, P520, DOI 10.1016/j.celrep.2016.05.092; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Fromentin G, 2012, NUTR RES REV, V25, P29, DOI 10.1017/S0954422411000175; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gomes P, 2007, MECH AGEING DEV, V128, P383, DOI 10.1016/j.mad.2007.04.003; Gray JV, 2004, MICROBIOL MOL BIOL R, V68, P187, DOI 10.1128/MMBR.68.2.187-206.2004; Haber JE, 2012, GENETICS, V191, P33, DOI 10.1534/genetics.111.134577; Han SK, 2016, ONCOTARGET, V7, P56147, DOI 10.18632/oncotarget.11269; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Hartman JL, 2015, GENES-BASEL, V6, P24, DOI 10.3390/genes6010024; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; Hu J, 2014, AGING CELL, V13, P457, DOI 10.1111/acel.12202; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Jiang JC, 2000, FASEB J, V14, P2135; Johnson JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097729; Jones DL, 2011, NAT CELL BIOL, V13, P506, DOI 10.1038/ncb0511-506; Jung PP, 2018, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-018-0022-6; Juricic P, 2020, J GERONTOL A-BIOL, V75, P24, DOI 10.1093/gerona/glz080; Kabil H, 2011, P NATL ACAD SCI USA, V108, P16831, DOI 10.1073/pnas.1102008108; Kalhan SC, 2012, J BIOL CHEM, V287, P19786, DOI 10.1074/jbc.R112.357194; Kapahi P, 2017, AGEING RES REV, V39, P3, DOI 10.1016/j.arr.2016.12.005; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; Kory N, 2018, SCIENCE, V362, P791, DOI 10.1126/science.aat9528; Kwan EX, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002250; Kyryakov P, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00256; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Laporte D, 2016, MOL BIOL CELL, V27, P1875, DOI 10.1091/mbc.E16-01-0069; Lee Johnny C-Y, 2013, FEMS Yeast Res, V13, P618, DOI 10.1111/1567-1364.12063; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Ljungdahl PO, 2012, GENETICS, V190, P885, DOI 10.1534/genetics.111.133306; Longo VD, 2012, CELL METAB, V16, P18, DOI 10.1016/j.cmet.2012.06.002; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ludovico P, 2001, MICROBIOL-SGM, V147, P2409, DOI 10.1099/00221287-147-9-2409; MacLean M, 2001, YEAST, V18, P499, DOI 10.1002/yea.701; Maitra N, 2020, ELIFE, V9, DOI 10.7554/eLife.53127; Mansfeld J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10043; Maqani N, 2018, MICROB CELL, V5, P233, DOI 10.15698/mic2018.05.630; Maruyama Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151894; Matecic M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000921; MCCAY CM, 1957, GERONTOLOGY, V1, P7, DOI 10.1159/000210677; McIsaac RS, 2016, ANN NY ACAD SCI, V1363, P155, DOI 10.1111/nyas.13032; McNulty NP, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002701; Mirisola MG, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004113; Ocampo A, 2012, CELL METAB, V16, P55, DOI 10.1016/j.cmet.2012.05.013; Olin-Sandoval V, 2019, NATURE, V572, P249, DOI 10.1038/s41586-019-1442-6; Peter GJ, 2006, J BIOL CHEM, V281, P5546, DOI 10.1074/jbc.M513842200; PETERSEN JGL, 1988, GENETICS, V119, P527; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Qin Z, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8107; RAMOS F, 1982, EUR J BIOCHEM, V123, P571; Reverter-Branchat G, 2004, J BIOL CHEM, V279, P31983, DOI 10.1074/jbc.M404849200; Ron-Harel N, 2018, P NATL ACAD SCI USA, V115, P13347, DOI 10.1073/pnas.1804149115; Ruckenstuhl C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004347; Ruetenik A, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00400; Santos J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037090; Santos SM, 2021, GEROSCIENCE, V43, P941, DOI 10.1007/s11357-020-00265-2; Skorupa DA, 2008, AGING CELL, V7, P478, DOI 10.1111/j.1474-9726.2008.00400.x; Smith DL, 2007, AGING CELL, V6, P649, DOI 10.1111/j.1474-9726.2007.00326.x; Smith DL, 2016, EXP GERONTOL, V86, P113, DOI 10.1016/j.exger.2016.04.012; Sousa-Victor P, 2019, NAT METAB, V1, P276, DOI 10.1038/s42255-018-0023-6; Staschke KA, 2010, J BIOL CHEM, V285, P16893, DOI 10.1074/jbc.M110.121947; Swygert SG, 2019, MOL CELL, V73, P533, DOI 10.1016/j.molcel.2018.11.020; Tahara EB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056388; Wang GH, 2019, NEUROPHARMACOLOGY, V146, P39, DOI 10.1016/j.neuropharm.2018.11.025; Weinberger M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000748; Weinberger M, 2010, AGING-US, V2, P709, DOI 10.18632/aging.100215; Wierman MB, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00562-16; Wierman MB, 2015, AGING-US, V7, P177, DOI 10.18632/aging.100729; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415; Zeng JD, 2019, PHARMACOL RES, V149, DOI 10.1016/j.phrs.2019.104352; Zhou XH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00476	95	8	8	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100125	10.1074/jbc.RA120.015402	http://dx.doi.org/10.1074/jbc.RA120.015402			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33243834	gold, Green Published, Green Submitted			2023-01-03	WOS:000672866400104
J	Singh, A				Singh, Ameeta			In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Singh, Ameeta] Univ Alberta, Edmonton, AB, Canada	University of Alberta	Singh, A (corresponding author), Univ Alberta, Edmonton, AB, Canada.							Emanuel EJ, 2020, NEW YORK TIMES; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Schiffer JT, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa232; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]	4	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					JC3	JC3		10.7326/ACPJ202101190-003	http://dx.doi.org/10.7326/ACPJ202101190-003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33395331				2023-01-03	WOS:000619485200004
J	Johnson, G; Davies, P				Johnson, Graham; Davies, Patrick			Toxicological analysis of George's marvellous medicine: literature review	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PEDIATRIC BURNS	OBJECTIVE To analyse the therapeutic effects and toxicity of the eponymous concoction described in Roald Dahl's book George's Marvellous Medicine. DESIGN Literature review. SETTING Two literature loving households in England. PARTICIPANTS George Kranky and grandma Kranky. MAIN OUTCOME MEASURES Clinical and toxic effects of the individual ingredients, checked against those listed in ToxBase, the National Poisons Information Service's poisons database RESULTS The medicine contained 34 ingredients. The most common toxic effect identified on ToxBase was nausea and vomiting (16 ingredients, 47%). Potentially life threatening effects were associated with 13 (38%) ingredients, including depression of the central nervous system, kidney injury, convulsions, cardiac toxicity, and mucosal erosion. The effects described in the book were accurate initially but then diverted from the most likely clinical outcome (death). CONCLUSIONS Although Dahl ought to be applauded for his initial accuracy about the toxicology of the ingredients in George's marvellous medicine, the overall effect would be fatal catastrophic physiological collapse. Scientific exploration and experimentation should be encouraged in children, although any medicinal ingredients need to be checked for potential toxicity before being administered-to grandmas or anyone else.	[Johnson, Graham] Royal Derby Hosp, Univ Hosp Derby & Burton NHS Fdn Trust, Emergency Dept, Derby DE22 3NE, England; [Johnson, Graham; Davies, Patrick] Univ Nottingham, Sch Med, Nottingham, England; [Davies, Patrick] Nottingham Univ Hosp NHS Trust, Paediat Crit Care Dept, Nottingham, England	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust	Johnson, G (corresponding author), Royal Derby Hosp, Univ Hosp Derby & Burton NHS Fdn Trust, Emergency Dept, Derby DE22 3NE, England.; Johnson, G (corresponding author), Univ Nottingham, Sch Med, Nottingham, England.	graham.johnson4@nhs.net		Johnson, Graham/0000-0001-6004-6244				Alward A, 2015, CHILDRENS BOOK MONTH; Brewster CT, 2020, LANCET, V395, P1690, DOI 10.1016/S0140-6736(20)31144-2; D'Asta F, 2020, BURNS, V46, P1471, DOI 10.1016/j.burns.2020.06.028; Dahl R, 2016, GEORGES MARVELLOUS M; Dahl R., 2010, GEORGES MARVELLOUS M; Dahl R, 1981, GEORGES MARVELLOUS M; Dahl R., 1998, GEORGES MARVELLOUS M; European Child Safety Alliance, 2009, CHILDH POIS; European Child Safety Alliance, 2012, CHILD SAF REP CARDS, V31, P32; Health Research Authority, IS MY STUD RES; Lewins I., 2020, ADVICE TREATING BURN; National Poisons Information Service, 2020, TOXB; Readable, FLESCH READ EAS FLES; Rodgers GB, 2012, INJURY PREV, V18, P103, DOI 10.1136/injuryprev-2011-040008; Royal College of General Practitioners, 2015, ANN SPEC REP GMC, P1; Royal Society for the Prevention of Accidents, ACC CHILDR; Royal Society for the Prevention of Accidents, LIQ LAUNDR CAPS ROSP; Royal Society for the Prevention of Accidents, 2017, ACC RSFTPO; Williams T, 2020, CORONAVIRUS HOMESCHO	19	1	1	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2020	371								m4467	10.1136/bmj.m4467	http://dx.doi.org/10.1136/bmj.m4467			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH2WY	33303487	hybrid, Green Published			2023-01-03	WOS:000600280900014
J	Wilson, AM; Clark, AB; Cahn, T; Chilvers, ER; Fraser, W; Hammond, M; Livermore, DM; Maher, TM; Parfrey, H; Swart, AM; Stirling, S; Thickett, DR; Whyte, M				Wilson, Andrew M.; Clark, Allan B.; Cahn, Tony; Chilvers, Edwin R.; Fraser, William; Hammond, Matthew; Livermore, David M.; Maher, Toby M.; Parfrey, Helen; Swart, Ann Marie; Stirling, Susan; Thickett, David R.; Whyte, Moira		EME-TIPAC Team	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis The EME-TIPAC Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-STATUS; STANDARDIZATION; PIRFENIDONE; PROGRESSION	Importance Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole). Objective To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF. Design, Setting, and Participants Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity <= 75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (last patient follow-up). Interventions Study participants were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months. All patients received 5 mg of folic acid orally once daily. Main Outcomes and Measures The primary outcome was time to death (all causes), lung transplant, or first nonelective hospital admission. There were 15 secondary outcomes, including the individual components of the primary end point respiratory-related events, lung function (forced vital capacity and gas transfer), and patient-reported outcomes (Medical Research Council dyspnea scale, 5-level EuroQol 5-dimension questionnaire, cough severity, Leicester Cough Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores). Results Among 342 individuals who were randomized (mean age, 71.3 years; 46 [13%] women), 283 (83%) completed the trial. The median (interquartile range) duration of follow-up was 1.02 (0.35-1.73) years. Events per person-year of follow-up among participants randomized to the co-trimoxazole and placebo groups were 0.45 (84/186) and 0.38 (80/209), respectively, with a hazard ratio of 1.2 ([95% CI, 0.9-1.6]; P = .32). There were no statistically significant differences in other event outcomes, lung function, or patient-reported outcomes. Patients in the co-trimoxazole group had 696 adverse events (nausea [n = 89], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]). Conclusions and Relevance Among patients with moderate or severe IPF, treatment with oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo. Question What is the clinical efficacy of co-trimoxazole (trimethoprim-sulfamethoxazole) in idiopathic pulmonary fibrosis (IPF) in terms of time to death (all causes), lung transplant, or first nonelective hospital admission? Findings In this randomized clinical trial, which included 343 patients with moderate or severe IPF, the incidence of the composite outcome among those treated with oral co-trimoxazole, 960 mg twice daily, vs those treated with placebo was 0.45 vs 0.38 per person-year after a median follow-up of 1.02 years; the hazard ratio was not statistically significant. Meaning Co-trimoxazole compared with placebo did not improve a composite clinical outcome among patients with moderate or severe IPF. This randomized clinical trial compares the effects of co-trimoxazole (trimethoprim-sulfamethoxazole [TMP-SMX]) vs placebo on time to death, lung transplant, or hospital admission in patients with moderate or severe idiopathic pulmonary fibrosis (IPF).	[Wilson, Andrew M.; Clark, Allan B.; Fraser, William; Livermore, David M.] Univ East Anglia, Norwich Med Sch, Norwich Res Pk, Norwich, Norfolk, England; [Wilson, Andrew M.] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Dept Resp Med, Norwich, Norfolk, England; [Cahn, Tony] Bedford Hosp NHS Trust, Dept Resp Med, South Wing, Bedford, England; [Chilvers, Edwin R.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Fraser, William; Maher, Toby M.] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Dept Endocrinol & Clin Biochem, Colney Lane, Norwich, Norfolk, England; [Hammond, Matthew; Swart, Ann Marie; Stirling, Susan] Univ East Anglia, Norwich Clin Trials Unit, Norwich Res Pk, Norwich, Norfolk, England; [Maher, Toby M.] Univ Southern Calif, Hastings Ctr Pulm Res, Los Angeles, CA 90007 USA; [Maher, Toby M.] Univ Southern Calif, Keck Sch Med, Div Pulm Crit Care & Sleep Med, Los Angeles, CA 90007 USA; [Maher, Toby M.] Royal Brompton Hosp, NIHR Resp Clin Res Facil, London, England; [Parfrey, Helen] Royal Papworth Hosp NHS Fdn Trust, Papworth Rd,Cambridge Biomed Campus, Cambridge, England; [Thickett, David R.] Univ Birmingham, Inst Inflammat & Aging, Birmingham, W Midlands, England; [Whyte, Moira] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland	University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust; Imperial College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; University of East Anglia; University of Southern California; University of Southern California; Royal Brompton Hospital; Papworth Hospital; University of Birmingham; University of Edinburgh	Wilson, AM (corresponding author), Univ East Anglia, James Watson Rd,Norwich Res Pk, Norwich NR4 7TJ, Norfolk, England.	a.m.wilson@uea.ac.uk	Maher, Toby/AAM-1618-2020; Parfrey, Helen/GMW-4265-2022; Porter, Joanna/C-7162-2009	Maher, Toby/0000-0001-7192-9149; Swart, Ann Marie/0000-0002-9359-6995; PARR, DAVID/0000-0002-0099-7918; Clark, Allan/0000-0003-2965-8941; thickett, david/0000-0002-5456-6080; Chilvers, Edwin/0000-0002-4230-9677; Hammond, Matthew/0000-0002-0739-3412; Porter, Joanna/0000-0002-7307-169X	MRC [MC_PC_14145] Funding Source: UKRI; Medical Research Council [MC_PC_14145] Funding Source: Medline; Department of Health [CS-2013-13-017] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Anstrom KJ, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1326-1; Atkins CP, 2014, RESP MED, V108, P376, DOI 10.1016/j.rmed.2013.11.007; Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339; Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI; Fisher Mark, 2017, J Manag Care Spec Pharm, V23, pS17, DOI 10.18553/jmcp.2017.23.3-b.s17; Garzoni C, 2013, THORAX, V68, P1150, DOI 10.1136/thoraxjnl-2012-202917; Guenther A, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0845-5; Hammond M, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2453-6; Han MK, 2014, LANCET RESP MED, V2, P548, DOI 10.1016/S2213-2600(14)70069-4; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Invernizzi R, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01519-2019; Jenkins G, 2018, THORAX, V73, P485, DOI 10.1136/thoraxjnl-2017-211220; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; LACEY RW, 1980, LANCET, V1, P1270; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; Manali ED, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-32; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Molyneaux PL, 2014, AM J RESP CRIT CARE, V190, P906, DOI 10.1164/rccm.201403-0541OC; Nathan SD, 2019, RESP MED, V153, P44, DOI 10.1016/j.rmed.2019.04.016; Navaratnam V, 2011, THORAX, V66, P462, DOI 10.1136/thx.2010.148031; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Patel AS, 2012, THORAX, V67, P804, DOI 10.1136/thoraxjnl-2012-201581; Raghu G, 2012, NEW ENGL J MED, V366, P1968, DOI 10.1056/NEJMoa1113354; Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL; Richter AG, 2009, THORAX, V64, P692, DOI 10.1136/thx.2008.110445; Samara KD, 2012, INT J ONCOL, V40, P1397, DOI 10.3892/ijo.2012.1374; SAVICI D, 1989, AM REV RESPIR DIS, V139, P22, DOI 10.1164/ajrccm/139.1.22; Shulgina L, 2013, THORAX, V68, P155, DOI 10.1136/thoraxjnl-2012-202403; Sinha A, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2018-000363; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Varney VA, 2008, PULM PHARMACOL THER, V21, P178, DOI 10.1016/j.pupt.2007.02.001; Vidal S, 2006, CLIN MICROBIOL INFEC, V12, P231, DOI 10.1111/j.1469-0691.2005.01337.x; Wells AU, 2012, THORAX, V67, P938, DOI 10.1136/thoraxjnl-2012-202580; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Wilson ECF, 2014, PHARMACOECONOMICS, V32, P87, DOI 10.1007/s40273-013-0112-z	36	18	18	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2020	324	22					2282	2291		10.1001/jama.2020.22960	http://dx.doi.org/10.1001/jama.2020.22960			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD9VK	33289822	Green Submitted, Green Published, Bronze, Green Accepted			2023-01-03	WOS:000598023000019
J	Parri, N; Lazzeri, S				Parri, Niccolo; Lazzeri, Simone			Efficacy of ibuprofen in musculoskeletal post-traumatic pain in children: A systematic review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; INTRAVENOUS MORPHINE; MANAGEMENT-PRACTICES; ANALGESIA; EPIDEMIOLOGY; FRACTURES; FENTANYL; RELIEF; ACETAMINOPHEN	Musculoskeletal (MSK) injuries are one of the most frequent reason for pain-related evaluation in the emergency department (ED) in children. There is still no consensus as to what constitutes the best analgesic for MSK pain in children. However, ibuprofen is reported to be the most commonly prescribed analgesic and is considered the standard first-line treatment for MSK injury pain in children, even if it is argued that it provides inadequate relief for many patients. The purpose of this study was to review the most recent literature to assess the efficacy of ibuprofen for pain relief in MSK injuries in children evaluated in the ED. We performed a systematic review of randomized controlled trials on pharmacological interventions in children and adolescents under 19 years of age with MSK injuries according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome was the risk ratio for successful reduction in pain scores. Six studies met the inclusion criteria and provided data on 1028 children. A meta-analysis was not performed since studies were not comparable due to the different analgesic treatment used. No significant difference in term of main pain score reduction between all the analgesics used in the included studies was noted. Patients who received oral opioids had side effects more frequently when compared to children who received ibuprofen. The combination of effect on pain relief and tolerability would suggest ibuprofen as the initial drug of choice in providing relief from mild-to-moderate MSK pain in children in the ED. The results obtained in this review and current research suggest that there's no straightforward statistically significant evidence of the optimal analgesic agent to be used. However, ibuprofen may be preferable as the initial drug of choice in providing relief from MSK pain due to the favorable combination of effectiveness and safety profile. In fact, despite the non-significant pain reduction as compared to children who received opioids, there are less side effect associated to ibuprofen within studies. The wide range of primary outcomes measured in respect of pain scores and timing of recorded measures warrants a future standardization of study designs.	[Parri, Niccolo] Meyer Univ Childrens Hosp, Dept Emergency Med, Florence, Italy; [Parri, Niccolo] Meyer Univ Childrens Hosp, Trauma Ctr, Florence, Italy; [Lazzeri, Simone] Meyer Univ Childrens Hosp, Dept Orthopaed & Traumatol, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Parri, N (corresponding author), Meyer Univ Childrens Hosp, Dept Emergency Med, Florence, Italy.; Parri, N (corresponding author), Meyer Univ Childrens Hosp, Trauma Ctr, Florence, Italy.	niccolo.parri@meyer.it	Lazzeri, Simone/GQI-3662-2022	Lazzeri, Simone/0000-0002-5473-6510	Angelini SpA	Angelini SpA	NP and SL were supported by a grant from Angelini SpA. MG and FT have no competing interests to disclose with respect to the development of the present review. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2010, PEDIATR EMERG CARE, V26, P518, DOI 10.1097/PEC.0b013e3181e5c02b; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Brennan F, 2019, AM J PUBLIC HEALTH, V109, P61, DOI 10.2105/AJPH.2018.304743; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Clark E, 2007, PEDIATRICS, V119, P460, DOI 10.1542/peds.2006-1347; Cooper C, 2004, J BONE MINER RES, V19, P1976, DOI 10.1359/JBMR.040902; Derry C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001548.pub2; Drendel AL, 2006, PEDIATR EMERG CARE, V22, P94; Drendel AL, 2009, ANN EMERG MED, V54, P553, DOI 10.1016/j.annemergmed.2009.06.005; Fein JA, 2012, PEDIATRICS, V130, pE1391, DOI 10.1542/peds.2012-2536; Friday JH, 2009, ACAD EMERG MED, V16, P711, DOI 10.1111/j.1553-2712.2009.00471.x; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Green SM, 2016, ANN EMERG MED, V67, P573, DOI 10.1016/j.annemergmed.2015.06.002; Hagan JF, 2001, PEDIATRICS, V108, P793; Hartling L, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/5346819; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kanabar DJ, 2017, INFLAMMOPHARMACOLOGY, V25, P1, DOI 10.1007/s10787-016-0302-3; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kircher J, 2014, CLIN PEDIATR, V53, P1326, DOI 10.1177/0009922814555972; Kircher J, 2014, CAN J EMERG MED, V16, P449, DOI 10.2310/8000.2013.131211; Koller DM, 2007, PEDIATR EMERG CARE, V23, P627, DOI 10.1097/PEC.0b013e31814a6a39; Korownyk Christina, 2015, Can Fam Physician, V61, pe276; Landin LA, 1997, J PEDIATR ORTHOP B, V6, P79, DOI 10.1097/01202412-199704000-00002; Le May S, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0186; Le May S, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/4809394; Le May S, 2013, J EMERG MED, V44, P536, DOI 10.1016/j.jemermed.2012.06.027; Le May S, 2009, PEDIATR EMERG CARE, V25, P498, DOI 10.1097/PEC.0b013e3181b0a0af; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; Neri E, 2013, ARCH DIS CHILD, V98, P721, DOI 10.1136/archdischild-2012-303527; Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138; Pate JT, 1996, CHILD HEALTH CARE, V25, P281, DOI 10.1207/s15326888chc2504_4; Poonai N, 2014, CAN MED ASSOC J, V186, P1358, DOI 10.1503/cmaj.140907; Rennie L, 2007, INJURY, V38, P913, DOI 10.1016/j.injury.2007.01.036; Shepherd M, 2009, EMERG MED AUSTRALAS, V21, P484, DOI 10.1111/j.1742-6723.2009.01232.x; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147	38	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2020	15	12							e0243314	10.1371/journal.pone.0243314	http://dx.doi.org/10.1371/journal.pone.0243314			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC7AH	33270748	Green Published, gold			2023-01-03	WOS:000597149100031
J	Wheeler, M; Cooper, NR; Andrews, L; Hughes, JH; Juanchich, M; Rakow, T; Orbell, S				Wheeler, Mark; Cooper, Nicholas R.; Andrews, Leanne; Hacker Hughes, Jamie; Juanchich, Marie; Rakow, Tim; Orbell, Sheina			Outdoor recreational activity experiences improve psychological wellbeing of military veterans with post-traumatic stress disorder: Positive findings from a pilot study and a randomised controlled trial	PLOS ONE			English	Article							GENERALIZED ANXIETY DISORDER; SOCIAL-ADJUSTMENT SCALE; PSYCHOMETRIC PROPERTIES; DEPRESSION SEVERITY; MEASURING RESPONSE; COMBAT; PTSD; THERAPY; PSYCHOTHERAPY; OUTCOMES	Exposure to the natural environment is increasingly considered to benefit psychological health. Recent reports in the literature also suggest that outdoor exposure that includes recreational pursuits such as surfing or fishing coupled with opportunities for social interaction with peers may be beneficial to Armed Forces Veterans experiencing Post-Traumatic Stress Disorder (PTSD). Two studies were conducted to evaluate this possibility. In particular, these studies aimed to test the hypothesis that a brief group outdoor activity would decrease participants' symptoms as assessed by established measures of PTSD, depression, anxiety and perceived stress, and increase participants' sense of general social functioning and psychological growth. Experiment one employed a repeated measures design in which UK men and women military veterans with PTSD (N = 30) participated in a group outdoor activity (angling, equine care, or archery and falconry combined). Psychological measures were taken at 2 weeks prior, 2 weeks post, and at 4 month follow up. We obtained a significant within participant main effect indicating significant reduction in PTSD symptoms. Experiment two was a waitlist controlled randomised experiment employing an angling experience (N = 18) and 2 week follow up. In experiment 2 the predicted interaction of Group (Experimental vs. Waitlist Control) X Time (2 weeks pre vs. 2 weeks post) was obtained indicating that the experience resulted in significant reduction in PTSD symptoms relative to waitlist controls. The effect size was large. Additional analyses confirmed that the observed effects might also be considered clinically significant and reliable. In sum, peer outdoor experiences are beneficial and offer potential to complement existing provision for military veterans with Post Traumatic Stress Disorder.	[Wheeler, Mark; Cooper, Nicholas R.; Juanchich, Marie; Orbell, Sheina] Univ Essex, Dept Psychol, Colchester, Essex, England; [Andrews, Leanne] Univ Essex, Dept Hlth & Social Care, Colchester, Essex, England; [Hacker Hughes, Jamie] Northumbria Univ, Northern Hub Vet & Families Res, Newcastle Upon Tyne, Tyne & Wear, England; [Rakow, Tim] Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London, England	University of Essex; University of Essex; Northumbria University; University of London; King's College London	Cooper, NR (corresponding author), Univ Essex, Dept Psychol, Colchester, Essex, England.	ncooper@essex.ac.uk		Orbell, Sheina/0000-0002-8665-3541; Cooper, Nicholas/0000-0002-4315-3299				[Anonymous], 2018, LANCET HAEMATOL, V5, P378; APA, 2013, DIAGN STAT MAN MENT, V5th; Barton J, 2010, ENVIRON SCI TECHNOL, V44, P3947, DOI 10.1021/es903183r; Beard C, 2014, J ANXIETY DISORD, V28, P547, DOI 10.1016/j.janxdis.2014.06.002; Bennett JL, 2017, COMMUNITY MENT HLT J, V53, P756, DOI 10.1007/s10597-017-0124-9; Bird K, 2015, INT J MENT HEALTH, V44, P46, DOI 10.1080/00207411.2015.1009752; Blais RK, 2014, J TRAUMA STRESS, V27, P116, DOI 10.1002/jts.21888; Blais RK, 2013, J TRAUMA STRESS, V26, P77, DOI 10.1002/jts.21772; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Bryant RA, 2003, J CONSULT CLIN PSYCH, V71, P706, DOI 10.1037/0022-006X.71.4.706; Buckley RC, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00119; Burdett B, 2012, PROCEEDINGS OF THE ASME PRESSURE VESSELS AND PIPING CONFERENCE, PVP 2011, VOL 6, A AND B, P1; Cameron IM, 2008, BRIT J GEN PRACT, V58, P32, DOI 10.3399/bjgp08X263794; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Crawford R, 2016, THESIS; Dear Blake F., 2011, Cognitive Behaviour Therapy, V40, P216, DOI 10.1080/16506073.2011.582138; Dickstein BD, 2010, MIL PSYCHOL, V22, P224, DOI 10.1080/08995600903417399; Dietrich ZC, 2015, J EXPERIENT EDUC, V38, P394, DOI 10.1177/1053825915596431; Dustin D, 2011, THERAPEUTIC RECREATI, V45; Duvall J, 2014, J REHABIL RES DEV, V51, P685, DOI 10.1682/JRRD.2013.08.0190; Forbes D, 2010, J TRAUMA STRESS, V23, P537, DOI 10.1002/jts.20565; Frueh BC, 1996, BEHAV RES THER, V34, P533, DOI 10.1016/0005-7967(96)00020-4; Gelkopf M, 2013, PSYCHIAT RES, V209, P485, DOI 10.1016/j.psychres.2013.01.026; Gladwell VF, 2013, EXTREME PHYSIOL MED, V2, DOI 10.1186/2046-7648-2-3; Greer M., 2019, MILITARY BEHAV HLTH, V7, P286, DOI [10.1080/21635781.2018.1543063, DOI 10.1080/21635781.2018.1543063]; Gros DF, 2011, BEHAV THER, V42, P276, DOI 10.1016/j.beth.2010.07.005; Hawkins BL, 2016, THER RECREAT J, V50, P55, DOI 10.18666/TRJ-2016-V50-I1-6793; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hyer L, 1996, J CLIN PSYCHOL, V52, P263, DOI 10.1002/(SICI)1097-4679(199605)52:3<263::AID-JCLP3>3.0.CO;2-T; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Joseph S, 2012, PSYCHOL TRAUMA-US, V4, P420, DOI 10.1037/a0024740; KAPLAN S, 1995, J ENVIRON PSYCHOL, V15, P169, DOI 10.1016/0272-4944(95)90001-2; Keane T., 1991, PTSD CHECKLIST MILIT; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kulesza Magdalena, 2015, Mil Behav Health, V3, P230; Lenhard W., 2016, CALCULATION EFFECT S; Lundberg N, 2011, THER RECREAT J, V45, P105; Mellotte H, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1389207; Mo Defence, 2016, ANN POP SURV UK ARM; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; Murphy D, 2019, J MENT HEALTH, V28, P654, DOI 10.1080/09638237.2017.1385739; Oh B, 2017, ENVIRON HEALTH PREV, V22, DOI 10.1186/s12199-017-0677-9; Poulsen Dorthe Varning, 2016, Health Psychol Open, V3, p2055102916637090, DOI 10.1177/2055102916637090; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rogers CM, 2014, AM J OCCUP THER, V68, P395, DOI 10.5014/ajot.2014.011221; Rytwinski NK, 2013, J TRAUMA STRESS, V26, P299, DOI 10.1002/jts.21814; Sherman MD, 2015, PROF PSYCHOL-RES PR, V46, P355, DOI 10.1037/pro0000043; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Steenkamp MM, 2013, CLIN PSYCHOL REV, V33, P45, DOI 10.1016/j.cpr.2012.10.002; SUTKER PB, 1995, J ABNORM PSYCHOL, V104, P444, DOI 10.1037/0021-843X.104.3.444; Taylor JM, 2015, PSYCHOL ASSESSMENT, V27, P90, DOI 10.1037/a0038100; Thomsen JM, 2018, J PARK RECREAT ADM, V36, P123, DOI 10.18666/JPRA-2018-V36-I1-8095; Titov Nickolai, 2011, Cognitive Behaviour Therapy, V40, P126, DOI 10.1080/16506073.2010.550059; US Census Bureau, 2017, VET RUR AM 2017; Vella EJ, 2013, MIL MED, V178, P254, DOI 10.7205/MILMED-D-12-00308; Weathers F. W., 2014, PTSD CHECKLIST DSM 5; Wen Y, 2019, ENVIRON HEALTH PREV, V24, DOI 10.1186/s12199-019-0822-8; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28, P1392, DOI 10.1037/pas0000260; Zahra D, 2014, INT J PSYCHIAT CLIN, V18, P131, DOI 10.3109/13651501.2014.894072; Zinzow HM, 2012, CLIN PSYCHOL REV, V32, P741, DOI 10.1016/j.cpr.2012.09.002; 2012, JAMA-J AM MED ASSOC, V308, P753, DOI DOI 10.1001/2012.JAMA.10695	62	5	5	4	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2020	15	11							e0241763	10.1371/journal.pone.0241763	http://dx.doi.org/10.1371/journal.pone.0241763			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OX9PD	33237906	gold, Green Accepted, Green Published			2023-01-03	WOS:000593887000012
J	Bogliotti, C; Aksen, H; Isel, F				Bogliotti, Caroline; Aksen, Hatice; Isel, Frederic			Language experience in LSF development: Behavioral evidence from a sentence repetition task	PLOS ONE			English	Article							AMERICAN SIGN-LANGUAGE; WORKING-MEMORY; 2ND-LANGUAGE ACQUISITION; NONWORD REPETITION; DEAF SIGNERS; IMPAIRMENT; AGE; CHILDREN; IMPACT; 1ST	In psycholinguistics and clinical linguistics, the Sentence Repetition Task (SRT) is known to be a valuable tool to screen general language abilities in both spoken and signed languages. This task enables users to reliably and quickly assess linguistic abilities at different levels of linguistic analysis such as phonology, morphology, lexicon, and syntax. To evaluate sign language proficiency in deaf children using French Sign Language (LSF), we designed a new SRT comprising 20 LSF sentences. The task was administered to a cohort of 62 children- 34 native signers (6;09-12 years) and 28 non-native signers (6;08-12;08 years)-in order to study their general linguistic development as a function of age of sign language acquisition (AOA) and chronological age (CA). Previously, a group of 10 adult native signers was also evaluated with this task. As expected, our results showed a significant effect of AOA, indicating that the native signers repeated more signs and were more accurate than non-native signers. A similar pattern of results was found for CA. Furthermore, native signers made fewer phonological errors (i.e., handshape, movement, and location) than non-native signers. Finally, as shown in previous sign language studies, handshape and movement proved to be the most difficult parameters to master regardless of AOA and CA. Taken together, our findings support the assumption that AOA is a crucial factor in the development of phonological skills regardless of language modality (spoken vs. signed). This study thus constitutes a first step toward a theoretical description of the developmental trajectory in LSF, a hitherto understudied language.	[Bogliotti, Caroline; Isel, Frederic] CNRS, Lab MODYCO, Nanterre, France; [Bogliotti, Caroline; Isel, Frederic] Paris Nanterre Univ, Nanterre, France; [Aksen, Hatice] CNRS, Lab Struct Formelles Langage, Paris, France; [Aksen, Hatice] St Denis Univ, Paris, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Bogliotti, C (corresponding author), CNRS, Lab MODYCO, Nanterre, France.; Bogliotti, C (corresponding author), Paris Nanterre Univ, Nanterre, France.	caroline.bogliotti@parisnanterre.fr		Bogliotti, Caroline/0000-0003-1413-1135	Education, Audiovisual and Culture Executive Agency - EACEA [543264-LLP-1-2013-1-ITKA2-KA2MP]; EVASIGNE Project (Paris Lumiere University Fund)	Education, Audiovisual and Culture Executive Agency - EACEA; EVASIGNE Project (Paris Lumiere University Fund)	This research was partially supported by the Education, Audiovisual and Culture Executive Agency -EACEA (543264-LLP-1-2013-1-ITKA2-KA2MP "SignMET" -Principal Investigator: Pasquale Rinaldi). Sign Language coders were paid by the EVASIGNE Project (Paris Lumiere University Funding) (PI: Caroline Bogliotti & Marion Blondel). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Acheson DJ, 2009, J MEM LANG, V60, P329, DOI 10.1016/j.jml.2008.12.002; Acheson DJ, 2009, PSYCHOL BULL, V135, P50, DOI 10.1037/a0014411; Adams AM, 2000, INT J LANG COMM DIS, V35, P95; Alloway TP, 2005, EUR J COGN PSYCHOL, V17, P207, DOI 10.1080/09541440440000005; Anderson Diane, 2002, J Deaf Stud Deaf Educ, V7, P83, DOI 10.1093/deafed/7.2.83; Anderson Diane., 2006, ADV SIGN LANGUAGE DE, P135, DOI [https://doi.org/10.1093/acprof:oso/9780195180947.003.0006, DOI 10.1093/ACPROF:OSO/9780195180947.003.0006]; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Berk S. B., 2003, THESIS; Bishop DVM, 2009, CHILD DEV, V80, P593, DOI 10.1111/j.1467-8624.2009.01281.x; Bishop DVM, 1996, J CHILD PSYCHOL PSYC, V37, P391, DOI 10.1111/j.1469-7610.1996.tb01420.x; Bley-Vroman R., 1994, RES METHODOLOGY 2 LA, P245; Blondel M, 2008, LEADING RES SIGN LAN, P275; BONVILLIAN JD, 1983, CHILD DEV, V54, P1435, DOI 10.1111/j.1467-8624.1983.tb00059.x; Boutla M, 2004, NAT NEUROSCI, V7, P997, DOI 10.1038/nn1298; Boyes Braem P., 1990, GESTURE LANGUAGE HEA, P107, DOI [DOI 10.1007/978-3-642-74859-2_10, 10.1007/978-3-642-74859-2_10]; Brentari D, 1998, MODEL SIGN LANGUAGE; Caselli NK, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00428; Cheek A, 2001, LANGUAGE, V77, P292, DOI 10.1353/lan.2001.0072; Chen Pichler D, 2009, LANGUAGE DEV LIFESPA, P217; Chen-Pichler Deborah, 2012, HDB LINGUISTICS COMM, P647; Chiat S., 2013, ISSUES ASSESSMENT BI, P56; Conlin KE, 2000, LANGUAGE ACQUISITION BY EYE, P51; Conti-Ramsden G, 2001, J CHILD PSYCHOL PSYC, V42, P741, DOI 10.1111/1469-7610.00770; Corina DP, 2016, GESTURE, V15, P291, DOI 10.1075/gest.15.3.01cor; Corina DP, 2003, J COGNITIVE NEUROSCI, V15, P718, DOI 10.1162/jocn.2003.15.5.718; Cormier K, 2012, ANN M GERM LING SOC; Cormier K, 2012, COGNITION, V124, P50, DOI 10.1016/j.cognition.2012.04.003; Courtin C, 2000, J Deaf Stud Deaf Educ, V5, P266, DOI 10.1093/deafed/5.3.266; Courtin C., 2010, LANG INTERACT ACQUIS, V1, P129, DOI [10.1075/lia.1.1.08cou, DOI 10.1075/LIA.1.1.08COU, DOI 10.1075/LIA.1.1.08C0U]; Devescovi A, 2007, INT J LANG COMM DIS, V42, P187, DOI 10.1080/13682820601030686; Emmorey K, 2002, NEUROIMAGE, V17, P812, DOI 10.1006/nimg.2002.1187; Emmorey Karen., 2013, PERSPECTIVES CLASSIF; Fenson Larry, 1994, Monographs of the Society for Research in Child Development, V59, P1; Gathercole S. E., 1993, WORKING MEMORY LANGU; Guy-Guyenet E, 2018, 8 C INT SOC GEST STU; Haug T, 2016, GUIDELINES SIGN LANG; Haug T, 2008, J DEAF STUD DEAF EDU, V13, P138, DOI 10.1093/deafed/enm027; HULST H. van der, 1993, PHONOLOGY, V10, P209, DOI [10.1017/S095267570000004X, DOI 10.1017/S095267570000004X]; Jacob S., 2007, THESIS; Klem M, 2015, DEVELOPMENTAL SCI, V18, P146, DOI 10.1111/desc.12202; Komeili M, 2013, CLIN LINGUIST PHONET, V27, P152, DOI 10.3109/02699206.2012.751625; Liddell Scott, 1989, SIGN LANG STUD, V64, P195, DOI DOI 10.1353/SLS.1989.0027; Limousin F., 2011, THESIS, V8; Lu J, 2016, J CHILD LANG, V43, P537, DOI 10.1017/S0305000915000835; MacSweeney M, 2006, HUM BRAIN MAPP, V27, P63, DOI 10.1002/hbm.20167; MacSweeney M, 2008, NEUROIMAGE, V40, P1369, DOI 10.1016/j.neuroimage.2007.12.047; Mann W, 2010, LANG LEARN DEV, V6, P60, DOI 10.1080/15475440903245951; Marentette PF, 2000, LANGUAGE ACQUISITION BY EYE, P71; Marshall C, 2015, LANG LEARN DEV, V11, P237, DOI 10.1080/15475441.2014.917557; Mayberry R.I., 2006, ENCYCLOP LANG LINGUI, V11, P739; Mayberry RI, 2007, APPL PSYCHOLINGUIST, V28, P537, DOI 10.1017/S0142716407070294; Mayberry RI, 2003, BRAIN LANG, V87, P369, DOI 10.1016/S0093-934X(03)00137-8; MAYBERRY RI, 1989, MEM COGNITION, V17, P740, DOI 10.3758/BF03202635; McIntire M.L., 1977, SIGN LANG STUD, V1016, P247, DOI [10.1353/sls.1977.0019, DOI 10.1353/SLS.1977.0019]; Meier RP, 2008, LANG LEARN DEV, V4, P63, DOI 10.1080/15475440701377618; MEIER RP, 1995, LANGUAGE, GESTURE, AND SPACE, P391; Miller C, 2000, RECH LINGUISTIQUES V, P101; Millet Agn?s., 2019, GRAMMAIRE DESCRIPTIV; Mitchell Ross E, 2004, J Deaf Stud Deaf Educ, V9, P133, DOI 10.1093/deafed/enh017; Morford J. P., 2000, RECHERCHES LINGUISTI, V29, P121; Morford JP, 2000, LANGUAGE ACQUISITION BY EYE, P111; Morgan G, 2007, INT J LANG COMM DIS, V42, P97, DOI 10.1080/13682820600783178; Morgan G, 2007, APPL PSYCHOLINGUIST, V28, P3, DOI 10.1017/S0142716407070014; Morgan G, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01217; Naiman N., 1974, WORKING PAPERS BILIN; NATALICIO DS, 1977, BILINGUAL REV, V4, P107; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; Newman AJ, 2002, NAT NEUROSCI, V5, P76, DOI 10.1038/nn775; Newport E.L., 1985, CROSS LINGUISTIC STU, VVol. 1, P881; Niederberger N., 2001, TELSF TEST LANGUE SI; Niederberger N., 2005, ENFANCE, V4, P285; Ortega G., 2010, LANG INTERACT ACQUIS, V1, P67, DOI DOI 10.1075/LIA.1.1.05ORT; Paludneviiene Raylene., 2008, SIGN LANGUAGES SPINN, P160; PETITTO LA, 1987, COGNITION, V27, P1, DOI 10.1016/0010-0277(87)90034-5; Polisenska K, 2015, INT J LANG COMM DIS, V50, P106, DOI 10.1111/1460-6984.12126; Puissant-Schontz L, 2018, SIGN LANG ACQ ASS C; Ramirez NF, 2016, CEREB CORTEX, V26, P1015, DOI 10.1093/cercor/bhu273; Ramirez NF, 2013, J CHILD LANG, V40, P391, DOI 10.1017/S0305000911000535; Redmond SM, 2011, J SPEECH LANG HEAR R, V54, P99, DOI 10.1044/1092-4388(2010/10-0010); Riches NG, 2010, INT J LANG COMM DIS, V45, P47, DOI 10.3109/13682820802647676; Rinaldi P, 2018, J DEAF STUD DEAF EDU, V23, P408, DOI 10.1093/deafed/eny021; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Schein JD, 1997, HOME STRANGERS EXPLO; Schick B.S., 2006, ADV SIGN LANGUAGE DE; Siedlecki T, 1997, APPL PSYCHOLINGUIST, V18, P17, DOI 10.1017/S0142716400009851; Singleton JL, 2004, COGNITIVE PSYCHOL, V49, P370, DOI 10.1016/j.cogpsych.2004.05.001; Slobin D, 1971, LANGUAGE TRAINING EA, P170; Stokoe WC, 2005, J DEAF STUD DEAF EDU, V10, P3, DOI 10.1093/deafed/eni001; STOKOE WC, 1980, ANNU REV ANTHROPOL, V9, P365, DOI 10.1146/annurev.an.09.100180.002053; Supalla T, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00859; Sutton-Spence R, 2004, HDB APPL LINGUISTICS, P165; Tomasello M., 2005, CONSTRUCTING LANGUAG; Van der Kooij E., 2002, PHONOLOGICAL CATEGOR; VARGO ME, 1984, J CLIN PSYCHOL, V40, P1525, DOI 10.1002/1097-4679(198411)40:6<1525::AID-JCLP2270400644>3.0.CO;2-B; Weismer SE, 2000, J SPEECH LANG HEAR R, V43, P865, DOI 10.1044/jslhr.4304.865; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Woolfe T, 2010, J CHILD PSYCHOL PSYC, V51, P322, DOI 10.1111/j.1469-7610.2009.02151.x	97	2	2	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2020	15	11							e0236729	10.1371/journal.pone.0236729	http://dx.doi.org/10.1371/journal.pone.0236729			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ5ZL	33201887	Green Published, gold			2023-01-03	WOS:000595003900054
J	Jhun, J; Moon, J; Ryu, J; Shin, Y; Lee, S; Cho, KH; Kang, T; Cho, ML; Park, SH				Jhun, Jooyeon; Moon, Jeonghyeon; Ryu, Jaeyoon; Shin, Yonghee; Lee, Seangyoun; Cho, Keun-Hyung; Kang, Taewook; Cho, Mi-La; Park, Sung-Hwan			Liposome/gold hybrid nanoparticle encoded with CoQ10 (LGNP-CoQ10) suppressed rheumatoid arthritis via STAT3/Th17 targeting	PLOS ONE			English	Article							COENZYME Q(10); GOLD NANOCAGES; SUPPLEMENTATION; IMPROVEMENT; ABSORPTION; DELIVERY; THERAPY; CELLS; JOINT	Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble antioxidant. Although CoQ10 has not been approved as medication by the Food and Drug Administration, it is widely used in dietary supplements. Some studies have shown that CoQ10 has anti-inflammatory effects on various autoimmune disorders. In this study, we investigated the anti-inflammatory effects of liposome/gold hybrid nanoparticles encoded with CoQ10 (LGNP-CoQ10). Both CoQ10 and LGNP-CoQ10 were administered orally to mice with collagen-induced arthritis (CIA) for 10 weeks. The inflammation pathology of joint tissues of CIA mice was then analyzed using hematoxylin and eosin and Safranin O staining, as well as immunohistochemistry analysis. We obtained immunofluorescence staining images of spleen tissues using confocal microscopy. We found that pro-inflammatory cytokines were significantly decreased in LGNP-CoQ10 injected mice. Th17 cell and phosphorylated STAT3-expressed cell populations were also decreased in LGNP-CoQ10 injected mice. When human peripheral blood mononuclear cells (PBMCs) were treated with CoQ10 and LGNP-CoQ10, the IL-17 expression of PBMCs in the LGNP-CoQ10-treated group was significantly reduced. Together, these results suggest that LGNP-CoQ10 has therapeutic potential for the treatment of rheumatoid arthritis.	[Jhun, Jooyeon; Ryu, Jaeyoon; Lee, Seangyoun; Cho, Keun-Hyung; Cho, Mi-La; Park, Sung-Hwan] Catholic Univ Korea, Catholic Res Inst Med Sci, Coll Med, Rheumatism Res Ctr, Seoul, South Korea; [Moon, Jeonghyeon; Cho, Mi-La] Catholic Univ Korea, Coll Med, Lab Immune Network, Conversant Res Consortium Immunol Dis, Seoul, South Korea; [Shin, Yonghee; Kang, Taewook] Sogang Univ, Dept Chem & Biomol Engn, Seoul, South Korea; [Kang, Taewook] Sogang Univ, Inst Integrated Biotechnol, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Sogang University; Sogang University	Cho, ML; Park, SH (corresponding author), Catholic Univ Korea, Catholic Res Inst Med Sci, Coll Med, Rheumatism Res Ctr, Seoul, South Korea.; Cho, ML (corresponding author), Catholic Univ Korea, Coll Med, Lab Immune Network, Conversant Res Consortium Immunol Dis, Seoul, South Korea.; Kang, T (corresponding author), Sogang Univ, Dept Chem & Biomol Engn, Seoul, South Korea.; Kang, T (corresponding author), Sogang Univ, Inst Integrated Biotechnol, Seoul, South Korea.	twkang@sogang.ac.kr; iammila@catholic.ac.kr; rapark@catholic.ac.kr			Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C1062]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1062). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdollahzad H, 2015, ARCH MED RES, V46, P527, DOI 10.1016/j.arcmed.2015.08.006; AL-Megrin WA, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00064; [Anonymous], 2016, J LARGE SCALE RES FA, V2, pA49; Bauerova Katarina, 2011, Interdiscip Toxicol, V4, P33, DOI 10.2478/v10102-011-0007-9; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Chen HC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112550; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dhaouadi T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194883; El Agamy DF, 2019, BMC UROL, V19, DOI 10.1186/s12894-019-0534-9; Hernandez VA, 2015, BBA-BIOMEMBRANES, V1848, P2233, DOI 10.1016/j.bbamem.2015.05.002; Jhun J, 2016, IMMUNOPHARM IMMUNOT, V38, P103, DOI 10.3109/08923973.2015.1122619; Jhun J, 2015, IMMUNOL LETT, V166, P92, DOI 10.1016/j.imlet.2015.05.012; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Lajunen T, 2015, J CONTROL RELEASE, V203, P85, DOI 10.1016/j.jconrel.2015.02.028; Lee JH, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601838; Lee SY, 2017, J MED FOOD, V20, P821, DOI 10.1089/jmf.2016.3859; Lee SH, 2016, J MED FOOD, V19, P238, DOI 10.1089/jmf.2015.3535; Lee YC, 2007, J ETHNOPHARMACOL, V112, P40, DOI 10.1016/j.jep.2007.01.033; Lee Y, 2019, CHEM COMMUN, V55, P3195, DOI 10.1039/c8cc10037c; Liang RJ, 2017, BIOMATERIALS, V149, P41, DOI 10.1016/j.biomaterials.2017.09.029; Liu SS, 2019, BRAIN BEHAV IMMUN, V80, P711, DOI 10.1016/j.bbi.2019.05.020; Mohammadi FS, 2019, J CELL PHYSIOL, V234, P17159, DOI 10.1002/jcp.28495; Ochiai A, 2007, YAKUGAKU ZASSHI, V127, P1251, DOI 10.1248/yakushi.127.1251; Rengan AK, 2015, NANO LETT, V15, P842, DOI 10.1021/nl5045378; SANBE A, 1994, J PHARMACOL EXP THER, V269, P51; Sarmiento A, 2016, CURR DRUG METAB, V17, P345, DOI 10.2174/1389200216666151103115654; Song YZ, 2016, DRUG DEV IND PHARM, V42, P2044, DOI 10.1080/03639045.2016.1195399; Takekawa Y, 2016, BIOL PHARM BULL, V39, P301, DOI 10.1248/bpb.b15-00359; Weber C, 1997, MOL ASPECTS MED, V18, pS251; Weng L, 2010, ANN RHEUM DIS, V69, P1519, DOI 10.1136/ard.2009.121111; Xu N, 2019, BIOMATERIALS, V197, P380, DOI 10.1016/j.biomaterials.2019.01.034; Yap HY, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100161	32	10	10	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241080	10.1371/journal.pone.0241080	http://dx.doi.org/10.1371/journal.pone.0241080			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PV	33156836	Green Published, Green Submitted, gold			2023-01-03	WOS:000591376400014
J	Lelescu, CA; Urda-Cimpean, AE; Dumitras, DA; Taulescu, M; Muresan, C				Lelescu, Cristina A.; Urda-Cimpean, Andrada E.; Dumitras, Daria A.; Taulescu, Marian; Muresan, Cosmin			Effects of topical application of 0.4% oxybuprocaine hydrochloride ophthalmic solution and 1% ropivacaine hydrochloride on corneal sensitivity in rats	PLOS ONE			English	Article							0.5-PERCENT PROPARACAINE HYDROCHLORIDE; PERIBULBAR ANESTHESIA; LIDOCAINE; DURATION; BUPIVACAINE; SURGERY; MIXTURE	The aim of the present study was to determine and compare the degree and duration of corneal anesthesia following topical application of 0.4% oxybuprocaine hydrochloride ophthalmic solution and 1% ropivacaine hydrochloride treatment in healthy rats. A randomized, blinded, crossover study was conducted on 20 healthy adult Wistar rats, following complete physical and ophthalmological examination. Baseline corneal touch threshold (CTT) was determined in the central corneal area of both eyes with a Cochet-Bonnet aesthesiometer, in mm filament length. Oxybuprocaine was randomly applied to one eye and 0.9% sterile sodium chloride solution was instilled into the contralateral eye. Subsequent CTT measurements were performed in both eyes 5 minutes after topical application and at 5-minute intervals thereafter for 75-minutes in the anesthetized eye. Following a 2-week washout period, this protocol was repeated with ropivacaine. Quantitative data were summarized as mean +/- standard deviation, median and inter-quartile range (Q1-Q3). Repeated measures data were analyzed over time and between treatments using Friedman test and Wilcoxon signed-rank test with Bonferroni adjustment (p < 0.05). Baseline CTT values were 60 mm in all eyes. With oxybuprocaine, CTT values decreased significantly for 65 minutes (0-55 mm; p = 0.002) when compared with baseline; the maximal anesthetic effect (no blink response at 5 mm filament length) was maintained for up to 15 minutes (p < 0.0001). With ropivacaine, CTT values were significantly lower than baseline for 30 minutes (0-55 mm; p = 0.002), with a maximal anesthetic effect recorded at 5 minutes in 18 eyes (p < 0.0001). Oxybuprocaine induced a significantly lower CTT than ropivacaine (p = 0.002) from 10 to 65 minutes following topical application. Both anesthetic agents induced significant corneal anesthesia; however, oxybuprocaine provided a greater and longer anesthetic effect, making it more suitable for potentially painful ophthalmologic procedures.	[Lelescu, Cristina A.] VisionVet, Bologna, Italy; [Urda-Cimpean, Andrada E.] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Dept Med Informat & Biostat, Cluj Napoca, Romania; [Dumitras, Daria A.] Univ Agr Sci & Vet Med, Fac Vet Med, Dept Biochem, Cluj Napoca, Romania; [Taulescu, Marian] Univ Agr Sci & Vet Med, Fac Vet Med, Dept Pathol, Cluj Napoca, Romania; [Muresan, Cosmin] Univ Agr Sci & Vet Med, Fac Vet Med, Dept Surg, Cluj Napoca, Romania	Iuliu Hatieganu University of Medicine & Pharmacy; University of Agricultural Sciences & Veterinary Medicine Cluj Napoca; University of Agricultural Sciences & Veterinary Medicine Cluj Napoca; University of Agricultural Sciences & Veterinary Medicine Cluj Napoca	Muresan, C (corresponding author), Univ Agr Sci & Vet Med, Fac Vet Med, Dept Surg, Cluj Napoca, Romania.	muresanscosmin@gmail.com	Dumitras, Daria Antonia/X-6667-2018; Andrada, Urda-Cimpean Elena/AAA-6571-2020	Dumitras, Daria Antonia/0000-0001-8940-9651; muresan, cosmin/0000-0002-5064-6841	National Research Development Projects to finance excellence (PFE); Romanian Ministry of Research and Innovation [37/2018-2020]	National Research Development Projects to finance excellence (PFE); Romanian Ministry of Research and Innovation(Ministry of Research, Innovation and Digitization - Romania)	The publication was supported by funds from the National Research Development Projects to finance excellence (PFE) granted by the Romanian Ministry of Research and Innovation and awarded to CM (37/2018-2020). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, SMU SCI TECH L REV, V16, P43; Belyamani L, 2003, J FR OPHTALMOL, V26, P953; Binder DR, 2006, AM J VET RES, V67, P1780, DOI 10.2460/ajvr.67.10.1780; Borazan M, 2007, ACTA OPHTHALMOL SCAN, V85, P844, DOI 10.1111/j.1600-0420.2007.00976.x; Bryda Elizabeth C, 2013, Mo Med, V110, P207; Costa D, 2014, VET REC, V174, P478, DOI 10.1136/vr.102189; Douet JY, 2013, AM J VET RES, V74, P1321, DOI 10.2460/ajvr.74.10.1321; Drasner K, 2002, SCHNIDER LEVINSONS A, P73; Farkouh A, 2016, CLIN OPHTHALMOL, V10, P2433, DOI 10.2147/OPTH.S118409; Featherstone HJ., 2013, VET OPHTHALMOLOGY, V5th ed., P533; Giudici V, 2015, VET OPHTHALMOL, V18, P141, DOI 10.1111/vop.12179; Golebiowski B, 2011, EXP EYE RES, V92, P408, DOI 10.1016/j.exer.2011.02.016; Herring I, 2013, VET OPHTHALMOLOGY, P423; Herring IP, 2005, AM J VET RES, V66, P77, DOI 10.2460/ajvr.2005.66.77; Kashyap A, 2018, INDIAN J OPHTHALMOL, V66, P1268, DOI 10.4103/ijo.IJO_100_18; Kinra R, 2013, MEDIEV HIST J, V16, P251, DOI 10.1177/0971945813514887; Li M, 2014, DRUG DES DEV THER, V8, P1269, DOI 10.2147/DDDT.S57258; Little E, 2016, CAN J VET RES, V80, P329; Little WB, 2016, AUST VET J, V94, P181, DOI 10.1111/avj.12443; LYTLE J, 1992, ANAESTHESIA, V47, P616, DOI 10.1111/j.1365-2044.1992.tb02339.x; Martini E, 2002, J CATARACT REFR SURG, V28, P1018, DOI 10.1016/S0886-3350(01)01225-1; Meng ID, 2015, INVEST OPHTH VIS SCI, V56, P3347, DOI 10.1167/iovs.15-16717; MENGHER LS, 1986, ACTA OPHTHALMOL, V64, P79; Romero A.M., 2004, Anales Sis San Navarra, V27, P45, DOI 10.4321/s1137-66272004000200005; Wagatsuma JT, 2014, AM J VET RES, V75, P1040, DOI 10.2460/ajvr.75.12.1040; Williams D, 2007, EUR J COMPANION ANIM, V17, P242	33	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2020	15	11							e0241567	10.1371/journal.pone.0241567	http://dx.doi.org/10.1371/journal.pone.0241567			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PT	33151993	gold, Green Published			2023-01-03	WOS:000591376200060
J	Lina, TT; Johnson, SJ; Wagner, RD				Lina, Taslima T.; Johnson, Shemedia J.; Wagner, R. Doug			Intravaginal poly-(D, L-lactic-co-glycolic acid)-(polyethylene glycol) drug-delivery nanoparticles induce pro-inflammatory responses withCandida albicansinfection in a mouse model	PLOS ONE			English	Article							DENDRITIC CELLS; AUTOPHAGY; HALLMARK; IMMUNITY	In a recent study, using an in vitro model to study intravaginal nanoparticle exposure during yeast infections, we demonstrated thatC.albicansexposure suppressed apoptotic gene expression and induced oxidative stress and pyroptosis in vaginal epithelial cells. The mucous-penetrating drug delivery nanoparticles made from poly-(D, L-lactic-co-glycolic acid)-(polyethylene glycol) induced cytotoxicity by activating apoptosis, endoplasmic reticulum (ER) stress, oxidative stress, and DNA damage repair responses alone and, in some cases withC.albicans. In the current study we evaluated the effects of fluorescently-labelled nanoparticles in CBA/J mice challenged intravaginally for two hours followed by intravaginal challenge withC.albicansfor 18 hours. Nanoparticle treatment increased systemic translocation ofC.albicansthreefold in the heart.C.albicansalso increased systemic distribution of the nanoparticles fivefold in the heart. Flow cytometric assays showed co-localization of the nanoparticles with epithelial cells, macrophages and dendritic cells. Nanoparticle-treated,C.albicans-infected mice exhibited induction of autophagy, ER stress, apoptosis, and inflammatory serum cytokines.C.albicansinfection was associated with pyroptosis and suppressed expression of ER stress and apoptosis-related genes. Induction of apoptosis during nanoparticle treatment and in nanoparticle-treated-C.albicansinfected mice was observed as DNA damage responses, mitochondrial depolarization and (Poly [ADP-Ribose] Polymerase) cleavage.C.albicansinfection was associated with increased mRNA expression of anti-apoptotic genes. BothC.albicansinfection and nanoparticle treatment showed enhanced chemoattraction of dendritic cells and polymorphonuclear cells to factors in vaginal washings in a chemotaxis assay. This study shows that both intravaginal treatment of mice with the nanoparticles and infection withC.albicansinduce cytotoxic and inflammatory responses.C.albicansalso suppressed cell apoptosis. These results clarify our understanding of how nanoparticles modulate host cellular responses duringC.albicansinfection and will be applicable for future research and development of intravaginal nanomedicines.	[Lina, Taslima T.; Johnson, Shemedia J.; Wagner, R. Doug] US FDA, Microbiol Div, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [Lina, Taslima T.] US FDA, Off Regulatory & Risk Management, Natl Ctr Toxicol Res, Jefferson, AR USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Wagner, RD (corresponding author), US FDA, Microbiol Div, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.	doug.wagner@fda.hhs.gov			FDA Office of Women's Health	FDA Office of Women's Health	RDW received funding from the FDA Office of Women's Health. TTL was supported in part by an appointment to the ORISE Research Participation Program at the National Center for Toxicological Research, U.S. Food and Drug Administration, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA/NCTR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	[Anonymous], 1997, OFFICIAL J C, V236, P1; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; [Anonymous], 2007, 19 CENTURY GENDER ST, V3, P2; [Anonymous], 2017, REGNO DOCUMENTI, V7, P230; [Anonymous], 2015, EL CUADERNO, V66, P1; Barillet S, 2019, NANOTOXICOLOGY, V13, P606, DOI 10.1080/17435390.2018.1564078; Cook MT, 2018, J CONTROL RELEASE, V270, P145, DOI 10.1016/j.jconrel.2017.12.004; Cu Y, 2011, J CONTROL RELEASE, V156, P258, DOI 10.1016/j.jconrel.2011.06.036; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elsabahy M, 2013, CHEM SOC REV, V42, P5552, DOI 10.1039/c3cs60064e; Fidel Paul L Jr, 2005, Curr Opin Infect Dis, V18, P107; Iijima N, 2007, P NATL ACAD SCI USA, V104, P19061, DOI 10.1073/pnas.0707179104; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/nnano.2011.153, 10.1038/NNANO.2011.153]; Li JJ, 2010, BIOMATERIALS, V31, P5996, DOI 10.1016/j.biomaterials.2010.04.014; Liang GF, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-447; Lin MH, 2018, J BIOMED NANOTECHNOL, V14, P66, DOI 10.1166/jbn.2018.2459; Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Machado A, 2016, ACTA BIOMATER, V44, P332, DOI 10.1016/j.actbio.2016.08.018; Manke A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/942916; Matsuzawa-Ishimoto Y, 2018, ANNU REV IMMUNOL, V36, P73, DOI 10.1146/annurev-immunol-042617-053253; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Motulsky H., 1995, INTUITIVE BIOSTATIST; Nicolete R, 2011, INT IMMUNOPHARMACOL, V11, P1557, DOI 10.1016/j.intimp.2011.05.014; Oh N, 2014, INT J NANOMED, V9, P51, DOI 10.2147/IJN.S26592; Rahman Durdana, 2012, Methods Mol Biol, V845, P527, DOI 10.1007/978-1-61779-539-8_38; Rosati D, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8020144; Selders GS, 2017, REGEN BIOMATER, V4, P55, DOI 10.1093/rb/rbw041; Swamydas Muthulekha, 2015, Curr Protoc Immunol, V110, DOI 10.1002/0471142735.im0320s110; Wagner RD, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-58; Whaley KJ, 2010, ANTIVIR RES, V88, pS55, DOI 10.1016/j.antiviral.2010.09.006; Wong TW, 2014, EXPERT OPIN DRUG DEL, V11, P1419, DOI 10.1517/17425247.2014.924499; Yang EJ, 2012, BIOMATERIALS, V33, P6858, DOI 10.1016/j.biomaterials.2012.06.016; Yano J, 2010, INFECT IMMUN, V78, P5126, DOI 10.1128/IAI.00388-10; Yoshida M, 2004, J BIOMED MATER RES A, V71A, P45, DOI 10.1002/jbm.a.30131; Yu L, 2009, SMALL, V5, P2784, DOI 10.1002/smll.200901714; Zhang T, 2011, EUR J PHARM BIOPHARM, V79, P526, DOI 10.1016/j.ejpb.2011.06.007; Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	43	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2020	15	10							e0240789	10.1371/journal.pone.0240789	http://dx.doi.org/10.1371/journal.pone.0240789			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ON4AZ	33091017	Green Submitted, Green Published, gold			2023-01-03	WOS:000586647200021
J	Korpela, K; Helve, O; Kolho, KL; Saisto, T; Skogberg, K; Dikareva, E; Stefanovic, V; Salonen, A; Andersson, S; de Vos, WM				Korpela, Katri; Helve, Otto; Kolho, Kaija-Leena; Saisto, Terhi; Skogberg, Kirsi; Dikareva, Evgenia; Stefanovic, Vedran; Salonen, Anne; Andersson, Sture; de Vos, Willem M.			Maternal Fecal Microbiota Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut Microbial Development: A Proof-of-Concept Study	CELL			English	Article							BODY SITES; SHORT-TERM; SECTION; COLONIZATION; TRANSMISSION; REVEALS; SHAPES; RISK	Infants born by vaginal delivery are colonized with maternal fecal microbes. Cesarean section (CS) birth disturbs mother-to-neonate transmission. In this study (NCT03568734), we evaluated whether disturbed intestinal microbiota development could be restored in term CS-born infants by postnatal, orally delivered fecal microbiota transplantation (FMT). We recruited 17 mothers, of whom seven were selected after careful screening. Their infants received a diluted fecal sample from their own mothers, taken 3 weeks prior to delivery. All seven infants had an uneventful clinical course during the 3-month follow-up and showed no adverse effects. The temporal development of the fecal microbiota composition of FMT-treated CS-born infants no longer resembled that of untreated CS-born infants but showed significant similarity to that of vaginally born infants, This proof-of-concept study demonstrates that the intestinal microbiota of CS-born infants can be restored postnatally by maternal FMT. However, this should only be done after careful clinical and microbiological screening.	[Korpela, Katri; Dikareva, Evgenia; Salonen, Anne; de Vos, Willem M.] Univ Helsinki, Fac Med, Human Microbiome Res Program, Helsinki 00014, Finland; [Helve, Otto; Kolho, Kaija-Leena; Andersson, Sture] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki 00014, Finland; [Helve, Otto; Kolho, Kaija-Leena; Andersson, Sture] Helsinki Univ Hosp, Helsinki 00014, Finland; [Kolho, Kaija-Leena] Univ Tampere, Fac Med & Life Sci, Tampere 33100, Finland; [Kolho, Kaija-Leena] Tampere Univ Hosp, Dept Pediat, Tampere 33100, Finland; [Saisto, Terhi; Stefanovic, Vedran] Univ Helsinki, Dept Obstet & Gynecol, Helsinki 00029, Finland; [Saisto, Terhi; Stefanovic, Vedran] Helsinki Univ Hosp, Helsinki 00029, Finland; [Skogberg, Kirsi] Jorvi & Helsinki Univ Hosp, Clin Infect Dis, Helsinki 00014, Finland; [de Vos, Willem M.] Wageningen Univ, Lab Microbiol, NL-6703 WE Wageningen, Netherlands	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Wageningen University & Research	de Vos, WM (corresponding author), Univ Helsinki, Fac Med, Human Microbiome Res Program, Helsinki 00014, Finland.; de Vos, WM (corresponding author), Wageningen Univ, Lab Microbiol, NL-6703 WE Wageningen, Netherlands.	willem.devos@wur.nl	Stefanovic, Vedran/L-8905-2013; Salonen, Anne/AAW-1858-2020	Stefanovic, Vedran/0000-0001-5230-1698; Salonen, Anne/0000-0002-6960-7447; Helve, Otto/0000-0001-6254-3180	Academy of Finland [1297765, 1308255]; Pediatric Research Foundation, Finland; Finska Lakaresallskapet; Paulo Foundation; SIAM Gravitation [024.002.002]; Spinoza award of the Netherlands Organisation for Scientific Research	Academy of Finland(Academy of Finland); Pediatric Research Foundation, Finland; Finska Lakaresallskapet; Paulo Foundation; SIAM Gravitation; Spinoza award of the Netherlands Organisation for Scientific Research	We wish to thank the mothers and infants who participated in this study. This research was partly supported by grants 1297765 (to K.K.) and 1308255 (to W.M.d.V.) by the Academy of Finland, a grant from the Pediatric Research Foundation, Finland (to K.-L.K.), a special governmental subsidy to clinical research (to S.A.), Finska Lakaresallskapet (to S.A.), the Paulo Foundation (to A.S.), and SIAM Gravitation grant 024.002.002 and a Spinoza award of the Netherlands Organisation for Scientific Research (to W.M.d.V.). We are grateful to our research nurse, midwife Sirpa Nolvi, for skilled assistance.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Andersen V, 2020, CLIN EPIDEMIOL, V12, P287, DOI 10.2147/CLEP.S229056; Asnicar F, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00164-16; Ben-Amor K, 2005, APPL ENVIRON MICROB, V71, P4679, DOI 10.1128/AEM.71.8.4679-4689.2005; Blanton LV, 2016, SCIENCE, V351, DOI 10.1126/science.aad3311; Blaser MJ, 2017, NAT REV IMMUNOL, V17, P461, DOI 10.1038/nri.2017.77; Boerma T, 2018, LANCET, V392, P1341, DOI 10.1016/S0140-6736(18)31928-7; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Chu DM, 2017, NAT MED, V23, P314, DOI 10.1038/nm.4272; Clausen TD, 2016, EPIDEMIOLOGY, V27, P547, DOI 10.1097/EDE.0000000000000488; Costello EK, 2012, SCIENCE, V336, P1255, DOI 10.1126/science.1224203; Dominguez-Bello MG, 2016, NAT MED, V22, P250, DOI 10.1038/nm.4039; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ferretti P, 2018, CELL HOST MICROBE, V24, P133, DOI 10.1016/j.chom.2018.06.005; Fouhy F, 2012, ANTIMICROB AGENTS CH, V56, P5811, DOI 10.1128/AAC.00789-12; Fraser D, 2009, MYLES TXB MIDWIVES, V15th; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Hill CJ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0213-y; Jakobsson HE, 2014, GUT, V63, P559, DOI 10.1136/gutjnl-2012-303249; Keag OE, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002494; Korpela K, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0245-y; Korpela K, 2020, PEDIATR RES, V88, P438, DOI 10.1038/s41390-020-0761-5; Korpela K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028500; Korpela K, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0567-4; Korpela K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32037-6; Korpela K, 2018, CURR OPIN MICROBIOL, V44, P70, DOI 10.1016/j.mib.2018.06.003; Korpela K, 2018, GENOME RES, V28, P561, DOI 10.1101/gr.233940.117; Korpela K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10410; Kostic AD, 2015, CELL HOST MICROBE, V17, P260, DOI 10.1016/j.chom.2015.01.001; Martinez I, 2018, ELIFE, V7, DOI 10.7554/eLife.36521; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Milani C, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00036-17; Nagpal R, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01388; Nayfach S, 2016, GENOME RES, V26, P1612, DOI 10.1101/gr.201863.115; Oksanen J., 2020, VEGAN COMMUNITY ECOL, DOI DOI 10.4135/9781412971874.N145; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Pan WH, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0534-5; Pannaraj PS, 2017, JAMA PEDIATR, V171, P647, DOI 10.1001/jamapediatrics.2017.0378; Pinheiro J., 2018, NLME LINEAR NONLINEA; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; Ramiro-Garcia Javier, 2016, F1000Res, V5, P1791, DOI 10.12688/f1000research.9227.2; Sakwinska O, 2017, BENEF MICROBES, V8, P763, DOI 10.3920/BM2017.0064; Samuelsson U, 2015, DIABETOLOGIA, V58, P2517, DOI 10.1007/s00125-015-3716-3; Sandall J, 2018, LANCET, V392, P1349, DOI 10.1016/S0140-6736(18)31930-5; Schwab C, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02666; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Shao Y, 2019, NATURE, V574, P117, DOI 10.1038/s41586-019-1560-1; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Stiemsma LT, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2437; Tun HM, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0254-x; VENABLES WN, 2002, MODERN APPL STAT S; Yap Gaik Chin, 2014, BMC Res Notes, V7, P166, DOI 10.1186/1756-0500-7-166; Zijlmans MAC, 2015, PSYCHONEUROENDOCRINO, V53, P233, DOI 10.1016/j.psyneuen.2015.01.006; Zoetendal Erwin G., 2001, Microbial Ecology in Health and Disease, V13, P129, DOI 10.1080/089106001750462669	54	94	96	12	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2020	183	2					324	+		10.1016/j.cell.2020.08.047	http://dx.doi.org/10.1016/j.cell.2020.08.047			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	OB6UR	33007265	Bronze			2023-01-03	WOS:000578604900009
J	Ott, PA; Hu-Lieskovan, S; Chmielowski, B; Govindan, R; Naing, A; Bhardwaj, N; Margolin, K; Awad, MM; Hellmann, MD; Lin, JJ; Friedlander, T; Bushway, ME; Balogh, KN; Sciuto, TE; Kohler, V; Turnbull, SJ; Besada, R; Curran, RR; Trapp, B; Scherer, J; Poran, A; Harjanto, D; Barthelme, D; Ting, YS; Dong, JZ; Ware, Y; Huang, YT; Huang, ZP; Wanamaker, A; Cleary, LD; Moles, MA; Manson, K; Greshock, J; Khondker, ZS; Fritsch, E; Rooney, MS; DeMario, M; Gaynor, RB; Srinivasan, L				Ott, Patrick A.; Hu-Lieskovan, Siwen; Chmielowski, Bartosz; Govindan, Ramaswamy; Naing, Aung; Bhardwaj, Nina; Margolin, Kim; Awad, Mark M.; Hellmann, Matthew D.; Lin, Jessica J.; Friedlander, Terence; Bushway, Meghan E.; Balogh, Kristen N.; Sciuto, Tracey E.; Kohler, Victoria; Turnbull, Samantha J.; Besada, Rana; Curran, Riley R.; Trapp, Benjamin; Scherer, Julian; Poran, Asaf; Harjanto, Dewi; Barthelme, Dominik; Ting, Ying Sonia; Dong, Jesse Z.; Ware, Yvonne; Huang, Yuting; Huang, Zhengping; Wanamaker, Amy; Cleary, Lisa D.; Moles, Melissa A.; Manson, Kelledy; Greshock, Joel; Khondker, Zakaria S.; Fritsch, Ed; Rooney, Michael S.; DeMario, Mark; Gaynor, Richard B.; Srinivasan, Lakshmi			A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer	CELL			English	Article							METASTATIC UROTHELIAL CARCINOMA; OPEN-LABEL; CHECKPOINT BLOCKADE; PD-1 BLOCKADE; NIVOLUMAB; IMMUNOTHERAPY; MULTICENTER; GENERATION; RESPONSES; RECEPTOR	Neoantigens arise from mutations in cancer cells and are important targets of T cell-mediated anti-tumor immunity. Here, we report the first open-label, phase lb clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. De novo neoantigen-specific CD4(+) and CD8(+) T cell responses were observed post-vaccination in all of the patients. The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing. In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination. These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors.	[Ott, Patrick A.; Awad, Mark M.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA; [Ott, Patrick A.; Awad, Mark M.; Lin, Jessica J.] Harvard Med Sch, Boston, MA 02115 USA; [Hu-Lieskovan, Siwen; Chmielowski, Bartosz] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; [Govindan, Ramaswamy] Washington Univ, Sch Med, St Louis, MO USA; [Naing, Aung] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Bhardwaj, Nina] Icahn Sch Med, Tisch Canc Inst, New York, NY USA; [Margolin, Kim] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA; [Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Lin, Jessica J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Friedlander, Terence] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA; [Bushway, Meghan E.; Balogh, Kristen N.; Sciuto, Tracey E.; Kohler, Victoria; Turnbull, Samantha J.; Besada, Rana; Curran, Riley R.; Trapp, Benjamin; Scherer, Julian; Poran, Asaf; Harjanto, Dewi; Barthelme, Dominik; Ting, Ying Sonia; Dong, Jesse Z.; Ware, Yvonne; Huang, Yuting; Huang, Zhengping; Wanamaker, Amy; Cleary, Lisa D.; Moles, Melissa A.; Manson, Kelledy; Greshock, Joel; Khondker, Zakaria S.; Fritsch, Ed; Rooney, Michael S.; DeMario, Mark; Gaynor, Richard B.; Srinivasan, Lakshmi] Neon Therapeut BioNTech US, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai; City of Hope; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco; BioNTech SE	Ott, PA (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.; Ott, PA (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Srinivasan, L (corresponding author), Neon Therapeut BioNTech US, Cambridge, MA 02139 USA.	patrick_ott@dfci.harvard.edu; lakshmi.srinivasan@biontech.us		Balogh, Kristen/0000-0002-8746-745X; Chmielowski, Bartosz/0000-0002-2374-3320; Naing, Aung/0000-0002-4803-8513; Bhardwaj, Nina/0000-0003-1865-4187; Srinivasan, Lakshmi/0000-0003-1351-7407	Neon Therapeutics/BioNTech US	Neon Therapeutics/BioNTech US	We thank all of the patients and their families who participated in the study. We are grateful to all of the members of Neon Therapeutics/BioNTech US for support of and assistance in the study. We thank April Lamb and Jennifer Tepper for clinical operations; Marc Wolfgang, Scott White, Stephen Crimlisk, and Yeimy Garcia for technical operations; Jonathan McGee, Brian Sullivan, Daniel Kallin, Jeff Zhang, Amanda Aldous, and Robyn Eisert for peptide synthesis and manufacturing process development; Janani Sridar and Paul Turcott for tetramer reagent generation; Myranda Maynard and Sagar Chhangawala for bioinformatics support; Kerry Chios and John Curran for lab operation support and biobank management; and Hugh O'Dowd for support and guidance on the study. Wethank Bristol-Myers Squibb for the nivolumab supply. The study was sponsored by Neon Therapeutics/BioNTech US. This manuscript is dedicated to our late colleague, Ying Sonia Ting.	Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012; Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Banu N, 2014, SCI REP-UK, V4, DOI 10.1038/srep04166; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Blair CK, 2005, NEUROLOGY, V64, P268, DOI 10.1212/01.WNL.0000149643.91367.8A; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Challis D, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-8; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Cohen CJ, 2006, CANCER RES, V66, P8878, DOI 10.1158/0008-5472.CAN-06-1450; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Cottrell TR, 2018, ANN ONCOL, V29, P1853, DOI 10.1093/annonc/mdy218; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Erik Aronesty, 2011, EA UTILS COMMAND LIN; Fairfax BP, 2020, NAT MED, V26, P193, DOI 10.1038/s41591-019-0734-6; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Gettinger SN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05032-8; Haas BJ, 2017, STAR FUSION FAST ACC, DOI [DOI 10.1101/120295, 10.1101/120295]; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Hodi FS, 2018, J CLIN ONCOL, V36, P850, DOI 10.1200/JCO.2017.75.1644; Hosoi A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19548-y; Hu Z, 2018, NAT REV IMMUNOL, V18, P168, DOI 10.1038/nri.2017.131; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jansen CS, 2019, NATURE, V576, P465, DOI 10.1038/s41586-019-1836-5; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Kirsch I, 2015, MOL ONCOL, V9, P2063, DOI 10.1016/j.molonc.2015.09.003; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kuball J, 2007, BLOOD, V109, P2331, DOI 10.1182/blood-2006-05-023069; Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x; Ott PA, 2018, NAT REV CLIN ONCOL, V15, P267, DOI 10.1038/nrclinonc.2018.36; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Rimmer A, 2014, NAT GENET, V46, P912, DOI 10.1038/ng.3036; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodenko B, 2006, NAT PROTOC, V1, P1120, DOI 10.1038/nprot.2006.121; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Signorell A., 2016, DESCTOOLS TOOLS DESC; Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026; Thomas PG, 2013, P NATL ACAD SCI USA, V110, P1839, DOI 10.1073/pnas.1222149110; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; Topalian SL, 2020, SCIENCE, V367, P525, DOI 10.1126/science.aax0182; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valpione S, 2020, NAT CANCER, V1, P210, DOI 10.1038/s43018-019-0022-x; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444	77	189	195	17	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	2020	183	2					347	+		10.1016/j.cell.2020.08.053	http://dx.doi.org/10.1016/j.cell.2020.08.053			40	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	OB6UR	33064988	Bronze			2023-01-03	WOS:000578604900011
J	Halpern, SD				Halpern, Scott D.			Learning about End-of-Life Care from Grandpa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Halpern, Scott D.] Univ Penn, Palliat & Adv Illness Res PAIR Ctr, Philadelphia, PA 19104 USA; [Halpern, Scott D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy & Biostat Epidemiol &, Philadelphia, PA 19104 USA; [Halpern, Scott D.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA; [Halpern, Scott D.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halpern, SD (corresponding author), Univ Penn, Palliat & Adv Illness Res PAIR Ctr, Philadelphia, PA 19104 USA.; Halpern, SD (corresponding author), Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA.; Halpern, SD (corresponding author), Univ Penn, Dept Med Eth & Hlth Policy & Biostat Epidemiol &, Philadelphia, PA 19104 USA.; Halpern, SD (corresponding author), Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.; Halpern, SD (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.							Lo B, 2018, NEW ENGL J MED, V378, P2060, DOI 10.1056/NEJMp1802218; Lowers J, 2021, J PALLIAT MED, V24, P376, DOI 10.1089/jpm.2020.0223; National Academies of Sciences Engineering and Medicine, 2018, PHYS ASSISTED DEATH, DOI [10.17226/25131, DOI 10.17226/25131]	3	0	0	2	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	2021	384	5					400	401		10.1056/NEJMp2026629	http://dx.doi.org/10.1056/NEJMp2026629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX4QW	33085883				2023-01-03	WOS:000629333200008
J	Algera, AG; Pisani, L; Neto, AS; den Boer, SS; Bosch, FFH; Bruin, K; Klooster, PM; van der Meer, NJM; Nowitzky, RO; Purmer, IM; Slabbekoorn, M; Spronk, PE; van Vliet, J; Weenink, JJ; de Abreu, MG; Pelosi, P; Schultz, MJ; Paulus, F				Algera, Anna Geke; Pisani, Luigi; Serpa Neto, Ary; den Boer, Sylvia S.; Bosch, Frank F. H.; Bruin, Karina; Klooster, Pauline M.; van der Meer, Nardo J. M.; Nowitzky, Ralph O.; Purmer, Ilse M.; Slabbekoorn, Mathilde; Spronk, Peter E.; van Vliet, Jan; Weenink, Jan J.; Gama de Abreu, Marcelo; Pelosi, Paolo; Schultz, Marcus J.; Paulus, Frederique		Relax Collaborative Grp	Effect of a Lower vs Higher Positive End-Expiratory Pressure Strategy on Ventilator-Free Days in ICU Patients Without ARDS A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE-UNIT; OXYGEN-THERAPY; LUNG INJURY; MULTICENTER; PNEUMONIA; MORTALITY	IMPORTANCE: It is uncertain whether invasive ventilation can use lower positive end-expiratory pressure (PEEP) in : critically ill patients without acute respiratory distress syndrome (ARDS). OBJECTIVE: To determine whether a lower PEEP strategy is noninferior to a higher PEEP strategy regarding duration of mechanical ventilation at 28 days. DESIGN, SETTING, AND PARTICIPANTS: Noninferiority randomized clinical trial conducted from October 26, 2017, through December 17, 2019, in 8 intensive care units (ICUs) in the Netherlands among 980 patients without ARDS expected not to be extubated within 24 hours after start of ventilation. Final follow-up was conducted in March 2020. INTERVENTIONS: Participants were randomized to receive invasive ventilation using either lower PEEP, consisting of the lowest PEEP level between 0 and 5 cm H2O (n = 476), or higher PEEP, consisting of a PEEP level of 8 cm H2O (n = 493). MAIN OUTCOMES AND MEASURES: The primary outcome was the number of ventilator-free days at day 28, with a noninferiority margin for the difference in ventilator-free days at day 28 of -10%. Secondary outcomes included ICU and hospital lengths of stay; ICU, hospital, and 28- and 90-day mortality; development of ARDS, pneumonia, pneumothorax, severe atelectasis, severe hypoxemia, or need for rescue therapies for hypoxemia; and days with use of vasopressors or sedation. RESULTS: Among 980 patients who were randomized, 969 (99%) completed the trial (median age, 66 [interquartile range {IQR}, 56-74] years; 246 [36%] women). At day 28, 476 patients in the lower PEEP group had a median of 18 ventilator-free days (IQR, 0-27 days) and 493 patients in the higher PEEP group had a median of 17 ventilator-free days (IQR, 0-27 days) (mean ratio, 1.04; 95% CI, 0.95-infinity; P = .007 for noninferiority), and the lower boundary of the 95% CI was within the noninferiority margin. Occurrence of severe hypoxemia was 20.6% vs 17.6% (risk ratio, 1.17; 95% CI, 0.90-1.51; P = .99) and need for rescue strategy was 19.7% vs 14.6% (risk ratio, 1.35; 95% CI, 1.02-1.79; adjusted P = .54) in patients in the lower and higher PEEP groups, respectively. Mortality at 28 days was 38.4% vs 42.0% (hazard ratio, 0.89; 95% CI, 0.73-1.09; P = .99) in patients in the lower and higher PEEP groups, respectively. There were no statistically significant differences in other secondary outcomes. CONCLUSIONS AND RELEVANCE: Among patients in the ICU without ARDS who were expected not to be extubated within 24 hours, a lower PEEP strategy was noninferior to a higher PEEP strategy with regard to the number of ventilator-free days at day 28. These findings support the use of lower PEEP in patients without ARDS.	[Algera, Anna Geke; Pisani, Luigi; Schultz, Marcus J.; Paulus, Frederique] Amsterdam UMC, Dept Intens Care, Amsterdam, Netherlands; [Algera, Anna Geke; Pisani, Luigi; Schultz, Marcus J.; Paulus, Frederique] Amsterdam UMC, Lab Expt Intens Care & Anesthesiol, Amsterdam, Netherlands; [Serpa Neto, Ary] Hosp Israelita Albert Einstein, Dept Crit Care Med, Sao Paulo, Brazil; [Serpa Neto, Ary] Monash Univ, Australian & New Zealand Intens Care Res Ctr ANZI, Melbourne, Vic, Australia; [Serpa Neto, Ary] Austin Hosp, Data Analyt Res & Evaluat DARE Ctr, Melbourne, Vic, Australia; [Serpa Neto, Ary] Univ Melbourne, Melbourne, Vic, Australia; [den Boer, Sylvia S.; Weenink, Jan J.] Spaarne Gasthuis, Dept Intens Care, Haarlem, Netherlands; [den Boer, Sylvia S.; Weenink, Jan J.] Spaarne Gasthuis, Dept Intens Care, Hoofddorp, Netherlands; [Bosch, Frank F. H.; van Vliet, Jan] Rijnstate Hosp, Dept Intens Care, Arnhem, Netherlands; [Bruin, Karina] Westfriesgasthuis, Dept Intens Care, Hoorn, Netherlands; [Klooster, Pauline M.; Slabbekoorn, Mathilde] Haaglanden MC, Dept Intens Care, The Hague, Netherlands; [van der Meer, Nardo J. M.] Amphia Hosp, Dept Intens Care, Breda, Netherlands; [Nowitzky, Ralph O.; Purmer, Ilse M.] Haga Hosp, Dept Intens Care, The Hague, Netherlands; [Spronk, Peter E.] Gelre Hosp, Dept Intens Care, Apeldoorn, Netherlands; [Gama de Abreu, Marcelo] Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care, Pulm Engn Grp, Dresden, Germany; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, San Martino Policlin Hosp, IRCCS Oncol, Genoa, Italy; [Schultz, Marcus J.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Schultz, Marcus J.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit MORU, Bangkok, Thailand; [Paulus, Frederique] Amsterdam Univ Appl Sci, Fac Hlth, ACHIEVE Ctr Expertise, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Hospital Israelita Albert Einstein; Monash University; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Spaarne Hospital; Spaarne Hospital; Rijnstate Hospital; Amphia Hospital; Haga Hospital; Gelre Hospitals; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Genoa; University of Oxford; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University	Schultz, MJ (corresponding author), Univ Amsterdam, Med Ctr, Dept Intens Care, C3-423,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	marcus.j.schultz@gmail.com	Schultz, Marcus/AAB-6379-2021; Serpa Neto, Ary/D-1927-2012; Dongelmans, Dave/AAA-8974-2019; Pisani, Luigi/L-2287-2019	Schultz, Marcus/0000-0003-3969-7792; Serpa Neto, Ary/0000-0003-1520-9387; Dongelmans, Dave/0000-0001-8477-6671; Pisani, Luigi/0000-0001-7177-3594; Paulus, Frederique/0000-0002-0705-1463; Gama de Abreu, Marcelo/0000-0002-3554-883X	ZonMW (the Netherlands Organization for Health Research and Development)	ZonMW (the Netherlands Organization for Health Research and Development)(Netherlands Organization for Health Research and DevelopmentNetherlands Government)	This study was supported by a grant from ZonMW (the Netherlands Organization for Health Research and Development) and the Amsterdam University Medical Centers, Location AMC.	Algera AG, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2640-5; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Blackwood B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7237; Bos LD, 2017, INTENS CARE MED, V43, P1535, DOI 10.1007/s00134-017-4838-5; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Carvalho AR, 2008, INTENS CARE MED, V34, P2291, DOI 10.1007/s00134-008-1301-7; Carvalho ARS, 2006, CRIT CARE, V10, DOI 10.1186/cc5030; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Collino F, 2019, ANESTHESIOLOGY, V130, P119, DOI 10.1097/ALN.0000000000002458; de Abreu MG, 2019, JAMA-J AM MED ASSOC, V322, P1829, DOI 10.1001/jama.2019.14400; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Hashemian SM, 2014, NEW ENGL J MED, V370, P979, DOI 10.1056/NEJMc1400293; Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5; Manzano F, 2008, CRIT CARE MED, V36, P2225, DOI 10.1097/CCM.0b013e31817b8a92; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Penuelas O, 2020, INTENS CARE MED, V46, P444, DOI 10.1007/s00134-019-05867-9; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Schaefer MS, 2019, ANESTH ANALG, V129, P129, DOI 10.1213/ANE.0000000000003758; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Neto AS, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0208-7; Neto AS, 2016, LANCET RESP MED, V4, P882, DOI 10.1016/S2213-2600(16)30305-8; Simonis FD, 2018, JAMA-J AM MED ASSOC, V320, P1872, DOI 10.1001/jama.2018.14280; Suzuki S, 2014, CRIT CARE MED, V42, P1414, DOI 10.1097/CCM.0000000000000219; van Meenen DMP, 2018, JAMA-J AM MED ASSOC, V319, P993, DOI 10.1001/jama.2018.0949; Villar J, 2009, ANESTHESIOLOGY, V110, P1341, DOI 10.1097/ALN.0b013e31819fcba9; Vreugdenhil HA, 2004, EUR RESPIR J, V23, P122, DOI 10.1183/09031936.03.00035003; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP	28	24	25	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	2020	324	24					2509	2520		10.1001/jama.2020.23517	http://dx.doi.org/10.1001/jama.2020.23517		DEC 2020	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PO2FZ	33295981	Green Published, Bronze			2023-01-03	WOS:000597421500002
J	Patanavanich, R; Glantz, SA				Patanavanich, Roengrudee; Glantz, Stanton A.			Association between tobacco control policies and hospital admissions for acute myocardial infarction in Thailand, 2006-2017: A time series analysis	PLOS ONE			English	Article							SMOKE-FREE LEGISLATION; CONSUMPTION; DISEASES; TAXES; PRICE	Introduction Studies in many countries have documented reductions of acute myocardial infarction (AMI) hospitalizations with smokefree policies. However, evidence on the association of cigarette tax with AMI events is unclear. There have been no studies of the associations between these two policies and AMI hospitalizations in Thailand. Methods We used negative binomial time series analyses of AMI hospitalizations (ICD-10 codes I21.0-I21.9), stratified by sex and age groups, from October 2006 to September 2017 to determine whether there was a change in AMI hospitalizations as a result of the changes in cigarette prices and the implementation of a 100% smokefree law. Results Cigarette price increases were associated with a significant 4.7% drop in AMI hospitalizations among adults younger than 45 (incidence rate ratio [IRR], 0.953; 95% confidence interval [CI], 0.914-0.993; p = 0.021). Implementation of the 100% smokefree law was followed by a significant 13.1% drop in AMI hospitalizations among adults younger than 45 (IRR, 0.869; 95% CI, 0.801-0.993; P = 0.001). There were not significant associations in older age groups. Conclusions The Thai cigarette tax policy and the smokefree law were associated with reduced AMI hospitalizations among younger adults. To improve effectiveness of the policies, taxes should be high enough to increase cigarette price above inflation rates, making cigarettes less likely to be purchased; smokefree laws should be strictly enforced.	[Patanavanich, Roengrudee; Glantz, Stanton A.] Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, Dept Med, San Francisco, CA 94143 USA; [Patanavanich, Roengrudee] Mahidol Univ, Dept Community Med, Fac Med, Ramathibodi Hosp, Bangkok, Thailand	University of California System; University of California San Francisco; Mahidol University	Glantz, SA (corresponding author), Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, Dept Med, San Francisco, CA 94143 USA.	Stanton.Glantz@sonic.net		Patanavanich, Roengrudee/0000-0001-6277-3912; Glantz, Stanton/0000-0003-4620-6672	National Institute of Drug Abuse [R01DA043950]; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand	National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand	This work was supported by supported by National Institute of Drug Abuse grant R01DA043950 (SAG) and the Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand (RP). The funding agencies played no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit for publication.	[Anonymous], 2013, EC J WATCH, V10, pA1; [Anonymous], 2011, MED HIST, V55, P228; [Anonymous], 2013, AESTHETIC SURG J S, V22, p1S; Apollonio DE, 2020, NICOTINE TOB RES, V22, P967, DOI 10.1093/ntr/ntz068; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Barone-Adesi F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017419; Bundhamcharoen K, 2016, TOB CONTROL, V25, P532, DOI 10.1136/tobaccocontrol-2015-052319; Centers for Disease Control and Prevention, 2019, SMOK HEART DIS STROK; Chaloupka F J, 1999, Nicotine Tob Res, V1 Suppl 1, pS105; Chaloupka FJ, 1997, J HEALTH ECON, V16, P359, DOI 10.1016/S0167-6296(96)00530-9; Charoenca N, 2018, TOB USE INSIGHTS, V11, DOI 10.1177/1179173X18759945; Choudhury L, 1999, AM J MED, V107, P254, DOI 10.1016/S0002-9343(99)00218-1; Ding A, 2003, YALE J BIOL MED, V76, P115; Egred M, 2005, POSTGRAD MED J, V81, P741, DOI 10.1136/pgmj.2004.027532; Hou FJ, 2020, EXP THER MED, V19, P2766, DOI 10.3892/etm.2020.8484; Husain MJ, 2017, PREV MED, V105, pS4, DOI 10.1016/j.ypmed.2017.05.027; Iannaccone M, 2016, EUR HEART J-CARD IMG, V17, P1128, DOI 10.1093/ehjci/jev283; Krauss MJ, 2014, ALCOHOL CLIN EXP RES, V38, P2630, DOI 10.1111/acer.12533; Kungskulniti N, 2018, INT J HEALTH POLICY, V7, P919, DOI 10.15171/ijhpm.2018.47; Levy DT, 2008, TOB CONTROL, V17, P53, DOI 10.1136/tc.2007.022319; Limwattananon S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-S1-S6; Liu Echu, 2008, J Health Care Finance, V34, P91; Maas AHEM, 2010, NETH HEART J, V18, P598, DOI 10.1007/s12471-010-0841-y; Mead EL, 2016, PREV MED, V92, P169, DOI 10.1016/j.ypmed.2016.05.032; National Center for Chronic Disease Prevention and Health Promo- tion (U.S.) Office on Smoking and Health, 2014, HLTH CONSMOK 50 YE; National Statistical Office, 2018, SMOK DRINK BEH SURV; Panpiemras J, 2011, HEALTH POLICY, V103, P228, DOI 10.1016/j.healthpol.2011.08.008; Patanavanich R, 2019, DATA SMOKING SITUATI; Patanavanich R, 2018, TOB INDUC DIS, V16, DOI 10.18332/tid/98913; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Pinichka C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189909; Pitayarangsarit S., 2018, STAT REPORT TOBACCO; Pongpirul K, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-71; Ratanachena S, 2012, AFFORDABILITY CIGARE; Sarntisart I, 2003, EC ANAL TOBACCO CONT; Seo DC, 2007, J DRUG EDUC, V37, P217, DOI 10.2190/DE.37.3.a; STIMSON JA, 1978, SOCIOL METHOD RES, V6, P515, DOI 10.1177/004912417800600405; Tan CE, 2012, CIRCULATION, V126, P2177, DOI 10.1161/CIRCULATIONAHA.112.121301; Twose J, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-194; Vateesatokit P, 2000, TOB CONTROL, V9, P122, DOI 10.1136/tc.9.2.122; Weaver AM, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5153-y; White JS, 2015, HEALTH ECON, V24, P127, DOI 10.1002/hec.3004; WHO, 2017, WHO REPORT GLOBAL TO; World Bank Group, 2018, EC TOB TAX TOOLK 201; World Health Organization, 2019, WHO REP GLOB TOB EP; World Health Organization, 2008, WHO REP GLOB TOB EP; World Health Organization, 2009, WHO REPORT GLOBAL TO; World Health Organization, 2019, WHO REPORT GLOBAL TO; World Health Organization (WHO), 2011, BURD BEST BUYS RED E; Yong HH, 2010, ASIA-PAC J PUBLIC HE, V22, P98, DOI 10.1177/1010539509351303; ZIMMERMAN FH, 1995, J AM COLL CARDIOL, V26, P654, DOI 10.1016/0735-1097(95)00254-2; 2014, REG ANESTH PAIN MED, V0009, pE8878	52	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2020	15	12							e0242570	10.1371/journal.pone.0242570	http://dx.doi.org/10.1371/journal.pone.0242570			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PB8MS	33264315	Green Published, gold			2023-01-03	WOS:000596569200005
J	Krug, K; Jaehnig, EJ; Satpathy, S; Blumenberg, L; Karpova, A; Anurag, M; Miles, G; Mertins, P; Geffen, Y; Tang, LC; Heiman, DI; Cao, S; Maruvka, YE; Lei, JT; Huang, C; Kothadia, RB; Colaprico, A; Birger, C; Wang, J; Dou, YC; Wen, B; Shi, Z; Liao, YX; Wiznerowicz, M; Wyczalkowski, MA; Chen, XS; Kennedy, JJ; Paulovich, AG; Thiagarajan, M; Kinsinger, CR; Hiltke, T; Boja, ES; Mesri, M; Robles, AI; Rodriguez, H; Westbrook, TF; Ding, L; Getz, G; Clauser, KR; Fenyo, D; Ruggles, KV; Zhang, B; Mani, DR; Carr, SA; Ellis, MJ; Gillette, MA				Krug, Karsten; Jaehnig, Eric J.; Satpathy, Shankha; Blumenberg, Lili; Karpova, Alla; Anurag, Meenakshi; Miles, George; Mertins, Philipp; Geffen, Yifat; Tang, Lauren C.; Heiman, David, I; Cao, Song; Maruvka, Yosef E.; Lei, Jonathan T.; Huang, Chen; Kothadia, Ramani B.; Colaprico, Antonio; Birger, Chet; Wang, Jarey; Dou, Yongchao; Wen, Bo; Shi, Zhiao; Liao, Yuxing; Wiznerowicz, Maciej; Wyczalkowski, Matthew A.; Chen, Xi Steven; Kennedy, Jacob J.; Paulovich, Amanda G.; Thiagarajan, Mathangi; Kinsinger, Christopher R.; Hiltke, Tara; Boja, Emily S.; Mesri, Mehdi; Robles, Ana, I; Rodriguez, Henry; Westbrook, Thomas F.; Ding, Li; Getz, Gad; Clauser, Karl R.; Fenyo, David; Ruggles, Kelly, V; Zhang, Bing; Mani, D. R.; Carr, Steven A.; Ellis, Matthew J.; Gillette, Michael A.		Clinical Proteomic Tumor Anal Cons	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy	CELL			English	Article							QUANTITATIVE PROTEOMICS; INTEGRATIVE ANALYSIS; PANCREATIC-CANCER; SOMATIC MUTATIONS; CELL-CYCLE; EXPRESSION; REVEALS; GENOME; ACETYLATION; GENES	The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively. Here this "proteogenomics" approach was applied to 122 treatment-naive primary breast cancers accrued to preserve post-translational modifications, including protein phosphorylation and acetylation. Proteogenomics challenged standard breast cancer diagnoses, provided detailed analysis of the ERBB2 amplicon, defined tumor subsets that could benefit from immune checkpoint therapy, and allowed more accurate assessment of Rb status for prediction of CDK4/6 inhibitor responsiveness. Phosphoproteomics profiles uncovered novel associations between tumor suppressor loss and targetable kinases. Acetyl proteome analysis highlighted acetylation on key nuclear proteins involved in the DNA damage response and revealed cross-talk between cytoplasmic and mitochondrial acetylation and metabolism. Our results underscore the potential of proteogenomics for clinical investigation of breast cancer through more accurate annotation of targetable pathways and biological features of this remarkably heterogeneous malignancy.	[Krug, Karsten; Satpathy, Shankha; Mertins, Philipp; Geffen, Yifat; Tang, Lauren C.; Heiman, David, I; Maruvka, Yosef E.; Kothadia, Ramani B.; Birger, Chet; Getz, Gad; Clauser, Karl R.; Mani, D. R.; Carr, Steven A.; Gillette, Michael A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Jaehnig, Eric J.; Anurag, Meenakshi; Miles, George; Lei, Jonathan T.; Huang, Chen; Dou, Yongchao; Wen, Bo; Shi, Zhiao; Liao, Yuxing; Zhang, Bing; Ellis, Matthew J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Jaehnig, Eric J.; Anurag, Meenakshi; Miles, George; Lei, Jonathan T.; Huang, Chen; Dou, Yongchao; Wen, Bo; Shi, Zhiao; Liao, Yuxing; Zhang, Bing; Ellis, Matthew J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Blumenberg, Lili; Ruggles, Kelly, V] NYU, Grossman Sch Med, Inst Syst Genet, New York, NY 10016 USA; [Blumenberg, Lili; Ruggles, Kelly, V] NYU, Grossman Sch Med, Dept Med, New York, NY 10016 USA; [Karpova, Alla; Cao, Song; Wyczalkowski, Matthew A.; Ding, Li] Washington Univ, Dept Med & Genet, Siteman Canc Ctr, St Louis, MO 63110 USA; [Mertins, Philipp] Max Delbruck Ctr Mol Med Helmholtz Soc, Berlin, Germany; [Mertins, Philipp] Berlin Inst Hlth, Berlin, Germany; [Tang, Lauren C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Colaprico, Antonio; Chen, Xi Steven] Univ Miami, Miller Sch Med, Div Biostat, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Wang, Jarey; Westbrook, Thomas F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Dept Mol & Human Genet, Houston, TX 77030 USA; [Wang, Jarey; Westbrook, Thomas F.] Baylor Coll Med, Therapeut Innovat Ctr, Houston, TX 77030 USA; [Wiznerowicz, Maciej] Poznan Univ Med Sci, PL-61701 Poznan, Poland; [Wiznerowicz, Maciej] Int Inst Mol Oncol, PL-60203 Poznan, Poland; [Kennedy, Jacob J.; Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Thiagarajan, Mathangi] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA; [Kinsinger, Christopher R.; Hiltke, Tara; Boja, Emily S.; Mesri, Mehdi; Robles, Ana, I; Rodriguez, Henry] NCI, Off Canc Clin Prote Res, Bethesda, MD 20892 USA; [Getz, Gad] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02114 USA; [Fenyo, David] NYU, Grossman Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; [Gillette, Michael A.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Baylor College of Medicine; Baylor College of Medicine; New York University; New York University; Siteman Cancer Center; Washington University (WUSTL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Berlin Institute of Health; Columbia University; University of Miami; Baylor College of Medicine; Baylor College of Medicine; Poznan University of Medical Sciences; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; New York University; Harvard University; Massachusetts General Hospital	Mani, DR; Carr, SA; Gillette, MA (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ellis, MJ (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Ellis, MJ (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.; Gillette, MA (corresponding author), Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA.	manidr@broadinstitute.org; scarr@broad.mit.edu; mjellis@bcm.edu; gillette@broadinstitute.org	Karpova, Alla/AAV-2910-2020; Wen, Bo/I-1259-2019; jaehnig, eric/CCF-3596-2022; Satpathy, Shankha/AAX-6592-2020; Pandey, Akhilesh/CAI-9458-2022	Karpova, Alla/0000-0003-0467-0215; Wen, Bo/0000-0003-2261-3150; Pandey, Akhilesh/0000-0001-9943-6127; Tang, Lauren/0000-0001-8786-5418; Satpathy, Shankha/0000-0002-6040-4854; Maruvka, Yosef/0000-0002-8918-9887; Wang, Jarey/0000-0001-9038-4674; Ruggles, Kelly/0000-0002-0152-0863; Jaehnig, Eric/0000-0001-9618-6011; Lei, Jonathan/0000-0002-0209-8051; McGarvey, Peter/0000-0002-8312-6017; Robles, Ana/0000-0001-5019-4374; Tabb, David/0000-0001-7223-578X; Geffen, Yifat/0000-0003-3692-4689; huang, chen/0000-0003-2777-7365	National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium [U24CA160034, U24CA210986, U01CA214125, U24CA210979, U24CA210954, U24CA210972]; NIH [T32CA203690]; McNair Medical Institute at The Robert and Janice McNair Foundation; CPRIT (Cancer Prevention and Research Institute of Texas) Established Investigator Award [RR140027]	National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McNair Medical Institute at The Robert and Janice McNair Foundation; CPRIT (Cancer Prevention and Research Institute of Texas) Established Investigator Award	This work was supported by the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium through grants U24CA160034 (to S.A.C.), U24CA210986 (to S.A.C. and M.A.G.), U01CA214125 (to M.J.E. and S.A.C.), U24CA210979 (to D.R.M. and G.G.), U24CA210954 (to B.Z.), and U24CA210972 (to L.D. and D.F.) and by NIH grant T32CA203690 (to J.T.L.). M.J.E. is a Susan G. Komen Foundation Scholar, a McNair Scholar supported by the McNair Medical Institute at The Robert and Janice McNair Foundation, and a recipient of a CPRIT (Cancer Prevention and Research Institute of Texas) Established Investigator Award (RR140027).	Alhazzazi TY, 2016, ANTICANCER RES, V36, P49; Ali I, 2018, CHEM REV, V118, P340, DOI 10.1021/acs.chemrev.7b00181; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Anurag M, 2020, JNCI-J NATL CANCER I, V112, P737, DOI 10.1093/jnci/djz213; Anurag Meenakshi, 2018, Oncotarget, V9, P36252, DOI 10.18632/oncotarget.26363; Anurag M, 2018, CLIN CANCER RES, V24, P4887, DOI 10.1158/1078-0432.CCR-17-3702; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barker L, 2002, AM STAT, V56, P85, DOI 10.1198/000313002317572736; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012; Blumenberg L., 2019, BIORXIV, DOI [10.1101/825067, DOI 10.1101/825067]; Bouchal P, 2019, CELL REP, V28, P832, DOI 10.1016/j.celrep.2019.06.046; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Caldoe CE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00106; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chen X, 2012, CANCER INFORM, V11, P147, DOI 10.4137/CIN.S9983; Chiang Jonathan, 2012, Cells, V1, P886, DOI 10.3390/cells1040886; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Colaprico A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13803-0; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Condorelli R, 2019, ANN ONCOL, V30, P365, DOI 10.1093/annonc/mdz036; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Daily K, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.30; Dietze EC, 2015, NAT REV CANCER, V15, P248, DOI 10.1038/nrc3896; Dong H, 2019, NAT IMMUNOL, V20, P865, DOI 10.1038/s41590-019-0388-z; Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026; Eddy J.A., IMMUNITY, V51, P411; Ellis MJ, 2017, J CLIN ONCOL, V35, P1061, DOI 10.1200/JCO.2016.69.4406; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013; Gillette MA, 2013, NAT METHODS, V10, P28, DOI 10.1038/nmeth.2309; Giraldo N.A., GENOME BIOL; Goel S, 2018, TRENDS CELL BIOL, V28, P911, DOI 10.1016/j.tcb.2018.07.002; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Haricharan S, 2017, CANCER DISCOV, V7, P1168, DOI 10.1158/2159-8290.CD-16-1179; Harris LN, 2009, J CLIN ONCOL, V27, P3430, DOI 10.1200/JCO.2008.18.4085; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Hunt AL, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-4709; Hyman DM, 2017, CELL, V168, P584, DOI 10.1016/j.cell.2016.12.015; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Johansson HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09018-y; Kasar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9866; Kawamura D, 2017, ONCOL REP, V38, P3238, DOI 10.3892/or.2017.5974; Kim H, 2007, BIOINFORMATICS, V23, P1495, DOI 10.1093/bioinformatics/btm134; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krug K, 2019, MOL CELL PROTEOMICS, V18, P576, DOI 10.1074/mcp.TIR118.000943; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; Lee DD, 2001, ADV NEUR IN, V13, P556; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0406-x; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001; Lin CC, 2020, CELL DEATH DIFFER, V27, P2234, DOI 10.1038/s41418-020-0499-y; Lin YC, 2014, CELL DEATH DIS, V5, DOI [10.1038/cddis.2013.527, 10.1038/cddis.2014.14]; Liu CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189007; Liu YH, 2016, ONCOTARGET, V7, P1464, DOI 10.18632/oncotarget.6386; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Masuda M, 2017, EXPERT OPIN THER TAR, V21, P353, DOI 10.1080/14728222.2017.1297799; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mertins P, 2018, NAT PROTOC, V13, P1632, DOI 10.1038/s41596-018-0006-9; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Mertins P, 2014, MOL CELL PROTEOMICS, V13, P1690, DOI 10.1074/mcp.M113.036392; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Mishima Y, 2011, BLOOD, V118, P2443, DOI 10.1182/blood-2011-01-331892; Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701; Mullarky E, 2019, BIOORG MED CHEM LETT, V29, P2503, DOI 10.1016/j.bmcl.2019.07.011; Murphy JP, 2018, CELL REP, V24, P2381, DOI 10.1016/j.celrep.2018.07.086; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nusinow DP, 2020, CELL, V180, P387, DOI 10.1016/j.cell.2019.12.023; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Parkes EE, 2016, JNCI-J NATL CANCER I, P109; Patel JM, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-0160-4; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pernas S, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918786451; Poplin R., 2018, BIORXIV, DOI [10.1101/201178, 10]; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Ross JS, 2007, CLIN CANCER RES, V13, P2831, DOI 10.1158/1078-0432.CCR-06-2522; Ruggles KV, 2017, MOL CELL PROTEOMICS, V16, P959, DOI 10.1074/mcp.MR117.000024; Ruggles KV, 2016, MOL CELL PROTEOMICS, V15, P1060, DOI 10.1074/mcp.M115.056226; Salomonis N, 2016, STEM CELL REP, V7, P110, DOI 10.1016/j.stemcr.2016.05.006; Satpathy S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14381-2; Schmidlin T, 2019, CELL SYST, V9, P366, DOI 10.1016/j.cels.2019.08.005; Shadforth IP, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-145; Shin SY, 2016, GENES-BASEL, V7, DOI 10.3390/genes7080044; Shindo Y, 2019, CANCERS, V11, DOI 10.3390/cancers11091223; Smid M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12910; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Sokolov A, 2016, BIOCOMPUT-PAC SYM, P405; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Suehiro Y, 2018, ANTICANCER RES, V38, P6225, DOI 10.21873/anticanres.12977; Tan VYF, 2013, IEEE T PATTERN ANAL, V35, P1592, DOI 10.1109/TPAMI.2012.240; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Taylor-Weiner A, 2018, NAT METHODS, V15, P531, DOI 10.1038/s41592-018-0036-9; Telli ML, 2019, J NATL COMPR CANC NE, V17, P552, DOI 10.6004/jnccn.2019.5006; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Tyanova S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10259; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Varn FS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10248; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; Weinert BT, 2018, CELL, V174, P231, DOI 10.1016/j.cell.2018.04.033; Weinert BT, 2015, EMBO J, V34, P2620, DOI 10.15252/embj.201591271; Weinstabl H, 2019, J MED CHEM, V62, P7976, DOI 10.1021/acs.jmedchem.9b00718; Weygant N, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-103; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Xiong YL, 2016, INT J ONCOL, V49, P2227, DOI 10.3892/ijo.2016.3767; Yamamoto T, 2019, BREAST CANCER RES TR, V174, P615, DOI 10.1007/s10549-018-05104-9; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhang B, 2019, NAT REV CLIN ONCOL, V16, P256, DOI 10.1038/s41571-018-0135-7; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438	147	97	101	14	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	2020	183	5					1436	+		10.1016/j.cell.2020.10.036	http://dx.doi.org/10.1016/j.cell.2020.10.036			52	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	OW9ND	33212010	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000593203800022
J	Haikio, K; Cloutier, D; Rugkasa, J				Haikio, Kristin; Cloutier, Denise; Rugkasa, Jorun			Is health literacy of family carers associated with carer burden, quality of life, and time spent on informal care for older persons living with dementia?	PLOS ONE			English	Article							RESOURCE UTILIZATION; RUD INSTRUMENT; CAREGIVERS; PEOPLE; RELIABILITY; PREVALENCE; EDUCATION; VALIDITY; STATES	Introduction Family carers are cornerstones in the care of older people living with dementia. Family carers report extensive carer burden, reduced health-related quality of life (HRQoL), and extensive time spent on informal care (Time). Health literacy (HL) is a concept associated with people's ability to access health services, and navigate the healthcare system. This study's aim was to investigate HL among family carers, and investigate the associations between HL and carer burden, HRQoL, and Time spent on informal care. Method We designed a self-administered survey comprising validated instruments, including the Health Literacy Scale (HLS-N-Q12) to measure HL, Relative Stress Scale (RSS) to measure carer burden, the EQ-5D-5L instrument to measure HRQoL, and some modified questions from the Resource Utilization in Dementia (RUD) questionnaire to measure time spent on informal care (Time). Descriptive analysis in addition to bivariate and multiple linear regressions were undertaken. In multiple linear regression analysis, we used HL as the independent variable to predict the outcomes (carer burden, HRQoL, Time). Analyses were adjusted for the effects of explanatory independent variables: age, gender, education levels, urban residency, having worked as health personnel, caring for someone with severe/mild dementia, and being born abroad. Findings In a non-probability sample of 188 family carers from across Norway, most of them female and over the age of 60, we found high levels of HL. In the bivariate analysis, carer burden and HRQoL (EQvalue) showed significant associations with HL. In the multiple regression analyses, HL was statistically significantly associated with carer burden (B = -0.18 CI:-0.33,-0.02 p = 0.02), HRQoL (EQvalue: B = 0.003 with 95% CI: 0.001, 0.006 p = 0.04), and Time (B = -0.03 with 95% CI: -0.06, 0.000, p = 0.046), after adjusting for the effect of independent variables. Conclusion This is one of the first studies to investigate the associations between HL and different outcomes for family carers of older people living with dementia. Additional research into the associations identified here is needed to further develop our understanding of how to support family carers in their roles. Targeted support that increases family carers' HL may have potential to enhance their ability to provide sustainable care over time.	[Haikio, Kristin; Rugkasa, Jorun] Akershus Univ Hosp, HOKH Hlth Serv Res Unit, Lorenskog, Norway; [Haikio, Kristin] Oslo Metropolitan Univ, Fac Hlth Sci, Dept Nursing & Hlth Promot, Oslo, Norway; [Cloutier, Denise] Univ Victoria, Dept Geog, Victoria, BC, Canada; [Cloutier, Denise] Univ Victoria, Inst Aging & Lifelong Hlth, Victoria, BC, Canada; [Rugkasa, Jorun] Univ South Eastern Norway, Ctr Care Res, Porsgrunn, Norway	University of Oslo; Oslo Metropolitan University (OsloMet); University of Victoria; University of Victoria	Haikio, K (corresponding author), Akershus Univ Hosp, HOKH Hlth Serv Res Unit, Lorenskog, Norway.; Haikio, K (corresponding author), Oslo Metropolitan Univ, Fac Hlth Sci, Dept Nursing & Hlth Promot, Oslo, Norway.	haikio@oslomet.no	Rugkåsa, Jorun/ABI-6495-2020; Häikiö, Kristin/GPW-9840-2022	Haikio, Kristin/0000-0002-5573-711X	Norwegian Research Council [256431]	Norwegian Research Council(Research Council of NorwayEuropean Commission)	JR received funding to this Project (ref. nr. 256431) by the Norwegian Research Council, https://www.forskningsradet.no/en/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andren S, 2005, SCAND J CARING SCI, V19, P157, DOI 10.1111/j.1471-6712.2005.00328.x; Annerstedt L, 2000, SCAND J PUBLIC HEALT, V28, P23, DOI 10.1177/140349480002800106; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; Batterham RW, 2016, PUBLIC HEALTH, V132, P3, DOI 10.1016/j.puhe.2016.01.001; Berg ABS, 2019, PARORENDEUNDERSOKELS; BERGER EY, 1980, J AM GERIATR SOC, V28, P234, DOI 10.1111/j.1532-5415.1980.tb00527.x; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Bleijlevens MHC, 2015, J ADV NURS, V71, P1378, DOI 10.1111/jan.12561; Bowling A., 2014, RES METHODS HLTH INV, Vfourth; Calasanti T, 2006, J AGING STUD, V20, P253, DOI 10.1016/j.jaging.2005.08.001; Chertkow H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt198; Chiatti C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122679; Cianfrocca C, 2018, APPL NURS RES, V44, P100, DOI 10.1016/j.apnr.2018.10.004; Cokluk O, 2011, KURAM UYGUL EGIT BIL, V11, P303; DUNCAN MT, 1994, GERONTOLOGIST, V34, P235, DOI 10.1093/geront/34.2.235; Eberl A, 2020, SOC SCI RES, V85, DOI 10.1016/j.ssresearch.2019.06.010; Edwards M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-130; Engedal K, 2004, DEMENS FAKTA UTFORDR; EuroQol Group, 2011, EQ 5D 5L SPORR HELS; EuroQol Research Foundation, 2019, EQ 5D 5L USER GUIDE; Farina N, 2017, ALZHEIMERS DEMENT, V13, P572, DOI 10.1016/j.jalz.2016.12.010; Finbraten HS, 2017, J ADV NURS, V73, P2730, DOI 10.1111/jan.13342; Finbraten HS, 2018, VALIDATING FUNCTIONA; Finbraten HS, 2018, MEASURING HLTH LITER; Flyckt L, 2015, INT J SOC PSYCHIATR, V61, P684, DOI 10.1177/0020764015573088; Gaugler JE, 2018, INNOV AGING, V2, DOI 10.1093/geroni/igy015; Gele AA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3790-6; Greenwood N, 2019, MATURITAS, V124, P1, DOI 10.1016/j.maturitas.2019.03.006; Guttersrud O, PROGR HLTH LITERACY; Haikio K, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4478-2; Henderson AS, 2000, DEMENTIA, V2, P1; Hickey A, 2005, PHARMACOECONOMICS, V23, P971, DOI 10.2165/00019053-200523100-00002; Jacobs RJ, 2016, HEALTH INFORM J, V22, P81, DOI 10.1177/1460458214534092; Jansen T, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3197-4; Levy H, 2016, J HEALTH COMMUN, V21, P43, DOI 10.1080/10810730.2015.1131776; Lewis-Beck MS, 2003, SOCIAL SCI RES METHO; Lin SC, 2019, GERIATR NURS, V40, P494, DOI 10.1016/j.gerinurse.2019.03.013; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Lloyd BT, 2011, SOCIOL HEALTH ILL, V33, P899, DOI 10.1111/j.1467-9566.2010.01332.x; Lopez-Anuarbe M, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7020072; Manafo E, 2012, HEALTH EDUC RES, V27, P947, DOI 10.1093/her/cys067; Marcus B, 2005, J PERS, V73, P959, DOI 10.1111/j.1467-6494.2005.00335.x; Martindale-Adams J, 2016, GERONTOLOGIST, V56, P1053, DOI 10.1093/geront/gnv121; Mullins J, 2016, J WOUND OSTOMY CONT, V43, P539, DOI 10.1097/WON.0000000000000263; Nikzad-Terhune KA, 2010, SOC WORK HEALTH CARE, V49, P734, DOI 10.1080/00981381003635296; Norwegian Ministry of Health and Care Services, 2018, MELD ST 15 LEV HEL L; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Panagioti M, 2018, QUAL LIFE RES, V27, P1257, DOI 10.1007/s11136-017-1775-2; Popham F, 2013, J EPIDEMIOL COMMUN H, V67, P412, DOI 10.1136/jech-2012-201525; Pudelewicz A, 2019, SCAND J CARING SCI, V33, P336, DOI 10.1111/scs.12626; Rigby T, 2019, INNOV AGING, V3, DOI 10.1093/geroni/igz027; Rosen H, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1343-4; Rudd RE, 2007, AM J HEALTH BEHAV, V31, pS8; Rugkasa J, 2015, CARE CULTURE CARE RE; Russell R, 2001, J AGING STUD, V15, P351, DOI 10.1016/S0890-4065(01)00028-7; Schulz R, 2004, AM J GERIAT PSYCHIAT, V12, P240, DOI 10.1176/appi.ajgp.12.3.240; Sharma N, 2016, WORLD J PSYCHIATR, V6, P7, DOI 10.5498/wjp.v6.i1.7; Social care institute for excellence, 2015, SUPP CAR TIM DIAGN D; Sorensen K, 2015, EUR J PUBLIC HEALTH, V25, P1053, DOI 10.1093/eurpub/ckv043; Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80; Statistics Norway, 2019, BEF UTD STAT; Statistics Norway, 2020, 05182 PERS IMM CAT S; Sudore RL, 2006, J AM GERIATR SOC, V54, P770, DOI 10.1111/j.1532-5415.2006.00691.x; Sutcliffe C, 2017, J AM MED DIR ASSOC, V18, P967, DOI 10.1016/j.jamda.2017.06.004; Twigg J., 1994, CARERS PERCEIVED POL; Ulstein I, 2007, INT J GERIATR PSYCH, V22, P61, DOI 10.1002/gps.1654; Vossius C, 2015, ALDERSPSYKIATRISK FO; Walters R, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08991-0; Willert B, 2021, APPL RES QUAL LIFE, V16, P943, DOI 10.1007/s11482-019-09786-1; Wimo A, 2010, J NUTR HEALTH AGING, V14, P685, DOI 10.1007/s12603-010-0316-2; Wimo A, 2013, ALZHEIMERS DEMENT, V9, P429, DOI 10.1016/j.jalz.2012.06.008; Wimo A, 2007, ARCH GERONTOL GERIAT, V44, P71, DOI 10.1016/j.archger.2006.03.001; Wolfs C.A.G., 2011, ALZ DIS ASSOC DIS, V26, P197; World Health Organization, 2018, DEM PLAN WHO GUID; Yamashita T, 2015, J HEALTH COMMUN, V20, P406, DOI 10.1080/10810730.2014.977469; Yuen EYN, 2018, HEALTH SOC CARE COMM, V26, pE191, DOI 10.1111/hsc.12368; Zheng MY, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-1031-7	77	6	7	5	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0241982	10.1371/journal.pone.0241982	http://dx.doi.org/10.1371/journal.pone.0241982			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PA5CL	33216771	Green Published, gold			2023-01-03	WOS:000595653500045
J	Lenze, EJ; Mattar, C; Zorumski, CF; Stevens, A; Schweiger, J; Nicol, GE; Miller, JP; Yang, L; Yingling, M; Avidan, MS; Reiersen, AM				Lenze, Eric J.; Mattar, Caline; Zorumski, Charles F.; Stevens, Angela; Schweiger, Julie; Nicol, Ginger E.; Miller, J. Philip; Yang, Lei; Yingling, Michael; Avidan, Michael S.; Reiersen, Angela M.			Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIGMA-1 RECEPTOR CHAPERONE; BRAIN	Importance Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of an excessive immune response. Fluvoxamine may prevent clinical deterioration by stimulating the sigma-1 receptor, which regulates cytokine production. Objective To determine whether fluvoxamine, given during mild COVID-19 illness, prevents clinical deterioration and decreases the severity of disease. Design, Setting, and Participants Double-blind, randomized, fully remote (contactless) clinical trial of fluvoxamine vs placebo. Participants were community-living, nonhospitalized adults with confirmed severe acute respiratory syndrome coronavirus 2 infection, with COVID-19 symptom onset within 7 days and oxygen saturation of 92% or greater. One hundred fifty-two participants were enrolled from the St Louis metropolitan area (Missouri and Illinois) from April 10, 2020, to August 5, 2020. The final date of follow-up was September 19, 2020. Interventions Participants were randomly assigned to receive 100 mg of fluvoxamine (n = 80) or placebo (n = 72) 3 times daily for 15 days. Main Outcomes and Measures The primary outcome was clinical deterioration within 15 days of randomization defined by meeting both criteria of (1) shortness of breath or hospitalization for shortness of breath or pneumonia and (2) oxygen saturation less than 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater. Results Of 152 patients who were randomized (mean [SD] age, 46 [13] years; 109 [72%] women), 115 (76%) completed the trial. Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. Conclusions and Relevance In this preliminary study of adult outpatients with symptomatic COVID-19, patients treated with fluvoxamine, compared with placebo, had a lower likelihood of clinical deterioration over 15 days. However, the study is limited by a small sample size and short follow-up duration, and determination of clinical efficacy would require larger randomized trials with more definitive outcome measures. This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects vs placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild coronavirus disease 2019 (COVID-19) illness.	[Lenze, Eric J.; Zorumski, Charles F.; Stevens, Angela; Schweiger, Julie; Nicol, Ginger E.; Yang, Lei; Yingling, Michael; Reiersen, Angela M.] Washington Univ, Dept Psychiat, Sch Med, 660 S Euclid Ave,POB 8134, St Louis, MO 63110 USA; [Mattar, Caline] Washington Univ, Dept Internal Med, Div Infect Dis, Sch Med, St Louis, MO 63110 USA; [Miller, J. Philip] Washington Univ, Informat Inst, Div Biostat, Sch Med, St Louis, MO 63110 USA; [Avidan, Michael S.] Washington Univ, Dept Anesthesiol, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Lenze, EJ (corresponding author), Washington Univ, Dept Psychiat, Sch Med, 660 S Euclid Ave,POB 8134, St Louis, MO 63110 USA.	lenzee@wustl.edu	Miller, John J/GZG-5663-2022; Lenze, Eric J/AAW-8652-2021	Lenze, Eric/0000-0002-0471-9368	Taylor Family Institute for Innovative Psychiatric Treatment atWashington University; COVID-19 Early Treatment Fund; Center for Brain Research in Mood Disorders atWashington University; Bantly Foundation; National Institutes of Health [UL1TR002345]	Taylor Family Institute for Innovative Psychiatric Treatment atWashington University; COVID-19 Early Treatment Fund; Center for Brain Research in Mood Disorders atWashington University; Bantly Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the Taylor Family Institute for Innovative Psychiatric Treatment atWashington University and the COVID-19 Early Treatment Fund. Additional support came from the Center for Brain Research in Mood Disorders atWashington University, the Bantly Foundation, and grant UL1TR002345 from the National Institutes of Health.	Assimon MM, 2019, J AM SOC NEPHROL, V30, P611, DOI 10.1681/ASN.2018101032; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971; Christensen M, 2002, CLIN PHARMACOL THER, V71, P141, DOI 10.1067/mcp.2002.121788; Cobos EJ, 2008, CURR NEUROPHARMACOL, V6, P344, DOI 10.2174/157015908787386113; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Fung OS, 2019, VIROLOGY, V533, P34, DOI 10.1016/j.virol.2019.05.002; Gillings D., 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hallifax D, 2007, DRUG METAB DISPOS, V35, P1325, DOI 10.1124/dmd.107.015131; Hashimoto K, 2015, J PHARMACOL SCI, V127, P6, DOI 10.1016/j.jphs.2014.11.010; Hashimoto K, 2013, PROG NEUROBIOL, V100, P15, DOI 10.1016/j.pneurobio.2012.09.001; Homolak J, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106044; Hosszu A, 2017, J AM SOC NEPHROL, V28, P152, DOI 10.1681/ASN.2015070772; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Ishikawa M, 2007, BIOL PSYCHIAT, V62, P878, DOI 10.1016/j.biopsych.2007.04.001; Ishima T, 2014, EUR J PHARMACOL, V727, P167, DOI 10.1016/j.ejphar.2014.01.064; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0; Lippi G, 2020, PROG CARDIOVASC DIS, V63, P390, DOI 10.1016/j.pcad.2020.03.001; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mofsen AM, 2019, JMIR MENT HEALTH, V6, DOI 10.2196/11845; Nicol GE, J CLIN PSYCHIAT, DOI [10.4088/JCP.20com13373, DOI 10.4088/JCP.20C0M13373]; Nicol GE, 2020, J AM GERIATR SOC, V68, P922, DOI 10.1111/jgs.16443; Omori IM, 2009, J PSYCHOPHARMACOL, V23, P539, DOI 10.1177/0269881108089876; Prasad A, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00370; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Rosen DA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5266; Schlienger Raymond G, 2003, Am J Cardiovasc Drugs, V3, P149, DOI 10.2165/00129784-200303030-00001; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; WHO, NOV COR; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]	33	238	255	5	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2020	324	22					2292	2300		10.1001/jama.2020.22760	http://dx.doi.org/10.1001/jama.2020.22760		NOV 2020	9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD9VK	33180097	Green Published, Bronze			2023-01-03	WOS:000592281900001
J	Dempsey, G; Hungerford, D; McHale, P; McGarey, L; Benison, E; Morton, B				Dempsey, Ged; Hungerford, Dan; McHale, Phil; McGarey, Lauren; Benison, Edward; Morton, Ben			Long term outcomes for elderly patients after emergency intensive care admission: A cohort study	PLOS ONE			English	Article							MORTALITY; ICU; FRAILTY; TRIAGE; IMPACT; OLDER	Background Elderly patients (>= 80 years of age) surviving an episode of critical illness suffer long-term morbidity and risk of mortality. Identifying high risk groups could assist in informing discussions with patients and families. Aim To determine factors associated with long-term survival following ICU admission. Design A cohort study of patients aged >= 80 years of age admitted to the ICU as an emergency. Methods Patients admitted from January 2010 to December 2018 were included in the study. Primary outcome was five year survival. Mortality was assessed using a multivariable flexible parametric survival analysis adjusted for demographics, and clinically relevant covariates. Results There were 828 patients. Mean age was 84 years (SD 3.2) and 419 (51%) were male. Patients were categorised into medical (423 (51%)) and surgical (405 (49%)) admissions. Adjusted hazard ratios (aHR) for mortality were highest for serum lactate (>8 mmol/l aHR 2.56 (C.I. 1.79-3.67)), lowest systolic blood pressure (< 70 mmHg aHR 2.04 (C.I. 1.36-3.05)) and pH (< 7.05 aHR 4.70 (C.I 2.67-8.21)). There were no survivors beyond one year with severe abnormalities of pH and lactate (< 7.05 and > 8 mmol/l respectively). Relative survival for medical patients was below that expected for the general population for the duration of the study. Conclusion Overall five-year survival was 27%. For medical and surgical patients it was 19% and 35% respectively. Survival at 30 days and one year was 61% and 46%. The presence of features of circulatory shock predicted poor short and long term survival.	[Dempsey, Ged; McGarey, Lauren; Benison, Edward; Morton, Ben] Liverpool Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England; [Hungerford, Dan] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England; [McHale, Phil] Univ Liverpool, Inst Populat Hlth Sci, Dept Publ Hlth & Policy, Liverpool, Merseyside, England; [Morton, Ben] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England; [Morton, Ben] Malawi Liverpool Wellcome Trust, Clin Res Programme, Blantyre, Malawi	University of Liverpool; University of Liverpool; Liverpool School of Tropical Medicine; University of Malawi	Dempsey, G (corresponding author), Liverpool Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England.	ged.dempsey@aintree.nhs.uk		Hungerford, Daniel/0000-0002-9770-0163; Benison, Edward/0000-0001-6986-7153; Morton, Ben/0000-0002-6164-2854				Andersen FH, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0053-0; Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Atramont A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3215; Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7768; Boumendil A, 2005, J AM GERIATR SOC, V53, P88, DOI 10.1111/j.1532-5415.2005.53016.x; Chin-Yee N, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1689-y; de Rooij SE, 2006, INTENS CARE MED, V32, P1039, DOI 10.1007/s00134-006-0171-0; de Rooij SE, 2007, CRIT CARE, V11, DOI 10.1186/cc5716; Dickman PW, 2015, STATA J, V15, P186, DOI 10.1177/1536867X1501500112; Flaatten H, 2017, INTENS CARE MED, V43, P1319, DOI 10.1007/s00134-017-4718-z; Flaatten H, 2017, INTENS CARE MED, V43, P1820, DOI 10.1007/s00134-017-4940-8; Fuchs L, 2012, INTENS CARE MED, V38, P1654, DOI 10.1007/s00134-012-2629-6; Groll DL, 2006, AM J PHYS MED REHAB, V85, P574, DOI 10.1097/01.phm.0000223220.91914.61; Guidet B, 2017, JAMA-J AM MED ASSOC, V318, P1450, DOI 10.1001/jama.2017.13889; Guidet B, 2014, J CRIT CARE, V29, P896, DOI 10.1016/j.jcrc.2014.08.004; Haas LEM, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1061-z; Heyland DK, 2016, CRIT CARE MED, V44, P1718, DOI 10.1097/CCM.0000000000001762; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Jones A, 2020, CRIT CARE MED, V48; Lambert PC, 2009, STATA J, V9, P265, DOI 10.1177/1536867X0900900206; Lown DJ, 2013, CRIT CARE RESUSC, V15, P49; Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0; Nielsson MS, 2014, ACTA ANAESTH SCAND, V58, P19, DOI 10.1111/aas.12211; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Philippart F, 2013, INTENS CARE MED, V39, P1565, DOI 10.1007/s00134-013-2976-y; Pietilainen L, 2018, INTENS CARE MED, V44, P1221, DOI 10.1007/s00134-018-5273-y; Roch A, 2011, CRIT CARE, V15, DOI 10.1186/cc9984; Sprung CL, 2012, CRIT CARE MED, V40, P132, DOI 10.1097/CCM.0b013e318232d6b0	29	0	0	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0241244	10.1371/journal.pone.0241244	http://dx.doi.org/10.1371/journal.pone.0241244			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG8YH	33119649	Green Published, Green Accepted, gold			2023-01-03	WOS:000600013600012
J	Li, S; Liu, M; Do, MH; Chou, C; Stamatiades, EG; Nixon, BG; Shi, W; Zhang, X; Li, P; Gao, SY; Capistrano, KJ; Xu, H; Cheung, NKV; Li, MO				Li, Shun; Liu, Ming; Do, Mytrang H.; Chou, Chun; Stamatiades, Efstathios G.; Nixon, Briana G.; Shi, Wei; Zhang, Xian; Li, Peng; Gao, Shengyu; Capistrano, Kristelle J.; Xu, Hong; Cheung, Nai-Kong V.; Li, Ming O.			Cancer immunotherapy via targeted TGF-beta signalling blockade in T(H)cells	NATURE			English	Article							T-CELL SURVEILLANCE; MONOCLONAL-ANTIBODY; TUMOR; RESISTANCE; VEGF; MICROENVIRONMENT; POLARIZATION; IMMUNITY; DISEASE; CD4	4T-Trap, a bispecific molecule designed to recognize CD4 and bind TGF-beta, blocks TGF-beta signalling in T helper cells, causing interleukin-4-dependent vascular reorganization and cancer cell death in a mouse model of breast cancer. Cancer arises from malignant cells that exist in dynamic multilevel interactions with the host tissue. Cancer therapies aiming to directly kill cancer cells, including oncogene-targeted therapy and immune-checkpoint therapy that revives tumour-reactive cytotoxic T lymphocytes, are effective in some patients(1,2), but acquired resistance frequently develops(3,4). An alternative therapeutic strategy aims to rectify the host tissue pathology, including abnormalities in the vasculature that foster cancer progression(5,6); however, neutralization of proangiogenic factors such as vascular endothelial growth factor A (VEGFA) has had limited clinical benefits(7,8). Here, following the finding that transforming growth factor-beta (TGF-beta) suppresses T helper 2 (T(H)2)-cell-mediated cancer immunity(9), we show that blocking TGF-beta signalling in CD4(+)T cells remodels the tumour microenvironment and restrains cancer progression. In a mouse model of breast cancer resistant to immune-checkpoint or anti-VEGF therapies(10,11), inducible genetic deletion of the TGF-beta receptor II (TGFBR2) in CD4(+)T cells suppressed tumour growth. For pharmacological blockade, we engineered a bispecific receptor decoy by attaching the TGF-beta-neutralizing TGFBR2 extracellular domain to ibalizumab, a non-immunosuppressive CD4 antibody(12,13), and named it CD4 TGF-beta Trap (4T-Trap). Compared with a non-targeted TGF-beta-Trap, 4T-Trap selectively inhibited T(H)cell TGF-beta signalling in tumour-draining lymph nodes, causing reorganization of tumour vasculature and cancer cell death, a process dependent on the T(H)2 cytokine interleukin-4 (IL-4). Notably, the 4T-Trap-induced tumour tissue hypoxia led to increased VEGFA expression. VEGF inhibition enhanced the starvation-triggered cancer cell death and amplified the antitumour effect of 4T-Trap. Thus, targeted TGF-beta signalling blockade in helper T cells elicits an effective tissue-level cancer defence response that can provide a basis for therapies directed towards the cancer environment.	[Li, Shun; Liu, Ming; Do, Mytrang H.; Chou, Chun; Stamatiades, Efstathios G.; Nixon, Briana G.; Shi, Wei; Zhang, Xian; Li, Peng; Gao, Shengyu; Capistrano, Kristelle J.; Li, Ming O.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA; [Do, Mytrang H.; Nixon, Briana G.; Li, Ming O.] Cornell Univ, Weill Cornell Grad Sch Med Sci, Immunol & Microbial Pathogenesis Program, New York, NY 10021 USA; [Gao, Shengyu; Li, Ming O.] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10021 USA; [Xu, Hong; Cheung, Nai-Kong V.] Mem Sloan Kettering Canc Ctr, Dept Pediat, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Li, MO (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA.; Li, MO (corresponding author), Cornell Univ, Weill Cornell Grad Sch Med Sci, Immunol & Microbial Pathogenesis Program, New York, NY 10021 USA.; Li, MO (corresponding author), Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10021 USA.	lim@mskcc.org		Stamatiades, Efstathios/0000-0002-2785-9005; Zhang, Xian/0000-0001-9674-7886; Gao, Shengyu/0000-0003-2844-6306	Howard Hughes Medical Institute Faculty Scholar Award; Mr William H. and Mrs Alice Goodwin and the Commonwealth Foundation for Cancer Research; Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center [P30 CA08748]; Cancer Center Support Grant [P30 CA08748]; Cancer Research Institute; National Institutes of Health [F31 CA210332, F30 AI29273-03]; Alan and Sandra Gerry Metastasis and Tumour Ecosystems Center of Memorial Sloan Kettering Cancer Center	Howard Hughes Medical Institute Faculty Scholar Award; Mr William H. and Mrs Alice Goodwin and the Commonwealth Foundation for Cancer Research; Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center; Cancer Center Support Grant; Cancer Research Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alan and Sandra Gerry Metastasis and Tumour Ecosystems Center of Memorial Sloan Kettering Cancer Center	We thank members of the M.O.L. laboratory for helpful discussions and S. Gong for help with the recombineering technique and BAC DNA purification. This work was supported by a Howard Hughes Medical Institute Faculty Scholar Award (M.O.L.), an award from Mr William H. and Mrs Alice Goodwin and the Commonwealth Foundation for Cancer Research and the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center (M.O.L.) and a Cancer Center Support Grant (P30 CA08748). S.L., C.C. and X.Z. are Cancer Research Institute Irvington Fellows supported by the Cancer Research Institute. M.H.D. and B.G.N. are recipients of F31 CA210332 and F30 AI29273-03 awards from National Institutes of Health. E.G.S. is a recipient of a Fellowship from the Alan and Sandra Gerry Metastasis and Tumour Ecosystems Center of Memorial Sloan Kettering Cancer Center.	Allison JP, 2015, CELL, V162, P1203, DOI 10.1016/j.cell.2015.08.047; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; BURKLY LC, 1992, J IMMUNOL, V149, P1779; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Donkor MK, 2012, ONCOIMMUNOLOGY, V1, P162, DOI 10.4161/onci.1.2.18481; Donkor MK, 2011, IMMUNITY, V35, P123, DOI 10.1016/j.immuni.2011.04.019; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Huang S, 2012, PROG BIOPHYS MOL BIO, V110, P69, DOI 10.1016/j.pbiomolbio.2012.05.001; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488; Liu M, 2020, NATURE, V587, P115, DOI 10.1038/s41586-020-2836-1; Mouquet H, 2012, P NATL ACAD SCI USA, V109, P875, DOI 10.1073/pnas.1120059109; Oh SA, 2017, P NATL ACAD SCI USA, V114, pE7536, DOI 10.1073/pnas.1706356114; Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012; Pickup MW, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022285; Ravi R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02696-6; Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059; Sabnis AJ, 2019, TRENDS MOL MED, V25, P185, DOI 10.1016/j.molmed.2018.12.009; Sarkar A, 2011, ONCOTARGET, V2, P1339; Sawyers CL, 2009, NAT MED, V15, P1158, DOI 10.1038/nm1009-1158; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sledzinska A, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001674; Song RJ, 2010, J VIROL, V84, P6935, DOI 10.1128/JVI.00453-10; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	36	98	100	6	91	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 5	2020	587	7832					121	+		10.1038/s41586-020-2850-3	http://dx.doi.org/10.1038/s41586-020-2850-3		OCT 2020	26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ON9KH	33087933	Green Accepted			2023-01-03	WOS:000580947900006
J	Thompson, HM; Faig, W; VanKim, NA; Sharma, B; Afshar, M; Karnik, NS				Thompson, Hale M.; Faig, Walter; VanKim, Nicole A.; Sharma, Brihat; Afshar, Majid; Karnik, Niranjan S.			Differences in length of stay and discharge destination among patients with substance use disorders: The effect of Substance Use Intervention Team (SUIT) consultation service	PLOS ONE			English	Article							ADDICTION CONSULTATION; HOSPITALIZED-PATIENTS; CARE; BUPRENORPHINE; PERSPECTIVES; IMPACT; COSTS	Background Addiction medicine consultation services (ACS) may improve outcomes of hospitalized patients with substance use disorders (SUD). Our aim was to examine the difference in length of stay and the hazard ratio for a routine hospital discharge between SUD patients receiving and not receiving ACS. Methods Structured EHR data from 2018 of 1,900 adult patients with a SUD-related diagnostic code at an urban academic health center were examined among 35,541 total encounters. Cox proportional hazards regression models were fit using a cause-specific approach to examine differences in hospital outcome (i.e., routine discharge, leaving against medical advice, in-hospital death, or transfer to another level of care). Models were adjusted for age, sex, race, ethnicity, insurance status, and comorbidities. Results Length of stay was shorter among encounters with a SUD that received a SUIT consultation versus those admissions that did not receive one (5.77 v. 6.54 days, p<0.01). In adjusted analyses, admissions that received a SUIT consultation had a higher hazard of a routine discharge [hazard ratio (95% confidence interval): 1.16 (1.03-1.30)] compared to those not receiving a SUIT consultation. Conclusions The SUIT consultation service was associated with a reduced length of stay and an increased hazard of a routine discharge. The SUIT model may serve as a benchmark and inform other health systems attempting to improve outcomes in SUD patient cohorts.	[Thompson, Hale M.; Faig, Walter; Sharma, Brihat; Karnik, Niranjan S.] Rush Univ, Med Ctr, Dept Psychiat & Behav Sci, Sect Community Behav Hlth, Chicago, IL 60612 USA; [VanKim, Nicole A.] Univ Massachusetts Amherst, Dept Biostat & Epidemiol, Sch Publ Hlth & Hlth Sci, Amherst, MA USA; [Afshar, Majid] Loyola Univ, Div Pulm & Crit Care, Dept Publ Hlth Sci, Ctr Hlth Outcomes & Informat Res, Maywood, IL 60153 USA	Rush University; University of Massachusetts System; University of Massachusetts Amherst; Loyola University Chicago	Thompson, HM (corresponding author), Rush Univ, Med Ctr, Dept Psychiat & Behav Sci, Sect Community Behav Hlth, Chicago, IL 60612 USA.	Hale_Thompson@rush.edu	Karnik, Niranjan/N-4103-2019	Karnik, Niranjan/0000-0001-7650-3008; VanKim, Nicole/0000-0001-6711-9127; Thompson, Hale/0000-0002-9704-934X	ACCELERAT (A Chicago Center of Excellence in Learning Health Systems Research Training) from the Agency for Healthcare Research and Quality [K12-HS026385]; National Institute on Alcohol Abuse and Alcoholism (NIAAA) [K23-AA024503]; National Center for Advancing Translational Sciences [UL1-TR002398, KL2-TR002387]; National Institute on Drug Abuse [R01-DA041071, UG1-DA049467]; Endowment Fund at Rush University Medical Center; Illinois Department of Human Services, Division of Substance Use Prevention and Recovery, as part of the Illinois Opioid-State Targeted Response grant from the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis [TI-080231]	ACCELERAT (A Chicago Center of Excellence in Learning Health Systems Research Training) from the Agency for Healthcare Research and Quality; National Institute on Alcohol Abuse and Alcoholism (NIAAA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Endowment Fund at Rush University Medical Center; Illinois Department of Human Services, Division of Substance Use Prevention and Recovery, as part of the Illinois Opioid-State Targeted Response grant from the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis	HT is supported by ACCELERAT (A Chicago Center of Excellence in Learning Health Systems Research Training) under grant number K12-HS026385 from the Agency for Healthcare Research and Quality. MA is supported by K23-AA024503 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). NK is supported by the National Center for Advancing Translational Sciences (UL1-TR002398, KL2-TR002387), the National Institute on Drug Abuse (R01-DA041071, UG1-DA049467), and the Cynthia Oudejans Harris, MD, Endowment Fund at Rush University Medical Center. The SUIT services were supported in-part by a contract to Rush University Medical Center from the Illinois Department of Human Services, Division of Substance Use Prevention and Recovery, as part of the Illinois Opioid-State Targeted Response grant from the U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (TI-080231). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham AJ, 2017, AM J PUBLIC HEALTH, V107, P31, DOI 10.2105/AJPH.2016.303558; Afshar M, 2019, J AM MED INFORM ASSN, V26, P254, DOI 10.1093/jamia/ocy166; Alcala H. E., INSURANCE TYPES USUA, DOI [10.3122/jabfm.2020.04.190419, DOI 10.3122/JABFM.2020.04.190419]; Allison PD, 2018, CAUSAL ANAL COMPETIN; Andrews C, 2015, HEALTH AFFAIR, V34, P828, DOI 10.1377/hlthaff.2014.1330; [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501; [Anonymous], 2017, JAP CLASS ES CANC, V14, P1, DOI [DOI 10.1007/s10388-016-0551-7, DOI 10.1093/GERONT/GNY014]; [Anonymous], 2013, CAN J DIABETES S3, V37, pS357; Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Besselink M, 2013, PANCREATOLOGY, V13, pE1, DOI 10.1016/j.pan.2013.07.063; Blanchard J., 2019, SUBST USE MISUSE, V6084, P1; Buum HT, 2021, J INTERPROF CARE, V35, P641, DOI 10.1080/13561820.2019.1640190; Centers for Disease Control and Prevention, 2016, EXC ALC US, P3; Chicago Department of Public Health, 2017, EP BRIEF CHAR OP US, VIL, P2017; Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010; Collins D, 2019, J GEN INTERN MED, DOI 10.1007/s11606-019-05311-0; Durante F, 2017, CURR OPIN PSYCHOL, V18, P43, DOI 10.1016/j.copsyc.2017.07.033; Englander H, 2019, J GEN INTERN MED, V34, P2796, DOI 10.1007/s11606-019-05251-9; Englander H, 2017, J HOSP MED, V12, P339, DOI 10.12788/jhm.2736; Fanucchi L, 2016, NEW ENGL J MED, V375, P811, DOI 10.1056/NEJMp1606157; FOX K, 1995, AM J PUBLIC HEALTH, V85, P48, DOI 10.2105/AJPH.85.1.48; Gryczynski J, 2013, AM J ADDICTION, V22, P285, DOI 10.1111/j.1521-0391.2012.12004.x; Hawk M, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0196-4; Hsu DJ, 2017, ADDICTION, V112, P1558, DOI 10.1111/add.13795; Hyshka E, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.025; Lau B, 2009, AM J EPIDEMIOL, V170, P244, DOI 10.1093/aje/kwp107; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Mallow PJ, 2018, J PAIN RES, V11, P3079, DOI 10.2147/JPR.S184724; McNeil R, 2016, ADDICTION, V111, P685, DOI 10.1111/add.13214; Noordzij M, 2013, NEPHROL DIAL TRANSPL, V28, P2670, DOI 10.1093/ndt/gft355; Norcross JC, 2011, J CLIN PSYCHOL, V67, P143, DOI 10.1002/jclp.20758; Priest KC, 2019, J ADDICT MED, V13, P104, DOI 10.1097/ADM.0000000000000496; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Sledge WH, 2015, PSYCHOTHER PSYCHOSOM, V84, P208, DOI 10.1159/000379757; Trowbridge P, 2017, J SUBST ABUSE TREAT, V79, P1, DOI 10.1016/j.jsat.2017.05.007; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Vyas DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMms2004740; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Walley AY, 2012, J ADDICT MED, V6, P50, DOI 10.1097/ADM.0b013e318231de51; Wei J, 2015, J GEN INTERN MED, V30, P365, DOI 10.1007/s11606-014-2968-9	41	9	9	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2020	15	10							e0239761	10.1371/journal.pone.0239761	http://dx.doi.org/10.1371/journal.pone.0239761			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3WA	33035229	Green Published, gold			2023-01-03	WOS:000581817500010
J	Mathiasen, MK; Jorgensen, LB; From, M; Aadal, L; Pallesen, H				Mathiasen, Mia Krogager; Jorgensen, Lene Bastrup; From, Mette; Aadal, Lena; Pallesen, Hanne			The temporality of uncertainty in decision-making and treatment of severe brain injury	PLOS ONE			English	Article							REHABILITATION; PROGRAM	The aim of the study is to investigate how time and uncertainties of clinical action and decision-making plays out in the practical work of early neurorehabilitation in order to present new analytical ways to understand the underlying logics and dynamic social processes that take place during professional treatment of patients with severe acquired brain injury. Drawing on ethnographic fieldwork in a Danish neuro-intensive step-down unit (NISU) specialising in early neurorehabilitation, we found that negotiation of futures takes place in the modern ICU in the present by strategically building upon past experiences. We have argued that the clinical programme therefore cannot be understood only from a "here and now perspective", since the early neurorehabilitation practice is embedded in overlapping temporalities of the past, the present, and desired futures. The study discusses the underlying logics often hidden or unnoticed that impact clinical practice of early neurorehabilitation, in what we have termed a logic of clinical reenactment, a logic of future negotiation and a logic of paradox.	[Mathiasen, Mia Krogager; Jorgensen, Lene Bastrup; From, Mette] Silkeborg Reg Hosp, Ctr Elect Surg, RM, Silkeborg, Denmark; [Jorgensen, Lene Bastrup; Aadal, Lena; Pallesen, Hanne] Aarhus Univ, Ctr Elect Surg, Dept Clin Med, Aarhus, Denmark; [Aadal, Lena; Pallesen, Hanne] Aarhus Univ, Hammel Neurorehabil Ctr, RM, Aarhus, Denmark; [Aadal, Lena; Pallesen, Hanne] Aarhus Univ, Univ Res Clin, RM, Aarhus, Denmark	Aarhus University; Silkeborg Central Hospital; Aarhus University; Aarhus University; Aarhus University	Mathiasen, MK (corresponding author), Silkeborg Reg Hosp, Ctr Elect Surg, RM, Silkeborg, Denmark.	mia_mathiasen@hotmail.com	Jørgensen, Lene Bastrup/AAM-8993-2021; Pallesen, Hanne/W-1204-2017; aadal, lena/U-9172-2017	Jørgensen, Lene Bastrup/0000-0001-7873-6139; Krogager Mathiasen, Mia/0000-0003-2077-1286; Pallesen, Hanne/0000-0001-6010-2306; aadal, lena/0000-0001-7365-3916				Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Anderson B, 2010, PROG HUM GEOG, V34, P777, DOI 10.1177/0309132510362600; [Anonymous], 2015, QUALITATIVE RES INTE; Benner P., 1984, NOVICE EXPERT EXCELL; Clarke DJ, 2014, J CLIN NURS, V23, P1201, DOI 10.1111/jocn.12334; Coleman ER, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0686-6; Crary MA, 2005, ARCH PHYS MED REHAB, V86, P1516, DOI 10.1016/j.apmr.2004.11.049; Daugaard Morten, 2013, Ugeskr Laeger, V175, P3101; Daugbjerg M., 2017, ARCHAEOLOGY TIME TRA, P159; Daugbjerg M, 2014, INT J HERIT STUD, V20, P724, DOI 10.1080/13527258.2013.848820; Edwards I., 2008, CLIN REASONING HLTH, V3rd ed; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Frederiksberg Kommune, 2018, FRED KOMM TRAEP; Gell Alfred, 1998, ART AGENCY; GOLD RL, 1958, SOC FORCES, V36, P217, DOI 10.2307/2573808; Green J, 2005, QUALITATIVE METHODS; Hammersley M, 2000, ETHNOGRAPHY; Hastrup K., 2010, GRUNDBOG ANTROPOLOGI; Heck G., 2000, NEUROL REHABIL, V6, P125; Higginson IJ, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0177-2; Ingold T, 2000, PERCEPTION ENV ESSAY; Janssen H, 2014, DISABIL REHABIL, V36, P255, DOI 10.3109/09638288.2013.788218; Kemper B, 2002, ACT NEUR S, V79, P37; Khan F, 2016, J REHABIL MED, V48, P417, DOI 10.2340/16501977-2081; Kjeldsen SS, 2020, DISABIL REHABIL, V42, P528, DOI 10.1080/09638288.2018.1501772; Korupolu R, 2009, CONT CRIT CARE, V6, P1; Kristensen K, 2007, VEJLEDNING BRUG EARL; Mattingly C., 1994, CLIN REASONING FORMS; Miyazaki H, 2006, CULT ANTHROPOL, V21, P147, DOI 10.1525/can.2006.21.2.147; Morgan D., 1997, FOCUS GROUPS QUALITA, DOI [10.4135/9781412984287, DOI 10.4135/9781412984287]; Nielsen M, 2014, J ROY ANTHROPOL INST, V20, P166, DOI 10.1111/1467-9655.12099; Pallesen H, 2017, EUR J PHYSIOTHER, V19, P13, DOI 10.1080/21679169.2016.1229027; Parker Ann, 2013, Curr Phys Med Rehabil Rep, V1, P307; Pink Sarah, 2017, ANTHR FUTURES RES EM; Regionshospitalet Hammel Neurocenter, 2004, RANCH AM SCAL RLAS L; Regionshospitalet Hammel Neurocenter, 2004, GLASG OUTC SCAL EXT; Regionshospitalet Hammel Neurocenter, 2007, VEJLEDNING BRUG FIM; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Spradley J. P, 1980, PARTICIPANT OBSERVAT; Sundhedsstyrelsen [The National Board of Health Denmark], 2017, SERV GEN REH MENN ME; Sundhedsstyrelsen [The National Board of Health Denmark], 2011, HJERN 7ED TE5N; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Watts Laura, 2008, 21 CENTURY SOC J ACA, V3, P187, DOI [10.1080/17450140802062193, DOI 10.1080/17450140802062193]; Xyrichis A, SOCIAL SCI MED, V181	44	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2020	15	10							e0238506	10.1371/journal.pone.0238506	http://dx.doi.org/10.1371/journal.pone.0238506			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OS6KJ	33002026	Green Published, gold			2023-01-03	WOS:000590270000016
J	Chen, ZY; Xie, DF; Liu, ZY; Zhong, YQ; Zeng, JY; Chen, Z; Chen, XL				Chen, Zi-ying; Xie, Dan-feng; Liu, Zhi-yuan; Zhong, Yong-qi; Zeng, Jing-yan; Chen, Zheng; Chen, Xin-lin			Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; DRUG DISCOVERY; MILD STRESS; ANTIDEPRESSANT; MODELS; BEHAVIORS; MECHANISM; PI3K/AKT/FOXO3A; COMPLEMENTARY; PRESCRIPTION	Banxia Houpu decoction (BXHPD) has been used to treat depression in clinical practice for centuries. However, the pharmacological mechanisms of BXHPD still remain unclear. Network Pharmacology (NP) approach was used to explore the potential molecular mechanisms of BXHPD in treating depression. Potential active compounds of BXHPD were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform Database. STRING database was used to build a interaction network between the active compounds and target genes associated with depression. The topological features of nodes were visualized and calculated. Significant pathways and biological functions were identified using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses. A total of 44 active compounds were obtained from BXHPD, and 121 potential target genes were considered to be therapeutically relevant. Pathway analysis indicated that MAPK signaling pathway, ErbB signaling pathway, HIF-1 signaling pathway and PI3K-Akt pathway were significant pathways in depression. They were mainly involved in promoting nerve growth and nutrition and alleviating neuroinflammatory conditions. The result provided some potential ways for modern medicine in the treatment of depression.	[Chen, Zi-ying; Xie, Dan-feng; Liu, Zhi-yuan; Zhong, Yong-qi; Zeng, Jing-yan] Guangzhou Univ Chinese Med, Shenzhen Clin Coll, Guangzhou, Peoples R China; [Chen, Zheng] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou, Peoples R China; [Chen, Xin-lin] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China	Guangzhou University of Chinese Medicine; Sun Yat Sen University; Guangzhou University of Chinese Medicine	Chen, Z (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Stomatol, Guangzhou, Peoples R China.; Chen, XL (corresponding author), Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou, Peoples R China.	chenxlsums@126.com; chenzh68@mail.sysu.edu.cn	Chen, Xin-lin/AAZ-7287-2021	Chen, Xin-lin/0000-0002-2650-8051	Natural Science Foundation of Guangdong Province [2017A030313827]; National Training Program of Innovation and Entrepreneurship for Undergraduates of China [201910572016]; Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine [XH20190102]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Training Program of Innovation and Entrepreneurship for Undergraduates of China; Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine	This study was funded by the Natural Science Foundation of Guangdong Province (2017A030313827), the National Training Program of Innovation and Entrepreneurship for Undergraduates of China (201910572016) and the Science Program for Overseas Scholars (Xinhuo plan) of Guangzhou University of Chinese Medicine (XH20190102). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinrinde AS, 2019, NEUROTOXICOLOGY, V74, P252, DOI 10.1016/j.neuro.2019.07.005; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Butler L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/739716; Caraci F, 2018, PHARMACOL RES, V130, P374, DOI 10.1016/j.phrs.2018.02.007; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Carboni L, 2018, NEUROPSYCHOPHARMACOL, V43, P2134, DOI 10.1038/s41386-018-0117-6; Catalan R, 1998, BIOL PSYCHIAT, V44, P15, DOI 10.1016/S0006-3223(97)00539-8; Caviedes A, 2017, CURR PHARM DESIGN, V23, P3154, DOI 10.2174/1381612823666170111141915; Chen BY, 2018, ACTA PHARM SIN B, V8, P64, DOI 10.1016/j.apsb.2017.11.012; Cui RJ, 2015, CURR NEUROPHARMACOL, V13, P480, DOI 10.2174/1570159X1304150831123535; Dalmagro AP, 2019, CHEM-BIOL INTERACT, V314, DOI 10.1016/j.cbi.2019.108843; Delgado PL, 2000, J CLIN PSYCHIAT, V61, P7; Du HX, 2019, NEUROPSYCH DIS TREAT, V15, P2231, DOI 10.2147/NDT.S211288; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Duric V, 2010, NAT MED, V16, P1328, DOI 10.1038/nm.2219; Fang JS, 2017, J ETHNOPHARMACOL, V196, P281, DOI 10.1016/j.jep.2016.11.034; Feng DD, 2016, NEUROPSYCH DIS TREAT, V12, P2387, DOI 10.2147/NDT.S114560; Gadotti VM, 2019, ISCIENCE, V16, P12, DOI 10.1016/j.isci.2019.05.012; Gratacos M, 2009, AM J MED GENET B, V150B, P808, DOI 10.1002/ajmg.b.30902; Guo QY, 2015, REJUV RES, V18, P313, DOI 10.1089/rej.2014.1635; Hamaker M, 2018, J HAND SURG-AM, V43, DOI 10.1016/j.jhsa.2017.08.013; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ishisaka M, 2011, BIOL PHARM BULL, V34, P1481, DOI 10.1248/bpb.34.1481; Kalariya M, 2010, PHARM BIOL, V48, P1207, DOI 10.3109/13880201003586887; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kessler RC, 2001, AM J PSYCHIAT, V158, P289, DOI 10.1176/appi.ajp.158.2.289; Knaudt PR, 1999, J NERV MENT DIS, V187, P692, DOI 10.1097/00005053-199911000-00007; Kuang WH, 2018, KAOHSIUNG J MED SCI, V34, P370, DOI 10.1016/j.kjms.2018.02.004; Lee B, 2013, KOREAN J PHYSIOL PHA, V17, P393, DOI 10.4196/kjpp.2013.17.5.393; Li JM, 2003, LIFE SCI, V74, P55, DOI 10.1016/j.lfs.2003.06.030; Li J, 2017, BEHAV BRAIN RES, V320, P12, DOI 10.1016/j.bbr.2016.11.035; Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032; Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.1016/S1875-5364(13)60037-0, 10.3724/SP.J.1009.2013.00110]; Liao DH, 2018, DRUG DES DEV THER, V12, P231, DOI 10.2147/DDDT.S151511; Lonstein JS, 2014, J NEUROENDOCRINOL, V26, P649, DOI 10.1111/jne.12188; Luo L, 2015, EUR J PHARMACOL, V762, P357, DOI 10.1016/j.ejphar.2015.05.036; Ma ZQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/213739; Marunaka Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22020209; McGregor G, 2017, FASEB J, V31, P3449, DOI 10.1096/fj.201601293RR; Mottolese R, 2014, P NATL ACAD SCI USA, V111, P8637, DOI 10.1073/pnas.1319810111; Nemeroff CB, 2007, J PSYCHIATR RES, V41, P189, DOI 10.1016/j.jpsychires.2006.05.008; Niu XF, 2017, INFLAMMATION, V40, P1111, DOI 10.1007/s10753-017-0553-1; Niu XF, 2015, CHEM-BIOL INTERACT, V239, P34, DOI 10.1016/j.cbi.2015.06.026; Pacher P, 2008, AM J PHYSIOL-RENAL, V295, pF1303, DOI 10.1152/ajprenal.90343.2008; Patel NJ, 2010, EUR J PHARMACOL, V633, P1, DOI 10.1016/j.ejphar.2010.01.012; Polter A, 2009, BIOL PSYCHIAT, V65, P150, DOI 10.1016/j.biopsych.2008.08.005; Qiao J, 2019, EXP THER MED, V18, P580, DOI 10.3892/etm.2019.7633; Radin DP, 2017, BIOMED PHARMACOTHER, V87, P636, DOI 10.1016/j.biopha.2017.01.024; Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/nchembio.1199, 10.1038/NCHEMBIO.1199]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shariq AS, 2019, REV NEUROSCIENCE, V30, P1, DOI 10.1515/revneuro-2018-0027; Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5; Tian RH, 2019, BRAIN RES, V1725, DOI 10.1016/j.brainres.2019.146472; Tibbitts J, 2016, MABS-AUSTIN, V8, P229, DOI 10.1080/19420862.2015.1115937; United Nations Convention to Combat Desertification (UNCCD), 2014, UNCCD NEWS, V6, P13; van West Dirk, 1999, Neuro Endocrinol Lett, V20, P11; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Wang JQ, 2019, MOL NEUROBIOL, V56, P6197, DOI 10.1007/s12035-019-1524-3; Wang Sheng-Min, 2018, Chonnam Med J, V54, P101, DOI 10.4068/cmj.2018.54.2.101; Wang T, 2018, BEHAV BRAIN RES, V336, P236, DOI 10.1016/j.bbr.2017.09.012; Wang Y, 2015, CLIN EXP PHARMACOL P, V42, P465, DOI 10.1111/1440-1681.12378; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Wu ZT, 2018, NEUROREPORT, V29, P1256, DOI 10.1097/WNR.0000000000001096; Xiao L, 2018, ELIFE, V7, DOI 10.7554/eLife.33892; Xiong Z, 2011, BIOL PHARM BULL, V34, P253, DOI 10.1248/bpb.34.253; Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964; Yamanishi Y, 2010, BIOINFORMATICS, V26, pi246, DOI 10.1093/bioinformatics/btq176; Yang LF, 2015, CURR NEUROPHARMACOL, V13, P494, DOI 10.2174/1570159X1304150831150507; Yang XJ, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/2357653; Ye YL, 2019, BEHAV BRAIN RES, V362, P199, DOI 10.1016/j.bbr.2019.01.008; Yeung WF, 2014, J PSYCHIATR RES, V57, P165, DOI 10.1016/j.jpsychires.2014.05.016; Yi LT, 2009, ARCH PHARM RES, V32, P1417, DOI 10.1007/s12272-009-2011-6; Zeng BQ, 2016, J MOL NEUROSCI, V59, P567, DOI 10.1007/s12031-016-0779-7; Zhang RY, 2018, NEUROCHEM RES, V43, P2111, DOI 10.1007/s11064-018-2635-3; Zhao DH, 2016, MAR DRUGS, V14, DOI 10.3390/md14070123; Zhao FL, 2015, J ETHNOPHARMACOL, V168, P1, DOI 10.1016/j.jep.2015.03.035; Zhou LY, 2018, NEUROPSYCHOPHARMACOL, V43, P1343, DOI 10.1038/npp.2017.278	77	2	2	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2020	15	9							e0239843	10.1371/journal.pone.0239843	http://dx.doi.org/10.1371/journal.pone.0239843			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YT	32997725	Green Published, gold			2023-01-03	WOS:000577103100012
J	Williams-Yuen, J; Minaker, G; Buxton, J; Gadermann, A; Palepu, A				Williams-Yuen, Jordan; Minaker, Gordon; Buxton, Jane; Gadermann, Anne; Palepu, Anita			'You're not just a medical professional': Exploring paramedic experiences of overdose response within Vancouver's downtown eastside	PLOS ONE			English	Article							OPIOID USE; POLICE OFFICERS; REFLEXIVITY; EMPATHY; BURNOUT	Background Overdose response has become an increasingly relevant component of paramedic practice, particularly in light of increased opioid overdose globally. Previous studies have noted gaps in our understanding regarding the unique challenges which paramedics face during this form of pre-hospital emergency care. The aim of this study is to explore and describe the ways in which paramedics experience overdose response, specifically within a community markedly affected by the overdose crisis. Methods Ten participants were recruited from a single ambulance station located in an urban center in Western Canada. Two rounds of semi-structured individual interviews were conducted, and data saturation was found to have been reached. Verbatim transcripts were produced and subject to two rounds of descriptive and pattern coding. A second researcher reviewed all of the codes, with disagreements being handled by discussion until agreement was obtained. Themes were identified, along with a Core Category which seeks to describe the underlying dynamics of overdose response represented in our data. The concept of a Core Category was borrowed from Grounded Theory methodology. Findings Five major themes were identified:Connecting with patients' lived experiences; Occupying roles as clinicians and patient advocates; Navigating on-scene hazards; Difficulties with transitions of care; and Emotional burden of the overdose crisis. A core category was identified asOne's capacity to help. Conclusions This research contributes to existing literature on overdose response by specifically examining paramedic experiences during this form of emergency care. While paramedics felt highly confident in providing clinical care, their capacity to address underlying causes of drug use was understood as much more limited. Participants found ways to address this lack of control, along with feelings of frustration, by trying to understand patient perspectives and adopting empathetic attitudes.	[Williams-Yuen, Jordan; Minaker, Gordon; Palepu, Anita] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Buxton, Jane; Gadermann, Anne] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Buxton, Jane] BC Ctr Dis Control, Vancouver, BC, Canada; [Gadermann, Anne; Palepu, Anita] Univ British Columbia, Fac Med, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Williams-Yuen, J (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.	Jordan.williams-yuen@alumni.ubc.ca		Williams-Yuen, Jordan/0000-0002-4060-3119; Palepu, Anita/0000-0002-7881-4800	Mach-Gaensslen Foundation	Mach-Gaensslen Foundation	This project was supported by a grant from the Mach-Gaensslen Foundation to JWY. The funder had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. There was no specific grant number associated with the support. http://mach-gaensslen.ca/.	Alho H, 2020, INT J DRUG POLICY, V76, DOI 10.1016/j.drugpo.2019.102616; Banta-Green CJ, 2013, J URBAN HEALTH, V90, P1102, DOI 10.1007/s11524-013-9814-y; Bastian B., 2019, MORTALITY TRENDS US; BC Center for Disease Control, 2017, PUBL HLTH EM BC; BC Center for Disease Control, 2019, OV RESP IND; BC Emergency Health Services, 2018, BCEHS HDB; BC Emergency Health Services, 2018, PAR CRED LEV CAR; BC Emergency Health Services, 2016, NEWS STOR; Belzak L, 2018, HEALTH PROMOT CHRON, V38, P224, DOI 10.24095/hpcdp.38.6.02; Berger R, 2015, QUAL RES, V15, P219, DOI 10.1177/1468794112468475; Buetow S, 2019, INT J NURS STUD, V89, P8, DOI 10.1016/j.ijnurstu.2018.09.013; Castillo-Montoya M, 2016, QUAL REP, V21, P811; Davis CS, 2014, ACAD EMERG MED, V21, P1173, DOI 10.1111/acem.12485; Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9; DeJonckheere M, 2019, FAM MED COMMUNITY HE, V7, DOI 10.1136/fmch-2018-000057; Dodgson JE, 2019, J HUM LACT, V35, P220, DOI 10.1177/0890334419830990; Elliott L, 2019, ADDICTION, V114, P1379, DOI 10.1111/add.14608; Fincham JE, 2018, INT J PHARM PRACT, V26, P91, DOI 10.1111/ijpp.12446; Fleming T, 2019, INT J DRUG POLICY, V71, P169, DOI 10.1016/j.drugpo.2018.12.012; Glaser BG, 2005, GROUNDED THEORY REV, V4, P1; Glidewell R, 2000, THESIS; Gough B, 2017, J POSIT PSYCHOL, V12, P311, DOI 10.1080/17439760.2016.1262615; Government of Canada: Public Health Infobase, 2019, OP REL HARMS CAN; Heavey SC, 2018, J COMMUN HEALTH, V43, P304, DOI 10.1007/s10900-017-0422-8; Huang T, 2019, DOWNTOWN EASTSIDE LO; Lamothe M, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-15; Linden IA, 2013, J URBAN HEALTH, V90, P559, DOI 10.1007/s11524-012-9771-x; Miles M. B., 2014, QUALITATIVE DATA ANA; Palinkas LA, 2019, AM J PUBLIC HEALTH, V109, P26, DOI 10.2105/AJPH.2018.304833; Petrie K, 2018, SOC PSYCH PSYCH EPID, V53, P897, DOI 10.1007/s00127-018-1539-5; Pike E, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107620; Poeran J, 2020, BRIT J ANAESTH, V124, P17, DOI 10.1016/j.bja.2019.09.033; Rando J, 2015, AM J EMERG MED, V33, P1201, DOI 10.1016/j.ajem.2015.05.022; Read BL, 2018, INT J QUAL METH, V17, DOI 10.1177/1609406918783452; Rees N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205813; Saldaua, 2016, CODING MANUAL QUALIT; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Saunders E, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.107555; Schafer SK, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02704-y; Spearn B, 2019, JOURNEY HOPE UPDATE; Statistics Canada, 2020, POP EST Q; Statistics Canada, 2019, CHANG LIF EXP SEL CA; The National Association of State EMS Officials (NASEMSO), 2017, NAT MOD EMS CLIN GUI; Thirioux B, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00763; UNODC, 2019, WORLD DRUG REPORT 20; Vancouver Coastal Health, 2018, CHIEF MED OFF HLTH R; Williams B, 2017, PSYCHOL RES BEHAV MA, V10, P329, DOI 10.2147/PRBM.S145810; World Health Organization (WHO), 2014, COMM MAN OP OV	48	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2020	15	9							e0239559	10.1371/journal.pone.0239559	http://dx.doi.org/10.1371/journal.pone.0239559			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY3AW	32986736	Green Published, gold			2023-01-03	WOS:000576267900070
J	Meric-Bernstam, F; Larkin, J; Tabernero, J; Bonini, C				Meric-Bernstam, Funda; Larkin, James; Tabernero, Josep; Bonini, Chiara			Enhancing anti-tumour efficacy with immunotherapy combinations	LANCET			English	Review							NIVOLUMAB PLUS IPILIMUMAB; T-CELLS; PHASE-I; TUMOR MICROENVIRONMENT; DONOR LYMPHOCYTES; ADOPTIVE TRANSFER; DOUBLE-BLIND; PATIENTS PTS; CHEMOTHERAPY; MONOTHERAPY	Several tumour types are responsive to immunotherapy, as shown by regulatory approvals for immune checkpoint inhibitors. However, many patients either do not respond or do not have durable clinical benefit. Thus, there is great interest in developing predictors of response to immunotherapy and rational combination therapies that can enhance efficacy by overcoming primary and acquired resistance. In this Review, we provide an assessment of immunotherapy response biomarkers that can identify patients who will benefit from monotherapy rather than from combinations. We review the rationale for combination therapy and different strategies, including combinations with chemotherapy, targeted therapy, radiation therapy, intratumoural therapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptors and other novel T-cell receptor-based therapies. There are many combination partners in development; therefore, a programmatic approach is needed to develop a framework for biomarker-driven combination therapy selection.	[Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Larkin, James] Royal Marsden NHS FoundationTrust, Canc Serv, London, England; [Tabernero, Josep] Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain; [Bonini, Chiara] Univ Vita Salute San Raffaele, Expt Hematol Unit, Milan, Italy; [Bonini, Chiara] Ist Sci San Raffaele, Expt Hematol Unit, IRCCS Osped, Milan, Italy	University of Texas System; UTMD Anderson Cancer Center; Vall d'Hebron Institut d'Oncologia (VHIO); Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Meric-Bernstam, F (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.	fmeric@mdanderson.org		Larkin, James/0000-0001-5569-9523				Amin A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0420-0; Ascierto PA, 2019, NAT MED, V25, P941, DOI 10.1038/s41591-019-0448-9; Baas P, 2020, J THORAC ONCOL, V15, pE42; Bentebibel SE, 2019, CANCER DISCOV, V9, P711, DOI 10.1158/2159-8290.CD-18-1495; Bernabei L, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119514; Besser MJ, 2013, CLIN CANCER RES, V19, P4792, DOI 10.1158/1078-0432.CCR-13-0380; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Casucci M, 2013, BLOOD, V122, P3461, DOI 10.1182/blood-2013-04-493361; Chang CH, 2017, CANCER RES, V77, P5384, DOI 10.1158/0008-5472.CAN-16-3431; Chen LM, 2018, CANCER DISCOV, V8, P1156, DOI 10.1158/2159-8290.CD-17-1033; Chen N, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273302; Chesney J, 2018, J CLIN ONCOL, V36, P1658, DOI 10.1200/JCO.2017.73.7379; Chong EA, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119502; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Ciceri F, 2009, LANCET ONCOL, V10, P489, DOI 10.1016/S1470-2045(09)70074-9; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Cortes J, 2020, J CLIN ONCOL, V38; Davis AA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0768-9; Dreno B, 2019, EUR SOC MED ONC C 20; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0; Foote JB, 2017, CANCER IMMUNOL RES, V5, P468, DOI 10.1158/2326-6066.CIR-16-0284; Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2; Gadgeel SM, 2019, J CLIN ONCOL, V37; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gide TN, 2019, CANCER CELL, V35, P238, DOI 10.1016/j.ccell.2019.01.003; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Goswami S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc4220; Grenier JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00610; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gutzmer R, 2020, LANCET, V395, P1835, DOI 10.1016/S0140-6736(20)30934-X; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hodi FS, 2018, LANCET ONCOL, V19, P1480, DOI 10.1016/S1470-2045(18)30700-9; Holmgaard RB, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0356-4; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Kansagra AJ, 2019, BONE MARROW TRANSPL, V54, P1868, DOI 10.1038/s41409-019-0451-2; Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133; Kobold S, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00285; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; Labrijn AF, 2019, NAT REV DRUG DISCOV, V18, P585, DOI 10.1038/s41573-019-0028-1; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li S, 2017, CLIN CANCER RES, V23, P6982, DOI 10.1158/1078-0432.CCR-17-0867; Lim WA, 2017, CELL, V168, P724, DOI 10.1016/j.cell.2017.01.016; Lisberg AE, 2020, J CLIN ONCOL, V38; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Makker V, 2019, LANCET ONCOL, V20, P711, DOI 10.1016/S1470-2045(19)30020-8; Martinez M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00128; Maude SL, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.103; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Menon H, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0718-6; Merck, 2014, KEYTR PEMBR INJ INTR; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Muller P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4925; Mumm JB, 2011, CANCER CELL, V20, P781, DOI 10.1016/j.ccr.2011.11.003; Naing A, 2019, LANCET ONCOL, V20, P1340, DOI 10.1016/S1470-2045(19)30490-5; Noviello M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08871-1; Osipov A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2578; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Paulson KG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06300-3; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Provasi E, 2012, NAT MED, V18, P807, DOI 10.1038/nm.2700; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Roberts NJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008982; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Rotte A, 2018, ANN ONCOL, V29, P71, DOI 10.1093/annonc/mdx686; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rupp LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00462-8; Sanmamed MF, 2017, ANN ONCOL, V28, P1988, DOI 10.1093/annonc/mdx190; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schmidt EV, 2019, SEMIN IMMUNOPATHOL, V41, P21, DOI 10.1007/s00281-018-0714-9; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Sharma M, 2020, PHASE 1 IN HUMAN OPE; Shukla SA, 2018, CELL, V173, P624, DOI 10.1016/j.cell.2018.03.026; Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Suarez ER, 2016, ONCOTARGET, V7, P34341, DOI 10.18632/oncotarget.9114; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Sweis RF, 2016, CANCER IMMUNOL RES, V4, P563, DOI 10.1158/2326-6066.CIR-15-0274; Tapia C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000665; Theelen WSME, 2019, JAMA ONCOL, V5, P1276, DOI 10.1001/jamaoncol.2019.1478; Tian G, 2014, CELL BIOCHEM BIOPHYS, V70, P37, DOI 10.1007/s12013-014-9903-x; Toffalori C, 2019, NAT MED, V25, P603, DOI 10.1038/s41591-019-0400-z; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Turtle CJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8621; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Welsh JW, 2019, CANCER IMMUNOL RES, V7, P1903, DOI 10.1158/2326-6066.CIR-18-0793; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wrzesinski C, 2010, J IMMUNOTHER, V33, P1, DOI 10.1097/CJI.0b013e3181b88ffc; Yau T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4012; Yoon DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020340	112	99	100	33	95	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 13	2021	397	10278					1010	1022		10.1016/S0140-6736(20)32598-8	http://dx.doi.org/10.1016/S0140-6736(20)32598-8		MAR 2021	13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV2NT	33285141				2023-01-03	WOS:000627814200029
J	Baruch, EN; Youngster, I; Ben-Betzalel, G; Ortenberg, R; Lahat, A; Katz, L; Adler, K; Dick-Necula, D; Raskin, S; Bloch, N; Rotin, D; Anafi, L; Avivi, C; Melnichenko, J; Steinberg-Silman, Y; Mamtani, R; Harati, H; Asher, N; Shapira-Frommer, R; Brosh-Nissimov, T; Eshet, Y; Ben-Simon, S; Ziv, O; Khan, MAW; Amit, M; Ajami, NJ; Barshack, I; Schachter, J; Wargo, JA; Koren, O; Markel, G; Boursi, B				Baruch, Erez N.; Youngster, Ilan; Ben-Betzalel, Guy; Ortenberg, Rona; Lahat, Adi; Katz, Lior; Adler, Katerina; Dick-Necula, Daniela; Raskin, Stephen; Bloch, Naamah; Rotin, Daniil; Anafi, Liat; Avivi, Camila; Melnichenko, Jenny; Steinberg-Silman, Yael; Mamtani, Ronac; Harati, Hagit; Asher, Nethanel; Shapira-Frommer, Ronnie; Brosh-Nissimov, Tal; Eshet, Yael; Ben-Simon, Shira; Ziv, Oren; Khan, Md Abdul Wadud; Amit, Moran; Ajami, Nadim J.; Barshack, Iris; Schachter, Jacob; Wargo, Jennifer A.; Koren, Omry; Markel, Gal; Boursi, Ben			Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients	SCIENCE			English	Article								The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials. In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma. We observed clinical responses in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. These early findings have implications for modulating the gut microbiota in cancer treatment.	[Baruch, Erez N.; Ben-Betzalel, Guy; Ortenberg, Rona; Melnichenko, Jenny; Steinberg-Silman, Yael; Harati, Hagit; Asher, Nethanel; Shapira-Frommer, Ronnie; Schachter, Jacob; Markel, Gal] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, Tel Hashomer, Israel; [Baruch, Erez N.; Markel, Gal] Tel Aviv Univ, Sackler Fac Med, Dept Clin Immunol & Microbiol, Tel Aviv, Israel; [Youngster, Ilan] Shamir Assaf Harofeh Med Ctr, Pediat Div & Microbiome Res Ctr, Beer Yaagov, Israel; [Youngster, Ilan; Raskin, Stephen; Eshet, Yael; Barshack, Iris; Schachter, Jacob; Boursi, Ben] Tel Aviv Univ, Sackler Fac Med, Sch Med, Tel Aviv, Israel; [Lahat, Adi] Sheba Med Ctr, Dept Gastroenterol, Tel Hashomer, Israel; [Katz, Lior] Hadassah Med Ctr, Dept Gastroenterol, Jerusalem, Israel; [Adler, Katerina] Bar Ilan Univ, Dept Math, Ramat Gan, Israel; [Dick-Necula, Daniela; Rotin, Daniil; Anafi, Liat; Avivi, Camila; Eshet, Yael; Barshack, Iris] Sheba Med Ctr, Inst Pathol, Tel Hashomer, Israel; [Raskin, Stephen] Sheba Med Ctr, Radiol Inst, Tel Hashomer, Israel; [Bloch, Naamah; Ben-Simon, Shira; Ziv, Oren; Koren, Omry] Bar Ilan Univ, Azrieli Fac Med, Safed, Israel; [Mamtani, Ronac] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA; [Brosh-Nissimov, Tal] Assuta Ashdod Univ Hosp, Infect Dis Unit, Ashdod, Israel; [Eshet, Yael] Sheba Med Ctr, Dept Nucl Med, Tel Hashomer, Israel; [Baruch, Erez N.; Khan, Md Abdul Wadud; Ajami, Nadim J.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Program Innovat Microbiome & Translat Res, Dept Genom Med, Houston, TX 77030 USA; [Amit, Moran] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Markel, Gal] Sheba Med Ctr, Talpiot Med Leadership Program, Tel Hashomer, Israel; [Boursi, Ben] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Boursi, Ben] Sheba Med Ctr, Dept Oncol, Tel Hashomer, Israel; [Baruch, Erez N.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Bar Ilan University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Bar Ilan University; University of Pennsylvania; Chaim Sheba Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center; University of Pennsylvania; Pennsylvania Medicine; Chaim Sheba Medical Center; University of Texas System; University of Texas Health Science Center Houston	Baruch, EN; Markel, G (corresponding author), Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol, Tel Hashomer, Israel.; Baruch, EN; Markel, G (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Clin Immunol & Microbiol, Tel Aviv, Israel.; Baruch, EN (corresponding author), Univ Texas MD Anderson Canc Ctr, Program Innovat Microbiome & Translat Res, Dept Genom Med, Houston, TX 77030 USA.; Markel, G (corresponding author), Sheba Med Ctr, Talpiot Med Leadership Program, Tel Hashomer, Israel.; Baruch, EN (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA.	erezbaruch@mail.tau.ac.il; gal.markel@sheba.heafth.gov.il	Eshet, Yael/AAO-1168-2021; Brosh-Nissimov, Tal/J-3378-2019; Youngster, Ilan/J-5047-2014	Eshet, Yael/0000-0002-8339-5823; Brosh-Nissimov, Tal/0000-0001-7154-2032; Adler, Katerina/0000-0001-5769-8284; Baruch, Erez Nissim/0000-0001-6001-6598; Youngster, Ilan/0000-0001-5233-1213; Raskin, Stephen/0000-0002-3549-0594	Ella Lemelbaum Institute for Immuno-Oncology internal funds; Allen Berg Fund for Excellence in Immuno-Oncology Research, Young Researcher Scholarship; Henry and Susan Samueli Foundation Grant for Integrative Immuno-Oncology	Ella Lemelbaum Institute for Immuno-Oncology internal funds; Allen Berg Fund for Excellence in Immuno-Oncology Research, Young Researcher Scholarship; Henry and Susan Samueli Foundation Grant for Integrative Immuno-Oncology	This trial was funded only by the Ella Lemelbaum Institute for Immuno-Oncology internal funds. E.N.B. was supported by the Allen Berg Fund for Excellence in Immuno-Oncology Research, Young Researcher Scholarship. G. M. was supported by the Henry and Susan Samueli Foundation Grant for Integrative Immuno-Oncology.	Abril-Rodriguez G, 2020, NAT CANCER, V1, P46, DOI 10.1038/s43018-019-0003-0; Ascierto PA, 2019, JAMA ONCOL, V5, P187, DOI 10.1001/jamaoncol.2018.4514; Bakken JS, 2011, CLIN GASTROENTEROL H, V9, P1044, DOI 10.1016/j.cgh.2011.08.014; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Benjamini Y., 1995, J R STAT SOC, V57, P289; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Borcoman E, 2019, ANN ONCOL, V30, P385, DOI 10.1093/annonc/mdz003; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Costello SP, 2019, JAMA-J AM MED ASSOC, V321, P156, DOI 10.1001/jama.2018.20046; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; FAITH DP, 1992, BIOL CONSERV, V61, P1, DOI 10.1016/0006-3207(92)91201-3; Fernandes AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067019; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Gershenwald JE, 2018, ANN SURG ONCOL, V25, P2105, DOI 10.1245/s10434-018-6513-7; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Guedan S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96976; Hasan NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097699; Iqbal U, 2018, EUR J GASTROEN HEPAT, V30, P730, DOI [10.1097/MEG.0000000000001147, 10.1097/meg.0000000000001147]; Ji SK, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01208; Law Charity W, 2016, F1000Res, V5, DOI 10.12688/f1000research.9005.3; Liebermeister W, 2014, P NATL ACAD SCI USA, V111, P8488, DOI 10.1073/pnas.1314810111; Lin SC, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12967; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Mandal Siddhartha, 2015, Microbial Ecology in Health and Disease, V26, P27663, DOI 10.3402/mehd.v26.27663; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McQuade JL, 2019, LANCET ONCOL, V20, pE77, DOI 10.1016/S1470-2045(18)30952-5; Mognol GP, 2017, P NATL ACAD SCI USA, V114, pE2776, DOI 10.1073/pnas.1620498114; National Cancer Institute, 2017, COMM TECHN CRIT ADV; Neuman T, 2016, J THORAC ONCOL, V11, P1863, DOI 10.1016/j.jtho.2016.08.146; Ni J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6888; Ottesen A, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0894-1; Paramsothy S, 2019, GASTROENTEROLOGY, V156, P1440, DOI 10.1053/j.gastro.2018.12.001; Parra ER, 2016, CLIN CANCER RES, V22, P6278, DOI 10.1158/1078-0432.CCR-15-2443; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Ponnusamy D, 2016, P NATL ACAD SCI USA, V113, P722, DOI 10.1073/pnas.1523817113; Ribas A, 2018, LANCET ONCOL, V19, pE219, DOI 10.1016/S1470-2045(18)30202-X; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Schaer DA, 2018, CELL REP, V22, P2978, DOI 10.1016/j.celrep.2018.02.053; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Smillie CS, 2018, CELL HOST MICROBE, V23, P229, DOI 10.1016/j.chom.2018.01.003; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1086862; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Trinchieri G, 2020, CANCER RES, V80, P24; Trujillo JA, 2018, CANCER IMMUNOL RES, V6, P990, DOI 10.1158/2326-6066.CIR-18-0277; Verma R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat6975; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Warner AB, 2020, J CLIN ONCOL, V38, P1655, DOI 10.1200/JCO.19.01464; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wlodarska M, 2015, CELL HOST MICROBE, V17, P577, DOI 10.1016/j.chom.2015.04.008; Woroniecka K, 2018, CLIN CANCER RES, V24, P4175, DOI 10.1158/1078-0432.CCR-17-1846; Youngster I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0680-9; Zhang ZD, 2016, IMMUNITY, V44, P330, DOI 10.1016/j.immuni.2016.01.004; Zmora N, 2018, CELL, V174, P1388, DOI 10.1016/j.cell.2018.08.041	64	348	357	59	228	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	2021	371	6529			SI		602	+		10.1126/science.abb5920	http://dx.doi.org/10.1126/science.abb5920			71	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD7TF	33303685				2023-01-03	WOS:000615715300048
J	Vediappan, RS; Bennett, C; Cooksley, C; Finnie, J; Trochsler, M; Quarrington, RD; Jones, CF; Bassiouni, A; Moratti, S; Psaltis, AJ; Maddern, G; Vreugde, S; Wormald, PJ				Vediappan, Rajan Sundaresan; Bennett, Catherine; Cooksley, Clare; Finnie, John; Trochsler, Markus; Quarrington, Ryan D.; Jones, Claire F.; Bassiouni, Ahmed; Moratti, Stephen; Psaltis, Alkis J.; Maddern, Guy; Vreugde, Sarah; Wormald, P. J.			Prevention of adhesions post-abdominal surgery: Assessing the safety and efficacy of Chitogel with Deferiprone in a rat model	PLOS ONE			English	Article							CHITOSAN-DEXTRAN GEL; ENDOSCOPIC SINUS SURGERY; PERITONEAL ADHESIONS; GALLIUM-PROTOPORPHYRIN; UNITED-STATES; SHEEP MODEL; OBSTRUCTION; HEMOSTASIS; HYDROGEL; BARRIERS	Introduction Adhesions are often considered to be an inevitable consequence of abdominal and pelvic surgery, jeopardizing the medium and long-term success of these procedures. Numerous strategies have been tested to reduce adhesion formation, however, to date, no surgical or medical therapeutic approaches have been successful in its prevention. This study demonstrates the safety and efficacy of Chitogel with Deferiprone and/or antibacterial Gallium Protoporphyrin in different concentrations in preventing adhesion formation after abdominal surgery. Materials and methods 112 adult (8-10 week old) male Wistar albino rats were subjected to midline laparotomy and caecal abrasion, with 48 rats having an additional enterotomy and suturing. Kaolin (0.005g/ml) was applied to further accelerate adhesion formation. The abrasion model rats were randomized to receive saline, Chitogel, or Chitogel plus Deferiprone (5, 10 or 20 mM), together with Gallium Protoporphyrin (250 mu g/mL). The abrasion with enterotomy rats were randomised to receive saline, Chitogel or Chitogel with Deferiprone (1 or 5 mM). At day 21, rats were euthanised, and adhesions graded macroscopically and microscopically; the tensile strength of the repaired caecum was determined by an investigator blinded to the treatment groups. Results Chitogel with Deferiprone 5 mM significantly reduced adhesion formation (p<0.01) when pathologically assessed in a rat abrasion model. Chitogel with Deferiprone 5 mM and 1 mM also significantly reduced adhesions (p<0.05) after abrasion with enterotomy. Def-Chitogel 1mM treatment did not weaken the enterotomy site with treated sites having significantly better tensile strength compared to control saline treated enterotomy rats. Conclusions Chitogel with Deferiprone 1 mM constitutes an effective preventative anti-adhesion barrier after abdominal surgery in a rat model. Moreover, this therapeutic combination of agents is safe and does not weaken the healing of the sutured enterotomy site.	[Vediappan, Rajan Sundaresan; Bennett, Catherine; Cooksley, Clare; Bassiouni, Ahmed; Psaltis, Alkis J.; Vreugde, Sarah; Wormald, P. J.] Univ Adelaide, Dept Surg Otolaryngol Head & Neck Surg, Adelaide, SA, Australia; [Finnie, John] Univ Adelaide, SA Pathol & Adelaide Med Sch, Adelaide, SA, Australia; [Trochsler, Markus; Maddern, Guy] Univ Adelaide, Dept Surg, Adelaide, SA, Australia; [Quarrington, Ryan D.; Jones, Claire F.] Univ Adelaide, Adelaide Med Sch, Adelaide Spinal Res Grp, Ctr Orthopaed & Trauma Res, Adelaide, SA, Australia; [Jones, Claire F.] Univ Adelaide, Sch Mech Engn, Adelaide, SA, Australia; [Moratti, Stephen] Univ Otago, Dept Chem, Dunedin, New Zealand	University of Adelaide; SA Pathology; University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide; University of Otago	Wormald, PJ (corresponding author), Univ Adelaide, Dept Surg Otolaryngol Head & Neck Surg, Adelaide, SA, Australia.	peterj.wormald@adelaide.edu.au	Quarrington, Ryan/R-6132-2019; Jones, Claire Frances/C-4942-2012	Quarrington, Ryan/0000-0002-0633-2482; Jones, Claire Frances/0000-0002-0995-1182; Bassiouni, Ahmed/0000-0002-5545-0194; Vediappan, Rajan Sundaresan/0000-0001-5370-8262	NHMRC [APP1171756]; Hospital Research Foundation; University of Adelaide under Australian Government Research Training Program Scholarship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Hospital Research Foundation; University of Adelaide under Australian Government Research Training Program Scholarship	This project is supported by an NHMRC Development grant APP1171756 awarded to SM, SV, GM and MT. RSV was supported by The Hospital Research Foundation and The University of Adelaide under Australian Government Research Training Program Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S., 2016, ACHIEV LIFE SCI, V10, P27, DOI DOI 10.1016/J.ALS.2016.04.001; [Anonymous], 2020, BMC PEDIATR, V20, P1, DOI DOI 10.1016/J.CLAE.2020.04.011; Athanasiadis T, 2008, LARYNGOSCOPE, V118, P1088, DOI 10.1097/MLG.0b013e31816ba576; Cabral JD, 2015, J BIOMED MATER RES A, V103, P2611, DOI 10.1002/jbm.a.35395; Cabral JD, 2014, J MATER SCI-MATER M, V25, P2743, DOI 10.1007/s10856-014-5292-3; Carney MJ, 2017, AM J SURG, V214, P287, DOI 10.1016/j.amjsurg.2017.01.001; Davey AK, 2007, J MINIM INVAS GYN, V14, P15, DOI 10.1016/j.jmig.2006.07.013; diZerega GSe, 2000, SPRINGERLINK PERITON; diZeregal GS, 2001, HUM REPROD UPDATE, V7, P547, DOI 10.1093/humupd/7.6.547; Giles D, 2019, SHACKELFORDS SURG AL, P1005; Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125; Ha T, 2018, INT FORUM ALLERGY RH, V8, P435, DOI 10.1002/alr.22057; Kennedy R, 1996, SURGERY, V120, P866, DOI 10.1016/S0039-6060(96)80096-1; Lauder CIW, 2012, J SURG RES, V176, P448, DOI 10.1016/j.jss.2011.10.029; Lauder CIW, 2011, J SURG RES, V171, P877, DOI 10.1016/j.jss.2010.06.028; Mais V, 2014, WORLD J GASTROENTERO, V20, P4917, DOI 10.3748/wjg.v20.i17.4917; Correa-Rovelo JM, 2015, CIR CIR, V83, P345, DOI 10.1016/j.circir.2015.05.024; Menzies D, 2001, ANN ROY COLL SURG, V83, P40; Munireddy S, 2010, SURG CLIN N AM, V90, P1227, DOI 10.1016/j.suc.2010.08.002; Okabayashi K, 2014, SURG TODAY, V44, P405, DOI 10.1007/s00595-013-0591-8; Ong SY, 2008, BIOMATERIALS, V29, P4323, DOI 10.1016/j.biomaterials.2008.07.034; Ooi ML, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00917; Paramasivan S, 2014, AM J RHINOL ALLERGY, V28, P361, DOI 10.2500/ajra.2014.28.4069; Ramezanpour M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38902-2; Ray NF, 1998, J AM COLL SURGEONS, V186, P1, DOI 10.1016/S1072-7515(97)00127-0; Richter K, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00481-17; Richter K, 2016, INT FORUM ALLERGY RH, V6, P737, DOI 10.1002/alr.21735; Sikirica V, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-13; ten Broek RPG, 2014, LANCET, V383, P48, DOI 10.1016/S0140-6736(13)61687-6; ten Broek RPG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5588; Ha TN, 2013, INT FORUM ALLERGY RH, V3, P573, DOI 10.1002/alr.21136; Trochsler M, 2014, LANCET, V383, P8, DOI 10.1016/S0140-6736(13)62002-4; Vakalopoulos KA, 2013, J SURG RES, V180, P290, DOI 10.1016/j.jss.2012.12.043; Valentine R, 2010, AM J RHINOL ALLERGY, V24, P70, DOI 10.2500/ajra.2010.24.3422; Valentine R, 2009, AM J RHINOL ALLERGY, V23, P71, DOI 10.2500/ajra.2009.23.3266; Vediappan RS, 2020, FRONT SURG, V7, DOI 10.3389/fsurg.2020.00012; Vediappan RS, 2020, J CLIN NEUROSCI, V72, P378, DOI 10.1016/j.jocn.2019.12.042; Venables W.N., 2002, MODERN APPL STAT S	38	2	2	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0244503	10.1371/journal.pone.0244503	http://dx.doi.org/10.1371/journal.pone.0244503			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4VV	33444337	Green Published, gold			2023-01-03	WOS:000609988100042
J	Juan-Giner, A; Kimathi, D; Grantz, KH; Hamaluba, M; Kazooba, P; Njuguna, P; Fall, G; Dia, M; Bob, NS; Monath, TP; Barrett, AD; Hombach, J; Mulogo, EM; Ampeire, I; Karanja, HK; Nyehangane, D; Mwanga-Amumpaire, J; Cummings, DAT; Bejon, P; Warimwe, GM; Grais, RF				Juan-Giner, Aitana; Kimathi, Derick; Grantz, Kyra H.; Hamaluba, Mainga; Kazooba, Patrick; Njuguna, Patricia; Fall, Gamou; Dia, Moussa; Bob, Ndeye S.; Monath, Thomas P.; Barrett, Alan D.; Hombach, Joachim; Mulogo, Edgar M.; Ampeire, Immaculate; Karanja, Henry K.; Nyehangane, Dan; Mwanga-Amumpaire, Juliet; Cummings, Derek A. T.; Bejon, Philip; Warimwe, George M.; Grais, Rebecca F.			Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial	LANCET			English	Article								Background Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared with standard dose of four WHO-prequalified yellow fever vaccines produced from three substrains. Methods We did this randomised, double-blind, non-inferiority trial at research centres in Mbarara, Uganda, and Kilifi, Kenya. Eligible participants were aged 18-59 years, had no contraindications for vaccination, were not pregnant or lactating, had no history of yellow fever vaccination or infection, and did not require yellow fever vaccination for travel. Eligible participants were recruited from communities and randomly assigned to one of eight groups, corresponding to the four vaccines at standard or fractional dose. The vaccine was administered subcutaneously by nurses who were not masked to treatment, but participants and other study personnel were masked to vaccine allocation. The primary outcome was proportion of participants with seroconversion 28 days after vaccination. Seroconversion was defined as post-vaccination neutralising antibody titres at least 4 times pre-vaccination measurement measured by 50% plaque reduction neutralisation test (PRNT 50). We defined non-inferiority as less than 10% decrease in seroconversion in fractional compared with standard dose groups 28 days after vaccination. The primary outcome was measured in the per-protocol population, and safety analyses included all vaccinated participants. This trial is registered with ClinicalTrials.gov, NCT02991495. Findings Between Nov 6, 2017, and Feb 21, 2018, 1029 participants were assessed for inclusion. 69 people were ineligible, and 960 participants were enrolled and randomly assigned to vaccine manufacturer and dose (120 to Bio-Manguinhos-Fiocruz standard dose, 120 to Bio-Manguinhos-Fiocruz fractional dose, 120 to Chumakov Institute of Poliomyelitis and Viral Encephalitides standard dose, 120 to Chumakov Institute of Poliomyelitis and Viral Encephalitides fractional dose, 120 to Institut Pasteur Dakar standard dose, 120 to Institut Pasteur Dakar fractional dose, 120 to Sanofi Pasteur standard dose, and 120 to Sanofi Pasteur fractional dose). 49 participants had detectable PRNT 50 at baseline and 11 had missing PRNT 50 results at baseline or 28 days. 900 were included in the per-protocol analysis. 959 participants were included in the safety analysis. The absolute difference in seroconversion between fractional and standard doses by vaccine was 1.71% (95% CI -2.60 to 5.28) for Bio-Manguinhos-Fiocruz, -0.90% (-4.24 to 3.13) for Chumakov Institute of Poliomyelitis and Viral Encephalitides, 1.82% (-2.75 to 5.39) for Institut Pasteur Dakar, and 0.0% (-3.32 to 3.29) for Sanofi Pasteur. Fractional doses from all four vaccines met the non-inferiority criterion. The most common treatment-related adverse events were headache (22.2%), fatigue (13.7%), myalgia (13.3%) and self-reported fever (9.0%). There were no study-vaccine related serious adverse events. Interpretation Fractional doses of all WHO-prequalified yellow fever vaccines were non-inferior to the standard dose in inducing seroconversion 28 days after vaccination, with no major safety concerns. These results support the use of fractional dosage in the general adult population for outbreak response in situations of vaccine shortage. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.	[Juan-Giner, Aitana; Grais, Rebecca F.] Epicentre, Paris, France; [Kimathi, Derick; Hamaluba, Mainga; Njuguna, Patricia; Karanja, Henry K.; Bejon, Philip; Warimwe, George M.] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya; [Kimathi, Derick; Hamaluba, Mainga; Bejon, Philip; Warimwe, George M.] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England; [Grantz, Kyra H.; Cummings, Derek A. T.] Univ Florida, Dept Biol, Gainesville, FL USA; [Grantz, Kyra H.; Cummings, Derek A. T.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA; [Grantz, Kyra H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Kazooba, Patrick; Nyehangane, Dan; Mwanga-Amumpaire, Juliet] Epicentre, Mbarara Res Ctr, Mbarara, Uganda; [Fall, Gamou; Dia, Moussa; Bob, Ndeye S.] Inst Pasteur, Dakar, Senegal; [Monath, Thomas P.] Crozet BioPharma LLC, Devens, MA USA; [Barrett, Alan D.] Univ Texas Med Branch, Sealy Inst Vaccines Sci, Galveston, TX 77555 USA; [Barrett, Alan D.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Hombach, Joachim] WHO, Immunizat Vaccines & Biol, Geneva, Switzerland; [Mulogo, Edgar M.] Mbarara Univ Sci & Technol, Dept Community Hlth, Mbarara, Uganda; [Ampeire, Immaculate] Minist Hlth, Expanded Program Immunizat, Kampala, Uganda	Kenya Medical Research Institute; University of Oxford; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Dakar; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; World Health Organization; Mbarara University of Science & Technology	Grais, RF (corresponding author), Epicentre, F-75019 Paris, France.	rebecca.grais@epicentre.msf.org		/0000-0001-9585-3820; Hombach, Joachim/0000-0002-3271-6033; Warimwe, George/0000-0002-4911-6333; Hamaluba, Mainga/0000-0002-0266-1414	Medecins Sans Frontieres Foundation; Wellcome Trust [092654]; UK Department for International Development	Medecins Sans Frontieres Foundation; Wellcome Trust(Wellcome Trust); UK Department for International Development	The study was funded by Medecins Sans Frontieres Foundation, Wellcome Trust (grant no. 092654), and the UK Department for International Development. Vaccines were donated in kind.	[Anonymous], 2019, Weekly Epidemiological Record, V94, P365; Campi-Azevedo AC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-391; Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430; DEMADRID AT, 1969, B WORLD HEALTH ORGAN, V40, P113; Ferguson Morag, 2010, Vaccine, V28, P8236, DOI 10.1016/j.vaccine.2010.10.070; Food and Drug Administration, 2007, TOX GRAD SCAL HLTH V; GEO, 2022, US; Hombach J, 2005, VACCINE, V23, P5205, DOI [10.1016/j.vaccine.2005.07.002, 10.1016/j.vaccine.2004.11.040]; Julander JG, 2011, VACCINE, V29, P6008, DOI 10.1016/j.vaccine.2011.06.034; Kimathi Derick, 2019, Wellcome Open Res, V4, P182, DOI 10.12688/wellcomeopenres.15579.1; LOPES OD, 1988, J BIOL STAND, V16, P77; Martins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041; Martins RM, 2013, HUM VACC IMMUNOTHER, V9, P879, DOI 10.4161/hv.22982; Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0; Monath TP, 2016, LANCET, V387, P1599, DOI 10.1016/S0140-6736(16)30195-7; Muyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007; Roukens AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001993; Roukens AHE, 2018, ANN INTERN MED, V169, P761, DOI 10.7326/M18-1529; Vannice K, 2018, NEW ENGL J MED, V379, P603, DOI 10.1056/NEJMp1803433; WHO, 2008, DET INV SER ADV EV F; WHO, 2017, GLOB STRAT EL YELL F; WHO, 2016, SAGE M; World Health Organization, 2013, WEEKLY EPIDEMIOLOGIC, V88, P269; World Health Organization, 2016, FRACT DOS YELL FEV V; World Health Organization, REC ASS QUAL SAF EFF; World Hlth Org, 2017, VACCINE, V35, P5751, DOI 10.1016/j.vaccine.2017.06.087; Wu JT, 2016, LANCET, V388, P2904, DOI 10.1016/S0140-6736(16)31838-4	29	14	14	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	2021	397	10269					119	127						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR5IA	33422245	Green Published, hybrid			2023-01-03	WOS:000607269000029
J	Jeong, S; Kim, S; Choi, Y; Jung, HN; Lee, K; Park, MH				Jeong, Soohyun; Kim, Sujin; Choi, Youngjoo; Jung, Han Na; Lee, Kangwon; Park, Min Hee			Development of Glycerol-Rose Bengal-Polidocanol (GRP) foam for enhanced sclerosis of a cyst for cystic diseases	PLOS ONE			English	Article							SODIUM TETRADECYL SULFATE; BUBBLE-SIZE; E-CADHERIN; SCLEROTHERAPY; MANAGEMENT; STABILITY; COALESCENCE; COLLAGEN; THERAPY; ETHANOL	Polycystic kidney disease (PKD) is a common genetic disorder that results in a proliferating and enlarging cyst and ultimately leads to loss of kidney function. Because an enlarged cyst is a primary factor for limited kidney function, the large cyst is surgically removed by laparoscopic deroofing or sclerosant. This a relatively nascent treatment method entails complications and sometimes fail due to the cyst fluid refilling and infection. This study proposes using a more stable and effective polidocanol foam with glycerol and Rose Bengal (GRP form) to prevent cyst regeneration and irritation, which is caused by the required body movement during the treatment. Specifically, the foam retention time and viscosity were increased by adding glycerol up to 10% (w/v). The GRP form inhibited cellular proliferation and disrupted cellular junctions, e-cadherin, and cyst formation, demonstrated by the LDH, Live and Dead, and re-plating culture assays. The GRP foam was shown to be a safe and effective treatment as a commercial grade polidocanol foam form by an in vivo study in which subcutaneously injected mice injected with commercial 3% polidocanol, and the GRP foam showed no difference in inflammation. Thus, this study provides an advanced polidocanol form by adding glycerol and Rose-Bengal to help existing sclerotherapy.	[Jeong, Soohyun; Kim, Sujin; Choi, Youngjoo; Jung, Han Na] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Program Nanosci & Technol, Seoul, South Korea; [Lee, Kangwon] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Program Dept Appl Bioengn, Seoul, South Korea; [Park, Min Hee] Korea Inst Ceram Engn & Technol, Ctr Convergence Bioceram Mat, Cheo Ngju, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea Institute of Ceramic Engineering & Technology	Lee, K (corresponding author), Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Program Dept Appl Bioengn, Seoul, South Korea.; Park, MH (corresponding author), Korea Inst Ceram Engn & Technol, Ctr Convergence Bioceram Mat, Cheo Ngju, South Korea.	kangwonlee@snu.ac.kr; minheepark@kicet.re.kr	Park, Min Hee/H-8173-2017	Park, Min Hee/0000-0002-6311-3040; Choi, Youngjoo/0000-0003-4246-4009	National Research Foundation of Korea (NRF) - Korea government (MSIT) [2018R1C1B6002333, 2017M3A7B4049848, 2016M3A9B4919711]	National Research Foundation of Korea (NRF) - Korea government (MSIT)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2018R1C1B6002333, No. 2017M3A7B4049848 and No. 2016M3A9B4919711). The NRF, and MSIT is not involved in any way in the preparation of this manuscript or the decision this submit it, and couldn't have influenced its outcome.	Alarcon EI, 2017, ACS OMEGA, V2, P6646, DOI 10.1021/acsomega.7b00675; Amescua G, 2017, CORNEA, V36, P1141, DOI 10.1097/ICO.0000000000001265; Amsterdam E, 2008, ACTA MATER, V56, P609, DOI 10.1016/j.actamat.2007.10.034; Arboleda A, 2014, AM J OPHTHALMOL, V158, P64, DOI 10.1016/j.ajo.2014.04.007; Bai TP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33992-w; Bernhardt WM, 2007, AM J PATHOL, V170, P830, DOI 10.2353/ajpath.2007.060455; BHARGAVA DK, 1992, AM J GASTROENTEROL, V87, P182; Bonomi M, 2019, NAT METHODS, V16, P670, DOI 10.1038/s41592-019-0506-8; Bottaro E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46262-0; Brady AP, 1944, J AM CHEM SOC, V66, P1348, DOI 10.1021/ja01236a045; Capra J, 2017, LAB INVEST, V97, P1453, DOI 10.1038/labinvest.2017.89; Casteleijn NF, 2014, NEPHROL DIAL TRANSPL, V29, P142, DOI 10.1093/ndt/gfu073; Cherfan D, 2013, INVEST OPHTH VIS SCI, V54, P3426, DOI 10.1167/iovs.12-11509; Cho YS, 2002, CAN J CHEM ENG, V80, P299, DOI 10.1002/cjce.5450800216; Cho YS, 2002, INT J MINER PROCESS, V64, P69, DOI 10.1016/S0301-7516(01)00064-3; Coleridge-Smith PD, 2009, J VASC SURG, V49, P804, DOI 10.1016/j.jvs.2009.01.003; Costa-Pinto A, 2016, TESTING NATURAL BIOM; Dell'Atti L, 2015, UROL ANNALS, V7, P310, DOI 10.4103/0974-7796.152026; Elia Natalie, 2009, Curr Protoc Cell Biol, VChapter 4, DOI 10.1002/0471143030.cb0422s43; Ellison CA, 2018, REGUL TOXICOL PHARM, V99, P61, DOI 10.1016/j.yrtph.2018.09.008; FRIBERG SE, 1989, J COLLOID INTERF SCI, V127, P573, DOI 10.1016/0021-9797(89)90062-3; Gonzalez-Rubio S, 2009, CHEM RES TOXICOL, V22, P1984, DOI 10.1021/tx900327t; Hilgenfeldt S, 2001, PHYS REV LETT, V86, P4704, DOI 10.1103/PhysRevLett.86.4704; Iliuta IA, 2019, KIDNEY MED, V1, P366, DOI 10.1016/j.xkme.2019.07.015; Inouye M, 2014, ANGEW CHEM INT EDIT, V53, P14392, DOI 10.1002/anie.201408193; Kowalczuk PB, 2013, IND ENG CHEM RES, V52, P11752, DOI 10.1021/ie401263k; Lantinga MA, 2017, NEPHROL DIAL TRANSPL, V32, P144, DOI 10.1093/ndt/gfv452; Liu B, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-109; Martinez JD, 2018, CORNEA, V37, pe46, DOI 10.1097/ICO.0000000000001701; Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0; McAree B, 2012, EUR J VASC ENDOVASC, V43, P721, DOI 10.1016/j.ejvs.2012.02.026; MONSALVE A, 1984, J COLLOID INTERF SCI, V97, P327, DOI 10.1016/0021-9797(84)90303-5; Murshid NS, 2020, J INTERPERS VIOLENCE, V35, P854, DOI 10.1177/0886260517690873; Nastasa V, 2015, INT J PHARMACEUT, V478, P588, DOI 10.1016/j.ijpharm.2014.11.056; Ohta S, 1997, UROL INT, V58, P145, DOI 10.1159/000282971; Peterson JD, 2011, PHLEBOLOGY, V26, P232, DOI 10.1258/phleb.2010.010028; Roitbak T, 2004, MOL BIOL CELL, V15, P1334, DOI 10.1091/mbc.E03-05-0296; Shao Q, 2013, J X-RAY SCI TECHNOL, V21, P419, DOI 10.3233/XST-130393; Stucker M, 2010, DERMATOL SURG, V36, P983, DOI 10.1111/j.1524-4725.2009.01406.x; Szyszka D, 2018, MINERALS-BASEL, V8, DOI 10.3390/min8100431; Tessari L, 2001, DERMATOL SURG, V27, P58, DOI 10.1111/j.1524-4725.2001.00192.x; van Adelsberg J, 2000, NEPHROL DIAL TRANSPL, V15, P1, DOI 10.1093/ndt/15.1.1; Wang AJ, 2016, ENDOSC ULTRASOUND, V5, P218, DOI 10.4103/2303-9027.187840; Wollmann JC, 2010, PHLEBOLOGIE, V39, P208; Yonguc T, 2015, INT UROL NEPHROL, V47, P603, DOI 10.1007/s11255-015-0953-9; Zarei-Ghanavati Mehran, 2017, J Ophthalmic Vis Res, V12, P241, DOI 10.4103/jovr.jovr_70_17	46	1	1	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2021	16	1							e0244635	10.1371/journal.pone.0244635	http://dx.doi.org/10.1371/journal.pone.0244635			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR2KR	33400697	Green Published, gold			2023-01-03	WOS:000607070700009
J	Sayadi, JJ; Sayadi, L; Satteson, E; Chopan, M				Sayadi, Jamasb Joshua; Sayadi, Lohrasb; Satteson, Ellen; Chopan, Mustafa			Nerve injury and repair in a ketogenic milieu: A systematic review of traumatic injuries to the spinal cord and peripheral nervous tissue	PLOS ONE			English	Review							DIETARY RESTRICTION; KETONE-BODIES; BETA-HYDROXYBUTYRATE; OXIDATIVE STRESS; METABOLISM; HEALTH; REGENERATION; ISCHEMIA; DISEASE; DEPRIVATION	Dietary interventions such as intermittent fasting and the ketogenic diet have demonstrated neuroprotective effects in various models of neurological insult. However, there has been a lack of evaluation of these interventions from a surgical perspective despite their potential to augment reparative processes that occur following nerve injury. Thus, we sought to analyze the effects of these dietary regimens on nerve regeneration and repair by critical appraisal of the literature. Following PRISMA guidelines, a systematic review was performed to identify studies published between 1950 and 2020 that examined the impact of either the ketogenic diet or intermittent fasting on traumatic injuries to the spinal cord or peripheral nerves. Study characteristics and outcomes were analyzed for each included article. A total of 1,890 articles were reviewed, of which 11 studies met inclusion criteria. Each of these articles was then assessed based on a variety of qualitative parameters, including type of injury, diet composition, timing, duration, and outcome. In total, seven articles examined the ketogenic diet, while four examined intermittent fasting. Only three studies examined peripheral nerves. Neuroprotective effects manifested as either improved histological or functional benefits in most of the included studies. Overall, we conclude that intermittent fasting and the ketogenic diet may promote neuroprotection and facilitate the regeneration and repair of nerve fibers following injury; however, lack of consistency between the studies in terms of animal models, diet compositions, and timing of dietary interventions preclude synthesis of their outcomes as a whole.	[Sayadi, Jamasb Joshua] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Sayadi, Lohrasb] Univ Calif Irvine, Dept Plast Surg, Irvine, CA USA; [Satteson, Ellen; Chopan, Mustafa] Univ Florida Hlth, Dept Surg, Div Plast & Reconstruct Surg, Gainesville, FL 32611 USA	Stanford University; University of California System; University of California Irvine; State University System of Florida; University of Florida	Chopan, M (corresponding author), Univ Florida Hlth, Dept Surg, Div Plast & Reconstruct Surg, Gainesville, FL 32611 USA.	mustafa.chopan@surgery.ufl.edu		Sayadi, Jamasb/0000-0001-7014-3187				Al-Zaid NS, 2007, ACTA CARDIOL, V62, P381, DOI 10.2143/AC.62.4.2022282; Albanese A, 2019, OBES SURG, V29, P292, DOI 10.1007/s11695-018-3523-2; [Anonymous], 2019, QUALITY MANAGEMENT, V11, pS1007; [Anonymous], 2018, VOX             0919; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Anton SD, 2018, OBESITY, V26, P254, DOI 10.1002/oby.22065; Arumugam TV, 2010, ANN NEUROL, V67, P41, DOI 10.1002/ana.21798; Camberos-Luna L, 2016, NEUROCHEM RES, V41, P600, DOI 10.1007/s11064-015-1700-4; Carter JD, 2006, OSTEOPOROSIS INT, V17, P1398, DOI 10.1007/s00198-006-0134-x; Cheesborough JE, 2015, SEMIN PLAST SURG, V29, P62, DOI 10.1055/s-0035-1544166; Cheng AW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2238; Choi IY, 2016, CELL REP, V15, P2136, DOI 10.1016/j.celrep.2016.05.009; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; de Cabo R, 2019, NEW ENGL J MED, V381, P2541, DOI 10.1056/NEJMra1905136; Demirel A, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04273-7; Di Francesco A, 2018, SCIENCE, V362, P770, DOI 10.1126/science.aau2095; Fann DYW, 2017, EXP GERONTOL, V89, P93, DOI 10.1016/j.exger.2017.01.014; Fitzgerald KC, 2018, MULT SCLER RELAT DIS, V23, P33, DOI 10.1016/j.msard.2018.05.002; Fu SP, 2015, J NEUROENDOCRINOL, V27, P212, DOI 10.1111/jne.12256; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Godar RJ, 2015, AUTOPHAGY, V11, P1537, DOI 10.1080/15548627.2015.1063768; Gross EC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040811; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; Hanna BG, 2001, DEV MED CHILD NEUROL, V43, P847, DOI 10.1017/S0012162201221549; Huebner EA, 2009, RESULTS PROBL CELL D, V48, P339, DOI 10.1007/400_2009_19; Janis JE, 2016, PLAST RECONSTR SURG, V138, p9S, DOI 10.1097/PRS.0000000000002773; Jeong JH, 2016, EXP THER MED, V12, P3021, DOI 10.3892/etm.2016.3852; Jeong MA, 2011, J NEUROTRAUM, V28, P479, DOI 10.1089/neu.2010.1609; Kirsty Usher Boyd RVW, 2018, PLASTIC SURG, V1, P315, DOI [10.1111/tbj.13008, DOI 10.1111/TBJ.13008]; Kong GG, 2017, J NEUROTRAUM, V34, P2645, DOI 10.1089/neu.2017.5192; Kossoff Eric H, 2018, Epilepsia Open, V3, P175, DOI 10.1002/epi4.12225; Lee S, 2013, EXP GERONTOL, V48, P1085, DOI 10.1016/j.exger.2012.12.008; Leonetti F, 2015, OBES SURG, V25, P64, DOI 10.1007/s11695-014-1348-1; Li J, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900535; Liskiewicz A, 2016, NUTR NEUROSCI, V19, P116, DOI 10.1179/1476830514Y.0000000163; Lu Y, 2018, NEUROSCI LETT, V683, P13, DOI 10.1016/j.neulet.2018.06.016; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Mackinnon SE, 2018, J RECONSTR MICROSURG, V34, P672, DOI 10.1055/s-0038-1639353; Madorsky I, 2009, NEUROBIOL DIS, V34, P146, DOI 10.1016/j.nbd.2009.01.002; Marosi K, 2016, J NEUROCHEM, V139, P769, DOI 10.1111/jnc.13868; Masood W., 2022, STATPEARLS; Maswood N, 2004, P NATL ACAD SCI USA, V101, P18171, DOI 10.1073/pnas.0405831102; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Mattson MP, 2018, NAT REV NEUROSCI, V19, P81, DOI 10.1038/nrn.2017.156; Mattson MP, 2017, AGEING RES REV, V39, P46, DOI 10.1016/j.arr.2016.10.005; Mattson MP, 2014, P NATL ACAD SCI USA, V111, P16647, DOI 10.1073/pnas.1413965111; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; Mauro CR, 2016, J VASC SURG, V63, P500, DOI 10.1016/j.jvs.2014.07.004; Mayr KA, 2020, ENEURO, V7, DOI 10.1523/ENEURO.0178-20.2020; Most J, 2018, AM J PHYSIOL-ENDOC M, V314, pE396, DOI 10.1152/ajpendo.00261.2017; Muller H, 2001, SCAND J RHEUMATOL, V30, P1, DOI 10.1080/030097401750065256; NAGAYAMA M, 1990, JPEN-PARENTER ENTER, V14, P245, DOI 10.1177/0148607190014003245; Nencioni A, 2018, NAT REV CANCER, V18, P707, DOI 10.1038/s41568-018-0061-0; Ok JH, 2018, ANTICANCER RES, V38, P6519, DOI 10.21873/anticanres.13017; Peres RC, 2013, TOXICOL MECH METHOD, V23, P144, DOI 10.3109/15376516.2012.735276; Pilone V, 2018, SURG OBES RELAT DIS, V14, P1013, DOI 10.1016/j.soard.2018.03.018; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Plunet WT, 2010, ANN NY ACAD SCI, V1198, pE1, DOI 10.1111/j.1749-6632.2010.05564.x; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Ruskin DN, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00033; S3-Leitlinie, 2017, SOMNOLOGIE, V20, pS97 S180; Sajoux I, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102368; Santosa KB, 2020, CLIN PLAST SURG, V47, P311, DOI 10.1016/j.cps.2020.01.004; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Schiavo L, 2018, OBES SURG, V28, P2215, DOI 10.1007/s11695-018-3145-8; Seo JH, 2007, EPILEPSIA, V48, P801, DOI 10.1111/j.1528-1167.2007.01025.x; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Shukla SK, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-18; Snorek M, 2012, PHYSIOL RES, V61, P567, DOI 10.33549/physiolres.932338; Stekovic S, 2019, CELL METAB, V30, P462, DOI 10.1016/j.cmet.2019.07.016; Streijger F, 2014, J NEUROSCI RES, V92, P870, DOI 10.1002/jnr.23372; Streijger F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078765; Streijger F, 2011, J NEUROTRAUM, V28, P1051, DOI 10.1089/neu.2010.1715; Swindell WR, 2012, AGEING RES REV, V11, P254, DOI 10.1016/j.arr.2011.12.006; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Tan BT, 2020, NEURAL REGEN RES, V15, P1912, DOI 10.4103/1673-5374.280327; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Wan RQ, 2003, J NUTR, V133, P1921, DOI 10.1093/jn/133.6.1921; Wang XM, 2017, NEUROSCIENCE, V366, P36, DOI 10.1016/j.neuroscience.2017.09.056; Xu K, 2017, ADV EXP MED BIOL, V977, P205, DOI 10.1007/978-3-319-55231-6_28; Xu XL, 2019, EXP ANIM TOKYO, V68, P371, DOI 10.1538/expanim.18-0084; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y	85	3	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2021	16	1							e0244244	10.1371/journal.pone.0244244	http://dx.doi.org/10.1371/journal.pone.0244244			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR2KB	33395427	gold, Green Published			2023-01-03	WOS:000607069100022
J	Barb, AW				Barb, Adam W.			Fc gamma receptor compositional heterogeneity: Considerations for immunotherapy development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NATURAL-KILLER-CELLS; ANTI-CD20 MONOCLONAL-ANTIBODY; NK CELLS; IGG FC; CLINICAL-EFFICACY; HIGH-AFFINITY; GLYCOSYLATION; BINDING; POLYMORPHISMS; THERAPY	The antibody-binding crystallizable fragment (Fc) gamma receptors (Fc gamma Rs) are expressed by leukocytes and activate or suppress a cellular response once engaged with an antibody-coated target. Therapeutic mAbs that require Fc gamma R binding for therapeutic efficacy are now frontline treatments for multiple diseases. However, substantially fewer development efforts are focused on the Fc gamma Rs, despite accounting for half of the antibody-receptor complex. The recent success of engineered cell-based immunotherapies now provides a mechanism to introduce modified Fc gamma Rs into the clinic. Fc gamma Rs are highly heterogeneous because of multiple functionally distinct alleles for many genes, the presence of membrane-tethered and soluble forms, and a high degree of post-translational modification, notably asparagine-linked glycans. One significant factor limiting Fc gamma R improvement is the fundamental lack of knowledge regarding endogenous receptor forms present in the human body. This review describes the composition of Fc gamma Rs isolated from primary human leukocytes, summarizes recent efforts to engineer Fc gamma Rs, and concludes with a description of potential Fc gamma R features to enrich for enhanced function. Further understanding Fc gamma R biology could accelerate the development of new clinical therapies targeting immunerelated disease.	[Barb, Adam W.] Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Barb, AW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	abarb@uga.edu		Barb, Adam/0000-0003-3290-8649	National Institutes of Health (National Institute of General Medical Sciences) [R01 GM115489]; National Institutes of Health (National Institute of Allergy and Infectious Diseases) [R21 AI142122]	National Institutes of Health (National Institute of General Medical Sciences)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health (National Institute of Allergy and Infectious Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health under Award No. R01 GM115489 (National Institute of General Medical Sciences) and R21 AI142122 (National Institute of Allergy and Infectious Diseases) (to A. W. B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Battella S, 2016, J LEUKOCYTE BIOL, V99, P87, DOI 10.1189/jlb.5VMR0415-141R; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bobrowicz P, 2004, GLYCOBIOLOGY, V14, P757, DOI 10.1093/glycob/cwh104; Bonifant CL, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.11; Bruhns P, 2009, BLOOD, V113, P3716, DOI 10.1182/blood-2008-09-179754; Cambay F, 2020, MOL IMMUNOL, V121, P144, DOI 10.1016/j.molimm.2020.03.010; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chenoweth AM, 2020, IMMUNOL CELL BIOL, V98, P287, DOI 10.1111/imcb.12326; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; deHaas M, 1996, J IMMUNOL, V156, P2948; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Falconer DJ, 2018, ACS CHEM BIOL, V13, P2179, DOI 10.1021/acschembio.8b00342; Giovannone N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05770-9; GONG JH, 1994, LEUKEMIA, V8, P652; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hamilton SR, 2006, SCIENCE, V313, P1441, DOI 10.1126/science.1130256; Hayes JM, 2017, MOL CELL PROTEOMICS, V16, P1770, DOI 10.1074/mcp.M117.066944; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; Ho M, 2006, P NATL ACAD SCI USA, V103, P9637, DOI 10.1073/pnas.0603653103; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Jing YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121788; Jochems C, 2016, ONCOTARGET, V7, P86359, DOI 10.18632/oncotarget.13411; Kapur R, 2014, BLOOD, V123, P471, DOI 10.1182/blood-2013-09-527978; Klingemann H, 2013, TRANSFUSION, V53, P412, DOI 10.1111/j.1537-2995.2012.03764.x; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Li W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07966-3; Li XR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007097; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Mace EM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00545; Marklin M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0606-0; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; Moremen KW, 2012, NAT REV MOL CELL BIO, V13, P448, DOI 10.1038/nrm3383; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Niederfellner G, 2011, BLOOD, V118, P358, DOI 10.1182/blood-2010-09-305847; Nimmerjahn F, 2011, CURR TOP MICROBIOL, V350, P105, DOI 10.1007/82_2010_86; Patel KR, 2019, MOL CELL PROTEOMICS, V18, P2178, DOI 10.1074/mcp.RA119.001607; Patel KR, 2020, GLYCOBIOLOGY, V30, P427, DOI 10.1093/glycob/cwaa002; Patel KR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00223; Patel KR, 2018, J BIOL CHEM, V293, P3477, DOI 10.1074/jbc.RA117.001207; Rezvani K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00578; Roberts JT, 2020, MOL CELL PROTEOMICS, V19, P362, DOI 10.1074/mcp.RA119.001733; Roberts JT, 2018, J BIOL CHEM, V293, P19899, DOI 10.1074/jbc.RA118.005273; Romain G, 2014, BLOOD, V124, P3241, DOI 10.1182/blood-2014-04-569061; Saggu G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07506-1; Salles G, 2012, BLOOD, V119, P5126, DOI 10.1182/blood-2012-01-404368; Saunders KO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01296; Sehn LH, 2016, LANCET ONCOL, V17, P1081, DOI 10.1016/S1470-2045(16)30097-3; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Snyder KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02873; Srpan K, 2018, J CELL BIOL, V217, P3267, DOI 10.1083/jcb.201712085; Subedi GP, 2018, J BIOL CHEM, V293, P16842, DOI 10.1074/jbc.RA118.004998; Subedi GP, 2017, BIOCHEMISTRY-US, V56, P3174, DOI 10.1021/acs.biochem.7b00392; Subedi GP, 2016, MABS-AUSTIN, V8, P1512, DOI 10.1080/19420862.2016.1218586; Tanaka H, 2016, CLIN CANCER RES, V22, P4405, DOI 10.1158/1078-0432.CCR-15-2714; Umekawa M, 2010, J BIOL CHEM, V285, P511, DOI 10.1074/jbc.M109.059832; Vervecken W, 2004, APPL ENVIRON MICROB, V70, P2639, DOI 10.1128/AEM.70.5.2639-2646.2004; Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128; Wang XH, 2018, PROTEIN CELL, V9, P63, DOI 10.1007/s13238-017-0473-8; Wang Y, 2013, BBA-MOL CELL RES, V1833, P680, DOI 10.1016/j.bbamcr.2012.11.027; Washburn N, 2019, MOL CELL PROTEOMICS, V18, P534, DOI 10.1074/mcp.RA118.001142; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Wiernik A, 2013, CLIN CANCER RES, V19, P3844, DOI 10.1158/1078-0432.CCR-13-0505; Wojcik I, 2020, ANAL CHEM, V92, P13172, DOI 10.1021/acs.analchem.0c02342; Yagi H., 2018, SCI REP-UK, V8; Yamaguchi Y, 2020, GLYCOBIOLOGY, V30, P214, DOI 10.1093/glycob/cwz068; Yeap WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep34310; Zeck A, 2011, J PROTEOME RES, V10, P3031, DOI 10.1021/pr1012653; Zhang C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00533; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021; Zhu H, 2020, BLOOD, V135, P399, DOI 10.1182/blood.2019000621	72	7	7	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN-JUN	2021	296								100057	10.1074/jbc.REV120.013168	http://dx.doi.org/10.1074/jbc.REV120.013168			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TI5TQ	33172893	Green Published, gold			2023-01-03	WOS:000672866400039
J	Kirpalani, H; Bell, EF; Hintz, SR; Tan, S; Schmidt, B; Chaudhary, AS; Johnson, KJ; Crawford, MM; Newman, JE; Vohr, BR; Carlo, WA; D'Angio, CT; Kennedy, KA; Ohls, RK; Poindexter, BB; Schibler, K; Whyte, RK; Widness, JA; Zupancic, JAF; Wyckoff, MH; Truog, WE; Walsh, MC; Chock, VY; Laptook, AR; Sokol, GM; Yoder, BA; Patel, RM; Cotten, CM; Carmen, MF; Devaskar, U; Chawla, S; Seabrook, R; Higgins, RD; Das, A				Kirpalani, Haresh; Bell, Edward F.; Hintz, Susan R.; Tan, Sylvia; Schmidt, Barbara; Chaudhary, Aasma S.; Johnson, Karen J.; Crawford, Margaret M.; Newman, Jamie E.; Vohr, Betty R.; Carlo, Waldemar A.; D'Angio, Carl T.; Kennedy, Kathleen A.; Ohls, Robin K.; Poindexter, Brenda B.; Schibler, Kurt; Whyte, Robin K.; Widness, John A.; Zupancic, John A. F.; Wyckoff, Myra H.; Truog, William E.; Walsh, Michele C.; Chock, Valerie Y.; Laptook, Abbot R.; Sokol, Gregory M.; Yoder, Bradley A.; Patel, Ravi M.; Cotten, C. Michael; Carmen, Melissa F.; Devaskar, Uday; Chawla, Sanjay; Seabrook, Ruth; Higgins, Rosemary D.; Das, Abhik		Eunice Kennedy Shriver NICHD Neona	Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-CELL TRANSFUSIONS; BIRTH-WEIGHT INFANTS; NECROTIZING ENTEROCOLITIS; CLINICAL-OUTCOMES; PREMATURE-INFANTS; RANDOMIZED-TRIAL; ASSOCIATION; STANDARD; ANEMIA; FRESH	BACKGROUND Limited data suggest that higher hemoglobin thresholds for red-cell transfusions may reduce the risk of cognitive delay among extremely-low-birth-weight infants with anemia. METHODS We performed an open, multicenter trial in which infants with a birth weight of 1000 g or less and a gestational age between 22 weeks 0 days and 28 weeks 6 days were randomly assigned within 48 hours after delivery to receive red-cell transfusions at higher or lower hemoglobin thresholds until 36 weeks of postmenstrual age or discharge, whichever occurred first. The primary outcome was a composite of death or neurodevelopmental impairment (cognitive delay, cerebral palsy, or hearing or vision loss) at 22 to 26 months of age, corrected for prematurity. RESULTS A total of 1824 infants (mean birth weight, 756 g; mean gestational age, 25.9 weeks) underwent randomization. There was a between-group difference of 1.9 g per deciliter (19 g per liter) in the pretransfusion mean hemoglobin levels throughout the treatment period. Primary outcome data were available for 1692 infants (92.8%). Of 845 infants in the higher-threshold group, 423 (50.1%) died or survived with neurodevelopmental impairment, as compared with 422 of 847 infants (49.8%) in the lower-threshold group (relative risk adjusted for birth-weight stratum and center, 1.00; 95% confidence interval [CI], 0.92 to 1.10; P=0.93). At 2 years, the higher- and lower-threshold groups had similar incidences of death (16.2% and 15.0%, respectively) and neurodevelopmental impairment (39.6% and 40.3%, respectively). At discharge from the hospital, the incidences of survival without severe complications were 28.5% and 30.9%, respectively. Serious adverse events occurred in 22.7% and 21.7%, respectively. CONCLUSIONS In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion did not improve survival without neurodevelopmental impairment at 22 to 26 months of age, corrected for prematurity. (Funded by the National Heart, Lung, and Blood Institute and others; TOP ClinicalTrials.gov number, NCT01702805.)	[Kirpalani, Haresh; Schmidt, Barbara; Chaudhary, Aasma S.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Schmidt, Barbara; Chaudhary, Aasma S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bell, Edward F.; Johnson, Karen J.; Widness, John A.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Hintz, Susan R.; Chock, Valerie Y.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA; [Hintz, Susan R.; Chock, Valerie Y.] Lucile Packard Childrens Hosp, Palo Alto, CA USA; [Devaskar, Uday] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Tan, Sylvia; Crawford, Margaret M.] RTI Int, Biostat & Epidemiol Div, Res Triangle Pk, NC USA; [Cotten, C. Michael] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA; [Newman, Jamie E.; Das, Abhik] RTI Int, Biostat & Epidemiol Div, Rockville, MD USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Vohr, Betty R.; Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Birmingham, AL USA; [D'Angio, Carl T.; Carmen, Melissa F.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Kennedy, Kathleen A.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, McGovern Med Sch, Houston, TX 77030 USA; [Wyckoff, Myra H.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Ohls, Robin K.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA; [Ohls, Robin K.; Yoder, Bradley A.] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT USA; [Poindexter, Brenda B.; Sokol, Gregory M.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Poindexter, Brenda B.; Schibler, Kurt] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Seabrook, Ruth] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Seabrook, Ruth] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Whyte, Robin K.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Zupancic, John A. F.] Harvard Med Sch, Dept Neonatol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Truog, William E.] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA; [Patel, Ravi M.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Atlanta, GA USA; [Chawla, Sanjay] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Higgins, Rosemary D.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Iowa; Stanford University; Lucile Packard Children's Hospital (LPCH); University of California System; University of California Los Angeles; Research Triangle Institute; Duke University; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Brown University; Women & Infants Hospital Rhode Island; University of Alabama System; University of Alabama Birmingham; University of Rochester; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of New Mexico; University of New Mexico's Health Sciences Center; Utah System of Higher Education; University of Utah; Indiana University System; Indiana University Bloomington; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Dalhousie University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Children's Mercy Hospital; Children's Healthcare of Atlanta (CHOA); Emory University; Wayne State University; George Mason University	Kirpalani, H (corresponding author), Univ Penn, Div Neonatol, Childrens Hosp Philadelphia, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	kirpalanih@email.chop.edu	Das, Abhik/AAF-1883-2020; Patel, Ravi/B-7218-2011	Das, Abhik/0000-0003-2722-0479; Patel, Ravi/0000-0002-7444-5550; Hintz, Susan/0000-0001-7023-4433; Newman, Jamie/0000-0001-8880-8132; Tan, Sylvia Margaret/0000-0002-2987-0072; Crawford, Margaret/0000-0003-2129-8267	National Heart, Lung, and Blood Institute (NHLBI) [U01 HL112776, U01 HL112748]; NICHD [UG1 HD068244, UG1 HD053109, U24 HD095254]; NIH; NHBLI; National Center for Research Resources; National Center for Advancing Translational Sciences	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHBLI; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by grants (U01 HL112776 and U01 HL112748, to Drs. Kirpalani, Bell, and Das) from the National Heart, Lung, and Blood Institute (NHLBI), grants (UG1 HD068244, UG1 HD053109, and U24 HD095254, to the Neonatal Research Network site investigators) from the NICHD, and grant support through cooperative agreements from the NIH, the NICHD, the NHBLI, the National Center for Research Resources, and the National Center for Advancing Translational Sciences.	Abu Jawdeh EG, 2014, J PERINATOL, V34, P921, DOI 10.1038/jp.2014.115; Achenbach T. M., 2001, MANUAL ASEBA PRESCHO; Andersen CC, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1117; [Anonymous], 1992, CMAJ, V147, P1781; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bell EF, 2005, PEDIATRICS, V115, P1685, DOI 10.1542/peds.2004-1884; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Christensen RD, 2014, TRANSFUSION, V54, P104, DOI 10.1111/trf.12234; Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642; Cooke RWI, 1997, EUR J PEDIATR, V156, P47; Fergusson D, 2003, JAMA-J AM MED ASSOC, V289, P1950, DOI 10.1001/jama.289.15.1950; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Franz AR, 2020, JAMA-J AM MED ASSOC, V324, P560, DOI 10.1001/jama.2020.10690; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Guillen U, 2012, SEMIN PERINATOL, V36, P244, DOI 10.1053/j.semperi.2012.04.004; Hay S, 2017, SEMIN PERINATOL, V41, P80, DOI 10.1053/j.semperi.2016.09.021; Juul SE, 2020, NEW ENGL J MED, V382, P233, DOI 10.1056/NEJMoa1907423; Keir AK, 2015, TRANSFUSION, V55, P1340, DOI 10.1111/trf.12998; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Kirpalani H, 2012, SEMIN PERINATOL, V36, P269, DOI 10.1053/j.semperi.2012.04.007; Kirpalani H, 2011, J PEDIATR-US, V159, P359, DOI 10.1016/j.jpeds.2011.05.002; Maier RF, 2000, J PEDIATR-US, V136, P220, DOI 10.1016/S0022-3476(00)70105-3; Mann H, 2005, J MED ETHICS, V31, P548, DOI 10.1136/jme.2004.010736; MCGRADY GA, 1987, AM J EPIDEMIOL, V126, P1165, DOI 10.1093/oxfordjournals.aje.a114754; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; Nopoulos PC, 2011, ARCH PEDIAT ADOL MED, V165, P443, DOI 10.1001/archpediatrics.2010.269; dos Santos AMN, 2011, J PEDIATR-US, V159, P371, DOI 10.1016/j.jpeds.2011.02.040; Olsen IE, 2010, PEDIATRICS, V125, pE214, DOI 10.1542/peds.2009-0913; Palisano RJ, 2006, DEV MED CHILD NEUROL, V48, P424, DOI 10.1017/S0012162206000934; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Patel RM, 2016, JAMA-J AM MED ASSOC, V315, P889, DOI 10.1001/jama.2016.1204; Patel RM, 2016, TRANSFUS MED REV, V30, P165, DOI 10.1016/j.tmrv.2016.06.005; Silverman W. A., 1980, RETROLENTAL FIBROPLA; Slidsborg C, 2016, OPHTHALMOLOGY, V123, P796, DOI 10.1016/j.ophtha.2015.12.019; Spinella PC, 2019, JAMA-J AM MED ASSOC, V322, P2179, DOI 10.1001/jama.2019.17478; Walsh Michele C, 2003, J Perinatol, V23, P451, DOI 10.1038/sj.jp.7210963; Whyte R, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000512.pub2; Whyte RK, 2009, PEDIATRICS, V123, P207, DOI 10.1542/peds.2008-0338; Widness JA, 1996, J PEDIATR-US, V129, P680, DOI 10.1016/S0022-3476(96)70150-6; Zagol K, 2012, J PEDIATR-US, V161, P417, DOI 10.1016/j.jpeds.2012.02.044	40	60	62	2	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2020	383	27					2639	2651		10.1056/NEJMoa2020248	http://dx.doi.org/10.1056/NEJMoa2020248			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP1SJ	33382931	Green Accepted, Bronze			2023-01-03	WOS:000605648000013
J	Hasegawa, N; Takeda, K; Mancini, M; King, LA; Horak, FB; Asaka, T				Hasegawa, Naoya; Takeda, Kenta; Mancini, Martina; King, Laurie A.; Horak, Fay B.; Asaka, Tadayoshi			Differential effects of visual versus auditory biofeedback training for voluntary postural sway	PLOS ONE			English	Article							AUGMENTED FEEDBACK; BALANCE; INFORMATION; GAIT	Augmented sensory biofeedback training is often used to improve postural control. Our previous study showed that continuous auditory biofeedback was more effective than continuous visual biofeedback to improve postural sway while standing. However, it has also been reported that both discrete visual and auditory biofeedback training, presented intermittently, improves bimanual task performance more than continuous visual biofeedback training. Therefore, this study aimed to investigate the relative effectiveness of discrete visual biofeedback versus discrete auditory biofeedback to improve postural control. Twenty-two healthy young adults were randomly assigned to either a visual or auditory biofeedback group. Participants were asked to shift their center of pressure (COP) by voluntary postural sway forward and backward in line with a hidden target, which moved in a sinusoidal manner and was displayed intermittently. Participants were asked to decrease the diameter of a visual circle (visual biofeedback) or the volume of a sound (auditory biofeedback) based on the distance between the COP and the target in the training session. The feedback and the target were given only when the target reached the inflection points of the sine curves. In addition, the perceptual magnitudes of visual and auditory biofeedback were equalized using Stevens' power law. Results showed that the mean and standard deviation of the distance between COP and the target were reduced int the test session, removing the augmented sensory biofeedback, in both biofeedback training groups. However, the temporal domain of the performance improved in the test session in the auditory biofeedback training group, but not in the visual biofeedback training group. In conclusion, discrete auditory biofeedback training was more effective for the motor learning of voluntarily postural swaying compared to discrete visual biofeedback training, especially in the temporal domain.	[Hasegawa, Naoya; Asaka, Tadayoshi] Hokkaido Univ, Dept Rehabil Sci, Fac Hlth Sci, Sapporo, Hokkaido, Japan; [Takeda, Kenta] Res Inst Natl Ctr Persons Disabil, Dept Rehabil Movement Funct, Tokorozawa, Saitama, Japan; [Mancini, Martina; King, Laurie A.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA	Hokkaido University; Oregon Health & Science University	Asaka, T (corresponding author), Hokkaido Univ, Dept Rehabil Sci, Fac Hlth Sci, Sapporo, Hokkaido, Japan.	ask-chu@hs.hokudai.ac.jp	Hasegawa, Naoya/AAN-3153-2020		Japan Society for the Promotion of Science (JSPS) [20K19371, 18K10702]; National Institutes of Health [R01AG006457]; Department of Veterans Affairs Merit Award [5I01RX001075]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs Merit Award(US Department of Veterans Affairs)	This study was supported by Grant-in-Aid for Early-Career Scientists (No. 20K19371, NH) and for Scientific Research (No. 18K10702, TA) from Japan Society for the Promotion of Science (JSPS), the National Institutes of Health under award (No. R01AG006457, PI: FBH), and Department of Veterans Affairs Merit Award (No. 5I01RX001075, PI: FBH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhasan H, 2017, CLIN INTERV AGING, V12, P487, DOI 10.2147/CIA.S127023; Arrighi R, 2006, J VISION, V6, P260, DOI 10.1167/6.3.6; Carpinella I, 2017, ARCH PHYS MED REHAB, V98, P622, DOI 10.1016/j.apmr.2016.11.003; Chen HY, 2012, HUM MOVEMENT SCI, V31, P1660, DOI 10.1016/j.humov.2012.06.001; Chiou SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149221; Dozza M, 2007, EXP BRAIN RES, V178, P37, DOI 10.1007/s00221-006-0709-y; Dozza Marco, 2005, J Neuroeng Rehabil, V2, P13, DOI 10.1186/1743-0003-2-13; Dozza M, 2011, GAIT POSTURE, V34, P313, DOI 10.1016/j.gaitpost.2011.05.016; Foxe JJ, 2009, CURR BIOL, V19, pR373, DOI 10.1016/j.cub.2009.03.029; Ghai S, 2019, ANN NY ACAD SCI, V1438, P50, DOI 10.1111/nyas.13967; Ghai S, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00142; Ginis P, 2016, PARKINSONISM RELAT D, V22, P28, DOI 10.1016/j.parkreldis.2015.11.004; Halliday DM, 1995, PROG BIOPHYS MOL BIO, V64, P237, DOI 10.1016/S0079-6107(96)00009-0; Hasegawa N, 2017, GAIT POSTURE, V58, P188, DOI 10.1016/j.gaitpost.2017.08.001; Holcombe AO, 2009, TRENDS COGN SCI, V13, P216, DOI 10.1016/j.tics.2009.02.005; Hove MJ, 2013, NEUROIMAGE, V67, P313, DOI 10.1016/j.neuroimage.2012.11.032; Kim SJ, 2015, IEEE T BIO-MED ENG, V62, P2244, DOI 10.1109/TBME.2015.2420851; Lakhani B, 2015, GAIT POSTURE, V41, P499, DOI 10.1016/j.gaitpost.2014.12.003; Moore S.T., 1993, PHYSICAL THERAPY PRA, V2, P1; Nijhawan R, 2008, BEHAV BRAIN SCI, V31, P179, DOI 10.1017/S0140525X08003804; Petersen H, 1996, SCAND J REHABIL MED, V28, P217; Pinsault N, 2008, ARCH PHYS MED REHAB, V89, P1772, DOI 10.1016/j.apmr.2008.02.024; POSNER MI, 1976, PSYCHOL REV, V83, P157, DOI 10.1037/0033-295X.83.2.157; Radhakrishnan SM, 2011, EXP BRAIN RES, V213, P423, DOI 10.1007/s00221-011-2792-y; Radhakrishnan SM, 2010, GAIT POSTURE, V32, P650, DOI 10.1016/j.gaitpost.2010.09.010; Ranganathan R, 2009, J MOTOR BEHAV, V41, P317, DOI 10.3200/JMBR.41.4.317-330; Ronsse R, 2011, CEREB CORTEX, V21, P1283, DOI 10.1093/cercor/bhq209; Schmidt RC, 1997, ECOL PSYCHOL, V9, P189, DOI 10.1207/s15326969eco0903_2; Schmitz G, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-32; Sienko KH, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00944; Sigrist R, 2013, PSYCHON B REV, V20, P21, DOI 10.3758/s13423-012-0333-8; Sotirakis H, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9193952; STEVENS SS, 1957, PSYCHOL REV, V64, P153, DOI 10.1037/h0046162; Takeda K, 2017, J PHYSIOL ANTHROPOL, V36, DOI 10.1186/s40101-017-0147-5; Witt ST, 2008, NEUROIMAGE, V42, P343, DOI 10.1016/j.neuroimage.2008.04.025; Zijlstra A, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-58	36	5	6	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2020	15	12							e0244583	10.1371/journal.pone.0244583	http://dx.doi.org/10.1371/journal.pone.0244583			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM2BQ	33370408	Green Published, gold			2023-01-03	WOS:000603611900062
J	Xie, Y; Bowe, B; Maddukuri, G; Al-Aly, Z				Xie, Yan; Bowe, Benjamin; Maddukuri, Geetha; Al-Aly, Ziyad			Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KIDNEY OUTCOMES; INHIBITORS; NITROGEN	OBJECTIVE To comparatively examine differences in risk of clinical manifestations and death among people admitted to hospital with coronavirus disease 2019 (covid-19) and seasonal influenza. DESIGN Cohort study. SETTING US Department of Veterans Affairs. PARTICIPANTS Patients admitted to hospital with covid-19 between 1 February 2020 and 17 June 2020 (n=3641) and seasonal influenza between 2017 and 2019 (n=12 676). MAIN OUTCOME MEASURES Risks of clinical manifestations, healthcare resource use (including use of mechanical ventilation, admission to intensive care, and length of stay), and death, estimated using a doubly robust approach to build propensity scores that were then used along with covariates to adjust the outcome models. RESULTS Compared with seasonal influenza, covid-19 was associated with higher risk of acute kidney injury (odds ratio 1.52, 95% confidence interval 1.37 to 1.69), incident renal replacement therapy (4.11, 3.13 to 5.40), incident insulin use (1.86, 1.62 to 2.14), severe septic shock (4.04, 3.38 to 4.83), vasopressor use (3.95, 3.46 to 4.51), pulmonary embolism (1.50, 1.18 to 1.90), deep venous thrombosis (1.50, 1.20 to 1.88), stroke (1.62, 1.17 to 2.24), acute myocarditis (7.82, 3.53 to 17.36), arrythmias and sudden cardiac death (1.76, 1.40 to 2.20), elevated troponin (1.75, 1.50 to 2.05), elevated aspartate aminotransferase (3.16, 2.91 to 3.43), elevated alanine aminotransferase (2.65, 2.43 to 2.88), and rhabdomyolysis (1.84, 1.54 to 2.18). Compared with seasonal influenza, covid-19 was also associated with higher risk of death, mechanical ventilator use, and admission to intensive care (hazard ratio 4.97, (95% confidence interval 4.42 to 5.58), 4.01 (3.53 to 4.54), and 2.41 (2.25 to 2.59), respectively) and 3.00 (2.20 to 3.80) additional days of hospital stay. Differences in rates of death per 100 patients between covid-19 and seasonal influenza were most pronounced in people over 75 years of age with chronic kidney disease or dementia and those with black race and obesity, diabetes, or chronic kidney disease. CONCLUSIONS Among people admitted to hospital, compared with seasonal influenza, covid-19 was associated with increased risk of extrapulmonary organ dysfunction, death, and increased health resource use. The findings may inform the global discussion about the comparative risks of covid-19 and seasonal influenza and may help the ongoing effort to manage the covid-19 global pandemic.	[Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Res & Dev Serv, Clin Epidemiol Ctr, St Louis, MO 63106 USA; [Xie, Yan; Bowe, Benjamin] St Louis Univ, Coll Publ Hlth & Social Justice, Dept Epidemiol & Biostat, St Louis, MO 63103 USA; [Xie, Yan; Bowe, Benjamin; Al-Aly, Ziyad] Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA; [Maddukuri, Geetha; Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63103 USA; [Al-Aly, Ziyad] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Al-Aly, Ziyad] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Res & Dev Serv, Clin Epidemiol Ctr, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Al-Aly, Z (corresponding author), Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA.	zalaly@gmail.com	; Al-Aly, Ziyad/S-4439-2016	Xie, Yan/0000-0002-2457-9382; Al-Aly, Ziyad/0000-0002-2600-0434	United States Department of Veterans Affairs; Institute for Public Health at Washington University in Saint Louis, MO, USA; American Society of Nephrology and KidneyCure	United States Department of Veterans Affairs(US Department of Veterans Affairs); Institute for Public Health at Washington University in Saint Louis, MO, USA; American Society of Nephrology and KidneyCure	This research was funded by the United States Department of Veterans Affairs and the Institute for Public Health at Washington University in Saint Louis, MO, USA (for ZAA), and the American Society of Nephrology and KidneyCure pre-doctoral fellowship awards (for YX and BB). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The contents do not represent the views of the US Department of Veterans Affairs or the US government.	Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bhopal SS, 2020, LANCET, V396, P532, DOI 10.1016/S0140-6736(20)31748-7; Bowe B, 2021, CLIN J AM SOC NEPHRO, V16, P14, DOI 10.2215/CJN.09610620; Bowe B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15834; Bowe B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022450; Bowe B, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4412; Bowe B, 2017, LANCET PLANET HEALTH, V1, pE267, DOI 10.1016/S2542-5196(17)30117-1; Bowe B, 2017, CLIN J AM SOC NEPHRO, V12, P603, DOI 10.2215/CJN.09710916; Chan LL, 2020, KIDNEY360, V1, P588, DOI 10.34067/KID.0003722020; Dallan C, 2020, LANCET CHILD ADOLESC, V4, pE21, DOI 10.1016/S2352-4642(20)30164-4; Faust JS, 2020, JAMA INTERN MED, V180, P1045, DOI 10.1001/jamainternmed.2020.2306; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Funk MJ, 2011, AM J EPIDEMIOL, V173, P761, DOI 10.1093/aje/kwq439; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Han LF, 2019, EPIDEMIOLOGY, V30, P405, DOI 10.1097/EDE.0000000000000984; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Linden A, 2017, J EVAL CLIN PRACT, V23, P697, DOI 10.1111/jep.12714; Lytras T, 2019, EUROSURVEILLANCE, V24, P11, DOI 10.2807/1560-7917.ES.2019.24.14.1800118; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Maynard C., 2019, VIREC DAT METH SEM F; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Morgan OW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009694; Palevsky PM, 2013, AM J KIDNEY DIS, V61, P649, DOI 10.1053/j.ajkd.2013.02.349; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Pettit NN, 2020, OBESITY, V28, P1806, DOI 10.1002/oby.22941; Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2013400, 10.1056/NEJMc2011400]; Ren HH, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01035-2; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937; Rubino F, 2020, NEW ENGL J MED, V383, P789, DOI [10.1056/NEJMc2018688, 10.1056/NEJMc2021832]; Salgado CD, 2002, LANCET INFECT DIS, V2, P145, DOI 10.1016/S1473-3099(02)00221-9; Tsigaris P, 2020, NICOTINE TOB RES, V22, P1646, DOI 10.1093/ntr/ntaa121; University JH, 2020, COV 19 MAP; van Zyl-Smit RN, 2020, LANCET RESP MED, V8, P664, DOI 10.1016/S2213-2600(20)30239-3; Vincent BM, 2018, HEALTH SERV OUTCOME, V18, P143, DOI 10.1007/s10742-018-0178-3; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Xie Y, 2020, DIABETES CARE, V43, P2785, DOI 10.2337/dc20-1231; Xie Y, 2020, DIABETES CARE, V43, P2859, DOI 10.2337/dc20-1890; Xie Y, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1580; Xie Y, 2018, KIDNEY INT, V93, P741, DOI 10.1016/j.kint.2017.08.033; Xie Y, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015735; Xie Y, 2017, KIDNEY INT, V91, P1482, DOI 10.1016/j.kint.2016.12.021; Xie Y, 2016, J AM SOC NEPHROL, V27, P3153, DOI 10.1681/ASN.2015121377; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575	45	68	69	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 15	2020	371								m4677	10.1136/bmj.m4677	http://dx.doi.org/10.1136/bmj.m4677			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PI0XH	33323357	Green Published, hybrid			2023-01-03	WOS:000600823100002
J	Xu, XQ; Zhu, TT; Shi, TT; Chen, J; Jin, L				Xu, Xiaoqiong; Zhu, Tiantian; Shi, Tingting; Chen, Juan; Jin, Ling			Quality suitability regionalization analysis of Angelica sinensis in Gansu, China	PLOS ONE			English	Article							ROOT	The genus Angelica encompasses 80 species worldwide. Among them, only Angelica sinensis is widely used in China and Japan. To explore the quality and geographical distribution of A. sinensis, we collected 1,530 plants from Gansu Province and analyzed them for their contents of chlorogenic acid (CA), ferulic acid (FA), senkyunolide I(SI), senkyunolide A(SA), senkyunolide H (SH), coniferyl ferulate (CF), ligustilide (LI), and butenyl phthalide (BP) using UPLC. We also assessed the relationship between the ecological environment and quality of A. sinensis through maximum entropy modeling and a geographical information system. The habitat suitability distribution demonstrated that the most influential ecological factors for the growth of A. sinensis were altitude, precipitation during March, May, and December, precipitation during the wettest month, and the soil pH. The most suitable areas for cultivation are concentrated to the south of Gansu Province, including Linxia Hui Autonomous Prefecture, Dingxi City, Tianshui City, south of Wuwei City, east of Gannan Tibetan Autonomous Prefecture, north of Longnan City, and northwest of Pingliang City. The quality suitability regionalization analysis divulged that the most influential ecological factors for the index components of A. sinensis were the altitude, sunshine, rainfall, temperature, and soil pH. The highest quality A. sinensis grow in Dingxi City, Tangchang, Lixian, and Wen counties in Longnan City, Wushan County in Tianshui City, Lintan, Zhouqu, and Zhuoni counties in Gannan Tibetan Autonomous Prefecture, Kangle and Linxia counties in Linxia Hui Autonomous Prefecture. The experiment yielded highly accurate results (accuracy of 0.955), suggesting that the results were consistent with the actual distribution of A. sinensis in Gansu. The inferences of this research will naturally draw the attention of the authorities in the fields of natural resources and agriculture departments and provide a scientific basis for the rational selection of A. sinensis cultivation areas.	[Xu, Xiaoqiong; Zhu, Tiantian; Jin, Ling] Gansu Univ Chinese Med, Sch Pharm, Lanzhou, Gansu, Peoples R China; [Xu, Xiaoqiong] Gansu Med Coll, Pingliang, Gansu, Peoples R China; [Shi, Tingting] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat, State Key Lab Breeding Base Dao Di Herbs, Beijing, Peoples R China; [Chen, Juan] Lanzhou Univ, Sch Pharm, Lanzhou, Gansu, Peoples R China; [Jin, Ling] Res Inst Chinese Tibetan Med Resources, Lanzhou, Gansu, Peoples R China	Gansu University of Chinese Medicine; Gansu Medical College; China Academy of Chinese Medical Sciences; Lanzhou University	Jin, L (corresponding author), Gansu Univ Chinese Med, Sch Pharm, Lanzhou, Gansu, Peoples R China.; Jin, L (corresponding author), Res Inst Chinese Tibetan Med Resources, Lanzhou, Gansu, Peoples R China.	xxq198498@163.com		xu, xiaoqiong/0000-0002-7624-2976	National Natural Science Foundation of China [81360615];  [Y520000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 	Initials of the author who received each award: L J Grant number awarded to the author: 81360615 The full name of each funder: National Natural Science Foundation of China URL of each funder website: http://www.nsfc.gov.cn/Specific grant numbers: Y520000.	Chinese Academy of Sciences China vegetation map editor commttee, 2007, VEG MAP PEOPL REP CH; Computer network information center Chinese academy of sciences., 2015, GEOSPATIAL DATA CLOU; de Oliveira JB, 2019, FOOD RES INT, V121, P870, DOI 10.1016/j.foodres.2019.01.011; Hook ILI, 2014, J ETHNOPHARMACOL, V152, P1, DOI 10.1016/j.jep.2013.12.018; Jeong SY, 2015, CHEM PHARM BULL, V63, P504, DOI 10.1248/cpb.c15-00081; Kan WLT, 2008, J ETHNOPHARMACOL, V120, P36, DOI 10.1016/j.jep.2008.07.027; Katoh A, 2011, AM J CHINESE MED, V39, P757, DOI 10.1142/S0192415X11009172; Li ZY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48397-6; Lima VA, 2017, AN ACAD BRAS CIENC, V89, P1167, DOI 10.1590/0001-3765201720150770; National Meteorological Information Center China Meteorological Administration., 2015, CHIN MET DAT NETW; Shang Zhong-hui, 2015, Zhong Yao Cai, V38, P1370; Shao M, 2011, PLANTA MED, V77, P809, DOI 10.1055/s-0030-1250573; Tang SN, 2015, CANCER PREV RES, V8, P835, DOI 10.1158/1940-6207.CAPR-15-0051; The Lancet Global Health, 2016, LANCET GLOB HEALTH, V4, pe427; The Office for the second National Soil Survey of China, 1996, SOIL SER CHIN; Walden-Schreiner C, 2017, J ENVIRON MANAGE, V193, P52, DOI 10.1016/j.jenvman.2017.01.076; Wei WL, 2016, J ETHNOPHARMACOL, V190, P116, DOI 10.1016/j.jep.2016.05.023; Yan Hui, 2016, Zhongguo Zhong Yao Za Zhi, V41, P3139, DOI 10.4268/cjcmm20161705; Yan JJ, 2013, BIOL PHARM BULL, V36, P140, DOI 10.1248/bpb.b12-00798; Ojeda-Perez ZZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186540; Zhao L, 2012, FITOTERAPIA, V83, P1712, DOI 10.1016/j.fitote.2012.09.029; Zhu SD, 2017, SCI REP-UK, V7, DOI 10.1038/srep42417	22	4	5	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243750	10.1371/journal.pone.0243750	http://dx.doi.org/10.1371/journal.pone.0243750			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315941	Green Published, gold			2023-01-03	WOS:000600186100068
J	Taniguchi, C; Saka, H; Oze, I; Nakamura, S; Nozaki, Y; Tanaka, H				Taniguchi, Chie; Saka, Hideo; Oze, Isao; Nakamura, Sumie; Nozaki, Yasuhiro; Tanaka, Hideo			Relationship between the strength of craving as assessed by the Tobacco Craving Index and success of quitting smoking in Japanese smoking cessation therapy	PLOS ONE			English	Article							WITHDRAWAL SYMPTOMS; ABSTINENCE; DEPENDENCE; DYNAMICS; RELAPSE; SMOKERS; URGES	Background We previously developed the Tobacco Craving Index (TCI) to assess craving of smokers. In the present study, we validated the relationship between the TCI grade over the 5 sessions of Japanese smoking cessation therapy (SCT) and success of quitting smoking among 889 Japanese patients. Methods The Japanese SCT consists of 5 sessions of SCT (first session and sessions 2, 4, 8 and 12 weeks later). In the TCI questionnaire, patients are asked to rate their strength of craving and frequency of craving, each on a four-point Likert scale. Patients are classified into one of four grades based on their responses (0, I, II, III, with III indicating severe craving). The TCI questionnaire was administered to each participant at each session of the SCT. This study included participants of Japanese SCT who answered the TCI at the first session of the SCT at five Japanese smoking cessation clinics. Patients who dropped out of the SCT from the second to the fifth sessions were considered to have failed smoking cessation. To elucidate how much the TCI grade predicts smoking status at the last session, we performed multivariate logistic regression analysis with adjustment for confounding factors. Results Participants who had higher TCI grade(III) in the 2(nd) through 5(th) sessions showed significantly lower probability for success of quitting smoking than those who had lower TCI grades(0 or I) (adjusted odds ratio: 2(nd) session: 0.30, 3(rd) session: 0.15, 4(th) session: 0.06, 5(th) session: 0.02). Conclusions We validated the usefulness of the TCI grade for assessing probability of quitting smoking by using a large number of smoking cessation settings.	[Taniguchi, Chie] Aichi Med Univ, Coll Nursing, Nagakute, Aichi, Japan; [Taniguchi, Chie] Natl Hosp Org Nagoya Med Ctr, Dept Clin Res Ctr, Nagoya, Aichi, Japan; [Saka, Hideo] Matsunami Gen Hosp, Dept Resp Med, Gifu, Japan; [Saka, Hideo] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan; [Oze, Isao] Aichi Canc Ctr, Div Canc Epidemiol & Prevent, Dept Prevent Med, Res Inst, Nagoya, Aichi, Japan; [Nakamura, Sumie] Natl Hosp Org Nagoya Med Ctr, Dept Nursing, Nagoya, Aichi, Japan; [Nozaki, Yasuhiro] Japan Community Healthcare Org, Dept Resp Med, Chukyo Hosp, Nagoya, Aichi, Japan; [Nozaki, Yasuhiro] Tokoname Municipal Hosp, Dept Resp Med, Tokoname, Aichi, Japan; [Tanaka, Hideo] Fujiidera Publ Hlth Ctr Osaka Prefecture, Fujidera, Osaka, Japan	Aichi Medical University; Nagoya Medical Center; Nagoya Medical Center; Aichi Cancer Center; Nagoya Medical Center	Taniguchi, C (corresponding author), Aichi Med Univ, Coll Nursing, Nagakute, Aichi, Japan.; Taniguchi, C (corresponding author), Natl Hosp Org Nagoya Med Ctr, Dept Clin Res Ctr, Nagoya, Aichi, Japan.	c-taniguchi@aichi-med-u.ac.jp		Taniguchi, Chie/0000-0002-2529-8697	MEXT KAKENHI [19K19582]	MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a MEXT KAKENHI Grant-in-Aid for Young Scientist, Grant Number 19K19582 who received C.T. (https://www.jsps.go.jp/j-grantsinaid/) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen SS, 2008, NICOTINE TOB RES, V10, P35, DOI 10.1080/14622200701705076; Brown J, 2013, PSYCHOPHARMACOLOGY, V229, P209, DOI 10.1007/s00213-013-3100-2; Drummond DC, 2001, ADDICTION, V96, P33, DOI 10.1046/j.1360-0443.2001.961333.x; Durcan MJ, 2002, CLIN THER, V24, P540, DOI 10.1016/S0149-2918(02)85130-X; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hughes JR, 2010, NICOTINE TOB RES, V12, P459, DOI [10.1093/ntr/ntq009, 10.1093/ntr/ntq059]; Javitz HS, 2012, ADDICTION, V107, P1501, DOI 10.1111/j.1360-0443.2012.03838.x; Moreno-Rius J, 2017, DRUG ALCOHOL DEPEN, V173, P151, DOI 10.1016/j.drugalcdep.2016.12.028; Motschman CA, 2018, PSYCHOPHARMACOLOGY, V235, P2001, DOI 10.1007/s00213-018-4898-4; Padovano HT, 2020, NICOTINE TOB RES, V22, P492, DOI 10.1093/ntr/ntz002; Piasecki TM, 2003, EXP CLIN PSYCHOPHARM, V11, P276, DOI 10.1037/1064-1297.11.4.276; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reese ED, 2016, NICOTINE TOB RES, V18, P48, DOI 10.1093/ntr/ntv054; Reid HH, 2016, ADDICT RES THEORY, V24, P48, DOI 10.3109/16066359.2015.1060967; ROBERTS RE, 1983, AM J PSYCHIAT, V140, P41; SHIFFMAN SM, 1976, PSYCHOPHARMACOLOGY, V50, P35, DOI 10.1007/BF00634151; Strong DR, 2011, J ABNORM PSYCHOL, V120, P999, DOI 10.1037/a0023666; Swan GE, 1996, ADDICT BEHAV, V21, P481, DOI 10.1016/0306-4603(95)00070-4; Sweitzer MM, 2013, NICOTINE TOB RES, V15, P36, DOI 10.1093/ntr/nts080; Taniguchi C, 2019, TOB INDUC DIS, V17, DOI 10.18332/tid/114164; Taniguchi C, 2017, J ADV NURS, V73, P1681, DOI 10.1111/jan.13258; Taniguchi C, 2013, NURS RES, V62, P414, DOI 10.1097/NNR.0000000000000000; Watson NL, 2018, DRUG ALCOHOL DEPEN, V185, P75, DOI 10.1016/j.drugalcdep.2017.11.037; Wray JM, 2013, NICOTINE TOB RES, V15, P1167, DOI 10.1093/ntr/nts268; Zuo YT, 2017, PSYCHOPHARMACOLOGY, V234, P761, DOI 10.1007/s00213-016-4509-1	25	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243374	10.1371/journal.pone.0243374	http://dx.doi.org/10.1371/journal.pone.0243374			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PD8LW	33284809	Green Published, gold			2023-01-03	WOS:000597930500055
J	Cowen, LE				Cowen, Leah E.			Drugs from bugs in creatures of the sea A bacterium from the sea squirt microbiome makes a natural product with antifungal activity	SCIENCE			English	Editorial Material									[Cowen, Leah E.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1M1, Canada	University of Toronto	Cowen, LE (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1M1, Canada.	leah.cowen@utoronto.ca			Canadian Institutes of Health Research Foundation [FDN-154288]; U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases [1R01AI127375-01, 1R01AI120958-01A1, 1R21AI141080-01]	Canadian Institutes of Health Research Foundation(Canadian Institutes of Health Research (CIHR)); U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	L.E.C. is supported by the Canadian Institutes of Health Research Foundation Grant (FDN-154288) and U.S. National Institutes of Health National Institute of Allergy and Infectious Diseases R01 grants (1R01AI127375-01, 1R01AI120958-01A1) and R21 grant 1R21AI141080-01. L.E.C. is a Canada Research Chair in Microbial Genomics and Infectious Disease and codirector of the Canadian Institute for Advanced Research Fungal Kingdom:Threats and Opportunities program. L.E.C. is a cofounder and shareholder in Bright Angel Therapeutics and a consultant for Boragen.	Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Davies J, 2013, J ANTIBIOT, V66, P361, DOI 10.1038/ja.2013.61; Fisher MC, 2018, SCIENCE, V360, P739, DOI 10.1126/science.aap7999; Kupferschmidt K., 2019, SCIENCE, DOI [10.1126/science.aaz9475, DOI 10.1126/SCIENCE.AAZ9475]; O'Brien J, 2011, CURR OPIN BIOTECH, V22, P552, DOI 10.1016/j.copbio.2011.03.010; Perfect JR, 2017, NAT REV DRUG DISCOV, V16, P603, DOI 10.1038/nrd.2017.46; Piotrowski JS, 2017, NAT CHEM BIOL, V13, P982, DOI [10.1038/NCHEMBIO.2436, 10.1038/nchembio.2436]; Robbins N, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.FUNK-0002-2016; Roemer T, 2013, NAT CHEM BIOL, V9, P222, DOI [10.1038/NCHEMBIO.1205, 10.1038/nchembio.1205]; Wright GD, 2017, NAT PROD REP, V34, P694, DOI 10.1039/c7np00019g; Xue A, 2021, ANN NY ACAD SCI, V1496, P5, DOI 10.1111/nyas.14484; Zhang F, 2020, SCIENCE, V370, P974, DOI 10.1126/science.abd6919	12	0	0	16	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	2020	370	6519					906	907		10.1126/science.abf1675	http://dx.doi.org/10.1126/science.abf1675			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OY7RX	33214262				2023-01-03	WOS:000594441500013
J	Chen, CC; Lim, CY; Lee, PJ; Hsu, AL; Ching, TT				Chen, Chia-Chang; Lim, Chiao Yin; Lee, Pin-Jung; Hsu, Ao-Lin; Ching, Tsui-Ting			S-adenosyl methionine synthetase SAMS-5 mediates dietary restriction-induced longevity in Caenorhabditis elegans	PLOS ONE			English	Article							LIFE-SPAN; CALORIC RESTRICTION; ADENOSYLMETHIONINE; GENES; EXPRESSION; POLYAMINES; DISEASE	S-adenosyl methionine synthetase (SAMS) catalyzes the biosynthesis of S-adenosyl methionine (SAM), which serves as a universal methyl group donor for numerous biochemical reactions. Previous studies have clearly demonstrated that SAMS-1, a C. elegans homolog of mammalian SAMS, is critical for dietary restriction (DR)-induced longevity in Caenorhabditis elegans. In addition to SAMS-1, three other SAMS paralogs have been identified in C. elegans. However, their roles in longevity regulation have never been explored. Here, we show that depletion of sams-5, but not sams-3 or sams-4, can extend lifespan in worms. However, the phenotypes and expression pattern of sams-5 are distinct from sams-1, suggesting that these two SAMSs might regulate DR-induced longevity via different mechanisms. Through the genetic epistasis analysis, we have identified that sams-5 is required for DR-induced longevity in a pha-4/FOXA dependent manner.	[Chen, Chia-Chang; Lee, Pin-Jung; Ching, Tsui-Ting] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei, Taiwan; [Lim, Chiao Yin; Hsu, Ao-Lin] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Lim, Chiao Yin] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan; [Lim, Chiao Yin] Acad Sinica, Taipei, Taiwan; [Hsu, Ao-Lin] China Med Univ, Res Ctr Hlth Aging, Taichung, Taiwan; [Hsu, Ao-Lin] Univ Michigan, Dept Internal Med, Div Geriatr & Palliat Med, Ann Arbor, MI 48109 USA	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; China Medical University Taiwan; University of Michigan System; University of Michigan	Ching, TT (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei, Taiwan.	ttching@ym.edu.tw	Hsu, Ao-Lin Allen/AAX-1856-2020	Ching, Tsui-Ting/0000-0001-7650-1766; Hsu, Ao-Lin/0000-0002-2864-3134	Minister of Science and Technology, Taiwan [NSC 103-2311-B-010-007, MOST 106-2311-B-010-005, MOST 108-2628B-010-002]; National Health Research Institute, Taiwan [NHRIEX103-1034NI]	Minister of Science and Technology, Taiwan; National Health Research Institute, Taiwan(National Health Research Institutes - Taiwan)	The authors received funding from the Minister of Science and Technology, Taiwan with the grants NSC 103-2311-B-010-007 and MOST 106-2311-B-010-005 to T.C. and MOST 108-2628B-010-002 to A.H.. T.C. was also funded by National Health Research Institute, Taiwan (NHRIEX103-1034NI). Some strains were provided by the Caenorhabditis Genetics Center (CGC). Taiwan C. elegans Core Facility (CECF) provided technical support. The funders had no role in study design, data collection and analysis to publish, or preparation of the manuscript.	Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035; Chapman T, 1996, NATURE, V381, P189, DOI 10.1038/381189a0; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Ching TT, 2010, AGING CELL, V9, P545, DOI 10.1111/j.1474-9726.2010.00580.x; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; Hansen M, 2005, PLOS GENET, V1, P119, DOI 10.1371/journal.pgen.0010017; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Li Y, 2011, J BIOCHEM, V149, P529, DOI 10.1093/jb/mvr025; Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Nakano S, 2010, DEVELOPMENT, V137, P4017, DOI 10.1242/dev.058834; ORENTREICH N, 1993, J NUTR, V123, P269; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Richie JP, 2004, NUTRITION, V20, P800, DOI 10.1016/j.nut.2004.05.009; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Tamiya H, 2013, J RECEPT SIG TRANSD, V33, P56, DOI 10.3109/10799893.2012.756896; WAINFAN E, 1989, CANCER RES, V49, P4094; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3	31	3	3	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2020	15	11							e0241455	10.1371/journal.pone.0241455	http://dx.doi.org/10.1371/journal.pone.0241455			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0LY	33175851	Green Published, gold			2023-01-03	WOS:000593946900024
J	Mogaka, JJO; Chimbari, MJ				Mogaka, John Jules O.; Chimbari, Moses J.			The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach	PLOS ONE			English	Article							DRUG DISCOVERY; BREAST-CANCER; GENETIC TESTS; RECOMMENDATIONS; ENGAGEMENT; STRATEGIES; BIOMARKERS; LESSONS; PROJECT; FUTURE	Precision medicine emphasizes predictive, preventive and personalized treatment on the basis of information gleaned from personal genetic and environmental data. Its implementation at health systems level is regarded as multifactorial, involving variables associated with omics technologies, public genomic awareness and adoption tendencies for new medical technologies. However, interrelationships of the various factors and their synergy has not been sufficiently quantified. Based on a survey of 270 participants involved in the use of molecular tests (omics-based biomarkers, OBMs), this study examined how characteristics of omics biomarkers influence precision medicine implementation outcomes (ImO) through an intermediary factor, public genomic awareness (represented by User Response, UsR). A structural equation modelling (SEM) approach was applied to develop and test a 3 latent variable mediation model; each latent variable being measured by a set of indicators ranging between three and six. Mediation analysis results confirmed a partial mediation effect (an indirect effect represented as the product of paths 'a' and 'b' (a*b)) of 0.36 at 90% confidence level, CI = [0.03, 9.94]. Results from the individual mediation paths 'a' and 'b' however, showed that these effects were negative(a = -0.38, b = -0.94). Path 'a' represents the effect of characteristics of OBMs on the mediator, UsR; 'b' represents the effect of the mediator, UsR on implementation outcomes, ImO, holding OBMs constant. The results have both theoretical and practice implications for biomedical genomics research and clinical genomics, respectively. For instance, the results imply better ways have to be devised to more effectively engage the public in addressing extended family support for extended family cascade screening, especially for monogenic hereditary conditions likeBRCA-related breast cancer and colorectal cancer in Lynch syndrome families. At basic biomedical research level, results suggest an integrated biomarker development pipeline, with early consideration of factors that may influence biomarker uptake. The results are also relevant at health systems level in indicating which factors should be addressed for successful.	[Mogaka, John Jules O.; Chimbari, Moses J.] Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South Africa	University of Kwazulu Natal	Mogaka, JJO (corresponding author), Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South Africa.	johnmogaka2@gmail.com	Mogaka, John J O/I-7004-2016	Mogaka, John J O/0000-0001-9902-865X	University of KwaZulu-Natal, College of Health Sciences Research office	University of KwaZulu-Natal, College of Health Sciences Research office	Authors would like to thank the University of KwaZulu-Natal, College of Health Sciences Research office for general support.	Aguilar-Martinez P, 2011, HAEMATOL-HEMATOL J, V96, P507, DOI 10.3324/haematol.2010.029751; [Anonymous], 2018, GEN ENGL POLL; [Anonymous], 2016, RUMIYAH         1111, V3, P24, DOI DOI 10.30897/IJEGEO.306468; Avard D, 2010, INT J CONSUM STUD, V34, P508, DOI 10.1111/j.1470-6431.2010.00914.x; Bakhtiar Ray, 2008, Journal of Pharmacological and Toxicological Methods, V57, P85, DOI 10.1016/j.vascn.2007.10.002; Bakhtiari MR, LAB DIAGNOSIS; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bartlett J., 2008, PANEL ANTIRETROVIRAL, P42; Bullock J.G., 2008, EXPT APPROACHE UNPUB; Bullock JG, 2010, J PERS SOC PSYCHOL, V98, P550, DOI 10.1037/a0018933; Burke W, 2001, AM J MED GENET, V106, P233, DOI 10.1002/ajmg.10011; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Cumming G, 2012, AUST J PSYCHOL, V64, P138, DOI 10.1111/j.1742-9536.2011.00037.x; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Devlieger I, 2017, METHODOLOGY; Efron B., 1986, STAT SCI, P54; Etchegary H, 2015, HEALTH EXPECT, V18, P1413, DOI 10.1111/hex.12122; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Feldstein AC, 2008, JT COMM J QUAL PATIE, V34, P228, DOI 10.1016/S1553-7250(08)34030-6; Garraway LA, 2013, J CLIN ONCOL, V31, P1803, DOI 10.1200/JCO.2013.49.4799; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Glasgow RE, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170271; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Green RC, 2016, AM J HUM GENET, V98, P1051, DOI 10.1016/j.ajhg.2016.04.011; Hann KEJ, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4375-8; Holtzman NA, 2000, WILL GENETICS REVOLU; Hubbard R, 1996, PITFALLS GENETIC TES; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; JAMES LR, 1980, J APPL PSYCHOL, V65, P415, DOI 10.1037/0021-9010.65.4.415; Khoury MJ, 2008, HEALTH AFFAIR, V27, P1600, DOI 10.1377/hlthaff.27.6.1600; Kitson AL, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-1; Lefever S, 2007, BRIT J EDUC TECHNOL, V38, P574, DOI 10.1111/j.1467-8535.2006.00638.x; MacKinnon DP, 2007, ANNU REV PSYCHOL, V58, P593, DOI 10.1146/annurev.psych.58.110405.085542; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; McCabe LL, 2008, ANNU REV MED, V59, P163, DOI 10.1146/annurev.med.59.110106.132016; Mignani S, 2016, DRUG DISCOV TODAY, V21, P239, DOI 10.1016/j.drudis.2015.09.007; Newsom J, 2015, PRACTICAL APPROACHES; Novelli G, 2008, CLIN CASES MINER BON, V5, P149; Ottesen EA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000317; Rabe-Hesketh S, 2004, PSYCHOMETRIKA, V69, P167, DOI 10.1007/BF02295939; Revelle W., 2012, PROCEDURES PSYCHOL P, P9; Revelle W, 2009, PSYCHOMETRIKA, V74, P145, DOI 10.1007/s11336-008-9102-z; Rosseel Y., 2017, PACKAGE LAVAAN; Rosseel Y., 2012, PACKAGE LAVAAN R PAC; Rungtusanatham M, 2014, J OPER MANAG, V32, P99, DOI 10.1016/j.jom.2014.01.002; Rycroft-Malone J, 2004, J NURS CARE QUAL, V19, P297, DOI 10.1097/00001786-200410000-00002; Samuel G, 2018, AM J BIOETHICS, V18, P39, DOI 10.1080/15265161.2018.1431724; Samuel GN, 2018, PUBLIC UNDERST SCI, V27, P352, DOI 10.1177/0963662517747200; Schrag D, 2000, JAMA-J AM MED ASSOC, V283, P617, DOI 10.1001/jama.283.5.617; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; Speerschneider KK, 2013, R US C USER JUL 10 1; Team RC, 2016, R LANG ENV STAT COMP; Warnich Louise, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P191; Wechalekar AD, 2016, LANCET, V387, P2641, DOI 10.1016/S0140-6736(15)01274-X; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A	59	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240585	10.1371/journal.pone.0240585	http://dx.doi.org/10.1371/journal.pone.0240585			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052984	Green Published, gold			2023-01-03	WOS:000581820200063
J	Takeuchi, K; Nakamura, M				Takeuchi, Kosuke; Nakamura, Masatoshi			The optimal duration of high-intensity static stretching in hamstrings	PLOS ONE			English	Article							LOWER-BODY STIFFNESS; PASSIVE STRETCH; MECHANICAL-PROPERTIES; INJURY INCIDENCE; MUSCLE; FLEXIBILITY; STRENGTH; MOTION; RANGE; TORQUE	Objectives The purpose of this study was to compare the duration of high-intensity static stretching on flexibility and strength in the hamstrings. Methods Fourteen healthy males (20.8 +/- 0.6 years, 170.7 +/- 6.5 cm, 66.4 +/- 9.9 kg) underwent high-intensity static stretching for three different durations (10, 15, and 20 seconds). The intensity of static stretching was set at the maximum point of discomfort. To examine the change in flexibility and strength, range of motion, peak passive torque, relative passive torque, muscle-tendon unit stiffness, peak torque of isokinetic knee flexion, and knee angle at peak torque of isokinetic knee flexion were measured. To evaluate a time course of pain, a numerical rating scale was described. Results Range of motion (P< 0.01), peak passive torque (P< 0.01), and knee angle at peak torque were increased at all interventions. Relative passive torque (P< 0.01) and muscle-tendon unit stiffness (P< 0.01) were decreased at all interventions. Peak torque decreased after 10 seconds of stretching (P< 0.05). Numerical rating scale during stretching was 8-9 levels in all interventions, the pain disappeared immediately after the post-measurements (median = 0). Conclusion The results suggested that muscle-tendon unit stiffness decreased regardless of duration of high-intensity static stretching. However, peak torque of isokinetic knee flexion decreased after 10 seconds of high-intensity static stretching, though it was no change after for more than 15 seconds of stretching.	[Takeuchi, Kosuke] Kobe Int Univ, Dept Phys Therapy, Kobe, Hyogo, Japan; [Nakamura, Masatoshi] Niigata Univ Hlth & Welf, Inst Human Movement & Med Sci, Niigata, Niigata, Japan	Niigata University	Takeuchi, K (corresponding author), Kobe Int Univ, Dept Phys Therapy, Kobe, Hyogo, Japan.	ktakeuchi@kobe-kiu.ac.jp						Apostolopoulos NC, 2018, APPL PHYSIOL NUTR ME, V43, P806, DOI 10.1139/apnm-2017-0841; Avela J, 2004, J APPL PHYSIOL, V96, P2325, DOI 10.1152/japplphysiol.01010.2003; Balle SS, 2015, SCAND J MED SCI SPOR, V25, P764, DOI 10.1111/sms.12399; Behm DG, 2016, APPL PHYSIOL NUTR ME, V41, P1, DOI 10.1139/apnm-2015-0235; Behm DG, 2011, EUR J APPL PHYSIOL, V111, P2633, DOI 10.1007/s00421-011-1879-2; Brazier J, 2019, J STRENGTH COND RES, V33, P1156, DOI 10.1519/JSC.0000000000002283; Brusco CM, 2019, EUR J APPL PHYSIOL, V119, P1691, DOI 10.1007/s00421-019-04159-w; Chaabene H, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01468; EKSTRAND J, 1983, INT J SPORTS MED, V4, P124, DOI 10.1055/s-2008-1026025; Folpp H, 2006, AUST J PHYSIOTHER, V52, P45, DOI 10.1016/S0004-9514(06)70061-7; Fowles JR, 2000, J APPL PHYSIOL, V89, P1179, DOI 10.1152/jappl.2000.89.3.1179; Freitas SR, 2018, SCAND J MED SCI SPOR, V28, P794, DOI 10.1111/sms.12957; Huijing PA, 1999, J BIOMECH, V32, P329, DOI 10.1016/S0021-9290(98)00186-9; Kataura S, 2017, J STRENGTH COND RES, V31, P3403, DOI 10.1519/JSC.0000000000001752; Katayama K, 2019, J PHYSIOL SCI, V69, P589, DOI 10.1007/s12576-019-00669-6; Kay AD, 2009, J APPL PHYSIOL, V106, P1249, DOI 10.1152/japplphysiol.91476.2008; Law RYW, 2009, PHYS THER, V89, P1016, DOI 10.2522/ptj.20090056; Lorimer AV, 2016, SPORTS MED, V46, P1921, DOI 10.1007/s40279-016-0526-9; Magnusson SP, 1998, SCAND J MED SCI SPOR, V8, P65; Magnusson SP, 1996, J PHYSIOL-LONDON, V497, P291, DOI 10.1113/jphysiol.1996.sp021768; Magnusson SP, 1997, SCAND J MED SCI SPOR, V7, P195; Matsubara T, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/543291; Matsuo S, 2013, J STRENGTH COND RES, V27, P3367, DOI 10.1519/JSC.0b013e318290c26f; Medeiros DM, 2016, PHYSIOTHER THEOR PR, V32, P438, DOI 10.1080/09593985.2016.1204401; Medeiros Diulian Muniz, 2018, Foot (Edinb), V34, P28, DOI 10.1016/j.foot.2017.09.006; Mizuno T, 2013, INT J SPORTS MED, V34, P484, DOI 10.1055/s-0032-1327655; Mizuno T, 2013, SCAND J MED SCI SPOR, V23, P23, DOI 10.1111/j.1600-0838.2011.01329.x; Mizuno T, 2014, J STRENGTH COND RES, V28, P147, DOI 10.1519/JSC.0b013e3182964220; Morse CI, 2008, J PHYSIOL-LONDON, V586, P97, DOI 10.1113/jphysiol.2007.140434; Morse CI, 2011, EUR J APPL PHYSIOL, V111, P2149, DOI 10.1007/s00421-011-1845-z; Nakamura M., 2019, J PHYS FITNESS SPORT, V8, P113, DOI [DOI 10.7600/jpfsm.8.113, 10.7600/jpfsm.8.113, DOI 10.7600/JPFSM.8.113]; Nakamura M, 2013, MANUAL THER, V18, P211, DOI 10.1016/j.math.2012.09.010; Nakano J, 2012, PHYS THER SPORT, V13, P180, DOI 10.1016/j.ptsp.2011.11.003; Radford JA, 2006, BRIT J SPORT MED, V40, P870, DOI 10.1136/bjsm.2006.029348; Rodriguez ECP, 2017, SPORT BIOMECH, V16, P361, DOI 10.1080/14763141.2017.1319970; Samson M, 2012, J SPORT SCI MED, V11, P279; Sato S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228583; Shiro Y, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-146; Simenz CJ, 2005, J STRENGTH COND RES, V19, P495, DOI 10.1519/15264.1; Takeuchi K., 2019, INT J SPORT HLTH SCI, V17, P72, DOI [10.5432/ijshs.201829, DOI 10.5432/IJSHS.201829]; Takeuchi K, 2020, J SPORT SCI MED, V19, P429; Trajano GS, 2017, SPORTS MED, V47, P1531, DOI 10.1007/s40279-017-0682-6; Trajano GS, 2014, J APPL PHYSIOL, V117, P1486, DOI 10.1152/japplphysiol.00809.2014; Trajano GS, 2013, J APPL PHYSIOL, V115, P212, DOI 10.1152/japplphysiol.00333.2013; Watsford ML, 2010, AM J SPORT MED, V38, P2058, DOI 10.1177/0363546510370197; Weir DE, 2005, EUR J APPL PHYSIOL, V93, P614, DOI 10.1007/s00421-004-1265-4; Witvrouw E, 2004, SPORTS MED, V34, P443, DOI 10.2165/00007256-200434070-00003	47	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2020	15	10							e0240181	10.1371/journal.pone.0240181	http://dx.doi.org/10.1371/journal.pone.0240181			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YX	33007014	gold, Green Published			2023-01-03	WOS:000577103500066
J	Jones, RM; Kimenju, G; Subbiah, S; Styles, A; Pearson, N; Rajasekharan, S				Jones, Rachel M.; Kimenju, Grace; Subbiah, Shalini; Styles, Amy; Pearson, Nicholas; Rajasekharan, Sathyanath			A Short Message Service (SMS) increases postpartum care-seeking behavior and uptake of family planning of mothers in peri-urban public facilities in Kenya	PLOS ONE			English	Article							HEALTH; INTERVENTIONS; MHEALTH	Background It is estimated that one third of maternal deaths in Kenya in 2014 could have been prevented by more timely care-seeking. Mobile health interventions are increasingly being recognized as tools for the delivery of health education and promotion. Many maternal deaths occur in the first few weeks after delivery and mothers who are given adequate care in the postpartum period have better health outcomes. Kiambu County, Kenya has a high level of literacy and phone ownership amongst mothers delivering in public hospitals and was chosen as a site for a postpartum short message service intervention. Methods Women were recruited after delivery and randomized to receive a package of mobile messages or standard of care only. Messages covered danger signs, general postpartum topics, and family planning. Endline phone surveys were conducted at 8 weeks postpartum to assess knowledge, care seeking behavior and family planning uptake. Analysis was conducted using Stata and is presented in odds ratios. Results Women who received the danger sign messages were 1.6 times more likely to be able to list at least 1 danger sign and 3.51 times more likely to seek treatment if they experienced postpartum danger signs. There was no significant difference in routine postpartum care seeking or care seeking behaviors concerning newborns. Women who received family planning messages were 1.85 times more likely to uptake family planning services compared to controls and 2.1 times more likely to choose a long-acting method. Conclusions Simple, low-cost mobile interventions can support women in the early postpartum period when the information is targeted to particular points in the postpartum continuum. Additional research is needed to understand the interplay between healthcare providers and mobile health interventions. Health policy makers should consider direct mobile interventions for women as an option for supporting positive maternal health outcomes in certain populations.	[Jones, Rachel M.; Kimenju, Grace; Subbiah, Shalini; Pearson, Nicholas; Rajasekharan, Sathyanath] Jacaranda Hlth, Dept Res & Design, Nairobi, Kenya; [Subbiah, Shalini] Scope, Dept Impact & Evaluat, Helsinki, Finland		Jones, RM (corresponding author), Jacaranda Hlth, Dept Res & Design, Nairobi, Kenya.	Rjones@jacarandahealth.org		Jones, Rachel M./0000-0002-4004-154X	Johnson & Johnson Family of Companies Foundation [78081]	Johnson & Johnson Family of Companies Foundation	The Johnson & Johnson Family of Companies Foundation (https://www.jjfemea.org/) supported the funding of this work through grant number 78081 to Jacaranda Health. The funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials. The funder provided support in the form of salaries for authors [RJ, SR, GK, NP] and fees related to the independent researcher who supported analysis [AS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2014, PEERJ, V2, pe447; Battle JD, 2015, HEALTHCARE, V3, P180, DOI 10.1016/j.hjdsi.2015.10.011; Cardiovascular Disease and Risk Management, 2019, DIABETES CARE, V2, pS103, DOI 10.2337/dc19-S010; Chepchirchir M., 2017, J MIDWIFERY REPROD H, V5, P1032; Colaci D, 2016, ANN GLOB HEALTH, V82, P922, DOI 10.1016/j.aogh.2016.09.001; Communications Authority of Kenya, 2017, 1 QUART SECT STAT RE; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Galobardes B, 2006, J EPIDEMIOL COMMUN H, V60, P95, DOI 10.1136/jech.2004.028092; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Harrington EK, 2017, EVALUATION MHEALTH S; Hoj L, 2003, BJOG-INT J OBSTET GY, V110, P995, DOI 10.1016/S1470-0328(03)03907-7; Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6; Kenya Ministry of Health, 2017, SAV MOTH LIV 2017 1; Kenya National Bureau of Statistics, 2015, KEN DEM HLTH SURV 20; Killewo J, 2006, J HEALTH POPUL NUTR, V24, P403; Kruk ME, 2018, LANCET GLOB HEALTH, V6, pE1196, DOI 10.1016/S2214-109X(18)30386-3; Levitt C, 2004, BIRTH-ISS PERINAT C, V31, P196, DOI 10.1111/j.0730-7659.2004.00305.x; McConnell M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0914-z; Moore Z, 2015, CONTRACEPTION, V92, P31, DOI 10.1016/j.contraception.2015.03.007; Nankwanga A, 2004, FACTORS INFLUENCING; Pasha O, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-S2-S11; Perrier T, 2015, P 33 ANN ACM C HUM F; Phanice OK, 2018, KNOWLEDGE OBSTETRIC; Schuttner L, 2014, TELEMED E-HEALTH, V20, P721, DOI 10.1089/tmj.2013.0240; The Lancet Global Health, 2018, LANCET GLOB HLTH, V6, pE593; UN inter-agency group for child mortality estimation, 2018, ESTIMATION LEVEL TRE; Unger JA, 2018, BJOG-INT J OBSTET GY, V125, P1620, DOI 10.1111/1471-0528.15337; World Health Organization, 2018, REP WHO TECHN CONS B; World Health Organization (WHO), 2018, CLASS DIG HLTH INT V	29	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2020	15	9							e0239213	10.1371/journal.pone.0239213	http://dx.doi.org/10.1371/journal.pone.0239213			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ4YT	32997684	gold, Green Published			2023-01-03	WOS:000577103100038
J	Nonaka, M; Mabashi-Asazuma, H; Jarvis, DL; Yamasaki, K; Akama, TO; Nagaoka, M; Sasai, T; Kimura-Takagi, I; Suwa, Y; Yaegashi, T; Huang, CT; Nishizawa-Harada, C; Fukuda, MN				Nonaka, Motohiro; Mabashi-Asazuma, Hideaki; Jarvis, Donald L.; Yamasaki, Kazuhiko; Akama, Tomoya O.; Nagaoka, Masato; Sasai, Toshio; Kimura-Takagi, Itsuko; Suwa, Yoichi; Yaegashi, Takashi; Huang, Chun-Teng; Nishizawa-Harada, Chizuko; Fukuda, Michiko N.			Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides	PLOS ONE			English	Article							DEPENDENT LUNG COLONIZATION; ENDOTHELIAL RECEPTOR; E-SELECTIN; IDENTIFICATION; GELDANAMYCIN; LIGANDS; SYSTEM	We previously reported that IF7 peptide, which binds to the annexin A1 (ANXA1) N-terminus, functions as a tumor vasculature-targeted drug delivery vehicle after intravenous injection. To enhance IF7 stability in vivo, we undertook mirror-image peptide phage display using a synthetic D-peptide representing the ANXA1 N-terminus as target. We then identified peptide sequences, synthesized them as D-amino acids, and designated the resulting peptide dTIT7, which we showed bound to the ANXA1 N-terminus. Whole body imaging of mouse brain tumor models injected with near infrared fluorescent IRDye-conjugated dTIT7 showed fluorescent signals in brain and kidney. Furthermore, orally-administered dTIT7/geldanamycin (GA) conjugates suppressed brain tumor growth. Ours is a proof-of-concept experiment showing that ANXA1-binding D-peptide can be developed as an orally-administrable tumor vasculature-targeted therapeutic.	[Nonaka, Motohiro; Nishizawa-Harada, Chizuko; Fukuda, Michiko N.] Natl Inst Adv Ind Sci & Technol, Lab Drug Discovery, Tsukuba, Ibaraki, Japan; [Nonaka, Motohiro] Kyoto Univ, Grad Sch Med, Dept Biol Chem, Human Hlth Sci, Kyoto, Japan; [Mabashi-Asazuma, Hideaki; Jarvis, Donald L.] Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; [Yamasaki, Kazuhiko] Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, Tsukuba, Ibaraki, Japan; [Akama, Tomoya O.] Kansai Med Univ, Dept Pharmacol, Hirakata, Osaka, Japan; [Nagaoka, Masato; Sasai, Toshio; Kimura-Takagi, Itsuko; Suwa, Yoichi; Yaegashi, Takashi] Yakult Cent Inst, Kunitachi, Tokyo, Japan; [Huang, Chun-Teng; Fukuda, Michiko N.] Sanford Burnham Prebys Med Discovery Inst, Canc Ctr, La Jolla, CA 92037 USA	National Institute of Advanced Industrial Science & Technology (AIST); Kyoto University; University of Wyoming; National Institute of Advanced Industrial Science & Technology (AIST); Kansai Medical University; Yakult Honsha Company, Limited; Sanford Burnham Prebys Medical Discovery Institute	Fukuda, MN (corresponding author), Natl Inst Adv Ind Sci & Technol, Lab Drug Discovery, Tsukuba, Ibaraki, Japan.; Fukuda, MN (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Canc Ctr, La Jolla, CA 92037 USA.	michiko@sbpdiscovery.org		Huang, Chun-Teng/0000-0003-3737-7875; Mabashi-Asazuma, Hideaki/0000-0001-5302-6536	institutional grant LEAD at National Institute of Advanced Industrial Science and Technology; Project for Cancer Research and Therapeutic Evolution (PCREATE) from the Japan Agency for Medical Research and Development (AMED) [P41 GM103390, P41 RR005351]; Nakajima Foundation	institutional grant LEAD at National Institute of Advanced Industrial Science and Technology; Project for Cancer Research and Therapeutic Evolution (PCREATE) from the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Nakajima Foundation	This study was supported by an institutional grant LEAD at National Institute of Advanced Industrial Science and Technology, by the Project for Cancer Research and Therapeutic Evolution (PCREATE) from the Japan Agency for Medical Research and Development (AMED) to MNF, and by P41 GM103390 and P41 RR005351. NM is a recipient of a Research Grant for Young Japanese Scientists from The Nakajima Foundation.	Chen F, 2020, J LABELLED COMPD RAD, V63, P494, DOI 10.1002/jlcr.3865; Chen F, 2019, J RADIOANAL NUCL CH, V320, P525, DOI 10.1007/s10967-019-06500-1; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080390; CHOREV M, 1995, TRENDS BIOTECHNOL, V13, P438, DOI 10.1016/S0167-7799(00)88999-4; Corbeil CR, 2012, J COMPUT AID MOL DES, V26, P775, DOI 10.1007/s10822-012-9570-1; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; Fukuda MN, 2000, CANCER RES, V60, P450; Funke SA, 2009, MOL BIOSYST, V5, P783, DOI 10.1039/b904138a; Gu XB, 2016, J RADIOANAL NUCL CH, V308, P851, DOI 10.1007/s10967-015-4533-3; Hatakeyama S, 2011, P NATL ACAD SCI USA, V108, P19587, DOI 10.1073/pnas.1105057108; Hatakeyama S, 2009, P NATL ACAD SCI USA, V106, P3095, DOI 10.1073/pnas.0810110106; Ikebe E, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.30; Jarvis DL, 2009, METHOD ENZYMOL, V463, P191, DOI 10.1016/S0076-6879(09)63014-7; Kang MH, 2012, PEDIATR BLOOD CANCER, V59, P185, DOI 10.1002/pbc.23154; Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j; Li YP, 2013, J CHROMATOGR B, V912, P43, DOI 10.1016/j.jchromb.2012.09.002; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Mandler R, 2000, BIOORG MED CHEM LETT, V10, P1025, DOI 10.1016/S0960-894X(00)00155-4; Nonaka M, 2020, BRIT J CANCER, V123, P1633, DOI 10.1038/s41416-020-01066-2; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Oh P, 2014, NAT MED, V20, P1062, DOI 10.1038/nm.3623; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Ronnen EA, 2006, INVEST NEW DRUG, V24, P543, DOI 10.1007/s10637-006-9208-z; Rosengarth A, 2001, J MOL BIOL, V306, P489, DOI 10.1006/jmbi.2000.4423; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shesham RD, 2008, PROTEIN ENG DES SEL, V21, P115, DOI 10.1093/protein/gzm094; Suzuki M, 2005, GLYCOBIOLOGY, V15, P887, DOI 10.1093/glycob/cwi071; Wiesehan K, 2003, CHEMBIOCHEM, V4, P748, DOI 10.1002/cbic.200300631; Wong TZ, 2002, NEUROIMAG CLIN N AM, V12, P615, DOI 10.1016/S1052-5149(02)00033-3; Wuthrich K, 1986, NMR PROTEINS NUCL AC, DOI DOI 10.1051/EPN/19861701011; Yu DH, 2015, BIOCONJUGATE CHEM, V26, P1702, DOI 10.1021/acs.bioconjchem.5b00283; Zhang JN, 2002, CANCER RES, V62, P4194; Zorzi A, 2017, CURR OPIN CHEM BIOL, V38, P24, DOI 10.1016/j.cbpa.2017.02.006	36	1	1	3	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2021	16	1							e0241157	10.1371/journal.pone.0241157	http://dx.doi.org/10.1371/journal.pone.0241157			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS4TL	33406123	Green Published, gold, Green Submitted			2023-01-03	WOS:000607915500076
J	Abraham, SB; Abdulla, N; Himratul-Aznita, WH; Awad, M; Samaranayake, LP; Ahmed, HMA				B. Abraham, Sheela; Abdulla, Nizam; Himratul-Aznita, Wan Harun; Awad, Manal; Samaranayake, Lakshman Perera; Ahmed, Hany Mohamed Aly			Antibiotic prescribing practices of dentists for endodontic infections; a cross-sectional study	PLOS ONE			English	Article							GENERAL DENTAL PRACTICE; AMERICAN-ASSOCIATION; PENICILLIN; PRESCRIPTION; PAIN; MANAGEMENT; RESISTANCE; MEMBERS	Objective The indiscriminate prescription of antibiotics has led to the emergence of resistance microbes worldwide. This study aimed to investigate the antibiotic prescribing practices amongst general dental practitioners and specialists in managing endodontic infections in the United Arab Emirates (UAE). Design General dental practitioners and specialists in the UAE were invited to participate in an online questionnaire survey which included questions on socio-demographics, practitioner's antibiotic prescribing preferences for various pulpal and periapical diseases, and their choice, in terms of the type, dose and duration of the antibiotic. The link to the survey questionnaire was sent to 250 invited dentists. Data were analyzed by descriptive statistics and chi-square tests for independence and level of significance was set at 0.05. Results A total of 174 respondents participated in the survey (response rate = 70%). The respondents who prescribed antibiotics at least once a month were 38.5% while 17.2% did so, more than three times a week; amoxicillin 500 mg was the antibiotic of choice for patients not allergic to penicillin (43.7%), and in cases of penicillin allergies, erythromycin 500 mg (21.3%). There was a significant difference in the antibiotic prescribing practices of GDPs compared to endodontists and other specialties especially in clinical cases such as acute apical abscesses with swelling and moderate to severe pre-operative symptoms and retreatment of endodontic cases (p<0.05). Approximately, three quarters of the respondents (78.7%) did not prescribe a loading dose when prescribing antibiotics. About 15% respondents prescribed antibiotics to their patients if they were not accessible to patients due to a holiday/weekend. Conclusions In general, the antibiotic prescribing practices of UAE dentists are congruent with the international norms. However, there were occasions of inappropriate prescriptions such as in patients with irreversible pulpitis, necrotic pulps with no systemic involvement and/or with sinus tracts.	[B. Abraham, Sheela; Awad, Manal] Univ Sharjah, Dept Prevent & Restorat Dent, Coll Dent Med, Sharjah, U Arab Emirates; [B. Abraham, Sheela; Ahmed, Hany Mohamed Aly] Univ Malaya, Dept Restorat Dent, Fac Dent, Kuala Lumpur, Malaysia; [Abdulla, Nizam; Samaranayake, Lakshman Perera] Univ Sharjah, Dept Oral & Craniofacial Hlth Sci, Coll Dent Med, Sharjah, U Arab Emirates; [Himratul-Aznita, Wan Harun] Univ Malaya, Dept Oral & Craniofacial Sci, Fac Dent, Kuala Lumpur, Malaysia; [Samaranayake, Lakshman Perera] Univ Hong Kong, Fac Dent, Hong Kong, Peoples R China	University of Sharjah; Universiti Malaya; University of Sharjah; Universiti Malaya; University of Hong Kong	Ahmed, HMA (corresponding author), Univ Malaya, Dept Restorat Dent, Fac Dent, Kuala Lumpur, Malaysia.	hany_endodontist@hotmail.com	HARUN, WAN HIMRATUL AZNITA WAN/C-1019-2010; /K-4947-2018	HARUN, WAN HIMRATUL AZNITA WAN/0000-0001-5792-8596; /0000-0002-9122-336X; Ahmed, Hany Mohamed Aly/0000-0003-0776-9288				Al-Ahmad A, 2014, J ENDODONT, V40, P223, DOI 10.1016/j.joen.2013.07.023; Al-Haroni M, 2007, J ANTIMICROB CHEMOTH, V59, P1161, DOI 10.1093/jac/dkm090; Alattas HA, 2017, J GLOB ANTIMICROB RE, V9, P82, DOI 10.1016/j.jgar.2017.01.012; Andersson Lars, 2016, Pediatr Dent, V38, P369; [Anonymous], 2017, J Endod, V43, P1409, DOI 10.1016/j.joen.2017.08.015; [Anonymous], 2016, J LARGE SCALE RES FA, V2, pA49; BAHAL N, 1992, ANN PHARMACOTHER, V26, P46, DOI 10.1177/106002809202600112; Bjelovucic R, 2019, INT DENT J, V69, P273, DOI 10.1111/idj.12460; Bolfoni MR, 2018, INT ENDOD J, V51, P148, DOI 10.1111/iej.12823; Cope AL, 2016, COMMUNITY DENT ORAL, V44, P145, DOI 10.1111/cdoe.12199; Dar-Odeh NS, 2010, THER CLIN RISK MANAG, V6, P301; Fincham JE, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj720243; Fouad AF, 1996, ORAL SURG ORAL MED O, V81, P590, DOI 10.1016/S1079-2104(96)80054-0; Germack M, 2017, J ENDODONT, V43, P1615, DOI 10.1016/j.joen.2017.05.009; Henry M, 2001, J ENDODONT, V27, P117, DOI 10.1097/00004770-200102000-00016; Karki AJ, 2011, BRIT DENT J, V210, DOI 10.1038/sj.bdj.2010.1179; Kuriyama T, 2007, ORAL MICROBIOL IMMUN, V22, P285, DOI 10.1111/j.1399-302X.2007.00365.x; Lewis MAO, 2008, BRIT DENT J, V205, P537, DOI 10.1038/sj.bdj.2008.984; Marra F, 2016, J AM DENT ASSOC, V147, P320, DOI 10.1016/j.adaj.2015.12.014; Maslamani M, 2018, MED PRIN PRACT, V27, P66, DOI 10.1159/000486416; Nabavizadeh Mohammad Reza, 2011, Iran Endod J, V6, P54; Nagle D, 2000, ORAL SURG ORAL MED O, V90, P636, DOI 10.1067/moe.2000.109777; Oberoi SS, 2015, INT DENT J, V65, P4, DOI 10.1111/idj.12146; Pallasch T J, 1993, J Calif Dent Assoc, V21, P46; Palmer NAO, 2000, BRIT DENT J, V188, P554, DOI 10.1038/sj.bdj.4800538a; Pickenpaugh L, 2001, J ENDODONT, V27, P53, DOI 10.1097/00004770-200101000-00019; Poeschl PW, 2011, J ENDODONT, V37, P1201, DOI 10.1016/j.joen.2011.05.029; Roche Y, 1997, J ANTIMICROB CHEMOTH, V40, P353, DOI 10.1093/jac/40.3.353; Rodriguez-Nunez A, 2009, J ENDODONT, V35, P1198, DOI 10.1016/j.joen.2009.05.031; Samaranayake L., 2018, ESSENTIAL MICROBIOLO, V5th; Sedgley CM, 2008, J ENDODONT, V34, P570, DOI 10.1016/j.joen.2008.02.014; Segura-Egea JJ, 2018, INT ENDOD J, V51, P20, DOI 10.1111/iej.12781; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Smieja M, 1998, Can J Infect Dis, V9, P22; Thornhill MH, 2019, BRIT DENT J, V227, P1044, DOI 10.1038/s41415-019-1002-3; WALTON RE, 1993, J ENDODONT, V19, P466, DOI 10.1016/S0099-2399(06)80535-2; Whitten BH, 1996, J AM DENT ASSOC, V127, P1333, DOI 10.14219/jada.archive.1996.0444; Wright AJ, 1999, MAYO CLIN PROC, V74, P290, DOI 10.4065/74.3.290; Yingling NM, 2002, J ENDODONT, V28, P396, DOI 10.1097/00004770-200205000-00012	39	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2020	15	12							e0244585	10.1371/journal.pone.0244585	http://dx.doi.org/10.1371/journal.pone.0244585			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TQ	33378378	gold, Green Published			2023-01-03	WOS:000605651300076
J	Wu, M; Whittemore, K; Huang, CC; Corrado, RE; Culp, GM; Lim, S; Schluger, NW; Daskalakis, DC; Lucero, DE; Vora, NM				Wu, Melody; Whittemore, Katherine; Huang, Chaorui C.; Corrado, Rachel E.; Culp, Gretchen M.; Lim, Sungwoo; Schluger, Neil W.; Daskalakis, Demetre C.; Lucero, David E.; Vora, Neil M.			Community-setting pneumonia-associated hospitalizations by level of urbanization-New York City versus other areas of New York State, 2010-2014	PLOS ONE			English	Article							INFECTIOUS-DISEASES SOCIETY; ACQUIRED PNEUMONIA; HEALTH; DIAGNOSIS; BURDEN; ADULTS; IMPACT; URBAN; RISK	Background New York City (NYC) reported a higher pneumonia and influenza death rate than the rest of New York State during 2010-2014. Most NYC pneumonia and influenza deaths are attributed to pneumonia caused by infection acquired in the community, and these deaths typically occur in hospitals. Methods We identified hospitalizations of New York State residents aged >= 20 years discharged from New York State hospitals during 2010-2014 with a principal diagnosis of community-setting pneumonia or a secondary diagnosis of community-setting pneumonia if the principal diagnosis was respiratory failure or sepsis. We examined mean annual age-adjusted community-setting pneumonia-associated hospitalization (CSPAH) rates and proportion of CSPAH with in-hospital death, overall and by sociodemographic group, and produced a multivariable negative binomial model to assess hospitalization rate ratios. Results Compared with non-NYC urban, suburban, and rural areas of New York State, NYC had the highest mean annual age-adjusted CSPAH rate at 475.3 per 100,000 population and the highest percentage of CSPAH with in-hospital death at 13.7%. NYC also had the highest proportion of CSPAH patients residing in higher-poverty-level areas. Adjusting for age, sex, and area-based poverty, NYC residents experienced 1.3 (95% confidence interval [CI], 1.2-1.4), non-NYC urban residents 1.4 (95% CI, 1.3-1.6), and suburban residents 1.2 (95% CI, 1.1-1.3) times the rate of CSPAH than rural residents. Conclusions In New York State, NYC as well as other urban areas and suburban areas had higher rates of CSPAH than rural areas. Further research is needed into drivers of CSPAH deaths, which may be associated with poverty.	[Wu, Melody] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Wu, Melody; Whittemore, Katherine; Huang, Chaorui C.; Corrado, Rachel E.; Daskalakis, Demetre C.; Lucero, David E.; Vora, Neil M.] New York City Dept Hlth & Mental Hyg, Div Dis Control, Queens, NY 10013 USA; [Culp, Gretchen M.; Lim, Sungwoo] New York City Dept Hlth & Mental Hyg, Div Epidemiol, Queens, NY USA; [Schluger, Neil W.] Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Schluger, Neil W.] Columbia Univ, Dept Med, Vagelos Coll Phys & Surg, New York, NY USA; [Schluger, Neil W.] Columbia Univ, Dept Epidemiol, Vagelos Coll Phys & Surg, New York, NY USA; [Schluger, Neil W.] Columbia Univ, Dept Environm Hlth Sci, Vagelos Coll Phys & Surg, New York, NY USA; [Schluger, Neil W.] Mailman Sch Publ Hlth, New York, NY USA; [Vora, Neil M.] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Ctr Preparedness & Response, Atlanta, GA USA	Columbia University; New York City Department of Health & Mental Hygiene; New York City Department of Health & Mental Hygiene; Columbia University; Columbia University; Columbia University; Columbia University; Centers for Disease Control & Prevention - USA	Wu, M (corresponding author), Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10027 USA.; Wu, M (corresponding author), New York City Dept Hlth & Mental Hyg, Div Dis Control, Queens, NY 10013 USA.	mw2893@caa.columbia.edu	Schluger, Neil/ABA-1793-2021; Vora, Neil Manhar/AAJ-7269-2021	Vora, Neil Manhar/0000-0002-4989-3108; Wu, Melody/0000-0002-7928-0126	Epi Scholars program, New York City Department of Health and Mental Hygiene	Epi Scholars program, New York City Department of Health and Mental Hygiene	MW was supported by the Epi Scholars program, New York City Department of Health and Mental Hygiene (https://www1.nyc.gov/site/doh/about/employment/epi-scholar.page).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIDSINFO, 2019, GUID PREV TREATM OPP; American Lung Association, 2019, 2019 STAT AIR, DOI [10.1702/3169.31501, DOI 10.1702/3169.31501]; AMJS, 2020, MIN FAT; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Beninca E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180797; BLUSTEIN J, 1994, AM J PUBLIC HEALTH, V84, P1018, DOI 10.2105/AJPH.84.6.1018; Bureau of Health Informatics, 2014, SPARCS INP OUTP DAT; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Cordoba E, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy020; Corrado RE, 2017, CHEST, V152, P930, DOI 10.1016/j.chest.2017.04.162; Ehrlich SF, 2010, DIABETES CARE, V33, P55, DOI 10.2337/dc09-0880; Flanders WD, 1999, J GEN INTERN MED, V14, P333, DOI 10.1046/j.1525-1497.1999.00351.x; Gross AE, 2014, ANTIMICROB AGENTS CH, V58, P5262, DOI 10.1128/AAC.02582-14; Gu CH, 2018, PUBLIC HEALTH REP, V133, P584, DOI 10.1177/0033354918792009; Hall MJ, 2014, NCHS DATA BRIEF, V17, P12; Hayes BH, 2018, CHEST, V153, P427, DOI 10.1016/j.chest.2017.09.041; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Karpati A., 2004, HLTH DISPARITIES NEW; Klein RJ, 2001, HLTH PEOPLE 2010 STA, V20, P1; Knox EG, 2008, J EPIDEMIOL COMMUN H, V62, P442, DOI 10.1136/jech.2007.065862; Krieger J, 2002, AM J PUBLIC HEALTH, V92, P758, DOI 10.2105/AJPH.92.5.758; Lave JR, 1996, J GEN INTERN MED, V11, P415, DOI 10.1007/BF02600189; Loeb MB, 2004, CLIN INFECT DIS, V38, P1293, DOI 10.1086/383469; Lutfiyya MN, 2007, INT J QUAL HEALTH C, V19, P141, DOI 10.1093/intqhc/mzm010; Lutfiyya MN, 2006, AM FAM PHYSICIAN, V73, P442; Medicaid and CHIP Payment and Access Commission, 2018, ACC BRIEF RURU URB H; Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST; National Center for Health Statistics  Centers for Disease Control and Prevention, 2018, INFL PNEUM MORT STAT; New York City Department of Health and Mental Hygiene, 2020, COVID 19 DAT; New York State Department of Health, 2020, END AIDS EP NEW YORK; New York State Department of Health, 2014, SPARCS FAC RAC ETHN; New York State Department of Health, STAT PLANN RES COOP; New York State Department of Health, 2014, 1603 NY STAT DEP HLT; New York State Department of Health, 2018, LEAD CAUS DEATH NEW; Office on Smoking and Health  National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, 2019, SMOK COPD; Remington PL, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0044-2; Shirey L., RURAL URBAN HLTH; Stringer SM, 2015, HIDDEN HOUSEHOLDS; Torres A, 2015, THORAX, V70, P984, DOI 10.1136/thoraxjnl-2015-206780; United States Census Bureau, 2018, COMP ACS DAT; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5	41	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2020	15	12							e0244367	10.1371/journal.pone.0244367	http://dx.doi.org/10.1371/journal.pone.0244367			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PL4CI	33362262	Green Published, gold			2023-01-03	WOS:000603071600023
J	Goyal, N; Rongsen-Chandola, T; Sood, M; Sinha, B; Kumar, A; Qazi, SA; Aboubaker, S; Nisar, YB; Bahl, R; Bhan, MK; Bhandari, N				Goyal, Nidhi; Rongsen-Chandola, Temsunaro; Sood, Mangla; Sinha, Bireshwar; Kumar, Amit; Qazi, Shamim Ahmad; Aboubaker, Samira; Nisar, Yasir Bin; Bahl, Rajiv; Bhan, Maharaj Kishan; Bhandari, Nita			Management of possible serious bacterial infection in young infants closer to home when referral is not feasible: Lessons from implementation research in Himachal Pradesh, India	PLOS ONE			English	Article							INJECTABLE PROCAINE BENZYLPENICILLIN; COMMUNITY-HEALTH WORKERS; CLINICAL SIGNS; OPEN-LABEL; GENTAMICIN; MORTALITY; NEWBORNS; CARE	Background Government of India and the World Health Organization have guidelines for outpatient management of young infants 0-59 days with signs of Possible Serious Bacterial Infection (PSBI), when referral is not feasible. Implementation research was conducted to identify facilitators and barriers to operationalizing these guidelines. Methods Himachal Pradesh government implemented the guidelines in program settings supported by Centre for Health Research and Development, Society for Applied Studies. The strategy included community sensitization, skill enhancement of Accredited Social Health Activists (ASHA), Auxiliary Nurse Midwives (ANMs) and Medical Officers (MOs) to identify PSBI and treat when referral was not feasible. The research team collected information on facilitators and barriers. A technical support unit provided training and oversight. Findings Among 1997 live births from June 2017 to January 2019, we identified 160 cases of PSBI in young infants resulting in a coverage of 80%, assuming an incidence of 10%. Of these,29(18.1%) had signs of critical illness (CI), 92 (57.5%) had clinical severe infection (CSI), 5 (3.1%)had severe pneumonia (only fast breathing in young infants 0-6 days), while 34 (21%) had pneumonia (only fast breathing in young infants 7-59 days). Hospital referral was accepted by 48/160 (30%), whereas 112/160 (70%) were treated with the simplified treatment regimens at primary level facilities. Of the 29 infants with CI, 18 (62%) accepted referral; 26 (90%) recovered while 3 (10%) who had accepted referral, died. Of the 92 infants who had CSI, 86 (93%) recovered, 65 (71%) received simplified treatment and one infant who had accepted referral, died. All the five infants who had severe pneumonia, recovered; 3 (60%) had received simplified treatment. Of the 34 pneumonia cases, 33 received simplified treatment of which 5 (15%) failed treatment; two out of these 5 died. Overall, 6/160 infants died (case-fatality-rate 3.4%); 2 in the simplified treatment (case-fatality-rate 1.8%) and 4 in the hospital group (case-fatality-rate 8.3%). Delayed identification and care-seeking by families and health system weaknesses like manpower gaps and interrupted supplies were challenges in implementation. Conclusions Implementation of the guidelines in program settings is possible and acceptable. Scaling up would require creating community awareness, early identification and appropriate care-seeking, strengthening ASHA home-visitation program, building skills and confidence of MOs and ANMs, uninterrupted supplies and a dependable referral system.	[Goyal, Nidhi; Rongsen-Chandola, Temsunaro; Sinha, Bireshwar; Kumar, Amit; Bhandari, Nita] Soc Appl Studies, Ctr Hlth Res & Dev, New Delhi, India; [Sood, Mangla] Indira Gandhi Med Coll, Dept Pediat, Shimla, Himachal Prades, India; [Sood, Mangla] Natl Hlth Mission, Child Hlth, Shimla, Himachal Prades, India; [Qazi, Shamim Ahmad; Aboubaker, Samira; Nisar, Yasir Bin; Bahl, Rajiv] WHO, Dept Maternal Newborn Child & Adolescent Hlth & A, Geneva, Switzerland; [Bhan, Maharaj Kishan] Indian Inst Technol Delhi, New Delhi, India; [Bhan, Maharaj Kishan] Biotechnol Ind Res Assistance Council BIRAC, Knowledge Integrat & Translat Platform KnIT, New Delhi, India	Indira Gandhi Medical College & Hospital Shimla; World Health Organization; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Delhi; Biotechnology Industry Research Assistance Council (BIRAC)	Rongsen-Chandola, T (corresponding author), Soc Appl Studies, Ctr Hlth Res & Dev, New Delhi, India.	naro@sas.org.in	Nisar, Yasir Bin/AFO-2407-2022; Sinha, Bireshwar/AEA-9974-2022; Sood, Mangla/AAO-2493-2020	Sinha, Bireshwar/0000-0002-7408-7474; Sood, Mangla/0000-0002-9616-5410	Bill and Melinda Gates Foundation (BMGF) through the Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland [OPP1114815]; Technical Service Agreement with WHO [2016/640408-0]	Bill and Melinda Gates Foundation (BMGF) through the Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland; Technical Service Agreement with WHO	The study was supported by a grant from the Bill and Melinda Gates Foundation (BMGF Grant No. OPP1114815) through the Department of Maternal, Newborn, Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland. TRC received funds through a Technical Service Agreement with WHO, (WHO Reference 2016/640408-0). URL of funder website: www.gatesfoundation.org.The funder, BMGF had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. SAQ, SA, YBN and RB from WHO were involved in study design, decision to publish and preparation of the manuscript.	[Anonymous], 2017, LANCET GLOB HEALTH, V5, pe428; Applegate JA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229988; Applegate JA, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001643; Awasthi S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234212; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Baqui AH, 2015, LANCET GLOB HEALTH, V3, pE279, DOI 10.1016/S2214-109X(14)70347-X; Bhandari N, 1996, LANCET, V347, P1774, DOI 10.1016/S0140-6736(96)90856-9; Bhura M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240688; Fadel SA, 2017, LANCET, V390, P1972, DOI 10.1016/S0140-6736(17)32162-1; [GOI MOHFW], 2014, OP GUID US GENT ANMS; [GOI MoHFW], 2017, ADD OP GUID US GENT; [GOI MoHFW], 2011, HOM BAS NEWB CAR OP; Government of India, 2018, NAVJ SHISH SUR KAR B; Guenther T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229248; Harden SM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00071; Khanal S, 2011, J HEALTH POPUL NUTR, V29, P255, DOI 10.3329/jhpn.v29i3.7873; Kozuki N, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2330-0; Kumar Pratyush, 2018, J Family Med Prim Care, V7, P1157, DOI 10.4103/jfmpc.jfmpc_254_18; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; National Health Authority, 2018, AYS BHAR PRADH MANTR; NFHS4-Telangana, 2015, NATL FAMILY HLTH SUR; Owais A, 2011, J PERINATOL, V31, P586, DOI 10.1038/jp.2010.191; Rahman AE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232675; Roy S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236355; Seale AC, 2014, LANCET INFECT DIS, V14, P731, DOI 10.1016/S1473-3099(14)70804-7; Taneja S, 2018, ACTA PAEDIATR, V107, P80, DOI 10.1111/apa.14428; Tshefu A, 2015, LANCET, V385, P1767, DOI 10.1016/S0140-6736(14)62284-4; Wammanda RD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228718; World Health Organization, 2015, GUID MAN POSS SER BA; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C; Zaidi AKM, 2012, PEDIATR INFECT DIS J, V31, P667, DOI 10.1097/INF.0b013e318256f86c	31	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2020	15	12							e0243724	10.1371/journal.pone.0243724	http://dx.doi.org/10.1371/journal.pone.0243724			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CG	33351810	Green Published, gold			2023-01-03	WOS:000603071400033
J	[Anonymous]				[Anonymous]			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	5	5	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2020	371								m4779	10.1136/bmj.m4779	http://dx.doi.org/10.1136/bmj.m4779			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PI0VM	33334781	Bronze			2023-01-03	WOS:000600818400002
J	Morean, ME; Bold, KW; Kong, G; Camenga, DR; Jackson, A; Simon, P; Davis, DR; Krishnan-Sarin, S				Morean, Meghan E.; Bold, Krysten W.; Kong, Grace; Camenga, Deepa R.; Jackson, Asti; Simon, Patricia; Davis, Danielle R.; Krishnan-Sarin, Suchitra			High school students' use of JUUL pod flavors before and after JUUL implemented voluntary sales restrictions on certain flavors in 2018	PLOS ONE			English	Article							UNITED-STATES	Objectives In November 2018, JUUL, Inc. restricted sales of mango, fruit medley, creme brulee, and cucumber pods to its website. Physical/online sales of tobacco, menthol, and mint pods continued. We examined rates of adolescent JUUL device and flavored pod use before and after restrictions were implemented to examine their potential impact. Methods Students from 4 Connecticut high schools completed cross-sectional surveys in 2018 (N = 3170) and 2019 (N = 3074). Results Compared to 2018, current (past-month) JUUL use decreased in 2019 (30.2-25.6%). Among current JUUL users, restricted flavor use (mango [62.8-36.9%]; cucumber [27.7-11.9%]; fruit [23.5-11.4%]; creme brulee [12.3-5.0%]) and the total number of flavors used (2.09[SD = 1.71]-1.51[SD = 1.33]) decreased (p-values < .001), while mint pod use increased (62.0-68.6%, p < .01). Tobacco and menthol pod use remained stable. Conclusions Following voluntary sales restrictions implemented by JUUL, Inc., restricted flavor use and the total number of flavors used decreased among JUUL users while mint use increased. Results suggest flavor restrictions may impact adolescents' e-cigarette use. While 2020 Food and Drug Administration restrictions on mint pods may further limit youth JUUL use, research is needed to determine where youth acquire restricted flavors and if restrictions prompt increased popularity of unrestricted devices/e-liquids.	[Morean, Meghan E.; Bold, Krysten W.; Kong, Grace; Jackson, Asti; Simon, Patricia; Davis, Danielle R.; Krishnan-Sarin, Suchitra] Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA; [Camenga, Deepa R.] Yale Sch Med, Dept Emergency Med, New Haven, CT USA; [Camenga, Deepa R.] Yale Sch Med, Dept Pediat, New Haven, CT USA	Yale University; Yale University; Yale University	Morean, ME (corresponding author), Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA.	meghan.morean@yale.edu		morean, meghan/0000-0003-4865-1155	NIDA [P50DA036151, U54DA036151]; FDA Center for Tobacco Products (CTP)	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FDA Center for Tobacco Products (CTP)(United States Department of Health & Human Services)	Research reported in this publication was supported by grant numbers P50DA036151 and U54DA036151 from the NIDA and FDA Center for Tobacco Products (CTP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration. These grants were received by SKS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administration UFaD, 2020, ENF PRIOR EL NIC DEL; [Anonymous], 2019, NATL YOUTH TOBACCO S; Barrington-Trimis JL, 2018, NEW ENGL J MED, V379, P1099, DOI 10.1056/NEJMp1805758; Cullen KA, 2019, JAMA-J AM MED ASSOC, V322, P2095, DOI 10.1001/jama.2019.18387; Delnevo C, 2020, TOB CONTROL, V29, pE150, DOI 10.1136/tobaccocontrol-2019-055485; Erythropel HC, 2019, AM J PREV MED, V57, P425, DOI 10.1016/j.amepre.2019.04.004; Johnson AL, 2018, NICOTINE TOB RES, V1, P1; JUUL Inc, 2019, UPD JUUL COMS ONL AG; Kong G, 2019, DRUG ALCOHOL DEPEN, V205, DOI 10.1016/j.drugalcdep.2019.107691; Krishnan-Sarin S, 2019, DRUG ALCOHOL DEPEN, V194, P395, DOI 10.1016/j.drugalcdep.2018.10.022; Leavens ELS, 2019, ADDICT BEHAV, V95, P178, DOI 10.1016/j.addbeh.2019.02.011; Leventhal AM, 2019, JAMA-J AM MED ASSOC, V322, P2132, DOI 10.1001/jama.2019.17968; Liber A, 2020, AM J PUBLIC HEALTH, V110, P785, DOI 10.2105/AJPH.2020.305667; Walley SC, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2741; Wang TW, 2019, MMWR SURVEILL SUMM, V68, P1, DOI 10.15585/mmwr.ss6812a1	15	5	5	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2020	15	12							e0243368	10.1371/journal.pone.0243368	http://dx.doi.org/10.1371/journal.pone.0243368			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH3TP	33320885	Green Published, gold			2023-01-03	WOS:000600339800030
J	Olakunde, BO; Pharr, JR; Chien, LC; Benfield, RD; Sy, FS				Olakunde, Babayemi O.; Pharr, Jennifer R.; Chien, Lung-Chang; Benfield, Rebecca D.; Sy, Francisco S.			Individual- and country-level correlates of female permanent contraception use in sub-Saharan Africa	PLOS ONE			English	Article							MULTILEVEL LOGISTIC-REGRESSION; BRIEF CONCEPTUAL TUTORIAL; TUBAL-LIGATION; SOCIAL EPIDEMIOLOGY; FERTILITY DESIRES; BEHAVIORAL-MODEL; STERILIZATION; WOMEN; ACCESS; HEALTH	Background Female permanent contraception is a cost-effective contraceptive method that can help clients with the desire to limit childbearing achieve their reproductive intention. However, despite its benefits, the use of FPC remains low in sub-Saharan Africa (SSA), and limited studies have examined the correlates of its uptake. In this study, we assessed the individual- and country-level factors associated with the use of FPC among married or in-union women using modern contraceptive methods to limit childbearing in SSA. Methods This study was a secondary data analysis of individual- and country-level data obtained from the Demographic and Health Surveys (DHS) Program and three open data repositories. The study included 29,777 married or in-union women aged 15-49 years using modern contraceptive methods to limit childbearing from DHS conducted in 33 sub-Sahara African countries between 2010 and 2018. We performed descriptive statistics and fitted multilevel logistic regression models to determine the predisposing, enabling, and need factors associated with the use of FPC. Results Approximately 13% of the women used FPC. About 20% of the variance in the odds of using FPC was attributable to between-country differences. In the full model, the significant individual-level factors associated with the use of FPC compared with other modern contraceptive methods were: age (odds ratio [OR] = 1.10; 95%CI = 1.08-1.12), living children (OR = 1.11, 95%CI = 1.04-1.16), high household wealth (OR = 1.39, 95%CI = 1.18-1.64), rural residence (OR = 0.83, 95% CI = 0.71-0.97), joint contraceptive decision with partner (OR = 1.68, 95% = 1.43-1.99), contraceptive decision by partner and others (OR = 2.46, 95% = 1.97-3.07), and the number of living children less than the ideal number of children (OR = 1.40, 95%CI = 1.21-1.62). The significantly associated country-level factors were births attended by skilled health providers (OR = 1.03, 95%CI = 1.00-1.05) and density of medical doctors (OR = 1.37, 95%CI = 1.01-1.85). Conclusions Our results suggest that both individual- and country-level factors affect uptake of FPC in SSA. Increasing geographic, economic, and psychosocial access to FPC may improve its uptake in SSA.	[Olakunde, Babayemi O.; Pharr, Jennifer R.; Sy, Francisco S.] Univ Nevada, Sch Publ Hlth, Dept Environm & Occupat Hlth, Las Vegas, NV 89154 USA; [Olakunde, Babayemi O.] Natl Agcy Control AIDS, Dept Community Prevent & Care Serv, Abuja, Nigeria; [Chien, Lung-Chang] Univ Nevada, Sch Publ Hlth, Dept Epidemiol & Biostat, Las Vegas, NV 89154 USA; [Benfield, Rebecca D.] Univ Nevada, Sch Nursing, Las Vegas, NV 89154 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas	Olakunde, BO (corresponding author), Univ Nevada, Sch Publ Hlth, Dept Environm & Occupat Hlth, Las Vegas, NV 89154 USA.; Olakunde, BO (corresponding author), Natl Agcy Control AIDS, Dept Community Prevent & Care Serv, Abuja, Nigeria.	olakunde@unlv.nevada.edu		Pharr, Jennifer/0000-0002-0383-2641				Adegoke A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040220; Alemayehu M, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-6; Andersen R, 1968, BEHAV MODEL FAMILIES BEHAV MODEL FAMILIES; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Andersen RM, 2008, MED CARE, V46, P647, DOI 10.1097/MLR.0b013e31817f4d48; Anderson JE, 2012, CONTRACEPTION, V85, P552, DOI 10.1016/j.contraception.2011.10.009; Austin PC, 2017, STAT MED, V36, P3257, DOI 10.1002/sim.7336; Baatiema L, 2019, ADV PUBLIC HEAL, V2019, P1; Balogun OR, 2017, J MED BIOMED SCI, V6, P1, DOI 10.4314/jmbs.v6i3.1; Bass LE, 2013, SOCIOL FOCUS, V46, P47; Blackstone SR, 2017, INT Q COMMUNITY HEAL, V37, P79, DOI 10.1177/0272684X16685254; Blanc AK, 2001, STUD FAMILY PLANN, V32, P189, DOI 10.1111/j.1728-4465.2001.00189.x; Borrero S, 2007, OBSTET GYNECOL, V109, P94, DOI 10.1097/01.AOG.0000249604.78234.d3; Bradley SEK, 2011, DHS ANAL STUDIES; Casterline JB, 2017, DEMOGR RES, V36, P427, DOI 10.4054/DemRes.2017.36.14; Channon MD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219736; CHIBALONZA K, 1989, STUD FAMILY PLANN, V20, P273, DOI 10.2307/1966764; Choi Y, 2019, CONTRACEPTION, V99, P131, DOI 10.1016/j.contraception.2018.10.006; Croft TN, 2018, GUIDE DHS STAT; Daniele MAS, 2018, B WORLD HEALTH ORGAN, V96, P450, DOI [10.2471/BLT.17.206466, 10.2471/blt.17.206466]; Darroch JE, 2017, ADDING IT INVESTING; de Oliveira IT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086654; Dereuddre R, 2016, SOC SCI MED, V161, P1, DOI [10.10161/j.socscimed.2016.05.030, 10.1016/j.socscimed.2016.05.030]; EASTERLIN RA, 1988, STUD FAMILY PLANN, V19, P257, DOI 10.2307/1966791; EASTERLIN RA, 1975, STUD FAMILY PLANN, V6, P54, DOI 10.2307/1964934; Edmeades J, 2011, GLOB PUBLIC HEALTH, V6, P407, DOI 10.1080/17441692.2010.533686; EngenderHealth, 2002, CONTR STER GLOB ISS; Fabic MS, 2019, GLOB HEALTH-SCI PRAC, V7, P564, DOI 10.9745/GHSP-D-19-00298; Festin MPR, 2016, CONTRACEPTION, V94, P289, DOI 10.1016/j.contraception.2016.05.015; Ghosh S, 2017, J BIOSOC SCI, V49, P48, DOI 10.1017/S0021932016000080; Gordon-Maclean C, 2014, INT J GYNECOL OBSTET, V124, P34, DOI 10.1016/j.ijgo.2013.07.016; Guttmacher Institute, 2017, ADD IT INV CONTR MAT; Jacobs C, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00011; Jacobstein R, 2013, STUD FAMILY PLANN, V44, P85, DOI 10.1111/j.1728-4465.2013.00345.x; Kriel Y, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0749-y; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Lunde B, 2013, OBSTET GYNECOL, V122, P304, DOI 10.1097/AOG.0b013e31829b5a11; Lutala PM, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-38; Marie Stopes International EngenderHealth  International IntraHealth  International Planned Parenthood Federation Population Council Jhpiego, 2014, INCR ACC HIGH QUAL V; Mengesha ZB, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0598-9; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; Micks EA, 2015, WOMENS HEALTH, V11, P769, DOI 10.2217/whe.15.69; Midi H, 2010, J INTERDISCIP MATH, V13, P253, DOI 10.1080/09720502.2010.10700699; Mohanty SK, 2020, BMC WOMENS HEALTH, V20, DOI 10.1186/s12905-020-0884-1; Musalia JM, 2005, SEX ROLES, V53, P835, DOI 10.1007/s11199-005-8296-0; Nuccio O, 2017, HEALTH POLICY PLANN, V32, P163, DOI 10.1093/heapol/czw105; Nyongesa C, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1727-z; Olakunde BO, 2019, CONTRACEPTION, V99, P205, DOI 10.1016/j.contraception.2018.12.007; Perpetuo HIO, 2003, POVERTY FERTILITY FA, P311; Ren R., NOTE DHS STANDARD WE; RODRIGUES J, 1995, J BIOSOC SCI, V27, P339, DOI 10.1017/S0021932000022860; Rutaremwa G, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1611-y; Seiber EE, 2007, INT FAM PLAN PERSPEC, V33, P117, DOI 10.1363/3311707; Sennott C, 2012, INT PERSPECT SEX R H, V38, P34, DOI 10.1363/3803412; Shattuck D, 2011, AM J PUBLIC HEALTH, V101, P1089, DOI 10.2105/AJPH.2010.300091; Sonfield A, 2013, SOCIAL EC BENEFITS W; Speizer IS, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0729-3; Speizer IS, 2000, INT FAM PLAN PERSPEC, V26, P13, DOI 10.2307/2648285; Stephenson R, 2006, J HEALTH POPUL NUTR, V24, P100; The RESPOND Project, 2014, MATT FACT MATT CHOIC; Thind A, 2005, J FAM PLAN REPROD H, V31, P34, DOI 10.1783/0000000052972762; Tumlinson K, 2015, CONTRACEPTION, V92, P143, DOI 10.1016/j.contraception.2015.04.002; United Nations Department of Economic and Social Affairs Population Division., 2019, CONTR US METH 2019 D; United Nations Department of Economic and Social Affairs Population Division, 2015, TRENDS CONTR US WORL; Van Lith LM, 2013, GLOB HEALTH-SCI PRAC, V1, P97, DOI 10.9745/GHSP-D-12-00036; Von Lengerke T., 2014, HLTH CARE UTILIZATIO, P11, DOI [10.1007/978-1-4614-9191-0_2, DOI 10.1007/978-1-4614-9191-0_2]; Westoff CF, 2000, INT FAM PLAN PERSPEC, V26, P56, DOI 10.2307/2648268; Westoff CF, 2012, UNMET NEED MODERN CO; White K, 2015, WOMEN HEALTH ISS, V25, P628, DOI 10.1016/j.whi.2015.06.011; World Health Organization, 2012, WHO REC OPT HLTH WOR	71	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2020	15	12							e0243316	10.1371/journal.pone.0243316	http://dx.doi.org/10.1371/journal.pone.0243316			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH3TP	33320877	gold, Green Published			2023-01-03	WOS:000600339800005
J	Wongyingsinn, M; Kohmongkoludom, P; Trakarnsanga, A; Horthongkham, N				Wongyingsinn, Mingkwan; Kohmongkoludom, Pasawang; Trakarnsanga, Atthaphorn; Horthongkham, Navin			Postoperative clinical outcomes and inflammatory markers after inguinal hernia repair using local, spinal, or general anesthesia: A randomized controlled trial	PLOS ONE			English	Article							STRESS-RESPONSE; HERNIORRHAPHY; LIDOCAINE; INTERLEUKIN-6; ADHESION; SURGERY	Background No consensus has yet been reached regarding the best anesthetic technique for inguinal hernia repair. This study aimed to compare postoperative clinical outcomes and inflammatory markers among patients who were anesthetized using local, spinal, or general anesthesia for inguinal hernia repair. Methods This randomized controlled trial included patients scheduled to undergo elective unilateral inguinal hernioplasty at Siriraj Hospital during November 2014 to September 2015 study period. Patients were randomly assigned to the local (LA), spinal (SA), or general (GA) anesthesia groups. Primary outcomes were postoperative pain at rest and on mobilization at 8 and 24 hours after surgery. Results Fifty-four patients were included, with 18 patients randomly assigned to each group. Patient demographic and clinical characteristics were similar among groups. There were no significant differences among groups for postoperative pain at rest or on mobilization at 8 and 24 hours after surgery. No significant differences were observed for interleukin-1 beta, interleukin-6, and interleukin-10 at any time points in any groups. Patients with local anesthesia was associated with less time spent in anesthesia (p = 0.010) and surgery (p = 0.009), lower intraoperative cost (p = 0.003) and total cost in hospital (p = 0.036); however, patient satisfaction in the local anesthesia group (94/100) was statistically significantly lower than the spinal and general anesthesia groups (100/100) (p = 0.010). Conclusions No statistically significant difference was observed among groups for postoperative pain scores, duration of hospital stays, complications, or change in inflammatory markers. However, time spent in anesthesia and surgery, the intraoperative cost and total cost for hernia repair, and patient satisfaction were significantly lower in the local anesthesia group than in the other two groups.	[Wongyingsinn, Mingkwan; Kohmongkoludom, Pasawang] Mahidol Univ, Fac Med, Dept Anesthesiol, Siriraj Hosp, Bangkok, Thailand; [Trakarnsanga, Atthaphorn] Mahidol Univ, Div Gen Surg, Dept Surg, Minimally Invas Surg Unit,Fac Med,Siriraj Hosp, Bangkok, Thailand; [Horthongkham, Navin] Mahidol Univ, Fac Med, Dept Microbiol, Siriraj Hosp, Bangkok, Thailand	Mahidol University; Mahidol University; Mahidol University	Wongyingsinn, M (corresponding author), Mahidol Univ, Fac Med, Dept Anesthesiol, Siriraj Hosp, Bangkok, Thailand.	mingkwan.won@mahidol.ac.th	Horthongkham, Navin/AAZ-7963-2021	Wongyingsinn, Mingkwan/0000-0003-4508-5661; trakarnsanga, atthaphorn/0000-0002-1980-7782	Faculty of Medicine Siriraj Hospital, Mahidol University [R015720002]	Faculty of Medicine Siriraj Hospital, Mahidol University	This research project was supported by Faculty of Medicine Siriraj Hospital, Mahidol University, Grant Number (IO) R015720002.	AMID PK, 1994, ANN SURG, V220, P735, DOI 10.1097/00000658-199412000-00004; Amid PK, 1996, EUR J SURG, V162, P447; Azuma Y, 2000, INT J IMMUNOPHARMACO, V22, P789, DOI 10.1016/S0192-0561(00)00040-0; Bhattacharya SD, 2012, AM SURGEON, V78, P798; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; Carli F, 2001, BRIT J ANAESTH, V87, P531, DOI 10.1093/bja/87.4.531; Cassuto J, 2006, ACTA ANAESTH SCAND, V50, P265, DOI 10.1111/j.1399-6576.2006.00936.x; CHANG FC, 1977, ARCH SURG-CHICAGO, V112, P1069; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Di Vita G, 2000, AM J SURG, V180, P203, DOI 10.1016/S0002-9610(00)00445-1; Doran C, 2013, PAIN CLINIC, V19, P207; GIDDON DB, 1972, AM J PATHOL, V68, P327; Goldenberg Alberto, 2005, Acta Cir. Bras., V20, P347, DOI 10.1590/S0102-86502005000500002; Gurleyik E, 1998, AM J SURG, V175, P179, DOI 10.1016/S0002-9610(97)00293-6; HILL ADK, 1995, SURG ENDOSC-ULTRAS, V9, P695; Hollmann MW, 2001, ANESTHESIOLOGY, V95, P113, DOI 10.1097/00000542-200107000-00021; Huntington CR, 2015, AM SURGEON, V81, P704; JOB CA, 1979, NEW YORK STATE J MED, V79, P1730; Kehlet H, 1999, WORLD J SURG, V23, P801, DOI 10.1007/s002689900583; Kehlet H, 2005, WORLD J SURG, V29, P1058, DOI 10.1007/s00268-005-7969-8; KINGSNORTH AN, 1981, BRIT J SURG, V68, P273, DOI 10.1002/bjs.1800680416; Lan W, 2005, ANESTH ANALG, V100, P409, DOI 10.1213/01.ANE.0000142113.39092.87; MACGREGOR RR, 1980, BLOOD, V56, P203; Mikawa K, 2003, EUR J ANAESTH, V20, P104, DOI 10.1097/00003643-200302000-00004; Nordin P, 2004, ANN SURG, V240, P187, DOI 10.1097/01.sla.0000130726.03886.93; O'Dwyer PJ, 2003, ANN SURG, V237, P574, DOI 10.1097/00000658-200304000-00020; OHSAKA A, 1994, EXP HEMATOL, V22, P460; Schmidt W, 1997, ANESTHESIOLOGY, V87, P617, DOI 10.1097/00000542-199709000-00023; Schwab R, 2004, Hernia, V8, P226; Sungurtekin H, 2003, J CLIN ANESTH, V15, P201, DOI 10.1016/S0952-8180(03)00032-1; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; YOUNG DV, 1987, AM J SURG, V153, P560, DOI 10.1016/0002-9610(87)90154-1; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e	34	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2020	15	11							e0242925	10.1371/journal.pone.0242925	http://dx.doi.org/10.1371/journal.pone.0242925			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT2ZY	33253306	Green Published, gold			2023-01-03	WOS:000608488200107
J	Leni, Z; Cassagnes, LE; Daellenbach, KR; El Haddad, I; Vlachou, A; Uzu, G; Prevot, ASH; Jaffrezo, JL; Baumlin, N; Salathe, M; Baltensperger, U; Dommen, J; Geiser, M				Leni, Zaira; Cassagnes, Laure Estelle; Daellenbach, Kaspar R.; El Haddad, Imad; Vlachou, Athanasia; Uzu, Gaelle; Prevot, Andre S. H.; Jaffrezo, Jean-Luc; Baumlin, Nathalie; Salathe, Matthias; Baltensperger, Urs; Dommen, Josef; Geiser, Marianne			Oxidative stress-induced inflammation in susceptible airways by anthropogenic aerosol	PLOS ONE			English	Article							SOURCE APPORTIONMENT; AIR-POLLUTION; MASS; PM10; PARTICLES; IDENTIFICATION; ASTHMA	Ambient air pollution is one of the leading five health risks worldwide. One of the most harmful air pollutants is particulate matter (PM), which has different physical characteristics (particle size and number, surface area and morphology) and a highly complex and variable chemical composition. Our goal was first to comparatively assess the effects of exposure to PM regarding cytotoxicity, release of pro-inflammatory mediators and gene expression in human bronchial epithelia (HBE) reflecting normal and compromised health status. Second, we aimed at evaluating the impact of various PM components from anthropogenic and biogenic sources on the cellular responses. Air-liquid interface (ALI) cultures of fully differentiated HBE derived from normal and cystic fibrosis (CF) donor lungs were exposed at the apical cell surface to water-soluble PM filter extracts for 4 h. The particle dose deposited on cells was 0.9-2.5 and 8.8-25.4 mu g per cm(2) of cell culture area for low and high PM doses, respectively. Both normal and CF HBE show a clear dose-response relationship with increasing cytotoxicity at higher PM concentrations. The concurrently enhanced release of pro-inflammatory mediators at higher PM exposure levels links cytotoxicity to inflammatory processes. Further, the PM exposure deregulates genes involved in oxidative stress and inflammatory pathways leading to an imbalance of the antioxidant system. Moreover, we identify compromised defense against PM in CF epithelia promoting exacerbation and aggravation of disease. We also demonstrate that the adverse health outcome induced by PM exposure in normal and particularly in susceptible bronchial epithelia is magnified by anthropogenic PM components. Thus, including health-relevant PM components in regulatory guidelines will result in substantial human health benefits and improve protection of the vulnerable population.	[Leni, Zaira; Geiser, Marianne] Univ Bern, Inst Anat, Bern, Switzerland; [Cassagnes, Laure Estelle; Daellenbach, Kaspar R.; El Haddad, Imad; Vlachou, Athanasia; Prevot, Andre S. H.; Baltensperger, Urs; Dommen, Josef] Paul Scherrer Inst, Lab Atmospher Chem, Villigen, Switzerland; [Uzu, Gaelle; Jaffrezo, Jean-Luc] Univ Grenoble Alpes, CNRS, IRD, INP,IGE, Grenoble, France; [Baumlin, Nathalie; Salathe, Matthias] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA	University of Bern; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut de Recherche pour le Developpement (IRD); University of Kansas; University of Kansas Medical Center	Geiser, M (corresponding author), Univ Bern, Inst Anat, Bern, Switzerland.; Dommen, J (corresponding author), Paul Scherrer Inst, Lab Atmospher Chem, Villigen, Switzerland.	marianne.geiser@ana.unibe.ch; josef.dommen@psi.ch	jaffrezo, jean-luc/HIU-0016-2022; Prevot, Andre S. H./C-6677-2008; Daellenbach, Kaspar/AAY-4521-2020; Dällenbach, Kaspar Rudolf/ABB-4630-2020; Haddad, Imad El/B-8073-2011; UZU, Gaelle/L-9005-2017; Cassagnes, Laure-Estelle/M-5046-2016	Prevot, Andre S. H./0000-0002-9243-8194; Dällenbach, Kaspar Rudolf/0000-0003-1246-6396; Haddad, Imad El/0000-0002-2461-7238; UZU, Gaelle/0000-0002-7720-0233; Cassagnes, Laure-Estelle/0000-0002-5858-1827	Swiss National Science Foundation (SNSF) [CR32I3_166325]; SNSF mobility grant [P2EZP2_181599]; National Institutes of Health (NIH) [NIH R01-HL139365, NIH R01-HL-133240]; "Investissements d'avenir"program [ANR-15-IDEX-02]; LABEX OSUG@2020 [ANR-10-LABX-56]	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); SNSF mobility grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); "Investissements d'avenir"program(French National Research Agency (ANR)); LABEX OSUG@2020	This study was supported by the Swiss National Science Foundation (SNSF) grant CR32I3_166325. K.R.D. acknowledges support by the SNSF mobility grant P2EZP2_181599. M.S. and N.B. acknowledge funding by the National Institutes of Health (NIH) grants NIH R01-HL139365 and NIH R01-HL-133240. G.U. and J.-L.J. acknowledge support by the "Investissements d'avenir"program (ANR-15-IDEX-02) and LABEX OSUG@2020(ANR-10-LABX-56).	[Anonymous], 2018, NEW ENGL J MED, V379, P2429, DOI [DOI 10.1056/NEJMOA1804492, 10.1056/NEJMoa1804492]; [Anonymous], 2005, PART FIBRE TOXICOL, V2, P8; [Anonymous], 2008, PUBLIC CULTURE, V20, P75; [Anonymous], 2007, ZESZYTY NAUKOWE WALB, V1, P174; Barmpadimos I, 2011, ATMOS CHEM PHYS, V11, P1813, DOI 10.5194/acp-11-1813-2011; Bates JT, 2019, ENVIRON SCI TECHNOL, V53, P4003, DOI 10.1021/acs.est.8b03430; Bates JT, 2015, ENVIRON SCI TECHNOL, V49, P13605, DOI 10.1021/acs.est.5b02967; Birch ME, 1996, AEROSOL SCI TECH, V25, P221, DOI 10.1080/02786829608965393; Calas A, 2018, ATMOS CHEM PHYS, V18, P7863, DOI 10.5194/acp-18-7863-2018; Calas A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11979-3; Canonaco F, 2013, ATMOS MEAS TECH, V6, P3649, DOI 10.5194/amt-6-3649-2013; Cassee FR, 2013, INHAL TOXICOL, V25, P802, DOI 10.3109/08958378.2013.850127; Daellenbach KR, 2016, ATMOS MEAS TECH, V9, P23, DOI 10.5194/amt-9-23-2016; Daellenbach KR, 2019, ATMOS CHEM PHYS, V19, P5973, DOI 10.5194/acp-19-5973-2019; Daellenbach KR, 2017, ATMOS CHEM PHYS, V17, P13265, DOI 10.5194/acp-17-13265-2017; Delfino RJ, 2013, J EXPO SCI ENV EPID, V23, P466, DOI 10.1038/jes.2013.25; Delfino RJ, 2005, ENVIRON HEALTH PERSP, V113, P934, DOI 10.1289/ehp.7938; European Environment Agency, 2018, EEA Report, DOI 10.2800/777411; Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365; Fulcher M Leslie, 2005, Methods Mol Med, V107, P183; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; Goss CH, 2004, AM J RESP CRIT CARE, V169, P816, DOI 10.1164/rccm.200306-779OC; Jaffrezo JL, 1998, ATMOS ENVIRON, V32, P2705, DOI 10.1016/S1352-2310(98)00026-0; Kim MD, 2019, AM J RESP CRIT CARE; Krapf M, 2017, ENVIRON SCI-PROC IMP, V19, P538, DOI [10.1039/c6em00586a, 10.1039/C6EM00586A]; Kunzi L, 2015, SCI REP-UK, V5, DOI 10.1038/srep11801; Lelieveld J, 2017, FARADAY DISCUSS, V200, P693, DOI 10.1039/c7fd90032e; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; McDonald JD, 2012, INHAL TOXICOL, V24, P689, DOI 10.3109/08958378.2012.712164; Miller FJ, 2016, J AEROSOL SCI, V99, P14, DOI 10.1016/j.jaerosci.2016.01.018; Morakinyo OM, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060592; Naili M. B., 2010, ARAB J CHEM, V3, P79; Paatero P, 1999, J COMPUT GRAPH STAT, V8, P854, DOI 10.2307/1390831; Peters-Hall JR, 2015, AM J RESP CELL MOL, V53, P22, DOI 10.1165/rcmb.2014-0256RC; Pillai DK, 2014, AM J RESP CELL MOL, V50, P292, DOI 10.1165/rcmb.2013-0188OC; Piot C, 2012, ATMOS MEAS TECH, V5, P141, DOI 10.5194/amt-5-141-2012; Ruckerl R, 2011, INHAL TOXICOL, V23, P555, DOI 10.3109/08958378.2011.593587; Sacks JD, 2011, ENVIRON HEALTH PERSP, V119, P446, DOI 10.1289/ehp.1002255; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Torseth K, 2012, ATMOS CHEM PHYS, V12, P5447, DOI 10.5194/acp-12-5447-2012; Usemann J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20736-z; Van Den Heuvel R, 2016, ENVIRON RES, V149, P48, DOI 10.1016/j.envres.2016.04.029; van der Kamp J, 2015, ENVIRON SCI TECHNOL, V49, P2929, DOI 10.1021/es5054607; Verma V, 2012, ENVIRON SCI TECHNOL, V46, P11384, DOI 10.1021/es302484r; Vlachou A, 2018, ATMOS CHEM PHYS, V18, P6187, DOI 10.5194/acp-18-6187-2018; Waked A, 2014, ATMOS CHEM PHYS, V14, P3325, DOI 10.5194/acp-14-3325-2014; Wilder Gary, 2009, PUBLIC CULTURE, V21; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Zheng YX, 2017, ENVIRON RES LETT, V12, DOI 10.1088/1748-9326/aa8a32	49	15	15	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0233425	10.1371/journal.pone.0233425	http://dx.doi.org/10.1371/journal.pone.0233425			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VG	33206642	Green Published, gold			2023-01-03	WOS:000595265900011
J	Gedeborg, R; Garmo, H; Robinson, D; Stattin, P				Gedeborg, Rolf; Garmo, Hans; Robinson, David; Stattin, Par			Prescription-based prediction of baseline mortality risk among older men	PLOS ONE			English	Article							MEDICATION REGIMEN COMPLEXITY; CHRONIC DISEASE SCORE; REGISTER; PEOPLE; SWEDEN	Background Understanding the association between patients' history of prescribed medications and mortality rate could optimize characterization of baseline risk when the Charlson Comorbidity Index is insufficient. Methods Using a Swedish cohort of men selected randomly as controls to men with prostate cancer diagnosed 2007-2013, we estimated the association between medications prescribed during the previous year and mortality rates, using Cox regression stratified for age. Results Among the 326,450 older men with median age of 69 years included in this study, 73% were categorized as free of comorbidity according to the Charlson Comorbidity Index; however, 84% had received at least one prescription during the year preceding the follow-up. This was associated with a 60% overall increase in mortality rate (hazard ratio [HR] = 1.60, 95% confidence interval [CI] 1.56 to 1.64). Some drugs that were unexpectedly associated with mortality included locally acting antacids (HR = 4.7, 95% CI 4.4 to 5.1), propulsives (HR = 4.7, 95% CI 4.4 to 5.0), vitamin A and D (HR = 4.6, 95% CI 4.3 to 4.9), and loop diuretics, for example furosemide (HR = 3.7; 95% CI 3.6 to 3.8). Thiazide diuretics, however, were only weakly associated with a mortality risk (HR = 1.5; 95% CI 1.4 to 1.5). Surprisingly, only weak associations with mortality were seen for major cardiovascular drug classes. Conclusions A majority of older men had a history of prescribed medications and many drug classes were associated with mortality rate, including drug classes not directly indicated for a specific comorbidity represented in commonly used comorbidity measures. Prescription history can improve baseline risk assessment but some associations might be context-sensitive.	[Gedeborg, Rolf] Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden; [Garmo, Hans; Stattin, Par] Uppsala Univ, Dept Surg Sci, Urol, Uppsala, Sweden; [Garmo, Hans] Kings Coll London, Sch Canc & Pharmaceut Sci, Guys Hosp, Translat Oncol & Urol Res TOUR, London, England; [Garmo, Hans] Uppsala Univ Hosp, Reg Canc Ctr Uppsala Orebro, Uppsala, Sweden; [Robinson, David] Ryhov Hosp, Dept Urol, Jonkoping, Sweden	Uppsala University; Uppsala University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Uppsala University; Uppsala University Hospital	Gedeborg, R (corresponding author), Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden.	rolf.gedeborg@surgsci.uu.se	Gedeborg, Rolf/AAV-6702-2020	Gedeborg, Rolf/0000-0002-8850-7863; Robinson, David/0000-0002-3433-8873	Swedish Cancer Society [17-0474]; Swedish Research Council [17-00847]; Clinical Cancer Research Foundation in Jonkoping, Sweden	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Clinical Cancer Research Foundation in Jonkoping, Sweden	Par Stattin received funding from the Swedish Cancer Society 17-0474 and the Swedish Research Council 17-00847. David Robinson received funding from the Clinical Cancer Research Foundation in Jonkoping, Sweden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1987, NATURWISSENSCHAFTLIC, V40, P373; Barlow L, 2009, ACTA ONCOL, V48, P27, DOI 10.1080/02841860802247664; Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Hagel E, 2009, SCAND J UROL NEPHROL, V43, P342, DOI 10.3109/00365590903024577; Huang SP, 2019, DRUG SAFETY, V42, P67, DOI 10.1007/s40264-018-0720-9; Johnson ML, 2006, MED CARE, V44, P793, DOI 10.1097/01.mlr.0000218804.41758.ef; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Masclee GMC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204746; Pratt NL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021122; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Schink T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203362; Sonnebring G, 2014, PCBASESWEDEN PLATFOR; Sylvestre E, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0586-x; Van Hemelrijck M, 2016, INT J EPIDEMIOL, V45, P73, DOI 10.1093/ije/dyv305; Vitry A, 2009, AUST NZ J PUBL HEAL, V33, P126, DOI 10.1111/j.1753-6405.2009.00357.x; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; Wallerstedt SM, 2016, BASIC CLIN PHARMACOL, V119, P464, DOI 10.1111/bcpt.12613; Wimmer BC, 2016, ANN PHARMACOTHER, V50, P89, DOI 10.1177/1060028015621071; Wimmer BC, 2016, J GERONTOL A-BIOL, V71, P831, DOI 10.1093/gerona/glv219	20	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0241439	10.1371/journal.pone.0241439	http://dx.doi.org/10.1371/journal.pone.0241439			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG8YH	33119680	Green Published, gold			2023-01-03	WOS:000600013600083
J	McGalliard, RJ; McWilliam, SJ; Maguire, S; Jones, CA; Jennings, RJ; Siner, S; Newland, P; Peak, M; Chesters, C; Jeffers, G; Broughton, C; McColl, L; Lane, S; Paulus, S; Cunliffe, NA; Baines, P; Carrol, ED				McGalliard, Rachel J.; McWilliam, Stephen J.; Maguire, Samuel; Jones, Caroline A.; Jennings, Rebecca J.; Siner, Sarah; Newland, Paul; Peak, Matthew; Chesters, Christine; Jeffers, Graham; Broughton, Caroline; McColl, Lynsey; Lane, Steven; Paulus, Stephane; Cunliffe, Nigel A.; Baines, Paul; Carrol, Enitan D.			Identifying critically ill children at high risk of acute kidney injury and renal replacement therapy	PLOS ONE			English	Article							GELATINASE-ASSOCIATED LIPOCALIN; ANGINA INDEX; URINARY BIOMARKER; SERUM CREATININE; PREDICTION; INITIATION; MORTALITY	Acute kidney injury (AKI), a common complication in paediatric intensive care units (PICU), is associated with increased morbidity and mortality. In this single centre, prospective, observational cohort study, neutrophil gelatinase-associated lipocalin in urine (uNGAL) and plasma (pNGAL) and renal angina index (RAI), and combinations of these markers, were assessed for their ability to predict severe (stage 2 or 3) AKI in children and young people admitted to PICU. In PICU children and young people had initial and serial uNGAL and pNGAL measurements, RAI calculation on day 1, and collection of clinical data, including serum creatinine measurements. Primary outcomes were severe AKI and renal replacement therapy (RRT). Secondary outcomes were length of stay, hospital acquired infection and mortality. The area under the Receiver Operating Characteristic (ROC) curves and You-den index was used to determine biomarker performance and identify optimum cut-off values. Of 657 children recruited, 104 met criteria for severe AKI (15.8%) and 47 (7.2%) required RRT. Severe AKI was associated with increased length of stay, hospital acquired infection, and mortality. The area under the curve (AUC) for severe AKI prediction for Day 1 uNGAL, Day 1 pNGAL and RAI were 0.75 (95% Confidence Interval [CI] 0.69, 0.81), 0.64 (95% CI 0.56, 0.72), and 0.73 (95% CI 0.65, 0.80) respectively. The optimal combination of measures was RAI and day 1 uNGAL, giving an AUC of 0.80 for severe AKI prediction (95% CI 0.71, 0.88). In this heterogenous PICU cohort, urine or plasma NGAL in isolation had poorer prediction accuracy for severe AKI than in previously reported homogeneous populations. However, when combined together with RAI, they produced good prediction for severe AKI.	[McGalliard, Rachel J.; McWilliam, Stephen J.; Jones, Caroline A.; Jennings, Rebecca J.; Siner, Sarah; Newland, Paul; Peak, Matthew; Chesters, Christine; Paulus, Stephane; Cunliffe, Nigel A.; Baines, Paul; Carrol, Enitan D.] Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England; [McGalliard, Rachel J.; Broughton, Caroline; Paulus, Stephane; Cunliffe, Nigel A.; Carrol, Enitan D.] Univ Liverpool, Inst Infect Vet & Ecol Sci, Liverpool, Merseyside, England; [McWilliam, Stephen J.] Univ Liverpool, Dept Womens & Childrens Hlth, Inst Life Course & Med Sci, Liverpool, Merseyside, England; [McWilliam, Stephen J.] Univ Liverpool, MRC Ctr Drug Safety Sci, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England; [McWilliam, Stephen J.; Cunliffe, Nigel A.; Carrol, Enitan D.] Liverpool Hlth Partners, First Floor Liverpool Sci Pk, Liverpool, Merseyside, England; [Maguire, Samuel] Univ Liverpool, Sch Med, Liverpool, Merseyside, England; [Peak, Matthew; Jeffers, Graham; Lane, Steven] Univ Liverpool, Inst Life Course & Med Sci, Liverpool, Merseyside, England; [McColl, Lynsey] Select Stat Serv, Exeter, Devon, England	Alder Hey Children's NHS Foundation Trust; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool	McWilliam, SJ (corresponding author), Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England.; McWilliam, SJ (corresponding author), Univ Liverpool, Dept Womens & Childrens Hlth, Inst Life Course & Med Sci, Liverpool, Merseyside, England.; McWilliam, SJ (corresponding author), Univ Liverpool, MRC Ctr Drug Safety Sci, Inst Syst Mol & Integrat Biol, Liverpool, Merseyside, England.; McWilliam, SJ (corresponding author), Liverpool Hlth Partners, First Floor Liverpool Sci Pk, Liverpool, Merseyside, England.	stevemcw@liverpool.ac.uk		Paulus, Stephane/0000-0002-0703-9114; McWilliam, Stephen/0000-0002-0509-7425	NIHR Biomedical Research Centre in Microbial Diseases, Liverpool; Alder Hey Charity	NIHR Biomedical Research Centre in Microbial Diseases, Liverpool; Alder Hey Charity	This work was funded by the NIHR Biomedical Research Centre in Microbial Diseases, Liverpool and the Alder Hey Charity. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asinobi AO, 2016, CLIN KIDNEY J, V9, P63, DOI 10.1093/ckj/sfv112; Basu RK, 2018, LANCET CHILD ADOLESC, V2, P112, DOI 10.1016/S2352-4642(17)30181-5; Basu RK, 2014, CLIN J AM SOC NEPHRO, V9, P654, DOI 10.2215/CJN.09720913; Basu RK, 2014, KIDNEY INT, V85, P659, DOI 10.1038/ki.2013.349; Basu Rajit K, 2011, Recent Pat Biomark, V1, P49; Bellomo R, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0260-y; Calderon-Margalit R, 2018, NEW ENGL J MED, V378, P428, DOI 10.1056/NEJMoa1700993; Devarajan P, 2003, MOL GENET METAB, V80, P365, DOI 10.1016/j.ymgme.2003.09.012; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Gulla KM, 2015, INDIAN J CRIT CARE M, V19, P613, DOI 10.4103/0972-5229.167044; Hjortrup PB, 2013, CRIT CARE, V17, DOI 10.1186/cc11855; Jetton JG, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00068; Kaddourah A, 2017, NEW ENGL J MED, V376, P11, DOI 10.1056/NEJMoa1611391; Kuwabara T, 2009, KIDNEY INT, V75, P285, DOI 10.1038/ki.2008.499; Li S, 2011, CRIT CARE MED, V39, P1493, DOI 10.1097/CCM.0b013e31821201d3; Menon S, 2016, NEPHROL DIAL TRANSPL, V31, P586, DOI 10.1093/ndt/gfv457; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Modem V, 2014, CRIT CARE MED, V42, P943, DOI 10.1097/CCM.0000000000000039; Noto A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/612032; Pottel H, 2008, CLIN CHIM ACTA, V396, P49, DOI 10.1016/j.cca.2008.06.017; Roy JP, 2019, PEDIATR NEPHROL, V34, P1777, DOI 10.1007/s00467-019-04294-8; Royakkers AA, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/712695; Sanchez-de-Toledo J, 2016, PEDIATR CARDIOL, V37, P623, DOI 10.1007/s00246-015-1323-1; Schneider J, 2010, CRIT CARE MED, V38, P933, DOI 10.1097/CCM.0b013e3181cd12e1; Selewski DT, 2014, INTENS CARE MED, V40, P1481, DOI 10.1007/s00134-014-3391-8; Wang C, 2017, NEPHROLOGY, V22, P7, DOI 10.1111/nep.12890; Weisbord SD, 2006, SEMIN RESP CRIT CARE, V27, P262, DOI 10.1055/s-2006-945527; Westrope CA, 2018, PEDIATR CRIT CARE ME, V19, P210, DOI 10.1097/PCC.0000000000001431; World Health Organization, 2017, DEPR OTH COMM MENT D	29	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0240360	10.1371/journal.pone.0240360	http://dx.doi.org/10.1371/journal.pone.0240360			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG8YH	33119655	gold, Green Published			2023-01-03	WOS:000600013600089
J	Horby, PW; Landray, MJ; Mafham, M; Bell, JL; Linsell, L; Staplin, N; Emberson, JR; Palfreeman, A; Raw, J; Elmahi, E; Prudon, B; Green, C; Carley, S; Chadwick, D; Davies, M; Wise, MP; Baillie, JK; Chappell, LC; Faust, SN; Jaki, T; Jeffery, K; Lim, WS; Montgomery, A; Rowan, K; Juszczak, E; Haynes, R				Horby, Peter W.; Landray, Martin J.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Emberson, Jonathan R.; Palfreeman, Adrian; Raw, Jason; Elmahi, Einas; Prudon, Benjamin; Green, Christopher; Carley, Simon; Chadwick, David; Davies, Matthew; Wise, Matthew P.; Baillie, J. Kenneth; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jeffery, Katie; Lim, Wei Shen; Montgomery, Alan; Rowan, Kathryn; Juszczak, Edmund; Haynes, Richard		RECOVERY Collaborative Grp	Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	LANCET			English	Article							LOPINAVIR/RITONAVIR; CORONAVIRUS; PHARMACOKINETICS	Background Lopinavir-ritonavir has been proposed as a treatment for COVID-19 on the basis of in vitro activity, preclinical studies, and observational studies. Here, we report the results of a randomised trial to assess whether lopinavir-ritonavir improves outcomes in patients admitted to hospital with COVID-19. Methods In this randomised, controlled, open-label, platform trial, a range of possible treatments was compared with usual care in patients admitted to hospital with COVID-19. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge (or one of the other RECOVERY treatment groups: hydroxychloroquine, dexamethasone, or azithromycin) using web-based simple (unstratified) randomisation with allocation concealment. Randomisation to usual care was twice that of any of the active treatment groups (eg, 2:1 in favour of usual care if the patient was eligible for only one active group, 2:1:1 if the patient was eligible for two active groups). The primary outcome was 28-day all-cause mortality. Analyses were done on an intention-to-treat basis in all randomly assigned participants. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings Between March 19, 2020, and June 29, 2020, 1616 patients were randomly allocated to receive lopinavir-ritonavir and 3424 patients to receive usual care. Overall, 374 (23%) patients allocated to lopinavir-ritonavir and 767 (22%) patients allocated to usual care died within 28 days (rate ratio 1.03, 95% CI 0.91-1.17; p=0.60). Results were consistent across all prespecified subgroups of patients. We observed no significant difference in time until discharge alive from hospital (median 11 days [IQR 5 to >28] in both groups) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 0.98, 95% CI 0.91-1.05; p=0.53). Among patients not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion who met the composite endpoint of invasive mechanical ventilation or death (risk ratio 1.09, 95% CI 0.99-1.20; p=0.092). Interpretation In patients admitted to hospital with COVID-19, lopinavir-ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. These findings do not support the use of lopinavir-ritonavir for treatment of patients admitted to hospital with COVID-19. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.	[Horby, Peter W.; Landray, Martin J.; RECOVERY Collaborative Grp] RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England		Horby, PW; Landray, MJ (corresponding author), RECOVERY Cent Coordinating Off, Oxford OX3 7LF, England.		Pessoa-Amorim, Guilherme/AAV-4151-2021; carley, simon/GXV-1178-2022; Baillie, Kenneth/AEK-6650-2022; Baillie, John Kenneth/F-3124-2011; Tso, Simon/N-2422-2014; Wu, Henry H.L./B-9400-2019; Faust, Saul/J-9779-2014	Pessoa-Amorim, Guilherme/0000-0002-4050-6191; Baillie, Kenneth/0000-0001-5258-793X; Baillie, John Kenneth/0000-0001-5258-793X; Tso, Simon/0000-0001-9221-7618; Wu, Henry H.L./0000-0002-4561-0844; Barker, Joseph/0000-0002-5483-9608; Landray, Martin/0000-0001-6646-827X; Loke, Tuck-Kay/0000-0002-4608-2756; Emberson, Jonathan/0000-0001-7792-9422; Green, Christopher/0000-0002-1984-4014; Spears, Mark/0000-0003-4381-5819; Stewart, Grant D./0000-0003-3188-9140; Patel, Manish/0000-0003-3012-7507; Burge, Sarah/0000-0002-2506-927X; Burden, Christy/0000-0001-6409-5238; Soiza, Roy/0000-0002-1397-4272; Montgomery, Alan/0000-0003-0450-1606; Haynes, Richard/0000-0002-1179-0023; Lim, Wei Shen/0000-0002-7694-3051; Faust, Saul/0000-0003-3410-7642; Shah, Pallav/0000-0002-9052-4638; Cooper, Jamie/0000-0003-3812-7026	Medical Research Council; National Institute for Health Research; MRC [MC_U137686860, MC_PC_18033, MC_PC_19056, MC_UU_12026/4, MC_UU_00017/3, MC_U137686861, MC_UU_00002/14] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Medical Research Council and National Institute for Health Research.	Arshad U, 2020, CLIN PHARMACOL THER, V108, P775, DOI 10.1002/cpt.1909; Baldelli S, 2020, J ANTIMICROB CHEMOTH, V75, P2704, DOI 10.1093/jac/dkaa190; Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318; Best BM, 2011, JAIDS-J ACQ IMM DEF, V58, P385, DOI 10.1097/QAI.0b013e318232b057; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cattaneo D, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104898; Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392; Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003; Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786; Dagens A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1936; de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; EMC, 2020, KAL 200MG 50MG FILM; Gregoire M, 2020, J ANTIMICROB CHEMOTH, V75, P2702, DOI 10.1093/jac/dkaa195; Havlichek D, 2020, NEW ENGL J MED, V382; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Le MP, 2020, J ANTIMICROB CHEMOTH, V75, P2657, DOI 10.1093/jac/dkaa261; Lecronier M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03117-9; Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001; Marzolini C, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01177-20; Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030; Osborne V, 2020, DRUG SAFETY, V43, P809, DOI 10.1007/s40264-020-00966-9; Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20; Schoergenhofer C, 2020, ANN INTERN MED, V173, P670, DOI 10.7326/M20-1550; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; WHO, 2020, SOL CLIN TRIAL COVID; Yan D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00799-2020; Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706	30	359	364	1	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2020	396	10259					1345	1352		10.1016/S0140-6736(20)32013-4	http://dx.doi.org/10.1016/S0140-6736(20)32013-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OF2SS	33031764	Green Published, hybrid			2023-01-03	WOS:000581064900030
J	Khajah, MA; EL-Hashim, AZ; Orabi, KY; Hawai, S; Sary, HG				Khajah, Maitham A.; EL-Hashim, Ahmed Z.; Orabi, Khaled Y.; Hawai, Sanaa; Sary, Hanan G.			Onion bulb extract can both reverse and prevent colitis in mice via inhibition of pro-inflammatory signaling molecules and neutrophil activity	PLOS ONE			English	Article							BOWEL-DISEASE; ULCERATIVE-COLITIS; CROHNS-DISEASE; PATHOGENESIS; CYTOKINES; SAFETY; RISK; CONSUMPTION; TARGET; RATS	Background Onion is one of the most commonly used plants in the traditional medicine for the treatment of various diseases. We recently demonstrated the anti-inflammatory properties of onion bulb extract (OBE) in reducing colitis severity in mice when administered at the same time of colitis induction. However, whether onion can reverse established colitis or even prevent its development has not been investigated. Hypothesis To test 1. whether OBE can reduce colitis severity when given either before (preventative approach) or after (treatment approach) colitis induction and if so, 2. what are the mechanisms by which onion can achieve these effects. Methods Colitis was induced by dextran sulfate sodium (DSS) administration using treatment and preventative approaches. The severity of the inflammation was determined by the gross and histological assessments. The colonic level/activity of pro-inflammatory molecules and immune cell markers was assessed by immunofluorescence and western blotting analysis. In vitro neutrophil superoxide release and survival was assessed by chemilumenecense and Annexin-V/7AAD assays respectively. Results OBE treatment significantly reduced colitis severity in both approaches, the colonic expression/activity profile of pro-inflammatory molecules, inhibited WKYMVm-induced superoxide release, and increased spontaneous apoptosis of neutrophils in vitro. Conclusions OBE can be used as an effective option in the prevention and/or the treatment of established colitis.	[Khajah, Maitham A.; EL-Hashim, Ahmed Z.; Hawai, Sanaa] Kuwait Univ, Fac Pharm, Dept Pharmacol & Therapeut, Safat, Kuwait; [Orabi, Khaled Y.; Sary, Hanan G.] Kuwait Univ, Fac Pharm, Dept Pharmaceut Chem, Safat, Kuwait	Kuwait University; Kuwait University	Khajah, MA (corresponding author), Kuwait Univ, Fac Pharm, Dept Pharmacol & Therapeut, Safat, Kuwait.	maitham@hsc.edu.kw		Orabi, Khaled/0000-0003-0262-4637	Kuwait Foundation for the Advancement of Sciences (KFAS) [P11613PT01];  [SRUL02/13]	Kuwait Foundation for the Advancement of Sciences (KFAS)(Kuwait Foundation for the Advancement of Sciences (KFAS)); 	This work was supported by Kuwait Foundation for the Advancement of Sciences (KFAS) (grant number: P11613PT01). Parts of this work were supported by grant SRUL02/13 to the Research Unit for Genomics, Proteomics and Cellomics Studies (OMICS), Kuwait University. We would like to thank Dr. Ananthalakshmi KV for the technical help, the histology unit in the faculty of Allied Health, and the animal unit in Health Science Center, Kuwait University.	[Anonymous], 2020, NAT MED, V26, P1, DOI 10.1038/s41591-019-0740-8; [Anonymous], 2016, CHILD NEUROPSYCHOL, V13, P1; [Anonymous], 2015, FUEL CELLS B, V2015, P3, DOI [10.1016/S1464-2859(15)30109-7, DOI 10.1016/S1464-2859(15)30109-7]; [Anonymous], 2017, MEDICINE, V96, pe6504; Avila-Roman J, 2016, BRIT J NUTR, V116, P2044, DOI 10.1017/S0007114516004189; Ballini A, 2019, ENDOCR METAB IMMUNE, V19, P373, DOI 10.2174/1871530319666181221150352; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Becker C, 2006, J IMMUNOL, V177, P2760, DOI 10.4049/jimmunol.177.5.2760; Benninghoff AD, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020544; Bhattacharyya Sumit, 2017, Nutr Healthy Aging, V4, P181, DOI 10.3233/NHA-170023; BHIVA/ BASHH, 2019, HIV MED S2, V20, ps2; Bonovas S, 2018, BEST PRACT RES CL GA, V32-33, P43, DOI 10.1016/j.bpg.2018.05.005; Borisova MA, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020445; Bruell V, 2015, BRIT J NUTR, V114, P1263, DOI 10.1017/S0007114515002950; Castro-Lopez J, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1486-0; Chiu HF, 2016, PHYTOTHER RES, V30, P380, DOI 10.1002/ptr.5537; Dodda D, 2014, INDIAN J PHARMACOL, V46, P286, DOI 10.4103/0253-7613.132160; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Emamat H, 2018, INDIAN J CLIN BIOCHE, V33, P75, DOI 10.1007/s12291-017-0636-7; Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365, DOI DOI 10.1016/J.JACR.2018.09.023; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gabbani T, 2016, EXPERT OPIN DRUG SAF, V15, P1427, DOI 10.1080/14740338.2016.1218468; Gao Y, 2019, J CELL PHYSIOL, V234, P10625, DOI 10.1002/jcp.27739; Ge J, 2015, TURK J GASTROENTEROL, V26, P492, DOI 10.5152/tjg.2015.0106; Gong ZZ, 2018, MOL IMMUNOL, V104, P11, DOI 10.1016/j.molimm.2018.09.004; Gormaz JG, 2015, CURR TOP MED CHEM, V15, P1735, DOI 10.2174/1568026615666150427124357; Hagan M, 2015, EXPERT OPIN DRUG SAF, V14, P1473, DOI 10.1517/14740338.2015.1063612; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Huang XL, 2011, INFLAMM RES, V60, P727, DOI 10.1007/s00011-011-0325-6; Hussain MT, 2019, DNA CELL BIOL, V38, P1025, DOI 10.1089/dna.2019.5024; Jang J, 2019, INT IMMUNOPHARMACOL, V72, P124, DOI 10.1016/j.intimp.2019.03.062; Joo M, 2015, KOREAN J PHYSIOL PHA, V19, P43, DOI 10.4196/kjpp.2015.19.1.43; Leon AJ, 2006, MED CLIN-BARCELONA, V127, P145, DOI 10.1157/13090382; Khajah M, 2013, J IMMUNOL, V190, P2208, DOI 10.4049/jimmunol.1200322; Khajah M, 2011, J LEUKOCYTE BIOL, V89, P945, DOI 10.1189/jlb.0809546; Khajah MA, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.112008; Khajah MA, 2017, DEV COMP IMMUNOL, V74, P200, DOI 10.1016/j.dci.2017.05.005; Khajah MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150861; Khalili H, 2018, NAT REV GASTRO HEPAT, V15, P525, DOI 10.1038/s41575-018-0022-9; Khan HMW, 2015, CLIN EXP GASTROENTER, V8, P293, DOI 10.2147/CEG.S57248; Li F, 2015, EUR J GASTROEN HEPAT, V27, P623, DOI 10.1097/MEG.0000000000000330; Lieber JG, 2004, BLOOD, V103, P852, DOI 10.1182/blood-2003-04-1030; Lin XJ, 2018, MUCOSAL IMMUNOL, V11, P1663, DOI 10.1038/s41385-018-0018-3; Makhezer N, 2019, MUCOSAL IMMUNOL, V12, P117, DOI 10.1038/s41385-018-0086-4; Miranda PM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0433-4; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Nelson SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179143; Oliveira TT, 2015, DARU, V23, DOI 10.1186/s40199-015-0098-5; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; Peng XD, 2010, J PHARMACOL EXP THER, V332, P46, DOI 10.1124/jpet.109.153494; Plevy SE, 1997, J IMMUNOL, V159, P6276; Rhodes Jesse H., 2020, P NUTR SOC, P1; Rogler G, 2014, CANCER LETT, V345, P235, DOI 10.1016/j.canlet.2013.07.032; Romero M, 2017, FOOD FUNCT, V8, P2702, DOI [10.1039/c7fo00755h, 10.1039/C7FO00755H]; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Sturniolo GC, 2001, INFLAMM BOWEL DIS, V7, P94, DOI 10.1097/00054725-200105000-00003; Tang GY, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080857; Thoreson R, 2007, SURG CLIN N AM, V87, P575, DOI 10.1016/j.suc.2007.03.001; Toh JY, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0368-y; Wang DD, 2019, INT J BIOL MACROMOL, V125, P572, DOI 10.1016/j.ijbiomac.2018.12.092; Wang F, 2017, CLIN NUTR, V36, P1259, DOI 10.1016/j.clnu.2016.10.009; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41	66	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2020	15	10							e0233938	10.1371/journal.pone.0233938	http://dx.doi.org/10.1371/journal.pone.0233938			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ON4BV	33095803	gold, Green Published			2023-01-03	WOS:000586649400010
J	Sartori, CR; Pagliusi, M; Bonet, IJM; Tambeli, CH; Parada, CA				Sartori, Cesar Renato; Pagliusi, Marco, Jr.; Bonet, Ivan Jose Magayewski; Tambeli, Claudia Herrera; Parada, Carlos Amilcar			Running wheel exercise induces therapeutic and preventive effects on inflammatory stimulus-induced persistent hyperalgesia in mice	PLOS ONE			English	Article							LOW-INTENSITY EXERCISE; NEUROPATHIC PAIN; OXIDATIVE STRESS; SCIATIC-NERVE; FIBROMYALGIA; INJURY; RAT; PATHOPHYSIOLOGY; CONSTRICTION; ACTIVATION	Chronic pain affects significant portion of the world's population and physical exercise has been extensively indicated as non-pharmacological clinical intervention to relieve symptoms in chronic pain conditions. In general, studies on pain chronification and physical exercise intervention have focused on neuropathic pain, although chronic pain commonly results from an original inflammatory episode. Based on this, the objective of the present study was to investigate the therapeutic and preventive effect of the running wheel exercise on the persistent hyperalgesia induced by repetitive inflammatory stimulus, a rodent model that simulates clinical conditions of chronic pain that persist even with no more inflammatory stimulus present. To evaluate the therapeutic effect of physical exercise, we first induced persistent hyperalgesia through 14 days of PGE2 hind paw injections and, after that, mice have access to the regular voluntary running wheel. To evaluate the preventive effect of physical exercise, we first left the mice with access to the regular voluntary running wheel and, after that, we performed 14 days of PGE2 hind paw injection. Our results showed that voluntary running wheel exercise reduced persistent mechanical and chemical hyperalgesia intensity induced by repetitive inflammatory stimulus. In addition, we showed that this therapeutic effect is long-lasting and is observed even if started belatedly, i.e. two weeks after the development of hyperalgesia. Also, our results showed that voluntary running wheel exercise absolutely prevented persistent mechanical and chemical hyperalgesia induction. We can conclude that physical exercise has therapeutic and preventive effect on inflammatory stimulus-induced persistent hyperalgesia. Our data from animal experiments bypass placebo effects bias of the human studies and reinforce physical exercise clinical recommendations to treat and prevent chronic pain.	[Sartori, Cesar Renato; Pagliusi, Marco, Jr.; Bonet, Ivan Jose Magayewski; Tambeli, Claudia Herrera; Parada, Carlos Amilcar] Univ Estadual Campinas, Dept Struct & Funct Biol, Campinas, SP, Brazil	Universidade Estadual de Campinas	Sartori, CR (corresponding author), Univ Estadual Campinas, Dept Struct & Funct Biol, Campinas, SP, Brazil.	sartoric@unicamp.br	Parada, Carlos Amilcar/C-3974-2012; Pagliusi, Marco O Finocchio/G-2016-2019; Bonet, Ivan/AAC-8101-2022; Tambeli, Claudia/AAQ-4409-2021	Pagliusi, Marco O Finocchio/0000-0002-8379-9131; Bonet, Ivan/0000-0002-6008-3237; Amilcar Parada, Carlos/0000-0001-5209-8853; Sartori, Cesar Renato/0000-0003-2713-3914	Sao Paulo Research Foundation (FAPESP) [2011/23531-6, 2012/08922-1]; Coordenacao de Aperfeicoamento de Pess oal de Nivel Superior - Brasil (CAPES) [001]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pess oal de Nivel Superior - Brasil (CAPES)	CRS, CAP and CHT was supported by the Sao Paulo Research Foundation (FAPESP - http://www.fapesp.br) #2011/23531-6 and #2012/08922-1. MPJr, and IJMB was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES - https://www.capes.gov.br) - Finance Code 001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abiru N, 2020, DIABETOL INT, V11, P1, DOI 10.1007/s13340-019-00415-8; Ahn AH, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0379-y; Almeida C, 2015, PAIN, V156, P504, DOI 10.1097/01.j.pain.0000460339.23976.12; Ambrose KR, 2015, BEST PRACT RES CL RH, V29, P120, DOI 10.1016/j.berh.2015.04.022; Ballantyne JC, 2017, ANESTH ANALG, V125, P1769, DOI 10.1213/ANE.0000000000002500; Batista ML, 2010, CYTOKINE, V49, P102, DOI 10.1016/j.cyto.2009.10.007; Bement MKH, 2005, ARCH PHYS MED REHAB, V86, P1736, DOI 10.1016/j.apmr.2005.03.029; Benatti FB, 2015, NAT REV RHEUMATOL, V11, P86, DOI 10.1038/nrrheum.2014.193; Birmann PT, 2019, J TRACE ELEM MED BIO, V54, P126, DOI 10.1016/j.jtemb.2019.04.014; Bobinski F, 2018, PAIN, V159, P437, DOI 10.1097/j.pain.0000000000001109; Bobinski F, 2015, PAIN, V156, P2595, DOI 10.1097/j.pain.0000000000000372; Boldt I, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009177.pub2; Booz GW, 2011, FREE RADICAL BIO MED, V51, P1054, DOI 10.1016/j.freeradbiomed.2011.01.007; Brandao AF, 2020, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01453; Brioche T, 2016, CURR PHARM DESIGN, V22, P2664, DOI 10.2174/1381612822666160219120531; Broom DM, 1998, ADV STUD BEHAV, V27, P371; Che L, 2017, ADV EXP MED BIOL, V999, P43, DOI 10.1007/978-981-10-4307-9_3; Chen YW, 2012, ANESTH ANALG, V114, P1330, DOI 10.1213/ANE.0b013e31824c4ed4; Cobianchi S, 2010, NEUROSCIENCE, V168, P273, DOI 10.1016/j.neuroscience.2010.03.035; Cunha TM, 2004, BRAZ J MED BIOL RES, V37, P401, DOI 10.1590/S0100-879X2004000300018; de Moraes AA, 2018, NEUROL RES, V40, P955, DOI 10.1080/01616412.2018.1504180; Dias EV, 2015, EUR J NEUROSCI, V42, P2380, DOI 10.1111/ejn.13015; Ferrari LF, 2014, P NATL ACAD SCI USA, V111, P18363, DOI 10.1073/pnas.1420601111; FERREIRA SH, 1990, PAIN, V42, P365, DOI 10.1016/0304-3959(90)91149-D; Gatchel RJ, 2014, AM PSYCHOL, V69, P119, DOI 10.1037/a0035514; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; Hauser W, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3002; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Hylands-White N, 2017, RHEUMATOL INT, V37, P29, DOI 10.1007/s00296-016-3481-8; Jones KD, 2009, RHEUM DIS CLIN N AM, V35, P373, DOI 10.1016/j.rdc.2009.05.004; Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107; Kroll HR, 2015, PHYS MED REH CLIN N, V26, P263, DOI 10.1016/j.pmr.2014.12.007; Kuphal KE, 2007, J PAIN, V8, P989, DOI 10.1016/j.jpain.2007.08.001; Lima L. V., 2017, PAIN; Mattson MP, 2012, AGEING RES REV, V11, P347, DOI 10.1016/j.arr.2012.01.007; Mazzardo-Martins L, 2010, J PAIN, V11, P1384, DOI 10.1016/j.jpain.2010.03.015; Moghetti P, 2016, FRONT HORM RES, V47, P44, DOI 10.1159/000445156; Nalk AK, 2006, EUR J PAIN, V10, P573, DOI 10.1016/j.ejpain.2005.08.006; Palandi J, 2020, NEUROSCI BIOBEHAV R, V108, P781, DOI 10.1016/j.neubiorev.2019.12.016; Pedersen BK, 2017, EUR J CLIN INVEST, V47, P600, DOI 10.1111/eci.12781; Ploner M, 2017, TRENDS COGN SCI, V21, P100, DOI 10.1016/j.tics.2016.12.001; Radak Z, 2008, AGEING RES REV, V7, P34, DOI 10.1016/j.arr.2007.04.004; Rooks DS, 2008, CURR OPIN RHEUMATOL, V20, P208, DOI 10.1097/BOR.0b013e3282f5687a; Sarifakioglu B, 2014, RHEUMATOL INT, V34, P1361, DOI 10.1007/s00296-014-2978-2; Smith C., 2010, J EVAL CLIN PRACT; Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122; Stagg NJ, 2011, ANESTHESIOLOGY, V114, P940, DOI 10.1097/ALN.0b013e318210f880; Tai HH, 2011, PROSTAG OTH LIPID M, V96, P37, DOI 10.1016/j.prostaglandins.2011.06.005; Thomas EN, 2010, RHEUMATOL INT, V30, P1143, DOI 10.1007/s00296-010-1369-6; Timmerman KL, 2008, J LEUKOCYTE BIOL, V84, P1271, DOI 10.1189/jlb.0408244; van Middelkoop M, 2010, BEST PRACT RES CL RH, V24, P193, DOI 10.1016/j.berh.2010.01.002; Vase L, 2019, BRIT J ANAESTH, V123, pE254, DOI 10.1016/j.bja.2019.01.040; Villarreal CF, 2009, BIOCHEM PHARMACOL, V77, P867, DOI 10.1016/j.bcp.2008.11.015; Watkins BA, 2018, MOL ASPECTS MED, V64, P68, DOI 10.1016/j.mam.2018.10.001; Whitehead RA, 2017, ANESTH ANALG, V124, P346, DOI 10.1213/ANE.0000000000001662	55	6	6	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2020	15	10							e0240115	10.1371/journal.pone.0240115	http://dx.doi.org/10.1371/journal.pone.0240115			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3UK	33048957	Green Published, gold			2023-01-03	WOS:000581813300006
J	Etafa, W; Wakuma, B; Fetensa, G; Tsegaye, R; Abdisa, E; Oluma, A; Tolossa, T; Mulisa, D; Takele, T				Etafa, Werku; Wakuma, Bizuneh; Fetensa, Getahun; Tsegaye, Reta; Abdisa, Eba; Oluma, Adugna; Tolossa, Tadesse; Mulisa, Diriba; Takele, Tagay			Nurses' knowledge about palliative care and attitude towards end- of-life care in public hospitals in Wollega zones: A multicenter cross-sectional study	PLOS ONE			English	Article								Background Palliative care is nowadays essential in nursing care, due to the increasing number of patients who require attention in the final stages of their life. Lack of knowledge of and negative attitude palliative care among nurses is one of the most common barriers to quality palliative care. This study, therefore, aimed to assess nurses' knowledge about palliative care and attitude toward end-of-life care in public hospitals in Wollega zones, Ethiopia. Methods A multicenter institutional-based cross-sectional study design was employed to collect data from 372 nurses working in public hospitals in Wollega zones from October 02-22, 2019. A self-administered questionnaire with three different parts: Demographic characteristics of nurses, the Palliative Care Quiz for Nursing (PCQN), and the Frommelt Attitudes Towards Care of the Dying (FATCOD). SPSS version 21 was used for analysis used for data analysis. The binary logistic regression test was used for analysis at p < 0.05. Findings Our final sample size was 422 nurses (response rate = 88%). With the mean total PCQN scores (9.34), the majority of them showed an inadequate level of knowledge about palliative care. The mean total FATCOD scores (79.58) displayed a positive attitude toward end-of-life care, with 52% of respondents eager to care for a dying person and their family. Nurses who had PC service experience [AOR = 1.94 CI (1.10-3.42), p = 0.02] and had ever attended training/lecture on PC [AOR = 1.87 CI (1.01-3.46), p = 0.04] were independently associated with nurses' knowledge about PC. Similarly, nurses who had no PC service experience [AOR = 0.41, CI (0.21-0.79), p = 0.008], who read articles/brochures about PC [AOR = 1.94, CI (1.11-3.39), p = 0.01] and had provided care for a smaller number of terminally ill patients [AOR = 1.74, CI (1.01-2.97), p = 0.04] were significantly associated with nurses' attitude towards end-of-life care. Conclusion The study highlighted that nurses' knowledge about palliative care is inadequate, and showed a less favorable attitude toward end-of-life care. The findings also provide evidence for greater attentions and resources should be directed towards educating and supporting nurses caring for patients with palliative care needs in Wollega Zones.	[Etafa, Werku; Wakuma, Bizuneh; Fetensa, Getahun; Tsegaye, Reta; Abdisa, Eba; Oluma, Adugna; Mulisa, Diriba] Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia; [Tolossa, Tadesse] Wollega Univ, Inst Hlth Sci, Dept Publ Hlth, Nekemte, Ethiopia; [Takele, Tagay] Wollega Univ, Dept Math, Coll Nat & Computat Sci, Nekemte, Ethiopia		Etafa, W (corresponding author), Wollega Univ, Inst Hlth Sci, Sch Nursing & Midwifery, Nekemte, Ethiopia.	witafay@gmail.com	Ebi, Werku Etafa/Q-2742-2019; Hirko, Getahun Fetensa/ABY-0109-2022	Ebi, Werku Etafa/0000-0001-9576-8888; 	Wollega University	Wollega University	Wollega University provided us a financial support to conduct this study. But, no fund is received from other organizations. Mr. Werku Etafa received from Wollega University only. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abudari G, 2014, INT J PALLIAT NURS, V20, P435, DOI 10.12968/ijpn.2014.20.9.435; Al Qadire M, 2014, NURS EDUC TODAY, V34, P714, DOI 10.1016/j.nedt.2013.08.019; Brajtman S, 2009, INT J PALLIAT NURS, V15, P233, DOI 10.12968/ijpn.2009.15.5.42349; Brazil K, 2012, INT J PALLIAT NURS, V18, P77, DOI 10.12968/ijpn.2012.18.2.77; Chover-Sierra E, 2017, CONOCIMIENTOS CUIDAD; Dimoula M, 2019, NURS EDUC TODAY, V74, P7, DOI 10.1016/j.nedt.2018.11.025; End of Life Nursing Education Consortium (ELNEC), 2019, FACT SHEET; Farmani AH, 2019, DATA BRIEF, V22, P319, DOI 10.1016/j.dib.2018.11.133; Freeze J, 2018, PROCEEDINGS OF THE 51ST ANNUAL HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS), P913; Frommelt K H, 1991, Am J Hosp Palliat Care, V8, P37, DOI 10.1177/104990919100800509; Gielen J, 2011, INDIAN J PALLIAT CAR, V17, P33, DOI 10.4103/0973-1075.78447; Gott M, 2012, PALLIATIVE MED, V26, P232, DOI 10.1177/0269216311408993; Iranmanesh S, 2014, PALLIAT SUPPORT CARE, V12, P203, DOI 10.1017/S1478951512001058; Kassa H, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-6; Kim S, 2014, EUR J CARDIOVASC NUR, V13, P124, DOI 10.1177/1474515113519521; Knapp CA, 2009, INT J PALLIAT NURS, V15, P432, DOI 10.12968/ijpn.2009.15.9.44255; Landrine H, 2016, TOB CONTROL, V25, pe142; May P, 2017, PALLIATIVE MED, V31, P378, DOI 10.1177/0269216317690098; Mpanga Sebuyira Lydia, 2003, J Palliat Med, V6, P341; Mutto EM, 2010, J PALLIAT MED, V13, P1445, DOI 10.1089/jpm.2010.0301; Ronaldson S, 2008, INT J OLDER PEOPLE N, V3, P258, DOI 10.1111/j.1748-3743.2008.00136.x; Ross MM, 1996, J ADV NURS, V23, P126; Sanderson C, 2010, AUST FAM PHYSICIAN, V39, P341; Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367; Skar R, 2010, NURS EDUC TODAY, V30, P132, DOI 10.1016/j.nedt.2009.06.012; Smets T, 2018, PALLIATIVE MED, V32, P1487, DOI 10.1177/0269216318785295; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Wang L, CLIN NURSES ATTITUDE; Wang LP, 2016, J CANCER EDUC, V31, P123, DOI 10.1007/s13187-015-0810-7; World Health Organization, 2006, WHO DEF PALL CAR; World Health Organization, 2016, PLANNING IMPLEMENTIN; World Health Organization, 2014, GLOBAL ATLAS PALLIAT; World Health Organization (WHO), WHO PALL CAR FACT SH	33	7	7	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2020	15	10							e0238357	10.1371/journal.pone.0238357	http://dx.doi.org/10.1371/journal.pone.0238357			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3SJ	33027265	Green Published, gold			2023-01-03	WOS:000581808000008
J	Dersch-Mills, D; Kaplan, BJ				Dersch-Mills, Deonne; Kaplan, Bonnie J.			Giving oral medicines and supplements to children	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEAD ROTATION; STRATEGIES; PARENTS		[Dersch-Mills, Deonne] Alberta Hlth Serv, Calgary, AB, Canada; [Kaplan, Bonnie J.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada	Alberta Health Services (AHS); University of Calgary; University of Calgary	Kaplan, BJ (corresponding author), Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.	kaplan@ucalgary.ca						[Anonymous], 2013, HELPING MEDICATIONS; BABBITT RL, 1991, J DEV BEHAV PEDIATR, V12, P229; Bergene EH, 2017, SCAND J PRIM HEALTH, V35, P221, DOI 10.1080/02813432.2017.1333308; Cowley E, 2001, CURR THER RES CLIN E, V62, P627, DOI 10.1016/S0011-393X(01)80069-2; Forough AS, 2018, PATIENT PREFER ADHER, V12, P1337, DOI 10.2147/PPA.S164406; Gardiner P, 2006, AM FAM PHYSICIAN, V74, P793; Gudeman J, 2013, DRUGS R&D, V13, P1, DOI 10.1007/s40268-013-0005-9; Kaplan B., BETTER SPOONFUL SUGA; Kaplan Bonnie J, 2010, Paediatr Child Health, V15, pe1; Kimland E, 2012, CLIN PHARMACOL THER, V91, P796, DOI 10.1038/clpt.2012.26; LOGEMANN JA, 1989, ARCH PHYS MED REHAB, V70, P767; Nahata MC, 2009, ARCH DIS CHILD-FETAL, V94, pF392, DOI 10.1136/adc.2009.160192; Ohmae Y, 1998, ANN OTO RHINOL LARYN, V107, P344, DOI 10.1177/000348949810700414; Patel A, 2015, PEDIATRICS, V135, P883, DOI 10.1542/peds.2014-2114; Polaha J, 2008, SOUTH MED J, V101, P1106, DOI 10.1097/SMJ.0b013e318180645d; Rawlence E, 2018, ARCH DIS CHILDHOOD-E, V103, P310, DOI 10.1136/archdischild-2016-312132; Simon HK, 1997, ARCH PEDIAT ADOL MED, V151, P654, DOI 10.1001/archpedi.1997.02170440016003; Solanki R, 2017, ARCH DIS CHILD, V102, P651, DOI 10.1136/archdischild-2016-311877; Yin HS, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0357	19	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2020	371								m3550	10.1136/bmj.m3550	http://dx.doi.org/10.1136/bmj.m3550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC8XK	33020053				2023-01-03	WOS:000579439300001
J	Nakamura, Y; Taniguchi, H; Ikeda, M; Bando, H; Kato, K; Morizane, C; Esaki, T; Komatsu, Y; Kawamoto, Y; Takahashi, N; Ueno, M; Kagawa, Y; Nishina, T; Kato, T; Yamamoto, Y; Furuse, J; Denda, T; Kawakami, H; Oki, E; Nakajima, T; Nishida, N; Yamaguchi, K; Yasui, H; Goto, M; Matsuhashi, N; Ohtsubo, K; Yamazaki, K; Tsuji, A; Okamoto, W; Tsuchihara, K; Yamanaka, T; Miki, I; Sakamoto, Y; Ichiki, H; Hata, M; Yamashita, R; Ohtsu, A; Odegaard, JI; Yoshino, T				Nakamura, Yoshiaki; Taniguchi, Hiroya; Ikeda, Masafumi; Bando, Hideaki; Kato, Ken; Morizane, Chigusa; Esaki, Taito; Komatsu, Yoshito; Kawamoto, Yasuyuki; Takahashi, Naoki; Ueno, Makoto; Kagawa, Yoshinori; Nishina, Tomohiro; Kato, Takeshi; Yamamoto, Yoshiyuki; Furuse, Junji; Denda, Tadamichi; Kawakami, Hisato; Oki, Eiji; Nakajima, Takako; Nishida, Naohiro; Yamaguchi, Kensei; Yasui, Hisateru; Goto, Masahiro; Matsuhashi, Nobuhisa; Ohtsubo, Koushiro; Yamazaki, Kentaro; Tsuji, Akihito; Okamoto, Wataru; Tsuchihara, Katsuya; Yamanaka, Takeharu; Miki, Izumi; Sakamoto, Yasutoshi; Ichiki, Hiroko; Hata, Masayuki; Yamashita, Riu; Ohtsu, Atsushi; Odegaard, Justin, I; Yoshino, Takayuki			Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; CHOLANGIOCARCINOMA; MULTICENTER; VALIDATION; RESISTANCE; MUTATIONS; BIOPSIES; TRIALS	Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in similar to 2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.	[Nakamura, Yoshiaki; Taniguchi, Hiroya; Ohtsu, Atsushi; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan; [Nakamura, Yoshiaki; Taniguchi, Hiroya; Okamoto, Wataru; Tsuchihara, Katsuya; Miki, Izumi; Sakamoto, Yasutoshi; Ichiki, Hiroko; Hata, Masayuki] Natl Canc Ctr Hosp East, Translat Res Support Sect, Kashiwa, Chiba, Japan; [Ikeda, Masafumi] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan; [Bando, Hideaki] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan; [Kato, Ken] Natl Canc Ctr, Dept Gastrointestinal Oncol, Tokyo, Japan; [Kato, Ken] Natl Canc Ctr, Biobank Translat Res Support Sect, Tokyo, Japan; [Morizane, Chigusa] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan; [Esaki, Taito] Natl Hosp Org Kyushu Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan; [Komatsu, Yoshito; Kawamoto, Yasuyuki] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan; [Takahashi, Naoki] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan; [Ueno, Makoto] Kanagawa Canc Ctr, Dept Gastroenterol, Hepatobiliary & Pancreat Med Oncol Div, Yokohama, Kanagawa, Japan; [Kagawa, Yoshinori] Kansai Rosai Hosp, Dept Colorectal Surg, Amagasaki, Hyogo, Japan; [Nishina, Tomohiro] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan; [Kato, Takeshi] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Yamamoto, Yoshiyuki] Univ Tsukuba Hosp, Dept Gastroenterol & Hepatol, Tsukuba, Ibaraki, Japan; [Furuse, Junji] Kyorin Univ Hosp, Dept Med Oncol, Mitaka, Tokyo, Japan; [Denda, Tadamichi] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan; [Kawakami, Hisato] Kindai Univ Hosp, Dept Med Oncol, Osakasayama, Japan; [Oki, Eiji] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan; [Nakajima, Takako] St Marianna Univ, Sch Med, Dept Med Oncol, Kawasaki, Kanagawa, Japan; [Nishida, Naohiro] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka, Japan; [Yamaguchi, Kensei] Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Canc Inst Hosp, Tokyo, Japan; [Yasui, Hisateru] Kobe City Med Ctr, Dept Med Oncol, Gen Hosp, Kobe, Hyogo, Japan; [Goto, Masahiro] Osaka Med Coll Hosp, Canc Chemotherapy Ctr, Takatsuki, Osaka, Japan; [Matsuhashi, Nobuhisa] Gifu Univ, Grad Sch Med, Dept Surg Oncol, Gifu, Japan; [Ohtsubo, Koushiro] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa, Japan; [Yamazaki, Kentaro] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan; [Tsuji, Akihito] Kagawa Univ Hosp, Dept Clin Oncol, Miki, Kagawa, Japan; [Okamoto, Wataru] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan; [Tsuchihara, Katsuya; Yamashita, Riu] Natl Canc Ctr, Div Translat Informat, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan; [Yamanaka, Takeharu] Natl Canc Ctr Hosp East, Div Biostat, Kashiwa, Chiba, Japan; [Odegaard, Justin, I] Guardant Hlth, Redwood City, CA USA	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Aichi Cancer Center; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Kyushu Cancer Center; Hokkaido University; Kanagawa Prefectural Cancer Center; Kansai Rosai Hospital; Osaka National Hospital; University of Tsukuba; Kyorin University; Chiba Cancer Center; Kyushu University; Saint Marianna University; Osaka University; Japanese Foundation for Cancer Research; Kobe City Medical Center General Hospital; Osaka Medical College; Gifu University; Kanazawa University; Shizuoka Cancer Center; Kagawa University; Hiroshima University; National Cancer Center - Japan; National Cancer Center - Japan	Yoshino, T (corresponding author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan.	tyoshino@east.ncc.go.jp	Okamoto, Wataru/AIE-0808-2022; Kawakami, Hisato/L-6845-2019; Morizane, Chigusa/AFV-4780-2022; Kawamoto, Yasuyuki/GWQ-7700-2022	Kawakami, Hisato/0000-0002-3280-4850; Morizane, Chigusa/0000-0002-6560-7503; Yamamoto, Yoshiyuki/0000-0002-2932-5904; Bando, Hideaki/0000-0001-5041-2765; Ikeda, Masafumi/0000-0002-4050-2086; Kato, Ken/0000-0002-1733-5072	Japan Agency for Medical Research and Development [19ck0106445h0002]; National Cancer Center Research and Development Fund [31-A-5]; SCRUM-Japan Funds	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research and Development Fund(National Cancer Center - Japan); SCRUM-Japan Funds	The authors thank all of the patients and their families who participated in this study; all SCRUM-Japan GI-SCREEN and GOZILA investigators and site personnel; M. Yuasa, Y. Ogata, S. Horasawa, M. Fujita, T. Nakamura, K. Kitajima, N. Kuramoto, H. Sokuoka and H. Uchigata (Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Japan) for study management and data center support; and Genomedia Inc. for data analysis. This work was supported by grants from the Japan Agency for Medical Research and Development (no. 19ck0106445h0002 to Y.N.), National Cancer Center Research and Development Fund (no. 31-A-5 to A.O.) and SCRUM-Japan Funds (http://www.scrum-japan.ncc.go.jp/index.html).	Abou-Alfa GK, 2020, LANCET ONCOL, V21, P796, DOI 10.1016/S1470-2045(20)30157-1; Aggarwal C, 2019, JAMA ONCOL, V5, P173, DOI 10.1001/jamaoncol.2018.4305; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; [Anonymous], 2017, NATURE, V541, P169, DOI [DOI 10.1038/NATURE20805, 10.1038/nature20805]; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Bando H, 2017, CURR PROB CANCER, V41, P166, DOI 10.1016/j.currproblcancer.2017.02.003; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Deng JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01730-x; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Golan T, 2017, ONCOLOGIST, V22, P804, DOI 10.1634/theoncologist.2016-0415; Hu YB, 2017, CLIN CANCER RES, V23, P7351, DOI 10.1158/1078-0432.CCR-17-1745; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624; Li H., 2013, ARXIV; Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6; Lih CJ, 2017, J MOL DIAGN, V19, P313, DOI 10.1016/j.jmoldx.2016.10.007; Lim C, 2016, J THORAC ONCOL, V11, P79, DOI 10.1016/j.jtho.2015.09.006; Maron SB, 2019, CLIN CANCER RES, V25, P7098, DOI 10.1158/1078-0432.CCR-19-1704; Meric-Bernstam F, 2016, ANN ONCOL, V27, P795, DOI 10.1093/annonc/mdw018; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakamura Y, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000600; Nakamura Y, 2018, ONCOLOGIST, V23, P1310, DOI 10.1634/theoncologist.2017-0621; Nance T, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-4272; Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Salem ME, 2018, MOL CANCER RES, V16, P805, DOI 10.1158/1541-7786.MCR-17-0735; Spiegel ML, 2017, CANCER-AM CANCER SOC, V123, P4800, DOI 10.1002/cncr.31056; Strickler JH, 2018, CANCER DISCOV, V8, P164, DOI 10.1158/2159-8290.CD-17-1009; Thompson JC, 2016, CLIN CANCER RES, V22, P5772, DOI 10.1158/1078-0432.CCR-16-1231; Villaflor V, 2016, ONCOTARGET, V7, P66880, DOI 10.18632/oncotarget.11801; Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324; Zhang L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw332	34	108	111	1	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12								10.1038/s41591-020-1063-5	http://dx.doi.org/10.1038/s41591-020-1063-5		OCT 2020	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33020649				2023-01-03	WOS:000575801100008
J	Cook, DJ; Takaoka, A; Hoad, N; Swinton, M; Clarke, FJ; Rudkowski, JC; Heels-Ansdell, D; Boyle, A; Toledo, F; Dennis, BB; Fiest, K; Vanstone, M				Cook, Deborah J.; Takaoka, Alyson; Hoad, Neala; Swinton, Marilyn; Clarke, France J.; Rudkowski, Jill C.; Heels-Ansdell, Diane; Boyle, Anne; Toledo, Felida; Dennis, Brittany B.; Fiest, Kirsten; Vanstone, Meredith			Clinician Perspectives on Caring for Dying Patients During the Pandemic A Mixed-Methods Study	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has affected the hospital experience for patients, visitors, and staff. Objective: To understand clinician perspectives on adaptations to end-of-life care for dying patients and their families during the pandemic. Design: Mixed-methods embedded study. (ClinicalTrials.gov: NCT04602520) Setting: 3 acute care medical units in a tertiary care hospital from 16 March to 1 July 2020. Participants: 45 dying patients, 45 family members, and 45 clinicians. Intervention: During the pandemic, clinicians continued an existing practice of collating personal information about dying patients and "what matters most," eliciting wishes, and implementing acts of compassion. Measurements: Themes from semistructured clinician interviews that were summarized with representative quotations. Results: Many barriers to end-of-life care arose because of infection control practices that mandated visiting restrictions and personal protective equipment, with attendant practical and psychological consequences. During hospitalization, family visits inside or outside the patient's room were possible for 36 patients (80.0%); 13 patients (28.9%) had virtual visits with a relative or friend. At the time of death, 20 patients (44.4%) had a family member at the bedside. Clinicians endeavored to prevent unmarked deaths by adopting advocacy roles to "fill the gap" of absent family and by initiating new and established ways to connect patients and relatives. Limitation: Absence of clinician symptom or wellness metrics; a single-center design. Conclusion: Clinicians expressed their humanity through several intentional practices to preserve personalized, compassionate end-of-life care for dying hospitalized patients during the SARS-CoV-2 pandemic.	[Cook, Deborah J.; Takaoka, Alyson; Swinton, Marilyn; Clarke, France J.; Rudkowski, Jill C.; Heels-Ansdell, Diane; Boyle, Anne; Dennis, Brittany B.; Vanstone, Meredith] McMaster Univ, Hamilton, ON, Canada; [Cook, Deborah J.; Hoad, Neala; Rudkowski, Jill C.; Boyle, Anne; Toledo, Felida] St Josephs Healthcare, Hamilton, ON, Canada; [Fiest, Kirsten] Univ Calgary, Calgary, AB, Canada; [Cook, Deborah J.; Rudkowski, Jill C.; Boyle, Anne] McMaster Univ, Hlth Sci Ctr, Dept Med, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Cook, Deborah J.; Rudkowski, Jill C.; Boyle, Anne] McMaster Univ, Hlth Sci Ctr, Dept Hlth Res Methods Evidence & Impact, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada; [Takaoka, Alyson; Swinton, Marilyn; Clarke, France J.; Heels-Ansdell, Diane] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 2C10,1280 Main St West, Hamilton, ON L8S 4K1, Canada; [Hoad, Neala] St Josephs Healthcare Hamilton, Room D-176,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada; [Rudkowski, Jill C.] St Josephs Healthcare Hamilton, Room F-507,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada; [Boyle, Anne; Vanstone, Meredith] McMaster Univ, Dept Family Med, 100 Main St West, Hamilton, ON L8S 1H6, Canada; [Toledo, Felida] St Josephs Healthcare Hamilton, Bishop Dowling Wing,Level 1,Room D-126, Hamilton, ON L8N 4A6, Canada; [Dennis, Brittany B.] McMaster Univ, Dept Med, MDCL 3101A,1280 Main St West, Hamilton, ON L8S 4K1, Canada; [Fiest, Kirsten] Cumming Sch Med, 3134 Hosp Dr Northwest, Calgary, AB T2N 4Z6, Canada	McMaster University; University of Calgary; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; McMaster University; McMaster University; McMaster University; McMaster University	Cook, DJ (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada.; Cook, DJ (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Hlth Res Methods Evidence & Impact, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada.	debcook@mcmaster.ca		Takaoka, Alyson/0000-0003-1442-080X; Clarke, France/0000-0001-7020-1391; Dennis, Brittany/0000-0002-3691-5400	Canadian Institutes of Health Research; Canadian Critical Care Trials Group Research Coordinator Fund	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Critical Care Trials Group Research Coordinator Fund	By the Canadian Institutes of Health Research and Canadian Critical Care Trials Group Research Coordinator Fund.	Amass TH, 2020, CRIT CARE MED, V48, P176, DOI 10.1097/CCM.0000000000004113; Azoulay E, 2020, AM J RESP CRIT CARE, V202, P1388, DOI 10.1164/rccm.202006-2568OC; Bartels JB, 2014, CRIT CARE NURSE, V34, P74, DOI 10.4037/ccn2014962; Benatti Simone V, 2020, Ann Intern Med, V172, P628, DOI 10.7326/M20-1137; Bone N, 2018, AM J CRIT CARE, V27, P212, DOI 10.4037/ajcc2018300; Chochinov HM, 2020, J PALLIAT MED, V23, P1294, DOI 10.1089/jpm.2020.0406; Chochinov HM, 2015, J PAIN SYMPTOM MANAG, V49, P974, DOI 10.1016/j.jpainsymman.2014.11.291; Choi J, 2019, HEART LUNG, V49, P553, DOI 10.1016/j.hrtlng.2019.09.001; Chua IS, 2020, J PALLIAT MED, V23, P1507, DOI 10.1089/jpm.2020.0298; Clark VLP, 2008, J FAM ISSUES, V29, P1543, DOI 10.1177/0192513X08318251; Cook D, 2014, NEW ENGL J MED, V370, P2506, DOI 10.1056/NEJMra1208795; Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894; Curtis JR, 2014, INTENS CARE MED, V40, P606, DOI 10.1007/s00134-013-3201-8; Downar J, 2020, CAN J ANESTH, V67, P685, DOI 10.1007/s12630-020-01573-z; Eggerstedt M, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102643; Fenn D, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03150-8; Ferrell BR, 2020, J PAIN SYMPTOM MANAG, V60, pE7, DOI 10.1016/j.jpainsymman.2020.06.034; Fram SM, 2013, QUAL REP, V18; Goldstein J., 2020, NEW YORK TIMES; Hart JL, 2020, J PAIN SYMPTOM MANAG, V60, pE93, DOI 10.1016/j.jpainsymman.2020.04.017; Hoad N, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029810; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Kanaris C, 2021, INTENS CARE MED, V47, P141, DOI 10.1007/s00134-020-06194-0; Kennedy NR, 2021, ANN AM THORAC SOC, V18, P838, DOI 10.1513/AnnalsATS.202006-729OC; Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976; Landry A, 2020, EMERG MED J, V37, P526, DOI 10.1136/emermed-2020-209987; Life Lines Team, 2020, INTENS CRIT CARE NUR, V60, DOI [10.1016/j.iccn.2020, DOI 10.1016/J.ICCN.2020]; Marra A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03035-w; Moore B, 2020, HASTINGS CENT REP, V50, P13, DOI 10.1002/hast.1122; Neville TH, 2020, J PALLIAT MED, V23, P990, DOI 10.1089/jpm.2020.0242; Neville TH, 2019, J PALLIAT MED, V22, P1561, DOI 10.1089/jpm.2019.0135; Ortega G, 2020, HEALTH POLICY TECHN, V9, P368, DOI 10.1016/j.hlpt.2020.08.001; Public Health Ontario, ONT COVID 19 DAT TOO; Robert R, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00702-7; Samanta J, 2003, BRIT MED J, V327, P225, DOI 10.1136/bmj.327.7408.225-a; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Sandelowski M, 2010, RES NURS HEALTH, V33, P77, DOI 10.1002/nur.20362; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Selman LE, 2020, J PAIN SYMPTOM MANAG, V60, pE81, DOI 10.1016/j.jpainsymman.2020.04.024; Takaoka A, PREPRINT, DOI [10.21203/rs.3.rs-91142/v1, DOI 10.21203/RS.3.RS-91142/V1]; Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689; UCLA Health, 3 WISH PROGR; Valley TS, 2020, AM J RESP CRIT CARE, V202, P883, DOI 10.1164/rccm.202005-1706LE; Vanstone M, 2020, BMC PALLIAT CARE, V19, DOI 10.1186/s12904-020-00601-5; Vanstone M, 2020, PALLIATIVE MED, V34, P1263, DOI 10.1177/0269216320929538; Vanstone M, 2020, ANN INTERN MED, V172, P1, DOI 10.7326/M19-2438; Wakam GK, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2007781; White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046; Yardley S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1472; Zulman DM, 2020, JAMA-J AM MED ASSOC, V323, P70, DOI 10.1001/jama.2019.19003	50	21	21	2	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR	2021	174	4					493	+		10.7326/M20-6943	http://dx.doi.org/10.7326/M20-6943			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU1WZ	33284683	Green Published			2023-01-03	WOS:000644942400036
J	Webster, P				Webster, Paul			COVID-19 highlights Canada's care home crisis	LANCET			English	Editorial Material								COVID-19 deaths in long-term care have been called a national disgrace, and experts are calling for the army to intervene. Paul Webster reports from Toronto.											0	19	19	4	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 16	2021	397	10270					183	183						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU3BS	33453769	Bronze, Green Published			2023-01-03	WOS:000609179800009
J	Gamage, SD; Ross, N; Kralovic, SM; Simbartl, LA; Roselle, GA; Berkelman, RL; Chamberlain, AT				Gamage, Shantini D.; Ross, Natasha; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.; Berkelman, Ruth L.; Chamberlain, Allison T.			Health after Legionnaires' disease: A description of hospitalizations up to 5 years after Legionella pneumonia	PLOS ONE			English	Article								Background and objectives Research on Legionnaires' Disease (LD) suggests there may be long-term health complications, but data are limited. This study investigated whether Intensive Care Unit (ICU) admission during LD hospitalization may be associated with adverse health outcomes and characterized subsequent discharge diagnoses in patients with LD up to 5 years post-LD. Methods We conducted a retrospective case series study with follow up for 5 years among patients hospitalized at a Department of Veterans Affairs (VA) Medical Center between 2005 and 2010 with LD. Data were collected from medical records on health history, LD severity (including ICU admission), and discharge diagnoses for 5 years post-LD or until death. We used ordinal logistic regression to explore associations between ICU admission and hospitalizations post-LD. Frequency counts were used to determine the most prevalent discharge diagnoses in the 5 years post-LD. Results For the 292 patients with laboratory-confirmed LD, those admitted to the ICU during LD hospitalization were more likely to have a greater number of hospitalizations within 5 years compared to non-ICU patients (ORHosp 1.92 CI95% 1.25, 2.95). Fifty-five percent (161/292) had >= 1 hospitalization within 5 years post-LD. After accounting for pre-existing diagnosis codes in patients with at least one hospitalization in the 2 years prior to LD (n = 77/161 patients, 47.8%), three of the four most frequent new diagnoses in the 5 years post-LD were non-chronic conditions: acute renal failure (n = 22, 28.6%), acute respiratory failure (n = 17, 22.1%) and unspecified pneumonia (n = 15, 19.5%). Conclusions Our findings indicate that LD requiring ICU admission is associated with more subsequent hospitalizations, a factor that could contribute to poorer future health for people with severe LD. In addition to chronic conditions prevalent in this study population, we found new diagnoses in the 5-year post-LD period including acute renal failure. With LD incidence increasing, more research is needed to understand conditions and factors that influence long term health after LD.	[Gamage, Shantini D.; Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] US Dept Vet Affairs, Natl Infect Dis Serv, Specialty Care Serv, Vet Hlth Adm, Washington, DC USA; [Gamage, Shantini D.; Kralovic, Stephen M.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH USA; [Ross, Natasha; Berkelman, Ruth L.; Chamberlain, Allison T.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Kralovic, Stephen M.; Roselle, Gary A.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA; [Ross, Natasha] Emory Healthcare, Off Qual, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; University of Cincinnati; Emory University; Rollins School Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Emory University	Chamberlain, AT (corresponding author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.	Allison.chamberlain@emory.edu		Chamberlain, Allison/0000-0001-6009-537X				Ajayi OO, 2017, AM J MED SCI, V353, P445, DOI 10.1016/j.amjms.2017.03.002; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; Amodeo MR, 2010, CLIN MICROBIOL INFEC, V16, P1405, DOI 10.1111/j.1469-0691.2009.03125.x; BAKER PCH, 1981, J NEUROL NEUROSUR PS, V44, P1054, DOI 10.1136/jnnp.44.11.1054; Brown SH, 2003, INT J MED INFORM, V69, P135, DOI 10.1016/S1386-5056(02)00131-4; Buxbaum JD, 2019, HEALTH SERV RES, V54, P1326, DOI 10.1111/1475-6773.13207; CARLIER B, 1981, ACTA CLIN BELG, V36, P12; Cassini A, IMPACT INFECT DIS PO; Centers for Disease Control and Prevention, 2019, NAT NOT DIS SURV SYS; CHASTRE J, 1987, CHEST, V91, P57, DOI 10.1378/chest.91.1.57; Cho J, 2016, J AM GERIATR SOC, V64, P1250, DOI 10.1111/jgs.14161; Coronel D, 2016, THER APHER DIAL, V20, P686, DOI 10.1111/1744-9987.12421; Cunha BA, 2016, LANCET, V387, P376, DOI 10.1016/S0140-6736(15)60078-2; Daumas Aurelie, 2012, J Med Case Rep, V6, P100, DOI 10.1186/1752-1947-6-100; Department of Veterans Affairs Office of Inspector General, 2013, HEALTHC INSP PREV LE; Gamage SD, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0230; Gupta Samir, 2018, EGEMS (Wash DC), V6, P4, DOI 10.5334/egems.198; Hellwege JN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11704-w; Hicks Lauri A., 2011, Morbidity and Mortality Weekly Report, V60, P1083; Hou JK, 2014, DIGEST DIS SCI, V59, P2406, DOI 10.1007/s10620-014-3174-7; Jonkers RE, 2004, CLIN INFECT DIS, V38, P605, DOI 10.1086/381199; Kheirbek RE, 2017, J AM GERIATR SOC, V65, P2100, DOI 10.1111/jgs.14900; Lettinga KD, 2002, CLIN INFECT DIS, V35, P11, DOI 10.1086/340738; National Academies of Sciences Engineering and Medicine, 2019, MANAGEMENT LEGIONELL, DOI [10.17226/25474, DOI 10.17226/25474]; Neil K, 2008, CLIN INFECT DIS, V47, P591, DOI 10.1086/590557; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; PEARSON SB, 1981, POSTGRAD MED J, V57, P109, DOI 10.1136/pgmj.57.664.109; Peterson R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132664; POULTER N, 1981, CLIN NEPHROL, V15, P216; RELMAN AS, 1978, NEW ENGL J MED, V298, P1014, DOI 10.1056/NEJM197805042981810; Sutarjono B, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-229243; Sutton SS, 2019, CTS-CLIN TRANSL SCI, V12, P698, DOI 10.1111/cts.12676; Thakar CV, 2009, CRIT CARE MED, V37, P2552, DOI 10.1097/CCM.0b013e3181a5906f; Valley TS, 2015, JAMA-J AM MED ASSOC, V314, P1272, DOI 10.1001/jama.2015.11068; van Loenhout JAF, 2014, J INFECTION, V68, P527, DOI 10.1016/j.jinf.2014.01.004; Viasus D, 2013, MEDICINE, V92, P51, DOI 10.1097/MD.0b013e31827f6104; Villa P, 2016, J AM GERIATR SOC, V64, P536, DOI 10.1111/jgs.14031; Wilson NJ, 1997, HEALTH AFFAIR, V16, P200, DOI 10.1377/hlthaff.16.4.200; Wingfield T, 2013, CLIN MED, V13, P152, DOI 10.7861/clinmedicine.13-2-152; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x; Yogarajah Meera, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-208367	41	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2021	16	1							e0245262	10.1371/journal.pone.0245262	http://dx.doi.org/10.1371/journal.pone.0245262			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QY4UJ	33428684	gold, Green Published			2023-01-03	WOS:000630036100049
J	Hernandez, SE; Dorta, R; Suero, J; Barros-Loscertales, A; Gonzalez-Mora, JL; Rubia, K				Hernandez, Sergio Elias; Dorta, Roberto; Suero, Jose; Barros-Loscertales, Alfonso; Gonzalez-Mora, Jose Luis; Rubia, Katya			Larger whole brain grey matter associated with long-term Sahaja Yoga Meditation: A detailed area by area comparison	PLOS ONE			English	Article							VOXEL-BASED MORPHOMETRY; GRAY-MATTER; MENTAL SILENCE; CORTEX; PARCELLATION; VOLUME; CONNECTIVITY; HIPPOCAMPAL; EXTENT	Objectives Our previous study showed that long-term practitioners of Sahaja Yoga Meditation (SYM) had around 7% larger grey matter volume (GMV) in the whole brain compared with healthy controls; however, when testing individual regions, only 5 small brain areas were statistically different between groups. Under the hypothesis that those results were statistically conservative, with the same dataset, we investigated in more detail the regional differences in GMV associated with the practice of SYM, with a different statistical approach. Design Twenty-three experienced practitioners of SYM and 23 healthy non-meditators matched on age, sex and education level, were scanned using structural magnetic resonance imaging (MRI). Their GMV were extracted and compared using Voxel-Based Morphometry (VBM). Using a novel ad-hoc general linear model, statistical comparisons were made to observe if the GMV differences between meditators and controls were statistically significant. Results In the 16 lobe area subdivisions, GMV was statistically significantly different in 4 out of 16 areas: in right hemispheric temporal and frontal lobes, left frontal lobe and brainstem. In the 116 AAL area subdivisions, GMV difference was statistically significant in 11 areas. The GMV differences were statistically more significant in right hemispheric brain areas. Conclusions The study shows that long-term practice of SYM is associated with larger GMV overall, and with significant differences mainly in temporal and frontal areas of the right hemisphere and the brainstem. These neuroplastic changes may reflect emotional and attentional control mechanisms developed with SYM. On the other hand, our statistical ad-hoc method shows that there were more brain areas with statistical significance compared to the traditional methodology which we think is susceptible to conservative Type II errors.	[Hernandez, Sergio Elias] Univ La Laguna, Dept Ingn Ind, Tenerife, Spain; [Dorta, Roberto] Univ La Laguna, Dept Matemat, Estad Invest Operat, Tenerife, Spain; [Suero, Jose] Sermas, Ctr Salud Jazmin, Madrid, Spain; [Barros-Loscertales, Alfonso] Univ Jaume 1, Dept Psicol Bas Clin & Psicobiol, Castellon de La Plana, Spain; [Gonzalez-Mora, Jose Luis] Univ La Laguna, Dept Fisiol, Tenerife, Spain; [Rubia, Katya] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England	Universidad de la Laguna; Universidad de la Laguna; Universitat Jaume I; Universidad de la Laguna; University of London; King's College London	Hernandez, SE (corresponding author), Univ La Laguna, Dept Ingn Ind, Tenerife, Spain.	sehdez@ull.edu.es	Rubia, Katya/H-7497-2012; Dorta-Guerra, Roberto/F-8947-2016	Rubia, Katya/0000-0002-1410-7701; Dorta-Guerra, Roberto/0000-0002-7269-1889; Hernandez Alonso, Sergio Elias/0000-0001-5043-1341				Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; [Anonymous], 2010, VBM TUTORIAL; [Anonymous], 1988, J PERCEPT MOTOR SKIL; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Badre D, 2018, TRENDS COGN SCI, V22, P170, DOI 10.1016/j.tics.2017.11.005; Beauregard M, 2006, NEUROSCI LETT, V405, P186, DOI 10.1016/j.neulet.2006.06.060; Bellato A, 2020, NEUROSCI BIOBEHAV R, V108, P182, DOI 10.1016/j.neubiorev.2019.11.001; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergouignan L, 2009, NEUROIMAGE, V45, P29, DOI 10.1016/j.neuroimage.2008.11.006; Boccia M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/419808; Brod G, 2016, J NEUROSCI, V36, P8103, DOI 10.1523/JNEUROSCI.0045-16.2016; Chung SC, 2012, J ALTERN COMPLEM MED, V18, P589, DOI 10.1089/acm.2011.0038; COWARD HG, 1985, J ANAL PSYCHOL, V30, P379, DOI 10.1111/j.1465-5922.1985.t01-1-00379.x; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Dixon ML, 2017, PSYCHOL BULL, V143, P1033, DOI 10.1037/bul0000096; Dodich A, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1159; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Draganski B, 2006, J NEUROSCI, V26, P6314, DOI 10.1523/JNEUROSCI.4628-05.2006; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Hernandez SE, 2018, NEUROSCIENCE, V371, P395, DOI 10.1016/j.neuroscience.2017.12.017; Hernandez SE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150757; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; Glasser MF, 2016, NATURE, V536, P171, DOI 10.1038/nature18933; Gonoi W, 2010, NEURORADIOLOGY, V52, P865, DOI 10.1007/s00234-009-0641-5; Harrison L.J., 2004, CLIN, V9, P479, DOI [10.1177/1359104504046155, DOI 10.1177/1359104504046155]; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Hernandez SE, 2015, J ALTERN COMPLEM MED, V21, P175, DOI 10.1089/acm.2013.0450; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hung YW, 2018, HUM BRAIN MAPP, V39, P4065, DOI 10.1002/hbm.24232; Jancke L, 2009, RESTOR NEUROL NEUROS, V27, P521, DOI 10.3233/RNN-2009-0519; Kapogiannis D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007180; Kokodoko A, 2014, LIBR J, V139, P96; Lindquist KA, 2012, BEHAV BRAIN SCI, V35, P121, DOI 10.1017/S0140525X11000446; Lorenz R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03657-3; Luders E, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00034; Luders E, 2011, NEUROIMAGE, V57, P1308, DOI 10.1016/j.neuroimage.2011.05.075; Luders E, 2009, NEUROIMAGE, V45, P672, DOI 10.1016/j.neuroimage.2008.12.061; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Malone IB, 2015, NEUROIMAGE, V104, P366, DOI 10.1016/j.neuroimage.2014.09.034; Manocha R, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/960583; Manocha R, 2002, THORAX, V57, P110, DOI 10.1136/thorax.57.2.110; Manocha R, 2007, J CLIN PSYCHOL MED S, V14, P266, DOI 10.1007/s10880-007-9076-5; Manocha R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/350674; Marciniak R, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00017; Mechelli A, 2005, CURR MED IMAGING, V1, P105, DOI 10.2174/1573405054038726; Morgan A., 2001, TRANSPERSONAL PSYCHO; Nakata H, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01489; Panjwani U, 1996, INDIAN J MED RES, V103, P165; Panjwani U, 2000, APPL PSYCHOPHYS BIOF, V25, P1, DOI 10.1023/A:1009523904786; Panjwani Usha, 1995, Indian Journal of Physiology and Pharmacology, V39, P111; Pavlov SV, 2015, INT J PSYCHOPHYSIOL, V95, P363, DOI 10.1016/j.ijpsycho.2015.01.002; Peelle JE, 2012, NEUROIMAGE, V60, P1503, DOI 10.1016/j.neuroimage.2011.12.086; Poldrack RA, 2007, SOC COGN AFFECT NEUR, V2, P67, DOI 10.1093/scan/nsm006; RAININKO R, 1994, NEURORADIOLOGY, V36, P364, DOI 10.1007/BF00612119; Rolls ET, 2015, NEUROIMAGE, V122, P1, DOI 10.1016/j.neuroimage.2015.07.075; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Rubia K, 2007, CHILD NEUROPSYCHOL, V13, P276, DOI 10.1080/09297040600770761; Rubia K, 2009, BIOL PSYCHOL, V82, P1, DOI 10.1016/j.biopsycho.2009.04.003; Ryman SG, 2019, HUM BRAIN MAPP, V40, P955, DOI 10.1002/hbm.24424; Sampaio-Baptista C, 2014, NEUROIMAGE, V96, P158, DOI 10.1016/j.neuroimage.2014.03.056; Sedlmeier P, 2012, PSYCHOL BULL, V138, P1139, DOI 10.1037/a0028168; Shao YH, 2015, MOL PHYS, V113, P184, DOI 10.1080/00268976.2014.952696; Singleton O, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00033; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takeda Y, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00241; Taki Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022734; Tang YY, 2009, P NATL ACAD SCI USA, V106, P8865, DOI 10.1073/pnas.0904031106; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Venkatraman A, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00015; Vestergaard-Poulsen P, 2009, NEUROREPORT, V20, P170, DOI 10.1097/WNR.0b013e328320012a; Vossel S, 2014, NEUROSCIENTIST, V20, P150, DOI 10.1177/1073858413494269; Woo CW, 2014, NEUROIMAGE, V91, P412, DOI 10.1016/j.neuroimage.2013.12.058; Yang CC, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9504642	76	5	5	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2020	15	12							e0237552	10.1371/journal.pone.0237552	http://dx.doi.org/10.1371/journal.pone.0237552			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM2BQ	33370272	Green Published, gold, Green Submitted			2023-01-03	WOS:000603611900039
J	Hammond, MM; Shen, CY; Li, SI; Kazi, DS; Sabe, MA; Garan, AR; Markson, LJ; Manning, WJ; Klein, AL; Nagueh, SF; Strom, JB				Hammond, Michael M.; Shen, Changyu; Li, Stephanie; Kazi, Dhruv S.; Sabe, Marwa A.; Garan, A. Reshad; Markson, Lawrence J.; Manning, Warren J.; Klein, Allan L.; Nagueh, Sherif F.; Strom, Jordan B.			Retrospective evaluation of echocardiographic variables for prediction of heart failure hospitalization in heart failure with preserved versus reduced ejection fraction: A single center experience	PLOS ONE			English	Article							END-DIASTOLIC PRESSURE; LEFT ATRIAL FUNCTION; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; MORTALITY; DISEASE; MODELS	Background Limited data exist on the differential ability of variables on transthoracic echocardiogram (TTE) to predict heart failure (HF) readmission across the spectrum of left ventricular (LV) systolic function. Methods We linked 15 years of TTE report data (1/6/2003-5/3/2018) at Beth Israel Deaconess Medical Center to complete Medicare claims. In those with recent HF, we evaluated the relationship between variables on baseline TTE and HF readmission, stratified by LVEF. Results After excluding TTEs with uninterpretable diastology, 5,900 individuals (mean age: 76.9 years; 49.1% female) were included, of which 2545 individuals (41.6%) were admitted for HF. Diastolic variables augmented prediction compared to demographics, comorbidities, and echocardiographic structural variables (p < 0.001), though discrimination was modest (c-statistic = 0.63). LV dimensions and eccentric hypertrophy predicted HF in HF with reduced (HFrEF) but not preserved (HFpEF) systolic function, whereas LV wall thickness, NT-proBNP, pulmonary vein D- and Ar-wave velocities, and atrial dimensions predicted HF in HFpEF but not HFrEF (all interaction p < 0.10). Prediction of HF readmission was not different in HFpEF and HFrEF (p = 0.93). Conclusions In this single-center echocardiographic study linked to Medicare claims, left ventricular dimensions and eccentric hypertrophy predicted HF readmission in HFrEF but not HFpEF and left ventricular wall thickness predicted HF readmission in HFpEF but not HFrEF. Regardless of LVEF, diastolic variables augmented prediction of HF readmission compared to echocardiographic structural variables, demographics, and comorbidities alone. The additional role of medication adherence, readmission history, and functional status in differential prediction of HF readmission by LVEF category should be considered for future study.	[Hammond, Michael M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Shen, Changyu; Kazi, Dhruv S.; Strom, Jordan B.] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Div Cardiovasc Med, Boston, MA 02215 USA; [Shen, Changyu; Kazi, Dhruv S.; Sabe, Marwa A.; Garan, A. Reshad; Manning, Warren J.; Strom, Jordan B.] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc Med, Boston, MA 02215 USA; [Shen, Changyu; Li, Stephanie; Kazi, Dhruv S.; Sabe, Marwa A.; Garan, A. Reshad; Markson, Lawrence J.; Manning, Warren J.; Strom, Jordan B.] Harvard Med Sch, Boston, MA 02115 USA; [Li, Stephanie] Beth Israel Deaconess Med Ctr, Ctr Healthcare Delivery Sci, Boston, MA 02215 USA; [Markson, Lawrence J.] Beth Israel Deaconess Med Ctr, Informat Syst, Boston, MA 02215 USA; [Manning, Warren J.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; [Klein, Allan L.] Cleveland Clin, Lerner Coll Med, Robert & Suzanne Tomsich Dept Cardiovasc Med, Cleveland, OH 44106 USA; [Nagueh, Sherif F.] Houston Methodist Hosp, Weill Cornell Med Coll, Dept Cardiol, Houston, TX 77030 USA	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Case Western Reserve University; Cleveland Clinic Foundation; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston	Strom, JB (corresponding author), Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Div Cardiovasc Med, Boston, MA 02215 USA.; Strom, JB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc Med, Boston, MA 02215 USA.; Strom, JB (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	jstrom@bidmc.harvard.edu			National, Heart, Lung, and Blood Institute [1K23HL144907]	National, Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The work was funded by a grant from the National, Heart, Lung, and Blood Institute (1K23HL144907; Dr Strom).	[Anonymous], 2015, CATALAN HIST REV, V8, P96; Benfari G, 2019, JACC-HEART FAIL, V7, P808, DOI 10.1016/j.jchf.2019.04.024; Dokainish H, 2011, EUR J ECHOCARDIOGR, V12, P857, DOI 10.1093/ejechocard/jer157; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fabiani I, 2019, INT J CARDIOVAS IMAG, V35, P1231, DOI 10.1007/s10554-019-01560-6; Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Johansen ND, 2017, AM HEART J, V188, P136, DOI 10.1016/j.ahj.2017.03.013; Kundi H, 2019, INT J CARDIOL, V292, P68, DOI 10.1016/j.ijcard.2019.06.061; Kundi H, 2019, JAMA CARDIOL, V4, P16, DOI 10.1001/jamacardio.2018.4051; Kundi H, 2019, AM J CARDIOL, V123, P132, DOI 10.1016/j.amjcard.2018.09.016; Kundi H, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.005048; Kurt M, 2009, CIRC-CARDIOVASC IMAG, V2, P10, DOI 10.1161/CIRCIMAGING.108.813071; Kushwaha S, 2014, NATL TRENDS ADMISSIO; Liang HY, 2006, AM J CARDIOL, V97, P866, DOI 10.1016/j.amjcard.2005.09.136; Machino-Ohtsuka T, 2019, EUR HEART J-CARD IMG, V20, P1129, DOI 10.1093/ehjci/jez082; McMurray JJV, 2020, CIRCULATION, V141, P338, DOI 10.1161/CIRCULATIONAHA.119.044491; Meyer T, 2013, ANN INTERN MED, V158, DOI 10.7326/0003-4819-158-1-201301010-01001; Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011; Nagueh SF, 2011, CIRC-CARDIOVASC IMAG, V4, P220, DOI 10.1161/CIRCIMAGING.111.963496; Nauta JF, 2020, EUR J HEART FAIL, V22, P1147, DOI 10.1002/ejhf.1632; Omar AMS, 2016, CIRC RES, V119, P357, DOI 10.1161/CIRCRESAHA.116.309128; Ouwerkerk W, 2018, J AM COLL CARDIOL, V71, P386, DOI 10.1016/j.jacc.2017.11.041; Ouwerkerk W, 2014, JACC-HEART FAIL, V2, P429, DOI 10.1016/j.jchf.2014.04.006; Persson H, 2019, INT J CARDIOL, V274, P202, DOI 10.1016/j.ijcard.2018.06.078; Ristow B, 2010, J AM SOC ECHOCARDIOG, V23, P406, DOI 10.1016/j.echo.2010.01.019; Roger VL, 2013, J AM COLL CARDIOL, V61, P1268, DOI 10.1016/j.jacc.2013.01.011; Schwammenthal E, 2000, AM J CARDIOL, V86, P169, DOI 10.1016/S0002-9149(00)00855-9; Shah AM, 2019, J AM COLL CARDIOL, V74, P2858, DOI 10.1016/j.jacc.2019.09.063; Silbiger JJ, 2019, J AM SOC ECHOCARDIOG, V32, P216, DOI 10.1016/j.echo.2018.11.011; Stevens SM, 2009, JACC-CARDIOVASC IMAG, V2, P11, DOI 10.1016/j.jcmg.2008.08.004; Steyerberg EW, 2014, EUR HEART J, V35, P1925, DOI 10.1093/eurheartj/ehu207; Torii Y, 2019, J AM SOC ECHOCARDIOG, V32, P1286, DOI 10.1016/j.echo.2019.06.006; Upshaw JN, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.116.003146; Welles CC, 2012, J AM COLL CARDIOL, V59, P673, DOI 10.1016/j.jacc.2011.11.012	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2020	15	12							e0244379	10.1371/journal.pone.0244379	http://dx.doi.org/10.1371/journal.pone.0244379			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CG	33351853	Green Published, gold			2023-01-03	WOS:000603071400030
J	Detering, T; Mundry, K; Berger, RG				Detering, Thorben; Mundry, Katharina; Berger, Ralf G.			Generation of 4-vinylguaiacol through a novel high-affinity ferulic acid decarboxylase to obtain smoke flavours without carcinogenic contaminants	PLOS ONE			English	Article							MECHANISM; LACCASE	Traditional smoke flavours bear the risk of containing a multitude of contaminating carcinogenic side-products. Enzymatic decarboxylation of ferulic acid released from agro-industrial side-streams by ferulic acid esterases (FAE) enables the sustainable generation of pure, food grade 4-vinylguaiacol (4-VG), the impact compound of smoke flavour. The first basidiomycetous ferulic acid decarboxylase (FAD) was isolated from Schizophyllum commune (ScoFAD) and heterologously produced by Komagataella phaffii. It showed a molecular mass of 21 kDa, catalytic optima at pH 5.5 and 35 degrees C, and a sequence identity of 63.6% to its next relative, a FAD from the ascomycete Cordyceps farinosa. The ScoFAD exhibited a high affinity to its only known substrate ferulic acid (FA) of 0.16 mmol L-1 and a turnover number of 750 s(-1). The resulting catalytic efficiency k(cat) K-M(-1) of 4,779 L s(-1) mmol(-1) exceeded the next best known enzyme by more than a factor of 50. Immobilised on AminoLink Plus Agarose, ScoFAD maintained its activity for several days. The combination with FAEs and agro-industrial side-streams paves the way for a new generation of sustainable, clean, and safe smoke flavours.	[Detering, Thorben; Mundry, Katharina; Berger, Ralf G.] Leibniz Univ Hannover, Inst Food Chem, Hannover, Lower Saxony, Germany	Leibniz University Hannover	Detering, T (corresponding author), Leibniz Univ Hannover, Inst Food Chem, Hannover, Lower Saxony, Germany.	thorben.detering@lci.uni-hannover.de			BMBF cluster Rauchenzym [031B0586]; Open Access fund of the Gottfried Wilhelm Leibniz Universitat Hannover	BMBF cluster Rauchenzym(Federal Ministry of Education & Research (BMBF)); Open Access fund of the Gottfried Wilhelm Leibniz Universitat Hannover	This research was funded the BMBF cluster Rauchenzym, grant number 031B0586. The APC was funded by the Open Access fund of the Gottfried Wilhelm Leibniz Universitat Hannover. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeboye PT, 2017, SCI REP-UK, V7, DOI 10.1038/srep42635; Behrens CJ, 2017, PROTEIN EXPRES PURIF, V137, P34, DOI 10.1016/j.pep.2017.06.014; Bhuiya MW, 2015, APPL ENVIRON MICROB, V81, P4216, DOI 10.1128/AEM.00762-15; Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340; Ciofalo V, 2006, REGUL TOXICOL PHARM, V45, P1, DOI 10.1016/j.yrtph.2006.02.001; Ferguson KL, 2016, BIOCHEMISTRY-US, V55, P2857, DOI 10.1021/acs.biochem.6b00170; Grosse M, 2020, J AGR FOOD CHEM, V68, P10329, DOI 10.1021/acs.jafc.9b06105; Hokkanen M., 2018, J CHEM, V2018, P1; Huang HK, 2012, J IND MICROBIOL BIOT, V39, P55, DOI 10.1007/s10295-011-0998-4; IIYAMA K, 1994, PLANT PHYSIOL, V104, P315, DOI 10.1104/pp.104.2.315; Ishii T, 1997, PLANT SCI, V127, P111, DOI 10.1016/S0168-9452(97)00130-1; Kolwek J, 2018, J IND MICROBIOL BIOT, V45, P89, DOI 10.1007/s10295-017-1998-9; Li LL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01798; Lin FM, 2015, ACS CHEM BIOL, V10, P1137, DOI 10.1021/cb5008103; Lin-Cereghino J, 2005, BIOTECHNIQUES, V38, P44, DOI 10.2144/05381BM04; Linke D, 2017, FUNGAL BIOL-UK, V121, P763, DOI 10.1016/j.funbio.2017.05.006; Maeda M, 2018, J BIOSCI BIOENG, V126, P162, DOI 10.1016/j.jbiosc.2018.02.009; Matte A, 2010, ACTA CRYSTALLOGR F, V66, P1407, DOI 10.1107/S174430911003246X; Mittmann E, 2019, MICROMACHINES-BASEL, V10, DOI 10.3390/mi10120795; Nagy EZA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36977-x; Nieter A, 2017, NEW BIOTECHNOL, V37, P153, DOI 10.1016/j.nbt.2017.01.002; Nieter A, 2016, BIORESOURCE TECHNOL, V220, P38, DOI 10.1016/j.biortech.2016.08.045; Ohm RA, 2010, NAT BIOTECHNOL, V28, P957, DOI 10.1038/nbt.1643; Payer SE, 2019, ADV SYNTH CATAL, V361, P2402, DOI 10.1002/adsc.201900275; Schwarz KJ, 2012, J I BREWING, V118, P280, DOI 10.1002/jib.41; Siebert M, 2019, LWT-FOOD SCI TECHNOL, V115, DOI 10.1016/j.lwt.2019.108426; Suguitan Jr AL, 2011, PLOS ONE, V6; Thompson CA, 2010, AM J HEALTH-SYST PH, V67, P93, DOI 10.2146/news100005; Woods L., 2003, ENCY FOOD SCI NUTR, P5296, DOI [10.1016/B0-12-227055-X/01093-2, DOI 10.1016/B0-12-227055-X/01093-2]; Zhao ZH, 2008, FOOD CHEM, V109, P691, DOI 10.1016/j.foodchem.2008.02.039	30	3	3	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2020	15	12							e0244290	10.1371/journal.pone.0244290	http://dx.doi.org/10.1371/journal.pone.0244290			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CD	33347481	Green Published, gold			2023-01-03	WOS:000603071100040
J	[Anonymous]				[Anonymous]			Update to living systematic review on drug treatments for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material													Khamis, Assem/P-8992-2017	Khamis, Assem/0000-0002-5567-7065					0	0	0	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2020	371								m4852	10.1136/bmj.m4852	http://dx.doi.org/10.1136/bmj.m4852			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PI0VM	33334735	Bronze			2023-01-03	WOS:000600818400005
J	Nowossadeck, E; Prutz, F; Teti, A				Nowossadeck, Enno; Prutz, Franziska; Teti, Andrea			Population change and the burden of hospitalization in Germany 2000-2040: Decomposition analysis and projection	PLOS ONE			English	Article							DEMOGRAPHIC TIME-BOMB; CARE; REHABILITATION; MULTIMORBIDITY; OUTPATIENT; MEDICINE.; DISEASE; IMPACT	Demographic factors, such as population aging and shrinkage, and non-demographic factors, such as hospitalization rate and length of hospital stay, generate challenges for inpatient care. This paper used decomposition analysis to assess how changes in these factors affected the number of hospital treatment days from 2000 to 2015 in Germany. Demographic aging was linked to increases in the number of treatment days for women (+10.0%) and men (+19.2%) and in hospitalization rates for women +6.0% and men +5.4%. However, these increases were offset by decreases in the number of hospital days (women: 16.5%; men: 7.3%) and length of stay (women: -27.4%; men -26.3%). For the projection up to 2040, 12 scenarios were developed (six for women and six for men) using three variants for future population demographics and two variants for future length of stay and hospitalization rates. One of the two variants for future length of stay and hospitalization rates provides for a constant value for the year 2015. For the second of these two variants variant, a logarithmic model was estimated on the basis of values from 2000 to 2015. and the trends were extrapolated using this model until 2040. The strongest overall predicted increase was 18.4% between 2015 and 2040, including a 22.4% increase for men. In two scenarios for women, only slight declines were predicted. All results, both for the decomposition analysis and projection, indicated a moderate but sustained effect of demographic aging on the number of hospital treatment days, leading to a significant increase in hospital treatment days over the study period. Non-demographic factors also had strong influences, especially in shorter time periods, but these effects offset each other over time. The change in the population size in the period under study had very little effect on the number of hospital treatment days.	[Nowossadeck, Enno] Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Social Determinants Hlth, Berlin, Germany; [Prutz, Franziska] Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Hlth Reporting, Berlin, Germany; [Teti, Andrea] Univ Vechta, Inst Gerontol, Vechta, Germany	Robert Koch Institute; Robert Koch Institute	Nowossadeck, E (corresponding author), Robert Koch Inst, Dept Epidemiol & Hlth Monitoring, Unit Social Determinants Hlth, Berlin, Germany.	NowossadeckE@rki.de	Nowossadeck, Enno/O-7898-2016	Nowossadeck, Enno/0000-0002-8534-0463				[Anonymous], 2013, J LABEL COMPD RADIOP, V56, pS88, DOI 10.1002/jlcr.3058; [Anonymous], 2014, J NURS REGUL, V5, pS3; [Anonymous], 2013, OFF J EUR UNION L, VL13, P46; [Anonymous], 2014, CANC DISCOV, V4, pOF1; AQUA-Institut, 2012, BESCHR QUAL ERF 2012; Astolfi R, 2012, HEALTH POLICY, V107, P1, DOI 10.1016/j.healthpol.2012.05.001; Balk BM, 2004, ECON LETT, V82, P107, DOI 10.1016/j.econlet.2003.09.006; Baumann W, 2016, ONKOLOGE, V22, P158, DOI 10.1007/s00761-016-0003-y; Biermann J, 2010, MED KLIN, V105, P876, DOI 10.1007/s00063-010-1152-1; Braun B, 2009, GESUNDHEITSVERSORGUN, P117; Braun GE, 2008, INFRASTRUKTURPROBLEM, P207; Braun T, 2008, KRANKENHAUSVERGUTUNG, P3; Busse R, 2017, LANCET, V390, P882, DOI 10.1016/S0140-6736(17)31280-1; Busse R, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f3197; Christiansen M, 2018, GESUNDHEITSWESEN, V80, P489, DOI 10.1055/s-0042-121597; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; Contrast Media Research 2017 Durango CU, 2017, INVEST RADIOL, V52, P758; Dieleman JL, 2017, JAMA-J AM MED ASSOC, V318, P1668, DOI 10.1001/jama.2017.15927; Dietzenbacher E., 1998, ECON SYST RES, V10, P307, DOI [10.1080/09535319800000023, DOI 10.1080/09535319800000023]; Dinkel RH, 2008, WAS IST ALTERN NEUE, P97; Doblhammer G, 2011, BUNDESGESUNDHEITSBLA, V54, P907, DOI 10.1007/s00103-011-1315-0; Flintrop J., 2006, DTSCH ARZTEBL, V103, P46; Frank J, 2015, GESUNDHEITSWESEN, V77, P932, DOI 10.1055/s-0034-1390417; Fuchs J, 2015, ATHENS J SOCIAL SCI, V2, P109, DOI DOI 10.30958/AJSS.2-2-3; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Herbermann JD, 2012, B WORLD HEALTH ORGAN, V90, P6, DOI 10.2471/BLT.12.020112; Hilgers S., 2011, DRG VERGUTUNG DTSCH; Keyfitz N, 2005, STAT BIOL HEALTH, P1, DOI 10.1007/b139042; KEYFITZ N, 1972, J AM STAT ASSOC, V67, P347, DOI 10.2307/2284381; Kirchberger I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030556; Kis A, 2017, J DTSCH DERMATOL GES, V15, P1199, DOI 10.1111/ddg.13379; Klosterman RE, 1990, COMMUNITY ANAL PLANN; Knopf H, 2013, BUNDESGESUNDHEITSBLA, V56, P868, DOI 10.1007/s00103-013-1667-8; Kolb GF, 2017, Z GERONTOL GERIATR, V50, P657, DOI 10.1007/s00391-017-1281-8; Kwok CL, 2017, INT J HEALTH POLICY, V6, P155, DOI 10.15171/ijhpm.2016.108; Layzell B, 2009, STUD HEALTH TECHNOL, V146, P166, DOI 10.3233/978-1-60750-024-7-166; Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Nations United, 2013, GLOB TRENDS CHALL SU; Neiner Jennifer A, 2004, Health Promot Pract, V5, P69, DOI 10.1177/1524839903257692; Niermann I, 2007, DTSCH ARZTEBL INT, V104, P923; Ha NT, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0554-9; Nowossadeck E, 2010, BUNDESGESUNDHEITSBLA, V53, P427, DOI 10.1007/s00103-010-1048-5; Nowossadeck E, 2019, REHABILITATION, V58, P96, DOI 10.1055/a-0603-6864; Nowossadeck E, 2018, BUNDESGESUNDHEITSBLA, V61, P358, DOI 10.1007/s00103-018-2695-1; Nowossadeck E, 2012, DTSCH ARZTEBL INT, V109, P151, DOI 10.3238/arztebl.2012.0151; Potzsch O., 2015, BEV DEUTSCHL BIS 206; Reinhold T, 2009, GESUNDHEITSWESEN, V71, P306, DOI 10.1055/s-0028-1119399; Casado JMR, 2012, EUR GERIATR MED, V3, P228, DOI 10.1016/j.eurger.2012.01.002; Roeder N, 2006, INTERNIST, V47, P684, DOI 10.1007/s00108-006-1646-3; Schulz E, 2004, HEALTH POLICY, V67, P57, DOI 10.1016/S0168-8510(03)00083-6; Schulz E., 2015, DIW WOCHENBERICHT, V82, P330; Standl T, 2016, AMBULANTES OPERIEREN, V3; Statistische Amter des Bundes und der Lander, 2010, DEM WAND DEUTSCHL HE, V2, P2010; Statistisches Bundesamt, 2016, BEV ERW BEV GRUNDL Z, P2016; Statistisches Bundesamt, 2016, KRANK DIAGN PAT PAT; Stock C, 2015, GESUNDHEITSWESEN, V77, P939, DOI 10.1055/s-0034-1398605; Tikkanen T, 2011, ENABLING INNOVATION: INNOVATIVE CAPABILITY - GERMAN AND INTERNATIONAL VIEWS, P249, DOI 10.1007/978-3-642-24503-9_26; von Eiff W, 2011, DTSCH ARZTEBLATT, V108, P1164; Wiedemann A, 2015, Z ALLG MED, V91, P494; Yarnall AJ, 2017, AGE AGEING, V46, P882, DOI 10.1093/ageing/afx150	61	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243322	10.1371/journal.pone.0243322	http://dx.doi.org/10.1371/journal.pone.0243322			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH0WM	33306705	gold, Green Published			2023-01-03	WOS:000600144200037
J	Hailemeskel, HS; Assebe, T; Alemayehu, T; Belay, DM; Teshome, F; Baye, A; Bayih, WA				Hailemeskel, Habtamu Shimels; Assebe, Tesfaye; Alemayehu, Tadesse; Belay, Demeke Mesfin; Teshome, Fentaw; Baye, Alemwork; Bayih, Wubet Alebachew			Determinants of short birth interval among ever married reproductive age women: A community based unmatched case control study at Dessie city administration, Northern Ethiopia	PLOS ONE			English	Article							INTERPREGNANCY INTERVAL; PREGNANCY INTERVAL; HEALTH; INFANT; RISK	Background Short birth interval is a universal public health problem resulting in adverse fetal, neonatal, child and maternal outcomes. In Ethiopia, more than 50% of the overall inter birth spacing is short. However, prior scientific evidence on its determinants is limited and even then findings are inconsistent. Methods A community -based unmatched case-control study was employed on 218 cases and 436 controls. Cases were ever married reproductive age women whose last delivery has been in the past five years with birth interval of less than 3 years between the latest two successive live births whereas those women with birth interval of 3-5 years were taken as controls. A multistage sampling technique was employed on 30% of the kebeles in Dessie city administration. A pre-tested interviewer based questionnaire was used to collect data by 16 trained diploma nurses and 8 health extension workers supervised by 4 BSc nurses. The collected data were cleaned, coded and double entered into Epi-data version 4.2 and exported to SPSS version 22. Binary logistic regression model was considered and those variables with PResult In this study, contraceptive use (AOR = 11.2, 95% CI: 5.95-21.15), optimal breast feeding for at least 2 years (AOR = 0.098, 95% CI:0.047-0.208), age at first birth <25 years (AOR = 0.36, 95% CI: 0.282-0.761), having male preceding child (AOR = 0.46, 95% CI: 0.166-0.793) and knowing the duration of optimum birth interval correctly (AOR = 0.45, 95% CI: 0.245-0.811) were significant determinants of short birth interval. Conclusion Contraceptive use, duration of breast feeding, age at first birth, preceding child sex and correct understanding of the duration of birth interval were significant determinants of short birth interval. Fortunately, all these significant factors are likely modifiable. Thus, the existing efforts of optimizing birth interval should be enhanced through proper designation and implementation of different strategies on safe breastfeeding practice, modern contraceptive use and maternal awareness about the health merits of optimum birth interval.	[Hailemeskel, Habtamu Shimels; Belay, Demeke Mesfin; Bayih, Wubet Alebachew] Debre Tabor Univ, Coll Hlth Sci, Dept Nursing, Debre Tabor, Ethiopia; [Assebe, Tesfaye] Haramaya Univ, Coll Hlth & Med Sci, Sch Nursing & Midwifery, Harar, Ethiopia; [Alemayehu, Tadesse] Haramaya Univ, Coll Hlth & Med Sci, Sch Publ Hlth, Harar, Ethiopia; [Teshome, Fentaw] Debre Tabor Univ, Dept Hlth Serv Management, Debre Tabor, Ethiopia; [Baye, Alemwork] Wollo Univ, Dept Environm Hlth, Dessie, Ethiopia	Haramaya University; Haramaya University	Hailemeskel, HS (corresponding author), Debre Tabor Univ, Coll Hlth Sci, Dept Nursing, Debre Tabor, Ethiopia.	habtamushimels21@gmail.com	Teshome, Fentaw/ADZ-0398-2022; Belay, Demeke Mesfin/ABD-7714-2021; Bayih, Wubet Alebachew/AAF-5099-2019	Belay, Demeke Mesfin/0000-0003-4786-2866; Bayih, Wubet Alebachew/0000-0003-1439-4402; Teshome Dagnaw, Fentaw/0000-0002-4496-9089; Hailemeskel, Habtamu/0000-0002-5972-4818				[Anonymous], 2014, SPECIAL ISSUE LIBELL, V10, P5; [Anonymous], 2013, PANCREATOLOGY, V13, pe1; Appareddy S, 2017, J MATERN-FETAL NEO M, V30, P2640, DOI 10.1080/14767058.2016.1260115; Begna Z, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-116; Bener Abdulbari, 2012, Rev. Bras. Saude Mater. Infant., V12, P233, DOI 10.1590/S1519-38292012000300003; Class QA, 2018, INT J EPIDEMIOL, V47, P1159, DOI 10.1093/ije/dyy042; Class QA, 2017, OBSTET GYNECOL, V130, P1304, DOI 10.1097/AOG.0000000000002358; Conde-Agudelo A, 2012, STUD FAMILY PLANN, V43, P93, DOI 10.1111/j.1728-4465.2012.00308.x; CSA (Comite de la Securite Alimentaire Mondiale), 2012, P COM S CUR AL MOND, P1; CSA ICF, 2016, ETH DEM HLTH SURV; Dadi AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126759; de Jonge HCC, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0427-6; Dereje Tesfaye, 2015, TURKIYEKLINIKLERI J, V7, P63; Durkin MS, 2015, J AUTISM DEV DISORD, V45, P2056, DOI 10.1007/s10803-015-2368-y; Geidam Ad, 2016, BORNO MED J BORNO MED J, V13, P132; Gemmill A, 2013, OBSTET GYNECOL, V122, P64, DOI 10.1097/AOG.0b013e3182955e58; Hailu Desta, 2016, Int J Reprod Med, V2016, P6072437, DOI 10.1155/2016/6072437; Hanley GE, 2017, OBSTET GYNECOL, V129, P408, DOI 10.1097/AOG.0000000000001891; Kesetebirhan A., 2011, NATL GUIDELINE FAMIL; Mahande MJ, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0929-5; OsotsiAwiti Japheth, 2013, PRECEDING BIRTH INTE; Owonikoko KM., 2015, INT J REPROD CONTRAC, V4, P316, DOI [10.5455/2320-1770.ijrcog20150406, DOI 10.5455/2320-1770.IJRCOG20150406]; Rabbi AMF., 2013, DHAKA U J SCI, V61, P105, DOI 10.3329/dujs.v61i1.15105; Saadehl R., 1990, WHO B OMS, V68; Shahjada A., 2014, INT J MED SCI PUBLIC, V3, P723, DOI [10.5455/ijmsph.2014.070420141, DOI 10.5455/IJMSPH.2014.070420141]; Thapaliya R., 2015, Health Renaissance, V13, P169, DOI 10.3126/hren.v13i3.17965; Tsegaye D, 2017, INT J NURSING MIDWIF, V9, P102, DOI DOI 10.5897/IJNM2017.0258; UNICEF, 2015, BREASTF NUTR; Wendt A, 2012, PAEDIATR PERINAT EP, V26, P239, DOI 10.1111/j.1365-3016.2012.01285.x; World Health Organization, 2004, CONTR ISS AD HLTH DE; World Health Organization, 2006, REP WHO TECHN CONS B; Yohannes S, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-38	32	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2020	15	12							e0243046	10.1371/journal.pone.0243046	http://dx.doi.org/10.1371/journal.pone.0243046			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC7AS	33275603	Green Published, gold			2023-01-03	WOS:000597150200016
J	Chen, CP; Lin, YC; Chen, TC; Tseng, TY; Wong, HL; Kuo, CY; Lin, WP; Huang, SR; Wang, WY; Liao, JH; Liao, CS; Hung, YP; Lin, TH; Chang, TY; Hsiao, CF; Huang, YW; Chung, WS; Cheng, CY; Cheng, SH				Chen, Cheng-Pin; Lin, Yi-Chun; Chen, Tsung-Chia; Tseng, Ting-Yu; Wong, Hon-Lai; Kuo, Cheng-Yu; Lin, Wu-Pu; Huang, Sz-Rung; Wang, Wei-Yao; Liao, Jia-Hung; Liao, Chung-Shin; Hung, Yuan-Pin; Lin, Tse-Hung; Chang, Tz-Yan; Hsiao, Chin-Fu; Huang, Yi-Wen; Chung, Wei-Sheng; Cheng, Chien-Yu; Cheng, Shu-Hsing		Taiwan HCQ Study Grp	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)	PLOS ONE			English	Article							CHLOROQUINE	Objective In this study, we evaluated the efficacy of hydroxychloroquine (HCQ) against coronavirus disease 2019 (COVID-19) via a randomized controlled trial (RCT) and a retrospective study. Methods Subjects admitted to 11 designated public hospitals in Taiwan between April 1 and May 31, 2020, with COVID-19 diagnosis confirmed by pharyngeal real-time RT-PCR for SARS-CoV-2, were randomized at a 2:1 ratio and stratified by mild or moderate illness. HCQ (400 mg twice for 1 d or HCQ 200 mg twice daily for 6 days) was administered. Both the study and control group received standard of care (SOC). Pharyngeal swabs and sputum were collected every other day. The proportion and time to negative viral PCR were assessed on day 14. In the retrospective study, medical records were reviewed for patients admitted before March 31, 2020. Results There were 33 and 37 cases in the RCT and retrospective study, respectively. In the RCT, the median times to negative rRT-PCR from randomization to hospital day 14 were 5 days (95% CI; 1, 9 days) and 10 days (95% CI; 2, 12 days) for the HCQ and SOC groups, respectively (p = 0.40). On day 14, 81.0% (17/21) and 75.0% (9/12) of the subjects in the HCQ and SOC groups, respectively, had undetected virus (p = 0.36). In the retrospective study, 12 (42.9%) in the HCQ group and 5 (55.6%) in the control group had negative rRT-PCR results on hospital day 14 (p = 0.70). Conclusions Neither study demonstrated that HCQ shortened viral shedding in mild to moderate COVID-19 subjects.	[Chen, Cheng-Pin; Lin, Yi-Chun; Cheng, Chien-Yu; Cheng, Shu-Hsing] Minist Hlth & Welf, Taoyuan Gen Hosp, Dept Infect Dis, Taoyuan, Taiwan; [Chen, Cheng-Pin] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan; [Lin, Yi-Chun] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Chen, Tsung-Chia; Tseng, Ting-Yu; Chung, Wei-Sheng] Minist Hlth & Welf, Taichung Hosp, Dept Internal Med, Taichung, Taiwan; [Wong, Hon-Lai] Minist Hlth & Welf, Keelung Hosp, Dept Internal Med, Keelung, Taiwan; [Kuo, Cheng-Yu] Minist Hlth & Welf, Pingtung Hosp, Dept Internal Med, Pingtung, Taiwan; [Lin, Wu-Pu] Minist Hlth & Welf, Taipei Hosp, Dept Internal Med, New Taipei, Taiwan; [Huang, Sz-Rung] Minist Hlth & Welf, Miaoli Gen Hosp, Dept Internal Med, Miaoli, Taiwan; [Wang, Wei-Yao] Minist Hlth & Welf, Feng Yuan Hosp, Dept Internal Med, Taichung, Taiwan; [Liao, Jia-Hung] Minist Hlth & Welf, Nantou Hosp, Dept Internal Med, Nantou, Taiwan; [Liao, Chung-Shin] Minist Hlth & Welf, Chia Yi Hosp, Dept Internal Med, Chiayi, Taiwan; [Hung, Yuan-Pin] Minist Hlth & Welf, Tainan Hosp, Dept Internal Med, Tainan, Taiwan; [Lin, Tse-Hung; Chang, Tz-Yan; Huang, Yi-Wen] Minist Hlth & Welf, Chang Hua Hosp, Dept Internal Med, Changhua, Taiwan; [Hsiao, Chin-Fu] Natl Hlth Res Inst, Inst Populat Hlth Sci, Zhunan, Taiwan; [Huang, Yi-Wen] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Chung, Wei-Sheng] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan; [Chung, Wei-Sheng] Cent Taiwan Univ Sci & Technol, Dept Healthcare Adm, Taichung, Taiwan; [Cheng, Chien-Yu] Natl Yang Ming Univ, Sch Publ Hlth, Taipei, Taiwan; [Cheng, Shu-Hsing] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei Medical University; National Health Research Institutes - Taiwan; Chung Shan Medical University; China Medical University Taiwan; Central Taiwan University Science & Technology; National Yang Ming Chiao Tung University; Taipei Medical University	Cheng, SH (corresponding author), Minist Hlth & Welf, Taoyuan Gen Hosp, Dept Infect Dis, Taoyuan, Taiwan.; Cheng, SH (corresponding author), Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan.	shcheng@mail.tygh.gov.tw	hong, hesse/EUM-0179-2022	hong, hesse/0000-0003-1006-705X; Chen, Cheng-Pin/0000-0002-0629-9790; Hsiao, Chin-Fu/0000-0003-1284-7260	Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare	Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare	SHC received research grant from the Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare (https://www.hso.mohw.gov.tw/). This funding source played no role in study design or conduction, data collection, analysis or interpretation, writing of the manuscript, or decision to submit it for publication.	[Anonymous], 2020, LANCET INFECT DIS, V20, P511; Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Caly Leon, 2020, Antiviral Res, V178, P104787, DOI 10.1016/j.antiviral.2020.104787; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03; Chen Z, 2020, EFFICACY HYDROXYCHLO, P114, DOI [10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]; Cheng CY, 2020, J MICROBIOL IMMUNOL, V53, P488, DOI 10.1016/j.jmii.2020.03.032; Cheng SC, 2020, J FORMOS MED ASSOC, V119, P747, DOI 10.1016/j.jfma.2020.02.007; Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027; Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047; Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004; National Health Commission of the People's Republic of China, NAT REC DIAGN TREATM; Rose-John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6; Taiwan CDC, INT GUID CLIN MAN SA; Taiwan Centers for Disease Control, CECC CONF 1 MOR IMP; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; U.S. Food and Drug Administration, REPL REQ EM US AUTH; Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69; Wang M., 2020, CELL RES, V30, P269, DOI [10.1038/s41422-020-0282-02020, DOI 10.1038/s41422-020-0282-0]; WHO, STAT 2 M INT HLTH RE; WHO, WHO DIR GEN OP REM M; World Health Organization, NOV COR SIT REP 151; World Health Organization, DIAGN DET 2019 NCOV; World Health Organization (WHO), NAM COR DIS COVID 19; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Zhang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104854	35	33	35	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2020	15	12							e0242763	10.1371/journal.pone.0242763	http://dx.doi.org/10.1371/journal.pone.0242763			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB8MS	33264337	Green Submitted, Green Published, gold			2023-01-03	WOS:000596569200079
J	Wood, FA; Howard, JP; Finegold, JA; Nowbar, AN; Thompson, DM; Arnold, AD; Rajkumar, CA; Connolly, S				Wood, Frances A.; Howard, James P.; Finegold, Judith A.; Nowbar, Alexandra N.; Thompson, David M.; Arnold, Ahran D.; Rajkumar, Christopher A.; Connolly, Susan			N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter								Patients who had discontinued statins because of side effects received four bottles of a statin, four bottles of placebo, and four empty bottles, each to be used for 1 month in a random sequence for 12 months. The symptom burden with placebo was 90% of the symptom burden with the statin.	[Wood, Frances A.; Howard, James P.; Finegold, Judith A.; Nowbar, Alexandra N.; Thompson, David M.; Arnold, Ahran D.; Rajkumar, Christopher A.; Connolly, Susan] Imperial Coll London, London, England	Imperial College London	Wood, FA (corresponding author), Imperial Coll London, London, England.	research@cardiologists.london	Arnold, Ahran/AAX-8935-2020	Arnold, Ahran/0000-0002-7597-0170; Howard, James/0000-0002-9989-6331; Cegla, Jaimini/0000-0003-1168-0366; Shun-Shin, Matthew/0000-0002-1179-0867; Stride, Christopher/0000-0001-9960-2869	British Heart Foundation [PG/15/7/31235]; Wellcome Trust [212183/Z/18/Z]; Medical Research Council [MR/S021108/1]; National Institute for Health Research Imperial Biomedical Research Centre; Imperial Clinical Trials Unit	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Imperial Biomedical Research Centre; Imperial Clinical Trials Unit	Supported by a grant (PG/15/7/31235) from the British Heart Foundation; a grant (212183/Z/18/Z, to Dr. Howard) from the Wellcome Trust; a grant (MR/S021108/1, to Dr. Rajkumar) from the Medical Research Council; the National Institute for Health Research Imperial Biomedical Research Centre; and the Imperial Clinical Trials Unit.	Finegold JA, 2014, EUR J PREV CARDIOL, V21, P464, DOI 10.1177/2047487314525531; Gupta A, 2017, LANCET, V389, P2473, DOI 10.1016/S0140-6736(17)31075-9; Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043; Stulc T, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0552-3	4	113	114	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 26	2020	383	22					2182	2184		10.1056/NEJMc2031173	http://dx.doi.org/10.1056/NEJMc2031173			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA6RJ	33196154	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000595759900017
J	Dong, ZJ; Tao, QC; Yan, BB; Sun, GJ				Dong, Zuojun; Tao, Qiucheng; Yan, Bobo; Sun, Guojun			Availability, prices and affordability of essential medicines in Zhejiang Province, China	PLOS ONE			English	Article								Objective To evaluate the availability, prices, and affordability of essential medicines in Zhejiang Province, China. Methods The survey was carried out in Zhejiang Province in 2018 following the methodology of the World Health Organization (WHO) and Health Action International (HAI). This method is an international standard method.Data on 50 medicines were collected from public health facilities and private pharmacies. Medication prices were compared with international reference prices to obtain a median price ratio. The affordability of medicines was measured based on the daily wage of the lowest-paid unskilled government worker. In private pharmacies, the mean availability of Originator Brands (OBs) and Lowest-priced Generics (LPGs) was 36.7% and 40.3%, respectively. Findings The effects of the mean availability of OBs and LPGs were seen in private pharmacies. Correspondingly, the average availability of OBs and LPGs was 41.8% and 35.1% in the public sector, respectively. In the public sector, the median price ratios (MPRs) were 5.21 for generics and 13.49 for OBs. In the private sector, the MPRs were 4.94 for generics and 14.75 for OBs. Treating common diseases with LPGs was generally affordable, while treatment with OBs was less affordable. Conclusions In Zhejiang Province, low availability was observed for medicines surveyed in the public and private sectors. Price differences between originator brands and generics in both sectors are apparent. OBs were more expensive than LPGs in both the public and private sectors. Low availability affects access to essential medicines. Policy measures should be taken to improve the availability of essential medicines.	[Dong, Zuojun; Tao, Qiucheng; Yan, Bobo; Sun, Guojun] Zhejiang Univ Technol, Coll Pharm, Hangzhou, Zhejiang, Peoples R China	Zhejiang University of Technology	Sun, GJ (corresponding author), Zhejiang Univ Technol, Coll Pharm, Hangzhou, Zhejiang, Peoples R China.	zmsgj@zjut.edu.cn						Alefan Q, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3593-9; [Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1; [Anonymous], 2016, EUR J PREV CARDIOL, V23, pNP1; [Anonymous], 2019, HLTH EC RES, V36, P13; Force MGT., 2008, DELIVERING GLOBAL PA; Hai Z, 2018, PHARM CARE RES, V18, P470; Jiang M, PLOS ONE; Jiang MH, 2015, INT J CLIN PHARM-NET, V37, P12, DOI 10.1007/s11096-014-0037-4; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Lang R, 2019, PHARMACOECONOMI 0603; Management Sciences for Health (MSH, 2015, INT DRUG PRIC IND GU; Shengpeng W, 2018, CHINESE PHARM MATTER, V32, P1034; Song Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201582; The Ministry of Health, 2012, CHIN NAT EML; World Health Organization Health Action International, 2008, MEAS MED PRIC AV AFF; Xi XY, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1008-8; Xin Z, 2018, CHINA PRIMARY HLTH C, V32, P13; Yanan S, 2017, HLTH EC RES, V08, P57; Zhejiang Province Human Resources and Social Security Department, 2018, LOW WAG STAND ZHEJ P; Zongying W, 2014, CHINESE MED GUIDELIN, V12, P394	20	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2020	15	11							e0241761	10.1371/journal.pone.0241761	http://dx.doi.org/10.1371/journal.pone.0241761			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA8EQ	33232336	Green Published, gold			2023-01-03	WOS:000595863100007
J	Foa, R; Bassan, R; Vitale, A; Elia, L; Piciocchi, A; Puzzolo, MC; Canichella, M; Viero, P; Ferrara, F; Lunghi, M; Fabbiano, F; Bonifacio, M; Fracchiolla, N; Di Bartolomeo, P; Mancino, A; De Propris, MS; Vignetti, M; Guarini, A; Rambaldi, A; Chiaretti, S				Foa, Robin; Bassan, Renato; Vitale, Antonella; Elia, Loredana; Piciocchi, Alfonso; Puzzolo, Maria-Cristina; Canichella, Martina; Viero, Piera; Ferrara, Felicetto; Lunghi, Monia; Fabbiano, Francesco; Bonifacio, Massimiliano; Fracchiolla, Nicola; Di Bartolomeo, Paolo; Mancino, Alessandra; De Propris, Maria-Stefania; Vignetti, Marco; Guarini, Anna; Rambaldi, Alessandro; Chiaretti, Sabina			Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; ELDERLY-PATIENTS; HYPER-CVAD; CHEMOTHERAPY; IMATINIB; PLUS; COMBINATION; GUIDELINES; OUTCOMES	BackgroundOutcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment. MethodsWe conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment. ResultsOf the 63 patients (median age, 54 years; range, 24 to 82) who were enrolled, a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1(plus)]). ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall, 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft, and 1 death was related to transplantation (4%). ConclusionsA chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others; GIMEMA LAL2116 D-ALBA EudraCT number, 2016-001083-11; ClinicalTrials.gov number, NCT02744768.) In patients who have acute lymphoblastic leukemia with tumor cells that bear the Philadelphia chromosome, traditional therapy is not very effective. The use of the ABL kinase inhibitor dasatinib to achieve remission, followed by the bifunctional antibody blinatumomab (which has both anti-CD3 and anti-CD19 specificity as maintenance therapy), led to complete remission in 98% of the patients.	[Foa, Robin; Vitale, Antonella; Elia, Loredana; Puzzolo, Maria-Cristina; Canichella, Martina; De Propris, Maria-Stefania; Vignetti, Marco; Chiaretti, Sabina] Sapienza Univ Rome, Div Hematol, Dept Translat & Precis Med, Via Benevento 6, I-00161 Rome, Italy; [Piciocchi, Alfonso; Vignetti, Marco] Fdn GIMEMA Franco Mandelli Onlus, Grp Italiano Malattie Ematol Adulto GIMEMA Data C, Rome, Italy; [Guarini, Anna] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Bassan, Renato; Viero, Piera; Mancino, Alessandra] Osped Angelo, Hematol Unit, Venice, Italy; [Bassan, Renato; Viero, Piera; Mancino, Alessandra] Osped SS Giovanni & Paolo, Venice, Italy; [Ferrara, Felicetto] Cardarelli Hosp, Div Hematol, Naples, Italy; [Lunghi, Monia] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy; [Fabbiano, Francesco] Osped Riuniti Villa Sofia Cervello, Div Hematol & Bone Marrow Transplantat, Palermo, Italy; [Bonifacio, Massimiliano] Univ Verona, Sect Hematol, Dept Med, Verona, Italy; [Fracchiolla, Nicola] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan, Milan, Italy; [Rambaldi, Alessandro] Univ Milan, Dept Oncol Hematol, Milan, Italy; [Di Bartolomeo, Paolo] Osped Civile, Dept Hematol, Pescara, Italy; [Rambaldi, Alessandro] Azienda Sociosanitaria Terr Papa Giovanni XXIII, Bergamo, Italy	Sapienza University Rome; Fondazione GIMEMA; Sapienza University Rome; ULSS 3 Serenissima; Ospedale dell'Angelo Mestre; IRCCS Istituto Tumori Bari Giovanni Paolo II; ULSS 3 Serenissima; Ospedale SS Giovanni Paolo Venezia; Antonio Cardarelli Hospital; University of Eastern Piedmont Amedeo Avogadro; University of Verona; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Milan; ASST Papa Giovanni XXIII	Foa, R (corresponding author), Sapienza Univ Rome, Div Hematol, Dept Translat & Precis Med, Via Benevento 6, I-00161 Rome, Italy.	rfoa@bce.uniroma1.it	Venditti, Adriano/E-4139-2015; Chiaretti, sabina/AAC-4657-2022; Piciocchi, Alfonso/AAC-4866-2022	Venditti, Adriano/0000-0002-0245-0553; Piciocchi, Alfonso/0000-0001-8648-885X; BONIFACIO, Massimiliano/0000-0003-0716-1686; PUZZOLO, MARIA CRISTINA/0000-0002-1948-8515; CHIARETTI, Sabina/0000-0001-8499-4492	Associazione Italiana per la Ricerca sul Cancro (5x1000, Special Program Metastases) [21198]; Finanziamento Medi Progetti Universitari 2015, Sapienza University of Rome and PRIN 2017 [2017PPS2X4_002]	Associazione Italiana per la Ricerca sul Cancro (5x1000, Special Program Metastases)(Fondazione AIRC per la ricerca sul cancro); Finanziamento Medi Progetti Universitari 2015, Sapienza University of Rome and PRIN 2017	Supported by grants from Associazione Italiana per la Ricerca sul Cancro (5x1000, Special Program Metastases, No. 21198, Milan, to Dr. Foa); and Finanziamento Medi Progetti Universitari 2015, Sapienza University of Rome and PRIN 2017 (No. 2017PPS2X4_002, to Dr. Chiaretti).	Aldoss I, 2016, BIOL BLOOD MARROW TR, V22, P1900, DOI 10.1016/j.bbmt.2016.06.022; Bassan R, 2010, J CLIN ONCOL, V28, P3644, DOI 10.1200/JCO.2010.28.1287; Chiaretti S, 2016, HAEMATOLOGICA, V101, P1544, DOI 10.3324/haematol.2016.144535; Chiaretti S, 2015, BLOOD, V126; Choi JK, 2018, INFECT CHEMOTHER, V50, P153, DOI 10.3947/ic.2018.50.2.153; de Labarthe A, 2007, BLOOD, V109, P1408, DOI 10.1182/blood-2006-03-011908; Delannoy A, 2006, LEUKEMIA, V20, P1526, DOI 10.1038/sj.leu.2404320; Duell J, 2017, LEUKEMIA, V31, P2181, DOI 10.1038/leu.2017.41; Elia L, 2003, HAEMATOLOGICA, V88, P275; Fedullo AL, 2019, HAEMATOLOGICA, V104, P312, DOI 10.3324/haematol.2018.196055; Fielding AK, 2014, BLOOD, V123, P843, DOI 10.1182/blood-2013-09-529008; Foa R, 2011, BLOOD, V118, P6521, DOI 10.1182/blood-2011-05-351403; Gokbuget N, 2018, BLOOD, V131, P1522, DOI 10.1182/blood-2017-08-798322; Gruber F, 2009, BRIT J HAEMATOL, V145, P581, DOI 10.1111/j.1365-2141.2009.07666.x; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Ishiyama K, 2017, LEUKEMIA, V31, P268, DOI [10.1038/leu.2016.188, 10.1038/leu.2016.174]; Jabbour E, 2014, ASH ANN M, V124, P2289; Jabbour E, 2015, LANCET ONCOL, V16, P1547, DOI 10.1016/S1470-2045(15)00207-7; Kim DY, 2015, BLOOD, V126, P746, DOI 10.1182/blood-2015-03-636548; Martinelli G, 2017, BLOOD, V130; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; Pfeifer H, 2019, LEUKEMIA, V33, P1910, DOI 10.1038/s41375-019-0413-0; Pfeifer H, 2018, BLOOD, V131, P1464, DOI 10.1182/blood-2017-07-796862; Ravandi F, 2016, BLOOD ADV, V1, P250, DOI 10.1182/bloodadvances.2016001495; Ravandi F, 2010, BLOOD, V116, P2070, DOI 10.1182/blood-2009-12-261586; Ribera JM, 2010, HAEMATOL-HEMATOL J, V95, P87, DOI 10.3324/haematol.2009.011221; Rousselot P, 2016, BLOOD, V128, P774, DOI 10.1182/blood-2016-02-700153; Tanguy-Schmidt A, 2013, BIOL BLOOD MARROW TR, V19, P150, DOI 10.1016/j.bbmt.2012.08.021; Thyagu S, 2012, BRIT J HAEMATOL, V158, P506, DOI 10.1111/j.1365-2141.2012.09182.x; van der Velden VHJ, 2007, LEUKEMIA, V21, P604, DOI 10.1038/sj.leu.2404586; Vignetti M, 2007, BLOOD, V109, P3676, DOI 10.1182/blood-2006-10-052746; Wassmann B, 2006, BLOOD, V108, P1469, DOI 10.1182/blood-2005-11-4386; Yanada M, 2006, J CLIN ONCOL, V24, P460, DOI 10.1200/JCO.2005.03.2177; Yoon JH, 2016, ANN ONCOL, V27, P1081, DOI 10.1093/annonc/mdw123	35	131	135	3	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	2020	383	17					1613	1623		10.1056/NEJMoa2016272	http://dx.doi.org/10.1056/NEJMoa2016272			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH4XI	33085860	Bronze			2023-01-03	WOS:000582579100008
J	Chen, WT; Kuo, YY; Lin, GB; Lu, CH; Hsu, HP; Sun, YK; Chao, CY				Chen, Wei-Ting; Kuo, Yu-Yi; Lin, Guan-Bo; Lu, Chueh-Hsuan; Hsu, Hao-Ping; Sun, Yi-Kun; Chao, Chih-Yu			Thermal cycling protects SH-SY5Y cells against hydrogen peroxide and beta-amyloid-induced cell injury through stress response mechanisms involving Akt pathway	PLOS ONE			English	Article							INSULIN-DEGRADING ENZYME; HEAT-SHOCK PROTEINS; OXIDATIVE STRESS; NRF2 PATHWAY; MOUSE MODEL; HYPERTHERMIA; DAMAGE; CREB; METABOLISM	Neurodegenerative diseases (NDDs) are becoming a major threat to public health, according to the World Health Organization (WHO). The most common form of NDDs is Alzheimer's disease (AD), boasting 60-70% share. Although some debates still exist, excessive aggregation of beta-amyloid protein (A beta) and neurofibrillary tangles has been deemed one of the major causes for the pathogenesis of AD. A growing number of evidences from studies, however, have suggested that reactive oxygen species (ROS) also play a key role in the onset and progression of AD. Although scientists have had some understanding of the pathogenesis of AD, the disease still cannot be cured, with existing treatment only capable of providing a temporary relief at best, partly due to the obstacle of blood-brain barrier (BBB). The study was aimed to ascertain the neuroprotective effect of thermal cycle hyperthermia (TC-HT) against hydrogen peroxide (H2O2) and A beta-induced cytotoxicity in SH-SY5Y cells. Treating cells with this physical stimulation beforehand significantly improved the cell viability and decreased the ROS content. The underlying mechanisms may be due to the activation of Akt pathway and the downstream antioxidant and prosurvival proteins. The findings manifest significant potential of TC-HT in neuroprotection, via inhibition of oxidative stress and cell apoptosis. It is believed that coupled with the use of drugs or natural compounds, this methodology can be even more effective in treating NDDs.	[Chen, Wei-Ting; Kuo, Yu-Yi; Lin, Guan-Bo; Lu, Chueh-Hsuan; Chao, Chih-Yu] Natl Taiwan Univ, Dept Phys, Lab Med Phys & Biomed Engn, Taipei, Taiwan; [Chen, Wei-Ting; Kuo, Yu-Yi; Lin, Guan-Bo; Lu, Chueh-Hsuan; Sun, Yi-Kun; Chao, Chih-Yu] Natl Taiwan Univ, Biomed & Mol Imaging Ctr, Coll Med, Taipei, Taiwan; [Hsu, Hao-Ping] Natl Taiwan Univ, Dept Med, Coll Med, Taipei, Taiwan; [Chao, Chih-Yu] Natl Taiwan Univ, Grad Inst Appl Phys, Biophys Div, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University	Chao, CY (corresponding author), Natl Taiwan Univ, Dept Phys, Lab Med Phys & Biomed Engn, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Biomed & Mol Imaging Ctr, Coll Med, Taipei, Taiwan.; Chao, CY (corresponding author), Natl Taiwan Univ, Grad Inst Appl Phys, Biophys Div, Taipei, Taiwan.	cychao@phys.ntu.edu.tw			Ministry of Science and Technology [MOST 1082112-M-002-016, 105-2112-M-002-006-MY3]; Ministry of Education of the Republic of China [MOE 106R880708]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Education of the Republic of China(Ministry of Education, Taiwan)	This work was supported by grants from Ministry of Science and Technology (MOST 1082112-M-002-016 and 105-2112-M-002-006-MY3 to CYC) and Ministry of Education (MOE 106R880708 to CYC) of the Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alghazwi M, 2019, NEUROCHEM INT, V124, P215, DOI 10.1016/j.neuint.2019.01.010; Bachurin SO, 2017, MED RES REV, V37, P1186, DOI 10.1002/med.21434; Baranova KA, 2014, NEUROCHEM J+, V8, P17, DOI 10.1134/S1819712414010048; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Caracciolo L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04445-9; Chen WT, 2019, INT J ONCOL, V55, P617, DOI 10.3892/ijo.2019.4844; Chen XP, 2012, NEURAL REGEN RES, V7, P376, DOI 10.3969/j.issn.1673-5374.2012.05.009; Choi ML, 2018, FEBS J, V285, P3631, DOI 10.1111/febs.14587; Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030; Christophi C, 1998, SURG ONCOL, V7, P83, DOI 10.1016/S0960-7404(99)00007-9; de Oliveira MR, 2018, MOL NEUROBIOL, V55, P4777, DOI 10.1007/s12035-017-0684-2; Deane CAS, 2016, CELL STRESS CHAPERON, V21, P837, DOI 10.1007/s12192-016-0708-2; Dewhirst MW, 2003, INT J HYPERTHER, V19, P267, DOI 10.1080/0265673031000119006; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frazier N, 2016, J CONTROL RELEASE, V241, P186, DOI 10.1016/j.jconrel.2016.09.030; Gong B, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00004; Habash Riadh W. Y., 2006, Critical Reviews in Biomedical Engineering, V34, P459, DOI 10.1615/CritRevBiomedEng.v34.i6.20; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Han SM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-286; Hatayama T, 2001, BIOCHEM BIOPH RES CO, V288, P528, DOI 10.1006/bbrc.2001.5802; Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200; Huang HC, 2009, J ALZHEIMERS DIS, V16, P15, DOI 10.3233/JAD-2009-0960; Huang Y, 2015, J NUTR BIOCHEM, V26, P1401, DOI 10.1016/j.jnutbio.2015.08.001; Jin XH, 2017, INT J MOL MED, V39, P1409, DOI 10.3892/ijmm.2017.2979; Kampinga HH, 2016, LANCET NEUROL, V15, P748, DOI 10.1016/S1474-4422(16)00099-5; Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325; Kubben N, 2016, CELL, V165, P1361, DOI 10.1016/j.cell.2016.05.017; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Liu ZD, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8091265; Lord-Fontaine S, 2002, FREE RADICAL BIO MED, V32, P752, DOI 10.1016/S0891-5849(02)00769-4; Lu CH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217676; Manczak M, 2006, HUM MOL GENET, V15, P1437, DOI 10.1093/hmg/ddl066; Masters SL, 2011, TRENDS MOL MED, V17, P276, DOI 10.1016/j.molmed.2011.01.005; Matsumoto K, 2001, TRANSPLANTATION, V71, P862, DOI 10.1097/00007890-200104150-00007; Matsuoka Y, 2001, NEUROSCIENCE, V104, P609, DOI 10.1016/S0306-4522(01)00115-4; Mesihovic A, 2016, PLANT REPROD, V29, P93, DOI 10.1007/s00497-016-0281-y; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mustafi SB, 2009, CELL STRESS CHAPERON, V14, P579, DOI 10.1007/s12192-009-0109-x; Partanen A, 2013, MED PHYS, V40, DOI 10.1118/1.4769116; Qin ZH, 2013, FUTURE MED CHEM, V5, P1451, DOI 10.4155/fmc.13.111; Rosa E, 2015, NEUROBIOL AGING, V36, P2406, DOI 10.1016/j.neurobiolaging.2015.04.014; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Sbardella D, 2018, CELL MOL LIFE SCI, V75, P3441, DOI 10.1007/s00018-018-2807-y; Schaaf L, 2016, CANCER RES, V76, P2868, DOI 10.1158/0008-5472.CAN-15-2908; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Son SM, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0054-3; Tchouague M, 2019, CHEM-BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.06.030; Thomas MP, 2013, IMMUNOL REV, V253, P237, DOI 10.1111/imr.12052; Tundo GR, 2017, CRIT REV BIOCHEM MOL, V52, P554, DOI 10.1080/10409238.2017.1337707; Tundo GR, 2013, J BIOL CHEM, V288, P2281, DOI 10.1074/jbc.M112.393108; Wang Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00500-5; Wu XL, 2017, ACS CHEM NEUROSCI, V8, P676, DOI 10.1021/acschemneuro.6b00388; Xicoy H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0149-0; Yang YH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39090-9; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Yida Z, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-468; Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075; Zhao Y, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/316523	62	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2020	15	10							e0240022	10.1371/journal.pone.0240022	http://dx.doi.org/10.1371/journal.pone.0240022			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OS6KJ	33002038	gold, Green Submitted, Green Published			2023-01-03	WOS:000590270000089
J	Sun, YJ; Wang, RY; Tang, WW; Li, C; Huo, N				Sun, Yanjie; Wang, Rongying; Tang, Weiwei; Li, Chao; Huo, Nan			Trends and factors of botanical dietary supplement use among US adults with COPD from 1999 to 2016	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ALTERNATIVE MEDICINE USE; NATIONAL-HEALTH; SYSTEMATIC ANALYSIS; HERBAL MEDICINES; LIFE EXPECTANCY; GLOBAL BURDEN; COMPLEMENTARY; ANEMIA; ASTHMA	Background The potential effects of botanical dietary supplements (BDS) in the treatment of asthma have been proposed. However, the evidence of the effects of BDS use among patients with COPD is limited. The objective of our study was to exam the trends and effects of BDS use among US adults with COPD. Methods A serial, cross-sectional study was conducted by using data of the NHANSE from 1999 to 2016 (n = 53,348). COPD (n = 2,580) was identified by using self-reported diagnosis history, and any BDS use was identified in the past 30 days. The prevalence of BDS use was calculated for respondents with and without COPD. Simple linear regression models were applied to test for trends in BDS use. Multiple logistic regression models were used to identify the factors of BDS use and patients' clinical outcomes, including all-cause hospitalization and abnormal hemoglobin levels, associated with BDS use. The results were weighted to represent national estimates. Results The prevalence of BDS use was greater among participants who had COPD compared to the referent group (mean 16.77% vs. 15.11%, p = 0.044). The trend of BDS use decreased from 1999 through 2016 in COPD group (p = 0.0023), but the trend remained stable in the non-COPD group (P>0.05). Results of multivariate logistic regression models showed that patients with higher family income (>= 100% FPL) and graduated from college were more likely to use BDS compared with non-users. BDS use was associated with a lower likelihood of having all-cause hospitalization (adjusted odds ratio = 0.64; 95% CI 0.45-0.92) and abnormal levels of hemoglobin (adjusted odds ratio = 0.67; 95% CI 0.49-0.92) among adult COPD patients, after adjusting for covariates. Conclusions The overall use of BDS decreased during 1999 through 2016 for US adults with COPD. The potential benefit of these supplemental medications use for clinical outcomes might exist for adult COPD patients.	[Sun, Yanjie; Wang, Rongying] Hebei Med Univ, Dept Gen Practice, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Tang, Weiwei] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing, Jiangsu, Peoples R China; [Tang, Weiwei] Nanjing Med Univ, Ctr Global Hlth, Nanjing, Jiangsu, Peoples R China; [Tang, Weiwei] Nanjing Med Univ, Inst Hlth Jiangsu Dev, Nanjing, Jiangsu, Peoples R China; [Li, Chao] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA; [Huo, Nan] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Hebei Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Auburn University System; Auburn University; Mayo Clinic	Huo, N (corresponding author), Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.	huo.nan@mayo.edu	Huo, Nan/AAD-9300-2022; Huo, Nan/AAO-3467-2021	Huo, Nan/0000-0002-4980-2421; 				Adeloye D, 2015, J GLOB HEALTH, V5, P186, DOI 10.7189/jogh.05.020415; Akram K, 2006, DIABETIC MED, V23, P750, DOI 10.1111/j.1464-5491.2006.01880.x; Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299; Boutou AK, 2013, RESPIRATION, V85, P126, DOI 10.1159/000338792; Boutou AK, 2011, RESPIRATION, V82, P237, DOI 10.1159/000326899; Chen WJ, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003360; Clarke Tainya C, 2015, Natl Health Stat Report, P1; Cote C, 2007, EUR RESPIR J, V29, P923, DOI 10.1183/09031936.00137106; Hoepers ATD, 2015, CLIN EXP PHARMACOL P, V42, P231, DOI 10.1111/1440-1681.12357; Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Galati G, 2004, FREE RADICAL BIO MED, V37, P287, DOI 10.1016/j.freeradbiomed.2004.04.034; Galati G, 2006, FREE RADICAL BIO MED, V40, P570, DOI 10.1016/j.freeradbiomed.2005.09.014; Gross D, 2002, Monaldi Arch Chest Dis, V57, P242; Guo R, 2006, EUR RESPIR J, V28, P330, DOI 10.1183/09031936.06.00119905; Halpern Michael T, 2006, Cost Eff Resour Alloc, V4, P17; Harrison RA, 2004, BRIT J NUTR, V91, P617, DOI 10.1079/BJN20031076; Huo N, 2018, J ALLER CL IMM-PRACT, V6, P936, DOI 10.1016/j.jaip.2017.09.015; Huo N, 2015, J ASTHMA, V52, P308, DOI 10.3109/02770903.2014.963867; Ioannides C, 2002, XENOBIOTICA, V32, P451, DOI 10.1080/00498250210124147; Izzo AA, 2001, DRUGS, V61, P2163, DOI 10.2165/00003495-200161150-00002; Izzo AA, 2005, FUND CLIN PHARMACOL, V19, P1, DOI 10.1111/j.1472-8206.2004.00301.x; Kantor ED, 2016, JAMA-J AM MED ASSOC, V316, P1464, DOI 10.1001/jama.2016.14403; Kao GD, 2000, CANCER, V88, P615, DOI 10.1002/(SICI)1097-0142(20000201)88:3<615::AID-CNCR18>3.0.CO;2-P; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31470-2; Kent BD, 2011, INT J CHRONIC OBSTR, V6, P199, DOI 10.2147/COPD.S10611; Kheir MM, 2010, FOOD CHEM TOXICOL, V48, P1105, DOI 10.1016/j.fct.2010.01.033; Li C, 2018, CANCER-AM CANCER SOC, V124, P1207, DOI 10.1002/cncr.31183; Li SG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057604; Marino LA, 2010, J ASTHMA, V47, P521, DOI 10.3109/02770900903576320; Martinez FJ, 2006, AM J RESP CRIT CARE, V173, P1326, DOI 10.1164/rccm.200510-1677OC; Ni HY, 2002, MED CARE, V40, P353, DOI 10.1097/00005650-200204000-00011; Palinkas LA, 2000, J FAM PRACTICE, V49, P1121; Plesner LL, 2017, HEART LUNG CIRC, V26, P101, DOI 10.1016/j.hlc.2016.04.020; Samenuk D, 2002, MAYO CLIN P; Sharma R, 2004, EUR HEART J, V25, P1021, DOI 10.1016/j.ehj.2004.04.023; Shinto L, 2005, COMPLEMENT THER MED, V13, P264, DOI 10.1016/j.ctim.2005.07.007; SILBERBERG JS, 1989, AM J CARDIOL, V64, P222, DOI 10.1016/0002-9149(89)90462-1; Similowski T, 2006, EUR RESPIR J, V27, P390, DOI 10.1183/09031936.06.00143704; Soriano JB, 2005, CHEST, V128, P2099, DOI 10.1378/chest.128.4.2099; Stickel F, 2000, PUBLIC HEALTH NUTR, V3, P113, DOI [10.1017/S1368980000000161, 10.1017/S1368980000000586]; Tilert Timothy, 2018, EC Pulmonol Respir Med, V7, P650; Vasquez A, 2016, COPD, V13, P100, DOI 10.3109/15412555.2015.1043519; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016; Wei Z M, 1996, Zhongguo Zhong Xi Yi Jie He Za Zhi, V16, P402; Wu CH, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/872320; Wu CH, 2011, CLIN THER, V33, P1749, DOI 10.1016/j.clinthera.2011.09.024; Yohannes AM, 2011, RESP CARE, V56, P644, DOI 10.4187/respcare.01002; Zhao C Y, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P264	51	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2020	15	9							e0239674	10.1371/journal.pone.0239674	http://dx.doi.org/10.1371/journal.pone.0239674			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY8KQ	32991612	Green Published, gold			2023-01-03	WOS:000576632300048
J	Bowles, KH; McDonald, M; Barron, Y; Kennedy, E; O'Connor, M; Mikkelsen, M				Bowles, Kathryn H.; McDonald, Margaret; Barron, Yolanda; Kennedy, Erin; O'Connor, Melissa; Mikkelsen, Mark			Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; VALIDITY; OASIS	Background: Little is known about recovery from coronavirus disease 2019 (COVID-19) after hospital discharge. Objective: To describe the home health recovery of patients with COVID-19 and risk factors associated with rehospitalization or death. Design: Retrospective observational cohort. Setting: New York City. Participants: 1409 patients with COVID-19 admitted to home health care (HHC) between 1 April and 15 June 2020 after hospitalization. Measurements: Covariates and outcomes were obtained from the mandated OASIS (Outcome and Assessment Information Set). Cox proportional hazards models were used to estimate the hazard ratio (HR) of risk factors associated with rehospitalization or death. Results: After an average of 32 days in HHC, 94% of patients were discharged and most achieved statistically significant improvements in symptoms and function. Activity-ofdaily-living dependencies decreased from an average of 6 (95% CI, 5.9 to 6.1) to 1.2 (CI, 1.1 to 1.3). Risk for rehospitalization or death was higher for male patients (HR, 1.45 [CI, 1.04 to 2.03]); White patients (HR, 1.74 [CI, 1.22 to 2.47]); and patients with heart failure (HR, 2.12 [CI, 1.41 to 3.19]), diabetes with complications (HR, 1.71 [CI, 1.17 to 2.52]), 2 or more emergency department visits in the past 6 months (HR, 1.78 [CI, 1.21 to 2.62]), pain daily or all the time (HR, 1.46 [CI, 1.05 to 2.05]), cognitive impairment (HR, 1.49 [CI, 1.04 to 2.13]), or functional dependencies (HR, 1.09 [CI, 1.00 to 1.20]). Eleven patients (1%) died, 137 (10%) were rehospitalized, and 23 (2%) remain on service. Limitations: Care was provided by 1 home health agency. Information on rehospitalization and death after HHC discharge is not available. Conclusion: Symptom burden and functional dependence were common at the time of HHC admission but improved for most patients. Comorbid conditions of heart failure and diabetes, as well as characteristics present at admission, identified patients at greatest risk for an adverse event.	[Bowles, Kathryn H.] 418 Curie Blvd,Room 340 Claire M Fagin Hall, Philadelphia, PA 19104 USA; [McDonald, Margaret] 5 Penn Plaza,12th Floor, New York, NY 10001 USA; [Barron, Yolanda] 135 Fairview Ave, Berkeley Hts, NJ 07922 USA; [Kennedy, Erin] 112 South 19th St,Apartment 2105, Philadelphia, PA 19103 USA; [O'Connor, Melissa] 800 Lancaster Ave,316 Driscoll Hall, Villanova, PA 19085 USA; [Mikkelsen, Mark] 1246 Knox Rd, Wynnewood, PA 19096 USA		Bowles, KH (corresponding author), 418 Curie Blvd,Room 340 Claire M Fagin Hall, Philadelphia, PA 19104 USA.	bowles@upenn.edu		Barron, Yolanda/0000-0002-7064-937X; Kennedy, Erin/0000-0002-1981-0260; McDonald, Margaret/0000-0003-1045-0956; Bowles, Kathryn/0000-0001-7740-5725; O'Connor, Melissa/0000-0002-2550-3590	Gordon and Betty Moore Foundation [GBMF9048]; National Institute of Nursing Research; National Institute on Aging; Agency for Healthcare Research and Quality; Ruth L. Kirschstein National Research Service Award [2 T32 NR009356-11]	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Drs. O'Connor and Bowles are supported by grant GBMF9048 from the Gordon and Betty Moore Foundation. Dr. Bowles, Ms. McDonald, and Ms. Barron receive salary support from the National Institute of Nursing Research, the National Institute on Aging, and the Agency for Healthcare Research and Quality. Ms. Kennedy is funded by a Ruth L. Kirschstein National Research Service Award (2 T32 NR009356-11).	Al-Salameh A, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3388; Arora VS, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200408.641535, DOI 10.1377/HBLOG20200408.641535]; Avalere, 2019, CHARTB; Bowles KH, 2020, J AM MED DIR ASSOC, V21, P84, DOI 10.1016/j.jamda.2019.11.001; Bowles KH, 2019, J AM MED DIR ASSOC, V20, P408, DOI 10.1016/j.jamda.2018.08.016; Bryant B., NEW YORK HOME HLTH A; Bwire George M, 2020, SN Compr Clin Med, V2, P874, DOI 10.1007/s42399-020-00341-w; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Centers for Disease Control and Prevention, US COVID 19 CAS DEAT; Centers for Medicare & Medicaid Services, PREL MED COVID 19 SN; Deb P, 2019, MED CARE, V57, P633, DOI 10.1097/MLR.0000000000001152; Grabowski DC, 2020, JAMA-J AM MED ASSOC, V323, P2007, DOI 10.1001/jama.2020.4686; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Hittle David F, 2003, Home Health Care Serv Q, V22, P43; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152; Keim Susan K, 2017, AMIA Annu Symp Proc, V2017, P1051; Kinatukara S, 2005, HOME HEALTH CARE SER, V24, P23, DOI 10.1300/J027v24n03_02; New York City Health, COVID 19 DAT SUMM; New York State Department of Health, 2020, NYSDOH COVID 19 TRAC; O'Connor M, 2015, RES NURS HEALTH, V38, P257, DOI 10.1002/nur.21665; O'Connor Melissa, 2012, Home Health Care Serv Q, V31, P267, DOI 10.1080/01621424.2012.703908; Oppel RA Jr, 2020, NEW YORK TIMES 0705; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P1381, DOI 10.1001/jama.2020.17709; Shang JJ, 2020, J HEALTHC QUAL, V42, P136, DOI 10.1097/JHQ.0000000000000214; Sheehy Lisa Mary, 2020, JMIR Public Health Surveill, V6, pe19462, DOI 10.2196/19462; Siegler Eugenia L, 2006, Home Health Care Serv Q, V25, P27, DOI 10.1300/J027v25n03_02; Sockolow PS, 2020, J AM MED INFORM ASSN, V27, P1278, DOI 10.1093/jamia/ocaa087; Werner RM, 2019, JAMA INTERN MED, V179, P617, DOI 10.1001/jamainternmed.2018.7998; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization, 153 WHO	33	51	51	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					316	+		10.7326/M20-5206	http://dx.doi.org/10.7326/M20-5206			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33226861	Green Published			2023-01-03	WOS:000629294000014
J	Palla, AR; Ravichandran, M; Wang, YX; Alexandrova, L; Yang, AV; Kraft, P; Holbrook, CA; Schurch, CM; Ho, ATV; Blau, HM				Palla, A. R.; Ravichandran, M.; Wang, Y. X.; Alexandrova, L.; Yang, A., V; Kraft, P.; Holbrook, C. A.; Schurch, C. M.; Ho, A. T., V; Blau, H. M.			Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength	SCIENCE			English	Article							MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE; UBIQUITIN LIGASES; ARACHIDONIC-ACID; GENE-EXPRESSION; SELF-RENEWAL; SARCOPENIA; ATROPHY; ATROGIN-1; TRANSPLANTATION	Treatments are lacking for sarcopenia, a debilitating age-related skeletal muscle wasting syndrome. We identifed increased amounts of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the prostaglandin E-2 (PGE(2))-degrading enzyme, as a hallmark of aged tissues, including skeletal muscle. The consequent reduction in PGE(2) signaling contributed to musde atrophy in aged mice and results from 15-PGDH-expressing myofibers and interstitial cells, such as macrophages, within muscle. Overexpression of 15-PGDH in young muscles induced atrophy. Inhibition of 15-PGDH, by targeted genetic depletion or a small-molecule inhibitor, increased aged muscle mass, strength, and exercise performance. These benefits arise from a physiological increase in PGE(2) concentrations, which augmented mitochondrial function and autophagy and decreased transforming growth factor-beta signaling and activity of ubiquitinproteasome pathways. Thus, PGE(2) signaling ameliorates muscle atrophy and rejuvenates muscle function, and 15-PGDH may be a suitable therapeutic target for countering sarcopenia.	[Palla, A. R.; Ravichandran, M.; Wang, Y. X.; Yang, A., V; Kraft, P.; Holbrook, C. A.; Ho, A. T., V; Blau, H. M.] Stanford Sch Med, Blau Lab, Stanford, CA 94305 USA; [Palla, A. R.; Ravichandran, M.; Wang, Y. X.; Yang, A., V; Kraft, P.; Holbrook, C. A.; Schurch, C. M.; Ho, A. T., V; Blau, H. M.] Stanford Sch Med, Inst Stem Cell Biol & Regenerat Med, Baxter Lab Stem Cell Biol, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Schurch, C. M.] Stanford Sch Med, Nolan Lab, Stanford, CA 94305 USA; [Alexandrova, L.] Stanford Univ, Vincent Coates Fdn Mass Spectrometry Lab, Stanford, CA 94305 USA; [Ho, A. T., V] Univ Paris, Funct & Adapt Biol CNRS, UMR8251, F-75013 Paris, France	Stanford University; Stanford University; Stanford University; Stanford University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Blau, HM (corresponding author), Stanford Sch Med, Blau Lab, Stanford, CA 94305 USA.; Blau, HM (corresponding author), Stanford Sch Med, Inst Stem Cell Biol & Regenerat Med, Baxter Lab Stem Cell Biol, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	hblau@stanford.edu	Schürch, Christian/L-6188-2019; Ho, Andrew Tri Van/D-9681-2019	Schürch, Christian/0000-0002-1792-1768; Ho, Andrew Tri Van/0000-0002-5501-6419; Wang, Yu Xin/0000-0001-8440-9388; Palla, Adelaida/0000-0003-2695-9335	Baxter Foundation; California Institute for Regenerative Medicine [DISC2-10604]; U.S. National Institutes of Health (NIH) [5R01AG02096115, 1R01AG069858-01, RHG009674A]; National Institutes of Health Shared Instrumentation grant [S10OD026962]; Canadian Institutes of Health Research; SNF Early Postdoc Mobility Fellowship [P2EZP3_184231]; SNF Postdoc Mobility Fellowship; National Center for Research Resources (NCRR) [1S10RR026780-01]; Li Ka Shing Foundation; NIH K99 award [K99NS120278]	Baxter Foundation; California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Shared Instrumentation grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); SNF Early Postdoc Mobility Fellowship; SNF Postdoc Mobility Fellowship; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Li Ka Shing Foundation; NIH K99 award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the Baxter Foundation, the Li Ka Shing Foundation, California Institute for Regenerative Medicine grant DISC2-10604, and U.S. National Institutes of Health (NIH) grants 5R01AG02096115, 1R01AG069858-01, and RHG009674A (H.M.B.). This work utilized the Xevo TQ-XS mass spectrometer system that was purchased with funding from National Institutes of Health Shared Instrumentation grant S10OD026962. Y.X.W. was supported by the Canadian Institutes of Health Research and NIH K99 award K99NS120278, M.R by an SNF Early Postdoc Mobility Fellowship P2EZP3_184231, and C.M.S. by an SNF Postdoc Mobility Fellowship. Work using TEM described here was supported, in part, by ARRA Award no. 1S10RR026780-01 from the National Center for Research Resources (NCRR).	Altun M, 2010, J BIOL CHEM, V285, P39597, DOI 10.1074/jbc.M110.129718; Austin S, 2012, J CELL SCI, V125, P4963, DOI 10.1242/jcs.113662; AZZARELLO G, 1987, J CANCER RES CLIN, V113, P417, DOI 10.1007/BF00390035; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Berdeaux R, 2012, AM J PHYSIOL-ENDOC M, V303, pE1, DOI 10.1152/ajpendo.00555.2011; Berg J.M., 2002, BIOCHEMISTRY-US; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389; Bondesen BA, 2006, AM J PHYSIOL-CELL PH, V290, pC1651, DOI 10.1152/ajpcell.00518.2005; Brun CE, 2018, METHODS MOL BIOL, V1686, P149, DOI 10.1007/978-1-4939-7371-2_11; Calvani R, 2013, BIOL CHEM, V394, P393, DOI 10.1515/hsz-2012-0247; Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08097-7; Clavel S, 2006, MECH AGEING DEV, V127, P794, DOI 10.1016/j.mad.2006.07.005; Cohen S, 2015, NAT REV DRUG DISCOV, V14, P58, DOI 10.1038/nrd4467; Cosgrove BD, 2014, NAT MED, V20, P255, DOI 10.1038/nm.3464; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dubowitz V., 2020, MUSCLE BIOPSY PRACTI; Elkina Y, 2011, J CACHEXIA SARCOPENI, V2, P143, DOI 10.1007/s13539-011-0035-5; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Fielding RA, 2011, J AM MED DIR ASSOC, V12, P249, DOI 10.1016/j.jamda.2011.01.003; Fujino Hiromichi, 2006, Mol Pharmacol, V69, P5; Gilbert PM, 2010, SCIENCE, V329, P1078, DOI 10.1126/science.1191035; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Ho ATV, 2017, P NATL ACAD SCI USA, V114, P6675, DOI 10.1073/pnas.1705420114; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ibebunjo C, 2013, MOL CELL BIOL, V33, P194, DOI 10.1128/MCB.01036-12; Joseph GA, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00141-19; Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Konya V, 2013, PHARMACOL THERAPEUT, V138, P485, DOI 10.1016/j.pharmthera.2013.03.006; Korotkova M, 2014, NAT REV RHEUMATOL, V10, P295, DOI 10.1038/nrrheum.2014.2; Larsson L, 2019, PHYSIOL REV, V99, P427, DOI 10.1152/physrev.00061.2017; Leduc-Gaudet JP, 2015, ONCOTARGET, V6, P17923, DOI 10.18632/oncotarget.4235; Lee CE, 2007, CLIN NUTR, V26, P524, DOI 10.1016/j.clnu.2007.05.005; Lenk K, 2010, J CACHEXIA SARCOPENI, V1, P9, DOI 10.1007/s13539-010-0007-1; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo LQ, 2019, CELL REP, V29, P749, DOI 10.1016/j.celrep.2019.09.023; Milan G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7670; Mintz EL, 2016, JOVE-J VIS EXP, DOI 10.3791/54487; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098; Prasain JK, 2013, JOVE-J VIS EXP, DOI 10.3791/50447; Quiros Pedro M, 2017, Curr Protoc Mouse Biol, V7, P47, DOI 10.1002/cpmo.21; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Raue U, 2012, J APPL PHYSIOL, V112, P1625, DOI 10.1152/japplphysiol.00435.2011; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; RODEMANN HP, 1982, J BIOL CHEM, V257, P1632; RODEMANN HP, 1982, J BIOL CHEM, V257, P8716; Rolland Y, 2008, J NUTR HEALTH AGING, V12, P433, DOI 10.1007/BF02982704; Romanello V, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00422; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schurch CM, 2020, CELL, V182, P1341, DOI 10.1016/j.cell.2020.07.005; Segales J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13832-9; Sheth KA, 2018, NEUROBIOL AGING, V67, P128, DOI 10.1016/j.neurobiolaging.2018.03.016; Shin JH, 2013, MOL THER, V21, P750, DOI 10.1038/mt.2012.283; Smith LR, 2014, SKELET MUSCLE, V4, DOI 10.1186/2044-5040-4-21; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Trappe TA, 2013, J APPL PHYSIOL, V115, P909, DOI 10.1152/japplphysiol.00061.2013; Ubaida-Mohien C, 2019, ELIFE, V8, DOI 10.7554/eLife.49874; Vinel C, 2018, NAT MED, V24, P1360, DOI 10.1038/s41591-018-0131-6; von Haehling S, 2010, J CACHEXIA SARCOPENI, V1, P1, DOI 10.1007/s13539-010-0002-6; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Welle S, 2003, PHYSIOL GENOMICS, V14, P149, DOI 10.1152/physiolgenomics.00049.2003; Wu YH, 2008, STRUCTURE, V16, P1714, DOI 10.1016/j.str.2008.09.007; Xu XT, 2015, STEM CELL REP, V5, P419, DOI 10.1016/j.stemcr.2015.07.016; Zaglia T, 2014, J CLIN INVEST, V124, P2410, DOI 10.1172/JCI66339; Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	74	45	46	11	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	2021	371	6528					483	+	eabc8059	10.1126/science.abc8059	http://dx.doi.org/10.1126/science.abc8059			55	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ8HP	33303683	Green Accepted			2023-01-03	WOS:000612983100036
J	Tsegaw, SA; Dawed, YA; Amsalu, ET				Tsegaw, Shambel Aychew; Ali Dawed, Yeshimebet; Tadesse Amsalu, Erkihun			Exploring the determinants of exclusive breastfeeding among infants under-six months in Ethiopia using multilevel analysis	PLOS ONE			English	Article							EPIDEMIOLOGY	Introduction Exclusive breastfeeding (EBF) is the safest and healthiest option of feeding among infants in the first 6 months throughout the world. Thus, the promotion of EBF is essential to prevent complex infant health problems even at the adulthood level. But the majority of previous studies focused on individual- level determinants of EBF by using basic regression models in localized areas. This study aimed to identify the determinants of EBF at the individual and community level which would be helpful to design appropriate strategies for improving the practice of EBF. Methods It is a secondary data analysis using the 2016 Ethiopian Demographic and Health Survey (EDHS) data. A total of 1185 infants under 6 months of age were included in the analysis. A Multilevel logistic regression model was employed to investigate factors significantly associated with EBF among under-six infants in Ethiopia. Adjusted odds ratio (AOR) with 95% confidence interval (CI) was used to measure the association of variables whereas Intracluster correlation (ICC), median odds ratio (MOR), and proportional change in variance (PCV) were used to measure random effects (variation). Result In multilevel logistic regression; 4-5 months age infant (AOR = 0.04, 95%CI:0.02-0.07), female infants (AOR = 2.51, 95%CI:1.61-3.91), infant comorbidities (AOR = 0.35, 95%CI: 0.21-0.57), richest household wealth index (AOR = 10.34, 95%CI: 3.14-34.03) and antenatal care (AOR = 2.25, 95%CI:1.32-3.82) were individual- level determinants significantly associated with exclusive breastfeeding. Whereas, contextual region (AOR = 0.30, 95%CI: 0.10-0.87), community- level of postnatal visit (AOR = 2.77, 95%CI: 1.26-6.58) and community -level of maternal employment (AOR = 2.8, 95%CI: 1.21-6.47) were community level determinants significantly associated with EBF. The full model showed that46.8% of the variation of exclusive breastfeeding was explained by the combined factors at the individual and community levels. Similarly, it showed that the variation in exclusive breastfeeding across communities remained statistically significant (ICC = 8.77% and variance = 0.32 with P<0.001). Conclusion and recommendation Our study showed that both individual and community level determinants were significantly associated with EBF practice among under 6 infants. Based on our findings, it is recommended to promote and enhance antenatal and postnatal care services utilization of mothers to improve exclusive breastfeeding practice and more emphasis should be given to infants with comorbid conditions and those who were living in the pastoralist regions.	[Tsegaw, Shambel Aychew] Dessie Hlth Sci Coll, Dept Publ Hlth, Dessie, Ethiopia; [Ali Dawed, Yeshimebet] Wollo Univ, Sch Publ Hlth, Dept Nutr, Coll Med & Hlth Sci, Dessie, Ethiopia; [Tadesse Amsalu, Erkihun] Wollo Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Dessie, Ethiopia	University of Gondar; University of Gondar	Amsalu, ET (corresponding author), Wollo Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Dessie, Ethiopia.	brhaneyared07@gmail.com	Tadesse, Erkihun/AAS-1819-2021	Tadesse, Erkihun/0000-0003-0677-7315				Adugna B, 2017, INT BREASTFEED J, V12, DOI 10.1186/s13006-017-0137-6; [Anonymous], 2016, LANCET, V387, P404, DOI 10.1016/S0140-6736(16)00210-5; [Anonymous], 2017, J19 J 19 CENTURY AM, V5, P55; [Anonymous], 2017, EXPERT OPIN THER PAT, V27, P1, DOI DOI 10.1017/S0959270917000065; [Anonymous], 2017, DRUG SAF UPDATE, DOI DOI 10.1186/s13104-016-2345-3; [Anonymous], 2019, IRISH EC SOCIAL HIST, V46, P62; [Anonymous], 2017, AETHIOPICA, V20, P70; Azeze GA, 2019, INT J PEDIAT, V2019, DOI 10.1155/2019/1483024; Bazie E., 2019, INT J HOMEOPAT NAT M, V5, P42; Belachew AB, 2016, ARCH PUBLIC HEALTH, V74, DOI 10.1186/s13690-016-0117-0; Dalcastagne SV, 2018, SAO PAULO MED J, V136, P533, DOI 10.1590/1516-3180.2018.0262161118; Egenti NB, 2018, INT J MED RES HEALTH, V7, P57; Endoscopy CSoD, 2017, CHINESE J GASTROINTE, V4, P145; FDRE Pacc, 2008, SUMM STAT REP 2007 P; FMoH, NAT NUTR PROGR 2 201, P20; Hanieh S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2431-9; Horn IOD, 2017, UNICEF ANN REPORT 20, P1; Hox J.J., 2010, MULTILEVEL ANAL TECH, Vsecond, DOI DOI 10.4324/9781315650982; Hussein Tamara H, 2019, Int J MCH AIDS, V8, P32, DOI 10.21106/ijma.258; ICF C, 2016, ETH DEM HLTH SURV 20, pDF; Indongo N, 2017, INT J SCI, V36, P159; Issaka AI, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014145; Kandeel W, 2018, OPEN ACCESS MACED J; Lenja A, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0091-8; Manyeh AK, 2020, INT BREASTFEED J, V15, DOI 10.1186/s13006-020-0253-6; Meng CS, 2017, 25TH ACM SIGSPATIAL INTERNATIONAL CONFERENCE ON ADVANCES IN GEOGRAPHIC INFORMATION SYSTEMS (ACM SIGSPATIAL GIS 2017), DOI 10.1145/3139958.3139984; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; Mututho LN, 2017, FACTORS ASS EXCLUSIV, V4, P4358, DOI [10.18203/2394-6040.ijcmph20175305, DOI 10.18203/2394-6040.IJCMPH20175305]; Nkoka O, 2019, INT BREASTFEED J, V14, DOI 10.1186/s13006-019-0232-y; Nussbaumer-Streit B, 2019, WHO GUIDELINE COUNSE; Ogbo FA, 2019, INT BREASTFEED J, V14, DOI 10.1186/s13006-019-0214-0; Raman S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111900; Ruan Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223251; Tambe BA, 2018, DETERMINANTS EXCLUSI; Tariku A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179056; Tesfahunegn A, 2019, INDIVIDUAL COMMUNITY; Thomas JV, 2016, BARRIERS EXCLUSIVE B; UNICEF, 2018, INF YOUNG CHILD FEED; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; WHO U, 2019, INCR COMM BREASTF FU; World Health Organization, 2017, PROTECTING PROMOTING	41	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0245034	10.1371/journal.pone.0245034	http://dx.doi.org/10.1371/journal.pone.0245034			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4UT	33439886	Green Published, gold			2023-01-03	WOS:000609985300051
J	Bielinis, E; Janeczko, E; Takayama, N; Zawadzka, A; Slupska, A; Pietka, S; Lipponen, M; Bielinis, L				Bielinis, Ernest; Janeczko, Emilia; Takayama, Norimasa; Zawadzka, Anna; Slupska, Alicja; Pietka, Slawomir; Lipponen, Maija; Bielinis, Lidia			The effects of viewing a winter forest landscape with the ground and trees covered in snow on the psychological relaxation of young Finnish adults: A pilot study	PLOS ONE			English	Article							STRESS RELIEF MEASURES; OLFACTORY STIMULATION; THERAPY; ENVIRONMENTS; TOURISM; DEPRESSION; PROGRAM; STATES	Forest bathing is an outdoor activity, and it might be a promising preventive treatment for social problems involving stress. A vast number of studies confirm the positive effects of this activity on people's health. Nevertheless, little is known about the influence of winter forest bathing when conducted in an environment with snow cover on the ground and trees. Thus, a crossover experiment was designed in this study, with the participation of twenty-two healthy university students from Finland. During the experiment, a short exposition by a forest environment or landscape with buildings (as a control) was applied. Participants self-reported their psychological relaxation before and after the exposition, and the results were analyzed and compared. The mood, emotions, restorativeness, and subjective vitality were recorded as indices reflecting the psychological relaxation effect. The negative mood indices decreased significantly after exposition by the snow-covered environment, but the positive 'vigor' indices did not increase or decrease significantly. The level of negative emotions increased after the exposition with the control environment. Likewise, positive emotions decreased after the interaction with the control. Restorativeness was significantly increased after the exposition by the experimental forest but decreased after the viewing of the control buildings. The size of the effect in terms of restorativeness was the highest in this experiment. The subjective vitality was lowered as affected by the control, but it did not increase or decrease after the exposition with the experimental forest. There is probably an effect from the slight interruption in the process from the influence of the forest greens on participants because their vigor and vitality did not increase after the exposition with this environment in the study. However, snow might influence the participants as a calming and emotion-lowering component of the environment, but this idea needs to be further explored with the involvement of participants from other countries who would be viewing forest environments with snow cover and whose psychological relaxation could be measured.	[Bielinis, Ernest; Zawadzka, Anna; Slupska, Alicja; Pietka, Slawomir] Univ Warmia & Mazury, Dept Forestry & Forest Ecol, Fac Environm Management & Agr, Olsztyn, Poland; [Janeczko, Emilia] Univ Life Sci Warsaw, Inst Forest Sci, Dept Forest Utilizat, Warsaw, Poland; [Takayama, Norimasa] Forestry & Forest Prod Res Inst Japan, Dept Forest Management, Environm Planning Lab, Tsukuba, Ibaraki, Japan; [Lipponen, Maija] Nat Resources Inst Finland LUKE, Paltamo, Finland; [Bielinis, Lidia] Fac Social Sci, Dept Gen Pedag, Olsztyn, Poland	University of Warmia & Mazury; Warsaw University of Life Sciences; Forestry & Forest Products Research Institute - Japan; Natural Resources Institute Finland (Luke)	Bielinis, E (corresponding author), Univ Warmia & Mazury, Dept Forestry & Forest Ecol, Fac Environm Management & Agr, Olsztyn, Poland.	ernest.bielinis@uwm.edu.pl		Slupska, Alicja/0000-0001-7892-4834; Bielinis, Ernest/0000-0002-6384-4898	Forest Department of the Warsaw University of Life Sciences (SGGW); Department of General Pedagogy at the University of Warmia and Mazury in Olsztyn	Forest Department of the Warsaw University of Life Sciences (SGGW); Department of General Pedagogy at the University of Warmia and Mazury in Olsztyn	The publication costs of this article were covered by the Forest Department of the Warsaw University of Life Sciences (SGGW) and from the Department of General Pedagogy at the University of Warmia and Mazury in Olsztyn.	[Anonymous], 2007, POWER ELECT, V3, P38; [Anonymous], 1999, ABC RELAXATION THEOR; Bell S., 2007, Living Reviews in Landscape Research, V1, P2; Bielinis E, FF ECTS FOREST THERA, P1; Bielinis E, 2019, FORESTS, V10, DOI 10.3390/f10100827; Bielinis E, 2018, BALT FOR, V24, P218; Bielinis E, 2018, URBAN FOR URBAN GREE, V29, P276, DOI 10.1016/j.ufug.2017.12.006; Chun MH, 2017, INT J NEUROSCI, V127, P199, DOI 10.3109/00207454.2016.1170015; Crawford JR, 2004, BRIT J CLIN PSYCHOL, V43, P245, DOI 10.1348/0144665031752934; Doimo I, 2020, FORESTS, V11, DOI 10.3390/f11080791; El Ansari W, 2015, CENT EUR J PUBL HEAL, V23, P306, DOI 10.21101/cejph.a4195; Elliot AJ, 2014, ANNU REV PSYCHOL, V65, P95, DOI 10.1146/annurev-psych-010213-115035; Elsadek M, 2019, URBAN FOR URBAN GREE, V42, P51, DOI 10.1016/j.ufug.2019.05.007; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Hansen MM, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14080851; Hauru K, 2012, LANDSCAPE URBAN PLAN, V107, P361, DOI 10.1016/j.landurbplan.2012.07.002; Hee Kim Min, 2015, [Journal of Korean Society of Forest Science, 한국산림과학회지], V104, P133, DOI 10.14578/jkfs.2015.104.1.133; Hiltunen P, 2004, J AFFECT DISORDERS, V78, P111, DOI 10.1016/S0165-0327(02)00239-2; Ikei H, 2016, J WOOD SCI, V62, P568, DOI 10.1007/s10086-016-1576-1; Ikei H, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-6; Kim BJ, 2015, EUR J INTEGR MED, V7, P474, DOI 10.1016/j.eujim.2015.06.004; Konijnendijk C., 2005, URBAN FORESTS TREES, DOI [10.1007/3-540-27684-X, DOI 10.1007/3-540-27684-X_3, DOI 10.1007/3-540-27684-X]; Korpela KM, 2008, HEALTH PLACE, V14, P636, DOI 10.1016/j.healthplace.2007.10.008; Lee I, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030321; Lee J, 2011, PUBLIC HEALTH, V125, P93, DOI 10.1016/j.puhe.2010.09.005; Makinen TM, 2006, INT J BIOMETEOROL, V51, P27, DOI 10.1007/s00484-006-0040-0; Matsumoto T, 2014, J ALTERN COMPLEM MED, V20, P500, DOI 10.1089/acm.2013.0425; McNair D. M, 1992, PROFILE MOOD STATES; Mcpherson EG, 2016, ASSESSING BENEFITS C; Meneguzzo F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16244915; Morita E, 2007, PUBLIC HEALTH, V121, P54, DOI 10.1016/j.puhe.2006.05.024; Neuvonen M., 2018, Leisure/Loisir, V42, P365, DOI 10.1080/14927713.2019.1581991; Ochiai H, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12155969; Ochiai H, 2015, INT J ENV RES PUB HE, V12, P15222, DOI 10.3390/ijerph121214984; Ochiai H, 2015, INT J ENV RES PUB HE, V12, P2532, DOI 10.3390/ijerph120302532; Ohe Y, 2017, TOURISM MANAGE, V62, P322, DOI 10.1016/j.tourman.2017.04.010; Park BJ, 2011, LANDSCAPE URBAN PLAN, V102, P24, DOI 10.1016/j.landurbplan.2011.03.005; Park BJ, 2009, SILVA FENN, V43, P291, DOI 10.14214/sf.213; Park SA, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14091087; Poulsen Dorthe Varning, 2016, Health Psychol Open, V3, p2055102916637090, DOI 10.1177/2055102916637090; Ryan RM, 1997, J PERS, V65, P529, DOI 10.1111/j.1467-6494.1997.tb00326.x; Saarijarvi S, 1999, ACTA PSYCHIAT SCAND, V99, P95, DOI 10.1111/j.1600-0447.1999.tb07206.x; Shephard RJ, 1997, SPORTS MED, V23, P211, DOI 10.2165/00007256-199723040-00001; Shin Won Sop, 2012, Environmental Health and Preventive Medicine, V17, P73, DOI 10.1007/s12199-011-0215-0; Simkin J, 2020, URBAN FOR URBAN GREE, V48, DOI 10.1016/j.ufug.2019.126567; Smith J.C., 2005, RELAXATION MEDITATIO; Smith J. C., 2007, BIOFEEDBACK, V35, P85; Smith JC, 2000, PSYCHOL REP, V86, P1201, DOI 10.2466/PR0.86.3.1201-1208; Song CR, 2015, INT J ENV RES PUB HE, V12, P14216, DOI 10.3390/ijerph121114216; Song CR, 2013, J PHYSIOL ANTHROPOL, V32, DOI 10.1186/1880-6805-32-18; Takayama N., 2018, J ENV INF SCI, V2017, P49, DOI [DOI 10.11492/CEISPAPERSEN.2017.2, DOI 10.11492/ceispapersen.2017.2_49]; Takayama N, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16081456; Takayama N, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070800; Takayama N, 2017, PROG EARTH PLANET SC, V4, DOI 10.1186/s40645-017-0129-6; Takayama N, 2014, INT J ENV RES PUB HE, V11, P7207, DOI 10.3390/ijerph110707207; Tsunetsugu Y, 2013, LANDSCAPE URBAN PLAN, V113, P90, DOI 10.1016/j.landurbplan.2013.01.014; Tsunetsugu Yuko, 2010, Environmental Health and Preventive Medicine, V15, P27, DOI 10.1007/s12199-009-0091-z; Tuulentie S, 2014, SCAND J HOSP TOUR, V14, P367, DOI 10.1080/15022250.2014.967998; Tyrvainen L, 2017, SCAND J FOREST RES, V32, P349, DOI 10.1080/02827581.2016.1241892; Tyrvainen L, 2014, J ENVIRON PSYCHOL, V38, P1, DOI 10.1016/j.jenvp.2013.12.005; Tyrvainen L, 2014, LANDSCAPE URBAN PLAN, V122, P1, DOI 10.1016/j.landurbplan.2013.10.003	61	11	11	13	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244799	10.1371/journal.pone.0244799	http://dx.doi.org/10.1371/journal.pone.0244799			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PS6NW	33411751	gold, Green Published			2023-01-03	WOS:000608044300079
J	Huberty, JL; Green, J; Puzia, ME; Larkey, L; Laird, B; Vranceanu, AM; Vlisides-Henry, R; Irwin, MR				Huberty, Jennifer L.; Green, Jeni; Puzia, Megan E.; Larkey, Linda; Laird, Breanne; Vranceanu, Ana-Maria; Vlisides-Henry, Robert; Irwin, Michael R.			Testing a mindfulness meditation mobile app for the treatment of sleep-related symptoms in adults with sleep disturbance: A randomized controlled trial	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; STRESS REDUCTION; INSOMNIA; FATIGUE; QUALITY; EPIDEMIOLOGY; METAANALYSIS; PREVALENCE; SCALE; INDEX	The objective of this randomized controlled trial was to test whether a commercially available, mindfulness meditation mobile app, (i.e., Calm app), was effective in reducing fatigue (primary outcome), pre-sleep arousal, and daytime sleepiness (secondary outcomes) in adults with sleep disturbance (Insomnia Severity Index Score >10) as compared to a wait-list control group. Associations between the use of the Calm app (i.e., adherence to the intervention) and changes in sleep quality was also explored in the intervention group only. Adults with sleep disturbance were recruited (N = 640). Eligible and consenting participants (N = 263) were randomly assigned to the intervention (n = 124) or a wait-list control (n = 139) group. Intervention participants were asked to meditate using the Calm app >= 10 minutes/day for eight weeks. Fatigue, daytime sleepiness, and pre-sleep arousal were assessed at baseline, mid- (4-weeks) and post-intervention (8-weeks) in both groups, whereas sleep quality was evaluated only in the intervention group. Findings from intent-to-treat analyses suggest the use of the Calm app for eight weeks significantly decreased daytime fatigue (p = .018) as well as daytime sleepiness (p = .003) and cognitive (p = .005) and somatic (p < .001) pre-sleep arousal as compared to the wait-list control group. Within the intervention group, use of the Calm app was associated with improvements in sleep quality (p < .001). This randomized controlled trial demonstrates that the Calm app can be used to treat fatigue, daytime sleepiness, and pre-sleep arousal in adults with sleep disturbance. Given that the Calm app is affordable and widely accessible, these data have implications for community level dissemination of a mobile app to improve sleep-related symptoms associated with sleep disturbance.	[Huberty, Jennifer L.; Green, Jeni; Laird, Breanne] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ 85004 USA; [Puzia, Megan E.] Behav Res & Analyt LLC, Salt Lake City, UT USA; [Larkey, Linda] Arizona State Univ, Edson Coll Nursing & Hlth Innovat, Phoenix, AZ USA; [Vranceanu, Ana-Maria] Harvard Med Sch, Massachusetts Gen Hospital, Dept Psychiat, Integrated Brain Hlth Clin & Res Program, Boston, MA 02115 USA; [Vlisides-Henry, Robert] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA; [Irwin, Michael R.] Univ Calif Los Angeles, Jane & Terry Semel Insitute Neurosci & Human Beha, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA; [Irwin, Michael R.] Univ Calif Los Angeles, Jane & Terry Semel Insitute Neurosci & Human Beha, Mindful Awareness Res Ctr, Los Angeles, CA USA; [Irwin, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	Arizona State University; Arizona State University-Downtown Phoenix; Arizona State University; Arizona State University-Downtown Phoenix; Harvard University; Harvard Medical School; Utah System of Higher Education; University of Utah; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Huberty, JL (corresponding author), Arizona State Univ, Coll Hlth Solut, Phoenix, AZ 85004 USA.	jhuberty@asu.edu	Irwin, Michael/H-4870-2013	Irwin, Michael/0000-0002-1502-8431; Laird, Breanne/0000-0002-3768-8764	Behavioral Research and Analytics, LLC	Behavioral Research and Analytics, LLC	Behavioral Research and Analytics, LLC provided support in the form of salary for Dr. Puzia. The specific roles of these authors are articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abad Vivien C, 2003, Dialogues Clin Neurosci, V5, P371; Ballesio A, 2018, SLEEP MED REV, V37, P114, DOI 10.1016/j.smrv.2017.01.006; Black DS, 2015, JAMA INTERN MED, V175, P494, DOI 10.1001/jamainternmed.2014.8081; Buysse D J, 1989, Psychiatry Res, V28, P193; Carlson LE, 2005, INT J BEHAV MED, V12, P278, DOI 10.1207/s15327558ijbm1204_9; Center for Disease Control and Prevention, 2017, CTR DIS CONTROL PREV, DOI DOI 10.14423/SMJ.0000000000000632; Clark VL., 1990, JAMA-J AM MED ASSOC, V264, P2808, DOI DOI 10.1001/JAMA.1990.03450210108045; Cohen J., 2013, STAT POWER ANAL BEHA; Congdon, 2000, COMPUT SOFTWARE LINC; Cowie J, 2018, COGN BEHAV PRACT, V25, P442, DOI 10.1016/j.cbpra.2017.09.005; Donker T, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2791; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Federici S., 2017, CONTINENTAL THOUGHT, V1, P19; Feingold A, 2009, PSYCHOL METHODS, V14, P43, DOI 10.1037/a0014699; Ferrie JE, 2011, INT J EPIDEMIOL, V40, P1431, DOI 10.1093/ije/dyr203; Foundation U. H, 2020, AM HLTH RANKINGS ANA; Garland Sheila N, 2016, Curr Sleep Med Rep, V2, P142, DOI 10.1007/s40675-016-0050-3; Gong H, 2016, J PSYCHOSOM RES, V89, P1, DOI 10.1016/j.jpsychores.2016.07.016; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Grossman P, 2010, NEUROLOGY, V75, P1141, DOI 10.1212/WNL.0b013e3181f4d80d; Huberty J, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/15648; Huberty J, 2019, JMIR CANCER, V5, DOI 10.2196/14292; Huberty J, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/14273; Huberty Jennifer, 2019, JMIR Form Res, V3, pe12662, DOI 10.2196/12662; Irwin MR, 2017, J CLIN ONCOL, V35, P2656, DOI 10.1200/JCO.2016.71.0285; Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205; Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kanen JW, 2015, ADOLES PSYCHIAT-NETH, V5, P105, DOI 10.2174/2210676605666150311222928; Kendzerska TB, 2014, SLEEP MED REV, V18, P321, DOI 10.1016/j.smrv.2013.08.002; KRUPP LB, 1993, J PSYCHOSOM RES, V37, P325, DOI 10.1016/0022-3999(93)90134-2; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kuhn E, 2016, J CLIN SLEEP MED, V12, P597, DOI 10.5664/jcsm.5700; Lee RA, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/mental.8324; Liu Y, 2016, MMWR-MORBID MORTAL W, V65, P137, DOI 10.15585/mmwr.mm6506a1; Maich KHG, 2018, BEHAV SLEEP MED, V16, P117, DOI 10.1080/15402002.2016.1173556; Mairs L, 2015, INT J BEHAV MED, V22, P635, DOI 10.1007/s12529-015-9467-1; Mani M, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4328; Mccoy CE, 2017, WEST J EMERG MED, V18, P1075, DOI 10.5811/westjem.2017.8.35985; Mesa, 2019, MYELOPROLIFERATIVE N; Morgan K, 2012, J AM GERIATR SOC, V60, P1803, DOI 10.1111/j.1532-5415.2012.04175.x; Morin CM, 2013, SLEEP MED CLIN, V8, P281, DOI 10.1016/j.jsmc.2013.05.002; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Mrazek AJ, 2019, CURR OPIN PSYCHOL, V28, P81, DOI 10.1016/j.copsyc.2018.11.012; Naaim M, 2016, HOUILLE BLANCHE, P12, DOI 10.1051/lhb/2016055; NICASSIO PM, 1985, BEHAV RES THER, V23, P263, DOI 10.1016/0005-7967(85)90004-X; Nordin A, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0167-6; Norman J, 2018, EUR J CARDIOVASC NUR, V17, P54, DOI 10.1177/1474515117715843; Ong JC, 2020, CURR OPIN PSYCHOL, V34, P18, DOI 10.1016/j.copsyc.2019.08.020; Pew Research Center, 2019, MOB FACT SHEET; Raudenbush S.W., 2019, HLM 8 WINDOWS; Rung AL, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/15943; Rusch HL, 2019, ANN NY ACAD SCI, V1445, P5, DOI 10.1111/nyas.13996; Shallcross AJ, 2019, CURR OPIN PSYCHOL, V28, P37, DOI 10.1016/j.copsyc.2018.10.005; Shin JC, 2017, JMIR MHEALTH UHEALTH, V5, P14, DOI 10.2196/mhealth.7244; Singareddy R, 2012, SLEEP MED, V13, P346, DOI 10.1016/j.sleep.2011.10.033; Soh HL, 2020, SLEEP MED, V75, P315, DOI 10.1016/j.sleep.2020.08.020; Surawy C, 2005, BEHAV COGN PSYCHOTH, V33, P103, DOI 10.1017/S135246580400181X; Tomlinson M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001382; Wang X, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/9359807; Williams J, 2013, CHEST, V143, P554, DOI 10.1378/chest.12-0731; Winbush NY, 2007, EXPLORE-NY, V3, P585, DOI 10.1016/j.explore.2007.08.003; Yu JS, 2019, TRANSL BEHAV MED, V9, P110, DOI 10.1093/tbm/iby014	65	16	16	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244717	10.1371/journal.pone.0244717	http://dx.doi.org/10.1371/journal.pone.0244717			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PS6NW	33411779	Green Published, gold			2023-01-03	WOS:000608044300101
J	IsHak, WW; Korouri, S; Darwish, T; Vanle, B; Dang, J; Edwards, G; Black, JT; Aronow, H; Kimchi, A; Spiegel, B; Hedrick, R; Chernoff, R; Diniz, MA; Mirocha, J; Manoukian, V; Harold, J; Ong, MK; Wells, K; Hamilton, M; Danovitch, I				IsHak, Waguih William; Korouri, Samuel; Darwish, Tarneem; Vanle, Brigitte; Dang, Jonathan; Edwards, Gabriel; Black, Jeanne T.; Aronow, Harriet; Kimchi, Asher; Spiegel, Brennan; Hedrick, Rebecca; Chernoff, Robert; Diniz, Marcio A.; Mirocha, James; Manoukian, Vicki; Harold, John; Ong, Michael K.; Wells, Kenneth; Hamilton, Michele; Danovitch, Itai			Personalized treatments for depressive symptoms in patients with advanced heart failure: A pragmatic randomized controlled trial	PLOS ONE			English	Article							BEHAVIORAL ACTIVATION TREATMENT; QUALITY-OF-LIFE; COLLABORATIVE CARE; HEALTH-STATUS; ANTIDEPRESSANT; MANAGEMENT; EFFICACY; THERAPY; RISK; INTERVENTIONS	Objectives Heart Failure is a chronic syndrome affecting over 5.7 million in the US and 26 million adults worldwide with nearly 50% experiencing depressive symptoms. The objective of the study is to compare the effects of two evidence-based treatment options for adult patients with depression and advanced heart failure, on depressive symptom severity, physical and mental health related quality of life (HRQoL), heart-failure specific quality of life, caregiver burden, morbidity, and mortality at 3, 6 and 12-months. Methods Trial design. Pragmatic, randomized, comparative effectiveness trial. Interventions. The treatment interventions are: (1) Behavioral Activation (BA), a patient-centered psychotherapy which emphasizes engagement in enjoyable and valued personalized activities as selected by the patient; or (2) Antidepressant Medication Management administered using the collaborative care model (MEDS). Participants. Adults aged 18 and over with advanced heart failure (defined as New York Heart Association (NYHA) Class II, III, and IV) and depression (defined as a score of 10 or above on the PHQ-9 and confirmed by the MINI International Neuropsychiatric Interview for the DSM-5) selected from all patients at Cedars-Sinai Medical Center who are admitted with heart failure and all patients presenting to the outpatient programs of the Smidt Heart Institute at Cedars-Sinai Medical Center. We plan to randomize 416 patients to BA or MEDS, with an estimated 28% loss to follow-up/inability to collect follow-up data. Thus, we plan to include 150 in each group for a total of 300 participants from which data after randomization will be collected and analyzed. Conclusions The current trial is the first to compare the impact of BA and MEDS on depressive symptoms, quality of life, caregiver burden, morbidity, and mortality in patients with depression and advanced heart failure. The trial will provide novel results that will be disseminated and implemented into a wide range of current practice settings. Registration ClinicalTrials.Gov Identifier: NCT03688100.	[IsHak, Waguih William; Korouri, Samuel; Darwish, Tarneem; Vanle, Brigitte; Dang, Jonathan; Edwards, Gabriel; Hedrick, Rebecca; Chernoff, Robert; Manoukian, Vicki; Danovitch, Itai] Cedars Sinai Med Ctr, Dept Psychiat & Behav Neurosci, Los Angeles, CA 90048 USA; [IsHak, Waguih William; Spiegel, Brennan; Ong, Michael K.; Wells, Kenneth] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Black, Jeanne T.; Aronow, Harriet; Spiegel, Brennan] Cedars Sinai Med Ctr, Dept Med, Div Hlth Serv Res, Los Angeles, CA 90048 USA; [Kimchi, Asher; Harold, John; Hamilton, Michele] Cedars Sinai Smidt Heart Inst, Los Angeles, CA USA; [Spiegel, Brennan; Ong, Michael K.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Diniz, Marcio A.; Mirocha, James] Cedars Sinai Med Ctr, Biostat Res Ctr, Los Angeles, CA 90048 USA; [Ong, Michael K.; Wells, Kenneth] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; Cedars Sinai Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	IsHak, WW (corresponding author), Cedars Sinai Med Ctr, Dept Psychiat & Behav Neurosci, Los Angeles, CA 90048 USA.; IsHak, WW (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.	Waguih.IsHak@cshs.org	IsHak, Waguih/O-7956-2019; Danovitch, Itai/AAG-5313-2021; Hedrick, Rebecca/AAG-5479-2021; Janson, Patrick/AAC-7581-2022; Ong, Michael/AAR-3310-2020; IsHak, Waguih William/C-1336-2011	IsHak, Waguih/0000-0003-1970-4756; Danovitch, Itai/0000-0001-9580-6450; Hedrick, Rebecca/0000-0002-3692-8826; Ong, Michael/0000-0001-8530-7754; IsHak, Waguih William/0000-0003-1970-4756; HAROLD, JOHN GORDON/0000-0001-6475-4002; Aronow, Harriet/0000-0001-9765-872X	Patient-Centered Outcomes Research Institute(R) (PCORI(R)) Award [2017C2-7716 -IsHak]	Patient-Centered Outcomes Research Institute(R) (PCORI(R)) Award(Patient-Centered Outcomes Research Institute - PCORI)	Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (R) (PCORI (R)) Award (2017C2-7716 -IsHak). https://www.pcori.org The funders had a role in the formation of the stakeholder team in the the study design.	Abramson J, 2001, ARCH INTERN MED, V161, P1725, DOI 10.1001/archinte.161.14.1725; [Anonymous], 2014, CIRCULATION, V130, pE201; Artinian Nancy T, 2004, J Cardiovasc Nurs, V19, pS47; Audigier V, 2018, STAT SCI, V33, P160, DOI 10.1214/18-STS646; Bhatt KN, 2016, INT J CARDIOL, V221, P246, DOI 10.1016/j.ijcard.2016.07.057; Celano CM, 2016, VALUE HEALTH, V19, P185, DOI 10.1016/j.jval.2015.12.015; Cohen HW, 2000, AM J MED, V108, P2, DOI 10.1016/S0002-9343(99)00301-0; Cuijpers P, 2007, CLIN PSYCHOL REV, V27, P318, DOI 10.1016/j.cpr.2006.11.001; DeFilippis EM, 2020, JACC-HEART FAIL, V8, P681, DOI 10.1016/j.jchf.2020.05.006; Diez-Quevedo C, 2013, INT J CARDIOL, V167, P1217, DOI 10.1016/j.ijcard.2012.03.143; Dimidjian S, 2006, J CONSULT CLIN PSYCH, V74, P658, DOI 10.1037/0022-006X.74.4.658; Dracup K, 2004, HEART LUNG, V33, P354, DOI 10.1016/j.hrtlng.2004.06.003; DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273; Eilers PHC, 2008, STAT MED, V27, P3430, DOI 10.1002/sim.3188; Ekers D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100100; Evangelista LS, 2016, CURR OPIN SUPPORT PA, V10, P24, DOI 10.1097/SPC.0000000000000182; Glassman AH, 1998, AM J PSYCHIAT, V155, P4, DOI 10.1176/ajp.155.1.4; Gottlieb SS, 2004, J AM COLL CARDIOL, V43, P1542, DOI 10.1016/j.jacc.2003.10.064; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Guck Thomas P, 2003, Congest Heart Fail, V9, P163, DOI 10.1111/j.1527-5299.2003.01356.x; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385; Hooley Peter J D, 2005, Congest Heart Fail, V11, P303, DOI 10.1111/j.1527-5299.2005.03620.x; Huffman JC, 2011, CIRC-CARDIOVASC QUAL, V4, P198, DOI 10.1161/CIRCOUTCOMES.110.959379; Humphrey L, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-84; Jacobson NS, 2001, CLIN PSYCHOL-SCI PR, V8, P255, DOI 10.1093/clipsy/8.3.255; Jeyanantham K, 2017, HEART FAIL REV, V22, P731, DOI 10.1007/s10741-017-9640-5; Johansson Peter, 2006, Prog Cardiovasc Nurs, V21, P202, DOI 10.1111/j.0889-7204.2006.05415.x; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Katon Wayne J, 2011, Dialogues Clin Neurosci, V13, P7; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lane DA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003329.pub2; Lejuez CW, 2011, BEHAV MODIF, V35, P111, DOI 10.1177/0145445510390929; Lesperance F, 2007, JAMA-J AM MED ASSOC, V297, P367, DOI 10.1001/jama.297.4.367; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Moraska AR, 2013, CIRC-HEART FAIL, V6, P387, DOI 10.1161/CIRCHEARTFAILURE.112.000118; Muller-Tasch T, 2007, J CARD FAIL, V13, P818, DOI 10.1016/j.cardfail.2007.07.008; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; O'Connor CM, 2010, J AM COLL CARDIOL, V56, P692, DOI 10.1016/j.jacc.2010.03.068; Ong MK, 2016, JAMA INTERN MED, V176, P310, DOI 10.1001/jamainternmed.2015.7712; Resche-Rigon M, 2018, STAT METHODS MED RES, V27, P1634, DOI 10.1177/0962280216666564; Richards DA, 2016, LANCET, V388, P871, DOI 10.1016/S0140-6736(16)31140-0; Richards SH, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22300; Rigby RA, 2005, J R STAT SOC C-APPL, V54, P507, DOI 10.1111/j.1467-9876.2005.00510.x; Rollman BL, 2009, JAMA-J AM MED ASSOC, V302, P2095, DOI 10.1001/jama.2009.1670; Rondeau V, 2007, BIOSTATISTICS, V8, P708, DOI 10.1093/biostatistics/kxl043; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sheehan DV, 2010, J CLIN PSYCHIAT, V71, P313, DOI 10.4088/JCP.09m05305whi; Sherwood A, 2011, J AM COLL CARDIOL, V57, P418, DOI 10.1016/j.jacc.2010.09.031; Sullivan M, 2004, J CARD FAIL, V10, P390, DOI 10.1016/j.cardfail.2004.01.011; Svarstad BL, 1999, PATIENT EDUC COUNS, V37, P113, DOI 10.1016/S0738-3991(98)00107-4; Team RC, 2016, LANG ENV STAT COMP; Unutzer J, 1999, MILBANK Q, V77, P225, DOI 10.1111/1468-0009.00132; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Vaccarino V, 2001, J AM COLL CARDIOL, V38, P199, DOI 10.1016/S0735-1097(01)01334-1; van Buuren S, 2001, STAT MED, V20, P1259, DOI 10.1002/sim.746; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wells KB, 2013, J GEN INTERN MED, V28, P1268, DOI 10.1007/s11606-013-2484-3; Yohannes AM, 2010, INT J GERIATR PSYCH, V25, P1209, DOI 10.1002/gps.2463	60	0	0	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244453	10.1371/journal.pone.0244453	http://dx.doi.org/10.1371/journal.pone.0244453			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PS6NW	33412562	Green Published, gold			2023-01-03	WOS:000608044300050
J	Sevinc, M; Hasbal, NB; Sakaci, T; Basturk, T; Ahbap, E; Ortaboz, M; Mazi, EE; Pirdogan, E; Ling, J; Unsal, A				Sevinc, Mustafa; Hasbal, Nuri Baris; Sakaci, Tamer; Basturk, Taner; Ahbap, Elbis; Ortaboz, Mustafa; Mazi, Emrah Erkan; Pirdogan, Efruz; Ling, Jonathan; Unsal, Abdulkadir			Frequency of depressive symptoms in Syrian refugees and Turkish maintenance hemodialysis patients during COVID-19 pandemic	PLOS ONE			English	Article							QUALITY-OF-LIFE; INVENTORY; MALNUTRITION; DIAGNOSIS; STAGE	Introduction Pneumonia of unknown cause was detected on 30 December 2019 in China. It was categorized as an outbreak and named as COVID-19 by the World Health Organization. The pandemic affects all people, but patient groups such as hemodialysis (HD) patients have been particularly affected. We do not know if refugees suffered more during the outbreak. In this study, we compared depressive symptom frequency between Syrian refugee HD patients and Turkish ones. Methods The study had a single-center, cross-sectional design. Demographic and clinical data were collected retrospectively from patients' files containing details about past medical history, demographic variables and laboratory values. Validated Turkish and Arabic forms of Beck Depression Inventory (BDI) were used to assess depressive symptoms. BDI scores were compared according to nationality, demographic features and clinical data. A BDI score more than 14 was accepted as suspicion of depression. Results 119 patients were enrolled in the study. After the exclusion of 22 patients, 75 Turkish and 22 Syrian patients were included for further analysis. The median BDI (interquartile range) score for Turkish and Syrian patients were 12 (7-23) and 19.5 (12.7-25.2), respectively (p = 0.03). Suspicion of depression was present at 42.7% of Turkish, and 72.7% of Syrian HD patients (p = 0.013). Regarding all patients, phosphorus level, Kt/V, and nationality were significantly different between patients with and without suspicion of depression (p = 0.023, 0.039, 0.013, respectively). Conclusion Syrian patients had higher BDI scores and more depressive symptoms than Turkish patients. Additional national measures for better integration and more mental support to Syrian HD patients are needed.	[Sevinc, Mustafa; Sakaci, Tamer; Ahbap, Elbis; Ortaboz, Mustafa; Mazi, Emrah Erkan] Sisli Hamidiye Etfal Educ & Training Hosp, Nephrol Dept, Istanbul, Turkey; [Hasbal, Nuri Baris] Basaksehir Cam & Sakura City Hosp, Nephrol Dept, Istanbul, Turkey; [Basturk, Taner; Unsal, Abdulkadir] Univ Hlth Sci, Sisli Hamidiye Etfal Educ & Training Hosp, Nephrol Dept, Istanbul, Turkey; [Pirdogan, Efruz] Sisli Hamidiye Etfal Educ & Training Hosp, Psychiat Dept, Istanbul, Turkey; [Ling, Jonathan] Univ Sunderland, Fac Mental Hlth & Wellbeing, Sunderland, England	Istanbul Sisli Hamidiye Etfal Training & Research Hospital; Istanbul Sisli Hamidiye Etfal Training & Research Hospital; University of Health Sciences Turkey; Istanbul Sisli Hamidiye Etfal Training & Research Hospital; University of Sunderland	Sakaci, T (corresponding author), Sisli Hamidiye Etfal Educ & Training Hosp, Nephrol Dept, Istanbul, Turkey.	sakacitamer@hotmail.com	Hasbal, Nuri Baris/X-3192-2019; MAZI, EMRAH ERKAN/AAP-4267-2021; ORTABOZ, MUSTAFA/AAP-4301-2021; Ling, Jonathan/AAY-4098-2020; sevinc, mustafa/L-8486-2017	Hasbal, Nuri Baris/0000-0002-2229-5140; Ling, Jonathan/0000-0003-2932-4474; sevinc, mustafa/0000-0003-2804-4884				Abdel-Khalek AM, 1998, PSYCHOL REP, V82, P264, DOI 10.2466/PR0.82.1.264-266; Acarturk C, 2018, J NERV MENT DIS, V206, P40, DOI 10.1097/NMD.0000000000000693; Bautovich A, 2018, AUSTRALAS PSYCHIATRY, V26, P281, DOI 10.1177/1039856218758582; Beck A.T., 1996, BDI 2 BECK DEPRESSIO, V10; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bhopal RS, 2020, PUBLIC HEALTH, V182, P161, DOI 10.1016/j.puhe.2020.04.010; Bilgic A, 2007, J RENAL NUTR, V17, P381, DOI 10.1053/j.jrn.2007.08.008; Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740; Cohen SD, 2007, CLIN J AM SOC NEPHRO, V2, P1332, DOI 10.2215/CJN.03951106; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Durankus F, 2022, J MATERN-FETAL NEO M, V35, P205, DOI 10.1080/14767058.2020.1763946; Fuhr DC, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796019000660; Goncalves J, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113000; Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040; Gursu M, 2019, KIDNEY BLOOD PRESS R, V44, P43, DOI 10.1159/000498832; Hedayati SS, 2006, KIDNEY INT, V69, P1662, DOI 10.1038/sj.ki.5000308; Hisli N., 1989, PSIKOLOJI DERGISI, V23, P3; Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954; Ibrahim S, 2008, AM J NEPHROL, V28, P784, DOI 10.1159/000131101; Julia B, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20263; Kalender B, 2006, NEPHRON CLIN PRACT, V102, pC115, DOI 10.1159/000089669; Koo JR, 2003, AM J KIDNEY DIS, V41, P1037, DOI 10.1016/S0272-6386(03)00201-4; Ma TKW, 2016, NEPHROLOGY, V21, P639, DOI 10.1111/nep.12742; Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165; Ozdin S, 2020, INT J SOC PSYCHIATR, V66, P504, DOI 10.1177/0020764020927051; Pop-Jordanova Nada, 2017, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V38, P103, DOI 10.1515/prilozi-2017-0014; Sevinc M, 2019, TRANSPL P, V51, P2279, DOI 10.1016/j.transproceed.2019.01.194; Tekeli-Yesil S, 2018, AM J PUBLIC HEALTH, V108, P938, DOI 10.2105/AJPH.2018.304405; Yilmaz M, 2019, TURK J NEPHROL, V28, P269, DOI 10.5152/turkjnephrol.2019.3493	30	5	5	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2021	16	1							e0244347	10.1371/journal.pone.0244347	http://dx.doi.org/10.1371/journal.pone.0244347			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PR2KB	33395428	Green Published, gold, Green Accepted			2023-01-03	WOS:000607069100034
J	Watanabe, T; Asai, K; Fukuhara, S; Uozumi, R; Bessho, K				Watanabe, Takuma; Asai, Keita; Fukuhara, Shizuko; Uozumi, Ryuji; Bessho, Kazuhisa			Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage	PLOS ONE			English	Article							MEDICATION-RELATED OSTEONECROSIS; BISPHOSPHONATE-RELATED OSTEONECROSIS; TREATMENT OUTCOMES; POSITION PAPER; MANAGEMENT; THERAPY; ASSOCIATION; PATIENT; MRONJ	Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an adverse event induced by antiresorptive agents (ARAs). The purpose of this study was to evaluate variables, mainly surgery and hyperbaric oxygen (HBO) therapy, associated with treatment outcomes in patients with a diagnosis of ARONJ at a single center. We enrolled consecutive patients who presented to our hospital for the management of stage 2 or 3 ARONJ between January 2003 and December 2019. The relationship between potentially predictive factors and outcome variables was examined using statistical analyses, along with a subgroup analysis based on disease stage. Of 252 patients included in this study, 206 had stage 2 ARONJ and 46 had stage 3 ARONJ. There were 119 patients with osteoporosis and 133 with malignant disease. In total, 139 patients were healed, and the healing rate of patients with stage 3 ARONJ was lower than that of patients with stage 2 ARONJ. With regard to the combination of surgery and HBO therapy, most patients underwent HBO before and after surgery. In the univariable analysis, surgery showed a therapeutic effect in both stage 2 and 3 ARONJ, whereas HBO showed a therapeutic effect in stage 2 ARONJ. In the multivariable analysis for stage 2 ARONJ, extensive surgery showed a stronger association with healing than conservative surgery, whereas >= 46 sessions of HBO therapy was less associated with healing than was non-HBO therapy. Our findings suggest that extensive surgery is highly effective against ARONJ regardless of disease stage if there is a sequestrum separation and systemic tolerance, whereas HBO therapy before and after surgical approach can be effective. Further studies are needed to identify treatment strategies for patients with treatment-refractory ARONJ who may be forced to undergo long-term HBO therapy with the expectation of sequestrum separation.	[Watanabe, Takuma; Asai, Keita; Fukuhara, Shizuko; Bessho, Kazuhisa] Kyoto Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kyoto, Japan; [Uozumi, Ryuji] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan	Kyoto University; Kyoto University	Watanabe, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Kyoto, Japan.	takuma@kuhp.kyoto-u.ac.jp		watanabe, takuma/0000-0002-4051-1505				Akashi M, 2018, ORAL MAXILLOFAC SURG, V22, P369, DOI 10.1007/s10006-018-0732-8; Albanese M, 2020, CLIN EXP DENT RES, V6, P512, DOI 10.1002/cre2.303; Allen BW, 2009, J APPL PHYSIOL, V106, P662, DOI 10.1152/japplphysiol.91109.2008; Boykin Joseph V Jr, 2007, Adv Skin Wound Care, V20, P382, DOI 10.1097/01.ASW.0000280198.81130.d5; Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103; El-Rabbany M, 2019, J ORAL MAXIL SURG, V77, P1816, DOI 10.1016/j.joms.2019.03.040; Ewald F, 2021, CLIN ORAL INVEST, V25, P2801, DOI 10.1007/s00784-020-03595-9; Fatema CN, 2015, ODONTOLOGY, V103, P105, DOI 10.1007/s10266-013-0129-y; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6; Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019; Freiberger JJ, 2012, J ORAL MAXIL SURG, V70, P1573, DOI 10.1016/j.joms.2012.04.001; Graziani F, 2012, J ORAL MAXIL SURG, V70, P2501, DOI 10.1016/j.joms.2012.05.019; Grisar K, 2016, INT J ORAL MAX SURG, V45, P1592, DOI 10.1016/j.ijom.2016.06.016; Hayashida S, 2017, J BONE MINER RES, V32, P2022, DOI 10.1002/jbmr.3191; Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108; Jasper V, 2020, J CRANIO MAXILL SURG, V48, P435, DOI 10.1016/j.jcms.2020.02.017; Khan AA, 2008, J RHEUMATOL, V35, P1391; Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405; Kim HY, 2017, J ORAL MAXIL SURG, V75, P1404, DOI 10.1016/j.joms.2016.12.014; Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005; Lee CYS, 2011, IMPLANT DENT, V20, P331, DOI 10.1097/ID.0b013e3182310f03; Lee Cameron Y S, 2007, J Oral Implantol, V33, P371, DOI 10.1563/1548-1336(2007)33[371:UOPPIT]2.0.CO;2; MARX RE, 1983, J ORAL MAXIL SURG, V41, P351, DOI 10.1016/S0278-2391(83)80005-6; Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278-2391(03)00720-1; Nicolatou-Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008; Ruggiero SL, 2015, J ORAL MAXIL SURG, V73, pS94, DOI 10.1016/j.joms.2015.09.024; Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031; Rupel K, 2014, ORAL ONCOL, V50, P1049, DOI 10.1016/j.oraloncology.2014.08.016; Sacco R, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9051026; Shimura K, 2006, INT J HEMATOL, V84, P343, DOI 10.1532/IJH97.06110; Sozen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048; Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007; Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774-016-0810-7; Zirk M, 2017, J CRANIO MAXILL SURG, V45, P1183, DOI 10.1016/j.jcms.2017.05.027	34	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2021	16	1							e0244859	10.1371/journal.pone.0244859	http://dx.doi.org/10.1371/journal.pone.0244859			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PR2KB	33395446	Green Published, gold			2023-01-03	WOS:000607069100043
J	Lemieux, J; Abdollah, V; Powelske, B; Kawchuk, G				Lemieux, James; Abdollah, Vahid; Powelske, Brandyn; Kawchuk, Greg			Comparing the effectiveness of group-based exercise to other non-pharmacological interventions for chronic low back pain: A systematic review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; FITNESS PROGRAM; THERAPY; PHYSIOTHERAPY; DISABILITY	Background Low back pain (LBP) is the leading cause of disability worldwide with a substantial financial burden on individuals and health care systems. To address this, clinical practice guidelines often recommend non-pharmacological, non-invasive management approaches. One management approach that has been recommended and widely implemented for chronic LBP is group-based exercise programs, however, their clinical value compared with other non-pharmacological interventions has not been investigated systematically. Objective To compare the effectiveness of group-based exercise with other non-pharmacological interventions in people with chronic LBP. Methods Four electronic databases were searched by two independent reviewers. Only randomized controlled trials that compared group-based exercise with other non-pharmacological interventions for chronic LBP were eligible. Study quality was assessed using the Cochrane Handbook for systematic reviews of Interventions by two independent reviewers. Results Eleven studies were eligible. We identified strong evidence of no difference between group exercise and other non-pharmacologic interventions for disability level and pain scores 3-month post-intervention in people with chronic LBP. We could not find any strong or moderate evidence for or against the use of group-based exercise in the rehabilitation of people with chronic LBP for other time-points and health measurement outcomes. We found no statistically significant differences in disability and quality of life and pain between the group and individual non-pharmacological interventions that included exercise. Conclusion With this equivocal finding, group-based exercise may be a preferred choice given potential advantages in other domains not reviewed here such as motivation and cost. Further research in this area is needed to evaluate this possibility.	[Lemieux, James; Abdollah, Vahid; Powelske, Brandyn; Kawchuk, Greg] Univ Alberta, Fac Rehabil Med, Dept Phys Therapy, Edmonton, AB, Canada	University of Alberta	Kawchuk, G (corresponding author), Univ Alberta, Fac Rehabil Med, Dept Phys Therapy, Edmonton, AB, Canada.	greg.kawchuk@ualberta.ca		Lemieux, James/0000-0001-9879-4766; Abdollah, Vahid/0000-0003-0672-8265				Bernstein IA, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6748; Bialocerkowski A, 2010, INT J THER REHABIL, V17, P114, DOI 10.12968/ijtr.2010.17.3.46743; Bussieres AE, 2018, J MANIP PHYSIOL THER, V41, P265, DOI 10.1016/j.jmpt.2017.12.004; Carr JL, 2005, DISABIL REHABIL, V27, P929, DOI 10.1080/09638280500030639; Cornelius LR, 2011, J OCCUP REHABIL, V21, P259, DOI 10.1007/s10926-010-9261-5; Daulat, 2016, INT MUSCULOSKELET ME, V38, P97, DOI [10.1080/17536146.2016.1261234, DOI 10.1080/17536146.2016.1261234]; Francisco-Fernandez M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147505; Frost H, 1998, PAIN, V75, P273, DOI 10.1016/S0304-3959(98)00005-0; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Froud R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164573; Harris A, 2017, EUR J PAIN, V21, P1397, DOI 10.1002/ejp.1041; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428; Hurley DA, 2015, PAIN, V156, P131, DOI 10.1016/j.pain.0000000000000013; Jerosch-Herold C., 2005, BRIT J OCCUP THER, V68, P347, DOI [10.1177/030802260506800803, DOI 10.1177/030802260506800803]; Johnson RE, 2007, SPINE, V32, P1578, DOI 10.1097/BRS.0b013e318074f890; Lewis JS, 2005, SPINE, V30, P711, DOI 10.1097/01.brs.0000157469.27779.de; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Masharawi Y, 2013, J BACK MUSCULOSKELET, V26, P353, DOI 10.3233/BMR-130391; Moffett JAK, 2004, SPINE, V29, P1167, DOI 10.1097/00007632-200406010-00002; Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006; O'Keeffe M, 2020, BRIT J SPORT MED, V54, P782, DOI 10.1136/bjsports-2019-100780; O'Keeffe M, 2017, BRIT J SPORT MED, V51, P126, DOI 10.1136/bjsports-2015-095410; Reme SE, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-152; Ryan CG, 2010, MANUAL THER, V15, P382, DOI 10.1016/j.math.2010.03.003; Sahin N, 2011, J REHABIL MED, V43, P224, DOI 10.2340/16501977-0650; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Stochkendahl MJ, 2018, EUR SPINE J, V27, P60, DOI 10.1007/s00586-017-5099-2; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Vandenbroucke JP, 2007, ANN INTERN MED, V147, pW163, DOI 10.7326/0003-4819-147-8-200710160-00010-w1; Wong JJ, 2017, EUR J PAIN, V21, P201, DOI 10.1002/ejp.931	32	1	1	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2020	15	12							e0244588	10.1371/journal.pone.0244588	http://dx.doi.org/10.1371/journal.pone.0244588			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TQ	33378346	gold, Green Published			2023-01-03	WOS:000605651300063
J	Onyeka, TC; Iloanusi, N; Namisango, E; Onu, JU; Okunade, KS; Mohammed, AD; Gadanya, MA; Nagoma, AU; Ojiakor, S; Ilo, C; Okuzu, O; Oduche, C; Ugwu, N; Allsop, MJ				Onyeka, Tonia C.; Iloanusi, Nneka; Namisango, Eve; Onu, Justus U.; Okunade, Kehinde S.; Mohammed, Alhassan Datti; Gadanya, Muktar A.; Nagoma, Abubakar U.; Ojiakor, Samuel; Ilo, Chukwudi; Okuzu, Okey; Oduche, Chinelo; Ugwu, Ngozi; Allsop, Matthew J.			Project OPUS: Development and evaluation of an electronic platform for pain management education of medical undergraduates in resource-limited settings	PLOS ONE			English	Article							LEARNING-PROGRAMS; PROFESSIONALS; EXPERIENCE; STUDENTS; CARE	Introduction Pain is a very frequent symptom that is reported by patients when they present to health professionals but remains undertreated or untreated, particularly in low-resource settings including Nigeria. Lack of training in pain management remains the most significant obstacle to pain treatment alongside an inadequate emphasis on pain education in undergraduate medical curricula, negatively impacting on subsequent care of patients. This study aimed to determine the effect of a 12-week structured e-Learning course on the knowledge of pain management among Nigerian undergraduate medical students. Methods Prospective, multisite, pre-post study conducted across five medical colleges in Nigeria. Structured modules covering aspects of pain management were delivered on an e-Learning platform. Pre- and post-test self-assessments were carried out in the 12-week duration of the study. User experience questionnaires and qualitative interviews were conducted via instant messaging to evaluate user experiences of the platform. User experience data was analysed using the UEQ Data Analysis Tool and Framework Analysis. Results A total of 216 of 659 eligible students completed all sections of the e-Learning course. Participant mean age was 23.52 years, with a slight female predominance (55.3%). Across all participants, an increase in median pre- and post-test scores occurred, from 40 to 60 (Z = 11.3, p<0.001, effect size = 1.3), suggestive of increased knowledge acquisition relating to pain management. Participants suggested e-Learning is a valuable approach to delivering pain education alongside identifying factors to address in future iterations. Conclusion e-Learning approaches to pain management education can enhance traditional learning methods and may increase students' knowledge. Future iterations of e-Learning approaches will need to consider facilitating the download of data and content for the platform to increase user uptake and engagement. The platform was piloted as an optional adjunct to existing curricula. Future efforts to advocate and support integration of e-Learning for pain education should be two-fold; both to include pain education in the curricula of medical colleges across Nigeria and the use of e-Learning approaches to enhance teaching where feasible.	[Onyeka, Tonia C.] Univ Nigeria, Dept Anaesthesia Pain & Palliat Care Unit, Coll Med, Ituku Ozalla Campus, Enugu, Enugu State, Nigeria; [Onyeka, Tonia C.; Iloanusi, Nneka; Onu, Justus U.] Univ Nigeria, Coll Med, EPAC Res Team, Ituku Ozalla Campus, Enugu, Enugu State, Nigeria; [Iloanusi, Nneka] Univ Nigeria, Dept Radiat Med, Coll Med, Ituku Ozalla Campus, Enugu, Enugu State, Nigeria; [Namisango, Eve] African Palliat Care Assoc, Kampala, Uganda; [Onu, Justus U.] Nnamdi Azikiwe Univ, Fac Med, Dept Mental Hlth, Awka, Anambra State, Nigeria; [Okunade, Kehinde S.] Univ Lagos, Coll Med, Dept Obstet & Gynaecol, Oncol & Pathol Studies OPS Unit,Lagos Univ Teachi, Lagos, Nigeria; [Mohammed, Alhassan Datti; Nagoma, Abubakar U.] Bayero Univ, Coll Hlth Sci, Dept Anaesthesia, Aminu Kano Teaching Hosp, Kano, Kano State, Nigeria; [Gadanya, Muktar A.] Bayero Univ, Dept Community Med, Aminu Kano Teaching Hosp, Kano, Kano State, Nigeria; [Ojiakor, Samuel] Nnamdi Azikiwe Univ, Coll Med, Dept Anaesthesia, Awka, Anambra State, Nigeria; [Ilo, Chukwudi] Enugu State Univ Sci & Technol, Coll Med, Enugu, Enugu State, Nigeria; [Okuzu, Okey; Oduche, Chinelo] InStrat Global Hlth Solut, Abuja, Nigeria; [Ugwu, Ngozi] Alex Ekwueme Fed Univ Teaching Hosp, Dept Haematol, Abakaliki, Ebonyi State, Nigeria; [Allsop, Matthew J.] Univ Leeds, Acad Unit Palliat Care, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England	University of Nigeria; University of Nigeria; University of Nigeria; University of Lagos; Bayero University; Bayero University; University of Leeds	Allsop, MJ (corresponding author), Univ Leeds, Acad Unit Palliat Care, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England.	m.j.allsop@leeds.ac.uk	; ONYEKA, TONIA/F-3749-2012; OKUNADE, KEHINDE/A-8201-2017	Allsop, Matthew/0000-0002-7399-0194; ONYEKA, TONIA/0000-0001-8138-3100; OKUNADE, KEHINDE/0000-0002-0957-7389	International Association for the Study of Pain (IASP) through the 2019 IASP Developing Countries Project: Initiative for Improving Pain Education Grant, a scientific grant; IASP	International Association for the Study of Pain (IASP) through the 2019 IASP Developing Countries Project: Initiative for Improving Pain Education Grant, a scientific grant; IASP	The e-Learning platform development was funded by the International Association for the Study of Pain (IASP) through the 2019 IASP Developing Countries Project: Initiative for Improving Pain Education Grant, a scientific grant awarded to T.C. Onyeka, M. Allsop, N. Iloanusi and E. Namisango. IASP funding supported the development of the e-Learning platform. Institutional support was provided by the College of Medicine, University of Nigeria (Enugu, Nigeria) and the African Palliative Care Association (Kampala, Uganda) to support staff costs to undertake research and evaluation activities. The funders provided support in the form of salaries for authors [TO, EN], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The commercial partner for this study, InStrat Global Health Solutions [OO, CO], did not provide funding to support this project. InStrat Global Health Solutions did not contribute to the study design, analysis or decision to publish. The platform developed by InStrat Global Health Solutions supported the collection of study data entered by study participants and the company provided technical input into the manuscript, supporting the description of the functionality of the eLearning platform. The specific roles of these authors are articulated in the 'author contributions' section.	Acosta ML, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209004; Adam R, 2015, PATIENT EDUC COUNS, V98, P269, DOI 10.1016/j.pec.2014.11.003; African Palliative Care Association, 2010, BEAT PAIN; Allisy A., 1993, J INT COMMISSION RAD, V26, DOI 10.1093/jicru/ndq001; Ambler SW, 2012, DISCIPLINED AGILE DE; Ameringer S, 2012, J PALLIAT MED, V15, P978, DOI 10.1089/jpm.2011.0536; [Anonymous], 2017, J ENDOCRINOL METAB D, V22, pS1; [Anonymous], 2018, DIABETES CARE S1, V4, pS4, DOI 10.2337/dc18-Srev01; [Anonymous], 2020, J CLIN MED, V9; Aparicio M, 2016, EDUC TECHNOL SOC, V19, P292; Argyra E, 2015, PAIN MED, V16, P301, DOI 10.1111/pme.12568; Barteit S, 2019, J MED INTERNET RES, V21, DOI 10.2196/12449; Briggs EV, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006984; Chukwunyere N.D., 2019, PALLIATIVE CARE NIGE; Dabbs AD, 2009, CIN-COMPUT INFORM NU, V27, P175, DOI 10.1097/NCN.0b013e31819f7c7c; Degerfalt Jan, 2017, BMC Res Notes, V10, P39, DOI 10.1186/s13104-017-2372-8; Ebenso B, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022174; Eze SC, 2018, INT J EDUC TECHNOL H, V15, DOI 10.1186/s41239-018-0116-z; Finnerup N.B., 2020, PAIN; Frehywot S, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-4; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Gibson K., 2020, QUALITATIVE RES PSYC, P1; Goucke CR, 2018, ANESTH ANALG, V126, P1283, DOI 10.1213/ANE.0000000000002736; Guder, 2013, AM J BUSINESS ED, V6, P333, DOI DOI 10.19030/ajbe.v6i3.7813; International Association for the Study of Pain, 2020, IASP CURR OUTL PAIN; Liossi C, 2018, PAIN, V159, P631, DOI 10.1097/j.pain.0000000000001146; Loeser JD, 2017, POSTGRAD MED, V129, P332, DOI 10.1080/00325481.2017.1297668; Mayadas AF, 2009, SCIENCE, V323, P85, DOI 10.1126/science.1168874; Mezei L, 2011, J PAIN, V12, P1199, DOI 10.1016/j.jpain.2011.06.006; Nicoll P, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9085; Onyeka TC, 2011, INDIAN J PALLIAT CAR, V17, P131, DOI 10.4103/0973-1075.84534; Otu A, 2016, HUM RESOUR HEALTH, V14, DOI 10.1186/s12960-016-0100-4; Perkins GD, 2010, RESUSCITATION, V81, P877, DOI 10.1016/j.resuscitation.2010.03.019; Puljak L, 2011, PAIN MED, V12, P854, DOI 10.1111/j.1526-4637.2011.01104.x; Salkind NJ, 2010, ENCY RES DESIGN, DOI [10.1097/SMJ.0b013e3181eab419, DOI 10.1097/SMJ.0B013E3181EAB419]; Schrepp M, 2016, USER EXPERIENCE QUES; Schrepp M, 2017, INT J INTERACT MULTI, V4, P40, DOI 10.9781/ijimai.2017.445; Simonsen J., 2013, ROUTLEDGE INT HDB PA; Sinatra R, 2010, PAIN MED, V11, P1859, DOI 10.1111/j.1526-4637.2010.00983.x; Tellier PP, 2013, PAIN RES MANAG, V18, P259, DOI 10.1155/2013/920961; Tompkins DA, 2017, DRUG ALCOHOL DEPEN, V173, pS11, DOI 10.1016/j.drugalcdep.2016.12.002; Vadivelu N, 2012, PAIN PRACT, V12, P663, DOI 10.1111/j.1533-2500.2012.00580.x; Zhang Q, 2010, J INTERNET SERV APPL, V1, P7, DOI 10.1007/s13174-010-0007-6; 2019, BRAIN STIMUL MAR, V12	44	4	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2020	15	12							e0243573	10.1371/journal.pone.0243573	http://dx.doi.org/10.1371/journal.pone.0243573			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WB	33301477	gold, Green Published			2023-01-03	WOS:000600143100084
J	Agarwal, A; Yancy, CW; Huffman, MD				Agarwal, Anubha; Yancy, Clyde W.; Huffman, Mark D.			Improving Care for Heart Failure With Reduced Ejection Fraction-A Potential Polypill-Based Strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH	This Viewpoint proposes that a polypill combination of a beta-blocker, renin angiotensin inhibitor, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor might be the most efficient way to deliver guideline-directed HFrEF therapy, and proposes a research roadmap to design and evaluate the pill and implementation strategies for getting it to patients.	[Agarwal, Anubha; Yancy, Clyde W.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA; [Huffman, Mark D.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Agarwal, A (corresponding author), Northwestern Univ, Feinberg Sch Med, 676 N St Clair St,Arkes Family Pavil,Ste 600, Chicago, IL 60611 USA.	anubha.agarwal@northwestern.edu		Agarwal, Anubha/0000-0002-7090-5601				Agarwal A, 2019, HEART, V105, P431, DOI 10.1136/heartjnl-2018-314129; Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Burnett H, 2017, CIRC-HEART FAIL, V10, DOI 10.1161/CIRCHEARTFAILURE.116.003529; Jamison DT, 2018, LANCET, V391, P1108, DOI 10.1016/S0140-6736(17)32906-9; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Roshandel G, 2019, LANCET, V394, P672, DOI 10.1016/S0140-6736(19)31791-X; The Global Fund, GLOB FUND OV; Tromp J, 2020, LANCET GLOB HEALTH, V8, pE411, DOI 10.1016/S2214-109X(20)30004-8; Waltz TJ, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0295-0	9	10	10	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2020	324	22					2259	2260		10.1001/jama.2020.21395	http://dx.doi.org/10.1001/jama.2020.21395		NOV 2020	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD9VK	33211084				2023-01-03	WOS:000592680800001
J	Chiu, YC; Manousakas, I; Kuo, SM; Shiao, JW; Chen, CL				Chiu, Yen-Chun; Manousakas, Ioannis; Kuo, Shyh Ming; Shiao, Jen-Wen; Chen, Chien-Liang			Influence of quantified dry cupping on soft tissue compliance in athletes with myofascial pain syndrome	PLOS ONE			English	Article							SLEEP QUALITY; THERAPY	Purpose This study aimed to develop a quantitative dry cupping system that can monitor negative pressure attenuation and soft tissue pull-up during cupping to quantify soft tissue compliance. Methods Baseball players with myofascial pain syndrome were recruited to validate the benefits of cupping therapy. Nine of 40 baseball players on the same team were diagnosed with trapezius myofascial pain syndrome; another nine players from the same team were recruited as controls. All participants received cupping with a negative pressure of 400 mmHg for 15 minutes each time, twice a week, for 4 weeks. Subjective perception was investigated using upper extremity function questionnaires, and soft tissue compliance was quantified objectively by the system. Results During the 15-minute cupping procedure, pressure attenuation in the normal group was significantly greater than that in the myofascial group (p = 0.017). The soft tissue compliance in the normal group was significantly higher than that in the myofascial group (p = 0.050). Moreover, a 4-week cupping intervention resulted in an obvious increase in soft tissue lift in the myofascial pain group (p = 0.027), although there was no statistical difference in the improvement of soft tissue compliance. Shoulder (p = 0.023) and upper extremity function (p = 0.008) were significantly improved in both groups, but there was no significant difference between the two groups. Conclusion This quantitative cupping monitoring system could immediately assess tissue compliance and facilitate the improvement of soft tissues after cupping therapy. Hence, it can be used in athletes to improve their functional recovery and maintain soft tissues health during the offseason period.	[Chiu, Yen-Chun] I Shou Univ, E Da Hosp, Dept Orthoped, Kaohsiung, Taiwan; [Chiu, Yen-Chun] I Shou Univ, Dept Elect Engn, Kaohsiung, Taiwan; [Manousakas, Ioannis; Kuo, Shyh Ming] I Shou Univ, Dept Biomed Engn, Kaohsiung, Taiwan; [Shiao, Jen-Wen] I Shou Univ, Ctr Gen Educ, Kaohsiung, Taiwan; [Chen, Chien-Liang] I Shou Univ, Dept Phys Therapy, Kaohsiung, Taiwan	E-Da Hospital; I Shou University; I Shou University; I Shou University; I Shou University; I Shou University	Chen, CL (corresponding author), I Shou Univ, Dept Phys Therapy, Kaohsiung, Taiwan.	chencl@isu.edu.tw	Manousakas, Ioannis/AAI-7440-2021; Chen, Chien-Liang/X-2500-2019	Manousakas, Ioannis/0000-0003-2295-1096; Chen, Chien-Liang/0000-0002-9503-1322	E-Da Healthcare Group of the Republic of China [EDCHM108001]	E-Da Healthcare Group of the Republic of China	This work is funded by the E-Da Healthcare Group of the Republic of China under the contract EDCHM108001. The grant was awarded to YCC and CLC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Bedah AMN, 2019, J TRADIT COMPL MED, V9, P90, DOI 10.1016/j.jtcme.2018.03.003; AlKhadhrawi N, 2019, J BODYW MOV THER, V23, P532, DOI 10.1016/j.jbmt.2019.05.016; Arslan M, 2015, INDIAN J TRADIT KNOW, V14, P359; Bridgett R, 2018, J ALTERN COMPLEM MED, V24, P208, DOI 10.1089/acm.2017.0191; Cao HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031793; Chan YC, 2015, J PHYS THER SCI, V27, P217, DOI 10.1589/jpts.27.217; Chen CL, 2018, ADV INTELL SYST COMP, V603, P73, DOI 10.1007/978-3-319-60822-8_7; Cummings M, 2007, BEST PRACT RES CL RH, V21, P367, DOI 10.1016/j.berh.2006.12.006; Desai MJ, 2013, PAIN THER, V2, P21, DOI 10.1007/s40122-013-0006-y; El Sayed SM, 2014, MED HYPOTHESES, V83, P238, DOI 10.1016/j.mehy.2014.04.001; 김재은, 2017, [Journal of the Korean Society of Physical Medicine, 대한물리의학회지], V12, P23; Giamberardino MA, 2011, BEST PRACT RES CL RH, V25, P185, DOI 10.1016/j.berh.2011.01.002; Jafri M Saleet, 2014, Int Sch Res Notices, V2014; Jing-Shia Tang, 2019, Advances in Social and Occupational Ergonomics. Proceedings of the AHFE 2018 International Conference on Social and Occupational Ergonomics. Advances in Intelligent Systems and Computing (AISC 792), P309, DOI 10.1007/978-3-319-94000-7_32; Kim SA, 2014, J MUSCULOSKELET PAIN, V22, P232, DOI 10.3109/10582452.2014.883036; KIRSCH KA, 1980, PFLUG ARCH EUR J PHY, V387, P239, DOI 10.1007/BF00580976; Lee MS, 2011, J ACUPUNCT MERIDIAN, V4, P1, DOI 10.1016/S2005-2901(11)60001-0; Li T, 2017, BIOMED OPT EXPRESS, V8, P223, DOI 10.1364/BOE.8.000223; Morikawa Y, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00186; Munoz-Munoz S, 2012, J MANIP PHYSIOL THER, V35, P608, DOI 10.1016/j.jmpt.2012.09.003; Nasb M, 2020, J ALTERN COMPLEM MED, V26, P44, DOI 10.1089/acm.2019.0231; Ozden Ali Veysel, 2016, J Clin Med Res, V8, P513, DOI 10.14740/jocmr2589w; Rozenfeld E, 2016, J BODYW MOV THER, V20, P173, DOI 10.1016/j.jbmt.2015.11.009; SKOOTSKY SA, 1989, WESTERN J MED, V151, P157; Volpato MP, 2020, J ACUPUNCT MERIDIAN, V13, P48, DOI 10.1016/j.jams.2019.11.004; Yap EC, 2007, ANN ACAD MED SINGAP, V36, P43	26	5	5	7	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2020	15	11							e0242371	10.1371/journal.pone.0242371	http://dx.doi.org/10.1371/journal.pone.0242371			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM0RU	33211769	Green Published, gold			2023-01-03	WOS:000603518300048
J	Kungu, W; Khasakhala, A; Agwanda, A				Kungu, Wambui; Khasakhala, Anne; Agwanda, Alfred			Use of long-acting reversible contraception among adolescents and young women in Kenya	PLOS ONE			English	Article							RAPID REPEAT PREGNANCY; INTERVENTIONS	The Kenya Demographic and Health Survey (KDHS 2014) revealed changing patterns in the contraceptive use of young women aged 15-24, shifting from injectable methods to implants. Long-acting reversible contraception (LARC) is user friendly, long-term, and more effective than other modern methods. It could be a game-changer in dealing with unintended pregnancies and herald a new chapter in the reproductive health and rights of young women. This study determined the factors associated with LARC use among adolescent girls and young women to expand the evidence of its potential as the most effective method of reducing unwanted pregnancies among the cohort. This study analysed secondary data from KDHS 2014 using binary logistic regression. The findings showed a rise in LARC use (18%), with identified predictors of reduced odds being aged 15-19 [OR = 0.735, 95% CI = 0.549-0.984], residence (rural) [OR = 0.674, CI = 0.525-0.865], religion (Protestant/other Christian) [OR = 0.377, CI = 0.168-0.842], married, [OR = 0.746, CI = 0.592-0.940], and region (high contraception) [OR = 0.773, CI = 0.626-0.955], while the number of living children showed increased odds for 1-2 children [OR = 17.624, CI = 9.482-32.756] and 3+ children [OR = 23.531, CI = 11.751-47.119]. This study established the rising popularity of LARC and identified factors that can be addressed to promote it. Its increased uptake could help Kenya achieve the International Conference on Population and Development 25's first and second commitments on teenage pregnancies and maternal and new-born health, thus promoting the health, wellbeing, educational goals, and rights of this critical cohort. This study can guide the accelerated efforts needed in Kenya's march towards the five zeros of unmet need for contraception, teenage pregnancies, unsafe abortions, preventable maternal deaths, and preventable neonatal/infant deaths.	[Kungu, Wambui; Khasakhala, Anne; Agwanda, Alfred] Univ Nairobi, Populat Studies & Res Inst, Nairobi, Kenya	University of Nairobi	Kungu, W (corresponding author), Univ Nairobi, Populat Studies & Res Inst, Nairobi, Kenya.	buikungu@yahoo.com	Kungu, Wambui/ABC-5612-2021	Kungu, Wambui/0000-0003-4441-7927				Achwoka D, 2018, CONTRACEPTION, V97, P227, DOI 10.1016/j.contraception.2017.10.001; Adedini SA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217574; American College of Obstetricians and Gynaecologists, 2018, OBSTET GYNECOL, V20, P8; [Anonymous], 2019, NAIR SUMM ICPD25; Askew I, 2019, KENYAS FERTILITY TRA; Baldwin MK, 2013, J ADOLESCENT HEALTH, V52, pS47, DOI 10.1016/j.jadohealth.2012.10.278; Chandra-Mouli V, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-1; Cooper CM, 2017, MATERN CHILD HLTH J, V21, P1880, DOI 10.1007/s10995-017-2341-9; Darroch JE, 2018, ADDING IT COSTS BENE; Dempsey AR, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.014; Duvall S, 2014, GLOB HEALTH-SCI PRAC, V2, P72, DOI 10.9745/GHSP-D-13-00116; Glinski A, 2014, UNDERSTANDING ADOLES, DOI DOI 10.1017/CBO9781107415324.004; Hubacher D, 2012, CONTRACEPTION, V86, P511, DOI 10.1016/j.contraception.2012.04.013; Jacobstein R, 2018, GLOB HEALTH-SCI PRAC, V6, P17, DOI 10.9745/GHSP-D-17-00396; Kavanaugh ML, 2013, J PEDIATR ADOL GYNEC, V26, P86, DOI 10.1016/j.jpag.2012.10.006; Kenya National Bureau of Statistics, 2019, KEN POP HOUS CENS, VIII; Kenya National Bureau of Statistics Ministry of Health National AIDS Control Council Kenya Medical Research Institute, 2015, KEN DEM HLTH SURV 20; Keyonzo N, 2015, REPROD HEALTH MATTER, V23, P103, DOI 10.1016/j.rhm.2015.06.010; Kimani M., 2013, African Population Studies, V27, P43; Kungu W, F1000 RES; Larsson C., 2014, African Population Studies, V28, P1022; Li ZH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.21437; Magadi MA, 2003, STUD FAMILY PLANN, V34, P149, DOI 10.1111/j.1728-4465.2003.00149.x; Ministry of Health Kenya, 2012, NAT FAM PLANN COST I; Ministry of Health Kenya, 2015, NATL ADOLESCENT SEXU; Ministry of Health Kenya, 2017, NAT FAM PLANN COST I; Monitoring Performance and Accountability, 2018, ADOLESCENTS YOUNG AD; Monitoring Performance and Accountability, 2017, ADOLESCENT HLTH BRIE; Norton M, 2017, GLOB HEALTH-SCI PRAC, V5, P547, DOI 10.9745/GHSP-D-17-00131; Coll CDN, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0686-9; Ochako R, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0314-6; Ochako R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1483-1; Ontiri S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091543; Planning Family, 2015, GLOBAL CONSENSUS STA; Population Services International, 2015, WOM HLTH PROJ BEST P; Sedgh G, 2015, J ADOLESCENT HEALTH, V56, P223, DOI 10.1016/j.jadohealth.2014.09.007; Shoupe D, 2016, CONTRACEP REPROD MED, V1, DOI 10.1186/s40834-016-0011-8; Solo J, 2019, GLOB HEALTH-SCI PRAC, V7, P371, DOI 10.9745/GHSP-D-19-00130; Temple-Smith M, 2017, AUST FAM PHYSICIAN, V46, P710; Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051; WHO, 2015, WHO REC ASS HIV TEST; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855; Yinger N, 2016, M NEED FULF PROM YOU, DOI [10.1093/jmt/thw010, DOI 10.1093/JMT/THW010]	44	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2020	15	11							e0241506	10.1371/journal.pone.0241506	http://dx.doi.org/10.1371/journal.pone.0241506			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OV7KH	33170851	Green Published, gold			2023-01-03	WOS:000592383400064
J	Schmidt, TA				Schmidt, Tannin A.			Lubricating lipids in hydrogels	SCIENCE			English	Editorial Material							BOUNDARY LUBRICATION; BIOLOGY; TISSUE		[Schmidt, Tannin A.] Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Biomed Engn, Farmington, CT 06030 USA	University of Connecticut	Schmidt, TA (corresponding author), Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Biomed Engn, Farmington, CT 06030 USA.	tschmidt@uchc.edu						Bonnevie ED, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143415; Briscoe WH, 2006, NATURE, V444, P191, DOI 10.1038/nature05196; Das N, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201800166; Dowson D., 1968, P I MECH ENG, V184, P181; Gong JP, 2006, SOFT MATTER, V2, P544, DOI 10.1039/b603209p; JAY GD, 1992, CONNECT TISSUE RES, V28, P71, DOI 10.3109/03008209209014228; Jay GD, 2014, MATRIX BIOL, V39, P17, DOI 10.1016/j.matbio.2014.08.008; Khademhosseini A, 2007, BIOMATERIALS, V28, P5087, DOI 10.1016/j.biomaterials.2007.07.021; Lin WF, 2020, SCIENCE, V370, P335, DOI 10.1126/science.aay8276; Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612; Petrey AC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00101; RADIN EL, 1970, NATURE, V228, P377, DOI 10.1038/228377a0; Schmidt TA, 2007, ARTHRITIS RHEUM-US, V56, P882, DOI 10.1002/art.22446; Seror J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7497; Singh A, 2014, NAT MATER, V13, P988, DOI [10.1038/nmat4048, 10.1038/NMAT4048]	15	4	4	8	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	2020	370	6514					288	289		10.1126/science.abd3831	http://dx.doi.org/10.1126/science.abd3831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OC5EM	33060347				2023-01-03	WOS:000579179500038
J	Hassan, S; Peluso, J; Chalhoub, S; Gillet, YI; Benkirane-Jessel, N; Rochel, N; Fuhrmann, G; Ubeaud-Sequier, G				Hassan, Sarah; Peluso, Jean; Chalhoub, Sandra; Idoux Gillet, Ysia; Benkirane-Jessel, Nadia; Rochel, Natacha; Fuhrmann, Guy; Ubeaud-Sequier, Genevieve			Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1 alpha and MDR1	PLOS ONE			English	Article							PANCREATIC-CANCER; INTERVENTION; EXPRESSION	The impact of cancer on lifespan is significantly increasing worldwide. Enhanced activity of drug efflux pumps and the incidences of the tumor microenvironment such as the apparition of a hypoxic gradient inside of the bulk tumor, are the major causes of chemotherapy failure. For instance, expression of Hypoxia-inducible factor (HIF-1 alpha) has been associated with metastasis, resistance to chemotherapy and reduced survival rate. One of the current challenges to fight against cancer is therefore to find new molecules with therapeutic potential that could overcome this chemoresistance. In the present study, we focused on the bioactive plant flavonoid quercetin, which has strong antioxidant and anti-proliferative properties. We examined the efficacy of combined treatments of quercetin and the anti-cancer drugs gemcitabine and doxorubicin, known to specifically act on human pancreatic and hepatic cancer cells, respectively. Moreover, our study aimed to investigate more in-depth the implication of the multidrug transporter MDR1 and HIF-1 alpha n chemoresistance and if quercetin could act on the activity of the drug efflux pumps and the hypoxia-associated effects. We observed that the anti-cancer drugs, were more effective when administered in combination with quercetin, as shown by an increased percentage of dead cells up to 60% in both 2D and 3D cultures. In addition, our results indicated that the combination of anti-cancer drugs and quercetin down-regulated the expression of HIF-1 alpha and increased the expression levels of the regulator of apoptosis p53. Moreover, we observed that quercetin could inhibit the efflux activity of MDR1. Finally, our in vitro study suggests that the efficiency of the chemotherapeutic activity of known anti-cancer drugs might be significantly increased upon combination with quercetin. This flavonoid may therefore be a promising pharmacological agent for novel combination therapy since it potentializes the cytotoxic activity of gemcitabine and doxorubicin on by targeting the chemoresistance developed by the pancreatic and liver cancer cells respectively.	[Hassan, Sarah; Idoux Gillet, Ysia; Benkirane-Jessel, Nadia; Fuhrmann, Guy; Ubeaud-Sequier, Genevieve] Univ Strasbourg, Regenerat Nanomed, INSERM UMR 1260, FMTS, Strasbourg, France; [Hassan, Sarah; Peluso, Jean; Ubeaud-Sequier, Genevieve] Univ Strasbourg, Fac Pharm, Platform EBiocyt UPS1401, Strasbourg, France; [Chalhoub, Sandra; Rochel, Natacha] Univ Strasbourg, Dept Integrat Struct Biol, Inst Genet & & Biol Mol Cellulaire, INSERM,U964,CNRS,UMR 7104, Strasbourg, France; [Ubeaud-Sequier, Genevieve] Strasbourg Univ Hosp, Dept Pharm, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hassan, S (corresponding author), Univ Strasbourg, Regenerat Nanomed, INSERM UMR 1260, FMTS, Strasbourg, France.; Hassan, S (corresponding author), Univ Strasbourg, Fac Pharm, Platform EBiocyt UPS1401, Strasbourg, France.	sarah.w.hassan@gmail.com	Rochel, Natacha/A-5718-2016	Rochel, Natacha/0000-0002-3573-5889; Idoux-Gillet, Ysia/0000-0002-0436-1968; hassan, sarah/0000-0002-0025-2895				Abdallah HM, 2015, J ADV RES, V6, P45, DOI 10.1016/j.jare.2014.11.008; Adcock A., 2015, J ANAL BIOANAL TECH, V6, P3; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Barannyk LL, 2012, MATH COMPUT SIMULAT, V82, P1008, DOI 10.1016/j.matcom.2010.11.015; Berrouet C, 2020, BIORXIV; Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Breslin S, 2016, ONCOTARGET, V7, P45745, DOI 10.18632/oncotarget.9935; Brito AF, 2015, CURR MED CHEM, V22, P3025, DOI 10.2174/0929867322666150812145435; Brown JM, 2002, CANCER BIOL THER, V1, P453, DOI 10.4161/cbt.1.5.157; Chang JE, 2012, PHARM RES-DORDR, V29, P795, DOI 10.1007/s11095-011-0603-6; Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Griffiths Keith, 2016, Diseases, V4, DOI 10.3390/diseases4030028; Guo JH, 2017, CHINESE MED J-PEKING, V130, P203, DOI 10.4103/0366-6999.198003; Hassan S, 2017, INT J CURR ADV RES S, V6, P7275; Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108; Kanji ZS, 2018, ANN SURG ONCOL, V25, P1052, DOI 10.1245/s10434-018-6334-8; Kee JY, 2016, PHYTOMEDICINE, V23, P1680, DOI 10.1016/j.phymed.2016.09.011; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Lee YH, 2017, ONCOL LETT, V14, P171, DOI 10.3892/ol.2017.6132; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mohammed A, 2015, CANCERS, V7, P1499, DOI 10.3390/cancers7030850; Mokhtari RB, 2017, ONCOTARGET, V8, P38022, DOI 10.18632/oncotarget.16723; Nadia Salem Alrawaiq, 2014, International Journal of PharmTech Research, V6, P933; Nakagawa T, 2009, CANCER LETT, V273, P250, DOI 10.1016/j.canlet.2008.08.004; Polya G., 1921, Math. Ann., V84, P149, DOI DOI 10.1007/BF01458701; Pratheeshkumar P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/324021; Pratheeshkumar P, 2014, TOXICOL APPL PHARM, V281, P230, DOI 10.1016/j.taap.2014.10.008; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Senthebane DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071586; Seo K, 2014, INFLAMMATION, V37, P712, DOI 10.1007/s10753-013-9789-6; Seo S, 2016, BIOL PHARM BULL, V39, P1830, DOI 10.1248/bpb.b16-00414; Thani NAA, 2014, J CLIN PATHOL, V67, P949, DOI 10.1136/jclinpath-2013-202075; Wong S, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0159-3; Zhao Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132746; Zhao Yu-pei, 2011, Zhonghua Wai Ke Za Zhi, V49, P771	39	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240676	10.1371/journal.pone.0240676	http://dx.doi.org/10.1371/journal.pone.0240676			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052979	Green Published, gold			2023-01-03	WOS:000581820200002
J	Yang, GH; Zhou, R; Guo, XF; Yan, CY; Lei, JL; Shi, YG				Yang, Guanghui; Zhou, Rui; Guo, Xuefei; Yan, Chuangye; Lei, Jianlin; Shi, Yigong			Structural basis of gamma-secretase inhibition and modulation by small molecule drugs	CELL			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA; INTRAMEMBRANE PROTEOLYSIS; TRANSMEMBRANE DOMAIN; MISSENSE MUTATIONS; PHASE-I; NOTCH; PRESENILIN; PROTEIN; SEMAGACESTAT	Development of y-secretase inhibitors (GSIs) and modulators (GSMs) represents an attractive therapeutic opportunity for Alzheimer's disease (AD) and cancers. However, how these GSIs and GSMs target gamma-secretase has remained largely unknown. Here, we report the cryoelectron microscopy (cryo-EM) structures of human gamma-secretase bound individually to two GSI clinical candidates, Semagacestat and Ava9acestat, a transition state analog GSI L685,458, and a classic GSM E2012, at overall resolutions of 2.6-3.1 angstrom. Remark-ably, each of the GSIs occupies the same general location on presenilin 1 (PS1) that accommodates the beta strand from amyloid precursor protein or Notch, interfering with substrate recruitment. L685,458 directly coordinates the two catalytic aspartate residues of PS1. E2012 binds to an allosteric site of gamma-secretase on the extracellular side, potentially explaining its modulating activity. Structural analysis reveals a set of shared themes and variations for inhibitor and modulator recognition that will guide development of the next-generation substrate-selective inhibitors.	[Yang, Guanghui; Zhou, Rui; Guo, Xuefei; Yan, Chuangye; Shi, Yigong] Tsinghua Univ, Sch Life Sci, Tsinghua Peking Joint Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol, Beijing 100084, Peoples R China; [Yang, Guanghui; Zhou, Rui; Guo, Xuefei; Yan, Chuangye; Shi, Yigong] Tsinghua Univ, Sch Life Sci, Tsinghua Peking Joint Ctr Life Sci, Res Ctr Biol Struct, Beijing 100084, Peoples R China; [Yang, Guanghui] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China; [Lei, Jianlin] Tsinghua Univ, Technol Ctr Prot Sci, Sch Life Sci, Minist Educ,Key Lab Prot Sci, Beijing 100084, Peoples R China; [Shi, Yigong] Westlake Univ, Sch Life Sci, Key Lab Struct Biol Zhejiang Prov, 18 Shilongshan Rd, Hangzhou 310024, Zhejiang, Peoples R China; [Shi, Yigong] Westlake Inst Adv Study, Inst Biol, 18 Shilongshan Rd, Hangzhou 310024, Zhejiang, Peoples R China	Tsinghua University; Tsinghua University; China Agricultural University; Tsinghua University; Westlake University; Westlake University	Shi, YG (corresponding author), Tsinghua Univ, Sch Life Sci, Tsinghua Peking Joint Ctr Life Sci, Beijing Adv Innovat Ctr Struct Biol, Beijing 100084, Peoples R China.; Shi, YG (corresponding author), Tsinghua Univ, Sch Life Sci, Tsinghua Peking Joint Ctr Life Sci, Res Ctr Biol Struct, Beijing 100084, Peoples R China.; Shi, YG (corresponding author), Westlake Univ, Sch Life Sci, Key Lab Struct Biol Zhejiang Prov, 18 Shilongshan Rd, Hangzhou 310024, Zhejiang, Peoples R China.; Shi, YG (corresponding author), Westlake Inst Adv Study, Inst Biol, 18 Shilongshan Rd, Hangzhou 310024, Zhejiang, Peoples R China.	syg@westlake.edu.cn	Yan, Chuangye/AAJ-5832-2021	Shi, Yigong/0000-0003-2030-168X; Zhou, Rui/0000-0002-0782-4761; Yan, Chuangye/0000-0001-9338-8048	Beijing Advanced Innovation Center for Structural Biology; National Key R&D Program of China [2020YFA0509300]; Ministry of Science and Technology of China; National Natural Science Foundation of China [81920108015, 31930059]; Key R&D Program of Zhejiang Province [2020C04001]	Beijing Advanced Innovation Center for Structural Biology; National Key R&D Program of China; Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key R&D Program of Zhejiang Province	We thank the Tsinghua University Branch of China National Center for Protein Sciences (Beijing) for the cryo-EM facility and the computational facility support, and Dr. Xiaomin Li and Dr. Fan Yang for technical support in EM data acquisition. R.Z. is supported by fellowships from the Beijing Advanced Innovation Center for Structural Biology. This work was supported by funds from the National Key R&D Program of China (2020YFA0509300), the Ministry of Science and Technology of China, the National Natural Science Foundation of China (81920108015 and 31930059), and the Key R&D Program of Zhejiang Province (2020C04001).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Andersson CX, 2005, BIOCHEM J, V387, P377, DOI 10.1042/BJ20041387; Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127; Bai XC, 2015, ELIFE, V4, DOI 10.7554/eLife.11182; Bai XC, 2015, NATURE, V525, P212, DOI 10.1038/nature14892; Bateman RJ, 2009, ANN NEUROL, V66, P48, DOI 10.1002/ana.21623; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Best JD, 2006, J PHARMACOL EXP THER, V317, P786, DOI 10.1124/jpet.105.100271; Bolduc DM, 2016, P NATL ACAD SCI USA, V113, pE509, DOI 10.1073/pnas.1512952113; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Bursavich MG, 2016, J MED CHEM, V59, P7389, DOI 10.1021/acs.jmedchem.5b01960; Cai T, 2017, J NEUROSCI, V37, P12272, DOI 10.1523/JNEUROSCI.1628-17.2017; Chau DM, 2012, J BIOL CHEM, V287, P17288, DOI 10.1074/jbc.M111.300483; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Chen SX, 2013, ULTRAMICROSCOPY, V135, P24, DOI 10.1016/j.ultramic.2013.06.004; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Coric V, 2015, JAMA NEUROL, V72, P1324, DOI 10.1001/jamaneurol.2015.0607; Coric V, 2012, ARCH NEUROL-CHICAGO, V69, P1430, DOI 10.1001/archneurol.2012.2194; Crump CJ, 2013, BIOCHEMISTRY-US, V52, P3197, DOI 10.1021/bi400377p; Crump CJ, 2012, BIOCHEMISTRY-US, V51, P7209, DOI 10.1021/bi301137h; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; De Strooper B, 2014, CELL, V159, P721, DOI 10.1016/j.cell.2014.10.016; Diaz-Padilla I, 2015, GYNECOL ONCOL, V137, P216, DOI 10.1016/j.ygyno.2015.03.005; Doody RS, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0121-6; Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Funamoto S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3529; Gertsik N, 2017, CELL CHEM BIOL, V24, P3, DOI 10.1016/j.chembiol.2016.12.006; Gillman KW, 2010, ACS MED CHEM LETT, V1, P120, DOI 10.1021/ml1000239; Golde TE, 2010, EXP NEUROL, V223, P252, DOI 10.1016/j.expneurol.2009.07.035; Grant T, 2015, ELIFE, V4, DOI 10.7554/eLife.06980; Griciuc A, 2019, NEURON, V103, P820, DOI 10.1016/j.neuron.2019.06.010; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Henley DB, 2009, EXPERT OPIN PHARMACO, V10, P1657, DOI 10.1517/14656560903044982; Hitzenberger M, 2019, ACS CHEM NEUROSCI, V10, P3398, DOI 10.1021/acschemneuro.9b00272; Hur JY, 2020, NATURE, V586, P735, DOI 10.1038/s41586-020-2681-2; Karran E, 2014, ANN NEUROL, V76, P185, DOI 10.1002/ana.24188; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; Kimanius D, 2016, ELIFE, V5, DOI 10.7554/eLife.18722; Kimura T., 2005, PCT Int. Appl., Patent No. [WO 2005115990 A1 70051208, 2005115990]; Kounnas MZ, 2010, NEURON, V67, P769, DOI 10.1016/j.neuron.2010.08.018; Krop I, 2012, J CLIN ONCOL, V30, P2307, DOI 10.1200/JCO.2011.39.1540; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lei JL, 2005, J STRUCT BIOL, V150, P69, DOI 10.1016/j.jsb.2005.01.002; Li Y, 2014, STRUCTURE, V22, P125, DOI 10.1016/j.str.2013.09.018; Liu Q, 2014, JAMA NEUROL, V71, P1481, DOI 10.1001/jamaneurol.2014.2482; Lu PL, 2014, NATURE, V512, P166, DOI 10.1038/nature13567; Mayer SC, 2008, J MED CHEM, V51, P7348, DOI 10.1021/jm801252w; Pettersen E.F., 2004, J COMPUTATIONAL CHEM; Pozdnyakov N, 2013, J BIOL CHEM, V288, P9710, DOI 10.1074/jbc.M112.398602; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Sato C, 2008, J NEUROSCI, V28, P6264, DOI 10.1523/JNEUROSCI.1163-08.2008; Scheres SHW, 2012, J MOL BIOL, V415, P406, DOI 10.1016/j.jmb.2011.11.010; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tagami S, 2017, CELL REP, V21, P259, DOI 10.1016/j.celrep.2017.09.032; Takami M, 2009, J NEUROSCI, V29, P13042, DOI 10.1523/JNEUROSCI.2362-09.2009; Tian Y, 2010, NAT STRUCT MOL BIOL, V17, P151, DOI 10.1038/nsmb.1743; Tolcher AW, 2012, J CLIN ONCOL, V30, P2348, DOI 10.1200/JCO.2011.36.8282; Uemura K, 2006, NEUROSCI LETT, V402, P278, DOI 10.1016/j.neulet.2006.04.018; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wagner SL, 2014, BIOCHEMISTRY-US, V53, P702, DOI 10.1021/bi401537v; Wei P, 2010, MOL CANCER THER, V9, P1618, DOI 10.1158/1535-7163.MCT-10-0034; Wolfe MS, 2008, CURR ALZHEIMER RES, V5, P158, DOI 10.2174/156720508783954767; Wolfe MS, 2012, J NEUROCHEM, V120, P89, DOI 10.1111/j.1471-4159.2011.07501.x; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yang GH, 2019, NATURE, V565, P192, DOI 10.1038/s41586-018-0813-8; Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zhou R, 2019, SCIENCE, V363, P708, DOI 10.1126/science.aaw0930	82	43	45	22	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2021	184	2					521	+		10.1016/j.cell.2020.11.049	http://dx.doi.org/10.1016/j.cell.2020.11.049		JAN 2021	27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY8KT	33373587	Bronze			2023-01-03	WOS:000612290800021
J	Hwang, IC; Kim, KK; Lee, KR				Hwang, In Cheol; Kim, Kyoung Kon; Lee, Kyu Rae			Cryolipolysis-induced abdominal fat change: Split-body trials	PLOS ONE			English	Article							SUBCUTANEOUS FAT; ADIPOSE-TISSUE; RISK-FACTORS; LIPOSUCTION; DEPOTS	Cryolipolysis has been considered as a noninvasive alternative to surgical procedures for reducing subcutaneous fat without affecting the surrounding tissues. However, no clinical trial has investigated changes in the abdominal fat tissue by 12 weeks after cryolipolysis. Therefore, in this split-body trial, we explored whether a single session of unilateral cryolipolysis could change visceral and subcutaneous adipose tissue over a period of 12 weeks. We compared the cross-sectional areas of the abdominal adipose tissue of 15 subjects (9 women; 38.3 [10.8] years) by computed tomography before and at 12 weeks after a single treatment of cryolipolysis to the left abdomen and used the right abdomen as untreated control. In addition, we measured participants' waist circumference, percentage of body fat (by bioelectrical impedance analysis) at baseline and at 6- and 12-weeks post-treatment. Single unilateral cryolipolysis tended to reduce the cross-sectional areas of visceral adipose tissue, by 8.4 cm(2) (9.9%), the waist circumferences, and the percent body fat, by 2.8 cm(2) (0.6%), overall. The cross-sectional area of visceral adipose tissues on the treated side significantly decreased, by 6.8 cm(2) (15.6%; P = 0.003), and that of the untreated side tended to decrease by 1.2 cm(2) (3.6%). Thus, a single unilateral session of noninvasive selective cryolipolysis can be considered as a safe and effective treatment for reduction of visceral adipose tissue over a period of 12 weeks, which should result in metabolic improvement.	[Hwang, In Cheol; Kim, Kyoung Kon; Lee, Kyu Rae] Gachon Univ, Family Med, Incheon, South Korea	Gachon University	Lee, KR (corresponding author), Gachon Univ, Family Med, Incheon, South Korea.	baria07@daum.net	Kim, Kyoung-Kon/GXV-1730-2022	Kim, Kyoung-Kon/0000-0003-0374-2571; lee, kyu rae/0000-0003-2178-0459	Gachon University [GCU-2018-5258]	Gachon University	This study was fully supported by a grant from the Gachon University research fund of 2018. (GCU-2018-5258). The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham TM, 2015, CIRCULATION, V132, P1639, DOI 10.1161/CIRCULATIONAHA.114.015000; Avram MM, 2009, LASER SURG MED, V41, P703, DOI 10.1002/lsm.20864; BEACHAM BE, 1980, ARCH DERMATOL, V116, P1025, DOI 10.1001/archderm.116.9.1025; Bellini E, 2017, ANN MED SURG, V24, P53, DOI 10.1016/j.amsu.2017.10.024; BELLISARI A, 1993, INT J OBESITY, V17, P475; Berry MG, 2011, J PLAST RECONSTR AES, V64, P985, DOI 10.1016/j.bjps.2010.11.018; Chang JC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45354-1; Coleman SR, 2009, AESTHET PLAST SURG, V33, P482, DOI 10.1007/s00266-008-9286-8; Efremova A, 2020, J PHYSIOL BIOCHEM, V76, P185, DOI 10.1007/s13105-019-00721-4; EPSTEIN EH, 1970, NEW ENGL J MED, V282, P966, DOI 10.1056/NEJM197004232821709; Faull F, 2013, G POWER VERSION 3 1; Garibyan L, 2020, PLAST RECONSTR SURG, V145, p725E, DOI 10.1097/PRS.0000000000006658; Hu F., 2008, OBESITY EPIDEMIOLOGY, P53, DOI DOI 10.1093/ACPROF:OSO/9780195312911; Jalian HR, 2014, JAMA DERMATOL, V150, P317, DOI 10.1001/jamadermatol.2013.8071; Juhasz M, 2020, DERMATOL SURG, V46, P1461, DOI 10.1097/DSS.0000000000002135; Kaess BM, 2012, DIABETOLOGIA, V55, P2622, DOI 10.1007/s00125-012-2639-5; Karow Jr AM, 1960, CRYOBIOLOGY, V2, P99; Klein S, 2004, NEW ENGL J MED, V350, P2549, DOI 10.1056/NEJMoa033179; Lee D, 2018, J BIOSCIENCES MED, V6, P44, DOI [10.1080/14764172.2018.1525742, DOI 10.1080/14764172.2018.1525742]; Manstein D, 2008, LASER SURG MED, V40, P595, DOI 10.1002/lsm.20719; MATSUZAWA Y, 1995, OBES RES, V3, pS187, DOI 10.1002/j.1550-8528.1995.tb00462.x; McLaughlin T, 2011, J CLIN ENDOCR METAB, V96, pE1756, DOI 10.1210/jc.2011-0615; Mohammed BS, 2008, OBESITY, V16, P2648, DOI 10.1038/oby.2008.418; Oh CH, 2020, ARCH PLAST SURG-APS, V47, P62, DOI 10.5999/aps.2019.01305; Rosenquist KJ, 2013, JACC-CARDIOVASC IMAG, V6, P762, DOI 10.1016/j.jcmg.2012.11.021; Shuster A, 2012, BRIT J RADIOL, V85, P1, DOI 10.1259/bjr/38447238; Stewart KJ, 2006, J PLAST RECONSTR AES, V59, P1152, DOI 10.1016/j.bjps.2005.12.060; Weiner J, 2017, MOL METAB, V6, P482, DOI 10.1016/j.molmet.2017.03.004; Zelickson B, 2009, DERMATOL SURG, V35, P1462, DOI 10.1111/j.1524-4725.2009.01259.x	29	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0242782	10.1371/journal.pone.0242782	http://dx.doi.org/10.1371/journal.pone.0242782			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BU	33373395	Green Published, gold			2023-01-03	WOS:000603612300014
J	Adrawa, N; Alege, JB; Izudi, J				Adrawa, Norbert; Alege, John Bosco; Izudi, Jonathan			Alcohol consumption increases non-adherence to ART among people living with HIV enrolled to the community-based care model in rural northern Uganda	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; EPIDEMIOLOGY STROBE; SELF-REPORT; ADHERENCE; MEDICATION; OUTCOMES	Background Non-adherence to anti-retroviral therapy (ART) is associated with considerable morbidity and mortality among people living with Human Immunodeficiency Virus (PLHIV). Community-based ART delivery model offers a decentralized and patient-centered approach to care for PLHIV, with the advantage of improved adherence to ART hence good treatment outcomes. However, data are limited on the magnitude of non-adherence to ART among PLHIV enrolled to the community-based ART model of care. In this study, we determined the frequency of non-adherence to ART and the associated factors among PLHIV enrolled to the community-based ART delivery model in a large health facility in rural northern Uganda. Methods This analytic cross-sectional study randomly sampled participants from 21 community drug distribution points at the AIDS Support Organization (TASO) in Gulu district, northern Uganda. Data were collected using a standardized and pre-tested questionnaire, entered in Epi-Data and analyzed in Stata at univariate, bivariate, and multivariate analyses levels. Binary logistic regression analysis was used to determine factors independently associated with non-adherence to ART, reported using odds ratio (OR) and 95% confidence level (CI). The level of statistical significance was 5%. Results Of 381 participants, 25 (6.6%) were non-adherent to ART and this was significantly associated with alcohol consumption (Adjusted (aOR), 3.24; 95% CI, 1.24-8.34). Other factors namely being single/or never married (aOR, 1.97; 95% CI, 0.62-6.25), monthly income exceeding 27 dollars (aOR, 1.36; 95% CI, 0.52-3.55), being on ART for more than 5 years (aOR, 0.60; 95% CI, 0.23-1.59), receipt of health education on ART side effects (aOR, 0.36; 95% CI, 0.12-1.05), and disclosure of HIV status (aOR, 0.37; 95% CI, 0.04-3.20) were not associated with non-adherence in this setting. Conclusion Non-adherence to ART was low among PLHIV enrolled to community-based ART delivery model but increases with alcohol consumption. Accordingly, psychosocial support programs should focus on alcohol consumption.	[Adrawa, Norbert] AIDS Support Org, Ctr Clin Excellence, Gulu, Uganda; [Adrawa, Norbert] Islamic Univ Uganda, Fac Management Studies, Dept Business Studies, Mbale, Uganda; [Adrawa, Norbert; Alege, John Bosco; Izudi, Jonathan] Clarke Int Univ, Inst Publ Hlth & Management, Kampala, Uganda; [Izudi, Jonathan] Mbarara Univ Sci & Technol, Fac Med, Dept Community Hlth, Mbarara, Uganda	Mbarara University of Science & Technology	Izudi, J (corresponding author), Clarke Int Univ, Inst Publ Hlth & Management, Kampala, Uganda.; Izudi, J (corresponding author), Mbarara Univ Sci & Technol, Fac Med, Dept Community Hlth, Mbarara, Uganda.	jonahzd@gmail.com		Izudi, Jonathan/0000-0001-9065-0389; Adrawa, Norbert/0000-0003-3133-8840				Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Arya R, 2012, INDIAN J PEDIATR, V79, P1482, DOI 10.1007/s12098-012-0763-3; AVERT, 2019, IS THERE CURE HIV 20; Bajunirwe Francis, 2014, PLoS One, V9, pe113152, DOI 10.1371/journal.pone.0113152; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548; Centers for Diseases Control and Prevention (CDC), 2020, GLOB STAT GLOB HIV A; De Geest S, 2018, ANN INTERN MED, V169, P30, DOI 10.7326/M18-0543; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; HIV/AIDS JUNPo, 2014, 90 90 90 AMB TREATM, P33; Ickovics JR, 2002, ANTIVIR THER, V7, P185; Izudi J, 2016, J ONCOL, V2016, DOI 10.1155/2016/5473681; Lauritsen J, 2003, COMPREHENSIVE TOOL V; Low-Beer S, 2000, J ACQ IMMUN DEF SYND, V23, P295; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Mbonye M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078243; McNabb J, 2001, CLIN INFECT DIS, V33, P700, DOI 10.1086/322590; Morojele NK, 2014, AIDS BEHAV, V18, P519, DOI 10.1007/s10461-013-0583-0; Murray S, 2011, INT STUD REV, V13, P709, DOI 10.1111/j.1468-2486.2011.01079.x; Okoboi S, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.5.20841; Okoboi S, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0077-4; Oyugi J, 2003, ABSTRACT PRESENTED S; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Republic of Uganda, 2018, CONS GUID PREV TREAT; Republic of Uganda, 2020, CONS GUID PREV TREAT; StataCorp LP, 2017, STAT DAT AN STAT SOF, V15; The AIDS Support Organization (TASO), 2015, TASO GUL 2015; UNAIDS, 90 90 90 TREATM ALL; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wagner GJ, 2002, AIDS PATIENT CARE ST, V16, P599, DOI 10.1089/108729102761882134	32	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2020	15	11							e0242801	10.1371/journal.pone.0242801	http://dx.doi.org/10.1371/journal.pone.0242801			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA8EQ	33232369	Green Published, gold			2023-01-03	WOS:000595863100053
J	Liu, XJ; Bao, XH; Hu, MJ; Chang, HM; Jiao, M; Cheng, J; Xie, LY; Huang, Q; Li, F; Li, CY				Liu, Xinjian; Bao, Xuhui; Hu, Mengjie; Chang, Hanman; Jiao, Meng; Cheng, Jin; Xie, Liyi; Huang, Qian; Li, Fang; Li, Chuan-Yuan			Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer	NATURE			English	Article							T-CELLS; RECEPTOR; ANTIBODY; DEGRADATION; SAFETY; LDL; CHOLESTEROL; ALIROCUMAB; DECREASES; PATHWAY	Despite its success in achieving the long-term survival of 10-30% of treated individuals, immune therapy is still ineffective for most patients with cancer(1,2). Many efforts are therefore underway to identify new approaches that enhance such immune 'checkpoint' therapy(3-5) (so called because its aim is to block proteins that inhibit checkpoint signalling pathways in T cells, thereby freeing those immune cells to target cancer cells). Here we show that inhibiting PCSK9-a key protein in the regulation of cholesterol metabolism(6-8)-can boost the response of tumours to immune checkpoint therapy, through a mechanism that is independent of PCSK9's cholesterol-regulating functions. Deleting the PCSK9 gene in mouse cancer cells substantially attenuates or prevents their growth in mice in a manner that depends on cytotoxic T cells. It also enhances the efficacy of immune therapy that is targeted at the checkpoint protein PD1. Furthermore, clinically approved PCSK9-neutralizing antibodies synergize with anti-PD1 therapy in suppressing tumour growth in mouse models of cancer. Inhibiting PCSK9-either through genetic deletion or using PCSK9 antibodies-increases the expression of major histocompatibility protein class I (MHC I) proteins on the tumour cell surface, promoting robust intratumoral infiltration of cytotoxic T cells. Mechanistically, we find that PCSK9 can disrupt the recycling of MHC I to the cell surface by associating with it physically and promoting its relocation and degradation in the lysosome. Together, these results suggest that inhibiting PCSK9 is a promising way to enhance immune checkpoint therapy for cancer. Inhibiting the PCSK9 protein, a regulator of cholesterol metabolism, enhances immune checkpoint therapy in mouse models of cancer, in a manner that depends on the regulation of antigen-presenting MHC I molecules.	[Liu, Xinjian; Bao, Xuhui; Hu, Mengjie; Chang, Hanman; Jiao, Meng; Li, Fang; Li, Chuan-Yuan] Duke Univ, Med Ctr, Dept Dermatol, Durham, NC 27708 USA; [Liu, Xinjian] Sun Yat sen Univ, Sch Med, Dept Biochem, Mol Canc Res Ctr, Shenzhen, Guangdong, Peoples R China; [Cheng, Jin; Huang, Qian] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Mol Diagnost Lab Canc Ctr, Sch Med, Shanghai, Peoples R China; [Xie, Liyi] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Li, Chuan-Yuan] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Li, Chuan-Yuan] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27708 USA	Duke University; Sun Yat Sen University; Shanghai Jiao Tong University; Fudan University; Duke University; Duke University	Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Dermatol, Durham, NC 27708 USA.; Li, CY (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.; Li, CY (corresponding author), Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27708 USA.	Chuan.Li@duke.edu		Li, Chuan-Yuan/0000-0002-0418-6231; Jiao, Meng/0000-0001-6698-3482	US National Institutes of Health (NIH) [ES024015, CA208852, CA216876]; Cancer Center Support Grant (CCSG) [CA014236]; Guangdong Basic and Applied Basic Research Foundation [2020B1515020054]; Shenzhen Science and Technology Program grant [JCYJ20190807154813511]	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant (CCSG); Guangdong Basic and Applied Basic Research Foundation; Shenzhen Science and Technology Program grant	We thank J. M. Cook and colleagues at the Flow Cytometry Facility of Duke University School of Medicine for their assistance. We also thank the Duke University Light Microscopy Core Facility for professional help with confocal microscopy. We thank I. Li for proofreading our manuscript. We also thank S. Coffman of MedMedia Solutions for help with illustrations. C.-Y.L. is supported by US National Institutes of Health (NIH) grants ES024015, CA208852 and CA216876, and by a Cancer Center Support Grant (CCSG, CA014236) to Duke University. X.L. is supported by Guangdong Basic and Applied Basic Research Foundation grant 2020B1515020054 and Shenzhen Science and Technology Program grant JCYJ20190807154813511.	Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; Blom DJ, 2014, NEW ENGL J MED, V370, P1809, DOI 10.1056/NEJMoa1316222; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Canuel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064145; Carstens JL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15095; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan JCY, 2009, P NATL ACAD SCI USA, V106, P9820, DOI 10.1073/pnas.0903849106; Chandramohan V, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0614-0; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Curtsinger JM, 1998, J IMMUNOL, V160, P3236; Demers A, 2015, ARTERIOSCL THROM VAS, V35, P2517, DOI 10.1161/ATVBAHA.115.306032; Duff CJ, 2009, BIOCHEM J, V419, P577, DOI 10.1042/BJ20082407; Fasano T, 2009, ATHEROSCLEROSIS, V203, P166, DOI 10.1016/j.atherosclerosis.2008.10.027; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Jonas MC, 2008, EMBO REP, V9, P916, DOI 10.1038/embor.2008.132; Kim K, 2014, P NATL ACAD SCI USA, V111, P11774, DOI 10.1073/pnas.1410626111; Kuhnast S, 2014, J LIPID RES, V55, P2103, DOI 10.1194/jlr.M051326; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lagace TA, 2006, J CLIN INVEST, V116, P2995, DOI 10.1172/JCI29383; Ma EH, 2019, IMMUNITY, V51, P856, DOI 10.1016/j.immuni.2019.09.003; Ma XZ, 2018, J EXP MED, V215, P1555, DOI 10.1084/jem.20171576; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Maxwell KN, 2005, P NATL ACAD SCI USA, V102, P2069, DOI 10.1073/pnas.0409736102; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Park SJ, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0514-7; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Poirier S, 2008, J BIOL CHEM, V283, P2363, DOI 10.1074/jbc.M708098200; Poirier S, 2009, J BIOL CHEM, V284, P28856, DOI 10.1074/jbc.M109.037085; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shan LX, 2008, BIOCHEM BIOPH RES CO, V375, P69, DOI 10.1016/j.bbrc.2008.07.106; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Zhang DW, 2007, J BIOL CHEM, V282, P18602, DOI 10.1074/jbc.M702027200; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	45	97	99	23	122	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 24	2020	588	7839					693	+		10.1038/s41586-020-2911-7	http://dx.doi.org/10.1038/s41586-020-2911-7		NOV 2020	32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8KJ	33177715	Green Accepted			2023-01-03	WOS:000588617900002
J	Capizzi, J; Leahy, J; Wheelock, H; Garcia, J; Strnad, L; Sikka, M; Englander, H; Thomas, A; Korthuis, PT; Menza, TW				Capizzi, Jeffrey; Leahy, Judith; Wheelock, Haven; Garcia, Jonathan; Strnad, Luke; Sikka, Monica; Englander, Honora; Thomas, Ann; Korthuis, P. Todd; Menza, Timothy William			Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS INFECTIONS; UNITED-STATES; METHAMPHETAMINE; INCREASES; EPIDEMICS	Background Injection drug use has far-reaching social, economic, and health consequences. Serious bacterial infections, including skin/soft tissue infections, osteomyelitis, bacteremia, and endocarditis, are particularly morbid and mortal consequences of injection drug use. Methods We conducted a population-based retrospective cohort analysis of hospitalizations among patients with a diagnosis code for substance use and a serious bacterial infection during the same hospital admission using Oregon Hospital Discharge Data. We examined trends in hospitalizations and costs of hospitalizations attributable to injection drug use-related serious bacterial infections from January 1, 2008 through December 31, 2018. Results From 2008 to 2018, Oregon hospital discharge data included 4,084,743 hospitalizations among 2,090,359 patients. During the study period, hospitalizations for injection drug use-related serious bacterial infection increased from 980 to 6,265 per year, or from 0.26% to 1.68% of all hospitalizations (P0.001). The number of unique patients with an injection drug use-related serious bacterial infection increased from 839 to 5,055, or from 2.52% to 8.46% of all patients (P0.001). While hospitalizations for all injection drug use-related serious bacterial infections increased over the study period, bacteremia/sepsis hospitalizations rose most rapidly with an 18-fold increase. Opioid use diagnoses accounted for the largest percentage of hospitalizations for injection drug use-related serious bacterial infections, but hospitalizations for amphetamine-type stimulant-related serious bacterial infections rose most rapidly with a 15-fold increase. People living with HIV and HCV experienced increases in hospitalizations for injection drug use-related serious bacterial infection during the study period. Overall, the total cost of hospitalizations for injection drug use-related serious bacterial infections increased from $16,305,129 in 2008 to $150,879,237 in 2018 (P0.001). Conclusions In Oregon, hospitalizations for injection drug use-related serious bacterial infections increased dramatically and exacted a substantial cost on the health care system from 2008 to 2018. This increase in hospitalizations represents an opportunity to initiate substance use disorder treatment and harm reduction services to improve outcomes for people who inject drugs.	[Capizzi, Jeffrey; Leahy, Judith; Thomas, Ann; Korthuis, P. Todd; Menza, Timothy William] Oregon Hlth Author, Publ Hlth Div, Portland, OR 97232 USA; [Wheelock, Haven] OutsideIn, Portland, OR USA; [Garcia, Jonathan] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA; [Strnad, Luke; Sikka, Monica; Englander, Honora; Korthuis, P. Todd; Menza, Timothy William] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA	Oregon State University; Oregon Health & Science University	Menza, TW (corresponding author), Oregon Hlth Author, Publ Hlth Div, Portland, OR 97232 USA.; Menza, TW (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.	TIMOTHY.W.MENZA@dhsoha.state.or.us		Menza, Timothy/0000-0003-4154-7718; Korthuis, Philip/0000-0001-5556-3597	NIH National Institute on Drug Abuse [UH3DA044831, U01TR002631, UG1DA015815]	NIH National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	This work was supported by grants from the NIH National Institute on Drug Abuse (UH3DA044831, U01TR002631, UG1DA015815) to PTK. The URL for the National Institute on Drug Abuse is drugabuse.gov. The funder had no role in study design, implementation, analysis, or manuscript review.	Alemayehu B, 2004, HEALTH SERV RES, V39, P627, DOI 10.1111/j.1475-6773.2004.00248.x; [Anonymous], 3330190005 OAR; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; [Anonymous], 2019, HIV INCREASES 2019 P; [Anonymous], RUR FRONT DAT; [Anonymous], 2015, COMMUNITY OUTBREAK H; Barocas JA, 2020, CLIN INFECT DIS PUBL, DOI [10.1093/cid/ciaa1346, DOI 10.1093/CID/CIAA134632901815]; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Bottner R, 2020, J ADDICT MED, V14, P178, DOI 10.1097/ADM.0000000000000545; Collins D, 2019, J GEN INTERN MED, DOI 10.1007/s11606-019-05311-0; Ellis MS, 2018, DRUG ALCOHOL DEPEN, V193, P14, DOI 10.1016/j.drugalcdep.2018.08.029; Englander H, 2019, J GEN INTERN MED, V34, P2796, DOI 10.1007/s11606-019-05251-9; Englander H, 2019, J ADDICT MED, V13, P85, DOI 10.1097/ADM.0000000000000487; Englander H, 2017, J HOSP MED, V12, P339, DOI 10.12788/jhm.2736; Furukawa NW, CLIN INFECT DIS, DOI 10.1093/cid/ciaa507/5829012; Gbinigie OA, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1205-0; Gray ME, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3408-y; Jackson KA, 2018, MMWR-MORBID MORTAL W, V67, P625, DOI 10.15585/mmwr.mm6722a2; Keeshin SW, 2016, AM J MED SCI, V352, P609, DOI 10.1016/j.amjms.2016.10.002; Kidd SE, 2019, MMWR-MORBID MORTAL W, V68, P144, DOI 10.15585/mmwr.mm6806a4; Kropenske V, 1994, PROTECTING CHILDREN, DOI DOI 10.1037/E300212004-001; Kuo YF, 2018, J AM GERIATR SOC, V66, P945, DOI 10.1111/jgs.15332; Larochelle MR, 2019, DRUG ALCOHOL DEPEN, V204, DOI 10.1016/j.drugalcdep.2019.06.039; Leahy J, 2019, CD SUMMARY SEX DRUGS; Lopez A. M., 2019, COUSE METHAMPHETAMIN; Marks LR, 2019, CLIN INFECT DIS, V68, P1935, DOI 10.1093/cid/ciy924; National Institute on Drug Abuse, 2020, OR OP INV DEATHS REL; OHA Public Health Division, 2018, HIV INF OR, P6; Oregon Health Authority, HOSP REP PROGR OFF H; Oregon Health Authority, PRESCR OV DAT OR OP; Oregon Workers' Compensation Division, MED FEE SCHED MED ST; Paquette CE, 2018, INT J DRUG POLICY, V57, P104, DOI 10.1016/j.drugpo.2018.04.004; Peters PJ, 2016, NEW ENGL J MED, V375, P229, DOI 10.1056/NEJMoa1515195; Price CN, 2020, J INFECT DIS, V222, pS494, DOI 10.1093/infdis/jiaa025; Robles F., 2018, NEW YORK TIMES; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Schranz A, 2018, ANN INTERN MED, DOI [10.7326/M18-2124, DOI 10.7326/M18-2124]; Serota DP, 2020, CLIN INFECT DIS, V70, P968, DOI 10.1093/cid/ciz804; Springer SA, 2018, ANN INTERN MED, V169, P335, DOI 10.7326/M18-1203; Suzuki J, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy194; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Tookes H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129360; Velez CM, 2017, J GEN INTERN MED, V32, P296, DOI 10.1007/s11606-016-3919-4; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Weinstein ZM, 2020, DRUG ALCOHOL DEPEN, V213, DOI 10.1016/j.drugalcdep.2020.108081; Winkelman TNA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3758; Zibbell JE, 2018, AM J PUBLIC HEALTH, V108, P175, DOI 10.2105/AJPH.2017.304132	47	24	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2020	15	11							e0242165	10.1371/journal.pone.0242165	http://dx.doi.org/10.1371/journal.pone.0242165			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OV7JZ	33166363	gold, Green Published			2023-01-03	WOS:000592382600066
J	Franz, M; Schmidt, B; Hecht, H; Naumann, E; Miltner, WHR				Franz, Marcel; Schmidt, Barbara; Hecht, Holger; Naumann, Ewald; Miltner, Wolfgang H. R.			Suggested deafness during hypnosis and simulation of hypnosis compared to a distraction and control condition: A study on subjective experience and cortical brain responses	PLOS ONE			English	Article							EVENT-RELATED POTENTIALS; HARVARD GROUP SCALE; INTRACEREBRAL POTENTIALS; HYPNOTIC DEAFNESS; VISUAL-STIMULI; RARE TARGET; NEURAL GENERATORS; P300; PAIN; ATTENTION	Hypnosis is a powerful tool to affect the processing and perception of stimuli. Here, we investigated the effects of hypnosis on the processing of auditory stimuli, the time course of event-related-potentials (ERP; N1 and P3b amplitudes) and the activity of cortical sources of the P3b component. Forty-eight participants completed an auditory oddball paradigm composed of standard, distractor, and target stimuli during a hypnosis (HYP), a simulation of hypnosis (SIM), a distraction (DIS), and a control (CON) condition. During HYP, participants were suggested that an earplug would obstruct the perception of tones and during SIM they should pretend being hypnotized and obstructed to hear the tones. During DIS, participants' attention was withdrawn from the tones by focusing participants' attention onto a film. In each condition, subjects were asked to press a key whenever a target stimulus was presented. Behavioral data show that target hit rates and response time became significantly reduced during HYP and SIM and loudness ratings of tones were only reduced during HYP. Distraction from stimuli by the film was less effective in reducing target hit rate and tone loudness. Although, the N1 amplitude was not affected by the experimental conditions, the P3b amplitude was significantly reduced in HYP and SIM compared to CON and DIS. In addition, source localization results indicate that only a small number of neural sources organize the differences of tone processing between the control condition and the distraction, hypnosis, and simulation of hypnosis conditions. These sources belong to brain areas that control the focus of attention, the discrimination of auditory stimuli, and the organization of behavioral responses to targets. Our data confirm that deafness suggestions significantly change auditory processing and perception but complete deafness is hard to achieve during HYP. Therefore, the term 'deafness' may be misleading and should better be replaced by 'hypoacusis'.	[Franz, Marcel; Schmidt, Barbara; Hecht, Holger; Miltner, Wolfgang H. R.] Friedrich Schiller Univ Jena, Inst Psychol, Jena, Germany; [Naumann, Ewald] Univ Trier, Inst Psychol, Trier, Germany; [Miltner, Wolfgang H. R.] Friedrich Schiller Univ Jena, Med Fac, Jena, Germany	Friedrich Schiller University of Jena; Universitat Trier; Friedrich Schiller University of Jena	Franz, M (corresponding author), Friedrich Schiller Univ Jena, Inst Psychol, Jena, Germany.	wolfgang.miltner@uni-jena.de	Schmidt, Barbara/AAH-4517-2020	Schmidt, Barbara/0000-0002-6828-5546	Deutsche Forschungsgemeinschaft (DFG) [MI 265/15-1, NA 482/5-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Grant number: MI 265/15-1 awarded to Miltner, Wolfgang H.R. NA 482/5-1 awarded to Naumann, Ewald. Name of funder: Deutsche Forschungsgemeinschaft (DFG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accardi MC, 2009, J BEHAV MED, V32, P328, DOI 10.1007/s10865-009-9207-6; Barabasz A, 1999, INT J CLIN EXP HYP, V47, P5, DOI 10.1080/00207149908410019; BARBER T X, 1972, American Journal of Clinical Hypnosis, V15, P112; BARBER TX, 1963, J ABNORM PSYCHOL, V67, P557, DOI 10.1037/h0047040; BARBER TX, 1965, PSYCHOL REP, V16, P809, DOI 10.2466/pr0.1965.16.3.809; BARBER TX, 1964, BRIT J PSYCHOL, V55, P439, DOI 10.1111/j.2044-8295.1964.tb00930.x; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; BECK EC, 1965, J NERV MENT DIS, V140, P154, DOI 10.1097/00005053-196502000-00005; Bigdely-Shamlo N, 2013, IEEE ENG MED BIO, P5845, DOI 10.1109/EMBC.2013.6610881; Blundon EG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173237; BONGARTZ W, 1985, INT J CLIN EXP HYP, V33, P131, DOI 10.1080/00207148508406643; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen XF, 2018, J PAIN RES, V11, P1921, DOI 10.2147/JPR.S174490; Clarke JM, 1999, CLIN NEUROPHYSIOL, V110, P1226, DOI 10.1016/S1388-2457(99)00064-4; Coull JT, 1998, PROG NEUROBIOL, V55, P343, DOI 10.1016/S0301-0082(98)00011-2; Cox RE, 2008, ADV HYPNOSIS RES MET, P311; CRAWFORD HJ, 1979, AM J PSYCHOL, V92, P193, DOI 10.2307/1421920; De Angelis V, 2018, NEUROIMAGE, V180, P291, DOI 10.1016/j.neuroimage.2017.11.020; De Pascalis V, 2000, INT J CLIN EXP HYP, V48, P44, DOI 10.1080/00207140008410360; DEECKE L, 1976, BIOL CYBERN, V23, P99, DOI 10.1007/BF00336013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Delorme A, 2007, NEUROIMAGE, V34, P1443, DOI 10.1016/j.neuroimage.2006.11.004; Dynes JB, 1932, J ABNORM SOC PSYCH, V27, P79, DOI 10.1037/h0073199; Erickson MH, 1939, J GEN PSYCHOL, V20, P61, DOI 10.1080/00221309.1939.9709999; Erickson MH, 1938, J GEN PSYCHOL, V19, P151, DOI 10.1080/00221309.1938.9711192; FIELD PETER B., 1965, INT J CLIN EXP HYPN, V13, P238, DOI 10.1080/00207146508412946; Fischli P, 1987, LAUF DINGE; Franz M, SUGGESTED BLINDNESS; Friederich M, 2001, PSYCHOPHYSIOLOGY, V38, P768, DOI 10.1017/S0048577201000221; Glaesmer H, 2015, PATIENT EDUC COUNS, V98, P1112, DOI 10.1016/j.pec.2015.05.007; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Herrmann CS, 2001, NEUROSCI BIOBEHAV R, V25, P465, DOI 10.1016/S0149-7634(01)00027-6; Hof W. J. op ' t, 1993, ZWOLS HIST TIJDSCHRI, V10, P22; Jegindo EME, 2013, INT J PSYCHOL RELIG, V23, P171, DOI 10.1080/10508619.2012.759065; Jensen MP, 2017, NEUROSCI CONSCIOUS, V3, DOI 10.1093/nc/nix004; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1111/1469-8986.3720163; Kanwisher N, 2010, P NATL ACAD SCI USA, V107, P11163, DOI 10.1073/pnas.1005062107; Katayama J, 1996, INT J PSYCHOPHYSIOL, V23, P33, DOI 10.1016/0167-8760(96)00030-X; Katayama J, 1996, EVOKED POTENTIAL, V100, P555, DOI 10.1016/S0168-5597(96)95171-0; Kiehl KA, 2001, J PSYCHOPHYSIOL, V15, P221, DOI 10.1027//0269-8803.15.4.221; Kiehl KA, 2001, PSYCHOPHYSIOLOGY, V38, P133, DOI 10.1017/S0048577201981867; Kihlstrom J.F., 2012, OXFORD HDB HYPNOSIS, P21, DOI [DOI 10.1093/OXFORDHB/9780198570097.013.0002, 10.1093/oxfordhb/9780198570097.013.0002]; Kihlstrom JF, 2003, INT J CLIN EXP HYP, V51, P166, DOI 10.1076/iceh.51.2.166.14611; Kihlstrom JF, 2013, CORTEX, V49, P365, DOI 10.1016/j.cortex.2012.05.016; Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5; Kiss G, 2011, ANAESTH INTENS CARE, V39, P1139, DOI 10.1177/0310057X1103900626; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Kolassa IT, 2007, COGNITION EMOTION, V21, P1721, DOI 10.1080/02699930701229189; Kolassa IT, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-38; Kolassa IT, 2007, BEHAV BRAIN FUNCT, V3, DOI 10.1186/1744-9081-3-59; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Kosslyn SM, 2000, AM J PSYCHIAT, V157, P1279, DOI 10.1176/appi.ajp.157.8.1279; Kujala T, 2010, PROG NEUROBIOL, V91, P55, DOI 10.1016/j.pneurobio.2010.01.006; Lakens Daniel, 2013, Front Psychol, V4, P863, DOI 10.3389/fpsyg.2013.00863; Larbig W, 2013, ALLGEMEINARZT, V35, P60; Larbig W, 2015, PSYCHOPHYSIOLOGY EXZ, P279; Lima CF, 2016, TRENDS NEUROSCI, V39, P527, DOI 10.1016/j.tins.2016.06.003; Litvak V, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/852961; Lynn S., 2012, OXFORD HDB HYPNOSIS, P111, DOI DOI 10.1093/OXFORDHB/9780198570097.013.0005; Lynn SJ, 2012, SOCIAL COGNITIVE THE, P111; MEIER W, 1993, PAIN, V53, P175, DOI 10.1016/0304-3959(93)90078-4; MILTNER W, 1989, PAIN, V38, P303, DOI 10.1016/0304-3959(89)90217-0; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Miltner WHR, 2006, PROGR PSYCHOL SCI WO; Moerel M, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00225; Montenegro G, 2017, AM J CLIN HYPN, V59, P414, DOI 10.1080/00029157.2016.1172057; ORNE M, 1971, INT J CLIN EXP HYP, V19, P183, DOI 10.1080/00207147108407167; ORNE MT, 1962, AM PSYCHOL, V17, P776, DOI 10.1037/h0043424; Plakke B, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00199; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; R Core Team, 2021, R LANG ENV STAT COMP; Riegel B, 2018, VERHALTENSTHERAPIE, V28, P44, DOI 10.1159/000464339; Sarbin T.R., 1972, HYPNOSIS SOCIAL PSYC; SCHEIBE KE, 1968, INT J CLIN EXP HYP, V16, P158, DOI 10.1080/00207146808410587; Schmidt B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05195-2; Schuler G, 1996, HYPN KOGN, V13, P79; Shadish WR, 2003, EXPT QUASIEXPERIMENT, DOI [10.1111/j.1752-0606.2003.tb01694.x, DOI 10.1111/J.1752-0606.2003.TB01694.X]; SPANOS NP, 1992, J ABNORM PSYCHOL, V101, P192, DOI 10.1037/0021-843X.101.1.192; SPANOS NP, 1974, AM PSYCHOL, V29, P500, DOI 10.1037/h0036795; SPANOS NP, 1982, J ABNORM PSYCHOL, V91, P75, DOI 10.1037/0021-843X.91.1.75; Tervaniemi M, 1997, NEUROREPORT, V8, P2571, DOI 10.1097/00001756-199707280-00030; Trippe RH, 2004, ANASTH INTENSIVMED, V45, P642; Verleger R, 2020, PSYCHOPHYSIOLOGY, V57, DOI 10.1111/psyp.13542; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; Willford AC, 2018, PAC AFF, V91, P644; Wronka E, 2012, ACTA NEUROBIOL EXP, V72, P51	92	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0240832	10.1371/journal.pone.0240832	http://dx.doi.org/10.1371/journal.pone.0240832			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PG8YH	33119665	Green Published, gold			2023-01-03	WOS:000600013600006
J	Zanoni, BC; Archary, M; Sibaya, T; Musinguzi, N; Haberer, JE				Zanoni, Brian C.; Archary, Moherndran; Sibaya, Thobekile; Musinguzi, Nicholas; Haberer, Jessica E.			Transition from pediatric to adult care for adolescents living with HIV in South Africa: A natural experiment and survival analysis	PLOS ONE			English	Article							YOUNG-ADULTS; INFECTED ADOLESCENTS; OUTCOMES; PEOPLE; HEALTH	Objective To determine rates of retention and viral suppression among adolescents living with perinatally-acquired HIV who remained in pediatric care compared to those who transitioned to adult care. Methods We evaluated a natural experiment involving adolescents living with perinatally-acquired HIV who were attending a government-supported antiretroviral clinic in KwaZulu-Natal, South Africa. Prior to 2011, all adolescents transitioned to adult care at 12 years of age. Due to a policy change, all adolescents were retained in pediatric care after 2011. We analyzed adolescents two years before and two years after this policy change. Outcomes were retention in care and HIV viral suppression one year after transition to adult care or the 13(th) birthday if remaining in pediatric care. Results In the natural experiment, 180 adolescents who turned 12 years old between 2011 and 2014 were evaluated; 35 (20%) transitioned to adult care under the old policy and 145 (80%) remained in pediatric care under the new policy. Adolescents who transitioned to the adult clinic had lower rates of retention in care (49%; 17/35) compared to adolescents remaining in the pediatric clinic (92%; 134/145; p<0.001). Retention in care was lower (ARR 0.59; 95%CI 0.43-0.82; p = 0.001) and viral suppression was similar (ARR = 1.06, 95%CI 0.89-1.26; p = 0.53) for adolescents who transitioned to adult care compared to adolescents remaining in pediatric care. Conclusion Adolescents living with perinatally-acquired HIV appear to have higher retention in care when cared for in pediatric clinics compared to adult clinics. Longer-term follow-up is needed to fully assess viral suppression.	[Zanoni, Brian C.] Emory Univ, Atlanta, GA 30322 USA; [Zanoni, Brian C.; Haberer, Jessica E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Zanoni, Brian C.; Haberer, Jessica E.] Harvard Med Sch, Boston, MA 02115 USA; [Archary, Moherndran; Sibaya, Thobekile] Univ KwaZulu Natal, Nelson Mandela Sch Med, Durban, South Africa; [Musinguzi, Nicholas] Mbarara Univ Sci & Technol, Mbarara, Uganda	Emory University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Kwazulu Natal; Mbarara University of Science & Technology	Zanoni, BC (corresponding author), Emory Univ, Atlanta, GA 30322 USA.; Zanoni, BC (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.; Zanoni, BC (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	bzanoni@emory.edu	Zanoni, Brian/AAI-4916-2021	Zanoni, Brian/0000-0002-8640-7703; Archary, Moherndran/0000-0003-3082-9234	Harvard Catalyst [4KL2 TR00110004]; National Institute on Mental Health [K24MH114732]	Harvard Catalyst; National Institute on Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	BCZ, Harvard Catalyst, 4KL2 TR00110004, https://catalyst.harvard.edu JEH, National Institute on Mental Health, K24MH114732, https://www.nimh.nih.gov/index.shtml The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anabwani G, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0643-5; Andiman WA, 2011, J PEDIATR-US, V159, P714, DOI 10.1016/j.jpeds.2011.06.040; Brousseau DC, 2010, JAMA-J AM MED ASSOC, V303, P1288, DOI 10.1001/jama.2010.378; Cervia JS, 2013, AIDS PATIENT CARE ST, V27, P692, DOI 10.1089/apc.2013.0253; Cohen J, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e8; Davies Mary-Ann, 2017, J Int AIDS Soc, V20, P21668, DOI 10.7448/IAS.20.4.21668; Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365, DOI DOI 10.1016/J.JACR.2018.09.023; Fish R, 2014, HIV MED, V15, P239, DOI 10.1111/hiv.12091; Funck-Brentano I, 2005, AIDS, V19, P1501, DOI 10.1097/01.aids.0000183124.86335.0a; Haghighat R, 2019, JAIDS-J ACQ IMM DEF, V82, P166, DOI 10.1097/QAI.0000000000002125; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Hunt SE, 2010, JAMA-J AM MED ASSOC, V304, P408, DOI 10.1001/jama.2010.1026; Izzo I, 2018, AIDS RES HUM RETROV, V34, P241, DOI [10.1089/aid.2017.0120, 10.1089/AID.2017.0120]; Jensen PT, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0197-6; Joint Unitied Nations Programme on HIV/AIDS, 2015, AMB TREATM TARG WRIT; Judd A, 2018, CURR OPIN HIV AIDS, V13, P236, DOI [10.1097/COH.0000000000000448, 10.1097/coh.0000000000000448]; Judd A, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21577; Maskew M, 2019, LANCET HIV, V6, pE760, DOI 10.1016/S2352-3018(19)30234-6; Menon A, 2007, JAIDS-J ACQ IMM DEF, V46, P349, DOI 10.1097/QAI.0b013e3181565df0; Pierce JE, 2017, INT J STROKE, V12, P7; Ryscavage P, 2016, AIDS CARE, V28, P561, DOI 10.1080/09540121.2015.1131967; Ryscavage PA, 2011, JAIDS-J ACQ IMM DEF, V58, P193, DOI [10.1097/QAI.0B013E31822D7564, 10.1097/QAI.0b013e31822d7564]; Sherman GG, 2014, SAMJ S AFR MED J, V104, P235, DOI [10.7196/SAMJ.7598, 10.7196/samj.7598]; Sherr L, 2018, AIDS CARE, V30, P92, DOI 10.1080/09540121.2018.1476664; Sobota A, 2014, J PEDIAT HEMATOL ONC, V36, P389, DOI 10.1097/MPH.0000000000000110; South Africa National Department of Health, 2018, NAT CONS GUID PREV M; South African National Department of Health, 2012, 2012 NAT ANT SENT HI; Statistics South Africa, 2013, REC LIV BIRTHS 2013; Tanner AE, 2018, J ADOLESCENT HEALTH, V63, P157, DOI 10.1016/j.jadohealth.2018.02.004; Tassiopoulos K, 2019, CLIN INFECT DIS, DOI [10.1093/cid/ciz747, DOI 10.1093/CID/CIZ74731584617]; Teasdale CA, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21748; the SABSSM V Team, 2019, S AFRICAN NATL HIV P; Toth G, 2018, AIDS RES THER, V15, DOI 10.1186/s12981-018-0195-x; Tsondai PR, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25447; Weijsenfeld AM, 2016, CLIN INFECT DIS, V63, P1105, DOI 10.1093/cid/ciw487; WHO, 2013, HIV AD GUID HIV TEST; Xia Q, 2018, AIDS, V32, P1821, DOI [10.1097/QAD.0000000000001923, 10.1097/qad.0000000000001923]; Zanoni BC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190260; Zanoni BC, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000004; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0240918	10.1371/journal.pone.0240918	http://dx.doi.org/10.1371/journal.pone.0240918			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8WV	33108396	Green Published, gold			2023-01-03	WOS:000588372400041
J	Bruk, LA; Dunkelberger, KE; Khampang, P; Hong, WZ; Sadagopan, S; Alper, CM; Fedorchak, MV				Bruk, Liza A.; Dunkelberger, Katherine E.; Khampang, Pawjai; Hong, Wenzhou; Sadagopan, Srivatsun; Alper, Cuneyt M.; Fedorchak, Morgan V.			Controlled release of ciprofloxacin and ceftriaxone from a single ototopical administration of antibiotic-loaded polymer microspheres and thermoresponsive gel	PLOS ONE			English	Article							ACUTE OTITIS-MEDIA; 3-DAY INTRAMUSCULAR CEFTRIAXONE; IN-VITRO; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; DRUG-DELIVERY; ANTIMICROBIAL AGENTS; CLINICAL-EFFICACY; HEARING-LOSS; SUSCEPTIBILITIES	Acute otitis media (AOM) is the main indication for pediatric antibiotic prescriptions, accounting for 25% of prescriptions. While the use of topical drops can minimize the administered dose of antibiotic and adverse systemic effects compared to oral antibiotics, their use has limitations, partially due to low patient compliance, high dosing frequency, and difficulty of administration. Lack of proper treatment can lead to development of chronic OM, which may require invasive interventions. Previous studies have shown that gel-based drug delivery to the ear is possible with intratympanic injection or chemical permeation enhancers (CPEs). However, many patients are reluctant to accept invasive treatments and CPEs have demonstrated toxicity to the tympanic membrane (TM). We developed a novel method of delivering therapeutics to the TM and middle ear using a topical, thermoresponsive gel depot containing antibiotic-loaded poly(lactic-co-glycolic acid) microspheres. Ourin vitroandex vivoresults suggest that the sustained presentation can safely allow therapeutically relevant drug concentrations to penetrate the TM to the middle ear for up to 14 days. Animal results indicate sufficient antibiotic released for treatment from topical administration 24h after bacterial inoculation. However, animals treated 72h after inoculation, a more clinically relevant treatment practice, displayed spontaneous clearance of infection as is also often observed in the clinic. Despite this variability in the disease model, data suggest the system can safely treat bacterial infection, with future studies necessary to optimize microsphere formulations for scaled up dosage of antibiotic as well as further investigation of the influence of spontaneous bacterial clearance and of biofilm formation on effectiveness of treatment. To our knowledge, this study represents the first truly topical drug delivery system to the middle ear without the use of CPEs.	[Bruk, Liza A.; Dunkelberger, Katherine E.; Sadagopan, Srivatsun; Fedorchak, Morgan V.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA; [Khampang, Pawjai; Hong, Wenzhou] Med Coll Wisconsin, Dept Otolaryngol & Commun Sci, Milwaukee, WI 53226 USA; [Sadagopan, Srivatsun] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA; [Alper, Cuneyt M.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Alper, Cuneyt M.] UPMC Childrens Hosp Pittsburgh, Div Pediat Otolaryngol, Pittsburgh, PA 15224 USA; [Alper, Cuneyt M.; Fedorchak, Morgan V.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA; [Fedorchak, Morgan V.] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA; [Fedorchak, Morgan V.] Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fedorchak, MV (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.; Fedorchak, MV (corresponding author), Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA.; Fedorchak, MV (corresponding author), Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA.; Fedorchak, MV (corresponding author), Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA.	fedorchak@pitt.edu		Bruk, Liza/0000-0003-1202-1629	University of Pittsburgh Center for Medical Innovation; Eye and Ear Foundation of Pittsburgh; Research to Prevent Blindness; NIH [CORE P30 EY008098]	University of Pittsburgh Center for Medical Innovation; Eye and Ear Foundation of Pittsburgh; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by funding to MVF from the University of Pittsburgh Center for Medical Innovation (https://www.engineering.pitt.edu/cmi/), the Eye and Ear Foundation of Pittsburgh (https://eyeandear.org/), an unrestricted grant from Research to Prevent Blindness (https://www.rpbusa.org/rpb/), and NIH CORE P30 EY008098 (https://www.nei.nih.gov/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGIUS AM, 1994, CLIN OTOLARYNGOL, V19, P138, DOI 10.1111/j.1365-2273.1994.tb01198.x; Ahn JY, 2008, CLIN EXP OTORHINOLAR, V1, P139, DOI 10.3342/ceo.2008.1.3.139; Al-mahallawi AM, 2014, INT J PHARMACEUT, V472, P304, DOI 10.1016/j.ijpharm.2014.06.041; Albuquerque Agnes Afrodite Sumarelli, 2009, Rev. Bras. Otorrinolaringol., V75, P43, DOI 10.1590/S0034-72992009000100007; Amali Amin, 2017, Electron Physician, V9, P3823, DOI 10.19082/3823; [Anonymous], 2018, LANCET PUBLIC HEALTH, V3, pE153, DOI 10.1016/S2468-2667(18)30053-7; [Anonymous], 2012, REGEN MED S3, V7, pS14; [Anonymous], 1987, CETR; [Anonymous], 2018, OECD GUIDELINES TEST; Bakaletz LO, 2007, PEDIATR INFECT DIS J, V26, pS17, DOI 10.1097/INF.0b013e318154b273; Belfield K, 2015, INT J PEDIATR OTORHI, V79, P296, DOI 10.1016/j.ijporl.2015.01.003; Bluestone CD, 1998, INT J PEDIATR OTORHI, V42, P207, DOI 10.1016/S0165-5876(97)00147-X; Bolt P, 2008, ARCH DIS CHILD, V93, P40, DOI 10.1136/adc.2006.110429; Cohen R, 1999, PEDIATR INFECT DIS J, V18, P403, DOI 10.1097/00006454-199905000-00002; da Costa SS, 2009, EUR ARCH OTO-RHINO-L, V266, P221, DOI 10.1007/s00405-008-0739-0; Daniel M, 2012, ARCH OTOLARYNGOL, V138, P942, DOI 10.1001/archotol.2013.238; England RJA, 2000, J LARYNGOL OTOL, V114, P24, DOI 10.1258/0022215001903834; Fedorchak MV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09379-8; Fedorchak MV, 2014, EXP EYE RES, V125, P210, DOI 10.1016/j.exer.2014.06.013; Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001; Fradis M, 1997, ARCH OTOLARYNGOL, V123, P1057; Furue M, 2015, BRIT J DERMATOL, V172, P272, DOI 10.1111/bjd.13377; Gan CW, 2013, LARYNGOSCOPE, V123, P1770, DOI 10.1002/lary.23895; Gates GA, 2001, PEDIATR INFECT DIS J, V20, P104, DOI 10.1097/00006454-200101000-00038; Gates GA, 1996, OTOLARYNG HEAD NECK, V114, P525, DOI 10.1016/S0194-5998(96)70243-7; Gehanno P, 1999, ANTIMICROB AGENTS CH, V43, P16, DOI 10.1128/AAC.43.1.16; Gimeno M, 2015, EUR J PHARM BIOPHARM, V96, P264, DOI 10.1016/j.ejpb.2015.08.007; Gray RF, 2005, CLIN OTOLARYNGOL, V30, P105, DOI 10.1111/j.1365-2273.2004.00950.x; GREEN SM, 1993, PEDIATRICS, V91, P23; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Hoberman A, 2016, NEW ENGL J MED, V375, P2446, DOI 10.1056/NEJMoa1606043; Hong WZ, 2007, INFECT IMMUN, V75, P958, DOI 10.1128/IAI.01691-06; Hong WZ, 2019, INT J PEDIATR OTORHI, V125, P134, DOI 10.1016/j.ijporl.2019.07.002; Hong WZ, 2009, J INNATE IMMUN, V1, P215, DOI 10.1159/000205937; Jang CH, 2003, INT J PEDIATR OTORHI, V67, P313, DOI 10.1016/S0165-5876(03)00033-8; Jensen RG, 2013, INT J PEDIATR OTORHI, V77, P1530, DOI 10.1016/j.ijporl.2013.06.025; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Khoo XJ, 2013, BIOMATERIALS, V34, P1281, DOI 10.1016/j.biomaterials.2012.10.025; Klouda L, 2008, EUR J PHARM BIOPHARM, V68, P34, DOI 10.1016/j.ejpb.2007.02.025; Kundu B, 2010, PHARM RES-DORDR, V27, P1659, DOI 10.1007/s11095-010-0166-y; Kurabi A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30031-6; Kurabi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep22663; Leibovitz E, 2000, PEDIATR INFECT DIS J, V19, P1040, DOI 10.1097/00006454-200011000-00003; Leibovitz E, 1998, PEDIATR INFECT DIS J, V17, P1126, DOI 10.1097/00006454-199812000-00005; Li WJ, 2015, BIOMED REP, V3, P617, DOI 10.3892/br.2015.481; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; Lim D. J., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P101; Mair EA, 2016, ANN OTO RHINOL LARYN, V125, P105, DOI 10.1177/0003489415599001; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; Mammen A, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.12; Minovi Amir, 2014, GMS Curr Top Otorhinolaryngol Head Neck Surg, V13, pDoc11, DOI 10.3205/cto000114; Mittal R, 2014, INT J INFECT DIS, V29, P259, DOI 10.1016/j.ijid.2014.10.015; Mujica-Mota MA, 2015, LARYNGOSCOPE, V125, P1444, DOI 10.1002/lary.25080; Natsch A, 2011, TOXICOL IN VITRO, V25, P733, DOI 10.1016/j.tiv.2010.12.014; Nwokoye NN, 2015, J LARYNGOL OTOL, V129, P779, DOI 10.1017/S0022215115001127; Onusko E, 2004, AM FAM PHYSICIAN, V70, P1713; Pacifici GM, 2017, INT J PEDIATR-MASSHA, V5, P6383, DOI 10.22038/ijp.2017.26942.2320; Pichichero ME, 2013, PEDIATR CLIN N AM, V60, P391, DOI 10.1016/j.pcl.2012.12.007; Piu F, 2011, OTOL NEUROTOL, V32, P171, DOI 10.1097/MAO.0b013e3182009d29; Pollock JF, 2010, ACTA BIOMATER, V6, P1307, DOI 10.1016/j.actbio.2009.11.027; Prasad S, 2008, J FAM PRACTICE, V57, P370; Rothstein SN, 2011, J MATER CHEM, V21, P29, DOI 10.1039/c0jm01668c; Samarei R, 2014, Glob J Health Sci, V6, P144, DOI 10.5539/gjhs.v6n7p144; SHANKS JE, 1981, J SPEECH HEAR RES, V24, P557, DOI 10.1044/jshr.2404.557; Siegel RM, 2010, PEDIATRICS, V125, P384, DOI 10.1542/peds.2009-3208; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; Thornsberry C, 1999, ANTIMICROB AGENTS CH, V43, P2612, DOI 10.1128/AAC.43.11.2612; Vergison A, 2010, LANCET INFECT DIS, V10, P195, DOI 10.1016/S1473-3099(10)70012-8; Wang XB, 2014, OTOL NEUROTOL, V35, P459, DOI 10.1097/MAO.0000000000000261; Wilson SL, 2015, TOXICOLOGY, V327, P32, DOI 10.1016/j.tox.2014.11.003; World Health Organization, 2017, DEPR OTH COMM MENT D; Yang R, 2019, MOL PHARMACEUT, V16, P1555, DOI 10.1021/acs.molpharmaceut.8b01235; Yang R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf4363; Yokell Z, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4030410	74	6	6	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2020	15	10							e0240535	10.1371/journal.pone.0240535	http://dx.doi.org/10.1371/journal.pone.0240535			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TU	33045028	Green Published, gold			2023-01-03	WOS:000581811700041
J	Colton, BS; Hornstein, N; Timmerman, J; Larson, S; Glaspy, J				Colton, B. Scott; Hornstein, Nicholas; Timmerman, John; Larson, Sarah; Glaspy, John			Nivolumab Treatment of Burkitt Lymphoma: A Case Report	ANNALS OF INTERNAL MEDICINE			English	Letter									[Colton, B. Scott; Hornstein, Nicholas; Timmerman, John; Larson, Sarah; Glaspy, John] Univ Calif Los Angeles, 100 UCLA Med Plaza,Suites 550 & 555, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Colton, BS (corresponding author), Univ Calif Los Angeles, 100 UCLA Med Plaza,Suites 550 & 555, Los Angeles, CA 90095 USA.	bscolton@mednet.ucla.edu						Ansell SM, 2019, J CLIN ONCOL, V37, P481, DOI 10.1200/JCO.18.00766; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Armand P, 2019, J CLIN ONCOL, V37, P3291, DOI 10.1200/JCO.19.01389; Dunleavy K, 2018, J ONCOL PRACT, V14, P665, DOI 10.1200/JOP.18.00148; Magrath I, 1996, J CLIN ONCOL, V14, P925, DOI 10.1200/JCO.1996.14.3.925	5	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR	2021	174	4					567	+		10.7326/L20-1090	http://dx.doi.org/10.7326/L20-1090			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU1WZ	33105097				2023-01-03	WOS:000644942400049
J	Huang, SY; Ziegler, CGK; Austin, J; Mannoun, N; Vukovic, M; Ordovas-Montanes, J; Shalek, AK; von Andrian, UH				Huang, Siyi; Ziegler, Carly G. K.; Austin, John; Mannoun, Najat; Vukovic, Marko; Ordovas-Montanes, Jose; Shalek, Alex K.; von Andrian, Ulrich H.			Lymph nodes are innervated by a unique population of sensory neurons with immunomodulatory potential	CELL			English	Article							ROOT GANGLION NEURONS; GENE-EXPRESSION; NERVOUS-SYSTEM; VASCULAR DEVELOPMENT; DENDRITIC CELLS; GROWTH-FACTORS; DIVERSE ROLES; IMMUNE CELLS; SINGLE CELLS; HOST-DEFENSE	Barrier tissue immune responses are regulated in part by nociceptors. Nociceptor ablation alters local immune responses at peripheral sites and within draining lymph nodes (LNs). The mechanisms and significance of nociceptor-dependent modulation of LN function are unknown. Using high-resolution imaging, viral tracing, single-cell transcriptomics, and optogenetics, we identified and functionally tested a sensory neuro-immune circuit that is responsive to lymph-bome inflammatory signals. Transcriptomics profiling revealed that multiple sensory neuron subsets, predominantly peptidergic nociceptors, innervate LNs, distinct from those innervating surrounding skin. To uncover LN-resident cells that may interact with LN-innervating sensory neurons, we generated a LN single-cell transcriptomics atlas and nominated nociceptor target populations and interaction modalities. Optogenetic stimulation of LN-innervating sensory fibers triggered rapid transcriptional changes in the predicted interacting cell types, particularly endothelium, stromal cells, and innate leukocytes. Thus, a unique population of sensory neurons monitors peripheral LNs and may locally regulate gene expression.	[Huang, Siyi; Ziegler, Carly G. K.; Austin, John; Mannoun, Najat; Vukovic, Marko; Ordovas-Montanes, Jose; Shalek, Alex K.; von Andrian, Ulrich H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Huang, Siyi; Austin, John; Mannoun, Najat; Shalek, Alex K.; von Andrian, Ulrich H.] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Huang, Siyi; Austin, John; Mannoun, Najat; Shalek, Alex K.; von Andrian, Ulrich H.] Harvard Univ, HMS Ctr Immune Imaging, Boston, MA 02115 USA; [Ziegler, Carly G. K.; Vukovic, Marko; Ordovas-Montanes, Jose; Shalek, Alex K.] MIT, Inst Med Engn & Sci IMES, Dept Chem, Cambridge, MA 02139 USA; [Ziegler, Carly G. K.; Vukovic, Marko; Ordovas-Montanes, Jose; Shalek, Alex K.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Ziegler, Carly G. K.; Vukovic, Marko; Ordovas-Montanes, Jose; Shalek, Alex K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Ziegler, Carly G. K.; Shalek, Alex K.] Harvard Med Sch, Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA; [Ziegler, Carly G. K.] Harvard Univ, Harvard Grad Program Biophys, Boston, MA 02115 USA; [Ordovas-Montanes, Jose] Boston Childrens Hosp, Div Gastroenterol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Boston Children's Hospital	Huang, SY; Shalek, AK; von Andrian, UH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Huang, SY; Shalek, AK; von Andrian, UH (corresponding author), Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA.; Huang, SY; Shalek, AK; von Andrian, UH (corresponding author), Harvard Univ, HMS Ctr Immune Imaging, Boston, MA 02115 USA.; Shalek, AK (corresponding author), MIT, Inst Med Engn & Sci IMES, Dept Chem, Cambridge, MA 02139 USA.; Shalek, AK (corresponding author), MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.; Shalek, AK (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Shalek, AK (corresponding author), Harvard Med Sch, Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA.	siyi_huang@hms.harvard.edu; shalek@mit.edu; uva@hms.harvard.edu			NIH [NIAMS 5R01AR068383-03, 5T32HL066987-17, 1DP2GM119419, 2RM1HG006193, T32GM007753, AR068383]; GSK; Searle Scholars Program; Beckman Young Investigator Program; Pew-Stewart Scholars Program for Cancer Research; Sloan Fellowship in Chemistry; Ragon Institute of MGH, MIT and Harvard; HHMI Damon Runyon Cancer Research Foundation fellowship [DRG-2274-16]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GSK(GlaxoSmithKline); Searle Scholars Program; Beckman Young Investigator Program; Pew-Stewart Scholars Program for Cancer Research; Sloan Fellowship in Chemistry; Ragon Institute of MGH, MIT and Harvard; HHMI Damon Runyon Cancer Research Foundation fellowship	We thank Guiying Cheng for technical assistance with LN injections, Dr. Constance Cepko and Dr. Ralph Adams for sharing mouse lines, Dr. Ste-phen Liberles's lab for sharing the laser/shutter setup for optogenetic stimulation, Dr. David Ginty's lab for sharing the Zeiss microscope for whole-mount spinal cord and DRG imaging, the Microscopy Resources On the North Quad (MicRoN) facility for confocal microcopy, the HMS Center for Immune Imaging for provision of imaging and image analysis resources, and the members of the von Andrian and Shalek labs for comments and discussions of the project. We acknoweldge S. Knemeyer and V. Yeung (SciStories, LLC) for illustrations. S.H. was supported by the NIH (NIAMS 5R01AR068383-03 and 5T32HL066987-17) and a GSK postdoctoral fellowship. A.K.S. was supported by the Searle Scholars Program, the Beckman Young Investigator Program, the Pew-Stewart Scholars Program for Cancer Research, a Sloan Fellowship in Chemistry, the NIH (1DP2GM119419 and 2RM1HG006193), and the Ragon Institute of MGH, MIT and Harvard. J.O.M. was supported by HHMI Damon Runyon Cancer Research Foundation fellowship DRG-2274-16. C.G.K.Z. was supported by T32GM007753 from the NIH. U.H.v.A. was supported by the Ragon Institute of MGH, MIT and Harvard and NIH grant AR068383.	Abrahamsen B, 2008, SCIENCE, V321, P702, DOI 10.1126/science.1156916; Adams RH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001875; Aicher TP, 2019, METHODS MOL BIOL, V1979, P111, DOI 10.1007/978-1-4939-9240-9_8; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Andoh T, 2007, J INVEST DERMATOL, V127, P2042, DOI 10.1038/sj.jid.5700810; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Assas BM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00023; Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2; Baral P, 2018, NAT MED, V24, P417, DOI 10.1038/nm.4501; Barkas N, 2019, NAT METHODS, V16, P695, DOI 10.1038/s41592-019-0466-z; BELLINGER DL, 1992, INT J IMMUNOPHARMACO, V14, P329, DOI 10.1016/0192-0561(92)90162-E; Belvisi MG, 2002, CURR OPIN PHARMACOL, V2, P211, DOI 10.1016/S1471-4892(02)00145-5; Blake KJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02448-6; Bley KR, 1998, TRENDS PHARMACOL SCI, V19, P141, DOI 10.1016/S0165-6147(98)01185-7; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Brierley SM, 2004, GASTROENTEROLOGY, V127, P166, DOI 10.1053/j.gastro.2004.04.008; Buettner M, 2012, CLIN EXP IMMUNOL, V169, P205, DOI 10.1111/j.1365-2249.2012.04602.x; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chakrabarty A, 2011, NEUROSCI LETT, V495, P67, DOI 10.1016/j.neulet.2011.03.043; Chavan SS, 2017, IMMUNITY, V46, P927, DOI 10.1016/j.immuni.2017.06.008; Chiu IM, 2013, NATURE, V501, P52, DOI 10.1038/nature12479; Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144; Cho C, 2019, ELIFE, V8, DOI 10.7554/eLife.45542; Choi I, 2011, BLOOD, V117, P362, DOI 10.1182/blood-2010-07-298562; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cohen JN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087740; Cohen JA, 2019, CELL, V178, P919, DOI 10.1016/j.cell.2019.06.022; Cohen M, 2018, CELL, V175, P1031, DOI 10.1016/j.cell.2018.09.009; Cordeiro OG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151848; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; Diogenes A, 2011, J DENT RES, V90, P759, DOI 10.1177/0022034511400225; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drew LJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-12-j0001.2002; Drokhlyancky E., 2019, CELL, V1B2; Eelen G, 2018, NATURE, V561, P63, DOI 10.1038/s41586-018-0466-7; Ehling M, 2013, DEVELOPMENT, V140, P3051, DOI 10.1242/dev.093351; Evrard M, 2018, IMMUNITY, V48, P364, DOI 10.1016/j.immuni.2018.02.002; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/nmeth.3734, 10.1038/NMETH.3734]; FELTEN DL, 1992, EUR J CLIN INVEST, V22, P37; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; Fletcher AL, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00035; Foster SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01463; Gautron L, 2011, J COMP NEUROL, V519, P3085, DOI 10.1002/cne.22667; Gierahn TM, 2017, NAT METHODS, V14, P395, DOI 10.1038/nmeth.4179; Godinho-Silva C, 2019, ANNU REV IMMUNOL, V37, P19, DOI 10.1146/annurev-immunol-042718-041812; Gonzalez-Castillo C, 2015, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00443; Green DP, 2019, NEURON, V101, P412, DOI 10.1016/j.neuron.2019.01.012; Hanes William M, 2016, Bioelectron Med, V3, P18, DOI 10.15424/bioelectronmed.2016.00001; Hempel CM, 2007, NAT PROTOC, V2, P2924, DOI 10.1038/nprot.2007.416; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Hu J, 2006, J PHYSIOL-LONDON, V577, P815, DOI 10.1113/jphysiol.2006.117648; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hughes T.K., 2019, HIGHLY EFFICIENT MAS, DOI [10.1101/689273, DOI 10.1101/689273]; Iannacone M, 2010, NATURE, V465, P1079, DOI 10.1038/nature09118; Iftakhar-E-Khuda I, 2016, P NATL ACAD SCI USA, V113, P10643, DOI 10.1073/pnas.1602357113; Inoshima I, 2011, NAT MED, V17, P1310, DOI 10.1038/nm.2451; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; Kashem SW, 2015, IMMUNITY, V43, P515, DOI 10.1016/j.immuni.2015.08.016; Kawashima H, 2005, NAT IMMUNOL, V6, P1096, DOI 10.1038/ni1259; Kharchenko PV, 2014, NAT METHODS, V11, P740, DOI [10.1038/NMETH.2967, 10.1038/nmeth.2967]; Klein RS, 2017, NAT IMMUNOL, V18, P132, DOI 10.1038/ni.3656; Kuehn ED, 2019, P NATL ACAD SCI USA, V116, P9168, DOI 10.1073/pnas.1901378116; Kulkarni RM, 2009, MECH DEVELOP, V126, P350, DOI 10.1016/j.mod.2009.02.003; Kupari J, 2019, CELL REP, V27, P2508, DOI 10.1016/j.celrep.2019.04.096; KURKOWSKI R, 1990, PEPTIDES, V11, P13, DOI 10.1016/0196-9781(90)90103-C; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; Larrivee B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144; Lawson SN, 2002, J PHYSIOL-LONDON, V540, P989, DOI 10.1113/jphysiol.2001.013086; Lewin G.R., 2000, MOL BASIS PAIN INDUC, P129; Li LS, 2011, CELL, V147, P1615, DOI 10.1016/j.cell.2011.11.027; Lorton D, 2000, NEUROIMMUNOMODULAT, V7, P115, DOI 10.1159/000026429; Lutter S, 2012, J CELL BIOL, V197, P837, DOI 10.1083/jcb.201110132; Mack JJ, 2018, CURR OPIN HEMATOL, V25, P212, DOI 10.1097/MOH.0000000000000425; Mackenzie F, 2012, DEVELOPMENT, V139, P1371, DOI 10.1242/dev.072348; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Mao CG, 2008, BBA-MOL CELL BIOL L, V1781, P424, DOI 10.1016/j.bbalip.2008.06.002; Mason MRJ, 2010, MOL THER, V18, P715, DOI 10.1038/mt.2010.19; McCarter GC, 1999, NEUROSCI LETT, V273, P179, DOI 10.1016/S0304-3940(99)00665-5; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; McMahon SB, 2015, NAT REV NEUROSCI, V16, P389, DOI 10.1038/nrn3946; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Meseguer V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4125; Mithal DS, 2012, J NEUROIMMUNE PHARM, V7, P820, DOI 10.1007/s11481-011-9336-x; MOORE TC, 1989, IMMUNOLOGY, V67, P109; Mooster JL, 2015, J EXP MED, V212, P185, DOI 10.1084/jem.20140979; Nakai A, 2014, J EXP MED, V211, P2583, DOI 10.1084/jem.20141132; Nassar MA, 2004, P NATL ACAD SCI USA, V101, P12706, DOI 10.1073/pnas.0404915101; Nonomura K, 2017, NATURE, V541, P176, DOI 10.1038/nature20793; Norris GT, 2019, J EXP MED, V216, P60, DOI 10.1084/jem.20180199; Oaklander AL, 2005, J AM ACAD DERMATOL, V53, P1027, DOI 10.1016/j.jaad.2005.08.049; Oh SW, 2014, NATURE, V508, P207, DOI 10.1038/nature13186; Ordovas-Montanes J, 2015, TRENDS IMMUNOL, V36, P578, DOI 10.1016/j.it.2015.08.007; Palazzo E, 2012, J CELL PHYSIOL, V227, P1017, DOI 10.1002/jcp.22811; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Pham THM, 2010, J EXP MED, V207, P17, DOI 10.1084/jem.20091619; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Pinho-Ribeiro FA, 2018, CELL, V173, P1083, DOI 10.1016/j.cell.2018.04.006; Pongratz G, 2013, NAT REV RHEUMATOL, V9, P117, DOI 10.1038/nrrheum.2012.181; POPPER P, 1988, PEPTIDES, V9, P257, DOI 10.1016/0196-9781(88)90258-6; Prinz M, 2017, NAT NEUROSCI, V20, P136, DOI 10.1038/nn.4475; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Ranade SS, 2014, NATURE, V516, P121, DOI 10.1038/nature13980; Reardon C, 2013, P NATL ACAD SCI USA, V110, P1410, DOI 10.1073/pnas.1221655110; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Rice F.L., 2008, CUTANEOUS MECH TACTI; Riol-Blanco L, 2014, NATURE, V510, P157, DOI 10.1038/nature13199; ROBERTSON B, 1990, HISTOCHEMISTRY, V94, P81; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Sharma N, 2020, NATURE, V577, P392, DOI 10.1038/s41586-019-1900-1; Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054; Shepherd AJ, 2005, J NEUROIMMUNOL, V164, P115, DOI 10.1016/j.jneuroim.2005.04.008; Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sudhof TC, 2018, NEURON, V100, P276, DOI 10.1016/j.neuron.2018.09.040; Suvas S, 2017, J IMMUNOL, V199, P1543, DOI 10.4049/jimmunol.1601751; Takahashi Y, 1996, PAIN, V67, P197, DOI 10.1016/0304-3959(96)03116-8; Takeda A, 2019, IMMUNITY, V51, P561, DOI 10.1016/j.immuni.2019.06.027; Tallini YN, 2006, PHYSIOL GENOMICS, V27, P391, DOI 10.1152/physiolgenomics.00092.2006; Trombetta J.J., 2014, CURR PROTOC MOL BIOL, V107; Uchimura K, 2005, NAT IMMUNOL, V6, P1105, DOI 10.1038/ni1258; Ulvmar MH, 2014, NAT IMMUNOL, V15, P623, DOI 10.1038/ni.2889; Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881; Vaahtomeri K, 2017, GENE DEV, V31, P1615, DOI 10.1101/gad.303776.117; Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739; Veiga-Fernandes H, 2016, CELL, V165, P801, DOI 10.1016/j.cell.2016.04.041; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303; Wacker MJ, 2002, AM J PHYSIOL-HEART C, V282, pH482, DOI 10.1152/ajpheart.00624.2001; Waltman L, 2013, EUR PHYS J B, V86, DOI 10.1140/epjb/e2013-40829-0; Winkler C, 2014, BRIT J PHARMACOL, V171, P905, DOI 10.1111/bph.12462; Woo SH, 2015, NAT NEUROSCI, V18, P1756, DOI 10.1038/nn.4162; Wood J.N., 2018, DORSAL ROOT GANGLION; Wu HT, 2010, DEVELOPMENT, V137, P1017, DOI 10.1242/dev.038711; Wu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092857; Yamano T, 2019, J EXP MED, V216, P1027, DOI 10.1084/jem.20181430; Yang XM, 2010, BIOCHEM BIOPH RES CO, V396, P571, DOI 10.1016/j.bbrc.2010.04.152; Ye X, 2010, TRENDS MOL MED, V16, P417, DOI 10.1016/j.molmed.2010.07.003; Zeng WZ, 2018, SCIENCE, V362, P464, DOI 10.1126/science.aau6324; Zhang G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7625; Zhou P, 2003, AM J TRANSPLANT, V3, P259, DOI 10.1034/j.1600-6143.2003.00067.x	149	42	42	8	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 21	2021	184	2					441	+		10.1016/j.cell.2020.11.028	http://dx.doi.org/10.1016/j.cell.2020.11.028		JAN 2021	44	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY8KT	33333021	Green Accepted, Bronze			2023-01-03	WOS:000612290800016
J	Zimmermann, GG; Jasper, SP; Kmiecik, LL; Neto, LS; da Silva, TX; Oiole, YA				Zimmermann, Gabriel Ganancini; Jasper, Samir Paulo; Kmiecik, Leonardo Leonidas; Neto, Lauro Strapasson; da Silva, Thiago Xavier; Oiole, Yasser Alabi			Development of test bench to determine the distribution of granular fertilizers in planting rows using spiral roller, two spiral rollers and fluted roller	PLOS ONE			English	Article							SYSTEM	The success of the application of granular fertilizers (GFs) in planting rows depends on the uniformity and performance of product dispensing systems, which are influenced by external factors. The objective of this study was to determine the outflow rates of two GF formulations (GF(1) 04-14-08 and GF(2) 04-30-10) using three types of fertilizer spreader-with one spiral roller (A), two spiral rollers (B), or a fluted roller (C)-and three operating speeds (1,11, 1.94, and 2.77 m s(-1)). The following parameters were determined in GFs: density, angle of repose, water content, and segregation (particle size). In the designed test bench, GFs were transferred from a reservoir to a spreader, and ultimately to a container, where they were weighed, and data were transmitted to the data acquisition system (DAS). A total of 7,560 outflow data points were collected (g s(-1)) and subjected to descriptive analysis of measures of central tendency, dispersion, asymmetry, and kurtosis, and Shewhart control charts were generated. Particle density and segregation were significantly different between the GFs, whereas the angle of repose and water content were not significantly different. The bench design and the DAS allowed measuring the outflow of GFs in different spreaders and demonstrated that this parameter was influenced by particle segregation. The segregation of GF(1) was higher than that of GF(2). The outflow variability at the speed of 1.11 m s(-1) was lower, and the spreader with a fluted roller had the highest uniformity and was the most suitable for application with variable rates.	[Zimmermann, Gabriel Ganancini; Jasper, Samir Paulo; Kmiecik, Leonardo Leonidas; Oiole, Yasser Alabi] Univ Fed Parana, Soil & Engn Dept Agr, Grad Program Soil Sci, Agr Sci Sect, Curitiba, Parana, Brazil; [Neto, Lauro Strapasson; da Silva, Thiago Xavier] Univ Fed Parana, Agron, Gearing Farm Tractor Lab, Agr Sci Sect, Curitiba, Parana, Brazil	Universidade Federal do Parana; Universidade Federal do Parana	Zimmermann, GG (corresponding author), Univ Fed Parana, Soil & Engn Dept Agr, Grad Program Soil Sci, Agr Sci Sect, Curitiba, Parana, Brazil.	gabrielganancini@gmail.com		Zimmermann, Gabriel/0000-0002-9709-4458				Dalacort R, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18113991; Noronha RHD, 2011, BRAGANTIA, V70, P931, DOI 10.1590/S0006-87052011000400028; Franck CJ, 2015, REV BRAS ENG AGR AMB, V19, P512, DOI 10.1590/1807-1929/agriambi.v19n5p512-518; Ministerio da Agricultura, 2017, MAP MAN MET AN OF FE; Osaki M, 2014, AGR SYST, V127, P178, DOI 10.1016/j.agsy.2014.02.002; Roy ED, 2016, NAT PLANTS, V2, DOI [10.1038/nplants.2016.43, 10.1038/NPLANTS.2016.43]; Su N, 2015, INT J AGR BIOL ENG, V8, P19, DOI 10.3965/j.ijabe.20150804.1644; Wijekularathna DK, 2022, COMMUN STAT-SIMUL C, V51, P757, DOI 10.1080/03610918.2019.1658780	8	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243799	10.1371/journal.pone.0243799	http://dx.doi.org/10.1371/journal.pone.0243799			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315901	gold, Green Published			2023-01-03	WOS:000600186100001
J	Filardo, TD; Khan, MR; Krawczyk, N; Galitzer, H; Karmen-Tuohy, S; Coffee, M; Schaye, VE; Eckhardt, BJ; Cohen, GM				Filardo, Thomas D.; Khan, Maria R.; Krawczyk, Noa; Galitzer, Hayley; Karmen-Tuohy, Savannah; Coffee, Megan; Schaye, Verity E.; Eckhardt, Benjamin J.; Cohen, Gabriel M.			Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020)	PLOS ONE			English	Article							OUTCOMES	Background Despite evidence of socio-demographic disparities in outcomes of COVID-19, little is known about characteristics and clinical outcomes of patients admitted to public hospitals during the COVID-19 outbreak. Objective To assess demographics, comorbid conditions, and clinical factors associated with critical illness and mortality among patients diagnosed with COVID-19 at a public hospital in New York City (NYC) during the first month of the COVID-19 outbreak. Design Retrospective chart review of patients diagnosed with COVID-19 admitted to NYC Health + Hospitals / Bellevue Hospital from March 9(th) to April 8(th), 2020. Results A total of 337 patients were diagnosed with COVID-19 during the study period. Primary analyses were conducted among those requiring supplemental oxygen (n = 270); half of these patients (135) were admitted to the intensive care unit (ICU). A majority were male (67.4%) and the median age was 58 years. Approximately one-third (32.6%) of hypoxic patients managed outside the ICU required non-rebreather or non-invasive ventilation. Requirement of renal replacement therapy occurred in 42.3% of ICU patients without baseline end-stage renal disease. Overall, 30-day mortality among hypoxic patients was 28.9% (53.3% in the ICU, 4.4% outside the ICU). In adjusted analyses, risk factors associated with mortality included dementia (adjusted risk ratio (aRR) 2.11 95%CI 1.50-2.96), age 65 or older (aRR 1.97, 95%CI 1.31-2.95), obesity (aRR 1.37, 95%CI 1.07-1.74), and male sex (aRR 1.32, 95%CI 1.04-1.70). Conclusion COVID-19 demonstrated severe morbidity and mortality in critically ill patients. Modifications in care delivery outside the ICU allowed the hospital to effectively care for a surge of critically ill and severely hypoxic patients.	[Filardo, Thomas D.; Coffee, Megan; Eckhardt, Benjamin J.; Cohen, Gabriel M.] NYU, Grossman Sch Med, Div Infect Dis & Immunol, New York, NY 10016 USA; [Khan, Maria R.; Krawczyk, Noa] NYU, Grossman Sch Med, Dept Populat Hlth, New York, NY USA; [Galitzer, Hayley; Karmen-Tuohy, Savannah] NYU, Grossman Sch Med, New York, NY USA; [Coffee, Megan; Schaye, Verity E.; Eckhardt, Benjamin J.; Cohen, Gabriel M.] NYC Hlth Hosp, Bellevue Hosp Ctr, New York, NY USA; [Schaye, Verity E.] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA	New York University; New York University; New York University; Bellevue Hospital Center; New York University	Filardo, TD (corresponding author), NYU, Grossman Sch Med, Div Infect Dis & Immunol, New York, NY 10016 USA.	Thomas.Filardo@nyulangone.org	coffee, megan/AAD-9793-2022; Coffee, Megan/AAY-6752-2020	Coffee, Megan/0000-0002-4581-111X; Galitzer, Hayley/0000-0002-4688-496X; Karmen-Tuohy, Savannah/0000-0001-7502-6772; Schaye, Verity/0000-0003-0816-4037; Cohen, Gabriel/0000-0002-8653-4518; Filardo, Thomas/0000-0002-1077-9164				[Anonymous], 2020, NEW YORK CITYS PUBLI; [Anonymous], 2020, 51 WHO; [Anonymous], 2012, STAND ASS AC ILL SEV; Argenziano Michael G, 2020, medRxiv, DOI 10.1101/2020.04.20.20072116; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432; Foley NC, 2015, DEMENT GERIATR COGN, V39, P52, DOI 10.1159/000367783; Furlow B, 2020, LANCET RHEUMATOL, V2, pE592, DOI 10.1016/S2665-9913(20)30313-1; Goldfarb DS, 2020, CLIN J AM SOC NEPHRO, V15, P880, DOI 10.2215/CJN.05180420; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923; MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/bmj.m1588; New York City Department of Health, COVID 19 DAT; Nori P, 2021, INFECT CONT HOSP EP, V42, P84, DOI 10.1017/ice.2020.368; Olson DR, 2020, MMWR-MORBID MORTAL W, V69, P603, DOI 10.15585/mmwr.mm6919e5; Perico L, 2020, NEPHRON, V144, P213, DOI 10.1159/000507305; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Selvin S., 1996, STAT ANAL EPIDEMIOLO; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	30	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2020	15	11							e0242760	10.1371/journal.pone.0242760	http://dx.doi.org/10.1371/journal.pone.0242760			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5BU	33227019	Green Published, gold			2023-01-03	WOS:000595651800039
J	Shah, ASV; Wood, R; Gribben, C; Caldwell, D; Bishop, J; Weir, A; Kennedy, S; Reid, M; Smith-Palmer, A; Goldberg, D; McMenamin, J; Fischbacher, C; Robertson, C; Hutchinson, S; McKeigue, P; Colhoun, H; McAllister, DA				Shah, Anoop S. V.; Wood, Rachael; Gribben, Ciara; Caldwell, David; Bishop, Jennifer; Weir, Amanda; Kennedy, Sharon; Reid, Martin; Smith-Palmer, Alison; Goldberg, David; McMenamin, Jim; Fischbacher, Colin; Robertson, Chris; Hutchinson, Sharon; McKeigue, Paul; Colhoun, Helen; McAllister, David A.			Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To assess the risk of hospital admission for coronavirus disease 2019 (covid-19) among patient facing and non-patient facing healthcare workers and their household members. DESIGN Nationwide linkage cohort study. SETTING Scotland, UK, 1 March to 6 June 2020. PARTICIPANTS Healthcare workers aged 18-65 years, their households, and other members of the general population. MAIN OUTCOME MEASURE Admission to hospital with covid-19. RESULTS The cohort comprised 158445 healthcare workers, most of them (90733; 57.3%) being patient facing, and 229905 household members. Of all hospital admissions for covid-19 in the working age population (18-65 year olds), 17.2% (360/2097) were in healthcare workers or their households. After adjustment for age, sex, ethnicity, socioeconomic deprivation, and comorbidity, the risk of admission due to covid-19 in non-patient facing healthcare workers and their households was similar to the risk in the general population (hazard ratio 0.81 (95% confidence interval 0.52 to 1.26) and 0.86 (0.49 to 1.51), respectively). In models adjusting for the same covariates, however, patient facing healthcare workers, compared with non-patient facing healthcare workers, were at higher risk (hazard ratio 3.30, 2.13 to 5.13), as were household members of patient facing healthcare workers (1.79, 1.10 to 2.91). After sub-division of patient facing healthcare workers into those who worked in "front door," intensive care, and non-intensive care aerosol generating settings and other, those in front door roles were at higher risk (hazard ratio 2.09, 1.49 to 2.94). For most patient facing healthcare workers and their households, the estimated absolute risk of hospital admission with covid-19 was less than 0.5%, but it was 1% and above in older men with comorbidity. CONCLUSIONS Healthcare workers and their households contributed a sixth of covid-19 cases admitted to hospital. Although the absolute risk of admission was low overall, patient facing healthcare workers and their household members had threefold and twofold increased risks of admission with covid-19.	[Shah, Anoop S. V.] London Sch Hyg & Trop Med, Noncommunicable Dis Epidemiol, London, England; [Shah, Anoop S. V.] Imperial Coll NHS Trust, Dept Cardiol, London, England; [Wood, Rachael; Gribben, Ciara; Caldwell, David; Bishop, Jennifer; Weir, Amanda; Kennedy, Sharon; Reid, Martin; Smith-Palmer, Alison; Goldberg, David; McMenamin, Jim; Fischbacher, Colin; Robertson, Chris; Hutchinson, Sharon; Colhoun, Helen; McAllister, David A.] Publ Hlth Scotland, Edinburgh, Midlothian, Scotland; [Wood, Rachael] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Hutchinson, Sharon] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland; [McKeigue, Paul] Univ Edinburgh, MRC Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Colhoun, Helen] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [McAllister, David A.] Univ Glasgow, Inst Hlth & Wellbeing, 1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland	University of London; London School of Hygiene & Tropical Medicine; University of Edinburgh; Glasgow Caledonian University; University of Edinburgh; University of Edinburgh; University of Glasgow	McAllister, DA (corresponding author), Publ Hlth Scotland, Edinburgh, Midlothian, Scotland.; McAllister, DA (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, 1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland.	David.mcallister@glasgow.ac.uk		Wood, Rachael/0000-0003-4453-623X; Shah, Anoop/0000-0002-2825-3419; Colhoun, Helen/0000-0002-8345-3288; COVID-19 Research, Diabetes Medical Informatics and Epidemiology Group/0000-0003-0505-8634	British Heart Foundation through an intermediate clinical research fellowship [FS/19/17/34172]; Wellcome Trust; Beit fellowship [201492/Z/16/Z]	British Heart Foundation through an intermediate clinical research fellowship; Wellcome Trust(Wellcome Trust); Beit fellowship	ASVS is funded via the British Heart Foundation through an intermediate clinical research fellowship (FS/19/17/34172), and DAM is funded via a Wellcome Trust intermediate clinical fellowship and Beit fellowship (201492/Z/16/Z). The funders had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.	Adams JG, 2020, JAMA-J AM MED ASSOC, V323, P1439, DOI 10.1001/jama.2020.3972; [Anonymous], 2020, ISARIC CCP UK PROSPE; Avo C, 2020, J HOSP INFECT, V106, P208, DOI 10.1016/j.jhin.2020.06.024; Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632; European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR; Health Protection Scotland, 2020, NOV COR COVID 19 GUI; Houghton C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013582; Houlihan CF, 2020, LANCET, V396, pE6, DOI 10.1016/S0140-6736(20)31484-7; Iversen K, 2020, LANCET INFECT DIS; Joseph Bobby, 2016, Indian J Occup Environ Med, V20, P71, DOI 10.4103/0019-5278.197518; Liu M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2195; Mateos P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022943; McAllister DA, 2018, CIRCULATION, V138, P2774, DOI 10.1161/CIRCULATIONAHA.118.034986; McConnell D, 2020, J MED ETHICS, V46, P360, DOI 10.1136/medethics-2020-106250; McKeigue PM, 2020, RAPID EPIDEMIOLOGICA, P2020; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412; Nguyen LH, 2020, RICK COVID 19 FRONTL; Office for National Statistics, 2020, COR COVID 19 REL DEA; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Pouwels KB, 2020, COMMUNITY PREVALENCE, DOI [10.1101/2020.07.06.20147348v1, DOI 10.1101/2020.07.06.20147348V1]; Scottish Government, 2021, SCOTT IND MULT DEPR; Shah ASV, 2020, CIRCULATION, V141, P2067, DOI 10.1161/CIRCULATIONAHA.119.044913; Shah ASV, 2018, LANCET, V392, P919, DOI 10.1016/S0140-6736(18)31923-8; Treibel TA, 2020, LANCET, V395, P1608, DOI 10.1016/S0140-6736(20)31100-4; VBRC, 2020, TC HAROLD COVID 19 V; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Williams TC, 2020, SENSITIVITY RT PCR T, DOI [10.1101/2020.06.19.20135756v1, DOI 10.1101/2020.06.19.20135756V1]	28	177	177	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2020	371								m3582	10.1136/bmj.m3582	http://dx.doi.org/10.1136/bmj.m3582			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH6CC	33115726	Green Submitted, Green Accepted, Green Published, hybrid			2023-01-03	WOS:000582674300003
J	Bar-Sela, G; Cohen, I; Avisar, A; Loven, D; Aharon, A				Bar-Sela, Gil; Cohen, Idan; Avisar, Adva; Loven, David; Aharon, Anat			Circulating blood extracellular vesicles as a tool to assess endothelial injury and chemotherapy toxicity in adjuvant cancer patients	PLOS ONE			English	Article							ANGIOSTATIN; MICROPARTICLES; MICROVESICLES; ACTIVATION; THROMBOSIS; APOPTOSIS; SURFACE; CELLS; BINDS	Extracellular vesicles (EVs) are subcellular membrane blebs that include exosomes and microparticles, which represent a potential source for cancer biomarker discovery. We assess EVs characteristics as a tool to evaluate the endothelial and anti-tumor treatment injury during adjuvant chemotherapy in breast (BC) and colon cancer (CC) patients. Blood samples were taken from 29 BC and 25 CC patients before and after chemotherapy, as well as from healthy control donors (HC). Circulating blood EVs were isolated and characterized by size/concentration, membrane antigens for cell origin, thrombogenicity, and protein content. We observed higher EVs concentration and particle size in CC patients after chemotherapy compared with HC. Higher levels of endothelial EVs (CD144-positive) and vascular endothelial growth factor receptor 1 (VEGFR1), apparently as an indication of endothelial dysfunction, were found in all cancer patients, regardless of a given treatment, compared to HC. Levels of EVs labeled CD62E, CD34(+)41(-), the lymphocyte markers CD11(+) and CD-14(+), Annexin-V, and the coagulation proteins TF and TFPI, however, sometimes demonstrate significant differences between patients, although HC did not show significant differences between patients pre- and post-chemotherapy. Most importantly, increasing levels of EVs encapsulated Angiostatin were found in patients with CC, while chemotherapy treatment leads to its notable rise in circulating blood EVs. Our results demonstrate the potential of EVs encapsulated Angiostatin as a tool to evaluate endothelial damage during adjuvant chemotherapy in BC and CC patients.	[Bar-Sela, Gil; Aharon, Anat] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel; [Bar-Sela, Gil; Cohen, Idan; Loven, David] Emek Med Ctr, Canc Ctr, Afula, Israel; [Avisar, Adva] Univ Haifa, Haifa, Israel; [Aharon, Anat] Sourasky Med Ctr, Hematol & Bone Marrow Transplantat, Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Emek Medical Center; University of Haifa; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Bar-Sela, G (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Haifa, Israel.; Bar-Sela, G (corresponding author), Emek Med Ctr, Canc Ctr, Afula, Israel.	gil_ba@clalit.org.il	Cohen‬, ‪Idan/AAD-6997-2021	Cohen‬, ‪Idan/0000-0001-6933-9385; Bar-Sela, Gil/0000-0001-6579-1841	Israel Science Foundation (ISF) [1413/21]; Rappaport Family Institute [2012-2014]	Israel Science Foundation (ISF)(Israel Science Foundation); Rappaport Family Institute	This work was funded by the: Israel Science Foundation (ISF), grant No 1413/21, and Rappaport Family Institute Grant 2012-2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aharon A, 2009, BEST PRACT RES CL HA, V22, P61, DOI 10.1016/j.beha.2008.11.002; [Anonymous], 2018, CANC DISCOV, V8, pOF6; [Anonymous], 2015, PEDIATRICS, V135, pe1097; [Anonymous], 2017, EUR GERIATR MED, V8, pS98; [Anonymous], 2013, J CROHNS COLITIS, V7, P769; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; Aubertin K, 2016, SCI REP-UK, V6, DOI 10.1038/srep35376; Azim HA, 2011, ANN ONCOL, V22, P1939, DOI 10.1093/annonc/mdq683; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cameron AC, 2016, CAN J CARDIOL, V32, P852, DOI 10.1016/j.cjca.2015.12.023; Chi SL, 2006, CANCER RES, V66, P875, DOI 10.1158/0008-5472.CAN-05-2806; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Geddings JE, 2016, J THROMB HAEMOST, V14, P153, DOI 10.1111/jth.13181; Gupta N, 2001, EMBO REP, V2, P536, DOI 10.1093/embo-reports/kve115; Helal O, 2011, NUTR METAB CARDIOVAS, V21, P665, DOI 10.1016/j.numecd.2010.01.004; Ida M, 2004, J BIOCHEM, V135, P583, DOI 10.1093/jb/mvh071; Iii APO, 2012, MICROPARTICLES HEMOS, V108, P1284; Lima LG, 2013, BIOSCIENCE REP, V33, P701, DOI 10.1042/BSR20130057; Lucas R, 1998, BLOOD, V92, P4730; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Nestle, 2007, NUTRIPRO NESTLE PROF, V1, P1; Nurgali K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00245; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Razak NBA, 2018, CANCERS, V10, DOI 10.3390/cancers10100380; Rider P, 2017, J IMMUNOL, V198, P1395, DOI 10.4049/jimmunol.1601342; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Stortecky S, 2010, CURR OPIN ONCOL, V22, P312, DOI 10.1097/CCO.0b013e32833ab6f1; Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370; Tesselaar MET, 2007, J THROMB HAEMOST, V5, P520, DOI 10.1111/j.1538-7836.2007.02369.x; Timp JF, 2013, BLOOD, V122, P1712, DOI 10.1182/blood-2013-04-460121; Tripisciano C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03262-2; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Vanhoutte PM, 2009, ACTA PHYSIOL, V196, P193, DOI 10.1111/j.1748-1716.2009.01964.x; VanWijk MJ, 2003, CARDIOVASC RES, V59, P277, DOI 10.1016/S0008-6363(03)00367-5; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Zheng XZ, 2007, BLOOD, V109, P1003, DOI 10.1182/blood-2006-06-032086; Zhu TJ, 2016, INT J CLIN EXP MED, V9, P5233	38	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0240994	10.1371/journal.pone.0240994	http://dx.doi.org/10.1371/journal.pone.0240994			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8WV	33108394	gold, Green Published			2023-01-03	WOS:000588372400007
J	Hu, FP; Liao, CC; Chen, TL; Yeh, CC; Shi, LW; Shih, CC				Hu, Feng-Ping; Liao, Chien-Chan; Chen, Ta-Liang; Yeh, Chun-Chieh; Shi, Luwen; Shih, Chun-Chuan			Prevalence, expenditures, and associated factors of purchasing non-prescribed Chinese herbal medicine in Taiwan	PLOS ONE			English	Article							ACUPUNCTURE USE; UNITED-STATES; DRUGS; OUTPATIENTS	Background and aims Purchasing Chinese herbal medicine (CHM) without a physician's prescription may have adverse effects on health. However, the recent status of purchasing non-prescribed CHM and the associated factors are not completely understood. We aimed to report the prevalence of purchasing CHM and associated factors. Methods Using data from the 2017 Taiwan Survey of Family Income and Expenditure, we identified 16,528 individuals (householders) aged 18 years and older. Sociodemographic factors, expenditures on medical services and health behaviours were compared between people with and without a history of purchasing non-prescribed CHM by calculating adjusted odds ratios (ORs) and 95% confidence intervals (CIs) in a multiple logistic regression analysis. Results The one-year prevalence of purchasing non-prescribed CHM was 74.8% in Taiwan. In addition to sociodemographics, marital status (OR 2.14, 95% CI 1.88-2.44), the use of traditional Chinese medicine (OR 3.62, 95% CI 3.30-3.97), the purchasing of non-prescribed biochemical medications (OR 3.09, 95% CI 2.75-3.48), the purchasing of health foods (OR 2.59, 95% CI 2.33-2.86), the use of folk therapy (OR 2.27, 95% CI 1.95-2.64), and a high level of expenditure on alcohol (OR 3.79, 95% CI 3.29-4.36) were strongly correlated with purchasing non-prescribed CHM. Conclusion The one-year prevalence of purchasing non-prescribed CHM is very high in Taiwan and is correlated with sociodemographics, health behaviours, and the utilization of medical care. The interaction of non-prescribed CHM with physician-prescribed herbal medicine and biomedical medications requires more attention.	[Hu, Feng-Ping; Shi, Luwen] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China; [Liao, Chien-Chan] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Liao, Chien-Chan; Chen, Ta-Liang] Taipei Med Univ Hosp, Anesthesiol & Hlth Policy Res Ctr, Taipei, Taiwan; [Liao, Chien-Chan; Chen, Ta-Liang] Taipei Med Univ, Coll Med, Sch Med, Dept Anesthesiol, Taipei, Taiwan; [Liao, Chien-Chan] Taipei Med Univ, Wan Fang Hosp, Res Ctr Big Data & Meta Anal, Taipei, Taiwan; [Liao, Chien-Chan] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan; [Chen, Ta-Liang] Taipei Med Univ, Wan Fang Hosp, Dept Anesthesiol, Taipei, Taiwan; [Yeh, Chun-Chieh] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Yeh, Chun-Chieh] Univ Illinois, Dept Surg, Chicago, IL 60680 USA; [Shih, Chun-Chuan] I Shou Univ, Coll Med, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan; [Shih, Chun-Chuan] Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Dev Herbal Med, Taipei, Taiwan	Peking University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; I Shou University; Taipei Medical University	Shih, CC (corresponding author), I Shou Univ, Coll Med, Sch Chinese Med Postbaccalaureate, Kaohsiung, Taiwan.; Shih, CC (corresponding author), Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Dev Herbal Med, Taipei, Taiwan.	hwathai@seed.net.tw			Taiwan's Ministry of Health and Welfare [MOHW108-NRICM-M-114-000003]; Taiwan's Ministry of Science and Technology [MOST108-2320-B-214-003-MY3, MOST106-2314-B-038-036-MY3]	Taiwan's Ministry of Health and Welfare; Taiwan's Ministry of Science and Technology	This study is based on data obtained from Health and Welfare Information Science Center, Ministry of Health and Welfare, Taiwan. Our study was supported by the Taiwan's Ministry of Health and Welfare (MOHW108-NRICM-M-114-000003); and by the Taiwan's Ministry of Science and Technology (MOST108-2320-B-214-003-MY3; MOST106-2314-B-038-036-MY3).	Al-Ramahi R, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0764-7; [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501; [Anonymous], 2010, J OIL GAS KAZAKHTAN, V4, P69; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Burke A, 2006, J ALTERN COMPLEM MED, V12, P639, DOI 10.1089/acm.2006.12.639; Chang CC, 2016, J ETHNOPHARMACOL, V177, P46, DOI 10.1016/j.jep.2015.11.028; Chen KC, 2015, COMPUT METH PROG BIO, V122, P462, DOI 10.1016/j.cmpb.2015.09.006; Clarke Tainya C, 2015, Natl Health Stat Report, P1; He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233; Hequet D, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1658-0; Hori S, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-14; Huang CW, 2019, J CHIN MED ASSOC, V82, P665, DOI 10.1097/JCMA.0000000000000131; Husain I, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1887; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869; Kim JH, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-336; Liao HL, 2008, J ALTERN COMPLEM MED, V14, P741, DOI 10.1089/acm.2007.7111; Liu CY, 2010, ASIA-PAC J PUBLIC HE, V22, P51, DOI 10.1177/1010539509352024; Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489; Nahin Richard L, 2016, Natl Health Stat Report, P1; Shih CC, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1679-2; Upchurch DM, 2014, J ALTERN COMPLEM MED, V20, P32, DOI 10.1089/acm.2012.0120; Wang SJ, 2012, ALLERGY, V67, P583, DOI 10.1111/j.1398-9995.2012.02806.x; Yang L, 2017, ACUPUNCT MED, V35, P189, DOI 10.1136/acupmed-2016-011179; Zhong LLD, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0099-4	25	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2020	15	10							e0240311	10.1371/journal.pone.0240311	http://dx.doi.org/10.1371/journal.pone.0240311			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8VY	33104738	Green Published, gold			2023-01-03	WOS:000588370000011
J	Iommi, M; Rosa, S; Fusaroli, M; Rucci, P; Fantini, MP; Poluzzi, E				Iommi, Marica; Rosa, Simona; Fusaroli, Michele; Rucci, Paola; Fantini, Maria Pia; Poluzzi, Elisabetta			Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions	PLOS ONE			English	Article							ADMINISTRATIVE DATABASES; COMORBIDITY; MORTALITY; HEALTH	Background Estimating the morbidity of a population is strategic for health systems to improve healthcare. In recent years administrative databases have been increasingly used to predict health outcomes. In 1992, Von Korff proposed a Chronic Disease Score (CDS) to predict 1-year mortality by only using drug prescription data. Because pharmacotherapy underwent many changes over the last 3 decades, the original version of the CDS has limitations. The aim of this paper is to report on the development of the modified version of the CDS. Methods The modified CDS (M-CDS) was developed using 33 variables (from drug prescriptions within two-year before 01/01/2018) to predict one-year mortality in Bologna residents aged >= 50 years. The population was split into training and testing sets for internal validation. Score weights were estimated in the training set using Cox regression model with LASSO procedure for variables selection. The external validation was carried out on the Imola population. The predictive ability of M-CDS was assessed using ROC analysis and compared with that of the Charlson Comorbidity Index (CCI), that is based on hospital data only, and of the Multisource Comorbidity Score (MCS), which uses hospital and pharmaceutical data. Results The predictive ability of M-CDS was similar in the training and testing sets (AUC 95% CI: training [0.760-0.770] vs. testing [0.750-0.772]) and in the external population (Imola AUC 95% CI [0.756-0.781]). M-CDS was significantly better than CCI (M-CDS AUC = 0.761, 95% CI [0.750-0.772] vs. CCI-AUC = 0.696, 95% CI [0.681-0.711]). No significant difference was found between M-CDS and MCS (MCS AUC = 0.762, 95% CI [0.749-0.775]). Conclusions M-CDS, using only drug prescriptions, has a better performance than the CCI score in predicting 1-year mortality, and is not inferior to the multisource comorbidity score. M-CDS can be used for population risk stratification, for risk-adjustment in association studies and to predict the individual risk of death.	[Iommi, Marica; Rosa, Simona; Rucci, Paola; Fantini, Maria Pia] Univ Bologna, Hyg & Biostat Unit, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Fusaroli, Michele; Poluzzi, Elisabetta] Univ Bologna, Pharmacol Unit, Dept Med & Surg Sci, Bologna, Italy	University of Bologna; University of Bologna	Iommi, M (corresponding author), Univ Bologna, Hyg & Biostat Unit, Dept Biomed & Neuromotor Sci, Bologna, Italy.	marica.iommi2@unibo.it	Fusaroli, Michele/AAK-6107-2021; Fusaroli, Michele/AAJ-6956-2021	Fusaroli, Michele/0000-0002-0254-2212; Fusaroli, Michele/0000-0002-0254-2212; POLUZZI, ELISABETTA/0000-0002-7209-0426; Rucci, Paola/0000-0002-7704-0831; Iommi, Marica/0000-0003-4589-3474				Ahlgren-Rimpilainen AJ, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112801; Chang W, 2020, SCHIZOPHR B, DOI [10.1093/schbul/sbaa013/5743103, DOI 10.1093/SCHBUL/SBAA013/5743103]; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chini F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-688; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Corrao G, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019503; Dudoit S, 2005, STAT METHODOL, V2, P131, DOI [10.1016/j.stamet.2005.02.003, DOI 10.1016/J.STAMET.2005.02.003]; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ellis R.P., 2018, RISK ADJUSTMENT RISK, P55, DOI [10.1016/B978-0-12-811325-7.00003-8, DOI 10.1016/B978-0-12-811325-7.00003-8]; Gallo JJ, 2005, AM J GERIAT PSYCHIAT, V13, P748, DOI 10.1176/appi.ajgp.13.9.748; Hastie T., 2009, ELEMENTS STAT LEARNI, DOI [10.1007/978-0-387-84858-7, DOI 10.1007/978-0-387-84858-7]; Heila H, 2005, PSYCHOL MED, V35, P725, DOI 10.1017/S0033291704004118; Huber CA, 2013, J CLIN EPIDEMIOL, V66, P1118, DOI 10.1016/j.jclinepi.2013.04.011; Kass G.V., 1980, J R STAT SOC C, V29, P119, DOI 10.2307/2986296; Leal JR, 2010, CLIN MICROBIOL INFEC, V16, P715, DOI 10.1111/j.1469-0691.2009.02867.x; Mehta HB, 2016, MED CARE, V54, P519, DOI 10.1097/MLR.0000000000000517; Needham DM, 2005, J CRIT CARE, V20, P12, DOI 10.1016/j.jcrc.2004.09.007; Payne RA, 2020, CAN MED ASSOC J, V192, pE107, DOI 10.1503/cmaj.190757; Preen DB, 2004, J CLIN EPIDEMIOL, V57, P1295, DOI 10.1016/j.jclinepi.2004.03.016; Robusto F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149203; Sharabiani MTA, 2012, MED CARE, V50, P1109, DOI 10.1097/MLR.0b013e31825f64d0; Stirland LE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m160; Strom BL, 2013, TEXTBOOK OF PHARMACOEPIDEMIOLOGY, 2ND EDITION, P118; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; Walker ER, 2015, JAMA PSYCHIAT, V72, P334, DOI 10.1001/jamapsychiatry.2014.2502; Zielinski A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-347	27	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2020	15	10							e0240899	10.1371/journal.pone.0240899	http://dx.doi.org/10.1371/journal.pone.0240899			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OM3IA	33064757	gold, Green Published			2023-01-03	WOS:000585918300049
J	Goldenberg, JZ; Day, A; Brinkworth, GD; Sato, J; Yamada, S; Jonsson, T; Beardsley, J; Johnson, JA; Thabane, L; Johnston, BC				Goldenberg, Joshua Z.; Day, Andrew; Brinkworth, Grant D.; Sato, Junko; Yamada, Satoru; Jonsson, Tommy; Beardsley, Jennifer; Johnson, Jeffrey A.; Thabane, Lehana; Johnston, Bradley C.			Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-FAT DIET; PARTICIPANT OUTCOME DATA; PERSPECTIVE NUTRIGRADE; SCORING SYSTEM; META-EVIDENCE; NUTRITION THERAPY; GLYCEMIC CONTROL; WEIGHT-LOSS; RESTRICTION; MANAGEMENT	OBJECTIVE To determine the efficacy and safety of low carbohydrate diets (LCDs) and very low carbohydrate diets (VLCDs) for people with type 2 diabetes. DESIGN Systematic review and meta-analysis. DATA SOURCES Searches of CENTRAL, Medline, Embase, CINAHL, CAB, and grey literature sources from inception to 25 August 2020. STUDY SELECTION Randomized clinical trials evaluating LCDs (<130 g/ day or <26% of a 2000 kcal/day diet) and VLCDs (<10% calories from carbohydrates) for at least 12 weeks in adults with type 2 diabetes were eligible. DATA EXTRACTION Primary outcomes were remission of diabetes (HbA 1c <6.5% or fasting glucose <7.0 mmol/L, with or without the use of diabetes medication), weight loss, HbA 1c, fasting glucose, and adverse events. Secondary outcomes included health related quality of life and biochemical laboratory data. All articles and outcomes were independently screened, extracted, and assessed for risk of bias and GRADE certainty of evidence at six and 12 month follow-up. Risk estimates and 95% confidence intervals were calculated using random effects meta-analysis. Outcomes were assessed according to a priori determined minimal important differences to determine clinical importance, and heterogeneity was investigated on the basis of risk of bias and seven a priori subgroups. Any subgroup effects with a statistically significant test of interaction were subjected to a five point credibility checklist. RESULTS Searches identified 14 759 citations yielding 23 trials (1357 participants), and 40.6% of outcomes were judged to be at low risk of bias. At six months, compared with control diets, LCDs achieved higher rates of diabetes remission (defined as HbA 1c <6.5%) (76/133 (57%) v 41/131 (31%); risk difference 0.32, 95% confidence interval 0.17 to 0.47; 8 studies, n=264, I2=58%). Conversely, smaller, non-significant effect sizes occurred when a remission definition of HbA 1c <6.5% without medication was used. Subgroup assessments determined as meeting credibility criteria indicated that remission with LCDs markedly decreased in studies that included patients using insulin. At 12 months, data on remission were sparse, ranging from a small effect to a trivial increased risk of diabetes. Large clinically important improvements were seen in weight loss, triglycerides, and insulin sensitivity at six months, which diminished at 12 months. On the basis of subgroup assessments deemed credible, VLCDs were less effective than less restrictive LCDs for weight loss at six months. However, this effect was explained by diet adherence. That is, among highly adherent patients on VLCDs, a clinically important reduction in weight was seen compared with studies with less adherent patients on VLCDs. Participants experienced no significant difference in quality of life at six months but did experience clinically important, but not statistically significant, worsening of quality of life and low density lipoprotein cholesterol at 12 months. Otherwise, no significant or clinically important between group differences were found in terms of adverse events or blood lipids at six and 12 months. CONCLUSIONS On the basis of moderate to low certainty evidence, patients adhering to an LCD for six months may experience remission of diabetes without adverse consequences. Limitations include continued debate around what constitutes remission of diabetes, as well as the efficacy, safety, and dietary satisfaction of longer term LCDs.	[Goldenberg, Joshua Z.; Johnston, Bradley C.] Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA; [Goldenberg, Joshua Z.] Natl Univ Nat Med, Helfgott Res Inst, Portland, OR USA; [Day, Andrew] Day Family Med, Poulsbo, WA USA; [Brinkworth, Grant D.] Commonwealth Sci & Ind Res Org CSIRO Hlth & Biose, Sydney, NSW, Australia; [Sato, Junko] Juntendo Univ, Dept Metab & Endocrinol, Grad Sch Med, Tokyo, Japan; [Yamada, Satoru] Kitasato Univ, Kitasato Inst Hosp, Diabet Ctr, Tokyo, Japan; [Jonsson, Tommy] Lund Univ Reg Skane, Skane Univ Hosp, Ctr Primary Hlth Care Res, Malmo, Sweden; [Johnson, Jeffrey A.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Thabane, Lehana; Johnston, Bradley C.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Thabane, Lehana] St Josephs Healthcare, Biostat Unit, Hamilton, ON, Canada	Texas A&M University System; Texas A&M University College Station; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Juntendo University; Kitasato University; Lund University; Skane University Hospital; University of Alberta; McMaster University	Johnston, BC (corresponding author), Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA.; Johnston, BC (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.	bradley.johnston@tamu.edu	Sato, Junko/GQQ-8846-2022	Beardsley, Jennifer/0000-0002-7848-5381; Brinkworth, Grant/0000-0001-9017-8395	Texas AM University	Texas AM University	This study was funded in part by Texas A&M University. The university had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457; Akl EA, 2015, SYST REV-LONDON, V4, DOI 10.1186/s13643-015-0083-6; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Archer E, 2018, J CLIN EPIDEMIOL, V104, P113, DOI 10.1016/j.jclinepi.2018.08.003; Batterham MJ, 2013, NUTRITION, V29, P1024, DOI 10.1016/j.nut.2013.01.017; Brakenhoff TB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192298; Breukelman G. J., 2019, Asian Journal of Sports Medicine, V10, DOI 10.5812/asjsm.86905; Buse JB, 2009, DIABETES CARE, V32, P2133, DOI 10.2337/dc09-9036; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P80; Crowe TC, 2005, OBES REV, V6, P235, DOI 10.1111/j.1467-789X.2005.00196.x; da Costa BR, 2013, J CLIN EPIDEMIOL, V66, P847, DOI 10.1016/j.jclinepi.2013.03.009; Daly ME, 2006, DIABETIC MED, V23, P15, DOI 10.1111/j.1464-5491.2005.01760.x; Davis NJ, 2009, DIABETES CARE, V32, P1147, DOI 10.2337/dc08-2108; DeFronzo RA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.19; Dyson PA, 2010, DIETARY ADVICE PEOPL; Ebrahim S, 2013, J CLIN EPIDEMIOL, V66, P1014, DOI 10.1016/j.jclinepi.2013.03.014; Evert AB, 2019, DIABETES CARE, V42, P731, DOI 10.2337/dci19-0014; Evert AB, 2013, DIABETES CARE, V36, P3821, DOI 10.2337/dc13-2042; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; Gibson AA, 2015, OBES REV, V16, P64, DOI 10.1111/obr.12230; Giovannucci E, 2020, ANN INTERN MED, V172, P510, DOI 10.7326/L20-0069; Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f; Goldstein T., 2011, e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, V6, pe178; Guldbrand H, 2012, DIABETOLOGIA, V55, P2118, DOI 10.1007/s00125-012-2567-4; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2017, J CLIN EPIDEMIOL, V87, P14, DOI 10.1016/j.jclinepi.2017.05.005; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Iqbal N, 2010, OBESITY, V18, P1733, DOI 10.1038/oby.2009.460; Johnston BC, 2020, VERY LOW CARBOHYDRAT; Johnston BC, 2016, AM J CLIN NUTR, V104, P1197, DOI 10.3945/ajcn.115.123315; Johnston BC, 2016, CAN MED ASSOC J, V188, P25, DOI 10.1503/cmaj.150430; Jonsson T, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-35; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Korsmo-Haugen HK, 2019, DIABETES OBES METAB, V21, P15, DOI 10.1111/dom.13499; Lee P, 2013, DIABETIC MED, V30, P47; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Meerpohl JJ, 2017, ADV NUTR, V8, P789, DOI 10.3945/an.117.016188; Morris E, 2020, DIABETES OBES METAB, V22, P512, DOI 10.1111/dom.13915; Naude CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100652; Nishimori E., 2018, DIABETES, V61, P297; Perna S., 2019, BAHRAIN MEDICAL B, V41, P159; Prentice RL, 2020, ANN INTERN MED, V172, P354, DOI 10.7326/M19-3290; Sainsbury E, 2018, DIABETES RES CLIN PR, V139, P239, DOI 10.1016/j.diabres.2018.02.026; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Saslow LR, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.5806; Saslow LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091027; Sato J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188892; Sato J, 2017, CLIN NUTR, V36, P992, DOI 10.1016/j.clnu.2016.07.003; Schunemann H, 2013, GRADE HDB; Schwingshackl L, 2017, ADV NUTR, V8, P790, DOI 10.3945/an.117.016469; Schwingshackl L, 2016, ADV NUTR, V7, P994, DOI 10.3945/an.116.013052; Seidelmann SB, 2018, LANCET PUBLIC HEALTH, V3, pE419, DOI 10.1016/S2468-2667(18)30135-X; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Snorgaard O, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000354; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Sun X, 2014, JAMA-J AM MED ASSOC, V311, P405, DOI 10.1001/jama.2013.285063; Tay J, 2019, LANCET DIABETES ENDO, V7, P331, DOI 10.1016/S2213-8587(18)30368-1; Tay J, 2014, DIABETES CARE, V37, P2909, DOI 10.2337/dc14-0845; Thorlund K, 2011, RES SYNTH METHODS, V2, P188, DOI 10.1002/jrsm.46; van Zuuren EJ, 2018, AM J CLIN NUTR, V108, P300, DOI 10.1093/ajcn/nqy096; Vlachos D, 2011, DIABETOLOGIA, V54, pS355; Volek JS, 2008, PROG LIPID RES, V47, P307, DOI 10.1016/j.plipres.2008.02.003; Westman EC, 2008, NUTR METAB, V5, DOI [10.1186/1743-7075-5-10, 10.1186/1743-7075-5-36]; Westman EC, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-36; Yamada Y, 2014, INTERNAL MED, V53, P13, DOI [10.2169/internalmedicine.53.0861, 10.2169/interna]; Yancy WS, 2010, ARCH INTERN MED, V170, P136, DOI 10.1001/archinternmed.2009.492; Zadeh MAM, 2018, J DIABETES METAB DIS, V17, P253, DOI 10.1007/s40200-018-0368-0; Zheng Y, 2018, NAT REV ENDOCRINOL, V14, P88, DOI 10.1038/nrendo.2017.151	71	81	84	12	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2021	372								m4743	10.1136/bmj.m4743	http://dx.doi.org/10.1136/bmj.m4743			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT1QG	33441384	Green Published, hybrid			2023-01-03	WOS:000608393200002
J	Zitter, JN				Zitter, Jessica Nutik			Hummingbird Lessons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Zitter, Jessica Nutik] Highland Hosp, 1411 E 31st Ave, Oakland, CA 94602 USA		Zitter, JN (corresponding author), Highland Hosp, 1411 E 31st Ave, Oakland, CA 94602 USA.	info@jessicazitter.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	2021	325	2					131	132		10.1001/jama.2020.24862	http://dx.doi.org/10.1001/jama.2020.24862			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PS4FO	33433579				2023-01-03	WOS:000607879400013
J	Chen, CY; Liang, SH; Su, YY; Chiang, NJ; Wang, HC; Chiu, CF; Chen, LT; Bai, LY				Chen, Chia-Yu; Liang, Shih-Hsin; Su, Yung-Yeh; Chiang, Nai-Jung; Wang, Hui-Ching; Chiu, Chang-Fang; Chen, Li-Tzong; Bai, Li-Yuan			Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan	PLOS ONE			English	Article							RANDOMIZED PHASE-II; DOSE RATE INFUSION; 30-MINUTE INFUSION; PLUS LEUCOVORIN; CANCER; OXALIPLATIN; SURVIVAL; PLASMA; TRIAL	Background In pancreatic cancer, toxicities associated with current chemotherapeutic regimens remain concerning. A modified combination of gemcitabine, S-1, and leucovorin (GSL) was used as the first-line treatment for newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma patients. Methods GSL was administered every 2 weeks-intravenous gemcitabine 800 mg/m(2) at a fixed-dose rate of 10 mg/m(2)/min on day 1 and oral S-1 (80-120 mg/day) plus leucovorin 30 mg twice daily on days 1-7. We retrospectively analyzed the feasibility of GSL and patient outcomes in three medical centers in Taiwan. Results Overall, 49 patients received GSL with a median follow-up of 24.9 months from May 2015 to March 2019. The median patient age was 68 years (range, 47-83 years), with a marginally higher number of females (57.1%). Among the 44 patients who underwent image evaluation, 13 demonstrated a partial response (29.5%) and 17 presented with stable disease (38.6%). The partial response rate and stable disease rate was 26.5% and 34.7%, respectively, in the intent-to-treat analysis. The median time-to-treatment failure was 5.79 months (95% C.I., 2.63-8.94), progression-free survival was 6.94 months (95% C.I., 5.55-8.33), and overall survival time was 11.53 months (95% C.I., 9.94-13.13). For GSL treatment, the most common grade 3 or worse toxicities were anemia (18.3%), neutropenia (6.1%), nausea (4.1%), and mucositis (4.1%). Treatment discontinuation was mostly due to disease progression (65.3%). Conclusions The modified GSL therapy can be a promising and affordable treatment for patients with advanced and metastatic pancreatic cancer in Taiwan. A prospective trial of modified GSL for elderly patients is currently ongoing in Taiwan.	[Chen, Chia-Yu; Liang, Shih-Hsin; Chiu, Chang-Fang; Bai, Li-Yuan] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan; [Liang, Shih-Hsin] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Internal Med, Chiayi, Taiwan; [Su, Yung-Yeh; Chiang, Nai-Jung; Chen, Li-Tzong] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Su, Yung-Yeh; Chiang, Nai-Jung; Chen, Li-Tzong] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Tainan, Taiwan; [Wang, Hui-Ching; Chen, Li-Tzong] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Chiu, Chang-Fang; Bai, Li-Yuan] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan; [Chiu, Chang-Fang] China Med Univ Hosp, Ctr Canc, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Bai, LY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan.; Chen, LT (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan.; Chen, LT (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Tainan, Taiwan.; Chen, LT (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.; Bai, LY (corresponding author), China Med Univ, Sch Med, Coll Med, Taichung, Taiwan.	leochen@nhri.edu.tw; lybai6@gmail.com		Su, Yung-Yeh/0000-0002-5133-5316	National Health Research Institutes, Taiwan [NHRI-109A1-CACO-13202002]; Ministry of Health and Welfare, Taiwan [MOHW109-TDU-B-212-134026, MOHW109-TDU-B-212-010001]; Ministry of Science and Technology, Taiwan [MOST109-2321-8-006-011-]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Health and Welfare, Taiwan; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	LYB: grants from the National Health Research Institutes, Taiwan (NHRI-109A1-CACO-13202002), the Ministry of Health and Welfare, Taiwan (MOHW109-TDU-B-212-134026), and Ministry of Science and Technology, Taiwan (MOST109-2321-8-006-011-) during the study. CFC: grants from the Ministry of Health and Welfare, Taiwan (MOHW109-TDU-B-212-010001).	ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Attia S, 2009, CANCER CHEMOTH PHARM, V64, P45, DOI 10.1007/s00280-008-0844-1; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen JS, 2015, ANN ONCOL, V26, P943, DOI 10.1093/annonc/mdv035; Chiang NJ, 2020, EUR J CANCER, V124, P123, DOI 10.1016/j.ejca.2019.10.023; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; GRUNEWALD R, 1992, J CLIN ONCOL, V10, P406, DOI 10.1200/JCO.1992.10.3.406; Health Promotion Administration, 2016, CANC REG ANN REP 201; Hironaka S, 2016, LANCET ONCOL, V17, P99, DOI 10.1016/S1470-2045(15)00410-6; Koizumi W, 2010, ANN ONCOL, V21, P766, DOI 10.1093/annonc/mdp371; Li J, 2017, CANCER SCI, V108, P2045, DOI 10.1111/cas.13335; Ozaka M, 2018, CANCER CHEMOTH PHARM, V81, P1017, DOI 10.1007/s00280-018-3577-9; Poplin E, 2009, J CLIN ONCOL, V27, P3778, DOI 10.1200/JCO.2008.20.9007; Saito K, 2019, INVEST NEW DRUG, V37, P338, DOI 10.1007/s10637-018-0691-9; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Ueno M, 2016, ANN ONCOL, V27, P502, DOI 10.1093/annonc/mdv603; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369	18	2	2	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0244487	10.1371/journal.pone.0244487	http://dx.doi.org/10.1371/journal.pone.0244487			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BU	33373398	Green Published, gold			2023-01-03	WOS:000603612300025
J	Hutson, SP; Golden, A; Odoi, A				Hutson, Sadie P.; Golden, Ashley; Odoi, Agricola			Geographic distribution of hospice, homecare, and nursing home facilities and access to end-of-life care among persons living with HIV/AIDS in Appalachia	PLOS ONE			English	Article							HEALTH; DISPARITIES; TENNESSEE; STROKE; GIS	Background Access to healthcare services, from diagnosis through end of life (EOL), is important among persons living with Human Immunodeficiency Syndrome (HIV) and Acquired Immunodeficiency Syndrome (AIDS) (PLWHA). However, little is known about the availability of hospice services in Appalachian areas. Therefore, the objective of this study is to describe the geographic distribution of hospice, homecare and nursing home facilities in order to demonstrate current existence of and access to resources for EOL care among PLWHA in the Appalachian regions of Tennessee and Alabama. Methods This paper reports on the second aim of a larger sequential, mixed methods qualitative-quantitative (qual -> quan) study. Data from advance care planning (ACP) surveys were collected by both electronic (n = 28) and paper copies (n = 201) and, among other things, obtained information on zip codes of residence of PLWHA. This enabled assessment of the geographic distribution of residences of PLWHA in relation to the distribution of healthcare services such as hospice and home healthcare services. Hospice and Home Healthcare data were obtained from the Tennessee and Alabama Departments of Health. The street addresses of these facilities were used to geocode and map the geographic distributions of the facilities using Street Map USA. Travel times to Hospice and Home Healthcare facilities were computed and mapped using ArcGIS 10.3. Results We identified a total of 32 hospice and 69 home healthcare facilities in the Tennessee Appalachian region, while the Alabama Appalachian region had a total of 110 hospice and 86 home healthcare facilities. Most care facilities were located in urban centers. The distribution of care facilities was worse in Tennessee with many counties having no facilities, requiring up to an hour drive time to reach patients. A total of 86% of the PLWHA indicated preference to die at home. Conclusions Persons living with HIV/AIDS in Appalachia face a number of challenges at the end of life that make access to EOL services difficult. Although respondents indicated a preference to die at home, the hospice/homecare infrastructure and resources are overwhelmingly inadequate to meet this need. There is need to improve access to EOL care in the Appalachian regions of both Tennessee and Alabama although the need is greater in Tennessee.	[Hutson, Sadie P.] Univ Tennessee, Coll Nursing, Knoxville, TN 37901 USA; [Golden, Ashley] Oak Ridge Associated Univ, Oak Ridge, TN USA; [Odoi, Agricola] Univ Tennessee, Inst Agr, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37901 USA	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Hutson, SP (corresponding author), Univ Tennessee, Coll Nursing, Knoxville, TN 37901 USA.	shutson@utk.edu	Odoi, Agricola/I-9532-2019; Golden, Ashley/AAG-9445-2021	Odoi, Agricola/0000-0001-5050-6737; Golden, Ashley/0000-0002-9430-7702	National Institute of Nursing Research of the National Institutes of Health [R21NR014055]	National Institute of Nursing Research of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This work was funded by the National Institute of Nursing Research of the National Institutes of Health under Award Number R21NR014055 to SPH. ninr.nih.gov The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appalachian Regional Commission, 2017, CREAT CULT HLTH APP; Bone AE, 2018, PALLIATIVE MED, V32, P329, DOI 10.1177/0269216317734435; Busingye D, 2011, SPAT SPATIO-TEMPORAL, V2, P247, DOI 10.1016/j.sste.2011.07.010; Campbell CL, 2009, J NURS SCHOLARSHIP, V41, P420, DOI 10.1111/j.1547-5069.2009.01310.x; Carlson MDA, 2010, J PALLIAT MED, V13, P1331, DOI 10.1089/jpm.2010.0209; Casey Michelle M, 2005, Am J Hosp Palliat Care, V22, P363, DOI 10.1177/104990910502200509; Centers for Disease Control and Prevention, 2016, HIV SURV REP, V28; Centers for Disease Control and Prevention (CDC) National HIV Surveillance System, 2012, 2012 HIV PREV RAT PE; Chukwusa E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231666; Chukwusa E, 2019, INT J HEALTH GEOGR, V18, DOI 10.1186/s12942-019-0172-1; ESRI, 2015, ARCGIS DESKT REL 10; Finucane AM, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0490-x; Gatrell AC, 2012, HEALTH PLACE, V18, P832, DOI 10.1016/j.healthplace.2012.03.009; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Griffith BN, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-229; Hawley P., 2017, BARRIERS ACCESS PALL, DOI [10.1177/1178224216688887, DOI 10.1177/1178224216688887]; Heckman TG, 1998, AIDS CARE, V10, P365, DOI 10.1080/713612410; Jenkins TM, 2009, PREV CHRONIC DIS, P6; Kohli S, 1995, J Med Syst, V19, P425, DOI 10.1007/BF02260846; Lindley LC, 2015, AM J HOSP PALLIAT ME, V32, P849, DOI 10.1177/1049909114543641; Lyon ME, 2008, J PALLIAT MED, V11, P459, DOI 10.1089/jpm.2007.0148; Madigan Elizabeth A, 2009, Policy Polit Nurs Pract, V10, P71, DOI 10.1177/1527154409333861; McLafferty SL, 2003, ANNU REV PUBL HEALTH, V24, P25, DOI 10.1146/annurev.publhealth.24.012902.141012; Medicare Payment Advisory Commission, 2009, C MED PAYM POL; Pedigo AS, 2010, ANN EPIDEMIOL, V20, P924, DOI 10.1016/j.annepidem.2010.06.013; Rainsford S, 2018, HEALTH SOC CARE COMM, V26, P273, DOI 10.1111/hsc.12385; Rainsford S, 2017, PALLIATIVE MED, V31, P895, DOI 10.1177/0269216316685234; Ray N, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-63; Rhodes RL, 2016, J PAIN SYMPTOM MANAG, V51, P120, DOI 10.1016/j.jpainsymman.2015.08.010; Schuurman Nadine, 2006, Int J Health Geogr, V5, P43, DOI 10.1186/1476-072X-5-43; Tansley G, 2019, CAN J SURG, V62, P123, DOI 10.1503/cjs.004218; Tansley G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141113; US Census Bureau Geography Division, 2016, CART BOUNDR FIL DESC; Virnig BA, 2006, J PALLIAT MED, V9, P1292, DOI 10.1089/jpm.2006.9.1292; Walker BB, 2017, RURAL REMOTE HEALTH, V17, DOI 10.22605/RRH4210; World Health Organization, 2020, PALLI8 ENS PALL CAR	36	0	0	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243814	10.1371/journal.pone.0243814	http://dx.doi.org/10.1371/journal.pone.0243814			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH1MP	33315923	gold, Green Published			2023-01-03	WOS:000600186100038
J	Jiang, LW; Wang, YJ; Zhao, J; Uehara, M; Hou, QM; Kasinath, V; Ichimura, T; Banouni, N; Dai, L; Li, XF; Greiner, DL; Shultz, LD; Zhang, XL; Sun, ZYJ; Curtin, I; Vangos, NE; Yeoh, ZC; Geffken, EA; Seo, HS; Liu, ZX; Heffron, GJ; Shah, K; Dhe-Paganon, S; Abdi, R				Jiang, Liwei; Wang, Yi-Jun; Zhao, Jing; Uehara, Mayuko; Hou, Qingming; Kasinath, Vivek; Ichimura, Takaharu; Banouni, Naima; Dai, Li; Li, Xiaofei; Greiner, Dale L.; Shultz, Leonard D.; Zhang, Xiaolong; Sun, Zhen-Yu Jim; Curtin, Ian; Vangos, Nicholas E.; Yeoh, Zoe C.; Geffken, Ezekiel A.; Seo, Hyuk-Soo; Liu, Ze-Xian; Heffron, Gregory J.; Shah, Khalid; Dhe-Paganon, Sirano; Abdi, Reza			Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy	CELL			English	Article								Cancer therapies kill tumors either directly or indirectly by evoking immune responses and have been combined with varying levels of success. Here, we describe a paradigm to control cancer growth that is based on both direct tumor killing and the triggering of protective immunity. Genetic ablation of serine protease inhibitor SerpinB9 (Sb9) results in the death of tumor cells in a granzyme B (GrB)-dependent manner. Sb9-deficient mice exhibited protective T cell-based host immunity to tumors in association with a decline in GrB-expressing immunosuppressive cells within the tumor microenvironment (TME). Maximal protection against tumor development was observed when the tumor and host were deficient in Sb9. The therapeutic utility of Sb9 inhibition was demonstrated by the control of tumor growth, resulting in increased survival times in mice. Our studies describe a molecular target that permits a combination of tumor ablation, interference within the TME, and immunotherapy in one potential modality.	[Jiang, Liwei; Wang, Yi-Jun; Zhao, Jing; Uehara, Mayuko; Hou, Qingming; Kasinath, Vivek; Banouni, Naima; Dai, Li; Li, Xiaofei; Abdi, Reza] Harvard Med Sch, Transplantat Res Ctr, Brigham & Womens Hosp, Renal Div, Boston, MA 02115 USA; [Ichimura, Takaharu] Harvard Med Sch, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; [Greiner, Dale L.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; [Shultz, Leonard D.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA; [Hou, Qingming] Qingdao Univ, Inst Neuroregenerat & Neurorehabil, Qingdao 266071, Peoples R China; [Zhang, Xiaolong; Liu, Ze-Xian] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Peoples R China; [Sun, Zhen-Yu Jim; Seo, Hyuk-Soo; Heffron, Gregory J.; Dhe-Paganon, Sirano] Harvard Med Sch, Blavatnik Inst, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA; [Shah, Khalid] Harvard Med Sch, Ctr Stem Cell Therapeut & Imaging, Brigham & Womens Hosp, Boston, MA 02115 USA; [Shah, Khalid] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Sun, Zhen-Yu Jim; Curtin, Ian; Vangos, Nicholas E.; Yeoh, Zoe C.; Geffken, Ezekiel A.; Seo, Hyuk-Soo; Dhe-Paganon, Sirano] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; [Shah, Khalid; Abdi, Reza] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Jackson Laboratory; Qingdao University; State Key Lab Oncology South China; Sun Yat Sen University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University	Abdi, R (corresponding author), Harvard Med Sch, Transplantat Res Ctr, Brigham & Womens Hosp, Renal Div, Boston, MA 02115 USA.; Abdi, R (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.	rabdi@rics.bwh.harvard.edu	Wang, Yu/GZL-9655-2022; Wang, Yijun/GXW-1763-2022; Wang, Yixuan/GZK-6559-2022; wang, yixuan/GXW-2866-2022; Li, xiaofei/GXF-7187-2022; Wang, Yin/HCI-9352-2022; Liu, Zexian/D-1153-2011; wang, yi/GVT-8516-2022	Liu, Zexian/0000-0001-9698-0610; Seo, Hyuk-Soo/0000-0003-0646-2102	National Institute of Allergy and Infectious Diseases; Office of the Director of the NIH [R01-AI132963, R24-OD018259]; National Cancer Institute [CA034196]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of the Director of the NIH; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institute of Allergy and Infectious Diseases and Office of the Director of the NIH (R01-AI132963 to L.D.S. and R24-OD018259 to L.D.S. and D.L.G.), as well as by a National Cancer Institute core grant (CA034196 to L.D.S.).	Andersson A, 2009, J IMMUNOL, V182, P6951, DOI 10.4049/jimmunol.0803340; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Azzi J, 2013, J IMMUNOL, V191, P2319, DOI 10.4049/jimmunol.1300851; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bots M, 2008, J LEUKOCYTE BIOL, V84, P1238, DOI 10.1189/jlb.0208140; Bots M, 2006, BLOOD, V107, P4974, DOI 10.1182/blood-2006-01-0291; Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007; D'Eliseo D, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0302-6; D'Eliseo D, 2010, INT J CANCER, V127, P1283, DOI 10.1002/ijc.25135; El Haddad N, 2011, J IMMUNOL, V187, P2252, DOI 10.4049/jimmunol.1003981; El Haddad N, 2011, BLOOD, V117, P1176, DOI 10.1182/blood-2010-06-287979; Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Hirst CE, 2003, J IMMUNOL, V170, P805, DOI 10.4049/jimmunol.170.2.805; Hu SX, 2003, BRIT J CANCER, V89, P135, DOI 10.1038/sj.bjc.6601051; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kar UK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018758; Kather JN, 2018, ELIFE, V7, DOI 10.7554/eLife.36967; KENDAL WS, 1987, CANCER RES, V47, P3835; Kim MT, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00295; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kontani K, 2001, EUR J SURG ONCOL, V27, P180, DOI 10.1053/ejso.2000.1060; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Lauricella M, 2016, INT J ONCOL, V49, P352, DOI 10.3892/ijo.2016.3495; Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Mangan MSJ, 2008, TISSUE ANTIGENS, V72, P1, DOI 10.1111/j.1399-0039.2008.01059.x; Mangan MSJ, 2016, J BIOL CHEM, V291, P3626, DOI 10.1074/jbc.M115.699298; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; Mestres J, 2009, TRENDS PHARMACOL SCI, V30, P470, DOI 10.1016/j.tips.2009.07.004; Nilendu P, 2018, CELL ONCOL, V41, P353, DOI 10.1007/s13402-018-0388-2; Pearson JD, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-199; Peoples GE, 2019, LANCET ONCOL, V20, P316, DOI 10.1016/S1470-2045(19)30068-3; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Pinkoski MJ, 2001, J BIOL CHEM, V276, P12060, DOI 10.1074/jbc.M009038200; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMc1801663, 10.1056/NEJMra1703481]; Prakash MD, 2014, IMMUNITY, V41, P960, DOI 10.1016/j.immuni.2014.11.012; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rizzitelli A, 2012, IMMUNOL CELL BIOL, V90, P841, DOI 10.1038/icb.2012.29; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Slyper M, 2020, NAT MED, V26, P792, DOI 10.1038/s41591-020-0844-1; Smits AH, 2019, NAT METHODS, V16, P1087, DOI 10.1038/s41592-019-0614-5; Sun JR, 1997, J BIOL CHEM, V272, P15434, DOI 10.1074/jbc.272.24.15434; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Tamang DL, 2006, CYTOKINE, V36, P148, DOI 10.1016/j.cyto.2006.11.008; Tellez-Gabriel M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122142; Trujillo JA, 2018, CANCER IMMUNOL RES, V6, P990, DOI 10.1158/2326-6066.CIR-18-0277; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Wei LS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1104-x; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zhang ML, 2006, IMMUNITY, V24, P451, DOI 10.1016/j.immuni.2006.02.002; Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238	59	20	23	5	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 25	2020	183	5					1219	+		10.1016/j.cell.2020.10.045	http://dx.doi.org/10.1016/j.cell.2020.10.045			33	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	OW9ND	33242418	Green Accepted, Bronze			2023-01-03	WOS:000593203800008
J	Ganbaatar, O; Konnai, S; Okagawa, T; Nojima, Y; Maekawa, N; Minato, E; Kobayashi, A; Ando, R; Sasaki, N; Miyakoshi, D; Ichii, O; Kato, Y; Suzuki, Y; Murata, S; Ohashi, K				Ganbaatar, Otgontuya; Konnai, Satoru; Okagawa, Tomohiro; Nojima, Yutaro; Maekawa, Naoya; Minato, Erina; Kobayashi, Atsushi; Ando, Ryo; Sasaki, Nobuya; Miyakoshi, Daisuke; Ichii, Osamu; Kato, Yukinari; Suzuki, Yasuhiko; Murata, Shiro; Ohashi, Kazuhiko			PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade	PLOS ONE			English	Article							T-CELL EXHAUSTION; TUMOR-CELLS; ANTIBODY; RECEPTOR; MEK; SELECTION; INCREASE; LIGANDS; HORSES; SAFETY	Programmed death-1 (PD-1) is an immunoinhibitory receptor expressed on lymphocytes. Interaction of PD-1 with its ligand PD-ligand 1 (PD-L1) delivers inhibitory signals and impairs proliferation, cytokine production, and cytotoxicity of T cells. In our previous studies, we have developed anti-bovine PD-L1 monoclonal antibodies (mAbs) and reported that the PD-1/PD-L1 pathway was closely associated with T-cell exhaustion and disease progression in bovine chronic infections and canine tumors. Furthermore, we found that blocking antibodies that target PD-1 and PD-L1 restore T-cell functions and could be used in immunotherapy in cattle and dogs. However, the immunological role of the PD-1/PD-L1 pathway for chronic equine diseases, including tumors, remains unclear. In this study, we identified cDNA sequences of equine PD-1 (EqPD-1) and PD-L1 (EqPD-L1) and investigated the role of anti-bovine PD-L1 mAbs against EqPD-L1 using in vitro assays. In addition, we evaluated the expression of PD-L1 in tumor tissues of equine malignant melanoma (EMM). The amino acid sequences of EqPD-1 and EqPD-L1 share a considerable identity and similarity with homologs from non-primate species. Two clones of the anti-bovine PD-L1 mAbs recognized EqPD-L1 in flow cytometry, and one of these cross-reactive mAbs blocked the binding of equine PD-1/PD-L1. Of note, immunohistochemistry confirmed the PD-L1 expression in EMM tumor tissues. A cultivation assay revealed that PD-L1 blockade enhanced the production of Th1 cytokines in equine immune cells. These findings showed that our anti-PD-L1 mAbs would be useful for analyzing the equine PD-1/PD-L1 pathway. Further research is warranted to discover the immunological role of PD-1/PD-L1 in chronic equine diseases and elucidate a future application in immunotherapy for horses.	[Ganbaatar, Otgontuya; Konnai, Satoru; Nojima, Yutaro; Murata, Shiro; Ohashi, Kazuhiko] Hokkaido Univ, Fac Vet Med, Dept Dis Control, Sapporo, Hokkaido, Japan; [Konnai, Satoru; Okagawa, Tomohiro; Maekawa, Naoya; Suzuki, Yasuhiko; Murata, Shiro; Ohashi, Kazuhiko] Hokkaido Univ, Fac Vet Med, Dept Adv Pharmaceut, Sapporo, Hokkaido, Japan; [Minato, Erina; Kobayashi, Atsushi] Hokkaido Univ, Fac Vet Med, Dept Vet Clin Med, Sapporo, Hokkaido, Japan; [Ando, Ryo] Kitasato Univ, Sch Vet Med, Lab Vet Pathol, Towada, Aomori, Japan; [Sasaki, Nobuya] Kitasato Univ, Sch Vet Med, Lab Lab Anim Sci & Med, Towada, Aomori, Japan; [Miyakoshi, Daisuke] NOSAI Minami, Mitsuishi Anim Med Ctr, Shinhidaka, Japan; [Ichii, Osamu] Hokkaido Univ, Fac Vet Med, Dept Vet Basic Sci, Sapporo, Hokkaido, Japan; [Suzuki, Yasuhiko] Tohoku Univ, Grad Sch Med, Dept Antibody Drug Dev, Sendai, Miyagi, Japan; [Suzuki, Yasuhiko] Tohoku Univ, New Ind Creat Hatchery Ctr, Sendai, Miyagi, Japan; [Suzuki, Yasuhiko] Hokkaido Univ, Res Ctr Zoonosis Control, Div Bioresources, Sapporo, Hokkaido, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Kitasato University; Kitasato University; Hokkaido University; Tohoku University; Tohoku University; Hokkaido University	Konnai, S (corresponding author), Hokkaido Univ, Fac Vet Med, Dept Dis Control, Sapporo, Hokkaido, Japan.; Konnai, S (corresponding author), Hokkaido Univ, Fac Vet Med, Dept Adv Pharmaceut, Sapporo, Hokkaido, Japan.	konnai@vetmed.hokudai.ac.jp	Okagawa, Tomohiro/AAX-1284-2021	Satoru, Konnai/0000-0002-3230-7109; Kato, Yukinari/0000-0001-5385-8201	JSPS KAKENHI [19KK0172, 19H03114]; Project of the NARO, Bio-oriented Technology Research Advancement Institution (Research Program on Development of Innovative Technology) [26058 BC]; Northern Advancement Center for Science & Technology of Hokkaido Japan; AMED [JP20am0101078]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Project of the NARO, Bio-oriented Technology Research Advancement Institution (Research Program on Development of Innovative Technology); Northern Advancement Center for Science & Technology of Hokkaido Japan; AMED	This work was supported by JSPS KAKENHI grant number 19KK0172 [to S.K.] and 19H03114 [to S.K.], grants from the Project of the NARO, Bio-oriented Technology Research Advancement Institution (Research Program on Development of Innovative Technology 26058 BC [to S.K.], Grants-in-Aid for Regional R&D Proposal-Based Program from Northern Advancement Center for Science & Technology of Hokkaido Japan [to T.O.], and AMED under grant number JP20am0101078 [to Y.K.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brosnahan MM, 2003, J AM VET MED ASSOC, V223, P93, DOI 10.2460/javma.2003.223.93; Cavalleri JMV, 2015, PFERDEHEILKUNDE, V31, P448, DOI 10.21836/PEM20150504; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dong H, 2002, NAT REV IMMUNOL, V2, P545, DOI 10.1038/nm730; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Goto S, 2020, JPN J VET RES, V68, P77, DOI 10.14943/jjvr.68.2.77; Goto S, 2017, IMMUN INFLAMM DIS, V5, P355, DOI 10.1002/iid3.173; Ikebuchi R, 2014, IMMUNOLOGY, V142, P551, DOI 10.1111/imm.12243; Ikebuchi R, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-59; Ikebuchi R, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-103; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; Iwai Y, 2005, INT IMMUNOL, V17, P133, DOI 10.1093/intimm/dxh194; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jiang LY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-131; Jiang XF, 2013, CLIN CANCER RES, V19, P598, DOI 10.1158/1078-0432.CCR-12-2731; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339; Maekawa N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09444-2; Maekawa N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157176; Maekawa N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098415; McFADYEAN JOHN, 1933, JOUR COMP PATH AND THERAP, V46, P186; Nishimori A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174916; Nishimura H, 1998, INT IMMUNOL, V10, P1563, DOI 10.1093/intimm/10.10.1563; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Malley DP, 2019, MODERN PATHOL, V32, P929, DOI 10.1038/s41379-019-0210-3; Okagawa T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00650; Okagawa T, 2016, INFECT IMMUN, V84, P2779, DOI 10.1128/IAI.00278-16; Okagawa T, 2016, INFECT IMMUN, V84, P77, DOI 10.1128/IAI.01014-15; Pielberg GR, 2008, NAT GENET, V40, P1004, DOI 10.1038/ng.185; Sajiki Y, 2019, J IMMUNOL, V203, P1313, DOI 10.4049/jimmunol.1900342; Sajiki Y, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00910-17, 10.1128/iai.00910-17]; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Valentine BA, 2006, J VET DIAGN INVEST, V18, P123, DOI 10.1177/104063870601800121; VALENTINE BA, 1995, J VET INTERN MED, V9, P291, DOI 10.1111/j.1939-1676.1995.tb01087.x; Welsh CE, 2016, PREV VET MED, V131, P137, DOI 10.1016/j.prevetmed.2016.07.011	45	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0234218	10.1371/journal.pone.0234218	http://dx.doi.org/10.1371/journal.pone.0234218			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5CL	33216754	Green Published, Green Submitted, gold			2023-01-03	WOS:000595653500049
J	Stohr, E; Aksoy, A; Campbell, M; Al Zaidi, M; Ozturk, C; Vorloeper, J; Lange, J; Sugiura, A; Wilde, N; Becher, MU; Diepenseifen, C; Heister, U; Nickenig, G; Zimmer, S; Tiyerili, V				Stoehr, Elisabeth; Aksoy, Adem; Campbell, Meghan; Al Zaidi, Muntadher; Oeztuerk, Can; Vorloeper, Julia; Lange, Jonas; Sugiura, Atsushi; Wilde, Nihal; Becher, Marc Ulrich; Diepenseifen, Christian; Heister, Ulrich; Nickenig, Georg; Zimmer, Sebastian; Tiyerili, Vedat			Hospital admissions during Covid-19 lock-down in Germany: Differences in discretionary and unavoidable cardiovascular events	PLOS ONE			English	Article								Background A decline in hospitalization for cardiovascular events and catheter laboratory activation was reported for the United States and Italy during the initial stage of the Covid-19 pandemic of 2020. We report on the deployment of emergency services for cardiovascular events in a defined region in western Germany during the government-imposed lock-down period. Methods We examined 5799 consecutive patients who were treated by emergency services for cardiovascular events during the Covid-19 pandemic (January 1 to April 30, 2020), and compared those to the corresponding time frame in 2019. Examining the emergency physicians' records provided by nine locations in the area, we found a 20% overall decline in cardiovascular admissions. Results The greatest reduction could be seen immediately following the government-imposed social restrictions. This reduction was mainly driven by a reduction in discretionary admissions for dizziness/syncope (-53%), heart failure (-38%), exacerbated COPD (-28%) and unstable angina (-23%), while unavoidable admissions for ST-elevation myocardial infarction (STEMI), cardiopulmonary resuscitation (CPR) and stroke were unchanged. There was a greater decline in emergency admissions for patients >= 60 years. There was also a greater reduction in emergency admissions for those living in urban areas compared to suburban areas. Conclusions During the Covid-19 pandemic, a significant decline in hospitalization for cardiovascular events was observed during the government-enforced shutdown in a predefined area in western Germany. This reduction in admissions was mainly driven by "discretionary" cardiovascular events (unstable angina, heart failure, exacerbated COPD and dizziness/syncope), but events in which admission was unavoidable (CPR, STEMI and stroke) did not change.	[Stoehr, Elisabeth; Aksoy, Adem; Campbell, Meghan; Al Zaidi, Muntadher; Oeztuerk, Can; Vorloeper, Julia; Lange, Jonas; Sugiura, Atsushi; Wilde, Nihal; Becher, Marc Ulrich; Nickenig, Georg; Zimmer, Sebastian; Tiyerili, Vedat] Univ Bonn, Dept Cardiol, Heart Ctr, Bonn, Germany; [Campbell, Meghan] Univ Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany; [Diepenseifen, Christian] Amt Bevolkerungsschutz, Siegburg, Germany; [Heister, Ulrich] Univ Bonn, Dept Anesthesiol & Crit Care Med, Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Tiyerili, V (corresponding author), Univ Bonn, Dept Cardiol, Heart Ctr, Bonn, Germany.	vedat.tiyerili@ukbonn.de	Al Zaidi, Muntadher/GQQ-1994-2022	Ozturk, Can/0000-0002-5419-2488; Campbell, Meghan A./0000-0001-5378-2411; Al Zaidi, Muntadher/0000-0002-3534-3121				De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166; Dimsdale JE, 2008, J AM COLL CARDIOL, V51, P1237, DOI 10.1016/j.jacc.2007.12.024; Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; Rattka M, 2020, CLIN RES CARDIOL, V109, P1476, DOI 10.1007/s00392-020-01681-2; Rosa SD, REDUCTION HOSPITALIZ, P6; Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631; Ute W-L, 2008, NEW ENGLAND J MED, P9, DOI [10.1056/NEJMoa0706467, DOI 10.1056/NEJM0A0706467]; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	11	19	19	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0242653	10.1371/journal.pone.0242653	http://dx.doi.org/10.1371/journal.pone.0242653			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5CL	33216804	Green Published, gold			2023-01-03	WOS:000595653500008
J	Aloudah, N; Alhumsi, A; Alobeid, N; Aboheimed, N; Aboheimed, H; Aboheimed, G				Aloudah, Nouf; Alhumsi, Areej; Alobeid, Nada; Aboheimed, Nourah; Aboheimed, Hind; Aboheimed, Ghada			Factors impeding the supply of over-the-counter medications according to evidence-based practice: A mixed-methods study	PLOS ONE			English	Article							SAUDI-ARABIA; PHARMACISTS; MEDICINES	Objective Despite the positive attitudes pharmacists have toward evidence-based practices (EBPs), its application in community pharmacies in Saudi Arabia is lacking. Therefore, this study aimed to explore and assess EBPs by community pharmacists in Saudi Arabia when they dispense over-the-counter (OTC) medications for three minor ailments: diarrhea, cough, and the common cold. Research design and methods We used a mixed-methods approach consisting of two study parts. The first was a quantitative investigation that used mystery shoppers. Four researchers, posing as mystery shoppers, visited 214 randomly selected pharmacies in the Riyadh region of Saudi Arabia. They used 14 questions from a standardized checklist to examine EBPs by community pharmacists. The qualitative part of the study entailed three focus-group discussions with 13 pharmacists from different community practice settings and explored factors that affected the application of EBPs when supplying OTC medications from the pharmacists' point of view. Results The analysis indicated that 40% of pharmacists dispensed OTC medications according to EBPs. Logistic regression analysis showed that one question, "Describe your symptoms", predicted the correct supply of OTC medications (p = 0.021). The qualitative section of the study identified nine factors that affected EBP. Some of these factors facilitated EBP, such as established patient-pharmacist relationships, some acted as barriers such as conflicts between available evidence, while other factors could either facilitate or hinder EBPs, such as the health literacy of the patient. Conclusion Given that dispensing OTC medication is a core function of pharmacists, this study uncovered low adherence to EBPs by community pharmacists in Saudi Arabia when dispensing OTC medication for three minor ailments: diarrhea, cough, and the common cold. Furthermore, this study identified a number of explanatory factors for this low adherence. Targeting these factors could help change the behavior of pharmacists and decrease undesirable outcomes.	[Aloudah, Nouf; Aboheimed, Ghada] King Saud Univ, Dept Clin Pharm, Riyadh, Saudi Arabia; [Alhumsi, Areej] Becton Dickinson, Sales & Clin Specialist Oncol, Riyadh, Saudi Arabia; [Alobeid, Nada] Saudi Food & Drug Author, Benefit Risk Assessment Dept, Riyadh, Saudi Arabia; [Aboheimed, Nourah] Princess Nourah bint Abdulrahman Univ, Dept Pharm Practice, Riyadh, Saudi Arabia; [Aboheimed, Hind] King Abdulaziz Med City Riyadh, Natl Guard Hlth Affairs, Pharmaceut Care Serv, Riyadh, Saudi Arabia	King Saud University; Princess Nourah bint Abdulrahman University; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Ministry of National Guard - Health Affairs; National Guard Health Affairs - Saudi Arabia	Aloudah, N (corresponding author), King Saud Univ, Dept Clin Pharm, Riyadh, Saudi Arabia.	naloudah@ksu.edu.sa	aboheimed, Nourah/GXV-2895-2022; Aboheimed, Ghada I./GXV-3323-2022; Aloudah, Nouf M/K-2061-2019	Aboheimed, Ghada I./0000-0002-4752-6363; Aloudah, Nouf M/0000-0002-7603-1642	"Research Center of the Female Scientific and Medical Colleges", Deanship of Scientific Research, King Saud University	"Research Center of the Female Scientific and Medical Colleges", Deanship of Scientific Research, King Saud University(King Saud University)	This research project was supported by a grant from the "Research Center of the Female Scientific and Medical Colleges", Deanship of Scientific Research, King Saud University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. It was only provided financial support in the form of authors' salaries [Aloudah, N.; Abuheimd, G.]. The Becton Dickinson company had no role in study design, data collection and analysis, decision to publish, preparation of the manuscript and did not provided financial support in the form of author' salaries [Alhemsi, A.] at the time of study. The specific roles of these authors are articulated in the `author contributions' section."	Al-Mohamadi A, 2013, SAUDI PHARM J, V21, P13, DOI 10.1016/j.jsps.2011.11.003; Alaqeel S, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1220-6; Aljadhey H, 2015, SAUDI MED J, V36, P328, DOI 10.15537/smj.2015.3.10523; Bin Saleh G, 2015, SAUDI PHARM J, V23, P573, DOI 10.1016/j.jsps.2015.02.019; Burkiewicz JS, 2005, ANN PHARMACOTHER, V39, P1214, DOI 10.1345/aph.1E663; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Collins JC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-019462; Edwards D. J., 2018, CANADIAN PHARM J CPJ, V152, P16, DOI [10.1177/1715163518816646, DOI 10.1177/1715163518815717]; Halila Gerusa C., 2015, Pharmacy Pract (Granada), V13, DOI 10.18549/PharmPract.2015.04.597; Hanna Lezley-Anne, 2012, Int J Pharm Pract, V20, P275, DOI 10.1111/j.2042-7174.2012.00244.x; Hanna LA, 2010, DRUG SAFETY, V33, P245, DOI 10.2165/11319050-000000000-00000; Inch J, 2017, INT J PHARM PRACT, V25, P253, DOI 10.1111/ijpp.12305; Jacob S, 2018, INT REV ADM SCI, V84, P164, DOI 10.1177/0020852315618018; Johnson H, 2013, MED WRITING, V22, P275; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10; Morse J.M., 2009, MIXED METHOD DESIGN; Parnapy Jawaid, 2013, COMMUNITY CLIN PHARM; Paudyal V, 2013, RES SOC ADMIN PHARM, V9, P251, DOI 10.1016/j.sapharm.2012.05.001; Rutter P, 2014, J EVAL CLIN PRACT, V20, P425, DOI 10.1111/jep.12157; Seubert LJ, 2017, PHARMACY, V5, DOI 10.3390/pharmacy5040065; Tsoi SLNMTA, 2018, ADV HEALTH SCI EDUC, V23, P549, DOI 10.1007/s10459-018-9812-7; U.S. Food and Drug Administration, 2020, DRUG APPL OV THE COU; van Hoof JJ, 2014, HEALTH POLICY, V117, P353, DOI 10.1016/j.healthpol.2014.07.009; Wagner R, 2020, SAUDI WOMEN ENTER PH; Watson MC, 2008, PHARM WORLD SCI, V30, P526, DOI 10.1007/s11096-008-9202-y; WATSON MC, 2006, INT J PHARM PRACT, V14, P83; Xiong CG, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3011-3	28	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2020	15	11							e0240913	10.1371/journal.pone.0240913	http://dx.doi.org/10.1371/journal.pone.0240913			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM0RU	33211738	Green Published, gold			2023-01-03	WOS:000603518300012
J	Sikombe, K; Mody, A; Kadota, J; Pry, JJ; Simbeza, S; Eshun-Wilson, I; Situmbeko, SR; Bukankala, C; Beres, L; Mukamba, N; Mwanza, MW; Bolton-Moore, C; Holmes, CB; Geng, EH; Sikazwe, I				Sikombe, Kombatende; Mody, Aaloke; Kadota, Jillian; Pry, Jesse Jake; Simbeza, Sandra; Eshun-Wilson, Ingrid; Situmbeko, Sitali Richard; Bukankala, Chama; Beres, Laura; Mukamba, Njekwa; Mwanza, Mwanza Wa; Bolton-Moore, Carolyn; Holmes, Charles B.; Geng, Elvin H.; Sikazwe, Izukanji			Understanding patient transfers across multiple clinics in Zambia among HIV infected adults	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; FOLLOW-UP; CARE; AFRICA; RETENTION; OUTCOMES; LOST; PROGRAMS; REASONS; SERVICE	Many patients in HIV care in Africa considered lost to follow up (LTFU) at one facility are reportedly accessing care in another. The success of these unofficial transfers as measured by time to re-entry at the new-facility, prevalence of treatment interruptions, speed of ART-initiation, and overall continuity of care is not well characterized but may reveal opportunities for improvement. We traced a random sample of LTFU HIV-infected patients in Zambia. Among those found alive and reported in care at a new-facility, we reviewed records at the receiving facility to verify transfer; and when verified, documented the transfer experience. We used Kaplan-Meier methods to examine incidence of ART-initiation after transfer to new clinic. We assessed demographic and clinical characteristics, official and cross-provincial transfer for associations with HIV treatment re-engagement using Poisson regression models and associations between official-transfer and same-day ART initiation at the new-facility. Among 350 LTFU-patients, 178 (51%) were successfully verified through chart review at the new-facility. 132 (74.2%) were female, 72 (40.4%) aged 25-35, and 51% were ever recorded as previously being on ART. 110 patients (61.8%) were registered under new ART-IDs and 97 (54.5%) received a new HIV test. 54% of those previously on ART-initiated on the same-day. Using the same ART-ID was associated with same-day initiation compared to those receiving a new ART-ID (p = 0.07). 80% (n = 91) of those ever on ART had evidence of medication initiation at new clinic. Among these, initiation reached 66% (95% CI: 56-75) by 30 days, 77.5% (95% CI: 68-86) by 90 days after new-facility presentation. Many patients use new identifiers at new facilities, indicative of inefficiencies. Re-entry into new facilities among the unofficial-transfer population is often delayed and timely treatment initiation is inconsistent, suggesting interruptions in treatment. Health systems innovations to ensure smooth and safe transfers are needed to maintain quality HIV care.	[Sikombe, Kombatende; Pry, Jesse Jake; Simbeza, Sandra; Situmbeko, Sitali Richard; Bukankala, Chama; Mukamba, Njekwa; Mwanza, Mwanza Wa; Bolton-Moore, Carolyn; Holmes, Charles B.; Sikazwe, Izukanji] Ctr Infect Dis Res Zambia, Res Dept, Lusaka, Zambia; [Sikombe, Kombatende] London Sch Hyg & Trop Med, Dept Publ Hlth Environm & Soc, London, England; [Mody, Aaloke; Pry, Jesse Jake; Eshun-Wilson, Ingrid; Geng, Elvin H.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; [Kadota, Jillian] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Kadota, Jillian] Univ Calif San Francisco, Ctr TB, San Francisco, CA 94143 USA; [Beres, Laura; Holmes, Charles B.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; [Bolton-Moore, Carolyn] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA; [Holmes, Charles B.] Georgetown Univ, Ctr Global Hlth & Qual, Washington, DC USA	University of London; London School of Hygiene & Tropical Medicine; Washington University (WUSTL); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Georgetown University	Sikombe, K (corresponding author), Ctr Infect Dis Res Zambia, Res Dept, Lusaka, Zambia.; Sikombe, K (corresponding author), London Sch Hyg & Trop Med, Dept Publ Hlth Environm & Soc, London, England.	Kombatendes.sikombe@cidz.org	Sikombe, Kombatende/AAW-5080-2021; Pry, Jake Michael/V-7245-2019	Sikombe, Kombatende/0000-0002-8187-8661; Pry, Jake Michael/0000-0001-6312-4420; Bolton Moore, Carolyn/0000-0001-9103-7746; Beres, Laura/0000-0002-4731-7828	Bill and Melinda Gates Foundation [OPP1105071]; National Institutes for Allergy and Infectious Diseases [P30 AI027763, K24 AI134413]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); National Institutes for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was made possible by funding support from the Bill and Melinda Gates Foundation [grant number OPP1105071] and National Institutes for Allergy and Infectious Diseases [P30 AI027763 and K24 AI134413 to Elvin H. Geng]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Camlin CS, 2014, POPUL SPACE PLACE, V20, P528, DOI 10.1002/psp.1794; Clouse K, 2017, INT HEALTH, V9, P203, DOI 10.1093/inthealth/ihx024; Clouse K, 2017, JAIDS-J ACQ IMM DEF, V74, P383, DOI 10.1097/qai.0000000000001284; Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365; Farahani M, 2014, LANCET GLOB HEALTH, V2, pE44, DOI 10.1016/S2214-109X(13)70149-9; Geng EH, 2016, CLIN INFECT DIS, V62, P935, DOI 10.1093/cid/civ1004; Geng EH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021797; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Gill MJ, 2016, AIDS CARE, V28, P1073, DOI 10.1080/09540121.2016.1139042; Hickey MD, 2016, AIDS CARE, V28, P1386, DOI 10.1080/09540121.2016.1179253; Holmes CB, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002489; Kinfu Y, 2009, B WORLD HEALTH ORGAN, V87, P225, DOI 10.2471/BLT.08.051599; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Labonte R, 2015, HUM RESOUR HEALTH, V13, DOI 10.1186/s12960-015-0093-4; Luebbert J, 2012, CLIN INFECT DIS, V55, P441, DOI 10.1093/cid/cis438; Lv Z., 2008, PLOS ONE, V3, pe3933; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2; Mwamba C, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001007; Nglazi MD, 2011, JAIDS-J ACQ IMM DEF, V56, pE1, DOI 10.1097/QAI.0b013e3181ff0bdc; Schneider H, 2006, REPROD HEALTH MATTER, V14, P12, DOI 10.1016/S0968-8080(06)27232-X; Sikazwe I, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002811; Stime KJ, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3154-2; Tweya H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075761; Vincenty Thaddeus, 1975, SURVEY REV; Ware NC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001369; Wilkinson LS, 2015, TROP MED INT HEALTH, V20, P365, DOI 10.1111/tmi.12434; World Bank, 2018, ROL DIG ID HEALTHC E; World Health Organization (WHO), 2015, GUID START ANT THER, P78; Zanolini A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002636	29	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2020	15	11							e0241477	10.1371/journal.pone.0241477	http://dx.doi.org/10.1371/journal.pone.0241477			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OR6WM	33147250	Green Published, gold			2023-01-03	WOS:000589609300076
J	Abe, R; Takagi, H; Fujimoto, K; Sugiura, K				Abe, Reiko; Takagi, Hiroko; Fujimoto, Kyoko; Sugiura, Katsuaki			Evaluation of the antimicrobial use in pigs in Japan using dosage-based indicators	PLOS ONE			English	Article							THERAPEUTIC-USE; DRUG USAGE; QUANTIFICATION; TRENDS	The use of antimicrobial agents in food-producing animals may lead to the emergence and spread of antimicrobial resistance in bacteria of animal origin. The use of antimicrobial agents in pigs in 2018 in Japan was evaluated in terms of the weight of active ingredient and number of defined daily doses (DDD), using annual sales data of veterinary antimicrobials sold for use in pigs. In addition, the use of antimicrobial agents in the Japanese pig sector in 2008 to 2017 was evaluated to determine whether or not there were any differences in temporal change pattern by use of different metrics. In 2018, 447 metric tons of active ingredient, corresponding to 77,379 x 10(6) kg-days (Japanese DDD) and 34,903 x 10(6) kg-days (European DDD) were sold. The proportion of the sales amount of sulfonamides, trimethoprim and lincosamides to the total sales amount was significantly different depending on the metric used. For most antimicrobial classes, the number of Japanese DDDs was greater than the number of European DDDs. These results indicate that the DDD-based metric, which is more reflective of the selective pressure of antimicrobials, is recommended for use in monitoring the antimicrobial use in pigs in Japan. The differences in the number of Japanese DDDs and European DDDs appear to confirm the need for Japanese DDDs.	[Abe, Reiko; Takagi, Hiroko; Fujimoto, Kyoko; Sugiura, Katsuaki] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Global Agr Sci, Tokyo, Japan	University of Tokyo	Sugiura, K (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Global Agr Sci, Tokyo, Japan.	aksugiur@mail.ecc.u-tokyo.ac.jp		Sugiura, Katsuaki/0000-0002-8807-7584	Ministry of Agriculture, Forestry and Fisheries of Japan [JPJ008617.17935699]	Ministry of Agriculture, Forestry and Fisheries of Japan(Ministry of Agriculture Forestry & Fisheries - Japan)	KS JPJ008617.17935699 Ministry of Agriculture, Forestry and Fisheries of Japan https://www.maff.go.jp/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AACTING-network, DESCR EX MON SYST CO; Aarestrup FM, 2005, BASIC CLIN PHARMACOL, V96, P271, DOI 10.1111/j.1742-7843.2005.pto960401.x; Arnold S, 2004, PHARMACOEPIDEM DR S, V13, P323, DOI 10.1002/pds.874; Bos MEH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077525; Bosman AL, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00220; Brault SA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00330; Chauvin C, 2008, J VET PHARMACOL THER, V31, P301, DOI 10.1111/j.1365-2885.2008.00960.x; Collineau L, 2017, ZOONOSES PUBLIC HLTH, V64, P165, DOI 10.1111/zph.12298; EMA, PRINC ASS DEF DAIL D; EMA, DEF DAIL DOS AN DDDV; European Medicine Agency (EMA), SAL VET ANT AG 30 EU; European Medicines Agency (EMA), DEF DAIL DPS AN DDDV; Filippitzi ME, 2014, VLAAMS DIERGEN TIJDS, V83, P215; French Agency for Food Environmental and Occupational Health and Safety, SAL SURV VET MED PRO; Gonzalez SM, 2010, PREV VET MED, V95, P50, DOI 10.1016/j.prevetmed.2010.03.004; Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0; Hosoi Y, 2014, REV SCI TECH OIE, V33, P1007, DOI 10.20506/rst.33.3.2337; Jensen VF, 2004, PREV VET MED, V64, P201, DOI 10.1016/j.prevetmed.2004.04.001; Kasabova S, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00116; Matsuda M, 2017, J ANIMAL HYG, V42, P191; Mills HL, 2018, VET REC, V182, P379, DOI 10.1136/vr.104701; Ministry of Agriculture, 2018, SAL AM MED QUASI MED; Netherlands Veterinary Institute (SDa), US ANT AGR LIV NETH; O'Neill J., REV ANTIMICROBIAL RE; Sanders P, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00540; Staten Serum Institute, DANMAP 2017 US ANT A; Takagi H., 2020, NIPPON JUISHIKAI ZAS, V73, P352; Takagi H, 2019, JAP J ANIM HYG, V45, P155; Timmerman T, 2006, PREV VET MED, V74, P251, DOI 10.1016/j.prevetmed.2005.10.003; Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112; WHO Collaborating Centre for Drug Statistics Methodology, 2012, ATCVET	31	5	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2020	15	10							e0241644	10.1371/journal.pone.0241644	http://dx.doi.org/10.1371/journal.pone.0241644			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8VN	33125427	gold, Green Published			2023-01-03	WOS:000588368900007
J	Achterhof, AB; Rozsnyai, Z; Reeve, E; Jungo, KT; Floriani, C; Poortvliet, RKE; Rodondi, N; Gussekloo, J; Streit, S				Achterhof, Alexandra B.; Rozsnyai, Zsofia; Reeve, Emily; Jungo, Katharina Tabea; Floriani, Carmen; Poortvliet, Rosalinde K. E.; Rodondi, Nicolas; Gussekloo, Jacobijn; Streit, Sven			Potentially inappropriate medication and attitudes of older adults towards deprescribing	PLOS ONE			English	Article							PEOPLES ATTITUDES; POLYPHARMACY; WILLINGNESS; VALIDATION; MEDICINES; CRITERIA	Introduction Multimorbidity and polypharmacy are current challenges when caring for the older population. Both have led to an increase of potentially inappropriate medication (PIM), illustrating the need to assess patients' attitudes towards deprescribing. We aimed to assess the prevalence of PIM use and whether this was associated with patient factors and willingness to deprescribe. Method We analysed data from the LESS Study, a cross-sectional study on self-reported medication and on barriers and enablers towards the willingness to deprescribe (rPATD questionnaire). The survey was conducted among multimorbid (>= 3 chronic conditions) participants >= 70 years with polypharmacy (>= 5 long-term medications). A subset of the Beers 2019 criteria was applied for the assessment of medication appropriateness. Results Data from 300 patients were analysed. The mean age was 79.1 years (SD 5.7). 53% had at least one PIM (men: 47.8%%, women: 60.4%%; p = 0.007). A higher number of medications was associated with PIM use (p = 0.002). We found high willingness to deprescribe in both participants with and without PIM. Willingness to deprescribe was not associated with PIM use (p = 0.25), nor number of PIMs (p = 0.81). Conclusion The willingness of older adults with polypharmacy towards deprescribing was not associated with PIM use in this study. These results suggest that patients may not be aware if they are taking PIMs. This implies the need for raising patients' awareness about PIMs through education, especially in females, in order to implement deprescribing in daily practice.	[Achterhof, Alexandra B.; Rozsnyai, Zsofia; Jungo, Katharina Tabea; Floriani, Carmen; Rodondi, Nicolas; Streit, Sven] Univ Bern, Inst Primary Hlth Care Bern BIHAM, Bern, Switzerland; [Achterhof, Alexandra B.; Jungo, Katharina Tabea] Univ Bern, Grad Sch Hlth Sci, Bern, Switzerland; [Reeve, Emily] Univ South Australia, Qual Use Med & Pharm Res Ctr, UniSA Clin & Hlth Sci, Adelaide, SA, Australia; [Reeve, Emily] Dalhousie Univ, Geriatr Med Res, Halifax, NS, Canada; [Reeve, Emily] Nova Scotia Hlth Author, Halifax, NS, Canada; [Reeve, Emily] Dalhousie Univ, Coll Pharm, Halifax, NS, Canada; [Poortvliet, Rosalinde K. E.; Gussekloo, Jacobijn] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [Rodondi, Nicolas] Univ Bern, Bern Univ Hosp, Dept Gen Internal Med, Inselspital, Bern, Switzerland; [Gussekloo, Jacobijn] Leiden Univ, Dept Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands	University of Bern; University of Bern; University of South Australia; Dalhousie University; Dalhousie University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Bern; University Hospital of Bern; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Streit, S (corresponding author), Univ Bern, Inst Primary Hlth Care Bern BIHAM, Bern, Switzerland.	sven.streit@biham.unibe.ch	Gussekloo, Jacobijn/ABE-3879-2021; Jungo, Katharina Tabea/L-8856-2019; Reeve, Emily/AFL-3604-2022	Gussekloo, Jacobijn/0000-0001-7186-8278; Jungo, Katharina Tabea/0000-0002-1782-1345; Reeve, Emily/0000-0002-1405-999X; Rodondi, Nicolas/0000-0001-9083-6896	Swiss Society of General Internal Medicine (SGAIM); NHMRC-ARC Dementia Research Development Fellowship	Swiss Society of General Internal Medicine (SGAIM); NHMRC-ARC Dementia Research Development Fellowship(Australian Research CouncilNational Health and Medical Research Council (NHMRC) of Australia)	This study was funded with a grant (PI Prof. S. Streit) by the Swiss Society of General Internal Medicine (SGAIM). ER is support-ed by a NHMRC-ARC Dementia Research Development Fellowship.	Al-Azayzih A, 2019, PHARM PRACT-GRANADA, V17, DOI 10.18549/PharmPract.2019.2.1439; Alhawassi TM, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1168-1; [Anonymous], 2015, CANC DISCOV, V5, pOF2; [Anonymous], 2015, CANC DISCOV, V5, pOF2; [Anonymous], 2017, CANC DISCOVERY, V7, pOF12; [Anonymous], 2017, EUR J TRANSL MYOL, V27, p7X; [Anonymous], 2018, CANC DISCOV, V8, pOF6; Aubert CE, 2016, EUR J INTERN MED, V35, P35, DOI 10.1016/j.ejim.2016.05.022; Awad A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218174; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Chinese guidelines on prevention and treatment of dyslipidemia in adults, 2016, CHIN CIRC J, V16, P15, DOI [10.1016/j.atherosclerosis.2016.02.006, DOI 10.1016/J.ATHEROSCLEROSIS.2016.02.006]; Curtin D, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619829431; Cvetkovic Z, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55070332; Dhalla IA, 2002, J AM GERIATR SOC, V50, P995, DOI 10.1046/j.1532-5415.2002.50252.x; Fajardo MA, 2019, BRIT J CLIN PHARMACO, V85, P1396, DOI 10.1111/bcp.13912; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Frank C, 2014, CAN MED ASSOC J, V186, P1369, DOI 10.1503/cmaj.131873; Galazzi A, 2016, INT J CLIN PHARM-NET, V38, P454, DOI 10.1007/s11096-016-0279-4; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Hafferty JD, 2018, J CLIN EPIDEMIOL, V94, P132, DOI 10.1016/j.jclinepi.2017.10.013; Holzer BM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-780; Jiron M, 2016, J AM GERIATR SOC, V64, P788, DOI 10.1111/jgs.14077; Komagamine J, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0788-1; Kua KP, 2019, INT J CLIN PHARM-NET, V41, P793, DOI 10.1007/s11096-019-00829-z; Liew TM, 2019, ANN FAM MED, V17, P257, DOI 10.1370/afm.2373; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Martin LM, 2000, AM J PREV MED, V18, P215, DOI 10.1016/S0749-3797(99)00158-0; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McCarthy LM, 2019, J AM GERIATR SOC, V67, P1023, DOI 10.1111/jgs.15800; Moen J, 2009, PATIENT EDUC COUNS, V74, P135, DOI 10.1016/j.pec.2008.08.019; Morin L, 2018, CLIN EPIDEMIOL, V10, P289, DOI 10.2147/CLEP.S153458; Morin L, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.06.011; National Institute for Clinical Effectiveness (NICE), 2016, MULT CLIN ASS MAN NI; NICE, 2015, MED OPT SAF EFF US M; Nothelle SK, 2019, INT J PHARM PRACTICE; Nusair MB, 2020, J PHARM HEALTH SERV, V11, P173, DOI 10.1111/jphs.12340; Nyborg G, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0608-z; Nyborg G, 2012, EUR J CLIN PHARMACOL, V68, P1085, DOI 10.1007/s00228-012-1223-8; Qi K, 2015, INT J CLIN PHARM-NET, V37, P949, DOI 10.1007/s11096-015-0147-7; Reeve E, 2019, J AM GERIATR SOC, V67, P1204, DOI 10.1111/jgs.15804; Reeve E, 2018, JAMA INTERN MED, V178, P1673, DOI 10.1001/jamainternmed.2018.4720; Reeve E, 2017, EUR J INTERN MED, V38, P3, DOI 10.1016/j.ejim.2016.12.021; Reeve E, 2016, DRUG AGING, V33, P913, DOI 10.1007/s40266-016-0410-1; Reeve E, 2015, BRIT J CLIN PHARMACO, V80, P1254, DOI 10.1111/bcp.12732; Reeve E, 2015, EXPERT OPIN DRUG MET, V11, P491, DOI 10.1517/17425255.2015.1004310; Reeve E, 2014, MED J AUSTRALIA, V201, P386, DOI 10.5694/mja13.00200; Reeve E, 2013, J AM GERIATR SOC, V61, P1508, DOI 10.1111/jgs.12418; Rozsnyai Z, LESS STUDY PRIMARY C; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Scott S, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1127-x; Shi S, 2008, EUR J CLIN PHARMACOL, V64, P183, DOI 10.1007/s00228-007-0422-1; Sirois C, 2017, RES SOC ADMIN PHARM, V13, P864, DOI 10.1016/j.sapharm.2016.08.006; Wallace E, 2017, J GERONTOL A-BIOL, V72, P271, DOI 10.1093/gerona/glw140; Wallace E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h176; World Health Organization, 2015, AG HLTH; Xing XX, 2019, ANN PHARMACOTHER, P1	56	19	19	5	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2020	15	10							e0240463	10.1371/journal.pone.0240463	http://dx.doi.org/10.1371/journal.pone.0240463			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8VY	33104695	Green Published, Green Accepted, gold			2023-01-03	WOS:000588370000053
J	Hakanson, CA; Fredriksson, F; Lilja, HE				Arana Hakanson, Cecilia; Fredriksson, Fanny; Engstrand Lilja, Helene			Attention deficit hyperactivity disorder and educational level in adolescent and adult individuals after anesthesia and abdominal surgery during infancy	PLOS ONE			English	Article							EARLY EXPOSURE; BEHAVIORAL OUTCOMES; CHILDHOOD EXPOSURE; CHILDREN; ASSOCIATION; AGE; NEUROTOXICITY; PREVALENCE; APOPTOSIS; IMPACT	Aim Several studies in animal models have found that exposure to anesthetics in early life can cause cognitive dysfunction. Human studies show conflicting results and studies of cognitive function after anesthesia and neonatal surgery are scarce. The aim of this study was to investigate whether exposure to anesthesia and abdominal surgery during infancy was associated with cognitive dysfunction from the perspective of educational level, disposable income and attention deficit hyperactivity disorders (ADHD) in adolescent and adult individuals. Methods A cohort study with patients born 1976 to 2002 that underwent abdominal surgery during infancy at a pediatric surgical center were matched by age, sex, and gestational age to ten randomly selected individuals from the Swedish Medical Birth Register. Individuals with chromosomal aberrations were excluded. Data on highest level of education and annual disposable income were attained from Statistics Sweden and the diagnosis of ADHD were retrieved from the Swedish National Patient Register. Results 485 individuals and 4835 controls were included. Median gestational age was 38 weeks (24-44) and median age at surgery was seven days (0-365). Three hundred sixty-six individuals (70.0%) underwent surgery during the neonatal period (< 44 gestational weeks). Median operating time was 80 minutes (10-430). The mean age at follow-up was 28 years. Fisher's exact test for highest level of education for the exposed and unexposed groups were respectively: university 35% and 33%, upper secondary 44% and 47%, compulsory 21% and 20% (p = 0.6718). The median disposable income was 177.7 versus 180.9 TSEK respectively (p = 0.7532). Exposed individuals had a prevalence of ADHD of 5.2% and unexposed 4.4% (p = 0.4191). Conclusions This study shows that exposure to anesthesia and abdominal surgery during infancy is not associated with cognitive dysfunction from the perspective of educational level, disposable income and ADHD in adolescent and adult individuals. Further studies in larger cohorts at earlier gestational ages are needed to verify these findings.	[Arana Hakanson, Cecilia; Fredriksson, Fanny; Engstrand Lilja, Helene] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Fredriksson, Fanny; Engstrand Lilja, Helene] Univ Childrens Hosp, Dept Pediat Surg, Uppsala, Sweden	Uppsala University	Hakanson, CA (corresponding author), Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.	cecilia.arana_hakanson@kbh.uu.se	Lilja, Helene Engstrand/AAR-6586-2021	Lilja, Helene Engstrand/0000-0002-1998-5212; Arana Hakanson, Cecilia/0000-0001-5271-8274	(CAH) HRH Crown Princess Lovisa's Association for Child Care [2017-00382, 2018-00455, 2019-00497]; Gillbergska Foundation; (CAH) Specific Clinical Research Funding from Uppsala County	(CAH) HRH Crown Princess Lovisa's Association for Child Care; Gillbergska Foundation; (CAH) Specific Clinical Research Funding from Uppsala County	This work was supported by (CAH) HRH Crown Princess Lovisa's Association for Child Care, http://www.kronprinsessanlovisa.se/, grantIDs: 2017-00382; 2018-00455; 2019-00497, (CAH) the Gillbergska Foundation, http://www.gillbergska.se/; and (CAH) Specific Clinical Research Funding from Uppsala County. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold LE, 2020, J ATTEN DISORD, V24, P73, DOI 10.1177/1087054714566076; Backeljauw B, 2015, PEDIATRICS, V136, pE1, DOI 10.1542/peds.2014-3526; Bartels M, 2009, TWIN RES HUM GENET, V12, P246, DOI 10.1375/twin.12.3.246; Blau FD, 2017, J ECON LIT, V55, P789, DOI 10.1257/jel.20160995; Blomgren K, 2007, APOPTOSIS, V12, P993, DOI 10.1007/s10495-007-0754-4; Brambrink AM, 2012, ANN NEUROL, V72, P525, DOI 10.1002/ana.23652; Broad KD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173413; Broad KD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166784; Creeley C, 2013, BRIT J ANAESTH, V110, P29, DOI 10.1093/bja/aet173; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; Faraone SV, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.20; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Fredriksson F, 2016, BRIT J SURG, V103, P284, DOI 10.1002/bjs.10072; Giacobini M, 2018, J ATTEN DISORD, V22, P3, DOI 10.1177/1087054714554617; Glatz P, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2016.3470; Granstrom AL, 2016, ACTA PAEDIATR, V105, P1508, DOI 10.1111/apa.13594; Hansen TG, 2013, PEDIATR ANESTH, V23, P883, DOI 10.1111/pan.12225; Hansen TG, 2011, ANESTHESIOLOGY, V114, P1076, DOI 10.1097/ALN.0b013e31820e77a0; Hu DQ, 2017, ANESTHESIOLOGY, V127, P227, DOI 10.1097/ALN.0000000000001735; Ing C, 2017, ANESTH ANALG, V125, P1988, DOI 10.1213/ANE.0000000000002423; Ing C, 2012, PEDIATRICS, V130, pE476, DOI 10.1542/peds.2011-3822; Istaphanous GK, 2013, ANESTH ANALG, V116, P845, DOI 10.1213/ANE.0b013e318281e988; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kalkman CJ, 2009, ANESTHESIOLOGY, V110, P805, DOI 10.1097/ALN.0b013e31819c7124; Kleven H, 2019, AM ECON J-APPL ECON, V11, P181, DOI 10.1257/app.20180010; Lindstrom K, 2007, PEDIATRICS, V120, P70, DOI 10.1542/peds.2006-3260; Ludman L, 2001, J PEDIATR SURG, V36, P858, DOI 10.1053/jpsu.2001.23954; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lunardi N, 2010, NEUROTOX RES, V17, P179, DOI 10.1007/s12640-009-9088-z; Olsen EA, 2013, CURR OPIN ANESTHESIO, V26, P677, DOI 10.1097/ACO.0000000000000016; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Polanczyk GV, 2014, INT J EPIDEMIOL, V43, P434, DOI 10.1093/ije/dyt261; Psaty BM, 2015, JAMA-J AM MED ASSOC, V313, P1515, DOI 10.1001/jama.2015.1149; Raper J, 2015, ANESTHESIOLOGY, V123, P1084, DOI 10.1097/ALN.0000000000000851; Rappaport BA, 2015, NEW ENGL J MED, V372, P796, DOI 10.1056/NEJMp1414786; Sanders RD, 2013, BRIT J ANAESTH, V110, P53, DOI 10.1093/bja/aet054; Satomoto M, 2009, ANESTHESIOLOGY, V110, P628, DOI 10.1097/ALN.0b013e3181974fa2; Sprung J, 2012, MAYO CLIN PROC, V87, P120, DOI 10.1016/j.mayocp.2011.11.008; Thapar A, 2016, LANCET, V387, P1240, DOI 10.1016/S0140-6736(15)00238-X; Vutskits L, 2017, CURR OPIN ANESTHESIO, V30, P337, DOI 10.1097/ACO.0000000000000461; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Wu J, 2016, ANESTHESIOLOGY, V124, P624, DOI 10.1097/ALN.0000000000000981; Zou XJ, 2009, INT J DEV NEUROSCI, V27, P727, DOI 10.1016/j.ijdevneu.2009.06.010	45	6	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2020	15	10							e0240891	10.1371/journal.pone.0240891	http://dx.doi.org/10.1371/journal.pone.0240891			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OM3RJ	33085711	Green Published, gold			2023-01-03	WOS:000585943400038
J	Huang, MC; Yen, HR; Lin, CL; Lee, YC; Sun, MF; Wu, MY				Huang, Ming-Cheng; Yen, Hung-Rong; Lin, Cheng-Li; Lee, Yu-Chen; Sun, Mao-Feng; Wu, Mei-Yao			Acupuncture decreased the risk of stroke among patients with fibromyalgia in Taiwan: A nationwide matched cohort study	PLOS ONE			English	Article							CANNABINOID CB1 RECEPTOR; FOCAL CEREBRAL-ISCHEMIA; ELECTROACUPUNCTURE PRETREATMENT; ANTIINFLAMMATORY THERAPIES; SHAM ACUPUNCTURE; PAIN; DEPRESSION; POPULATION; ACTIVATION; HEALTH	Background The aim of this study was to investigate the effectiveness of acupuncture in decreasing the risk of stroke in patients with fibromyalgia. Methods We enrolled patients who was newly diagnosed as having fibromyalgia between 1 January, 2000 and 31 December, 2010 from the Taiwanese National Health Insurance Research Database. The claim data for both the acupuncture cohort and non-acupuncture cohort were assessed from the index date to 31 December, 2013. A Cox regression model adjusted for age, sex, comorbidities, and drugs use was used to compare the hazard ratios of the two cohorts. The cumulative incidence of stroke was estimated by using the Kaplan-Meier method. Results After performing a propensity score matching with a 1:1 ratio, there were 65,487 patients in the acupuncture and non-acupuncture cohorts with similar distributions in the baseline characteristics. The cumulative incidence of stroke was significantly lower in the acupuncture cohort (log-rank test, p < 0.001). In the follow-up period, 4,216 patients in the acupuncture cohort (11.01 per 1000 person-years) and 6,849 patients in the non-acupuncture cohort (19.82 per 1000 person-years) suffered from stroke (adjusted HR 0.53, 95% CI 0.51-0.55). Acupuncture favorably affected the incidence of stroke regardless of the patient's age, sex, comorbidities, and conventional drug use. Conclusions Our study found that acupuncture might have a beneficial effect on reducing the risk of stroke in patients with fibromyalgia in Taiwan. Additional clinical and basic science studies are warranted.	[Huang, Ming-Cheng; Yen, Hung-Rong; Lee, Yu-Chen; Sun, Mao-Feng; Wu, Mei-Yao] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan; [Huang, Ming-Cheng] China Med Univ, Sch Chinese Med, Coll Chinese Med, Grad Inst Chinese Med, Taichung, Taiwan; [Yen, Hung-Rong] China Med Univ Hosp, Dept Med Res, Res Ctr Tradit Chinese Med, Taichung, Taiwan; [Yen, Hung-Rong] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan; [Yen, Hung-Rong] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Lee, Yu-Chen] China Med Univ, Coll Chinese Med, Grad Inst Acupuncture Sci, Taichung, Taiwan; [Sun, Mao-Feng] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan; [Wu, Mei-Yao] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan	Sun, MF; Wu, MY (corresponding author), China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan.; Sun, MF (corresponding author), China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan.; Wu, MY (corresponding author), China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung, Taiwan.	maofeng@mail.cmuh.org.tw; meiyaowu0919@gmail.com	Huang, Ming-Cheng/GRY-5937-2022; Yen, Hung-Rong/M-1373-2013	Huang, Ming-Cheng/0000-0003-0830-7093; Yen, Hung-Rong/0000-0002-0131-1658	"Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education in Taiwan [CMRC-CHM-2]; Taiwan Ministry of Health and Welfare Clinical Trial Center [MOHW109-TDU-B-212-114004]; health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence [MOHW109-TDU-B-212-124024]; Ministry of Science and Technology [MOST 107-2320-B-039-037]; China Medical University Hospital [DMR-109-009, DMR-109-168, DMR-108-115, DMR-108-116]; Taiwan Ministry of Health and Welfare [M09G1025]	"Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program by the Ministry of Education in Taiwan; Taiwan Ministry of Health and Welfare Clinical Trial Center; health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); China Medical University Hospital; Taiwan Ministry of Health and Welfare	This study was supported in part by the "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan (CMRC-CHM-2)(HRY), by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW109-TDU-B-212-114004) (HRY), by the health and welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW109-TDU-B-212-124024) (HRY); Ministry of Science and Technology (MOST 107-2320-B-039-037)(MFS), China Medical University Hospital (DMR-109-009) (MCH); (DMR-109-168)(MYW); (DMR-108-115) (HRY); (DMR-108-116) (HRY), and the Taiwan Ministry of Health and Welfare (M09G1025)(MCH). The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assefi NP, 2005, ANN INTERN MED, V143, P10, DOI 10.7326/0003-4819-143-1-200507050-00005; Back M, 2015, NAT REV CARDIOL, V12, P199, DOI 10.1038/nrcardio.2015.5; Banfi G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041186; Chen Y.H., 2018, P NATL ACAD SCI USA, V115; Chinn S, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0556-x; Clauw DJ, 2014, JAMA-J AM MED ASSOC, V311, P1547, DOI 10.1001/jama.2014.3266; Creed F, 2020, PAIN, V161, P1169, DOI 10.1097/j.pain.0000000000001819; Daut RA, 2019, FRONT NEUROENDOCRIN, V54, DOI 10.1016/j.yfrne.2019.04.003; Deare JC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007070.pub2; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Dimitrov N, 2017, ROM J MORPHOL EMBRYO, V58, P961; Du JA, 2010, BRAIN RES, V1360, P1, DOI 10.1016/j.brainres.2010.07.034; Duruoz MT, 2012, RHEUMATOL INT, V32, P663, DOI 10.1007/s00296-010-1693-x; Fitzcharles MA, 2018, EUR J PAIN, V22, P1565, DOI 10.1002/ejp.1252; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Goodson NJ, 2013, PAIN, V154, P1595, DOI 10.1016/j.pain.2013.04.043; Harris RE, 2008, ARTHRITIS RHEUM, V58, P903, DOI 10.1002/art.23223; Heidari F, 2017, RHEUMATOL INT, V37, P1527, DOI 10.1007/s00296-017-3725-2; Howard VJ, 2015, STROKE, V46, P1735, DOI 10.1161/STROKEAHA.115.006317; Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540; Irwin MR, 2019, NAT REV IMMUNOL, V19, P702, DOI 10.1038/s41577-019-0190-z; Islam MM, 2018, NEUROEPIDEMIOLOGY, V51, P166, DOI 10.1159/000490741; Jeong HG, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005671; Kalkonde YV, 2018, STROKE, V49, P3092, DOI 10.1161/STROKEAHA.118.017384; Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263; Kohler O, 2016, CURR NEUROPHARMACOL, V14, P732, DOI 10.2174/1570159X14666151208113700; Lin JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114948; Lismaniah, 2020, MED ACUPUNCT, V32, P80, DOI 10.1089/acu.2019.1370; Littlejohn G, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020015; Long M, 2019, INFLAMMATION, V42, P1777, DOI 10.1007/s10753-019-01040-y; Lu KW, 2017, ACUPUNCT MED, V35, DOI 10.1136/acupmed-2015-010986; Martin DP, 2006, MAYO CLIN PROC, V81, P749, DOI 10.4065/81.6.749; McDermott M, 2018, EXPERT REV NEUROTHER, V18, P523, DOI 10.1080/14737175.2018.1489239; Mims KN, 2016, SLEEP MED CLIN, V11, P39, DOI 10.1016/j.jsmc.2015.10.009; Mist SD, 2018, PAIN MED, V19, P1862, DOI 10.1093/pm/pnx322; Miyanohara J, 2015, BIOCHEM BIOPH RES CO, V467, P478, DOI 10.1016/j.bbrc.2015.10.027; Moise N, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003767; Molina F, 2019, BIOL RES NURS, V21, P224, DOI 10.1177/1099800418824716; Olsen MH, 2016, LANCET, V388, P2665, DOI 10.1016/S0140-6736(16)31134-5; de Landaluce LO, 2018, DRUG SAFETY, V41, P1325, DOI 10.1007/s40264-018-0695-6; Pan A, 2011, STROKE, V42, P2770, DOI 10.1161/STROKEAHA.111.617043; Pan A, 2011, JAMA-J AM MED ASSOC, V306, P1241, DOI 10.1001/jama.2011.1282; Patil S, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0552-1; Peyravian N, 2019, PROG NEUROBIOL, V182, DOI 10.1016/j.pneurobio.2019.101679; Prabhakar A, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926-019-0814-0; Ramirez-Tejero JA, 2018, J PROTEOMICS, V186, P47, DOI 10.1016/j.jprot.2018.07.009; Reinholdsson M, 2018, NEUROLOGY, V91, pE146, DOI 10.1212/WNL.0000000000006354; Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203; Rodriguez-Pinto I, 2014, IMMUNOL LETT, V161, P200, DOI 10.1016/j.imlet.2014.01.009; Schink T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203362; Schneider S, 2007, EUR J PAIN, V11, P387, DOI 10.1016/j.ejpain.2006.05.005; Sluka KA, 2016, NEUROSCIENCE, V338, P114, DOI 10.1016/j.neuroscience.2016.06.006; Stener-Victorin E, 2012, FERTIL STERIL, V97, P501, DOI 10.1016/j.fertnstert.2011.11.010; Targino RA, 2008, J REHABIL MED, V40, P582, DOI 10.2340/16501977-0216; Tseng CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002860; Ugurlu FG, 2017, ACTA REUMATOL PORT, V42, P32; Vas J, 2016, ACUPUNCT MED, V34, P257, DOI 10.1136/acupmed-2015-010950; Wang JY, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/8403064; Wang Q, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-24; Wang QA, 2011, STROKE, V42, P389, DOI 10.1161/STROKEAHA.110.597336; Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490; Wei HD, 2014, MOL NEUROBIOL, V49, P326, DOI 10.1007/s12035-013-8524-5; Wu QJ, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0357-8; Xu J, 2016, ANESTH ANALG, V122, P882, DOI 10.1213/ANE.0000000000001097; Yang TY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2039-y; Zhou H, 2013, BRAIN RES, V1529, P154, DOI 10.1016/j.brainres.2013.07.006	66	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2020	15	10							e0239703	10.1371/journal.pone.0239703	http://dx.doi.org/10.1371/journal.pone.0239703			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OS6KJ	33002009	Green Published, gold			2023-01-03	WOS:000590270000049
J	Ogunwole, SM; Zera, CA; Stanford, FC				Ogunwole, S. Michelle; Zera, Chloe A.; Stanford, Fatima Cody			Obesity Management in Women of Reproductive Age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ogunwole, S. Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, 2400 E Monument Ave,Ste 2300-A, Baltimore, MD 21230 USA; [Zera, Chloe A.] Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Boston, MA 02215 USA; [Stanford, Fatima Cody] Massachusetts Gen Hosp, Weight Ctr, Boston, MA 02114 USA; [Stanford, Fatima Cody] Massachusetts Gen Hosp, Dept Pediat Endocrinol, Boston, MA 02114 USA; [Stanford, Fatima Cody] Harvard Univ, Nutr Obes Res Ctr, Boston, MA 02115 USA	Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Ogunwole, SM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, 2400 E Monument Ave,Ste 2300-A, Baltimore, MD 21230 USA.	sogunwo1@jhmi.edu						Bellamy L, 2009, LANCET, V373, P1773, DOI 10.1016/S0140-6736(09)60731-5; Deputy NP, 2018, MMWR-MORBID MORTAL W, V67, P1201, DOI 10.15585/mmwr.mm6743a2; Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004; Kramer CK, 2019, DIABETOLOGIA, V62, P905, DOI 10.1007/s00125-019-4840-2; Kwong W, 2018, AM J OBSTET GYNECOL, V218, P573, DOI 10.1016/j.ajog.2018.02.003; Martinez-Hortelano JA, 2020, OBSTET GYNECOL, V135, P68, DOI 10.1097/AOG.0000000000003573; Singh GK, 2019, J OBES, V2019, DOI 10.1155/2019/2419263; Smith J, 2009, J CLIN ENDOCR METAB, V94, P4275, DOI 10.1210/jc.2009-0709; Sondergaard MM, 2020, JAMA CARDIOL, V5, P1390, DOI 10.1001/jamacardio.2020.4097; Voerman E, 2019, JAMA-J AM MED ASSOC, V321, P1702, DOI 10.1001/jama.2019.3820	10	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2021	325	5					433	434		10.1001/jama.2020.21096	http://dx.doi.org/10.1001/jama.2020.21096		JAN 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC6JP	33410868				2023-01-03	WOS:000605763700001
J	Weingart, SN				Weingart, Saul N.			Recalculating Readmissions: A Work in Progress	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Weingart, Saul N.] Tufts Med Ctr, 800 Washington St, Boston, MA 02111 USA; [Weingart, Saul N.] Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Weingart, SN (corresponding author), Tufts Med Ctr, 800 Washington St, Boston, MA 02111 USA.	sweingart@tuftsmedicalcenter.org						Abdul-Aziz AA, 2017, JAMA CARDIOL, V2, P200, DOI 10.1001/jamacardio.2016.3704; Auerbach AD, 2016, JAMA INTERN MED, V176, P484, DOI 10.1001/jamainternmed.2015.7863; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Graham KL, 2018, ANN INTERN MED, V168, P766, DOI 10.7326/M17-1724; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Maddox KEJ, 2019, HEALTH SERV RES, V54, P327, DOI 10.1111/1475-6773.13133; Rau J., 2019, KAISER HLTH NEWS; Wadhera RK, 2021, ANN INTERN MED, V174, P86, DOI 10.7326/M20-3486; Zuckerman RB, 2017, NEW ENGL J MED, V377, P1551, DOI 10.1056/NEJMsa1701791; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	10	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					113	114		10.7326/M20-6254	http://dx.doi.org/10.7326/M20-6254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33045177				2023-01-03	WOS:000619485200035
J	Armstrong-Hough, M; Sharma, S; Kishore, SP; Akiteng, AR; Schwartz, JI				Armstrong-Hough, Mari; Sharma, Srish; Kishore, Sandeep P.; Akiteng, Ann R.; Schwartz, Jeremy I.			Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis	PLOS ONE			English	Article							ADHERENCE; ACCESS; CARE	Background Availability of essential medicines for non-communicable diseases (NCDs) is poor in low- and middle-income countries. Availability and cost are conventionally assessed using cross-sectional data. However, these characteristics may vary over time. Methods We carried out a prospective, descriptive analysis of the availability and cost of essential medicines in 23 Ugandan health facilities over a five-week period. We surveyed facility pharmacies in-person up to five times, recording availability and cost of 19 essential medicines for NCDs and four essential medicines for communicable diseases. Results Availability of medicines varied substantially over time, especially among public facilities. Among private-for-profit facilities, the cost of the same medicine varied from week to week. Private-not-for-profit facilities experienced less dramatic fluctuations in price. Conclusions We conclude that there is a need for standardized, continuous monitoring to better characterize the availability and cost of essential medicines, understand demand for these medicines, and reduce uncertainty for patients.	[Armstrong-Hough, Mari] NYU, Sch Global Publ Hlth, New York, NY 10012 USA; [Sharma, Srish] Wake Forest Sch Med, Winston Salem, NC 27101 USA; [Kishore, Sandeep P.] Icahn Sch Med Mt Sinai, Arnhold Inst Global Hlth, New York, NY 10029 USA; [Kishore, Sandeep P.] Young Profess Chron Dis Network, New York, NY USA; [Akiteng, Ann R.; Schwartz, Jeremy I.] Uganda Initiat Integrated Management Noncommun, Kampala, Uganda; [Schwartz, Jeremy I.] Yale Sch Med, Dept Internal Med, New Haven, CT USA	New York University; Wake Forest University; Icahn School of Medicine at Mount Sinai; Yale University	Armstrong-Hough, M (corresponding author), NYU, Sch Global Publ Hlth, New York, NY 10012 USA.	mah842@nyu.edu	Armstrong-Hough, Mari/AGF-1466-2022	Schwartz, Jeremy/0000-0003-0139-2600	MacMillan Center of Yale University; Yale Global Health Leadership Institute; Knoema	MacMillan Center of Yale University; Yale Global Health Leadership Institute; Knoema	The MacMillan Center of Yale University and the Yale Global Health Leadership Institute provided funding to support travel for JIS through the Hecht-Albert Pilot Innovation Award for Junior Faculty. Knoema provided funding for data collection and the development of the data collection and management tool. The funders played no further role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali Muhammed, 2017, BMC Res Notes, V10, P676, DOI 10.1186/s13104-017-3025-7; [Anonymous], 2016, IEEE-ASME T MECH, VPP, P1, DOI DOI 10.1109/IEEESTD.2016.7460875; Ansah EK, 2016, INT HEALTH, V8, P427, DOI 10.1093/inthealth/ihw041; Armstrong-Hough M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192332; Bahendeka S, 2016, TROP MED INT HEALTH, V21, P405, DOI 10.1111/tmi.12663; Chiwanga FS, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.31440; Fung V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191817; Gaziano T, 2015, HEALTH AFFAIR, V34, P1578, DOI 10.1377/hlthaff.2015.0351; Guwatudde D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138991; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; Kishore SP, 2018, J AM COLL CARDIOL, V71, P564, DOI 10.1016/j.jacc.2017.11.056; Kishore SP, 2015, HEALTH AFFAIR, V34, P1569, DOI 10.1377/hlthaff.2015.0375; Ministry of Health ROU, 2012, ESS MED HLTH SUPPL L; National Medical Logistics, FY 2017 18 NAT MED S; Pittman DG, 2011, AM J CARDIOL, V107, P1662, DOI 10.1016/j.amjcard.2011.01.052; Rash JA, 2016, PREV MED, V90, P155, DOI 10.1016/j.ypmed.2016.07.006; Robertson J, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0105-0; Schwartz JI, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0077-5; Siddharthan T, 2015, HEALTH AFFAIR, V34, P1506, DOI 10.1377/hlthaff.2015.0382; United Nations, 2018, SUST DEV GOALS REP 2; World Health Organization, 2014, NONC DIS GLOB MON FR; World Health Organization, 2015, UG WHO STAT PROF; Yadav P., 2010, ALWAYS COLA RARELY E	23	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2020	15	12							e0241555	10.1371/journal.pone.0241555	http://dx.doi.org/10.1371/journal.pone.0241555			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CI	33362249	gold, Green Submitted, Green Published			2023-01-03	WOS:000603071600065
J	Kirschner, J; Hunter, B				Kirschner, Jonathan; Hunter, Benton			In acute soft tissue injuries, NSAIDs do not differ from acetaminophen for pain reduction	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kirschner, Jonathan; Hunter, Benton] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Kirschner, J (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.							Busse JW, 2020, ANN INTERN MED, V173, P730, DOI 10.7326/M19-3601; Hsu JR, 2019, J ORTHOP TRAUMA, V33, pE158, DOI 10.1097/BOT.0000000000001430	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	2020	173	12					JC66	JC66		10.7326/ACPJ202012150-066	http://dx.doi.org/10.7326/ACPJ202012150-066			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM1AG	33316182				2023-01-03	WOS:000621511200004
J	Andre, T; Shiu, KK; Kim, TW; Jensen, BV; Jensen, LH; Punt, C; Smith, D; Garcia-Carbonero, R; Benavides, M; Gibbs, P; de la Fouchardiere, C; Rivera, F; Elez, E; Bendell, J; Le, DT; Yoshino, T; Van Cutsem, E; Yang, P; Farooqui, MZH; Marinello, P; Diaz, LA				Andre, T.; Shiu, K-K; Kim, T. W.; Jensen, B., V; Jensen, L. H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; de la Fouchardiere, C.; Rivera, F.; Elez, E.; Bendell, J.; Le, D. T.; Yoshino, T.; Van Cutsem, E.; Yang, P.; Farooqui, M. Z. H.; Marinello, P.; Diaz, L. A., Jr.		KEYNOTE-177 Investigators	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFICIENT; TUMORS; BRAF	BackgroundProgrammed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown. MethodsIn this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks. Patients receiving chemotherapy could cross over to pembrolizumab therapy after disease progression. The two primary end points were progression-free survival and overall survival. ResultsAt the second interim analysis, after a median follow-up (from randomization to data cutoff) of 32.4 months (range, 24.0 to 48.3), pembrolizumab was superior to chemotherapy with respect to progression-free survival (median, 16.5 vs. 8.2 months; hazard ratio, 0.60; 95% confidence interval [CI], 0.45 to 0.80; P=0.0002). The estimated restricted mean survival after 24 months of follow-up was 13.7 months (range, 12.0 to 15.4) as compared with 10.8 months (range, 9.4 to 12.2). As of the data cutoff date, 56 patients in the pembrolizumab group and 69 in the chemotherapy group had died. Data on overall survival were still evolving (66% of required events had occurred) and remain blinded until the final analysis. An overall response (complete or partial response), as evaluated with Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was observed in 43.8% of the patients in the pembrolizumab group and 33.1% in the chemotherapy group. Among patients with an overall response, 83% in the pembrolizumab group, as compared with 35% of patients in the chemotherapy group, had ongoing responses at 24 months. Treatment-related adverse events of grade 3 or higher occurred in 22% of the patients in the pembrolizumab group, as compared with 66% (including one patient who died) in the chemotherapy group. ConclusionsPembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.) Colorectal cancer is genetically heterogeneous. Tumors in some patients have defects in mismatch DNA repair. These tumors have a high level of mutations that can lead to immune recognition. In a group of patients with microsatellite-unstable tumors, pembrolizumab led to longer progression-free survival and was less toxic than standard chemotherapy.	[Diaz, L. A., Jr.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA; [Andre, T.] Sorbonne Univ, Paris, France; [Andre, T.] Hop St Antoine, Paris, France; [Smith, D.] Bordeaux Univ Hosp, Bordeaux, France; [de la Fouchardiere, C.] Leon Berard Ctr, Lyon, France; [Shiu, K-K] NHS Fdn Trust, Univ Coll Hosp, London, England; [Kim, T. W.] Univ Ulsan, Asan Med Ctr, Seoul, South Korea; [Jensen, B., V] Herlev & Gentofte Hosp, Herlev, Denmark; [Jensen, L. H.] Univ Hosp Southern Denmark, Vejle, Denmark; [Punt, C.] Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands; [Garcia-Carbonero, R.] Hosp Univ 12 Octubre, Imas12, Madrid, Spain; [Benavides, M.] Hosp Reg Univ, Malaga, Spain; [Rivera, F.] Hosp Univ Marques Valdecilla, Santander, Spain; [Elez, E.] Vall dHebron Inst Oncol, Barcelona, Spain; [Gibbs, P.] Western Hlth, St Albans, Vic, Australia; [Bendell, J.] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA; [Le, D. T.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Yoshino, T.] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan; [Van Cutsem, E.] Univ Hosp Gasthuisberg, Leuven, Belgium; [Van Cutsem, E.] Katholieke Univ Leuven, Leuven, Belgium; [Yang, P.] MSD China, Beijing, Peoples R China; [Farooqui, M. Z. H.; Marinello, P.] Merck, Kenilworth, NJ USA	Memorial Sloan Kettering Cancer Center; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Bordeaux; UNICANCER; Centre Leon Berard; Oxford University Hospitals NHS Foundation Trust; University of London; University College London; University of Ulsan; University of Southern Denmark; Lillebaelt Hospital; University of Amsterdam; Hospital Universitario 12 de Octubre; Hospital Universitario Marques de Valdecilla (HUMV); Vall d'Hebron Institut d'Oncologia (VHIO); Sarah Cannon Research Institute; Tennessee Oncology; Johns Hopkins University; Johns Hopkins Medicine; National Cancer Center - Japan; KU Leuven; University Hospital Leuven; KU Leuven; Merck & Company	Diaz, LA (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.	ldiaz@mskcc.org	Jensen, Lars Henrik/P-6252-2018; Diaz, Luis/ABD-5602-2021; de la Fouchardiere, Christelle/AAW-7887-2021; André, Thierry P/N-8830-2017; Van+Cutsem, Eric/ABE-1762-2021	Jensen, Lars Henrik/0000-0002-0020-1537; André, Thierry P/0000-0002-5103-7095; DE LA FOUCHARDIERE, CHRISTELLE/0000-0003-2291-5693; Elez, Elena/0000-0002-4653-6324; McDermott, Ray/0000-0002-8952-4315; Samuel, Leslie/0000-0002-8402-8670; Garcia-Carbonero, Rocio/0000-0002-3342-397X; George, Thomas/0000-0002-6249-9180	Merck Sharp and Dohme; Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant	Merck Sharp and Dohme(Merck & Company); Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant	Supported by Merck Sharp and Dohme and by a Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	[Anonymous], 2019, INTEL 64 IA 32 ARCHI, V3; Arnold CN, 2004, CANCER BIOL THER, V3, P73, DOI 10.4161/cbt.3.1.590; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]; Cohen R, 2019, JAMA ONCOL, V5, P551, DOI 10.1001/jamaoncol.2018.4942; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Goel A, 2012, GASTROENTEROLOGY, V143, P1442, DOI 10.1053/j.gastro.2012.09.032; Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867; Latham A, 2019, J CLIN ONCOL, V37, P286, DOI 10.1200/JCO.18.00283; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; LENZ H, 2020, J CLIN ONCOL S, V38; Ludford K., 2020, J NATL CANC I; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Martin-Romano P, 2020, CANCER MED-US, V9, P2643, DOI 10.1002/cam4.2797; National Comprehensive Cancer Network, 2020, NONSMALL CELL LUNG C; Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Tougeron D, 2020, INT J CANCER, V147, P285, DOI 10.1002/ijc.32879; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332; Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738; Zlobec I, 2010, INT J CANCER, V127, P367, DOI 10.1002/ijc.25042	27	684	717	28	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	2020	383	23					2207	2218		10.1056/NEJMoa2017699	http://dx.doi.org/10.1056/NEJMoa2017699			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB8PZ	33264544	Bronze, Green Published			2023-01-03	WOS:000596577700011
J	Zou, YY; Fineberg, S; Pearlman, A; Feinman, RD; Fine, EJ				Zou, Yiyu; Fineberg, Susan; Pearlman, Alexander; Feinman, Richard D.; Fine, Eugene J.			The effect of a ketogenic diet and synergy with rapamycin in a mouse model of breast cancer	PLOS ONE			English	Article							METABOLIC THERAPY; FEASIBILITY; CHEMOTHERAPY; INHIBITION; RADIATION; ONCOLOGY; CACHEXIA; OBESITY; TUMORS	Background The effects of diet in cancer, in general, and breast cancer in particular, are not well understood. Insulin inhibition in ketogenic, high fat diets, modulate downstream signaling molecules and are postulated to have therapeutic benefits. Obesity and diabetes have been associated with higher incidence of breast cancer. Addition of anti-cancer drugs together with diet is also not well studied. Methods Two diets, one ketogenic, the other standard mouse chow, were tested in a spontaneous breast cancer model in 34 mice. Subgroups of 3-9 mice were assigned, in which the diet were implemented either with or without added rapamycin, an mTOR inhibitor and potential anti-cancer drug. Results Blood glucose and insulin concentrations in mice ingesting the ketogenic diet (KD) were significantly lower, whereas beta hydroxybutyrate (BHB) levels were significantly higher, respectively, than in mice on the standard diet (SD). Growth of primary breast tumors and lung metastases were inhibited, and lifespans were longer in the KD mice compared to mice on the SD (p<0.005). Rapamycin improved survival in both mouse diet groups, but when combined with the KD was more effective than when combined with the SD. Conclusions The study provides proof of principle that a ketogenic diet a) results in serum insulin reduction and ketosis in a spontaneous breast cancer mouse model; b) can serve as a therapeutic anti-cancer agent; and c) can enhance the effects of rapamycin, an anti-cancer drug, permitting dose reduction for comparable effect. Further, the ketogenic diet in this model produces superior cancer control than standard mouse chow whether with or without added rapamycin.	[Zou, Yiyu; Pearlman, Alexander; Fine, Eugene J.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Fineberg, Susan; Fine, Eugene J.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Feinman, Richard D.] SUNY Downstate Hlth Sci Ctr, Brooklyn, NY USA	Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Fine, EJ (corresponding author), Albert Einstein Coll Med, Bronx, NY 10467 USA.; Fine, EJ (corresponding author), Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA.	eugene.fine@einsteinmed.org			CTSA Grant from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR002556]; ST Balchug	CTSA Grant from National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); ST Balchug	Generous funding for this project was provided by ST Balchug, a commercial company which operates in the real estate sector. In addition, the study was supported in part by the CTSA Grant UL1TR002556 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, REG ANESTH PAIN MED; [Anonymous], 2019, QUALITY MANAGEMENT, V11, pS1007; [Anonymous], 1995, NUTRIENT REQUIREMENT; [Anonymous], 2014, AM J PHYSIOL-RENAL, V307, pF891; Basho RK, 2018, ONCOLOGIST, V23, P1300, DOI 10.1634/theoncologist.2017-0498; BECK SA, 1989, CANCER RES, V49, P3800; Boone E, VALIDITY RELIABILITY; Champ CE, 2014, J NEURO-ONCOL, V117, P125, DOI 10.1007/s11060-014-1362-0; Fine EJ, 2012, NUTRITION, V28, P1028, DOI 10.1016/j.nut.2012.05.001; Goodwin PJ, 2015, BREAST, V24, pS56, DOI 10.1016/j.breast.2015.07.014; Goren HJ, 2004, ENDOCRINOLOGY, V145, P3307, DOI 10.1210/en.2003-1400; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4; Hsieh MH, 2019, CELL REP, V28, P1860, DOI 10.1016/j.celrep.2019.07.027; Iyikesici MS, 2019, INT J HYPERTHER, V36, P446, DOI 10.1080/02656736.2019.1589584; Jain V, 2017, MATURITAS, V104, P80, DOI 10.1016/j.maturitas.2017.08.006; Kabat GC, 2017, CANCER EPIDEM BIOMAR, V26, P1730, DOI 10.1158/1055-9965.EPI-17-0495; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Khodabakhshi A, 2020, NUTR CANCER, V72, P627, DOI 10.1080/01635581.2019.1650942; Kim HS, 2012, BJU INT, V110, P1062, DOI 10.1111/j.1464-410X.2012.10971.x; Klement RJ, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-1337-2; Klement RJ, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0991-5; Klement RJ, 2018, COMPLEMENT MED RES, V25, P102, DOI 10.1159/000484045; Nagini S, 2019, SEMIN CANCER BIOL, V56, P25, DOI 10.1016/j.semcancer.2017.12.010; NEBELING LC, 1995, J AM COLL NUTR, V14, P202; NIH Public Access Author Manuscript, 2011, J PHYS ACT HLTH, V8, pS257; Niraula S, 2012, BREAST CANCER RES TR, V135, P821, DOI 10.1007/s10549-012-2223-1; Pimentel I, 2019, BREAST, V48, P17, DOI 10.1016/j.breast.2019.08.003; Radogna F, 2015, BIOCHEM PHARMACOL, V94, P1, DOI 10.1016/j.bcp.2014.12.018; Senapati P, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0290-9; Seyfried TN, 2015, CANCER LETT, V356, P289, DOI 10.1016/j.canlet.2014.07.015; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Shishido SN, 2014, INT J CANCER, V134, P1474, DOI 10.1002/ijc.28461; Thakur B, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152652; TISDALE MJ, 1987, BRIT J CANCER, V56, P39, DOI 10.1038/bjc.1987.149; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Wilson AJ, 2010, CANCER RES, V70, P609, DOI 10.1158/0008-5472.CAN-09-2327; Woodhouse C, 2019, CURR ONCOL, V26, pE433, DOI 10.3747/co.26.4889; Zahra A, 2017, RADIAT RES, V187, P743, DOI [10.1667/RR14668.1, 10.1667/rr14668.1]; Zou YY, 1998, J NATL CANCER I, V90, P1130, DOI 10.1093/jnci/90.15.1130	40	13	14	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2020	15	12							e0233662	10.1371/journal.pone.0233662	http://dx.doi.org/10.1371/journal.pone.0233662			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC7AH	33270630	Green Published, gold, Green Submitted			2023-01-03	WOS:000597149100106
J	Shoji, J; Inada, N; Tomioka, A; Yamagami, S				Shoji, Jun; Inada, Noriko; Tomioka, Akiko; Yamagami, Satoru			Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjogren's syndrome-associated dry eyes	PLOS ONE			English	Article							CONJUNCTIVAL GOBLET CELLS; OCULAR SURFACE; EXPRESSION; TEAR; DIQUAFOSOL; MULTICENTER; OSMOLARITY; INCREASES; CYTOKINES; OPC-12759	Ocular surface mucins are thought to play vital roles in maintaining the homeostasis of the pre-ocular surface tear film. We performed ocular surface tests with impression cytology to assess the expression levels of mucin-related genes on the ocular surface in healthy eyes. In addition, we investigated alterations in mucin-related gene expression secondary to treatment with rebamipide ophthalmic suspension in patients with Sjogren's syndrome-associated dry eyes (SS-DE). Thirty-three healthy individuals (control group) and 13 patients from our hospital with SS-DE were enrolled. Impression cytology was performed using Schirmer's test paper for RNA sampling. The mRNA levels of SAM-pointed domain-containing ETS-like factor (SPDEF), mucin 5AC (MUC5AC), and mucin 16 (MUC16) were determined using a real-time reverse transcription-polymerase chain reaction. The ocular surface test was performed once for the control group, and at baseline as well as 2, 4, 8, and 12 weeks after treatment in the Sjogren's syndrome-associated dry eyes group. mRNA levels of SPDEF, MUC5AC, and MUC16 were not significantly different between the control and SS-DE groups before rebamipide ophthalmic suspension treatment. SPDEF mRNA levels in control subjects were significantly correlated with levels of MUC5AC. Among SS-DE patients, SPDEF mRNA levels were significantly increased at 2, 4, and 8 weeks after treatment compared with baseline levels. MUC16 mRNA levels were significantly decreased from baseline levels at 4 and 8 weeks post-treatment. Ocular surface test using impression cytology is a clinically useful tool for assessing mucous conditions on the ocular surface and can be used to determine the effects of instillation treatment with eye drops that affect mucin production at the ocular surface.	[Shoji, Jun; Inada, Noriko; Tomioka, Akiko; Yamagami, Satoru] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan	Nihon University	Yamagami, S (corresponding author), Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.	satoru.yamagami@nihon-u.ac.jp		Shoji, Jun/0000-0001-8957-3312	Otsuka Pharmaceutical Co., Ltd.	Otsuka Pharmaceutical Co., Ltd.(Otsuka Pharmaceutical)	This study was supported by a grant from Otsuka Pharmaceutical Co., Ltd. to Nihon University Itabashi Hospital. Otsuka Pharmaceutical Co., Ltd. had no role in the study design, data collection and analysis, and the decision to publish this manuscript.	Arakaki R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098390; Argueso P, 2002, INVEST OPHTH VIS SCI, V43, P1004; Aso H, 2019, CORNEA, V38, P706, DOI 10.1097/ICO.0000000000001904; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Bunya VY, 2013, CORNEA, V32, P922, DOI 10.1097/ICO.0b013e31827e2a5e; Caffery B, 2010, MOL VIS, V16, P1720; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Connor C G, 1999, J Am Optom Assoc, V70, P182; Corfield AP, 2015, BBA-GEN SUBJECTS, V1850, P236, DOI 10.1016/j.bbagen.2014.05.003; Corrales RM, 2003, CURR EYE RES, V27, P323, DOI 10.1076/ceyr.27.5.323.17221; Corrales RM, 2011, INVEST OPHTH VIS SCI, V52, P8363, DOI 10.1167/iovs.11-7655; Danjo Y, 1998, INVEST OPHTH VIS SCI, V39, P2602; Efron N, 2016, PROG RETIN EYE RES, V53, P140, DOI 10.1016/j.preteyeres.2016.04.004; Fujibayashi Takashi, 2004, Mod Rheumatol, V14, P425, DOI 10.3109/s10165-004-0338-x; Gipson IK, 2004, EXP EYE RES, V78, P379, DOI 10.1016/S0014-4835(03)00204-5; Gipson Ilene K, 2004, Ocul Surf, V2, P131; Gipson IK, 2016, PROG RETIN EYE RES, V54, P49, DOI 10.1016/j.preteyeres.2016.04.005; Gipson IK, 2016, EXP EYE RES, V145, P230, DOI 10.1016/j.exer.2015.12.009; Gipson IK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100393; Gregorieff A, 2009, GASTROENTEROLOGY, V137, P1333, DOI 10.1053/j.gastro.2009.06.044; Hansen A, 2005, CURR OPIN RHEUMATOL, V17, P558, DOI 10.1097/01.bor.0000172801.56744.c3; Hori Y, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23623; Hori Y, 2017, J OCUL PHARMACOL TH, V33, P493, DOI 10.1089/jop.2016.0092; Inada N, 2017, ALLERGOL INT, V66, P586, DOI 10.1016/j.alit.2017.03.004; Kase S, 2017, EXP THER MED, V13, P3516, DOI 10.3892/etm.2017.4390; Keating GM, 2015, DRUGS, V75, P911, DOI 10.1007/s40265-015-0409-7; Kinoshita S, 2014, AM J OPHTHALMOL, V157, P576, DOI 10.1016/j.ajo.2013.11.010; Kinoshita S, 2012, OPHTHALMOLOGY, V119, P2471, DOI 10.1016/j.ophtha.2012.06.052; Korb Donald R., 2002, CLAO Journal, V28, P211; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Machida Y, 2016, CASE REP OPHTHAL, V7, P208, DOI 10.1159/000445371; Marko CK, 2013, AM J PATHOL, V183, P35, DOI 10.1016/j.ajpath.2013.03.017; Moon I, 2018, J OCUL PHARMACOL TH, V34, P612, DOI 10.1089/jop.2018.0005; Mukhopadhyay S, 2013, INT OPHTHALMOL, V33, P153, DOI 10.1007/s10792-012-9670-x; Na KS, 2012, INVEST OPHTH VIS SCI, V53, P5443, DOI 10.1167/iovs.11-9417; Noah TK, 2010, EXP CELL RES, V316, P452, DOI 10.1016/j.yexcr.2009.09.020; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; PFLUGFELDER SC, 1990, OPHTHALMOLOGY, V97, P985; Pflugfelder SC, 2008, CORNEA, V27, P64, DOI 10.1097/ICO.0b013e318158f6dc; Shimazaki-Den S, 2013, CORNEA, V32, P1211, DOI 10.1097/ICO.0b013e318295a2a5; Takeji Y, 2012, J OCUL PHARMACOL TH, V28, P259, DOI 10.1089/jop.2011.0142; Terakado K, 2014, VET J, V202, P48, DOI 10.1016/j.tvjl.2014.05.022; Tomlinson A, 2006, INVEST OPHTH VIS SCI, V47, P4309, DOI 10.1167/iovs.05-1504; Uchino Y, 2016, EXP EYE RES, V153, P1, DOI 10.1016/j.exer.2016.10.007; Urashima H, 2012, J OCUL PHARMACOL TH, V28, P264, DOI 10.1089/jop.2011.0147; VANBIJST.OP, 1969, ARCH OPHTHALMOL-CHIC, V82, P10	46	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2020	15	11							e0242617	10.1371/journal.pone.0242617	http://dx.doi.org/10.1371/journal.pone.0242617			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA8EQ	33232357	gold, Green Published			2023-01-03	WOS:000595863100033
J	Sigglekow, F; Horsburgh, S; Parkin, L				Sigglekow, Finn; Horsburgh, Simon; Parkin, Lianne			Statin adherence is lower in primary than secondary prevention: A national follow-up study of new users	PLOS ONE			English	Article							ACUTE CORONARY SYNDROMES; 14 RANDOMIZED-TRIALS; HEALTH-CARE COSTS; MEDICATION ADHERENCE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; THERAPY; CHOLESTEROL; MAINTENANCE; PREDICTORS	Background Maintaining adherence to statins reduces the risk of an initial cardiovascular disease (CVD) event in high-risk individuals (primary prevention) and additional CVD events following the first event (secondary prevention). The effectiveness of statin therapy is limited by the level of adherence maintained by the patient. We undertook a nationwide study to compare adherence and discontinuation in primary and secondary prevention patients. Methods Dispensing data from New Zealand community pharmacies were used to identify patients who received their first statin dispensing between 2006 and 2011. The Medication Possession Ratio (MPR) and proportion who discontinued statin medication was calculated for the year following first statin dispensing for patients with a minimum of two dispensings. Adherence was defined as an MPR. 0.8. Previous CVD was identified using hospital discharge records. Multivariable logistic regression was used to control for demographic and statin characteristics. Results Between 2006 and 2011 289,666 new statin users were identified with 238,855 (82.5%) receiving the statin for primary prevention compared to 50,811 (17.5%) who received it for secondary prevention. The secondary prevention group was 1.55 (95% CI 1.51-1.59) times as likely to be adherent and 0.67 (95% CI 0.65-0.69) times as likely to discontinue statin treatment than the primary prevention group. An early gap in statin coverage increased the odds of discontinuing statin treatment. Conclusion Adherence to statin medication is higher in secondary prevention than primary prevention. Within each group, a range of demographic and treatment factors further influences adherence.	[Sigglekow, Finn; Horsburgh, Simon; Parkin, Lianne] Univ Otago, Otago Med Sch, Dept Prevent & Social Med, Dunedin Campus, Dunedin, New Zealand; [Horsburgh, Simon; Parkin, Lianne] Univ Otago, Pharmacoepidemiol Res Network, Dunedin, New Zealand	University of Otago; University of Otago	Horsburgh, S (corresponding author), Univ Otago, Otago Med Sch, Dept Prevent & Social Med, Dunedin Campus, Dunedin, New Zealand.; Horsburgh, S (corresponding author), Univ Otago, Pharmacoepidemiol Res Network, Dunedin, New Zealand.	simon.horsburgh@otago.ac.nz	Horsburgh, Simon/C-9861-2009	Horsburgh, Simon/0000-0002-1011-7996; Sigglekow, Finn/0000-0002-7197-1512; Parkin, Lianne/0000-0002-6824-6176	Dunedin School of Medicine Summer Scholarship; University of Otago Research Grant	Dunedin School of Medicine Summer Scholarship; University of Otago Research Grant	This research was funded by a Dunedin School of Medicine Summer Scholarship (FS) and a University of Otago Research Grant (SH and LP). The funders had no role in the study design in the collection, analysis and interpretation of data, in the writing of the report; or in the decision to submit the article for publication.	Aarnio E, 2016, CIRC-CARDIOVASC QUAL, V9, P704, DOI 10.1161/CIRCOUTCOMES.116.002728; Aarnio EJ, 2014, J CLIN LIPIDOL, V8, P117, DOI 10.1016/j.jacl.2013.09.008; [Anonymous], 2019, HAUOR REP STAG ON HL; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Carey IM, 2012, NUTR METAB CARDIOVAS, V22, P400, DOI 10.1016/j.numecd.2010.09.010; Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147; Chodick G, 2008, CLIN THER, V30, P2167, DOI 10.1016/j.clinthera.2008.11.012; Cutler RL, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-016982; Dragomir A, 2010, VALUE HEALTH, V13, P87, DOI 10.1111/j.1524-4733.2009.00583.x; Ellis JJ, 2004, J GEN INTERN MED, V19, P638, DOI 10.1111/j.1525-1497.2004.30516.x; Erickson SR, 2020, ANN PHARMACOTHER, V54, P1194, DOI 10.1177/1060028020934879; Gehi AK, 2007, ARCH INTERN MED, V167, P1798, DOI 10.1001/archinte.167.16.1798; Grenard JL, 2011, J GEN INTERN MED, V26, P1175, DOI 10.1007/s11606-011-1704-y; Grey C, 2018, NEW ZEAL MED J, V131, P21; Grey C, 2014, HEART, V100, P770, DOI 10.1136/heartjnl-2013-304960; Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986; Hope HF, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0201196; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jatrana S, 2011, J EPIDEMIOL COMMUN H, V65, P454, DOI 10.1136/jech.2009.099101; Kearney PM, 2008, LANCET, V371, P117, DOI 10.1016/S0140-6736(08)60104-X; Kerr AJ, 2016, J PRIM HEALTH CARE, V8, P238, DOI 10.1071/HC16013; Mann DM, 2010, ANN PHARMACOTHER, V44, P1410, DOI 10.1345/aph.1P150; Martin-Ruiz E, 2018, J CARDIOVASC PHARM T, V23, P200, DOI 10.1177/1074248417745357; Ministry of Health, 2020, PHARM DAT WEB TOOL V; Ministry of Health, 2018, CARD DIS RISK ASS MA; Ministry of Health, 2019, ANN DAT EXPL 2018 19; Ministry of Health, 2017, HISO 100012017 ETHNI; Ministry of Health, 2016, HLTH LOSS NZ 1990 20; Muntner P, 2014, AM J CARDIOL, V114, P826, DOI 10.1016/j.amjcard.2014.06.009; New Zealand Guidelines Group, 2009, NZ CARDIOVASCULAR GU; New Zealand Guidelines Group, 2003, ASS MAN CARD RISK; New Zealand Guidelines Group, 2012, NZ PRIM CAR HDB 2012; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Palmer SC, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1057-4; Perreault S, 2005, BRIT J CLIN PHARMACO, V59, P564, DOI 10.1111/j.1365-2125.2005.02355.x; Pittman DG, 2011, AM J CARDIOL, V107, P1662, DOI 10.1016/j.amjcard.2011.01.052; Pylypchuk R, 2018, LANCET, V391, P1897, DOI [10.1016/S0140-6736(18)30664-0, 10.1016/s0140-6736(18)30664-0]; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Salmond C., 2007, NZDEP2006 INDEX DEPR; Slejko JF, 2014, J MANAGE CARE PHARM, V20, P51, DOI 10.18553/jmcp.2014.20.1.51; Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5; Thornley S, 2012, EUR J PREV CARDIOL, V19, P349, DOI 10.1177/1741826711403069; Vinogradova Y, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3305; Vrijens B, 2012, BRIT J CLIN PHARMACO, V73, P691, DOI 10.1111/j.1365-2125.2012.04167.x; Watanabe JH, 2013, CURR MED RES OPIN, V29, P175, DOI 10.1185/03007995.2013.766164; Wells S, 2018, NEW ZEAL MED J, V131, P10; World Health Organization (WHO), 2018, DEF GEN CONS; Xie ZW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212117	50	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2020	15	11							e0242424	10.1371/journal.pone.0242424	http://dx.doi.org/10.1371/journal.pone.0242424			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM0RU	33211724	Green Published			2023-01-03	WOS:000603518300055
J	Abuhammad, S				Abuhammad, Sawsan			Predictors of maternal parenting self-efficacy for infants and toddlers: A Jordanian study	PLOS ONE			English	Article							SOCIAL SUPPORT; POSTNATAL DEPRESSION; WOMEN	Aim This study aimed to investigate the predictors of maternal parenting self-efficacy when the children concerned are in the early years of life. Method A descriptive-analytical research study was carried out among 213 women who were in the early months of the postpartum period and attending healthcare facilities in Irbid, Jordan. The State Anxiety Inventory (SAI) and the Maternal Parenting Self-Efficacy (PMP S-E) tool were used to collect the data. Results A significant correlation was found between the scores in self-efficacy and the quality of marriage relations (B = 3.56, P = 001), family income (B = 1.97, P = .05), employment (B = 4.027, P = .027), education (B = 2.48, P = .004), and living with extended family (B = 5.28, P = .02). Conclusion The findings of this study show that MPSE is significantly associated with various predictors. These predictors are the mother's education, income, whether she lives with extended family, her quality of marriage, and her employment. Maternal anxiety was found not to be a predictor for MPSE and this may explain other factors such as social support and living with extended family. Implication It is essential for nurses to understand maternal parenting self-efficacy, therefore, including the concept of maternal parenting self-efficacy in nursing curricula can help raise awareness of this important concept. Understanding maternal parenting self-efficacy is necessary for nurses to evaluate the mothers' parenting self-efficacy.	[Abuhammad, Sawsan] Jordan Univ Sci & Technol, Fac Nursing, Irbid, Jordan	Jordan University of Science & Technology	Abuhammad, S (corresponding author), Jordan Univ Sci & Technol, Fac Nursing, Irbid, Jordan.	Shabuhammad@just.edu.jo	ABUHAMMAD, SAWSAN/AAW-1875-2020	ABUHAMMAD, SAWSAN/0000-0001-5817-8950				Abdel-Khalek AM, 2000, PSYCHOL REP, V87, P478, DOI 10.2466/PR0.87.6.478-492; Abuhammad S, 2021, NURS OPEN, V8, P123, DOI 10.1002/nop2.610; Abuhammad S, 2020, J PEDIATR NURS, V51, pE45, DOI 10.1016/j.pedn.2019.08.002; Abuhammad S, 2018, INT J PEDIATR-MASSHA, V6, P8655, DOI 10.22038/ijp.2018.33637.2975; Aliabadi F, 2013, IRAN REHABIL J, V11, P7; [Anonymous], 2020, Circulation, V141, pe59, DOI 10.1161/CIR.0000000000000754; [Anonymous], 2012, DIABETES METAB RES R, V28, pS1; [Anonymous], 2007, THESIS; Bandura, 1997, SELF EFFICACY EXERCI, P37; Bryanton J, 2008, NURS RES, V57, P252, DOI 10.1097/01.NNR.0000313490.56788.cd; Farkas C, 2010, INFANT BEHAV DEV, V33, P654, DOI 10.1016/j.infbeh.2010.09.001; Gao LL, 2014, MIDWIFERY, V30, P532, DOI 10.1016/j.midw.2013.06.007; Gharaibeh MK, 2012, J RES NURS, V17, P289, DOI 10.1177/1744987110395352; Holzmann-Pazgal G., 2010, Morbidity and Mortality Weekly Report, V59, P185; Koury AJ, 2020, APPL PSYCHOL-HLTH WE, V12, P432, DOI 10.1111/aphw.12191; Lawal AM, 2017, PSYCHOL HEALTH MED, V22, P1230, DOI 10.1080/13548506.2017.1317824; Leahy-Warren P, 2011, MIDWIFERY, V27, P802, DOI 10.1016/j.midw.2010.07.008; Salonen AH, 2009, J ADV NURS, V65, P2324, DOI 10.1111/j.1365-2648.2009.05113.x; Sari C, 2020, PUBLIC HEALTH NURS, V37, P380, DOI 10.1111/phn.12712; Sercekus P, 2016, MIDWIFERY, V34, P166, DOI 10.1016/j.midw.2015.11.016; Shorey S, 2015, J ADV NURS, V71, P1260, DOI 10.1111/jan.12590; Shorey S, 2014, J CLIN NURS, V23, P2272, DOI 10.1111/jocn.12507; Spielberger C., 1983, MANUAL STATE TRAIT A; Stokes LO, PRENATAL ED POSTPART; Yap DFF, 2019, J APPL RES INTELLECT, V32, P841, DOI 10.1111/jar.12575; Zheng XJ, 2018, MIDWIFERY, V62, P151, DOI 10.1016/j.midw.2018.04.005	26	2	2	4	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0241585	10.1371/journal.pone.0241585	http://dx.doi.org/10.1371/journal.pone.0241585			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ9VG	33206672	gold, Green Published			2023-01-03	WOS:000595265900050
J	Goyala, A; Baruah, A; Mukhopadhyay, A				Goyala, Anita; Baruah, Aiswarya; Mukhopadhyay, Arnab			The genetic paradigms of dietary restriction fail to extend life span in cep-1(gk138) mutant of C. elegans p53 due to possible background mutations	PLOS ONE			English	Article							DOMINANT-NEGATIVE DMP53; CAENORHABDITIS-ELEGANS; INDUCED LONGEVITY; EXPRESSION; PATHWAY; MICE	Dietary restriction (DR) increases life span and improves health in most model systems tested, including non-human primates. In C. elegans, as in other models, DR leads to reprogramming of metabolism, improvements in mitochondrial health, large changes in expression of cytoprotective genes and better proteostasis. Understandably, multiple global transcriptional regulators like transcription factors FOXO/DAF-16, FOXA/PHA-4, HSF1/HSF-1 and NRF2/SKN-1 are important for DR longevity. Considering the wide-ranging effects of p53 on organismal biology, we asked whether the C. elegans ortholog, CEP-1 is required for DR-mediated longevity assurance. We employed the widely-used TJ1 strain of cep-1(gk138). We show that cep-1(gk138) suppresses the life span extension of two genetic paradigms of DR, but two non-genetic modes of DR remain unaffected in this strain. We find that two aspects of DR, increased autophagy and up-regulation of the expression of cytoprotective xenobiotic detoxification program (cXDP) genes, are dampened in cep-1(gk138). Importantly, we find that background mutation(s) in the strain may be the actual cause for the phenotypic differences that we observed and cep-1 may not be directly involved in genetic DR-mediated longevity assurance in worms. Identifying these mutation(s) may reveal a novel regulator of longevity required specifically by genetic modes of DR.	[Goyala, Anita; Mukhopadhyay, Arnab] Natl Inst Immunol, Mol Aging Lab, Aruna Asaf Ali Marg, New Delhi, India; [Baruah, Aiswarya] Assam Agr Univ, Dept Agr Biotechnol, Jorhat, Assam, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Assam Agricultural University	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Mol Aging Lab, Aruna Asaf Ali Marg, New Delhi, India.	arnab@nii.ac.in	Mukhopadhyay, Arnab/N-6005-2016	Mukhopadhyay, Arnab/0000-0002-5266-7849	National Bioscience Award for Career Development [BT/HRD/NBA/38/04/2016]; SERB-STAR award [STR/2019/000064]; DBT's Twinning Programme [BT/PR16823/NER/95/304/2015]; National Institute of Immunology; National Institute of Health Office of Research Infrastructure Programs [P40 OD010440]	National Bioscience Award for Career Development; SERB-STAR award; DBT's Twinning Programme; National Institute of Immunology; National Institute of Health Office of Research Infrastructure Programs	The research was supported in part by the National Bioscience Award for Career Development (BT/HRD/NBA/38/04/2016) and SERB-STAR award (STR/2019/000064) to AM, DBT's Twinning Programme for the NE (BT/PR16823/NER/95/304/2015) to AM and AB, and core funding from the National Institute of Immunology to AM. Some strains were provided by the Caenorhabditis Genetics Center, which is funded by National Institute of Health Office of Research Infrastructure Programs (P40 OD010440).	Arum O, 2007, J GERONTOL A-BIOL, V62, P951, DOI 10.1093/gerona/62.9.951; Baruah A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004097; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Bauer JH, 2007, P NATL ACAD SCI USA, V104, P13355, DOI 10.1073/pnas.0706121104; Bauer JH, 2010, MECH AGEING DEV, V131, P193, DOI 10.1016/j.mad.2010.01.007; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Chamoli M, 2014, AGING CELL, V13, P641, DOI 10.1111/acel.12218; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; de Keizer PLJ, 2010, AGING-US, V2, P377, DOI 10.18632/aging.100178; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Han SK, 2016, ONCOTARGET, V7, P56147, DOI 10.18632/oncotarget.11269; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; HOSONO R, 1989, EXP GERONTOL, V24, P251, DOI 10.1016/0531-5565(89)90016-8; Jolliffe AK, 2013, BRIEF FUNCT GENOMICS, V12, P129, DOI 10.1093/bfgp/els047; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lapierre LR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3267; Leung CK, 2012, FREE RADICAL BIO MED, V52, P937, DOI 10.1016/j.freeradbiomed.2011.12.009; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Matai L, 2019, P NATL ACAD SCI USA, V116, P17383, DOI 10.1073/pnas.1900055116; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; O'Rourke EJ, 2009, CELL METAB, V10, P430, DOI 10.1016/j.cmet.2009.10.002; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; Stiernagle Theresa, 2006, WormBook, P1; Tabrez SS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00370-5; Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730; Tavernarakis N, 2008, TRENDS CELL BIOL, V18, P228, DOI 10.1016/j.tcb.2008.02.004; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Ventura N, 2009, AGING CELL, V8, P380, DOI 10.1111/j.1474-9726.2009.00482.x; Waskar M, 2009, AGING-US, V1, P903, DOI 10.18632/aging.100099; Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070; Wu ZY, 2019, CELL METAB, V29, P1192, DOI 10.1016/j.cmet.2019.02.013	36	0	0	4	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2020	15	11							e0241478	10.1371/journal.pone.0241478	http://dx.doi.org/10.1371/journal.pone.0241478			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0MJ	33180887	Green Published, Green Submitted, gold			2023-01-03	WOS:000593948000044
J	Camilleri, J; Borg, J; Damidot, D; Salvadori, E; Pilecki, P; Zaslansky, P; Darvell, BW				Camilleri, Josette; Borg, Joseph; Damidot, Denis; Salvadori, Enrico; Pilecki, Peter; Zaslansky, Paul; Darvell, Brian W.			Colour and chemical stability of bismuth oxide in dental materials with solutions used in routine clinical practice	PLOS ONE			English	Article							MINERAL TRIOXIDE AGGREGATE; CALCIUM HYDROXIDE; TOOTH; HYPOCHLORITE; CONTACT; RADIOPACITY; SPECTRA; MTA	Bismuth(III) oxide is included as a radio-opacifier in dental materials, including hydraulic silicate cements, the material of choice for several endodontic procedures. It has been implicated in tooth discoloration after contact with endodontic irrigants, in particular NaOCl solution, To date, there has been no work on the chemistry: all reports have been of clinical findings only. The purpose now was to report the reactions leading to colour change from Bi2O3 in contact with solutions used in routine endodontic practice. Ten-gram portions of Bi2O3 were immersed in either water, NaOH, NaCl, NaOCl or HCl solution, either in the dark or exposed to visible light, and samples retrieved at 1, 4, 12 and 24 weeks. After washing, these were exposed to either added CO2 or not, for 1 week while drying, and under the same dark or light conditions. Changes in appearance were monitored by photography and colour measurement, and chemically by X-ray diffraction and Fourier-transform infrared spectroscopy. 24-week material was studied using electron paramagnetic resonance and Raman spectroscopy; NaOCl-treated material was also examined by scanning electron microscopy. With water, NaCl and NaOH, bismuth subcarbonate was formed. With or without added carbon dioxide, discoloration occurred from pale yellow to light brown when exposed to light, and to a lesser extent in the dark, intensifying with time. In contrast, exposure to NaOCl rapidly formed a dark brown-black sodium bismuthate. With HCl, white BiOCl was formed. Bi2O3 is not at all inert in this context as is commonly believed, denying its principle of use. Previously unreported solution-mediated reaction occurs readily even in water and NaCl solution, forming new compounds that discolour. In contact with NaOCl sodium bismuthate is formed; severe darkening occurs rapidly. The reactivity is such that Bi2O3 is not indicated for dental materials and should be withdrawn from use.	[Camilleri, Josette; Darvell, Brian W.] Univ Birmingham, Sch Dent, Birmingham, W Midlands, England; [Borg, Joseph] Triq L Uqija Ta L Ibrag, Is Swieqi, Malta; [Damidot, Denis] Ecole Mines, LGCgE GCE, Fac Civil Engn, Dept Civil & Struct Engn, Douai, France; [Salvadori, Enrico] Univ Torino, Dept Chem, Turin, Italy; [Pilecki, Peter] Kings Coll London, Imaging & Microscopy, London, England; [Zaslansky, Paul] Charite Univ Med Berlin, Ctr Zahn Mund & Kieferheilkunde, Dept Operat & Prevent Dent, Berlin, Germany	University of Birmingham; IMT - Institut Mines-Telecom; IMT Nord Europe; Universite de Lille - ISITE; Universite de Lille; University of Turin; University of London; King's College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Camilleri, J; Darvell, BW (corresponding author), Univ Birmingham, Sch Dent, Birmingham, W Midlands, England.	J.Camilleri@bham.ac.uk; b.w.darvell@hku.hk	zaslansky, paul/AAB-7322-2021; Damidot, Denis/G-3215-2011; camilleri, josette/N-9409-2015	zaslansky, paul/0000-0002-8714-4992; Damidot, Denis/0000-0001-6630-9607; camilleri, josette/0000-0003-3556-6365				[Anonymous], 2019, COL PART 4 CIE 1976; Bai Y, 2014, RSC ADV, V4, P19456, DOI 10.1039/c4ra01629g; Barel A.O., 2010, HDB COSMETIC SCI TEC; Camilleri J, 2008, INT ENDOD J, V41, P408, DOI 10.1111/j.1365-2591.2007.01370.x; Camilleri J, 2014, J ENDODONT, V40, P436, DOI 10.1016/j.joen.2013.09.040; Dabbagh B, 2012, PEDIAT DENT, V46, P137; Demirkaya K, 2017, HUM EXP TOXICOL, V36, P1071, DOI 10.1177/0960327116679713; Demirkaya K, 2016, EUR J ORAL SCI, V124, P75, DOI 10.1111/eos.12238; Dummer PMH, 2019, INT ENDOD J, V52, P923, DOI 10.1111/iej.13080; Erdem AP, 2009, EUR ARCH PAEDIATR DE, V10, P110, DOI 10.1007/BF03321611; Feret F.R., 2003, ADV X-RAY ANAL, V46, P381; Guimaraes BM, 2015, J ENDODONT, V41, P947, DOI 10.1016/j.joen.2015.02.008; Duarte MAH, 2009, J ENDODONT, V35, P737, DOI 10.1016/j.joen.2009.02.006; Ioannidis K, 2013, INT ENDOD J, V46, P137, DOI 10.1111/j.1365-2591.2012.02098.x; Jacobovitz M, 2008, INT ENDOD J, V41, P905, DOI 10.1111/j.1365-2591.2008.01412.x; Jacobovitz M, 2009, DENT TRAUMATOL, V25, pE32, DOI 10.1111/j.1600-9657.2008.00745.x; Lavalilee C., 2001, PAINT COATINGS IND, V17, P64; LEVIN EM, 1964, J RES NBS A PHYS CH, VA 68, P189, DOI 10.6028/jres.068A.019; Li Q, 2015, DENT MATER J, V34, P458, DOI 10.4012/dmj.2014-309; Liu H, 2011, CHIN J DENT RES, V14, P121; Marciano MA, 2015, ENDO-ENDOD PRACT TOD, V9, P39; Marciano MA, 2017, J ENDODONT, V43, P1001, DOI 10.1016/j.joen.2017.01.029; Marciano MA, 2015, CLIN ORAL INVEST, V19, P2201, DOI 10.1007/s00784-015-1466-8; Marciano MA, 2014, J ENDODONT, V40, P1235, DOI 10.1016/j.joen.2014.01.044; Meraji N, 2018, DENT MATER, V34, pE236, DOI 10.1016/j.dental.2018.05.017; Moore A, 2011, DENT TRAUMATOL, V27, P166, DOI 10.1111/j.1600-9657.2011.00984.x; NOVAK L, 1961, Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove, V4, P297; POZNYAK SK, 1990, HIGH ENERG CHEM+, V24, P39; POZNYAK SK, 1990, ELECTROCHIM ACTA, V35, P1941, DOI 10.1016/0013-4686(90)87103-9; RAPPAPORT H M, 1964, Oral Surg Oral Med Oral Pathol, V18, P785, DOI 10.1016/0030-4220(64)90480-3; Sauro S, 2009, OPER DENT, V34, P166, DOI 10.2341/08-56; SCHEUFELE J, 1952, Dtsch Zahnarztl Z, V7, P913; Sharma G, 2003, EL EN AP SI, P1; Shokouhinejad N, 2018, CLIN ORAL INVEST, V22, P1725, DOI 10.1007/s00784-017-2266-0; Simsek N, 2016, J MATER SCI-MATER M, V27, P1; STEWART G G, 1958, Oral Surg Oral Med Oral Pathol, V11, P1174, DOI 10.1016/0030-4220(58)90302-5; Suzuki EM, 2014, J FORENSIC SCI, V59, P1205, DOI 10.1111/1556-4029.12414; Tapley MW, 1929, J AM PHARM ASSOC, V15, P46; Taylor HF, 1997, CEMENT CHEM; TAYLOR P, 1984, CAN J CHEM, V62, P2863, DOI 10.1139/v84-484; Ulrich I, 2015, CLIN ORAL INVEST, V19, P1473, DOI 10.1007/s00784-014-1372-5; Valles M, 2013, CLIN ORAL INVEST, V17, P1155, DOI 10.1007/s00784-012-0794-1; Valles M, 2013, J ENDODONT, V39, P525, DOI 10.1016/j.joen.2012.12.021; Voveraityte V, 2017, AUST ENDOD J, V43, P11, DOI 10.1111/aej.12149; Wismayer PS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34547; Zehnder M, 2006, J ENDODONT, V32, P389, DOI 10.1016/j.joen.2005.09.014; Zehnder M, 2002, ORAL SURG ORAL MED O, V94, P756, DOI 10.1067/moe.2002.128961; 2013, ALSTOM GRID, V28, P31	48	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2020	15	11							e0240634	10.1371/journal.pone.0240634	http://dx.doi.org/10.1371/journal.pone.0240634			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0LY	33176336	Green Published, gold			2023-01-03	WOS:000593946900005
J	Parsonidis, P; Vlachou, I; Mamagkaki, A; Bouris, I; Daikopoulou, V; Papasotiriou, I				Parsonidis, Panagiotis; Vlachou, Ioanna; Mamagkaki, Alexandra; Bouris, Ioannis; Daikopoulou, Vasiliki; Papasotiriou, Ioannis			Evaluation of Tegaran Formula ZhenHua cytotoxicity against human cancer cell lines	PLOS ONE			English	Article							POLYPHENOLS; APOPTOSIS; P53	The aim of this study is to evaluate the potential health effects of Tegaran Formula ZhenHua, a nutritional supplement used mainly by cancer patients. Its active ingredients and cytotoxicity was assessed with analytical methods and viability assays, respectively. The analytical methods consisted of dissolution, disintegration, HPLC, LC/MS, GC/MS and NMR. Cytotoxicity was assessed by MTT, SRB, CVE colorimetric viability assays in 0, 24, 48 and 72h time points. The results indicate that Tegaran Formula ZhenHua supplement did not present any cytotoxic effects due to issues related to the capsules' solubility, distribution and identification of the active ingredient.	[Parsonidis, Panagiotis; Vlachou, Ioanna; Mamagkaki, Alexandra; Bouris, Ioannis; Daikopoulou, Vasiliki] Res Genet Canc Ctr SA, Ind Area Florina, Florina, Greece; [Papasotiriou, Ioannis] Res Genet Canc Ctr Int GmbH Headquarters, Baarerstr, Zug, Switzerland		Papasotiriou, I (corresponding author), Res Genet Canc Ctr Int GmbH Headquarters, Baarerstr, Zug, Switzerland.	papasotiriou.ioannis@rgcc-international.com		Parsonidis, Panagiotis/0000-0002-4922-3104				Albilescu M, 2015, PHYTOCHEMICALS ANTIT; [Anonymous], 2019, NEUE Z KARTELLRECHT, V7, P495; [Anonymous], 2020, CLIN DIABETOLOGY, V9, P1; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Cao ZH, 2019, BIOTECHNOL ADV, V37, P223, DOI 10.1016/j.biotechadv.2018.12.001; Chen MN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089288; Corbett GJ, 2012, ARAB ARCHAEOL EPIGR, V23, P174, DOI 10.1111/j.1600-0471.2012.00357.x; Jalili M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158545; Kehrer JP, 1994, NATURAL ANTIOXIDANTS, V2, P25; Khan N, 2008, CANCER LETT, V269, P269, DOI 10.1016/j.canlet.2008.04.014; Kuhnau J, 1976, FLAVONOIDS CLASS SEM; Lin TX, 2012, UROL ONCOL-SEMIN ORI, V30, P339, DOI 10.1016/j.urolonc.2010.04.011; Malik S, 2019, SOFTWARE ENGINEERING FOR EMBEDDED SYSTEMS: METHODS, PRACTICAL TECHNIQUES, AND APPLICATIONS, 2ND EDITION, P427, DOI 10.1016/B978-0-12-809448-8.00012-6; Marco ML, 2017, CURR OPIN BIOTECH, V44, P94, DOI 10.1016/j.copbio.2016.11.010; Nabavi SM, 2012, FOOD CHEM, V132, P931, DOI 10.1016/j.foodchem.2011.11.070; Patisaul HB, 2010, FRONT NEUROENDOCRIN, V31, P400, DOI 10.1016/j.yfrne.2010.03.003; Quideau S, 2011, ANGEW CHEM INT EDIT, V50, P586, DOI 10.1002/anie.201000044; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Song WO, 2007, J MED FOOD, V10, P571, DOI 10.1089/jmf.2006.0620; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yang CS, 1997, ENVIRON HEALTH PERSP, V105, P971, DOI 10.2307/3433312; Yang LL, 2000, CANCER LETT, V157, P65, DOI 10.1016/S0304-3835(00)00477-8; Yang Zhenhua, 2005, Proceedings of the American Association for Cancer Research Annual Meeting, V46, P146; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200	25	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2020	15	10							e0240969	10.1371/journal.pone.0240969	http://dx.doi.org/10.1371/journal.pone.0240969			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OM3RJ	33085705	gold, Green Published			2023-01-03	WOS:000585943400040
J	Nu, UT; Pervin, J; Rahman, AMQ; Rahman, M; Rahman, A				Nu, U. Tin; Pervin, Jesmin; Rahman, A. M. Q.; Rahman, Monjur; Rahman, Anisur			Determinants of care-seeking practice for neonatal illnesses in rural Bangladesh: A community-based cross-sectional study	PLOS ONE			English	Article							HEALTH; BEHAVIOR; DISTRICT	Background Proper utilization of skilled care services in neonatal illnesses is crucial to reduce neonatal morbidity and mortality. The study aimed to evaluate the level and factors associated with seeking care from skilled healthcare service providers for reported neonatal illnesses in rural Matlab, Bangladesh. Methods This community based cross-sectional study was based on data from a randomly selected sample comprised of 2223 women who delivered live-born babies in 2014. Data were collected from June to October 2015 through a structured questionnaire. We used a multivariable logistic regression model and presented the results by adjusted odds ratios (AOR) with 95% confidence intervals (CI). Results Of the neonates, 1361 (61.2%) suffered from at least one complication, and among these, 479 (35.2%) sought care from skilled healthcare service providers. In the multivariable logistic regression analysis, the participants' husbands' educational level, number of antenatal care visits, and place of childbirth were significantly associated with seeking skilled care for reported neonatal illnesses. The care-seeking from skilled healthcare service providers for neonatal illness was more than two times higher (AOR = 2.26, 95% CI = 1.51-3.39) in the group in which the participants' husband had attended school for more than 10 years as compared to the group in which they had attended school for less than six years. The AORs of seeking skilled care were 1.93 (95% CI = 1.42-2.62) and 2.26 (95% CI = 1.51-3.39) with the mothers receiving two to three and four or more antenatal care services, respectively, compared to the mothers with no or one antenatal care visit. Women who gave birth at a health facility were three times (AOR = 3.24, 95% CI = 2.50-4.19) more likely to seek skilled care for sick neonates compared to those who gave birth at home. Conclusion The utilization of skilled care for neonatal sicknesses was low in this rural setting in Bangladesh. The participants' husbands' higher school attendance, increased number of ANC visits, and facility delivery were positively associated with care-seeking from skilled healthcare providers for neonatal illness. The husbands with low school attendance should be targeted for intervention, and continue efforts to increase ANC coverage and facility delivery to improve neonatal health in this country's rural area.	[Nu, U. Tin; Pervin, Jesmin; Rahman, A. M. Q.; Rahman, Monjur; Rahman, Anisur] Int Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR)	Pervin, J (corresponding author), Int Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Dhaka, Bangladesh.	jpervin@icddrb.org		Rahman, Md Monjur/0000-0002-7877-858X	USAID through Partnerships for Enhanced Engagement in Research (PEER) Health [01122]	USAID through Partnerships for Enhanced Engagement in Research (PEER) Health	This work was supported by the USAID through Partnerships for Enhanced Engagement in Research (PEER) Health, Grant Number: 01122 (https://www.usaid.gov/bd; http://sites.nationalacademies.org/pga/peer/index.htm). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2001, J TROP PEDIATRICS, V47, P98, DOI 10.1093/tropej/47.2.98; Ahsan KZ, 2019, BANGLADESH DEMOGRAPH; Anmut W, 2017, J BIOMEDICAL SCI, V06; [Anonymous], 2017, INT J INFORM TECHNOL, V9, P85; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Bekele F, 2020, J NEONATAL NURSING; Bulto GA, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4583-7; Chowdhury HR, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-88; Chowdhury SK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204902; Darmstadt GL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009696; Diabetes Poland, 2011, DIABETOLOGIA DOSW SA, V11, P1; Dongre AR, 2008, INDIAN J PEDIATR, V75, P325, DOI 10.1007/s12098-008-0032-7; Dongre AR, 2009, INDIAN J PEDIATR, V76, P45, DOI 10.1007/s12098-009-0028-y; Herbert HK, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001183; Khanum P, 2002, USE OBSTET CARE SERV; Lama TP, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0123-z; Lassi Zohra S, 2019, F1000Res, V8, P200, DOI 10.12688/f1000research.17828.1; NIPORT ACPR ICF International, 2016, BANGL HLTH FAC SURV; NIPORT Mitra and Associates & ICF International, 2014, BANGL DEM HLTH SURV; Nunu WN, 2019, MIDWIFERY, V68, P15, DOI 10.1016/j.midw.2018.09.013; Ogunlesi TA, 2010, J TROP PEDIATRICS, V56, P379, DOI 10.1093/tropej/fmq009; Pervin J, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-111; Shah R, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-417; Syed U, 2008, J PERINATOL, V28, pS9, DOI 10.1038/jp.2008.165; United Nations Inter-agency Group for Child Mortality Estimation, 2020, LEVELS TRENDS CHILD; World Health Organization, 2012, CAR NEWB HOM TRAIN C; World Health Organization (WHO), 2015, HLTH 2015 MDGS MILL, DOI 10.1007/BF01918387	28	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240316	10.1371/journal.pone.0240316	http://dx.doi.org/10.1371/journal.pone.0240316			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052973	Green Published, gold			2023-01-03	WOS:000581820200033
J	Shi, J; Sabbagh, MN; Vellas, B				Shi, Jiong; Sabbagh, Marwan N.; Vellas, Bruno			Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DEMENTIA; DEPOSITION; PROTEIN		[Shi, Jiong; Sabbagh, Marwan N.] Cleveland Clin Nevada, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA; [Vellas, Bruno] CHU Toulouse, Ctr Excellence Neurodegenerat, Toulouse, France	CHU de Toulouse	Shi, J (corresponding author), Cleveland Clin Nevada, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA.	SHIJ3@ccf.org			NIH COBRE [5P20GM109025, R01AG059008]; Keep Memory Alive Foundation	NIH COBRE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keep Memory Alive Foundation	This study is supported by NIH COBRE, 5P20GM109025, R01AG059008, and the Keep Memory Alive Foundation.	Aisen PS, 2020, JPAD-J PREV ALZHEIM, V7, P146, DOI 10.14283/jpad.2020.24; Aschenbrenner AJ, 2018, NEUROLOGY, V91, pE859, DOI 10.1212/WNL.0000000000006075; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Delrieu J, 2019, ALZHEIMERS DEMENT, V15, P1392, DOI 10.1016/j.jalz.2019.07.008; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gauthier S, 2020, J PREV ALZHEIMERS DI, P1; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Marsland AL, 2015, BRAIN BEHAV IMMUN, V48, P195, DOI 10.1016/j.bbi.2015.03.015; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Smith AD, 2018, J ALZHEIMERS DIS, V62, P561, DOI 10.3233/JAD-171042; Soto C, 2006, TRENDS BIOCHEM SCI, V31, P150, DOI 10.1016/j.tibs.2006.01.002; Vermunt L, 2019, ALZHEIMERS DEMENT, V15, P888, DOI 10.1016/j.jalz.2019.04.001; Wang XY, 2019, CELL RES, V29, P787, DOI 10.1038/s41422-019-0216-x	20	20	22	5	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2020	371								m3684	10.1136/bmj.m3684	http://dx.doi.org/10.1136/bmj.m3684			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC9CF	33036984	hybrid, Green Published			2023-01-03	WOS:000579451800004
J	Deng, Q; Han, GC; Puebla-Osorio, N; Ma, NCJ; Chasen, PSB; Dai, EY; Dang, MH; Jain, N; Yang, HP; Wang, YX; Zhang, SJ; Wang, RP; Chen, RZ; Showell, J; Ghosh, S; Patchva, S; Zhang, Q; Sun, R; Hagemeister, F; Fayad, L; Samaniego, F; Lee, HC; Nastoupil, LJ; Fowler, N; Davis, RE; Westin, J; Neelapu, SS; Wang, LH; Green, MR				Deng, Qing; Han, Guangchun; Puebla-Osorio, Nahum; Ma, N. Chun John; Chasen, Paolo Strati Beth; Dai, Enyu; Dang, Minghao; Jain, Neeraj; Yang, Haopeng; Wang, Yuanxin; Zhang, Shaojun; Wang, Ruiping; Chen, Runzhe; Showell, Jordan; Ghosh, Sreejoyee; Patchva, Sridevi; Zhang, Qi; Sun, Ryan; Hagemeister, Frederick; Fayad, Luis; Samaniego, Felipe; Lee, Hans C.; Nastoupil, Loretta J.; Fowler, Nathan; Davis, R. Eric; Westin, Jason; Neelapu, Sattva S.; Wang, Linghua; Green, Michael R.			Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	NATURE MEDICINE			English	Article							CYTOKINE RELEASE SYNDROME; CD8(+); THERAPY; IMMUNOTHERAPY; EXHAUSTION; SUBSETS; NEUROTOXICITY; ACTIVATION; BIOMARKERS; PATHWAYS	Single-cell transcriptomics reveals that the heterogeneity of anti-CD19 CAR T cell infusion products contributes to variability in clinical response, early molecular response and development of immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphomas. Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than half of patients, and treatment-associated adverse events, such as immune effector cell-associated neurotoxicity syndrome (ICANS), are a clinical challenge. We performed single-cell RNA sequencing with capture-based cell identification on autologous axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T cell infusion products to identify transcriptomic features associated with efficacy and toxicity in 24 patients with LBCL. Patients who achieved a complete response by positron emission tomography/computed tomography at their 3-month follow-up had three-fold higher frequencies of CD8 T cells expressing memory signatures than patients with partial response or progressive disease. Molecular response measured by cell-free DNA sequencing at day 7 after infusion was significantly associated with clinical response (P= 0.008), and a signature of CD8 T cell exhaustion was associated (q= 2.8 x 10(-149)) with a poor molecular response. Furthermore, a rare cell population with monocyte-like transcriptional features was associated (P= 0.0002) with high-grade ICANS. Our results suggest that heterogeneity in the cellular and molecular features of CAR T cell infusion products contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 molecular response might serve as an early predictor of CAR T cell efficacy.	[Deng, Qing; Puebla-Osorio, Nahum; Ma, N. Chun John; Jain, Neeraj; Yang, Haopeng; Showell, Jordan; Ghosh, Sreejoyee; Patchva, Sridevi; Zhang, Qi; Hagemeister, Frederick; Fayad, Luis; Samaniego, Felipe; Lee, Hans C.; Nastoupil, Loretta J.; Fowler, Nathan; Davis, R. Eric; Westin, Jason; Neelapu, Sattva S.; Green, Michael R.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Han, Guangchun; Dai, Enyu; Dang, Minghao; Wang, Yuanxin; Zhang, Shaojun; Wang, Ruiping; Chen, Runzhe; Wang, Linghua; Green, Michael R.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Chasen, Paolo Strati Beth] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA; [Sun, Ryan] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Neelapu, SS; Green, MR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.; Wang, LH; Green, MR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	sneelapu@mdanderson.org; lwang22@mdanderson.org; mgreen5@mdanderson.org	Ghosh, Sreejoyee/AAQ-8421-2020; Han, Guangchun/AAU-8230-2021; ZHANG, QI/AAD-2659-2021	ZHANG, QI/0000-0003-3813-8032; Deng, Qing/0000-0001-5116-461X; Puebla, Nahum/0000-0001-6498-5230; Ma, John/0000-0002-2000-8144; Westin, Jason/0000-0002-1824-2337; Yang, Haopeng/0000-0002-3870-2679; , guangchun/0000-0001-9277-2507; JAIN, NEERAJ/0000-0002-3736-8621; Wang, Linghua/0000-0001-9380-0266	Schweitzer Family Fund; University of Texas MD Anderson Cancer Center B-Cell Lymphoma Moonshot; National Cancer Institute Cancer Center [P30 CA016672]; University of Texas MD Anderson Cancer Center; Leukemia and Lymphoma Society	Schweitzer Family Fund; University of Texas MD Anderson Cancer Center B-Cell Lymphoma Moonshot; National Cancer Institute Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Texas MD Anderson Cancer Center; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society)	This work was supported by the Schweitzer Family Fund (J.R.W., R.E.D. and M.R.G.), The University of Texas MD Anderson Cancer Center B-Cell Lymphoma Moonshot (S.S.N. and M.R.G.), a National Cancer Institute Cancer Center Support Grant to The University of Texas MD Anderson Cancer Center (P30 CA016672) and Institutional Research Grant start-up research funds provided to L.W. and M.R.G. by The University of Texas MD Anderson Cancer Center. H.Y. is supported by a Fellow Award from the Leukemia and Lymphoma Society. M.R.G. is supported by a Scholar Award from the Leukemia and Lymphoma Society.	Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Burugu S, 2018, SEMIN CANCER BIOL, V52, P39, DOI 10.1016/j.semcancer.2017.10.001; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Das RK, 2019, CANCER DISCOV, V9, P492, DOI 10.1158/2159-8290.CD-18-1314; Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021; Finney OC, 2019, J CLIN INVEST, V129, P2123, DOI 10.1172/JCI125423; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gargett T, 2019, CYTOTHERAPY, V21, P593, DOI 10.1016/j.jcyt.2019.03.003; Gargett T, 2016, MOL THER, V24, P1135, DOI 10.1038/mt.2016.63; Goldrath AW, 2004, P NATL ACAD SCI USA, V101, P16885, DOI 10.1073/pnas.0407417101; Green MR, 2020, CANCER DISCOV, V10, P492, DOI 10.1158/2159-8290.CD-20-0037; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Josefsson SE, 2019, CANCER IMMUNOL RES, V7, P355, DOI 10.1158/2326-6066.CIR-18-0351; KAZAZI F, 1989, J GEN VIROL, V70, P2661, DOI 10.1099/0022-1317-70-10-2661; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kochenderfer JN, 2009, J IMMUNOTHER, V32, P689, DOI 10.1097/CJI.0b013e3181ac6138; Kurtz DM, 2018, J CLIN ONCOL, V36, P2845, DOI 10.1200/JCO.2018.78.5246; Kurtz DM, 2015, BLOOD, V125, P3679, DOI 10.1182/blood-2015-03-635169; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Mueller KT, 2018, CLIN CANCER RES, V24, P6175, DOI 10.1158/1078-0432.CCR-18-0758; Nazarov VI, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0613-1; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Quigley M, 2010, NAT MED, V16, P1147, DOI 10.1038/nm.2232; Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256; Roschewski M, 2015, LANCET ONCOL, V16, P541, DOI 10.1016/S1470-2045(15)70106-3; Rossi J, 2018, BLOOD, V132, P804, DOI 10.1182/blood-2018-01-828343; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Scherer F, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8545; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sommermeyer D, 2016, LEUKEMIA, V30, P492, DOI 10.1038/leu.2015.247; Strati P, 2020, BLOOD ADV, V4, P3123, DOI 10.1182/bloodadvances.2020002328; Taraseviciute A, 2018, CANCER DISCOV, V8, P750, DOI 10.1158/2159-8290.CD-17-1368; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; Wang JM, 2020, CANCER IMMUNOL RES, V8, P794, DOI 10.1158/2326-6066.CIR-19-0619	56	123	125	2	23	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2020	26	12								10.1038/s41591-020-1061-7	http://dx.doi.org/10.1038/s41591-020-1061-7		OCT 2020	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PB8QO	33020644	Green Accepted			2023-01-03	WOS:000575801100002
J	Crane, AT; Chrostek, MR; Krishna, VD; Shiao, M; Toman, NG; Pearce, CM; Tran, SK; Sipe, CJ; Guo, W; Voth, JP; Vaid, S; Xie, H; Lu, WC; Swanson, W; Grande, AW; Schleiss, MR; Bierle, CJ; Cheeran, MCJ; Low, WC				Crane, Andrew T.; Chrostek, Matthew R.; Krishna, Venkatramana D.; Shiao, Maple; Toman, Nikolas G.; Pearce, Clairice M.; Tran, Sarah K.; Sipe, Christopher J.; Guo, Winston; Voth, Joseph P.; Vaid, Shivanshi; Xie, Hui; Lu, Wei-Cheng; Swanson, Will; Grande, Andrew W.; Schleiss, Mark R.; Bierle, Craig J.; Cheeran, Maxim C-J.; Low, Walter C.			Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells	PLOS ONE			English	Article							MOUSE MODEL	Zika virus (ZIKV) exhibits a tropism for brain tumor cells and has been used as an oncolytic virus to target brain tumors in mice with modest effects on extending median survival. Recent studies have highlighted the potential for combining virotherapy and immunotherapy to target cancer. We postulated that ZIKV could be used as an adjuvant to enhance the long-term survival of mice with malignant glioblastoma and generate memory T-cells capable of providing long-term immunity against cancer remission. To test this hypothesis mice bearing malignant intracranial GL261 tumors were subcutaneously vaccinated with irradiated GL261 cells previously infected with the ZIKV. Mice also received intracranial injections of live ZIKV, irradiation attenuated ZIKV, or irradiated GL261 cells previously infected with ZIKV. Long-term survivors were rechallenged with a second intracranial tumor to examine their immune response and look for the establishment of protective memory T-cells. Mice with subcutaneous vaccination plus intracranial irradiation attenuated ZIKV or intracranial irradiated GL261 cells previously infected with ZIKV exhibited the greatest extensions to overall survival. Flow cytometry analysis of immune cells within the brains of long-term surviving mice after tumor rechallenge revealed an increase in the number of T-cells, including CD4(+) and tissue-resident effector/effector memory CD4(+) T-cells, in comparison to long-term survivors that were mock-rechallenged, and in comparison to naive untreated mice challenged with intracranial gliomas. These results suggest that ZIKV can serve as an adjuvant to subcutaneous tumor vaccines that enhance long-term survival and generate protective tissue-resident memory CD4(+) T-cells.	[Crane, Andrew T.; Chrostek, Matthew R.; Shiao, Maple; Toman, Nikolas G.; Pearce, Clairice M.; Tran, Sarah K.; Sipe, Christopher J.; Guo, Winston; Voth, Joseph P.; Vaid, Shivanshi; Xie, Hui; Lu, Wei-Cheng; Swanson, Will; Grande, Andrew W.; Low, Walter C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; [Krishna, Venkatramana D.; Cheeran, Maxim C-J.] Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA; [Schleiss, Mark R.; Bierle, Craig J.] Univ Minnesota, Dept Pediat, Div Pediat Infect Dis & Immunol, Minneapolis, MN 55455 USA; [Crane, Andrew T.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Chrostek, Matthew R.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Sipe, Christopher J.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; [Guo, Winston] Weill Cornell Med, New York, NY USA; [Voth, Joseph P.] Univ Washington, Dept Neurosci, Seattle, WA 98195 USA; [Vaid, Shivanshi] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Xie, Hui] Shenyang Med Coll, Dept Histol & Embryol, Shenyang, Peoples R China; [Lu, Wei-Cheng] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang, Peoples R China	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Stanford University; University of Minnesota System; University of Minnesota Twin Cities; Cornell University; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; Shenyang Medical College; China Medical University	Crane, AT (corresponding author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.; Crane, AT (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	atcrane@umn.edu; lowwalt@umn.edu	Krishna, Venkatramana/AAB-1227-2021; Cheeran, Maxim C-J/C-2135-2009; Schleiss, Mark/ABI-8450-2020	Cheeran, Maxim C-J/0000-0002-5331-4746; Schleiss, Mark/0000-0002-2108-9433; Voth, Joseph/0000-0002-5328-9843; Bierle, Craig/0000-0002-7890-7409; Guo, Winston/0000-0003-0082-0511; Crane, Andrew/0000-0003-3452-2766	National Institute of Health funded Minnesota Research Evaluation and Commercialization Hub [U01HL127479]; Randy Shaver Cancer Research Fund; UMN AHC Faculty Research Development Grant [16.55]; Minnesota American Legion and Auxiliary	National Institute of Health funded Minnesota Research Evaluation and Commercialization Hub; Randy Shaver Cancer Research Fund; UMN AHC Faculty Research Development Grant; Minnesota American Legion and Auxiliary	This work was support in part by the National Institute of Health funded Minnesota Research Evaluation and Commercialization Hub (U01HL127479), the Randy Shaver Cancer Research Fund, and from funds provided by Suzanne M. Schwarz (all to WCL). MRS was supported by UMN AHC Faculty Research Development Grant #16.55, "Molecular and Translational Studies of Congenital Zika Virus" and by the Minnesota American Legion and Auxiliary. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amsen D, 2018, NAT IMMUNOL, V19, P538, DOI 10.1038/s41590-018-0114-2; Badovinac VP, 2005, NAT MED, V11, P748, DOI 10.1038/nm1257; Baer A, 2014, JOVE-J VIS EXP, DOI 10.3791/52065; Baronti C, 2014, GENOME ANNOUNCEMENTS, V2, DOI 10.1128/genomeA.00500-14; Becker CM, 2015, NEURO-ONCOLOGY, V17, P1210, DOI 10.1093/neuonc/nov081; Bi WL, 2014, NEURO-ONCOLOGY, V16, P1159, DOI 10.1093/neuonc/nou166; Bierle CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187720; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Chen Q, 2018, MBIO, V9, DOI 10.1128/mBio.01683-18; Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8; Foreman PM, 2017, NEUROTHERAPEUTICS, V14, P333, DOI 10.1007/s13311-017-0516-0; Geletneky K, 2017, MOL THER, V25, P2620, DOI 10.1016/j.ymthe.2017.08.016; Gong YB, 2014, 2014 15TH INTERNATIONAL CONFERENCE ON ELECTRONIC PACKAGING TECHNOLOGY (ICEPT), P28, DOI 10.1109/ICEPT.2014.6922567; Gorman MJ, 2018, CELL HOST MICROBE, V23, P672, DOI 10.1016/j.chom.2018.04.003; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Jiang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097407; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Lai Y.-P., 2011, ISRN IMMUNOL, V2011, P1, DOI [10.5402/2011/497397, DOI 10.5402/2011/497397]; MacLeod MKL, 2009, SEMIN IMMUNOL, V21, P53, DOI 10.1016/j.smim.2009.02.006; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Pino PA, 2011, JOVE-J VIS EXP, DOI 10.3791/2348; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Shan C, 2016, CELL HOST MICROBE, V19, P891, DOI 10.1016/j.chom.2016.05.004; Suzuki M, 2017, MOL THER, V25, P836, DOI 10.1016/j.ymthe.2017.03.005; Zhu Z, 2020, CELL STEM CELL, V26, P187, DOI 10.1016/j.stem.2019.11.016; Zhu Z, 2017, J EXP MED, V214, P2843, DOI 10.1084/jem.20171093	26	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2020	15	10							0232858	10.1371/journal.pone.0232858	http://dx.doi.org/10.1371/journal.pone.0232858			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OS6KJ	33002018	Green Submitted, gold, Green Published			2023-01-03	WOS:000590270000004
J	Robinson, JC				Robinson, James C.			Sophisticated Purchasing of Pharmaceuticals Learning From Other Countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GERMANY; PATIENT; PRICES		[Robinson, James C.] Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Room 5423,Berkeley Way W, Berkeley, CA 94720 USA.	james.robinson@berkeley.edu		Robinson, James/0000-0003-0056-3017				Berkemeier F, 2019, J MANAG CARE SPEC PH, V25, P1310, DOI 10.18553/jmcp.2019.25.12.1310; Chambers JD, 2019, HEALTH AFFAIR, V38, P1882, DOI 10.1377/hlthaff.2019.00201; Emanuel EJ, 2020, JAMA INTERN MED, V180, P1510, DOI 10.1001/jamainternmed.2020.4793; Park Y, 2017, J MANAG CARE SPEC PH, V23, P893, DOI 10.18553/jmcp.2017.23.8.893; Robinson JC, 2020, NEW ENGL J MED, V382, P2177, DOI 10.1056/NEJMp2000341; Robinson JC, 2018, JAMA-J AM MED ASSOC, V319, P2169, DOI 10.1001/jama.2018.5367; Robinson JC, 2019, HLTH AFFAIRS BLOG, DOI 10.1377/hblog20190318.475434/full/; Stauffer R, 2020, NATION LAW REV; The IQVIA Institute, 2019, GLOB US MED 2019 OUT	9	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2020	324	16					1617	1619		10.1001/jama.2020.15072	http://dx.doi.org/10.1001/jama.2020.15072		SEP 2020	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ8NK	32986119				2023-01-03	WOS:000576492400002
J	Nehme, M; Braillard, O; Alcoba, G; Perone, SA; Courvoisier, D; Chappuis, F; Guessous, I				Nehme, Mayssam; Braillard, Olivia; Alcoba, Gabriel; Perone, Sigiriya Aebischer; Courvoisier, Delphine; Chappuis, Francois; Guessous, Idris		COVICARE TEAM	COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings	ANNALS OF INTERNAL MEDICINE			English	Letter									[Nehme, Mayssam; Braillard, Olivia; Alcoba, Gabriel; Perone, Sigiriya Aebischer; Courvoisier, Delphine; Chappuis, Francois; Guessous, Idris] Geneva Univ Hosp, Geneva, Switzerland; [Alcoba, Gabriel] Med Sans Frontieres, Geneva, Switzerland; [Perone, Sigiriya Aebischer] Int Comm Red Cross, Geneva, Switzerland; [Chappuis, Francois; Guessous, Idris] Univ Geneva, Geneva, Switzerland	University of Geneva; Doctors Without Borders; University of Geneva	Nehme, M (corresponding author), Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.	Mayssam.nehme@hcuge.ch	Alcoba, Gabriel/AAY-5264-2021; Courvoisier, Delphine/H-6054-2011	Alcoba, Gabriel/0000-0002-9423-1533; Courvoisier, Delphine/0000-0002-1956-2607; Chappuis, Francois/0000-0003-0442-7610				Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Crosby Sondra S, 2021, Ann Intern Med, V174, P120, DOI 10.7326/M20-5126; Mahase E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2815; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P993, DOI 10.15585/mmwr.mm6930e1externalicon; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	5	71	72	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY	2021	174	5					723	+		10.7326/M20-5926	http://dx.doi.org/10.7326/M20-5926			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	SF2QB	33284676	Green Published			2023-01-03	WOS:000652604800041
J	Barnabas, RV; Brown, ER; Bershteyn, A; Karita, HCS; Johnston, C; Thorpe, LE; Kottkamp, A; Neuzil, KM; Laufer, MK; Deming, M; Paasche-Orlow, MK; Kissinger, PJ; Luk, A; Paolino, K; Landovitz, RJ; Hoffman, R; Schaafsma, TT; Krows, ML; Thomas, KK; Morrison, S; Haugen, HS; Kidoguchi, L; Wener, M; Greninger, AL; Huang, ML; Jerome, KR; Wald, A; Celum, C; Chu, HY; Baeten, JM				Barnabas, Ruanne, V; Brown, Elizabeth R.; Bershteyn, Anna; Karita, Helen C. Stankiewicz; Johnston, Christine; Thorpe, Lorna E.; Kottkamp, Angelica; Neuzil, Kathleen M.; Laufer, Miriam K.; Deming, Meagan; Paasche-Orlow, Michael K.; Kissinger, Patricia J.; Luk, Alfred; Paolino, Kristopher; Landovitz, Raphael J.; Hoffman, Risa; Schaafsma, Torin T.; Krows, Meighan L.; Thomas, Katherine K.; Morrison, Susan; Haugen, Harald S.; Kidoguchi, Lara; Wener, Mark; Greninger, Alexander L.; Huang, Meei-Li; Jerome, Keith R.; Wald, Anna; Celum, Connie; Chu, Helen Y.; Baeten, Jared M.		Hydroxychloroquine COVID-19 PEP St	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity against SARS-CoV-2, potentially permitting its use for prevention. Objective: To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection. Design: Household-randomized, double-blind, controlled trial of hydroxychloroquine postexposure prophylaxis. (ClinicalTrials.gov: NCT04328961) Setting: National U.S. multicenter study. Participants: Close contacts recently exposed (<96 hours) to persons with diagnosed SARS-CoV-2 infection. Intervention: Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days) or ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo-equivalent control. Measurements: Participants self-collected mid-turbinate swabs daily (days 1 to 14) for SARS-CoV-2 polymerase chain reaction (PCR) testing. The primary outcome was PCR-confirmed incident SARS-CoV-2 infection among persons who were SARS-CoV-2 negative at enrollment. Results: Between March and August 2020, 671 households were randomly assigned: 337 (407 participants) to the hydroxychloroquine group and 334 (422 participants) to the control group. Retention at day 14 was 91%, and 10 724 of 11 606 (92%) expected swabs were tested. Among the 689 (89%) participants who were SARS-CoV-2 negative at baseline, there was no difference between the hydroxychloroquine and control groups in SARS-CoV-2 acquisition by day 14 (53 versus 45 events; adjusted hazard ratio, 1.10 [95% CI, 0.73 to 1.66]; P>0.20). The frequency of participants experiencing adverse events was higher in the hydroxychloroquine group than the control group (66 [16.2%] versus 46 [10.9%], respectively; P=0.026). Limitation: The delay between exposure, and then baseline testing and the first dose of hydroxychloroquine or ascorbic acid, was a median of 2 days. Conclusion: This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.	[Barnabas, Ruanne, V; Karita, Helen C. Stankiewicz; Schaafsma, Torin T.; Krows, Meighan L.; Thomas, Katherine K.; Morrison, Susan; Haugen, Harald S.; Kidoguchi, Lara; Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Int Clin Res Ctr ICRC, UW Box 359927,325 Ninth Ave, Seattle, WA 98104 USA; [Brown, Elizabeth R.; Jerome, Keith R.] Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North, Seattle, WA 98109 USA; [Bershteyn, Anna] Translat Res Bldg,227 East 30th St, New York, NY 10016 USA; [Johnston, Christine] Univ Washington, Int Clin Res Ctr ICRC, Dept Global Hlth, UW Box 359928,325 Ninth Ave, Seattle, WA 98104 USA; [Thorpe, Lorna E.] NYU Grossman Sch Med, 180 Madison Ave, New York, NY 10016 USA; [Kottkamp, Angelica] Bellevue Hosp, 462 First Ave,H Bldg,16S 5-13, New York, NY 10016 USA; [Neuzil, Kathleen M.; Laufer, Miriam K.; Deming, Meagan] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, 685 West Baltimore St,Room 480, Baltimore, MD 21201 USA; [Paasche-Orlow, Michael K.] Boston Med Ctr, 801 Massachusetts Ave,Second Floor, Boston, MA 02119 USA; [Kissinger, Patricia J.] Tulane Univ, Sch Publ Hlth & Trop Med, 1440 Canal St,Suite 2004, New Orleans, LA 70112 USA; [Luk, Alfred] Tulane Univ, Sect Infect Dis, Hlth Sci Ctr, 1415 Tulane Ave, New Orleans, LA 70112 USA; [Paolino, Kristopher] Upstate Med Univ, Infect Dis Div, 725 Irving Ave,Suite 311, Syracuse, NY 13210 USA; [Landovitz, Raphael J.] UCLA, Ctr Clin Aids Res & Educ, 911 Broxton Ave,Suite 200, Los Angeles, CA 90024 USA; [Hoffman, Risa] UCLA, Div Infect Dis, Dept Med, 10833 Le Conte Ave,52-215 CHS, Los Angeles, CA 90095 USA; [Wener, Mark] Univ Washington, Dept Lab Med & Pathol, Med Ctr, Box 357110, Seattle, WA 98195 USA; [Greninger, Alexander L.; Huang, Meei-Li] Univ Washington, Virol Lab, 1616 Eastlake Ave East,Suite 320, Seattle, WA 98102 USA; [Wald, Anna] Univ Washington, 325 Ninth Ave,HMC 359928, Seattle, WA 98104 USA; [Chu, Helen Y.] Univ Washington, 750 Republican St UWMC 358061, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Bellevue Hospital Center; University System of Maryland; University of Maryland Baltimore; Boston Medical Center; Tulane University; Tulane University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Barnabas, RV (corresponding author), Univ Washington, Dept Global Hlth, Int Clin Res Ctr ICRC, UW Box 359927,325 Ninth Ave, Seattle, WA 98104 USA.	rbarnaba@uw.edu	Agrawal, Vaidehi/B-8282-2019; Luk, Alfred/AAW-1434-2021; Wener, Mark/ABE-4491-2021; Deming, Meagan/AEX-6400-2022; Hladik, Florian/G-1041-2012	Agrawal, Vaidehi/0000-0002-1958-630X; Luk, Alfred/0000-0002-2598-1031; Deming, Meagan/0000-0003-2574-0542; Kottkamp, Angelica/0000-0003-4103-1666; Thomas, Katherine K/0000-0002-7024-468X; Spoer, Ben/0000-0002-0311-7963; Brown, Elizabeth/0000-0003-4286-2111; Hladik, Florian/0000-0002-0375-2764; Stankiewicz Karita, Helen C./0000-0002-9458-286X; Foppiano Palacios, Carlo/0000-0002-2698-981X; Johnston, Christine/0000-0002-3073-0843; Greninger, Alexander/0000-0002-7443-0527; Bershteyn, Anna/0000-0002-6604-7093	Bill AMP; Melinda Gates Foundation [INV-016204]; University of Washington King K. Holmes Endowed Professorship in STDs and AIDS	Bill AMP; Melinda Gates Foundation(CGIAR); University of Washington King K. Holmes Endowed Professorship in STDs and AIDS	The HCQ COVID-19 PEP Study was funded by the Bill & Melinda Gates Foundation (INV-016204) through the COVID-19 Therapeutics Accelerator and the University of Washington King K. Holmes Endowed Professorship in STDs and AIDS. Hydroxychloroquine for the study was donated by Sandoz.	Abella BS, 2021, JAMA INTERN MED, V181, P195, DOI 10.1001/jamainternmed.2020.6319; [Anonymous], 2020, NEW ENGL J MED, DOI DOI 10.1056/NEJMoa2016638; Bar-Zeev N, 2020, LANCET, V396, P448, DOI 10.1016/S0140-6736(20)31611-1; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; CDC, 2020, COR DIS 2019 COVID 1; CDC, 2020, US PERS PROT EQ PPE; Centers for Disease Control and Prevention, 2020, ADV HELP PROT YOUR H; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Drake TM, 2020, LANCET DIGIT HEALTH, V2, pE385, DOI 10.1016/S2589-7500(20)30134-5; Gentile I, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113997; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3; Ikematsu H, 2020, NEW ENGL J MED, V383, P309, DOI 10.1056/NEJMoa1915341; Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988; Lieberman JA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00821-20; Madewell Zachary J, 2020, medRxiv, DOI 10.1101/2020.07.29.20164590; Madewell ZJ, 2020, MEDRXIV, DOI [10.1101/2020.07.29.20164590, DOI 10.1002/jmv.26286]; Mitja O, 2020, CLUSTER RANDOMIZED T, DOI [10.1101/2020.07.20.20157651, DOI 10.1101/2020.07.20.20157651]; Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Perera RAPM, 2020, EMERG INFECT DIS, V26, P2701, DOI 10.3201/eid2611.203219; Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), 2020, COVID 19 DEV DRUGS B; Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; WHO, 2020, MODES TRANSMISSION V; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237	36	43	45	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					344	+		10.7326/M20-6519	http://dx.doi.org/10.7326/M20-6519			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX4DA	33284679	Green Published			2023-01-03	WOS:000629294000017
J	Sato, N; Takaku, R; Higashi, H; Lefor, AK; Shiga, T				Sato, Nobuhiro; Takaku, Reo; Higashi, Hidenori; Lefor, Alan Kawarai; Shiga, Takashi			Factors associated with difficulty of hospital acceptance of patients suspected to have cerebrovascular diseases: A nationwide population-based observational study	PLOS ONE			English	Article							EMERGENCY PATIENTS; TIME; STROKE; SURVIVAL; SYSTEMS; ACCESS; JAPAN	Although it is essential to shorten the interval to initial treatment in the care of acute ischemic stroke, some hospitals in Japan reject requests for hospital acceptance from on-scene emergency medical service personnel because of limited resources, which can cause delays in care. We aimed to assess the risk factors for difficulty of hospital acceptance of patients suspected to have cerebrovascular diseases. We conducted a retrospective analysis of the national ambulance records of the Fire and Disaster Management Agency in Japan in 2016. Multivariable logistic regression analysis was used to assess the association between difficulty of hospital acceptance of patients suspected to have cerebrovascular diseases and prehospital factors. During the study period, a total of 222,926 patients were included, and 5283 patients (2.4%) experienced difficulties in hospital acceptance. In multivariable analysis, nights (adjusted odds ratio [AOR] 1.54, 95% confidence interval [CI] 1.45-1.64), weekends (AOR 1.32, 95% CI 1.24-1.40), <25 percentile ratio of emergency physicians and neurosurgeons to all physicians (AOR 1.13, 95% CI 1.03-1.23) (AOR 1.36, 95% CI 1.25-1.48), and mean age of physicians (AOR 1.06, 95% CI 1.05-1.07) were significantly associated with difficulties of hospital acceptance of patients suspected to have cerebrovascular disease. There was a marked regional variation in the difficulties of hospital acceptance. Among the national ambulance records of patients suspected to have cerebrovascular diseases, certain prehospital factors such as weekends were positively associated with difficulty of hospital acceptance. A comprehensive strategy for hospital acceptance of patients with cerebrovascular diseases considering regional variation is required.	[Sato, Nobuhiro] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Takaku, Reo] Hitotsubashi Univ, Grad Sch Econ, Kunitachi, Tokyo, Japan; [Higashi, Hidenori] Japanese Red Cross Wakayama Med Ctr, Dept Emergency & Crit Care Med, Wakayama, Japan; [Lefor, Alan Kawarai] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan; [Shiga, Takashi] Int Univ Hlth & Welf, Dept Emergency Med, Nasushiobara, Tochigi, Japan	Monash University; Hitotsubashi University; Jichi Medical University; International University of Health & Welfare	Sato, N (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.	nobuhiro.sato@monash.edu	Sato, Nobuhiro/AAA-3457-2020; Lefor, Alan/E-9979-2012	Sato, Nobuhiro/0000-0003-1624-7596; Lefor, Alan/0000-0001-6673-5630; Takaku, Reo/0000-0001-6091-9199				[Anonymous], 2016 WHIT BOOK EM SY; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Govindarajan P, 2020, PREHOSP EMERG CARE, V24, P505, DOI 10.1080/10903127.2019.1679303; Goyal M, 2014, STROKE, V45, pE252, DOI 10.1161/STROKEAHA.114.007366; Higashi H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215231; Hori Shingo, 2010, Keio Journal of Medicine, V59, P131, DOI 10.2302/kjm.59.131; Katayama Y, 2017, ACUTE MED SURG, V4, P401, DOI 10.1002/ams2.291; Katayama Y, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013849; Katz MH, 2019, JAMA INTERN MED, V179, P693, DOI 10.1001/jamainternmed.2019.0026; Kitamura T, 2014, ACUTE MED SURG, V1, P135, DOI 10.1002/ams2.25; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Matsuyama T, 2017, GERIATR GERONTOL INT, V17, P2441, DOI 10.1111/ggi.13098; Ministry of Health Labour and Welfare, VIT STAT 2018; Okamoto Y, 2013, CIRC J, V77, P2596, DOI 10.1253/circj.CJ-12-1604; Okubo M, 2017, RESUSCITATION, V115, P120, DOI 10.1016/j.resuscitation.2017.03.036; Quain DA, 2008, MED J AUSTRALIA, V189, P429, DOI 10.5694/j.1326-5377.2008.tb02114.x; Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Statistics Bureau of Japan, POP CENS JAP 2016; Takaku R, 2019, INT J HEALTH ECON MA, V19, P53, DOI 10.1007/s10754-018-9243-2; Tanigawa K, 2006, RESUSCITATION, V69, P365, DOI 10.1016/j.resuscitation.2006.04.001	23	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2021	16	1							e0245318	10.1371/journal.pone.0245318	http://dx.doi.org/10.1371/journal.pone.0245318			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4SP	33434216	Green Published, gold			2023-01-03	WOS:000609979700035
J	Kabadi, UM				Kabadi, Udaya M.			Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes	ANNALS OF INTERNAL MEDICINE			English	Letter									[Kabadi, Udaya M.] Univ Iowa, Broadlawns Med Ctr, Des Moines, IA 50312 USA	University of Iowa	Kabadi, UM (corresponding author), Univ Iowa, Broadlawns Med Ctr, Des Moines, IA 50312 USA.							de Jong M, 2020, DIABETES CARE, V43, P2050, DOI 10.2337/dc19-2363; Kabadi Udaya M, 2002, Endocr Pract, V8, P61; Kabadi UM, 2017, WORLD J PHARM MED RE, V3, P33; Kabadi UM, 2016, J DIABETES METAB DIS, V3, P67, DOI [10.15406/jdmdc.2016.03.00071, DOI 10.15406/JDMDC.2016.03.00071]; Tsapas A, 2020, ANN INTERN MED, V173, P278, DOI 10.7326/M20-0864	5	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					140	140		10.7326/L20-1277	http://dx.doi.org/10.7326/L20-1277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33460546				2023-01-03	WOS:000619485200048
J	Hirabayashi, G; Saito, M; Terayama, S; Akihisa, Y; Maruyama, K; Andoh, T				Hirabayashi, Go; Saito, Minami; Terayama, Sachiko; Akihisa, Yuki; Maruyama, Koichi; Andoh, Tomio			Lung-protective properties of expiratory flow-initiated pressure-controlled inverse ratio ventilation: A randomised controlled trial	PLOS ONE			English	Article							LAPAROSCOPIC RADICAL PROSTATECTOMY; PULMONARY GAS-EXCHANGE; CO2 ELIMINATION; OXYGENATION; PAUSE	Background Expiratory flow-initiated pressure-controlled inverse ratio ventilation (EF-initiated PC-IRV) reduces physiological dead space. We hypothesised that EF-initiated PC-IRV would be lung protective compared with volume-controlled ventilation (VCV). Methods Twenty-eight men undergoing robot-assisted laparoscopic radical prostatectomy were enrolled in this randomised controlled trial. The EF-initiated PC-IRV group (n = 14) used pressure-controlled ventilation with the volume guaranteed mode. The inspiratory to expiratory (I:E) ratio was individually adjusted by observing the expiratory flow-time wave. The VCV group (n = 14) used the volume control mode with a 1:2 I:E ratio. The Mann-Whitney U test was used to compare differences in the serum cytokine levels. Results There were no significant differences in serum IL-6 between the EF-initiated PC-IRV (median 34 pg ml(-1) (IQR 20.5 to 63.5)) and VCV (31 pg ml(-1) (24.5 to 59)) groups (P = 0.84). The physiological dead space rate (physiological dead space/expired tidal volume) was significantly reduced in the EF-initiated PC-IRV group as compared with that in the VCV group (0.31 +/- 0.06 vs 0.4 +/- 0.07; P<0.001). The physiological dead space rate was negatively correlated with the forced vital capacity (% predicted) in the VCV group (r = -0.85, P<0.001), but not in the EF-initiated PC-IRV group (r = 0.15, P = 0.62). Two patients in the VCV group had permissive hypercapnia with low forced vital capacity (% predicted). Conclusions There were no differences in the lung-protective properties between the two ventilatory strategies. However, EF-initiated PC-IRV reduced physiological dead space rate; thus, it may be useful for reducing the ventilatory volume that is necessary to maintain normocapnia in patients with low forced vital capacity (% predicted) during robot-assisted laparoscopic radical prostatectomy.	[Hirabayashi, Go; Saito, Minami; Terayama, Sachiko; Akihisa, Yuki; Maruyama, Koichi; Andoh, Tomio] Teikyo Univ, Mizonokuchi Hosp, Sch Med, Dept Anaesthesiol, Sagamiko, Kanagawa, Japan	Teikyo University	Hirabayashi, G (corresponding author), Teikyo Univ, Mizonokuchi Hosp, Sch Med, Dept Anaesthesiol, Sagamiko, Kanagawa, Japan.	goh@med.teikyo-u.ac.jp			Department of Anaesthesiology, Mizonokuchi Hospital Teikyo University School of Medicine, Kanagawa, Japan	Department of Anaesthesiology, Mizonokuchi Hospital Teikyo University School of Medicine, Kanagawa, Japan	This study was financially supported by internal funding from the Department of Anaesthesiology, Mizonokuchi Hospital Teikyo University School of Medicine, Kanagawa, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHAM E, 1990, CHEST, V98, P1445, DOI 10.1378/chest.98.6.1445; Balick-Weber CC, 2007, BRIT J ANAESTH, V99, P429, DOI 10.1093/bja/aem166; Cadi P, 2008, BRIT J ANAESTH, V100, P709, DOI 10.1093/bja/aen067; CHAN K, 1992, CHEST, V102, P1556, DOI 10.1378/chest.102.5.1556; Choi EM, 2011, J CLIN ANESTH, V23, P183, DOI 10.1016/j.jclinane.2010.08.006; Devaquet J, 2008, J APPL PHYSIOL, V105, P1944, DOI 10.1152/japplphysiol.90682.2008; Gainsburg DM, 2012, MINERVA ANESTESIOL, V78, P596; Hirabayashi G, 2018, EUR J ANAESTH, V35, P307, DOI 10.1097/EJA.0000000000000732; Kalmar AF, 2010, BRIT J ANAESTH, V104, P433, DOI 10.1093/bja/aeq018; Kim MS, 2018, INT J MED SCI, V15, P1522, DOI 10.7150/ijms.28442; Lestar M, 2011, ANESTH ANALG, V113, P1069, DOI 10.1213/ANE.0b013e3182075d1f; Markstrom Agneta M., 1996, Upsala Journal of Medical Sciences, V101, P257; MERCAT A, 1993, CHEST, V104, P871, DOI 10.1378/chest.104.3.871; Michelet P, 2006, ANESTHESIOLOGY, V105, P911, DOI 10.1097/00000542-200611000-00011; Ogurlu M, 2010, J MINIM INVAS GYN, V17, P295, DOI 10.1016/j.jmig.2009.10.007; Prella M, 2002, CHEST, V122, P1382, DOI 10.1378/chest.122.4.1382; Sturesson LW, 2016, BRIT J ANAESTH, V117, P243, DOI 10.1093/bja/aew194; THARRATT RS, 1988, CHEST, V94, P755, DOI 10.1378/chest.94.4.755; TWEED WA, 1992, CAN J ANAESTH, V39, P1036, DOI 10.1007/BF03008371; TWEED WA, 1991, CAN J ANAESTH, V38, P311, DOI 10.1007/BF03007620; Uttman L, 2003, CLIN PHYSIOL FUNCT I, V23, P252, DOI 10.1046/j.1475-097X.2003.00498.x; Wang SH, 2002, AM J SURG, V183, P151, DOI 10.1016/S0002-9610(01)00870-4; Zavala E, 1998, ANESTHESIOLOGY, V88, P35, DOI 10.1097/00000542-199801000-00008	23	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2020	15	12							e0243971	10.1371/journal.pone.0243971	http://dx.doi.org/10.1371/journal.pone.0243971			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8BZ	33332454	gold, Green Published			2023-01-03	WOS:000601310900104
J	Kinshella, MLW; Salimu, S; Chiwaya, B; Chikoti, F; Chirambo, L; Mwaungulu, E; Banda, M; Newberry, L; Njirammadzi, J; Hiwa, T; Vidler, M; Molyneux, EM; Dube, Q; Mfutso-Bengo, J; Goldfarb, DM; Kawaza, K; Nyondo-Mipando, AL				Kinshella, Mai-Lei Woo; Salimu, Sangwani; Chiwaya, Brandina; Chikoti, Felix; Chirambo, Lusungu; Mwaungulu, Ephrida; Banda, Mwai; Newberry, Laura; Njirammadzi, Jenala; Hiwa, Tamanda; Vidler, Marianne; Molyneux, Elizabeth M.; Dube, Queen; Mfutso-Bengo, Joseph; Goldfarb, David M.; Kawaza, Kondwani; Nyondo-Mipando, Alinane Linda			"So sometimes, it looks like it's a neglected ward": Health worker perspectives on implementing kangaroo mother care in southern Malawi	PLOS ONE			English	Article							DISTRICT	Introduction Kangaroo mother care (KMC) involves continuous skin-to-skin contact of baby on mother's chest to provide warmth, frequent breastfeeding, recognizing danger signs of illness, and early discharge. Though KMC is safe, effective and recommended by the World Health Organization, implementation remains limited in practice. The objective of this study is to understand barriers and facilitators to KMC practice at tertiary and secondary health facilities in southern Malawi from the perspective of health workers. Methods This study is part of the "Integrating a neonatal healthcare package for Malawi" project in the Innovating for Maternal and Child Health in Africa initiative. In-depth interviews were conducted between May-Aug 2019 with a purposively drawn sample of service providers and supervisors working in newborn health at a large tertiary hospital and three district-level hospitals in southern Malawi. Data were analyzed using a thematic approach using NVivo 12 software (QSR International, Melbourne, Australia). Findings A total of 27 nurses, clinical officers, paediatricians and district health management officials were interviewed. Staff attitudes, inadequate resources and reliance on families emerged as key themes. Health workers from Malawi described KMC practice positively as a low-cost, low-technology solution appropriate for resource-constrained health settings. However, staff perceptions that KMC babies were clinically stable was associated with lower prioritization in care and poor monitoring practices. Neglect of the KMC ward by medical staff, inadequate staffing and reliance on caregivers for supplies were associated with women self-discharging early. Conclusion Though routine uptake of KMC was policy for stable low birthweight and preterm infants in the four hospitals, there were gaps in monitoring and maintenance of practice. While conceptualized as a low-cost intervention, sustainable implementation requires investments in technologies, staffing and hospital provisioning of basic supplies such as food, bedding, and KMC wraps. Strengthening hospital capacities to support KMC is needed as part of a continuum of care for premature infants.	[Kinshella, Mai-Lei Woo; Vidler, Marianne] BC Childrens & Womens Hosp, Dept Obstet & Gynaecol, Vancouver, BC, Canada; [Kinshella, Mai-Lei Woo; Vidler, Marianne] Univ British Columbia, Vancouver, BC, Canada; [Salimu, Sangwani; Chiwaya, Brandina; Chikoti, Felix; Chirambo, Lusungu; Mwaungulu, Ephrida; Banda, Mwai; Newberry, Laura; Njirammadzi, Jenala; Hiwa, Tamanda; Molyneux, Elizabeth M.; Kawaza, Kondwani] Univ Malawi, Coll Med, Dept Pediat & Child Hlth, Blantyre, Malawi; [Dube, Queen; Kawaza, Kondwani] Queen Elizabeth Cent Hosp, Pediat, Blantyre, Malawi; [Mfutso-Bengo, Joseph; Nyondo-Mipando, Alinane Linda] Univ Malawi, Dept Hlth Syst & Policy, Sch Publ Hlth & Family Med, Coll Med, Blantyre, Malawi; [Mfutso-Bengo, Joseph] Ctr Bioeth Eastern & Southern Africa CEBESA, Blantyre, Malawi; [Goldfarb, David M.] BC Childrens & Womens Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of Malawi; University of Malawi; University of Malawi; University of British Columbia	Kinshella, MLW (corresponding author), BC Childrens & Womens Hosp, Dept Obstet & Gynaecol, Vancouver, BC, Canada.; Kinshella, MLW (corresponding author), Univ British Columbia, Vancouver, BC, Canada.	maggie.kinshella@cw.bc.ca	Kinshella, Mai-Lei Woo/AAA-8117-2022; Goldfarb, David/ABD-4623-2021; Nyondo, Alinane/AFN-8844-2022	Kinshella, Mai-Lei Woo/0000-0001-5846-3014; Nyondo, Alinane/0000-0002-3572-3810; Vidler, Marianne/0000-0002-7633-8812; Goldfarb, David/0000-0003-0835-9504	Canadian International Development Research Centre (IDRC); Global Affairs Canada (GAC); Canadian Institutes for Health Research (CIHR) [108030]	Canadian International Development Research Centre (IDRC); Global Affairs Canada (GAC)(CGIAR); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	MWK, ALNM, KK, QD and DG were funded by the Canadian International Development Research Centre (IDRC), Global Affairs Canada (GAC) and the Canadian Institutes for Health Research (CIHR). Project ID is 108030. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akseer N, 2015, INT J GYNECOL OBSTET, V131, pS43, DOI 10.1016/j.ijgo.2015.03.017; [Anonymous], 2018, CANC DISCOV, V8, pOF6; [Anonymous], 2016, WHO REC INT IMPR PRE; [Anonymous], 2017, CANC DISCOVERY, V7, pOF12; [Anonymous], 2010, EUR J VASC MED, V39, pS/78; Bergh AM, 2003, ACTA PAEDIATR, V92, P709, DOI 10.1080/08035250310002399; Bergh AM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-75; Bergh AM, 2008, HUM RESOUR HEALTH, V6, DOI 10.1186/1478-4491-6-13; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Boundy EO, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2238; Chan GJ, 2016, B WORLD HEALTH ORGAN, V94, P130, DOI 10.2471/BLT.15.157818; Charpak N, 2020, ACTA PAEDIATR, V109, P2278, DOI 10.1111/apa.15214; Conde-Agudelo A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002771.pub4; Department for Maternal NC& AHW, ONG RES PROJ OV IMM; Feucht U, 2016, SAMJ S AFR MED J, V106, P49, DOI [10.7196/SAMJ.2016.v106i1.10149, 10.7196/SAMJ.2016.V106I1.10149]; Gondwe A, 2016, MATERN CHILD HLTH J, V20, P1441, DOI 10.1007/s10995-016-1942-z; Hobart City Council, 2009, HOBART CITY COUNCIL, V5, P48; Hodgins S, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010306; Kambarami R. A., 1999, Central African Journal of Medicine, V45, P56; Kampekete G. S. M., 2018, African Journal of Midwifery and Women's Health, V12, P178, DOI 10.12968/ajmw.2018.12.4.178; Lancet Global Health, 2019, LANCET GLOB HEALTH, V7, pe1; Leonard A, 2008, HEALTH SA GESONDHEID, V13; Lincetto O, 2000, J TROP PEDIATRICS, V46, P293, DOI 10.1093/tropej/46.5.293; Medvedev MM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-4044-6; National Statistical Office Malawi ICF, 2017, MAL DEM HLTH SURV 20; Nyqvist KH, 2016, ACTA PAEDIATR, V105, P341, DOI 10.1111/apa.13236; Okoh BA., 2016, NIGER J PAEDIAT, V43, P252, DOI [DOI 10.4314/NJP.V43I4.4, 10.4314/njp.v43i4.4]; Phaphali Adzitey S, 2017, ANN MED HLTH SCI RES; Reddy J., 2007, EXPERIENCES MOTHERS, DOI DOI 10.4102/CURATIONIS.V30I3.1104; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Solomons N, 2012, S AFR J CLIN NUTR, V25, P33; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Vesel L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S5; Watkins HC, 2018, ACTA PAEDIATR, V107, P1541, DOI 10.1111/apa.14344; Weldearegay HG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225258	35	6	6	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2020	15	12							e0243770	10.1371/journal.pone.0243770	http://dx.doi.org/10.1371/journal.pone.0243770			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PI8BZ	33332395	Green Published, gold			2023-01-03	WOS:000601310900055
J	Bhatia, R; Klausner, J				Bhatia, Rajiv; Klausner, Jeffrey			Estimating individual risks of COVID-19-associated hospitalization and death using publicly available data	PLOS ONE			English	Article								We describe a method to estimate individual risks of hospitalization and death attributable to non-household and household transmission of SARS-CoV-2 using available public data on confirmed-case incidence data along with estimates of the clinical fraction, timing of transmission, isolation adherence, secondary infection risks, contact rates, and case-hospitalization and case-fatality ratios. Using the method, we estimate that risks for a 90-day period at the median daily summertime U.S. county confirmed COVID-19 case incidence of 10.8 per 100,000 and pre-pandemic contact rates range from 0.4 to 8.9 per 100,000 for the four deciles of age between 20 and 60 years. The corresponding 90-day period risk of hospitalization ranges from 13.7 to 69.2 per 100,000. Assuming a non-household secondary infection risk of 4% and pre-pandemic contact rates, the share of transmissions attributable to household settings ranges from 73% to 78%. These estimates are sensitive to the parameter assumptions; nevertheless, they are comparable to the COVID-19 hospitalization and fatality rates observed over the time period. We conclude that individual risk of hospitalization and death from SARS-CoV-2 infection is calculable from publicly available data sources. Access to publicly reported infection incidence data by setting and other exposure characteristics along with setting specific estimates of secondary infection risk would allow for more precise individual risk estimation.	[Bhatia, Rajiv] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Klausner, Jeffrey] Univ Calif Los Angeles, Dept Med & Publ Hlth, Los Angeles, CA USA	Stanford University; University of California System; University of California Los Angeles	Bhatia, R (corresponding author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.	drajiv@stanford.edu		Bhatia, Rajiv/0000-0002-3371-4101				Adam DC, 2020, NAT MED, V26, P1714, DOI 10.1038/s41591-020-1092-0; Anand S, 2020, LANCET, V396, P1335, DOI 10.1016/S0140-6736(20)32009-2; Bodas M, 2020, HEALTH AFFAIR, V39, P936, DOI 10.1377/hlthaff.2020.00382; Buitrago-Garcia D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003346; Casey M, 2020, ESTIMATING PRESYMPTO, DOI 10.1101/2020.05.08.20094870; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; de Bruin WB, 2020, AM J PREV MED, V59, P157, DOI 10.1016/j.amepre.2020.05.001; Endo Akira, 2020, Wellcome Open Res, V5, P67, DOI [10.12688/wellcomeopenres.15842.1, 10.12688/wellcomeopenres.15842.3]; Ferretti L., 2020, TIMING COVID 19 TRAN, DOI [10.2139/ssrn.3716879, DOI 10.1101/2020.09.04.20188516V2, 10.1101/2020.09.04.20188516, DOI 10.1101/2020.09.04.20188516]; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Havers FP, 2020, JAMA INTERN MED, DOI [10.1001/jamainternmed.2020.4130, DOI 10.1001/JAMAINTERNMED.2020.413032692365]; He X., 2020, NAT MED, V26, P672; Kim S, 2022, CLIN INFECT DIS, V74, P1594, DOI 10.1093/cid/ciab668; Koh WC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240205; Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495; Leclerc Quentin J, 2020, Wellcome Open Res, V5, P83, DOI [10.12688/wellcomeopenres.15889.1, 10.12688/wellcomeopenres.15889.2]; Lei H, 2020, J INFECTION, V81, P993, DOI 10.1016/j.jinf.2020.08.033; Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153; Madewell Zachary J, 2020, medRxiv, DOI 10.1101/2020.07.29.20164590; Marshall K, 2020, MMWR-MORBID MORTAL W, V69, P847, DOI 10.15585/mmwr.mm6926e4; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; Niepel C, 2020, BRIT J HEALTH PSYCH, V25, P883, DOI 10.1111/bjhp.12438; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Poletti P., 2020, PROBABILITY SYMPTOMS; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; Robbiani Davide F, 2020, Nature, V584, P437, DOI [10.1101/2020.05.13.092619, 10.1038/s41586-020-2456-9]; Tenforde MW, 2020, MMWR-MORBID MORTAL W, V69, P841, DOI 10.15585/mmwr.mm6926e3; Thompson Derek, 2020, ATLANTIC; Webster RK, 2020, PUBLIC HEALTH, V182, P163, DOI 10.1016/j.puhe.2020.03.007; WHO, 2020, REP WHO CHIN JOINT M	31	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243026	10.1371/journal.pone.0243026	http://dx.doi.org/10.1371/journal.pone.0243026			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD8LW	33284861	Green Published, gold, Green Submitted			2023-01-03	WOS:000597930500001
J	Puyat, JH; Ahmad, H; Avina-Galindo, AM; Kazanjian, A; Gupta, A; Ellis, U; Ashe, MC; Vila-Rodriguez, F; Halli, P; Salmon, A; Vigo, D; Almeida, A; De Bono, CE				Puyat, Joseph H.; Ahmad, Haroon; Avina-Galindo, Ana Michelle; Kazanjian, Arminee; Gupta, Aanchel; Ellis, Ursula; Ashe, Maureen C.; Vila-Rodriguez, Fidel; Halli, Priyanka; Salmon, Amy; Vigo, Daniel; Almeida, Alberto; De Bono, Christopher E.			A rapid review of home-based activities that can promote mental wellness during the COVID-19 pandemic	PLOS ONE			English	Review							PSYCHOLOGICAL DISTRESS; OLDER-ADULTS; HEALTH; YOGA; EXERCISE; RELIGION; STRESS; PARTICIPATION; INTERVENTION; DEPRESSION	Background During the COVID-19 pandemic, public health measures such as isolation, quarantine, and social distancing are needed. Some of these measures can adversely affect mental health. Activities that can be performed at home may mitigate these consequences and improve overall mental well-being. In this study, home-based activities that have potential beneficial effects on mental health were examined. Methods A rapid review was conducted based on a search of the following databases: MEDLINE, EMBASE, CINAHL, PyscINFO, Global Health, epistemonikos.org, covid19reviews.org, and eppi.ioe.ac.uk/covid19_map_v13.html. Eligible studies include randomized controlled trials and non-randomized studies published between 1/1/2000 and 28/05/2020 and that examined the impact of various activities on mental health outcomes in low-resource settings and contexts that lead to social isolation. Studies of activities that require mental health professionals or that could not be done at home were excluded. Two review authors performed title/abstract screening. At the full-text review stage, 25% of the potentially eligible studies were reviewed in full by two review authors; the rest were reviewed by one review author. Risk of bias assessment and data extraction were performed by one review author and checked by a second review author. The main outcome assessed was change or differences in mental health as expressed in Cohen's d; analysis was conducted following the synthesis without meta-analysis guidelines (SWiM). PROSPERO registration: CRD42020186082. Results Of 1,236 unique records identified, 160 were reviewed in full, resulting in 16 included studies. The included studies reported on the beneficial effects of exercise, yoga, progressive muscle relaxation, and listening to relaxing music. One study reported on the association between solitary religious activities and post traumatic stress disorder symptoms. While most of the included studies examined activities in group settings, particularly among individuals in prisons, the activities were described as something that can be performed at home and alone. All included studies were assessed to be at risk of bias in one or more of the bias domains examined. Conclusions There is some evidence that certain home-based activities can promote mental wellness during the COVID-19 pandemic. Guidelines are needed to help optimize benefits while minimizing potential risks when performing these activities.	[Puyat, Joseph H.; Gupta, Aanchel; Salmon, Amy] Providence Hlth Care, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Puyat, Joseph H.; Gupta, Aanchel; Salmon, Amy] Univ British Columbia, Vancouver, BC, Canada; [Puyat, Joseph H.; Kazanjian, Arminee; Gupta, Aanchel; Salmon, Amy; Vigo, Daniel] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Ahmad, Haroon; Halli, Priyanka; Vigo, Daniel] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC, Canada; [Avina-Galindo, Ana Michelle; Vila-Rodriguez, Fidel] Univ British Columbia, Dept Psychiat, Noninvas Neurostimulat Therapies Lab, Vancouver, BC, Canada; [Ellis, Ursula] Univ British Columbia, Woodward Lib, Vancouver, BC, Canada; [Ashe, Maureen C.] Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada; [Almeida, Alberto] Providence Hlth Care, Mental Hlth Program, Vancouver, BC, Canada; [De Bono, Christopher E.] Providence Hlth Care, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Puyat, JH (corresponding author), Providence Hlth Care, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada.; Puyat, JH (corresponding author), Univ British Columbia, Vancouver, BC, Canada.; Puyat, JH (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	jpuyat@cheos.ubc.ca	ashe, maureen/AAI-1350-2021; Ellis, Ursula/E-6606-2011; Puyat, Joseph H/ABA-6532-2021	Ellis, Ursula/0000-0002-5896-4852; Puyat, Joseph H/0000-0003-3710-5773; Vila-Rodriguez, Fidel/0000-0002-8273-8820; Ashe, Maureen C./0000-0002-6820-4435	Canadian Institutes of Health Research (CIHR) [202005CMS-442772-CMVCAAA-186414]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This study was funded by a Canadian Institutes of Health Research (CIHR) Knowledge Synthesis grant awarded to the team led by Dr. Joseph H. Puyat (#202005CMS-442772-CMVCAAA-186414). CIHR (https://cihr-irsc.gc.ca/) had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Abi-Jaoude E, 2020, CAN MED ASSOC J, V192, pE136, DOI 10.1503/cmaj.190434; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; [Anonymous], 2006, ANN REV LAW SOCIAL S, V2, P17, DOI DOI 10.1186/1745-0179-2-17; [Anonymous], 2020, J ULTRASOUND MED, V39, pE17; Baidawi S, 2016, J GERONTOL SOC WORK, V59, P252, DOI 10.1080/01634372.2016.1197353; Basaran Z., 2016, UNIVERSAL J ED RES, V4, P1080, DOI [10.13189/ujer.2016.040518, DOI 10.13189/UJER.2016.040518]; Battaglia C, 2015, CRIM BEHAV MENT HEAL, V25, P343, DOI 10.1002/cbm.1922; Bensimon M, 2015, INT J OFFENDER THER, V59, P406, DOI 10.1177/0306624X13511587; Bilderbeck AC, 2013, J PSYCHIATR RES, V47, P1438, DOI 10.1016/j.jpsychires.2013.06.014; Bonny H.L., 1986, MUSIC THERAPY, V6, P3, DOI [10.1093/mt/6.1.3, DOI 10.1093/MT/6.1.3]; Braam AW, 2019, J AFFECT DISORDERS, V257, P428, DOI 10.1016/j.jad.2019.06.063; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]; Brown, 2003, SPIRITUALITY HLTH, V4, P55, DOI [10.1002/shi.146, DOI 10.1002/SHI.146]; Brugman Teresa, 2002, J Psychosoc Nurs Ment Health Serv, V40, P24; Buckaloo BJ, 2009, PRISON J, V89, P328, DOI 10.1177/0032885509339508; Campbell M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6890; Cashin A, 2008, J PSYCHIATR MENT HLT, V15, P66, DOI 10.1111/j.1365-2850.2007.01207.x; CASPY T, 1988, MOTIV EMOTION, V12, P123, DOI 10.1007/BF00992169; Cherry KE, 2015, AGING MENT HEALTH, V19, P430, DOI 10.1080/13607863.2014.941325; Dishman R. K., 2012, FUNCTIONAL NEUROIMAG, P45, DOI [DOI 10.1007/978-1-4614-3293-7_3, 10.1007/978-1-4614-3293-7_3]; Ellison CG, 1998, HEALTH EDUC BEHAV, V25, P700, DOI 10.1177/109019819802500603; Everly G S Jr, 1989, Int J Psychosom, V36, P15; Fancourt D, 2020, BMJ; Ferendiuk Ewa, 2019, Folia Med Cracov, V59, P113, DOI 10.24425/fmc.2019.131140; Froeliger BE, 2012, FRONT INTEGR NEUROSC, P6, DOI [10.3389/fnint.2012.00006, DOI 10.3389/FNINT.2012.00006]; George LK, 2002, PSYCHOL INQ, V13, P190, DOI 10.1207/S15327965PLI1303_04; Granath Jens, 2006, Cognitive Behaviour Therapy, V35, P3, DOI 10.1080/16506070500401292; Harner H, 2010, NURS RES, V59, P389, DOI 10.1097/NNR.0b013e3181f2e6ff; Hill PC, 2003, AM PSYCHOL, V58, P64, DOI 10.1037/0003-066X.58.1.64; Huremovi D., 2019, PREPARING OUTBREAK, P65, DOI [10.1007/s00128-019-02595-0, DOI 10.1007/978-3-030-15346-5_6, 10.1007/978- 3- 030- 15346- 5_ 6.]; KANIASTY KZ, 1990, J APPL SOC PSYCHOL, V20, P85, DOI 10.1111/j.1559-1816.1990.tb00401.x; Karbandi S, 2015, N AM J MED SCI, V7, P266, DOI 10.4103/1947-2714.159332; Kerekes N, 2017, FRONT PSYCHIATRY, P8, DOI [10.3389/fpsyt.2017.00008, DOI 10.3389/FPSYT.2017.00008]; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; King VJ, 2022, SYST REV-LONDON, V11, DOI 10.1186/s13643-022-02011-5; Kinser PA, 2012, EXPLORE-NY, V8, P118, DOI 10.1016/j.explore.2011.12.005; Koltyn K. F., 1997, PHYS ACTIVITY MENTAL, P213; Labbe E, 2007, APPL PSYCHOPHYS BIOF, V32, P163, DOI 10.1007/s10484-007-9043-9; Legrand FD, 2020, ANXIETY STRESS COPIN, V33, P581, DOI 10.1080/10615806.2020.1768244; Li AW, 2012, ALTERN MED REV, V17, P21; McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411; Nelson M., 2006, J CORRECTIONAL ED, V57, P276; Nilsson Ulrica, 2008, AORN J, V87, P780, DOI 10.1016/j.aorn.2007.09.013; O'Toole S, 2018, INT J PRISON HEALTH, V14, P109, DOI 10.1108/IJPH-12-2016-0073; Psychou D, 2020, IMPACT EXERCISE INTE, DOI DOI 10.14198/JHSE.2021.161.13; Puyat JH, 2020, RAPID REV HOME ACTIV; Sfendla A, 2018, FRONT PSYCHIATRY, P9, DOI [10.3389/fpsyt.2018.00009, DOI 10.3389/FPSYT.2018.00009]; Sharma H, 2008, J PSYCHOSOM RES, V64, P213, DOI 10.1016/j.jpsychores.2007.07.003; Sistig B, 2015, J FORENSIC PSYCHI PS, V26, P824, DOI 10.1080/14789949.2015.1062996; Stanko KE, 2018, J RELIG SPIRITUAL A, V30, P292, DOI 10.1080/15528030.2018.1434853; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; The Lancet Hiv null, 2020, LANCET HIV, V7, pe75; Veritas Health Innovation, 2019, COV SYST REV SOFTW; Xie LQ, 2016, WESTERN J NURS RES, V38, P155, DOI 10.1177/0193945914551509; Zar A, 2017, REP HEALTH CARE, V3, P23	55	14	14	3	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2020	15	12							e0243125	10.1371/journal.pone.0243125	http://dx.doi.org/10.1371/journal.pone.0243125			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PC7AH	33270755	Green Published, gold			2023-01-03	WOS:000597149100050
J	Yin, DE; Ludema, C; Cole, SR; Golin, CE; Miller, WC; Warshaw, MG; McKinney, RE				Yin, Dwight E.; Ludema, Christina; Cole, Stephen R.; Golin, Carol E.; Miller, William C.; Warshaw, Meredith G.; McKinney, Ross E., Jr.		PENPACT Study Team	Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RITONAVIR-BOOSTED LOPINAVIR; MEDICATION ADHERENCE; DRUG-RESISTANCE; VIRAL LOAD; IMMUNOLOGICAL OUTCOMES; PEDIATRIC-PATIENTS; PILL BURDEN; ADOLESCENTS; NEVIRAPINE	Background Choice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naive children for differences in time to treatment disruption across randomly-assigned protease inhibitor versus non-nucleoside reverse transcriptase inhibitor-based initial antiretroviral therapy. Methods We performed a secondary analysis of a multicenter phase 2/3, randomized, open-label trial in Europe, North and South America from 2002 to 2009. Children aged 31 days to <18 years, who were living with HIV-1 and treatment-naive, were randomized to antiretroviral therapy with two nucleoside reverse transcriptase inhibitors plus a protease inhibitor or non-nucleoside reverse transcriptase inhibitor. Time to first documented treatment disruption to any component of antiretroviral therapy, derived from treatment records and adherence questionnaires, was analyzed using Kaplan-Meier estimators and Cox proportional hazards models. Results The modified intention-to-treat analysis included 263 participants. Seventy-two percent (n = 190) of participants experienced at least one treatment disruption during study. At 4 years, treatment disruption probabilities were 70% (protease inhibitor) vs. 63% (non-nucleoside reverse transcriptase inhibitor). The unadjusted hazard ratio (HR) for treatment disruptions comparing protease inhibitor vs. non-nucleoside reverse transcriptase inhibitor-based regimens was 1.19, 95% confidence interval [CI] 0.88-1.61 (adjusted HR 1.24, 95% CI 0.91-1.68). By study end, treatment disruption probabilities converged (protease inhibitor 81%, non-nucleoside reverse transcriptase inhibitor 84%) with unadjusted HR 1.11, 95% CI 0.84-1.48 (adjusted HR 1.13, 95% CI 0.84-1.50). Reported reasons for treatment disruptions suggested that participants on protease inhibitors experienced greater tolerability problems. Conclusions Children had similar time to treatment disruption for initial protease inhibitor and non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy, despite greater reported tolerability problems with protease inhibitor regimens. Initial pediatric antiretroviral therapy with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor may be acceptable for maintaining optimal, continuous therapy.	[Yin, Dwight E.] Childrens Mercy Kansas City, Dept Pediat, Div Infect Dis, Kansas City, MO 64108 USA; [Yin, Dwight E.] Childrens Mercy Kansas City, Dept Pediat, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA; [Yin, Dwight E.] Univ Missouri, Kansas City, MO 64110 USA; [Yin, Dwight E.] Duke Univ, Med Ctr, Dept Pediat, Div Infect Dis, Durham, NC 27710 USA; [Yin, Dwight E.; Cole, Stephen R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Ludema, Christina] Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA; [Golin, Carol E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC 27515 USA; [Golin, Carol E.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA; [Miller, William C.] Ohio State Univ, Coll Publ Hlth, Dept Epidemiol, Columbus, OH 43210 USA; [Warshaw, Meredith G.] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA; [McKinney, Ross E., Jr.] Assoc Amer Med Coll, Washington, DC USA; [Yin, Dwight E.] NIAID, Div AIDS, NIH, Rockville, MD 20892 USA; [Yin, Dwight E.] Childrens Mercy Kansas City, Kansas City, MO 64108 USA	Children's Mercy Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University System of Ohio; Ohio State University; Harvard University; Harvard T.H. Chan School of Public Health; Association of American Medical Colleges; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Children's Mercy Hospital	Yin, DE (corresponding author), Childrens Mercy Kansas City, Dept Pediat, Div Infect Dis, Kansas City, MO 64108 USA.; Yin, DE (corresponding author), Childrens Mercy Kansas City, Dept Pediat, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA.; Yin, DE (corresponding author), Univ Missouri, Kansas City, MO 64110 USA.; Yin, DE (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Infect Dis, Durham, NC 27710 USA.; Yin, DE (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Yin, DE (corresponding author), NIAID, Div AIDS, NIH, Rockville, MD 20892 USA.; Yin, DE (corresponding author), Childrens Mercy Kansas City, Kansas City, MO 64108 USA.	dwight_yin@yahoo.com	Miller, William C/H-4800-2014	Miller, William C/0000-0002-1934-7827; Yin, Dwight/0000-0002-8599-1004; Ludema, Christina/0000-0003-0779-810X	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [T32 HD043029]; Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center [T32 HD060558]; Paediatric European Network for Treatment of AIDS (PENTA) Foundation; Agence Nationale de Recherche sur le Sida et les hepatitis virales (ANRS); Pediatric AIDS Clinical Trials Group (PACTG); National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632]; National Institute of Mental Health (NIMH) [AI068632]; Statistical and Data Analysis Center at Harvard School of Public Health, under the National Institute of Allergy and Infectious Diseases [5 U01 AI41110]; PACTG [1 U01 AI068616]; IMPAACT Group; seventh framework programme (FP7/2007-2013) under the Eurocoord [260694, LSHP-CT-2006-018865, QLK2-CT-2000-00150]; PENTA Foundation; Istituto Superiore di Sanita-Progetto Terapia Antivirale; MRC; ANRS; NICHD; NICHD [K24HD069204, N01-DK-9-001/HHSN267200800001C]; National Institute of Allergy and Infectious Diseases (NIAID); NICHD International and Domestic Pediatric	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center; Paediatric European Network for Treatment of AIDS (PENTA) Foundation; Agence Nationale de Recherche sur le Sida et les hepatitis virales (ANRS)(ANRS); Pediatric AIDS Clinical Trials Group (PACTG); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Statistical and Data Analysis Center at Harvard School of Public Health, under the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PACTG; IMPAACT Group; seventh framework programme (FP7/2007-2013) under the Eurocoord; PENTA Foundation; Istituto Superiore di Sanita-Progetto Terapia Antivirale; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ANRS(ANRSFrench National Research Agency (ANR)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD International and Domestic Pediatric	DEY's work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) training grants to the Department of Pediatrics, Duke University Medical Center (T32 HD043029) and the Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center (T32 HD060558). The PENPACT-1 trial was sponsored jointly by the Paediatric European Network for Treatment of AIDS (PENTA) Foundation, Agence Nationale de Recherche sur le Sida et les hepatitis virales (ANRS) and the Pediatric AIDS Clinical Trials Group (PACTG), subsequently named the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). Overall support for PACTG/IMPAACT was provided by the National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) [AI068632]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under the National Institute of Allergy and Infectious Diseases cooperative agreement #5 U01 AI41110 with the PACTG and #1 U01 AI068616 with the IMPAACT Group. Support of the sites was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by NICHD (contract number N01-DK-9-001/HHSN267200800001C). PENTA is a coordinated action of the European Commission/European Union, supported by the seventh framework programme (FP7/2007-2013) under the Eurocoord grant agreement number 260694, the sixth framework contract number LSHP-CT-2006-018865, the fifth framework programme contract number QLK2-CT-2000-00150, and by the PENTA Foundation. UK clinical sites were supported by a grant from the MRC; those in Italy by a grant from the Istituto Superiore di Sanita-Progetto Terapia Antivirale 2004, 2005. GSK and BMS provided drugs in Romania. The trial was coordinated by four trials centers: the Medical Research Council (MRC) Clinical Trials Unit, London, UK (with support from the MRC); INSERM SC10, Paris, France (supported by ANRS); Frontier Science, New York, USA; and Westat, Maryland, USA (supported by NICHD). CEG's salary was partially supported by NICHD K24HD069204. Although the parent trial was overseen by members of the NIH and PENTA on the protocol team, the funders had no role in the study design, data analysis, decision to publish, or preparation of the manuscript for the secondary analysis.	Agwu A, 2008, AIDS PATIENT CARE ST, V22, P545, DOI 10.1089/apc.2007.0200; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Babiker A, 2011, LANCET INFECT DIS, V11, P273, DOI 10.1016/S1473-3099(10)70313-3; Bain-Brickley D, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009513; Bangsberg David R, 2007, Curr HIV/AIDS Rep, V4, P65, DOI 10.1007/s11904-007-0010-0; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2002, J GEN INTERN MED, V17, P812, DOI 10.1046/j.1525-1497.2002.20812.x; Barlow-Mosha L, 2016, CLIN INFECT DIS, V63, P1113, DOI 10.1093/cid/ciw488; Barro M, 2011, JAIDS-J ACQ IMM DEF, V57, pS44, DOI 10.1097/QAI.0b013e31821fd64f; Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334-200202011-00002; Becquet R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028510; Bhattacharya M, 2011, ANN TROP PAEDIATR, V31, P331, DOI 10.1179/1465328111Y.0000000031; Biadgilign S, 2009, SAHARA J-J SOC ASP H, V6, P148, DOI 10.1080/17290376.2009.9724943; Brackis-Cott Elizabeth, 2003, J Pediatr Health Care, V17, P252, DOI 10.1016/S0891-5245(02)88313-4; Brichard B, 2009, EUR J PEDIATR, V168, P387, DOI 10.1007/s00431-008-0914-8; Buchanan AL, 2012, PEDIATRICS, V129, pE1244, DOI 10.1542/peds.2011-1740; Buscher A, 2012, INT J STD AIDS, V23, P351, DOI 10.1258/ijsa.2011.011292; Byakika-Tusiime Jayne, 2009, AIDS Behav, V13 Suppl 1, P82, DOI 10.1007/s10461-009-9546-x; Clay PG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001677; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Coovadia A, 2010, JAMA-J AM MED ASSOC, V304, P1082, DOI 10.1001/jama.2010.1278; Czyzewski DI, 2000, AIDS READ, V10, P88; Dabis F, 2001, AIDS, V15, P771, DOI 10.1097/00002030-200104130-00013; Davies MA, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-34; Edessa D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220159; Elise A, 2005, JAIDS-J ACQ IMM DEF, V40, P498, DOI 10.1097/01.qai.0000168180.76405.5f; Esteban Gomez M J, 2004, Farm Hosp, V28, P34; Filho LFB, 2008, INT J STD AIDS, V19, P685, DOI 10.1258/ijsa.2008.008017; Fisher MC, 2008, PEDIATR INFECT DIS J, V27, P749, DOI 10.1097/INF.0b013e3181846e2e; Flynn PM, 2007, AIDS RES HUM RETROV, V23, P1208, DOI 10.1089/aid.2006.0290; Flynn PM, 2004, J INFECT DIS, V190, P271, DOI 10.1086/421521; Foster C, 2010, EXPERT REV ANTI-INFE, V8, P1403, DOI 10.1586/ERI.10.129; Gardner EM, 2009, AIDS, V23, P1035, DOI 10.1097/QAD.0b013e32832ba8ec; Garvie PA, 2007, PEDIATRICS, V119, pE893, DOI 10.1542/peds.2006-1488; Germanaud D, 2010, J ANTIMICROB CHEMOTH, V65, P118, DOI 10.1093/jac/dkp412; Giacomet V, 2003, ACTA PAEDIATR, V92, P1398, DOI 10.1080/08035250310006737; Giannattasio A, 2009, EXPERT OPIN PHARMACO, V10, P2773, DOI 10.1517/14656560903376178; Giralt AN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220408; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Gross R, 2001, AIDS, V15, P2109, DOI 10.1097/00002030-200111090-00006; Gross R YB, 2006, 13 C RETR OPP INF DE; Harrison L, 2015, JAIDS-J ACQ IMM DEF, V70, P42, DOI 10.1097/QAI.0000000000000671; Joint United Nations Programme on HIV/AIDS, 2018, UNAIDS DAT 2018; Kacanek D, 2019, AIDS, V33, P1923, DOI 10.1097/QAD.0000000000002301; Kapadia SN, 2018, SAGE OPEN MED, V6, DOI 10.1177/2050312118816919; Kekitiinwa A, 2016, ANTIVIR THER, V21, P579, DOI 10.3851/IMP3054; Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1; Leonard EG, 2005, INFECT DIS CLIN N AM, V19, P713, DOI 10.1016/j.idc.2005.05.006; Leonard EG, 2003, PEDIATR INFECT DIS J, V22, P77, DOI 10.1097/00006454-200301000-00018; Lin D, 2011, PHARMACOEPIDEM DR S, V20, P1246, DOI 10.1002/pds.2236; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Maggiolo F, 2007, HIV CLIN TRIALS, V8, P282, DOI 10.1310/hct0805-282; Mellins CA, 2004, PEDIATR INFECT DIS J, V23, P1035, DOI 10.1097/01.inf.0000143646.15240.ac; Mennella JA, 2017, CLIN THER, V39, P2038, DOI 10.1016/j.clinthera.2017.08.012; Molina JM, 2014, J INT AIDS SOC, V17, P6, DOI 10.7448/IAS.17.4.19490; Muller Alexandra D, 2009, Clin Infect Dis, V48, pe3, DOI 10.1086/595553; Murnane PM, 2017, CLIN INFECT DIS, V65, P477, DOI 10.1093/cid/cix335; Nachega JB, 2014, CLIN INFECT DIS, V58, P1297, DOI 10.1093/cid/ciu046; Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, GUID US ANT AG PED H; Pantuzza LL, 2017, EUR J CLIN PHARMACOL, V73, P1475, DOI 10.1007/s00228-017-2315-2; Pasipanodya B, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25214; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Patten G, 2019, PEDIATR INFECT DIS J, V38, P400, DOI 10.1097/INF.0000000000002156; Penazzato M, 2019, LANCET HIV, V6, pE623, DOI 10.1016/S2352-3018(19)30193-6; Pham K, 2016, J CONTROL RELEASE, V226, P88, DOI 10.1016/j.jconrel.2016.02.001; Pham PA, 2009, AIDS PATIENT CARE ST, V23, P803, DOI 10.1089/apc.2008.0269; Romero A.M., 2004, Anales Sis San Navarra, V27, P45, DOI 10.4321/s1137-66272004000200005; Ruel TD, 2014, JAIDS-J ACQ IMM DEF, V65, P535, DOI 10.1097/QAI.0000000000000071; Schlatter AF, 2016, AIDS RES TREAT, V2016, DOI 10.1155/2016/1654938; Snedecor SJ, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3975-6; Van der Linden D, 2009, EXPERT OPIN PHARMACO, V10, P1783, DOI 10.1517/14656560903012377; Van Dyke RB, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e61; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Violari A, 2012, NEW ENGL J MED, V366, P2380, DOI 10.1056/NEJMoa1113249	76	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2020	15	11							e0242405	10.1371/journal.pone.0242405	http://dx.doi.org/10.1371/journal.pone.0242405			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA5BU	33226999	gold, Green Published			2023-01-03	WOS:000595651800042
J	Lamontagne				Lamontagne			Update to living WHO guideline on drugs for covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2020	371								m4475	10.1136/bmj.m4475	http://dx.doi.org/10.1136/bmj.m4475			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ9TW	33214213	Bronze			2023-01-03	WOS:000595262300015
J	Venekamp, RP; Schilder, AGM; van den Heuvel, M; Hay, AD				Venekamp, Roderick P.; Schilder, Anne G. M.; van den Heuvel, Maaike; Hay, Alastair D.			Acute otitis media in children	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MIDDLE-EAR EFFUSION; RISK-FACTORS; DIAGNOSIS; SYMPTOMS; LIFE; PREVALENCE; CHILDHOOD; PARENTS; PLACEBO; TRIAL		[Venekamp, Roderick P.; Schilder, Anne G. M.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Schilder, Anne G. M.] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Schilder, Anne G. M.] UCL, Ear Inst, EvidENT, London, England; [van den Heuvel, Maaike] Leidsche Rijn Ctr, FLeiR Publ Pharm, Utrecht, Netherlands; [Hay, Alastair D.] Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Ctr Acad Primary Care,NIHR Sch Primary Care Res, Bristol, Avon, England	Utrecht University; Utrecht University Medical Center; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; University of Bristol	Venekamp, RP (corresponding author), Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.	R.P.Venekamp@umcutrecht.nl		Venekamp, Roderick P/0000-0002-1446-9614; Hay, Alastair/0000-0003-3012-375X; Schilder, Anne/0000-0002-5496-4580				Barber C, 2014, INT J PEDIATR OTORHI, V78, P300, DOI 10.1016/j.ijporl.2013.11.030; Bertin L, 1996, FUNDAM CLIN PHARM, V10, P387, DOI 10.1111/j.1472-8206.1996.tb00590.x; Bluestone CD, 2002, ANN OTO RHINOL LARYN, V111, P8, DOI 10.1177/00034894021110S304; Bowatte G, 2015, ACTA PAEDIATR, V104, P85, DOI 10.1111/apa.13151; Brennan-Jones CG, 2015, J PAEDIATR CHILD H, V51, P403, DOI 10.1111/jpc.12741; Brouwer CNM, 2005, CLIN OTOLARYNGOL, V30, P258, DOI 10.1111/j.1365-2273.2005.00995.x; Chonmaitree T, 2015, CLIN INFECT DIS, V60, P1, DOI 10.1093/cid/ciu714; Chonmaitree T, 2012, PEDIATR INFECT DIS J, V31, P325, DOI 10.1097/INF.0b013e318241afe4; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Cushen R, 2020, BRIT J GEN PRACT, V70, pE255, DOI 10.3399/bjgp20X708821; Fortanier AC, 2019, COCHRANE DB SYST REV, V5; Foxlee R, 2006, COCHRANE DB SYST REV, V3; Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998; Hansen MP, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0297-7; Hay AD, 2005, FAM PRACT, V22, P367, DOI 10.1093/fampra/cmi035; Hay AD, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23340; KARMA PH, 1989, INT J PEDIATR OTORHI, V17, P37, DOI 10.1016/0165-5876(89)90292-9; Kaur R, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0181; Laine MK, 2010, PEDIATRICS, V125, pE1154, DOI 10.1542/peds.2009-2689; Leach AJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004401.pub2; Legros JM, 2008, INT J PEDIATR OTORHI, V72, P23, DOI 10.1016/j.ijporl.2007.09.010; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; MacIntyre EA, 2010, PAED CHILD HEALT-CAN, V15, P437, DOI 10.1093/pch/15.7.437; McCormick DP, 2000, PEDIATR INFECT DIS J, V19, P256, DOI 10.1097/00006454-200003000-00019; Meherali S, 2019, J PATIENT EXPERIENCE, V6, P53, DOI 10.1177/2374373518771362; Monasta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036226; National Institute for Health and Care Excellence, 2019, CLIN GUID NG143 FEV; National Institute for Health and Care Excellence, 2018, CLIN GUID 91 OT MED; Newbould L, BR J GEN PRACT; Ngo CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150949; Norhayati MN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010089.pub2; Pichichero ME, 2005, INT J PEDIATR OTORHI, V69, P361, DOI 10.1016/j.ijporl.2004.10.013; Rosenfeld RM, 2014, OTOLARYNG HEAD NECK, V150, P1, DOI 10.1177/0194599813514365; Rosenfeld RM, 2013, OTOLARYNG HEAD NECK, V149, pS1, DOI 10.1177/0194599813487302; Rosenfeld RM, 2003, LARYNGOSCOPE, V113, P1645, DOI 10.1097/00005537-200310000-00004; Rosenfeld RM, 2002, INT J PEDIATR OTORHI, V64, P89, DOI 10.1016/S0165-5876(02)00073-3; Rovers MM, 2008, FAM PRACT, V25, P233, DOI 10.1093/fampra/cmn030; Rovers MM, 2006, LANCET, V368, P1429, DOI 10.1016/S0140-6736(06)69606-2; Schilder AGM, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.63; Smith L, 2010, BRIT J GEN PRACT, V60, P101, DOI 10.3399/bjgp10X483148; Suzuki HG, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035343; Tapiainen T, 2014, JAMA PEDIATR, V168, P635, DOI 10.1001/jamapediatrics.2013.5311; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; THOMPSON M, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F7027; van Dongen TMA, 2014, NEW ENGL J MED, V370, P723, DOI 10.1056/NEJMoa1301630; van Uum RT, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0908-9; Venekamp RP, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i308; Venekamp RP, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000219.pub4, 10.1002/14651858.CD000219.pub3]; Venekamp RP, 2018, COCHRANE DB SYST REV, V5; Weber PC, 2004, OTOLARYNG HEAD NECK, V130, pS89, DOI 10.1016/j.otohns.2003.12.009; Zhang YJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105725, 10.1371/journal.pone.0088491, 10.1371/journal.pone.0093458, 10.1371/journal.pone.0109159]	51	5	5	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2020	371								m4238	10.1136/bmj.m4238	http://dx.doi.org/10.1136/bmj.m4238			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ0EY	33208317	Green Submitted			2023-01-03	WOS:000594610800003
J	Tanner, M				Tanner, Michael			In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA(1c) and SBP and may reduce body weight	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Tanner, Michael] NYU, Grossman Sch Med, New York, NY 10003 USA	New York University	Tanner, M (corresponding author), NYU, Grossman Sch Med, New York, NY 10003 USA.			Tanner, Michael/0000-0002-3012-8641				Tsapas A, 2020, ANN INTERN MED, V173, P278, DOI 10.7326/M20-0864	1	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					JC52	JC52		10.7326/ACPJ202011170-052	http://dx.doi.org/10.7326/ACPJ202011170-052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OU5XD	33197349				2023-01-03	WOS:000591600700005
J	Liu, Y; Gong, ZZ; Zhou, JF; Yan, JK; Cai, W				Liu, Yang; Gong, Zizhen; Zhou, Jiefei; Yan, Junkai; Cai, Wei			Lin 28A/Occludin axis: An aberrantly activated pathway in intestinal epithelial cells leading to impaired barrier function under total parenteral nutrition	FASEB JOURNAL			English	Article						intestinal barrier function; Lin 28A; Occludin; RNA binding protein; total parenteral nutrition	MOUSE MODEL; MESSENGER-RNA; TRANSLATION; EXPRESSION; ATROPHY; BINDING; DIFFERENTIATION; REGULATOR; APOPTOSIS; OCCLUDIN	Disassembly of tight junctions is a major cause of intestinal barrier dysfunction under total parenteral nutrition (TPN), but the precise mechanisms have not been fully understood. Normally, RNA binding protein Lin 28A is highly restricted to embryonic stem cells and dramatically decreases as differentiation progresses; however, in our preliminary study it was found aberrantly increased in the intestinal epithelial cells of TPN rats, and thus its mechanism of action needs to be addressed. Herein, we report a pivotal role of Lin 28A in the regulation of tight junctions, which induces a sustained translational repression of Occludin, leading to disruption of intestinal barrier function under TPN. Using a rat model of TPN, we found time-dependent upregulation of Lin 28A, negatively correlated with Occludin. Using mouse intestinal organoids and human gut-derived Caco-2 cells as in vitro models, we found that expression of Occludin could be significantly suppressed by ectopic overexpression of Lin 28A. The underlying mechanisms may be partially attributed to translational repression, as the abundance of Occludin transcripts in polysomes was dramatically reduced by Lin 28A (polysomal profiling). Furthermore, Lin 28A was found to directly bind to Occludin mRNA 3 ' untranslated coding region (UTR), thereby repressing the translation of Occludin transcripts through decapping enzyme 1A (DCP1a). Taken together, our findings revealed that Lin 28A/Occludin axis may be a novel mechanism accounting for the development of barrier dysfunction under TPN.	[Liu, Yang; Gong, Zizhen; Zhou, Jiefei; Yan, Junkai; Cai, Wei] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai, Peoples R China; [Gong, Zizhen; Zhou, Jiefei; Yan, Junkai; Cai, Wei] Shanghai Inst Pediat Res, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai, Peoples R China	Shanghai Jiao Tong University	Yan, JK; Cai, W (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai Inst Pediat Res, Xin Hua Hosp,Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	yanjunkai@xinhuamed.com.cn; caiw204@sjtu.edu.cn			Shanghai Municipal Commission of Health and Family [20184Y0337]; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition [17DZ2272000]; National Natural Science Foundation of China [81630039, 81700787]; Science and Technology Commission of Shanghai Municipality [19495810500]; Foundation of Shanghai Municipal Health Commission [shslczdzk05702, 2019ZB0101]	Shanghai Municipal Commission of Health and Family; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Foundation of Shanghai Municipal Health Commission	Shanghai Municipal Commission of Health and Family, Grant/Award Number: 20184Y0337; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Grant/Award Number: 17DZ2272000; National Natural Science Foundation of China, Grant/Award Number: 81630039 and 81700787; Science and Technology Commission of Shanghai Municipality, Grant/Award Number: 19495810500; Foundation of Shanghai Municipal Health Commission, Grant/Award Number: shslczdzk05702 and 2019ZB0101	Balzer E, 2007, RNA BIOL, V4, P16, DOI 10.4161/rna.4.1.4364; Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895; Broutier L, 2016, NAT PROTOC, V11, P1724, DOI 10.1038/nprot.2016.097; Cho J, 2012, CELL, V151, P765, DOI 10.1016/j.cell.2012.10.019; Feng YJ, 2017, CELL MOL GASTROENTER, V3, P447, DOI 10.1016/j.jcmgh.2016.12.005; Feng YJ, 2013, J PHYSIOL-LONDON, V591, P3709, DOI 10.1113/jphysiol.2013.253518; Feng YJ, 2009, J PHYSIOL-LONDON, V587, P641, DOI 10.1113/jphysiol.2008.162719; Franks TM, 2008, MOL CELL, V32, P605, DOI 10.1016/j.molcel.2008.11.001; Freeman JJ, 2015, FASEB J, V29, P2943, DOI 10.1096/fj.14-269480; Hansraj NZ, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12858; Hartman C, 2018, CLIN NUTR, V37, P2418, DOI 10.1016/j.clnu.2018.06.956; Jin JY, 2011, NUCLEIC ACIDS RES, V39, P3724, DOI 10.1093/nar/gkq1350; Liu L, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00574-16; Liu L, 2015, MOL BIOL CELL, V26, P1797, DOI 10.1091/mbc.E14-11-1500; Luhur A, 2015, FLY, V9, P173, DOI 10.1080/19336934.2016.1158366; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Nagy P, 2017, DEVELOPMENT, V144, P3990, DOI 10.1242/dev.147033; O'Driscoll MC, 2010, AM J HUM GENET, V87, P354, DOI 10.1016/j.ajhg.2010.07.012; Peng SP, 2011, STEM CELLS, V29, P496, DOI 10.1002/stem.591; Pereira B, 2013, NUCLEIC ACIDS RES, V41, P3986, DOI 10.1093/nar/gkt087; Pironi L, 2019, CLIN LIVER DIS, V23, P279, DOI 10.1016/j.cld.2018.12.009; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Sun XY, 2008, AM J PHYSIOL-GASTR L, V294, pG139, DOI 10.1152/ajpgi.00386.2007; Takizawa Y, 2013, INT J PHARMACEUT, V450, P31, DOI 10.1016/j.ijpharm.2013.04.026; Wessel Jacqueline, 2017, Adv Pediatr, V64, P253, DOI 10.1016/j.yapd.2017.03.010; West JA, 2009, NATURE, V460, P909, DOI 10.1038/nature08210; Xiao WD, 2014, FASEB J, V28, P2073, DOI 10.1096/fj.13-238311; Yan JK, 2019, FASEB J, V33, P3378, DOI [10.1096/fj.201801695r, 10.1096/fj.201801695R]; Yan JK, 2018, J CELL MOL MED, V22, P1562, DOI 10.1111/jcmm.13430; Yan JK, 2017, CELL PHYSIOL BIOCHEM, V41, P711, DOI 10.1159/000458430; Yan JK, 2016, CELL PHYSIOL BIOCHEM, V39, P1581, DOI 10.1159/000447860; Yokoyama S, 2008, GENE EXPR PATTERNS, V8, P155, DOI 10.1016/j.gep.2007.11.001; Yu TX, 2016, AM J PHYSIOL-CELL PH, V310, pC54, DOI 10.1152/ajpcell.00112.2015; Yu TX, 2013, MOL BIOL CELL, V24, P85, DOI 10.1091/mbc.E12-07-0531; Yuan J, 2012, SCIENCE, V335, P1195, DOI 10.1126/science.1216557; Zhang T, 2019, JPEN-PARENTER ENTER, V43, P96, DOI 10.1002/jpen.1173; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033; Zhu H, 2010, NAT GENET, V42, P626, DOI 10.1038/ng.593; Zhu J, 2018, JPEN-PARENTER ENTER, V42, P436, DOI 10.1177/0148607116677048	41	1	1	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2021	35	2								10.1096/fj.202001819R	http://dx.doi.org/10.1096/fj.202001819R		NOV 2020	16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	RY3BC	33200449				2023-01-03	WOS:000592669100001
J	Thomalla, G; Boutitie, F; Ma, H; Koga, M; Ringleb, P; Schwamm, LH; Wu, O; Bendszus, M; Bladin, CF; Campbell, BCV; Cheng, B; Churilov, L; Ebinger, M; Endres, M; Fiebach, JB; Fukuda-Doi, M; Inoue, M; Kleinig, TJ; Latour, LL; Lemmens, R; Levi, CR; Leys, D; Miwa, K; Molina, CA; Muir, KW; Nighoghossian, N; Parsons, MW; Pedraza, S; Schellinger, PD; Schwab, S; Simonsen, CZ; Song, SS; Thijs, V; Toni, D; Hsu, CY; Wahlgren, N; Yamamoto, H; Yassi, N; Yoshimura, S; Warach, S; Hacke, W; Toyoda, K; Donnan, GA; Davis, SM; Gerloff, C				Thomalla, Goetz; Boutitie, Florent; Ma, Henry; Koga, Masatoshi; Ringleb, Peter; Schwamm, Lee H.; Wu, Ona; Bendszus, Martin; Bladin, Christopher F.; Campbell, Bruce C. V.; Cheng, Bastian; Churilov, Leonid; Ebinger, Martin; Endres, Matthias; Fiebach, Jochen B.; Fukuda-Doi, Mayumi; Inoue, Manabu; Kleinig, Timothy J.; Latour, Lawrence L.; Lemmens, Robin; Levi, Christopher R.; Leys, Didier; Miwa, Kaori; Molina, Carlos A.; Muir, Keith W.; Nighoghossian, Norbert; Parsons, Mark W.; Pedraza, Salvador; Schellinger, Peter D.; Schwab, Stefan; Simonsen, Claus Z.; Song, Shlee S.; Thijs, Vincent; Toni, Danilo; Hsu, Chung Y.; Wahlgren, Nils; Yamamoto, Haruko; Yassi, Nawaf; Yoshimura, Sohei; Warach, Steven; Hacke, Werner; Toyoda, Kazunori; Donnan, Geoffrey A.; Davis, Stephen M.; Gerloff, Christian		Evaluation Unknown Onset Stroke	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data	LANCET			English	Review							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; THROMBOLYSIS; THROMBECTOMY; GUIDELINES	Background Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0-2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1.49 [95% CI 1.10-2.03]; p=0.011), with low heterogeneity across studies (I-2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1.38 [95% CI 1.05-1.80]; p=0.019), and a higher odds of independent outcome (adjusted OR 1.50 [1.06-2.12]; p=0.022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4-6), compared with 102 (25%) patients in the control group (adjusted OR 0.76 [0.52-1.11]; p=0.15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2.06 [1.03-4.09]; p=0.040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5.58 [1.22-25.50]; p=0.024). Interpretation In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Thomalla, Goetz; Cheng, Bastian; Gerloff, Christian] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neurol, Kopf & Neurozentrum, D-20246 Hamburg, Germany; [Boutitie, Florent] Hosp Civils Lyon, Serv Biostat, Lyon, France; [Boutitie, Florent] Univ Lyon 1, Villeurbanne, France; [Boutitie, Florent] Lab Biometrie & Biol Evolut, Equipe Biostat Sante, Villeurbanne, France; [Ma, Henry] Monash Univ, Dept Med, Sch Clin Sci, Melbourne, Vic, Australia; [Koga, Masatoshi; Fukuda-Doi, Mayumi; Inoue, Manabu; Miwa, Kaori; Yoshimura, Sohei; Toyoda, Kazunori] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Suita, Osaka, Japan; [Fukuda-Doi, Mayumi] Natl Cerebral & Cardiovasc Ctr, Dept Data Sci, Suita, Osaka, Japan; [Yamamoto, Haruko] Natl Cerebral & Cardiovasc Ctr, Ctr Adv Clin & Translat Sci, Suita, Osaka, Japan; [Ringleb, Peter; Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany; [Bendszus, Martin] Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany; [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Bladin, Christopher F.] Monash Univ, Dept Neurosci, Eastern Hlth & Eastern Hlth Clin Sch, Box Hill, Vic, Australia; [Campbell, Bruce C. V.; Churilov, Leonid; Parsons, Mark W.; Yassi, Nawaf; Donnan, Geoffrey A.; Davis, Stephen M.] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Royal Melbourne Hosp, Melbourne, Vic, Australia; [Campbell, Bruce C. V.; Churilov, Leonid; Parsons, Mark W.; Yassi, Nawaf; Donnan, Geoffrey A.; Davis, Stephen M.] Univ Melbourne, Dept Neurol, Melbourne Brain Ctr, Royal Melbourne Hosp, Melbourne, Vic, Australia; [Ebinger, Martin; Endres, Matthias; Fiebach, Jochen B.] Charite Univ Med Berlin, Ctr Schlaganfallforsch Berlin, Berlin, Germany; [Endres, Matthias] Charite Univ Med Berlin, Klin & Hsch Ambulanz Neurol, Berlin, Germany; [Ebinger, Martin] Klin Neurol Med Pk Berlin Humboldtmuhle, Berlin, Germany; [Endres, Matthias] German Ctr Cardiovasc Res, Berlin, Germany; [Endres, Matthias] German Ctr Neurodegenerat Dis, Berlin, Germany; [Kleinig, Timothy J.] Royal Adelaide Hosp, Dept Neurol, Adelaide, SA, Australia; [Latour, Lawrence L.] NINDS, Acute Cerebrovasc Diagnost Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Lemmens, Robin] Univ Leuven, Dept Neurosci, Expt Neurol, KU Leuven, Leuven, Belgium; [Lemmens, Robin] VIB Ctr Brain & Dis Res, Leuven, Belgium; [Lemmens, Robin] Univ Hosp Leuven, Dept Neurol, Leuven, Belgium; [Levi, Christopher R.] Univ Newcastle, Prior Res Ctr Brain & Mental Hlth Res, John Hunter Hosp, Dept Neurol, Newcastle, NSW, Australia; [Leys, Didier] Univ Lille, INSERM, U1171, Lille, France; [Molina, Carlos A.] Hosp Univ Vall dHebron, Stroke Unit, Dept Neurol, Barcelona, Spain; [Muir, Keith W.] Univ Glasgow, Inst Neurosci & Psychol, Glasgow, Lanark, Scotland; [Nighoghossian, Norbert] Univ Claude Bernard Lyon 1, Dept Stroke Med, CarMeN Lab, INSERM,U1060,INRA 1397, Lyon, France; [Pedraza, Salvador] Hosp Dr Josep Trueta, Inst Diagnost Imatge, Dept Radiol, Inst Invest Biomed Girona, Girona, Spain; [Schellinger, Peter D.] Ruhr Univ Bochum, Johannes Wesling Klinikum Minden, Univ Klin Neurol, Muhlenkreiskliniken,Univ Klinikum, Minden, Germany; [Schwab, Stefan] Univ Erlangen Nurnberg, Dept Neurol, Erlangen, Germany; [Simonsen, Claus Z.] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark; [Song, Shlee S.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA; [Thijs, Vincent] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Thijs, Vincent] Austin Hlth, Dept Neurol, Heidelberg, Vic, Australia; [Toni, Danilo] Univ Roma La Sapienza, Dept Human Neurosci, Rome, Italy; [Hsu, Chung Y.] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Wahlgren, Nils] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Yassi, Nawaf] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia; [Warach, Steven] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Monash University; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Monash University; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; German Centre for Cardiovascular Research; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Royal Adelaide Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; John Hunter Hospital; University of Newcastle; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Hospital Universitari Vall d'Hebron; University of Glasgow; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Ruhr University Bochum; University of Erlangen Nuremberg; Aarhus University; Cedars Sinai Medical Center; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Sapienza University Rome; China Medical University Taiwan; Karolinska Institutet; Walter & Eliza Hall Institute; University of Texas System; University of Texas Austin	Thomalla, G (corresponding author), Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Neurol, Kopf & Neurozentrum, D-20246 Hamburg, Germany.	thomalla@uke.de	Yamamoto, Haruko/HII-5306-2022; Lückl, Janos/ABF-7183-2021; Latour, Larry/AAH-5663-2021; Koga, Masatoshi/GWR-2715-2022; Campbell, Bruce/AGY-4147-2022; Carmen, Team3/Y-7384-2019; Thijs, Vincent/C-3647-2009; Hankey, Graeme J/H-4968-2014; Cheng, Bastian/U-2232-2019; Muir, Keith W/A-7670-2011; Toni, Danilo/K-3151-2016; Fandler-Höfler, Simon/AAL-9956-2020; Campbell, Bruce/J-1220-2019; Oppenheim, Catherine/N-1635-2018; Poli, Sven/ACY-0995-2022; Davis, Stephen/L-5260-2013; Macleod, Malcolm Robert/B-2052-2010; Desmond, Patricia/D-1966-2014	Lückl, Janos/0000-0001-8094-771X; Latour, Larry/0000-0001-6160-5263; Koga, Masatoshi/0000-0002-6758-4026; Carmen, Team3/0000-0002-3614-0924; Thijs, Vincent/0000-0002-6614-8417; Hankey, Graeme J/0000-0002-6044-7328; Cheng, Bastian/0000-0003-2434-1822; Muir, Keith W/0000-0001-9535-022X; Toni, Danilo/0000-0003-2735-8427; Fandler-Höfler, Simon/0000-0001-9043-0378; Campbell, Bruce/0000-0003-3632-9433; Kleinschnitz, Christoph/0000-0002-1650-8875; Fukuda-Doi, Mayumi/0000-0003-0922-4417; Blacker, David/0000-0003-0046-9776; Becerra, Juan Luis/0000-0002-1968-9966; Hsia, Amie/0000-0002-0214-9736; Miwa, Kaori/0000-0002-7948-3636; kleinig, Timothy/0000-0003-4430-3276; Legrand, Laurence/0000-0003-3951-7405; Ihara, Masafumi/0000-0002-7102-4048; Wardlaw, Joanna/0000-0002-9812-6642; Iwama, Toru/0000-0002-9426-284X; Oppenheim, Catherine/0000-0003-3410-0862; Ng, Felix/0000-0001-6973-8677; Sprigg, Nikola/0000-0002-5871-8168; Perez de la Ossa, Natalia/0000-0002-6063-211X; Eschenfelder, Christoph/0000-0003-2766-2488; pedraza, salvador/0000-0003-2517-4413; Tsai, Li-Kai/0000-0001-8420-6951; Yassi, Nawaf/0000-0002-0685-0060; Eisele, Philipp/0000-0001-6831-4282; MA, HENRY/0000-0002-0510-8059; Modrau, Boris/0000-0003-4331-4491; Moulin, thierry/0000-0002-6639-8117; Poli, Sven/0000-0002-0286-8781; Majoie, Charles/0000-0002-7600-9568; Perry, Richard/0000-0002-4536-9018; wouters, anke/0000-0001-5229-2699; Davis, Stephen/0000-0003-0962-2300; Levi, Christopher/0000-0002-9474-796X; Ganeshan, Ramanan/0000-0003-4043-1115; MELLERIO, Charles/0000-0002-9987-9101; Appleton, Jason/0000-0002-2604-4410; Bonnet, Louise/0000-0002-3446-2276; Lab, Carmen/0000-0002-5935-3236; Yeh, Shin-Joe/0000-0003-1511-6295; Endres, Matthias/0000-0001-6520-3720; Macleod, Malcolm Robert/0000-0001-9187-9839; Wijeratne, Tissa/0000-0002-1701-7111; Christensen, Hanne/0000-0002-7472-3194; Zhao, Henry/0000-0002-4320-4287; Balabanski, Anna/0000-0003-3209-3101; Desmond, Patricia/0000-0002-4803-6323; Mikulik, Robert/0000-0002-7458-5166; Fiebach, Jochen B./0000-0002-7936-6958; Curtze, Sami/0000-0003-1545-8500; KANZAWA, TAKAO/0000-0002-8165-5652; Muller, Claire/0000-0002-9250-936X; De Smedt, Ann/0000-0003-0252-0600	EU Seventh Framework programme [278276]; National Health and Medical Research Council; Australian Government organisation; Commonwealth Scientific and Industrial Research Organisation; Japan Agency for Medical Research and Development (AMED) [19ek0210091h0003, 19lk0201094h0001]; Ministry of Health, Labour, and Welfare; Mihara Cerebrovascular Disorder Research Promotion Fund; Boehringer Ingelheim (Germany); NIH National Institute of Neurological Disorders and Stroke (NINDS) Specialized Program of Transitional Research in Acute Stroke (SPOTRIAS) [P50-NS051343]; NINDS Division of Intramural Research [P41EB015896]; P41 Biotechnology Resource Grant by the NIH National Institute of Biomedical Imaging and Bioengineering	EU Seventh Framework programme; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Government organisation; Commonwealth Scientific and Industrial Research Organisation(Commonwealth Scientific & Industrial Research Organisation (CSIRO)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Health, Labour, and Welfare(Ministry of Health, Labour and Welfare, Japan); Mihara Cerebrovascular Disorder Research Promotion Fund; Boehringer Ingelheim (Germany)(Boehringer Ingelheim); NIH National Institute of Neurological Disorders and Stroke (NINDS) Specialized Program of Transitional Research in Acute Stroke (SPOTRIAS); NINDS Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); P41 Biotechnology Resource Grant by the NIH National Institute of Biomedical Imaging and Bioengineering	WAKE-UP was supported by a grant (number 278276) from the EU Seventh Framework programme. EXTEND was funded by the National Health and Medical Research Council, an Australian Government organisation and Commonwealth Scientific and Industrial Research Organisation. Boehringer Ingelheim provided the study investigational products free of charge. THAWS was supported by the Japan Agency for Medical Research and Development (AMED; 19ek0210091h0003 and 19lk0201094h0001), and the Ministry of Health, Labour, and Welfare, and the Mihara Cerebrovascular Disorder Research Promotion Fund. ECASS-4 was an investigator-initiated trial supported by an unrestricted grant from Boehringer Ingelheim (Germany). MR WITNESS was supported by the NIH National Institute of Neurological Disorders and Stroke (NINDS) Specialized Program of Transitional Research in Acute Stroke (SPOTRIAS; P50-NS051343) and NINDS Division of Intramural Research, was done in part at the Athinoula A Martinos Center for Biomedical Imaging at Massachusetts General Hospital, using resources provided by the Center for Functional Neuroimaging Technologies (P41EB015896), a P41 Biotechnology Resource Grant supported by the NIH National Institute of Biomedical Imaging and Bioengineering. Genentech provided alteplase free of charge to the study for distribution to all sites except to the NINDS intramural branch and starting in year 2 provided supplemental site payments to permit expansion to 14 sites.	Ahmed N, 2019, EUR STROKE J, V4, P307, DOI 10.1177/2396987319863606; Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Barow E, 2019, JAMA NEUROL, V76, P641, DOI 10.1001/jamaneurol.2019.0351; Campbell BCV, 2019, LANCET, V394, P139, DOI 10.1016/S0140-6736(19)31053-0; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fischer U, 2017, STROKE, V48, P2912, DOI 10.1161/STROKEAHA.117.017208; Galinovic I, 2014, STROKE, V45, P1170, DOI 10.1161/STROKEAHA.113.002661; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Koga M, 2020, STROKE, V51, P1530, DOI 10.1161/STROKEAHA.119.028127; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Rimmele DL, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00035; Ringleb P, 2019, INT J STROKE, V14, P483, DOI 10.1177/1747493019840938; Scheldeman L, 2020, ANN NEUROL, V87, P931, DOI 10.1002/ana.25730; Schwamm LH, 2018, ANN NEUROL, V83, P980, DOI 10.1002/ana.25235; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355; Thomalla G, 2007, STROKE, V38, P313, DOI 10.1161/01.STR.0000254565.51807.22; Thomalla G, 2014, INT J STROKE, V9, P829, DOI 10.1111/ijs.12011; Thomalla G, 2011, LANCET NEUROL, V10, P978, DOI 10.1016/S1474-4422(11)70192-2; Toyoda K, 2019, NEUROL MED-CHIR, V59, P449, DOI 10.2176/nmc.st.2019-0177; von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4	26	49	53	8	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	2020	396	10262					1574	1584		10.1016/S0140-6736(20)32163-2	http://dx.doi.org/10.1016/S0140-6736(20)32163-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OQ4TW	33176180	Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000588778800029
J	Seymour, CW; Bauchner, H; Golub, RM				Seymour, Christopher W.; Bauchner, Howard; Golub, Robert M.			COVID-19 Infection-Preventing Clinical Deterioration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Seymour, Christopher W.] Univ Pittsburgh, Dept Crit Care Med, Keystone Bldg,3520 Fifth Ave,Ste 100, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Seymour, CW (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Keystone Bldg,3520 Fifth Ave,Ste 100, Pittsburgh, PA 15261 USA.	seymourcw@upmc.edu						Califf RM, 2020, JAMA-J AM MED ASSOC, V324, P625, DOI 10.1001/jama.2020.13319; Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742; Kim PS, 2020, JAMA-J AM MED ASSOC, V324, P2149, DOI 10.1001/jama.2020.22813; Lenze EJ, 2020, JAMA-J AM MED ASSOC, V324, P2292, DOI 10.1001/jama.2020.22760; Prescott HC, 2020, JAMA-J AM MED ASSOC, V324, P1292, DOI 10.1001/jama.2020.16747; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023	6	5	5	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2020	324	22					2300	2300		10.1001/jama.2020.21720	http://dx.doi.org/10.1001/jama.2020.21720		NOV 2020	1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD9VK	33180115	Bronze			2023-01-03	WOS:000592281900002
J	Chakravarthy, R; Stallings, SC; Williams, M; Hollister, M; Davidson, M; Canedo, J; Wilkins, CH				Chakravarthy, Rohini; Stallings, Sarah C.; Williams, Michael; Hollister, Megan; Davidson, Mario; Canedo, Juan; Wilkins, Consuelo H.			Factors influencing precision medicine knowledge and attitudes	PLOS ONE			English	Article							AFRICAN-AMERICAN; RESEARCH PARTICIPATION; SOCIOECONOMIC-STATUS; GENETIC TESTS; UNITED-STATES; INFORMATION; DIVERSITY; RECRUITMENT; BARRIERS; GENOMICS	Precision medicine holds great promise for improving health and reducing health disparities that can be most fully realized by advancing diversity and inclusion in research participants. Without engaging underrepresented groups, precision medicine could not only fail to achieve its promise but also further exacerbate the health disparities already burdening the most vulnerable. Yet underrepresentation by people of non-European ancestry continues in precision medicine research and there are disparities across racial groups in the uptake of precision medicine applications and services. Studies have explored possible explanations for population differences in precision medicine participation, but full appreciation of the factors involved is still developing. To better inform the potential for addressing health disparities through PM, we assessed the relationship of precision medicine knowledge and trust in biomedical research with sociodemographic variables. Using a series of linear regression models applied to survey data collected in a diverse sample, we analyzed variation in both precision medicine knowledge and trust in biomedical research with socioeconomic factors as a way to understand the range of precision medicine knowledge (PMK) in a broadly representative group and its relationship to trust in research and demographic characteristics. Our results demonstrate that identifying as Black, while significantly PMK, explains only 1.5% of the PMK variance in unadjusted models and 7% of overall variance in models adjusted for meaningful covariates such as age, marital status, employment, and education. We also found a positive association between PMK and trust in biomedical research. These results indicate that race is a factor affecting PMK, even after accounting for differences in sociodemographic variables. Additional work is needed, however, to identify other factors contributing to variation in PMK as we work to increase diversity and inclusion in precision medicine applications.	[Chakravarthy, Rohini] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Stallings, Sarah C.; Wilkins, Consuelo H.] Meharry Vanderbilt Alliance, Nashville, TN 37208 USA; [Williams, Michael; Hollister, Megan; Davidson, Mario] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Canedo, Juan; Wilkins, Consuelo H.] Vanderbilt Univ, Med Ctr, Dept Med, Div Geriatr, Nashville, TN 37232 USA	Vanderbilt University; Meharry Medical College; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wilkins, CH (corresponding author), Meharry Vanderbilt Alliance, Nashville, TN 37208 USA.; Wilkins, CH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Geriatr, Nashville, TN 37232 USA.	consuelo.h.wilkins@vanderbilt.edu	Davidson, Mario/AAX-1102-2021	Chakravarthy, Rohini/0000-0001-9640-8200	Patient-Centered Outcomes Research Institute [R-1306-04869]; Vanderbilt Institute for Clinical and Translational Research [5UL1TR000445-09]; Vanderbilt Medical Scholars Research Program; Vanderbilt-Meharry Alliance	Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); Vanderbilt Institute for Clinical and Translational Research; Vanderbilt Medical Scholars Research Program; Vanderbilt-Meharry Alliance	This project was made possible via Patient-Centered Outcomes Research Institutefunded grant (R-1306-04869, https://www.pcori.org/) (CW), Vanderbilt Institute for Clinical and Translational Research (https://victr.vumc.org/about-victr-2/) 5UL1TR000445-09 (CW), The Vanderbilt Medical Scholars Research Program (https://medschool.vanderbilt.edu/curriculum/medical-scholars-program/) (RC), and the Vanderbilt-Meharry Alliance (https://www.vumc.org/meharry-vanderbilt/welcome) (SS).	Agurs-Collins T, 2015, J CANCER EDUC, V30, P799, DOI 10.1007/s13187-014-0784-x; All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; [Anonymous], 2018, WHAT IS PREC MED; Aronson SJ, 2015, NATURE, V526, P336, DOI 10.1038/nature15816; Baty BJ, 2003, AM J MED GENET A, V118A, P146, DOI 10.1002/ajmg.a.10150; Bentley AR, 2017, J COMMUN GENET, V8, P255, DOI 10.1007/s12687-017-0316-6; Catz DS, 2005, COMMUNITY GENET, V8, P161, DOI 10.1159/000086759; Cheng JKY, 2018, J COMMUN GENET, V9, P263, DOI 10.1007/s12687-017-0350-4; Diaz VA, 2014, PUBLIC HEALTH GENOM, V17, P1, DOI 10.1159/000354785; Dye T, 2016, J AM MED INFORM ASSN, V23, P782, DOI 10.1093/jamia/ocv214; Erves J, J CLIN TRANSLATIONAL; Farmer DF, 2007, J HEALTH CARE POOR U, V18, P85, DOI 10.1353/hpu.2007.0008; Gadegbeku CA, 2008, CONTEMP CLIN TRIALS, V29, P837, DOI 10.1016/j.cct.2008.06.001; George S, 2014, AM J PUBLIC HEALTH, V104, pE16, DOI 10.2105/AJPH.2013.301706; Haga SB, 2012, PHARMACOGENOMICS J, V12, P197, DOI 10.1038/tpj.2011.1; Hahn S, 2010, PUBLIC HEALTH GENOM, V13, P63, DOI 10.1159/000218712; Hall MA, 2006, MED CARE, V44, P1048, DOI 10.1097/01.mlr.0000228023.37087.cb; Hauser D, 2018, HEALTH AFFAIR, V37, P793, DOI 10.1377/hlthaff.2017.1548; Heerman WJ, 2017, CONTEMP CLIN TRIALS, V62, P50, DOI 10.1016/j.cct.2017.08.006; Herring P, 2004, ETHNIC DIS, V14, P423; Hurle B, 2013, GENET MED, V15, P658, DOI 10.1038/gim.2013.14; Kaufman DJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160461; Landry LG, 2018, HEALTH AFFAIR, V37, P780, DOI 10.1377/hlthaff.2017.1595; Lennerz JK, 2016, J MOL DIAGN, V18, P697, DOI 10.1016/j.jmoldx.2016.04.003; Lewis KL, 2019, GENET MED, V21, P1355, DOI 10.1038/s41436-018-0341-9; Mainous AG, 2006, ANN FAM MED, V4, P247, DOI 10.1370/afm.541; Mamun A, 2019, ETHNIC DIS, V29, P517, DOI 10.18865/ed.29.3.517; McCarty CA, 2011, AM J MED GENET A, V155A, P737, DOI 10.1002/ajmg.a.33896; Molina Y, 2015, HEALTH EXPECT, V18, P2941, DOI 10.1111/hex.12278; Mouton CP, 1997, J NATL MED ASSOC, V89, P721; Moy E, 2014, PUBLIC HEALTH REP, V129, P62, DOI 10.1177/00333549141291S212; National Academies of Sciences Engineering and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Roundtable on Genomics and Precision Health., 2018, UND DISP ACC GEN MED; Need AC, 2009, TRENDS GENET, V25, P489, DOI 10.1016/j.tig.2009.09.012; Papaz T, 2012, PEDIATRICS, V130, pE1198, DOI 10.1542/peds.2012-0687; Popejoy AB, 2016, NATURE, V538, P161, DOI 10.1038/538161a; Rastogi S., 2011, BLACK POPULATION 201; Richardson A, 2012, J HEALTH CARE POOR U, V23, P1477, DOI 10.1353/hpu.2012.0181; Rothman R., 2019, NETWORK SUMMARY MID, P3; Roundtable on Health Literacy Board on Population Health and Public Health Practice Health and Medicine Division National Academies of Sciences Engineering and Medicine, 2016, REL HLTH LIT PREC ME; Scherr CL, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00548; Shields AE, 2008, GENET MED, V10, P404, DOI 10.1097/GIM.0b013e3181770184; Slomka J, 2008, AIDS CARE, V20, P1224, DOI 10.1080/09540120701866992; Smedley BD., 2003, COMMITTEE UNDERSTAND; Smith CE, 2016, HEALTH AFFAIR, V35, P1367, DOI 10.1377/hlthaff.2015.1476; Smith YR, 2007, J WOMENS HEALTH, V16, P423, DOI 10.1089/jwh.2006.0124; Spruill Ida, 2009, J Natl Black Nurses Assoc, V20, P20; Symonds RP, 2012, BRIT J CANCER, V107, P1017, DOI 10.1038/bjc.2012.240; The Mid-South Clinical Data Research Network-Phase I, 2014, MID S CLIN DATA RES; Thompson HS, 2003, PATIENT EDUC COUNS, V51, P217, DOI 10.1016/S0738-3991(02)00219-7; Trinh-Shevrin C, 2018, J RACIAL ETHN HEALTH, V5, P1, DOI 10.1007/s40615-016-0334-9; Viswanath K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014550; Wilkins CH, 2019, HEALTH AFFAIR, V38, P399, DOI 10.1377/hlthaff.2018.05046; Williams JR, 2019, J GENET COUNS, V28, P59, DOI 10.1007/s10897-018-0291-z; Wojcik GL, 2019, NATURE, V570, P514, DOI 10.1038/s41586-019-1310-4	54	2	2	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2020	15	11							e0234833	10.1371/journal.pone.0234833	http://dx.doi.org/10.1371/journal.pone.0234833			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OY0LY	33175834	Green Submitted, gold, Green Published			2023-01-03	WOS:000593946900015
J	Kobo, O; Efraim, R; Saada, M; Kofman, N; Abu Dogosh, A; Abramowitz, Y; Aronson, D; Minha, S; Roguin, A; Meisel, SR				Kobo, Ofer; Efraim, Roi; Saada, Majdi; Kofman, Natalia; Abu Dogosh, Ala; Abramowitz, Yigal; Aronson, Doron; Minha, Sa'ar; Roguin, Ariel; Meisel, Simcha R.			The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing of presentation and early outcomes of patients with ST-elevation myocardial infarction	PLOS ONE			English	Article							DEATH	Introduction Early reports described decreased admissions for acute cardiovascular events during the SarsCoV-2 pandemic. We aimed to explore whether the lockdown enforced during the SARSCoV-2 pandemic in Israel impacted the characteristics of presentation, reperfusion times, and early outcomes of ST-elevation myocardial infarction (STEMI) patients. Methods A multicenter prospective cohort comprising all STEMI patients treated by primary percutaneous coronary intervention admitted to four high-volume cardiac centers in Israel during lockdown (20/3/2020-30/4/2020). STEMI patients treated during the same period in 2019 served as controls. Results The study comprised 243 patients, 107 during the lockdown period of 2020 and 136 during the same period in 2019, with no difference in demographics and clinical characteristics. Patients admitted in 2020 had higher admission and peak troponin levels, had a 2.4 fold greater likelihood of Door-to-balloon times> 90 min (95%CI: 1.2-4.9, p = 0.01) and 3.3 fold greater likelihood of pain-to-balloon times> 12 hours (OR 3.3, 95%CI: 1.3-8.1, p<0.01). They experienced higher rates hemodynamic instability (25.2% vs 14.7%, p = 0.04), longer hospital stay (median, IQR [4, 3-6 Vs 5, 4-6, p = 0.03]), and fewer early (<72 hours) discharge (12.4% Vs 32.4%, p<0.001). Conclusions The lockdown imposed during the SARSCoV-2 pandemic was associated with a significant lag in the time to reperfusion of STEMI patients. Measures to improves this metric should be implemented during future lockdowns.	[Kobo, Ofer; Saada, Majdi; Roguin, Ariel; Meisel, Simcha R.] Hillel Yaffe Med Ctr, Dept Cardiol, Hadera, Israel; [Efraim, Roi; Aronson, Doron] Rambam Hlth Care Campus, Dept Cardiol, Haifa, Israel; [Kofman, Natalia; Minha, Sa'ar] Shamir Med Ctr, Dept Cardiol, Zerifin, Israel; [Kofman, Natalia; Minha, Sa'ar] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Abu Dogosh, Ala; Abramowitz, Yigal] Ben Gurion Univ Negev, Soroka Univ, Fac Hlth Sci, Dept Cardiol,Med Ctr, Beer Sheva, Israel; [Aronson, Doron; Roguin, Ariel; Meisel, Simcha R.] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel	Rambam Health Care Campus; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Soroka Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kobo, O (corresponding author), Hillel Yaffe Med Ctr, Dept Cardiol, Hadera, Israel.	Ofermkobo@gmail.com	Meisel, Simcha/AAH-8985-2021; Kobo, Ofer/AAT-6700-2021; Aronson, Doron/F-3390-2010	Kobo, Ofer/0000-0001-7418-498X; Meisel, Simcha/0000-0002-2041-2833				Allegra JR, 2005, J URBAN HEALTH, V82, P358, DOI 10.1093/jurban/jti087; De Filippo O, 2020, NEW ENGLAND J MED; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; De Rosa R, 2021, EUR HEART J-ACUTE CA, V10, P1160, DOI 10.1177/2048872620920475; Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Leor J, 1996, NEW ENGL J MED, V334, P413, DOI 10.1056/NEJM199602153340701; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314; Nepper-Christensen L, 2021, EUR HEART J-ACUTE CA, V10, P523, DOI 10.1177/2048872619886312; Secco GG, 2021, CATHETER CARDIO INTE, V97, P195, DOI 10.1002/ccd.28959; Swerdel JN, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001354; Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631	13	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2020	15	10							e0241149	10.1371/journal.pone.0241149	http://dx.doi.org/10.1371/journal.pone.0241149			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ON4BV	33095801	Green Published, gold			2023-01-03	WOS:000586649400039
J	Gashaye, KT; Tsegaye, AT; Abebe, SM; Woldetsadik, MA; Ayele, TA; Gashaw, ZM				Gashaye, Kiros Terefe; Tsegaye, Adino Tesfahun; Abebe, Solomon Mekonnen; Woldetsadik, Mulat Adefris; Ayele, Tadesse Awoke; Gashaw, Zelalem Mengistu			Determinants of long acting reversible contraception utilization in Northwest Ethiopia: An institution-based case control study	PLOS ONE			English	Article							UNINTENDED PREGNANCY; YOUNG-WOMEN; IUD USE; IMPLANTS; ATTITUDES; SAFETY	Background Though long-acting reversible contraceptives (LARCs) are highly effective, have minimal side effects, require minimal follow-up, and are low cost, only 10% of contraceptives used in Ethiopia are LARCs. The reason for this low uptake is not understood at the country or regional level. Therefore, this study identified determinants of LARC utilization in Northwest Ethiopia. Methods A facility-based unmatched case control study, using LARC users as cases and short- acting reversible contraception (SARC) users as controls, had been conducted at fourteen public health institutions in Northwest Ethiopia. A systematic random sampling technique was used to select participants with a 1:2 case to control ratio (n = 1167). Binary logistic regression analysis was used to identify determinants of LARC utilization among family planning service users. Results Wealth status [AOR:1.87, 95%CI (1.08, 3.24)], history of abortion [AOR:2.69, 95%CI (1.41, 5.12)], limiting family size [AOR: 2.38, 95%CI (1.01, 5.62)], good knowledge about LARCs [AOR: 2.52, 95%CI (1.17, 5.41)], method convenience [AOR: 0.23, 95%CI (0.16, 0.34)], good availability of method [AOR:0.10 (0.05, 0.19)], less frequent visits to health facility [AOR:2.95, 95% CI(1.89, 4.62)], health care providers advice [AOR:10.69, 95%CI (3.27, 34.87)], partner approval [AOR:0.66, 95%CI (0.45, 0.97)], and favorable attitude towards LARCs [AOR:13.0, 95%CI (8.60, 19.72)] were significantly associated with LARC utilization. Conclusion Professional support, favorable attitude towards LARC use, high economic status, history of abortion, advantage of less frequent visits, having good knowledge towards LARC and interest of limiting births were significantly associated with LARC Utilization. On the other hand, perceived method convenience, and contraception availability were inversely associated with it. Family planning education about the benefits of LARC should be done by health providers and media. Male involvement in the counselling and decision making about the advantage of using LARC may improve the negative influence of partners on LARC utilization. It is also recommended that, future qualitative research further explore perceptions of LARC use.	[Gashaye, Kiros Terefe; Woldetsadik, Mulat Adefris; Gashaw, Zelalem Mengistu] Univ Gondar, Sch Med, Dept Obstet & Gynecol, Coll Med & Hlth Sci, Gondar, Ethiopia; [Tsegaye, Adino Tesfahun; Ayele, Tadesse Awoke] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Coll Med & Hlth Sci, Gondar, Ethiopia; [Abebe, Solomon Mekonnen] Univ Gondar, Inst Publ Hlth, Dept Nutr, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Gashaye, KT (corresponding author), Univ Gondar, Sch Med, Dept Obstet & Gynecol, Coll Med & Hlth Sci, Gondar, Ethiopia.	hemenkiros2@gmail.com			Pre-Publication Support Service (PREPSS)	Pre-Publication Support Service (PREPSS)	The authors are very grateful that Pre-Publication Support Service (PREPSS) supported the development of this manuscript by providing pre-publication peer-review and copy editing. We would like to acknowledge the study participants for their time and willingness to participate.	Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; Alemayehu M, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0229-7; Alemayehu M, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-6; [Anonymous], 2011, FAM PLANN GLOB HDB P; [Anonymous], 2020, BMC PUBLIC HEALTH; [Anonymous], 2017, ECONOMICS-KIEL, V6, P1, DOI 10.1057/s11369-017-0051-3; Asker C, 2006, J FAM PLAN REPROD H, V32, P89, DOI 10.1783/147118906776276170; Bailey MJ, 2014, CESIFO ECON STUD, V60, P312, DOI 10.1093/cesifo/ifu011; Berek S, 2012, BEREK NOVAKS GYNECOL; Black KI, 2010, BEST PRACT RES CL OB, V24, P443, DOI 10.1016/j.bpobgyn.2010.02.002; Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026; Bongaarts J., 2012, FAMILY PLANNING PROG; Bracken J, 2014, EUR J CONTRACEP REPR, V19, P276, DOI 10.3109/13625187.2014.917623; Bulto GA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-46; Carey MS, 2012, OBSTET GYNAECOL, V14, P223, DOI 10.1111/j.1744-4667.2012.00126.x; Central statstical agency of Ethiopia, 2007, POP HOUS CENS ETH; Crede S, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-197; Dhont N, 2009, EUR J CONTRACEP REPR, V14, P420, DOI 10.3109/13625180903340584; Gariepy AM, 2014, CONTRACEPTION, V90, P174, DOI 10.1016/j.contraception.2014.03.010; Garrett CC, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0227-9; Gebreyesus B, 2015, AM J ADV NURS RES, V2, P36; Gilmore K, 2015, J ADOLESCENT HEALTH, V56, P658, DOI 10.1016/j.jadohealth.2015.02.016; Greenberg KB, 2013, J ADOLESCENT HEALTH, V52, P372, DOI 10.1016/j.jadohealth.2012.11.003; Habtamu A, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4445-3; Haimovich S, 2009, EUR J CONTRACEP REPR, V14, P187, DOI 10.1080/13625180902741436; Hoffman BL., 2016, WILLIAMS GYNECOLOGY; Hubacher D, 2015, CONTRACEPTION, V92, P382, DOI 10.1016/j.contraception.2015.06.115; Hubacher D, 2008, CONTRACEPTION, V78, P73, DOI 10.1016/j.contraception.2008.03.002; Hubachera D., 2008, Contraception, V78, P73, DOI 10.1016/j.contraception.2008.03.002; Joshi R, 2015, INT J GYNECOL OBSTET, V131, pS60, DOI 10.1016/j.ijgo.2015.04.024; Katz KR, 2002, INT FAM PLAN PERSPEC, V28, P26, DOI 10.2307/3088272; Kohan Shahnaz, 2014, Iran J Nurs Midwifery Res, V19, P451; Kumari SS, 2016, J OBSTET GYN INDIA, V66, P149, DOI 10.1007/s13224-016-0866-2; Leaf healthcare, 2015, CISC VIS NETW IND GL, P1; Madden T, 2011, CONTRACEPTION, V84, P571, DOI 10.1016/j.contraception.2011.03.018; Mavranezouli I, 2008, HUM REPROD, V23, P1338, DOI 10.1093/humrep/den091; Mekonnen G, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.98.3421; Mekonnen W, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-37; Meskele M, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-109; Mestad R, 2011, CONTRACEPTION, V84, P493, DOI 10.1016/j.contraception.2011.03.001; Moreau C, 2014, CONTRACEPTION, V89, P9, DOI 10.1016/j.contraception.2013.10.003; Moreau C, 2013, FERTIL STERIL, V100, P451, DOI 10.1016/j.fertnstert.2013.04.002; Mota K, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0209-y; Mutombo N, 2014, REPROD HLTH J, V11, P1; Mutombo N, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004643; Ochako R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1483-1; Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad; Schwingl PJ, 2000, FERTIL STERIL, V73, P923, DOI 10.1016/S0015-0282(00)00482-9; Stoddard A, 2011, DRUGS, V71, P969, DOI 10.2165/11591290-000000000-00000; Melka AS, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.246.5835; Teferra AS, 2015, SCIENCE, V3, P143; Teferra AS., 2015, SCI J PUBLIC HLTH, V3, P143, DOI DOI 10.11648/J.SJPH; Tsegaye Tegenu P.D, 2013, EXPONENTIAL POPULATI; White K, 2013, WOMEN HEALTH ISS, V23, pE257, DOI 10.1016/j.whi.2013.05.001; Winner B, 2012, OBSTET GYNECOL SURV, V67, P552; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855; World Health Organization, 2011, FAMILY PLANNING GLOB; Xu HN, 2012, OBSTET GYNECOL, V120, P21, DOI 10.1097/AOG.0b013e318259565a; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	64	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 20	2020	15	10							e0240816	10.1371/journal.pone.0240816	http://dx.doi.org/10.1371/journal.pone.0240816			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OM3QJ	33079973	gold, Green Published			2023-01-03	WOS:000585940600028
J	Chen, ZB; Rollo, B; Antonic-Baker, A; Anderson, A; Ma, YL; O'Brien, TJ; Ge, ZY; Wang, XF; Kwan, P				Chen, Zhibin; Rollo, Ben; Antonic-Baker, Ana; Anderson, Alison; Ma, Yuanlin; O'Brien, Terence J.; Ge, Zongyuan; Wang, Xuefeng; Kwan, Patrick			New era of personalised epilepsy management	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ANTIEPILEPTIC DRUGS; DRAVET SYNDROME; MORTALITY; MODEL		[Chen, Zhibin; Ma, Yuanlin; Wang, Xuefeng; Kwan, Patrick] Chongqing Med Univ, Chongqing Key Lab Neurol, Affiliated Hosp 1, Chongqing, Peoples R China; [Chen, Zhibin; Rollo, Ben; Antonic-Baker, Ana; Anderson, Alison; O'Brien, Terence J.; Kwan, Patrick] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic, Australia; [Chen, Zhibin; Kwan, Patrick] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [O'Brien, Terence J.; Kwan, Patrick] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia; [Ge, Zongyuan] Monash Univ, Fac Engn, Melbourne, Vic, Australia; [Ge, Zongyuan] Monash Univ, eRes Ctr, Melbourne, Vic, Australia; [Ge, Zongyuan] Airdoc Res Australia, Melbourne, Vic, Australia	Chongqing Medical University; Monash University; Monash University; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Kwan, P (corresponding author), Chongqing Med Univ, Chongqing Key Lab Neurol, Affiliated Hosp 1, Chongqing, Peoples R China.; Kwan, P (corresponding author), Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic, Australia.; Kwan, P (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.; Kwan, P (corresponding author), Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia.	patrick.kwan@monash.edu	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021; Anotnic-Baker, Ana/K-6361-2019; Chen, Zhibin/T-1567-2017	O'Brien, Terence/0000-0002-7198-8621; Anotnic-Baker, Ana/0000-0003-4275-7557; Rollo, Benjamin/0000-0001-6907-3468; Ge, Zongyuan/0000-0002-5880-8673; Chen, Zhibin/0000-0002-1888-6917	National Health and Medical Research Council (NHMRC) of Australia [GNT1156444]; Medical Research Future Fund (MRFF) from the NHMRC of Australia [MRF1136427]; MRFF Stem Cell Therapies grant [APP1201781]; Biscayne; Eisai; GW Pharmaceuticals; LivaNova; Novartis; UCB Pharma; Zynerba; NHMRC of Australia [APP1091593]; Royal Melbourne Hospital Neuroscience Foundation	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Future Fund (MRFF) from the NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); MRFF Stem Cell Therapies grant(Medical Research Future Fund (MRFF)); Biscayne; Eisai(Eisai Co Ltd); GW Pharmaceuticals; LivaNova; Novartis(Novartis); UCB Pharma(UCB Pharma SA); Zynerba; NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Royal Melbourne Hospital Neuroscience Foundation	We have read and understood BMJ policy on declaration of interests and have the following interests to declare: ZC is supported by an early career fellowship from the National Health and Medical Research Council (NHMRC) of Australia (GNT1156444). PK is supported by a Medical Research Future Fund (MRFF) from the NHMRC of Australia (MRF1136427). PK and BR are supported by a MRFF Stem Cell Therapies grant (APP1201781). His institution has received speaker or consultancy fees and/or research grants from Biscayne, Eisai, GW Pharmaceuticals, LivaNova, Novartis, UCB Pharma and Zynerba. TOB is supported by a programme grant from the NHMRC of Australia (APP1091593), and the Royal Melbourne Hospital Neuroscience Foundation. AAB, AA, YM, ZG, and XW report no conflicts of interest.	Bell GS, 2010, J NEUROL NEUROSUR PS, V81, P716, DOI 10.1136/jnnp.2008.170837; Bjellvi J, 2019, NEUROLOGY, V93, pE159, DOI 10.1212/WNL.0000000000007753; Catterall WA, 2018, CURR OPIN PHYSIOL, V2, P42, DOI 10.1016/j.cophys.2017.12.007; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chen ZB, 2018, JAMA NEUROL, V75, P279, DOI 10.1001/jamaneurol.2017.3949; Chen ZB, 2016, NEUROLOGY, V87, P718, DOI 10.1212/WNL.0000000000002984; Covert I, TEMPORAL GRAPH CONVO; Delen D, 2020, HEALTH INFORM J, V26, P449, DOI 10.1177/1460458219833120; Devinsky O, 2016, EPILEPSY BEHAV, V56, P32, DOI 10.1016/j.yebeh.2015.12.039; Duckrow RB, 2007, EPILEPSIA, V48, P1614, DOI 10.1111/j.1528-1167.2007.01091.x; Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z; Fiest KM, 2017, NEUROLOGY, V88, P296, DOI 10.1212/WNL.0000000000003509; Firkin AL, 2015, EPILEPSIA, V56, P1534, DOI 10.1111/epi.13127; Higurashi N, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-19; Jing J, 2020, JAMA NEUROL, V77, P103, DOI 10.1001/jamaneurol.2019.3485; Kuhlmann L, 2018, NAT REV NEUROL, V14, P618, DOI 10.1038/s41582-018-0055-2; Kumari D, 2015, STEM CELL TRANSL MED, V4, P800, DOI 10.5966/sctm.2014-0278; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lamberink HJ, 2020, LANCET NEUROL, V19, P748, DOI 10.1016/S1474-4422(20)30220-9; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; LEE JB, 2020, BIOINFORMATICS, V29, P393, DOI DOI 10.1044/2019_AJSLP-CAC48-18-0220; Liang MX, 2015, IEEE ACM T COMPUT BI, V12, P928, DOI 10.1109/TCBB.2014.2377729; Mertens J, 2015, NATURE, V527, P95, DOI 10.1038/nature15526; National Institute for Health and Care Excellence, 2012, EP DIAGN MAN CLIN GU, V137; Perucca E, 2020, LANCET NEUROL, V19, P544, DOI 10.1016/S1474-4422(20)30035-1; Perucca P, 2017, EPILEPSY RES, V131, P1, DOI 10.1016/j.eplepsyres.2017.02.001; Ribeiro MT, 2016, P 22 ACM SIGKDD INT; Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI 10.1146/annurev-bioeng-071516-044442; Shi XY, 2016, BRAIN DEV-JPN, V38, P40, DOI 10.1016/j.braindev.2015.06.008; Shickel B, 2018, IEEE J BIOMED HEALTH, V22, P1589, DOI 10.1109/JBHI.2017.2767063; Thomas RH, 2014, NAT REV NEUROL, V10, P283, DOI 10.1038/nrneurol.2014.62; Trujillo CA, 2019, CELL STEM CELL, V25, P558, DOI 10.1016/j.stem.2019.08.002; Tschandl P, 2020, NAT MED, V26, P1229, DOI 10.1038/s41591-020-0942-0; van der Maaten L, 2014, J MACH LEARN RES, V15, P3221; Yu FH, 2006, NAT NEUROSCI, V9, P1142, DOI 10.1038/nn1754; 2019, AM J HUM GENET, V105, P267	36	13	13	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 9	2020	371								m3658	10.1136/bmj.m3658	http://dx.doi.org/10.1136/bmj.m3658			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC9CF	33037001	Green Published, hybrid			2023-01-03	WOS:000579451800002
J	Wan, KS; Moy, FM; Yusof, KM; Mustapha, FI; Ali, ZM; Hairi, NN				Wan, Kim Sui; Moy, Foong Ming; Mohd Yusof, Khalijah; Mustapha, Feisul Idzwan; Mohd Ali, Zainudin; Hairi, Noran Naqiah			Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study	PLOS ONE			English	Article							TREATMENT INTENSIFICATION; THERAPY; PEOPLE; HYPERGLYCEMIA; ADHERENCE	Background Clinical inertia can lead to poor glycemic control among type 2 diabetes patients. However, there is paucity of information on clinical inertia in low- and middle-income countries including Malaysia. This study aimed to determine the time to treatment intensification among T2D patients with HbA1c of >= 7% (>= 53 mmol/mol) in Malaysian public health clinics. The proportion of patients with treatment intensification and its associated factors were also determined. Material and methods This was a five-year retrospective open cohort study using secondary data from the National Diabetes Registry. The study setting was all public health clinics (n = 47) in the state of Negeri Sembilan, Malaysia. Time to treatment intensification was defined as the number of years from the index year until the addition of another oral antidiabetic drug or initiation of insulin. Life table survival analysis based on best-worst case scenarios was used to determine the time to treatment intensification. Discrete-time proportional hazards model was fitted for the factors associated with treatment intensification. Results The mean follow-up duration was 2.6 (SD 1.1) years. Of 7,646 patients, the median time to treatment intensification was 1.29 years (15.5 months), 1.58 years (19.0 months) and 2.32 years (27.8 months) under the best-, average- and worst-case scenarios respectively. The proportion of patients with treatment intensification was 45.4% (95% CI: 44.2-46.5), of which 34.6% occurred only after one year. Younger adults, overweight, obesity, use of antiplatelet medications and poorer HbA1c were positively associated with treatment intensification. Patients treated with more oral antidiabetics were less likely to have treatment intensification. Conclusion Clinical inertia is present in the management of T2D patients in Malaysian public health clinics. We recommend further studies in lower- and middle-income countries to explore its causes so that targeted strategies can be developed to address this issue.	[Wan, Kim Sui; Moy, Foong Ming; Hairi, Noran Naqiah] Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur, Malaysia; [Wan, Kim Sui; Mohd Yusof, Khalijah; Mohd Ali, Zainudin] State Hlth Dept Negeri Sembilan, Seremban, Malaysia; [Mustapha, Feisul Idzwan] Minist Hlth, Dis Control Div, Putrajaya, Malaysia; [Mohd Yusof, Khalijah] State Hlth Dept Johor, Johor Baharu, Malaysia	Universiti Malaya; Kementerian Kesihatan Malaysia	Moy, FM (corresponding author), Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur, Malaysia.	moyfm@ummc.edu.my	HAIRI, NORAN/B-9339-2010; Wan, Kim Sui/ABC-1576-2021; Moy, Foong Ming/B-7899-2010	HAIRI, NORAN/0000-0002-2692-9016; Moy, Foong Ming/0000-0002-0306-4419; Wan, Kim Sui/0000-0002-0859-1648				American Diabetes Association, 2018, Diabetes Care, V41, pS55, DOI 10.2337/dc18-S006; [Anonymous], 2019, BMJ-BRIT MED J, V367, pl6131; [Anonymous], 2015, WORLD POP AG 2015 HI; Aris T, 2015, NATL HLTH MORBIDITY, VII; Arnold RJG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199011; Cahn A, 2015, DIABETES CARE, V38, P2293, DOI 10.2337/dc15-0187; Department of statistics, 2020, DEM STAT 1 Q; Department of Statistics Malaysia, 2019, ABR LIF TABL MAL 201; Fu AZ, 2011, DIABETES OBES METAB, V13, P765, DOI 10.1111/j.1463-1326.2011.01405.x; Garcia-Perez LE, 2013, DIABETES THER, V4, P175, DOI 10.1007/s13300-013-0034-y; Hair J.F., 2010, MULTIVARIATE DATA AN, Vseventh; Higgins JPT, 2008, CLIN TRIALS, V5, P225, DOI 10.1177/1740774508091600; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Inzucchi SE, 2015, DIABETES CARE, V38, P140, DOI 10.2337/dc14-2441; Kallenbach L, 2018, ENDOCR PRACT, V24, P805, DOI 10.4158/EP-2017-0261; Khunti K, 2016, DIABETES OBES METAB, V18, P401, DOI 10.1111/dom.12626; Khunti K, 2018, DIABETES OBES METAB, V20, P427, DOI 10.1111/dom.13088; Malaysia MoH, 2015, CLIN PRACTICE GUIDEL, V5th; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McEwen LN, 2009, DIABETES CARE, V32, P971, DOI 10.2337/dc08-1911; Ministry of Health Malaysia, 2013, NATL DIABETES REGIST, V1; Ministry of Health Malaysia, 2008, MAN PENGG AUD KLIN D; Pantalone KM, 2018, DIABETES CARE, V41, pE113, DOI 10.2337/dc18-0116; Pantalone KM, 2016, DIABETES CARE, V39, P1527, DOI 10.2337/dc16-0227; Paul SK, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-015-0178-3; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Pirela DV, 2019, ENDOCR PRACT, V25, P1317, DOI 10.4158/EP-2019-0303; Reach G, 2017, DIABETES METAB, V43, P501, DOI 10.1016/j.diabet.2017.06.003; Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9; Singer J., 2003, APPL LONGITUDINAL DA; Stone MA, 2013, DIABETES CARE, V36, P2628, DOI 10.2337/dc12-1759; Tunceli K., 2015, DIABETES MANAGEMENT, V5, P17, DOI DOI 10.2217/DIABETEST.14.45; Wong ND, 2016, DIABETES CARE, V39, P668, DOI 10.2337/dc15-2439; World Health Organization, 2000, WHO TECHN REP SER, V894	34	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2020	15	10							e0240531	10.1371/journal.pone.0240531	http://dx.doi.org/10.1371/journal.pone.0240531			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3WA	33035261	Green Published, gold			2023-01-03	WOS:000581817500039
J	Rehal, MS; Liebau, F; Wernerman, J; Rooyackers, O				Rehal, Martin Sundstrom; Liebau, Felix; Wernerman, Jan; Rooyackers, Olav			Whole-body protein kinetics in critically ill patients during 50 or 100% energy provision by enteral nutrition: A randomized cross-over study	PLOS ONE			English	Article							PARENTERAL-NUTRITION; CARE; REQUIREMENTS; TURNOVER; INFUSION; THERAPY; ADULTS	Background Enteral nutrition (EN) is a ubiquitous intervention in ICU patients but there is uncertainty regarding the optimal dose, timing and importance for patient-centered outcomes during critical illness. Our research group has previously found an improved protein balance during normocaloric versus hypocaloric parenteral nutrition in neurosurgical ICU patients. We now wanted to investigate if this could be demonstrated in a general ICU population with established enteral feeding, including patients on renal replacement therapy. Methods Patients with EN >80% of energy target as determined by indirect calorimetry were randomized to or 50% or 100% of current EN rate. After 24 hours, whole-body protein kinetics were determined by enteral and parenteral stable isotope tracer infusions. Treatment allocation was then switched, and tracer investigations repeated 24 hours later in a crossover design with patients serving as their own controls. Results Six patients completed the full protocol. During feeding with 100% EN all patients received >1.2 g/kg/day of protein. Mean whole-body protein balance increased from -6.07 to 2.93 mu mol phenylalanine/kg/h during 100% EN as compared to 50% (p = 0.044). The oxidation rate of phenylalanine was unaltered (p = 0.78). Conclusions It is possible to assess whole-body protein turnover using a stable isotope technique in critically ill patients during enteral feeding and renal replacement therapy. Our results also suggest a better whole-body protein balance during full dose as compared to half dose EN. As the sample size was smaller than anticipated, this finding should be confirmed in larger studies.	[Rehal, Martin Sundstrom; Liebau, Felix; Rooyackers, Olav] Karolinska Univ Hosp Huddinge, Dept Perioperat Med & Intens Care PMI, Stockholm, Sweden; [Rehal, Martin Sundstrom; Liebau, Felix; Wernerman, Jan; Rooyackers, Olav] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Anesthesia & Intens Care, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Rehal, MS (corresponding author), Karolinska Univ Hosp Huddinge, Dept Perioperat Med & Intens Care PMI, Stockholm, Sweden.; Rehal, MS (corresponding author), Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Anesthesia & Intens Care, Stockholm, Sweden.	martin.sundstrom@gamil.com		Liebau, Felix/0000-0002-8837-7034	Stockholm City Council [563170]; Swedish Research Council [04210]	Stockholm City Council; Swedish Research Council(Swedish Research CouncilEuropean Commission)	This study was funded by grants to JW from Stockholm City Council (https://www.sll.se/), grant #563170, and the Swedish Research Council (https://www.vr.se/english.html), grant #04210. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1539-3; Allingstrup M.J., 2017, INTENSIVE CARE MED; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Bear DE, 2018, CURR OPIN CLIN NUTR, V21, P417, DOI 10.1097/MCO.0000000000000507; Berg A, 2013, CRIT CARE, V17, DOI 10.1186/cc12837; Cahill NE, 2010, CRIT CARE MED, V38, P395, DOI 10.1097/CCM.0b013e3181c0263d; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chapman M, 2018, NEW ENGL J MED, V379, P1823, DOI 10.1056/NEJMoa1811687; Ferrie S, 2016, JPEN-PARENTER ENTER, V40, P795, DOI 10.1177/0148607115618449; Fetterplace K, 2018, JPEN-PARENTER ENTER, V42, P1252, DOI 10.1002/jpen.1166; Lambell KJ, 2018, JPEN-PARENTER ENTER, V42, P1112, DOI 10.1002/jpen.1151; LARSSON J, 1990, BRIT J SURG, V77, P413, DOI 10.1002/bjs.1800770418; Liebau F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0844-6; Liebau F, 2015, AM J CLIN NUTR, V101, P549, DOI 10.3945/ajcn.114.091934; Liebau F, 2014, CLIN NUTR, V33, P802, DOI 10.1016/j.clnu.2013.11.001; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Oudemans-van Straaten HM, 2012, CRIT CARE, V16, DOI 10.1186/cc11645; Rehal MS, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1892-x; Ridley EJ, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1939-7; Rooyackers O, 2015, CLIN NUTR, V34, P95, DOI 10.1016/j.clnu.2014.01.020; SHAW JHF, 1987, ANN SURG, V205, P288, DOI 10.1097/00000658-198703000-00012; Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037; Sundstrom-Rehal M, 2019, CURR OPIN CLIN NUTR, V22, P146, DOI 10.1097/MCO.0000000000000548; THOMPSON GN, 1989, AM J PHYSIOL, V256, pE631, DOI 10.1152/ajpendo.1989.256.5.E631; Wischmeyer PE, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1736-8; WOLFE RR, 1983, ANN SURG, V197, P163, DOI 10.1097/00000658-198302000-00007	26	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2020	15	10							e0240045	10.1371/journal.pone.0240045	http://dx.doi.org/10.1371/journal.pone.0240045			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OB4VZ	33017434	gold, Green Published			2023-01-03	WOS:000578470500040
J	Faruk, M; Ibrahim, S; Aminu, SM; Adamu, A; Abdullahi, A; Suleiman, AM; Rafindadi, AH; Mohammed, A; Iliyasu, Y; Idoko, J; Saidu, R; Randawa, AJ; Musa, HS; Ntekim, A; Shah, KZ; Abubakar, S; Adoke, KU; Manko, M; Awasum, CA				Faruk, Mohammed; Ibrahim, Sani; Aminu, Surajo Mohammed; Adamu, Ahmed; Abdullahi, Adamu; Suleiman, Aishatu Maude; Rafindadi, Abdulmumini Hassan; Mohammed, Abdullahi; Iliyasu, Yawale; Idoko, John; Saidu, Rakiya; Randawa, Abdullahi Jibril; Musa, Halimatu Sadiya; Ntekim, Atara; Shah, Khalid Zahir; Abubakar, Sani; Adoke, Kasimu Umar; Manko, Muhammad; Awasum, Cheh Agustin			Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin	PLOS ONE			English	Article							ADJUVANT CHEMOTHERAPY; IMMUNE CELLS; FOLLOW-UP; APOPTOSIS; TUMOR; INHIBITOR; COLON; FAMILY; LIVIN; CHEMORADIOTHERAPY	Evasion of apoptosis is associated with treatment resistance and metastasis in colorectal cancer (CRC). Various cellular processes are associated with evasion of apoptosis. These include overexpression of pro-apoptotic proteins (including p53 and PD-L1), anti-apoptotic proteins (BIRC7/Livin and Bcl-2), chemokine receptors (including DARC), and dysregulation of DNA mismatch repair proteins (including MSH2 and PMS2). The aim of this study was to determine the effect of folinic acid, 5-FU and oxaliplatin (FOLFOX) as a single agent and aspirin plus FOLFOX in various combinations on the aforementioned proteins in human CRC, SW480 cell line and rat models of N-Methyl-N-Nitrosourea (NMU)-induced CRC. In addition, effects of the NMU-induced CRC and chemotherapeutic regimens on haematological and biochemical parameters in the rat models were studied. Immunohistochemistry, immunofluorescence and immunoblot techniques were used to study the expression pattern of the related proteins in the human CRC cells pre- and post-treatment. Double contrast barium enema, post-mortem examination and histological analyses were used to confirm tumour growth and the effect of the treatment in vivo in rat models. Notably, we found in human mucinous CRC, a significant increase in expression of the BIRC7/Livin post-FOLFOX treatment compared with pre-treatment (p = 0.0001). This increase provides new insights into the prognostic role of BIRC7/Livin in evasion of apoptosis and facilitation of treatment resistance, local recurrence and metastasis particularly among mucinous CRCs post-FOLFOX chemotherapy. These poor prognostic features in the CRC may be further compounded by the significant suppression of DARC, PD-L1, PMS2 and overexpression of MSH2 and anti-apoptotic Bcl-2 and p53 proteins observed in our study (p < 0.05). Importantly, we found a significant reduction in expression of BIRC7/Livin and reactivation of DARC and PD-L1 with a surge in Annexin V expression in rat models of CRC cells post-treatment with a sequential dose of aspirin plus FOLFOX compared with other treatments in vivo (p <0.05). The mechanistic rational of these effects underscores the importance of expanded concept of possible aspirin combination therapy with FOLFOX sequentially in future CRC management. Validation of our findings through randomized clinical trials of aspirin plus FOLFOX sequentially in patients with CRC is therefore warranted.	[Faruk, Mohammed; Rafindadi, Abdulmumini Hassan; Mohammed, Abdullahi; Iliyasu, Yawale; Idoko, John] Ahmadu Bello Univ, Coll Med Sci, Fac Basic Clin Sci, Dept Pathol, Zaria, Nigeria; [Ibrahim, Sani] Ahmadu Bello Univ, Fac Life Sci, Dept Biochem, Zaria, Nigeria; [Aminu, Surajo Mohammed; Suleiman, Aishatu Maude] Ahmadu Bello Univ, Coll Med Sci, Fac Basic Clin Sci, Dept Haematol & Blood Transfus, Zaria, Nigeria; [Adamu, Ahmed] Ahmadu Bello Univ, Coll Med Sci, Fac Basic Clin Sci, Dept Surg, Zaria, Nigeria; [Abdullahi, Adamu] Ahmadu Bello Univ, Coll Med Sci, Fac Basic Clin Sci, Dept Radiotherapy & Oncol, Zaria, Nigeria; [Saidu, Rakiya] Univ Ilorin, Fac Med, Dept Obstet & Gynaecol, Ilorin, Nigeria; [Saidu, Rakiya] Univ Cape Town, Dept Obstet & Gynaecol, Cape Town, South Africa; [Randawa, Abdullahi Jibril] Ahmadu Bello Univ, Coll Med Sci, Fac Clin Sci, Dept Obstet & Gynaecol, Zaria, Nigeria; [Musa, Halimatu Sadiya; Awasum, Cheh Agustin] Ahmadu Bello Univ Zaria, Vet Teaching Hosp, Dept Vet Surg & Radiol, Zaria, Nigeria; [Ntekim, Atara] Univ Ibadan, Coll Med, Dept Radiat Oncol, Ibadan, Nigeria; [Shah, Khalid Zahir] Nova Med Ctr, Lahore, Pakistan; [Abubakar, Sani] Aminu Kano Univ Teaching Hosp, Dept Pathol, Kano, Nigeria; [Adoke, Kasimu Umar] Fed Med Ctr, Dept Pathol, Birnin Kebbi, Nigeria; [Manko, Muhammad] Ahmadu Bello Univ, Coll Med Sci, Fac Clin Sci, Dept Med, Zaria, Nigeria	Ahmadu Bello University; Ahmadu Bello University; Ahmadu Bello University; Ahmadu Bello University; Ahmadu Bello University; University of Ilorin; University of Cape Town; Ahmadu Bello University; Ahmadu Bello University; University of Ibadan; Ahmadu Bello University	Faruk, M (corresponding author), Ahmadu Bello Univ, Coll Med Sci, Fac Basic Clin Sci, Dept Pathol, Zaria, Nigeria.	fmohammed@abu.edu.ng	mohammed, faruk/AGW-5403-2022; Saidu, Rakiya/A-2275-2019	mohammed, faruk/0000-0003-2319-8948; Saidu, Rakiya/0000-0003-4959-8157; Iliyasu, Yawale/0000-0002-6030-8547; ABDULLAHI, ADAMU/0000-0002-2223-3820; Rafindadi, Abdulmumini/0000-0002-8071-1034; Abubakar, Sani Atta/0000-0002-5013-0706				Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161; [Anonymous], 2017, CANC RES S, V77, pCT030, DOI [10.1158/1538-7445.Am2017-ct030, DOI 10.1158/1538-7445.AM2017-CT030]; Aparicio J, 2005, CLIN COLORECTAL CANC, V5, P263, DOI 10.3816/CCC.2005.n.037; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; Bacso Z, 2000, CANCER RES, V60, P4623; Bashir AIJ, 2019, INT J ONCOL, V54, P1256, DOI 10.3892/ijo.2019.4701; Boland PM, 2017, CANCERS, V9, DOI 10.3390/cancers9050050; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Coyle C, 2016, CURR COLORECT CANC R, V12, P27, DOI 10.1007/s11888-016-0306-9; Deb J, 2011, ONCOL REP, V26, P557, DOI 10.3892/or.2011.1320; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Dibra HK, 2011, INTECH, V30, P743; Ding ZY, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-281; Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4; Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada S, 2020, ADV ANAT PATHOL, V27, P20, DOI 10.1097/PAP.0000000000000247; Hardwick JCH, 2004, CARCINOGENESIS, V25, P1293, DOI 10.1093/carcin/bgh118; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Hodek M, 2016, STRAHLENTHER ONKOL, V192, P632, DOI 10.1007/s00066-016-0988-6; Holowatyj AN, 2016, J CLIN ONCOL, V34, P2148, DOI 10.1200/JCO.2015.65.0994; Hu Z, 2019, NAT GENET, V51, P1113, DOI 10.1038/s41588-019-0423-x; Hugen N, 2013, ANN ONCOL, V24, P2819, DOI 10.1093/annonc/mdt378; Hugen N, 2016, NAT REV CLIN ONCOL, V13, P361, DOI 10.1038/nrclinonc.2015.140; Hugen N, 2015, J PATHOL CLIN RES, V1, P3, DOI 10.1002/cjp2.1; Jenkins BD, 2019, CANCER EPIDEM BIOMAR, V28, P690, DOI 10.1158/1055-9965.EPI-18-0955; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kim EM, 2017, CANCER RES, V77, P3092, DOI 10.1158/0008-5472.CAN-16-2098; Kingham TP, 2013, LANCET ONCOL, V14, pE158, DOI 10.1016/S1470-2045(12)70472-2; Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30093; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Langley RE, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.297; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Liang PS, 2020, CLIN TRANSL GASTROEN, V11, DOI 10.14309/ctg.0000000000000155; Liu KP, 2020, AM J CANCER RES, V10, P78; Liu LY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0512-3; Ma L, 2006, CELL DEATH DIFFER, V13, P2079, DOI 10.1038/sj.cdd.4401959; Mekenkamp LJM, 2012, EUR J CANCER, V48, P501, DOI 10.1016/j.ejca.2011.12.004; Mohelnikova-Duchonova B, 2014, WORLD J GASTROENTERO, V20, P10316, DOI 10.3748/wjg.v20.i30.10316; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Myung DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073262; Negri FV, 2013, ANTICANCER RES, V33, P4611; Oh BY, 2011, WORLD J GASTROENTERO, V17, P2563, DOI 10.3748/wjg.v17.i20.2563; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Sharma A, 2020, J SURG ONCOL, V121, P342, DOI 10.1002/jso.25768; Solomon H, 2018, ONCOGENE, V37, P1669, DOI 10.1038/s41388-017-0060-8; Stark LA, 2007, CARCINOGENESIS, V28, P968, DOI 10.1093/carcin/bgl220; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3; Verbeke H, 2011, CYTOKINE GROWTH F R, V22, P345, DOI 10.1016/j.cytogfr.2011.09.002; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wei YB, 2008, ACTA BIOCH BIOPH SIN, V40, P278, DOI 10.1111/j.1745-7270.2008.00407.x; Williams DS, 2020, MODERN PATHOL, V33, P483, DOI 10.1038/s41379-019-0353-2; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015; Zhang XR, 2017, ONCOTARGET, V8, P42602, DOI 10.18632/oncotarget.16645	66	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0245581	10.1371/journal.pone.0245581	http://dx.doi.org/10.1371/journal.pone.0245581			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY3TH	33465114	gold, Green Published			2023-01-03	WOS:000611969200050
J	Lim, XY; Tan, TYC; Rosli, SHM; Sa'at, MNF; Ali, SS; Mohamed, AFS				Lim, Xin Yi; Chin Tan, Terence Yew; Muhd Rosli, Siti Hajar; Farhan Sa'at, Muhammad Nor; Ali, Syazwani Sirdar; Syed Mohamed, Ami Fazlin			Cannabis sativa subsp. sativa's pharmacological properties and health effects: A scoping review of current evidence	PLOS ONE			English	Review							L. SEED; HEMP SEED; ACETYLCHOLINESTERASE INHIBITORS; CASE SERIES; OPEN-LABEL; ANTIOXIDANT; OIL; CBD; LIPOPOLYSACCHARIDE; NEUROINFLAMMATION	Introduction Hemp (Cannabis sativa subsp. sativa), commonly used for industrial purposes, is now being consumed by the public for various health promoting effects. As popularity of hemp research and claims of beneficial effects rises, a systematic collection of current scientific evidence on hemp's health effects and pharmacological properties is needed to guide future research, clinical, and policy decision making. Objective To provide an overview and identify the present landscape of hemp research topics, trends, and gaps. Methods A systematic search and analysis strategy according to the preferred reporting items for systematic review and meta-analysis-ScR (PRISMA-ScR) checklist on electronic databases including MEDLINE, OVID (OVFT, APC Journal Club, EBM Reviews), Cochrane Library Central and Clinicaltrials.gov was conducted to include and analyse hemp research articles from 2009 to 2019. Results 65 primary articles (18 clinical, 47 pre-clinical) were reviewed. Several randomised controlled trials showed hempseed pills (in Traditional Chinese Medicine formulation MaZiRenWan) improving spontaneous bowel movement in functional constipation. There was also evidence suggesting benefits in cannabis dependence, epilepsy, and anxiety disorders. Pre-clinically, hemp derivatives showed potential anti-oxidative, anti-hypertensive, anti-inflammatory, anti-diabetic, anti-neuroinflammatory, anti-arthritic, anti-acne, and anti-microbial activities. Renal protective effects and estrogenic properties were also exhibited in vitro. Conclusion Current evidence on hemp-specific interventions are still preliminary, with limited high quality clinical evidence for any specific therapeutic indication. This is mainly due to the wide variation in test item formulation, as the multiple variants of this plant differ in their phytochemical and bioactive compounds. Future empirical research should focus on standardising the hemp plant for pharmaceutical use, and uniformity in experimental designs to strengthen the premise of using hemp in medicine.	[Lim, Xin Yi; Chin Tan, Terence Yew; Muhd Rosli, Siti Hajar; Farhan Sa'at, Muhammad Nor; Ali, Syazwani Sirdar; Syed Mohamed, Ami Fazlin] Minist Hlth Malaysia, Inst Med Res, Natl Inst Hlth, Herbal Med Res Ctr, Shah Alam, Selangor, Malaysia	Kementerian Kesihatan Malaysia	Lim, XY (corresponding author), Minist Hlth Malaysia, Inst Med Res, Natl Inst Hlth, Herbal Med Res Ctr, Shah Alam, Selangor, Malaysia.	limxy@imr.gov.my		Tan, Terence/0000-0001-7178-7435; Lim, Xin Yi/0000-0002-2615-3166; Syed Mohamed, Ami Fazlin/0000-0003-2747-951X				Aiello G, 2017, J AGR FOOD CHEM, V65, P10174, DOI 10.1021/acs.jafc.7b03590; Akgun K, 2019, J CENT NERV SYST DIS, V11, DOI 10.1177/1179573519831997; Alagbonsi AI, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2541-5; Jesus CHA, 2019, BRAIN RES, V1715, P156, DOI 10.1016/j.brainres.2019.03.014; [Anonymous], 2017, LANCET HIV, V2017, pPE475; [Anonymous], 2001, EC BRIEFING PENANG S, V3, P5; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; [Anonymous], 2018, VOX             0919; [Anonymous], 2017, LANCET HIV, V2017, pPE475; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, https://doi.org/10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Aukema HM, 2011, MOL NUTR FOOD RES, V55, P1044, DOI 10.1002/mnfr.201000558; Australian Government Department of Health: The Office of Drug Control, 2018, HEMP PRODUCTS; Badowski M, 2017, CANCER CHEMOTH PHARM, V80, P441, DOI 10.1007/s00280-017-3387-5; Ballotta D., 2008, CANNABIS READER GLOB, P97; Banerjee S., 2019, CADTH RAPID RESPONSE; Banks WA, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-S1-S3; Beale C, 2018, CANNABIS CANNABINOID, V3, P94, DOI 10.1089/can.2017.0047; Belardo C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00352; Benson Jr JA, 1999, MARIJUANA MED ASSESS; BHIVA/ BASHH, 2019, HIV MED S2, V20, ps2; Blessing EM, 2015, NEUROTHERAPEUTICS, V12, P825, DOI 10.1007/s13311-015-0387-1; Bridgeman Mary Barna, 2017, P T, V42, P180; Capano A, 2020, POSTGRAD MED, V132, P56, DOI 10.1080/00325481.2019.1685298; Kogel CC, 2018, ADICCIONES, V30, P140, DOI 10.20882/adicciones.858; Chen JW, 2019, ANN PHARMACOTHER, V53, P603, DOI 10.1177/1060028018822124; Chen NY, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4757520; Chen TP, 2012, FOOD CHEM, V134, P1030, DOI 10.1016/j.foodchem.2012.03.009; Cheng CW, 2011, AM J GASTROENTEROL, V106, P120, DOI 10.1038/ajg.2010.305; Cherney JH, 2016, AGRONOMY-BASEL, V6, DOI 10.3390/agronomy6040058; Cicchese JM, 2018, IMMUNOL REV, V285, P147, DOI 10.1111/imr.12671; Citti C, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00120; Colovic MB, 2013, CURR NEUROPHARMACOL, V11, P315, DOI 10.2174/1570159X11311030006; Crescente G, 2018, PHYTOCHEM REV, V17, P733, DOI 10.1007/s11101-018-9556-2; Dale T, 2019, EPILEPSY RES, V151, P31, DOI 10.1016/j.eplepsyres.2019.02.001; Danielewicz D, 2017, CELLULOSE, V24, P5173, DOI 10.1007/s10570-017-1476-6; de Morais H, 2018, NEUROSCI LETT, V682, P62, DOI 10.1016/j.neulet.2018.06.006; Del Bo C, 2019, FOOD RES INT, V119, P469, DOI 10.1016/j.foodres.2018.12.045; Evohemp, 2018, 9 NUTR BEN HEMP SEED; Filippi M, 2018, NAT REV DIS PRIMERS, V4, DOI [10.1038/s41572-018-0046-z, 10.1038/s41572-018-0041-4]; Folch J, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8501693; Frassinetti S, 2018, FOOD CHEM, V262, P56, DOI 10.1016/j.foodchem.2018.04.078; Galimberti D, 2016, EXPERT OPIN INV DRUG, V25, P1181, DOI 10.1080/13543784.2016.1216972; Giacoppo S, 2015, EUR REV MED PHARMACO, V19, P4906; Giacoppo S, 2015, DARU, V23, DOI 10.1186/s40199-015-0131-8; Girgih AT, 2013, PLANT FOOD HUM NUTR, V68, P39, DOI 10.1007/s11130-013-0340-6; GIRGIH AT, 2013, EUROPEAN J NUTR, V53, P1237, DOI DOI 10.1007/S00394-013-0625-4; Guo TT, 2018, FOOD FUNCT, V9, P6609, DOI 10.1039/c8fo01896k; Guy GW, 2005, MIL DRUG TH, P231; Guzman-Martinez L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01008; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Huang T, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00270; Hughes Brendan, 2018, CANNABIS LEGISLATION; Iseppi R, 2019, MOLECULES, V24, DOI 10.3390/molecules24122302; Jeong M, 2014, J ETHNOPHARMACOL, V154, P745, DOI 10.1016/j.jep.2014.04.052; Kaushal N, 2020, NUTR METAB CARDIOVAS, V30, P330, DOI 10.1016/j.numecd.2019.09.006; Lee MJ, 2011, MOL CELLS, V31, P337, DOI 10.1007/s10059-011-0042-6; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Likar R, 2019, ANTICANCER RES, V39, P5797, DOI 10.21873/anticanres.13783; Luo Q, 2017, MOL CELL BIOCHEM, V428, P129, DOI 10.1007/s11010-016-2923-7; Malomo SA, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12897; Malomo SA, 2015, NUTRIENTS, V7, P7616, DOI 10.3390/nu7095358; MBG Health, 2019, 6 SCI BACK BEN HEMP; McPartland JM, 2018, CANNABIS CANNABINOID, V3, P203, DOI 10.1089/can.2018.0039; Mitelpunkt A, 2019, EPILEPSY BEHAV, V98, P233, DOI 10.1016/j.yebeh.2019.07.007; Moccia S, 2020, INT J FOOD SCI NUTR, V71, P410, DOI 10.1080/09637486.2019.1666804; Musio S, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01702; Muthumalage T, 2019, TOXICOL APPL PHARM, V382, DOI 10.1016/j.taap.2019.114713; Neubauer D, 2018, EPILEPSY BEHAV, V81, P79, DOI 10.1016/j.yebeh.2018.02.009; Nitecka-Buchta A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111886; O TM, 2018, OTOLARYNGOL CLIN N A, V51, pxvii; Palmieri B, 2019, CLIN TER, V170, pE93, DOI 10.7417/CT.2019.2116; Palmieri B, 2017, ISR MED ASSOC J, V19, P79; Pietrafusa N, 2019, PEDIATR DRUGS, V21, P283, DOI 10.1007/s40272-019-00341-x; Ren Y, 2016, J FUNCT FOODS, V26, P439, DOI 10.1016/j.jff.2016.07.024; Rezapour-Firouzi S, 2019, RES PHARM SCI, V14, P36, DOI 10.4103/1735-5362.251851; Russo E, 2006, MED HYPOTHESES, V66, P234, DOI 10.1016/j.mehy.2005.08.026; Saberivand A, 2010, METHOD FIND EXP CLIN, V32, P467, DOI 10.1358/mf.2010.32.7.1487085; Sangiovanni E, 2019, PHYTOTHER RES, V33, P2083, DOI 10.1002/ptr.6400; Schussel V, 2018, PHYTOTHER RES, V32, P567, DOI 10.1002/ptr.5975; Shahzad A, 2013, ADV MATER SCI ENG, V2013, DOI 10.1155/2013/325085; Shears J, 2013, ROMANTICISM, V19, P44, DOI 10.3366/rom.2013.0112; Silvestro S, 2019, MOLECULES, V24, DOI 10.3390/molecules24081459; Simmerman E, 2019, J SURG RES, V235, P210, DOI 10.1016/j.jss.2018.08.055; Smeriglio A, 2018, FITOTERAPIA, V127, P101, DOI 10.1016/j.fitote.2018.02.002; Smeriglio A, 2016, PHYTOTHER RES, V30, P1298, DOI 10.1002/ptr.5623; Solowij N, 2018, CANNABIS CANNABINOID, V3, P21, DOI 10.1089/can.2017.0043; Stein DM, 2017, CRIT CARE CLIN, V33, P1, DOI 10.1016/j.ccc.2016.08.008; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Sule-Suso J, 2019, SAGE OPEN MED CASE R, V7, DOI 10.1177/2050313X19832160; Tartaglia N, 2019, CANNABIS CANNABINOID, V4, P3, DOI 10.1089/can.2018.0053; Teh SS, 2016, FOOD CHEM, V203, P199, DOI 10.1016/j.foodchem.2016.02.057; Teh SS, 2015, FOOD CHEM, V187, P460, DOI 10.1016/j.foodchem.2015.04.043; Teh SS, 2014, ANTIOXIDANTS, V3, P67, DOI 10.3390/antiox3010067; Teh SS, 2014, ULTRASON SONOCHEM, V21, P346, DOI 10.1016/j.ultsonch.2013.08.002; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; US Food and Drug Administration, FDA APPR 1 DRUG COMP; Vahanvaty U.S, 2009, ICAN INFANT CHILD AD, V1, P232, DOI [10.1177/1941406409342121, DOI 10.1177/1941406409342121]; VanDolah HJ, 2019, MAYO CLIN PROC, V94, P1840, DOI 10.1016/j.mayocp.2019.01.003; Walitt B, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011694.pub2; Wang SS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030507; Wen ZS, 2019, INT J BIOL MACROMOL, V135, P203, DOI 10.1016/j.ijbiomac.2019.05.082; Werf H. M. G. van der, 1994, Industrial Crops and Products, V2, P219, DOI 10.1016/0926-6690(94)90039-6; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Winklmayr M, 2019, J ORTHOP RES, V37, P2540, DOI 10.1002/jor.24430; Women's Health, 2018, 8 BEN HEMP SEEDS 201; Yan XL, 2015, J AGR FOOD CHEM, V63, P10611, DOI 10.1021/acs.jafc.5b05282; Yousofi M, 2011, DEV PSYCHOBIOL, V53, P402, DOI 10.1002/dev.20534; Zanoni C, 2017, J AGR FOOD CHEM, V65, P8829, DOI 10.1021/acs.jafc.7b02742; Zettl UK, 2016, THER ADV NEUROL DISO, V9, P9, DOI 10.1177/1756285615612659; Zhang YN, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419826547; Zhong LLD, 2019, CLIN GASTROENTEROL H, V17, P1303, DOI 10.1016/j.cgh.2018.04.005; Zhou X, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00201; Zhou YF, 2018, ACS OMEGA, V3, P15988, DOI 10.1021/acsomega.8b02250; Zhou YF, 2018, PHYTOCHEM LETT, V23, P57, DOI 10.1016/j.phytol.2017.11.013; Zimniewska M, 2018, MOLECULES, V23, DOI 10.3390/molecules23081993; Zuardi Antonio W, 2017, Front Pharmacol, V8, P259, DOI 10.3389/fphar.2017.00259	116	7	7	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0245471	10.1371/journal.pone.0245471	http://dx.doi.org/10.1371/journal.pone.0245471			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY3TH	33465140	gold, Green Published			2023-01-03	WOS:000611969200055
J	Xie, WX; Patel, A; Boersma, E; Feng, L; Li, M; Gao, RL; Wu, YF				Xie, Wuxiang; Patel, Anushka; Boersma, Eric; Feng, Lin; Li, Min; Gao, Runlin; Wu, Yangfeng			Chronic kidney disease and the outcomes of fibrinolysis for ST-segment elevation myocardial infarction: A real-world study	PLOS ONE			English	Article							CARDIOVASCULAR EVENTS; SERUM CREATININE; RENAL-DISEASE; ASSOCIATION; MORTALITY; TRIALS; RISK	Background In low-resource regions, fibrinolytic therapy is often the only option for ST-elevation myocardial infarction (STEMI) patients as primary percutaneous coronary intervention (PCI) is often not available and patients are hardly transferred to a medical center with PCI capacity within the first 120 minutes. Chronic kidney disease (CKD) is one of the most frequently encountered complications of STEMI. However, the evidence for the efficacy of fibrinolytic therapy in STEMI patients with CKD is still limited. The aim of this study is to test whether CKD modifies the association between fibrinolytic therapy and short-term major adverse cardiovascular events (MACEs) among patients with STEMI. Methods and findings This is a real-world study analyzing the data from 9508 STEMI patients (mean age: 64.0 +/- 12.4 years; male: 70.1%) in the third phase of Clinical Pathways in Acute Coronary Syndromes program (CPACS-3), which is a large study of the management of acute coronary syndromes (ACS) in 101 county hospitals without PCI capacity in China. CKD was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m(2) at the admission. The primary outcome is short-term MACEs, including all-cause death, recurrent myocardial infarction, or nonfatal stroke. Patients were recruited consecutively between October 2011 and November 2014. Out of them, 1282 patients (13.5%) were classified as having CKD. Compared with non-CKD patients, CKD patients were less likely to receive fibrinolytic therapy than non-CKD patients (26.4% vs. 38.9%, P<0.001), more likely to experience a failed fibrinolytic therapy (32.8% vs. 16.9%), and had a higher risk of short-term MACEs (19.7% vs. 5.6%). After full adjustment, use of fibrinolytic therapy was associated with a significantly lower risk of short-term MACEs in non-CKD patients (relative risk [RR] = 0.87, 95% confidence interval [CI]: 0.76-0.99), but not in CKD patients (P for interaction = 0.026). Further analysis stratified by the success of fibrinolysis showed that compared with patients who did not receive fibrinolytic therapy, patients with successful fibrinolysis had a lower risk of short-term MACEs that was similar between patients with (RR = 0.71, 95% CI: 0.55-0.82) and without CKD (RR = 0.67, 95% CI: 0.55-0.92), while patients with unsuccessful fibrinolysis had a similarly higher risk in CKD patients (RR = 1.25, 95% CI: 1.09-1.43) and non-CKD patients (RR = 1.30, 95% CI: 1.13-1.50). Conclusions CKD reduced the likelihood of successful fibrinolysis and increased the risk of short-term MACEs in patients with STEMI. Attention should be paid to how to improve the success rate of fibrinolytic therapy for STEMI patients with CKD.	[Xie, Wuxiang; Feng, Lin; Wu, Yangfeng] Peking Univ, Clin Res Inst, Hosp 1, Beijing, Peoples R China; [Patel, Anushka] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Boersma, Eric] Erasmus Med Coll, Dept Cardiol, Rotterdam, Netherlands; [Feng, Lin; Wu, Yangfeng] Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing, Peoples R China; [Li, Min] Capital Med Univ, Beijing Friendship Hosp, Clin Epidemiol & EBM Ctr, Beijing, Peoples R China; [Gao, Runlin] Chinese Acad Med Sci, Fuwai Hosp, Dept Cardiol, Beijing, Peoples R China; [Gao, Runlin] Peking Union Med Coll, Beijing, Peoples R China; [Wu, Yangfeng] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hlth Sci Ctr, Beijing, Peoples R China	Peking University; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Erasmus University Rotterdam; Erasmus MC; Peking University; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking University	Wu, YF (corresponding author), Peking Univ, Clin Res Inst, Hosp 1, Beijing, Peoples R China.; Wu, YF (corresponding author), Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing, Peoples R China.; Wu, YF (corresponding author), Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hlth Sci Ctr, Beijing, Peoples R China.	wuyf@bjmu.edu.cn	Xie, Wuxiang/GYU-3990-2022	Wu, Yangfeng/0000-0002-4451-1932; Feng, Lin/0000-0002-6134-4937; Xie, Wuxiang/0000-0001-7527-1022; Patel, Anushka/0000-0003-3825-4092	Sanofi, China; George Institute for Global Health at PUHSC	Sanofi, China(Sanofi-Aventis); George Institute for Global Health at PUHSC	\Source of funding used to support the research and creation of the article is from Sanofi, China, through an unrestricted research grant. The George Institute for Global Health at PUHSC sponsored the study and owns the data. However, the authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Andersson C, 2012, JAMA-J AM MED ASSOC, V308, P882, DOI 10.1001/2012.jama.10779; [Anonymous], 2004, SAS USERS GROUP INT; Charytan D, 2006, KIDNEY INT, V70, P2021, DOI 10.1038/sj.ki.5001934; China Society of Cardiology of Chinese Medical Association Editorial Board of Chinese Journal of Cardiology, 2015, Zhonghua Xin Xue Guan Bing Za Zhi, V43, P380; Coca SG, 2006, JAMA-J AM MED ASSOC, V296, P1377, DOI 10.1001/jama.296.11.1377; Fox CS, 2010, CIRCULATION, V121, P357, DOI 10.1161/CIRCULATIONAHA.109.865352; Gackler A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212237; Gibson CM, 2003, J AM COLL CARDIOL, V42, P1535, DOI 10.1016/j.jacc.2003.06.001; Hobbach HP, 2003, J THROMB THROMBOLYS, V16, P167, DOI 10.1023/B:THRO.0000024055.13207.50; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Li J, 2015, LANCET, V385, P441, DOI 10.1016/S0140-6736(14)60921-1; Li SS, 2015, AM HEART J, V169, P349, DOI 10.1016/j.ahj.2014.12.005; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Medi C, 2009, JACC-CARDIOVASC INTE, V2, P26, DOI 10.1016/j.jcin.2008.09.010; Newsome BB, 2008, ARCH INTERN MED, V168, P609, DOI 10.1001/archinte.168.6.609; O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6; Schiffrin EL, 2007, CIRCULATION, V116, P85, DOI 10.1161/CIRCULATIONAHA.106.678342; Wang HB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016838; Washam JB, 2015, CIRCULATION, V131, P1123, DOI 10.1161/CIR.0000000000000183; Wu YF, 2019, JAMA CARDIOL, V4, P418, DOI 10.1001/jamacardio.2019.0897; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	22	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2021	16	1							e0245576	10.1371/journal.pone.0245576	http://dx.doi.org/10.1371/journal.pone.0245576			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY3TH	33465135	Green Published, gold			2023-01-03	WOS:000611969200017
J	Shoji, M; Sugimoto, M; Matsuno, K; Fujita, Y; Mii, T; Ayaki, S; Takeuchi, M; Yamaji, S; Tanaka, N; Takahashi, E; Noda, T; Kido, H; Tokuyama, T; Tokuyama, T; Tokuyama, T; Kuzuhara, T				Shoji, Masaki; Sugimoto, Minami; Matsuno, Kosuke; Fujita, Yoko; Mii, Tomohiro; Ayaki, Satomi; Takeuchi, Misa; Yamaji, Saki; Tanaka, Narue; Takahashi, Etsuhisa; Noda, Takeshi; Kido, Hiroshi; Tokuyama, Takaaki; Tokuyama, Takahito; Tokuyama, Takashi; Kuzuhara, Takashi			A novel aqueous extract from rice fermented with Aspergillus oryzae and Saccharomyces cerevisiae possesses an anti-influenza A virus activity	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; ANTIVIRAL AGENTS; PHENOLIC PROFILE; INFLUENZA; PEPTIDE; CELLS; RESISTANCE; MICE	Human influenza virus infections occur annually worldwide and are associated with high morbidity and mortality. Hence, development of novel anti-influenza drugs is urgently required. Rice Power(R) extract developed by the Yushin Brewer Co. Ltd. is a novel aqueous extract of rice obtained via saccharization and fermentation with various microorganisms, such as Aspergillus oryzae, yeast [such as Saccharomyces cerevisiae], and lactic acid bacteria, possessing various biological and pharmacological properties. In our previous experimental screening with thirty types of Rice Power(R) extracts, we observed that the 30(th) Rice Power(R) (Y30) extract promoted the survival of influenza A virus-infected Madin-Darby canine kidney (MDCK) cells. Therefore, to identify compounds for the development of novel anti-influenza drugs, we aimed to investigate whether the Y30 extract exhibits anti-influenza A virus activity. In the present study, we demonstrated that the Y30 extract strongly promoted the survival of influenza A H1N1 Puerto Rico 8/34 (A/PR/8/34), California 7/09, or H3N2 Aichi 2/68 (A/Aichi/2/68) viruses-infected MDCK cells and inhibited A/PR/8/34 or A/Aichi/2/68 viruses infection and growth in the co-treatment and pre-infection experiments. The pre-treatment of Y30 extract on MDCK cells did not induce anti-influenza activity in the cell. The Y30 extract did not significantly affect influenza A virus hemagglutination, and neuraminidase and RNA-dependent RNA polymerase activities. Interestingly, the electron microscopy experiment revealed that the Y30 extract disrupts the integrity of influenza A virus particles by permeabilizing the viral membrane envelope, suggesting that Y30 extract has a direct virucidal effect against influenza A virus. Furthermore, we observed that compared to the ethyl acetate (EtOAc) extract, the water extract of Y30 extract considerably promoted the survival of cells infected with A/PR/8/34 virus. These results indicated that more anti-influenza components were present in the water extract of Y30 extract than in the EtOAc extract. Our results highlight the potential of a rice extract fermented with A. oryzae and S. cerevisiae as an anti-influenza medicine and a drug source for the development of anti-influenza compounds.	[Shoji, Masaki; Sugimoto, Minami; Takeuchi, Misa; Yamaji, Saki; Tanaka, Narue; Kuzuhara, Takashi] Tokushima Bunri Univ, Lab Biochem, Fac Pharmaceut Sci, Yamashiro, Tokushima, Japan; [Matsuno, Kosuke; Mii, Tomohiro; Ayaki, Satomi; Tokuyama, Takaaki; Tokuyama, Takahito; Tokuyama, Takashi] Yushin Brewer Co Ltd, Ayagawa, Kagawa, Japan; [Fujita, Yoko; Noda, Takeshi] Kyoto Univ, Grad Sch Biostudies, Lab Ultrastruct Virol, Sakyo Ku, Shogoin Kawahara Cho, Kyoto, Japan; [Fujita, Yoko; Noda, Takeshi] Kyoto Univ, Inst Frontier Life & Med Sci, Lab Ultrastruct Virol, Sakyo Ku, Shogoin Kawahara Cho, Kyoto, Japan; [Takahashi, Etsuhisa; Kido, Hiroshi] Univ Tokushima, Inst Enzyme Res, Div Pathol & Metabolome Res Infect Dis & Host Def, Kuramoto Cho, Tokushima, Japan	Tokushima Bunri University; Kyoto University; Kyoto University; Tokushima University	Shoji, M; Kuzuhara, T (corresponding author), Tokushima Bunri Univ, Lab Biochem, Fac Pharmaceut Sci, Yamashiro, Tokushima, Japan.	masaki-shoji@ph.bunri-u.ac.jp; kuzuhara@ph.bunri-u.ac.jp		Fujita-Fujiharu, Yoko/0000-0002-2411-5473	Japan Society for the Promotion of Science (JSPS) [18K15173]; Yushin Brewer Co. Ltd.	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Yushin Brewer Co. Ltd.	This study was partially supported by the Japan Society for the Promotion of Science (JSPS), Grants-in-Aid for Young Scientists 18K15173 (to MS) and the Grants from Yushin Brewer Co. Ltd. The Yushin Brewer Co. Ltd. provided the Y30 extract, a part of the grant, and support in the form of salaries for authors [KM, TM, SA, TakaaT, TakahT, TakasT], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Akaike M, 2020, CURR MICROBIOL, V77, P632, DOI 10.1007/s00284-019-01718-4; Arakawa T, 2009, CURR MED CHEM, V16, P2485, DOI 10.2174/092986709788682065; Boonstra S, 2018, ANNU REV BIOPHYS, V47, P153, DOI 10.1146/annurev-biophys-070317-033018; Bunnoy A, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0624-5; Busath BHaDD, 2019, ADV COMPL ALT MED, V4, P358; Checkmahomed L, 2020, J INFECT DIS, V221, P63, DOI 10.1093/infdis/jiz418; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Di Sotto A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5919237; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Furihata C, 1996, CANCER DETECT PREV, V20, P193; Hamauzu Y, 2005, J AGR FOOD CHEM, V53, P928, DOI 10.1021/jf0494635; Hatakeyama S, 2007, JAMA-J AM MED ASSOC, V297, P1435, DOI 10.1001/jama.297.13.1435; Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197; Hiasa M, 2013, BRIT J PHARMACOL, V169, P115, DOI 10.1111/bph.12102; Hirai S, 2014, LIFE SCI, V117, P1, DOI 10.1016/j.lfs.2014.08.017; Ho BY, 2010, INTEGR CANCER THER, V9, P204, DOI 10.1177/1534735410365079; Holthausen DJ, 2017, IMMUNITY, V46, P587, DOI 10.1016/j.immuni.2017.03.018; Horie Y, 2016, APPL BIOCHEM BIOTECH, V178, P1599, DOI 10.1007/s12010-015-1970-y; Hurt Aeron C, 2006, Expert Rev Anti Infect Ther, V4, P795, DOI 10.1586/14787210.4.5.795; Ikeda K, 2020, JPN J INFECT DIS, V73, P8, DOI 10.7883/yoken.JJID.2018.522; Itoh M, 2012, PHYTOTHER RES, V26, P1661, DOI 10.1002/ptr.4631; Kim D, 2011, PLANT FOOD HUM NUTR, V66, P285, DOI 10.1007/s11130-011-0243-3; Kiyono T, 2013, J AGR FOOD CHEM, V61, P11660, DOI 10.1021/jf404381w; Kong B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08138-1; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; Lee CI, 2013, APPL MICROBIOL BIOT, V97, P1269, DOI 10.1007/s00253-012-4279-6; Lee CL, 2008, APPL MICROBIOL BIOT, V79, P829, DOI 10.1007/s00253-008-1480-8; Li QL, 2011, PEPTIDES, V32, P1518, DOI 10.1016/j.peptides.2011.05.015; Li ZT, 2018, J THORAC DIS, V10, pS2248, DOI 10.21037/jtd.2018.03.169; Lin CP, 2011, J PHARM PHARMACOL, V63, P1587, DOI 10.1111/j.2042-7158.2011.01364.x; Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54; Murakami M, 2005, J GASTROENTEROL, V40, P459, DOI 10.1007/s00535-005-1570-7; Ochiai M, 2013, BIOSCI BIOTECH BIOCH, V77, P243, DOI 10.1271/bbb.120638; Oh WS, 2020, FOOD SCI NUTR, V8, P1718, DOI 10.1002/fsn3.1460; Oxford John S., 2005, Antiviral Chemistry & Chemotherapy, V16, P129; Ozawa M, 2007, J VIROL, V81, P30, DOI 10.1128/JVI.01434-06; Boas LCPV, 2019, CELL MOL LIFE SCI, V76, P3525, DOI 10.1007/s00018-019-03138-w; Poland GA, 2009, CLIN INFECT DIS, V48, P1254, DOI 10.1086/598989; Popkin Daniel L, 2017, Pathog Immun, V2, P252, DOI 10.20411/pai.v2i2.200; Shigeta S, 1997, ANTIMICROB AGENTS CH, V41, P1423, DOI 10.1128/AAC.41.7.1423; Shin HY, 2019, FOOD CHEM, V272, P235, DOI 10.1016/j.foodchem.2018.07.174; Shirako S, 2019, NPJ SCI FOOD, V3, DOI 10.1038/s41538-019-0050-z; Shoji M, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1612-8; Shoji M, 2015, J BIOL CHEM, V290, P28001, DOI 10.1074/jbc.M115.669465; Shoji M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066337; Skalickova S, 2015, VIRUSES-BASEL, V7, P5428, DOI 10.3390/v7102883; Takahashi E, 2012, J VIROL, V86, P10924, DOI 10.1128/JVI.01207-12; Takahashi H, 2016, J AGR FOOD CHEM, V64, P8848, DOI 10.1021/acs.jafc.6b03516; Takashita E, 2019, EMERG INFECT DIS, V25, P2108, DOI 10.3201/eid2511.190757; Takeda Y, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070699; Tatsukami Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190040; Tseng WT, 2016, FOOD FUNCT, V7, P752, DOI [10.1039/c5fo00976f, 10.1039/C5FO00976F]; von Itzstein M, 2007, NAT REV DRUG DISCOV, V6, P967, DOI 10.1038/nrd2400; Watanabe T, 2014, CELL HOST MICROBE, V16, P795, DOI 10.1016/j.chom.2014.11.002; Webber DM, 2014, J FOOD SCI, V79, pH2383, DOI 10.1111/1750-3841.12658; WHO, INFL SEAS FACT SHEET; Xu X, 2019, MOLECULES, V24, DOI 10.3390/molecules24040671; Zhang L, 2010, MOLECULES, V15, P8507, DOI 10.3390/molecules15118507	58	0	0	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2021	16	1							e0244885	10.1371/journal.pone.0244885	http://dx.doi.org/10.1371/journal.pone.0244885			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4XD	33449947	Green Published, gold			2023-01-03	WOS:000609991600013
J	Gu, YY; Zhang, M; Cen, H; Wu, YF; Lu, ZY; Lu, FH; Liu, XS; Lan, HY				Gu, Yue-Yu; Zhang, Min; Cen, Huan; Wu, Yi-Fan; Lu, Zhaoyu; Lu, Fuhua; Liu, Xu-Sheng; Lan, Hui-Yao			Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study	PLOS ONE			English	Article							INTEGRATING INFORMATION; SARS-COV-2; GENES	Kidneys are one of the targets for SARS-CoV-2, it is reported that up to 36% of patients with SARS-CoV-2 infection would develop into acute kidney injury (AKI). AKI is associated with high mortality in the clinical setting and contributes to the transition of AKI to chronic kidney disease (CKD). Up to date, the underlying mechanisms are obscure and there is no effective and specific treatment for COVID-19-induced AKI. In the present study, we investigated the mechanisms and interactions between Quercetin and SARS-CoV-2 targets proteins by using network pharmacology and molecular docking. The renal protective effects of Quercetin on COVID-19-induced AKI may be associated with the blockade of the activation of inflammatory, cell apoptosis-related signaling pathways. Quercetin may also serve as SARS-CoV-2 inhibitor by binding with the active sites of SARS-CoV-2 main protease 3CL and ACE2, therefore suppressing the functions of the proteins to cut the viral life cycle. In conclusion, Quercetin may be a novel therapeutic agent for COVID-19-induced AKI. Inhibition of inflammatory, cell apoptosis-related signaling pathways may be the critical mechanisms by which Quercetin protects kidney from SARS-CoV-2 injury.	[Gu, Yue-Yu; Zhang, Min; Wu, Yi-Fan; Lu, Zhaoyu; Lu, Fuhua; Liu, Xu-Sheng] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Dept Nephrol, Guangzhou, Peoples R China; [Cen, Huan] Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Dept Ultrasound, Guangzhou, Peoples R China; [Lan, Hui-Yao] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Hong Kong, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese University of Hong Kong	Liu, XS (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, Dept Nephrol, Guangzhou, Peoples R China.; Lan, HY (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Hong Kong, Peoples R China.	hylan@cuhk.edu.hk; liuxusheng@gzucm.edu.cn	Lan, Hui Yao/C-9734-2015; Gu, Yue-Yu/AAJ-1947-2021	Lan, Hui Yao/0000-0003-4283-9755; Gu, Yue-Yu/0000-0003-4390-0108; Cen, Huan/0000-0002-9410-7006	Research Grants Council of Hong Kong [GRF 14163317, 14117418, 14104019, R4012-18, C7018-16G]; Lui Che Woo Institute of Innovative Medicine (CARE); Health and Medical Research Fund of Hong Kong [HMRF 05161326, 06173986, 14152321]; National Natural Science Foundation of China [81903956]; Project of Guangdong Province Administration of Traditional Chinese Medicine [20201133]	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Lui Che Woo Institute of Innovative Medicine (CARE); Health and Medical Research Fund of Hong Kong; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Guangdong Province Administration of Traditional Chinese Medicine	This work was supported by the Research Grants Council of Hong Kong (Grants GRF 14163317, 14117418, 14104019, R4012-18, and C7018-16G); Lui Che Woo Institute of Innovative Medicine (CARE); the Health and Medical Research Fund of Hong Kong (Grants HMRF 05161326, 06173986, and 14152321); the National Natural Science Foundation of China (No. 81903956), the Project of Guangdong Province Administration of Traditional Chinese Medicine (No. 20201133).	Abian O, 2020, INT J BIOL MACROMOL, V164, P1693, DOI 10.1016/j.ijbiomac.2020.07.235; Ahmed SSSJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040654; Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Aucoin M, 2020, ADV INTEGR MED, V7, P247, DOI 10.1016/j.aimed.2020.07.007; Braun F, 2020, LANCET, V396, P597, DOI 10.1016/S0140-6736(20)31759-1; Chaibi K, 2020, AM J RESP CRIT CARE, V202, P1299, DOI 10.1164/rccm.202005-1524LE; Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35; Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Biancatelli RMLC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01451; Ding T, 2018, PHYTOMEDICINE, V41, P45, DOI 10.1016/j.phymed.2018.01.026; Duret PM, 2020, ANN RHEUM DIS, V79, P1250, DOI 10.1136/annrheumdis-2020-217362; Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432; Fatoki TH, 2021, J BIOMOL STRUCT DYN, V39, P6195, DOI 10.1080/07391102.2020.1794971; Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9; Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293; Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129; Gu YY, 2018, PHYTOMEDICINE, V51, P214, DOI 10.1016/j.phymed.2018.10.004; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069; Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006; Hopkins AL, 2014, NAT REV DRUG DISCOV, V13, P105, DOI 10.1038/nrd4163; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang YF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104939; Kim S, 2016, EXPERT OPIN DRUG DIS, V11, P843, DOI 10.1080/17460441.2016.1216967; Kunutsor SK, 2020, ANN MED, V52, P345, DOI 10.1080/07853890.2020.1790643; Leija-Martinez JJ, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.109935; Li J, 2019, INTERDISCIP SCI, V11, P320, DOI 10.1007/s12539-019-00327-w; Lim JH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061718; Liu XH, 2019, FOOD FUNCT, V10, P3782, DOI 10.1039/c9fo00373h; Lu H, 2018, BIOCHEM PHARMACOL, V154, P203, DOI 10.1016/j.bcp.2018.05.007; Luo L, 2020, ACTA PHARMACOL SIN B, V10, P1192, DOI 10.1016/j.apsb.2020.05.007; Ma QH, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104850; Nain Z, 2020, PATHOGENETIC PROFILI, DOI [10.1093/bib/bbaa173, DOI 10.1093/BIB/BBAA173]; Noris M, 2020, KIDNEY INT, V98, P314, DOI 10.1016/j.kint.2020.05.013; Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943; Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Renu K, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117839; Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7; Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13; Ruan XF, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00346-6; Russo M, 2020, CHEM-BIOL INTERACT, V328, DOI 10.1016/j.cbi.2020.109211; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003; Tan RZ, 2020, PHYTOTHER RES, V34, P139, DOI 10.1002/ptr.6507; Tao QY, 2020, DRUG DEV IND PHARM, V46, P1345, DOI 10.1080/03639045.2020.1788070; Ursu O, 2011, WIRES COMPUT MOL SCI, V1, P760, DOI 10.1002/wcms.52; Vijayakumar BG, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173448; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2; Wang MZ, 2021, COMB CHEM HIGH T SCR, V24, P294, DOI 10.2174/1386207323666200806164635; Williams VR, 2018, CURR OPIN NEPHROL HY, V27, P35, DOI 10.1097/MNH.0000000000000378; Williamson G, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114123; Yang H, 2018, MED SCI MONITOR, V24, P4760, DOI 10.12659/MSM.909259; Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538	58	20	20	4	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0245209	10.1371/journal.pone.0245209	http://dx.doi.org/10.1371/journal.pone.0245209			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4VV	33444408	Green Published, gold			2023-01-03	WOS:000609988100006
J	Borensztajn, DM; Hagedoorn, NN; Calle, IR; Maconochie, IK; von Both, U; Carrol, ED; Dewez, JE; Emonts, M; van der Flier, M; de Groot, R; Herberg, J; Kohlmaier, B; Lim, E; Martinon-Torres, F; Nieboer, D; Nijman, RG; Pokorn, M; Strle, F; Tsolia, M; Vermont, C; Yeung, SM; Zavadska, D; Zenz, W; Levin, M; Moll, HA				Borensztajn, Dorine M.; Hagedoorn, Nienke N.; Rivero Calle, Irene; Maconochie, Ian K.; von Both, Ulrich; Carrol, Enitan D.; Dewez, Juan Emmanuel; Emonts, Marieke; van der Flier, Michiel; de Groot, Ronald; Herberg, Jethro; Kohlmaier, Benno; Lim, Emma; Martinon-Torres, Federico; Nieboer, Daan; Nijman, Ruud G.; Pokorn, Marko; Strle, Franc; Tsolia, Maria; Vermont, Clementien; Yeung, Shunmay; Zavadska, Dace; Zenz, Werner; Levin, Michael; Moll, Henriette A.		PERFORM Consortium Personalised Re	Variation in hospital admission in febrile children evaluated at the Emergency Department (ED) in Europe: PERFORM, a multicentre prospective observational study	PLOS ONE			English	Article							EARLY WARNING SCORE; LENGTH-OF-STAY; PEDIATRIC EMERGENCY; SOCIAL DETERMINANTS; INFECTION; ACCURACY; BACTERIAL; INFANTS; RATES; PEWS	Objectives Hospitalisation is frequently used as a marker of disease severity in observational Emergency Department (ED) studies. The comparison of ED admission rates is complex in potentially being influenced by the characteristics of the region, ED, physician and patient. We aimed to study variation in ED admission rates of febrile children, to assess whether variation could be explained by disease severity and to identify patient groups with large variation, in order to use this to reduce unnecessary health care utilization that is often due to practice variation. Design MOFICHE (Management and Outcome of Fever in children in Europe, part of the PERFORM study, ), is a prospective cohort study using routinely collected data on febrile children regarding patient characteristics (age, referral, vital signs and clinical alarming signs), diagnostic tests, therapy, diagnosis and hospital admission. Setting and participants Data were collected on febrile children aged 0-18 years presenting to 12 European EDs (2017-2018). Main outcome measures We compared admission rates between EDs by using standardised admission rates after adjusting for patient characteristics and initiated tests at the ED, where standardised rates >1 demonstrate higher admission rates than expected and rates Results We included 38,120 children. Of those, 9.695 (25.4%) were admitted to a general ward (range EDs 5.1-54.5%). Adjusted standardised admission rates ranged between 0.6 and 1.5. The largest variation was seen in short admission rates (0.1-5.0), PICU admission rates (0.2-2.2), upper respiratory tract infections (0.4-1.7) and fever without focus (0.5-2.7). Variation was small in sepsis/meningitis (0.9-1.1). Conclusions Large variation exists in admission rates of febrile children evaluated at European EDs, however, this variation is largely reduced after correcting for patient characteristics and therefore overall admission rates seem to adequately reflect disease severity or a potential for a severe disease course. However, for certain patient groups variation remains high even after adjusting for patient characteristics.	[Borensztajn, Dorine M.; Hagedoorn, Nienke N.; Moll, Henriette A.] Erasmus MC, Sophia Childrens Hosp, Dept Gen Paediat, Rotterdam, Netherlands; [Rivero Calle, Irene; Martinon-Torres, Federico] Hosp Clin Univ Santiago De Compostela, Genet Vaccines Infect & Pediat Res Grp GENVIP, Santiago De Compostela, Spain; [Maconochie, Ian K.; Herberg, Jethro; Nijman, Ruud G.; Levin, Michael] Imperial Coll Sci Technol & Med, Sect Paediat Infect Dis, London, England; [von Both, Ulrich] Ludwig Maximilians Univ LMU, Univ Hosp Ludwig, Dr von Hauner Childrens Hosp, Div Paediat Infect Dis, Munich, Germany; [Carrol, Enitan D.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England; [Carrol, Enitan D.] Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England; [Dewez, Juan Emmanuel; Yeung, Shunmay] London Sch Hyg & Trop Med, Fac Trop & Infect Dis, London, England; [Emonts, Marieke; Lim, Emma] Newcastle Upon Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Immunol Infect Dis & Allergy, Newcastle Upon Tyne, Tyne & Wear, England; [Emonts, Marieke] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Emonts, Marieke] Newcastle Upon Tyne Hosp NHS Trust, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England; [Emonts, Marieke] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [van der Flier, Michiel] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Pediat Infect Dis & Immunol, Utrecht, Netherlands; [van der Flier, Michiel] Radboud Univ Nijmegen, Amalia Childrens Hosp, Pediat Infect Dis & Immunol, Med Ctr, Nijmegen, Netherlands; [van der Flier, Michiel] Radboud Univ Nijmegen, Radboud Inst Mol Sci, Sect Pediat Infect Dis, Dept Lab Med,Lab Med Immunol,Med Ctr, Nijmegen, Netherlands; [de Groot, Ronald] Radboudumc Nijmegen, Stichting Katholieke Univ, Nijmegen, Netherlands; [Kohlmaier, Benno; Zenz, Werner] Med Univ Graz, Dept Gen Paediat, Graz, Austria; [Nieboer, Daan] Erasmus Univ, Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands; [Pokorn, Marko; Strle, Franc] Univ Med Ctr Ljubljana, Univ Klin Ctr, Dept Infect Dis, Ljubljana, Slovenia; [Tsolia, Maria] Natl & Kapodistrian Univ Athens, P&A Kyriakou Childrens Hosp, Dept Paediat 2, Athens, Greece; [Vermont, Clementien] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Infect Dis & Immunol, Rotterdam, Netherlands; [Zavadska, Dace] Rigas Stradina Univ, Dept Pediat, Children Clin Univ Hosp, Riga, Latvia	Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Complexo Hospitalario Universitario de Santiago de Compostela; Imperial College London; University of Munich; University of Liverpool; Alder Hey Children's NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Radboud University Nijmegen; Radboud University Nijmegen; Medical University of Graz; Erasmus University Rotterdam; Erasmus MC; University Medical Centre Ljubljana; National & Kapodistrian University of Athens; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Riga Stradins University	Borensztajn, DM (corresponding author), Erasmus MC, Sophia Childrens Hosp, Dept Gen Paediat, Rotterdam, Netherlands.	d.borensztajn@erasmusmc.nl	Zavadska, Dace/GXF-4730-2022; Zenz, Werner/AAZ-3375-2021; O'Connor, Daniel/AAF-4903-2019; Pokorn, Marko/H-5701-2019; Vermont, Clementien/GVT-8580-2022; von Both, Ulrich/HCI-1318-2022; van der Flier, Michiel/L-4307-2015; Martinon-Torres, Federico/E-4982-2016	O'Connor, Daniel/0000-0002-6902-9886; Pokorn, Marko/0000-0002-2341-2791; Rivero Calle, Irene/0000-0002-3678-9264; Emonts, Marieke/0000-0002-2822-3527; Nijman, Ruud Gerard/0000-0001-9671-8161; Hagedoorn, Nienke/0000-0001-9237-4904; Yeung, Shunmay/0000-0002-0997-0850; Levin, Michael/0000-0003-2767-6919; von Both, Ulrich/0000-0001-8411-1071; van der Flier, Michiel/0000-0003-1296-0159; Vermont, Clementien/0000-0002-2219-856X; Martinon-Torres, Federico/0000-0002-9023-581X; Maconochie, Ian/0000-0001-6319-8550	European Union's Horizon 2020 research and innovation programme [668303]; NIHR Newcastle Biomedical Research Centre at Newcastle Hospitals NHS foundation trust; National Institute for Health Research [CL-2018-21-007]	European Union's Horizon 2020 research and innovation programme; NIHR Newcastle Biomedical Research Centre at Newcastle Hospitals NHS foundation trust; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the European Union's Horizon 2020 research and innovation programme to ML (Grant No. 668303), the NIHR Newcastle Biomedical Research Centre at Newcastle Hospitals NHS foundation trust to ME, and the National Institute for Health Research to RGN (CL-2018-21-007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alan S, 2016, J MATERN-FETAL NEO M, V29, P2186, DOI 10.3109/14767058.2015.1079614; Barak-Corren Y, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2785; Beck AF, 2015, JAMA PEDIATR, V169, P846, DOI 10.1001/jamapediatrics.2015.1148; Boeddha NP, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2052-7; Borensztajn D, 2019, BMJ PAEDIATR OPEN, V3, DOI 10.1136/bmjpo-2019-000456; Bourgeois FT, 2014, PEDIATRICS, V134, P539, DOI 10.1542/peds.2014-1278; Bressan S, 2019, ARCH DIS CHILD, V104, P869, DOI 10.1136/archdischild-2019-316918; Campbell P, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4857; Chandrasekhar R, 2017, INFLUENZA OTHER RESP, V11, P479, DOI 10.1111/irv.12483; Chen WY, 2020, AM J EMERG MED, V38, P774, DOI 10.1016/j.ajem.2019.06.039; Cheung CR, 2013, ARCH DIS CHILD, V98, P57, DOI 10.1136/archdischild-2012-302277; Chime NO, 2017, PEDIATR EMERG CARE, V33, P278, DOI 10.1097/PEC.0000000000000557; Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, 2019, LANCET, V6, pe105; Conway R, 2016, QJM-INT J MED, V109, P675, DOI 10.1093/qjmed/hcw053; Diaz MG, 2016, PEDIATR EMERG CARE, V32, P664, DOI 10.1097/PEC.0000000000000401; Gold DL, 2014, ACAD EMERG MED, V21, P1249, DOI 10.1111/acem.12514; Goldman RD, 2009, PEDIATRICS, V124, P439, DOI 10.1542/peds.2007-3736; Gravel J, 2013, ANN EMERG MED, V61, P27, DOI 10.1016/j.annemergmed.2012.05.024; Greenberg RA, 2006, AM J EMERG MED, V24, P818, DOI 10.1016/j.ajem.2006.05.003; Hagedoorn NN, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003208; Herberg JA, 2016, JAMA-J AM MED ASSOC, V316, P835, DOI 10.1001/jama.2016.11236; Jacobstein CR, 2005, PEDIATR EMERG CARE, V21, P816, DOI 10.1097/01.pec.0000190228.97362.30; Jain S, 2014, PEDIATRICS, V133, P187, DOI 10.1542/peds.2013-1820; Khine H, 2014, EMERG MED INT, V2014, DOI 10.1155/2014/702053; Leigh S, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1275-z; Lillitos PJ, 2016, EMERG MED J, V33, P329, DOI 10.1136/emermed-2014-204355; Lind Carrie H, 2016, Hosp Pediatr, V6, P714, DOI 10.1542/hpeds.2016-0085; Macias Marta, 2015, Pediatr Nurs, V41, P285; Martinon-Torres F, 2018, LANCET CHILD ADOLESC, V2, P404, DOI 10.1016/S2352-4642(18)30113-5; Maybloom B, 2002, Intensive Crit Care Nurs, V18, P151, DOI 10.1016/S0964-3397(02)00007-1; McDowell KM, 2016, ANN AM THORAC SOC, V13, P1081, DOI 10.1513/AnnalsATS.201512-798OC; Neuman MI, 2013, PEDIATRICS, V132, P369, DOI 10.1542/peds.2013-1569; Nijman RG, 2015, PEDIATR EMERG CARE, V31, P633, DOI 10.1097/PEC.0000000000000466; Parshuram CS, 2009, CRIT CARE, V13, DOI 10.1186/cc7998; Rogers AJ, 2019, J EMERG MED, V56, P583, DOI 10.1016/j.jemermed.2019.03.003; Sands R, 2012, EMERG MED J, V29, P379, DOI 10.1136/emj.2010.106229; Scott-Jupp R, 2020, ARCH DIS CHILD, V105, P661, DOI 10.1136/archdischild-2019-317553; Scribano PV, 2001, PEDIATR EMERG CARE, V17, P321, DOI 10.1097/00006565-200110000-00001; Smith L, 2018, BMJ QUAL SAF, V27, P521, DOI 10.1136/bmjqs-2017-006605; Turner NM, 2017, ADV PAEDIAT LIFE SUP; Zachariasse JM, 2020, LANCET CHILD ADOLESC, V4, P583, DOI 10.1016/S2352-4642(20)30139-5; Zachariasse JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170811	42	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244810	10.1371/journal.pone.0244810	http://dx.doi.org/10.1371/journal.pone.0244810			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411810	Green Published, gold			2023-01-03	WOS:000608044300109
J	Ness, TE; Streatfield, AE; Simelane, T; Korsa, A; Dlamini, S; Guffey, D; Lukhele, B; Kay, AW				Ness, Tara E.; Streatfield, Ashish E.; Simelane, Tandzile; Korsa, Abiy; Dlamini, Sandile; Guffey, Danielle; Lukhele, Bhekumusa; Kay, Alexander W.			Evaluating antibiotic use and developing a tool to optimize prescribing in a family-centered HIV clinic in Eswatini	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; ANTIMICROBIAL RESISTANCE; CHILDREN; STEWARDSHIP; CARE	In a human immunodeficiency virus (HIV) clinic for children and their families in Eswatini, we sought to understand the use of antibiotics and identify specific areas for improvement. We performed a retrospective patient chart review as part of a quality improvement (QI) initiative to assess antimicrobial use before and after implementation of a standardized antimicrobial guide. For each prescribing period, 100 random patient encounters were selected for review if the indication for antibiotics, duration, and dose were consistent with World Health Organization (WHO) guidelines. Two physicians reviewed each encounter using a structured abstraction tool, with a third resolving discrepancies. Results were analyzed using a chi-square test of proportions and a structured survey was performed to assess perceptions of the guide. After the implementation of an antimicrobial guide, there was a significant decrease in the proportion of clinic visits with an antibiotic prescribed (p < 0.001). Incorrect indication for antimicrobial use decreased from 20.4% in the initial period to 10.31% and 10.2% but did not reach significance (p = .0621) in the subsequent periods after implementation. Incorrect dose/duration decreased from 10.47% in the initial period to 7.37% and 3.1% in the subsequent periods, but this was also was not significant (p = 0.139). All prescribers who completed the survey felt that it positively impacted their prescribing. Our study found that an antimicrobial guide reduced and improved the prescription of antimicrobials, demonstrating practical solutions can have a lasting impact on prescribing in low resource settings.	[Ness, Tara E.; Guffey, Danielle; Kay, Alexander W.] Baylor Coll Med, Houston, TX 77030 USA; [Ness, Tara E.; Kay, Alexander W.] Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA; [Streatfield, Ashish E.] United States Peace Corps, Community HIV AIDS Mitigat Project, Mbabane, Eswatini; [Simelane, Tandzile; Korsa, Abiy; Dlamini, Sandile; Lukhele, Bhekumusa; Kay, Alexander W.] Baylor Ctr Excellence, Mbabane, Eswatini; [Kay, Alexander W.] Texas Childrens Hosp, Global TB Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Ness, TE (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.; Ness, TE (corresponding author), Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA.	tara.ness@bcm.edu		Ness, Tara/0000-0002-4425-418X; Lukhele, Bhekumusa Wellington/0000-0001-6429-638X	National Institutes of Health [1K01TW011482-01A1]; Global Tuberculosis Program at Baylor College of Medicine and Texas Children's Hospital	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Global Tuberculosis Program at Baylor College of Medicine and Texas Children's Hospital	This work was supported by the National Institutes of Health (grant number 1K01TW011482-01A1 to A. W. K.) and by the Global Tuberculosis Program at Baylor College of Medicine and Texas Children's Hospital.	Adisa R, 2018, AFR HEALTH SCI, V18, P1189, DOI 10.4314/ahs.v18i4.40; Bebell LM, 2014, GLOB HEART, V9, P347, DOI 10.1016/j.gheart.2014.08.009; Boyles TH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079747; CDC, 2019, ANTIBIOTIC RESISTANC, DOI DOI 10.15620/CDC:82532; Centres for Disease Control and Prevention (US), 2019, ANT RES THREATS US 2; Chung A, 2007, BMJ-BRIT MED J, V335, P429, DOI 10.1136/bmj.39274.647465.BE; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; Cox JA, 2017, CLIN MICROBIOL INFEC, V23, P812, DOI 10.1016/j.cmi.2017.07.010; Dadgostar P, 2019, INFECT DRUG RESIST, V12, P3903, DOI 10.2147/IDR.S234610; Ianacone DC, 2017, INT J PEDIATR OTORHI, V103, P133, DOI 10.1016/j.ijporl.2017.10.024; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Mandomando I, 2010, AM J TROP MED HYG, V83, P152, DOI 10.4269/ajtmh.2010.09-0578; Marbou WJT, 2017, J INFECT PUBLIC HEAL, V10, P269, DOI 10.1016/j.jiph.2016.04.009; Morency-Potvin P, 2017, CLIN MICROBIOL REV, V30, P381, DOI 10.1128/CMR.00066-16; Ofori-Asenso R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3428-8; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; Roque F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1276; Thorpe KE, 2018, HEALTH AFFAIR, V37, P662, DOI 10.1377/hlthaff.2017.1153; Van Boeckel TP, 2014, LANCET INFECT DIS, V14, P742, DOI 10.1016/S1473-3099(14)70780-7; Van Dijck C, 2018, B WORLD HEALTH ORGAN, V96, P266, DOI 10.2471/BLT.17.203448; Versporten A, 2018, LANCET GLOB HEALTH, V6, pE619, DOI [10.1016/s2214-109x(18)30186-4, 10.1016/S2214-109X(18)30186-4]; WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1; Williams PCM, 2018, LANCET INFECT DIS, V18, pE33, DOI 10.1016/S1473-3099(17)30467-X	23	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244247	10.1371/journal.pone.0244247	http://dx.doi.org/10.1371/journal.pone.0244247			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411762	Green Published, gold			2023-01-03	WOS:000608044300019
J	Fritz, JM; Lane, E; McFadden, M; Brennan, G; Magel, JS; Thackeray, A; Minick, K; Meier, W; Greene, T				Fritz, Julie M.; Lane, Elizabeth; McFadden, Molly; Brennan, Gerard; Magel, John S.; Thackeray, Anne; Minick, Kate; Meier, Whitney; Greene, Tom			Physical Therapy Referral From Primary Care for Acute Back Pain With Sciatica A Randomized Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							LEG PAIN; PRACTICE GUIDELINES; DISABILITY; QUESTIONNAIRE; MANAGEMENT; EXTENSION; SUBGROUP; LOCATION; OUTCOMES; ADVICE	Background: Few studies have examined primary care management for acute sciatica, including referral to physical therapy. Objective: To evaluate whether early referral to physical therapy reduced disability more than usual care (UC) alone for patients with acute sciatica. Design: Randomized controlled clinical trial. (ClinicalTrials.gov: NCT02391350) Setting: 2 health care systems in Salt Lake City, Utah. Patients: 220 adults aged 18 to 60 years with sciatica of less than 90 days' duration who were making an initial primary care consultation. Intervention: All participants received imaging and medication at the discretion of the primary care provider before enrollment. A total of 110 participants randomly assigned to UC were provided 1 session of education, and 110 participants randomly assigned to early physical therapy (EPT) were provided 1 education session and then referred for 4 weeks of physical therapy, including exercise and manual therapy. Measurements: The primary outcome was the Oswestry Disability Index (OSW) score after 6 months. Secondary outcomes were pain intensity, patient-reported treatment success, health care use, and missed workdays. Results: Participants in the EPT group had greater improvement from baseline to 6 months for the primary outcome (relative difference, -5.4 points [95% CI, -9.4 to -1.3 points]; P = 0.009). The OSW and several secondary outcomes favored EPT after 4 weeks. After 1 year, between-group differences favored EPT for the OSW (relative difference, -4.8 points [CI, -8.9 to -0.7 points]) and back pain intensity (relative difference, -1.0 points [CI, -1.6 to -0.4 points]). The EPT group was more likely to self-report treatment success after 1 year (45.2%) than the UC group (27.6%) (relative risk, 1.6 [CI, 1.1 to 2.4]). There were no significant differences in health care use or missed workdays. Limitation: The patients and providers were unblinded, and specific physical therapy interventions responsible for effects could not be determined. Conclusion: Referral from primary care to physical therapy for recent-onset sciatica improved disability and other outcomes compared with UC. Primary Funding Source: Agency for Healthcare Research and Quality.	[Fritz, Julie M.] Univ Utah, Coll Hlth, 383 Colorow Dr,Room 391, Salt Lake City, UT 84108 USA; [Lane, Elizabeth; McFadden, Molly; Magel, John S.; Thackeray, Anne; Greene, Tom] Univ Utah, Sch Med, Williams Bldg,1st Floor,295 South Chipeta Way, Salt Lake City, UT 84108 USA; [Brennan, Gerard] Intermt Healthcare, Rehabil Serv, Salt Lake City, UT USA; [Minick, Kate] Intermt Healthcare, Salt Lake City, UT USA; [Meier, Whitney] Univ Utah Hlth, Salt Lake City, UT USA; [Lane, Elizabeth; Magel, John S.; Thackeray, Anne] Univ Utah, 520 Wakara Way, Salt Lake City, UT 84108 USA; [Brennan, Gerard; Minick, Kate] Intermt Healthcare, Rehabil Serv, Murray, KY 84107 USA; [Meier, Whitney] Univ Utah, Orthopaed Ctr, 590 Wakara Way, Salt Lake City, UT 84108 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Intermountain Healthcare; Intermountain Medical Center; Intermountain Healthcare; Intermountain Medical Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Fritz, JM (corresponding author), Univ Utah, Coll Hlth, 383 Colorow Dr,Room 391, Salt Lake City, UT 84108 USA.	julie.fritz@utah.edu		Thackeray, Anne/0000-0002-5496-7730; Minick, Kate/0000-0003-4683-1937; Lane, Elizabeth/0000-0002-2168-3731; Magel, John/0000-0001-9087-4753; Fritz, Julie/0000-0002-3599-1057	Agency for Healthcare Research and Quality [R18HS022641]; University of Utah Study Design and Biostatistics Center; National Center for Research Resources [5UL1TR001067-02, 8UL1TR000105, UL1RR025764]; National Center for Advancing Translational Sciences of the National Institutes of Health	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); University of Utah Study Design and Biostatistics Center; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The research reported in this publication was supported by the Agency for Healthcare Research and Quality through grant R18HS022641. The study was supported by the University of Utah Study Design and Biostatistics Center, with funding in part through grant 5UL1TR001067-02 (formerly 8UL1TR000105 and UL1RR025764) from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health.	Albert HB, 2012, SPINE, V37, P531, DOI 10.1097/BRS.0b013e31821ace7f; [Anonymous], YGTUTU; Bernstein IA, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6748; Borgan O., 2000, MODELING SURVIVAL DA, P169, DOI [10.1007/978-1-4757-3294-8, DOI 10.1007/978-1-4757-3294-8]; Boutron I, 2017, ANN INTERN MED, V167, P40, DOI 10.7326/M17-0046; Bronfort G, 2014, ANN INTERN MED, V161, P381, DOI 10.7326/M14-0006; Browder DA, 2007, PHYS THER, V87, P1608, DOI 10.2522/ptj.20060297; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459; Delitto A, 2012, J ORTHOP SPORT PHYS, V42, pA1, DOI 10.2519/jospt.2012.42.4.A1; Dieleman JL, 2020, JAMA-J AM MED ASSOC, V323, P863, DOI 10.1001/jama.2020.0734; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Finley CR, 2018, CAN FAM PHYSICIAN, V64, P832; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hartvigsen L, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1495-3; Hider SL, 2015, EUR SPINE J, V24, P444, DOI 10.1007/s00586-014-3355-2; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hofstee DJ, 2002, J NEUROSURG, V96, P45, DOI 10.3171/spi.2002.96.1.0045; Hurwitz EL, 2005, SPINE, V30, P1477, DOI 10.1097/01.brs.0000167821.39373.c1; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jensen RK, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6273; Kongsted A, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-171; Konstantinou K, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2686-x; Konstantinou K, 2018, SPINE J, V18, P1030, DOI 10.1016/j.spinee.2017.10.071; Ladeira CE, 2017, J ORTHOP SPORT PHYS, V47, P347, DOI 10.2519/jospt.2017.6561; Lauridsen HH, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-82; Linton SJ, 2018, PAIN, V159, P2437, DOI 10.1097/j.pain.0000000000001308; Luijsterburg PAJ, 2008, EUR SPINE J, V17, P509, DOI 10.1007/s00586-007-0569-6; McKenzie R, 2003, LUMBAR SPINE MECH DI; Mehling WE, 2012, SPINE, V37, P678, DOI 10.1097/BRS.0b013e318230ab20; Oliveira CB, 2018, EUR SPINE J, V27, P2791, DOI 10.1007/s00586-018-5673-2; Pangarkar SS, 2019, J GEN INTERN MED, V34, P2620, DOI 10.1007/s11606-019-05086-4; Pinto RZ, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4248; Porchet F, 2002, NEUROSURGERY, V50, P1253, DOI 10.1097/00006123-200206000-00014; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Roland M, 2000, BACK BOOK; Schoenfeld AJ, 2012, J SPINAL DISORD TECH, V25, P163, DOI 10.1097/BSD.0b013e3182146e55; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Stafford MA, 2007, BRIT J ANAESTH, V99, P461, DOI 10.1093/bja/aem238; Stochkendahl MJ, 2018, EUR SPINE J, V27, P60, DOI 10.1007/s00586-017-5099-2; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Traeger A, 2017, CAN MED ASSOC J, V189, pE1386, DOI 10.1503/cmaj.170527; Verwoerd AJH, 2015, PHYS THER, V95, P1217, DOI 10.2522/ptj.20140458; Vroomen PCAJ, 2002, BRIT J GEN PRACT, V52, P119; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WEBER H, 1993, SPINE, V18, P1433, DOI 10.1097/00007632-199309010-00006	48	13	13	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					8	+		10.7326/M20-4187	http://dx.doi.org/10.7326/M20-4187			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33017565	Green Accepted			2023-01-03	WOS:000619485200016
J	Hurst, CP; Rakkapao, N; Hay, K				Hurst, Cameron P.; Rakkapao, Nitchamon; Hay, Karen			Impact of diabetes self-management, diabetes management self-efficacy and diabetes knowledge on glycemic control in people with Type 2 Diabetes (T2D): A multi-center study in Thailand	PLOS ONE			English	Article							COMPLICATIONS; ASSOCIATION; POPULATION; MELLITUS; ADULTS	We investigate the relationship of diabetes knowledge, diabetes management self-efficacy and diabetes self-management with blood glucose control among people with Thai type 2 diabetes mellitus (T2D). Seven hundred outpatients from diabetes clinics from large university and small community hospitals in two provinces of Thailand (Khon Kaen and Bangkok) were interviewed to evaluate their diabetes knowledge (DK), diabetes management self-efficacy (DMSE) and diabetes self-management (DSM). In addition, patient medical records were accessed to obtain other patient characteristics including patients' HbA1c levels. Bivariate and multivariable logistic regression modelling was conducted and unadjusted and adjusted odds ratios obtained, respectively. Over half (52.4%) of the patients in our sample failed to control their blood glucose (HbA1c > 7%). All three psychometric measures (DK, DMSE and DSM) were identified as associated with blood glucose control in the bivariate analysis (ORDK(unadj) = 0.89, 95%CI: 0.82, 0.96; ORDSM(unadj) = 1.64, 95%CI: 1.46, 1.82; ORDMSE(unadj) = 2.84; 95%CI: 2.43, 3.32). However, after mutual adjustment and adjustment for other patient characteristics, of the three psychometric measures, only diabetes management self-efficacy remained associated with blood glucose control (ORDMSE(adj) = 2.67; 95%CI: 2.20, 3.25). Diabetes management self-efficacy is shown to be strongly associated with blood glucose control in the Thai Type 2 diabetes population. Current early diabetes interventions in Thailand tend to focus on disease knowledge. A stronger emphasis on enhancing patients' disease management self-efficacy in these interventions is likely to lead to substantial improvement in both diabetes self-management and blood glucose control, thereafter reducing the risk, or prolonging the development, of chronic diabetes complications.	[Hurst, Cameron P.; Hay, Karen] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Hurst, Cameron P.; Rakkapao, Nitchamon] Thammasat Univ, Fac Publ Hlth, Muang, Lampang, Thailand	QIMR Berghofer Medical Research Institute; Thammasat University	Rakkapao, N (corresponding author), Thammasat Univ, Fac Publ Hlth, Muang, Lampang, Thailand.	nitchamonbt@fph.tu.ac.th	Hay, Karen/AAY-7863-2021; Hurst, Cameron/P-5175-2017	Hay, Karen/0000-0001-8813-5855; Hurst, Cameron/0000-0002-4577-8962				Al-Khawaldeh OA, 2012, J DIABETES COMPLICAT, V26, P10, DOI 10.1016/j.jdiacomp.2011.11.002; Al-Qazaz HK, 2011, INT J CLIN PHARM-NET, V33, P1028, DOI 10.1007/s11096-011-9582-2; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS81, DOI 10.2337/dc14-S081; [Anonymous], 2018, R LANG ENV STAT COMP; [Anonymous], 2015, IDF DIABETES ATLAS; Bains SS, 2011, DIABETES TECHNOL THE, V13, P335, DOI 10.1089/dia.2010.0160; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Beeney L., 1994, HDB PSYCHOL DIABETES, P159; BRISLIN RW, 1970, J CROSS CULT PSYCHOL, V1, P185, DOI 10.1177/135910457000100301; BROWNE MW, 1992, SOCIOL METHOD RES, V21, P230, DOI 10.1177/0049124192021002005; Byrne B. M, 2006, STRUCTURAL EQUATION, V2; Cai L, 2013, BRIT J MATH STAT PSY, V66, P245, DOI 10.1111/j.2044-8317.2012.02050.x; Chalmers RP, 2012, J STAT SOFTW, V48, P1; Chatterjee S, 2011, HEALTH SOC CARE COMM, V19, P289, DOI 10.1111/j.1365-2524.2010.00981.x; Chavasit V, 2017, EUR J CLIN NUTR, V71, P839, DOI 10.1038/ejcn.2017.52; Coates VE, 1996, PATIENT EDUC COUNS, V29, P99, DOI 10.1016/0738-3991(96)00938-X; DeVellis R. F., 2012, SCALE DEV THEORY APP; Fitzpatrick SL, 2013, DIABETES RES CLIN PR, V100, P145, DOI 10.1016/j.diabres.2012.12.016; Guo XH, 2012, CHINESE MED J-PEKING, V125, P4175, DOI 10.3760/cma.j.issn.0366-6999.2012.23.003; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Heisler M, 2005, DIABETES CARE, V28, P816, DOI 10.2337/diacare.28.4.816; Houle J, 2015, DIABETIC MED, V32, P1247, DOI 10.1111/dme.12686; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hurst C, 2015, DIABETES METAB J, V39, P395, DOI 10.4093/dmj.2015.39.5.395; Institute for Health Metrics and Evaluation (IHME), 2017, GHDX; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; King DK, 2010, DIABETES CARE, V33, P751, DOI 10.2337/dc09-1746; Kline P, 2000, HDB PSYCHOL TESTING, V2; Lin CY, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018819897522; Lin KK, 2017, DIABETES RES CLIN PR, V131, P179, DOI 10.1016/j.diabres.2017.03.013; Maydeu-Olivares A, 2006, PSYCHOMETRIKA, V71, P713, DOI 10.1007/s11336-005-1295-9; McDowell Jan, 2005, Int J Nurs Pract, V11, P177, DOI 10.1111/j.1440-172X.2005.00518.x; McPherson ML, 2008, RES SOC ADMIN PHARM, V4, P37, DOI 10.1016/j.sapharm.2007.01.002; Olokoba Abdulfatai B, 2012, Oman Med J, V27, P269, DOI 10.5001/omj.2012.68; Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02; Sangruangake M, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/2503156; Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007; Shevlin M, 1998, PERS INDIV DIFFER, V25, P85, DOI 10.1016/S0191-8869(98)00055-5; Sieng S, 2015, DIABETES RES CLIN PR, V108, P265, DOI 10.1016/j.diabres.2015.02.005; Stolar M, 2010, AM J MED, V123, pS3, DOI 10.1016/j.amjmed.2009.12.004; Suksa-ard T, 2016, SITUATION NCDS KICK; Dao-Tran TH, 2018, NURS OPEN, V5, P507, DOI 10.1002/nop2.158; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; van der Bijl J, 1999, J ADV NURS, V30, P352, DOI 10.1046/j.1365-2648.1999.01077.x; Vasudevan Abu R, 2006, Treat Endocrinol, V5, P273, DOI 10.2165/00024677-200605050-00002; Wong CKH, 2015, DIABETES OBES METAB, V17, P128, DOI 10.1111/dom.12397; Wong CKH, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0324-3; Wong CKH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095328	50	8	8	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244692	10.1371/journal.pone.0244692	http://dx.doi.org/10.1371/journal.pone.0244692			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PP1TW	33382799	gold, Green Published			2023-01-03	WOS:000605651900057
J	Oyama, Y; Shuff, S; Davizon-Castillo, P; Clendenen, N; Eckle, T				Oyama, Yoshimasa; Shuff, Sydney; Davizon-Castillo, Pavel; Clendenen, Nathan; Eckle, Tobias			Intense light as anticoagulant therapy in humans	PLOS ONE			English	Article							CIRCADIAN CLOCK; INFARCT SIZE; MYOCARDIAL-ISCHEMIA; GENE; REPERFUSION; CARDIOPROTECTION; EXPRESSION; PER2; THROMBOPOIETIN; PLATELETS	Blood coagulation is central to myocardial ischemia and reperfusion (IR) injury. Studies on the light elicited circadian rhythm protein Period 2 (PER2) using whole body Per2(-/-) mice found deficient platelet function and reduced clotting which would be expected to protect from myocardial IR-injury. In contrast, intense light induction of PER2 protected from myocardial IR-injury while Per2 deficiency was detrimental. Based on these conflicting data, we sought to evaluate the role of platelet specific PER2 in coagulation and myocardial ischemia and reperfusion injury. We demonstrated that platelets from mice with tissue-specific deletion of Per2 in the megakaryocyte lineage (Per2(loxP/loxP)-PF4-CRE) significantly clot faster than platelets from control mice. We further found increases in infarct sizes or plasma troponin levels in Per2(loxP/loxP)-PF4-CRE mice when compared to controls. As intense light increases PER2 protein in human tissues, we also performed translational studies and tested the effects of intense light therapy on coagulation in healthy human subjects. Our human studies revealed that intense light therapy repressed procoagulant pathways in human plasma samples and significantly reduced the clot rate. Based on these results we conclude that intense light elicited PER2 has an inhibitory function on platelet aggregation in mice. Further, we suggest intense light as a novel therapy to prevent or treat clotting in a clinical setting.	[Oyama, Yoshimasa; Shuff, Sydney; Clendenen, Nathan; Eckle, Tobias] Univ Colorado, Dept Anesthesiol, Anschutz Med Campus, Aurora, CO 80045 USA; [Davizon-Castillo, Pavel] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Eckle, T (corresponding author), Univ Colorado, Dept Anesthesiol, Anschutz Med Campus, Aurora, CO 80045 USA.	tobias.eckle@cuanschutz.edu		Shuff, Sydney/0000-0002-5026-3461	National Heart, Lung, and Blood Institute (NIH-NHLBI) [5R01HL122472]; American Heart Association (AHA) Postdoctoral Fellowship [19POST34380105]	National Heart, Lung, and Blood Institute (NIH-NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association (AHA) Postdoctoral Fellowship(American Heart Association)	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Heart, Lung, and Blood Institute (NIH-NHLBI) 5R01HL122472 Grant to TE and American Heart Association (AHA) Postdoctoral Fellowship 19POST34380105 to YO.	Alva JA, 2006, DEV DYNAM, V235, P759, DOI 10.1002/dvdy.20643; [Anonymous], 2003, GASTROINTESTINAL S6, V5, pS3; Bagge A, 2018, SCAND J CLIN LAB INV, V78, P539, DOI 10.1080/00365513.2018.1516477; Bartman CM, 2019, CURR PHARM DESIGN, V25, P1075, DOI 10.2174/1381612825666190516081612; Bartman CM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176243; Bendova Z, 2006, PHYSIOL RES, V55, P623, DOI 10.33549/physiolres.930849; Bonney S, 2013, INT J BIOCHEM CELL B, V45, P667, DOI 10.1016/j.biocel.2012.12.022; Brainard J, 2015, ANESTHESIOLOGY, V122, P1170, DOI 10.1097/ALN.0000000000000596; Brainard J, 2015, SEMIN CARDIOTHORAC V, V19, P49, DOI 10.1177/1089253214553066; Braunwald E, 2012, CIRC RES, V110, P6, DOI 10.1161/CIRCRESAHA.111.260265; Budkowska M, 2019, THROMB RES, V182, P79, DOI 10.1016/j.thromres.2019.08.015; Candia J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14755-5; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516; Eckle T, 2007, CIRCULATION, V115, P1581, DOI 10.1161/CIRCULATIONAHA.106.669697; Eckle T, 2006, AM J PHYSIOL-HEART C, V291, pH2533, DOI 10.1152/ajpheart.00472.2006; Eckle T, 2011, JOVE-J VIS EXP, DOI 10.3791/2526; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Gawaz M, 2004, CARDIOVASC RES, V61, P498, DOI 10.1016/j.cardiores.2003.11.036; Guler AD, 2008, NATURE, V453, P102, DOI 10.1038/nature06829; Hall ME, 2011, AM J PHYSIOL-HEART C, V301, pH253, DOI 10.1152/ajpheart.00786.2010; Hartley PS, 2009, BRIT J HAEMATOL, V146, P185, DOI 10.1111/j.1365-2141.2009.07722.x; Jakubcakova V, 2007, NEURON, V54, P831, DOI 10.1016/j.neuron.2007.04.031; Kobayashi M, 2017, FEBS J, V284, P3804, DOI 10.1111/febs.14280; Kohler D, 2007, CIRCULATION, V116, P1784, DOI 10.1161/CIRCULATIONAHA.107.690180; Kronfeld-Schor N, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1354; Kupeli NY, 2018, PSYCHIAT RES, V260, P432, DOI 10.1016/j.psychres.2017.12.020; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Lindsey ML, 2018, AM J PHYSIOL-HEART C, V314, pH812, DOI 10.1152/ajpheart.00335.2017; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Oyama Y, 2020, MIL MED, V185, pE1542, DOI 10.1093/milmed/usaa088; Oyama Y, 2019, CELL REP, V28, P1471, DOI 10.1016/j.celrep.2019.07.020; Oyama Y, 2018, CURR PHARM DESIGN, V24, P3376, DOI 10.2174/1381612824666180924102530; Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706; Powell K, 2014, NAT MED, V20, P1082, DOI 10.1038/nm1014-1082; Reiter R, 2012, CIRC RES, V110, P105, DOI 10.1161/CIRCRESAHA.111.254284; Semenza GL, 2014, ANNU REV PHYSIOL, V76, P39, DOI 10.1146/annurev-physiol-021113-170322; Somanath PR, 2011, J CELL PHYSIOL, V226, P132, DOI 10.1002/jcp.22314; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Takeda N, 2010, HYPERTENS RES, V33, P645, DOI 10.1038/hr.2010.68; Tiedt R, 2007, BLOOD, V109, P1503, DOI 10.1182/blood-2006-04-020362; Tracey CJ, 2012, J THROMB HAEMOST, V10, P662, DOI 10.1111/j.1538-7836.2012.04643.x; Vasile VC, 2008, CLIN CHEM, V54, P617, DOI 10.1373/clinchem.2007.095604; Weig HJ, 2008, J MOL CELL CARDIOL, V44, P143, DOI 10.1016/j.yjmcc.2007.09.018; Westgate EJ, 2008, CIRCULATION, V117, P2087, DOI 10.1161/CIRCULATIONAHA.107.739227; White WB, 2001, BLOOD PRESS MONIT, V6, P63, DOI 10.1097/00126097-200104000-00001; Wu YL, 2017, CELL METAB, V25, P73, DOI 10.1016/j.cmet.2016.09.009; Xu YQ, 2006, AM J PHYSIOL-HEART C, V290, pH692, DOI 10.1152/ajpheart.00634.2005; Zhang JF, 2006, NATURE, V439, P340, DOI 10.1038/nature04368; Zhao Y, 2011, THROMB RES, V127, P122, DOI 10.1016/j.thromres.2010.11.025; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	52	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244792	10.1371/journal.pone.0244792	http://dx.doi.org/10.1371/journal.pone.0244792			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382840	Green Published, gold			2023-01-03	WOS:000605651900100
J	Akter, S; Rich, JL; Davies, K; Inder, KJ				Akter, Shahinoor; Rich, Jane Louise; Davies, Kate; Inder, Kerry Jill			Prevalence and factors associated with antenatal care service access among Indigenous women in the Chittagong Hill Tracts, Bangladesh: A cross-sectional study	PLOS ONE			English	Article							MATERNAL HEALTH-SERVICES; TRIBAL WOMEN; MORTALITY; DYNAMICS; BARRIERS; PEOPLES	Background Prevalence of accessing antenatal care (ANC) services among Indigenous women in the Chittagong Hill Tracts (CHT) is unknown. This study aims to estimate the prevalence of accessing ANC services by Indigenous women in the CHT and identify factors associated with knowledge of, and attendance at, ANC services. Methods Using a cross-sectional design three Indigenous groups in Khagrachari district, CHT, Bangladesh were surveyed between September 2017 and February 2018. Indigenous women within 36 months of delivery were asked about attending ANC services and the number who attended was used to estimate prevalence. Socio-demographic and obstetric characteristics were used to determine factors associated with knowledge and attendance using multivariable logistic regression techniques adjusted for clustering by village; results are presented as odds ratios (OR), adjusted OR, and 95% confidence intervals (CI). Results Of 494 indigenous women who met the inclusion criteria in two upazilas, 438 participated (89% response rate) in the study, 75% were aged 16-29 years. Sixty-nine percent were aware of ANC services and the prevalence of attending ANC services was 53% (n = 232, 95%CI 0.48-0.58). Half (52%; n = 121) attended private facilities. Independent factors associated with knowledge about ANC were age >= 30 years (OR 2.2, 95%CI 1.1-4.6), monthly household income greater than 20,000 Bangladeshi Taka (OR 3.4, 95%CI 1.4-8.6); knowledge of pregnancy-related complications (OR 3.6, 95%CI 1.6-8.1), knowledge about nearest health facilities (OR 4.3, 95%CI 2.1-8.8); and attending secondary school or above (OR 4.8, 95%CI 2.1-11). Independent factors associated with attending ANC services were having prior knowledge of ANC benefits (OR 7.7, 95%CI 3.6-16), Indigenous women residing in Khagrachhari Sadar subdistrict (OR 6.5, 95%CI 1.7-25); and monthly household income of 20,000 Bangladeshi Taka or above (OR 2.8, 95%CI 1.1-7.4). Conclusion Approximately half of Indigenous women from Chittagong Hill Tracts Bangladesh attended ANC services at least once. Better awareness and education may improve ANC attendance for Indigenous women. Cultural factors influencing attendance need to be explored.	[Akter, Shahinoor; Rich, Jane Louise] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Akter, Shahinoor; Inder, Kerry Jill] Univ Newcastle, Prior Res Ctr Generat Hlth & Ageing, Callaghan, NSW, Australia; [Akter, Shahinoor; Inder, Kerry Jill] Hunter Med Res Inst, New Lambton, NSW, Australia; [Akter, Shahinoor] Jagannath Univ, Dept Anthropol, Dhaka, Bangladesh; [Rich, Jane Louise] Ctr Brain & Mental Hlth Res, Callaghan, NSW, Australia; [Davies, Kate] Univ Newcastle, Fac Educ & Arts, Sch Humanities & Social Sci, Callaghan, NSW, Australia; [Inder, Kerry Jill] Univ Newcastle, Fac Hlth & Med, Sch Nursing & Midwifery, Callaghan, NSW, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; University of Newcastle	Akter, S (corresponding author), Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Callaghan, NSW, Australia.; Akter, S (corresponding author), Univ Newcastle, Prior Res Ctr Generat Hlth & Ageing, Callaghan, NSW, Australia.; Akter, S (corresponding author), Hunter Med Res Inst, New Lambton, NSW, Australia.; Akter, S (corresponding author), Jagannath Univ, Dept Anthropol, Dhaka, Bangladesh.	Shahinoor.Akter@uon.edu.au		Davies, Kate/0000-0003-2638-0980; Inder, Kerry/0000-0003-4412-0322; AKTER, SHAHINOOR/0000-0002-5236-3597				Adhikari T, 2016, INDIAN J MED RES, V143, P58, DOI 10.4103/0971-5916.193284; Akter S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033224; Akter S, 2019, INT J PUBLIC HEALTH, V64, P343, DOI 10.1007/s00038-018-1177-4; Ali N, 2018, HEALTH SERV RES MANA, V5, DOI 10.1177/2333392818781729; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Amano Tatsuya, 2016, PLoS Biol, V14, pe2000933, DOI 10.1371/journal.pbio.2000933; Badiuzzaman M, 2020, J DEV STUD, V56, P384, DOI 10.1080/00220388.2018.1554211; Bangladesh Bureau of Statistics, 2013, DISTR STAT 2011 KHAG; Barkat A., 2009, SOCIOECONOMIC BASELI; BHUTTA ZA, 2018, BMJ-BRIT MED J, V363, DOI DOI 10.1136/BMJ.K4884; Bursac Z, PURPOSEFUL SELECTION; Dahlui M, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.28822; Dansereau E., 2018, Maternal death and pregnancy-related morbidity among indigenous women of Mexico and Central America. An anthropological, epidemiological, and biomedical approach, P133; Davy C, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0450-5; DESAI S, 1994, POPUL DEV REV, V20, P115, DOI 10.2307/2137632; El Arifeen S, 2013, LANCET, V382, P2012, DOI 10.1016/S0140-6736(13)62149-2; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Ha BTT, 2015, INT J WOMENS HEALTH, V7, P699, DOI 10.2147/IJWH.S87276; Harris A, 2010, HEALTH POLICY PLANN, V25, P311, DOI 10.1093/heapol/czp062; Human Development Research Centre, 2014, STAT DEV CHITT HILL; Ibanez-Cuevas M, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0289-1; Islam MR, 2011, RURAL REMOTE HEALTH, V11; Islam RM, 2017, WOMEN HEALTH, V57, P108, DOI 10.1080/03630242.2016.1153020; IWGIA, STAT IND WOM GIRLS B; Ruiz MJ, 2013, CULT HEALTH SEX, V15, P205, DOI 10.1080/13691058.2012.751128; Kamal N, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0311-2; Kamal SMM, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1467, DOI 10.1177/1010539513485786; Kamal S M Mostafa, 2013, J Family Reprod Health, V7, P73; Lehmann U, 2007, STATE EVIDENCE PROGR, P1; Lennox C., 2013, ADDRESSING HLTH INEQ; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Miltenburg AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188279; MOHFW (Ministry of Health and Family Welfare), 2012, BANGL POP POL 2012; NIPORT ACPR ICF, 2018, BANGL HLTH FAC SURV; NIPORT icddrb Evaluation M, 2017, BANGLADESH MATERNAL; NIPORT Mitra and Associates & ICF International, 2014, BANGL DEM HLTH SURV; Pulok MH, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0970-4; Rahman A, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-016-0078-5; Razak BA, 2013, HLTH POLICY PLANNING, V29, P580, DOI 10.1093/heapol/czt044; Roy P., 2014, QUEST SECURITY EQUAL; SEDGWICK P, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G2979; SEDGWICK P, 2015, BMJ-BRIT MED J, V350, DOI DOI 10.1136/BMJ.H1286; Shah R, 2011, CAN STUD POPUL, V38, P83, DOI 10.25336/P6Z89V; Shahjahan M, 2017, MIDWIFERY, V52, P42, DOI 10.1016/j.midw.2017.05.011; Siddique AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205149; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Stephens C, 2005, LANCET, V366, P10, DOI 10.1016/S0140-6736(05)66801-8; Tuhin M, 2015, HLTH DISCOURSE CHITT; Uddin A, 2016, ETHNOPOLITICS, V15, P319, DOI 10.1080/17449057.2015.1037060; UNICEF, 2015, CHITTAGONG HILL TRAC; Van Schendel W, 2000, CHITTAGONG HILL TRAC, DOI [10.1103/PhysRevLett.84.2642, DOI 10.1103/PHYSREVLETT.84.2642]; Varma GR, 2011, J EGYPT PUBLIC HEAL, V86, P11, DOI 10.1097/01.EPX.0000395395.17777.be; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; White J, 2012, GLOB PUBLIC HEALTH, V7, P869, DOI 10.1080/17441692.2012.679743; WHO, 2022, WHO RECOMMENDATIONS; World Health Organization, 2015, 9241509090 WHO; World Health Organization, 2018, MAN COMPL PREGN CHIL	57	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0244640	10.1371/journal.pone.0244640	http://dx.doi.org/10.1371/journal.pone.0244640			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PM2BU	33373416	Green Published, gold			2023-01-03	WOS:000603612300023
J	Lee, J; Lee, W; Lee, YJ; Sim, H; Lee, WK				Lee, Joongyub; Lee, Woojoo; Lee, Yu Jin; Sim, Hyunman; Lee, Won Kyung			Effectiveness of bystander cardiopulmonary resuscitation in improving the survival and neurological recovery of patients with out-of-hospital cardiac arrest: A nationwide patient cohort study	PLOS ONE			English	Article							ASSOCIATION; PREDICTORS; LOCATION; GENDER	Introduction Few studies have focused on enhancing causality and yielding unbiased estimates on the effectiveness of bystander cardiopulmonary resuscitation (BCPR) on the outcomes of out-of-hospital cardiac arrest (OHCA) in a real-world setting. Therefore, this study evaluated the effect of BCPR on the outcomes of OHCA and its differences according to the characteristics of OHCA. Methods This study enrolled all patients with OHCA of cardiac etiology treated by emergency medical services (EMS) in Korea from 2012 to 2015. The endpoints were survival and neurological recovery at discharge, and the main exposure was BCPR conducted by a layperson. The effect of BCPR was analyzed after adjusting for confounders, determined using a directed acyclic graph, by inverse probability of treatment weighting (IPTW) and model-based standardization (STR). Moreover, differences in subgroups and time trends were evaluated. Results Among 10,505 eligible patients after excluding those with missing data on BCPR, 7,721 patients received BCPR, accounting for 74.3% of EMS-treated OHCA patients. BCPR increased the odds of survival and good neurological recovery at discharge by 1.67- (95% confidence interval (CI): 1.44-1.93) and 1.93- (95% CI: 1.56-2.39) fold, respectively, in the IPTW analysis. These findings were comparable to those obtained with STR. The odds ratios were 2.39 (95% CI: 1.91-2.94) and 2.70 (95% CI: 1.94-3.41), respectively, in the sensitivity analysis of the missing BCPR information considering confounders and the outcome variable. However, the effect of qualified BCPR was not evenly distributed, and it did not increase with time. BCPR was likely to be more effective in male patients aged <65 years, those who experienced an OHCA in a private place or non-capital region, and those with shockable rhythm at the scene. Conclusion Based on data from a nationwide registry, the estimated effect of BCPR on survival and neurological recovery was moderate and did not improve from 2012 to 2015.	[Lee, Joongyub] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Lee, Woojoo; Sim, Hyunman] Seoul Natl Univ, Grad Sch Publ Hlth, Dept Publ Hlth Sci, Seoul, South Korea; [Lee, Yu Jin] Inha Univ, Inha Univ Hosp, Sch Med, Dept Emergency Med, Incheon, South Korea; [Lee, Won Kyung] Inha Univ, Inha Univ Hosp, Sch Med, Dept Prevent & Management, Incheon, South Korea	Seoul National University (SNU); Seoul National University (SNU); Inha University; Inha University Hospital; Inha University; Inha University Hospital	Lee, WK (corresponding author), Inha Univ, Inha Univ Hosp, Sch Med, Dept Prevent & Management, Incheon, South Korea.	bluewhale65@inha.ac.kr		Lee, Won Kyung/0000-0002-6014-8854; Lee, Woojoo/0000-0001-7447-7045	Bio & Medical Technology Development Program of the National Research Foundation - Korean government (MSIT) [2019M3E5D1A0206962012]	Bio & Medical Technology Development Program of the National Research Foundation - Korean government (MSIT)	WKL received funding for this work by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Korean government (MSIT) (2019M3E5D1A0206962012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHA, 2018, AHA RELEASES LATEST; Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Blewer AL, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.004710; Bougouin W, 2015, RESUSCITATION, V94, P55, DOI 10.1016/j.resuscitation.2015.06.018; Chen KY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211792; Coute RA, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.118.004677; Eftestol T, 2004, CIRCULATION, V110, P10, DOI 10.1161/01.CIR.0000133323.15565.75; Fukuda T, 2016, EUR J INTERN MED, V30, P61, DOI 10.1016/j.ejim.2016.01.022; Gharibzadeh S, 2016, ARCH IRAN MED, V19, P666, DOI 0161909/AIM.0011; Graham R M.M., 2015, STRATEGIES IMPROVE C, P456; Hagihara A, 2018, INT J CARDIOL, V265, P240, DOI 10.1016/j.ijcard.2018.04.067; Han KS, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050644; Holmberg M, 2001, EUR HEART J, V22, P511, DOI 10.1053/euhj.2000.2421; Hyman MC, 2019, EUR HEART J, V40, P3835, DOI 10.1093/eurheartj/ehz504; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Kim DK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232999; Kim YT, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016925; Korea_Centers_for_Disease_Control_and_Prevention, 2019, WEEKL HLTH DIS, P35; Lee DE, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e134; Lee DW, 2019, AM J EMERG MED, V37, P1999, DOI 10.1016/j.ajem.2019.02.021; Lee SY, 2019, RESUSCITATION, V138, P198, DOI 10.1016/j.resuscitation.2019.01.045; Martinell L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1677-2; Maurer H, 2019, RESUSCITATION, V136, P78, DOI 10.1016/j.resuscitation.2018.12.009; Moon S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211804; Nikolaou N, 2019, RESUSCITATION, V138, P82, DOI 10.1016/j.resuscitation.2019.02.035; Park JH, 2018, RESUSCITATION, V125, P1, DOI 10.1016/j.resuscitation.2018.01.026; Rajan S, 2016, CIRCULATION, V134, P2095, DOI 10.1161/CIRCULATIONAHA.116.024400; Ro YS, 2017, ANN EMERG MED, V69, P52, DOI 10.1016/j.annemergmed.2016.07.028; Ro YS, 2016, AM J EMERG MED, V34, P1331, DOI 10.1016/j.ajem.2015.12.001; Shah M, 2018, PREHOSP EMERG CARE, V22, P222, DOI 10.1080/10903127.2017.1376133; Shimamoto T, 2020, INT HEART J, V61, P46, DOI 10.1536/ihj.19-301; Song J, 2018, SCANDINAVIAN J TRAUM; Song KJ, 2014, RESUSCITATION, V85, P34, DOI 10.1016/j.resuscitation.2013.06.004; Stecker EC, 2014, CIRC-ARRHYTHMIA ELEC, V7, P212, DOI 10.1161/CIRCEP.113.001034; Suttorp MM, 2015, NEPHROL DIAL TRANSPL, V30, P1418, DOI 10.1093/ndt/gfu325; Tanaka Y, 2015, RESUSCITATION, V86, P74, DOI 10.1016/j.resuscitation.2014.11.004; van Nieuwenhuizen BP, 2019, RESUSCITATION, V141, P44, DOI 10.1016/j.resuscitation.2019.05.018; Zhang ZW, 2016, STAT METHODS MED RES, V25, P2053, DOI 10.1177/0962280213513758	39	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2020	15	12							e0243757	10.1371/journal.pone.0243757	http://dx.doi.org/10.1371/journal.pone.0243757			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1IW	33326454	Green Published, gold			2023-01-03	WOS:000600176400061
J	Macdonald, KE; Stacey, HJ; Harkin, G; Hall, LML; Young, MJ; Jones, JD				Macdonald, Katherine E.; Stacey, Helen J.; Harkin, Gillian; Hall, Lesley M. L.; Young, Matthew J.; Jones, Joshua D.			Patient perceptions of phage therapy for diabetic foot infection	PLOS ONE			English	Article								Infections of diabetic foot ulcers are common, generally recalcitrant and often complicated by antibiotic resistance. Alternative antimicrobial strategies are needed. Phage therapy is a promising alternative that is being rediscovered. Despite phage therapy's 100-year history, there have been no investigations into patient thoughts and concerns. This study aimed to explore patient awareness of and concern about antibiotic resistance and gain insight into the perceptions of phage therapy among a patient group that could potentially benefit from phage therapy. Patients with an active or resolved (healed or amputated) diabetic foot ulcer were eligible to participate. A survey was distributed digitally to eligible patients across Scotland via the NHS Research Scotland Diabetes Network and hard copies were available in diabetic foot clinics at the Royal Infirmary of Edinburgh and Queen Elizabeth University Hospital, Glasgow. A focus group of five survey respondents was held in Glasgow. Fifty-five survey responses were obtained. There was a high level of awareness (76.4%; N = 55) and concern (83.3%; N = 54) about antibiotic resistance. While largely aware of viruses, most patients had not heard of phage or phage therapy. Patients were no more concerned about phage than antibiotic therapy, with most suggesting more information could alleviate any concerns. Patient acceptability of phage therapy was high, a finding confirmed by the focus group. Patients are concerned about antibiotic resistance and supportive of 'new' antimicrobials. We have demonstrated that patients are supportive, enthusiastic and accepting of phage therapy. Although 'Western' phage therapy remains in its infancy, an understanding of patient ideas, concerns and expectations will be important in eventually shaping and successfully reintroducing phage therapy.	[Macdonald, Katherine E.; Jones, Joshua D.] Univ Edinburgh, Edinburgh Med Sch Biomed Sci, Infect Med, Edinburgh, Midlothian, Scotland; [Stacey, Helen J.] Univ Edinburgh, Edinburgh Med Sch, Edinburgh, Midlothian, Scotland; [Harkin, Gillian; Hall, Lesley M. L.] Queen Elizabeth Univ Hosp, Diabet & Endocrinol, Glasgow, Lanark, Scotland; [Young, Matthew J.] Royal Infirm Edinburgh NHS Trust, Outpatient Dept 2, Diabet Foot Clin, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; Queen Elizabeth University Hospital (QEUH); Royal Infirmary of Edinburgh; University of Edinburgh	Jones, JD (corresponding author), Univ Edinburgh, Edinburgh Med Sch Biomed Sci, Infect Med, Edinburgh, Midlothian, Scotland.	josh.jones@ed.ac.uk			University of Edinburgh/Medical Research Council Confidence in Concept Grant [MC_PC_18046]; NHS Research Scotland (NRS), through Diabetes Network; MRC [MC_PC_18046] Funding Source: UKRI	University of Edinburgh/Medical Research Council Confidence in Concept Grant; NHS Research Scotland (NRS), through Diabetes Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was part of a University of Edinburgh/Medical Research Council Confidence in Concept Grant awarded to JDJ (MC_PC_18046). We also acknowledge the financial support of NHS Research Scotland (NRS), through Diabetes Network. The funders had no role in the design of the study and collection, analysis, or interpretation of data nor in writing the manuscript.	Abedon ST, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00981; Armstrong DG, 2017, NEW ENGL J MED, V376, P2367, DOI 10.1056/NEJMra1615439; Brookes-Howell L, 2012, J GEN INTERN MED, V27, P766, DOI 10.1007/s11606-011-1916-1; Comeau AM, 2008, RES MICROBIOL, V159, P306, DOI 10.1016/j.resmic.2008.05.001; Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Eleftheriadou L, 2010, DRUGS, V70, P1785, DOI 10.2165/11538070-000000000-00000; Fish R, 2016, J WOUND CARE, V25, pS27, DOI 10.12968/jowc.2016.25.Sup7.S27; Goettsche LS, 2019, J DERMATOL TREAT, V30, P92, DOI 10.1080/09546634.2018.1473549; Gupta P, 2019, INT J LOW EXTR WOUND, V18, P171, DOI 10.1177/1534734619835115; Henig O, 2018, OPEN FORUM INFECT DI, P5, DOI [10.1093/ofid/ofy245, DOI 10.1093/0FID/0FY245]; Jault P, 2019, LANCET INFECT DIS, V19, P35, DOI 10.1016/S1473-3099(18)30482-1; Kortright KE, 2019, CELL HOST MICROBE, V25, P219, DOI 10.1016/j.chom.2019.01.014; Morozova VV, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01696; Patel DR, 2021, INT J LOW EXTR WOUND, V20, P37, DOI 10.1177/1534734619881076; Prompers L, 2007, DIABETOLOGIA, V50, P18, DOI 10.1007/s00125-006-0491-1; Ray A, 2015, J AM PODIAT MED ASSN, V105, P520, DOI 10.7547/14-036.1; Rhoads D D, 2009, J Wound Care, V18, P237; Rogoz P, 2019, PHAGE THERAPY: A PRACTICAL APPROACH, P189, DOI 10.1007/978-3-030-26736-0_8; Schooley RT, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00954-17; Scottish Diabetes Survey Monitoring Group, 2018, SCOTT DIAB SURV 2018; Stacey HJ, 2019, ACTA DIABETOL, V56, P907, DOI 10.1007/s00592-019-01301-0; Tascini C, 2011, DIABETES RES CLIN PR, V94, P133, DOI 10.1016/j.diabres.2011.07.017; The International Diabetes Federation, 2020, DIAB FACTS FIG; Weber-Dabrowska B., 2001, Clinical and Applied Immunology Reviews, V1, P131, DOI 10.1016/S1529-1049(01)00015-0; Wright A, 2009, CLIN OTOLARYNGOL, V34, P349, DOI 10.1111/j.1749-4486.2009.01973.x; Young MJ, 2020, CLIN AUDIT DAT UNPUB	26	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243947	10.1371/journal.pone.0243947	http://dx.doi.org/10.1371/journal.pone.0243947			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315926	gold, Green Published			2023-01-03	WOS:000600186100044
J	Nowak, H; Zech, N; Asmussen, S; Rahmel, T; Tryba, M; Oprea, G; Grause, L; Schork, K; Moeller, M; Loeser, J; Gyarmati, K; Mittler, C; Saller, T; Zagler, A; Lutz, K; Adamzik, M; Hansen, E				Nowak, Hartmuth; Zech, Nina; Asmussen, Sven; Rahmel, Tim; Tryba, Michael; Oprea, Guenther; Grause, Lisa; Schork, Karin; Moeller, Manuela; Loeser, Johannes; Gyarmati, Katharina; Mittler, Corinna; Saller, Thomas; Zagler, Alexandra; Lutz, Katrin; Adamzik, Michael; Hansen, Ernil			Effect of therapeutic suggestions during general anaesthesia on postoperative pain and opioid use: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT-CONTROLLED ANALGESIA; SHORT-FORM; AWARENESS; MUSIC; METAANALYSIS; RECOVERY; SURGERY; ANXIETY; SCALE	OBJECTIVE To investigate the effect of therapeutic suggestions played to patients through earphones during surgery on postoperative pain and opioid use. DESIGN Blinded randomised controlled study. SETTING Five tertiary care hospitals in Germany. PARTICIPANTS 385 of 400 patients consecutively recruited from January to December 2018 who were to undergo surgery for 1-3 hours under general anaesthesia. In the per protocol analysis 191 patients were included in the intervention group and 194 patients in the control group. INTERVENTION The intervention comprised an audiotape of background music and positive suggestions based on hypnotherapeutic principles, which was played repeatedly for 20 minutes followed by 10 minutes of silence to patients through earphones during general anaesthesia. Patients in the control group were assigned to a blank tape. MAIN OUTCOME MEASURES The main outcome was dose of opioid administered by patient controlled analgesia or nurse controlled analgesia within the first postoperative 24 hours, based on regular evaluation of pain intensity on a numerical rating scale (range 0-10, with higher scores representing more severe pain). RESULTS Compared with the control group, the intervention group required a significantly (P=0.002) lower opioid dose within 24 hours after surgery, with a median of 4.0 mg (interquartile range 0-8) morphine equivalents versus 5.3 (2-12), and an effect size (Cohen's d) of 0.36 (95% confidence interval 0.16 to 0.56). The number of patients who needed opioids postoperatively was significantly (P=0.001) reduced in the intervention group: 121 of 191 (63%, 95% confidence interval 45% to 70%) patients in the intervention group versus 155 of 194 (80%, 74% to 85%) in the control group. The number needed to treat to avoid postoperative opioids was 6. Pain scores were consistently and significantly lower in the intervention group within 24 hours after surgery, with an average reduction of 25%. No adverse events were reported. CONCLUSIONS Therapeutic suggestions played through earphones during general anaesthesia could provide a safe, feasible, inexpensive, and non-drug technique to reduce postoperative pain and opioid use, with the potential for more general use. Based on the finding of intraoperative perception by a considerable number of patients, surgeons and anaesthetists should be careful about background noise and conversations during surgery.	[Nowak, Hartmuth; Asmussen, Sven; Rahmel, Tim; Oprea, Guenther; Grause, Lisa; Adamzik, Michael] Ruhr Univ Bochum, Univ Hosp Knappschaftskrankenhaus, Dept Anesthesiol Intens Care Med & Pain Therapy, Bochum, Germany; [Zech, Nina; Lutz, Katrin] Univ Regensburg, Univ Hosp Regensburg, Dept Anesthesiol, Regensburg, Germany; [Tryba, Michael] Kassel Hosp, Clin Anesthesiol Intens Care Med Emergency Med &, Kassel, Germany; [Tryba, Michael; Moeller, Manuela] Kassel Sch Med, Kassel, Germany; [Schork, Karin] Ruhr Univ Bochum, Med Proteom Ctr, Bochum, Germany; [Loeser, Johannes; Gyarmati, Katharina; Mittler, Corinna] Univ Cologne, Univ Hosp, Dept Anesthesiol & Intens Care Med, Cologne, Germany; [Saller, Thomas; Zagler, Alexandra] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Anaesthesiol, Munich, Germany; [Hansen, Ernil] Univ Hosp Regensburg, Dept Anaesthesiol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany	Ruhr University Bochum; University of Regensburg; Ruhr University Bochum; University of Cologne; University of Munich; University of Regensburg	Hansen, E (corresponding author), Univ Hosp Regensburg, Dept Anaesthesiol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	hansen@ukr.de	Adamzik, Michael/HGE-9286-2022; Saller, Thomas/AAB-6223-2022; Schork, Karin/AAU-9708-2021	Schork, Karin/0000-0003-3756-4347	de.NBI, a project of the German Federal Ministry of Education and Research (BMBF) [FKZ 031 A 534A]	de.NBI, a project of the German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This study received no direct funding. Statistical analysis was partly supported by de.NBI, a project of the German Federal Ministry of Education and Research (BMBF) (grant No FKZ 031 A 534A), without any role in study design, data collection, and publication.	CHEEK D B, 1962, Am J Proctol, V13, P287; CHEEK DB, 1962, AM J CLIN HYPN, V4, P227; Chen QS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7621; CLARK DL, 1973, ANESTHESIOLOGY, V38, P564, DOI 10.1097/00000542-197306000-00011; Dawson PR, 2001, ANAESTHESIA, V56, P65, DOI 10.1046/j.1365-2044.2001.01763-5.x; Frampton JE, 2010, DRUGS, V70, P1719, DOI 10.2165/11204470-000000000-00000; Gao WW, 2018, CURR MED SCI, V38, P349, DOI 10.1007/s11596-018-1886-1; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Hauser W, 2012, DTSCH ARZTEBL INT, V109, P459, DOI 10.3238/arztebl.2012.0459; Hajat Z, 2017, ANAESTHESIA, V72, P38, DOI 10.1111/anae.13739; Hansen E, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00077; Hauser W, 2016, DTSCH ARZTEBL INT, V113, P289, DOI 10.3238/arztebl.2016.0289; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hole J, 2015, LANCET, V386, P1659, DOI 10.1016/S0140-6736(15)60169-6; Kehlet H, 2005, ANESTHESIOLOGY, V102, P1083, DOI 10.1097/00000542-200506000-00004; Kekecs Z, 2014, ANESTH ANALG, V119, P1407, DOI 10.1213/ANE.0000000000000466; Kuhlmann AYR, 2018, BRIT J SURG, V105, P773, DOI 10.1002/bjs.10853; LEVINSON BW, 1965, BRIT J ANAESTH, V37, P544, DOI 10.1093/bja/37.7.544; MADLER C, 1991, BRIT J ANAESTH, V66, P81, DOI 10.1093/bja/66.1.81; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Matsota P, 2013, J ALTERN COMPLEM MED, V19, P298, DOI 10.1089/acm.2010.0235; McNicol ED, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003348.pub3; Merikle PM, 1996, CONSCIOUS COGN, V5, P525, DOI 10.1006/ccog.1996.0031; Messina AG, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007272.pub2; Migneault B, 2004, ANESTH ANALG, V98, P527, DOI 10.1213/01.ANE.0000096182.70239.23; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; Nilsson U, 2001, ACTA ANAESTH SCAND, V45, P812, DOI 10.1034/j.1399-6576.2001.045007812.x; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Richter M, 2010, PAIN, V148, P198, DOI 10.1016/j.pain.2009.08.009; Rief W, 2009, J AFFECT DISORDERS, V118, P1, DOI 10.1016/j.jad.2009.01.029; Riegel B, 2021, INT J CLIN EXP HYP, V69, P112, DOI 10.1080/00207144.2021.1836645; Roessler M, 2018, ANASTH INTENSIVMED, V59, P430, DOI 10.19224/ai2018.430; Rosendahl J, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0292-0; Samuelsson P, 2007, ANESTHESIOLOGY, V106, P26, DOI 10.1097/00000542-200701000-00009; Schnur Julie B, 2008, Contemp Hypn, V25, P114, DOI 10.1002/ch.364; Tasbihgou SR, 2018, ANAESTHESIA, V73, P112, DOI 10.1111/anae.14124; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652	38	16	16	2	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2020	371								m4284	10.1136/bmj.m4284	http://dx.doi.org/10.1136/bmj.m4284			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH2WY	33303476	Green Published, hybrid			2023-01-03	WOS:000600280900009
J	Robbins, C; Martocci, S				Robbins, Carolyn; Martocci, Samantha			Timing of Prenatal Care Initiation in the Health Resources and Services Administration Health Center Program in 2017	ANNALS OF INTERNAL MEDICINE			English	Article							PREGNANT-WOMEN; UNITED-STATES; DISPARITIES; ACCESS; COVERAGE	Background: Early prenatal care is vital for improving maternal health outcomes and health behaviors, but medically vulnerable and underserved populations are less likely to begin prenatal care in the first trimester. In 2017, the Health Center Program provided safety-net care to more than 27 million persons, including 573 026 prenatal patients, at approximately 12 000 sites across the United States and U.S. jurisdictions. As part of a mandatory reporting requirement, health centers tracked whether patients initiated prenatal care in their first trimester of pregnancy. Objective: To identify health center characteristics associated with the initiation of prenatal care in the first trimester, as well as actionable steps policymakers, providers, and health centers can take to promote early initiation of prenatal care. Design: Secondary analysis of cross-sectional data from the 2017 Uniform Data System. Setting: The United States and 8 U.S. jurisdictions. Participants: Health center grantees with prenatal patients (n = 1281). Measurements: Multinomial logistic regression (adjusted for state or jurisdiction clustering) was used to identify health center characteristics associated with achievement of the Healthy People 2020 baseline (77.1%) and target (84.8%) for women receiving prenatal care in the first trimester (Maternal, Infant, and Child Health Objective 10.1). Results: Overall, 57.4% of health centers met the Healthy People 2020 baseline (mean, 78%; median, 81%), and 37.9% met the Healthy People 2020 target. Several characteristics were positively associated with meeting the baseline (larger proportion of prenatal patients aged 20 to 24 years) and target (more total patients, prenatal care by referral only, a larger proportion of prenatal patients aged 25 to 44 or >= 45 years, and a larger proportion of White or privately insured patients). Other characteristics were negatively associated with the baseline (location outside New England, location in a rural area, and a large proportion of prenatal patients aged <15 years) and target (more prenatal patients, location outside New England, provision of prenatal care to women living with HIV, and more uninsured patients or patients eligible for both Medicare and Medicaid). Limitation: The data set is at the health center grantee level and does not contain information on timing or quality of follow-up prenatal care. Conclusion: Most health centers met the Healthy People 2020 baseline, but opportunities for improvement remain and the Healthy People 2020 target is still a challenge for many health centers. Policymakers, providers, and health centers can learn from high-achieving centers to promote early initiation of prenatal care among medically vulnerable and underserved populations.	[Robbins, Carolyn] US Dept HHS, Hlth Resources & Serv Adm, Rockville, MD USA; [Martocci, Samantha] Univ Chicago, NORC, 4350 East West Highway, Bethesda, MD 20814 USA; [Robbins, Carolyn] Hlth Resources & Serv Adm, 5600 Fishers Lane 14W-57A, Rockville, MD 20857 USA	United States Health Resources & Service Administration (HRSA); University of Chicago; United States Health Resources & Service Administration (HRSA)	Robbins, C (corresponding author), Hlth Resources & Serv Adm, 5600 Fishers Lane 14W-57A, Rockville, MD 20857 USA.	CRobbins@hrsa.gov			HRSA	HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))	Dr. Robbins reports financial support through employment at HRSA.	Atkins DN, 2018, PUBLIC HEALTH NURS, V35, P459, DOI 10.1111/phn.12524; Bircher H, 2009, MCN-AM J MATERN-CHIL, V34, P303, DOI 10.1097/01.NMC.0000360423.14110.96; Clapp MA, 2019, J PERINATOL, V39, P300, DOI 10.1038/s41372-018-0292-7; Committee to Study the Prevention of Low Birthweight; Division of Health Promotion and Disease Prevention; Institute of Medicine, 1985, PREV LOW BIRTHW; Daw JR, 2018, JAMA-J AM MED ASSOC, V319, P579, DOI 10.1001/jama.2018.0030; ElamEvans LD, 1996, OBSTET GYNECOL, V87, P575, DOI 10.1016/0029-7844(95)00474-2; Gadson A, 2017, SEMIN PERINATOL, V41, P308, DOI 10.1053/j.semperi.2017.04.008; Gjesfjeld CD, 2011, SOC WORK HEALTH CARE, V50, P682, DOI 10.1080/00981389.2011.575537; Goffman D, 2007, J PERINATOL, V27, P597, DOI 10.1038/sj.jp.7211810; Health Resources and Services Administration Bureau of Primary Health Care, 2017, NAT HLTH CTR DAT; Health Resources Services Administration, UN DAT SYST REP INST; Healy AJ, 2006, OBSTET GYNECOL, V107, P625, DOI 10.1097/01.AOG.0000201978.83607.96; Henderson J W, 1994, Health Care Financ Rev, V15, P21; HOAGBERG BL, 1990, SOC SCI MED, V30, P487, DOI 10.1016/0277-9536(90)90351-R; Howell EA, 2018, CLIN OBSTET GYNECOL, V61, P387, DOI 10.1097/GRF.0000000000000349; Nothnagle M, 2000, Matern Child Health J, V4, P251; Osterman Michelle J K, 2018, Natl Vital Stat Rep, V67, P1; Phillippi JC, 2009, J MIDWIFERY WOM HEAL, V54, P219, DOI 10.1016/j.jmwh.2009.01.002; Richards R, 2011, PEDIATRICS, V128, P438, DOI 10.1542/peds.2010-3491; Shah JS, 2018, MATERN CHILD HLTH J, V22, P1738, DOI 10.1007/s10995-018-2569-z; Shi LY, 2004, HEALTH SERV RES, V39, P1881, DOI 10.1111/j.1475-6773.2004.00323.x; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; Stein JA, 2000, HEALTH PSYCHOL, V19, P524; U.S. Department of Health and Human Services, HLTH PEOPL 2020 MAT; Yan J, 2017, HEALTH ECON, V26, P1001, DOI 10.1002/hec.3380	25	2	2	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2020	173			11			S29	S36		10.7326/M19-3248	http://dx.doi.org/10.7326/M19-3248			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QI2TF	33253020				2023-01-03	WOS:000618828900005
J	Ram, S; Russell, B; Kirkpatrick, C; Stewart, K; Scahill, S; Henning, M; Curley, L; Hussainy, S				Ram, Sanyogita (Sanya); Russell, Bruce; Kirkpatrick, Carl; Stewart, Kay; Scahill, Shane; Henning, Marcus; Curley, Louise; Hussainy, Safeera			Professionals' attitudes towards the use of cognitive enhancers in academic settings	PLOS ONE			English	Article							ILLICIT USE; PRESCRIPTION STIMULANTS; HEALTHY-INDIVIDUALS; NONMEDICAL USE; MEDICAL USE; STUDENTS; DIVERSION; MOTIVES	Introduction and aims The non-medical use of prescription stimulants such as methylphenidate, dexamphetamine and modafinil is increasing in popularity within tertiary academic settings. There is a paucity of information on awareness, attitudes, and acceptability by professionals of use in this context. This study aimed to investigate professionals' knowledge of and attitudes towards the use of cognitive enhancers (CEs) in academic settings, and their willingness to use a hypothetical CE. Design and methods A mail survey was sent to doctors, pharmacists, nurses, accountants and lawyers in New Zealand. These disciplines were chosen as they require professional registration to practice. The questionnaire comprised four sections: (1) demographics, (2) knowledge of CEs, (3) attitudes towards the use of CEs, and (4) willingness to use hypothetical CEs. Results The response rate was 34.5% (414/1200). Overall, participants strongly disagreed that it was fair to allow university students to use CEs for cognitive enhancement (Mdn = 1, IQR: 1,3), or that it is ethical for students without a prescription to use cognitive enhancers for any reason (Mdn = 1, IQR: 1,2). Professions differed in their attitudes towards whether it is ethical for students without a prescription to use CEs for any reason (p = 0.001, H 31.527). Discussion and conclusion Divergent views and lack of clear consensus within professions and between professionals on the use of CEs have the potential to influence both professionals and students as future professionals. These divergent views may stem from differences in the core values of self-identity as well as extrinsic factors of acceptability within the profession in balancing the elements of opportunity, fairness and authenticity in cognitive enhancement. Further research is required to inform the development of policy and guidelines that are congruent with all professions.	[Ram, Sanyogita (Sanya); Kirkpatrick, Carl; Stewart, Kay] Monash Univ, Fac Pharm & Pharmaceut Sci, Ctr Med Use & Safety, Parkville Campus, Parkville, Vic, Australia; [Ram, Sanyogita (Sanya); Scahill, Shane; Curley, Louise] Univ Auckland, Sch Pharm, Fac Med & Hlth Sci, Auckland, New Zealand; [Russell, Bruce] Univ Otago, Sch Pharm, Clin Pharm, Dunedin, New Zealand; [Henning, Marcus] Univ Auckland, Fac Med & Hlth Sci, Ctr Med & Hlth Sci Educ, Auckland, New Zealand; [Hussainy, Safeera] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary & Allied Hlth Care, Dept Gen Practice, Notting Hill, Vic, Australia	Monash University; University of Auckland; University of Otago; University of Auckland; Monash University	Ram, S (corresponding author), Monash Univ, Fac Pharm & Pharmaceut Sci, Ctr Med Use & Safety, Parkville Campus, Parkville, Vic, Australia.; Ram, S (corresponding author), Univ Auckland, Sch Pharm, Fac Med & Hlth Sci, Auckland, New Zealand.	Sanya.ram@auckland.ac.nz	Kirkpatrick, Carl MJ/F-1222-2010	Ram, Sanya/0000-0002-5774-1972; Kirkpatrick, Carl/0000-0002-5715-1534; Hussainy, Safeera/0000-0003-1418-8078				[Anonymous], 2000, MAIL INTERNET SURVEY; [Anonymous], 2010, SANGAKU SHUGEN, V45, P31; Banjo OC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014322; Bergstrom LS, 2008, SCAND J PUBLIC HEALT, V36, P532, DOI 10.1177/1403494807087558; Buchman Daniel Z, 2010, AJOB Neurosci, V1, P36; Coveney C, 2019, DRUG-EDUC PREV POLIC, V26, P319, DOI 10.1080/09687637.2019.1593318; Davis CG, 2010, ADDICT BEHAV, V35, P302, DOI 10.1016/j.addbeh.2009.11.001; DeSantis AD, 2008, J AM COLL HEALTH, V56, P315, DOI 10.3200/JACH.57.3.315-324; Duffull SB, 2018, RES SOC ADMIN PHARM, V14, P309, DOI 10.1016/j.sapharm.2017.04.049; Field A., 2018, DISCOVERING STAT USI; Fitz NS, 2014, NEUROETHICS-NETH, V7, P173, DOI 10.1007/s12152-013-9190-z; Forlini C, 2012, PUBLIC UNDERST SCI, V21, P606, DOI 10.1177/0963662510385062; Forlini C, 2009, NEUROETHICS-NETH, V2, P163, DOI 10.1007/s12152-009-9043-y; Forlini Cynthia., 2012, AJOB PRIMARY RES, V3, P33, DOI [DOI 10.1080/21507716.2011.645116, 10.1080/21507716.2011.645116]; Franke AG, 2011, PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Franke AG, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-102; Hall KM, 2005, J AM COLL HEALTH, V53, P167, DOI 10.3200/JACH.53.4.167-174; Herman-Stahl MA, 2007, ADDICT BEHAV, V32, P1003, DOI 10.1016/j.addbeh.2006.07.010; Judson R, 2009, PSYCHOL HEALTH MED, V14, P97, DOI 10.1080/13548500802126723; Kudlow PA, 2013, J PSYCHOACTIVE DRUGS, V45, P360, DOI 10.1080/02791072.2013.825033; Lazuras L, 2017, SUBST USE MISUSE, V52, P950, DOI 10.1080/10826084.2016.1267223; Lengvenyte A, 2016, NORD STUD ALCOHOL DR, V33, P173, DOI 10.1515/nsad-2016-0014; Maher B, 2008, NATURE, V452, P674, DOI 10.1038/452674a; Maier LJ, 2018, INT J DRUG POLICY, V58, P104, DOI 10.1016/j.drugpo.2018.05.009; Maier LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129805; Mayor E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213619; McCabe SE, 2006, J PSYCHOACTIVE DRUGS, V38, P43, DOI 10.1080/02791072.2006.10399827; McCabe SE, 2006, J AM COLL HEALTH, V54, P269, DOI 10.3200/JACH.54.5.269-278; McNiel AD, 2011, J DENT EDUC, V75, P365; Petersen MA, 2019, RES SOC ADMIN PHARM, V15, P1204, DOI 10.1016/j.sapharm.2018.10.005; Petersen MA, 2015, DRUG-EDUC PREV POLIC, V22, P201, DOI 10.3109/09687637.2014.970517; Ram S, DRUGS ED PREVENTION, V2020, P1; Ram S, 2017, SUBST USE MISUSE, V52, P1387, DOI 10.1080/10826084.2017.1281313; Ram S, 2016, DRUG ALCOHOL REV, V35, P345, DOI 10.1111/dar.12294; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Sales P, 2019, DRUG-EDUC PREV POLIC, V26, P301, DOI 10.1080/09687637.2019.1606895; Sattler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068821; Silveira Rodrigo da Rosa, 2014, Trends Psychiatry Psychother., V36, P101, DOI 10.1590/2237-6089-2013-0065; Singh I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105969; Teter CJ, 2005, J AM COLL HEALTH, V53, P253, DOI 10.3200/JACH.53.6.253-262; Wolff W, 2013, SUBST ABUSE TREAT PR, V8, DOI 10.1186/1747-597X-8-23	41	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0241968	10.1371/journal.pone.0241968	http://dx.doi.org/10.1371/journal.pone.0241968			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PA5CL	33216781	Green Published, gold			2023-01-03	WOS:000595653500027
J	Demissie, SD; Kozuki, N; Olorunsaiye, CZ; Gebrekirstos, P; Mohammed, S; Kiapi, L; Chantler, T; Karafillakis, E; Landegger, J				Demissie, Shiferaw Dechasa; Kozuki, Naoko; Olorunsaiye, Comfort Z.; Gebrekirstos, Petros; Mohammed, Siraj; Kiapi, Lilian; Chantler, Tracey; Karafillakis, Emilie; Landegger, Justine			Community engagement strategy for increased uptake of routine immunization and select perinatal services in north-west Ethiopia: A descriptive analysis	PLOS ONE			English	Article								Background Routine immunization coverage has stagnated over the past decade and fallen short of WHO targets in Ethiopia. Community engagement strategies that reach beyond traditional health systems may reduce dropout and increase coverage. This evaluation assesses changes in immunization, postpartum family planning, and antenatal care coverage after implementation of an enhanced community engagement and defaulter tracing strategy, entitled "Fifth Child" project, across two districts in Benishangul-Gumuz Regional State (BGRS), Ethiopia. Methods and findings A formative evaluation was conducted to examine the contribution of the strategy on immunization, postpartum family planning and antenatal care utilization in Assosa and Bambasi districts of BGRS. The quantitative findings are presented here. Routine and project-specific data were analyzed to assess changes in uptake of childhood vaccinations, postpartum family planning and antenatal care. Between January 2013 and December 2016, pentavalent-3 coverage increased from 63% to 84% in Assosa, and from 78% to 93% in Bambasi. Similarly, measles vaccine coverage increased from 77% to 81% in Assosa, and from 59% to 86% in Bambasi. Approximately 54% of all eligible infants across both woredas defaulted on scheduled vaccinations at least once during the period. Among defaulting children, 84% were identified and subsequently caught up on the vaccinations missed. Secondary outcomes of postpartum family planning and antenatal care also increased in both woredas. Conclusion The "Fifth Child" project likely contributed to enhanced immunization performance and increased utilization of immunization and select perinatal health services in two woredas of BGRS. Further research is required in order to determine the impact of this community engagement strategy.	[Demissie, Shiferaw Dechasa; Gebrekirstos, Petros; Mohammed, Siraj] Int Rescue Comm, Addis Ababa, Ethiopia; [Kozuki, Naoko; Olorunsaiye, Comfort Z.; Landegger, Justine] Int Rescue Comm, New York, NY 10018 USA; [Kiapi, Lilian] Int Rescue Comm, London, England; [Chantler, Tracey; Karafillakis, Emilie] London Sch Hyg & Trop Med, London, England	University of London; London School of Hygiene & Tropical Medicine	Kozuki, N (corresponding author), Int Rescue Comm, New York, NY 10018 USA.	naoko.kozuki@rescue.org		Chantler, Tracey/0000-0001-7776-7339; Kozuki, Naoko/0000-0003-2850-3956; Olorunsaiye, Comfort Z./0000-0003-4725-0448; Karafillakis, Emilie/0000-0001-8648-906X	International Initiative for Impact Evaluation (3ie); Pfizer Foundation	International Initiative for Impact Evaluation (3ie); Pfizer Foundation	International Initiative for Impact Evaluation (3ie) (https://www.3ieimpact.org) and Pfizer Foundation supported the study to JL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Animaw W, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-464; [Anonymous], 2017, ETH DEM HLTH SURV 20; [Anonymous], 2016, ADDR GAP EQ QUAL HLT; [Anonymous], 2015, HLTH SECT TRANSF PLA; [Anonymous], 2017, 5 CHILD PROJ INT REP; [Anonymous], 2012, ETH DEM HLTH SURV 20; Casey RM, 2016, GLOBAL ROUTINE VACCI; Chantler T, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040667; Etana B, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-566; Fetene N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156438; Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6; Legesse E, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0345-4; Mohamud AN, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-865; Okwaraji YB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-476; Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086; Tadesse H, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-150; Tesfaye F., 2014, INT J PUB HLTH SCI I, V3, P185; WHO, 2017, EST CHILD CAUS DEATH; WHO, 2017, IMM COV FACTSH REV M; World Health Organization, 2013, GLOB VACC ACT PLAN 2; World Health Organization, 2016, 2015 ASS REP GLOB VA	21	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0237319	10.1371/journal.pone.0237319	http://dx.doi.org/10.1371/journal.pone.0237319			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG8YH	33119604	Green Published, gold			2023-01-03	WOS:000600013600040
J	Landmesser, ME; Raup-Konsavage, WM; Lehman, HL; Stairs, DB				Landmesser, Mary E.; Raup-Konsavage, Wesley M.; Lehman, Heather L.; Stairs, Douglas B.			Loss of p120ctn causes EGFR-targeted therapy resistance and failure	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; E-CADHERIN; PROGNOSTIC VALUE; P120-CATENIN EXPRESSION; ACQUIRED-RESISTANCE; REDUCED EXPRESSION; COLORECTAL-CANCER; POOR SURVIVAL	Epidermal growth factor receptor (EGFR) plays a vital role in cell division and survival signaling pathways. EGFR is activated in nearly every cancer type, and its high expression in tumors is correlated with poor patient outcome. Altogether, EGFR is a prime candidate as a therapeutic target. While targeted EGFR therapy is initially effective in 75% of patients, a majority of patients relapse within the first year due to poorly understood mechanisms of resistance. p120-catenin (p120ctn) has recently been implicated as a biomarker for EGFR therapy. In previous studies, we demonstrated that p120ctn is a tumor suppressor and its loss is capable of inducing cancer. Furthermore, p120ctn down-regulation synergizes with EGFR overexpression to cause a highly invasive cell phenotype. The purpose of this present study was to investigate whether p120ctn down-regulation induced EGFR therapeutic resistance. Using human esophageal keratinocytes, we have found that EGFR-targeting compounds are toxic to cells overexpressing EGFR. Interestingly, these therapies do not cause toxicity in cells with EGFR overexpression and decreased p120ctn expression. These data suggest that decreased p120ctn causes resistance to EGFR therapy. We believe these findings are of utmost importance, as there is an unmet need to discover mechanisms of EGFR resistance.	[Landmesser, Mary E.; Stairs, Douglas B.] Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA; [Raup-Konsavage, Wesley M.] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA USA; [Lehman, Heather L.] Millersville Univ Pennsylvania, Dept Biol, Millersville, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State System of Higher Education (PASSHE); Millersville University of Pennsylvania	Stairs, DB (corresponding author), Penn State Univ, Coll Med, Dept Pathol, Hershey, PA 17033 USA.	dbs18@psu.edu		Stairs, Douglas/0000-0002-4875-6582; Raup-Konsavage, Wesley/0000-0001-9413-9852	American Cancer Society [RSG-16-219-01-TBG]; Department of Pathology Researcher-Initiated Grant; ET Program Development Award from the Penn State Cancer Institute; Penn State Cancer Institute; Highmark Community Health Reinvestment Grant	American Cancer Society(American Cancer Society); Department of Pathology Researcher-Initiated Grant; ET Program Development Award from the Penn State Cancer Institute; Penn State Cancer Institute; Highmark Community Health Reinvestment Grant	This research was supported by a Research Scholar Grant, RSG-16-219-01-TBG, from the American Cancer Society, a Department of Pathology Researcher-Initiated Grant, as well as an ET Program Development Award and a Program Project Development Award, both from the Penn State Cancer Institute and Highmark Community Health Reinvestment Grant (all to DBS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Ayyappan S, 2013, ANTICANCER RES, V33, P4139; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Chung Y, 2007, ANN SURG ONCOL, V14, P3260, DOI 10.1245/s10434-007-9511-8; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; Dillon DA, 1998, AM J PATHOL, V152, P75; Gold JS, 1998, CANCER LETT, V132, P193, DOI 10.1016/S0304-3835(98)00190-6; Greve G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1967-5; Ishizaki Y, 2004, J DERMATOL SCI, V34, P99, DOI 10.1016/j.jdermsci.2003.12.001; Kallakury BVS, 2001, CANCER, V92, P2786, DOI 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Koedel U, 2000, J INFECT DIS, V182, P1437, DOI 10.1086/315877; Lee HS, 2016, GUT LIVER, V10, P340, DOI 10.5009/gnl15465; Lehman Heather L, 2018, Oncotarget, V9, P11180, DOI 10.18632/oncotarget.24358; Lehman HL, 2015, AM J PATHOL, V185, P240, DOI 10.1016/j.ajpath.2014.09.008; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Liu Y, 2018, APPL IMMUNOHISTO M M, V26, P64, DOI 10.1097/PAI.0000000000000381; Lo Muzio L, 2013, OR SURG OR MED OR PA, V115, P789, DOI 10.1016/j.oooo.2013.03.006; Ma LW, 2012, J CLIN PATHOL, V65, P315, DOI 10.1136/jclinpath-2011-200516; Miao YA, 2010, MED ONCOL, V27, P880, DOI 10.1007/s12032-009-9300-2; Nakopoulou L, 2004, J CLIN PATHOL, V57, P523, DOI 10.1136/jcp.2003.008599; Nakopoulou L, 2000, ANTICANCER RES, V20, P4571; Noordhuis MG, 2011, CLIN CANCER RES, V17, P1317, DOI 10.1158/1078-0432.CCR-10-2320; Okawa T, 2007, GENE DEV, V21, P2788, DOI 10.1101/gad.1544507; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Raup-Konsavage WM, 2018, CANNABIS CANNABINOID, V3, P272, DOI 10.1089/can.2018.0065; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; Rigante D, 2017, CLIN RHEUMATOL, V36, P463, DOI 10.1007/s10067-016-3317-7; Russo A, 2015, ONCOTARGET, V6, P26814, DOI 10.18632/oncotarget.4254; Sacco AG, 2016, ONCOTARGETS THER, V9, P1927, DOI 10.2147/OTT.S93720; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shimazui T, 1996, CANCER RES, V56, P4154; Shishodia Shishir, 2004, Cancer Treat Res, V119, P139; Skoudy A, 1996, INT J CANCER, V68, P14, DOI 10.1002/(SICI)1097-0215(19960927)68:1<14::AID-IJC3>3.0.CO;2-#; Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007; Steeghs N, 2007, ANN SURG ONCOL, V14, P942, DOI 10.1245/s10434-006-9227-1; Stewart EL, 2015, TRANSL LUNG CANCER R, V4, P67, DOI 10.3978/j.issn.2218-6751.2014.11.06; Syrigos KN, 1998, EUR J CANCER, V34, P2037, DOI 10.1016/S0959-8049(98)00279-2; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Van P., 2009, J STAT MECH THEORY E, V2009, pP0254; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wijnhoven BPL, 2005, J SURG ONCOL, V92, P116, DOI 10.1002/jso.20344; Yang YL, 2012, CHINESE MED J-PEKING, V125, P450, DOI 10.3760/cma.j.issn.0366-6999.2012.03.009; Zaniboni A, 2016, CANCER CHEMOTH PHARM, V78, P233, DOI 10.1007/s00280-016-3032-8; Zhai B, 2008, WORLD J GASTROENTERO, V14, P5665, DOI 10.3748/wjg.14.5665; Zhu HT, 2018, J THORAC DIS, V10, P5328, DOI 10.21037/jtd.2018.09.18	52	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2020	15	10							e0241299	10.1371/journal.pone.0241299	http://dx.doi.org/10.1371/journal.pone.0241299			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8XL	33112928	Green Published, gold			2023-01-03	WOS:000588374000037
J	Spatz, ES; Bernheim, SM; Horwitz, LI; Herrin, J				Spatz, Erica S.; Bernheim, Susannah M.; Horwitz, Leora, I; Herrin, Jeph			Community factors and hospital wide readmission rates: Does context matter?	PLOS ONE			English	Article							LOW SOCIOECONOMIC-STATUS; HEALTH; RISK; ASSOCIATION; OUTCOMES	Background The environment in which a patient lives influences their health outcomes. However, the degree to which community factors are associated with readmissions is uncertain. Objective To estimate the influence of community factors on the Centers for Medicare & Medicaid Services risk-standardized hospital-wide readmission measure (HWR)-a quality performance measure in the U.S. Research design We assessed 71 community variables in 6 domains related to health outcomes: clinical care; health behaviors; social and economic factors; the physical environment; demographics; and social capital. Subjects Medicare fee-for-service patients eligible for the HWR measure between July 2014-June 2015 (n = 6,790,723). Patients were linked to community variables using their 5-digit zip code of residence. Methods We used a random forest algorithm to rank variables for their importance in predicting HWR scores. Variables were entered into 6 domain-specific multivariable regression models in order of decreasing importance. Variables with P-values <0.10 were retained for a final model, after eliminating any that were collinear. Results Among 71 community variables, 19 were retained in the 6 domain models and in the final model. Domains which explained the most to least variance in HWR were: physical environment (R-2 = 15%); clinical care (R-2 = 12%); demographics (R-2 = 11%); social and economic environment (R-2 = 7%); health behaviors (R-2 = 9%); and social capital (R-2 = 8%). In the final model, the 19 variables explained more than a quarter of the variance in readmission rates (R-2 = 27%). Conclusions Readmissions for a wide range of clinical conditions are influenced by factors relating to the communities in which patients reside. These findings can be used to target efforts to keep patients out of the hospital.	[Spatz, Erica S.; Herrin, Jeph] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Spatz, Erica S.; Bernheim, Susannah M.] Yale Yale New Haven Hlth Ctr Outcomes Res & Evalu, New Haven, CT 06510 USA; [Bernheim, Susannah M.] Yale Sch Med, Div Med, New Haven, CT USA; [Horwitz, Leora, I] NYU Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA; [Horwitz, Leora, I] NYU, Ctr Healthcare Innovat & Delivery Sci, Grossman Sch Med New York, New York, NY USA; [Horwitz, Leora, I] NYU, Sch Med, Dept Med, Div Gen Internal Med & Clin Innovat, New York, NY USA	Yale University; Yale University; New York University; New York University; New York University	Spatz, ES (corresponding author), Yale Sch Med, Sect Cardiovasc Med, New Haven, CT 06510 USA.; Spatz, ES (corresponding author), Yale Yale New Haven Hlth Ctr Outcomes Res & Evalu, New Haven, CT 06510 USA.	Erica.spatz@yale.edu			Agency for Healthcare Research and Quality [1 R01 HS022882 01]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was funded by a grant from the Agency for Healthcare Research and Quality, titled: Understanding Hospital Readmission Rates: Patient, Hospital and Community Effects, awarded to SMB, LIH, and JH (1 R01 HS022882 01).	Angraal S, 2018, AM J MED, V131, P1324, DOI 10.1016/j.amjmed.2018.06.013; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Area Health Resources Files (AHRF) 2013-2014, AREA HLTH RES FIL AH; Assari S, 2018, SOCIETIES, V8, DOI 10.3390/soc8020026; Assari S, 2018, SOC ISS POLICY REV, V12, P112, DOI 10.1111/sipr.12042; Assari S, 2018, J RACIAL ETHN HEALTH, V5, P375, DOI 10.1007/s40615-017-0381-x; Aswani MS, 2018, HEALTH SERV RES, V53, P4416, DOI 10.1111/1475-6773.13030; Belsley D.A., 2005, REGRESSION DIAGNOSTI, VVol. 571; Berkowitz SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4273; Bradley EH, 2016, HEALTH AFFAIR, V35, P760, DOI 10.1377/hlthaff.2015.0814; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Brewster AL, 2019, POPUL HEALTH MANAG, V22, P40, DOI 10.1089/pop.2018.0030; Brewster AL, 2018, HEALTH SERV RES, V53, P2892, DOI 10.1111/1475-6773.12775; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Damiani G, 2015, CLIN INTERV AGING, V10, P237, DOI 10.2147/CIA.S71165; Desai NR, 2016, JAMA-J AM MED ASSOC, V316, P2647, DOI 10.1001/jama.2016.18533; Fisher ES, 2014, JAMA-J AM MED ASSOC, V312, P2093, DOI 10.1001/jama.2014.13815; Fraze T, 2016, HEALTH AFFAIR, V35, P2109, DOI 10.1377/hlthaff.2016.0727; Gaskin DJ, 2018, MED CARE, V56, P934, DOI 10.1097/MLR.0000000000000988; Herrin J, 2015, HEALTH SERV RES, V50, P20, DOI 10.1111/1475-6773.12177; Horwitz LI, 2017, MED CARE, V55, P528, DOI 10.1097/MLR.0000000000000713; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Hsiao YL, 2018, J HEALTH ORGAN MANAG, V32, P638, DOI 10.1108/JHOM-09-2017-0228; Hu JH, 2018, AM J MED QUAL, V33, P493, DOI 10.1177/1062860617753063; Hu JH, 2014, HEALTH AFFAIR, V33, P778, DOI 10.1377/hlthaff.2013.0816; Jung D, 2018, J AM GERIATR SOC, V66, P1158, DOI 10.1111/jgs.15366; Kangovi S, 2014, J GEN INTERN MED, V29, P283, DOI 10.1007/s11606-013-2571-5; Kangovi S, 2013, HEALTH AFFAIR, V32, P1196, DOI 10.1377/hlthaff.2012.0825; Kern LM, 2016, ANN INTERN MED, V164, P395, DOI 10.7326/M14-2633; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Krumholz HM, 2014, ANN INTERN MED, V161, P833, DOI 10.7326/M14-2308; McCarthy D, 2013, JAMA-J AM MED ASSOC, V309, P351, DOI 10.1001/jama.2013.1; Nagasako EM, 2014, HEALTH AFFAIR, V33, P786, DOI 10.1377/hlthaff.2013.1148; North Carolina Department of Health and Human Services (NCDHHS), MED EXP HLTH OPP PIL; Riley Wayne J, 2012, Trans Am Clin Climatol Assoc, V123, P167; Shahu A, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012277; Taylor M., PARTNERING LOCAL SNF; The Lancet Global Health, 2018, LANCET GLOB HLTH, V6, pE593; Vest JR, 2015, J AM MED INFORM ASSN, V22, P435, DOI 10.1136/amiajnl-2014-002760; Villanueva C, 2013, J COMMUN HEALTH, V38, P690, DOI 10.1007/s10900-013-9666-0	40	4	4	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2020	15	10							e0240222	10.1371/journal.pone.0240222	http://dx.doi.org/10.1371/journal.pone.0240222			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ON4BV	33095775	Green Published, gold			2023-01-03	WOS:000586649400066
J	Oksuzyan, A; Hohn, A; Pedersen, JK; Rau, R; Lindahl-Jacobsen, R; Christensen, K				Oksuzyan, Anna; Hoehn, Andreas; Krabbe Pedersen, Jacob; Rau, Roland; Lindahl-Jacobsen, Rune; Christensen, Kaare			Preparing for the future: The changing demographic composition of hospital patients in Denmark between 2013 and 2050	PLOS ONE			English	Article							MEDICAL-STUDENTS; CARE; ATTITUDES	Background Population aging will pose huge challenges for healthcare systems and will require a promotion of positive attitudes towards older people and the encouragement of careers in geriatrics to attract young professionals into the field and to meet the needs of a rapidly growing number of old-aged patients. We describe the current demographic profile of hospital care use in Denmark and make projections for changes in the patient profile up to 2050. Methods The Danish population in 2013 (N = 5.63 million) was followed up for inpatient and emergency admissions recorded in Danish hospitals in 2013 using population-based registers. We combined age- and sex-specific hospital care use in 2013 with official population estimates to forecast the profile of hospital days up to 2050 with respect to age and sex. Results The total number of hospital days per year is projected to increase by 42% between 2013 and 2050, from 4.66 to 6.72 million days. While small changes are projected for the population aged 0-69, the largest change is projected to occur for the population aged 70+. The 2013 levels were 0.82 and 0.93 million days for men and women aged 70+, respectively. By 2050, these levels are projected to have reached 1.94 and 1.84 million days. While the population aged 70+ accounted for 37.5% of all days in 2013, its contribution is projected to increase to 56.2% by 2050. Conclusion Our study shows one possible scenario for changes in the hospital days due to population aging by 2050: Assuming no changes in hospital care use over the forecast period, the absolute contribution of individuals aged 70+ to the total hospital days will more than double, and the relative contribution of persons aged 70+ will account for nearly 60% of all hospital days by 2050, being largest among men.	[Oksuzyan, Anna; Hoehn, Andreas; Rau, Roland] Max Planck Inst Demog Res, Rostock, Germany; [Hoehn, Andreas; Krabbe Pedersen, Jacob; Lindahl-Jacobsen, Rune; Christensen, Kaare] Univ Southern Denmark, Dept Epidemiol Biostat & Biodemog, Odense, Denmark; [Hoehn, Andreas] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Krabbe Pedersen, Jacob; Christensen, Kaare] Univ Southern Denmark, Danish Aging Res Ctr, Odense, Denmark; [Rau, Roland] Univ Rostock, Dept Demog, Rostock, Germany	Max Planck Society; University of Southern Denmark; University of Edinburgh; University of Southern Denmark; University of Rostock	Oksuzyan, A (corresponding author), Max Planck Inst Demog Res, Rostock, Germany.	Oksuzyan@demogr.mpg.de	Lindahl-Jacobsen, Rune/J-2985-2012; Christensen, Kaare/C-2360-2009; Hoehn, Andreas/HGB-6848-2022	Lindahl-Jacobsen, Rune/0000-0002-4622-9826; Christensen, Kaare/0000-0002-5429-5292; Hoehn, Andreas/0000-0002-7170-1205; Oksuzyan, Anna/0000-0003-4138-5886; Pedersen, Jacob Krabbe/0000-0002-9042-0492	US National Institute of Health [2P01AG031719]	US National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Both grants - 2P01AG031719, US National Institute of Health and "On the edge of societies: Vulnerable populations, emerging challenges for social policies and future demands for social innovation. The experience of the Baltic Sea States (2016-2021)" - were received by Prof. James W. Vaupel, Interdisciplinary Centre on Population Dynamics, University of Southern Denmark (https://portal.findresearcher.sdu.dk/en/persons/jvaupel), who is not a co-author on this paper. The experience of the Baltic Sea States (2016-2021) provided by the Max Planck Society has no number. All funders had no role in the study design, the data collection and analysis, the interpretation of results, the decision to publish and the preparation of the manuscript.	Beard JR, 2015, LANCET; Behrman JR, 2011, DEMOGRAPHY, V48, P1347, DOI 10.1007/s13524-011-0052-1; Bodenheimer T, 2009, HEALTH AFFAIR, V28, P64, DOI 10.1377/hlthaff.28.1.64; Bohk-Ewald C, 2018, P NATL ACAD SCI US; Breyer F, 2010, OXFORD REV EC POLICY; Campisi J, 2013, ANN REV PHYSL; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Dall TM, 2013, HLTH AFF; Darzi A, 2016, LANCET, V388, P2576, DOI 10.1016/S0140-6736(16)32235-8; De Haas H, 2010, INT MIGR REV; Drickamer MA, 2006, J GEN INTERN MED, V21, P1230, DOI 10.1111/j.1525-1497.2006.00585.x; Etkind SN, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0860-2; Fisher JM, 2018, EDUC GERONTOL, V44, P551, DOI 10.1080/03601277.2018.1488387; Ganguly A, 2016, J HLTH MANAG; Groth MV, 2014, SCAND J PUBLIC HLTH; Hanlon P, 2007, J PUBLIC HLTH BANGKO; Hansen MF, 2013, DANMARKS FREMTIDIGE; HMD, 2020, HUM MORTALITY DATAB; Howdon D, 2018, J HLTH EC; Hughes NJ, 2008, J AM GERIATR SOC, V56, P334, DOI 10.1111/j.1532-5415.2007.01552.x; Hunt K, 2011, J HEALTH SERV RES PO, V16, P108, DOI 10.1258/jhsrp.2010.009131; Kim SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171394; Kolb G, 2011, EUR GERIATR MED, V2, P290, DOI 10.1016/j.eurger.2011.06.007; Kontis V, 2017, LANCET; Leening MJG, 2014, BMJ; McCloskey R, 2020, NURSE EDUC PRACT, V44, DOI 10.1016/j.nepr.2020.102760; Meiboom AA, 2015, BMC MED EDUC, V15, DOI 10.1186/s12909-015-0384-4; Oksuzyan A, 2013, AGE AGEING, V42, P42; Pallin DJ, 2014, J HOSP MED; Pearson S, 2010, ACTA PAEDIAT INT J P; Rasmussen KL, 2018, CMAJ; Samra R, 2015, AGE AGEING, V44, P776, DOI 10.1093/ageing/afv082; Schmidt M, 2012, BMJ; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Schofield DJ, 2006, AUST HLTH REV; Statistics Denmark, 2020, DOC STAT POP PROJ 20; Statistics Denmark, 2020, POPULATION PROJECTIO; Strandberg TE, 2007, LANCET, V369, P1328, DOI 10.1016/S0140-6736(12)62167-9; Strunk BC, 2006, HLTH AFF; United Nations Department of Economic and Social Affairs Population Division, 2017, WORLD POP PROSP 2017; Vaupel JW, 2010, NATURE, V464, P536, DOI 10.1038/nature08984; Vogl M, 2016, EUR J HEAL EC; Vrhovec J, 2016, HLTH POLICY NEW YORK; Wilson Mark A G, 2018, BMC Res Notes, V11, P71, DOI 10.1186/s13104-018-3186-z	44	1	1	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2020	15	9							e0238912	10.1371/journal.pone.0238912	http://dx.doi.org/10.1371/journal.pone.0238912			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ4YT	32997671	Green Accepted, Green Published, gold			2023-01-03	WOS:000577103100008
J	Robinson, JC				Robinson, James C.			Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the coronavirus disease 2019 (COVID-19) pandemic is sustainable, arguing that the same or greater level of public investment will be necessary if drug prices are to remain affordable and if the US wants to maintain its global leadership position.	[Robinson, James C.] Univ Calif Berkeley, Sch Publ Hlth, 2121 BerkeleyWay,Room 5423, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 2121 BerkeleyWay,Room 5423, Berkeley, CA 94720 USA.	james.robinson@berkeley.edu		Robinson, James/0000-0003-0056-3017				Coalition for Epidemic Preparedness Innovations, COVAX FAC EXPL PART; Daniel GW, 2017, JAMA-J AM MED ASSOC, V318, P1103, DOI 10.1001/jama.2017.10164; Emanuel EJ, 2020, JAMA INTERN MED, V180, P1510, DOI 10.1001/jamainternmed.2020.4793; Fordyce CB, 2015, J AM COLL CARDIOL, V65, P1567, DOI 10.1016/j.jacc.2015.03.016; Milne CP, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00144; Moschella D, 2020, COMPETING CHINA STRA; National Cancer Institute, 1998 2018 NAT EC IMP; Research America, 2019, US INV MED HLTH RES; US Department of Health and Human Services, FACT SHEET EXPL OP W	9	10	10	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	2021	325	9					825	826		10.1001/jama.2020.25384	http://dx.doi.org/10.1001/jama.2020.25384		JAN 2021	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QS4AP	33443546	Bronze			2023-01-03	WOS:000607739900002
J	Hasan, ATMH; Das, SC; Islam, MS; Mansur, M; Shawon, MSR; Hassan, R; Chowdhury, MSJH; Mondal, MBA; Mohammad, QD				Hasan, A. T. M. Hasibul; Das, Subir Chandra; Islam, Muhammad Sougatul; Mansur, Mohaimen; Shawon, Md. Shajedur Rahman; Hassan, Rashedul; Chowdhury, Mohammad Shah Jahirul Hoque; Mondal, Md. Badrul Alam; Mohammad, Quazi Deen			Impact of COVID-19 on hospital admission of acute stroke patients in Bangladesh	PLOS ONE			English	Article								Background With the proposed pathophysiologic mechanism of neurologic injury by SARS CoV-2, the frequency of stroke and henceforth the related hospital admissions were expected to rise. This paper investigated this presumption by comparing the frequency of admissions of stroke cases in Bangladesh before and during the pandemic. Methods This is a retrospective analysis of stroke admissions in a 100-bed stroke unit at the National Institute of Neurosciences and Hospital (NINS&H) which is considerably a large stroke unit. All the admitted cases from 1 January to 30 June 2020 were considered. Poisson regression models were used to determine whether statistically significant changes in admission rates can be found before and after 25 March since when there is a surge in COVID-19 infections. Results A total of 1394 stroke patients took admission in the stroke unit during the study period. Half of the patients were older than 60 years, whereas only 2.6% were 30 years old or younger. The male to female ratio is 1.06:1. From January to March 2020, the mean rate of admission was 302.3 cases per month, which dropped to 162.3 cases per month from April to June, with an overall reduction of 46.3% in acute stroke admission per month. In those two periods, reductions in average admission per month for ischemic stroke (IST), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and venous stroke (VS) were 45.5%, 37.2%, 71.4% and 39.0%, respectively. Based on weekly data, results of Poisson regressions confirm that the average number of admissions per week dropped significantly during the last three months of the sample period. Further, in the first three months, a total of 22 cases of hyperacute stroke management were done, whereas, in the last three months, there was an 86.4% reduction in the number of hyperacute stroke patients getting reperfusion treatment. Only 38 patients (2.7%) were later found to be RT-PCR SARS Cov-2 positive based on nasal swab testing. Conclusion This study revealed a more than fifty percent reduction in acute stroke admission during the COVID-19 pandemic. Whether the reduction is related to the fear of getting infected by COVID-19 from hospitalization or the overall restriction on public movement or stay-home measures remains unknown.	[Hasan, A. T. M. Hasibul; Das, Subir Chandra; Chowdhury, Mohammad Shah Jahirul Hoque; Mondal, Md. Badrul Alam; Mohammad, Quazi Deen] Natl Inst Neurosci & Hosp, Dept Neurol, Dhaka, Bangladesh; [Islam, Muhammad Sougatul] BioTED, Dhaka, Bangladesh; [Mansur, Mohaimen] Univ Dhaka, Inst Stat Res & Training, Dhaka, Bangladesh; [Shawon, Md. Shajedur Rahman] UNSW Med, Ctr Big Data Res Hlth, Sydney, NSW, Australia; [Hassan, Rashedul] Green Life Med Coll & Hosp, Dept Med, Dhaka, Bangladesh	University of Dhaka	Hasan, ATMH (corresponding author), Natl Inst Neurosci & Hosp, Dept Neurol, Dhaka, Bangladesh.	parag007us@gmail.com	Mansur, Mohaimen/GVS-8367-2022					Al Saiegh F, 2020, J NEUROL NEUROSUR PS, V91, P846, DOI 10.1136/jnnp-2020-323522; Bersano A, 2020, NEUROLOGY, V94, P905, DOI 10.1212/WNL.0000000000009508; Beyrouti R, 2020, J NEUROL NEUROSUR PS, V91, P889, DOI 10.1136/jnnp-2020-323586; Campiglio L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238159; Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243; Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179; Dhand A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09073-5; Health Services DG, 2020, COR VIR INF 16 AUG 2; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Hoyer C, 2020, STROKE, V51, P2224, DOI 10.1161/STROKEAHA.120.030395; Jillella DV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239443; Majidi S, 2020, STROKE, V51, P2656, DOI 10.1161/STROKEAHA.120.030397; Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127; Mathews P., 2010, SAMPLE SIZE CALCULAT; Muhammad S, 2020, BRAIN BEHAV IMMUN, V87, P150, DOI 10.1016/j.bbi.2020.05.015; Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787; Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187; Qin C, 2020, STROKE, V51, P2219, DOI 10.1161/STROKEAHA.120.030365; Qureshi AI, 2020, INT J STROKE, V15, P540, DOI 10.1177/1747493020923234; Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669; Siepmann T, 2021, EUR J NEUROL, V28, P238, DOI 10.1111/ene.14535; Stohr E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242653; World Health Organization, 2020, 16 WHO; Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335	24	6	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0240385	10.1371/journal.pone.0240385	http://dx.doi.org/10.1371/journal.pone.0240385			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4UT	33439890	Green Submitted, Green Published, gold			2023-01-03	WOS:000609985300054
J	Pascua, FV; Diaz, O; Medina, R; Contreras, B; Mistroff, J; Espinosa, D; Sekhon, A; Handal, DP; Pineda, E; Pineda, MV; Pineda, H; Diaz, M; Lewis, AS; Hesse, H; Lainez, MTC; Stevens, ML; Sierra-Hoffman, M; Ontai, SC; VanBuren, V				Valerio Pascua, Fernando; Diaz, Oscar; Medina, Rina; Contreras, Brian; Mistroff, Jeff; Espinosa, Daniel; Sekhon, Anupamjeet; Paz Handal, Diego; Pineda, Estela; Vargas Pineda, Miguel; Pineda, Hector; Diaz, Maribel; Lewis, Anita S.; Hesse, Heike; Castro Lainez, Miriams T.; Stevens, Mark L.; Sierra-Hoffman, Miguel; Ontai, Sidney C.; VanBuren, Vincent			A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients	PLOS ONE			English	Article							OUTCOMES	Purpose COVID-19 pandemic has multifaceted presentations with rising evidence of immune-mediated mechanisms underplay. We sought to explore the outcomes of severe COVID-19 patients treated with a multi-mechanism approach (MMA) in addition to standard-of-care (SC) versus patients who only received SC treatment. Materials and methods Data were collected retrospectively for patients admitted to the intensive care unit (ICU). This observational cohort study was performed at five institutions, 3 in the United States and 2 in Honduras. Patients were stratified for MMA vs. SC treatment during ICU stay. MMA treatment consists of widely available medications started immediately upon hospitalization. These interventions target immunomodulation, anticoagulation, viral suppression, and oxygenation. Primary outcomes included in-hospital mortality and length of stay (LOS) for the index hospitalization and were measured using logistic regression. Results Of 86 patients admitted, 65 (76%) who had severe COVID-19 were included in the study; 30 (46%) patients were in SC group, compared with 35 (54%) patients treated with MMA group. Twelve (40%) patients in the SC group died, compared with 5 (14%) in the MMA group (p-value = 0.01, Chi squared test). After adjustment for gender, age, treatment group, Q-SOFA score, the MMA group had a mean length of stay 8.15 days, when compared with SC group with 13.55 days. ICU length of stay was reduced by a mean of 5.4 days (adjusted for a mean age of 54 years, p-value 0.03) and up to 9 days (unadjusted for mean age), with no significant reduction in overall adjusted mortality rate, where the strongest predictor of mortality was the use of mechanical ventilation. Conclusion The finding that MMA decreases the average ICU length of stay by 5.4 days and up to 9 days in older patients suggests that implementation of this treatment protocol could allow a healthcare system to manage 60% more COVID-19 patients with the same number of ICU beds.	[Valerio Pascua, Fernando] Hosp Leonardo Martinez, Dept Crit Care, San Pedro Sula, Cortes, Honduras; [Diaz, Oscar] Hosp Reg Norte Inst Hondureno Seguridad Social, Dept Crit Care, San Pedro Sula, Cortes, Honduras; [Medina, Rina] Univ Nacl Autonoma Honduras, Tegucigalpa, Honduras; [Contreras, Brian] Texas A&M Coll Med Victoria, Detar Family Med Residency Program, Victoria, TX USA; [Mistroff, Jeff] Texas A&M Coll Med Victoria, Detar Family Med Residency Program, Victoria, TX USA; [Espinosa, Daniel] Detar Hosp, Victoria Hospitalist Associates, Victoria, TX USA; [Sekhon, Anupamjeet] Texas A&M Coll Med, Detar Family Med Residency Program, Victoria, TX USA; [Paz Handal, Diego] Univ Nacl Autonoma Honduras, San Pedro Sula, Cortes, Honduras; [Pineda, Estela; Vargas Pineda, Miguel] Hosp Leonardo Martinez, San Pedro Sula, Cortes, Honduras; [Pineda, Hector] Hosp Mario Catarino Rivas, Dept Neurol, San Pedro Sula, Cortes, Honduras; [Diaz, Maribel] Inst Hondureno Segur Social, Dept Allergy & Immunol, Soc Hondurena Inmunol, Tegucigalpa, Honduras; [Lewis, Anita S.] El Campo Mem Hosp, Pharm Dept, El Campo, TX USA; [Hesse, Heike] Univ Nacl Autonoma Honduras, Neurol Dept, Tegucigalpa, Honduras; [Castro Lainez, Miriams T.] Univ Nacl Autonoma Honduras, Fac Ciencias Med, Tegucigalpa, Honduras; [Stevens, Mark L.] Texas A&M Coll Med, Detar Family Med Residency Program, Res Dept, Victoria, TX USA; [Sierra-Hoffman, Miguel] Texas A&M Coll Med, Detar Family Med Residency Program, Res & Infect Dis Dept, Victoria, TX USA; [Ontai, Sidney C.] Texas A&M Univ, Coll Med, Detar Family Med Residency Program Dept, Victoria, TX USA; [VanBuren, Vincent] Texas A&M Coll Med, Round Rock Clin Campus, Round Rock, TX 78665 USA	Universidad Nacional Autonoma de Honduras; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Universidad Nacional Autonoma de Honduras; Universidad Nacional Autonoma de Honduras; Universidad Nacional Autonoma de Honduras; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	VanBuren, V (corresponding author), Texas A&M Coll Med, Round Rock Clin Campus, Round Rock, TX 78665 USA.	vanburen@tamu.edu		Diaz, Oscar/0000-0002-5268-3320; Valerio Pascua, Fernando/0000-0002-5880-7849; Vargas Pineda, Miguel Fernando/0000-0001-7912-4011				Alam N, 2014, RESUSCITATION, V85, P587, DOI 10.1016/j.resuscitation.2014.01.013; [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003; [Anonymous], 2020, LANCET, V395, P1054; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4; Cardiovascular Disease and Risk Management, 2019, DIABETES CARE, V2, pS103, DOI 10.2337/dc19-S010; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Despres C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03001-6; Edgar W, 2020, TEXAS TRIBUNE; Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255; Finkelsztein EJ, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1658-5; Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5; Guo HF, 2020, MATER RES EXPRESS, V7, DOI 10.1088/2053-1591/abcc2d; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Kewan T, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100418; Mafham MM, 2020, LANCET, V396, P381, DOI 10.1016/S0140-6736(20)31356-8; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Sabatino J, 2020, PLOS ONE, V15, DOI [10.1371/journal.pone.0237131, 10.1371/journal.pone.0243471, DOI 10.1371/JOURNAL.PONE.0237131]; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Semple K., 2020, NY TIMES; Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9	28	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0245025	10.1371/journal.pone.0245025	http://dx.doi.org/10.1371/journal.pone.0245025			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411780	Green Published, gold			2023-01-03	WOS:000608044300052
J	Baek, J; Kim, J; Cho, S; Jeong, Y; Kim, ED				Baek, Jungwon; Kim, Jia; Cho, Seunghee; Jeong, Yujin; Kim, Eung Don			Novel method for modified interlaminar approach using contralateral oblique view: A technical suggestion	PLOS ONE			English	Article								A modified interlaminar (MIL) approach has been proposed for improved accessibility to the target epidural space. However, even with fluoroscopic guidance, uncertainty about the distance between the needle tip and the epidural space can remain. Using the contralateral oblique (CLO) view, determination of the epidural space can be easier with clearer identification of the interlaminar opening. We inserted the needle at the midpoint of the interlaminar opening on the fluoroscopic anteroposterior (AP) view and made the needle oriented toward the pedicle of the target side. Then, CLO view was created by rotating the intensifier approximately 45 degrees to the contralateral side of the target. Through the CLO view, the ventral interlaminar line (VILL) was confirmed and the needle was able to enter the epidural space more easily. The medical records of 29 patients who were conducted MIL approach using CLO view were retrospectively analyzed to evaluate the effectiveness and safety of this procedure. The accessibility to the ventral epidural space was 93.1%. There was no procedure-related complication. Using CLO view, uncertainty can be reduced during the MIL approach, which in turn shortens procedure time and improves safety.	[Baek, Jungwon; Cho, Seunghee] Catholic Univ Korea, Dept Anesthesiol & Pain Med, Coll Med, Incheon St Marys Hosp, Seoul, South Korea; [Kim, Jia] Daejeon Vet Hosp, Dept Anesthesiol & Pain Med, Daejeon, South Korea; [Jeong, Yujin; Kim, Eung Don] Catholic Univ Korea, Dept Anesthesiol & Pain Med, Daejeon St Marys Hosp, Coll Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea	Kim, ED (corresponding author), Catholic Univ Korea, Dept Anesthesiol & Pain Med, Daejeon St Marys Hosp, Coll Med, Seoul, South Korea.	ehs99@catholic.ac.kr		kim, eungdon/0000-0002-2776-7020				Ackerman WE, 2007, ANESTH ANALG, V104, P1217, DOI 10.1213/01.ane.0000260307.16555.7f; Botwin Kenneth P, 2004, Pain Physician, V7, P77; Foris LA, 2022, STATPEARLS; Furman M, 2012, PAIN MED, V13, P1389, DOI 10.1111/j.1526-4637.2012.01484.x; Gill JS, 2016, PAIN MED, V17, P839, DOI 10.1093/pm/pnv031; Kim ED, 2016, PAIN MED, V17, P1620, DOI 10.1093/pm/pnv094; Lutz GE, 1998, ARCH PHYS MED REHAB, V79, P1362, DOI 10.1016/S0003-9993(98)90228-3; McLain Robert F, 2005, Spine J, V5, P191, DOI 10.1016/j.spinee.2004.10.046; Zhu J, 2011, PAIN PHYSICIAN, V14, P195	9	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2021	16	1							e0244992	10.1371/journal.pone.0244992	http://dx.doi.org/10.1371/journal.pone.0244992			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS4TL	33406115	Green Published, gold			2023-01-03	WOS:000607915500009
J	Manno, SHC; Manno, FAM; Tian, L; Khan, MS; Ahmed, I; Liu, YC; Li, VWT; Xu, SS; Xie, FJ; Hung, TF; Ma, V; Cho, W; Aldape, B; Cheng, SH; Lau, C				Manno, Sinai H. C.; Manno, Francis A. M.; Tian, Li; Khan, Muhammad S.; Ahmed, Irfan; Liu, Yuanchao; Li, Vincent W. T.; Xu, Shisan; Xie, Fangjing; Hung, Tak Fu; Ma, Victor; Cho, William; Aldape, Beatriz; Cheng, Shuk Han; Lau, Condon			Spectroscopic and microscopic examination of teeth exposed to green tea at different temperatures	PLOS ONE			English	Article							INDUCED BREAKDOWN SPECTROSCOPY; SURFACE-FREE-ENERGY; TOOTH ENAMEL; DENTIN EROSION; ELEMENTAL ANALYSIS; PLAQUE-FORMATION; CARIOUS TEETH; SOFT DRINKS; DEMINERALIZATION; SALIVA	Tea is a popular beverage consumed at different temperatures. The effect of tea on teeth at different temperatures has not been studied previously. The present study used an in vitro green tea immersed tooth model at different tea temperatures (hot and cold) compared to an in vivo tea administration model allowing rats to drink tea over the course of a week. The elements present in tea leaves were identified by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and compared to the elements in teeth (enamel surface) using Laser-Induced Breakdown Spectroscopy (LIBS). Here, LIBS demonstrated in vivo and in vitro green tea treatments resulted in a significant increase in the mineral elements found in enamel. For the in vitro assessment, elements in enamel varied based on cold-tea and hot-tea treatment; however, hot water reduced the elements in enamel. Atomic force microscopy found the in vivo tea group had a higher roughness average (RA) compared with the in vivo water group. Cold tea and hot tea in vitro groups demonstrated lower RA than in vitro water controls. Scanning electron microscopy found hot water induced cracks more than 1.3 mu m in enamel while cold tea and hot tea promoted the adhering of extrinsic matter to teeth. Overall, teeth treated to high temperature lost the mineral phase leading to demineralization. Our results indicate that green tea protects enamel, but its protective action in dental structures is enhanced at cold temperature.	[Manno, Sinai H. C.; Manno, Francis A. M.; Tian, Li; Li, Vincent W. T.; Xu, Shisan; Xie, Fangjing; Cheng, Shuk Han; Lau, Condon] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [Manno, Sinai H. C.; Tian, Li; Cheng, Shuk Han] City Univ Hong Kong, State Key Lab Marine Pollut SKLMP, Hong Kong, Peoples R China; [Manno, Sinai H. C.; Manno, Francis A. M.; Khan, Muhammad S.; Ahmed, Irfan; Liu, Yuanchao] City Univ Hong Kong, Dept Phys, Hong Kong, Peoples R China; [Ahmed, Irfan] Sukkur IBA Univ, Dept Elect Engn, Sukkur, Sindh, Pakistan; [Hung, Tak Fu; Cheng, Shuk Han] City Univ Hong Kong, Dept Mat Sci & Engn, Hong Kong, Peoples R China; [Ma, Victor; Cho, William] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China; [Aldape, Beatriz] Portal Univ Nacl Autonoma Mexico, Fac Odontol, Div Estudios Posgrad & Invest, Mexico City, DF, Mexico	City University of Hong Kong; City University of Hong Kong; City University of Hong Kong; Sukkur IBA University; City University of Hong Kong; Universidad Nacional Autonoma de Mexico	Cheng, SH; Lau, C (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Cheng, SH (corresponding author), City Univ Hong Kong, State Key Lab Marine Pollut SKLMP, Hong Kong, Peoples R China.; Cheng, SH (corresponding author), City Univ Hong Kong, Dept Mat Sci & Engn, Hong Kong, Peoples R China.	bhcheng@cityu.edu.hk; condon.lau@cityu.edu.hk	Ahmed, Irfan/HHD-1948-2022	Cheng, Shuk Han/0000-0002-5822-7238; Manno, Francis/0000-0002-0486-213X; XIE, Fangjing/0000-0003-4950-7040; H.C. Manno, Sinai/0000-0001-6410-6873; TIAN, Li/0000-0003-1674-2511; LIU, Yuanchao/0000-0001-7699-488X	Hong Kong Research Grants Council [ECS CityU21201217]; City University of Hong Kong [9610338, 9610378, 7005507]; University of Hong Kong [9610348]; CONACYT [CVU 622691, 739501]	Hong Kong Research Grants Council(Hong Kong Research Grants Council); City University of Hong Kong(City University of Hong Kong); University of Hong Kong(University of Hong Kong); CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was supported in part by the Hong Kong Research Grants Council (ECS CityU21201217 to CL) and the City University of Hong Kong (9610338, 9610378, and 7005507 to CL). It was also supported by the University of Hong Kong (9610348 to SHC) and CONACYT, CVU 622691 (support number: 739501 to SHCM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	14084 BSDBE. Foodstuffs, 14084 BSDBE, DOI [10.3403/02794284u, DOI 10.3403/02794284U]; Ahmed I, 2018, BIOMED OPT EXPRESS, V9, P4459, DOI 10.1364/BOE.9.004459; Ahmed I, 2018, BIOMED OPT EXPRESS, V9, P4184, DOI 10.1364/BOE.9.004184; Ahmed I, 2017, BIOMED OPT EXPRESS, V8, P4865, DOI 10.1364/BOE.8.004865; Alavi G, 2014, J Dent (Shiraz), V15, P33; Alvira FC, 2010, APPL SPECTROSC, V64, P313, DOI 10.1366/000370210790918328; Alvira FC, 2011, J ANTHROPOL SCI, V89, P153, DOI 10.4436/jass.89012; Amaechi BT, 1998, CARIES RES, V32, P351, DOI 10.1159/000016471; AMERONGEN AVN, 1987, CARIES RES, V21, P297; Annabi B, 2002, BBA-MOL CELL RES, V1542, P209, DOI 10.1016/S0167-4889(01)00187-2; [Anonymous], 2017, LANCET HIV, V2017, pPE475; Barbour ME, 2006, J DENT, V34, P207, DOI 10.1016/j.jdent.2005.06.002; Barron Robert P, 2003, J Can Dent Assoc, V69, P84; Bartlett DW, 2011, J DENT, V39, P811, DOI 10.1016/j.jdent.2011.08.014; Battistella E, 2010, BIOMIMETICS, LEARNING FROM NATURE, P399; Brown F, 2008, BURNS, V34, P648, DOI 10.1016/j.burns.2007.09.012; Chaussain-Miller C, 2006, J DENT RES, V85, P22, DOI 10.1177/154405910608500104; Cheng TO, 2006, INT J CARDIOL, V108, P301, DOI 10.1016/j.ijcard.2005.05.038; Dawes Colin, 2003, J Can Dent Assoc, V69, P722; de Sousa KR, 2012, INT J ENV RES PUB HE, V9, P3530, DOI 10.3390/ijerph9103530; Dincer B, 2002, AM J ORTHOD DENTOFAC, V122, P135, DOI 10.1067/mod.2002.124458; Dusevich V, 2013, ADV MICROS MICROANAL, P211; Enomoto A, 2012, BIOL TRACE ELEM RES, V148, P170, DOI 10.1007/s12011-012-9368-y; Farrokhpay S, 2012, APPL SPECTROSC REV, V47, P233, DOI 10.1080/05704928.2011.639424; Ganss C., 2006, DEFINITION EROSION L; Gazmeh M, 2015, APPL OPTICS, V54, P123, DOI 10.1364/AO.54.000123; GEDALIA I, 1991, J ORAL REHABIL, V18, P501, DOI 10.1111/j.1365-2842.1991.tb00072.x; Goldberg M, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00359; Graham D Y, 1996, Helicobacter, V1, P172, DOI 10.1111/j.1523-5378.1996.tb00034.x; Hahn DW, 2012, APPL SPECTROSC, V66, P347, DOI 10.1366/11-06574; Hamzaoui S, 2017, J APPL SPECTROSC+, V84, P82, DOI 10.1007/s10812-017-0431-5; Hannas AR, 2016, J APPL ORAL SCI, V24, P61, DOI 10.1590/1678-775720150289; Hemingway C A, 2006, Br Dent J, V201, P447, DOI 10.1038/sj.bdj.4814073; Humphrey LT, 2008, P NATL ACAD SCI USA, V105, P6834, DOI 10.1073/pnas.0711513105; Imam H, 2013, J APPL PHYS, V113, DOI 10.1063/1.4811186; Jalevik B, 2005, INT J PAEDIATR DENT, V15, P233, DOI DOI 10.1111/J.1365-263X.2005.00644.X; K, 2002, ORAL DEV HISTOLOGY; Kato MT, 2009, J APPL ORAL SCI, V17, P560, DOI 10.1590/S1678-77572009000600004; Kluyenko, 2002, SURFACE, P57; LARSEN MJ, 1973, SCAND J DENT RES, V81, P518; Lechner BD, 2015, ACS APPL MATER INTER, V7, P18937, DOI 10.1021/acsami.5b04790; Lee RJ, 2014, INT J DENT HYG, V12, P267, DOI 10.1111/idh.12096; Li X, 2017, HEART, V103, P783, DOI 10.1136/heartjnl-2016-310462; Liu YC, 2020, J ANAL ATOM SPECTROM, V35, P2224, DOI 10.1039/d0ja00164c; Lussi A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.9.097009; Lussi A, 2012, BRIT J NUTR, V107, P252, DOI 10.1017/S0007114511002820; Magalhaes AC, 2009, J DENT, V37, P994, DOI 10.1016/j.jdent.2009.08.007; Manno SHC, 2018, TALANTA, V189, P550, DOI 10.1016/j.talanta.2018.07.032; Maruyama T, 2011, ARCH ORAL BIOL, V56, P48, DOI 10.1016/j.archoralbio.2010.08.015; Moradian-Oldak J, 2012, FRONT BIOSCI-LANDMRK, V17, P1996, DOI 10.2741/4034; Mullan F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182406; Narotzki B, 2012, ARCH ORAL BIOL, V57, P429, DOI 10.1016/j.archoralbio.2011.11.017; Nunn J., 2001, BRIT DENT J, V190, P250, DOI [10.1038/sj.bdj.4800939, DOI 10.1038/SJ.BDJ.4800939]; O'Toole S, 2018, BRIT DENT J, V224, DOI 10.1038/sj.bdj.2018.127; Ozan G, 2020, MICROSC RES TECHNIQ, V83, P834, DOI 10.1002/jemt.23475; Pan HB, 2009, ACTA BIOMATER, V5, P1678, DOI 10.1016/j.actbio.2008.11.032; Passos VF, 2018, BRAZ ORAL RES, V32, DOI 10.1590/1807-3107bor-2018.vol32.0040; Plate U, 1998, CONNECT TISSUE RES, V38, P149, DOI 10.3109/03008209809017032; Poggio C, 2013, SCANNING, V35, P366, DOI 10.1002/sca.21077; Poggio C, 2010, J DENT, V38, P868, DOI 10.1016/j.jdent.2010.07.010; Prskalo K, 2017, ACTA CLIN CROAT, V56, P28, DOI 10.20471/acc.2017.56.01.05; Quartarone E, 2008, J APPL PHYS, V103, DOI 10.1063/1.2927386; QUIRYNEN M, 1995, J CLIN PERIODONTOL, V22, P1, DOI 10.1111/j.1600-051X.1995.tb01765.x; QUIRYNEN M, 1990, J CLIN PERIODONTOL, V17, P138, DOI 10.1111/j.1600-051X.1990.tb01077.x; Rashid Haroon, 2014, Eur J Dent, V8, P571, DOI 10.4103/1305-7456.143646; Rugg-Gunn AJ, 1998, CARIES RES, V32, P337, DOI 10.1159/000016469; Sa Y, 2012, J DENT, V40, pE26, DOI 10.1016/j.jdent.2012.02.010; Samek O, 1999, APPL PHYS A-MATER, V69, pS179, DOI 10.1007/s003399900277; Samek Ota, 2001, BMC Oral Health, V1, P1, DOI 10.1186/1472-6831-1-1; Sato C, 2013, J DENT RES, V92, P187, DOI 10.1177/0022034512470831; Simpson A, 2001, BRIT DENT J, V190, P374, DOI 10.1038/sj.bdj.4800977a; Singh VK, 2011, LASER MED SCI, V26, P307, DOI 10.1007/s10103-010-0786-9; SPEIRS RL, 1971, CALC TISS RES, V8, P1, DOI 10.1007/BF02010118; Sun LL, 2011, J DENT, V39, P686, DOI 10.1016/j.jdent.2011.07.011; Wang YL, 2019, J FORMOS MED ASSOC, V118, P39, DOI 10.1016/j.jfma.2018.01.001; West NX, 2000, J ORAL REHABIL, V27, P875, DOI 10.1046/j.1365-2842.2000.00583.x; Yueh FY, 2009, SPECTROCHIM ACTA B, V64, P1059, DOI 10.1016/j.sab.2009.07.025	77	0	0	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2020	15	12							e0244542	10.1371/journal.pone.0244542	http://dx.doi.org/10.1371/journal.pone.0244542			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TQ	33378409	gold, Green Published			2023-01-03	WOS:000605651300078
J	Okello, N; Oloro, J; Kyakwera, C; Kumbakumba, E; Obua, C				Okello, Nelson; Oloro, Joseph; Kyakwera, Catherine; Kumbakumba, Elias; Obua, Celestino			Antibiotic prescription practices among prescribers for children under five at public health centers III and IV in Mbarara district	PLOS ONE			English	Article							MANAGEMENT	Introduction Rational use of medicines requires that patients receive medications appropriate to their clinical needs. Irrational prescription of antibiotics has been reported in many health systems across the world. In Uganda, mainly nurses and assistant medical officers (Clinical officers) prescribe for children at level III and IV primary care facilities (health center II and IV). Nurses are not primarily trained prescribers; their antibiotic prescription maybe associated with errors. There is a need to understand the practices of antibiotic prescription among prescribers in the public primary care facilities. We therefore determined antibiotic prescription practices of prescribers for children under five years at health center III and IV in Mbarara district, South Western Uganda. Methods This was a retrospective descriptive cross-sectional study. We reviewed outpatient records of children <5 years of age retrospectively. Information obtained from the outpatient registers were captured in predesigned data abstraction form. Health care providers working at health centers III and IV were interviewed using a structured questionnaire. They provided information on socio-demographic, health facility, antibiotic prescription practices and availability of reference tools. Data was analyzed using STATA software version 13 center dot 0. Results There were 1218 outpatients records of children under five years reviewed and 35 health care providers interviewed. The most common childhood illness diagnosed was upper respiratory tract infection. It received the most antibiotic prescription (53%). The most commonly prescribed oral antibiotics were cotrimoxazole and amoxicillin, and ceftriaxone and benzyl penicillin were the commonest prescribed injectable antibiotics. Up to 68.4% of the antibiotic prescription was irrational. No prescriber or facility factors were associated with irrational antibiotic prescription practices. Conclusion Upper respiratory tract infection is the most diagnosed condition in children under five years with Cotrimoxazole and Amoxicillin being the most commonly prescribed antibiotics. Antibiotics are being prescribed irrationally at health centers III and IV in Mbarara District. Training and support supervision of prescribers at health centers III and IV in Mbarara district need to be prioritized by the district health team.	[Okello, Nelson; Kyakwera, Catherine; Kumbakumba, Elias] Mbarara Univ Sci & Technol, Dept Paediat & Child Hlth, Fac Med, Mbarara, Uganda; [Okello, Nelson] Lira Univ, Dept Paediat & Child Hlth, Fac Hlth Sci, Lira, Uganda; [Oloro, Joseph; Obua, Celestino] Mbarara Univ Sci & Technol, Dept Pharmacol & Therapeut, Fac Med, Mbarara, Uganda	Mbarara University of Science & Technology; Mbarara University of Science & Technology	Okello, N (corresponding author), Mbarara Univ Sci & Technol, Dept Paediat & Child Hlth, Fac Med, Mbarara, Uganda.; Okello, N (corresponding author), Lira Univ, Dept Paediat & Child Hlth, Fac Hlth Sci, Lira, Uganda.	docnelsons@gmail.com		Neli, Nelson/0000-0002-7791-4068	Makerere University - Swedish International development Agency (SIDA)	Makerere University - Swedish International development Agency (SIDA)	This study was funded by Makerere University - Swedish International development Agency (SIDA) research scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of manuscript.	Bozic B, 2015, ARCH DIS CHILD, V100, P966, DOI 10.1136/archdischild-2015-308274; Cochran W, 1963, G 1963 SAMPLING TECH; Dekker ARJ, 2017, FAM PRACT, V34, P169, DOI 10.1093/fampra/cmw125; DEMERS P, 1968, CAN MED ASSOC J, V99, P849; Desalegn AA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-170; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; health UMo, 2016, UG CLIN GUID, P335; HOGERZEIL HV, 1995, BRIT J CLIN PHARMACO, V39, P1; Kotwani A, 2012, J CLIN PHARM THER, V37, P308, DOI 10.1111/j.1365-2710.2011.01293.x; Maheshwari A, 2012, INDIAN J PEDIATR, V79, P75, DOI 10.1007/s12098-011-0540-8; Mihani J, 2018, OPEN ACCESS MACED J, DOI [10.3889/oamjms.2018.150, DOI 10.3889/0AMJMS.2018.150]; MoH, 2016, UG CLIN GUID; Nash DR, 2002, ARCH PEDIAT ADOL MED, V156, P1114, DOI 10.1001/archpedi.156.11.1114; Prah J, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.214.13940; Statistics UBo, 2016, NAT POP HOUS CENS 20; van Driel ML, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0470-7; World Health Organization, 2007, INT CLASS DIS REL HL	17	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2020	15	12							e0243868	10.1371/journal.pone.0243868	http://dx.doi.org/10.1371/journal.pone.0243868			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BQ	33370280	Green Published, gold			2023-01-03	WOS:000603611900072
J	Huskamp, HA; Busch, AB; Uscher-Pines, L; Barnett, ML; Riedel, L; Mehrotra, A				Huskamp, Haiden A.; Busch, Alisa B.; Uscher-Pines, Lori; Barnett, Michael L.; Riedel, Lauren; Mehrotra, Ateev			Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Huskamp, Haiden A.; Riedel, Lauren; Mehrotra, Ateev] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Busch, Alisa B.] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA; [Uscher-Pines, Lori] RAND Corp, Arlington, VA USA; [Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; McLean Hospital; RAND Corporation; Harvard University; Harvard T.H. Chan School of Public Health	Huskamp, HA (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	huskamp@hcp.med.harvard.edu	Busch, Alisa/ABE-1524-2021; Mehrotra, Ateev/AAO-8454-2021; Barnett, Michael/AAF-4017-2019	Mehrotra, Ateev/0000-0003-2223-1582; Barnett, Michael/0000-0002-4884-6609	National Institute on Drug Abuse (NIDA) [R01 DA048533, P30 DA035772]	National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))	This study was funded by the National Institute on Drug Abuse (NIDA; grants R01 DA048533 and P30 DA035772).	Lin L, 2020, JAMA PSYCHIAT, V77, P1209, DOI 10.1001/jamapsychiatry.2020.1698; Mehrotra A, IMPACT COVID 19 PAND; Ochalek TA, 2020, JAMA-J AM MED ASSOC, V324, P1673, DOI 10.1001/jama.2020.17477; OptumLabs, 2020, OPTUMLABS OPTUMLABS; Uscher-Pines L, 2020, J SUBST ABUSE TREAT, V118, DOI 10.1016/j.jsat.2020.108124	5	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2020	324	23					2440	2442		10.1001/jama.2020.21512	http://dx.doi.org/10.1001/jama.2020.21512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG8IH	33320214	Bronze, Green Published			2023-01-03	WOS:000599972000022
J	Donnelly, JP; Wang, XQ; Iwashyna, TJ; Prescott, HC				Donnelly, John P.; Wang, Xiao Qing; Iwashyna, Theodore J.; Prescott, Hallie C.			Readmission and Death After Initial Hospital Discharge Among Patients With COVID-19 in a Large Multihospital System	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study describes reasons for readmission, use of ICU interventions during readmission, and proportions of death after initial hospital discharge of COVID-19 patients from US Veterans Affairs (VA) hospitals March-June 2020.	[Donnelly, John P.] Univ Michigan, Dept Learning Hlth Sci, 2800 Plymouth Rd,NCRC Bldg 14,G100,G014-130, Ann Arbor, MI 48109 USA; [Wang, Xiao Qing] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Iwashyna, Theodore J.; Prescott, Hallie C.] HSR&D Ctr Innovat, VA Ctr Clin Management Res, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Donnelly, JP (corresponding author), Univ Michigan, Dept Learning Hlth Sci, 2800 Plymouth Rd,NCRC Bldg 14,G100,G014-130, Ann Arbor, MI 48109 USA.	jpdonn@med.umich.edu		Prescott, Hallie/0000-0002-8442-6724				Agency for Healthcare Research and Quality, 2020, CLIN CLASS SOFTW REF; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Scehnet J, 2020, VA COVID 19 SHARED D; Vincent BM, 2018, HEALTH SERV OUTCOME, V18, P143, DOI 10.1007/s10742-018-0178-3; Wang XQ, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0740-x	5	101	102	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2021	325	3					304	306		10.1001/jama.2020.21465	http://dx.doi.org/10.1001/jama.2020.21465		DEC 2020	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU8HP	33315057	Green Published, Bronze			2023-01-03	WOS:000599746500002
J	Lima, SIVC; Martins, RR; Saldanha, V; Silbiger, VN; dos Santos, ICC; de Araujo, IB; Oliveira, AG				Vieira Cunha Lima, Sara Iasmin; Martins, Rand Randall; Saldanha, Valdjane; Silbiger, Vivian Nogueira; Clemente dos Santos, Isabelle Cristina; de Araujo, Ivonete Batista; Oliveira, Antonio Gouveia			Development and validation of a clinical instrument to predict risk of an adverse drug reactions in hospitalized patients	PLOS ONE			English	Article							OLDER PATIENTS; EVENTS; PREVALENCE; REDUCE	Objective Development and internal validation of a clinical tool for assessment of the risk of adverse drug reactions (ADR) in hospitalized patients. Methodology Nested case-control study in an open cohort of all patients admitted to a general hospital. Cases of ADR were matched to two controls. Eighty four patient variables collected at the time of the ADR were analyzed by conditional logistic regression. Multivariate logistic regression with clustering of cases in a random sample of 2/3 of the cases and respective controls, with baseline odds-ratio corrected with an estimate of ADR incidence, was used to obtain regression coefficients for each risk factor and to develop a risk score. The clinical tool was validated in the remaining 1/3 observations. The study was approved by the institution's research ethics committee. Results In the 8060 hospitalized patients, ADR occurred in 343 (5.31%), who were matched to 686 controls. Fourteen variables were identified as independent risk factors of ADR: female, past history of ADR, heart rate >= 72 bpm, systolic blood pressure >= 148 mmHg, diastolic blood pressure <79 mmHg, diabetes mellitus, serum urea >= 67 mg/dL, serum sodium >= 141 mmol/L, serum potassium >= 4.9 mmol/L, main diagnosis of neoplasia, prescription of >= 3 ATC class B drugs, prescription of ATC class R drugs, prescription of intravenous drugs and >= 6 oral drugs. In the validation sample, the ADR risk tool based on those variables showed sensitivity 61%, specificity 73% and area under the ROC curve 0.73. Conclusion We report a clinical tool for ADR risk stratification in patients hospitalized in general wards based on 14 variables.	[Vieira Cunha Lima, Sara Iasmin; Saldanha, Valdjane; Clemente dos Santos, Isabelle Cristina; Oliveira, Antonio Gouveia] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Grad Program Pharmaceut Sci, Natal, RN, Brazil; [Martins, Rand Randall; de Araujo, Ivonete Batista; Oliveira, Antonio Gouveia] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Pharm Dept, Natal, RN, Brazil; [Silbiger, Vivian Nogueira] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Dept Clin & Toxicol Anal, Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	Lima, SIVC (corresponding author), Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Grad Program Pharmaceut Sci, Natal, RN, Brazil.	sivclima@gmail.com	Silbiger, Vivian/AAO-1027-2021; Silbiger, Vivian/E-9400-2010; Martins, Rand Randall/X-8188-2019	Martins, Rand Randall/0000-0001-9668-0482; Nogueira Silbiger, Vivian/0000-0002-9252-0278; Lima, Sara/0000-0002-4127-7909	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Hamid A, 2014, BRIT J CLIN PHARMACO, V78, P202, DOI 10.1111/bcp.12293; Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; Brier GW, 1950, MONTHLY WEATHER REV, V78, P1, DOI 10.1175/1520- 0493(1950) 0782.0.CO;2; Centre for Drug Statistics Methodology (NO), 2019, AN THER CHEM COD; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Claydon-Platt K, 2012, DIABETES RES CLIN PR, V97, P223, DOI 10.1016/j.diabres.2012.03.003; Donsa K, 2016, INT J MED INFORM, V90, P58, DOI 10.1016/j.ijmedinf.2016.03.007; DUPONT WD, 1988, BIOMETRICS, V44, P1157, DOI 10.2307/2531743; Evans RS, 2005, ANN PHARMACOTHER, V39, P1161, DOI 10.1345/aph.1E642; Gallagher RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028096; Griffin F.A., 2009, IHI INNOVATION SERIE, VSecond; Haile DB, 2013, ETHIOP J HEALTH SCI, V23, P39; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Klopotowska JE, 2013, EUR J CLIN PHARMACOL, V69, P75, DOI 10.1007/s00228-012-1316-4; Lexicomp Online, 2019, LEX ONL DRUG INT; McElnay JC, 1997, CLIN DRUG INVEST, V13, P47, DOI 10.2165/00044011-199713010-00006; Miguel A, 2012, PHARMACOEPIDEM DR S, V21, P1139, DOI 10.1002/pds.3309; Moons KGM, 2012, HEART, V98, P683, DOI 10.1136/heartjnl-2011-301246; Nair NP, 2016, CLIN INTERV AGING, V11, P497, DOI 10.2147/CIA.S99097; O'Connor MN, 2012, AGE AGEING, V41, P771, DOI 10.1093/ageing/afs046; Onder G, 2013, AGE AGEING, V42, P284, DOI 10.1093/ageing/aft038; Onder G, 2010, ARCH INTERN MED, V170, P1142, DOI 10.1001/archinternmed.2010.153; Pedros C, 2014, EUR J CLIN PHARMACOL, V70, P361, DOI 10.1007/s00228-013-1630-5; Reach G, 2013, DIABETES METAB, V39, P50, DOI 10.1016/j.diabet.2012.08.009; Suggett Emma, 2016, Drugs Real World Outcomes, V3, P241; Tandon VR, 2015, INDIAN J PHARMACOL, V47, P65, DOI 10.4103/0253-7613.150344; Tangiisuran B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111254; Trivalle C, 2010, J NUTR HEALTH AGING, V14, P57, DOI 10.1007/s12603-010-0010-4; Wong B, 2017, AM J MED, V130, P366, DOI 10.1016/j.amjmed.2016.09.034; World Health Organization (WHO), 1975, REQ ADV REACT; YOUDEN W. J., 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; 2014, REG ANESTH PAIN MED, V9	34	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243714	10.1371/journal.pone.0243714	http://dx.doi.org/10.1371/journal.pone.0243714			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WM	33306728	gold, Green Published			2023-01-03	WOS:000600144200027
J	Perez-San Martin, S; Suberviola, B; Garcia-Unzueta, MT; Lavin, BA; Campos, S; Santibanez, M				Perez-San Martin, S.; Suberviola, B.; Garcia-Unzueta, M. T.; Lavin, B. A.; Campos, S.; Santibanez, M.			Prognostic value of plasma pentraxin 3 levels in patients with septic shock admitted to intensive care	PLOS ONE			English	Article							EARLY LACTATE CLEARANCE; C-REACTIVE PROTEIN; SEVERE SEPSIS; INNATE IMMUNITY; MORTALITY; PTX3; INFLAMMATION; BIOMARKERS; MANAGEMENT; INFECTION	Objective To evaluate the usefulness of a new marker, pentraxin, as a prognostic marker in septic shock patients. Materials and methods Single-centre prospective observational study that included all consecutive patients 18 years or older who were admitted to the intensive care unit (ICU) with septic shock. Serum levels of procalcitonin (PCT), C-reactive protein (CRP) and pentraxin (PTX3) were measured on ICU admission. Results Seventy-five septic shock patients were included in the study. The best predictors of in-hospital mortality were the severity scores: SAPS II (AUC = 0.81), SOFA (AUC = 0.79) and APACHE II (AUC = 0.73). The ROC curve for PTX3 (ng/mL) yielded an AUC of 0.70, higher than the AUC for PCT (0.43) and CRP (0.48), but lower than lactate (0.79). Adding PTX3 to the logistic model increased the predictive capacity in relation to SAPS II, SOFA and APACHE II for in-hospital mortality (AUC 0.814, 0.795, and 0.741, respectively). In crude regression models, significant associations were found between in-hospital mortality and PTX3. This positive association increased after adjusting for age, sex and immunosuppression: adjusted OR T3 for PTX3 = 7.83, 95% CI 1.35-45.49, linear P trend = 0.024. Conclusion Our results support the prognostic value of a single determination of plasma PTX3 as a predictor of hospital mortality in septic shock patients.	[Perez-San Martin, S.; Garcia-Unzueta, M. T.; Lavin, B. A.] Univ Hosp Marques Valdecilla IDIVAL, Dept Clin Biochem, Santander, Spain; [Suberviola, B.; Campos, S.] Univ Hosp Marques Valdecilla IDIVAL, Intens Care Dept, Santander, Spain; [Santibanez, M.] Univ Cantabria, Sch Nursing, Hlth Res Inst Valdecilla IDIVAL, Santander, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria	Suberviola, B (corresponding author), Univ Hosp Marques Valdecilla IDIVAL, Intens Care Dept, Santander, Spain.	borja.suberviola@scsalud.es		Lavin-Gomez, Bernardo Alio/0000-0001-7279-7643				Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; ALLES VV, 1994, BLOOD, V84, P3483; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; Arora S, 2015, SHOCK, V43, P212, DOI 10.1097/SHK.0000000000000305; Bastrup-Birk S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073119; Becker KL, 2008, CRIT CARE MED, V36, P941, DOI 10.1097/CCM.0B013E318165BABB; Caironi P, 2017, EUR J CLIN INVEST, V47, P73, DOI 10.1111/eci.12704; Casserly B, 2015, CRIT CARE MED, V43, P567, DOI 10.1097/CCM.0000000000000742; Daigo K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00378; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Garcia-Alvarez M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0503-3; Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756; Global Sepsis Alliance, WHA AD RES SEPS; Haas SA, 2016, INTENS CARE MED, V42, P202, DOI 10.1007/s00134-015-4127-0; Hamed S, 2018, CLIN LAB, V64, P999, DOI 10.7754/Clin.Lab.2018.180116; Hu CG, 2018, ONCOTARGET, V9, P5125, DOI 10.18632/oncotarget.23701; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Jie HY, 2017, AM J MED SCI, V353, P242, DOI 10.1016/j.amjms.2017.01.003; Kibe S, 2011, J ANTIMICROB CHEMOTH, V66, pII33, DOI 10.1093/jac/dkq523; Kim SB, 2017, YONSEI MED J, V58, P370, DOI 10.3349/ymj.2017.58.2.370; LEE GW, 1993, J IMMUNOL, V150, P1804; Lee YT, 2018, J INFECTION, V76, P1, DOI 10.1016/j.jinf.2017.10.016; Levy B, 2005, LANCET, V365, P871, DOI 10.1016/S0140-6736(05)71045-X; Mantovani A, 2008, J CLIN IMMUNOL, V28, P1, DOI 10.1007/s10875-007-9126-7; Mauri T, 2010, INTENS CARE MED, V36, P621, DOI 10.1007/s00134-010-1752-5; Muller B, 2001, CRIT CARE MED, V29, P1404, DOI 10.1097/00003246-200107000-00017; Nassar AP, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.016; Nguyen HB, 2004, CRIT CARE MED, V32, P1637, DOI 10.1097/01.CCM.0000132904.35713.A7; Patel PA, 1999, INTENS CARE MED, V25, P977, DOI 10.1007/s001340050992; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; Porte R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00794; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Rivers EP, 2011, CHEST, V140, P1408, DOI 10.1378/chest.11-2563; Salluh JIF, 2014, CURR OPIN CRIT CARE, V20, P557, DOI 10.1097/MCC.0000000000000135; Samsudin Intan, 2017, Clin Biochem Rev, V38, P59; Schuetz P, 2017, EXPERT REV MOL DIAGN, V17, P593, DOI 10.1080/14737159.2017.1324299; Silvestre J, 2009, INTENS CARE MED, V35, P909, DOI 10.1007/s00134-009-1402-y; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Song J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020495; Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7; Uusitalo-Seppala R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053661; van Engelen TSR, 2018, CRIT CARE CLIN, V34, P139, DOI 10.1016/j.ccc.2017.08.010; Yamasaki K, 2009, CLIN CHEM LAB MED, V47, P471, DOI 10.1515/CCLM.2009.110	44	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2020	15	12							e0243849	10.1371/journal.pone.0243849	http://dx.doi.org/10.1371/journal.pone.0243849			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WB	33301518	Green Published, gold			2023-01-03	WOS:000600143100090
J	Romanov, GP; Pshennikova, VG; Lashin, SA; Solovyev, AV; Teryutin, FM; Cherdonova, AM; Borisova, TV; Sazonov, NN; Khusnutdinova, EK; Posukh, OL; Fedorova, SA; Barashkov, NA				Romanov, Georgii P.; Pshennikova, Vera G.; Lashin, Sergey A.; Solovyev, Aisen V.; Teryutin, Fedor M.; Cherdonova, Aleksandra M.; Borisova, Tuyara V.; Sazonov, Nikolay N.; Khusnutdinova, Elza K.; Posukh, Olga L.; Fedorova, Sardana A.; Barashkov, Nikolay A.			A new approach to estimating the prevalence of hereditary hearing loss: An analysis of the distribution of sign language users based on census data in Russia	PLOS ONE			English	Article							SPLICE-SITE MUTATION; EASTERN SIBERIA; GENE; DISEASES; GJB2; POPULATIONS; IMPAIRMENT; DIVERSITY; SPECTRUM	The absence of comparable epidemiological data challenges the correct estimation of the prevalence of congenital hearing loss (HL) around the world. Sign language (SL) is known as the main type of communication of deaf people. We suggest that the distribution of SL can be interpreted as an indirect indicator of the prevalence of congenital HL. Since a significant part of congenital HL is due to genetic causes, an assessment of the distribution of SL users can reveal regions with an extensive accumulation of hereditary HL. For the first time, we analyzed the data on the distribution of SL users that became available for the total population of Russia by the 2010 census. Seventy-three out of 85 federal regions of Russia were ranked into three groups by the 25th and 75th percentiles of the proportion of SL users: 14 regions-"low proportion"; 48 regions-"average proportion"; and 11 regions-"high proportion". We consider that the observed uneven prevalence of SL users can reflect underlying hereditary forms of congenital HL accumulated in certain populations by specific genetic background and population structure. At least, the data from this study indicate that the highest proportions of SL users detected in some Siberian regions are consistent with the reported accumulation of specific hereditary HL forms in indigenous Yakut, Tuvinian and Altaian populations.	[Romanov, Georgii P.; Pshennikova, Vera G.; Solovyev, Aisen V.; Teryutin, Fedor M.; Cherdonova, Aleksandra M.; Borisova, Tuyara V.; Sazonov, Nikolay N.; Fedorova, Sardana A.; Barashkov, Nikolay A.] MK Ammosov North Eastern Fed Univ, Mol Biol Lab, Yakutsk, Russia; [Romanov, Georgii P.; Pshennikova, Vera G.; Teryutin, Fedor M.; Fedorova, Sardana A.; Barashkov, Nikolay A.] Yakut Sci Ctr Complex Med Problems, Mol Genet Lab, Yakutsk, Russia; [Lashin, Sergey A.; Posukh, Olga L.] Russian Acad Sci, Siberian Branch, Fed Res Ctr Inst Cytol & Genet, Novosibirsk, Russia; [Lashin, Sergey A.; Posukh, Olga L.] Novosibirsk State Univ, Novosibirsk, Russia; [Solovyev, Aisen V.] Russian Acad Sci, Lab Human Arctic, Inst Humanitarian Res & North Indigenous Peoples, Fed Res Ctr,Yakut Sci Ctr,Siberian Branch, Yakutsk, Russia; [Khusnutdinova, Elza K.] Russian Acad Sci, Inst Biochem & Genet, Ufa Fed Res Ctr, Lab Human Mol Genet, Ufa, Russia; [Khusnutdinova, Elza K.] Bashkir State Univ, Dept Genet & Fundamental Med, Ufa, Russia	North-Eastern Federal University in Yakutsk; Yakut Science Centre of Complex Medical Problems; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Novosibirsk State University; Russian Academy of Sciences; Yakut Science Centre of Complex Medical Problems; Institute of Biochemistry & Genetics of Ufa Science Centre of the RAS; Russian Academy of Sciences; Bashkir State University	Barashkov, NA (corresponding author), MK Ammosov North Eastern Fed Univ, Mol Biol Lab, Yakutsk, Russia.; Barashkov, NA (corresponding author), Yakut Sci Ctr Complex Med Problems, Mol Genet Lab, Yakutsk, Russia.	barashkov2004@mail.ru	Lashin, Sergey/D-8142-2012; Romanov, Georgii P/E-6367-2017	Lashin, Sergey/0000-0003-3138-381X; Romanov, Georgii P/0000-0002-2936-5818	Project of the Ministry of Science and Higher Education of the Russian Federation [FSRG-2020-0016]; Project of the NEFU [0794-2017-0019 (FSRG-2017-0019)]; Budget Project of Institute of Cytology and Genetics SB RAS [0324-2019-0041]; Russian Foundation for Basic Research [17-29-06016_ofi_M, 18-05-600035_Arctika, 18-015-00212_A, 19-34-60023_Perspektiva, 20-015-00328_A]	Project of the Ministry of Science and Higher Education of the Russian Federation; Project of the NEFU; Budget Project of Institute of Cytology and Genetics SB RAS; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	The study was supported by the Project of the Ministry of Science and Higher Education of the Russian Federation (basic part of funding to MK Ammosov North-Eastern Federal University, #FSRG-2020-0016) (SAF), by the Project of the NEFU #0794-2017-0019 (FSRG-2017-0019) (SAF), by the Budget Project of Institute of Cytology and Genetics SB RAS #0324-2019-0041 (OLP), and by the Russian Foundation for Basic Research: 17-29-06016_ofi_M (OLP), 18-05-600035_Arctika (SAF), 18-015-00212_A (NAB), 19-34-60023_Perspektiva (AVS), 20-015-00328_A (VGP).	Barashkov Nikolay A, 2019, Int J Circumpolar Health, V78, P1630219, DOI 10.1080/22423982.2019.1630219; Barashkov NA, 2018, INT J PEDIATR OTORHI, V104, P94, DOI 10.1016/j.ijporl.2017.11.001; Barashkov NA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156300; Barashkov NA, 2011, J HUM GENET, V56, P631, DOI 10.1038/jhg.2011.72; Bliznetz EA, 2014, RUSS J GENET+, V50, P415, DOI 10.1134/S1022795414020045; Bliznetz EA, 2012, RUSS J GENET+, V48, P101, DOI 10.1134/S1022795412010036; Bliznetz EA, 2017, J HUM GENET, V62, P789, DOI 10.1038/jhg.2017.42; Bliznetz EA, 2009, EUR J HUM GENET, V17, P664, DOI 10.1038/ejhg.2008.234; Bozhkova V. P., 2010, Biophysics, V55, P453, DOI 10.1134/S0006350910030176; Bubbico L, 2007, Acta Otorhinolaryngol Ital, V27, P17; Butcher E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219600; Chibisova S. S., 2018, Vestnik Otorinolaringologii, V83, P37, DOI 10.17116/otorino201883437; Churbanov AY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153841; Dzhemilova LU, 2009, RUSS J GENET+, V45, P861, DOI 10.1134/S1022795409070151; El'chinova GI, 2015, RUSS J GENET+, V51, P1020, DOI 10.1134/S1022795415100051; El'chinova GI, 2011, RUSS J GENET+, V47, P999, DOI 10.1134/S1022795411080059; [Гольцова Т.В. Goltsova T.V.], 2006, [Вавиловский журнал генетики и селекции, Vavilovskii zhurnal genetiki i selektsii], V10, P126; Gundorova P, 2017, RUSS J GENET+, V53, P813, DOI [10.1134/S1022795417070043, 10.1134/s1022795417070043]; Gundorova P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201489; Harris MS, 2017, CURR OPIN OTOLARYNGO, V25, P353, DOI 10.1097/MOO.0000000000000392; Kazantseva A, 2006, SCIENCE, V314, P982, DOI 10.1126/science.1133276; Korver AMH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2016.94; Kurbatova OL, 2016, RUSS J GENET+, V52, P726, DOI 10.1134/S1022795416070061; Kurbatova Olga L., 2005, Journal of Physiological Anthropology and Applied Human Science, V24, P363, DOI 10.2114/jpa.24.363; Li CM, 2018, AM J PREV MED, V55, P326, DOI 10.1016/j.amepre.2018.03.022; Lobov S, 2011, IZVESTIYA SAMARSKOGO, V13, P251; Marakhonov AV, 2018, BMC MED GENOMICS, V11, DOI 10.1186/s12920-018-0326-1; Markova T. G., 2018, Vestnik Otorinolaringologii, V83, P31, DOI 10.17116/otorino201883431; Mitchell RE, 2006, J DEAF STUD DEAF EDU, V11, P112, DOI 10.1093/deafed/enj004; Morton CC, 2006, NEW ENGL J MED, V354, P2151, DOI 10.1056/NEJMra050700; Pascolini D, 2009, INT J AUDIOL, V48, P473, DOI 10.1080/14992020902803120; Petrova N V, 2016, J Cyst Fibros, V15, pe28, DOI 10.1016/j.jcf.2016.02.003; Posukh O, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-12; Posukh OL, 2019, GENES-BASEL, V10, DOI 10.3390/genes10060429; Pshennikova VG, 2017, RUSS J GENET+, V53, P688, DOI 10.1134/S1022795417030103; Puzyrev VP, 2008, RUSS J GENET+, V44, P1141, DOI 10.1134/S1022795408100037; Shein JD, 1974, DEAF POPULATION US; Stevens G, 2013, EUR J PUBLIC HEALTH, V23, P146, DOI 10.1093/eurpub/ckr176; Tarskaia LA, 2004, RUSS J GENET+, V40, P1264, DOI 10.1023/B:RUGE.0000048669.22362.1c; World Health Organisation, DEAFN HEAR LOSS; Wroblewska-Seniuk KE, 2017, PEDIATR RES, V81, P415, DOI 10.1038/pr.2016.250; Zhuravskii S, 2009, ROSSIYSKAYA OTORINOL, V38, P3; Zhuravsky S. G., 2008, Ekologiya Cheloveka / Human Ecology, P53; Zinchenko RA, 2007, RUSS J GENET+, V43, P1038, DOI 10.1134/S1022795407090104; Zinchenko RA, 2007, RUSS J GENET+, V43, P918, DOI 10.1134/S1022795407080145; Zinchenko RA, 2001, RUSS J GENET+, V37, P1312, DOI 10.1023/A:1012569411698; Zinchenko RA, 2001, RUSS J GENET+, V37, P290, DOI 10.1023/A:1009065311941; Zytsar MV, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070833	48	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2020	15	11							e0242219	10.1371/journal.pone.0242219	http://dx.doi.org/10.1371/journal.pone.0242219			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT2ZY	33253245	Green Published, gold			2023-01-03	WOS:000608488200028
J	Orishaba, P; Kalyango, JN; Byakika-Kibwika, P; Arinaitwe, E; Wandera, B; Katairo, T; Muzeyi, W; Nansikombi, HT; Nakato, A; Mutabazi, T; Kamya, MR; Dorsey, G; Nankabirwa, JI				Orishaba, Philip; Kalyango, Joan N.; Byakika-Kibwika, Pauline; Arinaitwe, Emmanuel; Wandera, Bonnie; Katairo, Thomas; Muzeyi, Wani; Nansikombi, Hildah Tendo; Nakato, Alice; Mutabazi, Tobius; Kamya, Moses R.; Dorsey, Grant; Nankabirwa, Joaniter I.			Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; PNEUMOCYSTIS-CARINII-PNEUMONIA; HIV-1-INFECTED ADULTS; ANTIRETROVIRAL THERAPY; HEMOGLOBIN LEVELS; COINFECTION; HIV/AIDS; BLOOD	Background Although WHO recommends cotrimoxazole (CTX) discontinuation among HIV patients who have undergone immune recovery and are living in areas of low prevalence of malaria, some countries including Uganda recommend CTX discontinuation despite having a high malaria burden. We estimated the prevalence and factors associated with malaria parasitaemia among adults living with HIV attending hospital outpatient clinic before and after discontinuation of CTX prophylaxis. Methods Between March and April 2019, 599 participants aged 18 years and above, and attending Kitgum hospital HIV clinic in Uganda were enrolled in a cross study. A standardized questionnaire was administered and physical examination conducted. A finger-prick blood sample was collected for identification of malaria parasites by microscopy. The prevalence of parasitaemia was estimated and compared among participants on and those who had discontinued CTX prophylaxis, and factors associated with malaria parasitaemia assessed. Results Of the enrolled participants, 27 (4.5%) had malaria parasites and 452 (75.5%) had stopped CTX prophylaxis. Prevalence of malaria parasitaemia was significantly higher in participants who had stopped CTX prophylaxis (5.5% versus 1.4% p = 0.03) and increased with increasing duration since the discontinuation of prophylaxis. Compared to participants taking CTX, those who discontinued prophylaxis for 3-5 months and >5 months were more likely to have malaria parasites (adjusted prevalence ratio (aPR) = 1.64, 95% CI 0.37-7.29, p = 0.51, and aPR = 6.06, 95% CI 1.34-27.3, P = 0.02). Low CD4 count (< 250cells/mm(3)) was also associated with increased risk of having parasites (aPR = 4.31, 95% CI 2.13-8.73, p <0.001). Conclusion People from malaria endemic settings living with HIV have a higher prevalence of malaria parasitaemia following discontinuation of CTX compared to those still on prophylaxis. The risk increased with increasing duration since discontinuation of the prophylaxis. HIV patients should not discontinue CTX prophylaxis in areas of Uganda where the burden of malaria remains high. Other proven malaria control interventions may also be encouraged in HIV patients following discontinuation of CTX prophylaxis.	[Orishaba, Philip; Kalyango, Joan N.; Katairo, Thomas; Muzeyi, Wani; Nansikombi, Hildah Tendo; Nakato, Alice; Mutabazi, Tobius; Nankabirwa, Joaniter I.] Makerere Univ, Coll Hlth Sci, Clin Epidemiol Unit, Kampala, Uganda; [Kalyango, Joan N.] Makerere Univ, Coll Hlth Sci, Dept Pharm, Kampala, Uganda; [Byakika-Kibwika, Pauline; Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Internal Med, Kampala, Uganda; [Arinaitwe, Emmanuel; Wandera, Bonnie; Katairo, Thomas; Kamya, Moses R.] Infect Dis Res Collaborat, Kampala, Uganda; [Dorsey, Grant] Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco, CA 94143 USA	Makerere University; Makerere University; Makerere University; University of California System; University of California San Francisco	Orishaba, P; Kalyango, JN (corresponding author), Makerere Univ, Coll Hlth Sci, Clin Epidemiol Unit, Kampala, Uganda.	orishabaphilip@gmail.com; nakayaga2001@yahoo.com		Orishaba, Philip/0000-0002-1236-8529; Muzeyi, Wani/0000-0002-6337-7636; Katairo, Thomas/0000-0002-2002-8911	Fogarty International Center of the National Institutes of Health [D43TW010526]; Fogarty International Center (Emerging Global Leader Award) [K43TW010365]	Fogarty International Center of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Fogarty International Center (Emerging Global Leader Award)	Research reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW010526. JIN is supported by the Fogarty International Center (Emerging Global Leader Award grant number K43TW010365). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Misses Rhoda Namubiru and Susan Balyejusa for the administrative and technical support. We are grateful to the study team and study participants for their involvement in the study.	Akotet MKB, 2018, PATHOG GLOB HEALTH, V112, P63, DOI 10.1080/20477724.2017.1401760; Alemu A, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-18; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Badri M, 2001, AIDS, V15, P1143, DOI 10.1097/00002030-200106150-00009; Chavale H, 2012, MEM I OSWALDO CRUZ, V107, P985, DOI 10.1590/S0074-02762012000800004; Di Gennaro F, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15092032; FASAN PO, 1971, ANN TROP MED PARASIT, V65, P117, DOI 10.1080/00034983.1971.11686737; Faure E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00441; Flateau C, 2011, LANCET INFECT DIS, V11, P541, DOI 10.1016/S1473-3099(11)70031-7; Fokam EB, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1228-3; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Hoffman IF, 1999, AIDS, V13, P487, DOI 10.1097/00002030-199903110-00007; Iliyasu Z, 2013, ACTA TROP, V128, P630, DOI 10.1016/j.actatropica.2013.09.011; Joint United Nations Programme on HIV/AIDS, 2017, UNAIDS DAT 2017, V2018; Kasirye RP, 2017, AIDS, V31, P577, DOI 10.1097/QAD.0000000000001344; Katrak S, 2016, J INFECT DIS, V213, P1971, DOI 10.1093/infdis/jiw057; Kenea O, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2811-1; Kirinyet JK, 2019, J TROP MED-US, V2019, DOI 10.1155/2019/5697383; Kublin JG, 2005, LANCET, V365, P233, DOI 10.1016/S0140-6736(05)17743-5; Lara AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033672; Njunda AL, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3647-z; Ministry of Health, 2005, NAT ANT TREATM CAR G; Ministry of Health, 2018, 2018 19 UG MAL IND S; Ministry of Health Uganda, 2018, CONS GUID PREV TREAT; Muhindo MK, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1489-x; Nankabirwa JI, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-1056-x; Newell K, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1128-6; Ogwang R, 2018, ACTA TROP, V188, P27, DOI 10.1016/j.actatropica.2018.08.023; Okullo AE, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1966-x; Polyak CS, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001934; Rubaihayo John, 2016, BMC Res Notes, V9, P501; Sanyaolu AO, 2013, AFR HEALTH SCI, V13, P295, DOI 10.4314/ahs.v13i2.14; Selemani M, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1311-9; Tagoe DNA, 2012, J INFECT DEV COUNTR, V6, P660, DOI 10.3855/jidc.2124; Taremwa IM, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4824-4; Uganda Ministry of Health, 2019, 2018 19 UG MAL IND S; Watera C, 2006, JAIDS-J ACQ IMM DEF, V42, P373, DOI 10.1097/01.qai.0000221679.14445.1b; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; WHO, 2018, WORLD MALARIA REPORT; World Health Organization, 2014, DEC 2014 2013 CONS S; World Health Organization Center for Disease Control, 2010, BAS MAL MICR TUT GUI	42	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2020	15	11							e0240838	10.1371/journal.pone.0240838	http://dx.doi.org/10.1371/journal.pone.0240838			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0LY	33175844	gold, Green Published			2023-01-03	WOS:000593946900029
J	Ouanes, S; Becetti, I; Ghuloum, S; Hammoudeh, S; Shehata, M; Ghabrash, H; Yehya, A; Al-Lawati, H; Al-Fakhri, N; Iram, H; Ajmal, N; Eltorki, Y; Al-Amin, H				Ouanes, Sami; Becetti, Imen; Ghuloum, Suhaila; Hammoudeh, Samer; Shehata, Mena; Ghabrash, Hany; Yehya, Areej; Al-Lawati, Hawra; Al-Fakhri, Nora; Iram, Huma; Ajmal, Nighat; Eltorki, Yassin; Al-Amin, Hassen			Patterns of prescription of antipsychotics in Qatar	PLOS ONE			English	Article							META-REGRESSION; SCHIZOPHRENIA; POLYPHARMACY; CLOZAPINE; MONOTHERAPY; PREVALENCE; GUIDELINES; INPATIENTS	Objective Even though all guidelines recommend generally against antipsychotic polypharmacy, antipsychotic polypharmacy appears to be a very common practice across the globe. This study aimed to examine the prescription patterns of antipsychotics in Qatar, in comparison with the international guidelines, and to scrutinize the sociodemographic and clinical features associated with antipsychotic polypharmacy. Methods All the medical records of all the inpatients and outpatients treated by antipsychotics at the Department of Psychiatry-Hamad Medical Corporation (HMC) in Doha, Qatar (between October 2012 and April 2014) were retrospectively analyzed. We retrieved the available sociodemographic data, psychiatric features, and details on the medication history. Results Our sample consisted of 537 individuals on antipsychotics (2/3 were male; mean age 33.8 +/- 10.2 years), prescribed for a psychotic disorder in 57%, a mood disorder in 9.3%, and various other diagnoses in 33.7%. About 55.9% received one antipsychotic, 29.6% received two antipsychotics, and 14.5% received more than two antipsychotics. Polypharmacy was associated with younger age (p = 0.025), being single (p<0.001), the diagnosis of a psychotic disorder (p<0.001), and previous admissions to psychiatry (p<0.001). Conclusions Antipsychotic polypharmacy appears to be quite common in Qatar, as it is the case in many other countries, in contrast with most international recommendations. Studies are needed to explore the reasons behind this disparity.	[Ouanes, Sami; Ghuloum, Suhaila; Shehata, Mena; Ghabrash, Hany; Iram, Huma; Ajmal, Nighat] Hamad Med Corp, Dept Psychiat, Doha, Qatar; [Becetti, Imen; Al-Lawati, Hawra; Al-Fakhri, Nora] Weill Cornell Med Coll, Med Educ, Doha, Qatar; [Hammoudeh, Samer; Yehya, Areej] Weill Cornell Med Coll, Res Dept, Doha, Qatar; [Eltorki, Yassin] Hamad Med Corp, Pharm Dept, Psychiat Hosp, Doha, Qatar; [Al-Amin, Hassen] Weill Cornell Med Coll, Psychiat Dept, Doha, Qatar	Hamad Medical Corporation; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Hamad Medical Corporation; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Al-Amin, H (corresponding author), Weill Cornell Med Coll, Psychiat Dept, Doha, Qatar.	haa2019@qatar-med.cornell.edu	Al-Amin, Hassen/ABC-3650-2020	Al-Amin, Hassen/0000-0001-6358-1541; Ouanes, Sami/0000-0003-0867-060X; Hammoudeh, Samer/0000-0003-0805-8111	Qatar National Research Fund (QNRF) [UREP 16-012-3-003]	Qatar National Research Fund (QNRF)(National Research Foundation of KoreaQatar National Research Fund (QNRF))	The study was funded by a Qatar National Research Fund (QNRF) grant: UREP 16-012-3-003. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkhadhari S, 2015, NEUROPSYCH DIS TREAT, V11, DOI 10.2147/NDT.S78788; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; Freudenreich O, 2002, ACTA PSYCHIAT SCAND, V106, P323, DOI 10.1034/j.1600-0447.2002.01331.x; Gallego JA, 2012, SCHIZOPHR RES, V138, P18, DOI 10.1016/j.schres.2012.03.018; Galling B, 2017, WORLD PSYCHIATRY, V16, P77, DOI 10.1002/wps.20387; Howes OD, 2012, BRIT J PSYCHIAT, V201, P481, DOI 10.1192/bjp.bp.111.105833; Hui CLM, 2019, INT REV PSYCHIATR, V31, P441, DOI 10.1080/09540261.2019.1613965; Ismail D, 2019, ASIAN J PSYCHIATR, V39, P93, DOI 10.1016/j.ajp.2018.12.011; Joukamaa M, 2006, BRIT J PSYCHIAT, V188, P122, DOI 10.1192/bjp.188.2.122; Kaneko K, 2018, YONAGO ACTA MED, V61, P91, DOI 10.33160/yam.2018.06.001; Kim HY, 2014, CLIN PSYCHOPHARM NEU, V12, P128, DOI 10.9758/cpn.2014.12.2.128; Lally J, 2019, IRISH J PSYCHOL MED, V36, P279, DOI 10.1017/ipm.2018.47; Larrayadieu A, 2011, AGE AGEING, V40, P368, DOI 10.1093/ageing/afr032; Man LSL, 2018, ASIAN J PSYCHIATR, V33, P113, DOI 10.1016/j.ajp.2018.03.012; Matsui K, 2019, SCHIZOPHR RES, V209, P50, DOI 10.1016/j.schres.2019.05.030; O'Sullivan ED, 2018, J ROY COLL PHYS EDIN, V48, P225, DOI 10.4997/JRCPE.2018.306; Remington G, 2017, CAN J PSYCHIAT, V62, P604, DOI 10.1177/0706743717720448; Stahl SM, 2004, CURR MED CHEM, V11, P313, DOI 10.2174/0929867043456070; Stahl SM, 2002, J CLIN PSYCHIAT, V63, P93, DOI 10.4088/JCP.v63n0201; Stringer Gary, 2015, VARIORUM EDITION POE, V3, P140; Stroup TS, 2014, PSYCHIAT SERV, V65, P186, DOI 10.1176/appi.ps.201300180; Tang Y, 2017, PSYCHIAT SERV, V68, P579, DOI 10.1176/appi.ps.201600041; Tiihonen J, 2019, JAMA PSYCHIAT, V76, P499, DOI 10.1001/jamapsychiatry.2018.4320; Tungaraza TE, 2017, THER ADV PSYCHOPHARM, V7, P103, DOI 10.1177/2045125316683151; Wilkinson S, 2018, NEW ZEAL MED J, V131, P61; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607; Xue QJ, 2014, INT CLIN PSYCHOPHARM, V29, P288, DOI 10.1097/YIC.0000000000000024; Yang SY, 2018, PSYCHIAT CLIN NEUROS, V72, P572, DOI 10.1111/pcn.12676; Yazici Esra, 2017, Clin Pract Epidemiol Ment Health, V13, P92, DOI 10.2174/1745017901713010092; Yoshimura R, 2006, PSYCHIAT CLIN NEUROS, V60, P778, DOI 10.1111/j.1440-1819.2006.01601.x; Young SL, 2015, J PSYCHOPHARMACOL, V29, P353, DOI 10.1177/0269881114562090	31	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2020	15	11							e0241986	10.1371/journal.pone.0241986	http://dx.doi.org/10.1371/journal.pone.0241986			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OV7JZ	33166337	Green Published, gold			2023-01-03	WOS:000592382600049
J	Lee, DE; Ryoo, HW; Moon, S; Park, JH; Shin, SD				Lee, Dong Eun; Ryoo, Hyun Wook; Moon, Sungbae; Park, Jeong Ho; Shin, Sang Do			Effect of citywide enhancement of the chain of survival on good neurologic outcomes after out-of-hospital cardiac arrest from 2008 to 2017	PLOS ONE			English	Article							HEART-ASSOCIATION GUIDELINES; ADVANCED AIRWAY MANAGEMENT; CARDIOPULMONARY-RESUSCITATION; CARE; UPDATE; TRENDS; RATES	Improving outcomes after out-of-hospital cardiac arrests (OHCAs) requires an integrated approach by strengthening the chain of survival and emergency care systems. This study aimed to identify the change in outcomes over a decade and effect of citywide intervention on good neurologic outcomes after OHCAs in Daegu. This is a before- and after-intervention study to examine the association between the citywide intervention to improve the chain of survival and outcomes after OHCA. The primary outcome was a good neurologic outcome, defined as a cerebral performance category score of 1 or 2. After dividing into 3 phases according to the citywide intervention, the trends in outcomes after OHCA by primary electrocardiogram rhythm were assessed. Logistic regression analysis was used to analyze the association between the phases and outcomes. Overall, 6203 patients with OHCA were eligible. For 10 years (2008-2017), the rate of survival to discharge and the good neurologic outcomes increased from 2.6% to 8.7% and from 1.5% to 6.6%, respectively. Especially for patients with an initial shockable rhythm, these changes in outcomes were more pronounced (survival to discharge: 23.3% in 2008 to 55.0% in 2017, good neurologic outcomes: 13.3% to 46.0%). Compared with phase 1, the adjusted odds ratio (AOR) and 95% confidence intervals (CI) for good neurologic outcomes was 1.20 (95% CI: 0.78-1.85) for phase 2 and 1.64 (1.09-2.46) for phase 3. For patients with an initial shockable rhythm, the AOR for good neurologic outcomes was 3.76 (1.88-7.52) for phase 2 and 5.51 (2.77-10.98) for phase 3. Citywide improvement was observed in the good neurologic outcomes after OHCAs of medical origin, and the citywide intervention was significantly associated with better outcomes, particularly in those with initial shockable rhythm.	[Lee, Dong Eun] Kyungpook Natl Univ, Dept Emergency Med, Chilgok Hosp, Sch Med, Daegu, South Korea; [Ryoo, Hyun Wook; Moon, Sungbae] Kyungpook Natl Univ, Dept Emergency Med, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea; [Park, Jeong Ho; Shin, Sang Do] Seoul Natl Univ, Dept Emergency Med, Coll Med, Seoul, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University Hospital; Seoul National University (SNU)	Ryoo, HW (corresponding author), Kyungpook Natl Univ, Dept Emergency Med, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea.	ryoo@knu.ac.kr		Lee, Dong Eun/0000-0002-2057-5261; Ryoo, Hyun Wook/0000-0002-1361-9887				[Anonymous], 2017, CANC DISCOVERY, V7, pOF12; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Cho H, 2014, CLIN EXP EMERG MED, V1, P94, DOI 10.15441/ceem.14.021; Ewy GA, 2015, RESUSCITATION, V96, P180, DOI 10.1016/j.resuscitation.2015.08.011; Grasner JT, 2011, CRIT CARE, V15, DOI 10.1186/cc10035; Homma Y, 2019, AM J EMERG MED, V37, P241, DOI 10.1016/j.ajem.2018.05.037; Jabre P, 2018, JAMA-J AM MED ASSOC, V319, P779, DOI 10.1001/jama.2018.0156; Jeong S, 2016, AM J EMERG MED, V34, P2101, DOI 10.1016/j.ajem.2016.07.025; Kim KH, 2020, PREHOSP EMERG CARE, V24, P485, DOI 10.1080/10903127.2019.1668989; Kim S, 2020, CLIN EXP EMERG MED, V7, P21, DOI 10.15441/ceem.19.002; Kragholm K, 2017, NEW ENGL J MED, V376, P1737, DOI 10.1056/NEJMoa1601891; Kronick SL, 2015, CIRCULATION, V132, pS397, DOI 10.1161/CIR.0000000000000258; Lascarrou JB, 2019, NEW ENGL J MED, V381, P2327, DOI 10.1056/NEJMoa1906661; Lee DE, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e134; Lee YJ, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e328; Moon S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211804; Myat A, 2018, LANCET, V391, P970, DOI 10.1016/S0140-6736(18)30472-0; Nadarajan GD, 2018, RESUSCITATION, V132, P85, DOI 10.1016/j.resuscitation.2018.08.022; Okubo M, 2017, RESUSCITATION, V115, P120, DOI 10.1016/j.resuscitation.2017.03.036; Park JH, 2019, EMERG MED AUSTRALAS, V31, P1073, DOI 10.1111/1742-6723.13326; Ro YS, 2017, ANN EMERG MED, V69, P52, DOI 10.1016/j.annemergmed.2016.07.028; Song KJ, 2016, CLIN EXP EMERG MED, V3, pS10, DOI 10.15441/ceem.16.129; The Lancet HIV, 2016, LANCET HIV, V3, pe191; Travers AH, 2010, CIRCULATION, V122, pS676, DOI 10.1161/CIRCULATIONAHA.110.970913; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Yukawa T, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0440-7; 2019, HUM REPROD, V0034, pE141	29	3	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241804	10.1371/journal.pone.0241804	http://dx.doi.org/10.1371/journal.pone.0241804			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PV	33156868	gold, Green Published			2023-01-03	WOS:000591376400024
J	Nieto, O; Brooks, RA; Landrian, A; Cabral, A; Fehrenbacher, AE				Nieto, Omar; Brooks, Ronald A.; Landrian, Amanda; Cabral, Alejandra; Fehrenbacher, Anne E.			PrEP discontinuation among Latino/a and Black MSM and transgender women: A need for PrEP support services	PLOS ONE			English	Article							PREEXPOSURE PROPHYLAXIS; HIV PREVENTION; ADHERENCE; HEALTH; MEN; ACCEPTABILITY; FACILITATORS; BARRIERS; CARE	Purpose Disparities persist in HIV infection among Black and Latino men who have sex with men (BLMSM) and Black and Latina transgender women (BLTW). Increasing uptake and subsequent consistent use of pre-exposure prophylaxis (PrEP), an effective biomedical strategy for preventing HIV acquisition, can dramatically reduce HIV incidence in these populations. The purpose of this study was to explore reasons for PrEP discontinuation among BLMSM and BLTW living in Los Angeles County to inform the development of support services for these populations to remain persistent with their PrEP regimen. Methods In-depth, semi-structured interviews were conducted with 15 BLMSM and 7 BLTW who reported either temporary or indefinite PrEP discontinuation. A thematic analysis approach was used to analyze qualitative data. Results Four themes emerged related to reasons for PrEP discontinuation, including: (1) lower perceived HIV risk related to changes in sexual behavior; (2) structural or logistical barriers (e.g., lapse or loss of health insurance, cost, difficulty navigating complex medical systems); (3) anticipated and experienced medication side effects, with a sub-theme of interactions between PrEP and feminizing hormone medications; and (4) challenges with medication adherence. Conclusions PrEP is an important prevention tool for BLMSM and BLTW, particularly during periods of heightened HIV risk. However, both individual (e.g., inability to adhere to medication, changes in HIV sexual risk behaviors) and structural/logistical (e.g., loss of insurance, navigating complex medical systems) factors can cause temporary or indefinite PrEP discontinuation. Additional support services, beyond those offered by medical providers, are needed to help BLMSM and BLTW PrEP users overcome barriers to discontinuation and assist them to remain persistent with their PrEP regimen. We describe potential options for support services such as PrEP case management, expanded PrEP navigation services, or text messaging services.	[Nieto, Omar; Brooks, Ronald A.; Landrian, Amanda; Cabral, Alejandra] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA; [Brooks, Ronald A.; Fehrenbacher, Anne E.] Univ Calif Los Angeles, Ctr HIV Identificat Prevent & Treatment Serv CHIP, Los Angeles, CA 90024 USA; [Landrian, Amanda; Cabral, Alejandra] Univ Calif Los Angeles, Dept Community Hlth Sci, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Fehrenbacher, Anne E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Brooks, RA (corresponding author), Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA.; Brooks, RA (corresponding author), Univ Calif Los Angeles, Ctr HIV Identificat Prevent & Treatment Serv CHIP, Los Angeles, CA 90024 USA.	rabrooks@mednet.ucla.edu			California Community Foundation [BA-17-136260]; National Institute of Mental Health [R21MH107339, T32MH109205]; UCLA Center for HIV Identification, Prevention, and Treatment (CHIPTS) [P30MH058107]	California Community Foundation; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); UCLA Center for HIV Identification, Prevention, and Treatment (CHIPTS)	RAB received funding from the California Community Foundation under Grant #BA-17-136260 (URL: https://www.calfund.org/); the National Institute of Mental Health under Grant #R21MH107339 and T32MH109205 (URL: https://www.nimh.nih.gov/); and the UCLA Center for HIV Identification, Prevention, and Treatment (CHIPTS) under Grant #P30MH058107 (URL: http://chipts.ucla.edu/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, CLIN INFECT DIS S5, V52, pS397; [Anonymous], 2020, WHAT IS END HIV EP P; Arnold T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172354; Auerbach J, 2009, HEALTH AFFAIR, V28, P1655, DOI 10.1377/hlthaff.28.6.1655; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brooks RA, 2019, J URBAN HLTH; Brooks RA, 2019, TRANSGENDER HEALTH, V4, P188, DOI 10.1089/trgh.2019.0014; Brooks RA, 2019, AIDS BEHAV, V23, P1964, DOI 10.1007/s10461-019-02397-9; CDC, 2019, HIV SURVEILLANCE REP; Centers for Disease Control and Prevention, 2019, HIV TRANSG PEOPL; Centers for Disease Control and Prevention, 2017, HIV GAY BIS MEN FACT; Cunningham WE, 2008, J NATL MED ASSOC, V100, P840, DOI 10.1016/S0027-9684(15)31379-1; Dean HD, 2010, PUBLIC HEALTH REP, V125, P1, DOI 10.1177/00333549101250S401; Doblecki-Lewis S, 2019, J INT ASS PROVID AID, V18, DOI 10.1177/2325958219848848; Dowshen N, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2015; FDA, 2019, FDA APPR 2 DRUG PREV; Fuchs JD, 2018, AIDS PATIENT CARE ST, V32, P104, DOI 10.1089/apc.2017.0255; Garofalo R, 2016, AIDS BEHAV, V20, P1049, DOI 10.1007/s10461-015-1192-x; Gerke DR, 2020, HEALTH PROMOT PRACT, V21, P716, DOI 10.1177/1524839920936242; Golub SA, 2013, AIDS PATIENT CARE ST, V27, P248, DOI 10.1089/apc.2012.0419; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hevey MA, 2018, AIDS EDUC PREV, V30, P393, DOI 10.1521/aeap.2018.30.5.393; Hiransuthikul A, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25338; HIV Prevention Trials Network, 2020, HPTN 083 STUD DEM SU; Hojilla JC, 2018, AIDS BEHAV, V22, P1096, DOI 10.1007/s10461-017-2009-x; Holloway IW, 2017, JAIDS-J ACQ IMM DEF, V74, P15, DOI 10.1097/QAI.0000000000001164; Katz MH, 2001, EFFECT CASE MANAGEME, V9; Kay ES, 2020, AM J PUBLIC HEALTH, V110, P61, DOI 10.2105/AJPH.2019.305389; Landovitz RJ, 2017, JAIDS-J ACQ IMM DEF, V76, P501, DOI [10.1097/QAI.0000000000001538, 10.1097/qai.0000000000001538]; Liu A, 2019, C RETR OPP INF CROI; Liu AY, 2019, CLIN INFECT DIS, V68, P2010, DOI 10.1093/cid/ciy810; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129; Mayer KH, 2020, ADV THER, V37, P1778, DOI 10.1007/s12325-020-01295-0; Mitchell JT, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/10456; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Morgan E, 2018, AIDS BEHAV, V22, P3645, DOI 10.1007/s10461-018-2125-2; Pathela P, 2020, JAIDS-J ACQ IMM DEF, V83, P357, DOI 10.1097/QAI.0000000000002274; Rael CT, 2018, AIDS BEHAV, V22, P3627, DOI 10.1007/s10461-018-2102-9; Rao DW, 2019, SEX TRANSM DIS, V46, P221, DOI 10.1097/OLQ.0000000000000965; Reback CJ, 2019, J COMMUN HEALTH, V44, P1193, DOI 10.1007/s10900-019-00705-x; Sevelius JM, 2016, GLOB PUBLIC HEALTH, V11, P1060, DOI 10.1080/17441692.2016.1154085; Sherman EM, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00275-2; Spinelli MA, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz101; The Lancet HIV, 2017, LANCET HIV, V4, pe51; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; U.S. Food & Drug Administration, 2012, PRESS ANN APPR 1 DRU; Wheeler DP, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25223; Whitfield THF, 2018, AIDS BEHAV, V22, P3566, DOI 10.1007/s10461-018-2045-1; Wood S, 2019, AIDS BEHAV, V23, P2719, DOI 10.1007/s10461-019-02502-y	50	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2020	15	11							e0241340	10.1371/journal.pone.0241340	http://dx.doi.org/10.1371/journal.pone.0241340			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OU2PT	33151997	Green Published, gold			2023-01-03	WOS:000591376200036
J	Langhorne, P; Audebert, HJ; Cadilhac, DA; Kim, J; Lindsay, P				Langhorne, Peter; Audebert, Heinrich J.; Cadilhac, Dominique A.; Kim, Joosup; Lindsay, Patrice			Stroke systems of care in high-income countries: what is optimal?	LANCET			English	Review							ACUTE ISCHEMIC-STROKE; PREHOSPITAL THROMBOLYSIS; COST-EFFECTIVENESS; PILOT PROJECT; SCIENTIFIC STATEMENT; TELEMEDICAL PROJECT; CONTROLLED-TRIAL; EUROPEAN STROKE; TELESTROKE; QUALITY	Stroke is a complex, time-sensitive, medical emergency that requires well functioning systems of care to optimise treatment and improve patient outcomes. Education and training campaigns are needed to improve both the recognition of stroke among the general public and the response of emergency medical services. Specialised stroke ambulances (mobile stroke units) have been piloted in many cities to speed up the diagnosis, triage, and emergency treatment of people with acute stroke symptoms. Hospital-based interdisciplinary stroke units remain the central feature of a modern stroke service. Many have now developed a role in the very early phase (hyperacute units) plus outreach for patients who return home (early supported discharge services). Different levels (comprehensive and primary) of stroke centre and telemedicine networks have been developed to coordinate the various service components with specialist investigations and interventions including rehabilitation. Major challenges include the harmonisation of resources for stroke across the whole patient journey (including the rapid, accurate triage of patients who require highly specialised treatment in comprehensive stroke centres) and the development of technology to improve communication across different parts of a service.	[Langhorne, Peter] Univ Glasgow, Royal Infirm, Inst Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland; [Audebert, Heinrich J.] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Audebert, Heinrich J.] Charite Univ Med Berlin, Ctr Stroke Res Berlin, Berlin, Germany; [Cadilhac, Dominique A.; Kim, Joosup] Monash Univ, Dept Med, Sch Clin Sci, Monash Hlth, Clayton, Vic, Australia; [Lindsay, Patrice] Heart & Stroke Fdn Canada, Toronto, ON, Canada	Royal Infirmary of Edinburgh; University of Glasgow; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Monash University	Langhorne, P (corresponding author), Univ Glasgow, Royal Infirm, Inst Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland.	peter.langhorne@glasgow.ac.uk	Cadilhac, D A/I-1912-2014	Cadilhac, D A/0000-0001-8162-682X; Audebert, Heinrich J./0000-0002-4785-0366				Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; Appleby E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225150; Asplund K, 2011, INT J STROKE, V6, P99, DOI 10.1111/j.1747-4949.2010.00557.x; Audebert H, 2017, INT J STROKE, V12, P932, DOI 10.1177/1747493017729268; Audebert HJ, 2006, LANCET NEUROL, V5, P742, DOI 10.1016/S1474-4422(06)70527-0; Audebert HJ, 2006, STROKE, V37, P1822, DOI 10.1161/01.STR.0000226741.20629.b2; Audebert HJ, 2009, STROKE, V40, P902, DOI 10.1161/STROKEAHA.108.529255; Audebert HJ, 2005, STROKE, V36, P287, DOI 10.1161/01.STR.0000153015.57892.66; Bagot K, 2020, J NURS SCHOLARSHIP, V52, P34, DOI 10.1111/jnu.12509; Bagot KL, 2017, J TELEMED TELECARE, V23, P850, DOI 10.1177/1357633X17734004; Bejot Y, 2013, STROKE, V44, P1796, DOI 10.1161/STROKEAHA.113.000949; Bergrath S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036796; Bladin CF, 2020, MED J AUSTRALIA, V212, P371, DOI 10.5694/mja2.50570; Bladin CF, 2014, STROKE, V45, P1876, DOI 10.1161/STROKEAHA.114.003825; Brady MC, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000425.pub3, 10.1002/14651858.CD000425.pub4]; Busingye D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022536; Cadilhac DA, 2018, INT J STROKE, V13, P166, DOI 10.1177/1747493017750924; Cadilhac DA, 2017, STROKE, V48, P1026, DOI 10.1161/STROKEAHA.116.015714; Cadilhac DA, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2150-2; Cadilhac DA, 2016, INT J STROKE, V11, P28, DOI 10.1177/1747493015607523; Calderon VJ, 2018, INTERV NEUROL, V7, P347, DOI 10.1159/000487334; Coutts SB, 2019, LANCET, V394, P97, DOI 10.1016/S0140-6736(19)31095-5; Demaerschalk BM, 2012, STROKE, V43, P3095, DOI 10.1161/STROKEAHA.112.666255; Demaerschalk BM, 2012, TELEMED E-HEALTH, V18, P230, DOI 10.1089/tmj.2011.0116; Dietrich M, 2014, CEREBROVASC DIS, V38, P457, DOI 10.1159/000371427; Ebinger M, 2014, JAMA-J AM MED ASSOC, V311, P1622, DOI 10.1001/jama.2014.2850; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fassbender K, 2017, LANCET NEUROL, V16, P227, DOI 10.1016/S1474-4422(17)30008-X; Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4; Forster A, 2013, LANCET, V382, P2069, DOI 10.1016/S0140-6736(13)61603-7; Ganesh A, INTEGRATED SYSTEMS S; Geisler F, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011729; Goyal M, 2019, STROKE, V50, P1325, DOI 10.1161/STROKEAHA.118.024482; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Grunwald IQ, 2016, CEREBROVASC DIS, V42, P332, DOI 10.1159/000446861; Gyrd-Hansen D, 2015, NEUROLOGY, V84, P1090, DOI 10.1212/WNL.0000000000001366; Hafsteinsdottir TB, 2011, PATIENT EDUC COUNS, V85, P14, DOI 10.1016/j.pec.2010.07.046; Handschu R, 2003, STROKE, V34, P2842, DOI 10.1161/01.STR.0000102043.70312.E9; Hankey GJ, 2019, WARLOWS STROKE PRACT; Helwig SA, 2019, JAMA NEUROL, V76, P1484, DOI 10.1001/jamaneurol.2019.2829; Holodinsky JK, 2017, STROKE, V48, P233, DOI 10.1161/STROKEAHA.116.014306; Hubert GJ, 2014, INT J STROKE, V9, P81; Itrat A, 2016, JAMA NEUROL, V73, P162, DOI 10.1001/jamaneurol.2015.3849; Jones SP, 2010, AGE AGEING, V39, P11, DOI 10.1093/ageing/afp196; Kepplinger J, 2014, INT J STROKE, V9, P160, DOI 10.1111/ijs.12032; Kobayashi A, 2018, EUR J NEUROL, V25, P425, DOI 10.1111/ene.13539; Kunz A, 2016, LANCET NEUROL, V15, P1035, DOI 10.1016/S1474-4422(16)30129-6; Lachkhem Y, 2018, EUR J PUBLIC HEALTH, V28, P426, DOI 10.1093/eurpub/cky066; Langhorne P, 2007, J REHABIL MED, V39, P103, DOI 10.2340/16501977-0042; Langhorne P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub4; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Laver KE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub2; Legg LA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003585.pub3; Levine SR, 1999, STROKE, V30, P464, DOI 10.1161/01.STR.30.2.464; Liman TG, 2012, STROKE, V43, P2086, DOI 10.1161/STROKEAHA.112.657270; Man SM, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.117.004512; Man SM, 2017, STROKE, V48, P412, DOI 10.1161/STROKEAHA.116.014426; McDermott M, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1298-2; McKevitt C, 2011, STROKE, V42, P1398, DOI 10.1161/STROKEAHA.110.598839; Meretoja A, 2017, NEUROLOGY, V88, P2123, DOI 10.1212/WNL.0000000000003981; Meretoja A, 2010, STROKE, V41, P1102, DOI 10.1161/STROKEAHA.109.577718; Meyer BC, 2008, LANCET NEUROL, V7, P787, DOI 10.1016/S1474-4422(08)70171-6; Mokin M, 2016, J AM COLL CARDIOL, V67, P2645, DOI 10.1016/j.jacc.2015.12.077; Morris S, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l1; Muller-Barna P, 2012, CURR OPIN NEUROL, V25, P5, DOI 10.1097/WCO.0b013e32834d5fe4; Nelson RE, 2011, NEUROLOGY, V77, P1590, DOI 10.1212/WNL.0b013e318234332d; Nguyen-Huynh MN, 2018, STROKE, V49, P133, DOI 10.1161/STROKEAHA.117.018413; Norrving B, 2018, EUR STROKE J, V3, P309, DOI 10.1177/2396987318808719; Oostema JA, 2019, STROKE, V50, P1193, DOI 10.1161/STROKEAHA.118.023885; Pollock A, 2014, INT J STROKE, V9, P965, DOI 10.1111/ijs.12339; Puetz V, 2013, NEUROLOGY, V80, P332, DOI 10.1212/WNL.0b013e31827f07d0; Pulvers JN, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00617; Quain DA, 2008, MED J AUSTRALIA, V189, P429, DOI 10.5694/j.1326-5377.2008.tb02114.x; Ringelstein EB, 2013, STROKE, V44, P828, DOI 10.1161/STROKEAHA.112.670430; Roebers S, 2007, STROKE, V38, P1298, DOI 10.1161/01.STR.0000259889.72520.07; Royal College of Physicians. Sentinel Stroke National Audit Programme (SSNAP), 2016, AC ORG AUD REP; Sarfo FS, 2018, J STROKE CEREBROVASC, V27, P2306, DOI 10.1016/j.jstrokecerebrovasdis.2018.05.013; Schenkel J, 2013, GESUNDHEITSWESEN, V75, P405, DOI 10.1055/s-0032-1321779; Schlemm L, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012665; Schwab S, 2007, NEUROLOGY, V69, P898, DOI 10.1212/01.wnl.0000269671.08423.14; Schwamm LH, 2009, STROKE, V40, P2616, DOI 10.1161/STROKEAHA.109.192360; Schwamm LH, 2004, ACAD EMERG MED, V11, P1193, DOI 10.1197/j.aem.2004.08.014; Schwamm LH, RECOMMENDATIONS IMPL; Shuaib A, 2018, BMJ INNOV, V4, P54; Silver FL, 2006, AM J PREV MED, V31, pS235, DOI 10.1016/j.amepre.2006.08.023; Smith EE, 2018, STROKE, V49, pE111, DOI 10.1161/STR.0000000000000160; Switzer JA, 2013, CIRC-CARDIOVASC QUAL, V6, P18, DOI 10.1161/CIRCOUTCOMES.112.967125; Vondrackova L, 2017, COR VASA, V59, pE546, DOI 10.1016/j.crvasa.2016.12.004; Walter S, 2012, LANCET NEUROL, V11, P397, DOI 10.1016/S1474-4422(12)70057-1; Weber JE, 2013, NEUROLOGY, V80, P163, DOI 10.1212/WNL.0b013e31827b90e5; Wechsler LR, 2017, STROKE, V48, pE3, DOI 10.1161/STR.0000000000000114; Wendt M, 2015, STROKE, V46, P740, DOI 10.1161/STROKEAHA.114.008159; Winter B, 2019, INT J STROKE, V14, P620, DOI 10.1177/1747493019830303; Wu TC, 2017, STROKE, V48, P493, DOI 10.1161/STROKEAHA.116.015363; Zerna C, 2018, LANCET, V392, P1247, DOI 10.1016/S0140-6736(18)31874-9; Zhao H, 2019, INT J STROKE, V14, P265, DOI 10.1177/1747493018790081; Zhao H, 2018, STROKE, V49, P945, DOI 10.1161/STROKEAHA.117.019307; Zhelev Z, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011427.pub2	98	4	4	3	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	2020	396	10260					1433	1442						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OI1EY	33129394	Green Accepted			2023-01-03	WOS:000583031700032
J	Kanagasabai, U; Singh, A; Shiraishi, RW; Ly, V; Hy, C; Sanith, S; Srun, S; Sansam, S; SopHeap, ST; Liu, YL; Jones, G; Ijeoma, UC; Bock, N; Benech, I; Selenic, D; Drammah, B; Gadde, R; Mili, FD				Kanagasabai, Udhayashankar; Singh, Adarshpal; Shiraishi, Ray W.; Ly, Vanthy; Hy, Chhaily; Sanith, Sou; Srun, Sok; Sansam, Sim; SopHeap, S. Teak; Liu, Yuliang; Jones, Gerald; Ijeoma, Ugonna C.; Bock, Naomi; Benech, Irene; Selenic, Dejana; Drammah, Bakary; Gadde, Renuka; Mili, Fatima D.			Improving injection safety practices of Cambodian healthcare workers through training	PLOS ONE			English	Article							POSTEXPOSURE PROPHYLAXIS; INFECTIONS	Background This study evaluated the impact of a safe injection safety training on healthcare worker (HCW) practice and knowledge following an HIV outbreak in Roka commune, Cambodia. Methods Surveys were conducted at baseline (September 2016) and seven months after a training intervention (March 2018) using the World Health Organization standardized injection practices assessment tool. HCWs were sampled at 15 purposively government health facilities in two provinces. HCWs were observed during injection practices and interviewed by trained experts from Becton-Dickinson and the Ministry of Health Cambodia. The Rao-Scott chi square test was used test for differences between baseline and follow-up. Results We completed 115 observations of practice at baseline and 206 at post-training follow-up. The proportion of patients whose identification was confirmed by HCWs prior to procedure being performed increased from 40.4% to 98% (p <0.0001). The proportion of HCWs who practiced correct hand hygiene increased from 22.0% to 80.6% (p = 0.056) [therapeutic observations] and 17.2% to 63.4% (p = 0.0012) [diagnostic observations]. Immediate disposal of sharps by HCWs decreased from 96.5% to 92.5% (p = 0.0030). Conclusions We found significant improvements in the practice of patient identity confirmation and hand hygiene but not in the immediate disposal of sharps in the post-training intervention. However, findings are not representative of all HCWs in the country. Further pre-service and in-service training and monitoring are necessary to ensure sustained behavior change.	[Kanagasabai, Udhayashankar] CDC, Epidem Intelligence Serv, DGHT, Atlanta, GA 30333 USA; [Singh, Adarshpal; Gadde, Renuka] Becton Dickinson & Co, Franklifn Lakes, NJ USA; [Shiraishi, Ray W.; Liu, Yuliang; Ijeoma, Ugonna C.; Bock, Naomi; Benech, Irene; Selenic, Dejana; Drammah, Bakary; Mili, Fatima D.] CDC, Div Global HIV AIDS & TB, Atlanta, GA 30333 USA; [Ly, Vanthy; Hy, Chhaily] US Ctr Dis Control & Prevent, Phnom Penh, Cambodia; [Sanith, Sou; Srun, Sok; Sansam, Sim] Minist Hlth, Phnom Pehn, Cambodia; [SopHeap, S. Teak] Pursat Prov Hlth Dept, Pursat, Cambodia; [Jones, Gerald] CDC, Div Hlth Informat & Surveillance Epidemiol & Lab, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Becton Dickinson; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kanagasabai, U (corresponding author), CDC, Epidem Intelligence Serv, DGHT, Atlanta, GA 30333 USA.	nqy2@cdc.gov	Kanagasabai, Udhayashankar/AID-9549-2022	Kanagasabai, Udhayashankar/0000-0003-1694-9344; Shiraishi, Ray/0000-0001-7640-0666	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S Centers for Disease Control and Prevention (CDC) [5U2GGH00814]	President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S Centers for Disease Control and Prevention (CDC)	This publication has been supported [in part] by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S Centers for Disease Control and Prevention (CDC) under the terms as part of Cooperative Agreement number [5U2GGH00814]. The commercial funder provided support in the form of salaries for authors [RG and AS] but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	[Anonymous], 2014, PLOS ONE, V9, P1, DOI [10.1371/journal.pone.0109970, DOI 10.1371/JOURNAL.PONE.0109970, DOI 10.1371/J0URNAL.P0NE.0109970]; [Anonymous], 2013, FLORA FOLIUMII, V8, P8; [Anonymous], 2012, ALRIV, V3, P125; [Anonymous], 2015, CANC DISCOV, V5, pOF2; Centers for Disease Control and Prevention, 2012, PROT PAT PREV HARM F; degli Atti MLC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-466; Diprose P, 2000, BRIT J ANAESTH, V84, P767, DOI 10.1093/oxfordjournals.bja.a013591; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Fan CX, 2012, INT HEALTH, V4, P295, DOI 10.1016/j.inhe.2012.08.002; Frcgp JDH, 2000, HAWTHORNE EFFECTS RE, P65; Girou E., 2002, BMJ-BRIT MED J, V325, P1; Gyawali S, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-3; Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182; Hauri AM, 2004, GLOBAL BURDEN DIS AT, P7; Hutin Y, 2005, B ETIN WHO, V81, P491; Ijeoma C. Ugonna, 2018, MORB MORTAL WKLY REP, V67, P135, DOI [10.15585/mmwr.mm6704a6, DOI 10.15585/MMWR.MM6704A6]; Kermode M, 2004, INT J INFECT DIS, V8, P325, DOI 10.1016/j.ijid.2004.03.005; Kosal S, 2015, CAMBODIA DEMOGRAPHIC; Logez S, 2004, AM J INFECT CONTROL, V32, P31, DOI 10.1016/j.ajic.2003.06.006; Mantel C, 2007, TROP MED INT HEALTH, V12, P422, DOI 10.1111/j.1365-3156.2006.01802.x; Marra AR, 2010, POSITIVE DEVIANCE NE; Maury E, 2000, AM J RESP CRIT CARE, V162, P324, DOI 10.1164/ajrccm.162.1.9908118; Miller MA, 1999, B WORLD HEALTH ORGAN, V77, P808; Morar MM, 2016, TRANSFUSION, V56, P3121, DOI 10.1111/trf.13816; Pandit NB, 2008, SINGAP MED J, V49, P936; Patel Y, 2018, MATER RELIG, V14, P1, DOI 10.1080/17432200.2017.1417215; Rouet F, 2018, CLIN INFECT DIS, V66, P1733, DOI 10.1093/cid/cix1071; Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789; Solomon J, 2006, J IN SERVICE ED, V25, P307; Turner F, 2017, TEACH DEV, V21, P175, DOI 10.1080/13664530.2016.1205508; Varghese GM, 2003, POSTGRAD MED J, V79, P324, DOI 10.1136/pmj.79.932.324; Vun MC, 2016, MMWR-MORBID MORTAL W, V65, P142, DOI 10.15585/mmwr.mm6506a2; Wilburn SQ, 2013, PREVENTING NEEDLESTI, V3525; World Health Organization, 2008, REV INJ SAF ASS TOOL; Yan Youwang, 2006, Indian J Med Sci, V60, P407; Zakar MZ, PRACTICES TRANSMISSI; Zaragoza M, 1999, AM J INFECT CONTROL, V27, P258, DOI 10.1053/ic.1999.v27.a97622	37	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2020	15	10							e0241176	10.1371/journal.pone.0241176	http://dx.doi.org/10.1371/journal.pone.0241176			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8VN	33126238	gold, Green Submitted, Green Published			2023-01-03	WOS:000588368900021
J	Rich, SN; Cook, RL; Yaghjyan, L; Francois, K; Puttkammer, N; Robin, E; Bae, J; Joseph, N; Pessoa-Brandao, L; Delcher, C				Rich, Shannan N.; Cook, Robert L.; Yaghjyan, Lusine; Francois, Kesner; Puttkammer, Nancy; Robin, Ermane; Bae, Jungjun; Joseph, Nadjy; Pessoa-Brandao, Luisa; Delcher, Chris			Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017	PLOS ONE			English	Article							VIROLOGICAL FAILURE; DRUG-RESISTANCE	Studies of viral suppression on first-line antiretroviral therapy (ART) in persons living with human immunodeficiency virus (PLHIV) in Haiti are limited, particularly among PLHIV outside of the Ouest department, where the capital Port-au-Prince is located. This study described the prevalence and risk factors for delayed viral suppression among PLHIV in all geographic departments of Haiti between 2013 and 2017. Individuals who received viral load testing 3 to 12 months after ART initiation were included. Data on demographics and clinical care were obtained from the Haitian Active Longitudinal Tracking of HIV database. Multivariable logistic regression was performed to predict delayed viral suppression, defined as a viral load >= 1000 HIV-1 RNA copies/mL after at least 3 months on ART. Viral load test results were available for 3,368 PLHIV newly-initiated on ART. Prevalence of delayed viral suppression was 40%, which is slightly higher than previous estimates in Haiti. In the multivariable analysis, delayed viral suppression was significantly associated with younger age, receiving of care in the Ouest department, treatment with lamivudine (3TC), zidovudine (AZT), and nevirapine (NVP) combined ART regimen, and CD4 counts below 200 cells/mm(3). In conclusion, this study was the first to describe and compare differences in delayed viral suppression among PLHIV by geographic department in Haiti. We identified populations to whom public health interventions, such as more frequent viral load testing, drug resistance testing, and ART adherence counseling should be targeted.	[Rich, Shannan N.; Cook, Robert L.; Yaghjyan, Lusine] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL 32611 USA; [Rich, Shannan N.; Cook, Robert L.; Yaghjyan, Lusine] Univ Florida, Coll Med, Gainesville, FL 32611 USA; [Rich, Shannan N.] Univ Florida, Coll Med, Dept Hlth Outcomes & Biomed Informat, Gainesville, FL 32611 USA; [Francois, Kesner; Robin, Ermane] Minist Sante Publ & Populat, Programme Natl Lutte SIDA, Port Au Prince, Haiti; [Puttkammer, Nancy] Univ Washington, Dept Global Hlth, Int Training & Educ Ctr Hlth I TECH, Seattle, WA 98195 USA; [Bae, Jungjun; Delcher, Chris] Univ Kentucky, Coll Pharm, Inst Pharmaceut Outcomes & Policy, Lexington, KY USA; [Joseph, Nadjy; Pessoa-Brandao, Luisa; Delcher, Chris] Natl Alliance State & Terr AIDS Directors, Port Au Prince, Haiti; [Delcher, Chris] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, Lexington, KY USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Washington; University of Washington Seattle; University of Kentucky; University of Kentucky	Rich, SN (corresponding author), Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL 32611 USA.; Rich, SN (corresponding author), Univ Florida, Coll Med, Gainesville, FL 32611 USA.; Rich, SN (corresponding author), Univ Florida, Coll Med, Dept Hlth Outcomes & Biomed Informat, Gainesville, FL 32611 USA.	shannanrich@ufl.edu		Bae, Jungjun/0000-0002-8975-4073; Rich, Shannan/0000-0002-1203-2443	National Alliance of State and Territorial AIDS Directors [ID00017061]	National Alliance of State and Territorial AIDS Directors	This work was supported by a grant (ID00017061) from the National Alliance of State and Territorial AIDS Directors to CD. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Uria G, 2012, TROP MED INT HEALTH, V17, P1152, DOI 10.1111/j.1365-3156.2012.02982.x; Auld AF, MORBIDITY MORTALITY; Ayele T, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0132-4; Cesar C, 2015, LANCET HIV, V2, pE492, DOI 10.1016/S2352-3018(15)00183-6; Charles M, 2008, B WORLD HEALTH ORGAN, V86, P970, DOI 10.2471/BLT.07.050120; Charles M, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17375; Chun HM, 2017, J INFECT DIS, V216, pS808, DOI 10.1093/infdis/jix404; Delcher Chris, 2016, J Registry Manag, V43, P10; ESRI, 2019, ARCGIS PRO 2 3; Haile-Selassie H, 2017, WHO HIV DRUG RESISTA; Hare AQ, 2014, AIDS BEHAV, V18, P2219, DOI 10.1007/s10461-014-0849-1; Hermans LE, 2018, LANCET INFECT DIS, V18, P188, DOI 10.1016/S1473-3099(17)30681-3; Jean SS, 1999, PEDIATR INFECT DIS J, V18, P58, DOI 10.1097/00006454-199901000-00014; Kerschberger B, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20092; Louis FJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192077; Lynen L, 2010, CURR OPIN HIV AIDS, V5, P1, DOI 10.1097/COH.0b013e3283333762; Mbuagbaw L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004246.pub4; McNairy ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175521; Pannus P, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005475; Ruperez M, 2015, J ANTIMICROB CHEMOTH, V70, P2639, DOI 10.1093/jac/dkv143; SAS Institute, 2015, SAS STAT 9 4 US GUID; Smit PW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086461; Velen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064459; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization, 2016, ANNEX 10 WHO CLIN ST	25	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2020	15	10							e0240817	10.1371/journal.pone.0240817	http://dx.doi.org/10.1371/journal.pone.0240817			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG8YH	33119631	Green Published, gold			2023-01-03	WOS:000600013600070
J	Vinogradova, Y; Coupland, C; Hippisley-Cox, J				Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia			Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; METAANALYSIS; MENOPAUSE	OBJECTIVE To assess the risks of breast cancer associated with different types and durations of hormone replacement therapy (HRT). DESIGN Two nested case-control studies. SETTING UK general practices contributing to QResearch or Clinical Practice Research Datalink (CPRD), linked to hospital, mortality, social deprivation, and cancer registry (QResearch only) data. PARTICIPANTS 98 611 women aged 50-79 with a primary diagnosis of breast cancer between 1998 and 2018, matched by age, general practice, and index date to 457 498 female controls. MAIN OUTCOME MEASURES Breast cancer diagnosis from general practice, mortality, hospital, or cancer registry records. Odds ratios for HRT types, adjusted for personal characteristics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs. Separate results from QResearch or CPRD were combined. RESULTS Overall, 33 703 (34%) women with a diagnosis of breast cancer and 134 391 (31%) controls had used HRT prior to one year before the index date. Compared with never use, in recent users (<5 years) with long term use (>= 5 years), oestrogen only therapy and combined oestrogen and progestogen therapy were both associated with increased risks of breast cancer (adjusted odds ratio 1.15 (95% confidence interval 1.09 to 1.21) and 1.79 (1.73 to 1.85), respectively). For combined progestogens, the increased risk was highest for norethisterone (1.88, 1.79 to 1.99) and lowest for dydrogesterone (1.24, 1.03 to 1.48). Past long term use of oestrogen only therapy and past short term (<5 years) use of oestrogen-progestogen were not associated with increased risk. The risk associated with past tong term oestrogen-progestogen use, however, remained increased (1.16, 1.11 to 1.21). In recent oestrogen only users, between three (in younger women) and eight (in older women) extra cases per 10 000 women years would be expected, and in oestrogen-progestogen users between nine and 36 extra cases per 10 000 women years. For past oestrogen-progestogen users, the results would suggest between two and eight extra cases per 10 000 women years. CONCLUSION This study has produced new generalisable estimates of the increased risks of breast cancer associated with use of different hormone replacement preparations in the UK. The levels of risks varied between types of HRT, with higher risks for combined treatments and for longer duration of use.	[Vinogradova, Yana; Coupland, Carol] Univ Nottingham, Div Primary Care, Univ Pk, Nottingham NG2 7RD, England; [Hippisley-Cox, Julia] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	University of Nottingham; University of Oxford	Vinogradova, Y (corresponding author), Univ Nottingham, Div Primary Care, Univ Pk, Nottingham NG2 7RD, England.	Yana.Vinogradova@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Vinogradova, Yana/0000-0002-3030-5257	National Institute for Health Research (NIHR) School for Primary Care Research [848619]; Cancer Research UK through the cancer research UK Oxford Centre [C5255/A18085]	National Institute for Health Research (NIHR) School for Primary Care Research(National Institute for Health Research (NIHR)); Cancer Research UK through the cancer research UK Oxford Centre	This work is partially funded by the National Institute for Health Research (NIHR) School for Primary Care Research (project reference 848619) and by Cancer Research UK (grant No C5255/A18085) through the cancer research UK Oxford Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.	Bakken K, 2011, INT J CANCER, V128, P144, DOI 10.1002/ijc.25314; Bakken L, 2004, INT J CANCER, V112, P130, DOI 10.1002/ijc.20389; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2012, LANCET ONCOL, V13, P1141, DOI 10.1016/S1470-2045(12)70425-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 2011, JNCI-J NATL CANCER I, V103, P296, DOI 10.1093/jnci/djq527; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Cancer Research UK, 2015, RISK FACT BREAST CAN; Caul S., 2019, CANC REGISTRATION ST; Chlebowski RT, 2015, JAMA ONCOL, V1, P296, DOI 10.1001/jamaoncol.2015.0494; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Delgado-Rodriguez M, 2004, J EPIDEMIOL COMMUN H, V58, P635, DOI 10.1136/jech.2003.008466; Etminan M, 2004, PHARMACOTHERAPY, V24, P1105, DOI 10.1592/phco.24.13.1105.38083; Feigelson HS, 2004, CANCER EPIDEM BIOMAR, V13, P220, DOI 10.1158/1055-9965.EPI-03-0301; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Fournier A, 2008, BREAST CANCER RES TR, V107, P103, DOI 10.1007/s10549-007-9523-x; Gartlehner G, 2017, JAMA-J AM MED ASSOC, V318, P2234, DOI 10.1001/jama.2017.16952; Lee S, 2006, INT J CANCER, V118, P1285, DOI 10.1002/ijc.21481; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Marjoribanks J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004143.pub5; National Collaborating Centre for Women's and Children's Health (UK), 2015, MEN FULL GUID; National Institute for Health and Care Excellence, 2015, MEN DIAGN MAN; Opatrny L, 2008, BJOG-INT J OBSTET GY, V115, P169, DOI 10.1111/j.1471-0528.2007.01520.x; Parkin DM, 2011, BRIT J CANCER, V105, pS42, DOI 10.1038/bjc.2011.483; Pizot C, 2016, EUR J CANCER, V52, P138, DOI 10.1016/j.ejca.2015.10.063; Prentice RL, 2008, AM J EPIDEMIOL, V167, P1207, DOI 10.1093/aje/kwn044; Roman M, 2016, CANCER EPIDEM BIOMAR, V25, P1464, DOI 10.1158/1055-9965.EPI-16-0240; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Rymer J, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5928; Saxena T, 2010, CANCER EPIDEM BIOMAR, V19, P2366, DOI 10.1158/1055-9965.EPI-10-0162; Vinogradova Y, 2019, PROTOCOL ASSESS RISK; Wang K, 2017, ONCOTARGET, V8, P81109, DOI 10.18632/oncotarget.20154; Zahl PH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124076; 2019, LANCET, V394, P1159, DOI DOI 10.1016/S0140-14	36	44	44	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2020	371								m3873	10.1136/bmj.m3873	http://dx.doi.org/10.1136/bmj.m3873			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH6CC	33115755	Green Published, hybrid			2023-01-03	WOS:000582674300004
J	Sperber, J; Nyberg, A; Krifors, A; Skorup, P; Lipcsey, M; Castegren, M				Sperber, Jesper; Nyberg, Axel; Krifors, Anders; Skorup, Paul; Lipcsey, Miklos; Castegren, Markus			Pre-exposure to mechanical ventilation and endotoxemia increases Pseudomonas aeruginosa growth in lung tissue during experimental porcine pneumonia	PLOS ONE			English	Article							PULMONARY ALVEOLAR MACROPHAGE; BACTERIAL CLEARANCE; IN-VIVO; DEFENSE; MODEL; LIPOPOLYSACCHARIDE; INHIBITION; SURFACTANT; TOLERANCE; MORTALITY	Background Immune system suppression during critical care contributes to the risk of acquired bacterial infections with Pseudomonas (P.) aeruginosa. Repeated exposure to endotoxin can attenuate systemic inflammatory cytokine responses. Mechanical ventilation affects the systemic inflammatory response to various stimuli. Aim To study the effect of pre-exposure to mechanical ventilation with and without endotoxin-induced systemic inflammation on P. aeruginosa growth and wet-to-dry weight measurements on lung tissue and plasma and bronchoalveolar lavage levels of tumor necrosis factor alpha, interleukins 6 and 10. Methods Two groups of pigs were exposed to mechanical ventilation for 24 hours before bacterial inoculation and six h of experimental pneumonia (total experimental time 30 h): A(30h+Etx) (n = 6, endotoxin 0.063 mu g x kg(-1) x h(-1)) and B-30h (n = 6, saline). A third group, C-6h (n = 8), started the experiment at the bacterial inoculation unexposed to endotoxin or mechanical ventilation (total experimental time 6 h). Bacterial inoculation was performed by tracheal instillation of 1x10(11) colony-forming units of P. aeruginosa. Bacterial cultures and wet-to-dry weight ratio analyses were done on lung tissue samples postmortem. Separate group comparisons were done between A(30h+Etx) vs.B-30h (Inflammation) and B-30h vs. C-6h (Ventilation Time) during the bacterial phase of 6 h. Results P. aeruginosa growth was highest in A(30h+Etx), and lowest in C-6h (Inflammation and Ventilation Time both p<0.05). Lung wet-to-dry weight ratios were highest in A(30h+Etx) and lowest in B-30h (Inflammation p<0.01, Ventilation Time p<0.05). C-6h had the highest TNF-alpha levels in plasma (Ventilation Time p<0.01). No differences in bronchoalveolar lavage variables between the groups were observed. Conclusions Mechanical ventilation and systemic inflammation before the onset of pneumonia increase the growth of P. aeruginosa in lung tissue. The attenuated growth of P. aeruginosa in the non-pre-exposed animals (C-6h) was associated with a higher systemic TNF-alpha production elicited from the bacterial challenge.	[Sperber, Jesper; Nyberg, Axel] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden; [Sperber, Jesper; Nyberg, Axel; Skorup, Paul] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Krifors, Anders] Uppsala Univ, Ctr Clin Res, Reg Vastmanland, Uppsala, Sweden; [Krifors, Anders; Castegren, Markus] Karolinska Inst, Dept Physiol & Pharmacol, FyFa, Stockholm, Sweden; [Lipcsey, Miklos] Uppsala Univ, Dept Surg Sci, Hedenstierna Lab, Anesthesiol & Intens Care,CIRRUS, Uppsala, Sweden; [Castegren, Markus] Karolinska Univ Hosp, Perioperat Med & Intens Care PMI, Stockholm, Sweden	Uppsala University; Uppsala University; Uppsala University; Karolinska Institutet; Uppsala University; Karolinska Institutet; Karolinska University Hospital	Sperber, J (corresponding author), Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden.; Sperber, J (corresponding author), Uppsala Univ, Dept Med Sci, Uppsala, Sweden.	jesper.sperber@regionsormland.se		Sperber, Jesper/0000-0001-8731-6953; Krifors, Anders/0000-0003-1230-0492; skorup, paul/0000-0002-5407-6612	Sormland County Council; Uppsala University Hospital; Family Olinder-Nielsens Foundation	Sormland County Council; Uppsala University Hospital; Family Olinder-Nielsens Foundation	The RD funds of the Sormland County Council and Uppsala University Hospital and the Family Olinder-Nielsens Foundation contributed with financial support to the main investigator JS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, AM J PHYSIOL-LUNG C, V311, pL970; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Castegren M, 2015, CRIT CARE RESUSC, V17, P174; Castegren M, 2012, SHOCK, V37, P501, DOI 10.1097/SHK.0b013e318249bb0d; Cavaillon JM, 2003, J ENDOTOXIN RES, V9, P101, DOI 10.1179/096805103125001487; Cavaillon JM, 2001, CELL MOL BIOL, V47, P695; Chang CC, 1996, AM J PHYSIOL-GASTR L, V271, pG539, DOI 10.1152/ajpgi.1996.271.4.G539; CHASE HM, 1979, SURG FORUM, V30, P165; Davies Claire A, 2003, Methods Mol Biol, V225, P305; DRINKWATER DC, 1981, ANN THORAC SURG, V32, P235, DOI 10.1016/S0003-4975(10)61044-2; Giampietri A, 2000, CYTOKINE, V12, P417, DOI 10.1006/cyto.1999.0576; GOLDSTEIN E, 1974, J CLIN INVEST, V54, P519, DOI 10.1172/JCI107788; GREEN GM, 1964, J EXP MED, V119, P167, DOI 10.1084/jem.119.1.167; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Hollenberg SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7706; HORGAN MJ, 1993, AM J PHYSIOL, V264, pH1161, DOI 10.1152/ajpheart.1993.264.4.H1161; Iba T, 2019, J THROMB HAEMOST, V17, P283, DOI 10.1111/jth.14371; JACOBS RF, 1986, AM REV RESPIR DIS, V134, P745; Kilkenny C, 2011, J CEREBR BLOOD F MET, V31, P991, DOI 10.1038/jcbfm.2010.220; Kolomaznik M, 2017, PHYSIOL RES, V66, pS147, DOI 10.33549/physiolres.933672; KOSTKA J, 1962, FOLIA MICROBIOL, V7, P191, DOI 10.1007/BF02928241; LAFORCE FM, 1973, J LAB CLIN MED, V82, P634; Lavoie EG, 2011, MICROBES INFECT, V13, P1133, DOI 10.1016/j.micinf.2011.07.011; Mason CM, 1997, J INFECT DIS, V176, P1293, DOI 10.1086/514125; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Monneret G, 2008, MOL MED, V14, P64, DOI 10.2119/2007-00102.Monneret; Murphey ED, 2007, SHOCK, V27, P289, DOI 10.1097/01.shk.0000245024.93740.28; Nieuwdorp A, 2009, ATHEROSCLEROSIS, V202, P296, DOI 10.1016/j.atherosclerosis.2008.03.024; Putensen C, 2007, ANESTHESIOLOGY, V106, P1085, DOI 10.1097/01.anes.0000265424.07486.8c; Ramirez-Estrada S, 2016, INFECT DRUG RESIST, V9, P7, DOI 10.2147/IDR.S50669; Reid KBM, 1998, IMMUNOBIOLOGY, V199, P200, DOI 10.1016/S0171-2985(98)80027-2; ROBIN ED, 1954, ARCH INTERN MED, V93, P713, DOI 10.1001/archinte.1954.00240290071008; Sawa T, 1997, J IMMUNOL, V159, P2858; Seymour CW, 2019, JAMA-J AM MED ASSOC, V321, P2003, DOI 10.1001/jama.2019.5791; SHENNIB H, 1984, AM REV RESPIR DIS, V130, P444; Skrupky LP, 2011, ANESTHESIOLOGY, V115, P1349, DOI 10.1097/ALN.0b013e31823422e8; Soni S, 2016, THORAX, V71, P1020, DOI 10.1136/thoraxjnl-2015-208032; Sperber J, 2015, BMC PULM MED, P15, DOI [10.1186/s12890-015-0004-4, DOI 10.1186/S12890-015-0004-425887940]; Sperber J, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0152-3; Sperber J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083182; TILSON MD, 1977, SURGERY, V82, P130; Torgersen C, 2009, ANESTH ANALG, V108, P1841, DOI 10.1213/ane.0b013e318195e11d; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC; WHITE JC, 1986, J INFECT DIS, V153, P202, DOI 10.1093/infdis/153.2.202; Williams BJ, 2010, RESPIROLOGY, V15, P1037, DOI 10.1111/j.1440-1843.2010.01819.x	45	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2020	15	10							e0240753	10.1371/journal.pone.0240753	http://dx.doi.org/10.1371/journal.pone.0240753			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8WV	33108383	Green Published, gold			2023-01-03	WOS:000588372400005
J	Carrol, DH; Chassagne, F; Dettweiler, M; Quave, CL				Carrol, Danielle H.; Chassagne, Francois; Dettweiler, Micah; Quave, Cassandra L.			Antibacterial activity of plant species used for oral health againstPorphyromonas gingivalis	PLOS ONE			English	Article							OLEA-EUROPAEA L.; PORPHYROMONAS-GINGIVALIS; JUGLANS-REGIA; CHEWING STICK; ETHNOBOTANICAL APPROACH; CHEMICAL-COMPOSITION; PERIODONTAL-DISEASE; INHIBITORY-ACTIVITY; MEDICINAL-PLANTS; ESSENTIAL OIL	Porphyromonas gingivalisis the keystone pathogen of periodontitis, a chronic inflammatory disease which causes tooth loss and deterioration of gingiva. Medicinal plants have been traditionally used for oral hygiene and health and might play a role as antibacterial agents against oral pathogens. In this work, we aimed to evaluate the antibacterial activity of plants used for oral hygiene or symptoms of periodontitis againstP.gingivalis. We first reviewed the literature to identify plant species used for oral hygiene or symptoms of periodontitis. Then, we cross-checked this species list with our in-house library of plant extracts to select extracts for testing. Antibacterial activity tests were then performed for each plant extract againstP.gingivalis, and their cytotoxicity was assessed on HaCaT cells. The selectivity index (SI) was then calculated. A total of 416 plant species belonging to 110 families and 305 genera were documented through our literature search, and 158 plant species were noted as being used by North American Native peoples Once cross-checked with the extracts contained in our library of natural products, 30 matches were identified and 21 were defined as high priority. Of the 109 extracts from 21 plant species selected and tested, 21 extracts from 11 plants had higher than 90% inhibition onP.gingivalisat 64 mu g/mL and were further selected for MIC (Minimum Inhibitory Concentration) assays. Out of 21 plant extracts, 13 extracts (7 plant species) had a SI > 10.Pistacia lentiscusfruits showed the best MIC with value of 8 mu g/mL, followed byZanthoxylum armatumfruits/seeds with a MIC of 16 mu g/mL.P.lentiscusfruits also showed the highest SI of 256. Most of the extracts tested present promising antibacterial activity and low cytotoxicity. Further testing for biofilm eradication and examination of activity against other dental pathogens and oral commensals should be performed to confirm the potential of these extracts as antibacterial agents. Future work will focus on application of a bioassay-guided fractionation approach to isolating and identifying the most active natural products in the top performing extracts. This study can serve as a basis for their future development as ingredients for oral hygiene products.	[Carrol, Danielle H.; Chassagne, Francois; Quave, Cassandra L.] Emory Univ, Ctr Study Human Hlth, Coll Arts & Sci, Atlanta, GA 30322 USA; [Dettweiler, Micah; Quave, Cassandra L.] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Emory University; Emory University	Quave, CL (corresponding author), Emory Univ, Ctr Study Human Hlth, Coll Arts & Sci, Atlanta, GA 30322 USA.; Quave, CL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA.	cquave@emory.edu	François, Chassagne/J-3082-2019	François, Chassagne/0000-0003-4179-7995	Emory University development funds	Emory University development funds	Funding for this study was provided by Emory University development funds to CLQ.	Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144; ADUTUTU M, 1979, ECON BOT, V33, P320, DOI 10.1007/BF02858262; Aksoy A, 2006, ARCH ORAL BIOL, V51, P476, DOI 10.1016/j.archoralbio.2005.11.003; Amabeoku GJ, 2010, J PHARM PHARMACOL, V62, P368, DOI 10.1211/jpp.62.03.0012; [Anonymous], 2010, JOVE J VISUALIZED EX, V15, pe1936; [Anonymous], 1896, STUDIO ILLUSTRATED M, V6, P58; Araghizadeh A, 2013, MED PRIN PRACT, V22, P368, DOI 10.1159/000348299; Ardila CM, 2010, J PERIODONTAL RES, V45, P557, DOI 10.1111/j.1600-0765.2010.01274.x; Aro AO, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2520-x; Attoub S, 2014, CELL PHYSIOL BIOCHEM, V33, P1400, DOI 10.1159/000358706; Aumeeruddy MZ, 2018, J ETHNOPHARMACOL, V213, P409, DOI 10.1016/j.jep.2017.11.030; Bairy Indira, 2002, Indian J Pathol Microbiol, V45, P307; Beikler T, 2004, J PERIODONTOL, V75, P169, DOI 10.1902/jop.2004.75.1.169; Belstrom D, 2011, INFECT IMMUN, V79, P1559, DOI 10.1128/IAI.01036-10; Boukeloua A, 2012, AFR J TRADIT COMPLEM, V9, P607, DOI 10.4314/ajtcam.v9i4.19; BOZORGI M, 2013, SCI WORLD J, DOI DOI 10.1155/2013/219815; Brown ED, 2016, NATURE, V529, P336, DOI 10.1038/nature17042; Cai LN, 1996, J NAT PROD, V59, P987, DOI 10.1021/np960451q; Cai LN, 2000, J AGR FOOD CHEM, V48, P909, DOI 10.1021/jf9909914; Chaieb K., 2013, Journal of Herbs, Spices & Medicinal Plants, V19, P168, DOI 10.1080/10496475.2012.762818; Chaieb K, 2007, PHYTOTHER RES, V21, P501, DOI 10.1002/ptr.2124; Chebbi Mahjoub R, 2011, ISRN Pharmacol, V2011, P564972, DOI 10.5402/2011/564972; Clinical and Laboratory Standards Institute, 2017, PERFORMANCE STANDARD; Colaric M, 2005, J AGR FOOD CHEM, V53, P6390, DOI 10.1021/jf050721n; Cornacchione LP, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.01271-19; COX PA, 1994, SCI AM, V270, P82, DOI 10.1038/scientificamerican0694-82; Djerrou Z, 2013, AFR J TRADIT COMPLEM, V10, P480, DOI 10.4314/ajtcam.v10i3.15; Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333; Dzotam JK, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1583510; Erdemoglu N, 2003, J ETHNOPHARMACOL, V89, P123, DOI 10.1016/S0378-8741(03)00282-4; Farooqui A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118431; Favela-Hernandez JMJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21020247; Govoni M, 2008, NITRIC OXIDE-BIOL CH, V19, P333, DOI 10.1016/j.niox.2008.08.003; Gyllenhaal C, 2012, PHARM BIOL, V50, P30, DOI 10.3109/13880209.2011.634424; Halberstein RA, 2008, NAT PROD COMMUN, V3, P1813; Hashioka S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153723; Hebbar SS, 2004, J ETHNOPHARMACOL, V94, P261, DOI 10.1016/j.jep.2004.04.021; HOMER KA, 1990, ARCH ORAL BIOL, V35, P421, DOI 10.1016/0003-9969(90)90203-M; Hussain Khaja Amjad, 2015, Rocz Panstw Zakl Hig, V66, P173; Jayanti Ipsita, 2018, J Contemp Dent Pract, V19, P415; Jepsen K, 2016, PERIODONTOL 2000, V71, P82, DOI 10.1111/prd.12121; Kamer AR, 2015, NEUROBIOL AGING, V36, P627, DOI 10.1016/j.neurobiolaging.2014.10.038; Karygianni L, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2461-4; Khan MF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00815; Kim J, 2006, ODONTOLOGY, V94, P10, DOI 10.1007/s10266-006-0060-6; Koychev S, 2017, J PERIODONTOL, V88, P511, DOI 10.1902/jop.2017.150691; Lakshmi T, 2015, Pharmacogn Rev, V9, P41, DOI 10.4103/0973-7847.156337; Lewis W., 2003, MED BOT, V2nd; Liao J, 2013, PHARM BIOL, V51, P1538, DOI 10.3109/13880209.2013.801995; Lundberg JO, 2004, NAT REV MICROBIOL, V2, P593, DOI 10.1038/nrmicro929; Mandal A, 2018, J NEPAL SOC PERIO OR, V2, P9, DOI [10.3126/jnspoi.v2i1.23602, DOI 10.3126/JNSPOI.V2I1.23602]; Masuda T, 2006, APPL ENVIRON MICROB, V72, P3458, DOI 10.1128/AEM.72.5.3458-3467.2006; Mehenni C, 2016, J FOOD DRUG ANAL, V24, P653, DOI 10.1016/j.jfda.2016.03.002; Minami M., 2019, Traditional & Kampo Medicine, V6, P79, DOI 10.1002/tkm2.1215; Mohieldin EAM, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1735-y; More G, 2008, J ETHNOPHARMACOL, V119, P473, DOI 10.1016/j.jep.2008.07.001; Muller PY, 2012, NAT REV DRUG DISCOV, V11, P751, DOI 10.1038/nrd3801; Mysak J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/476068; Nooreen Z, 2019, NAT PROD RES, V33, P665, DOI 10.1080/14786419.2017.1405404; Nooreen Z, 2017, BIOMED PHARMACOTHER, V89, P366, DOI 10.1016/j.biopha.2017.02.040; Omer SA, 2012, ASIAN J ANIM VET ADV, V7, P1175, DOI 10.3923/ajava.2012.1175.1182; Parkar SG, 2008, INT J FOOD MICROBIOL, V124, P295, DOI 10.1016/j.ijfoodmicro.2008.03.017; Persson GR, 2006, CLIN ORAL IMPLAN RES, V17, P386, DOI 10.1111/j.1600-0501.2006.01269.x; Phuyal N, 2019, J ETHNOPHARMACOL, V229, P326, DOI 10.1016/j.jep.2018.08.010; Pourhajibagher M, 2016, PHOTODIAGN PHOTODYN, V16, P50, DOI 10.1016/j.pdpdt.2016.08.013; Quave CL, 2008, J ETHNOPHARMACOL, V118, P418, DOI 10.1016/j.jep.2008.05.005; Ravanbakhsh A, 2016, ADV PHARM BULL, V6, P541, DOI [10.15171/apb.2016.068, 10.15171/apb.2016.067]; Reynolds EC, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.29125; Romero JB., 1954, BOT LORE CALIFORNIA; Rosas-Pinon Y, 2012, J ETHNOPHARMACOL, V141, P860, DOI 10.1016/j.jep.2012.03.020; ROTIMI VO, 1988, ANTIMICROB AGENTS CH, V32, P598, DOI 10.1128/AAC.32.4.598; Sakagami H, 2009, IN VIVO, V23, P215; Sakanaka A, 2016, MICROB PATHOGENESIS, V94, P42, DOI 10.1016/j.micpath.2015.10.003; Sarathy JP, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02404-19; SHEMLUCK M, 1982, J ETHNOPHARMACOL, V5, P303, DOI 10.1016/0378-8741(82)90016-2; Shetty Sunaina, 2013, Ayu, V34, P445, DOI 10.4103/0974-8520.127732; Shetty Y Sunaina, 2018, J Contemp Dent Pract, V19, P690; Silva LN, 2016, CHEM REV, V116, P9162, DOI 10.1021/acs.chemrev.6b00184; Singhrao SK, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/137357; Sofrata AH, 2008, J PERIODONTOL, V79, P1474, DOI [10.1902/jop.2008.070506, 10.1902/jop.2008.070506 ]; Stein PS, 2007, J AM DENT ASSOC, V138, P1314, DOI 10.14219/jada.archive.2007.0046; Sukkarwalla Adnan, 2013, Dent Res J (Isfahan), V10, P314, DOI 10.4103/1735-3327.115138; Tao NG, 2009, INT J FOOD SCI TECH, V44, P1281, DOI 10.1111/j.1365-2621.2009.01947.x; Taylor LA., 1940, PLANTS USED CURATIVE; Vennila K, 2016, Indian J Dent Res, V27, P15, DOI 10.4103/0970-9290.179808; Watanabe S, 2019, MEDICINES, V6, P1; Widyarman AS, 2018, CONTEMP CLIN DENT, V9, P298, DOI 10.4103/ccd.ccd_53_18; Wu CD, 2001, J PERIODONTAL RES, V36, P275, DOI 10.1034/j.1600-0765.2001.360502.x; Yang R.T., 2001, ADV CHEM ENG, P79, DOI DOI 10.1016/50065-2377(01)27004-5; [No title captured]	90	15	15	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2020	15	10							e0239316	10.1371/journal.pone.0239316	http://dx.doi.org/10.1371/journal.pone.0239316			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TB	33031410	gold, Green Published			2023-01-03	WOS:000581809800051
J	Choueiri, TK; Kaelin, WG				Choueiri, Toni K.; Kaelin, William G., Jr.			Targeting the HIF2-VEGF axis in renal cell carcinoma	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU-DISEASE; RANDOMIZED PHASE-II; PAS-B DOMAIN; DOUBLE-BLIND; INTERFERON-ALPHA; HIF-ALPHA; TUMOR SUPPRESSION; MAMMALIAN TARGET	Anticancer therapies that target the HIF oxygen-sensing pathways are moving into the clinic, in particular in kidney cancer. Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as VEGF, for the treatment of cancers caused byVHLinactivation, such as clear-cell renal cell carcinoma (ccRCC). Multiple VEGF inhibitors are now approved for the treatment of ccRCC, and a HIF2 alpha inhibitor has advanced to phase 3 development for this disease. These inhibitors are now also increasingly combined with immune-checkpoint blockers. In this Perspective, we describe the understanding of the mechanisms of oxygen sensing and hypoxia signaling that resulted in the development of HIF2 alpha-targeted therapies for patients with VHL-associated tumors. We also present future directions for extending the use of these therapies to other cancers.	[Choueiri, Toni K.; Kaelin, William G., Jr.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA; [Choueiri, Toni K.; Kaelin, William G., Jr.] Harvard Med Sch, Boston, MA 02115 USA; [Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Choueiri, TK; Kaelin, WG (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.; Choueiri, TK; Kaelin, WG (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Kaelin, WG (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	toni_choueiri@dfci.harvard.edu; william_kaelin@dfci.harvard.edu	Choueiri, Toni/K-5238-2019	Choueiri, Toni/0000-0002-9201-3217				Amin A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0420-0; Awada A, 2005, BRIT J CANCER, V92, P1855, DOI 10.1038/sj.bjc.6602584; Bakouny Z, 2020, CANCER DISCOV, V10, P348, DOI 10.1158/2159-8290.CD-19-1525; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Bhargava P, 2011, CURR ONCOL REP, V13, P103, DOI 10.1007/s11912-011-0154-3; Bindra RS, 2002, CANCER RES, V62, P3014; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Braun DA, 2020, NAT MED, V26, P909, DOI 10.1038/s41591-020-0839-y; Bristol Myers Squibb company, BRIST MYERS SQUIBB A; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145; Chakraborty AA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5272; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Cheng XT, 2020, J CLIN INVEST, V130, P2237, DOI 10.1172/JCI133194; Cherkasova E, 2011, ONCOGENE, V30, P4697, DOI 10.1038/onc.2011.179; Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022; Cho H, 2016, COLD SH Q B, V81, P113, DOI 10.1101/sqb.2016.81.030833; Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795; Choueiri T, 2019, 14 EUR INT KIDN CANC; Choueiri TK, 2019, ANN ONCOL, V30, P362; Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016; Choueiri TK, 2020, J CLIN ONCOL, V38; Choueiri TK, 2018, EUR J CANCER, V94, P115, DOI 10.1016/j.ejca.2018.02.012; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Chowdhury S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4506; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Courtney KD, 2019, CLIN CANCER RES, V15, P793; Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dahia PLM, 2017, CANCER CELL, V31, P159, DOI 10.1016/j.ccell.2017.01.009; Dahia PLM, 2014, NAT REV CANCER, V14, P108, DOI 10.1038/nrc3648; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511; Feldman DR, 2009, J CLIN ONCOL, V27, P1432, DOI 10.1200/JCO.2008.19.0108; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Flaherty KT, 2015, J CLIN ONCOL, V33, P2384, DOI 10.1200/JCO.2015.60.9727; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDE DW, 1981, ANN INTERN MED, V95, P71, DOI 10.7326/0003-4819-95-1-71; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Graham J, 2018, J CLIN ONCOL, V36, P3567, DOI 10.1200/JCO.2018.79.0147; Guo ZQ, 2017, ONCOTARGET, V8, P89761, DOI 10.18632/oncotarget.21125; Hu LX, 2020, CANCER DISCOV, V10, P460, DOI 10.1158/2159-8290.CD-19-0837; Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1; Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janiszewska AD, 2013, WSPOLCZESNA ONKOL, V17, P123, DOI 10.5114/wo.2013.34613; Jonasch E, 2020, J CLIN ONCOL, V38; Jonker L, 2014, MICROCIRCULATION, V21, P93, DOI 10.1111/micc.12099; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Katoh M, 2019, NAT REV CLIN ONCOL, V16, P105, DOI 10.1038/s41571-018-0115-y; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Klapper JA, 2008, CANCER-AM CANCER SOC, V113, P293, DOI 10.1002/cncr.23552; Koehler AN, 2010, CURR OPIN CHEM BIOL, V14, P331, DOI 10.1016/j.cbpa.2010.03.022; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; LaFleur MW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09656-2; Lalani AKA, 2017, ONCOTARGET, V8, P103428, DOI 10.18632/oncotarget.21952; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Ledford H, 2019, NATURE, V574, P161, DOI 10.1038/d41586-019-02963-0; Lee YS, 2005, CLIN CANCER RES, V11, P1059; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McKay RR, 2018, J CLIN ONCOL, V36, P3615, DOI 10.1200/JCO.2018.79.0253; Minamishima YA, 2009, MOL CELL BIOL, V29, P5729, DOI 10.1128/MCB.00331-09; Mohlin S, 2017, P NATL ACAD SCI USA, V114, pE10856, DOI 10.1073/pnas.1716644115; Molina AM, 2014, CANCER CHEMOTH PHARM, V73, P181, DOI 10.1007/s00280-013-2339-y; Montani M, 2010, AM J SURG PATHOL, V34, P806, DOI 10.1097/PAS.0b013e3181ddf54d; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2020, J CLIN ONCOL, V38; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Motzer RJ, 2016, LANCET ONCOL, V17, pE4, DOI 10.1016/S1470-2045(15)00543-4; Motzer RJ, 2015, LANCET ONCOL, V16, P1473, DOI 10.1016/S1470-2045(15)00290-9; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nakaigawa N, 2006, CANCER RES, V66, P3699, DOI 10.1158/0008-5472.CAN-05-0617; Nicholson HE, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aay0482; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Panda A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121522; Papadopoulos KP, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2508; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808; Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035; Purdue MP, 2011, NAT GENET, V43, P60, DOI 10.1038/ng.723; Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Renfrow JJ, 2018, FUTURE MED CHEM, V10, P2227, DOI 10.4155/fmc-2018-0163; Rini B, 2012, CANCER-AM CANCER SOC, V118, P6152, DOI 10.1002/cncr.27632; Rini BI, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.558; Rini BI, 2019, LANCET, V393, P2404, DOI 10.1016/S0140-6736(19)30723-8; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Rogers JL, 2013, J MED CHEM, V56, P1739, DOI 10.1021/jm301847z; Santoni M, 2014, BBA-REV CANCER, V1845, P221, DOI 10.1016/j.bbcan.2014.01.007; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI [10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185]; Scheuermann TH, 2009, P NATL ACAD SCI USA, V106, P450, DOI 10.1073/pnas.0808092106; Schietke RE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031034; Schodel J, 2012, NAT GENET, V44, P420, DOI 10.1038/ng.2204; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Sgambati MT, 2000, AM J HUM GENET, V66, P84, DOI 10.1086/302726; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siemeister G, 1996, CANCER RES, V56, P2299; Smith CC, 2018, J CLIN INVEST, V128, P4804, DOI 10.1172/JCI121476; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Sternberg CN, 2013, EUR J CANCER, V49, P1287, DOI 10.1016/j.ejca.2012.12.010; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Strowd RE, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2027; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Takahashi Y, 2008, J CLIN INVEST, V118, P1584, DOI 10.1172/JCI34409C1; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tannir NM, 2020, J CLIN ONCOL, V38; Thompson JM, 2017, ONCOGENE, V36, P1080, DOI 10.1038/onc.2016.272; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Tykodi SS, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4570; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; Von-Hippel E, 1904, ARCH OPHTHALMOL-CHIC, V59, P23, DOI [10.1007/BF01994821, DOI 10.1007/BF01994821]; Voss MH, 2017, CLIN CANCER RES, V23, P3557, DOI 10.1158/1078-0432.CCR-16-2395; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Wehn PM, 2018, J MED CHEM, V61, P9691, DOI 10.1021/acs.jmedchem.8b01196; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wu DL, 2015, NATURE, V524, P303, DOI 10.1038/nature14883; Xu R, 2019, J MED CHEM, V62, P6876, DOI 10.1021/acs.jmedchem.9b00719; Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264; Yamamoto Y, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-18; Yang GY, 2017, DRUG METAB REV, V49, P105, DOI 10.1080/03602532.2017.1293682; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Yi M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0974-6; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zheng B, 2015, CANCER LETT, V357, P468, DOI 10.1016/j.canlet.2014.11.012; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343; ZHUANG ZP, 1995, AM J PATHOL, V146, P620; ZHUANG ZP, 1994, ACTA CYTOL, V38, P671; Zhuang ZP, 1996, MODERN PATHOL, V9, P838; Zimmer M, 2004, MOL CANCER RES, V2, P89	173	135	140	8	29	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2020	26	10					1519	1530		10.1038/s41591-020-1093-z	http://dx.doi.org/10.1038/s41591-020-1093-z		OCT 2020	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	NX8MD	33020645				2023-01-03	WOS:000575801100007
J	Walter, F; Winter, E; Rahn, S; Heidland, J; Meier, S; Struzek, AM; Lettau, M; Philipp, LM; Beckinger, S; Otto, L; Moller, JL; Helm, O; Wesch, D; Scherliess, R; Sebens, S				Walter, Frederik; Winter, Elsa; Rahn, Sascha; Heidland, Judith; Meier, Saskia; Struzek, Anna-Maria; Lettau, Marcus; Philipp, Lisa-Marie; Beckinger, Silje; Otto, Lilli; Moeller, Julia Luisa; Helm, Ole; Wesch, Daniela; Scherliess, Regina; Sebens, Susanne			Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses	PLOS ONE			English	Article							PANCREATIC DUCTAL ADENOCARCINOMA; TARGETING DENDRITIC CELLS; CANCER-IMMUNOTHERAPY; INTRANASAL IMMUNIZATION; ANTITUMOR IMMUNITY; VACCINE DELIVERY; MUCOSAL; NASAL; PEPTIDE; MODEL	Cancer vaccinations sensitize the immune system to recognize tumor-specific antigensde novoor boosting preexisting immune responses. Dendritic cells (DCs) are regarded as the most potent antigen presenting cells (APCs) for induction of (cancer) antigen-specific CD8+ T cell responses. Chitosan nanoparticles (CNPs) used as delivery vehicle have been shown to improve anti-tumor responses. This study aimed at exploring the potential of CNPs as antigen delivery system by assessing activation and expansion of antigen-specific CD8+ T cells by DCs and subsequent T cell-mediated lysis of pancreatic ductal adenocarcinoma (PDAC) cells. As model antigen the ovalbumin-derived peptide SIINFEKL was chosen. Using imaging cytometry, intracellular uptake of FITC-labelled CNPs of three different sizes and qualities (90/10, 90/20 and 90/50) was demonstrated in DCs and in pro- and anti-inflammatory macrophages to different extents. While larger particles (90/50) impaired survival of all APCs, small CNPs (90/10) were not toxic for DCs. Internalization of SIINFEKL-loaded but not empty 90/10-CNPs promoted a pro-inflammatory phenotype of DCs indicated by elevated expression of pro-inflammatory cytokines. Treatment of murine DC2.4 cells with SIINFEKL-loaded 90/10-CNPs led to a marked MHC-related presentation of SIINFEKL and enabled DC2.4 cells to potently activate SIINFEKL-specific CD8+ OT-1 T cells finally leading to effective lysis of the PDAC cell line Panc-OVA. Overall, our study supports the suitability of CNPs as antigen vehicle to induce potent anti-tumor immune responses by activation and expansion of tumor antigen-specific CD8+ T cells.	[Walter, Frederik; Winter, Elsa; Philipp, Lisa-Marie; Beckinger, Silje; Otto, Lilli; Helm, Ole; Sebens, Susanne] Univ Kiel, Inst Expt Canc Res, Kiel, Germany; [Walter, Frederik; Winter, Elsa; Philipp, Lisa-Marie; Beckinger, Silje; Otto, Lilli; Helm, Ole; Sebens, Susanne] Univ Med Ctr Schleswig Holstein UKSH, Campus Kiel, Kiel, Germany; [Rahn, Sascha] Univ Kiel, Inst Biochem, Kiel, Germany; [Heidland, Judith; Meier, Saskia; Struzek, Anna-Maria; Scherliess, Regina] Univ Kiel, Dept Pharmaceut & Biopharmaceut, Kiel, Germany; [Lettau, Marcus; Wesch, Daniela] Univ Kiel, Inst Immunol, Kiel, Germany; [Lettau, Marcus; Wesch, Daniela] UKSH Campus Kiel, Kiel, Germany; [Moeller, Julia Luisa] Univ Med Ctr Schleswig Holstein UKSH, Dept Hematol & Oncol, Campus Kiel, Kiel, Germany	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Sebens, S (corresponding author), Univ Kiel, Inst Expt Canc Res, Kiel, Germany.; Sebens, S (corresponding author), Univ Med Ctr Schleswig Holstein UKSH, Campus Kiel, Kiel, Germany.	susanne.sebens@email.uni-kiel.de	Rahn, Sascha/AAE-7777-2021; Sebens, Susanne/C-1222-2010; Lettau, Marcus/H-7595-2019	Lettau, Marcus/0000-0002-3824-9923	Medical Faculty of the Christian-Albrecht-University, Kiel; UKSH Forderstiftung; DFG	Medical Faculty of the Christian-Albrecht-University, Kiel; UKSH Forderstiftung; DFG(German Research Foundation (DFG))	Financial support by the Medical Faculty of the Christian-Albrecht-University, Kiel (O.H.) and the UKSH Forderstiftung (S.Se.) is acknowledged. Financial support by DFG within the funding programme "Open Access Publizieren" (S.Se.) is acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alpar HO, 2005, ADV DRUG DELIVER REV, V57, P411, DOI 10.1016/j.addr.2004.09.004; [Anonymous], 2017, VIRCHOWS ARCH, DOI [10.1007/s00428-017-2205-0, DOI 10.1007/S00428-017-2205-0]; Arslan C, 2014, J GASTROINTEST ONCOL, V5, P280, DOI 10.3978/j.issn.2078-6891.2014.030; Arya G, 2011, NANOMED-NANOTECHNOL, V7, P859, DOI 10.1016/j.nano.2011.03.009; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bal SM, 2012, EUR J PHARM SCI, V45, P475, DOI 10.1016/j.ejps.2011.10.003; Baleeiro RB, 2016, J BIOMED NANOTECHNOL, V12, P1527, DOI 10.1166/jbn.2016.2267; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Banfalvi G, 2008, NAT PROTOC, V3, P663, DOI 10.1038/nprot.2008.34; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Blank F, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-016-0242-5; Braaten KP, 2008, REV OBSTET GYNECOL; Bradbury PA, 2008, J THORAC ONCOL, V3, pS164, DOI 10.1097/JTO.0b013e318174e9a7; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Chadwick S, 2010, ADV DRUG DELIVER REV, V62, P394, DOI 10.1016/j.addr.2009.11.012; Chadwick S, 2009, EXPERT OPIN BIOL TH, V9, P427, DOI [10.1517/14712590902849224, 10.1517/14712590902849224 ]; Chen Y, 2015, BIOCHEM BIOPH RES CO, V463, P336, DOI 10.1016/j.bbrc.2015.05.065; Colonna C, 2008, EUR J PHARM BIOPHARM, V70, P58, DOI 10.1016/j.ejpb.2008.04.014; Corbett TH, 1984, CANC RES; Csaba N, 2009, ADV DRUG DELIVER REV, V61, P140, DOI 10.1016/j.addr.2008.09.005; Davis SS, 2001, ADV DRUG DELIVER REV, V51, P21, DOI 10.1016/S0169-409X(01)00162-4; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; DeMaria PJ, 2019, HEMATOL ONCOL CLIN N, V33, P199, DOI 10.1016/j.hoc.2018.12.001; Diedrich A, 2015, THESIS; Dougan M, 2019, ANNU REV CANC BIOL, V3, P55, DOI 10.1146/annurev-cancerbio-030518-055552; Emens LA, 2017, EUR J CANCER, V81, P116, DOI 10.1016/j.ejca.2017.01.035; Foged C, 2012, EUR J PHARM SCI, V45, P482, DOI 10.1016/j.ejps.2011.08.016; Fokas E, 2015, BBA-REV CANCER, V1855, P61, DOI 10.1016/j.bbcan.2014.12.001; Garcia-Fuentes M, 2012, J CONTROL RELEASE, V161, P496, DOI 10.1016/j.jconrel.2012.03.017; Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003; Gordon S, 2008, J PHARM PHARMACOL, V60, P1591, DOI 10.1211/jpp/60.12.0004; Helm O, 2014, INT J CANCER, V135, P843, DOI 10.1002/ijc.28736; Huang XG, 2007, VACCINE, V25, P8874, DOI 10.1016/j.vaccine.2007.08.066; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5; Jadidi-Niaragh F, 2017, J CONTROL RELEASE, V246, P46, DOI 10.1016/j.jconrel.2016.12.012; Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Kim Ryungsa, 2007, P9, DOI 10.1016/B978-012372551-6/50066-3; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Knudsen ES, 2017, CLIN CANCER RES, V23, P4429, DOI 10.1158/1078-0432.CCR-17-0162; Koppolu B, 2013, BIOMATERIALS, V34, P2359, DOI 10.1016/j.biomaterials.2012.11.066; Kukutsch NA, 2000, J INVEST DERMATOL, V115, P449, DOI 10.1046/j.1523-1747.2000.00084.x; Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102; Li Xiaosong, 2013, Clin Dev Immunol, V2013, P387023, DOI 10.1155/2013/387023; Lunardi S, 2014, CANCER LETT, V343, P147, DOI 10.1016/j.canlet.2013.09.039; Maharjan S, 2016, BIOMATERIALS, V84, P286, DOI 10.1016/j.biomaterials.2016.01.043; Matsuo K, 2011, J CONTROL RELEASE, V152, P310, DOI 10.1016/j.jconrel.2011.03.009; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muzzarelli RAA, 2010, MAR DRUGS, V8, P292, DOI 10.3390/md8020292; Oliveira MI, 2012, EUR CELLS MATER, V24, P136, DOI 10.22203/eCM.v024a10; Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004; Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258; Palucka K, 2011, J IMMUNOL, V186, P1325, DOI 10.4049/jimmunol.0902539; Qian Y, 2016, BIOMATERIALS, V98, P171, DOI 10.1016/j.biomaterials.2016.05.008; Rietscher R, 2016, EUR J PHARM BIOPHARM, V102, P20, DOI 10.1016/j.ejpb.2016.02.014; Salomon JJ, 2014, MOL PHARMACEUT, V11, P995, DOI 10.1021/mp4006535; Scherlie R, 2015, RESP DRUG DELIVERY E, P269; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Shen Z, 1997, J IMMUNOL; Shi GN, 2017, BIOMATERIALS, V113, P191, DOI 10.1016/j.biomaterials.2016.10.047; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Silva AL, 2013, EUR J PHARM BIOPHARM, V83, P338, DOI 10.1016/j.ejpb.2012.11.006; Song C, 2016, INT J NANOMED, V11, P3753, DOI 10.2147/IJN.S110796; Syme R, 2001, J HEMATOTH STEM CELL, V10, P43, DOI 10.1089/152581601750098219; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Xia XJ, 2015, CELL REP, V11, P957, DOI 10.1016/j.celrep.2015.04.009; Xiao J, 2017, MED SCI MONITOR, V23, P1613, DOI 10.12659/MSM.901292; Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038; Yan SY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01060; Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871; Yuan XY, 2008, VACCINE, V26, P3727, DOI 10.1016/j.vaccine.2008.04.065	74	10	11	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2020	15	9							e0239369	10.1371/journal.pone.0239369	http://dx.doi.org/10.1371/journal.pone.0239369			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YT	32997691	gold, Green Published			2023-01-03	WOS:000577103100016
J	Vyas, AK; Oud, L				Kalla Vyas, Arpita; Oud, Lavi			Temporal patterns of hospitalizations for diabetic ketoacidosis in children and adolescents	PLOS ONE			English	Article							UNITED-STATES; CONSENSUS STATEMENT; INCIDENCE TRENDS; TYPE-1; DIAGNOSIS; PREVALENCE; SEARCH; YOUTH; COMPLICATIONS; EPIDEMIOLOGY	Objectives To examine the temporal patterns of hospitalizations with diabetic ketoacidosis (DKA) in the pediatric population and their associated fiscal impact. Methods The Texas Inpatient Public Use Data File was used to identify hospitalizations of state residents aged 1month-19 years with a primary diagnosis of DKA during 2005-2014. Temporal changes of population-adjusted hospitalization rates and hospitalization volumes were examined for the whole cohort and on stratified analyses of sociodemographic attributes. Changes in the aggregate and per-hospitalization charges were assessed overall and on stratified analyses. Results There were 24,072 DKA hospitalizations during the study period. The population-adjusted hospitalization rate for the whole cohort increased from 31.3 to 35.9 per 100,000 between 2005-2006 and 2013-2014. Hospitalization volume increased by 30.2% over the same period, driven mainly by males, ethnic minorities, those with Medicaid insurance and uninsured patients. The aggregate hospital charges increased from approximately $69 million to $130 million between 2005-2006 and 2013-2014, with 66% of the rise being due to increased per-hospitalization charges. Conclusions There was progressive rise in pediatric DKA hospitalizations over the last decade, with concurrent near-doubling of the associated fiscal footprint. Marked disparities were noted in the increasing hospitalization burden of DKA, born predominantly by racial and ethnic minorities, as well as by the underinsured and the uninsured. Further studies are needed to identify scalable preventive measures to achieve an equitable reduction of pediatric DKA events.	[Kalla Vyas, Arpita] Calif Northstate Univ, Coll Med, Dept Pediat, Elk Grove, CA 95757 USA; [Oud, Lavi] Texas Tech Univ, Hlth Sci Ctr Permian Basin, Dept Internal Med, Div Pulm & Crit Care Med, Odessa, TX 79763 USA	Texas Tech University System; Texas Tech University	Vyas, AK (corresponding author), Calif Northstate Univ, Coll Med, Dept Pediat, Elk Grove, CA 95757 USA.; Oud, L (corresponding author), Texas Tech Univ, Hlth Sci Ctr Permian Basin, Dept Internal Med, Div Pulm & Crit Care Med, Odessa, TX 79763 USA.	arpita.vyas@cnsu.edu; Lavi.oud@ttuhsc.edu						Benoit SR, 2018, MMWR-MORBID MORTAL W, V67, P362, DOI 10.15585/mmwr.mm6712a3; Bialo SR, 2015, WORLD J DIABETES, V6, P167, DOI 10.4239/wjd.v6.i1.167; Bureau of Labor Statistics, BUREAU LABOR STAT; Cameron FJ, 2014, DIABETES CARE, V37, P1554, DOI 10.2337/dc13-1904; Crossen SS, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3497; Dabelea D, 2014, JAMA-J AM MED ASSOC, V311, P1778, DOI 10.1001/jama.2014.3201; Dabelea D, 2014, PEDIATRICS, V133, pE938, DOI 10.1542/peds.2013-2795; Desai D, 2018, DIABETES CARE, V41, P1631, DOI 10.2337/dc17-1379; Dunger DB, 2004, ARCH DIS CHILD, V89, P188, DOI 10.1136/adc.2003.044875; Estrada CL, 2009, PEDIATRICS, V124, P926, DOI 10.1542/peds.2008-3826; Halebic M, 2012, TEXAS POPULATION GRO; Hekkala A, 2010, DIABETES CARE, V33, P1500, DOI 10.2337/dc09-2344; Kao KT, 2020, J PEDIATR-US, V221, P165, DOI 10.1016/j.jpeds.2020.02.069; Klingensmith GJ, 2016, PEDIATR DIABETES, V17, P266, DOI 10.1111/pedi.12281; Koves IH, 2014, PEDIATRICS, V134, pE848, DOI 10.1542/peds.2013-3764; Lee JM, 2007, DIABETES CARE, V30, P3035, DOI 10.2337/dc07-0769; Maahs DM, 2015, DIABETES CARE, V38, P1876, DOI 10.2337/dc15-0780; Maahs DM, 2010, ENDOCRIN METAB CLIN, V39, P481, DOI 10.1016/j.ecl.2010.05.011; Malik FS, 2016, J PEDIATR-US, V171, P104, DOI 10.1016/j.jpeds.2015.12.015; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mayer-Davis EJ, 2017, NEW ENGL J MED, V376, P1419, DOI 10.1056/NEJMoa1610187; Mayer-Davis EJ, 2009, DIABETES CARE, V32, pS112, DOI 10.2337/dc09-S203; McDermott K.W., 2017, HCUP STAT BRIEF; Oud L, 2015, CRIT CARE RES PRACT, V2015, DOI 10.1155/2015/618067; Patel A, 2016, CLIN PEDIATR, V55, P943, DOI 10.1177/0009922815617975; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rewers A, 2008, PEDIATRICS, V121, pE1258, DOI 10.1542/peds.2007-1105; Rhodes ET, 2007, DIABETES CARE, V30, P141, DOI 10.2337/dc06-1142; Shrestha SS, 2010, DIABETES CARE, V33, P2617, DOI 10.2337/dc10-1406; Smiley Dawn, 2011, Diabetes Manag (Lond), V1, P589; Smith HAB, 2009, CRIT CARE CLIN, V25, P593, DOI 10.1016/j.ccc.2009.05.002; Sun R, 2018, HEALTHCARE COST UTIL; Texas inpatient public use data file, TEXAS INPATIENT PUBL; Tieder JS, 2013, PEDIATRICS, V132, P229, DOI 10.1542/peds.2013-0359; White PC, 2013, J PEDIATR-US, V163, P761, DOI 10.1016/j.jpeds.2013.02.005; Witt WP, 2014, OVERVIEW HOSP STAYS, P1; Wolfsdorf J, 2006, DIABETES CARE, V29, P1150, DOI 10.2337/dc06-9909; Wolfsdorf JI, 2018, PEDIATR DIABETES, V19, P155, DOI 10.1111/pedi.12701; Yogaraj JS, 2002, PEDIATRICS, V110, P481, DOI 10.1542/peds.110.3.481; Zee-Cheng JE, 2017, INT J EMERG MED, V10, DOI 10.1186/s12245-017-0137-8; ZIMET GD, 1989, AM J DIS CHILD, V143, P1134	41	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0245012	10.1371/journal.pone.0245012	http://dx.doi.org/10.1371/journal.pone.0245012			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411822	Green Published, gold			2023-01-03	WOS:000608044300099
J	Iverson, NR; Lau, CY; Abe-Jones, Y; Fang, MC; Kangelaris, KN; Prasad, P; Shah, SJ; Najafi, N				Iverson, Nicholas R.; Lau, Catherine Y.; Abe-Jones, Yumiko; Fang, Margaret C.; Kangelaris, Kirsten N.; Prasad, Priya; Shah, Sachin J.; Najafi, Nader			Evaluation of a novel metric for personalized opioid prescribing after hospitalization	PLOS ONE			English	Article								Background The duration of an opioid prescribed at hospital discharge does not intrinsically account for opioid needs during a hospitalization. This discrepancy may lead to patients receiving much larger supplies of opioids on discharge than they truly require. Objective Assess a novel discharge opioid supply metric that adjusts for opioid use during hospitalization, compared to the conventional discharge prescription signature. Design, setting, & participants Retrospective study using electronic health record data from June 2012 to November 2018 of adults who received opioids while hospitalized and after discharge from a single academic medical center. Measures & analysis We ascertained inpatient opioids received and milligrams of opioids supplied after discharge, then determined days of opioids supplied after discharge by the conventional prescription signature opioid-days ("conventional days") and novel hospital-adjusted opioid-days ("adjusted days") metrics. We calculated descriptive statistics, within-subject difference between measurements, and fold difference between measures. We used multiple linear regression to determine patient-level predictors associated with high difference in days prescribed between measures. Results The adjusted days metric demonstrates a 2.4 day median increase in prescription duration as compared to the conventional days metric (9.4 vs. 7.0 days; P<0.001). 95% of all adjusted days measurements fall within a 0.19 to 6.90-fold difference as compared to conventional days measurements, with a maximum absolute difference of 640 days. Receiving a liquid opioid prescription accounted for an increased prescription duration of 135.6% by the adjusted days metric (95% CI 39.1-299.0%; P = 0.001). Of patients who were not on opioids prior to admission and required opioids during hospitalization but not in the last 24 hours, 325 (8.6%) were discharged with an opioid prescription. Conclusions The adjusted days metric, based on inpatient opioid use, demonstrates that patients are often prescribed a supply lasting longer than the prescription signature suggests, though with marked variability for some patients that suggests potential under-prescribing as well. Adjusted days is more patient-centered, reflecting the reality of how patients will take their prescription rather than providers' intended prescription duration.	[Iverson, Nicholas R.; Lau, Catherine Y.; Abe-Jones, Yumiko; Fang, Margaret C.; Kangelaris, Kirsten N.; Prasad, Priya; Shah, Sachin J.; Najafi, Nader] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Iverson, NR (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	nicholas.iverson@ucsf.edu			National Heart, Lung, And Blood Institute of the National Institutes of Health (NIH) [K24HL141354]	National Heart, Lung, And Blood Institute of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	MF was partially supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health (NIH) under Award Number K24HL141354, https://www.nhlbi.nih.gov/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Calcaterra SL, 2018, J GEN INTERN MED, V33, P898, DOI 10.1007/s11606-018-4335-8; Clark J, 2018, CRIT CARE MED, V46, P443, DOI 10.1097/01.ccm.0000528926.89845.07; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2013, CLIN J PAIN, V30, P1; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Lail Sharan, 2014, Can J Hosp Pharm, V67, P337; McPherson ML, 2010, DEMYSTIFYING OPIOID; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P1853, DOI 10.1007/s00520-013-1740-8; Moore C, 2006, J PALLIAT MED, V9, P41, DOI 10.1089/jpm.2006.9.41; Newman TB., 2019, EVIDENCE BASED DIAGN; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; SMV STD SKI, 2017, J AM GERIAT SOC, V65, pe109	14	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244735	10.1371/journal.pone.0244735	http://dx.doi.org/10.1371/journal.pone.0244735			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382802	Green Published, gold			2023-01-03	WOS:000605651900052
J	Dorjee, K; Kim, H; Bonomo, E; Dolma, R				Dorjee, Kunchok; Kim, Hyunju; Bonomo, Elizabeth; Dolma, Rinchen			Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients	PLOS ONE			English	Review							NEW-YORK-CITY; CLINICAL CHARACTERISTICS; ADULT PATIENTS; OUTCOMES; CHINA; EPIDEMIOLOGY; ASSOCIATION; EXPERIENCE; MORTALITY; FEATURES	Introduction Progression of COVID-19 to severe disease and death is insufficiently understood. Objective Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized. Methods We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore's adjusted confidence intervals to address heterogeneity. Results Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18-23%); 23% (19-27%) in the US and Europe and 11% (7-16%) for China. Of those that died, 85% were aged >= 60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46-60) for heart disease, 51% (43-59) for COPD, 48% (37-63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23-36%) for hypertension, and 24% (17-33%) for diabetes. Summary relative risk (sRR) of death were higher for age >= 60 years [sRR = 3.6; 95% CI: 3.0-4.4], males [1.3; 1.2-1.4], smoking history [1.3; 1.1-1.6], COPD [1.7; 1.4-2.0], hypertension [1.8; 1.6-2.0], diabetes [1.5; 1.4-1.7], heart disease [2.1; 1.8-2.4], CKD [2.5; 2.1-3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities. Conclusions Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.	[Dorjee, Kunchok; Bonomo, Elizabeth] Johns Hopkins Univ, Sch Med, Div Infect Dis, Ctr TB Res, Baltimore, MD 21205 USA; [Kim, Hyunju] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Dolma, Rinchen] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Providence, RI 02912 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Brown University	Dorjee, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Ctr TB Res, Baltimore, MD 21205 USA.	kdorjee1@jhmi.edu	Dorjee, Kunchok/ABG-9329-2021	Dorjee, Kunchok/0000-0003-0992-0631; Bonomo, Elizabeth/0000-0001-7059-6127; Kim, Hyunju/0000-0002-1707-7018	US National Institute of Allergy and Infectious Diseases of the National Institute of Health [K01AI148583]; Johns Hopkins Alliance for a Healthier World [80045453]; STOP TB PARTNERSHIP TB REACH [134126]; Pittsfield Anti-TB Association	US National Institute of Allergy and Infectious Diseases of the National Institute of Health; Johns Hopkins Alliance for a Healthier World; STOP TB PARTNERSHIP TB REACH; Pittsfield Anti-TB Association	Dr. Dorjee is supported by grants from the US National Institute of Allergy and Infectious Diseases of the National Institute of Health (Grant #K01AI148583); Johns Hopkins Alliance for a Healthier World (Grant #80045453); STOP TB PARTNERSHIP TB REACH (Grant #134126); the Pittsfield Anti-TB Association and dedicated private philanthropists.	Aggarwal S, 2020, DIAGNOSIS, V7, P91, DOI 10.1515/dx-2020-0046; Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055; Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; [Anonymous], 2020, NAT METHODS, V17, P1, DOI 10.1038/s41592-019-0703-5; [Anonymous], COVID 19 DASHB CTR S; [Anonymous], 2020, INDIAN J PUBLIC HLTH, V64, pS84; [Anonymous], 2020, NATL SMOKING RATES C, DOI DOI 10.1101/2020.06.12.20129825V1; Argenziano Michael G, 2020, medRxiv, DOI 10.1101/2020.04.20.20072116; Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI 10.1161/CIR.0000000000000659; Biener AI, 2019, JAMA-J AM MED ASSOC, V322, P602, DOI 10.1001/jama.2019.10241; Brill SE, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01665-z; Cai GS, 2020, AM J RESP CRIT CARE, V201, P1557, DOI 10.1164/rccm.202003-0693LE; Cao ZH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234764; Charlotte P, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20314; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004; Chen QQ, 2020, INFECTION, V48, P543, DOI 10.1007/s15010-020-01432-5; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Chilimuri S, 2020, WEST J EMERG MED, V21, P779, DOI 10.5811/westjem.2020.6.47919; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Ciceri F, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108509; Claudia G, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20316; Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Creamer MR, 2019, MMWR-MORBID MORTAL W, V68, P1013, DOI 10.15585/mmwr.mm6845a2; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Deng YT, 2020, CAMB CHINA LIBR, P1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020; Escalera-Antezana Juan Pablo, 2020, Infez Med, V28, P238; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Fang LW, 2018, LANCET RESP MED, V6, P421, DOI 10.1016/S2213-2600(18)30103-6; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; Ferguson J, 2020, EMERG INFECT DIS, V26, P1679, DOI 10.3201/eid2608.201776; Fryar Cheryl D, 2017, NCHS Data Brief, P1; Galloway JB, 2020, J INFECTION, V81, P282, DOI 10.1016/j.jinf.2020.05.064; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Garibaldi BT, 2021, ANN INTERN MED, V174, P33, DOI 10.7326/M20-3905; Giacomelli A, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104931; Gold JAW, 2020, MMWR-MORBID MORTAL W, V69, P545, DOI 10.15585/mmwr.mm6918e1; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Hewitt J, 2020, LANCET PUBLIC HEALTH, V5, pE444, DOI 10.1016/S2468-2667(20)30146-8; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hsu HE, 2020, MMWR-MORBID MORTAL W, V69, P864, DOI 10.15585/mmwr.mm6927a3; Hu C, 2018, DIABETES, V67, P3, DOI 10.2337/dbi17-0013; Hu L, 2020, CLIN INFECT DIS, V71, P2089, DOI 10.1093/cid/ciaa539; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hur K, 2020, OTOLARYNG HEAD NECK, V163, P170, DOI 10.1177/0194599820929640; Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324; Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388; Jang JG, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e209; Javanian M, 2020, ROM J INTERN MED, V58, P161, DOI 10.2478/rjim-2020-0013; Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859; Khalil K, 2020, J INFECTION, V81, pE85, DOI 10.1016/j.jinf.2020.06.027; Khamis F, 2020, J INFECT PUBLIC HEAL, V13, P906, DOI 10.1016/j.jiph.2020.06.002; Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097; Lendorf ME, 2020, DAN MED J, V67; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Li XT, 2020, HEART, V106, P1142, DOI 10.1136/heartjnl-2020-317062; Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014; Liu S, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-0538-1; Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775; Nikpouraghdam M, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104378; Nowak B, 2020, POL ARCH INTERN MED, V130, P407, DOI 10.20452/pamw.15361; Okoh AK, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01208-1; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Pan W, 2020, HYPERTENSION, V76, P732, DOI 10.1161/HYPERTENSIONAHA.120.15289; Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082; Pinto Bruna G G, 2020, medRxiv, DOI 10.1101/2020.03.21.20040261; Radzikowska U, 2020, ALLERGY, V75, P2829, DOI 10.1111/all.14429; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rivera-Izquierdo M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235107; Rossato M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01290-2020; Schiffrin EL, 2020, AM J HYPERTENS, V33, P373, DOI 10.1093/ajh/hpaa057; Shabrawishi M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237130; Shahriarirad R, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05128-x; Shekhar R, 2020, INFECT DIS-NOR, V52, P596, DOI 10.1080/23744235.2020.1774645; Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7; SHORE RE, 1993, BRIT J IND MED, V50, P971; South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Suleyman G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12270; Sun LJ, 2020, J MED VIROL, V92, P2055, DOI 10.1002/jmv.25966; Tian SJ, 2020, J INFECTION, V80, P401, DOI 10.1016/j.jinf.2020.02.018; Tomlins J, 2020, J INFECTION, V81, pE59, DOI 10.1016/j.jinf.2020.04.020; Turcotte JJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237558; United States Centers for Disease Control and Prevention, 2020, NAT DIAB STAT REP; United States Centers for Disease Control and Prevention, 2019, CHRON KIDN DIS US; Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang MH, 2019, LANCET RESP MED, V7, P35, DOI [10.1016/s2213-2600(18)30432-6, 10.1016/S2213-2600(18)30432-6]; Wang RR, 2020, INT J INFECT DIS, V95, P421, DOI 10.1016/j.ijid.2020.03.070; Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380; Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272; Wei YP, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05252-8; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang J, 2022, INT J ENVIRON AN CH, V102, P3638, DOI 10.1080/03067319.2020.1772775; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yao QC, 2020, POL ARCH INTERN MED, V130, P390, DOI 10.20452/pamw.15312; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Yu T, 2020, CLIN THER, V42, P964, DOI 10.1016/j.clinthera.2020.04.009; Yu X, 2020, TRANSBOUND EMERG DIS, V67, P1697, DOI 10.1111/tbed.13604; Zhan T, 2020, J INT MED RES, V48, DOI 10.1177/0300060520949039; Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8; Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889; Zhao XX, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05196-z; Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443; Zheng Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104821; Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu L, 2020, CARDIORENAL MED, V10, P470, DOI 10.1159/000510916	121	90	92	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243191	10.1371/journal.pone.0243191	http://dx.doi.org/10.1371/journal.pone.0243191			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD8LW	33284825	gold, Green Published			2023-01-03	WOS:000597930500030
J	Seid, M; Beyene, G; Alemu, Y; Workalemahu, B; Delbo, M; Taddesse, D; Biresaw, G; Manilal, A				Seid, Mohammed; Beyene, Getnet; Alemu, Yared; Workalemahu, Bereket; Delbo, Mulugeta; Taddesse, Dagimawie; Biresaw, Gelila; Manilal, Aseer			Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; STREPTOCOCCUS-PNEUMONIAE; INFECTED ADULTS; NASOPHARYNGEAL CARRIAGE; ANTIBIOTIC-RESISTANCE; COTE-DIVOIRE; COLONIZATION; PREVALENCE; IMPACT	Background Infections caused by antibiotic-resistant bacteria results in high rates of morbidity and mortality. Although the prolonged cotrimoxazole (CTX) prophylaxis is arguably associated with the risk of increasing drug resistance in the common pathogens, information regarding its impact on Streptococci pneumoniae / pneumococcus is very limited. Objective This study was conducted to investigate the effect of cotrimoxazole prophylaxis on nasopharyngeal colonization rate and antimicrobial resistance using Streptococci pneumoniae (pneumococcus) as an indicator organism among HIV patients in Arba Minch, Ethiopia. Materials and methods A comparative cross-sectional study was designed and conducted among HIV patients attending the Anti-Retroviral Treatment (ART) clinic of Arba Minch General Hospital (AMGH) from April 01 to August 31, 2018. A total of 252 participants were systematically selected and clustered into two study groups based on their CTX prophylaxis status, one taking CTX prophylaxis, and the second one, the control group (without prophylaxis). A structured questionnaire was used to collect socio-demographic and clinical data from patients. A nasopharyngeal swab was collected and cultured for pneumococcal isolation and identification in accordance with standard microbiological techniques. An antibiotics sensitivity test was performed according to the CLSI guidelines. Data were analyzed using the Statistical package for social science (SPSS) version 20. The primary outcome was determined using logistic regression analysis. Results Of the 252 enrolled HIV patients (mean age (37.38 +/- 9.03 years), 144 (57.14%) were males. The overall, nasopharyngeal colonization rate of S. pneumoniae was 13.5% (95% CI: 8.4-15.6). Asymptomatic pneumococcal carriage rates among patients on CTX prophylaxis and the control group were 16.3%, and 10.3% respectively (p-value = 0.03). Regarding the risk factors analyzed, CTX prophylaxis (AOR: 2.2; 95% CI: 1.05-4.9) and gender (AOR: 2.5; 95% CI: 1.09-5.93) were significantly associated with pneumococcal colonization, showing a male preponderance. Cotrimoxazole-resistant pneumococci were 85.7% vs. 47.4% in the prophylaxis group and the control group respectively and it was statistically significant (AOR: 6.7; 95% CI: 1.3-36). Percentages of multi-drug resistant isolates in these two groups were 38.09 and 15.38 respectively (p-value = 0.04). Among the CTX resistant pneumococci isolates, 85% were also found to be co-resistant towards penicillin and was statistically significant. Conclusion The percentage prevalence of nasopharyngeal pneumococci colonization was higher in patients taking CTX prophylaxis. It was noted that CTX prophylaxis eventually results in the selection of cotrimoxazole resistance and multi-drug resistance in pneumococci. There is evidence of existing cross-resistance between cotrimoxazole and penicillin antibiotics. Therefore, CTX prophylaxis must be administered judiciously. Surveillance for antimicrobial susceptibility is warranted where the prophylaxis is common.	[Seid, Mohammed; Taddesse, Dagimawie; Biresaw, Gelila; Manilal, Aseer] Arba Minch Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Arba Minch, Ethiopia; [Beyene, Getnet; Alemu, Yared] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Workalemahu, Bereket; Delbo, Mulugeta] Arba Minch Coll Hlth Sci, Dept Med Lab Sci, Arba Minch, Ethiopia	Arba Minch University; Jimma University	Seid, M; Manilal, A (corresponding author), Arba Minch Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Arba Minch, Ethiopia.	mohamedseid2005@gmail.com; aseermanilal@gmail.com	Manilal, Aseer/GPX-1261-2022; Manilal, Aseer/GRR-8490-2022; Manilal, Aseer/AAM-1726-2020	Manilal, Aseer/0000-0002-1146-8093; Manilal, Aseer/0000-0002-1146-8093; Manilal, Aseer/0000-0002-1146-8093; Abate, Dagimawie/0000-0002-3770-1957; Workalemahu, Bereket/0000-0002-8221-0604; Alemu, Yared/0000-0001-8752-8809				Abdel-Haq N, 1999, PEDIATR INFECT DIS J, V18, P647, DOI 10.1097/00006454-199907000-00017; Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 2018, GLOB BURD HIV AIDS; [Anonymous], 2018, M100 PERFORMANCE STA; Blossom DB, 2006, INT J INFECT DIS, V10, P458, DOI 10.1016/j.ijid.2006.05.010; Bradshaw JL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007911; Bronzwaer SLAM, 2002, EMERG INFECT DIS, V8, P278, DOI 10.3201/eid0803.010192; Conklin LM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-015-1312-2; Egwuatu C C, 2016, Afr J Infect Dis, V10, P156, DOI 10.21010/ajid.v10i2.12; El Moujaber G, 2017, J MED MICROBIOL, V66, P847, DOI 10.1099/jmm.0.000503; Feola TD, 2016, HUM VACC IMMUNOTHER, V12, P2441, DOI 10.1080/21645515.2016.1172758; GEDDES AM, 1979, J ANTIMICROB CHEMOTH, V5, P221, DOI 10.1093/jac/5.Supplement_B.221; Gill CJ, 2008, J INFECT DIS, V197, P1000, DOI 10.1086/528806; Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668; Gill CJ, 2004, B WORLD HEALTH ORGAN, V82, P290; Glennie SJ, 2013, CLIN INFECT DIS, V56, P291, DOI 10.1093/cid/cis842; Gordon SB, 2002, AIDS, V16, P1409, DOI 10.1097/00002030-200207050-00013; Hamel MJ, 2008, AM J TROP MED HYG, V79, P320, DOI 10.4269/ajtmh.2008.79.320; Harimurti K, 2016, J INFECT PUBLIC HEAL, V9, P633, DOI 10.1016/j.jiph.2016.01.004; Heinsbroek E, 2015, AIDS, V29, P1837, DOI 10.1097/QAD.0000000000000755; Iloliev A, 2008, CENT ASIAN SURV, V27, P59, DOI 10.1080/02634930802213924; Jordano Q, 2004, CLIN INFECT DIS, V38, P1623, DOI 10.1086/420933; Kibret GD, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0594-9; Marwa KJ, 2015, AIDS RES TREAT, V2015, DOI 10.1155/2015/103874; Mwambete KD, 2013, CLIN MICROBIOL, V3, P134; Mwenya DM, 2010, ANTIMICROB AGENTS CH, V54, P3756, DOI 10.1128/AAC.01409-09; Nicoletti C, 2007, DIAGN MICR INFEC DIS, V57, P259, DOI 10.1016/j.diagmicrobio.2006.08.021; Nunes MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027929; Onwubiko C, 2008, J CLIN MICROBIOL, V46, P3621, DOI 10.1128/JCM.01245-08; Pemba L, 2008, J INFECTION, V56, P171, DOI 10.1016/j.jinf.2007.12.003; RodriguezBarradas MC, 1997, J INFECT DIS, V175, P590, DOI 10.1093/infdis/175.3.590; Sibanda EL, 2011, CLIN INFECT DIS, V52, P1184, DOI 10.1093/cid/cir067; Tadesse BT, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2713-1; UNAIDS/WHO, 2000, PROV WHO UNAIDS SECR; Wasihun AG, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1056-x; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; William Buwembo, 2012, Int J Microbiol, V2012, P916129, DOI 10.1155/2012/916129; World Health Organization, 2003, MANUAL LAB IDENTIFIC; World Health Organization (WHO), 2006, GUID COTR PROPH HIV	40	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243054	10.1371/journal.pone.0243054	http://dx.doi.org/10.1371/journal.pone.0243054			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD8LW	33284828	gold, Green Published			2023-01-03	WOS:000597930500052
J	Roshdy, WH; Rashed, HA; Kandeil, A; Mostafa, A; Moatasim, Y; Kutkat, O; Shama, NMA; Gomaa, MR; El-Sayed, IH; El Guindy, NM; Naguib, A; Kayali, G; Ali, MA				Roshdy, Wael H.; Rashed, Helmy A.; Kandeil, Ahmed; Mostafa, Ahmed; Moatasim, Yassmin; Kutkat, Omnia; Abo Shama, Noura M.; Gomaa, Mokhtar R.; El-Sayed, Ibrahim H.; El Guindy, Nancy M.; Naguib, Amal; Kayali, Ghazi; Ali, Mohamed A.			EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2	PLOS ONE			English	Article							FACTOR-KAPPA-B; INFLUENZA-VIRUS INFECTION; BETA-SITOSTEROL; CYTOKINE STORM; NECK-CANCER; CURCUMIN; KINASE; INHIBITION; CELLS; PROLIFERATION	Due to the challenges for developing vaccines in devastating pandemic situations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing and screening of novel antiviral agents are peremptorily demanded. Herein, we developed EGYVIR as a potent immunomodulatory herbal extract with promising antiviral activity against SARS-CoV-2. It constitutes of a combination of black pepper extract with curcumin extract. The antiviral effect of EGYVIR extract is attributed to the two key phases of the disease in severe cases. First, the inhibition of the nuclear translocation of NF-k beta p50, attenuating the SARS-CoV-2 infection-associated cytokine storm. Additionally, the EGYVIR extract has an in vitro virucidal effect for SARS-CoV-2. The in vitro study of EGYVIR extract against SARS-CoV-2 on Huh-7 cell lines, revealed the potential role of NF-k beta/TNF alpha/IL-6 during the infection process. EGYVIR antagonizes the NF-k beta pathway in-silico and in-vitro studies. Consequently, it has the potential to hinder the release of IL-6 and TNF alpha, decreasing the production of essential cytokines storm elements.	[Roshdy, Wael H.; Rashed, Helmy A.; El Guindy, Nancy M.; Naguib, Amal] Minist Hlth & Populat, Cent Publ Hlth Lab, Cairo, Egypt; [Kandeil, Ahmed; Mostafa, Ahmed; Moatasim, Yassmin; Kutkat, Omnia; Abo Shama, Noura M.; Gomaa, Mokhtar R.; Ali, Mohamed A.] Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt; [El-Sayed, Ibrahim H.] Kafr El Sheikh Univ, Fac Sci, Biochem Dept, Kafr El Shaikh, Egypt; [Kayali, Ghazi] Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA; [Kayali, Ghazi] Human Link, Baabda, Lebanon	Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge Bank (EKB); Kafrelsheikh University; University of Texas System; University of Texas Health Science Center Houston	Roshdy, WH (corresponding author), Minist Hlth & Populat, Cent Publ Hlth Lab, Cairo, Egypt.; Ali, MA (corresponding author), Natl Res Ctr, Ctr Sci Excellence Influenza Viruses, Giza, Egypt.; Kayali, G (corresponding author), Univ Texas Houston, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.; Kayali, G (corresponding author), Human Link, Baabda, Lebanon.	waelhamedroshdy@yahoo.com; ghazi@human-link.org; mohamedahmedali2004@yahoo.com	Gomaa, Mokhtar Rizk/N-9125-2018; Moatasim, Yassmin/AAQ-8426-2020; Kandeil, Ahmed/N-5473-2019; kutkat, omnia/AAU-5582-2020; Mostafa, Ahmed/S-7462-2016; Ali, Mohamed/N-8768-2017	Moatasim, Yassmin/0000-0003-2159-2511; Kandeil, Ahmed/0000-0003-3253-6961; kutkat, omnia/0000-0003-2256-2816; Mostafa, Ahmed/0000-0002-2878-5714; ElGuindy, Nancy/0000-0002-5876-237X; Ali, Mohamed/0000-0002-5615-3212; Roshdy, Wael/0000-0001-8412-3128; Gomaa, Mokhtar/0000-0001-7947-3609	National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services [HHSN272201400006C]	National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)NIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services (under contract HHSN272201400006C). Also this work was funded by pure diagnostic company.	[Anonymous], 2018, EUR J PHYS REHAB MED, V54, P177; Arbab AH, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.30864; Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bouic PJD, 1996, INT J IMMUNOPHARMACO, V18, P693, DOI 10.1016/S0192-0561(97)85551-8; Cao J, 2006, TOXICOL SCI, V91, P476, DOI 10.1093/toxsci/kfj153; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Chen TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062482; Chen X, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05354-3; Cohen AN, 2009, ARCH OTOLARYNGOL, V135, P190, DOI 10.1001/archotol.135.2.190; Derosa G, 2016, PHARMACOL RES, V111, P394, DOI 10.1016/j.phrs.2016.07.004; Ferreira VH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124903; Fiehn Oliver, 2016, Curr Protoc Mol Biol, V114, DOI 10.1002/0471142727.mb3004s114; Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8; Han SG, 2018, CLIN EXP PHARMACOL P, V45, P84, DOI 10.1111/1440-1681.12848; HAYDEN FG, 1980, ANTIMICROB AGENTS CH, V18, P536, DOI 10.1128/AAC.18.4.536; IVORRA MD, 1988, ARCH INT PHARMACOD T, V296, P224; Kasinski AL, 2008, MOL PHARMACOL, V74, P654, DOI 10.1124/mol.108.046201; Kim SG, 2011, CLIN CANCER RES, V17, P5953, DOI 10.1158/1078-0432.CCR-11-1272; Kong LB, 2013, ANTIVIR RES, V98, P44, DOI 10.1016/j.antiviral.2013.02.003; Kuo YC, 2002, ANTIMICROB AGENTS CH, V46, P2854, DOI 10.1128/AAC.46.9.2854-2864.2002; Lee EC, 2016, NANOSCALE, V8, P16192, DOI 10.1039/c6nr03878f; Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685; Li YH, 2016, ACS APPL MATER INTER, V8, P24385, DOI 10.1021/acsami.6b06613; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Mayadevi M, 2012, BIOORGAN MED CHEM, V20, P6040, DOI 10.1016/j.bmc.2012.08.029; McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mostafa A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070991; Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014; Obata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070225; Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349; Perrone D, 2015, EXP THER MED, V10, P1615, DOI 10.3892/etm.2015.2749; Pradeep CR, 2004, INT IMMUNOPHARMACOL, V4, P1795, DOI 10.1016/j.intimp.2004.08.005; Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2; RAO GS, 1974, J PHARM SCI-US, V63, P471, DOI 10.1002/jps.2600630341; Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71; Reuter S, 2009, ANN NY ACAD SCI, V1171, P436, DOI 10.1111/j.1749-6632.2009.04731.x; Schuhmacher A, 2003, PHYTOMEDICINE, V10, P504, DOI 10.1078/094471103322331467; Siddique HR, 2011, LIFE SCI, V88, P285, DOI 10.1016/j.lfs.2010.11.020; Tanaka T, 2004, CHEM PHARM BULL, V52, P1242, DOI 10.1248/cpb.52.1242; Toden Shusuke, 2017, J Restor Med, V6, P27, DOI 10.14200/jrm.2017.6.0101; Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Xu YM, 2017, INFLUENZA OTHER RESP, V11, P457, DOI 10.1111/irv.12459; Yang M, 2016, MOLECULES, V21, DOI 10.3390/molecules21101401; Yang XX, 2017, NANOSCALE, V9, P16086, DOI 10.1039/c7nr06520e; Yang XX, 2016, NANOSCALE, V8, P3040, DOI 10.1039/c5nr07918g; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Zhang BY, 2019, FASEB J, V33, P13294, DOI 10.1096/fj.201901047RR; Zhang J, 1995, Zhongguo Zhong Yao Za Zhi, V20, P556; Zhang L, 2009, CANCER INVEST, V27, P163, DOI 10.1080/07357900802210745; Zhang YL, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0199-1; Zhao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117496	55	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0241739	10.1371/journal.pone.0241739	http://dx.doi.org/10.1371/journal.pone.0241739			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VG	33206688	gold, Green Published			2023-01-03	WOS:000595265900052
J	Rodriguez-Nogueira, O; Balaguer, JM; Lopez, AN; Merino, JR; Botella-Rico, JM; Del Rio-Medina, S; Poyato, AMR				Rodriguez-Nogueira, Oscar; Morera Balaguer, Jaume; Nogueira Lopez, Abel; Roldan Merino, Juan; Botella-Rico, Jose-Martin; Del Rio-Medina, Sonia; Moreno Poyato, Antonio R.			The psychometric properties of the person-centered therapeutic relationship in physiotherapy scale	PLOS ONE			English	Article							PATIENT-CENTEREDNESS; FIT INDEXES; CARE; REHABILITATION; ALLIANCE; QUALITY; SATISFACTION; PERCEPTIONS; CRITERIA; ELEMENTS	Objective To determine the psychometric properties of the Person-Centered Therapeutic Relationship in Physiotherapy Scale (PCTR-PT) in order to find the most appropriate fit for the tool. Methods Patients who had received treatment at the physiotherapy service of nine hospitals in Spain were invited to complete the 31 items of the PCTR-PT scale. To select the most appropriate items of the PCTR-PT, an exploratory factorial analysis (EFA) was performed using the maximum likelihood and oblique rotation (promin) methods. Factor validity, goodness-of-fit and psychometric properties were analyzed by confirmatory factor analysis (CFA). Convergent (CFA) and discriminant validity were calculated. Internal consistency was verified using the Cronbach's alpha coefficient. The intraclass correlation coefficient (ICC) was used to examine temporal stability. Results 366 patients over 18 years old who had received, at least, 15 physiotherapy treatment sessions completed the questionnaire. The results of the exploratory factor analysis revealed a tool with 15 items in four factors [Relational Bond (N items = 4); Individualized Partnership (N items = 4); Professional Empowerment (N items = 3) and Therapeutic Communication (N items = 4)], explaining 78.4% of the variance of the total variables of this tool. The confirmatory factor analysis further confirmed the four-structure model. Reliability of the tool was approved by Cronbach's alpha in all four dimensions, as all were above .70, ranging from .84 (Individualized Partnership) to .91 (Professional Empowerment). = 0.94. Test-retest was performed with two-week intervals, indicating an appropriate stability for the scale (ICC = 0.900). Conclusion The Person-Centered Therapeutic Relationship in Physiotherapy Scale (PCTR-PT) is a useful, valid and applicable instrument to evaluate the person-centered therapeutic relationship during physiotherapy interventions. It would be interesting to investigate the predictive capacity (sensitivity and specificity) of the PCTR-PT scale.	[Rodriguez-Nogueira, Oscar] Univ Leon, Dept Nursing & Physiotherapy, SALBIS Res Grp, Campus Ponferrada, Leon, Spain; [Morera Balaguer, Jaume; Botella-Rico, Jose-Martin; Del Rio-Medina, Sonia] Univ Cardenal Herrera CEU, Phys Therapy Dept, CEU Univ, Alicante, Spain; [Nogueira Lopez, Abel] European Univ Atlantic, Santander, Spain; [Nogueira Lopez, Abel] Int Ibero Amer Univ, Campeche, Campeche, Mexico; [Nogueira Lopez, Abel] Int Univ Cuanza, Dept Sport, Cuito, Angola; [Roldan Merino, Juan] Univ Barcelona, Sch Nursing, Campus Docent, St Joan De Deu Fundacio Privada, Barcelona, Spain; [Roldan Merino, Juan] Res Grp GIES Grp Invest Enfermeriia Educ & Soc, Barcelona, Spain; [Moreno Poyato, Antonio R.] Res Grp GEIMAC, Grp Studies Invarianza Instruments Measurement &, Barcelona, Spain; Univ Barcelona, Escola Infermeria, Fac Med & Ciencies Salut, Dept Infermeria Salut Publ Salut Mental & Materno, Campus Bellvitge,Pavello Govern, Barcelona, Spain	Universidad de Leon; Universidad CEU Cardenal Herrera; University of Barcelona; University of Barcelona	Balaguer, JM (corresponding author), Univ Cardenal Herrera CEU, Phys Therapy Dept, CEU Univ, Alicante, Spain.	jmorera.el@uchceu.es	Moreno-Poyato, Antonio R./O-3975-2019; Rodríguez, Oscar/AAF-8023-2021; Nogueira López, Abel/GVT-4093-2022; Roldan-Merino, Juan/H-9063-2019	Moreno-Poyato, Antonio R./0000-0002-5700-4315; Rodríguez, Oscar/0000-0002-4203-5784; Nogueira López, Abel/0000-0001-6761-2907; Roldan-Merino, Juan/0000-0002-7895-6083; Morera Balaguer, Jaume/0000-0001-8733-4406	CEU Cardenal Herrera University; San Pablo University-Santander Foundation (FUSP)	CEU Cardenal Herrera University; San Pablo University-Santander Foundation (FUSP)	Authors JMB, ORN, are recipients of a grant from CEU Cardenal Herrera University (www.uchceu.es) and the San Pablo University-Santander Foundation (FUSP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avecillas D. X. A., 2016, REV POLIT CNICA, V37, P68; Bagozzi R. P., 1988, J ACAD MARKETING SCI, V16, P74, DOI 10.1177/009207038801600107; BARKHAM M, 1993, BRIT J MED PSYCHOL, V66, P157, DOI 10.1111/j.2044-8341.1993.tb01738.x; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Bordin E.S., 1979, PSYCHOL PSYCHOTHER-T, V16, P252, DOI [10.1037/h0085885, DOI 10.1037/H0085885]; Brown T.A., 2015, CONFIRMATORY FACTOR, V2nd, DOI [10.1680/geot.8.B.012, DOI 10.1680/GEOT.8.B.012]; Byrne AL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229923; Byrne B., 2010, STRUCTURAL EQUATION; Castro EM, 2016, PATIENT EDUC COUNS, V99, P1923, DOI 10.1016/j.pec.2016.07.026; Constand MK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-271; DeVellis R. F., 2016, SCALE DEV THEORY APP; Diaz De Rada V., 2001, REV INT SOCIOL, V59, P133, DOI [10.3989/ris.2001.i29.759, DOI 10.3989/RIS.2001.I29.759]; Eklund JH, 2019, PATIENT EDUC COUNS, V102, P3, DOI 10.1016/j.pec.2018.08.029; Ekman N, 2020, INT J NURS STUD, V109, DOI 10.1016/j.ijnurstu.2020.103634; Del Bano-Aledo ME, 2014, PHYSIOTHERAPY, V100, P73, DOI 10.1016/j.physio.2013.05.001; Farrell AM, 2010, J BUS RES, V63, P324, DOI 10.1016/j.jbusres.2009.05.003; Fleiss J. L., 2011, DESIGN ANAL CLIN EXP; FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312; Hair J.F., 2010, MULTIVARIATE DATA AN, V7; Hall AM, 2010, PHYS THER, V90, P1099, DOI 10.2522/ptj.20090245; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; Institute of Medicine, 2001, SHAP FUT CROSS QUAL, DOI 10.17226/10027; Jaju A, 1999, AM MARK ASS, V10, P127; Kelley JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094207; Kline R. B, 2015, PRINCIPLES PRACTICE, V2nd; Lorenzo-Seva U, 1999, MULTIVAR BEHAV RES, V34, P347, DOI 10.1207/S15327906MBR3403_3; Luborsky L, 1996, J Psychother Pract Res, V5, P260; Maroco J. P., 2014, STRUCTURAL EQUATIONS, V2; McGuire-Snieckus R, 2007, PSYCHOL MED, V37, P85, DOI 10.1017/S0033291706009299; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Medina-Mirapeix F, 2013, ARCH PHYS MED REHAB, V94, P2248, DOI 10.1016/j.apmr.2013.04.018; Medina-Mirapeix F, 2013, CLIN REHABIL, V27, P555, DOI 10.1177/0269215512468142; Miciak M, 2019, PHYSIOTHER THEOR PR, V35, P40, DOI 10.1080/09593985.2018.1434707; Miciak Maxi, 2018, Arch Physiother, V8, P3, DOI 10.1186/s40945-018-0044-1; Morera-Balaguer J, 2021, PHYSIOTHER THEOR PR, V37, P17, DOI 10.1080/09593985.2019.1603258; Morera-Balaguer J, 2018, BRAZ J PHYS THER, V22, P484, DOI 10.1016/j.bjpt.2018.04.003; Morgan S, 2012, J HOLIST NURS, V30, P6, DOI 10.1177/0898010111412189; Nolte E, 2020, EUR OBS HEALTH SYST, P1; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; O'Keeffe M, 2016, PHYS THER, V96, P609, DOI 10.2522/ptj.20150240; Olsson LE, 2013, J CLIN NURS, V22, P456, DOI 10.1111/jocn.12039; Pinto RZ, 2012, J PHYSIOTHER, V58, P77, DOI 10.1016/S1836-9553(12)70087-5; Ramos A, 2018, REV PSICOL DEPORTE, V27, P87; Rathert C, 2015, HEALTH EXPECT, V18, P199, DOI 10.1111/hex.12020; Ree E, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-018-3798-y; Nogueira OR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228916; Santana MJ, 2018, HEALTH EXPECT, V21, P429, DOI 10.1111/hex.12640; Scholl I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107828; Sidani S, 2014, J INTERPROF CARE, V28, P134, DOI 10.3109/13561820.2013.862519; Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012; Wagner EH, 2005, J ALTERN COMPLEM MED, V11, pS7, DOI 10.1089/acm.2005.11.s-7; WHO, 2018, INT PRIM HLTH CAR BA; Wijma AJ, 2017, PHYSIOTHER THEOR PR, V33, P825, DOI 10.1080/09593985.2017.1357151; Yun D, 2019, INT J NURS STUD, V93, P74, DOI 10.1016/j.ijnurstu.2019.02.012; Zimmermann L, 2014, PATIENT EDUC COUNS, V96, P98, DOI 10.1016/j.pec.2014.04.015	57	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2020	15	11							e0241010	10.1371/journal.pone.0241010	http://dx.doi.org/10.1371/journal.pone.0241010			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OU2PV	33156867	Green Published, gold			2023-01-03	WOS:000591376400016
J	Di Carlo, P; Chiacchiaretta, P; Sinjari, B; Aruffo, E; Stuppia, L; De Laurenzi, V; Di Tomo, P; Pelusi, L; Potenza, F; Veronese, A; Vecchiet, J; Falasca, K; Ucciferri, C				Di Carlo, Piero; Chiacchiaretta, Piero; Sinjari, Bruna; Aruffo, Eleonora; Stuppia, Liborio; De Laurenzi, Vincenzo; Di Tomo, Pamela; Pelusi, Letizia; Potenza, Francesca; Veronese, Angelo; Vecchiet, Jacopo; Falasca, Katia; Ucciferri, Claudio			Air and surface measurements of SARS-CoV-2 inside a bus during normal operation	PLOS ONE			English	Article								Transmission pathways of SARS-CoV-2 are aerosol, droplet and touching infected material. The diffusion of the virus contagion among people is easier in indoor location, but direct detection of SARS-CoV-2 in air or on surfaces is quite sparse, especially regarding public transport, while it would be important to know how and if it is safe to use them. To answer these questions we analysed the air and the surfaces most usually touched by passengers inside a city bus during normal operation, in order to understand the possible spreading of the virus and the effectiveness of the protective measures. The measurements were carried out across the last week of the lockdown and the first week when, gradually, all the travel restrictions were removed. The air and surface samples were analysed with the RT-PCR for the detection of SARS-CoV-2 virus. After two weeks of measurements and more than 1100 passenger travelling on the bus the virus was never detected both on surfaces and on air, suggesting that the precautions adopted on public transportation are effective in reducing the COVID-19 spreading.	[Di Carlo, Piero; Aruffo, Eleonora; Stuppia, Liborio] Univ G dAnnunzio, Dept Psychol Hlth & Terr Sci, Chieti, Italy; [Di Carlo, Piero; Aruffo, Eleonora; Stuppia, Liborio; De Laurenzi, Vincenzo; Di Tomo, Pamela; Pelusi, Letizia; Potenza, Francesca; Veronese, Angelo] Univ G dAnnunzio, Ctr Adv Studies & Technol CAST, Chieti, Italy; [Chiacchiaretta, Piero] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Sinjari, Bruna; De Laurenzi, Vincenzo] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy; [Vecchiet, Jacopo; Falasca, Katia; Ucciferri, Claudio] Univ G dAnnunzio, Dept Med & Aging Sci, Chieti, Italy; [Vecchiet, Jacopo; Falasca, Katia; Ucciferri, Claudio] SS Annunziata Hosp, Clin Infect Dis, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Di Carlo, P (corresponding author), Univ G dAnnunzio, Dept Psychol Hlth & Terr Sci, Chieti, Italy.; Di Carlo, P (corresponding author), Univ G dAnnunzio, Ctr Adv Studies & Technol CAST, Chieti, Italy.	piero.dicarlo@unich.it	Chiacchiaretta, Piero/J-3972-2016; Sinjari, Bruna/AAG-5781-2019; Di Carlo, Piero/Q-4450-2016	Chiacchiaretta, Piero/0000-0003-1089-9809; Sinjari, Bruna/0000-0002-4444-3343; Di Carlo, Piero/0000-0003-4971-4509; DI TOMO, PAMELA/0000-0003-1995-3306; ARUFFO, ELEONORA/0000-0002-9164-7293; UCCIFERRI, Claudio/0000-0002-5866-3849	DISPUTER research funds	DISPUTER research funds	This work was partially supported by DISPUTER research funds. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Buonanno G., 2020, Environ Int, V141, P105794, DOI [DOI 10.1016/j.envint.2020.105794, 10.1016/j.envint.2020.105794]; Cheng SO, 2020, INT J SURG, V76, P71; Di Carlo P, 2020, NORMAL BREATHING REL; DPCM-Decree of the President of the Council of Ministers, 2020, GUID PUBL TRANSP; European Centre for Disease Prevention and Control, 2020, ANTIMICROBIAL RESIST; Faridi S, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138401; Hadei M, 2020, AEROSOL AIR QUAL RES, V20, P911, DOI 10.4209/aaqr.2020.04.0158; IHM-Italian Health Ministry, REP COR IT 2020; ISS-Istituto Superiore di Sanita, 2020, EP PUBL HLTH; Medicare.gov, 2022, COR DIS 2019 COVID 1; MIT- Minister of infrastructure and transport of the Italian Government, 2020, PROT SEC WORK PLAC T; Morawska L, 2020, ENVIRON INT, V139, DOI 10.1016/j.envint.2020.105730; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1101/2020.03.09.20033217, 10.1056/NEJMc2004973]; Vogels CBF, 2020, NAT MICROBIOL, V5, P1299, DOI 10.1038/s41564-020-0761-6	18	27	27	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2020	15	11							e0235943	10.1371/journal.pone.0235943	http://dx.doi.org/10.1371/journal.pone.0235943			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OU2PT	33151953	Green Submitted, Green Published, gold			2023-01-03	WOS:000591376200085
J	Montero-Ruiz, A; Fuentes, LA; Ruiz, EP; Soler, NGA; Rius-Diaz, F; Aguilera, PC; Frias, JP; Martin-Montanez, E				Montero-Ruiz, Alberto; Fuentes, Laura A.; Perez Ruiz, Estela; Garcia-Agua Soler, Nuria; Rius-Diaz, Francisca; Caro Aguilera, Pilar; Perez Frias, Javier; Martin-Montanez, Elisa			Effects of music therapy as an adjunct to chest physiotherapy in children with cystic fibrosis: A randomized controlled trial	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PHYSIOLOGICAL-RESPONSES; PREMATURE-INFANTS; ADHERENCE; DISTRESS; PEOPLE; ADOLESCENTS; WALKING; PAIN	Airway clearance therapy (ACT) is considered an important approach to improve airway clearance in children with cystic fibrosis (CF). Daily ACT administration requires substantial commitments of time and energy that complicate ACT and reduce its benefits. It is crucial to establish ACT as a positive routine. Music therapy (MT) is an aspect of integrative strategies to ameliorate the psycho-emotional consequences of chronic diseases, and a MT intervention could help children with CF between the ages of 2 and 17 develop a positive response. The aim of this randomized controlled trial was to evaluate the effects of specifically composed and recorded instrumental music as an adjunct to ACT. We compared the use of specifically composed music (Treated Group, TG), music that the patient liked (Placebo Group, PG), and no music (Control Group, CG) during the usual ACT routine in children with CF aged from 2 to 17. The primary outcomes, i.e., enjoyment and perception of time, were evaluated via validated questionnaires. The secondary outcome, i.e., efficiency, was evaluated in terms of avoided healthcare resources. Enjoyment increased after the use of the specifically composed music (children +0.9 units/parents +1.7 units; p<0.05) compared to enjoyment with no music (0 units) and familiar music (+0.5 units). Perception of time was 11.1 min (+/- 3.9) less than the actual time in the TG (p<0.05), 3.9 min (+/- 4.2) more than the actual time in the PG and unchanged in the CG. The potential cost saving related to respiratory exacerbations was euro6,704.87, while the cost increased to euro33,524.35 in the CG and to euro13,409.74 in the PG. In conclusion, the specifically composed, played and compiled instrumental recorded music is an effective adjunct to ACT to establish a positive response and is an efficient option in terms of avoided costs.	[Montero-Ruiz, Alberto; Fuentes, Laura A.; Perez Ruiz, Estela; Garcia-Agua Soler, Nuria; Caro Aguilera, Pilar; Perez Frias, Javier; Martin-Montanez, Elisa] Univ Malaga, Fac Med, Inst Invest Biomed Malaga, Dept Farmacol & Pediat, Malaga, Spain; [Montero-Ruiz, Alberto] Junta Andalucia, Consejeria Educ, Malaga, Spain; [Perez Ruiz, Estela; Caro Aguilera, Pilar; Perez Frias, Javier] Hosp Reg Univ Malaga, Secc Neumol Pediat, Malaga, Spain; [Rius-Diaz, Francisca] Univ Malaga, Fac Med, Dept Med Prevent & Salud Publ, Malaga, Spain	Universidad de Malaga; Universidad de Malaga	Frias, JP; Martin-Montanez, E (corresponding author), Univ Malaga, Fac Med, Inst Invest Biomed Malaga, Dept Farmacol & Pediat, Malaga, Spain.	jpf@uma.es; emartinm@uma.es	Martín-Montañez, Elisa/H-8999-2017	Martín-Montañez, Elisa/0000-0002-3637-3285	Consejeria de Salud de la Junta de Andalucia [PIN-0342-2016]; Plan Propio de Investigacion de la Universidad de Malaga	Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Plan Propio de Investigacion de la Universidad de Malaga	This research was supported by the project PIN-0342-2016 from Consejeri ' a de Salud de la Junta de Andaluci ' a and Plan Propio de Investigacio ' n de la Universidad de Ma ' laga. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler FR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156752; Albi G, 2012, RADIOLOGIA-MADRID, V54, P260, DOI 10.1016/j.rx.2011.04.007; Alexander S, 2017, ROYAL BROMPTON HAREF, V7th; Alvin J., 1997, MUSIC THERAPY; [Anonymous], 2014, CLIN CHEM LAB MED, V52, pS42; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2000, J CONSUMER RES, V29, P371; Bauldoff Gerene S, 2005, J Cardiopulm Rehabil, V25, P50, DOI 10.1097/00008483-200501000-00011; Bauldoff GS, 2002, CHEST, V122, P948, DOI 10.1378/chest.122.3.948; Bausewein C, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub3; Brown SD, 2017, JAAPA-J AM ACAD PHYS, V30, P23, DOI 10.1097/01.JAA.0000515540.36581.92; Calcaterra V, 2014, PEDIATRIC REP, V6, P44, DOI 10.4081/pr.2014.5534; Calik-Kutukcu E, 2016, COMPLEMENT THER CLIN, V23, P52, DOI 10.1016/j.ctcp.2016.03.002; Canga B, 2015, RESP MED, V109, P1532, DOI 10.1016/j.rmed.2015.10.001; Caparros-Gonzalez RA, 2018, ADV NEONAT CARE, V18, P58, DOI 10.1097/ANC.0000000000000448; Cassidy JW, 2009, J MUSIC THER, V46, P180, DOI 10.1093/jmt/46.3.180; Downs J A, 2006, Chron Respir Dis, V3, P19, DOI 10.1191/1479972306cd100oa; 2019, J AM COLL RADIOL, V16, pS141, DOI 10.1016/j.jacr.2019.02.015; Fernandez Batanero JM CFJ, 2016, MUSIC THERAPY SOCIAL, V38, P163; Gagnon L, 2003, COGNITION EMOTION, V17, P25, DOI 10.1080/02699930302279; Garcia Sanz E., 1989, REV INTERUNIV FORM P, P91; Goodfellow NA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0038-7; Hartling L, 2013, JAMA PEDIATR, V167, P826, DOI 10.1001/jamapediatrics.2013.200; Ho CF, 2012, COPD, V9, P447, DOI 10.3109/15412555.2012.685664; Irons JY, 2013, INT J THER REHABIL, V20, P144, DOI 10.12968/ijtr.2013.20.3.144; Irons JY., 2012, MUSIC MED, V4, P136, DOI [10.1177/1943862112452150, DOI 10.1177/1943862112452150]; Juslin PN, 2004, J NEW MUSIC RES, V33, P217, DOI 10.1080/0929821042000317813; Kaak I, 2011, PT Z PHYSIOTHERAPEUT, V63, P6; Karolyi O, 2012, INTRO MUSIC; Konstan MW, 2010, J CYST FIBROS, V9, P332, DOI 10.1016/j.jcf.2010.05.004; Lord VM, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-69; Loyola Elizondo E, 2006, SALHVXSPMVFECSC EPID; Malone AB, 1996, J MUSIC THER, V33, P19, DOI 10.1093/jmt/33.1.19; Marwah N, 2005, J Indian Soc Pedod Prev Dent, V23, P168; McNamara RJ, 2019, J THORAC DIS, V11, pS2192, DOI 10.21037/jtd.2019.10.29; McNamara RJ, 2015, PHYSIOTHERAPY, V101, P187, DOI 10.1016/j.physio.2014.09.002; Ministry of Health Social Services and Equality, AN DEV DRGS NAT HLTH; Modi AC, 2006, J PEDIATR PSYCHOL, V31, P846, DOI 10.1093/jpepsy/jsj096; Nicolais CJ, 2019, J CLIN PSYCHOL MED S, V26, P530, DOI 10.1007/s10880-018-9598-z; Noguchi LK, 2006, J MUSIC THER, V43, P16, DOI 10.1093/jmt/43.1.16; Nordoff P, 2006, MUSIC THERAPY SPECIA, DOI [10.1177/1359104506061418, DOI 10.1177/1359104506061418]; O'Sullivan BP, 2009, LANCET, V373, P1891, DOI 10.1016/S0140-6736(09)60327-5; Panigrahi A, 2014, TECHNOL HEALTH CARE, V22, P53, DOI 10.3233/THC-130773; Quittner AL, 2016, CURR OPIN PULM MED, V22, P187, DOI 10.1097/MCP.0000000000000244; Sawicki GS, 2015, PEDIATR PULM, V50, P127, DOI 10.1002/ppul.23017; Skingley A, 2018, PERSPECT PUBLIC HEAL, V138, P66, DOI 10.1177/1757913917740930; Smith BA, 2010, PEDIATR PULM, V45, P756, DOI 10.1002/ppul.21238; Smyth AR, 2014, J CYST FIBROS, V13, pS23, DOI 10.1016/j.jcf.2014.03.010; Szczesniak R, 2017, J CYST FIBROS, V16, P318, DOI 10.1016/j.jcf.2017.01.002; Wade L. M, 2002, MUSIC THERAPY PERSPE, V20, P31, DOI [10.1093/mtp/20.1.31, DOI 10.1093/MTP/20.1.31]; Warnock L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001401.pub3; Wilson LM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011231.pub2; Zanni RL, 2014, BMJ QUAL SAF, V23, P50, DOI 10.1136/bmjqs-2013-002352; 2011, CHIN J FRONT MED SCI, V3, P42	54	2	2	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2020	15	10							e0241334	10.1371/journal.pone.0241334	http://dx.doi.org/10.1371/journal.pone.0241334			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8VN	33125399	Green Published, gold			2023-01-03	WOS:000588368900029
J	Anand, S; Montez-Rath, M; Han, JL; Bozeman, J; Kerschmann, R; Beyer, P; Parsonnet, J; Chertow, GM				Anand, Shuchi; Montez-Rath, Maria; Han, Jialin; Bozeman, Julie; Kerschmann, Russell; Beyer, Paul; Parsonnet, Julie; Chertow, Glenn M.			Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study	LANCET			English	Article							STAGE RENAL-DISEASE; CHI-SQUARED TESTS; RACIAL-DIFFERENCES; POVERTY; AVAILABILITY; RISK	Background Many patients receiving dialysis in the USA share the socioeconomic characteristics of underserved communities, and undergo routine monthly laboratory testing, facilitating a practical, unbiased, and repeatable assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Methods For this cross-sectional study, in partnership with a central laboratory that receives samples from approximately 1300 dialysis facilities across the USA, we tested the remainder plasma of 28 503 randomly selected adult patients receiving dialysis in July, 2020, using a spike protein receptor binding domain total antibody chemiluminescence assay (100% sensitivity, 99.8% specificity). We extracted data on age, sex, race and ethnicity, and residence and facility ZIP codes from the anonymised electronic health records, linking patient-level residence data with cumulative and daily cases and deaths per 100 000 population and with nasal swab test positivity rates. We standardised prevalence estimates according to the overall US dialysis and adult population, and present estimates for four prespecified strata (age, sex, region, and race and ethnicity). Findings The sampled population had similar age, sex, and race and ethnicity distribution to the US dialysis population, with a higher proportion of older people, men, and people living in majority Black and Hispanic neighbourhoods than in the US adult population. Seroprevalence of SARS-CoV-2 was 8.0% (95% CI 7.7-8.4) in the sample, 8.3% (8.0-8.6) when standardised to the US dialysis population, and 9.3% (8.8-9.9) when standardised to the US adult population. When standardised to the US dialysis population, seroprevalence ranged from 3.5% (3.1-3.9) in the west to 27.2% (25.9-28.5) in the northeast. Comparing seroprevalent and case counts per 100 000 population, we found that 9.2% (8.7-9.8) of seropositive patients were diagnosed. When compared with other measures of SARS-CoV-2 spread, seroprevalence correlated best with deaths per 100 000 population (Spearman's p=0.77). Residents of non-Hispanic Black and Hispanic neighbourhoods experienced higher odds of seropositivity (odds ratio 3.9 [95% CI 3.4-4.6] and 2.3 [1.9-2.6], respectively) compared with residents of predominantly non-Hispanic white neighbourhoods. Residents of neighbourhoods in the highest population density quintile experienced increased odds of seropositivity (10.3 [8.7-12.2]) compared with residents of the lowest density quintile. County mobility restrictions that reduced workplace visits by at least 5% in early March, 2020, were associated with lower odds of seropositivity in July, 2020 (0.4 [0.3-0.5]) when compared with a reduction of less than 5%. Interpretation During the first wave of the COVID-19 pandemic, fewer than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed. Public health efforts to limit SARS-CoV-2 spread need to especially target racial and ethnic minority and densely populated communities. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Anand, Shuchi; Montez-Rath, Maria; Han, Jialin; Chertow, Glenn M.] Stanford Univ, Div Nephrol, Palo Alto, CA 94304 USA; [Parsonnet, Julie] Stanford Univ, Div Infect Dis & Geog Med, Palo Alto, CA 94304 USA; [Parsonnet, Julie; Chertow, Glenn M.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA; [Parsonnet, Julie; Chertow, Glenn M.] Stanford Univ, Dept Epidemiol & Populat Hlth, Palo Alto, CA 94304 USA; [Bozeman, Julie; Kerschmann, Russell; Beyer, Paul] Ascend Clin Lab, Redwood City, CA USA	Stanford University; Stanford University; Stanford University; Stanford University	Anand, S (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA.	sanand2@stanford.edu	Han, Jialin/AFQ-6523-2022	Parsonnet, Julie/0000-0001-7342-5366; Chertow, Glenn/0000-0002-7599-0534	Ascend Clinical Laboratories	Ascend Clinical Laboratories	Ascend Clinical Laboratories.	Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030; Bao YR, 2012, ARCH INTERN MED, V172, P1071, DOI 10.1001/archinternmed.2012.3020; Baqui P, 2020, LANCET GLOB HEALTH, V8, P1018, DOI 10.1016/S2214-109X(20)30285-0; Benatia D, 2020, ESTIMATING COVID 19, DOI [10.1101/2020.04.20.20072942v1, DOI 10.1101/2020.04.20.20072942V1]; Bendavid E., 2020, COVID 19 ANTIBODY SE, P1, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]; Bower KM, 2014, PREV MED, V58, P33, DOI 10.1016/j.ypmed.2013.10.010; Brugger SD, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005633; Caturegli G, 2020, ANN INTERN MED, V173, P614, DOI 10.7326/M20-2889; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Centers for Disease Control and Prevention, COVIDVIEW WEEKL SURV; Choi AI, 2009, AM J MED, V122, P672, DOI 10.1016/j.amjmed.2008.11.021; Clarke C, 2020, J AM SOC NEPHROL, V31, P1969, DOI 10.1681/ASN.2020060827; Cowger TL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16933; Crews DC, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-192; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Edey M, 2010, NEPHROLOGY, V15, P137, DOI 10.1111/j.1440-1797.2009.01268.x; Erickson KF, 2018, CLIN J AM SOC NEPHRO, V13, P265, DOI 10.2215/CJN.06470617; Frankel M, 2010, HANDBOOK OF SURVEY RESEARCH, 2ND EDITION, P83; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Havers FP, 2020, JAMA INTERN MED, V180, P1576, DOI 10.1001/jamainternmed.2020.4130; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; Hsu CY, 2003, J AM SOC NEPHROL, V14, P2902, DOI 10.1097/01.ASN.0000091586.46532.B4; Hung IFN, 2020, LANCET INFECT DIS, V20, P1051, DOI 10.1016/S1473-3099(20)30364-9; Kolenikov SJ, 2016, SURVEY PRACTICE, V9, P1; Koopmans M, 2020, NAT MED, V26, P1171, DOI 10.1038/s41591-020-1018-x; KORN EL, 1999, WILEY S PRO STAT SUR, P1; Liu WB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00461-20; Moore LV, 2008, AM J PREV MED, V34, P16, DOI 10.1016/j.amepre.2007.09.021; Payne DC, 2020, MMWR-MORBID MORTAL W, V69, P714, DOI 10.15585/mmwr.mm6923e4externalicon; Peeling RW, 2020, LANCET INFECT DIS, V20, pE245, DOI 10.1016/S1473-3099(20)30517-X; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Public Health England, 2020, EV SENS SPEC 4 COMM; RAO JNK, 1981, J AM STAT ASSOC, V76, P221, DOI 10.2307/2287815; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa038; Rosenberg ES, 2020, ANN EPIDEMIOL, V48, P23, DOI 10.1016/j.annepidem.2020.06.004; Sakurai A, 2020, NEW ENGL J MED, V383, P885, DOI 10.1056/NEJMc2013020; Schnurra C, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104544; Sood N, 2020, JAMA-J AM MED ASSOC, V323, P2425, DOI 10.1001/jama.2020.8279; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Sy Karla Therese L, 2020, medRxiv, DOI 10.1101/2020.06.12.20130021; United States Renal Data System, 2019, 2018 ANN DAT REP EP; US Food and Drug Administration, EUA AUTH SER TEST PR; US Food & Drug Administration, 2020, STUD ANT RESP SARS C; Utah Department of Health, OV COVID 19 SURV; Volkova N, 2008, J AM SOC NEPHROL, V19, P356, DOI 10.1681/ASN.2006080934; Ward H., 2020, ANTIBODY PREVALENCE, DOI [10.1101/2020.08.12.20173690, DOI 10.1101/2020.08.12.20173690]; Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548	49	171	171	4	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2020	396	10259					1335	1344		10.1016/S0140-6736(20)32009-2	http://dx.doi.org/10.1016/S0140-6736(20)32009-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OF2SS	32987007	Green Published, Bronze			2023-01-03	WOS:000581064900029
J	Chen, H; Libring, S; Ruddraraju, KV; Miao, JM; Solorio, L; Zhang, ZY; Wendt, MK				Chen, Hao; Libring, Sarah; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.			SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; ANTITUMOR IMMUNITY; KINASE INHIBITOR; ACTIVATION; CELLS; NERATINIB; PHOSPHORYLATION; MECHANISM; SUBSETS	Metastatic breast cancer (MBC) is an extremely recalcitrant disease capable of bypassing current targeted therapies via engagement of several growth promoting pathways. SH2 containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase known to facilitate growth and survival signaling downstream of numerous receptor inputs. Herein, we used inducible genetic depletion and two distinct pharmacological inhibitors to investigate the therapeutic potential of targeting SHP2 in MBC. Cells that acquired resistance to the ErbB kinase inhibitor, neratinib, displayed increased phosphorylation of SHP2 at the Y542 activation site. In addition, higher levels of SHP2 phosphorylation, but not expression, were associated with decreased survival of breast cancer patients. Pharmacological inhibition of SHP2 activity blocked ERK1/2 and AKT signaling generated from exogenous stimulation with FGF2, PDGF, and hGF and readily prevented MBC cell growth induced by these factors. SHP2 was also phosphorylated upon engagement of the extracellular matrix (ECM) via focal adhesion kinase. Consistent with the potential of SHP2-targeted compounds as therapeutic agents, the growth inhibitory property of SHP2 blockade was enhanced in ECM-rich 3D culture environments. In vivo blockade of SHP2 in the adjuvant setting decreased pulmonary metastasis and extended the survival of systemic tumor-bearing mice. Finally, inhibition of SHP2 in combination with FGFR-targeted kinase inhibitors synergistically blocked the growth of MBC cells. Overall, our findings support the conclusion that SHP2 constitutes a shared signaling node allowing MBC cells to simultaneously engage a diversity of growth and survival pathways, including those derived from the ECM.	[Chen, Hao; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Libring, Sarah; Solorio, Luis] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA; [Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wendt, MK (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.; Wendt, MK (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	mwendt@purdue.edu	Miao, Jinmin/AAU-8461-2021; Ruddraraju, Kasi Viswanatharaju/D-2384-2016	Ruddraraju, Kasi Viswanatharaju/0000-0002-5614-720X; Wendt, Mike/0000-0002-3665-7413; Libring, Sarah/0000-0001-8336-5862; Chen, Hao/0000-0002-2070-5062	National Cancer Institute [R01CA207751, RO1CA207288]; Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant [RSG-CSM-130259]; SIRG Graduate Research Assistantships Award [P30CA023168]; Purdue University Center for Cancer Research	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant(American Cancer Society); SIRG Graduate Research Assistantships Award; Purdue University Center for Cancer Research	This work was supported by National Cancer Institute (R01CA207751), Metavivor Foundation Translation Research Award, and American Cancer Society Research Scholar Grant (RSG-CSM-130259) to MKW and National Cancer Institute (RO1CA207288) to ZYZ. We gratefully acknowledge the SIRG Graduate Research Assistantships Award (P30CA023168) and the support from the Purdue University Center for Cancer Research. We thank Dr. Jill E. Hutchcroft, Dr. Wen-Hung Wang, and Flow Cytometry and Cell Separation Core Facility at Bindley Bioscience Center, Purdue University for technical support. We also thank Saeed Salehin Akhand, Hang Lin, Juan Sebastian Paez and other members at Wendt Lab for technical support.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Ahmed TA, 2019, CELL REP, V26, P65, DOI 10.1016/j.celrep.2018.12.013; Alexander PB, 2017, J BIOL CHEM, V292, P748, DOI 10.1074/jbc.M116.754960; ALI R, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Brown WS, 2016, ONCOTARGET, V7, P83424, DOI 10.18632/oncotarget.13117; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Koyama T, 2008, J BIOL CHEM, V283, P24234, DOI 10.1074/jbc.M803907200; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Liu W, 2017, LEUKEMIA, V31, P1415, DOI 10.1038/leu.2016.326; Mariotto AB, 2017, CANCER EPIDEM BIOMAR, V26, P809, DOI [10.1158/1055-9965.EPI-16-0889, 10.1158/1055-9965.epi-16-0889]; Martin M, 2017, LANCET ONCOL, V18, P1688, DOI 10.1016/S1470-2045(17)30717-9; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Palakurthi S, 2019, CANCER IMMUNOL RES, V7, P1457, DOI 10.1158/2326-6066.CIR-18-0595; Pulaski BA, 2000, CURR PROTOC IMMUNOL, V39, P20; Ran H, 2016, CANCER CELL, V30, P194, DOI 10.1016/j.ccell.2016.07.010; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sun J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3037; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wei T., 2017, STATISTICIAN, V56, pe24; Wendt MK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3623; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Ye TH, 2014, BREAST CANCER RES TR, V143, P435, DOI 10.1007/s10549-013-2829-y; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zeng LF, 2014, J MED CHEM, V57, P6594, DOI 10.1021/jm5006176; Zhang RY, 2016, ONCOTARGET, V7, P73817, DOI 10.18632/oncotarget.12074; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhao H, 2019, ONCOGENE, V38, P2275, DOI 10.1038/s41388-018-0574-8; Zhao MX, 2019, ACTA PHARM SIN B, V9, P304, DOI 10.1016/j.apsb.2018.08.009; Zhou B, 2014, MOL CANCER RES, V12, P143, DOI 10.1158/1541-7786.MCR-13-0184	53	12	12	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7166	7180		10.1038/s41388-020-01488-5	http://dx.doi.org/10.1038/s41388-020-01488-5		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33033382	hybrid, Green Published			2023-01-03	WOS:000576873200001
J	Elser, H; Kiang, MV; John, EM; Simard, JF; Bondy, M; Nelson, LM; Chen, WT; Linos, E				Elser, Holly; Kiang, Mathew V.; John, Esther M.; Simard, Julia F.; Bondy, Melissa; Nelson, Lorene M.; Chen, Wei-ting; Linos, Eleni			The Impact of the first COVID-19 shelter-in-place announcement on social distancing, difficulty in daily activities, and levels of concern in the San Francisco Bay Area: A cross-sectional social media survey	PLOS ONE			English	Article								Background The U.S. has experienced an unprecedented number of orders to shelter in place throughout the ongoing COVID-19 pandemic. We aimed to ascertain whether social distancing; difficulty with daily activities; and levels of concern regarding COVID-19 changed after the March 16, 2020 announcement of the nation's first shelter-in-place orders (SIPO) among individuals living in the seven affected counties in the San Francisco Bay Area. Methods We conducted an online, cross-sectional social media survey from March 14 -April 1, 2020. We measured changes in social distancing behavior; experienced difficulties with daily activities (i.e., access to healthcare, childcare, obtaining essential food and medications); and level of concern regarding COVID-19 after the March 16 shelter-in-place announcement in the San Francisco Bay Area versus elsewhere in the U.S. Results In this non-representative sample, the percentage of respondents social distancing all of the time increased following the shelter-in-place announcement in the Bay Area (9.2%, 95% CI: 6.6, 11.9) and elsewhere in the U.S. (3.4%, 95% CI: 2.0, 5.0). Respondents also reported increased difficulty obtaining hand sanitizer, medications, and in particular respondents reported increased difficulty obtaining food in the Bay Area (13.3%, 95% CI: 10.4, 16.3) and elsewhere (8.2%, 95% CI: 6.6, 9.7). We found limited evidence that level of concern regarding the COVID-19 crisis changed following the announcement. Conclusion This study characterizes early changes in attitudes, behaviors, and difficulties. As states and localities implement, rollback, and reinstate shelter-in-place orders, ongoing efforts to more fully examine the social, economic, and health impacts of COVID-19, especially among vulnerable populations, are urgently needed.	[Elser, Holly] Stanford Univ, Stanford Med Sch, Stanford, CA 94305 USA; [Elser, Holly; Kiang, Mathew V.] Stanford Univ, Ctr Populat Hlth Sci, Stanford, CA 94305 USA; [Kiang, Mathew V.; John, Esther M.; Simard, Julia F.; Bondy, Melissa; Nelson, Lorene M.; Linos, Eleni] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Chen, Wei-ting] Stanford Univ, Off Community Engagement, Stanford, CA 94305 USA; [Linos, Eleni] Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Linos, E (corresponding author), Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA.; Linos, E (corresponding author), Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA.	linos@stanford.edu	Kiang, Mathew/J-5390-2019	Kiang, Mathew/0000-0001-9198-150X	NIH [DP2CA225433, K24AR075060]; National Institute on Drug Abuse [T32DA035165]; Clinical and Translational Science Award Program of the National Institutes of Health's National Center for Advancing Translational Science [UL1 TR001085]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Clinical and Translational Science Award Program of the National Institutes of Health's National Center for Advancing Translational Science	EL is supported by the NIH (grants DP2CA225433 and K24AR075060). MVK is supported by the National Institute on Drug Abuse (T32DA035165). LMN is supported by the Clinical and Translational Science Award Program of the National Institutes of Health's National Center for Advancing Translational Science (UL1 TR001085). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Abouk R, 2021, PUBLIC HEALTH REP, V136, P245, DOI 10.1177/0033354920976575; Allday, 2020, LOCAL POLITICS WEB S; Angrist J., 2000, HDB LABOR EC, V3, P1277, DOI DOI 10.1016/S1573-4463(99)03004-7; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; [Anonymous], 2002, Bull World Health Organ, V80, P983; Badr HS, 2020, LANCET INFECT DIS, V20, P1247, DOI 10.1016/S1473-3099(20)30553-3; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Baker, 2020, ASS STATE LEVEL PHYS; Beland L.-P., 2020, 13159 IZA; Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008; Bui Q, 2020, THERE IS PLENTY FOOD; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; CHANG HH, 2020, AM J AGR ECON, DOI DOI 10.1111/AJAE.12158; Dave, 2020, 27522 NBER; Dave D, 2020, W26992 NBER; Dave D.M., 2020, BLACK LIVES MATTER P, DOI [DOI 10.3386/W27408, 10.3386/w27408]; Dave D, 2021, SOUTH ECON J, V87, P769, DOI 10.1002/soej.12475; Dave D, 2021, ECON INQ, V59, P29, DOI 10.1111/ecin.12944; Domonoske, 2020, EMPTY GROCERY SHELVE; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Fairlie R.W., 2020, 27246 NBER; Faria-e-Castro M, 2020, BACK OF THE ENVELOPE; Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460; Gratz KL, 2020, SUICIDE LIFE-THREAT, V50, P1140, DOI 10.1111/sltb.12654; Gupta S, 2020, TRACKING PUBLIC PRIV, DOI [10.3386/w27027, DOI 10.3386/W27027]; Imperial College London, 2020, 13 IMP COLL LOND; Kamerow D, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1367; Kauffman BY, 2022, J AM COLL HEALTH, V70, P478, DOI 10.1080/07448481.2020.1754223; Kishore N, 2020, LANCET DIGIT HEALTH, V2, pE622, DOI 10.1016/S2589-7500(20)30193-X; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0; Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]; Lyu W, 2020, HEALTH AFFAIR, V39, P1615, DOI 10.1377/hlthaff.2020.00719; Marroquin B, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113419; Puhani PA, 2012, ECON LETT, V115, P85, DOI 10.1016/j.econlet.2011.11.025; Richardson S, 2020, JAMA, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775]; Swales V, SEE WHICH STATES CIT, V1, P2020; Tan CC, 2006, ANN ACAD MED SINGAP, V35, P345; The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P1, DOI DOI 10.5194/GCHRON-2-1-2020; U.S. Department of Housing and Urban Development, 2020, HUD USPS ZIP COD CRO; United States Census Bureau, 2020, CART BOUND FIL SHAP; van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Weill JA, 2020, P NATL ACAD SCI USA, V117, P19658, DOI 10.1073/pnas.2009412117; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2020, PNEUM UNKN CAUS CHIN; WHO (World Health Organization), 2020, CONS QUAR IND CONT C; World Health Organization (WHO), 2020, Q COR COVID 19; Yaffe-Bellany, 2020, US FOOD SUPPLY CHAIN; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Yang, 2020, COVID 19 PREVENTION, P898; Zhang, 2020, RAPID ASSESSMENT PSY; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	55	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 14	2021	16	1							e0244819	10.1371/journal.pone.0244819	http://dx.doi.org/10.1371/journal.pone.0244819			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PV4VV	33444363	Green Published, gold			2023-01-03	WOS:000609988100095
J	Cho, P; Cheung, SW; Boost, MV				Cho, Pauline; Cheung, Sin Wan; Boost, Maureen V.			Categorisation of myopia progression by change in refractive error and axial elongation and their impact on benefit of myopia control using orthokeratology	PLOS ONE			English	Article							ATROPINE; CHILDREN; LENGTH; TRIAL; ONSET; GUIDELINES; IMI	Aims To compare the value of pre-treatment axial elongation (AE) and changes in refractive sphere (M change) for predicting the success in orthokeratology (ortho-k), in order to better identify suitable candidates for myopia control. Methods This study further analysed the data of 66 subjects receiving 7-month ortho-k treatment, following a 7-month observation period, during which single-vision spectacles were worn. Rate of myopia progression was determined by AE and M change and subjects categorised as slow, moderate, or rapid progressors based on these changes. Outcomes of myopia control, based on the AE reduction after ortho-k, were classified as 'ineffectual', 'clinically insignificant', or 'beneficial'. Results Of the 20 subjects, initially categorised as slow by AE and, of whom 95% were similarly categorised by M change, none benefitted from ortho-k. In contrast, of the 22 subjects with moderate AE, 77% and 23% displaying slow and moderate M change, respectively, the majority (73%) benefitted from ortho-k lens wear. The 24 subjects with rapid AE were poorly identified by M change, with only 21% correctly categorised. The vast majority of rapid progressors showed significant benefit after ortho-k. Conclusion Progression of AE is a good indicator of subsequent success of ortho-k treatment. Delaying commencement of therapy is prudent for children with slow progression as results indicate that they would be unlikely to benefit from this intervention. As change in refractive error frequently underestimates rapid progression of AE, its value for identifying appropriate candidates for myopia control is poor.	[Cho, Pauline; Cheung, Sin Wan; Boost, Maureen V.] Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Peoples R China	Hong Kong Polytechnic University	Cheung, SW (corresponding author), Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Peoples R China.	peggy.cheung@polyu.edu.hk			PolyU and Menicon Co. Ltd, Japan [ZG50, ZG7X]	PolyU and Menicon Co. Ltd, Japan	This study was supported by Collaborative Research Agreements between PolyU and Menicon Co. Ltd, Japan (Pauline Cho; ZG50, ZG7X) (http://www.menicon.com).The sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.	Charm J, 2013, OPTOMETRY VISION SCI, V90, P530, DOI 10.1097/OPX.0b013e318293657d; Chen CN, 2013, INVEST OPHTH VIS SCI, V54, P6510, DOI 10.1167/iovs.13-12527; Cheng D, 2010, ARCH OPHTHALMOL-CHIC, V128, P12, DOI 10.1001/archophthalmol.2009.332; Cheung SW, 2019, CONTACT LENS ANTERIO, V42, P392, DOI 10.1016/j.clae.2018.10.006; Chia A, 2016, OPHTHALMOLOGY, V123, P391, DOI 10.1016/j.ophtha.2015.07.004; Cho P, 2019, CLIN EXP OPTOM, V102, P364, DOI 10.1111/cxo.12839; Cho P, 2012, INVEST OPHTH VIS SCI, V53, P7077, DOI 10.1167/iovs.12-10565; Dong LM, 2013, INVEST OPHTH VIS SCI, V54, P7871, DOI 10.1167/iovs.13-12403; Driffield T, 2007, MED DECIS MAKING, V27, P178, DOI 10.1177/0272989X06297390; Fang PC, 2010, J OCUL PHARMACOL TH, V26, P341, DOI 10.1089/jop.2009.0135; Flitcroft DI, 2019, INVEST OPHTH VIS SCI, V60, pM20, DOI 10.1167/iovs.18-25957; Gifford KL, 2019, INVEST OPHTH VIS SCI, V60, pM184, DOI 10.1167/iovs.18-25977; Hiraoka T, 2012, INVEST OPHTH VIS SCI, V53, P3913, DOI 10.1167/iovs.11-8453; Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006; Hsu CC, 2017, BRIT J OPHTHALMOL, V101, P1611, DOI 10.1136/bjophthalmol-2016-309299; Jiang ZP, 2013, EYE CONTACT LENS, V39, P277, DOI 10.1097/ICL.0b013e318296790b; Kesarwani SS, 2019, INDIAN J OPHTHALMOL, V67, P461, DOI 10.4103/ijo.IJO_1457_18; Lam CSY, 2020, BRIT J OPHTHALMOL, V104, P363, DOI 10.1136/bjophthalmol-2018-313739; Lam CSY, 2014, BRIT J OPHTHALMOL, V98, P40, DOI 10.1136/bjophthalmol-2013-303914; Morgan I, 2005, PROG RETIN EYE RES, V24, P1, DOI 10.1016/j.preteyeres.2004.06.004; Morgan IG, 2018, PROG RETIN EYE RES, V62, P134, DOI 10.1016/j.preteyeres.2017.09.004; Mutti DO, 2007, INVEST OPHTH VIS SCI, V48, P2510, DOI 10.1167/iovs.06-0562; Paune J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/507572; Rabbetts RB, 2007, BENNETT RABBETTS CLI, P425; Ruiz-Pomeda A, 2018, GRAEF ARCH CLIN EXP, V256, P1011, DOI 10.1007/s00417-018-3906-z; Sankaridurg P, 2019, OPHTHAL PHYSL OPT, V39, P294, DOI 10.1111/opo.12621; Santodomingo-Rubido J, 2012, INVEST OPHTH VIS SCI, V53, P5060, DOI 10.1167/iovs.11-8005; Swarbrick HA, 2015, OPHTHALMOLOGY, V122, P620, DOI 10.1016/j.ophtha.2014.09.028; Wolffsohn JS, 2020, CONTACT LENS ANTERIO, V43, P9, DOI 10.1016/j.clae.2019.11.002; Wu PC, 2019, EYE, V33, P3, DOI 10.1038/s41433-018-0139-7; Wu PC, 2016, ASIA-PAC J OPHTHALMO, V5, P386, DOI 10.1097/APO.0000000000000236; Yam JC, 2019, OPHTHALMOLOGY, V126, P113, DOI 10.1016/j.ophtha.2018.05.029; Zadnik K, 2015, JAMA OPHTHALMOL, V133, P683, DOI 10.1001/jamaophthalmol.2015.0471; Zhao JL, 2004, OPTOMETRY VISION SCI, V81, P49, DOI 10.1097/00006324-200401000-00010	34	3	3	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2020	15	12							e0243416	10.1371/journal.pone.0243416	http://dx.doi.org/10.1371/journal.pone.0243416			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BU	33373370	gold, Green Published			2023-01-03	WOS:000603612300059
J	Ono, A; Ishikane, M; Kusama, Y; Tanaka, C; Ono, S; Tsuzuki, S; Muraki, Y; Yamasaki, D; Tanabe, M; Ohmagari, N				Ono, Akane; Ishikane, Masahiro; Kusama, Yoshiki; Tanaka, Chika; Ono, Sachiko; Tsuzuki, Shinya; Muraki, Yuichi; Yamasaki, Daisuke; Tanabe, Masaki; Ohmagari, Norio			The first national survey of antimicrobial use among dentists in Japan from 2015 to 2017 based on the national database of health insurance claims and specific health checkups of Japan	PLOS ONE			English	Article							DENTAL PRACTITIONERS; UNITED-STATES	Purpose To counter the global health threat of antimicrobial resistance, effective antimicrobial stewardship programs are needed to improve antimicrobial use (AMU) among dentists in addition to physicians. This study aimed to investigate the nationwide epidemiology of AMU among Japanese dentists to facilitate the development of dentist-centered programs. Methods We conducted a retrospective population-based study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan to analyze the AMU among Japanese dentists between 2015 and 2017. AMU was quantified as the defined daily doses per 1,000 inhabitants per day (DID). The trends in dentist-prescribed AMU were examined according to antimicrobial category and administration route. We also compared outpatient oral AMU between dentists and physicians as well as between on-site and off-site dispensing. Results The DID values of dentist-prescribed AMU were 1.23 in 2015, 1.22 in 2016, and 1.21 in 2017. During this study period, outpatient oral antimicrobials comprised the majority (approximately 99%) of dentist-prescribed AMU, and cephalosporins were the most frequently prescribed antimicrobials (>60% of all antimicrobials). The DID values of outpatient oral AMU were 1.21 for dentists and 12.11 for physicians. The DID value for on-site dispensing was 0.89 in 2017, in which cephalosporins were the predominantly used antimicrobials (DID: 0.60). Conclusions Interventions that target dentists in Japan should focus on on-site dispensing of oral antimicrobials (especially cephalosporins) for outpatients. Further studies are needed to ascertain the underlying factors of oral cephalosporin prescriptions to guide the development of effective antimicrobial stewardship programs.	[Ono, Akane; Ishikane, Masahiro; Kusama, Yoshiki; Tanaka, Chika; Tsuzuki, Shinya; Ohmagari, Norio] Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan; [Ishikane, Masahiro; Tanaka, Chika; Ohmagari, Norio] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan; [Ono, Sachiko] Univ Tokyo, Dept Eat Loss Med, Tokyo, Japan; [Muraki, Yuichi] Kyoto Pharmaceut Univ, Dept Clin Pharmacoepidemiol, Kyoto, Japan; [Yamasaki, Daisuke; Tanabe, Masaki] Mie Univ Hosp, Dept Infect Control & Prevent, Tsu, Mie, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; University of Tokyo; Kyoto Pharmaceutical University; Mie University	Kusama, Y (corresponding author), Natl Ctr Global Hlth & Med, AMR Clin Reference Ctr, Tokyo, Japan.	stone.bagle@gmail.com	Ohmagari, Norio/GLN-5290-2022; Tsuzuki, Shinya/S-7286-2019; Ono, Sachiko/HIZ-5537-2022; MURAKI, Yuichi/AAI-1961-2021; Tsuzuki, Shinya/S-7286-2019	Ohmagari, Norio/0000-0002-4622-8970; Tsuzuki, Shinya/0000-0002-8504-1244; Ono, Sachiko/0000-0003-4378-2578; MURAKI, Yuichi/0000-0001-6951-5676; Tsuzuki, Shinya/0000-0001-5732-846X; Ishikane, Masahirio/0000-0002-4719-651X; Kusama, Yoshiki/0000-0002-7072-2338	Ministry of Health, Labour and Welfare of Japan [20HA2003]	Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This study was supported by a research grant from the Ministry of Health, Labour and Welfare of Japan (Grant Number: 20HA2003).	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; AMR Clinical Reference Center, 2018, ANT US SURV BAS NDB; [Anonymous], 2020, J THORAC ONCOL, V13, pS322, DOI 10.1016/j.jtho.2018.08.241; Durkin MJ, 2017, J AM DENT ASSOC, V148, P878, DOI 10.1016/j.adaj.2017.07.019; Gross AE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz067; Halling F, 2017, J CRANIO MAXILL SURG, V45, P1854, DOI 10.1016/j.jcms.2017.08.010; Hicks LA, 2013, NEW ENGL J MED, V369, P1175, DOI 10.1056/NEJMc1306863; Hicks LA, 2013, NEW ENGL J MED, V368, P1461, DOI 10.1056/NEJMc1212055; Japanese Assoc Infect Dis Japanese, 2018, J INFECT CHEMOTHER, V24, P320, DOI 10.1016/j.jiac.2017.09.014; Kano Y, 2019, INFECT CONT HOSP EP, V40, P1081, DOI 10.1017/ice.2019.186; Koizumi R, KANSENSHOGAKU ZASSHI; Kusama Y, 2020, J INFECT CHEMOTHER, V26, P211, DOI 10.1016/j.jiac.2019.08.013; Kusama Y, 2019, JPN J INFECT DIS, V72, P326, DOI 10.7883/yoken.JJID.2018.417; Marra F, 2016, J AM DENT ASSOC, V147, P320, DOI 10.1016/j.adaj.2015.12.014; Ministry of Health Labour and Welfare, 2016, SURV PHYS DENT PHARM; Ministry of Health Labour and Welfare of Japan, 2020, SIT PREV CLAIM SUBM; Ministry of Health Labour and Welfare of Japan, 2018, SURV STAT DYN SURV M; Muraki Y, 2016, J GLOB ANTIMICROB RE, V7, P19, DOI 10.1016/j.jgar.2016.07.002; Nakatani S, 2019, CIRC J, V83, P1767, DOI 10.1253/circj.CJ-19-0549; Public Health England, 2016, DENT ANT STEW TOOLK; Roy KM, 2000, BRIT DENT J, V188, P674; Salako NO, 2004, J DENT, V32, P503, DOI 10.1016/j.jdent.2004.04.001; Statistics Bureau of Japan, RES POP EST; Suda KJ, 2018, CLIN INFECT DIS, V66, P185, DOI 10.1093/cid/cix773; Suda KJ, 2016, J AM PHARM ASSOC, V56, P621, DOI 10.1016/j.japh.2016.08.015; Teoh L, 2018, AUST DENT J, V63, P329, DOI 10.1111/adj.12622; The Government of Japan, 2016, VETFUTURES ACTION PL; [The Japanese Association for Infectious Diseases Japanese Society of Chemotherapy. The Japanese association for infectious diseases], 2014, JAID JSC GUID CLIN M; Thornhill MH, 2019, BRIT DENT J, V227, P1044, DOI 10.1038/s41415-019-1002-3; Tsutsui A, 2018, J INFECT CHEMOTHER, V24, P414, DOI 10.1016/j.jiac.2018.01.003; Yoshida K, 2018, JAPANESE J ENV INFEC, V33, P207; Ziegler J, 2014, IEEE INTEL TRANSP SY, V6, P8, DOI 10.1109/MITS.2014.2306552	32	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2020	15	12							e0244521	10.1371/journal.pone.0244521	http://dx.doi.org/10.1371/journal.pone.0244521			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PM2BQ	33370390	Green Published, gold			2023-01-03	WOS:000603611900014
J	OlaOlorun, FM; Anglewicz, P; Moreau, C				OlaOlorun, Funmilola M.; Anglewicz, Philip; Moreau, Caroline			From non-use to covert and overt use of contraception: Identifying community and individual factors informing Nigerian women's degree of contraceptive empowerment	PLOS ONE			English	Article								Objective In Nigeria, unmet need for contraception is high despite improved access to modern contraception. To identify factors that support Nigerian women's contraceptive decisions to achieve their reproductive goals, in the presence or absence of their partner's support, we seek to identify individual/couple and community level determinants of a spectrum of contraceptive practices, from non-use to covert and overt use of contraception. Methods Data were drawn from a national probability survey conducted by Performance Monitoring and Accountability 2020 in Nigeria in 2017-2018. A sample of 12,948 women 15-49 years was included, 6433 of whom were in need of contraception at the time of the survey. We conducted bivariate and multivariate analysis to identify individual/couple and community level factors associated with covert use relative to non-use and to overt use of contraception. Results Altogether, 58.0% of women in need of contraception were non-users, 4.5% were covert users and 37.5% used contraception overtly. Covert users were more educated and wealthier than non-users, but less educated and less wealthy than overt users. Covert users were less likely to cohabitate with their partner compared to non-users [AOR = 4.60 (95%CI: 3.06-6.93)] and overt users [AOR = 5.01 (95%CI: 3.24-7.76)] and more likely to reside in urban areas. At the community level, covert users were more likely to live in communities with higher contraceptive prevalence and higher levels of female education relative to non-users. They were also more likely to live in communities with higher female employment [AOR = 1.62, (95%CI: 0.96-2.73)] compared to overt users. Conclusion By identifying individual and community level factors associated with the spectrum from non-use to covert use and overt use of contraception, this study highlights the importance of integrating individual and community interventions to support women's realization of their reproductive goals.	[OlaOlorun, Funmilola M.] Univ Ibadan, Coll Med, Dept Community Med, Ibadan, Nigeria; [Anglewicz, Philip; Moreau, Caroline] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Moreau, Caroline] INSERM, Soins & Sante Primaire, CESP Ctr Res Epidemiol & Populat Hlth U1018, Villejuif, France	University of Ibadan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Institut National de la Sante et de la Recherche Medicale (Inserm)	OlaOlorun, FM (corresponding author), Univ Ibadan, Coll Med, Dept Community Med, Ibadan, Nigeria.	fmolaolorun@gmail.com	OlaOlorun, Funmilola/ABN-6506-2022	OlaOlorun, Funmilola/0000-0001-5544-2875	Bill and Melinda Gates Foundation [OPP1079004]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	PMA2020 was supported by a grant (OPP1079004) from the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adanikin AI, 2019, CULT HEALTH SEX, V21, P1439, DOI 10.1080/13691058.2019.1568576; Ajah LO, 2015, J OBSTET GYNAECOL, V35, P628, DOI 10.3109/01443615.2014.991287; Alvergne A, 2017, CONTRACEP REPROD MED, V2, DOI 10.1186/s40834-017-0052-7; [Anonymous], 2020, DIABETES TECHNOL THE, V22, pA, DOI 10.1089/dia.2020.2525.abstracts; Ashraf N, 2014, AM ECON REV, V104, P2210, DOI 10.1257/aer.104.7.2210; Awolude OA., 2019, NIGERIA NIGER J MED, V28, P56, DOI [10.4103/1115-2613.278617, DOI 10.4103/1115-2613.278617]; Ayanore MA, 2017, AFR J REPROD HEALTH, V21, P81, DOI 10.29063/ajrh2017/v21i2.10; Baiden F, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0310-x; Balogun O, 2016, ETHIOP J HEALTH SCI, V26, P439, DOI 10.4314/ejhs.v26i5.5; Biddlecom AE, 1998, STUD FAMILY PLANN, V29, P360, DOI 10.2307/172249; Blackstone SR, 2017, INT Q COMMUNITY HEAL, V37, P79, DOI 10.1177/0272684X16685254; Blanc Ann.K., 1996, NEGOTIATING REPROD O; Choiriyyah I, 2018, STUD FAMILY PLANN, V49, P143, DOI 10.1111/sifp.12053; Ejembi C.L., 2015, CONTEXTUAL FACTORS I; Gasca NC, 2018, J BIOSOC SCI, V50, P326, DOI 10.1017/S0021932017000256; Harris L, 2018, CONTRACEPTION, V98, P357, DOI 10.1016/j.contraception.2018.07.088; Heck CJ, 2018, CONTRACEPTION, V98, P41, DOI 10.1016/j.contraception.2018.02.017; Irani L, 2014, INT PERSPECT SEX R H, V40, DOI 10.1363/4001114; Islam MK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230143; Karp C, 2020, SOC SCI MED, V258, DOI 10.1016/j.socscimed.2020.113086; Kibira SPS, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08977-y; Kriel Y, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0749-y; McCarraher DR, 2006, J BIOSOC SCI, V38, P169, DOI 10.1017/S0021932005025897; Medhanyie AA, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0281-x; Okwor EU, 2010, INT Q COMMUNITY HEAL, V30, P223, DOI 10.2190/IQ.30.3.d; Sundararajan R, 2019, BMC WOMENS HEALTH, V19, DOI 10.1186/s12905-019-0802-6; Uysal J, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-00916-9; Wolff B, 2000, STUD FAMILY PLANN, V31, P124, DOI 10.1111/j.1728-4465.2000.00124.x; Zimmerman L, 2017, STUD FAMILY PLANN, V48, P293, DOI 10.1111/sifp.12031	29	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0242345	10.1371/journal.pone.0242345	http://dx.doi.org/10.1371/journal.pone.0242345			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OZ9VG	33206705	Green Published, gold			2023-01-03	WOS:000595265900026
J	Tomar, S; Dehingia, N; Dey, AK; Chandurkar, D; Raj, A; Silverman, JG				Tomar, Shweta; Dehingia, Nabamallika; Dey, Arnab K.; Chandurkar, Dharmendra; Raj, Anita; Silverman, Jay G.			Associations of intimate partner violence and reproductive coercion with contraceptive use in Uttar Pradesh, India: How associations differ across contraceptive methods	PLOS ONE			English	Article							UNINTENDED PREGNANCY; ABORTION; SAMPLE; HIV	Intimate partner violence (IPV) and reproductive coercion (RC)-largely in the form of pressuring pregnancy-appear to contribute to low use of contraceptives in India; however, little is known about the extent to which these experiences differentially affect use of specific contraceptive methods. The current study assessed the association of IPV and RC with specific contraceptive methods (Intrauterine Devices [IUDs], pills, condoms) among a large population-based sample of currently married women (15-49 years, n = 1424) living in Uttar Pradesh. Outcomes variables included past year modern contraceptive use and type of contraceptive used. Primary independent variables included lifetime experience of RC by current husband or in-laws, and lifetime experiences of physical IPV and sexual IPV by current husband. Multivariate logistic regression models were developed to determine the effect of each form of abuse on women's contraceptive use. Approximately 1 in 7 women (15.1%) reported experiencing RC from their current husband or in-laws ever in their lifetime, 37.4% reported experience of physical IPV and 8.3% reported experience of sexual IPV by their current husband ever in their lifetime. Women experiencing RC were less likely to use any modern contraceptive (AOR: 0.18; 95% CI: 0.9-0.36). Such women also less likely to report pill and condom use but were more likely to report IUD use. Neither form of IPV were associated with either overall or method specific contraceptive use. Study findings highlight that RC may influence contraceptive use differently based on type of contraceptive, with less detectable, female-controlled contraceptives such as IUD preferred in the context of women facing RC. Unfortunately, IUD uptake remains low in India. Increased access and support for use, particularly for women contending with RC, may be important for improving women's control over contraceptive use and reducing unintended pregnancy.	[Tomar, Shweta; Dehingia, Nabamallika; Dey, Arnab K.; Raj, Anita; Silverman, Jay G.] Univ Calif San Diego, Sch Med, Ctr Gender Equ & Hlth, Div Global Publ Hlth, La Jolla, CA 92093 USA; [Tomar, Shweta; Dehingia, Nabamallika; Dey, Arnab K.] Univ Calif San Diego, Joint Doctoral Program, San Diego, CA 92103 USA; [Chandurkar, Dharmendra] Sambodhi Res & Commun Pvt Ltd, Noida, Uttar Pradesh, India	University of California System; University of California San Diego; University of California System; University of California San Diego	Tomar, S (corresponding author), Univ Calif San Diego, Sch Med, Ctr Gender Equ & Hlth, Div Global Publ Hlth, La Jolla, CA 92093 USA.; Tomar, S (corresponding author), Univ Calif San Diego, Joint Doctoral Program, San Diego, CA 92103 USA.	stomar@health.ucsd.edu	Dehingia, Nabamallika/AAY-5588-2021; Dehingia, Nabamallika/AAF-1639-2021	Dehingia, Nabamallika/0000-0003-1787-9050; Dey, Arnab K./0000-0003-4585-3130; Tomar, Shweta/0000-0001-6991-1206	Bill and Melinda Gates Foundation [OPP1083531, INV-002967]	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was funded by the Bill and Melinda Gates Foundation Grant No. OPP1083531 (Monitoring and Evaluating the Uttar Pradesh Technical Support Unit) and INV-002967 (EMERGE-FP measures project). The funder provided support in the form of salaries for authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; American Institute of Ultrasound in Medicine, 2020, J ULTRASOUND MED, V21, pE1; [Anonymous], 2015, WHO UN SUST DEV SUMM; [Anonymous], 2020, DIABETES TECHNOL THE, V22, pA, DOI 10.1089/dia.2020.2525.abstracts; Askew I, 2017, GLOB HEALTH-SCI PRAC, V5, P658, DOI 10.9745/GHSP-D-17-00121; Baiden F, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0310-x; Bellizzi S, 2015, HUM REPROD, V30, P973, DOI 10.1093/humrep/deu348; Cleland J, 2017, CONTRACEPTION, V95, P519, DOI 10.1016/j.contraception.2017.03.009; Deering KN, 2013, SEX TRANSM DIS, V40, P168, DOI 10.1097/OLQ.0b013e31827df174; Fanslow J, 2008, AUST NZ J OBSTET GYN, V48, P83, DOI 10.1111/j.1479-828X.2007.00805.x; Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x; Grindlay K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201663; Guliani H, 2014, HEALTH POLICY PLANN, V29, P589, DOI 10.1093/heapol/czt045; IIPS ICF, 2017, IND NAT FAM HLTH SUR; Kumar G, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2473-6; Loll D, 2019, INT PERSPECT SEX R H, V45, P1, DOI 10.1363/45e7419; Miller E, 2016, CONTRACEPTION, V94, P58, DOI 10.1016/j.contraception.2016.02.009; Miller E, 2014, CONTRACEPTION, V89, P122, DOI 10.1016/j.contraception.2013.10.011; Miller Elizabeth, 2010, Expert Rev Obstet Gynecol, V5, P511, DOI 10.1586/eog.10.44; Miller E, 2010, CONTRACEPTION, V81, P316, DOI 10.1016/j.contraception.2009.12.004; Montgomery MR, 2000, DEMOGRAPHY, V37, P155, DOI 10.2307/2648118; Ochako R, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0168-2; Panchanadeswaran S, 2008, INT J DRUG POLICY, V19, P106, DOI 10.1016/j.drugpo.2007.11.013; Patel SN, 2014, AIDS BEHAV, V18, P1970, DOI 10.1007/s10461-014-0792-1; Raj Anita, 2015, Int J Gynaecol Obstet, V130 Suppl 3, pE56, DOI 10.1016/j.ijgo.2015.03.013; Santhya KG., 2016, UNDERSTANDING LIVES; Silverman JG, 2007, BJOG-INT J OBSTET GY, V114, P1246, DOI 10.1111/j.1471-0528.2007.01481.x; Silverman JG, 2019, SSM-POPUL HLTH, V9, DOI 10.1016/j.ssmph.2019.100484; Silverman JG, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001723; Singh S, 2018, LANCET GLOB HEALTH, V6, pE111, DOI 10.1016/s2214-109x(17)30453-9; Tancredi DJ, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0216-z; World Health Organization, 2005, WHO MULT STUD WOM HL; Zachor H, 2018, HEALTH EDUC RES, V33, P175, DOI 10.1093/her/cyy007	33	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2020	15	10							e0241008	10.1371/journal.pone.0241008	http://dx.doi.org/10.1371/journal.pone.0241008			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OM3IA	33064775	Green Published, gold			2023-01-03	WOS:000585918300002
J	Verhestraeten, C; Weijers, G; Debleu, D; Ciarka, A; Goethals, M; Droogmans, S; Maris, M				Verhestraeten, Caroline; Weijers, Gijs; Debleu, Daphne; Ciarka, Agnieszka; Goethals, Marc; Droogmans, Steven; Maris, Michael			Diagnosis, treatment, and follow-up of heart failure patients by general practitioners: A Delphi consensus statement	PLOS ONE			English	Article							QUALITY-OF-CARE; ESC GUIDELINES; SURVEY PROGRAM; MANAGEMENT; ADHERENCE; SPECIALISTS; EUROPE	Aims Creation of an algorithm that includes the most important parameters (history, clinical parameters, and anamnesis) that can be linked to heart failure, helping general practitioners in recognizing heart failure in an early stage and in a better follow-up of the patients. Methods and results The algorithm was created using a consensus-based Delphi panel technique with fifteen general practitioners and seven cardiologists from Belgium. The method comprises three iterations with general statements on diagnosis, referral and treatment, and follow-up. Consensus was obtained for the majority of statements related to diagnosis, referral, and follow-up, whereas a lack of consensus was seen for treatment statements. Based on the statements with good and perfect consensus, an algorithm for general practitioners was assembled, helping them in diagnoses and follow-up of heart failure patients. The diagnosis should be based on three essential pillars, i.e. medical history, anamnesis and clinical examination. In case of suspected heart failure, blood analysis, including the measurement of NT-proBNP levels, can already be performed by the general practitioner followed by referral to the cardiologist who is then responsible for proper diagnosis and initiation of treatment. Afterwards, a multidisciplinary health care process between the cardiologist and the general practitioner is crucial with an important role for the general practitioner who has a key role in the up-titration of heart failure medication, down-titration of the dose of diuretics and to assure drug compliance. Conclusions Based on the consensus levels of statements in a Delphi panel setting, an algorithm is created to help general practitioners in the diagnosis and follow-up of heart failure patients.	[Verhestraeten, Caroline; Debleu, Daphne; Maris, Michael] Novartis Pharma Nv Sa, Vilvoorde, Belgium; [Weijers, Gijs] Ctr Hosp Bois de Abbaye, Dept Cardiol, Seraing, Belgium; [Ciarka, Agnieszka] Univ Hosp Leuven, Dept Cardiovasc Dis, Leuven, Belgium; [Ciarka, Agnieszka] Katholieke Univ Leuven, Leuven, Belgium; [Goethals, Marc] OLV Hosp Aalst, Dept Cardiol, Aalst, Belgium; [Droogmans, Steven] Ctr Hart En Vaatziekten, Dept Cardiol, Jette, Belgium	KU Leuven; University Hospital Leuven; KU Leuven	Verhestraeten, C (corresponding author), Novartis Pharma Nv Sa, Vilvoorde, Belgium.	caroline.verhestraeten@novartis.com		Droogmans, Steven/0000-0003-3985-3249	Novartis Pharma Belgium, Medialaan 40, Vilvoorde	Novartis Pharma Belgium, Medialaan 40, Vilvoorde	This work was supported by Novartis Pharma Belgium, Medialaan 40, 1800 Vilvoorde Dr G. Weijers, Dr A. Ciarka, Dr M. Goethals and Dr S. Droogmans received a consultancy fee from Novartis Pharma Belgium for the interpretation of the results, development of the algorithm and review of the manuscript. Michael Maris and Caroline Verhestraeten are employees of Novartis Pharma Belgium. Daphne Debleu was doing an internship during the development of this project at Novartis Pharma Belgium The funder provided support in the form of salaries for authors CV and MM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; Calvert MJ, 2009, FAM PRACT, V26, P145, DOI 10.1093/fampra/cmn105; Cleland JGF, 2002, LANCET, V360, P1631, DOI 10.1016/S0140-6736(02)11601-1; Cleland JGF, 2003, EUR HEART J, V24, P442, DOI 10.1016/S0195-668X(02)00823-0; De Blois J, 2015, EUR HEART J-CARDIOVA, V1, P31, DOI 10.1093/ehjcvp/pvu010; Devroey D, 2011, VASC HEALTH RISK MAN, V7, P591, DOI 10.2147/VHRM.S24476; Fonarow GC, 2010, CIRCULATION, V122, P585, DOI 10.1161/CIRCULATIONAHA.109.934471; Fonseca C, 2006, HEART FAIL REV, V11, P95, DOI 10.1007/s10741-006-9481-0; Gezondheidszorgberoepen PvdCPvhAvd, 2018, JAARST BETR BEOF GEZ; Gonzalez-Juanatey JR, 2008, REV ESP CARDIOL, V61, P611; Hancock HC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003866; Hex C, 2018, J CLIN PATHOL, V71, P539, DOI 10.1136/jclinpath-2017-204746; Hsu C, 2007, RES EVALUAT, V12, P10, DOI [10.7275/pdz9-th90, DOI 10.7275/PDZ9-TH90]; Komajda M, 2005, EUR HEART J, V26, P1653, DOI 10.1093/eurheartj/ehi251; Komajda M, 2003, EUR HEART J, V24, P464, DOI 10.1016/S0195-668X(02)00700-5; Komajda M, 2017, EUR J HEART FAIL, V19, P1495, DOI 10.1002/ejhf.876; Network EH, 2019, HEART FAIL CARD DIS; Ouwerkerk W, 2017, EUR HEART J, V38, P1883, DOI 10.1093/eurheartj/ehx026; Pan YS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009181; Poelzl G, 2014, INT J CARDIOL, V175, P83, DOI 10.1016/j.ijcard.2014.04.255; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Ponikowski P, 2014, ESC HEART FAIL, V1, P4, DOI 10.1002/ehf2.12005; Rutten Frans H, 2016, Card Fail Rev, V2, P79, DOI 10.15420/cfr.2016:18:1; Shah BR, 2005, DIABETES CARE, V28, P600, DOI 10.2337/diacare.28.3.600; Smeets M, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4271-2; Smeets M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025922; Smeets M, 2019, ACTA CARDIOL, V74, P371, DOI 10.1080/00015385.2018.1507426; Smeets M, 2018, INT J CARDIOL, V257, P199, DOI 10.1016/j.ijcard.2017.06.108; Smeets M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013459; Smeets M, 2015, INT J CARDIOL, V191, P120, DOI 10.1016/j.ijcard.2015.05.002; Stewart D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188348; Thangaratinam S, 2005, OBSTET GYNAECOL, V7, P120, DOI 10.1576/toag.7.2.120.27071; Yang H, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000222; Zaphiriou A, 2005, EUR J HEART FAIL, V7, P537, DOI 10.1016/j.ejheart.2005.01.022	34	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2020	15	12							e0244485	10.1371/journal.pone.0244485	http://dx.doi.org/10.1371/journal.pone.0244485			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP1TW	33382755	Green Published, gold			2023-01-03	WOS:000605651900034
J	Oladapo, OT; Vogel, JP; Piaggio, G; Nguyen, MH; Althabe, F; Gulmezoglu, M; Bahl, R; Rao, SPN; De Costa, A; Gupta, S; Baqui, AH; Khanam, R; Shahidullah, M; Chowdhury, SB; Ahmed, S; Begum, N; Roy, AD; Shahed, MA; Jaben, IA; Yasmin, F; Rahman, MM; Ara, A; Khatoon, S; Ara, G; Akter, S; Akhter, N; Dey, PR; Sabur, MA; Azad, MT; Choudhury, SF; Matin, MA; Goudar, SS; Dhaded, SM; Metgud, MC; Pujar, YV; Somannavar, MS; Vernekar, SS; Herekar, VR; Bidri, SR; Mathapati, SS; Patil, PG; Patil, MM; Gudadinni, MR; Bijapure, HR; Mallapur, AA; Katageri, GM; Chikkamath, SB; Yelamali, BC; Pol, RR; Misra, SS; Das, L; Nanda, S; Nayak, RB; Singh, B; Qureshi, Z; Were, F; Osoti, A; Gwako, G; Laving, A; Kinuthia, J; Mohamed, H; Aliyan, N; Barassa, A; Kibaru, E; Mbuga, M; Thuranira, L; Githua, NJ; Lusweti, B; Ayede, AI; Falade, AG; Adesina, OA; Agunloye, AM; Iyiola, OO; Sanni, W; Ejinkeonye, IK; Idris, HA; Okoli, CV; Irinyenikan, TA; Olubosede, OA; Bello, O; Omololu, OM; Olutekunbi, OA; Akintan, AL; Owa, OO; Oluwafemi, RO; Eniowo, IP; Fabamwo, AO; Disu, EA; Agbara, JO; Adejuyigbe, EA; Kuti, O; Anyabolu, HC; Awowole, IO; Fehintola, AO; Kuti, BP; Isah, AD; Olateju, EK; Abiodun, O; Dedeke, OF; Akinkunmi, FB; Oyeneyin, L; Adesiyun, O; Raji, HO; Ande, ABA; Okonkwo, I; Ariff, S; Soofi, SB; Sheikh, L; Zulfiqar, S; Omer, S; Sikandar, R; Sheikh, S; Giordano, D; Gamerro, H; Carroli, G; Carvalho, J; Neilson, J; Molyneux, E; Yunis, K; Mugerwa, K; Chellani, HK				Oladapo, Olufemi T.; Vogel, Joshua P.; Piaggio, Gilda; Nguyen, My-Huong; Althabe, Fernando; Gulmezoglu, Metin; Bahl, Rajiv; Rao, Suman P. N.; De Costa, Ayesha; Gupta, Shuchita; Baqui, Abdullah H.; Khanam, Rasheda; Shahidullah, Mohammod; Chowdhury, Saleha B.; Ahmed, Salahuddin; Begum, Nazma; Roy, Arunangshu D.; Shahed, M. A.; Jaben, Iffat A.; Yasmin, Farida; Rahman, M. Mozibur; Ara, Anjuman; Khatoon, Soofia; Ara, Gulshan; Akter, Shaheen; Akhter, Nasreen; Dey, Probhat R.; Sabur, M. Abdus; Azad, Mohammad T.; Choudhury, Shahana F.; Matin, M. A.; Goudar, Shivaprasad S.; Dhaded, Sangappa M.; Metgud, Mrityunjay C.; Pujar, Yeshita V.; Somannavar, Manjunath S.; Vernekar, Sunil S.; Herekar, Veena R.; Bidri, Shailaja R.; Mathapati, Sangamesh S.; Patil, Preeti G.; Patil, Mallanagouda M.; Gudadinni, Muttappa R.; Bijapure, Hidaytullah R.; Mallapur, Ashalata A.; Katageri, Geetanjali M.; Chikkamath, Sumangala B.; Yelamali, Bhuvaneshwari C.; Pol, Ramesh R.; Misra, Sujata S.; Das, Leena; Nanda, Saumya; Nayak, Rashmita B.; Singh, Bipsa; Qureshi, Zahida; Were, Fredrick; Osoti, Alfred; Gwako, George; Laving, Ahmed; Kinuthia, John; Mohamed, Hafsa; Aliyan, Nawal; Barassa, Adelaide; Kibaru, Elizabeth; Mbuga, Margaret; Thuranira, Lydia; Githua, Njoroge J.; Lusweti, Bernadine; Ayede, Adejumoke I.; Falade, Adegoke G.; Adesina, Olubukola A.; Agunloye, Atinuke M.; Iyiola, Oluwatosin O.; Sanni, Wilfred; Ejinkeonye, Ifeyinwa K.; Idris, Hadiza A.; Okoli, Chinyere V.; Irinyenikan, Theresa A.; Olubosede, Omolayo A.; Bello, Olaseinde; Omololu, Olufemi M.; Olutekunbi, Olanike A.; Akintan, Adesina L.; Owa, Olorunfemi O.; Oluwafemi, Rosena O.; Eniowo, Ireti P.; Fabamwo, Adetokunbo O.; Disu, Elizabeth A.; Agbara, Joy O.; Adejuyigbe, Ebunoluwa A.; Kuti, Oluwafemi; Anyabolu, Henry C.; Awowole, Ibraheem O.; Fehintola, Akintunde O.; Kuti, Bankole P.; Isah, Anthony D.; Olateju, Eyinade K.; Abiodun, Olusanya; Dedeke, Olabisi F.; Akinkunmi, Francis B.; Oyeneyin, Lawal; Adesiyun, Omotayo; Raji, Hadijat O.; Ande, Adedapo B. A.; Okonkwo, Ikechukwu; Ariff, Shabina; Soofi, Sajid B.; Sheikh, Lumaan; Zulfiqar, Saima; Omer, Sadia; Sikandar, Raheel; Sheikh, Salma; Giordano, Daniel; Gamerro, Hugo; Carroli, Guillermo; Carvalho, Jose; Neilson, James; Molyneux, Elizabeth; Yunis, Khalid; Mugerwa, Kidza; Chellani, Harish K.			Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOSTEROIDS; MORTALITY; OUTCOMES; WOMEN	BACKGROUND The safety and efficacy of antenatal glucocorticoids in women in low-resource countries who are at risk for preterm birth are uncertain. METHODS We conducted a multicountry, randomized trial involving pregnant women between 26 weeks 0 days and 33 weeks 6 days of gestation who were at risk for preterm birth. The participants were assigned to intramuscular dexamethasone or identical placebo. The primary outcomes were neonatal death alone, stillbirth or neonatal death, and possible maternal bacterial infection; neonatal death alone and stillbirth or neonatal death were evaluated with superiority analyses, and possible maternal bacterial infection was evaluated with a noninferiority analysis with the use of a prespecified margin of 1.25 on the relative scale. RESULTS A total of 2852 women (and their 3070 fetuses) from 29 secondary- and tertiary-level hospitals across Bangladesh, India, Kenya, Nigeria, and Pakistan underwent randomization. The trial was stopped for benefit at the second interim analysis. Neonatal death occurred in 278 of 1417 infants (19.6%) in the dexamethasone group and in 331 of 1406 infants (23.5%) in the placebo group (relative risk, 0.84; 95% confidence interval [CI], 0.72 to 0.97; P=0.03). Stillbirth or neonatal death occurred in 393 of 1532 fetuses and infants (25.7%) and in 444 of 1519 fetuses and infants (29.2%), respectively (relative risk, 0.88; 95% CI, 0.78 to 0.99; P=0.04); the incidence of possible maternal bacterial infection was 4.8% and 6.3%, respectively (relative risk, 0.76; 95% CI, 0.56 to 1.03). There was no significant between-group difference in the incidence of adverse events. CONCLUSIONS Among women in low-resource countries who were at risk for early preterm birth, the use of dexamethasone resulted in significantly lower risks of neonatal death alone and stillbirth or neonatal death than the use of placebo, without an increase in the incidence of possible maternal bacterial infection. (Funded by the Bill and Melinda Gates Foundation and the World Health Organization; Australian and New Zealand Clinical Trials Registry number, ACTRN12617000476336; Clinical Trials Registry-India number, CTRI/2017/04/008326.)	[Oladapo, Olufemi T.; Vogel, Joshua P.; Piaggio, Gilda; Nguyen, My-Huong; Althabe, Fernando; Gulmezoglu, Metin; Bahl, Rajiv; Rao, Suman P. N.; De Costa, Ayesha; Gupta, Shuchita] WHO, Geneva, Switzerland; [Baqui, Abdullah H.; Khanam, Rasheda] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Shahidullah, Mohammod; Chowdhury, Saleha B.] Bangabandhu Sheikh Mujib Med Univ, Dhaka, Bangladesh; [Ahmed, Salahuddin; Begum, Nazma; Roy, Arunangshu D.; Shahed, M. A.; Jaben, Iffat A.] Projahnmo Res Fdn, Dhaka, Bangladesh; [Yasmin, Farida; Rahman, M. Mozibur] Inst Child & Mother Hlth, Dhaka, Bangladesh; [Ara, Anjuman; Khatoon, Soofia] Ctr Woman & Child Hlth, Dhaka, Bangladesh; [Ara, Gulshan; Akter, Shaheen] Enam Med Coll & Hosp, Dhaka, Bangladesh; [Akhter, Nasreen; Dey, Probhat R.] Sylhet Muhammad Ataul Gani Osmani Med Coll Hosp, Sylhet, Bangladesh; [Sabur, M. Abdus; Azad, Mohammad T.] Jalalabad Ragib Rabeya Med Coll Hosp, Sylhet, Bangladesh; [Choudhury, Shahana F.; Matin, M. A.] Sylhet Womens Med Coll Hosp, Sylhet, Bangladesh; [Goudar, Shivaprasad S.; Dhaded, Sangappa M.; Metgud, Mrityunjay C.; Pujar, Yeshita V.; Somannavar, Manjunath S.; Vernekar, Sunil S.; Herekar, Veena R.] Jawaharlal Nehru Med Coll, KLE Acad Higher Educ & Res, Belagavi, India; [Bidri, Shailaja R.; Mathapati, Sangamesh S.; Patil, Preeti G.; Patil, Mallanagouda M.; Gudadinni, Muttappa R.; Bijapure, Hidaytullah R.] Shri BM Patil Med Coll, Vijayapura, India; [Mallapur, Ashalata A.; Katageri, Geetanjali M.; Chikkamath, Sumangala B.; Yelamali, Bhuvaneshwari C.; Pol, Ramesh R.] S Nijalingappa Med Coll, Bagalkot, India; [Misra, Sujata S.; Das, Leena; Nanda, Saumya; Nayak, Rashmita B.; Singh, Bipsa] Srirama Chandra Bhanja Med Coll, Cuttack, India; [Chellani, Harish K.] Vardhman Mahavir Med Coll & Safdarjung Hosp, New Delhi, India; [Qureshi, Zahida; Were, Fredrick; Osoti, Alfred; Gwako, George; Laving, Ahmed] Univ Nairobi, Nairobi, Kenya; [Kinuthia, John] Kenyatta Natl Hosp, Nairobi, Kenya; [Mohamed, Hafsa; Aliyan, Nawal] Coast Prov Gen Hosp, Mombasa, Kenya; [Barassa, Adelaide; Kibaru, Elizabeth] Nakuru Level 5 Hosp, Nakuru, Kenya; [Mbuga, Margaret; Thuranira, Lydia] Kiambu Level 5 Hosp, Kiambu, Kenya; [Githua, Njoroge J.; Lusweti, Bernadine] Thika Level 5 Hosp, Thika, Kenya; [Ayede, Adejumoke I.; Falade, Adegoke G.; Adesina, Olubukola A.; Agunloye, Atinuke M.; Iyiola, Oluwatosin O.] Univ Ibadan, Coll Med, Ibadan, Nigeria; [Ayede, Adejumoke I.; Falade, Adegoke G.; Adesina, Olubukola A.; Agunloye, Atinuke M.; Iyiola, Oluwatosin O.] Univ Coll Hosp, Ibadan, Nigeria; [Sanni, Wilfred; Ejinkeonye, Ifeyinwa K.] Kubwa Gen Hosp, Kubwa, Nigeria; [Idris, Hadiza A.; Okoli, Chinyere V.] Nyanya Gen Hosp, Nyanya, Nigeria; [Irinyenikan, Theresa A.; Olubosede, Omolayo A.; Bello, Olaseinde] State Specialist Hosp, Akure, Nigeria; [Akintan, Adesina L.; Owa, Olorunfemi O.; Oluwafemi, Rosena O.; Eniowo, Ireti P.] Mother & Child Hosp, Akure, Nigeria; [Omololu, Olufemi M.; Olutekunbi, Olanike A.] Lagos Isl Matern Hosp, Lagos, Nigeria; [Fabamwo, Adetokunbo O.; Disu, Elizabeth A.; Agbara, Joy O.] Lagos State Univ, Teaching Hosp, Lagos, Nigeria; [Adejuyigbe, Ebunoluwa A.; Kuti, Oluwafemi; Anyabolu, Henry C.; Awowole, Ibraheem O.; Fehintola, Akintunde O.; Kuti, Bankole P.] Obafemi Awolowo Univ, Ife, Nigeria; [Isah, Anthony D.; Olateju, Eyinade K.] Univ Abuja, Abuja, Nigeria; [Abiodun, Olusanya; Dedeke, Olabisi F.] Sacred Heart Hosp, Abeokuta, Nigeria; [Akinkunmi, Francis B.; Oyeneyin, Lawal] Mother & Child Hosp, Ondo, Nigeria; [Adesiyun, Omotayo; Raji, Hadijat O.] Univ Ilorin, Ilorin, Nigeria; [Ande, Adedapo B. A.; Okonkwo, Ikechukwu] Univ Benin, Benin, Nigeria; [Ariff, Shabina; Soofi, Sajid B.; Sheikh, Lumaan] Aga Khan Univ, Karachi, Pakistan; [Zulfiqar, Saima; Omer, Sadia] Sheikh Zayed Med Coll & Hosp, Rahim Yar Khan, Pakistan; [Sikandar, Raheel; Sheikh, Salma] Liaquat Univ Hosp, Hyderabad, Pakistan; [Giordano, Daniel; Gamerro, Hugo; Carroli, Guillermo] Ctr Rosarino Estudios Perinat, Rosario, Argentina; [Carvalho, Jose] Stat Consultoria, Campinas, Brazil; [Neilson, James] Univ Liverpool, Liverpool, Merseyside, England; [Molyneux, Elizabeth] Univ Malawi, Coll Med, Blantyre, Malawi; [Yunis, Khalid] Amer Univ Beirut, Beirut, Lebanon; [Mugerwa, Kidza] Makerere Univ, Coll Hlth Sci, Kampala, Uganda	World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Bangabandhu Sheikh Mujib Medical University (BSMMU); Sylhet MAG Osmani Medical College; K.L.E. Academy of Higher Education & Research; Jawaharlal Nehru Medical College, Belgaum; BLDE (Deemed to be University); Srirama Chandra Bhanja Medical College & Hospital; Vardhman Mahavir Medical College & Safdarjung Hospital; University of Nairobi; Kenyatta National Hospital; University of Ibadan; University of Ibadan; University College Hospital, Ibadan; Lagos State University; Obafemi Awolowo University; University of Ilorin; University of Benin; Aga Khan University; University of Liverpool; University of Malawi; American University of Beirut; Makerere University	Oladapo, OT (corresponding author), WHO, Geneva, Switzerland.		Fehintola, Akintunde/AAV-4656-2021; Somannavar, Manjunath S/Q-3614-2019; Vogel, Joshua/K-7649-2019; Ahmed, Salahuddin/ABC-3497-2021; patil, mallanagouda/AAM-7538-2020; Gwako, George/GON-5701-2022; GOUDAR, SHIVAPRASAD S/S-1217-2019; Bijapure, Hidaytullah/AAC-5032-2021; Akinkunmi, Bola Francis/CAJ-5069-2022; Ahmed, Salahuddin/AAH-7005-2020; Vernekar, Sunil/AAD-5489-2020; Maranna, Sandhya/F-1458-2017	Somannavar, Manjunath S/0000-0002-8871-5072; Vogel, Joshua/0000-0002-3214-7096; patil, mallanagouda/0000-0002-8105-7273; Gwako, George/0000-0001-7245-8959; GOUDAR, SHIVAPRASAD S/0000-0002-8680-7053; Bijapure, Hidaytullah/0000-0001-5808-1657; Ahmed, Salahuddin/0000-0001-6771-0638; Vernekar, Sunil/0000-0002-0635-8041; Yunis, Khalid/0000-0002-6384-2745; Disu, Elizabeth/0000-0001-9876-820X; Maranna, Sandhya/0000-0003-3051-2915; Awowole, Ibraheem/0000-0001-7006-0824; Katageri, Geetanjali/0000-0001-6893-1504; Olutekunbi, Olanike/0000-0002-5822-7043; Olubosede, Olusayo/0000-0001-6542-4208; Adejuyigbe, Ebunoluwa/0000-0002-8671-4965; Shahed, M A/0000-0002-1661-124X	Bill and Melinda Gates Foundation [OPP1136821]; United Nations Development Program-United Nations Population Fund-United Nations Children's Fund-World Health Organization-World Bank Special Program of Research, Development, and Research Training in Human Reproduction, Department of Sexual and Reproducti; Department of Maternal, Newborn, Child, Adolescent Health and Ageing, World Health Organization, Geneva	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); United Nations Development Program-United Nations Population Fund-United Nations Children's Fund-World Health Organization-World Bank Special Program of Research, Development, and Research Training in Human Reproduction, Department of Sexual and Reproducti; Department of Maternal, Newborn, Child, Adolescent Health and Ageing, World Health Organization, Geneva	Supported by a grant (OPP1136821) from the Bill and Melinda Gates Foundation and by the United Nations Development Program-United Nations Population Fund-United Nations Children's Fund-World Health Organization-World Bank Special Program of Research, Development, and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research and the Department of Maternal, Newborn, Child, Adolescent Health and Ageing, World Health Organization, Geneva.	Althabe F, 2015, LANCET, V385, P629, DOI 10.1016/S0140-6736(14)61651-2; Amorim MMR, 1999, AM J OBSTET GYNECOL, V180, P1283, DOI 10.1016/S0002-9378(99)70630-7; Bahl R, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3488-z; BALLARD PL, 1995, AM J OBSTET GYNECOL, V173, P254, DOI 10.1016/0002-9378(95)90210-4; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berglund, 2010, SAS GLOB FOR SEATTL; di Pasquo E, 2020, EARLY HUM DEV, V143, DOI 10.1016/j.earlhumdev.2020.104984; E.U. Agency for Fund. Rights, 2019, 2019 UPD NGO SHIPS I; Fekih Meriem, 2002, Tunis Med, V80, P260; Gyamfi-Bannerman C, 2016, NEW ENGL J MED, V374, P1311, DOI 10.1056/NEJMoa1516783; Hodgins S, 2018, GLOB HEALTH-SCI PRAC, V6, P620, DOI 10.9745/GHSP-D-18-00461; Jobe AH, 2020, CTS-CLIN TRANSL SCI, V13, P391, DOI 10.1111/cts.12724; Kamath-Rayne BD, 2016, AM J OBSTET GYNECOL, V215, P423, DOI 10.1016/j.ajog.2016.06.023; Kemp MW, 2019, SEMIN FETAL NEONAT M, V24, P176, DOI 10.1016/j.siny.2019.05.003; Kemp MW, 2018, AM J OBSTET GYNECOL, V219, DOI 10.1016/j.ajog.2018.05.007; Kuper SG, 2018, J MATERN-FETAL NEO M, V31, P3095, DOI 10.1080/14767058.2017.1364724; Lopez AL, 1989, REV COLOMBIANA OBSTE, V40, P147; Pattinson RC, 1999, S AFR MED J, V89, P865; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Platt MJ, 2014, PUBLIC HEALTH, V128, P399, DOI 10.1016/j.puhe.2014.03.010; Qublan H. S., 2001, Clinical and Experimental Obstetrics and Gynecology, V28, P183; Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Seale AC, 2014, LANCET INFECT DIS, V14, P731, DOI 10.1016/S1473-3099(14)70804-7; Thaver D, 2009, PEDIATR INFECT DIS J, V28, pS3, DOI 10.1097/INF.0b013e3181958755; The WHO Alliance for Maternal and Newborn Health Improvement late pregnancy dating study group, 2020, LANCET GLOB HEALTH, V8, pe545; Vogel JP, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000398; Vogel JP, 2015, LANCET GLOB HEALTH, V3, pE589, DOI 10.1016/S2214-109X(15)00183-7; Vogel JP, 2014, LANCET, V384, P1869, DOI 10.1016/S0140-6736(14)60580-8; World Health Organization, 2015, WHO REC INT IMPR PRE	30	41	41	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	2020	383	26					2514	2525		10.1056/NEJMoa2022398	http://dx.doi.org/10.1056/NEJMoa2022398			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN1KP	33095526	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000604245400007
J	Slattery, M; Attard, H; Stewart, V; Roennfeldt, H; Wheeler, AJ				Slattery, Maddy; Attard, Hayley; Stewart, Victoria; Roennfeldt, Helena; Wheeler, Amanda J.			Participation in creative workshops supports mental health consumers to share their stories of recovery: A one-year qualitative follow-up study	PLOS ONE			English	Article							ART; PEOPLE; EXPERIENCES	Participation in creative activities has been linked with positive outcomes for people with mental illness. This longitudinal qualitative study is a one-year follow-up of eight mental health consumers who participated in a series of creative workshops in Brisbane, Australia that aimed to increase participants' capacity and skills in sharing their stories of recovery with others. It also sought to understand successful factors of the creative workshops to inform future workshops. Semi-structured interviews gathered information regarding participants' memories of the workshops and how they had shared their stories with others over the preceding 12 months. Interpretative phenomenological analysis identified that participants' enjoyed being engaged in a range of creative mediums in a group setting; that peer mentor support was highly valued; and that participants' recovery stories had become more positive and were shared more often and openly with others. Overall, participation in the creative workshops had long-lasting benefits for participants with respect to improved confidence and understanding about their illness. Future creative workshops should consider the inclusion of peer mentors with lived experience as a support for participants to reauthor their recovery story.	[Slattery, Maddy; Attard, Hayley; Stewart, Victoria; Roennfeldt, Helena; Wheeler, Amanda J.] Griffith Univ, Sch Human Serv & Social Work, Brisbane, Qld, Australia; [Wheeler, Amanda J.] Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand	Griffith University; University of Auckland	Stewart, V (corresponding author), Griffith Univ, Sch Human Serv & Social Work, Brisbane, Qld, Australia.	v.stewart@griffith.edu.au	Stewart, Victoria/P-2505-2018; Slattery, Maddy/ABF-5364-2021	Stewart, Victoria/0000-0003-2892-2288; Slattery, Maddy/0000-0001-5888-2534; Roennfeldt, Helena/0000-0002-4569-1226				[Anonymous], 2014, NAT PHOTONICS, V8, P1, DOI 10.1038/nphoton.2013.359; Bos Arjan E R, 2009, Issues Ment Health Nurs, V30, P509, DOI 10.1080/01612840802601382; Caddy L, 2012, J PSYCHIATR MENT HLT, V19, P327, DOI 10.1111/j.1365-2850.2011.01785.x; Cooper P, 2013, BRIT J OCCUP THER, V76, P186, DOI 10.4276/030802213X13651610908452; Dolling S., 2013, MENTAL HLTH PRACTICE, V16, P36, DOI [https://doi.org/10.7748/mhp2013.05.16.8.36.e855, DOI 10.7748/MHP2013.05.16.8.36.E855, DOI 10.7748/mhp2013.05.16.8.36.e855]; Elo S, 2014, SAGE OPEN, V4, DOI 10.1177/2158244014522633; Fade S, 2004, P NUTR SOC, V63, P647, DOI 10.1079/PNS2004398; Hacking S, 2008, HEALTH SOC CARE COMM, V16, P638, DOI 10.1111/j.1365-2524.2008.00789.x; Hilse C., 2007, BRIT J OCCUPATIONAL, V20, P431, DOI [10.1177/030802260707001004, DOI 10.1177/030802260707001004]; King R, 2013, INT J MENT HEALTH NU, V22, P444, DOI 10.1111/j.1447-0349.2012.00891.x; Lawson J, 2014, J HEALTH PSYCHOL, V19, P765, DOI 10.1177/1359105313479627; Makin S, 2012, CHRONIC ILLN, V8, P64, DOI 10.1177/1742395311422613; Marino C, 2016, PSYCHIATR REHABIL J, V39, P154, DOI 10.1037/prj0000171; Menard S., 2012, QUANTITATIVE APPL SO; Mizock L, 2015, PSYCHIATR REHABIL J, V38, P279, DOI 10.1037/prj0000111; Oster G. D., 2004, USING DRAWINGS ASSES; Qualitative Solution and Research, 2017, NVIV VERS 11; Roe D, 2005, Med Humanit, V31, P89, DOI 10.1136/jmh.2005.000214; Smith J., 2009, INTERPRETATIVE PHENO; Spandler H, 2007, J PSYCHIATR MENT HLT, V14, P791, DOI 10.1111/j.1365-2850.2007.01174.x; Stewart V, 2019, MENT HEALTH SOC INCL, V23, P16, DOI 10.1108/MHSI-08-2018-0029; Stickley T, 2007, J PSYCHIATR MENT HLT, V14, P783, DOI 10.1111/j.1365-2850.2007.01173.x; Stickley T, 2012, PUBLIC HEALTH, V126, DOI 10.1016/j.puhe.2012.04.002; Stickley T, 2018, J MENT HEALTH, V27, P367, DOI 10.1080/09638237.2018.1437609; Swan P, 2013, MENT HEALTH SOC INCL, V17, P19, DOI 10.1108/20428301311305278; Van Lith T, 2013, DISABIL REHABIL, V35, P1309, DOI 10.3109/09638288.2012.732188; Van Lith T, 2009, ADV MENT HEALTH, V8, P183, DOI 10.5172/jamh.8.2.183; Van Lith T, 2011, DISABIL REHABIL, V33, P652, DOI 10.3109/09638288.2010.505998; Whitley R, 2012, COMMUNITY MENT HLT J, V48, P547, DOI 10.1007/s10597-011-9427-4; Wilson C, 2017, INT J MENT HEALTH PR, V19, P268, DOI 10.1080/14623730.2017.1345688	30	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2020	15	12							e0243284	10.1371/journal.pone.0243284	http://dx.doi.org/10.1371/journal.pone.0243284			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PC7AH	33270738	Green Published, gold			2023-01-03	WOS:000597149100141
J	Piai, V; Nieberlein, L; Hartwigsen, G				Piai, Vitoria; Nieberlein, Laura; Hartwigsen, Gesa			Effects of transcranial magnetic stimulation over the left posterior superior temporal gyrus on picture-word interference	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; SPREADING-ACTIVATION THEORY; INFERIOR FRONTAL GYRUS; PREFRONTAL CORTEX; STATE-DEPENDENCY; TIME-COURSE; LANGUAGE; FACILITATION; MOTOR; TMS	Word-production theories argue that during language production, a concept activates multiple lexical candidates in left temporal cortex, and the intended word is selected from this set. Evidence for theories on spoken-word production comes, for example, from the picture-word interference task, where participants name pictures superimposed by congruent (e.g., picture: rabbit, distractor "rabbit"), categorically related (e.g., distractor "sheep"), or unrelated (e.g., distractor "fork") words. Typically, whereas congruent distractors facilitate naming, related distractors slow down picture naming relative to unrelated distractors, resulting in semantic interference. However, the neural correlates of semantic interference are debated. Previous neuroimaging studies have shown that the left mid-to-posterior STG (pSTG) is involved in the interference associated with semantically related distractors. To probe the functional relevance of this area, we targeted the left pSTG with focal repetitive transcranial magnetic stimulation (rTMS) while subjects performed a picture-word interference task. Unexpectedly, pSTG stimulation did not affect the semantic interference effect but selectively increased the congruency effect (i.e., faster naming with congruent distractors). The facilitatory TMS effect selectively occurred in the more difficult list with an overall lower name agreement. Our study adds new evidence to the causal role of the left pSTG in the interaction between picture and distractor representations or processing streams, only partly supporting previous neuroimaging studies. Moreover, the observed unexpected condition-specific facilitatory rTMS effect argues for an interaction of the task- or stimulusinduced brain state with the modulatory TMS effect. These issues should be systematically addressed in future rTMS studies on language production.	[Piai, Vitoria] Radboud Univ Nijmegen, Donders Ctr Cognit, Nijmegen, Netherlands; [Piai, Vitoria] Radboudumc, Donders Ctr Med Neurosci, Dept Med Psychol, Nijmegen, Netherlands; [Nieberlein, Laura; Hartwigsen, Gesa] Max Planck Inst Human Cognit & Brain Sci, Lise Meitner Res Grp Cognit & Plast, Leipzig, Germany	Radboud University Nijmegen; Radboud University Nijmegen; Max Planck Society	Piai, V (corresponding author), Radboud Univ Nijmegen, Donders Ctr Cognit, Nijmegen, Netherlands.; Piai, V (corresponding author), Radboudumc, Donders Ctr Med Neurosci, Dept Med Psychol, Nijmegen, Netherlands.; Hartwigsen, G (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Lise Meitner Res Grp Cognit & Plast, Leipzig, Germany.	v.piai@donders.ru.nl; hartwigsen@cbs.mpg.de	Hartwigsen, Gesa/M-1224-2019; Hartwigsen, Gesa/L-2283-2017; Piai, Vitória/D-5777-2012	Hartwigsen, Gesa/0000-0002-8084-1330; Hartwigsen, Gesa/0000-0002-8084-1330; Piai, Vitória/0000-0002-4860-5952	German Research Foundation (DFG) [HA-6414/3-1, HA-6314/4-1]; Max Planck Society; Netherlands Organisation for Scientific Research [451-17-003, 024.001.006]	German Research Foundation (DFG)(German Research Foundation (DFG)); Max Planck Society(Max Planck SocietyFoundation CELLEX); Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO))	GH is supported by the German Research Foundation (DFG, HA-6414/3-1 & HA-6314/4-1) and by the Max Planck Society. VP is supported by the Netherlands Organisation for Scientific Research (grant numbers 451-17-003 and Gravitation Grant 024.001.006 to the Language in Interaction Consortium) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel S, 2012, BRAIN BEHAV, V2, P109, DOI 10.1002/brb3.31; Alario FX, 2004, BEHAV RES METH INS C, V36, P140, DOI 10.3758/BF03195559; Andoh J, 2006, NEUROIMAGE, V29, P619, DOI 10.1016/j.neuroimage.2005.07.029; Andoh J, 2011, J COGNITIVE NEUROSCI, V23, P349, DOI 10.1162/jocn.2010.21449; Bergmann TO, 2016, NEUROIMAGE, V140, P4, DOI 10.1016/j.neuroimage.2016.02.012; Bestmann S, 2002, NEUROIMAGE, V17, P1512, DOI 10.1006/nimg.2002.1266; Boersma P, 2013, PRAAT DOING PHONETIC; Brodeur MB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010773; Burki A, 2020, J MEM LANG, V114, DOI 10.1016/j.jml.2020.104125; Cattaneo Z, 2008, EUR J NEUROSCI, V28, P1924, DOI 10.1111/j.1460-9568.2008.06466.x; Cheng XR, 2010, INT J PSYCHOPHYSIOL, V76, P130, DOI 10.1016/j.ijpsycho.2010.03.003; de Zubicaray GI, 2013, J EXP PSYCHOL GEN, V142, P131, DOI 10.1037/a0028717; de Zubicaray GI, 2009, COGN AFFECT BEHAV NE, V9, P260, DOI 10.3758/CABN.9.3.260; DELL GS, 1986, PSYCHOL REV, V93, P283, DOI 10.1037/0033-295X.93.3.283; Devlin JT, 2007, BRAIN, V130, P610, DOI 10.1093/brain/awl331; Devlin JT, 2003, J COGNITIVE NEUROSCI, V15, P71, DOI 10.1162/089892903321107837; Duecker F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057765; Finkbeiner M, 2006, CORTEX, V42, P790, DOI 10.1016/S0010-9452(08)70419-2; GLASER WR, 1984, J EXP PSYCHOL HUMAN, V10, P640, DOI 10.1037/0096-1523.10.5.640; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; Gough PM, 2005, J NEUROSCI, V25, P8010, DOI 10.1523/JNEUROSCI.2307-05.2005; Grefkes C, 2010, NEUROIMAGE, V50, P233, DOI 10.1016/j.neuroimage.2009.12.029; Hartwigsen G, 2015, BRAIN LANG, V148, P81, DOI 10.1016/j.bandl.2014.10.007; Hartwigsen G, 2015, CORTEX, V68, P100, DOI 10.1016/j.cortex.2014.08.027; Hartwigsen G, 2012, APHASIOLOGY, V26, P1131, DOI 10.1080/02687038.2011.590573; Hartwigsen G, 2010, P NATL ACAD SCI USA, V107, P16494, DOI 10.1073/pnas.1008121107; Hartwigsen G, 2010, NEUROPSYCHOLOGIA, V48, P3155, DOI 10.1016/j.neuropsychologia.2010.06.032; Heister J, 2011, PSYCHOL RUNDSCH, V62, P10, DOI 10.1026/0033-3042/a000029; Indefrey P, 2004, COGNITION, V92, P101, DOI 10.1016/j.cognition.2002.06.001; Indefrey P, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00255; Jung J, 2016, BRAIN STIMUL, V9, P58, DOI 10.1016/j.brs.2015.09.008; Klaus J, 2019, HUM BRAIN MAPP, V40, P3279, DOI 10.1002/hbm.24597; Kroczek LOH, 2019, CORTEX, V115, P86, DOI 10.1016/j.cortex.2019.01.010; Kuhnke P, 2020, NEUROIMAGE, V219, DOI 10.1016/j.neuroimage.2020.117041; Kuhnke P, 2017, NEUROIMAGE, V148, P254, DOI 10.1016/j.neuroimage.2017.01.013; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; LA HEIJ W, 1990, BRIT J PSYCHOL, V81, P511; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Madebach A, 2017, J EXP PSYCHOL HUMAN, V43, P1629, DOI 10.1037/xhp0000415; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Meyer L, 2018, NEUROIMAGE, V181, P598, DOI 10.1016/j.neuroimage.2018.07.059; Miniussi C, 2013, NEUROSCI BIOBEHAV R, V37, P1702, DOI 10.1016/j.neubiorev.2013.06.014; Miniussi C, 2010, CORTEX, V46, P128, DOI 10.1016/j.cortex.2009.03.004; Mottaghy FM, 2006, BEHAV NEUROL, V17, P177, DOI 10.1155/2006/768413; Mottaghy FM, 1999, NEUROLOGY, V53, P1806, DOI 10.1212/WNL.53.8.1806; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pascual-Leone, 2014, NEUROMETHODS TRANSCR; Piai V, 2018, PSYCHON B REV, V25, P710, DOI 10.3758/s13423-017-1301-0; Piai V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088674; Piai V, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00832; Python G, 2018, NEUROPSYCHOLOGIA, V121, P122, DOI 10.1016/j.neuropsychologia.2018.10.026; Rizio AA, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.660; ROELOFS A, 1992, COGNITION, V42, P107, DOI 10.1016/0010-0277(92)90041-F; Roelofs A, 2003, PSYCHOL REV, V110, P88, DOI 10.1037/0033-295X.110.1.88; Romei V, 2012, CURR BIOL, V22, P807, DOI 10.1016/j.cub.2012.03.025; Romero L, 2006, J COGNITIVE NEUROSCI, V18, P1147, DOI 10.1162/jocn.2006.18.7.1147; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Rumpf JJ, 2020, CEREB CORTEX, V30, P1030, DOI 10.1093/cercor/bhz145; Ruzzoli M, 2010, J NEUROPHYSIOL, V103, P2982, DOI 10.1152/jn.01096.2009; Sandrini M, 2011, NEUROSCI BIOBEHAV R, V35, P516, DOI 10.1016/j.neubiorev.2010.06.005; Schad DJ, 2020, J MEM LANG, V110, DOI 10.1016/j.jml.2019.104038; Schiller, 2019, OXFORD HDB NEUROLING; Schuhmann T, 2012, CEREB CORTEX, V22, P701, DOI 10.1093/cercor/bhr155; Shao ZS, 2014, BRAIN RES, V1586, P130, DOI 10.1016/j.brainres.2014.07.009; Siebner HR, 2009, CORTEX, V45, P1035, DOI 10.1016/j.cortex.2009.02.007; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Silvanto J, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00741; Silvanto J, 2017, BRAIN COGNITION, V119, P32, DOI 10.1016/j.bandc.2017.09.007; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Sparing R, 2001, J CLIN NEUROPHYSIOL, V18, P326, DOI 10.1097/00004691-200107000-00004; Starreveld PA, 1996, J EXP PSYCHOL LEARN, V22, P896, DOI 10.1037/0278-7393.22.4.896; Stoeckel C, 2009, CORTEX, V45, P1091, DOI 10.1016/j.cortex.2008.12.004; Stokes MG, 2005, J NEUROPHYSIOL, V94, P4520, DOI 10.1152/jn.00067.2005; Topper R, 1998, EXP BRAIN RES, V121, P371, DOI 10.1007/s002210050471; Valente A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00390; VENABLES WN, 2002, MODERN APPL STAT S; VITKOVITCH M, 1995, Q J EXP PSYCHOL-A, V48, P822, DOI 10.1080/14640749508401419; Walsh V, 2000, NAT REV NEUROSCI, V1, P73, DOI 10.1038/35036239; Wickham H., 2017, R PACKAGE VERSION 1; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Ziemann U, 2007, HDB TRANSKRANIELLEN, P60	82	2	2	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2020	15	11							e0242941	10.1371/journal.pone.0242941	http://dx.doi.org/10.1371/journal.pone.0242941			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT2ZY	33253319	Green Published, gold			2023-01-03	WOS:000608488200114
J	Pakwan, C; Chitov, T; Chantawannakul, P; Manasam, M; Bovonsombut, S; Disayathanoowat, T				Pakwan, Chonthicha; Chitov, Thararat; Chantawannakul, Panuwan; Manasam, Manop; Bovonsombut, Sakunnee; Disayathanoowat, Terd			Bacterial compositions of indigenous Lanna (Northern Thai) fermented foods and their potential functional properties	PLOS ONE			English	Article							LACTIC-ACID BACTERIA; MIANG; DIVERSITY; IDENTIFICATION; LACTOBACILLI; PROBIOTICS; DATABASE; FLORA	Many indigenous fermented foods of Northern Thailand and neighbouring regions have traditionally been known for their health benefits. In this study, we explored the communities of bacteria in selected fermented foods which are commonly consumed among ethnic groups around Northern Thailand, for which information on their microbial compositions or their functional properties is still limited. The selected food groups included Thua Nao (alkaline fermented soybean product), Nham (fermented pork sausage/loaf), Nam phak (fermented Chinese cabbage) and Miang (fermented leaves from Miang Tea trees). Bacteria in these fermented foods were isolated and enumerated. Bacterial communities were determined using a culture-independent (pyrosequencing) approach. Lactic acid bacteria were recovered from all of these fermented food samples, with levels ranging from 3.1 to 7.5 log CFU/g throughout the fermentation processes. Analysis of the 16S rRNA gene from the fermented food samples using 454-pyrosequencing resulted in 113,844 sequences after quality evaluation. Lactic acid bacteria were found in high proportions in Nham, Nam phak and Miang. Bacillus was predominant in Thua nao, in which significant proportions of Lactic acid bacteria of the family Leuconostocaceae were also found. Groups of lactic acid bacteria found varied among different food samples, but three genera were predominant: Lactococcus, Lactobacillus and Leuconostoc, of which many members are recognised as probiotics. The results showed that these traditional Thai fermented food products are rich sources of beneficial bacteria and can potentially be functional/probiotic foods.	[Pakwan, Chonthicha; Chitov, Thararat; Chantawannakul, Panuwan; Bovonsombut, Sakunnee; Disayathanoowat, Terd] Chiang Mai Univ, Dept Biol, Fac Sci, Chiang Mai, Thailand; [Chitov, Thararat; Chantawannakul, Panuwan; Bovonsombut, Sakunnee] Chiang Mai Univ, Environm Sci Res Ctr ESRC, Chiang Mai, Thailand; [Manasam, Manop] Chiang Mai Univ, Fac Fine Art, Dept Thai Art, Chiang Mai, Thailand; [Disayathanoowat, Terd] Chiang Mai Univ, Res Ctr Bioresources Agr Ind & Med, Chiang Mai, Thailand; [Disayathanoowat, Terd] Chiang Mai Univ, Res Ctr Microbial Divers & Sustainable Utilizat, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University; Chiang Mai University; Chiang Mai University; Chiang Mai University	Bovonsombut, S; Disayathanoowat, T (corresponding author), Chiang Mai Univ, Dept Biol, Fac Sci, Chiang Mai, Thailand.; Bovonsombut, S (corresponding author), Chiang Mai Univ, Environm Sci Res Ctr ESRC, Chiang Mai, Thailand.; Disayathanoowat, T (corresponding author), Chiang Mai Univ, Res Ctr Bioresources Agr Ind & Med, Chiang Mai, Thailand.; Disayathanoowat, T (corresponding author), Chiang Mai Univ, Res Ctr Microbial Divers & Sustainable Utilizat, Chiang Mai, Thailand.	sakunnee.b@cmu.ac.th; terd.dis@gmail.com	Chitov, Thararat/HJA-3276-2022	Disayathanoowat, Terd/0000-0002-6416-2266	Center of Excellence on Biodiversity (BDC), Office of Higher Education Commission [BDC-PG3-163006]; Chiang Mai University	Center of Excellence on Biodiversity (BDC), Office of Higher Education Commission; Chiang Mai University	This research was funded by the Center of Excellence on Biodiversity (BDC), Office of Higher Education Commission (BDC-PG3-163006) and partially supported by Chiang Mai University and the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amara AA, 2015, SAUDI PHARM J, V23, P107, DOI 10.1016/j.jsps.2013.07.001; Bhithakpol B, 1995, TRADITIONAL FERMENTE; Burintramart U, 2014, ASIA PAC J SCI TECHN, V19, P19; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chaikaew S, 2017, J MICROBIOL, V55, P720, DOI 10.1007/s12275-017-7195-8; Chakravarty K, 2019, CURR PHARM BIOTECHNO, V20, P137, DOI 10.2174/1389201020666190227203107; Chang TS, 2007, BIOSCI BIOTECH BIOCH, V71, P1330, DOI 10.1271/bbb.60573; Chantawannakul P., 2002, SCI ASIA, V28, P241, DOI [10.2306/scienceasia1513-1874.2002.28.241, DOI 10.2306/SCIENCEASIA1513-1874.2002.28.241]; Chao SH, 2008, INT J FOOD MICROBIOL, V123, P134, DOI 10.1016/j.ijfoodmicro.2007.12.010; Chettri R., 2014, INT J FERMENT FOODS, V3, P87, DOI [10.5958/2321-712X.2014.01311.8, DOI 10.5958/2321-712X.2014.01311.8]; Chukeatirote E., 2010, Research Journal of Microbiology, V5, P309; Chukeatirote Ekachai, 2015, Journal of Ethnic Foods, V2, P115; Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244; Cui SM, 2019, FOOD SCI NUTR, V7, P2214, DOI 10.1002/fsn3.1010; de Vrese M, 2008, ADV BIOCHEM ENG BIOT, V111, P1, DOI 10.1007/10_2008_097; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ercolini D, 2013, APPL ENVIRON MICROB, V79, P3148, DOI 10.1128/AEM.00256-13; Garcia MC, 1997, CRIT REV FOOD SCI, V37, P361, DOI 10.1080/10408399709527779; Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated; Inatsu Y, 2006, LETT APPL MICROBIOL, V43, P237, DOI 10.1111/j.1472-765X.2006.01966.x; Jung JY, 2011, APPL ENVIRON MICROB, V77, P2264, DOI 10.1128/AEM.02157-10; Khanongnuch Chartchai, 2017, Journal of Ethnic Foods, V4, P135; Khare A, 2020, CURR MICROBIOL, V77, P638, DOI 10.1007/s00284-020-01903-w; Klayraung S., 2008, Research Journal of Biological Sciences, V3, P1119; Klayraung S., 2008, Scientia Pharmaceutica, V76, P485, DOI 10.3797/scipharm.0806-11; Leejeerajumnean A., 2003, SILPAKORN U INT J, V3, P277, DOI DOI 10.1016/j.jef.2015.08.004; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Liu ML, 2019, FOOD FUNCT, V10, P1132, DOI 10.1039/c8fo02301h; Lopez HW, 2002, INT J FOOD SCI TECH, V37, P727, DOI 10.1046/j.1365-2621.2002.00618.x; Makhloufi KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070484; Miyashita M, 2012, MICROBIOL CULT COLL, V28, P1; Noonpakdee W, 2003, INT J FOOD MICROBIOL, V81, P137, DOI 10.1016/S0168-1605(02)00219-2; Nyanga-Koumou AP, 2012, CRIT REV MICROBIOL, V38, P185, DOI 10.3109/1040841X.2011.640978; OKADA S, 1986, J GEN APPL MICROBIOL, V32, P57, DOI 10.2323/jgam.32.57; Ouoba LII, 2010, J APPL MICROBIOL, V108, P2019, DOI 10.1111/j.1365-2672.2009.04603.x; Paludan-Muller C, 1999, INT J FOOD MICROBIOL, V46, P219, DOI 10.1016/S0168-1605(98)00204-9; Patel A, 2014, J MICROBIOL IMMUNOL, V47, P429, DOI 10.1016/j.jmii.2013.03.010; Rhee SJ, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S5; Rungrassamee W, 2012, J MICROBIOL METH, V91, P341, DOI 10.1016/j.mimet.2012.09.016; Shao ZX, 2020, NUCL INSTRUM METH A, V953, DOI 10.1016/j.nima.2019.163083; Smit G, 2005, FEMS MICROBIOL REV, V29, P591, DOI 10.1016/j.femsre.2005.04.002; Steele J, 2013, CURR OPIN BIOTECH, V24, P135, DOI 10.1016/j.copbio.2012.12.001; Suzuki T, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030763; Tamang Jyoti Prakash, 2015, Journal of Ethnic Foods, V2, P8; Tanasupawat S, 2007, J GEN APPL MICROBIOL, V53, P7, DOI 10.2323/jgam.53.7; Thiravattanamontri P, 1998, FOOD BIOTECHNOL, V12, P221, DOI 10.1080/08905439809549954; Unban K, 2019, J FOOD SCI TECH MYS, V56, P2687, DOI 10.1007/s13197-019-03758-x; Vandenplas Y, 2015, J PEDIAT-BRAZIL, V91, P6, DOI 10.1016/j.jped.2014.08.005; Viesser JA, 2020, FOOD RES INT, V136, DOI 10.1016/j.foodres.2020.109478; Wang YP, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02987; Xiong T, 2012, FOOD CONTROL, V26, P178, DOI 10.1016/j.foodcont.2012.01.027	52	6	6	4	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0242560	10.1371/journal.pone.0242560	http://dx.doi.org/10.1371/journal.pone.0242560			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VG	33206720	Green Published, gold			2023-01-03	WOS:000595265900059
J	Kirby, T				Kirby, Tony			New Zealanders approve euthanasia in landmark vote	LANCET			English	Editorial Material																			0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	2020	396	10261					1478	1478						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OO7II	33160556				2023-01-03	WOS:000587548800020
J	Begum, SZ; Nizam, NSM; Muhamad, A; Saiman, MI; Crouse, KA; Rahman, MBA				Begum, Sharifa Zaithun; Nizam, Nurul Shairah Mohd; Muhamad, Azira; Saiman, Mohd Izham; Crouse, Karen Anne; Rahman, Mohd Basyaruddin Abdul			Imidazole-rich copper peptides as catalysts in xenobiotic degradation	PLOS ONE			English	Article							WASTE-WATER; PHARMACEUTICALS; OXIDATION; LACCASE; REACTOR; AIR	Laccases, oxidative copper-enzymes found in fungi and bacteria were used as the basis in the design of nona- and tetrapeptides. Laccases are known to be excellent catalysts for the degradation of phenolic xenobiotic waste. However, since solvent extraction of laccases is environmentally-unfriendly and yields obtained are low, they are less preferred compared to synthetic catalysts. The histidine rich peptides were designed based on the active site of laccase extracted from Trametes versicolor through RCSB Protein Data Bank, LOMETS and PyMol software. The peptides were synthesized using Fmoc-solid phase peptide synthesis (SPPS) with 30-40% yield. These peptides were purified and characterized using LC-MS (purities >75%), FTIR and NMR spectroscopy. Synthesized copper(II)-peptides were crystallized and then analyzed spectroscopically. Their structures were elucidated using 1D and 2D NMR. Standards (o,m,p-cresol, 2,4-dichlorophenol) catalysed using laccase from Trametes versicolor (0.66 U/mg) were screened under different temperatures and stirring rate conditions. After optimizing the degradation of the standards with the best reaction conditions reported herein, medications with phenolic and aromatic structures such as ibuprofen, paracetamol (acetaminophen), salbutamol, erythromycin and insulin were screened using laccase (positive control), apo-peptides and copper-peptides. Their activities evaluated using GC-MS, were compared with those of peptide and copper-peptide catalysts. The tetrapeptide was found to have the higher degradation activity towards salbutamol (96.8%) compared with laccase at 42.8%. Ibuprofen (35.1%), salbutamol (52.9%) and erythromycin (49.7%) were reported to have the highest degradation activities using Cu-tetrapeptide as catalyst when compared with the other medications. Consequently, o-cresol (84%) was oxidized by Tp-Cu while the apo-peptides failed to oxidize the cresols. Copper(II)-peptides were observed to have higher catalytic activity compared to their parent peptides and the enzyme laccase for xenobiotic degradation.	[Begum, Sharifa Zaithun; Rahman, Mohd Basyaruddin Abdul] Univ Putra Malaysia, Fac Sci, Integrated Chem BioPhys Res, Serdang, Selangor, Malaysia; [Begum, Sharifa Zaithun; Nizam, Nurul Shairah Mohd] Univ Putra Malaysia, Fac Sci, Nanomol Lab, Serdang, Selangor, Malaysia; [Muhamad, Azira] Natl Inst Biotechnol Malaysia, Malaysia Genome Inst, Struct & Biophys Facil, Jalan Bangi, Bangi, Selangor, Malaysia; [Saiman, Mohd Izham; Crouse, Karen Anne; Rahman, Mohd Basyaruddin Abdul] Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang, Selangor, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Kebangsaan Malaysia; Universiti Putra Malaysia	Rahman, MBA (corresponding author), Univ Putra Malaysia, Fac Sci, Integrated Chem BioPhys Res, Serdang, Selangor, Malaysia.; Rahman, MBA (corresponding author), Univ Putra Malaysia, Fac Sci, Dept Chem, Serdang, Selangor, Malaysia.	basya@upm.edu.my		Abdul Rahman, Mohd Basyaruddin/0000-0002-5665-2564; Begum, Sharifa/0000-0003-4491-3365; Muhamad, Azira/0000-0002-7204-8789	Ministry of Higher Education [FRGS/01-01-15-1702FR (5524807)]; Research Management Centre, Universiti Putra Malaysia, Malaysia (RMC-UPM) [GP-IPS/2018/9664100]	Ministry of Higher Education(Science and Technology Development Fund (STDF)Ministry of Higher Education & Scientific Research (MHESR)); Research Management Centre, Universiti Putra Malaysia, Malaysia (RMC-UPM)	This research was funded by FRGS/01-01-15-1702FR (5524807) from the Ministry of Higher Education grant and Graduate Putra Grant (GP-IPS/2018/9664100) from the Research Management Centre, Universiti Putra Malaysia, Malaysia (RMC-UPM) to MBAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, NAT NANOTECHNOL, V11, P1, DOI 10.1038/nnano.2015.333; Arjmand F, 2013, SPECTROCHIM ACTA A, V108, P151, DOI 10.1016/j.saa.2013.01.059; Barnes CAS, 2002, ANAL CHEM, V74, P26, DOI 10.1021/ac0108562; Barton B, 2005, ORG PROCESS RES DEV, V9, P70, DOI 10.1021/op049844j; D'Annibale A, 1999, PROCESS BIOCHEM, V34, P697, DOI 10.1016/S0032-9592(98)00144-7; Duran N, 2000, APPL CATAL B-ENVIRON, V28, P83, DOI 10.1016/S0926-3373(00)00168-5; Eshelman MR, 2014, TETRAHEDRON, V70, P7651, DOI 10.1016/j.tet.2014.07.083; Gonzalez P, 2017, INORG CHEM, V56, P14870, DOI 10.1021/acs.inorgchem.7b01996; Hashim A. H., 2014, THESIS; Hautphenne C, 2016, ENVIRON TECHNOL INNO, V5, P250, DOI 10.1016/j.eti.2016.04.001; Huber MM, 2005, ENVIRON SCI TECHNOL, V39, P4290, DOI 10.1021/es048396s; Jackson E, 2016, PROCESS BIOCHEM, V51, P1248, DOI 10.1016/j.procbio.2016.06.001; Jones SM, 2015, CELL MOL LIFE SCI, V72, P869, DOI 10.1007/s00018-014-1826-6; Langenhoff A. A. M., 2009, Land Contamination & Reclamation, V17, P619, DOI 10.2462/09670513.962; Langenhoff A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/325806; Llorens-Blanch G, 2015, ENVIRON SCI-PROC IMP, V17, P429, DOI [10.1039/c4em00579a, 10.1039/C4EM00579A]; Ming LJ, 2010, J CHIN CHEM SOC-TAIP, V57, P285, DOI 10.1002/jccs.201000043; Ngoc Han Tran, 2010, Journal of Water and Environmental Technology, V8, P125, DOI 10.2965/jwet.2010.125; Oller I, 2011, SCI TOTAL ENVIRON, V409, P4141, DOI 10.1016/j.scitotenv.2010.08.061; Patneedi C. B., 2015, Rasayan Journal of Chemistry, V8, P67; Rodarte-Morales AI, 2012, BIODEGRADATION, V23, P145, DOI 10.1007/s10532-011-9494-9; Schwarzenbach RP, 2006, SCIENCE, V313, P1072, DOI 10.1126/science.1127291; Shoshan MS, 2013, JOVE-J VIS EXP, DOI 10.3791/50747; Szakacs Z., 2015, ANTHROPIC AWARENESS, P257, DOI DOI 10.1016/B978-0-12-419963-7.00007-9; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; Touahar IE, 2014, SCI TOTAL ENVIRON, V481, P90, DOI 10.1016/j.scitotenv.2014.01.132; Wen XH, 2009, CHEMOSPHERE, V75, P1003, DOI 10.1016/j.chemosphere.2009.01.052; Zaithun BS, 2018, RSC ADV, V8, P34004, DOI 10.1039/c8ra06814c	28	1	1	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2020	15	11							e0238147	10.1371/journal.pone.0238147	http://dx.doi.org/10.1371/journal.pone.0238147			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OR6WM	33147237	Green Accepted, gold, Green Published			2023-01-03	WOS:000589609300086
J	Car, J; Koh, GCH; Foong, PS; Wang, CJ				Car, Josip; Koh, Gerald Choon-Huat; Foong, Pin Sym; Wang, C. Jason			Video consultations in primary and specialist care during the covid-19 pandemic and beyond	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SKYPE		[Car, Josip] Nanyang Technol Univ, Lee Kong Chian Sch Med, Ctr Populat Hlth Sci, Singapore, Singapore; [Car, Josip] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London, England; [Koh, Gerald Choon-Huat; Foong, Pin Sym] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Wang, C. Jason] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Wang, C. Jason] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Wang, C. Jason] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA; [Wang, C. Jason] Koo Fdn, Sun Yat Sen Canc Ctr, New Sch Leadership Hlth Care, Taipei, Taiwan	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Imperial College London; National University of Singapore; Stanford University; Stanford University; Stanford University	Car, J (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Ctr Populat Hlth Sci, Singapore, Singapore.; Car, J (corresponding author), Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London, England.	josip.car@ntu.edu.sg			NIHR NW London Applied Research Collaboration; Singapore Ministry of Health's National Medical Research Council under the Singapore Population Health Improvement Centre Grant Programme; Singapore Ministry of Health's National Medical Research Council under the Diabetes, Tuberculosis and Neuroscience (Telehealth Core) Centre Grant Programme; NTU Singapore	NIHR NW London Applied Research Collaboration; Singapore Ministry of Health's National Medical Research Council under the Singapore Population Health Improvement Centre Grant Programme; Singapore Ministry of Health's National Medical Research Council under the Diabetes, Tuberculosis and Neuroscience (Telehealth Core) Centre Grant Programme; NTU Singapore(Nanyang Technological University)	JC gratefully acknowledges NTU Singapore's support for Centre for Population Health Sciences which enabled this work. JC's post at Imperial College London is supported by the NIHR NW London Applied Research Collaboration. GC-HK is supported by the Singapore Ministry of Health's National Medical Research Council under the Singapore Population Health Improvement Centre and the Diabetes, Tuberculosis and Neuroscience (Telehealth Core) Centre Grant Programmes. Funders were not involved in preparation, review, or approval of the manuscript.	Agency for Clinical Innovation, 2015, GUID US TEL CLIN NON; American Medical Association, 2020, MAINT MOM TEL COV 19; Armfield NR, 2015, INT J MED INFORM, V84, P737, DOI 10.1016/j.ijmedinf.2015.06.006; Australia Department of Health, 2020, COV 19 NAT HLTH PLAN; Australian Digital Health Agency, 2018, AUSTR NAT DIG HLTH S; Australian Government and Australian Digital Health Agency, 2018, SAF SEAML SEC EV HLT; Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924; Castle-Clarke S., 2018, WHAT WILL NEW TECHNO; Centers for Disease Control and Prevention, 2020, US TEL EXP ACC ESS H; Department of Health and Human Services Office for Civil Rights, 2020, NOT ENF DISCR TEL RE; Derkx H, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.027920; Deshpande A, 2008, REAL TIME SYNCHRONOU; Donaghy E, 2019, BRIT J GEN PRACT, V69, pE586, DOI 10.3399/bjgp19X704141; Duncan AB, 2014, J CLIN CHILD ADOLESC, V43, P115, DOI 10.1080/15374416.2013.836452; European Commission, 2016, J EUROPEAN UNIO 0427, V2016; Fatehi F, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1013-5; Freeman Kurt A, 2013, J Diabetes Sci Technol, V7, P727; Gavidia M., 2020, AM J MANAGED CARE; General Medical Council, 2013, MAK US VIS AUD REC P; General Medical Council, 2019, REM CONS ETH GUID; General Medical Council, 2020, REM CONS; Gray DJP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021161; GREENHALGH T, 2020, BMJ-BRIT MED J, V368, P3505, DOI DOI 10.1136/BMJ.M1182; Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m998; Greenhalgh T, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9897; Greenhalgh T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009388; Hammersley V, 2019, BRIT J GEN PRACT, V69, pE595, DOI 10.3399/bjgp19X704573; Hansen CR, 2017, EUR J ENDOCRINOL, V176, P727, DOI 10.1530/EJE-16-0811; Harris MA, 2015, DIABETES CARE, V38, P1427, DOI 10.2337/dc14-2469; Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; Ignatowicz A, 2019, DIGIT HEALTH, V5, DOI 10.1177/2055207619845831; Information Commissioner's Office, 2020, DAT PROT COR UK; Jakowenko JB, 2014, IMPLEMENTATION GUIDE; Kanani N., 2020, PREPAREDNESS LETT GE; Mallow Jennifer A, 2016, Ehealth Telecommun Syst Netw, V5, P39, DOI 10.4236/etsn.2016.52005; Maple Corporation, 2020, MAPL ONL DOCT VIRT H; McGrail Kimberlyn Marie, 2017, J Med Internet Res, V19, pe177, DOI 10.2196/jmir.7374; McKinstry B, 2009, BRIT J GEN PRACT, V59, P433, DOI 10.3399/bjgp09X420941; Ministry of Health, 2015, NAT TEL GUID RES STA; National Institute for Health Research, 2017, ALT FAC FAC CONS GP; NHS UK, 2020, ADV US VID CONS SYST; NHS UK, 2020, APP GEN PRACT ENGL; NHS UK, 2019, NHS LONG TERM PLAN; Pappas Y, 2019, J PATIENT EXPERIENCE, V6, P296, DOI 10.1177/2374373518803617; Robison SJ, 2018, CP SCOTLANDS DIGITAL; Sharp IR, 2011, ANN GEN PSYCHIATR, V10, DOI 10.1186/1744-859X-10-14; Shaw S, 2018, NIHR J LIB, DOI [10.3310/ hsdr06210, DOI 10.3310/HSDR06210]; Siriwardena LSAN, 2012, J TELEMED TELECARE, V18, P164, DOI 10.1258/jtt.2012.SFT110; Sucala M, 2012, J MED INTERNET RES, V14, P175, DOI 10.2196/jmir.2084; The Faculty of Forensic & Legal Medicine of the Royal College of Physicians, 2020, KEY PRINC INT CLIN A; The Royal Australasian College of Physicians, 2012, TEL GUID PRACT TIPS; The Royal Australian College of General Practitioners, 2011, STAND GEN PRACT OFF; The Royal Australian College of General Practitioners, 2020, GUID PROV TEL VID CO; US Department of Health and Human Services, 2013, SUMM HIPAA PRIV RUL; van Galen LS, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k1047; Vautrey RD, 2019, 5 YEAR FRAMEWORK GP; Wilkie RLFY, 2019, 2018 2024 STRATEGIC; Wilson LS, 2015, HEALTHC INFORM RES, V21, P213, DOI 10.4258/hir.2015.21.4.213; Zanaboni P, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1743-5	59	76	76	2	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 20	2020	371								m3945	10.1136/bmj.m3945	http://dx.doi.org/10.1136/bmj.m3945			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OD5ST	33082127	Bronze			2023-01-03	WOS:000579914300003
J	Hermes, C; Nydahl, P; Blobner, M; Dubb, R; Filipovic, S; Kaltwasser, A; Ulm, B; Schaller, SJ				Hermes, Carsten; Nydahl, Peter; Blobner, Manfred; Dubb, Rolf; Filipovic, Silke; Kaltwasser, Arnold; Ulm, Bernhard; Schaller, Stefan J.			Assessment of mobilization capacity in 10 different ICU scenarios by different professions	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; ACUTE RESPIRATORY-FAILURE; BREATHING COORDINATION; IDENTIFYING BARRIERS; EARLY REHABILITATION; ACTIVE MOBILIZATION; POINT-PREVALENCE; CRITICAL ILLNESS; ADULT PATIENTS	Background Mobilization of intensive care patients is a multi-professional task. Aim of this study was to explore how different professions working at Intensive Care Units (ICU) estimate the mobility capacity using the ICU Mobility Score in 10 different scenarios. Methods Ten fictitious patient-scenarios and guideline-related knowledge were assessed using an online survey. Critical care team members in German-speaking countries were invited to participate. All datasets including professional data and at least one scenario were analyzed. Kruskal Wallis test was used for the individual scenarios, while a linear mixed-model was used over all responses. Results In total, 515 of 788 (65%) participants could be evaluated. Physicians (p = 0.001) and nurses (p = 0.002) selected a lower ICU Mobility Score (-0.7 95% CI -1.1 to -0.3 and -0.4 95% CI -0.7 to -0.2, respectively) than physical therapists, while other specialists did not (p = 0.81). Participants who classified themselves as experts or could define early mobilization in accordance to the "S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders" correctly selected higher mobilization levels (0.2 95% CI 0.0 to 0.4, p = 0.049 and 0.3 95% CI 0.1 to 0.5, p = 0.002, respectively). Conclusion Different professions scored the mobilization capacity of patients differently, with nurses and physicians estimating significantly lower capacity than physical therapists. The exact knowledge of guidelines and recommendations, such as the definition of early mobilization, independently lead to a higher score. Interprofessional education, interprofessional rounds and mobilization activities could further enhance knowledge and practice of mobilization in the critical care team.	[Hermes, Carsten; Schaller, Stefan J.] CCRN, Bonn, Germany; [Nydahl, Peter] Univ Hosp Schleswig Holstein, Dept Anesthesiol & Intens Care Med, Nursing Res, Kiel, Germany; [Blobner, Manfred; Ulm, Bernhard; Schaller, Stefan J.] Tech Univ Munich, Dept Anesthesiol & Intens Care, Sch Med, Klinikum Rechts Isar, Munich, Germany; [Dubb, Rolf; Kaltwasser, Arnold] Acad Dist Clin Reutlingen, Reutlingen, Germany; [Filipovic, Silke] Univ Hosp Giessen & Marburg, Dept Physiotherapy, Marburg, Germany; [Schaller, Stefan J.] Charite Univ Med Berlin, Freie Univ Berlin, Berlin, Germany; [Schaller, Stefan J.] Charite Univ Med Berlin, Humboldt Univ Berlin, Berlin, Germany; [Schaller, Stefan J.] Berlin Inst Hlth, Dept Anesthesiol & Operat Intens Care Med, Berlin, Germany	University of Kiel; Schleswig Holstein University Hospital; Technical University of Munich; University Hospital of Giessen & Marburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Hermes, C; Schaller, SJ (corresponding author), CCRN, Bonn, Germany.; Schaller, SJ (corresponding author), Tech Univ Munich, Dept Anesthesiol & Intens Care, Sch Med, Klinikum Rechts Isar, Munich, Germany.; Schaller, SJ (corresponding author), Charite Univ Med Berlin, Freie Univ Berlin, Berlin, Germany.; Schaller, SJ (corresponding author), Charite Univ Med Berlin, Humboldt Univ Berlin, Berlin, Germany.; Schaller, SJ (corresponding author), Berlin Inst Hlth, Dept Anesthesiol & Operat Intens Care Med, Berlin, Germany.	stefan.schaller@charite.de	Schaller, Stefan J/L-8054-2019; Nydahl, Peter/V-4516-2019; Blobner, Manfred/R-4411-2017	Schaller, Stefan J/0000-0002-6683-9584; Nydahl, Peter/0000-0002-5178-0364; Hermes, Carsten/0000-0003-0889-1381; Blobner, Manfred/0000-0002-0370-5247; Dubb, Rolf/0000-0002-1832-6338	German Research Foundation (DFG); Open Access Publication Fund of Charite - Universitats medizin Berlin	German Research Foundation (DFG)(German Research Foundation (DFG)); Open Access Publication Fund of Charite - Universitats medizin Berlin	We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charite - Universitats medizin Berlin.	Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Bakhru RN, 2016, ANN AM THORAC SOC, V13, P1527, DOI 10.1513/AnnalsATS.201601-078OC; Balas MC, 2014, CRIT CARE MED, V42, P1024, DOI 10.1097/CCM.0000000000000129; Berney SC, 2019, ARCH PHYS MED REHAB, V100, P261, DOI 10.1016/j.apmr.2018.07.438; Brock C, 2018, HEART LUNG, V47, P380, DOI 10.1016/j.hrtlng.2018.04.004; Costa DK, 2017, CHEST, V152, P304, DOI 10.1016/j.chest.2017.03.054; de Queiroz RS, 2018, HEART LUNG, V47, P253, DOI 10.1016/j.hrtlng.2018.03.003; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Dubb R, 2016, ANN AM THORAC SOC, V13, P724, DOI 10.1513/AnnalsATS.201509-586CME; Fontela Paula Caitano, 2018, Rev. bras. ter. intensiva, V30, P187, DOI [10.5935/0103-507X.20180037, 10.5935/0103-507x.20180037]; Fuest K, 2018, CURR OPIN ANESTHESIO, V31, P144, DOI 10.1097/ACO.0000000000000568; Garzon-Serrano J, 2011, PM&R, V3, P307, DOI 10.1016/j.pmrj.2010.12.022; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Hickmann CE, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0184-y; Hodgson C, 2014, HEART LUNG, V43, P19, DOI 10.1016/j.hrtlng.2013.11.003; Hodgson CL, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0658-y; Holdsworth C, 2015, J CRIT CARE, V30, P1243, DOI 10.1016/j.jcrc.2015.08.010; Jolley SE, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-84; Jolley SE, 2017, CRIT CARE MED, V45, P205, DOI 10.1097/CCM.0000000000002058; Krupp A, 2018, INTENS CRIT CARE NUR, V47, P30, DOI 10.1016/j.iccn.2018.04.003; Lee H, 2016, BLOOD PURIFICAT, V42, P83, DOI 10.1159/000446175; Lord RK, 2013, CRIT CARE MED, V41, P717, DOI 10.1097/CCM.0b013e3182711de2; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Nessizius S, 2017, MED KLIN-INTENSIVMED, V112, P308, DOI 10.1007/s00063-017-0280-2; Nickels M, 2017, AUST CRIT CARE, V30, P79, DOI 10.1016/j.aucc.2016.03.003; Nydahl P, 2017, MED KLIN-INTENSIVMED, V112, P156, DOI 10.1007/s00063-016-0210-8; Nydahl P, 2016, MED KLIN-INTENSIVMED, V111, P153, DOI 10.1007/s00063-015-0073-4; Nydahl P, 2020, HEART LUNG, V49, P301, DOI 10.1016/j.hrtlng.2019.12.004; Nydahl P, 2017, ANN AM THORAC SOC, V14, P766, DOI 10.1513/AnnalsATS.201611-843SR; Nydahl P, 2014, CRIT CARE MED, V42, P1178, DOI 10.1097/CCM.0000000000000149; Parry SM, 2018, INTENS CARE MED, V44, P470, DOI 10.1007/s00134-017-4908-8; Parry SM, 2017, INTENS CARE MED, V43, P531, DOI 10.1007/s00134-017-4685-4; Parry SM, 2017, J CRIT CARE, V38, P137, DOI 10.1016/j.jcrc.2016.11.005; Schaller SJ, 2019, INTENS CARE MED, V45, P201, DOI 10.1007/s00134-019-05528-x; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schaller SJ, 2016, J CRIT CARE, V32, P201, DOI 10.1016/j.jcrc.2015.12.020; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sibilla A, 2020, J INTENSIVE CARE MED, V35, P55, DOI 10.1177/0885066617728486; Taito S, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0179-7; Toonstra AL, 2017, DISABIL REHABIL, V39, P1143, DOI 10.1080/09638288.2016.1186751; Waldauf P, 2020, CRIT CARE MED, V48, P1055, DOI 10.1097/CCM.0000000000004382; Workowski KA, 2015, MMWR RECOMM REP, V64, P1, DOI 10.15585/mmwr.rr7004a1; Young DL, 2018, AM J CRIT CARE, V27, P186, DOI 10.4037/ajcc2018368; [No title captured]; [No title captured]	46	10	9	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2020	15	10							e0239853	10.1371/journal.pone.0239853	http://dx.doi.org/10.1371/journal.pone.0239853			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3UY	33057435	gold, Green Published			2023-01-03	WOS:000581814700016
J	Quinn, KL; Shurrab, M; Gitau, K; Kavalieratos, D; Isenberg, SR; Stall, NM; Stukel, TA; Goldman, R; Horn, D; Cram, P; Detsky, AS; Bell, CM				Quinn, Kieran L.; Shurrab, Mohammed; Gitau, Kevin; Kavalieratos, Dio; Isenberg, Sarina R.; Stall, Nathan M.; Stukel, Therese A.; Goldman, Russell; Horn, Daphne; Cram, Peter; Detsky, Allan S.; Bell, Chaim M.			Association of Receipt of Palliative Care Interventions With Health Care Use, Quality of Life, and Symptom Burden Among Adults With Chronic Noncancer Illness: A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ADVANCED HEART-FAILURE; RANDOMIZED-TRIAL; END; PATIENT; DISEASE; OUTCOMES; MODELS; TEAM; TRAJECTORIES; MANAGEMENT	Key PointsQuestionIs receipt of palliative care interventions associated with lower acute health care use and better patient-centered outcomes in adults with noncancer illness? FindingsIn this systematic review and meta-analysis of 28 randomized clinical trials of patients with primarily noncancer illness, receipt of palliative care interventions, compared with usual care, was statistically significantly associated with less acute health care use and modestly lower symptom burden, but there was no significant difference in quality of life. MeaningAmong patients with primarily noncancer illness, receipt of palliative care interventions was associated with lower acute health care use and modestly lower symptom burden, although analyses for some outcomes were based predominantly on studies of patients with heart failure, which may limit the generalizability of these findings to other chronic illnesses. ImportanceThe evidence for palliative care exists predominantly for patients with cancer. The effect of palliative care on important end-of-life outcomes in patients with noncancer illness is unclear. ObjectiveTo measure the association between palliative care and acute health care use, quality of life (QOL), and symptom burden in adults with chronic noncancer illnesses. Data SourcesMEDLINE, Embase, CINAHL, PsycINFO, and PubMed from inception to April 18, 2020. Study SelectionRandomized clinical trials of palliative care interventions in adults with chronic noncancer illness. Studies involving at least 50% of patients with cancer were excluded. Data Extraction and SynthesisTwo reviewers independently screened, selected, and extracted data from studies. Narrative synthesis was conducted for all trials. All outcomes were analyzed using random-effects meta-analysis. Main Outcomes and MeasuresAcute health care use (hospitalizations and emergency department use), disease-generic and disease-specific quality of life (QOL), and symptoms, with estimates of QOL translated to units of the Functional Assessment of Chronic Illness Therapy-Palliative Care scale (range, 0 [worst] to 184 [best]; minimal clinically important difference, 9 points) and symptoms translated to units of the Edmonton Symptom Assessment Scale global distress score (range, 0 [best] to 90 [worst]; minimal clinically important difference, 5.7 points). ResultsTwenty-eight trials provided data on 13664 patients (mean age, 74 years; 46% were women). Ten trials were of heart failure (n=4068 patients), 11 of mixed disease (n=8119), 4 of dementia (n=1036), and 3 of chronic obstructive pulmonary disease (n=441). Palliative care, compared with usual care, was statistically significantly associated with less emergency department use (9 trials [n=2712]; 20% vs 24%; odds ratio, 0.82 [95% CI, 0.68-1.00]; I-2=3%), less hospitalization (14 trials [n=3706]; 38% vs 42%; odds ratio, 0.80 [95% CI, 0.65-0.99]; I-2=41%), and modestly lower symptom burden (11 trials [n = 2598]; pooled standardized mean difference (SMD), -0.12; [95% CI, -0.20 to -0.03]; I-2=0%; Edmonton Symptom Assessment Scale score mean difference, -1.6 [95% CI, -2.6 to -0.4]). Palliative care was not significantly associated with disease-generic QOL (6 trials [n=1334]; SMD, 0.18 [95% CI, -0.24 to 0.61]; I-2=87%; Functional Assessment of Chronic Illness Therapy-Palliative Care score mean difference, 4.7 [95% CI, -6.3 to 15.9]) or disease-specific measures of QOL (11 trials [n=2204]; SMD, 0.07 [95% CI, -0.09 to 0.23]; I-2=68%). Conclusions and RelevanceIn this systematic review and meta-analysis of randomized clinical trials of patients with primarily noncancer illness, palliative care, compared with usual care, was statistically significantly associated with less acute health care use and modestly lower symptom burden, but there was no significant difference in quality of life. Analyses for some outcomes were based predominantly on studies of patients with heart failure, which may limit generalizability to other chronic illnesses. This meta-analysis estimates the association between palliative care and health care use, disease-generic and disease-specific measures of quality of life, and symptom burden among adults with noncancer illness.	[Quinn, Kieran L.; Gitau, Kevin; Cram, Peter; Detsky, Allan S.; Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Quinn, Kieran L.; Shurrab, Mohammed; Stukel, Therese A.; Cram, Peter; Bell, Chaim M.] ICES, Toronto, ON, Canada; [Quinn, Kieran L.; Shurrab, Mohammed; Stall, Nathan M.; Stukel, Therese A.; Cram, Peter; Detsky, Allan S.; Bell, Chaim M.] Univ Toronto, Inst Hlth & Evaluat, Toronto, ON, Canada; [Quinn, Kieran L.; Horn, Daphne; Cram, Peter; Detsky, Allan S.; Bell, Chaim M.] Sinai Hlth Syst, Dept Med, Toronto, ON, Canada; [Shurrab, Mohammed] Hlth Sci North Res Inst, Sudbury, ON, Canada; [Shurrab, Mohammed] Laurentian Univ, Northern Ontario Sch Med, Sudbury, ON, Canada; [Kavalieratos, Dio] Emory Univ, Div Palliat Med, Dept Family & Prevent Med, Atlanta, GA 30322 USA; [Isenberg, Sarina R.; Goldman, Russell] Temmy Latner Ctr Palliat Care, Toronto, ON, Canada; [Isenberg, Sarina R.; Goldman, Russell] Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Isenberg, Sarina R.; Goldman, Russell] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Stall, Nathan M.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Stall, Nathan M.] Univ Toronto, Div Geriatr Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Health Sciences North; Northern Ontario School of Medicine; Laurentian University; Northern Ontario School of Medicine; Emory University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto	Quinn, KL (corresponding author), Sinai Hlth Syst, 60 Murray St,Second Floor,Room 404, Toronto, ON M5T 3L9, Canada.	kieran.quinn@mail.utoronto.ca	Isenberg, Sarina/AAE-4407-2021; Kavalieratos, Dio/GLV-4567-2022; Kavalieratos, Dio/GLR-1388-2022	Kavalieratos, Dio/0000-0001-5283-0792; Gitau, Kevin/0000-0001-6494-8958				Agar M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181020; Ahronheim J C, 2000, J Palliat Med, V3, P265, DOI 10.1089/jpm.2000.3.265; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Alla F, 2002, EUR J HEART FAIL, V4, P337, DOI 10.1016/S1388-9842(02)00006-5; Alzheimer Society Canada, DEM NUMB CAN; Au DH, 2012, CHEST, V141, P726, DOI 10.1378/chest.11-0362; Bahadori Katayoon, 2007, Int J Chron Obstruct Pulmon Dis, V2, P241; Bekelman DB, 2018, JAMA INTERN MED, V178, P511, DOI 10.1001/jamainternmed.2017.8667; Bekelman DB, 2015, JAMA INTERN MED, V175, P725, DOI 10.1001/jamainternmed.2015.0315; Brannstrom M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151; Brereton L, 2017, PALLIATIVE MED, V31, P781, DOI 10.1177/0269216317701890; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Courtright KR, 2018, ANN INTERN MED, V168, P71, DOI 10.7326/M17-2164; Deeks J, 2019, COCHRANE HDB SYSTEMA; Ernecoff NC, 2020, J PALLIAT MED, V23, P389, DOI 10.1089/jpm.2019.0349; Farquhar MC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1304-6; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Gaertner J, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2925; Gershon AS, 2010, ARCH INTERN MED, V170, P560, DOI 10.1001/archinternmed.2010.17; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Hopp FP, 2016, J CARD FAIL, V22, P1033, DOI 10.1016/j.cardfail.2016.04.004; Hui D, 2017, J PAIN SYMPTOM MANAG, V53, P630, DOI 10.1016/j.jpainsymman.2016.10.370; Janssens JP, 2019, RESPIRATION, V97, P406, DOI 10.1159/000495312; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kavalieratos D, 2014, J PALLIAT MED, V17, P475, DOI 10.1089/jpm.2013.0526; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kousaie K, 2017, J PALLIAT MED, V20, P1313, DOI 10.1089/jpm.2017.0380; Lang JJ, 2018, CAN MED ASSOC J, V190, pE1296, DOI 10.1503/cmaj.180698; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Lyons KD, 2009, J PAIN SYMPTOM MANAG, V37, P23, DOI 10.1016/j.jpainsymman.2007.12.015; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; McIlvennan CK, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1010; Meurer WJ, 2017, JAMA-J AM MED ASSOC, V317, P1068, DOI 10.1001/jama.2016.20441; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Consensus Project for Quality Palliative Care, 2018, CLIN PRACT GUID QUAL, V4th; Nieminen MS, 2015, INT J CARDIOL, V191, P256, DOI 10.1016/j.ijcard.2015.04.235; O'Donnell AE, 2018, JAMA CARDIOL, V3, P516, DOI 10.1001/jamacardio.2018.0589; Pantilat SZ, 2010, ARCH INTERN MED, V170, P2038, DOI 10.1001/archinternmed.2010.460; Phongtankuel V, 2018, AM J HOSP PALLIAT ME, V35, P173, DOI 10.1177/1049909116674669; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Possin KL, 2019, JAMA INTERN MED, V179, P1658, DOI 10.1001/jamainternmed.2019.4101; Quinn KL, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2257; Quinn KL, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.013844; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Radwany SM, 2014, POPUL HEALTH MANAG, V17, P106, DOI 10.1089/pop.2013.0017; Rahman AN, 2019, J PALLIAT MED, V22, P1274, DOI 10.1089/jpm.2019.0031; Rogers JG, 2017, J AM COLL CARDIOL, V70, P332, DOI 10.1016/j.jacc.2017.05.030; Sampson EL, 2011, PALLIATIVE MED, V25, P197, DOI 10.1177/0269216310391691; Seow H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021147; Sidebottom AC, 2015, J PALLIAT MED, V18, P134, DOI 10.1089/jpm.2014.0192; Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367; Stall N, 2019, CAN MED ASSOC J, V191, pE245, DOI 10.1503/cmaj.190204; Steinberg L, 2017, CAN FAM PHYSICIAN, V63, P674; Steinhauser KE, 2017, J PAIN SYMPTOM MANAG, V54, P898, DOI 10.1016/j.jpainsymman.2017.06.003; Steinhauser KE, 2011, J PAIN SYMPTOM MANAG, V42, P331, DOI 10.1016/j.jpainsymman.2010.11.006; Steinhauser KE, 2008, J PALLIAT MED, V11, P1234, DOI 10.1089/jpm.2008.0078; Tanuseputro P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191322; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Van den Block L, 2020, JAMA INTERN MED, V180, P233, DOI 10.1001/jamainternmed.2019.5349; Van Spall HGC, 2019, JAMA-J AM MED ASSOC, V321, P753, DOI 10.1001/jama.2019.0710; Wong FKY, 2016, HEART, V102, P1100, DOI 10.1136/heartjnl-2015-308638; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	69	53	53	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2020	324	14					1439	1450		10.1001/jama.2020.14205	http://dx.doi.org/10.1001/jama.2020.14205			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OS4TT	33048152	Bronze, Green Published			2023-01-03	WOS:000590158000020
J	Hayashida, M; Miki, A; Nakai, S; Matsumiya, W; Imai, H; Kusuhara, S; Nakamura, M				Hayashida, Mayuka; Miki, Akiko; Nakai, Shunichiro; Matsumiya, Wataru; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto			Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity	PLOS ONE			English	Article							M-CHARTS	This retrospective study was conducted to investigate the predictive factors associated with metamorphopsia after reduced-fluence photodynamic therapy (RFPDT) in patients with central serous chorioretinopathy (CSC) with good baseline visual acuity. A total of 36 eyes of 36 consecutive patients with resolved CSC after RFPDT and best-corrected visual acuity (BCVA) better than 1.0 (logarithm of the minimal angle of resolution (logMAR) 0) at baseline were examined. Metamorphopsia was measured using M-CHARTS at 12 months after RFPDT. An average of the horizontal and vertical M-CHARTS scores was applied for defining the extent of metamorphopsia. The association between M-CHARTS score at 12 months after RFPDT and clinical parameters (age, sex, duration of symptoms, BCVA, and findings of optical coherence tomography (OCT)) was investigated at baseline or 12 months after RFPDT. The M-CHARTS score at 12 months correlated significantly with duration of symptoms (P= 0.005), baseline outer nuclear layer (ONL) thickness (P= 0.009), central foveal thickness (CFT) (P= 0.001) at 12 months, and ONL thickness (P= 0.001) at 12 months after RFPDT. In the multivariate analysis of baseline-related factors, thinner ONL thickness before RFPDT (P= 0.010) was significantly associated with large metamorphopsia at 12 months after RFPDT in CSC patients with good baseline BCVA. Baseline ONL thickness may be a useful predictive factor of metamorphopsia after RFPDT in CSC patients with good baseline BCVA.	[Hayashida, Mayuka; Miki, Akiko; Nakai, Shunichiro; Matsumiya, Wataru; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan	Kobe University	Miki, A (corresponding author), Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.	acacyey@med.kobe-u.ac.jp						AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521; Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535; Bae S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0170-4; Fujita K, 2014, RETINA-J RET VIT DIS, V34, P964, DOI 10.1097/IAE.0000000000000027; Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130; Kinoshita T, 2015, CLIN OPHTHALMOL, V9, P225, DOI 10.2147/OPTH.S76847; Klais CM, 2006, RETINA, V4th, P1135; Matuskova V, 2018, SEMIN OPHTHALMOL, V33, P690, DOI 10.1080/08820538.2017.1416414; Ooto S, 2010, OPHTHALMOLOGY, V117, P1800, DOI 10.1016/j.ophtha.2010.01.042; Ozdemir I, 2019, INT OPHTHALMOL, V39, P1323, DOI 10.1007/s10792-018-0950-y; Stewart JM, 2006, BRIT J OPHTHALMOL, V90, P805, DOI 10.1136/bjo.2006.093328; Tsai MJ, 2014, OPTOMETRY VISION SCI, V91, P1140, DOI 10.1097/OPX.0000000000000360; van Rijssen TJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202549; Yu J, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1089-y	14	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2020	15	10							e0240557	10.1371/journal.pone.0240557	http://dx.doi.org/10.1371/journal.pone.0240557			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TU	33044997	Green Published, gold			2023-01-03	WOS:000581811700005
J	Lin, XH; Pan, HY; Cheng, FJ; Huang, KC; Li, CJ; Chen, CC; Chuang, PC				Lin, Xin-Hong; Pan, Hsiu-Yung; Cheng, Fu-Jen; Huang, Kuo-Chen; Li, Chao-Jui; Chen, Chien-Chih; Chuang, Po-Chun			Association between liberal oxygen therapy and mortality in patients with paraquat poisoning: A multi-center retrospective cohort study	PLOS ONE			English	Article							HERBICIDE PARAQUAT; TOXICITY; LUNG; RAT; MECHANISMS; APOPTOSIS	Paraquat (N, N'-dimethyl-4, 4'-bipyridinium dichloride, PQ) intoxication is a common cause of lethal poisoning. This study aimed to identify the risk of using liberal oxygen therapy in patients with PQ poisoning. This was a multi-center retrospective cohort study involving four medical institutions in Taiwan. Data were extracted from the Chang Gung Research Database (CGRD) from January 2004 to December 2016. Patients confirmed to have PQ intoxication with a urine PQ concentration >= 5 ppm were analyzed. Patients who received oxygen therapy before marked hypoxia (SpO2 >= 90%) were defined as receiving liberal oxygen therapy. The association between mortality and patient demographics, blood paraquat concentration (ppm), and liberal oxygen therapy were analyzed. A total of 416 patients were enrolled. The mortality rate was higher in the liberal oxygen therapy group (87.8% vs. 73.7%, P = 0.007), especially in 28-day mortality (adjusted odds ratio [aOR]: 4.71, 95% confidence interval [CI]: 1.533-14.471) and overall mortality (aOR: 5.97, 95% CI: 1.692-21.049) groups. Mortality in patients with PQ poisoning was also associated with age (aOR: 1.04, 95% CI: 1.015-1.073), blood creatinine level (aOR: 1.49, 95% CI: 1.124-1.978), and blood paraquat concentration (ppm) (aOR, 1.51; 95% CI: 1.298-1.766). Unless the evidence of hypoxia (SpO2 < 90%) is clear, oxygen therapy should be avoided because it is associated with increased mortality.	[Lin, Xin-Hong; Pan, Hsiu-Yung; Cheng, Fu-Jen; Huang, Kuo-Chen; Li, Chao-Jui; Chen, Chien-Chih; Chuang, Po-Chun] Chang Gung Univ, Dept Emergency Med, Kaohsiung Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan; [Pan, Hsiu-Yung; Cheng, Fu-Jen] Chang Gung Univ, Coll Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University	Chuang, PC (corresponding author), Chang Gung Univ, Dept Emergency Med, Kaohsiung Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan.	zhungboqun@gmail.com	Huang, James/ADK-6342-2022					ADAM A, 1990, ENVIRON HEALTH PERSP, V85, P113, DOI 10.2307/3430673; Bertolote JM, 2006, B WORLD HEALTH ORGAN, V84, P260; Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005; BUS JS, 1976, ENVIRON HEALTH PERSP, V16, P139, DOI 10.2307/3428594; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; Cappelletti G, 1998, CELL BIOL INT, V22, P671, DOI 10.1006/cbir.1998.0305; Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200; Chan BSH, 1998, PHARMACOL THERAPEUT, V79, P193, DOI 10.1016/S0163-7258(98)00015-1; Chang S-S, 2019, BANNING PARAQUAT WOU, V33, P119; Del Rio MJ, 2008, GROWTH FACTORS, V26, P49, DOI 10.1080/08977190801984205; Denicola A, 2005, TOXICOLOGY, V208, P273, DOI 10.1016/j.tox.2004.11.023; Dinis-Oliveira RJ, 2008, CRIT REV TOXICOL, V38, P13, DOI 10.1080/10408440701669959; DODGE AD, 1971, ENDEAVOUR, V30, P130, DOI 10.1016/0160-9327(71)90039-1; GARDINER AJ, 1972, THORAX, V27, P132, DOI 10.1136/thx.27.1.132; Gawarammana I, 2018, CLIN TOXICOL, V56, P633, DOI 10.1080/15563650.2017.1394465; Gawarammana IB, 2011, BRIT J CLIN PHARMACO, V72, P745, DOI 10.1111/j.1365-2125.2011.04026.x; Gunnell D, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-357; Hoet PHM, 1997, HUM EXP TOXICOL, V16, P305, DOI 10.1177/096032719701600602; Hsu CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048397; Kang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078160; Kang X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121691; KEELING PL, 1982, BIOCHEM PHARMACOL, V31, P3243, DOI 10.1016/0006-2952(82)90557-3; KEHRER JP, 1979, DRUG CHEM TOXICOL, V2, P397, DOI 10.3109/01480547909016033; KELNER MJ, 1989, ARCH BIOCHEM BIOPHYS, V274, P366, DOI 10.1016/0003-9861(89)90450-5; Khazraei S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52939-3; Khosya Surendra, 2012, Case Rep Crit Care, V2012, P652146, DOI 10.1155/2012/652146; Ko DR, 2017, YONSEI MED J, V58, P859, DOI 10.3349/ymj.2017.58.4.859; Lee Y, 2012, CLIN TOXICOL, V50, P52, DOI 10.3109/15563650.2011.639716; Li KK, 2017, FOOD CHEM TOXICOL, V106, P356, DOI 10.1016/j.fct.2017.05.067; Lin HY, 2017, J CHIN MED ASSOC, V80, P227, DOI 10.1016/j.jcma.2016.10.009; Lin JL, 2011, INTENS CARE MED, V37, P1006, DOI 10.1007/s00134-010-2127-7; Nagata I, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018635; Oghabian Z, 2019, J RES PHARM PRACT, V8, P129, DOI 10.4103/jrpp.JRPP_18_71; Pratt I S, 1980, Arch Toxicol Suppl, V4, P415; Saeed SAM, 2001, POSTGRAD MED J, V77, P329, DOI 10.1136/pmj.77.907.329; SEVITT S, 1974, J CLIN PATHOL, V27, P21, DOI 10.1136/jcp.27.1.21; SMITH P, 1976, CRC CR REV TOXICOL, V4, P411, DOI 10.1080/10408447609164020; Suntres ZE, 2002, TOXICOLOGY, V180, P65, DOI 10.1016/S0300-483X(02)00382-7; Tawara T, 1996, ARCH TOXICOL, V70, P585, DOI 10.1007/s002040050316; The WHO Alliance for Maternal and Newborn Health Improvement late pregnancy dating study group, 2020, LANCET GLOB HLTH, V8, pe545; Weng CH, 2017, ONCOTARGET, V8, P51345, DOI 10.18632/oncotarget.17975; Weng CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082695; Weng CH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051743; Wu MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195071; Yang W, 2007, J TOXICOL ENV HEAL A, V70, P1849, DOI 10.1080/15287390701459262; YASAKA T, 1981, ARCH INTERN MED, V141, P1169, DOI 10.1001/archinte.141.9.1169; Zhou CY, 2015, CLIN TOXICOL, V53, P551, DOI 10.3109/15563650.2015.1046183; Zyoud SH, 2018, AM J IND MED, V61, P462, DOI 10.1002/ajim.22835	48	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 15	2021	16	1							e0245363	10.1371/journal.pone.0245363	http://dx.doi.org/10.1371/journal.pone.0245363			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4XD	33449962	Green Published, gold			2023-01-03	WOS:000609991600006
J	Tsapas, A; Karagiannis, T; Avgerinos, I; Matthews, DR; Bekiari, E				Tsapas, Apostolos; Karagiannis, Thomas; Avgerinos, Ioannis; Matthews, David R.; Bekiari, Eleni			Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes RESPONSE	ANNALS OF INTERNAL MEDICINE			English	Letter									[Tsapas, Apostolos; Karagiannis, Thomas; Avgerinos, Ioannis; Bekiari, Eleni] Aristotle Univ Thessaloniki, Clin Res & Evidence Based Med Unit, Thessaloniki, Greece; [Tsapas, Apostolos; Bekiari, Eleni] Aristotle Univ Thessaloniki, Ctr Diabet, Thessaloniki, Greece; [Tsapas, Apostolos; Matthews, David R.] Univ Oxford, Harris Manchester Coll, Oxford, England; [Matthews, David R.] Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England	Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; University of Oxford; University of Oxford	Tsapas, A (corresponding author), Aristotle Univ Thessaloniki, Clin Res & Evidence Based Med Unit, Thessaloniki, Greece.; Tsapas, A (corresponding author), Aristotle Univ Thessaloniki, Ctr Diabet, Thessaloniki, Greece.; Tsapas, A (corresponding author), Univ Oxford, Harris Manchester Coll, Oxford, England.		Avgerinos, Ioannis/AGY-7425-2022; Karagiannis, Thomas/H-9476-2019	Avgerinos, Ioannis/0000-0003-2232-1342; Karagiannis, Thomas/0000-0001-5242-0574; Bekiari, Eleni/0000-0001-9975-3835				Bhandari M, 2004, CAN MED ASSOC J, V170, P477; Fralick M, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107704; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Reaven PD, 2019, NEW ENGL J MED, V380, P2215, DOI 10.1056/NEJMoa1806802; Tsapas A, 2020, ANN INTERN MED, V173, P278, DOI 10.7326/M20-0864	5	1	1	5	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					141	141		10.7326/L20-1278	http://dx.doi.org/10.7326/L20-1278			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33460545				2023-01-03	WOS:000619485200049
J	Wadhera, RK; Maddox, KEJ; Desai, NR; Landon, BE; Vaduganathan, M; Gilstrap, LG; Shen, CY; Yeh, RW				Wadhera, Rishi K.; Maddox, Karen E. Joynt; Desai, Nihar R.; Landon, Bruce E.; Vaduganathan, Muthiah; Gilstrap, Lauren G.; Shen, Changyu; Yeh, Robert W.			Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program	ANNALS OF INTERNAL MEDICINE			English	Article							ASSOCIATION; MORTALITY; PENALTIES; RATES	The Hospital Readmissions Reduction Program (HRRP) has penalized hospitals with higher 30-day readmission rates more than $3 billion to date. Clinicians and policy experts have raised concerns that the 30-day readmission measure used in this program provides an incomplete picture of performance because it does not capture all hospital encounters that may occur after discharge. In contrast, the excess days in acute care (EDAC) measure, which currently is not used in the HRRP, captures the full spectrum of hospital encounters (emergency department, observation stay, inpatient readmission) and their associated lengths of stay within 30 days of discharge. This study of 3173 hospitals that participated in the HRRP in fiscal year 2019 compared performance on the readmission and EDAC measures and evaluated whether using the EDAC measure would change hospitals' penalty status for 3 conditions targeted by the HRRP. Overall, only moderate agreement was found on hospital performance rankings by using the readmission and EDAC measures (weighted kappa statistic: heart failure, 0.45 [95% CI, 0.42 to 0.47]; acute myocardial infarction [AMI], 0.37 [CI, 0.35 to 0.40]; and pneumonia, 0.50 [CI, 0.47 to 0.52]). Under the HRRP, the penalty status of 769 (27.0%) of 2845 hospitals for heart failure, 581 (28.3%) of 2055 for AMI, and 724 (24.9%) of 2911 for pneumonia would change if the EDAC measure were used instead of the readmission measure to evaluate performance. Fewer small and rural hospitals would receive penalties. The Centers for Medicare & Medicaid Services should consider using the EDAC measure, which provides a more comprehensive picture of postdischarge hospital use, rather than the 30-day readmission measure to evaluate health care system performance under federal quality, reporting, and value-based programs.	[Wadhera, Rishi K.; Landon, Bruce E.; Shen, Changyu; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Wadhera, Rishi K.; Landon, Bruce E.; Vaduganathan, Muthiah; Shen, Changyu; Yeh, Robert W.] Harvard Med Sch, Boston, MA 02115 USA; [Maddox, Karen E. Joynt] Washington Univ, Sch Med, 660 South Euclid Ave, St Louis, MO 63110 USA; [Desai, Nihar R.] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA; [Vaduganathan, Muthiah] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Gilstrap, Lauren G.] Dartmouth Med Sch, Lebanon, NH USA; [Wadhera, Rishi K.; Shen, Changyu; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, 375 Longwood Ave,4th Floor, Boston, MA 02215 USA; [Desai, Nihar R.] Cardiovasc Med, 15 York St,POB 208017, New Haven, CT 06520 USA; [Landon, Bruce E.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA; [Vaduganathan, Muthiah] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Washington University (WUSTL); Yale University; Harvard University; Brigham & Women's Hospital; Dartmouth College; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Wadhera, RK (corresponding author), Beth Israel Deaconess Med Ctr, Richard A & Susan F Smith Ctr Outcomes Res Cardio, 375 Longwood Ave,4th Floor, Boston, MA 02215 USA.	rwadhera@bidmc.harvard.edu		Wadhera, Rishi/0000-0003-1089-3896	NCATS NIH HHS [UL1 TR001863] Funding Source: Medline; NHLBI NIH HHS [K23 HL148525] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdul-Aziz AA, 2017, JAMA CARDIOL, V2, P200, DOI 10.1001/jamacardio.2016.3704; Bilimoria KY, 2016, JAMA-J AM MED ASSOC, V316, P1761, DOI 10.1001/jama.2016.13679; Boccuti C, AIMING FEWER HOSP U; Centers for Medicare & Medicaid Services, NEW STRAT METH HOSP; Cicchetti DV., 1971, AM J EEG TECHNOL, V11, P101, DOI [10.1080/00029238.1971.11080840, DOI 10.1080/00029238.1971.11080840]; Fonarow GC, 2018, JAMA-J AM MED ASSOC, V320, P2539, DOI 10.1001/jama.2018.19325; Fonarow GC, 2017, J AM COLL CARDIOL, V70, P1931, DOI 10.1016/j.jacc.2017.08.046; Gupta A, 2018, JACC-HEART FAIL, V6, P607, DOI 10.1016/j.jchf.2018.02.012; Gupta A, 2018, EUR J HEART FAIL, V20, P1169, DOI 10.1002/ejhf.1212; Gupta A, 2018, JAMA CARDIOL, V3, P44, DOI 10.1001/jamacardio.2017.4265; Hernandez AF, 2019, J AM COLL CARDIOL, V74, P235, DOI 10.1016/j.jacc.2019.05.030; Hsuan CL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3857; Huckfeldt P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0634; Huckfeldt P, 2018, J AM COLL CARDIOL, V72, P2539, DOI 10.1016/j.jacc.2018.08.2174; Ibrahim AM, 2018, JAMA INTERN MED, V178, P290, DOI 10.1001/jamainternmed.2017.6148; Jha AK, 2018, JAMA-J AM MED ASSOC, V319, P431, DOI 10.1001/jama.2017.21623; Johnston KJ, 2019, J GEN INTERN MED, V34, P1645, DOI 10.1007/s11606-019-05009-3; Joshi S, 2019, JAMA INTERN MED, V179, P1735, DOI 10.1001/jamainternmed.2019.5111; Joynt KE, 2013, NEW ENGL J MED, V368, P1175, DOI 10.1056/NEJMp1300122; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Kangovi S, 2015, J HOSP MED, V10, P718, DOI 10.1002/jhm.2436; Kundi H, 2019, JAMA CARDIOL, V4, P1084, DOI 10.1001/jamacardio.2019.3511; Maddox KEJ, 2019, JAMA INTERN MED, V179, P769, DOI 10.1001/jamainternmed.2019.0117; Maddox KEJ, 2019, HEALTH SERV RES, V54, P327, DOI 10.1111/1475-6773.13133; Maddox KEJ, 2018, NEW ENGL J MED, V378, P977, DOI 10.1056/NEJMp1715455; Noel-Miller C, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20151028.051459/, DOI 10.1377/HBLOG20151028.051459/]; Ody C, 2019, HEALTH AFFAIR, V38, P36, DOI 10.1377/hlthaff.2018.05178; Papanicolas I, 2020, HEALTH SERV RES, V55, P249, DOI 10.1111/1475-6773.13268; Psotka MA, 2020, JACC-HEART FAIL, V8, P1, DOI 10.1016/j.jchf.2019.07.012; Roberts ET, 2018, JAMA INTERN MED, V178, P1498, DOI 10.1001/jamainternmed.2018.4481; Sabbatini AK, 2018, NEW ENGL J MED, V378, P2062, DOI 10.1056/NEJMp1800732; Singh S, 2019, ANN INTERN MED, V170, P749, DOI 10.7326/M18-2526; Sukul D, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3290; The Medicare Payment Advisory Commission, 2018, MAND REP EFF HOSP RE; US Government Accountability Office, RUR HOSP CLOS NUMB C; Wadhera RK, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4563; Wadhera RK, 2019, NEW ENGL J MED, V380, P2289, DOI 10.1056/NEJMp1901225; Wadhera RK, 2018, JAMA-J AM MED ASSOC, V320, P2542, DOI 10.1001/jama.2018.19232; Wadhera RK, 2018, NEW ENGL J MED, V379, P2193, DOI 10.1056/NEJMp1806260; Ziaeian B, 2019, J CARD FAIL, V25, P227, DOI 10.1016/j.cardfail.2019.02.017	40	5	5	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					86	+		10.7326/M20-3486	http://dx.doi.org/10.7326/M20-3486			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33045180	Green Accepted			2023-01-03	WOS:000619485200025
J	Williamson, LE; Gilliland, T; Yadav, PK; Binshtein, E; Bombardi, R; Kose, N; Nargi, RS; Sutton, RE; Durie, CL; Armstrong, E; Carnahan, RH; Walker, LM; Kim, AS; Fox, JM; Diamond, MS; Ohi, MD; Klimstra, WB; Crowe, JE				Williamson, Lauren E.; Gilliland, Theron, Jr.; Yadav, Pramod K.; Binshtein, Elad; Bombardi, Robin; Kose, Nurgun; Nargi, Rachel S.; Sutton, Rachel E.; Durie, Clarissa L.; Armstrong, Erica; Carnahan, Robert H.; Walker, Lauren M.; Kim, Arthur S.; Fox, Julie M.; Diamond, Michael S.; Ohi, Melanie D.; Klimstra, William B.; Crowe, James E., Jr.			Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection	CELL			English	Article							CRYO-EM STRUCTURE; HUMAN MONOCLONAL-ANTIBODIES; ENCEPHALOMYELITIS VIRUS; SYNTHETIC PEPTIDES; SINDBIS VIRUS; B-CELLS; ALPHAVIRUS; VENEZUELAN; GLYCOPROTEIN; MECHANISMS	Eastern equine encephalitis virus (EEEV) is one of the most virulent viruses endemic to North America. No licensed vaccines or antiviral therapeutics are available to combat this infection, which has recently shown an increase in human cases. Here, we characterize human monoclonal antibodies (mAbs) isolated from a survivor of natural EEEV infection with potent (<20 pM) inhibitory activity of EEEV Cryo-electron microscopy reconstructions of two highly neutralizing mAbs, EEEV-33 and EEEV-143, were solved in complex with chimeric Sindbis/EEEV virions to 7.2 angstrom and 8.3 angstrom, respectively. The mAbs recognize two distinct antigenic sites that are critical for inhibiting viral entry into cells. EEEV-33 and EEEV-143 protect against disease following stringent lethal aerosol challenge of mice with highly pathogenic EEEV. These studies provide insight into the molecular basis for the neutralizing human antibody response against EEEV and can facilitate development of vaccines and candidate antibody therapeutics.	[Williamson, Lauren E.; Walker, Lauren M.; Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Gilliland, Theron, Jr.; Klimstra, William B.] Univ Pittsburgh, Ctr Vaccine Res, Pittsburgh, PA USA; [Yadav, Pramod K.; Durie, Clarissa L.; Ohi, Melanie D.] Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA; [Binshtein, Elad; Bombardi, Robin; Kose, Nurgun; Nargi, Rachel S.; Sutton, Rachel E.; Armstrong, Erica; Carnahan, Robert H.; Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA; [Klimstra, William B.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA; [Kim, Arthur S.; Fox, Julie M.; Diamond, Michael S.] Washington Univ, Dept Med, St Louis, MO 63110 USA; [Kim, Arthur S.; Diamond, Michael S.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA; [Ohi, Melanie D.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Michigan System; University of Michigan; Vanderbilt University	Crowe, JE (corresponding author), Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Crowe, JE (corresponding author), Vanderbilt Univ, Vanderbilt Vaccine Ctr, Med Ctr, Nashville, TN 37232 USA.; Crowe, JE (corresponding author), Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA.	james.crowe@vumc.org	Carnahan, Robert H/N-7429-2013; Yadav, Pramod K./A-6166-2010; Crowe, James/B-5549-2009; Fox, Julie/GLQ-8895-2022	Carnahan, Robert H/0000-0001-5230-1532; Yadav, Pramod K./0000-0003-0026-1684; Crowe, James/0000-0002-0049-1079; Ohi, Melanie/0000-0003-1750-4793; Walker, Lauren/0000-0003-2122-6271; Binshtein, Elad/0000-0003-2745-104X; Durie, Clarissa/0000-0002-4027-4386	U-M Life Sciences Institute; U-M Biosciences Initiative; NIH [S10OD020011, T32 HL069765, F31 AI145189, U19 AI142790, R01 AI095436]; U.S. Defense Threat Reduction Agency [HDTRA1-13-10034, HDTRA1-15-1-0047]; U.S. NCATS [CTSA UL1 TR002243]	U-M Life Sciences Institute; U-M Biosciences Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); U.S. NCATS	We thank J.D. Laughlin for performing Octet HTX experiments. We thank P. Gilchuk, C. Slaughter, M. Vogt, and S. Zost at Vanderbilt for helpful discussions and training. We thank D. Yousif, M. Jensen, N. Murphy, M. Goff, I. Kovach, J. Rodriguez, C. Gainza, W. Reichard, M. Majedi, J. Reidy, A. Trivette, and R. Troseth for technical support. We thank M. Leksell, M. Mayo, K. Moton, T. Martin, V. Morris, A. Bunnell, and A. Jordan for administrative assistance and R. Irving for lab management. The University of Michigan Cryo-EM Facility has received support from the U-M Life Sciences Institute and the U-M Biosciences Initiative. We acknowledge M. Su, A. Bondy, L. Keopping, C. Lilienthal, and B. Battey for U-M cryo-EM technical and IT support. Cryo-EM computation done at the LSI was supported by NIH (S10OD020011). EM data collections of EEEV VLP and EEEV VLP:rEEEV-143 Fab were conducted at the Center for Structural Biology Cryo-EM facility at Vanderbilt University. L.E.W. was supported by NIH (T32 HL069765 and F31 AI145189). This project received support from the U.S. Defense Threat Reduction Agency (HDTRA1-13-10034 to J.E.C. and HDTRA1-15-1-0047 to W.B.K.), NIH (U19 AI142790 to J.E.C. and M.S.D. and R01 AI095436 to W.B.K.), and by CTSA UL1 TR002243 from the U.S. NCATS. The graphical abstract was made in part with tools at Biorender.com.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; AGAPOV EV, 1994, ARCH VIROL, V139, P173, DOI 10.1007/BF01309462; Armstrong PM, 2013, NEW ENGL J MED, V368, P1670, DOI 10.1056/NEJMp1213696; AYRES JC, 1949, NEW ENGL J MED, V240, P960, DOI 10.1056/NEJM194906162402403; Baxter VK, 2016, J GEN VIROL, V97, P2908, DOI 10.1099/jgv.0.000613; Bernard E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011479; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637; Burke CW, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008157; Burke CW, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040147; Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314; Chen CL, 2020, P NATL ACAD SCI USA, V117, P8890, DOI 10.1073/pnas.1910670117; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; de la Rosa-Trevin JM, 2016, J STRUCT BIOL, V195, P93, DOI 10.1016/j.jsb.2016.04.010; de la Rosa-Trevin JM, 2013, J STRUCT BIOL, V184, P321, DOI 10.1016/j.jsb.2013.09.015; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; Earnest JT, 2019, J EXP MED, V216, P2282, DOI 10.1084/jem.20190736; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fernandez-Leiro R, 2017, ACTA CRYSTALLOGR D, V73, P496, DOI 10.1107/S2059798316019276; Fibriansah G, 2015, SCIENCE, V349, P88, DOI 10.1126/science.aaa8651; FLYNN DC, 1990, J VIROL, V64, P3643, DOI 10.1128/JVI.64.8.3643-3653.1990; Fong RH, 2014, J VIROL, V88, P14364, DOI 10.1128/JVI.01943-14; Fox JM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5062; Fox JM, 2015, CELL, V163, P1095, DOI 10.1016/j.cell.2015.10.050; Gardner CL, 2017, J VIROL, V91, DOI 10.1128/JVI.00226-17; Gardner CL, 2011, P NATL ACAD SCI USA, V108, P16026, DOI 10.1073/pnas.1110617108; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P716, DOI 10.1101/pdb.prot5634; Grant T, 2018, ELIFE, V7, DOI 10.7554/eLife.35383; Griffin D, 1997, IMMUNOL REV, V159, P155, DOI 10.1111/j.1600-065X.1997.tb01013.x; GRIFFIN DE, 1995, SEMIN VIROL, V6, P249, DOI 10.1006/smvy.1995.0030; Griffin DE, 2016, NEUROTHERAPEUTICS, V13, P455, DOI 10.1007/s13311-016-0434-6; Hasan SS, 2018, CELL REP, V25, P3136, DOI 10.1016/j.celrep.2018.11.067; Henderson R, 2012, STRUCTURE, V20, P205, DOI 10.1016/j.str.2011.12.014; Holmes AC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008876; Hulseweh B, 2014, MABS-AUSTIN, V6, P717, DOI 10.4161/mabs.28170; Hunt AR, 2006, J GEN VIROL, V87, P2467, DOI 10.1099/vir.0.81925-0; Hunt AR, 2011, VIROLOGY, V414, P146, DOI 10.1016/j.virol.2011.03.016; Hunt AR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000739; HUNT AR, 1985, VIROLOGY, V142, P334, DOI 10.1016/0042-6822(85)90342-3; HUNT AR, 1990, VIROLOGY, V179, P701, DOI 10.1016/0042-6822(90)90137-G; HUNT AR, 1995, VACCINE, V13, P281, DOI 10.1016/0264-410X(95)93315-Z; HUNT AR, 1991, VIROLOGY, V185, P281, DOI 10.1016/0042-6822(91)90775-7; Jin J, 2015, CELL REP, V13, P2553, DOI 10.1016/j.celrep.2015.11.043; Jose J, 2009, FUTURE MICROBIOL, V4, P837, DOI 10.2217/FMB.09.59; Kim AS, 2019, NAT MICROBIOL, V4, P187, DOI 10.1038/s41564-018-0286-4; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Ko SY, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3113; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Lednicky JA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006972; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; Lindsey NP, 2020, MMWR-MORBID MORTAL W, V69, P50, DOI 10.15585/mmwr.mm6902a4; Lindsey NP, 2018, AM J TROP MED HYG, V98, P1472, DOI 10.4269/ajtmh.17-0927; Long F, 2015, P NATL ACAD SCI USA, V112, P13898, DOI 10.1073/pnas.1515558112; Ma HM, 2020, NATURE, V588, P308, DOI 10.1038/s41586-020-2915-3; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; Metcalf TU, 2013, J VIROL, V87, P2420, DOI 10.1128/JVI.01769-12; Metcalf TU, 2011, J VIROL, V85, P11490, DOI 10.1128/JVI.05379-11; MEYER WJ, 1993, J VIROL, V67, P5117, DOI 10.1128/JVI.67.9.5117-5125.1993; MITCHELL CJ, 1992, SCIENCE, V257, P526, DOI 10.1126/science.1321985; Morens DM, 2019, NEW ENGL J MED, V381, P1989, DOI 10.1056/NEJMp1914328; Neves V, 2016, TRENDS BIOTECHNOL, V34, P36, DOI 10.1016/j.tibtech.2015.10.005; Nilaratanakul V, 2018, J VIROL, V92, DOI 10.1128/JVI.02081-17; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312; Pereboev AV, 1996, ARCH VIROL, V141, P2191, DOI 10.1007/BF01718225; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phelps AL, 2019, VIROL J, V16, DOI 10.1186/s12985-018-1103-7; Porta J, 2014, J VIROL, V88, P9616, DOI 10.1128/JVI.01286-14; Powell LA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008517; Pulgar VM, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01019; Quiroz JA, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008061; Reichert E, 2009, BIOSECUR BIOTERROR, V7, P413, DOI 10.1089/bsp.2009.0032; ROEHRIG JT, 1988, VIROLOGY, V165, P66, DOI 10.1016/0042-6822(88)90659-9; ROEHRIG JT, 1982, VIROLOGY, V118, P269, DOI 10.1016/0042-6822(82)90346-4; ROEHRIG JT, 1985, VIROLOGY, V142, P347, DOI 10.1016/0042-6822(85)90343-5; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Ronca SE, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00959; Rose PP, 2011, CELL HOST MICROBE, V10, P97, DOI 10.1016/j.chom.2011.06.009; Salimi H, 2020, MBIO, V11, DOI 10.1128/mBio.02731-19; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115; Selvarajah S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002423; Sherwood JA, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000308; Sidwell RW, 2003, ANTIVIR RES, V57, P101, DOI 10.1016/S0166-3542(02)00203-6; Smith SA, 2015, CELL HOST MICROBE, V18, P86, DOI 10.1016/j.chom.2015.06.009; Sorzano Carlos Oscar, 2013, Methods Mol Biol, V950, P171, DOI 10.1007/978-1-62703-137-0_11; Sun CQ, 2014, J VIROL, V88, P2035, DOI 10.1128/JVI.02990-13; Sun EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069349; Sun EC, 2013, APPL MICROBIOL BIOT, V97, P6359, DOI 10.1007/s00253-013-4819-8; Sun S., 2013, CHIKUNGUNYA VIRUS, V2; Tan Y, 2018, J VIROL, V92, DOI 10.1128/JVI.00074-18; Trobaugh DW, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007584; Turchaninova MA, 2016, NAT PROTOC, V11, P1599, DOI 10.1038/nprot.2016.093; Turula H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050237; Voss JE, 2010, NATURE, V468, P709, DOI 10.1038/nature09555; Wirawan M, 2019, STRUCTURE, V27, P253, DOI 10.1016/j.str.2018.10.009; Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231; Yu XC, 2008, J IMMUNOL METHODS, V336, P142, DOI 10.1016/j.jim.2008.04.008; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003; Zhang R, 2018, NATURE, V557, P570, DOI 10.1038/s41586-018-0121-3; Zhang R, 2011, EMBO J, V30, P3854, DOI 10.1038/emboj.2011.261; Zhao J, 2012, VET IMMUNOL IMMUNOP, V148, P364, DOI 10.1016/j.vetimm.2012.06.021; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193; Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166	104	9	9	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	2020	183	7					1884	+		10.1016/j.cell.2020.11.011	http://dx.doi.org/10.1016/j.cell.2020.11.011			40	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PL1OT	33301709	Green Accepted, Bronze			2023-01-03	WOS:000602900800012
J	Pierzak, M; Kubala-Kukus, A; Banas, D; Stabrawa, I; Wudarczyk-Mocko, J; Gluszek, S				Pierzak, Monika; Kubala-Kukus, Aldona; Banas, Dariusz; Stabrawa, Ilona; Wudarczyk-Mocko, Jolanta; Gluszek, Stanislaw			Study of chromium, selenium and bromine concentrations in blood serum of patients with parenteral nutrition treatment using total reflection X-ray fluorescence analysis	PLOS ONE			English	Article							TRACE-ELEMENTS; TXRF	Total reflection X-ray fluorescence analysis (TXRF) was used to determine chromium, selenium and bromine concentrations in blood serum samples of 50 patients with parenteral nutrition treatment. The concentrations were measured two times, namely in the first day (I measurement) of the treatment and the seventh day (II measurement) after the chromium and selenium supplementation. For comparison purposes also serum samples of 50 patients without nutritional disorders, admitted to a planned surgical procedure to remove the gall bladder (cholecystectomy), were analyzed and treated as the control group. Descriptive statistics of measured concentrations of Cr, Se and Br both for the studied and control groups was determined. In order to check the effectiveness of Cr and Se supplementation, the results of the first and seventh day measurements for studied group were statistically compared with each other, with literature reference values and with the results of the control group (two-group comparison). These comparisons indicate the effectiveness of selenium supplementation in the applied treatment procedure. In the case of Cr and Br concentrations no statistically significant differences were observed. We conclude that monitoring of the concentration of the important trace elements in human serum should be standard procedure in parenteral nutrition treatment. In this monitoring the TXRF technique can be successfully used.	[Pierzak, Monika; Kubala-Kukus, Aldona] Jan Kochanowski Univ Humanities & Sci, Inst Hlth Sci, Kielce, Poland; [Kubala-Kukus, Aldona; Banas, Dariusz; Stabrawa, Ilona] Jan Kochanowski Univ Humanities & Sci, Inst Phys, Kielce, Poland; [Kubala-Kukus, Aldona; Banas, Dariusz; Stabrawa, Ilona; Wudarczyk-Mocko, Jolanta] Holycross Canc Ctr, Kielce, Poland; [Gluszek, Stanislaw] Jan Kochanowski Univ Humanities & Sci, Inst Med Sci, Kielce, Poland; [Gluszek, Stanislaw] Reg Hosp, Clin Gen Oncol & Endocrinol Surg, Kielce, Poland	Jan Kochanowski University; Jan Kochanowski University; Jan Kochanowski University	Kubala-Kukus, A (corresponding author), Jan Kochanowski Univ Humanities & Sci, Inst Phys, Kielce, Poland.; Kubala-Kukus, A (corresponding author), Holycross Canc Ctr, Kielce, Poland.	aldona.kubala-kukus@ujk.edu.pl	Banaś, Dariusz/F-5025-2011	Banaś, Dariusz/0000-0003-1566-5446; Gluszek, Stanislaw/0000-0001-7752-0459; Pierzak, Monika/0000-0002-4367-4465; Kubala-Kukus, Aldona/0000-0003-1547-3348	European Regional Development Fund in the framework of the Polish Innovative Economy Operational Program [WNP-POIG.02.02.00-26-023/08]; Development of Eastern Poland Program (Jan Kochanowski University, Kielce, Poland) [POPW.01.01.00-26-013/09-04]	European Regional Development Fund in the framework of the Polish Innovative Economy Operational Program; Development of Eastern Poland Program (Jan Kochanowski University, Kielce, Poland)	European Regional Development Fund in the framework of the Polish Innovative Economy Operational Program (contract no. WNP-POIG.02.02.00-26-023/08) and the Development of Eastern Poland Program (contract no. POPW.01.01.00-26-013/09-04) (Jan Kochanowski University, Kielce, Poland).	Ashraf A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37431-8; Duntas LH, 2015, ENDOCRINE, V48, P756, DOI 10.1007/s12020-014-0477-6; Fairweather-Tait SJ, 2011, ANTIOXID REDOX SIGN, V14, P1337, DOI 10.1089/ars.2010.3275; Fernandes AP, 2015, BBA-GEN SUBJECTS, V1850, P1642, DOI 10.1016/j.bbagen.2014.10.008; Godzialska A, 2013, WSPOLCZESNE KIERUNKI; Jeffery J, 2019, ANN CLIN BIOCHEM, V56, P170, DOI 10.1177/0004563218793163; Kabata-Pendias A., 2007, TRACE ELEMEN SOIL HU, DOI [10.1007/978-3-540-32714-1_20, 10.1007/978-3-540-32714-1, DOI 10.1007/978-3-540-32714-1]; Klecha Barbara, 2016, Bromatologia i Chemia Toksykologiczna, V49, P818; Klockenkamper R, 2015, CHEM ANAL SERIES MON, V181; Klockenkamper R., 1997, TOTAL REFLECTION XRA; Kubala-Kukus A, 2017, X-RAY SPECTROM, V46, P412, DOI 10.1002/xrs.2778; Kubala-Kukus A, 2004, SPECTROCHIM ACTA B, V59, P1283, DOI 10.1016/j.sab.2004.05.020; Kubala-Kukus A, 2014, BIOL TRACE ELEM RES, V158, P22, DOI 10.1007/s12011-013-9884-4; Lee H, 1990, SPRINGER SCI; Liui Y, 2015, ADV XRAY CHEM ANAL J, V46, P13; Magalhaes T, 2010, SPECTROCHIM ACTA B, V65, P493, DOI 10.1016/j.sab.2010.04.001; Majewska U, 2018, SPECTROCHIM ACTA B, V147, P121, DOI 10.1016/j.sab.2018.05.014; Majewska U, 2016, SPECTROCHIM ACTA B, V122, P56, DOI 10.1016/j.sab.2016.05.001; Majewska U, 2014, ACTA PHYS POL A, V125, P864, DOI 10.12693/APhysPolA.125.864; McCall AS, 2014, CELL, V157, P1380, DOI 10.1016/j.cell.2014.05.009; Pertkiewicz M, 2005, STANDARDY ZYWIENIA P; Salomone V.N., 2017, INT J EXP SPECTROSC, V2, P1; Solecka M, 2018, MED STUD, V34, P153, DOI 10.5114/ms.2018.76877; Spodaryk M, 2008, PRAKTYCZNE ASPEKTY L; Steinbrenner H, 2015, ADV NUTR, V6, P73, DOI 10.3945/an.114.007575; Stosnach H, 2009, SPECTROCHIM ACTA B, V64, P354, DOI 10.1016/j.sab.2009.03.019; User Manual S2 PICOFOX, 2012, US MAN S2 PICOFOX TX; User Manual SPECTRA 7, 2011, US MAN SPECTRA 7 SOF; Wrzochal A, 2019, MED STUD, V35, P128, DOI 10.5114/ms.2019.86332; Zarkadas C, 2001, SPECTROCHIM ACTA B, V56, P2219, DOI 10.1016/S0584-8547(01)00343-3	30	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2020	15	12							e0243492	10.1371/journal.pone.0243492	http://dx.doi.org/10.1371/journal.pone.0243492			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH3TP	33320863	Green Published, gold			2023-01-03	WOS:000600339800035
J	Chaniad, P; Tewtrakul, S; Sudsai, T; Langyanai, S; Kaewdana, K				Chaniad, Prapaporn; Tewtrakul, Supinya; Sudsai, Teeratad; Langyanai, Supat; Kaewdana, Kantarakorn			Anti-inflammatory, wound healing and antioxidant potential of compounds from Dioscorea bulbifera L. bulbils	PLOS ONE			English	Article							FLAVONOIDS; EXTRACT; INTEGRASE	Background Dioscorea bulbifera L. (Dioscoreaceae) has been traditionally used in Thai folk medicine as a diuretic and anthelmintic, for longevity preparations, and for wound and inflammation treatment. This plant is also commonly used in traditional Indian and Chinese medicines in the treatment of sore throat, gastric cancer, rectal carcinoma and goiters. However, the wound healing effects of the active compounds in this plant have not been investigated. Objective This study aimed to identify compounds responsible for the wound healing activity of D. bulbifera and determine their potential anti-inflammatory and antioxidant activities. Methods Crude extracts of D. bulbifera bulbils, their derived fractions and eleven purified compounds were tested for anti-inflammatory activity against LPS-induced NO production in RAW264.7 macrophages. The wound healing effects were evaluated via cell proliferation and migration assays using human dermal fibroblasts (HDFs), and the antioxidant effects were determined using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and hydroxyl radical ((OH)-O-center dot) scavenging activity assays. Results 15,16-Epoxy-6 alpha-O-acetyl-8 beta-hydroxy-19-nor-clero-13(16),14-diene-17,12;18,2-diolide (2), (+)-catechin (5), quercetin (6) and myricetin (11) exhibited significantly potent wound healing effects and promoted marked cell proliferation, resulting in % viabilities of 107.4-137.6, 121.1-151.9, 98.0-131.9, 90.9-115.9, respectively. Among them, (+)-catechin produced the highest % cell migration, resulting in 100.0% wound closure sooner (at day 2) than the other compounds. In addition, 1 mu g/ml (+)-catechin significantly increased fibroblast migration by 2.4-fold compared to that in the control after 24 h. Regarding anti-inflammatory properties, kaempferol (7) and quercetin (6) decreased (p < 0.005) NO production, with IC50 values of 46.6 and 56.2 mu M, respectively. In addition, the crude extracts, solvent fractions and flavonoid compounds were also found to possess marked antioxidant activity in both DPPH and (OH)-O-center dot radical scavenging assays. Conclusions These findings provide more evidence to support the traditional use of D. bulbifera for the treatment of wounds and inflammation.	[Chaniad, Prapaporn; Kaewdana, Kantarakorn] Walailak Univ, Sch Med, Nakhon Si Thammarat, Thailand; [Tewtrakul, Supinya; Sudsai, Teeratad; Langyanai, Supat] Prince Songkla Univ, Fac Pharmaceut Sci, Hat Yai, Songkhla, Thailand	Walailak University; Prince of Songkla University	Chaniad, P (corresponding author), Walailak Univ, Sch Med, Nakhon Si Thammarat, Thailand.	prapaporn.ch@wu.ac.th			Research Institute for Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand [WU-IRG-62-049]	Research Institute for Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand	This work was supported by a grant from the Research Institute for Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand (Grant No. WU-IRG-62-049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed Zabeer, 2009, Diabetologia Croatica, V38, P63; Alsawalha M, 2019, PHARMACOGN MAG, V15, P483, DOI 10.4103/pm.pm_81_19; Ambiga S, 2007, ANC SCI LIFE, V26, P45; Sanchez MC, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7080098; Chaniad P., 2016, Songklanakarin Journal of Science and Technology, V38, P229; Chaniad P, 2016, PHARM BIOL, V54, P1077, DOI 10.3109/13880209.2015.1103272; Dey P, 2016, PHARM BIOL, V54, P1474, DOI 10.3109/13880209.2015.1104702; Dioscorea bulbifera L, 2010, DIOSC BULB L; Dunnill C, 2015, INT WOUND J, P14; Fu R, 2013, J ETHNOPHARMACOL, V147, P517, DOI 10.1016/j.jep.2013.03.058; Gadkari PV, 2015, FOOD BIOPROD PROCESS, V93, P122, DOI 10.1016/j.fbp.2013.12.004; Garcia-Aranda MI, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115427; Ghosh S, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/929051; Gopalakrishnan A, 2016, INDIAN J EXP BIOL, V54, P187; Harper D, 2014, SURGERY OXFORD, V32, P445, DOI DOI 10.1016/j.mpsur.2014.06.010; Hwang KA, 2019, J CHIN MED ASSOC, V82, P251, DOI 10.1097/JCMA.0000000000000051; Jarbrink K, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0329-y; Jing LL, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0820-3; Kim HH, 2013, ARCH PHARM RES, V36, P1533, DOI 10.1007/s12272-013-0147-x; Lim JS, 2018, J MED FOOD, V21, P1204, DOI 10.1089/jmf.2018.4187; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Mandal S, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep072; Mbiantcha M, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/912935; Muzolf-Panek M, 2012, EUR FOOD RES TECHNOL, V235, P1001, DOI 10.1007/s00217-012-1826-4; Nagaraja S, 2014, J IMMUNOL, V192, P1824, DOI 10.4049/jimmunol.1302481; Okigbo R, 2009, INT J INTEGR BIOL, P6; Panduraju T., 2010, Journal of Pharmacy Research, V3, P3138; Schmidt CA, 2010, J NAT PROD, V73, P2035, DOI 10.1021/np100523s; Sharifi R, 2013, PHARM BIOL, V51, P298, DOI 10.3109/13880209.2012.721789; Sinno Hani, 2013, Plast Surg Int, V2013, P146764, DOI 10.1155/2013/146764; Sorg H, 2017, EUR SURG RES, V58, P81, DOI 10.1159/000454919; Sudsai T, 2013, J ETHNOPHARMACOL, V150, P223, DOI 10.1016/j.jep.2013.08.038; Takano-Ishikawa Y, 2006, PHYTOMEDICINE, V13, P310, DOI 10.1016/j.phymed.2005.01.016; Thiruvoth FM, 2015, PLAST AESTHET RES, V2, P250, DOI [10.4103/2347-9264.158851, DOI 10.4103/2347-9264.158851]; Treml J, 2016, COMPR REV FOOD SCI F, V15, P720, DOI 10.1111/1541-4337.12204; Wild T, 2010, NUTRITION, V26, P862, DOI 10.1016/j.nut.2010.05.008	36	9	9	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243632	10.1371/journal.pone.0243632	http://dx.doi.org/10.1371/journal.pone.0243632			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WM	33306733	Green Published, gold			2023-01-03	WOS:000600144200019
J	Petrovskaya, A; Kirillov, B; Asmolova, A; Galli, G; Feurra, M; Medvedeva, A				Petrovskaya, Aleksandra; Kirillov, Bogdan; Asmolova, Anastasiya; Galli, Giulia; Feurra, Matteo; Medvedeva, Angela			Examining the effects of transcranial direct current stimulation on human episodic memory with machine learning	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; NONINVASIVE BRAIN-STIMULATION; SEMANTIC ELABORATION; TDCS; ITEM; REPRODUCIBILITY; RETRIEVAL; HEALTHY	We aimed to replicate a published effect of transcranial direct-current stimulation (tDCS)-induced recognition enhancement over the human ventrolateral prefrontal cortex (VLPFC) and analyse the data with machine learning. We investigated effects over an adjacent region, the dorsolateral prefrontal cortex (DLPFC). In total, we analyzed data from 97 participants after exclusions. We found weak or absent effects over the VLPFC and DLPFC. We conducted machine learning studies to examine the effects of semantic and phonetic features on memorization, which revealed no effect of VLPFC tDCS on the original dataset or the current data. The highest contributing factor to memory performance was individual differences in memory not explained by word features, tDCS group, or sample size, while semantic, phonetic, and orthographic word characteristics did not contribute significantly. To our knowledge, this is the first tDCS study to investigate cognitive effects with machine learning, and future studies may benefit from studying physiological as well as cognitive effects with data-driven approaches and computational models.	[Petrovskaya, Aleksandra; Asmolova, Anastasiya; Feurra, Matteo] Natl Res Univ Higher Sch Econ, Psychol Dept, Moscow, Russia; [Petrovskaya, Aleksandra; Asmolova, Anastasiya; Feurra, Matteo] Natl Res Univ Higher Sch Econ, Inst Cognit Neurosci, Moscow, Russia; [Kirillov, Bogdan] Skolkovo Inst Sci & Technol, Ctr Life Sci, Skolkovo, Russia; [Galli, Giulia] Kingston Univ, Dept Psychol, Kingston Upon Thames, Surrey, England; [Medvedeva, Angela] Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Houston, TX USA; [Petrovskaya, Aleksandra] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia	HSE University (National Research University Higher School of Economics); HSE University (National Research University Higher School of Economics); Skolkovo Institute of Science & Technology; Kingston University; University of Texas System; University of Texas Health Science Center Houston; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Kirillov, B (corresponding author), Skolkovo Inst Sci & Technol, Ctr Life Sci, Skolkovo, Russia.	Bogdan.Kirillov@skoltech.ru	Feurra, Matteo/K-1524-2019; Petrovskaya, Alexandra/B-6122-2017; Asmolova, Anastasiya/AAV-2471-2021	Feurra, Matteo/0000-0003-0934-6764; Asmolova, Anastasiya/0000-0003-1789-754X; Petrovskaia, Aleksandra/0000-0001-9202-0727; Kirillov, Bogdan/0000-0002-7104-8613; Galli, Giulia/0000-0001-9894-3514	Russian Academic Excellence Project '5-100'	Russian Academic Excellence Project '5-100'(Ministry of Education and Science, Russian FederationProject 5-100, Ministry of Education and Science, Russian Federation)	The article was prepared within the framework of the HSE University Basic Research Program and funded by the Russian Academic Excellence Project '5-100'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, DIABETOL KLIN SA, V4, pA1; [Anonymous], 2011, METHODS MODELS PSYCH, V2, P45; Balzarotti S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159555; Blumenfeld RS, 2007, NEUROSCIENTIST, V13, P280, DOI 10.1177/1073858407299290; Blumenfeld RS, 2014, NEUROPSYCHOLOGIA, V53, P197, DOI 10.1016/j.neuropsychologia.2013.11.021; Blumenfeld RS, 2013, CEREB CORTEX, V23, P2457, DOI 10.1093/cercor/bhs223; Blumenfeld RS, 2011, J COGNITIVE NEUROSCI, V23, P257, DOI 10.1162/jocn.2010.21459; Blumenfeld RS, 2006, J NEUROSCI, V26, P916, DOI 10.1523/JNEUROSCI.2353-05.2006; Bojanowski P., 2017, T ASSOC COMPUT LING, V5, P135; Bradley AP, 1997, PATTERN RECOGN, V30, P1145, DOI 10.1016/S0031-3203(96)00142-2; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Cesario J, 2014, PERSPECT PSYCHOL SCI, V9, P40, DOI 10.1177/1745691613513470; de Lara Gabriel A, 2017, Front Neurosci, V11, P452, DOI 10.3389/fnins.2017.00452; Dedoncker J, 2016, J NEURAL TRANSM, V123, P1159, DOI 10.1007/s00702-016-1558-x; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; EINSTEIN GO, 1980, J EXP PSYCHOL-HUM L, V6, P588, DOI 10.1037/0278-7393.6.5.588; Fertonani A, 2010, BEHAV BRAIN RES, V208, P311, DOI 10.1016/j.bbr.2009.10.030; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fuster JM, 2000, EXP BRAIN RES, V133, P66, DOI 10.1007/s002210000401; Galli G, 2019, BRAIN STIMUL, V12, P231, DOI 10.1016/j.brs.2018.11.008; Giordano J, 2017, DOSE-RESPONSE, V15, DOI 10.1177/1559325816685467; Gray SJ, 2015, CORTEX, V73, P188, DOI 10.1016/j.cortex.2015.09.003; Habich A, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00542; Hammer A, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-72; Hawco C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073789; Heroux ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175635; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Javadi AH, 2013, BRAIN STIMUL, V6, P668, DOI 10.1016/j.brs.2012.10.007; Javadi AH, 2012, BRAIN STIMUL, V5, P231, DOI 10.1016/j.brs.2011.06.007; Jones KT, 2014, EXP BRAIN RES, V232, P4043, DOI 10.1007/s00221-014-4090-y; Joulin A, 2018, ARXIV180407745; Lafontaine MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081721; Lu Y, 2015, CURR BIOL, V25, P780, DOI 10.1016/j.cub.2015.01.055; Lyashevskaya O., 2009, FREQUENCY DICT MODER; Manenti R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00049; Manenti R, 2012, BRAIN STIMUL, V5, P103, DOI 10.1016/j.brs.2012.03.004; Matzen LE, 2015, BRAIN RES, V1624, P286, DOI 10.1016/j.brainres.2015.07.036; Medvedeva A, 2019, CEREB CORTEX, V29, P657, DOI 10.1093/cercor/bhx347; Meinzer M, 2014, CORTEX, V50, P137, DOI 10.1016/j.cortex.2013.07.013; Mendoza H, 2019, SPRING SER CHALLENGE, P135, DOI 10.1007/978-3-030-05318-5_7; Minarik T, 2016, FRONT HUM NEUROSCI, V10, DOI [10.3399/fnhum.2016.00453, 10.3389/fnhum.2016.00453]; Murray LJ, 2007, J NEUROSCI, V27, P5515, DOI 10.1523/JNEUROSCI.0406-07.2007; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Olsen RK, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00146; Olson RS, 2019, SPRING SER CHALLENGE, P151, DOI 10.1007/978-3-030-05318-5_8; Paquette C, 2011, J CEREBR BLOOD F MET, V31, P2086, DOI 10.1038/jcbfm.2011.72; Paszke A., 2017, 31 C NEUR INF PROC S; Pergolizzi D, 2016, BRAIN COGNITION, V108, P56, DOI 10.1016/j.bandc.2016.06.009; Peterchev AV, 2017, ELIFE, V6, DOI 10.7554/eLife.25812; Pisoni A, 2015, NEUROPSYCHOLOGIA, V66, P267, DOI 10.1016/j.neuropsychologia.2014.11.025; Polania R, 2018, NAT NEUROSCI, V21, P174, DOI 10.1038/s41593-017-0054-4; Raposo A, 2009, NEUROPSYCHOLOGIA, V47, P2261, DOI 10.1016/j.neuropsychologia.2008.10.024; Sandrini M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00289; Smirni D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144838; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; Stagg CJ, 2014, ELIFE, V3, DOI 10.7554/eLife.01465; Staresina BP, 2009, NEURON, V63, P267, DOI 10.1016/j.neuron.2009.06.024; Staresina BP, 2009, CEREB CORTEX, V19, P1198, DOI 10.1093/cercor/bhn165; Szczepanski SM, 2014, NEURON, V83, P1002, DOI 10.1016/j.neuron.2014.08.011; Takahashi E, 2007, NEUROIMAGE, V34, P827, DOI 10.1016/j.neuroimage.2006.10.009; Vannorsdall TD, 2016, COGN BEHAV NEUROL, V29, P11, DOI 10.1097/WNN.0000000000000086; Zhang Dongxu, 2018, ARXIV180408166; Zwissler B, 2014, J NEUROSCI, V34, P4022, DOI 10.1523/JNEUROSCI.5407-13.2014	63	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2020	15	12							e0235179	10.1371/journal.pone.0235179	http://dx.doi.org/10.1371/journal.pone.0235179			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE8QN	33296363	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000598626100032
J	Cai, ZC; Chen, H; Chen, JJ; Yang, R; Zou, LS; Wang, CC; Chen, JL; Tan, MX; Mei, YQ; Wei, LF; Yin, SX; Liu, XH				Cai, Zhichen; Chen, Huan; Chen, Jiajia; Yang, Rong; Zou, Lisi; Wang, Chengcheng; Chen, Jiali; Tan, Mengxia; Mei, Yuqi; Wei, Lifang; Yin, Shengxin; Liu, Xunhong			Metabolomics characterizes the metabolic changes of Lonicerae Japonicae Flos under different salt stresses	PLOS ONE			English	Article							BIOSYNTHESIS; DROUGHT; TOLERANCE; RESPONSES; THUNB.; PLANTS; COLD	Salt stress affects the metabolic homeostasis of medicinal plants. However, medicinal plants are sessile organisms that cannot escape from salt stress. They acclimatize themselves to the stress by reprogramming their metabolic pathways. Lonicerae Japonicae Flos (LJF) with strong antioxidant activity is commonly used in traditional Chinese medicine, tea, and beverage. Nevertheless, the variation of integrated metabolites in LJF under different salt stresses remains unclear. In this study, High Performance Liquid Chromatography tandem triple time-of-flight mass spectrometry (HPLC- triple TOF-MS/MS) coupled with multivariate statistical analysis was applied to comparatively investigate the metabolites changes in LJF under different salt stress (0, 100, 200, 300 mM NaCl). Total 47 differential metabolites were screened from 79 metabolites identified in LJF under different salt stress. Low salt-treated group (100 mM NaCl) appeared to be the best group in terms of relative contents (peak areas) of the wide variety in bioactive components. Additionally, the phenylpropanoid pathway, monoterpenoid biosynthesis, glycolysis, TCA cycle, and alkaloid biosynthesis were disturbed in all salt-stress LJF. The results showed that LJF metabolisms were dramatically induced under salt stress and the quality of LJF was better under low salt stress. The study provides novel insights into the quality assessment of LJF under salt stress and a beneficial framework of knowledge applied to improvement the medicinal value of LJF.	[Cai, Zhichen; Chen, Huan; Chen, Jiajia; Yang, Rong; Zou, Lisi; Wang, Chengcheng; Chen, Jiali; Tan, Mengxia; Mei, Yuqi; Wei, Lifang; Yin, Shengxin; Liu, Xunhong] Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Peoples R China	Nanjing University of Chinese Medicine	Liu, XH (corresponding author), Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Peoples R China.	liuxunh1959@163.com		cai, zhichen/0000-0002-0911-5934	Jiangsu Graduate Scientific Research and Practice Innovation Plan [KYCX20-1499]	Jiangsu Graduate Scientific Research and Practice Innovation Plan	This study was supported by the Jiangsu Graduate Scientific Research and Practice Innovation Plan (KYCX20-1499).	Arbona V, 2013, INT J MOL SCI, V14, P4885, DOI 10.3390/ijms14034885; Bose J, 2014, J EXP BOT, V65, P1241, DOI 10.1093/jxb/ert430; Cai ZC, 2019, MOLECULES, V24, DOI 10.3390/molecules24101936; Chen CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103042; Chen XG, 2007, CHROMATOGRAPHIA, V65, P141, DOI 10.1365/s10337-006-0137-y; Cipollini D, 2008, J CHEM ECOL, V34, P144, DOI 10.1007/s10886-008-9426-2; Couteau D, 2001, J APPL MICROBIOL, V90, P873, DOI 10.1046/j.1365-2672.2001.01316.x; Deng M., 2018, GUANGDONG CHEM IND, V45, P96; Hasegawa PM, 2000, ANNU REV PLANT PHYS, V51, P463, DOI 10.1146/annurev.arplant.51.1.463; Hoffmann L, 2003, J BIOL CHEM, V278, P95, DOI 10.1074/jbc.M209362200; Janska A, 2010, PLANT BIOLOGY, V12, P395, DOI 10.1111/j.1438-8677.2009.00299.x; KUHNL T, 1987, ARCH BIOCHEM BIOPHYS, V258, P226, DOI 10.1016/0003-9861(87)90339-0; Niggeweg R, 2004, NAT BIOTECHNOL, V22, P746, DOI 10.1038/nbt966; Paczkowska M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13983-9; Patra B, 2013, BBA-GENE REGUL MECH, V1829, P1236, DOI 10.1016/j.bbagrm.2013.09.006; Rosenthal GA, 2012, HERBIVORES THEIR INT, P2; Saito MA, 2015, SCIENCE, V6201, P1173; Sakuraba Y, 2017, PLANT J, V92, P1106, DOI 10.1111/tpj.13747; Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6; Shang XF, 2011, J ETHNOPHARMACOL, V138, P1, DOI 10.1016/j.jep.2011.08.016; Sun CX, 2015, PLANT SOIL, V388, P99, DOI 10.1007/s11104-014-2309-0; Wang LN, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8968940; Wei LF, 2020, MOLECULES, V25, DOI 10.3390/molecules25020340; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Wold S., 2002, ENCY COMPUTATIONAL C; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; Yan K, 2017, PLANT PHYSIOL BIOCH, V112, P326, DOI 10.1016/j.plaphy.2017.01.020; Yan K, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01563; Yang Qian-Ru, 2016, Zhongguo Zhong Yao Za Zhi, V41, P1204, DOI 10.4268/cjcmm20160708; Yang YQ, 2018, NEW PHYTOL, V217, P523, DOI 10.1111/nph.14920; Yokoi S, 2002, JIRCAS WORKING REP, V23, P25; Zandalinas SI, 2018, PHYSIOL PLANTARUM, V162, P2, DOI 10.1111/ppl.12540; Zhao GM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12696; Zhou LK, 2020, CELL DISCOV, P6, DOI [10.1038/s41421-020-0141-7, DOI 10.1038/S41421-020-0141-7]; Zhu JK, 2016, CELL, V167, P313, DOI 10.1016/j.cell.2016.08.029	35	9	11	5	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2020	15	12							e0243111	10.1371/journal.pone.0243111	http://dx.doi.org/10.1371/journal.pone.0243111			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB7NK	33259548	gold, Green Published			2023-01-03	WOS:000596503200036
J	Hadizadeh, M; Kawchuk, GN; Prasad, N; Fritz, JM				Hadizadeh, Maliheh; Kawchuk, Gregory Neil; Prasad, Narasimha; Fritz, Julie M.			Predicting who responds to spinal manipulative therapy using a short-time frame methodology: Results from a 238-participant study	PLOS ONE			English	Article							LOW-BACK-PAIN; SUBPOPULATION PROGRAM; CHIROPRACTIC TREATMENT; PRIMARY-CARE; SHORT-TERM; IMPROVEMENT; OUTCOMES; RULE; QUESTIONNAIRE; EXPECTATIONS	Background Spinal manipulative therapy (SMT) is among the nonpharmacologic interventions that has been recommended in clinical guidelines for patients with low back pain, however, some patients appear to benefit substantially more from SMT than others. Several investigations have examined potential factors to modify patients' responses prior to SMT application. The objective of this study was to determine if the baseline prediction of SMT responders can be improved through the use of a restricted, non-pragmatic methodology, established variables of responder status, and newly developed physical measures observed to change with SMT. Materials and methods We conducted a secondary analysis of a prior study that provided two applications of standardized SMT over a period of 1 week. After initial exploratory analysis, principal component analysis and optimal scaling analysis were used to reduce multicollinearity among predictors. A multiple logistic regression model was built using a forward Wald procedure to explore those baseline variables that could predict response status at 1-week reassessment. Results Two hundred and thirty-eight participants completed the 1-week reassessment (age 40.0 +/- 11.8 years; 59.7% female). Response to treatment was predicted by a model containing the following 8 variables: height, gender, neck or upper back pain, pain frequency in the past 6 months, the STarT Back Tool, patients' expectations about medication and strengthening exercises, and extension status. Our model had a sensitivity of 72.2% (95% CI, 58.1-83.1), specificity of 84.2% (95% CI, 78.0-89.0), a positive likelihood ratio of 4.6 (CI, 3.2-6.7), a negative likelihood ratio of 0.3 (CI, 0.2-0.5), and area under ROC curve, 0.79. Conclusion It is possible to predict response to treatment before application of SMT in low back pain patients. Our model may benefit both patients and clinicians by reducing the time needed to re-evaluate an initial trial of care.	[Hadizadeh, Maliheh; Kawchuk, Gregory Neil] Univ Alberta, Fac Rehabil Med, Dept Phys Therapy, Edmonton, AB, Canada; [Prasad, Narasimha] Univ Alberta, Dept Math & Stat Sci, Edmonton, AB, Canada; [Fritz, Julie M.] Univ Utah, Coll Hlth, Salt Lake City, UT USA	University of Alberta; University of Alberta; Utah System of Higher Education; University of Utah	Kawchuk, GN (corresponding author), Univ Alberta, Fac Rehabil Med, Dept Phys Therapy, Edmonton, AB, Canada.	gkawchuk@ualberta.ca	Fritz, Julie/AAC-5638-2021		National Center for Complimentary and Integrative Health at the National Institutes of Health [1UH3AT00929301]	National Center for Complimentary and Integrative Health at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This project was funded by the National Center for Complimentary and Integrative Health at the National Institutes of Health (1UH3AT00929301). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, LANCET RESP MED, V8, P1, DOI [10.1016/S22132600(19)30402-3, 10.1016/S2213-2600(19)30449-7]; [Anonymous], 2016, LANCET ONCOL, V17, P1, DOI 10.1016/S1470-2045(15)00568-9; [Anonymous], 2007, BIBINT, V15, p[1, 5], DOI DOI 10.1093/pan/mpl008; Asher AM, 2020, SPINE J, V20, P847, DOI 10.1016/j.spinee.2020.01.010; Axen I, 2005, J MANIP PHYSIOL THER, V28, P381, DOI 10.1016/j.jmpt.2005.06.008; Axen I, 2005, J MANIP PHYSIOL THER, V28, P153, DOI 10.1016/j.jmpt.2005.02.007; Axen I, 2002, J MANIP PHYSIOL THER, V25, P450, DOI 10.1067/mmt.2002.126473; Burton AK, 2004, MANUAL THER, V9, P30, DOI 10.1016/S1356-689X(03)00052-3; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Cecchi F, 2011, EUR J PHYS REHAB MED, V47, P381; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Cleland JA, 2009, SPINE, V34, P2720, DOI 10.1097/BRS.0b013e3181b48809; Constantinides Minas, 2009, Facial Plast Surg Clin North Am, V17, P1, DOI 10.1016/j.fsc.2008.09.005; Eklund A, 2019, EUR J PAIN, V23, P1378, DOI 10.1002/ejp.1407; Field J, 2012, CHIROPR MAN THER, V20, DOI 10.1186/2045-709X-20-17; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Fritz JM, 2006, SPINE, V31, P77, DOI 10.1097/01.brs.0000193898.14803.8a; Fritz JM, 2001, PHYS THER, V81, P776, DOI 10.1093/ptj/81.2.776; Fritz JM, 2001, PHYS THER, V81, P1546, DOI 10.1093/ptj/81.9.1546; Fritz JM, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2692-6; Fritz JM, 2011, SPINE, V36, P1772, DOI 10.1097/BRS.0b013e318216337d; Gatchel RJ, 2010, SPINE J, V10, P321, DOI 10.1016/j.spinee.2009.10.015; Glattacker M, 2013, J REHABIL MED, V45, P268, DOI 10.2340/16501977-1104; Hadizadeh M, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2543-y; Harvey E, 2003, MANUAL THER, V8, P46, DOI 10.1054/math.2002.0472; Hayden JA, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011284.pub2; Hebert JJ, 2010, ARCH PHYS MED REHAB, V91, P78, DOI 10.1016/j.apmr.2009.08.146; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Iles RA, 2009, J OCCUP REHABIL, V19, P25, DOI 10.1007/s10926-008-9161-0; Kiesel KB, 2007, MANUAL THER, V12, P161, DOI 10.1016/j.math.2006.06.011; Kongsted A, 2014, SPINE, V39, P81, DOI 10.1097/BRS.0000000000000059; Koppenhaver SL, 2011, J ORTHOP SPORT PHYS, V41, P389, DOI 10.2519/jospt.2011.3632; Leboeuf-Yde C, 2005, J MANIP PHYSIOL THER, V28, P472, DOI 10.1016/j.jmpt.2005.07.003; Leboeuf-Yde C, 2005, J MANIP PHYSIOL THER, V28, P90, DOI 10.1016/j.jmpt.2005.01.010; Leboeuf-Yde C, 2004, J MANIP PHYSIOL THER, V27, P493, DOI 10.1016/j.jmpt.2004.08.001; Magee DJ, 2007, ORTHOPEDIC PHYS ASSE; Maher CG, 1998, PHYS THER, V78, P289, DOI 10.1093/ptj/78.3.289; Maigne R, 1996, MANUAL MED APPROACH; Maitland G., 2005, MAITLANDS VERTEBRAL, V6th ed.; McCormick K, 2017, SPSS STAT DATA ANAL, DOI [10.1002/9781119183426, DOI 10.1002/9781119183426]; Metcalfe CJ, 2005, PATIENTS EXPECTATION, P55; Meulman J, 2000, OPTIMAL SCALING METH; Myers SS, 2008, J GEN INTERN MED, V23, P148, DOI 10.1007/s11606-007-0460-5; Newell D, 2007, CLIN CHIROPR, V10, P179; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Peterson CK, 2012, J MANIP PHYSIOL THER, V35, P525, DOI 10.1016/j.jmpt.2012.06.003; Skargren EI, 1998, PAIN, V77, P201, DOI 10.1016/S0304-3959(98)00101-8; Thakral M, 2014, J AM GERIATR SOC, V62, P1891, DOI 10.1111/jgs.13070; Underwood MR, 2007, RHEUMATOLOGY, V46, P1297, DOI 10.1093/rheumatology/kem113; Van Wolde Ellen, 2008, BIBLICAL INTERPRETAT, V16, P1, DOI DOI 10.1163/156851508X247602; Vavrek D, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0632-0; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; WADDELL G, 1992, SPINE, V17, P617, DOI 10.1097/00007632-199206000-00001; Wong AYL, 2019, EUR SPINE J, V28, P259, DOI 10.1007/s00586-018-5851-2; Wong AYL, 2017, PM&R, V9, P816, DOI 10.1016/j.pmrj.2016.12.001; 作者不详, 2010, [农业生物技术学报, Journol of Agricultural Biotechnology], V18, P1	58	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2020	15	11							e0242831	10.1371/journal.pone.0242831	http://dx.doi.org/10.1371/journal.pone.0242831			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA8EQ	33232379	gold, Green Published			2023-01-03	WOS:000595863100041
J	Zhou, L; Lapping, S; Liao, XD; Lu, Y; Zhou, GJ; Matoba, K; Vasudevan, N; Wang, LM; Nayak, L				Zhou, Lin; Lapping, Stephanie; Liao, Xudong; Lu, Yuan; Zhou, Guangjin; Matoba, Keiichiro; Vasudevan, Neelakantan; Wang, Lemin; Nayak, Lalitha			The thromboprotective effect of traditional Chinese medicine Tongji 2 granules is dependent on anti-inflammatory activity by suppression of NF-kappa B pathways	PLOS ONE			English	Article							INFLAMMATION; INHIBITION; TISSUE	Inflammation is a vital physiological response of the immune system meant to protect against the invasion of pathogens. However, accumulating evidence describes an intimate link between inflammation and thrombosis and cellular elements of the immune system of the immune system such as neutrophils and monocytes/macrophages are emerging as key players in the generation of a prothrombotic milieu suggesting that anti-inflammatory therapy may have a role in the management of thrombosis that is driven by inflammation. Tongji 2 (TJ2) is a traditional Chinese medication manufactured as granules by Tongji hospital of Tongji University (Shanghai, China) with known anti-inflammatory properties. In this study, we examine the effects of TJ2 on inflammation and thrombosis. Our study shows that TJ2 modulates NF-kappa B activation and thus generates a prominent anti-inflammatory effect. Further, we use mouse models of thrombosis to demonstrate that TJ2 has a beneficial effect in both arterial and venous thrombosis that occurs in the absence of alterations in platelet activation or coagulation.	[Zhou, Lin; Wang, Lemin] Tongji Univ, Tongji Hosp, Dept Cardiol, Shanghai, Peoples R China; [Lapping, Stephanie; Liao, Xudong; Lu, Yuan; Zhou, Guangjin; Vasudevan, Neelakantan] Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland Med Ctr, Case Cardiovasc Res Inst, Cleveland, OH 44106 USA; [Matoba, Keiichiro] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet Endocrinol & Metab, Tokyo, Japan; [Nayak, Lalitha] Case Western Reserve Univ, Sch Med, Div Hematol & Oncol, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA	Tongji University; Case Western Reserve University; University Hospitals of Cleveland; Jikei University; Case Western Reserve University; University Hospitals of Cleveland	Nayak, L (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol & Oncol, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.	lxn64@case.edu			NIH/NHLBI [HL142647, HL143402]	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	LN is supported by the NIH/NHLBI: HL142647 and HL143402 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achyut BR, 2016, ONCOTARGETS THER, V9, P1047, DOI 10.2147/OTT.S102907; [Anonymous], 1997, REVIJA SOCIJALNU POL, V4, P41; [Anonymous], 2015, DIABETES CARE, V38, P394; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Chao LK, 2010, J AGR FOOD CHEM, V58, P3472, DOI 10.1021/jf904207m; Esmon CT, 2003, J THROMB HAEMOST, V1, P1343, DOI 10.1046/j.1538-7836.2003.00261.x; Holmqvist ME, 2012, JAMA-J AM MED ASSOC, V308, P1350, DOI 10.1001/2012.jama.11741; Jou IM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/316482; Khan S, 2013, J ETHNOPHARMACOL, V145, P626, DOI 10.1016/j.jep.2012.12.001; Khan S, 2011, J CELL BIOCHEM, V112, P2179, DOI 10.1002/jcb.23137; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Nagareddy P, 2013, CURR OPIN HEMATOL, V20, P457, DOI 10.1097/MOH.0b013e328364219d; Nayak L, 2014, BLOOD, V123, P3828, DOI 10.1182/blood-2014-01-547448; Nikzad-Langerodi R, 2017, TALANTA, V175, P264, DOI 10.1016/j.talanta.2017.07.045; Pawlinski R, 2010, BLOOD, V116, P806, DOI 10.1182/blood-2009-12-259267; Qiu LH, 2017, EXP THER MED, V14, P2401, DOI 10.3892/etm.2017.4739; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WROBLESKI SK, 2011, JOVE J VIS EXP JUN, DOI DOI 10.3791/2738; Yang X., 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/204840; Yau JW, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872-015-0124-z	22	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2020	15	11							e0241607	10.1371/journal.pone.0241607	http://dx.doi.org/10.1371/journal.pone.0241607			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OY0MJ	33180821	Green Published, gold			2023-01-03	WOS:000593948000080
J	Huang, HL; Lu, WR; Liu, CL; Chang, HJ				Huang, Hsiu-Li; Lu, Wei-Ru; Liu, Chien-Liang; Chang, Hong-Jer			Advance care planning information intervention for persons with mild dementia and their family caregivers: Impact on end-of-life care decision conflicts	PLOS ONE			English	Article							OLDER-PEOPLE; PERCEPTIONS; RESIDENTS; MAKERS	Persons with dementia are at high risk for loss of decision-making ability due to increased cognitive decline as the disease progresses. Participation in advance care planning (ACP) discussions in the early stages of dementia is crucial for end-of-life (EoL) decision-making to ensure quality of EoL care. A lack of discussions about ACP and EoL care between persons with dementia and family caregivers (FCGs), can lead to decisional conflicts when persons with dementia are in the later stages of the disease. This study explored the effects of a family-centered ACP information intervention among persons with dementia and FCGs. The study was conducted in outpatient clinics in Taiwan. Participants were dyads (n = 40) consisting of persons diagnosed with mild cognitive impairment or mild dementia and their FCGs. A one-group, pretest-posttest, pre-experimental design was employed. The intervention was provided by an ACP-trained senior registered nurse and was guided by ACP manuals and family-centered strategies. Outcome data were collected with four structured questionnaires regarding knowledge of end-stage dementia treatment, knowledge of ACP, attitude towards ACP, and EoL decisional conflict about acceptance or refusal of cardiopulmonary resuscitation, ventilators, and tracheostomy. Paired t tests compared differences between pre-intervention data and 4-weeks' post-intervention data. The intervention resulted in significant improvements among persons with dementia and FCGs for knowledge of end-stage dementia treatment (p= .008 and p < .001, respectively), knowledge of ACP (bothp< .001), and significant reductions in decisional conflicts (both p < .001). Scores for positive and negative attitude toward ACP did not change for persons with dementia; however, there was a reduction in negative attitude for FCGs (p= .001). Clinical care for persons with dementia should incorporate ACP interventions that provide knowledge about EoL dementia care using family-centered care strategies that facilitate regular and continuous communication between FCGs, persons with dementia, and medical personnel to reduce decisional conflicts for EoL care.	[Huang, Hsiu-Li; Chang, Hong-Jer] Natl Taipei Univ Nursing & Hlth Sci, Coll Hlth Technol, Dept Long Term Care, Taipei, Taiwan; [Lu, Wei-Ru] Sijhih Cathay Gen Hosp, Dept Nursing, New Taipei, Taiwan; [Liu, Chien-Liang] Taipei City Hosp, Dementia Ctr, Taipei, Taiwan; [Liu, Chien-Liang] Univ Taipei, Taipei, Taiwan	National Taipei University of Nursing & Health Science (NTUNHS); Cathay General Hospital; Taipei City Hospital; University of Taipei	Huang, HL (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Coll Hlth Technol, Dept Long Term Care, Taipei, Taiwan.	hsiuli@ntunhs.edu.tw			Ministry of Science and Technology of Taiwan [MOST 106-2314-B-182 -006 -MY3]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan)	This study received a fund from the Ministry of Science and Technology of Taiwan (MOST 106-2314-B-182 -006 -MY3). The funder had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Alzheimer's Disease International, 2018, GLOB VOIC DEM DEM ST; Bonner GJ, 2014, DEMENTIA-LONDON, V13, P79, DOI 10.1177/1471301212449408; Boopathiraj C., 2013, INT J SOC SCI INTERD, V2, P2; Brazil K, 2018, PALLIATIVE MED, V32, P603, DOI 10.1177/0269216317722413; Capacity Assessment Office, 2020, GUID COND ASS CAP; Caron CD., 2005, DEMENTIA, V4, P113, DOI [10.1177/1471301205049193, DOI 10.1177/1471301205049193]; Chan HYL, 2011, J CLIN NURS, V20, P1454, DOI 10.1111/j.1365-2702.2010.03670.x; Chang WZD, 2020, AM J SPEECH-LANG PAT, V29, P185, DOI 10.1044/2019_AJSLP-19-0028; Chung RY, 2017, J AM MED DIRECTORS A, V18, DOI 10.1016/j.jamda.2016.12.066; Clarfield AM, 2003, ARCH INTERN MED, V163, P2219, DOI 10.1001/archinte.163.18.2219; COHEN J, 1988, APPL PSYCH MEAS, V12, P425, DOI 10.1177/014662168801200410; Dementia Care Central, 2020, STAG ALZH DEM SCAL U; Dening KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159056; Department of Medical Affairs Ministry of Health and Welfare Taiwan ROC, 2015, PROT PAT AUT PAT AUT; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Dickinson C, 2013, INT PSYCHOGERIATR, V25, P2011, DOI 10.1017/S1041610213001531; Fox S, 2017, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-017-0221-0; Gao X, 2015, PALLIAT SUPPORT CARE, V13, P1677, DOI 10.1017/S147895151500067X; Giguere AMC, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2697-1; Gjerberg E, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0096-y; Goodman C, 2013, INT J NURS STUD, V50, P1639, DOI 10.1016/j.ijnurstu.2013.06.008; Hickman SE, 2016, J AM GERIATR SOC, V64, P2385, DOI 10.1111/jgs.14463; Hinderer KA, 2019, APPL NURS RES, V49, P91, DOI 10.1016/j.apnr.2019.04.003; Ho A, 2008, SCAND J CARING SCI, V22, P128, DOI 10.1111/j.1471-6712.2007.00561.x; Houben CH, 2014, J AM MED DIR ASSOC, V15, P454, DOI [10.1016/j.jamda.2014.04.016, DOI 10.1016/J.JAMDA.2014.04.016]; Huang, 2015, J LONG TERM CARE, V19, P295, DOI [10.6317/LTC.19.295, DOI 10.6317/LTC.19.295, 10.6317/LTC.2015.19(3).295-303, DOI 10.6317/LTC.2015.19(3).295-303]; Huang HL, 2018, J NURS RES, V26, P231, DOI 10.1097/jnr.0000000000000240; Huang HL, 2018, INT PSYCHOGERIATR, V30, P341, DOI 10.1017/S1041610217001661; Jones K, 2016, DEMENTIA-LONDON, DOI [10.1177/1471301216676121, DOI 10.1177/147130121667612127821714]; Kabasakalian A, 2009, INT REV NEUROBIOL, V84, P283, DOI 10.1016/S0074-7742(09)00415-2; Kaur J, 2016, ENDOCRINOL DIAB META, DOI 10.1530/EDM-16-0059; Lee H.-T.S., 2012, TAIWAN J HOSP PALLIA, V17, P187, DOI [10.6537/TJHPC.2012.17(2).5, DOI 10.6537/TJHPC.2012.17(2).5]; Lee MC, 2018, GERONTOL GERIATR MED, V4, DOI 10.1177/2333721418778195; Lord K, 2015, INT PSYCHOGERIATR, V27, P1301, DOI 10.1017/S1041610215000411; MAHONEY F I, 1965, Md State Med J, V14, P61; Mohamad MM, 2015, PROCD SOC BEHV, V204, P164, DOI 10.1016/j.sbspro.2015.08.129; National End of Life Care Programme, 2020, CAP CAR PLANN ADV CA; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Ouldred Emma, 2008, Br J Nurs, V17, P308; PAHO Pan American Health Organization, 2019, TOP 10 CAUS DEATH WO; Piers R, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0332-2; Poppe M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060412; Shalowitz DI, 2006, ARCH INTERN MED, V166, P493, DOI 10.1001/archinte.166.5.493; Snyder EA, 2013, J AM MED DIR ASSOC, V14, P114, DOI 10.1016/j.jamda.2012.10.011; Sun A, 2017, J IMMIGR MINOR HEALT, V19, P381, DOI 10.1007/s10903-016-0365-7; Sun Y, 2014, REGION ANESTH PAIN M, V9, pe100303, DOI 10.1371/journal.pone.0100303; Sung HC, 2019, CLIN GERONTOLOGIST, V42, P238, DOI 10.1080/07317115.2017.1336142; Taiwan Alzheimer's Disease Association, 2019, AW DEM; Tay SY, 2015, J AM MED DIR ASSOC, V16, P957, DOI 10.1016/j.jamda.2015.05.014; van der Steen JT, 2016, ARCH GERONTOL GERIAT, V65, P225, DOI 10.1016/j.archger.2016.04.005; van der Steen JT, 2014, J ALZHEIMERS DIS, V40, P743, DOI 10.3233/JAD-131967; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685; Wolfson C, 2001, NEW ENGL J MED, V344, P1111, DOI 10.1056/NEJM200104123441501; Yang CL, 2011, CANCER NURS, V34, P98, DOI 10.1097/NCC.0b013e3181f22cac	54	10	10	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240684	10.1371/journal.pone.0240684	http://dx.doi.org/10.1371/journal.pone.0240684			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3XB	33052970	Green Published, gold			2023-01-03	WOS:000581820200025
J	Seiberth, JM; Moritz, K; Kucukay, N; Schiek, S; Bertsche, T				Seiberth, Jasmin Mina; Moritz, Katharina; Kuecuekay, Nagihan; Schiek, Susanne; Bertsche, Thilo			What is the attitude towards and the current practice of information exchange during self-medication counselling in German community pharmacies? An assessment through self-report and non-participant observation	PLOS ONE			English	Article							DRUG-RELATED PROBLEMS; THE-COUNTER DRUGS; NONPRESCRIPTION MEDICINES; PATIENTS WANT; PATIENT; COMMUNICATION; CARE; PHARMACOVIGILANCE; IMPLEMENTATION; CONSULTATIONS	Background Guidelines encourage relevant information exchange between pharmaceutical staff and patients during self-medication consultation. Thereby, assessing the patient's situation and providing information is crucial for patient safety. So far, limited studies have investigated this information exchange, particularly in Germany. We aimed to assess the attitude towards and the current practice of guideline-recommended information exchange in German community pharmacies. Methods In total, twelve guideline-recommended parameters were predefined for gathering patient-related information and for the provision of information. These information exchange parameters were evaluated in two parts: Firstly, in a self-report of pharmaceutical staff via an online questionnaire to assess the reported importance, difficulty and frequency of the parameters as well as barriers to their implementation; secondly, in a non-participant observation in five pharmacies to evaluate the actual consultation practice. Results In the self-report, all parameters were rated by more than 76% of 1068 participants as important. 'Concurrent medication' was determined to be the most difficult parameter to address (54%). All parameters of information gathering were rated to be addressed during routine counselling by at least 70% of the respondents. Parameters of information provision were all rated to be addressed by at least 45%. 'Lack of patient's interest' was identified as the most frequent barrier to appropriate counselling (84%). During the observation, the information gathering parameters were each addressed between 8 to 63% in the consultations, parameters of information provision between 3 to 34%. Conclusion Despite broad acceptance, the guideline parameters of information exchange were comparatively little addressed during the actual routine care. This might be due to a perceived 'lack of patient's interest' in counselling. Our results suggest to scrutinize whether patients are in fact not interested in counselling and to further explore how the positive intention of pharmaceutical staff towards information exchange can be further translated into everyday practice.	[Seiberth, Jasmin Mina; Moritz, Katharina; Kuecuekay, Nagihan; Schiek, Susanne; Bertsche, Thilo] Univ Leipzig, Fac Med, Inst Pharm, Dept Clin Pharm, Leipzig, Germany; [Seiberth, Jasmin Mina; Moritz, Katharina; Kuecuekay, Nagihan; Schiek, Susanne; Bertsche, Thilo] Univ Hosp Leipzig, Drug Safety Ctr, Leipzig, Germany; [Seiberth, Jasmin Mina; Moritz, Katharina; Kuecuekay, Nagihan; Schiek, Susanne; Bertsche, Thilo] Univ Leipzig, Leipzig, Germany	Leipzig University; Leipzig University; Leipzig University	Bertsche, T (corresponding author), Univ Leipzig, Fac Med, Inst Pharm, Dept Clin Pharm, Leipzig, Germany.; Bertsche, T (corresponding author), Univ Hosp Leipzig, Drug Safety Ctr, Leipzig, Germany.; Bertsche, T (corresponding author), Univ Leipzig, Leipzig, Germany.	thilo.bertsche@uni-leipzig.de		Bertsche, Thilo/0000-0002-4930-6655; Moritz, Katharina/0000-0001-5100-7761	ABDA Federal Union of German Associations of Pharmacists; AVOXA - Media Group German Pharmacist GmbH	ABDA Federal Union of German Associations of Pharmacists; AVOXA - Media Group German Pharmacist GmbH	Jasmin Mina Seiberth and Katharina Moritz were financially supported by the ABDA Federal Union of German Associations of Pharmacists (https://www.abda.de/) and the AVOXA - Media Group German Pharmacist GmbH (https://avoxa.de/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adepu R, 2009, INDIAN J PHARM SCI, V71, P285, DOI 10.4103/0250-474X.56029; Alaqeel S, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1220-6; Alte D, 2007, ANN PHARMACOTHER, V41, P1023, DOI 10.1345/aph.1H565; AMBADY N, 1993, J PERS SOC PSYCHOL, V64, P431, DOI 10.1037/0022-3514.64.3.431; American Society of Health-System Pharmacists, 1997, AM J HEALTH-SYST PH, V54, P431, DOI [DOI 10.1093/AJHP/54.4.431, 10.1093/ajhp/54.4.431]; [Anonymous], 2019, APPROBATIONSORDNUNG; Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939; Atkinson J, 2014, PHARMACY, V2, P231, DOI 10.3390/pharmacy2030231; Barrenberg E, 2015, EUR J CLIN PHARMACOL, V71, P1389, DOI 10.1007/s00228-015-1929-5; Barrenberg E, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6020052; Beitz R, 2004, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V47, P1043, DOI 10.1007/s00103-004-0923-3; Benrimoj SI, 2007, QUAL SAF HEALTH CARE, V16, P354, DOI 10.1136/qshc.2006.019463; Berger K, 2005, J CLIN PHARM THER, V30, P45, DOI 10.1111/j.1365-2710.2004.00611.x; Berger Karin, 2012, Pharm Unserer Zeit, V41, P276, DOI 10.1002/pauz.201200475; Berreni A, 2015, FUND CLIN PHARMACOL, V29, P517, DOI 10.1111/fcp.12140; Berry DC, 1997, PSYCHOL HEALTH, V12, P467, DOI 10.1080/08870449708406723; Bertsche T, 2012, INT J CLIN PHARM-NET, V34, P17, DOI 10.1007/s11096-011-9584-0; Blenkinsopp A, 1996, BRIT MED J, V312, P629; Blom L., 1998, INT J PHARM PRACT, V6, P72, DOI [10.1111/j.2042-7174.1998.tb00919.x, DOI 10.1111/J.2042-7174.1998.TB00919.X]; Boeni F, 2015, PATIENT PREFER ADHER, V9, P597, DOI 10.2147/PPA.S76027; Bosch-Lenders D, 2016, AGE AGEING, V45, P402, DOI 10.1093/ageing/afw045; Brata C, 2019, PHARM PRACT-GRANADA, V17, DOI [10.18549/PharmPract.2019.2.1452, 10.18549/pharmpract.2019.2.1452]; Brata C, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-014-0670-6; Brata C, 2013, RES SOC ADMIN PHARM, V9, P370, DOI 10.1016/j.sapharm.2012.08.001; Buring SM, 2007, AM J PHARM EDUC, V71, DOI 10.5688/aj710108; Cohen J., 2013, STAT POWER ANAL BEHA; Collins JC, 2017, INT J CLIN PHARM-NET, V39, P697, DOI 10.1007/s11096-017-0505-8; Deyoung M, 1996, AM J HEALTH-SYST PH, V53, P1277, DOI 10.1093/ajhp/53.11.1277; Dickinson D, 2003, BRIT MED J, V327, P861, DOI 10.1136/bmj.327.7419.861-a; Divine H, 2017, HDB NONPRESCRIPTION, P17; Eickhoff C, 2006, ANN PHARMACOTHER, V40, P729, DOI 10.1345/aph.1G458; Eickhoff C, 2012, PHARMACOEPIDEM DR S, V21, P254, DOI 10.1002/pds.2241; Federal Chamber of Pharmacists, 2017, KOMP LERNZ PHARM PER; Federal Chamber of Pharmacists, 2019, GUID FED CHAMB PHARM; Federal Union of German Associations of Pharmacists, 2020, LEITL; Federal Union of German Associations of Pharmacists, 2019, GERM PHARM FIG DAT F; Freyer J, 2016, DEUT MED WOCHENSCHR, V141, pE149, DOI 10.1055/s-0042-108618; Garner M, 2007, PATIENT EDUC COUNS, V65, P51, DOI 10.1016/j.pec.2006.05.004; Gokcekus L, 2012, INT J CLIN PHARM-NET, V34, P312, DOI 10.1007/s11096-011-9605-z; Gollwitzer PM, 2006, ADV EXP SOC PSYCHOL, V38, P69, DOI 10.1016/S0065-2601(06)38002-1; Hassell K, 1998, J Health Serv Res Policy, V3, P219; Hibbert D, 2002, SOCIOL HEALTH ILL, V24, P46, DOI 10.1111/1467-9566.00003; International Pharmaceutical Federation, 1997, STAND QUAL PHRM SERV; Jin HK, 2018, ADV HEALTH SCI EDUC, V23, P633, DOI 10.1007/s10459-017-9791-0; Kaae S, 2013, RES SOC ADMIN PHARM, V9, P958, DOI 10.1016/j.sapharm.2012.10.003; Keller K., 1994, DRUG INF J, V28, P453, DOI [10.1177/009286159402800219, DOI 10.1177/009286159402800219]; Krishnan HS, 2000, PHARM WORLD SCI, V22, P102, DOI 10.1023/A:1008733207854; Krueger JL, 2011, J AM PHARM ASSOC, V51, P510, DOI 10.1331/JAPhA.2011.10069; Langer B, 2018, PHARM PHARM, V9, P257, DOI [10.4236/pp.2018.97020, DOI 10.4236/PP.2018.97020]; Langer Bernhard, 2019, F1000Res, V8, P1841, DOI 10.12688/f1000research.21045.1; Langer B, 2018, INT J PHARM PRACT, V26, P310, DOI 10.1111/ijpp.12405; Laven A, 2018, INT J CLIN PHARM-NET, V40, P1317, DOI 10.1007/s11096-018-0710-0; Leiner D, 2017, SOSCI SURVEY VERSION; Locquet M, 2017, DRUG AGING, V34, P359, DOI 10.1007/s40266-017-0445-y; Montastruc JL, 2016, THERAPIE, V71, P257, DOI 10.1016/j.therap.2016.02.012; Moritz K, 2019, J CLIN PHARM THER, V44, P895, DOI 10.1111/jcpt.13013; Nair K, 2002, CAN FAM PHYSICIAN, V48, P104; Narhi U, 2000, J CLIN PHARM THER, V25, P177; Netere AK, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0930-7; Pharmaceutical Society of Australia, 2017, PROF PRACT STAND V5; Pharmaceutical Society of Australia, 2000, CARER PROT PHARM MED; Rutter P, 2015, INTEGR PHARM RES PRA, V4, P57, DOI 10.2147/IPRP.S70403; Sclar DA, 1996, J CLIN PHARM THER, V21, P177; Seiberth JM, 2021, HEALTH SOC CARE COMM, V29, P194, DOI 10.1111/hsc.13082; Seubert LJ, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7020073; Seubert LJ, 2018, RES SOC ADMIN PHARM, V14, P979, DOI 10.1016/j.sapharm.2017.12.001; Seubert LJ, 2017, PHARMACY, V5, DOI 10.3390/pharmacy5040065; Shah BK, 2011, RES SOC ADMIN PHARM, V7, P272, DOI 10.1016/j.sapharm.2010.07.001; Smith H, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7168; Surur AS, 2017, PHARM PRACT-GRANADA, V15, DOI [10.18549/PharmPract.2017.01.890, 10.18549/pharmpract.2017.01.890]; Watson MC, 2006, QUAL SAF HEALTH CARE, V15, P244, DOI 10.1136/qshc.2005.014035; Watson MC, 2008, PHARM WORLD SCI, V30, P526, DOI 10.1007/s11096-008-9202-y; Westerlund LOT, 2001, ANN PHARMACOTHER, V35, P1343	73	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2020	15	10							e0240672	10.1371/journal.pone.0240672	http://dx.doi.org/10.1371/journal.pone.0240672			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OG3XB	33052955	gold, Green Published			2023-01-03	WOS:000581820200005
J	Kim, SJ; Kim, HS; Hwang, SO; Jung, WJ; Roh, YI; Cha, KC; Shin, SD; Song, KJ				Kim, Sun Ju; Kim, Hye Sim; Hwang, Sung Oh; Jung, Woo Jin; Roh, Young Il; Cha, Kyoung-Chul; Shin, Sang Do; Song, Kyoung Jun		Korean Cardiac Arrest Res Consor	Ionized calcium level at emergency department arrival is associated with return of spontaneous circulation in out-of-hospital cardiac arrest	PLOS ONE			English	Article							NOREPINEPHRINE	Background Calcium level is associated with sudden cardiac death based on several cohort studies. However, there is limited evidence on the association between ionized calcium, active form of calcium, and resuscitation outcome. This study aimed to evaluate the potential role of ionized calcium in predicting resuscitation outcome in patients with out-of-hospital cardiac arrest. Methods We analyzed the Korean Cardiac Arrest Research Consortium data (KoCARC) registry, a web-based multicenter registry that included 65 participating hospitals throughout the Republic of Korea. The patients with out-of-hospital cardiac arrest over 19 years old and acquired laboratory data including calcium, ionized calcium, potassium, phosphorus, creatinine, albumin at emergency department (ED) arrival were included. The primary outcome was successful rate of return of spontaneous circulation (ROSC) and the secondary outcomes were survival hospital discharge and favorable neurological outcome (cerebral performance category 1 or 2) at hospital discharge. Results Eight-hundred and eighty-three patients were enrolled in the final analysis and 448 cases (54%) had ROSC. In multivariable logistic regression analysis, ionized calcium level was associated with ROSC (odds ratio, 1.77; 95% CI1.28-2.45;p= 0.001) even though calcium level was not associated with ROSC (odds ratio, 0.87; 95% CI 0.70-1.08;p= 0.199). However, ionized calcium level was not associated with survival discharge (odds ratio, 0.99; 95% CI 0.72-1.36;p= 0.948) or favorable neurologic outcome (odds ratio, 0.45; 95% CI 0.03-6.55,p= 0.560). Conclusion A high ionized calcium level measured during cardiopulmonary resuscitation was associated with an increased likelihood of ROSC.	[Kim, Sun Ju; Hwang, Sung Oh; Jung, Woo Jin; Roh, Young Il; Cha, Kyoung-Chul] Yonsei Univ, Wonju Coll Med, Dept Emergency Med, Wonju, South Korea; [Kim, Hye Sim] Yonsei Univ, Wonju Coll Med, Ctr Biomed Data Sci, Wonju, South Korea; [Shin, Sang Do] Seoul Natl Univ Hosp, Dept Emergency Med, Seoul, South Korea; [Song, Kyoung Jun] Seoul Natl Univ, Boramae Med Ctr, Dept Emergency Med, Seoul, South Korea	Yonsei University; Yonsei University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Cha, KC (corresponding author), Yonsei Univ, Wonju Coll Med, Dept Emergency Med, Wonju, South Korea.	chaemp@yonsei.ac.kr	Hwang, Sung Oh/AAO-5838-2021	Hwang, Sung Oh/0000-0003-4585-3181; KIM, SUN JU/0000-0002-8169-5750; Kim, Hye Sim/0000-0002-7431-9722; Cha, Kyoung-Chul/0000-0003-1818-2466	Korea Centers for Disease Control and Prevention	Korea Centers for Disease Control and Prevention	This study was supported by the Korea Centers for Disease Control and Prevention.	Allgrove J, 2009, ENDOCR DEV, V16, P8, DOI 10.1159/000223685; [Anonymous], 2000, Circulation, V102, pI86; [Anonymous], 1974, JAMA-J AM MED ASSOC, V227, P833, DOI 10.1001/jama.227.7.833; [Anonymous], 2005, CIRCULATION, V112, pIV; [Anonymous], 2013, IEEE MULTIMEDIA, V20, P72; [Anonymous], 2014, AUGAHI, V64, P187; [Anonymous], 2000, CIRCULATION S1, V102, pI12; Baird GS, 2011, CLIN CHIM ACTA, V412, P696, DOI 10.1016/j.cca.2011.01.004; Bellomo R, 2015, BEST PRAC RES-CL ANA, V29, P471, DOI 10.1016/j.bpa.2015.10.003; Bushinsky DA, 1998, LANCET, V352, P306, DOI 10.1016/S0140-6736(97)12331-5; BUYLAERT WA, 1989, RESUSCITATION, V17, pS189, DOI 10.1016/0300-9572(89)90104-4; Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Enders DB, 2001, TIETZ FUNDAMENTALS C, P795; ERDMANN E, 1991, BRIT J ANAESTH, V67, P178, DOI 10.1093/bja/67.2.178; FISCH C, 1973, CIRCULATION, V47, P408, DOI 10.1161/01.CIR.47.2.408; HEINING MPD, 1984, ANAESTHESIA, V39, P1079, DOI 10.1111/j.1365-2044.1984.tb08926.x; Kaku Y, 2015, NEPHRON EXTRA, V5, P39, DOI 10.1159/000437215; KENNY AD, 1964, N-S ARCH EX PATH PH, V248, P144, DOI 10.1007/BF00246669; Kim JY, 2018, CLIN EXP EMERG MED, V5, P165, DOI 10.15441/ceem.17.259; LJUNHGALL S, 1984, EXP CLIN ENDOCRINOL, V84, P313, DOI 10.1055/s-0029-1210404; MUSSO E, 1978, CIRC RES, V42, P276, DOI 10.1161/01.RES.42.2.276; Pfitzenmeyer P, 2007, ARCH GERONTOL GERIAT, V45, P151, DOI 10.1016/j.archger.2006.10.006; Sejersted OM, 2011, J PHYSIOL-LONDON, V589, P2919, DOI 10.1113/jphysiol.2011.210989; STEMPIEN A, 1986, ANN INTERN MED, V105, P603, DOI 10.7326/0003-4819-105-4-603; STUEVEN H, 1983, ANN EMERG MED, V12, P136, DOI 10.1016/S0196-0644(83)80551-4; The Federation of State Medical Boards of The United States, 1999, S D J MED, V52, P25; Vaidyanathan J, 2016, CALCIUM GLUCONATE IN; Youngquist ST, 2010, RESUSCITATION, V81, P117, DOI 10.1016/j.resuscitation.2009.10.002	28	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2020	15	10							e0240420	10.1371/journal.pone.0240420	http://dx.doi.org/10.1371/journal.pone.0240420			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OG3TU	33045006	gold, Green Published			2023-01-03	WOS:000581811700057
J	Binachon, A; Grateau, A; Allou, N; Ferdynus, C; Allyn, JM; Dangers, L; Martinet, O; Boisson, V; Gauthier, A; Jabot, J; Persichini, R				Binachon, Antoine; Grateau, Adeline; Allou, Nicolas; Ferdynus, Cyril; Allyn, Jerome; Dangers, Laurence; Martinet, Olivier; Boisson, Veronique; Gauthier, Alexandre; Jabot, Julien; Persichini, Romain			Acute severe asthma requiring invasive mechanical ventilation in the era of modern resuscitation techniques: A 10-year bicentric retrospective study	PLOS ONE			English	Article							EXTRACORPOREAL MEMBRANE-OXYGENATION; RESPIRATORY-FAILURE; EXACERBATIONS; ADMISSIONS; MANAGEMENT; MORTALITY; OUTCOMES; ADULT	Purpose Patients with acute severe asthma (ASA) may in rare cases require invasive mechanical ventilation (IMV). However, recent data on this issue are lacking. Materials and methods In this retrospective and bicentric study conducted on a 10 year period, we investigate the in-hospital mortality in patients with ASA requiring IMV. We compare this mortality to that of patients with other types of respiratory distress using a standardized mortality ratio (SMR) model. Results Eighty-one episodes of ASA requiring IMV were evaluated. Factors significantly associated with in-hospital mortality were cardiac arrest on day of admission, cardiac arrest as the reason for intubation, absence of decompensation risk factors, need for renal replacement therapy on day of admission, and intubation in pre-hospital setting. Non-survivors had higher SAPS II, SOFA, creatinine and lactate levels as well as lower blood pressure, pH, and HCO(3)on day of admission. In-hospital mortality was 15% (n = 12). Compared to a reference population of 2,670 patients, the SMR relative to the SAPS II was very low at 0.48 (95% CI, 0.25-0.84). The only factor independently associated with in-hospital mortality was cardiac arrest on day of admission. In-hospital mortality was 69% in patients with cardiac arrest on day of admission and 4% in others (p < 0.01). Salvage therapies were given to 7 patients, sometimes in combination with each other: ECMO (n = 6), halogenated gas (n = 1) and anti-IL5 antibody (n = 1). Death occurred in only 2 of these 7 patients, both of whom had cardiac arrest on day of admission. Conclusion Nowadays, the mortality of patients with ASA requiring IMV is low. Death is due to multi-organ failure, with cardiac arrest on day of admission being the most important risk factor. In patients who did not have cardiac arrest on day of admission the mortality is even lower (4%) which allows an aggressive management.	[Binachon, Antoine; Grateau, Adeline; Allou, Nicolas; Allyn, Jerome; Dangers, Laurence; Martinet, Olivier; Jabot, Julien; Persichini, Romain] CHU Felix Guyon, Med Surg Intens Care Unit, St Denis, La Reunion, France; [Binachon, Antoine; Boisson, Veronique; Gauthier, Alexandre] CHU Sud Reunion, Med Surg Intens Care Unit, St Pierre, La Reunion, France; [Ferdynus, Cyril] CHU Felix Guyon, Methodol Support & Biostat Unit, St Denis, La Reunion, France; [Ferdynus, Cyril] INSERM, CIC 1410, St Pierre, La Reunion, France	CHU Reunion; CHU Reunion; CHU Reunion; Institut National de la Sante et de la Recherche Medicale (Inserm)	Persichini, R (corresponding author), CHU Felix Guyon, Med Surg Intens Care Unit, St Denis, La Reunion, France.	romain.persichini@hotmail.fr	ferdynus, cyril/AFV-1963-2022	ferdynus, cyril/0000-0003-1502-0672				Abdelkarim H, 2020, J ASTHMA, V57, P398, DOI 10.1080/02770903.2019.1571082; Agnihotri NT, 2019, ALLERGY ASTHMA PROC, V40, P406, DOI 10.2500/aap.2019.40.4258; Al-Dorzi HM, 2014, ANN THORAC MED, V9, P33, DOI 10.4103/1817-1737.124441; Althoff MD, 2020, AM J RESP CRIT CARE; [Anonymous], 1996, EUR RESPIR J, V9, P687, DOI DOI 10.1183/09031936.96.09040687; Cabieses B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105347; Delmas MC, 2010, REV MAL RESPIR, V27, P151, DOI 10.1016/j.rmr.2009.09.001; Ebmeier S, 2017, LANCET, V390, P935, DOI [10.1016/S0140-6736(17)31448-4, 10.1016/s0140-6736(17)31448-4]; Edris A, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1138-3; ELSO The Department of Intensive Care at The Alfred Hospital (Melbourne), DEP INT CAR ALFR HOS; Emma R, 2018, THER ADV RESPIR DIS, V12, DOI 10.1177/1753466618808490; Fan E, 2016, INTENS CARE MED, V42, P712, DOI 10.1007/s00134-016-4314-7; Ferkol Thomas, 2014, Ann Am Thorac Soc, V11, P404, DOI 10.1513/AnnalsATS.201311-405PS; Global Initiative for Asthma, 2019, GLOB STRAT ASTHM MAN; Gupta D, 2004, CRIT CARE, V8, pR112, DOI 10.1186/cc2835; Hebbar KB, 2009, CRIT CARE, V13, DOI 10.1186/cc7735; Kao CC, 2008, J ASTHMA, V45, P552, DOI 10.1080/02770900801999090; Koulenti D, 2017, EUR J CLIN MICROBIOL, V36, P1999, DOI 10.1007/s10096-016-2703-z; Krishnan V, 2006, AM J RESP CRIT CARE, V174, P633, DOI 10.1164/rccm.200601-007OC; Laher AE, 2018, J INTENSIVE CARE MED, V33, P491, DOI 10.1177/0885066617740079; Le Conte P, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0584-x; Leatherman J, 2015, CHEST, V147, P1671, DOI 10.1378/chest.14-1733; Louie S, 2012, CLIN REV ALLERG IMMU, V43, P30, DOI 10.1007/s12016-011-8274-y; MALTAIS F, 1994, CHEST, V106, P1401, DOI 10.1378/chest.106.5.1401; McFadden ER, 2003, AM J RESP CRIT CARE, V168, P740, DOI 10.1164/rccm.200208-902SO; Mikkelsen ME, 2009, ASAIO J, V55, P47, DOI 10.1097/MAT.0b013e3181901ea5; Nanchal R, 2014, RESP CARE, V59, P644, DOI 10.4187/respcare.02505; Papiris SA, 2009, DRUGS, V69, P2363, DOI 10.2165/11319930-000000000-00000; Pendergraft TB, 2004, ANN ALLERG ASTHMA IM, V93, P29, DOI 10.1016/S1081-1206(10)61444-5; Schmidt M, 2014, AM J RESP CRIT CARE, V189, P1374, DOI 10.1164/rccm.201311-2023OC; Secombe P, 2019, CRIT CARE RESUSC, V21, P53; Society for Endocrinology MaDoSAS, 2017, J ENDOCRINOL METAB D, V21, pS1; Solet JL, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7031-7; Tello K, 2019, RESPIR MED CASE REP, V28, DOI 10.1016/j.rmcr.2019.100927; Vaschetto R, 2009, CURR DRUG TARGETS, V10, P826, DOI 10.2174/138945009789108747; World Health Organization, 2019, ASTHMA	36	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2020	15	10							e0240063	10.1371/journal.pone.0240063	http://dx.doi.org/10.1371/journal.pone.0240063			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YX	33007018	gold, Green Published			2023-01-03	WOS:000577103500065
J	Ishtiaq, M; Maqbool, M; Ajaib, M; Ahmed, M; Hussain, I; Khanam, H; Mushtaq, W; Hussain, T; Azam, S; Bhatti, KH; Ghani, A				Ishtiaq, Muhammad; Maqbool, Mehwish; Ajaib, Muhammad; Ahmed, Maqsood; Hussain, Iqbal; Khanam, Humaira; Mushtaq, Waheeda; Hussain, Tanveer; Azam, Shehzad; Hayat Bhatti, Khizar; Ghani, Abdul			Ethnomedicinal and folklore inventory of wild plants used by rural communities of valley Samahni, District Bhimber Azad Jammu and Kashmir, Pakistan	PLOS ONE			English	Article							XANTHOCARPUM FRUIT EXTRACT; MEDICINAL-PLANTS; INDIGENOUS KNOWLEDGE; SOLANUM-XANTHOCARPUM; ETHNOBOTANICAL SURVEY; NATIONAL-PARK; ETHNOPHARMACOLOGICAL SURVEY; TRADITIONAL KNOWLEDGE; HERBAL DRUGS; FOOD PLANTS	The current study describes ethnobotanical (EB) and traditional ethnomedicinal (TEMs) uses of medicinal plants (MPs) of Tehsil Samahni area of Azad Jammu and Kashmir, Pakistan. Indigenous inhabitants of the area mostly reside in remote mountainous areas and depend on wild plants for life necessities and treatment of different diseases. This paper presents first quantitative ethnobotanical study describing the popularity level of MPs in indigenous communities by using relative popularity level (RPL) and rank order of priority (ROP) indices. The data of TEMs and EB uses were collected from 200 interviewees consisting of traditional herbal practioners (110) and farmers (90) from study area using structured and semi-structured interview methodology during year 2019. It was found that illiterate peasants have more knowledge and practice of TEMs than other people. A total of 150 plant species belonging to 58 families with botanical and local names, parts used, mode of recipes preparation, administration mechanism and TEMs uses were documented in systematic manner. It was explored that highest number (7.69%) of plants of Moraceae were used in TEMs and followed by species of Asteraceae (6.29%). The ethnobotanical data was analyzed by using quantitative ethnobotanical tools viz: informant consensus factor (ICF), fidelity level (FL), relative frequency of citation (RFC), use value index (UVI), relative importance of plants (RIP), relative populatiry level (RPL) and rank order of popularity (ROP). The leaf ranked first (36.49%) and fruit 2(nd) (12.07%) being used in TEMs while prevalent use-form was decoction (29.28%), followed by tea (23.05%) and preferably taken as oral (46.66%). ICF analysis proved that diabetes, hypertension, rabies, snake sting and joint pains were the most prevalent occurring infirmities. The highest RFC (0.95) was found for Acacia modesta, followed by Boerhavia procumbens (RFC:0.87) and Berberis lycium (RFC:0.85). The relative importance of MPs was calculated by using UVI and Moringa oleifera showed highest (1.38), followed by Zanthoxylum armatum (1.25) and Withania somnifera (1.24) use-values. High UVI of plants depicts that these species are predominantly used in local health care system. The plants Phyllanthus emblica, Morus macruora, Justicia adhatoda and Melia azedarach depicted high values (1.00) of FL and RPL proving that these taxa are commonly used in indigenous medicines by local inhabitants and have better potential for drug discovery by ethnopharmacological analysis. Out of total, 26 species had more than 50% ROP index and Phyllanthus emblica and Flacourtia indica (ROP = 100) followed by Morus macruora (ROP: 97) were used to cure 'hypertension and hyperlipidemia' and 'cough, chest infection', respectively. It was found that 30% of total species were previously reported as medicinal while 70% plants were first time reported to be used in TEMs and authenticated by using of quantitative ethnobotanical tools. Ethnopharmacological potential of indigenous plants was confirmed by RIP and RPL indices which had been used to cure one or more body systems and were promulgated in the local herbal medicine system. The research provides clues to screen these plant species by using latest phytochemical and pharmacological analysis for novel drug discovery. This study will also be useful for conservation of bioculture traditional knowledge of indigenous communities and the most important is to conserve medicinal plants of the study area for future generations.	[Ishtiaq, Muhammad; Maqbool, Mehwish; Ajaib, Muhammad; Ahmed, Maqsood; Khanam, Humaira; Mushtaq, Waheeda; Hussain, Tanveer; Azam, Shehzad] Mirpur Univ Sci & Technol MUST, Dept Bot, Mirpur, Azad Jammu & Ka, Pakistan; [Hussain, Iqbal] Univ Faisalabad, Dept Bot, Govt Coll, Faisalabad, Pakistan; [Hayat Bhatti, Khizar] Univ Gujrat, Dept Bot, Ahmedabad, Gujarat, Pakistan; [Ghani, Abdul] Univ Sargodha, Dept Bot, Sargodha, Pakistan	Government College University Faisalabad; University of Sargodha	Ishtiaq, M (corresponding author), Mirpur Univ Sci & Technol MUST, Dept Bot, Mirpur, Azad Jammu & Ka, Pakistan.	drishtiaq.bot@must.edu.pk	Hussain, Iqbal/B-2295-2013; Ishtiaq, Muhammad/F-5152-2010; Hussain, Tanveer/GWQ-5172-2022; Ishtiaq, Muhammad/GSN-4278-2022; Ishtiaq, Muhammad/AAG-3124-2021	Hussain, Iqbal/0000-0002-8449-0494; Ishtiaq, Muhammad/0000-0003-2468-1413; 				Abbasi AM, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-66; Abbasi MA, 2011, ASIAN J CHEM, V23, P3353; Abbasi MA, 2009, J CHEM SOC PAKISTAN, V31, P955; Ahmed E, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-13; Ajaib M., 2016, FUUAST J BIOL, V6, P247; Alam N, 2011, PAK J BOT, V43, P773; Ali H, 2009, PAK J BOT, V41, P2009; Ali SI, 2008, PAK J BOT, V40, P967; Ali SI, 1990, FLORA PAKISTAN 191 1; Ali SI., 2001, NATURAL HIST RES PAK; Ali-Shtayeh MS, 2000, J ETHNOPHARMACOL, V73, P221, DOI 10.1016/S0378-8741(00)00316-0; Amjad MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171896; Amjad Muhammad Shoaib, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P234, DOI 10.1016/S2221-1691(15)30011-3; Amjad Muhammad Shoaib, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P952; Arshad M, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-13; Awang DVC, 1997, FOOD DRUG LAW J, V52, P341; Ayyanar M, 2011, J ETHNOPHARMACOL, V134, P851, DOI 10.1016/j.jep.2011.01.029; Azam S, 2017, PAK J BOT, V49, P211; Belayneh A, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-18; Bernhoft A.J.A.B., 2010, BRIEF REV BIOACTIVE, P11; Bibi T, 2014, J ETHNOPHARMACOL, V157, P79, DOI 10.1016/j.jep.2014.08.042; Bolson M, 2015, J ETHNOPHARMACOL, V161, P1, DOI 10.1016/j.jep.2014.11.045; Boudjelal A, 2013, J ETHNOPHARMACOL, V148, P395, DOI 10.1016/j.jep.2013.03.082; Bradacs G, 2011, J ETHNOPHARMACOL, V137, P434, DOI 10.1016/j.jep.2011.05.050; BUDHIRAJA RD, 1987, J SCI IND RES INDIA, V46, P488; Cakilcioglu U, 2011, J ETHNOPHARMACOL, V137, P469, DOI 10.1016/j.jep.2011.05.046; Cechinel-Filho, 2012, PLANT BIOACTIVES DRU; Colvard MD, 2006, J ETHNOPHARMACOL, V107, P134, DOI 10.1016/j.jep.2006.04.005; Cook F. E. M., 1995, Economic botany data collection standard.; Cox PA, 2000, SCIENCE, V287, P44, DOI 10.1126/science.287.5450.44; De Wet H, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-51; Devi P. Uma, 1993, Indian Journal of Experimental Biology, V31, P607; FAIZ AUH, 2014, BIOLOGIA-LAHORE, V60, P43; Farnsworth NR, 1988, BIODIVERSITY, P83; Farooq S., 2012, PAKISTAN J WEED SCI, V18, P277; Frei B, 1998, J ETHNOPHARMACOL, V62, P149, DOI 10.1016/S0378-8741(98)00051-8; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Gilani AH, 2005, J ETHNOPHARMACOL, V100, P43, DOI 10.1016/j.jep.2005.06.001; Govaerts R, 2001, TAXON, V50, P1085, DOI 10.2307/1224723; Govindan S, 1999, J ETHNOPHARMACOL, V66, P205, DOI 10.1016/S0378-8741(98)00160-3; Hamayun M., 2005, ETHNOBOTANICAL LEAFL, V2005, P1; Hayta S, 2014, J ETHNOPHARMACOL, V154, P613, DOI 10.1016/j.jep.2014.04.026; HEINRICH M, 1992, J ETHNOPHARMACOL, V36, P63, DOI 10.1016/0378-8741(92)90062-V; Heinrich M, 1998, SOC SCI MED, V47, P1859, DOI 10.1016/S0277-9536(98)00181-6; Husain SZ, 2008, PAK J BOT, V40, P1897; Hussain F, 1996, P 1 TRAIN WORKSH ETH, P207; Hussain T., 2009, ETHNOBOTANICAL LEAFL, V2009, P6; Hussain Talib, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P454, DOI 10.1016/S2221-1691(12)60075-6; Ibrar M, 2007, PAKISTAN J BOT, V39, P329; Ignacimuthu S, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-25; Inta A, 2013, J ETHNOPHARMACOL, V149, P344, DOI 10.1016/j.jep.2013.06.047; Ishtiaq Ch. Muhammad, 2006, Asian Journal of Plant Sciences, V5, P390; Ishtiaq M, 2010, PLANT BIOSYST, V144, P288, DOI 10.1080/11263501003750185; Ishtiaq M., 2017, INT J BIOSCI, V10, P265, DOI DOI 10.12692/ijb/10.3.265-274; Ishtiaq M., 2016, J MED PLANTS, V3, P97; Ishtiaq M, 2015, J ETHNOPHARMACOL, V168, P201, DOI 10.1016/j.jep.2015.01.054; Ishtiaq M, 2013, PAK J BOT, V45, P157; Ishtiaq M, 2012, PAK J BOT, V44, P245; Ishtiaq Muhammad, 2007, Pak J Biol Sci, V10, P2241, DOI 10.3923/pjbs.2007.2241.2256; Ju Y, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-28; Kadir MF, 2012, J ETHNOPHARMACOL, V144, P627, DOI 10.1016/j.jep.2012.10.003; Kamal M., 2009, PAKISTAN J PLANT SCI, V15, P87; Kaval I, 2014, J ETHNOPHARMACOL, V155, P171, DOI 10.1016/j.jep.2014.05.014; Kayani S, 2015, J ETHNOPHARMACOL, V164, P186, DOI 10.1016/j.jep.2015.02.004; Kayani S, 2014, J ETHNOPHARMACOL, V156, P47, DOI 10.1016/j.jep.2014.08.005; Khaling Mikawlrawng, 2014, International Journal of Herbal Medicine, V2, P1; Khan M. A., 2012, Pakistan Journal of Weed Science Research, V18, P495; Khan M. A., 2010, Ethnobotany Research and Applications, V8, P107; Khan M. B., 2008, THESIS; Khatoon S., 2004, INT J BIOTECHNOLOGY, V1, P584; Lai YJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21050553; Leto C, 2013, J ETHNOPHARMACOL, V146, P90, DOI 10.1016/j.jep.2012.11.042; Luitel DR, 2014, J ETHNOBIOL ETHNOMED, V10, DOI 10.1186/1746-4269-10-5; Mahmood A, 2013, J ETHNOPHARMACOL, V148, P714, DOI 10.1016/j.jep.2013.05.035; Mahmood A, 2011, J MED PLANTS RES, V5, P4493; Mahmood A, 2011, PAK J BOT, V43, P105; Mahmood A, 2011, J MED PLANTS RES, V5, P2348; Mahmood AS, 2011, J APPL PHARM, V3, P212, DOI DOI 10.21065/19204159.3.212; MANANDHAR NP, 1995, ECON BOT, V49, P371, DOI 10.1007/BF02863087; MAQBOOL M, 2019, APPL ECOL ENV RES, V17, P12023; Maqbool M., 2019, P PAKISTAN ACAD SCI, V56, P55; Mehwish M, P PAKISTAN ACAD SCI, V56, P5574; Mesfin F, 2009, J ETHNOBIOL ETHNOMED, V5, DOI 10.1186/1746-4269-5-28; Moerman DE, 1996, J ETHNOPHARMACOL, V52, P1, DOI 10.1016/0378-8741(96)01393-1; Mugisha MK, 2014, J ETHNOPHARMACOL, V155, P194, DOI 10.1016/j.jep.2014.05.012; Muhammad Ishtiaq, 2012, African Journal of Biotechnology, V11, P3087; Neeraj Kumar, 2010, Indian Journal of Natural Products and Resources, V1, P470; Njoroge N. G., 2004, Lyonia, V7, P71; Padmavathi B, 2005, EVID-BASED COMPL ALT, V2, P99, DOI 10.1093/ecam/neh064; Parmesan C, 2006, ANNU REV ECOL EVOL S, V37, P637, DOI 10.1146/annurev.ecolsys.37.091305.110100; Patel PK, 2012, J YOUNG PHARM, V4, P164, DOI 10.4103/0975-1483.100022; Priya P., 2010, Pharmacognosy Journal, V2, P400; Qaisar, 2009, FLORA W PAKISTAN KAS; Qaisar M, 2009, FLORA PAKISTAN 194 2; Qureshi R, 2001, PAKISTAN J BOT, V33, P109; Qureshi R., 2002, HAMDARD MED, V45, P86; Qureshi R, 2008, FITOTERAPIA, V79, P468, DOI 10.1016/j.fitote.2008.03.010; Rehman MN, 2017, REV BRAS FARMACOGN, V27, P751, DOI 10.1016/j.bjp.2017.09.004; Revathi P., 2013, Journal of Medicinal Plants Research, V7, P2083; Rokaya MB, 2010, J ETHNOPHARMACOL, V130, P485, DOI 10.1016/j.jep.2010.05.036; Saric-Kundalic B, 2010, J ETHNOPHARMACOL, V131, P33, DOI 10.1016/j.jep.2010.05.061; Seshagirirao K., 2016, ROXBURGHIA, V6, P111; Shinwari MI, 2000, J ETHNOPHARMACOL, V69, P45, DOI 10.1016/S0378-8741(99)00135-X; Shinwari ZK, 2010, J MED PLANTS RES, V4, P161; Singh H, 2014, J ETHNOPHARMACOL, V154, P98, DOI 10.1016/j.jep.2014.03.026; Singh OM, 2010, J SCI IND RES INDIA, V69, P732; Song MJ, 2013, J ETHNOBIOL ETHNOMED, V9, DOI 10.1186/1746-4269-9-48; Srithi K, 2009, J ETHNOPHARMACOL, V123, P335, DOI 10.1016/j.jep.2009.02.035; Ssegawa P, 2007, J ETHNOPHARMACOL, V113, P521, DOI 10.1016/j.jep.2007.07.014; Stevens P.F, 2017, ANGIOSPERM PHYLOGENY; Stewart RR, 1982, HIST EXPLORATION PLA, P86; Tabuti JRS, 2003, J ETHNOPHARMACOL, V88, P19, DOI 10.1016/S0378-8741(03)00161-2; Trotter RT., 1986, PLANTS INDIGENOUS ME, P91, DOI [10.4324/9781315060385-6, DOI 10.4324/9781315060385-6]; Ugulu I, 2009, J MED PLANTS RES, V3, P345; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Vijayakumar S, 2015, J ETHNOPHARMACOL, V161, P238, DOI 10.1016/j.jep.2014.12.006; Vitalini S, 2013, J ETHNOPHARMACOL, V145, P517, DOI 10.1016/j.jep.2012.11.024; Vyas S, 2004, AGROBIOS; WHO, 2002, TRAD MED ALT MED; Yuan HD, 2017, MOLECULES, V22, DOI 10.3390/molecules22071135; Zandial, 1994, THESIS; Zheng XL, 2013, J ETHNOPHARMACOL, V148, P964, DOI 10.1016/j.jep.2013.05.051	122	18	18	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0243151	10.1371/journal.pone.0243151	http://dx.doi.org/10.1371/journal.pone.0243151			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4UT	33439877	gold, Green Published			2023-01-03	WOS:000609985300017
J	Jordan, S; Prout, H; Carter, N; Dicomidis, J; Hayes, J; Round, J; Carson-Stevens, A				Jordan, Sue; Prout, Hayley; Carter, Neil; Dicomidis, John; Hayes, Jamie; Round, Jeffrey; Carson-Stevens, Andrew			Nobody ever questions-Polypharmacy in care homes: A mixed methods evaluation of a multidisciplinary medicines optimisation initiative	PLOS ONE			English	Article							ADVERSE DRUG-REACTIONS; LONG-TERM-CARE; OLDER-ADULTS; EVENTS; HOSPITALIZATIONS; METAANALYSIS; ENGLAND; PEOPLE	Background Nurse-led monitoring of patients for signs and symptoms associated with documented 'undesirable effects' of medicines has potential to prevent avoidable harm, and optimise prescribing. Intervention The Adverse Drug Reaction Profile for polypharmacy (ADRe-p) identifies and documents putative adverse effects of medicines commonly prescribed in primary care. Nurses address some problems, before passing ADRe-p to pharmacists and prescribers for review, in conjunction with prescriptions. Objectives We investigated changes in: the number and nature of residents' problems as recorded on ADRe-p; prescription regimens; medicines optimisation: and healthcare costs. We explored aetiologies of problems identified and stakeholders' perspectives. Setting and participants In three UK care homes, 19 residents completed the study, December 2018 to May 2019. Two service users, three pharmacists, six nurses gave interviews. Methods This mixed-method process evaluation integrated data from residents' ADRe-ps and medicines charts, at the study's start and 5-10 weeks later. Results We recruited three of 27 homes approached and 26 of 45 eligible residents; 19 completed ADRe-p at least twice. Clinical gains were identified for 17/19 residents (mean number of symptoms 3 SD 1.67, range 0-7). Examples included management of: pain (six residents), seizures (three), dyspnoea (one), diarrhoea (laxatives reduced, two), falls (two of five able to stand). One or more medicine was de-prescribed or dose reduced for 12/19 residents. ADRe administration and review cost similar to 30 pound in staff time. ADRe-p helped carers and nurses bring residents' problems to the attention of prescribers. Implications ADRe-p relieved unnecessary suffering. It supported carers and nurses by providing a tool to engage with pharmacists and prescribers, and was the only observable strategy for multidisciplinary team working around medicines optimisation. ADRe-p improved care by: a) regular systematic checks and problem documentation; b) information transfer from care home staff to prescribers and pharmacists; c) recording changes. Registration NLM Identifier NCT03955133; ClinicalTrials. gov.	[Jordan, Sue; Carter, Neil] Swansea Univ, Fac Hlth & Life Sci, Swansea, W Glam, Wales; [Prout, Hayley] Cardiff Univ, Coll Biomed & Life Sci, Ctr Trials Res, Cardiff, Wales; [Dicomidis, John] Care Home Governance, Pontypool, Wales; [Dicomidis, John] Natl Lead Pharm Informat, Pontypool, Wales; [Hayes, Jamie] Cardiff Univ, Sch Med, Sch Pharm & Pharmaceut Sci, Cardiff, Wales; [Round, Jeffrey] Inst Hlth Econ, Edmonton, AB, Canada; [Carson-Stevens, Andrew] Cardiff Univ, Sch Med, Div Populat Med, Cardiff, Wales	Swansea University; Cardiff University; Cardiff University; Cardiff University	Jordan, S (corresponding author), Swansea Univ, Fac Hlth & Life Sci, Swansea, W Glam, Wales.	s.e.jordan@swansea.ac.uk		jordan, sue/0000-0002-5691-2987; Round, Jeff/0000-0002-3103-6984	Health Foundation [457154]	Health Foundation	The study was funded by 75,000 pound from the Health Foundation https://www.health.org.uk/funding-and-partnerships/funding-forimprovement-projects.Innovating for Improvement Round 6. Project title: Nurse-led intervention to minimise adverse drug reactions for older adults in care homes (ACS, SJ, JH, JR, HP). The Unique Award Reference Number is 457154, allocated August 2017. The funders played no role in study design, collection, management, analysis and interpretation of data or writing of the report. They did not play any role in the decision to submit the report for publication. They have no ultimate authority over any of these activities. There was no involvement from commercial companies.	Abbott RA, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-019-4728-3; Agbabiaka TB, 2008, DRUG SAFETY, V31, P21, DOI 10.2165/00002018-200831010-00003; Altman DG, 1991, PRACTICAL STAT MED R; [Anonymous], 2018, NAT REV GENET, V19, P1, DOI 10.1038/nrg.2017.141; [Anonymous], 2016, ANN NURS PR; [Anonymous], 2018, POL GUID REAL PRESCR; [Anonymous], 2020, CLIN DIABETOLOGY, V9, P1; Aronson JK, 2016, BRIT J CLIN PHARMACO, V81, P56, DOI 10.1111/bcp.12706; Aspinall SL, 2017, INNOV AGING, V1, DOI 10.1093/geroni/igx031; Basch E, 2018, J CLIN ONCOL, V36, P3120, DOI 10.1200/JCO.2018.78.8620; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; Braithwaite J, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01563-4; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brenner S, 2012, BMJ QUAL SAF, V21, P670, DOI 10.1136/bmjqs-2011-000643; Care Quality Commission, 2019, MED HLTH SOC CAR; Cooper A, 2017, AGE AGEING, V46, P833, DOI 10.1093/ageing/afx044; Cooper J, 2018, B WORLD HEALTH ORGAN, V96, P498, DOI 10.2471/BLT.17.199802; Curtis L, 2019, UNIT COSTS HLTH SOCI; De Baetselier E, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036269; Denzin NK, 2012, J MIX METHOD RES, V6, P80, DOI 10.1177/1558689812437186; Disalvo D, 2020, EUR J CLIN PHARMACOL, V76, P567, DOI 10.1007/s00228-019-02820-z; Eiring O, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007848; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Foss C, 2002, J ADV NURS, V40, P242, DOI 10.1046/j.1365-2648.2002.02366.x; Gabe ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096682; Gabe ME, 2011, J NURS MANAGE, V19, P377, DOI 10.1111/j.1365-2834.2011.01204.x; Gao L, 2018, AGE AGEING, V47, P220, DOI 10.1093/ageing/afx158; Garrett D MN, 2019, COMMITMENT CARE PEOP; General Medical Council,, 2013, GOOD PRACT PRESCR MA; Gray SL, 2018, J AM GERIATR SOC, V66, P282, DOI 10.1111/jgs.15195; Gurwitz JH, 2005, AM J MED, V118, P251, DOI 10.1016/j.amjmed.2004.09.018; Hakkarainen KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073166; Hanjani LS, 2019, DRUG AGING, V36, P247, DOI 10.1007/s40266-018-0620-9; Hart JT, 1981, HLTH DIS READER, P129; Hart LA, 2020, J AM GERIATR SOC, V68, P1334, DOI 10.1111/jgs.16369; Horton T, 2018, SPREAD CHALLENGE; Hughes D, 2020, GERIATRICS-BASEL, V5, DOI 10.3390/geriatrics5040079; Iacobucci G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1827; IBM, 2013, SPSS STAT WIND; Jennings E, 2019, AGE AGEING, V48, P10, DOI 10.1093/ageing/afy157; Jones Richard, 2016, Nurs Stand, V31, P42; Jordan S, 2004, Int Nurs Rev, V51, P208, DOI 10.1111/j.1466-7657.2004.00251.x; Jordan S, 1998, J ADV NURS, V27, P1060, DOI 10.1046/j.1365-2648.1998.00611.x; Jordan S, 2000, Nurs Times, V96, P39; Jordan S., 2002, NURSING DIVISION LAB, P129; Jordan S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220885; Jordan S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023377; Jordan S, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6030102; Jordan S, 2014, SCI WORLD J, DOI 10.1155/2014/843621; Jordan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140203; Killip S, 2004, ANN FAM MED, V2, P204, DOI 10.1370/afm.141; Krishnaswami A, 2019, J AM COLL CARDIOL, V73, P2584, DOI 10.1016/j.jacc.2019.03.467; Lloyd T, 2019, BMJ QUAL SAF, V28, P534, DOI 10.1136/bmjqs-2018-009130; Logan V, 2021, NURS OPEN, V8, P592, DOI 10.1002/nop2.664; Lucas B, 2015, HABITS IMPROVER THIN; Medical Research Council, 2007, MRC ETH GUID MED RES; MITCHELL JC, 1983, SOCIOL REV, V31, P187, DOI 10.1111/j.1467-954X.1983.tb00387.x; Monteiro L, 2019, J MED INTERNET RES, V21, DOI 10.2196/15385; National Assembly for Wales (NAfW), 2018, US ANT MED CAR HOM; NHS England, 2020, COR 2 PHAS NHS RESP; NHS England NHS Improvement, 2019, NHS PAT SAF STRAT; NICE, 2015, MED OPT SAF EFF US M; O'Dwyer M, 2018, THER ADV DRUG SAF, V9, P535, DOI 10.1177/2042098618782785; Office for National Statistics, 2018, HLTH STAT LIF EXP NA; Ogrinc G, 2016, J SURG RES, V200, P676, DOI 10.1016/j.jss.2015.09.015; Panesar SS, 2016, BMJ QUAL SAF, V25, P544, DOI 10.1136/bmjqs-2015-004178; Paque K, 2019, PALLIATIVE MED, V33, P37, DOI 10.1177/0269216318801124; Patel NS, 2017, EUR J CLIN PHARMACOL, V73, P385, DOI 10.1007/s00228-016-2170-6; Patterson SM, 2010, J AM GERIATR SOC, V58, P44, DOI 10.1111/j.1532-5415.2009.02617.x; Piggott KL, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m261; Rankin A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub4; Rieckert A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1822; Rossi Peter H., 1987, RES SOCIAL PROBLEMS, V4, P3; Royal Pharmaceurical Society (RPS), IMPR PAT OUTC BETT U; Royal Pharmaceutical Society (RPS), 2016, RIGHT MED IMPR CAR C; Ryan AM, 2016, LANCET, V388, P268, DOI 10.1016/S0140-6736(16)00276-2; Schroll JB, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002101; Steinman MA, 2011, J AM GERIATR SOC, V59, P1513, DOI 10.1111/j.1532-5415.2011.03500.x; Thomas RE, 2020, GERIATRICS-BASEL, V5, DOI 10.3390/geriatrics5020037; World Health Organization, 2017, MED HARM GLOB PAT SA; Wu TY, 2010, J ROY SOC MED, V103, P239, DOI 10.1258/jrsm.2010.100113; Xu DJ, 2019, BMJ QUAL SAF, V28, P524, DOI 10.1136/bmjqs-2018-008924	82	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0244519	10.1371/journal.pone.0244519	http://dx.doi.org/10.1371/journal.pone.0244519			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PS6NW	33411824	Green Published, gold, Green Accepted			2023-01-03	WOS:000608044300032
J	Jubair, L; Lam, AK; Fallaha, S; McMillan, NAJ				Jubair, Luqman; Lam, Alfred K.; Fallaha, Sora; McMillan, Nigel A. J.			CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice	PLOS ONE			English	Article							DNA COMPLEXES; STAPHYLOCOCCUS-AUREUS; PLASMID-DNA; DELIVERY; PARTICLES; DRUGS	Gene-editing has raised the possibility of being able to treat or cure cancers, but key challenges remain, including efficient delivery, in vivo efficacy, and its safety profile. Ideal targets for cancer therapy are oncogenes, that when edited, cause cell death. Here, we show, using the human papillomavirus (HPV) type 16 cancer cell line TC1, that CRISPR/Cas9 targeting the E7 oncogene and packaged in PEGylated liposomes cleared established tumours in immunocompetent mice. Treatment caused no significant toxicity in the spleen or liver. An ideal therapeutic outcome would be the induction of an immunogenic cell death (ICD), such that recurrent tumours would be eliminated by the host immune system. We show here for the first time that CRISPR/Cas9-mediated cell death via targeting E7 did not result in ICD. Overall, our data show that in vivo CRISPR/Cas targeting of oncogenes is an effective treatment approach for cancer.	[Jubair, Luqman; Fallaha, Sora; McMillan, Nigel A. J.] Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia; [Jubair, Luqman; McMillan, Nigel A. J.] Menzies Hlth Inst Queensland, Southport, Qld, Australia; [Lam, Alfred K.] Griffith Univ, Sch Med, Gold Coast, Qld, Australia	Griffith University; Griffith University	McMillan, NAJ (corresponding author), Griffith Univ, Sch Med Sci, Gold Coast, Qld, Australia.; McMillan, NAJ (corresponding author), Menzies Hlth Inst Queensland, Southport, Qld, Australia.	n.mcmillan@griffith.edu.au	Lam, Alfred/C-1652-2008; McMillan, Nigel/AAQ-5416-2021	Lam, Alfred/0000-0003-2771-564X; McMillan, Nigel/0000-0002-9471-1406				Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187; Boyer SN, 1996, CANCER RES, V56, P4620; Cattel L, 2003, TUMORI, V89, P237, DOI 10.1177/030089160308900302; Charlesworth CT, 2018, BIORXIV; Chew WL, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1408; Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993; Colque-Navarro P, 2010, CLIN VACCINE IMMUNOL, V17, P1117, DOI 10.1128/CVI.00506-09; Crudele JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05843-9; Dokka S, 2000, PHARMACEUT RES, V17, P521, DOI 10.1023/A:1007504613351; Dow SW, 1999, HUM GENE THER, V10, P2961, DOI 10.1089/10430349950016375; Dow SW, 1999, J IMMUNOL, V163, P1552; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; FDA, 2018, FDA APPROVES ONPATTR; Garg AD, 2015, INT J DEV BIOL, V59, P131, DOI 10.1387/ijdb.150061pa; Guschin DY, 2010, METHODS MOL BIOL, V649, P247, DOI 10.1007/978-1-60761-753-2_15; He ZY, 2017, SCI CHINA LIFE SCI, V60, P458, DOI 10.1007/s11427-017-9033-0; Jubair L, 2019, MOL THER, V27, P2091, DOI 10.1016/j.ymthe.2019.08.012; Jung IY, 2018, CANCER RES, V78, P4692, DOI 10.1158/0008-5472.CAN-18-0030; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Khairuddin N, 2012, IMMUNOL CELL BIOL, V90, P187, DOI 10.1038/icb.2011.19; Kolata JB, 2015, J INFECT DIS, V212, P830, DOI 10.1093/infdis/jiv128; Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1; McCaskill J, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.22; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934; Naito Y, 2015, BIOINFORMATICS, V31, P1120, DOI 10.1093/bioinformatics/btu743; Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a; Noguchi A, 1998, FEBS LETT, V433, P169, DOI 10.1016/S0014-5793(98)00837-0; Parker SE, 1997, HUM GENE THER, V8, P393, DOI 10.1089/hum.1997.8.4-393; Goncalves GAR, 2017, EINSTEIN-SAO PAULO, V15, P369, DOI [10.1590/s1679-45082017rb4024, 10.1590/S1679-45082017RB4024]; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Sakuma T, 2014, SCI REP-UK, V4, DOI 10.1038/srep05400; Senapati S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0004-3; Tan S, 2012, CURR CANCER DRUG TAR, V12, P170, DOI 10.2174/156800912799095135; Vasievich EA, 2011, CANCER IMMUNOL IMMUN, V60, P629, DOI 10.1007/s00262-011-0970-1; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Whitmore M, 1999, GENE THER, V6, P1867, DOI 10.1038/sj.gt.3301026; Wu SY, 2011, GENE THER, V18, P14, DOI 10.1038/gt.2010.113; Wu SY, 2009, PHARM RES-DORDR, V26, P512, DOI 10.1007/s11095-008-9766-1; Zelenay S, 2003, EUR J IMMUNOL, V33, P1382, DOI 10.1002/eji.200323614; Zhu D, 2018, MOL THER, V26, P2443, DOI 10.1016/j.ymthe.2018.07.019	41	7	7	4	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0223288	10.1371/journal.pone.0223288	http://dx.doi.org/10.1371/journal.pone.0223288			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411765	Green Published, gold			2023-01-03	WOS:000608044300095
J	Dia, A; Cifu, AS; Shah, AP				Dia, AbdulRahman; Cifu, Adam S.; Shah, Atman P.			Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLOSURE; THERAPY	This Clinical Guidelines Synopsis summarizes the American Academy of Neurology's practice advisory update on management of patients with a patent foramen ovale who have a history of stroke or transient ischemic attack.	[Dia, AbdulRahman; Cifu, Adam S.; Shah, Atman P.] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	University of Chicago	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu						Carroll JD, 2013, NEW ENGL J MED, V368, P1092, DOI 10.1056/NEJMoa1301440; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Kasner SE, 2018, LANCET NEUROL, V17, P1053, DOI 10.1016/S1474-4422(18)30319-3; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Mas JL, 2017, NEW ENGL J MED, V377, P1011, DOI 10.1056/NEJMoa1705915; Messe SR, 2020, NEUROLOGY, V94, P876, DOI 10.1212/WNL.0000000000009443; Sanna T, 2014, NEW ENGL J MED, V370, P2478, DOI 10.1056/NEJMoa1313600; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; Thaler DE, 2013, INT J STROKE, V8, P612, DOI 10.1111/j.1747-4949.2012.00843.x; WEBSTER MWI, 1988, LANCET, V2, P11	10	2	2	3	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	2021	325	1					81	82		10.1001/jama.2020.22176	http://dx.doi.org/10.1001/jama.2020.22176			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PS1ZR	33399834				2023-01-03	WOS:000607728800020
J	Santos, JE; Magarinos, CR; Gago, LG; Jarrin, DA; Pertega, S; Rodriguez-Carmona, A; Falcon, TG; Fontan, MP				Santos, Joana Eugenio; Rodriguez Magarinos, Catuxa; Garcia Gago, Leticia; Astudillo Jarrin, Daniela; Pertega, Sonia; Rodriguez-Carmona, Ana; Garcia Falcon, Teresa; Perez Fontan, Miguel			Long-term trends in the incidence of peritoneal dialysis-related peritonitis disclose an increasing relevance of streptococcal infections: A longitudinal study	PLOS ONE			English	Article							TECHNIQUE FAILURE; OUTCOMES; MICROBIOLOGY; PREDICTORS; RECOMMENDATIONS; MUPIROCIN; PATIENT	Background The selective impact of strategies for prevention of PD-related peritonitis (PDrP) may have modified, in the long term, the causal spectrum, clinical presentation and outcomes of these infections. Objectives To compare trends in the incidence of PDrP by different microorganisms during a 30-year period, with a particular focus on streptococcal infections. To analyze the clinical presentation and outcomes of these infections. Secondarily, to investigate how the isolation of different species of streptococci can influence the clinical course of PDrP by this genus of bacteria. Method Following a retrospective, observational design we investigated 1061 PDrP (1990-2019). We used joinpoint regression analysis to explore trends in the incidence of PDrP by different microorganisms, and compared the risk profile (Cox), clinical presentation and outcomes (logistic regression) of these infections. Main results Our data showed a progressive decline in the incidence of PDrP by staphylococci and Gram negative bacteria, while the absolute rates of streptococcal (average annual percent change +1.6%, 95% CI -0.1/+3.2) and polymicrobial (+1.8%, +0.1/+3.5) infections tended to increase, during the same period. Remarkably, streptococci were isolated in 58.6% of polymicrobial infections, and patients who suffered a streptococcal PDrP had a 35.8% chance of presenting at least one other infection by the same genus. The risk profile for streptococcal infections was comparable to that observed for PDrP overall. Streptococcal PDrP were associated with a severe initial inflammatory response, but their clinical course was generally nonaggressive thereafter. We did not observe a differential effect of different groups of streptococci on the clinical presentation or outcome of PDrP. Conclusions Time trends in the incidence of PDrP by different microorganisms have granted streptococci an increasing relevance as causative agents of these infections, during the last three decades. This behaviour suggests that current measures of prevention of PDrP may not be sufficiently effective, in the case of this genus of microorganisms.	[Santos, Joana Eugenio] Ctr Hosp Espirito Santo, Evora, Portugal; [Rodriguez Magarinos, Catuxa; Garcia Gago, Leticia; Astudillo Jarrin, Daniela; Rodriguez-Carmona, Ana; Garcia Falcon, Teresa; Perez Fontan, Miguel] Univ Hosp A Coruna, Div Nephrol, La Coruna, Spain; [Pertega, Sonia] Univ Hosp A Coruna, Div Epidmiol, La Coruna, Spain; [Perez Fontan, Miguel] Univ A Coruna, Fac Hlth Sci, La Coruna, Spain	Complejo Hospitalario Universitario A Coruna; Complejo Hospitalario Universitario A Coruna; Universidade da Coruna	Fontan, MP (corresponding author), Univ Hosp A Coruna, Div Nephrol, La Coruna, Spain.; Fontan, MP (corresponding author), Univ A Coruna, Fac Hlth Sci, La Coruna, Spain.	miguel.perez.fontan@sergas.es	Perez-Fontán, Miguel/ABG-4064-2020; Pértega-Díaz, Sonia/E-4353-2013	Perez-Fontán, Miguel/0000-0001-7027-2296; Pértega-Díaz, Sonia/0000-0003-3891-3203				Abranches J, 2018, MICROBIOL SPECTR, V6, DOI 10.1128/microbiolspec.GPP3-0042-2018; Barraclough K, 2010, AM J KIDNEY DIS, V55, P121, DOI 10.1053/j.ajkd.2009.08.020; Boudville N, 2019, NEPHROL DIAL TRANSPL, V34, P2118, DOI 10.1093/ndt/gfy204; Burke M, 2011, AM J KIDNEY DIS, V58, P429, DOI 10.1053/j.ajkd.2011.03.022; Chao CT, 2015, PERITON DIALYSIS INT, V35, P333, DOI 10.3747/pdi.2013.00108; Chidambaram M, 2011, PERITON DIALYSIS INT, V31, P565, DOI 10.3747/pdi.2010.00096; Chow KM, 2006, CLIN J AM SOC NEPHRO, V1, P768, DOI 10.2215/CJN.01010306; Basalo FJDY, 2012, CONSTR BUILD MATER, V32, P55, DOI 10.1016/j.conbuildmat.2010.12.063; Fontan MP, 2005, PERITON DIALYSIS INT, V25, P274; Ghali JR, 2011, PERITON DIALYSIS INT, V31, P651, DOI 10.3747/pdi.2010.00131; Govindarajulu S, 2010, PERITON DIALYSIS INT, V30, P311, DOI 10.3747/pdi.2008.00258; Haenni M, 2018, MICROBIOL SPECTR, V6, DOI 10.1128/microbiolspec.ARBA-0008-2017; Htay H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007554.pub3; Htay H, 2018, AM J KIDNEY DIS, V71, P814, DOI 10.1053/j.ajkd.2017.10.017; Kim GC, 2000, AM J KIDNEY DIS, V36, P1000, DOI 10.1053/ajkd.2000.19102; Kim HJ, 2001, STAT MED, V20, P655, DOI 10.1002/sim.811; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kolesnyk I, 2010, PERITON DIALYSIS INT, V30, P170, DOI 10.3747/pdi.2008.00277; Kumar VA, 2014, PERITON DIALYSIS INT, V34, P171, DOI 10.3747/pdi.2012.00165; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Liu Y, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1078-z; McDonald SR, 2004, PERITON DIALYSIS INT, V24, P340; Mujais S, 2006, KIDNEY INT, V70, pS55, DOI 10.1038/sj.ki.5001916; Nataatmadja M, 2016, PERITON DIALYSIS INT, V36, P472, DOI 10.3747/pdi.2016.00114; O'Shea S, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-19; PEREZFONTAN M, 1993, AM J KIDNEY DIS, V22, P708, DOI 10.1016/S0272-6386(12)80434-3; Perl J, 2020, AM J KIDNEY DIS, V76, P42, DOI 10.1053/j.ajkd.2019.09.016; Piraino B, 2005, PERITON DIALYSIS INT, V25, P107; Pulliam J, 2014, AM J KIDNEY DIS, V64, P761, DOI 10.1053/j.ajkd.2014.04.025; Ribera-Sanchez R, 2018, PERITON DIALYSIS INT, V38, P139, DOI 10.3747/pdi.2017.00184; Rocha A, 2012, BLOOD PURIFICAT, V33, P284, DOI 10.1159/000337377; Ruoff KL, 2015, MANDELL DOUGLAS BENN, P2283; Santos C, 2016, PERITON DIALYSIS INT, V36, P43, DOI 10.3747/pdi.2014.00131; Shukla A, 2006, NEPHROL DIAL TRANSPL, V21, P3545, DOI 10.1093/ndt/gfl407; Szeto CC, 2017, PERITON DIALYSIS INT, V37, P141, DOI 10.3747/pdi.2016.00120; van Esch S, 2014, PERITON DIALYSIS INT, V34, P162, DOI 10.3747/pdi.2013.00275; Wang Q, 2003, AM J KIDNEY DIS, V41, P664, DOI 10.1053/ajkd.2003.50128; Xu R, 2013, PERITON DIALYSIS INT, V33, P436, DOI 10.3747/pdi.2012.00163; Ye HJ, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0588-4; Zelenitsky SA, 2017, PERITON DIALYSIS INT, V37, P170, DOI 10.3747/pdi.2016.00136; Zhang L, 2015, PERITON DIALYSIS INT, V35, P712, DOI 10.3747/pdi.2014.00206	41	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2020	15	12							e0244283	10.1371/journal.pone.0244283	http://dx.doi.org/10.1371/journal.pone.0244283			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CD	33347487	Green Published, gold			2023-01-03	WOS:000603071100023
J	Faust, JS; Krumholz, HM; Du, CA; Mayes, KD; Lin, ZQ; Gilman, C; Walensky, RP				Faust, Jeremy Samuel; Krumholz, Harlan M.; Du, Chengan; Mayes, Katherine Dickerson; Lin, Zhenqiu; Gilman, Cleavon; Walensky, Rochelle P.			All-Cause Excess Mortality and COVID-19-Related Mortality Among US Adults Aged 25-44 Years, March-July 2020	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Faust, Jeremy Samuel] Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA; [Krumholz, Harlan M.] Yale Sch Med, Sect Cardiovasc Med, New Haven, CT USA; [Du, Chengan; Lin, Zhenqiu] Yale Sch Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Mayes, Katherine Dickerson] Harvard Affiliated Emergency Med Residency, Boston, MA USA; [Gilman, Cleavon] Yuma Reg Med Ctr, Dept Emergency Med, Yuma, AZ USA; [Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Yale University; Yale University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Faust, JS (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 10 Vining St, Boston, MA 02115 USA.	jsfaust@gmail.com		Mayes, Katherine/0000-0002-9069-2439				Cunningham JW, 2021, JAMA INTERN MED, V181, P379, DOI 10.1001/jamainternmed.2020.5313; Woolf SH, 2020, JAMA-J AM MED ASSOC, V324, P1562, DOI 10.1001/jama.2020.19545	2	57	58	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	2021	325	8					785	787		10.1001/jama.2020.24243	http://dx.doi.org/10.1001/jama.2020.24243		DEC 2020	3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM7LT	33325994	Green Published, Bronze			2023-01-03	WOS:000599747200001
J	Coventry, PA; McMillan, D; Clegg, A; Brown, L; van der Feltz-Cornelis, C; Gilbody, S; Ali, S				Coventry, Peter A.; McMillan, Dean; Clegg, Andrew; Brown, Lesley; van der Feltz-Cornelis, Christina; Gilbody, Simon; Ali, Shehzad			Frailty and depression predict instrumental activities of daily living in older adults: A population-based longitudinal study using the CARE75+cohort	PLOS ONE			English	Article							LATE-LIFE; SCALE; PEOPLE; CARE; LONELINESS; STRENGTH; GENDER; COHORT	Objectives To evaluate if depression contributes, independently and/or in interaction with frailty, to loss of independence in instrumental activities of daily living (ADL) in older adults with frailty. Methods Longitudinal cohort study of people aged >= 75 years living in the community. We used multi-level linear regression model to quantify the relationship between depression (>= 5 Geriatric Depression Scale) and frailty (electronic frailty index), and instrumental activities of daily living (Nottingham Extended Activities of Daily Living scale; range: 0-66; higher score implies greater independence). The model was adjusted for known confounders (age; gender; ethnicity; education; living situation; medical comorbidity). Results 553 participants were included at baseline; 53% were female with a mean age of 81 (5.0 SD) years. Depression and frailty (moderate and severe levels) were independently associated with reduced instrumental activities of daily living scores. In the adjusted analysis, the regression coefficient was -6.4 (95% CI: -8.3 to -4.5, p<0.05) for depression, -1.5 (95% CI: -3.8 to 0.9, p = 0.22) for mild frailty, -6.1 (95% CI: -8.6 to -3.6, p<0.05) for moderate frailty, and -10.1 (95% CI: -13.5 to -6.8, p<0.05) for severe frailty. Moreover, depression interacted with frailty to further reduce instrumental activities of daily living score in individuals with mild or moderate frailty. These relationships remained significant after adjusting for confounders. Conclusion Frailty and depression are independently associated with reduced independence in instrumental activities of daily living. Also, depression interacts with frailty to further reduce independence for mild to moderately frail individuals, suggesting that clinical management of frailty should integrate physical and mental health care.	[Coventry, Peter A.] Univ York, Dept Hlth Sci, York, N Yorkshire, England; [McMillan, Dean; van der Feltz-Cornelis, Christina; Gilbody, Simon] Univ York, Dept Hlth Sci, York, N Yorkshire, England; [McMillan, Dean; van der Feltz-Cornelis, Christina; Gilbody, Simon] Univ York, Hull York Med Sch, York, N Yorkshire, England; [Clegg, Andrew] Univ Leeds, Acad Unit Elderly Care & Rehabil, Bradford, W Yorkshire, England; [Brown, Lesley] Inst Hlth Res, Acad Unit Elderly Care & Rehabil, Bradford, W Yorkshire, England; [Ali, Shehzad] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada	University of York - UK; University of York - UK; University of Hull; University of York - UK; University of Leeds; Western University (University of Western Ontario)	Coventry, PA (corresponding author), Univ York, Dept Hlth Sci, York, N Yorkshire, England.	peter.coventry@york.ac.uk	Gilbody, Simon/AAY-3720-2021; Van der Feltz-Cornelis, Christina/R-7107-2016; Coventry, Peter/H-6714-2014	Gilbody, Simon/0000-0002-8236-6983; Van der Feltz-Cornelis, Christina/0000-0001-6925-8956; Clegg, Andrew/0000-0001-5972-1097; Coventry, Peter/0000-0003-0625-3829; Brown, Lesley/0000-0001-5499-9145	NIHR Applied Research Collaboration Yorkshire; NIHR Applied Research Collaboration Humber	NIHR Applied Research Collaboration Yorkshire; NIHR Applied Research Collaboration Humber	The research was funded by the NIHR Applied Research Collaboration Yorkshire and Humber https://www.arc-yh.nihr.ac.uk/.The views expressed are those of the author(s), and not necessarily those of the NIHR or the Department of Health and Social Care.	Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Blakemore A, 2014, INT J CHRONIC OBSTR, V9, P501, DOI 10.2147/COPD.S58136; Brundle C, 2019, AGE AGEING, V48, P152, DOI 10.1093/ageing/afy162; Chatterji S, 2015, LANCET, V385, P563, DOI 10.1016/S0140-6736(14)61462-8; Chiesi F, 2018, PSYCHOL REP, V121, P1167, DOI 10.1177/0033294117745561; Chiesi F, 2018, J AFFECT DISORDERS, V227, P471, DOI 10.1016/j.jad.2017.11.045; Clegg A, 2016, AGE AGEING, V45, P353, DOI 10.1093/ageing/afw039; Clegg A, 2015, AGE AGEING, V44, P547, DOI 10.1093/ageing/afv044; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; Coventry P, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h638; Coventry PA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-49; Crocker TF, 2019, QUAL LIFE RES, V28, P2041, DOI 10.1007/s11136-019-02149-1; de Keijzer C, 2019, ENVIRON INT, V122, P346, DOI 10.1016/j.envint.2018.11.046; Dunlop DD, 1997, AM J PUBLIC HEALTH, V87, P378, DOI 10.2105/AJPH.87.3.378; Farmer C, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4843; Feng ZY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178383; Fukumori N, 2015, AGE AGEING, V44, P592, DOI 10.1093/ageing/afv013; Gierveld JDJ, 2010, EUR J AGEING, V7, P121, DOI 10.1007/s10433-010-0144-6; GLADMAN JRF, 1993, AGE AGEING, V22, P419, DOI 10.1093/ageing/22.6.419; Harrison JK, 2015, AGE AGEING, V44, P732, DOI 10.1093/ageing/afv085; Hartig T, 2014, ANNU REV PUBL HEALTH, V35, P207, DOI 10.1146/annurev-publhealth-032013-182443; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650-199601000-00006; Kojima G, 2017, DISABIL REHABIL, V39, P1897, DOI 10.1080/09638288.2016.1212282; Lohman M, 2016, J GERONTOL B-PSYCHOL, V71, P630, DOI 10.1093/geronb/gbu180; Lohman MC, 2017, AGING MENT HEALTH, V21, P399, DOI 10.1080/13607863.2015.1102199; Mezuk B, 2013, AM J GERIAT PSYCHIAT, V21, P560, DOI 10.1016/j.jagp.2012.12.019; NHS England, 2014, 5 YEAR FORW VIEW; Office for National Statistics, 2018, LIV LONG OUR POP IS; Orgeta V, 2017, BRIT J PSYCHIAT, V211, P274, DOI 10.1192/bjp.bp.117.205021; Perissinotto CM, 2012, ARCH INTERN MED, V172, P1078, DOI 10.1001/archinternmed.2012.1993; Prince MJ, 2015, LANCET, V385, P549, DOI 10.1016/S0140-6736(14)61347-7; Rantanen T, 1999, JAMA-J AM MED ASSOC, V281, P558, DOI 10.1001/jama.281.6.558; Ryan A, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0355-9; Soysal P, 2017, AGEING RES REV, V36, P78, DOI 10.1016/j.arr.2017.03.005; Testa G, 2011, EUR J CLIN INVEST, V41, P1310, DOI 10.1111/j.1365-2362.2011.02544.x; Verger P, 2009, EUR J PUBLIC HEALTH, V19, P618, DOI 10.1093/eurpub/ckp057; Vetrano D. L., 2018, J GERONTOL A-BIOL, V74, P659, DOI DOI 10.1093/GERONA/GLY110; Wancata J, 2006, ACTA PSYCHIAT SCAND, V114, P398, DOI 10.1111/j.1600-0447.2006.00888.x; Wang D, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015794; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; Yu RB, 2018, J AM MED DIR ASSOC, V19, P528, DOI 10.1016/j.jamda.2017.12.015	42	9	9	6	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2020	15	12							e0243972	10.1371/journal.pone.0243972	http://dx.doi.org/10.1371/journal.pone.0243972			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PH3TP	33320913	Green Published, Green Accepted, gold			2023-01-03	WOS:000600339800056
J	Laplana, M; Yuguero, O; Fibla, J				Laplana, Marina; Yuguero, Oriol; Fibla, Joan			Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients	PLOS ONE			English	Article							OLD DRUG	Background The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age range and incidence region. COVID-19 disease prevalence was compared between treated and untreated-matched control sample. Results A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value = 0.027). Conclusion We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection measures as the general population.	[Laplana, Marina] Univ Lleida, Dept Ciencia Anim, Lleida, Spain; [Yuguero, Oriol] Hosp Univ Arnau Vilanova Lleida, Lleida, Spain; [Yuguero, Oriol; Fibla, Joan] Inst Recerca Biomed Lleida, Lleida, Spain; [Fibla, Joan] Dept Ciencies Med Basiques, Unitat Genet Humana, Lleida, Spain	Universitat de Lleida; University Hospital Arnau de Vilanova; Institut de Recerca Biomedica - IRB Lleida	Fibla, J (corresponding author), Inst Recerca Biomed Lleida, Lleida, Spain.; Fibla, J (corresponding author), Dept Ciencies Med Basiques, Unitat Genet Humana, Lleida, Spain.	joan.fibla@udl.cat	Fibla, Joan/C-5561-2008; Yuguero, Oriol/AAV-3749-2021; Laplana, Marina/G-2653-2010	Fibla, Joan/0000-0002-3255-2227; Laplana, Marina/0000-0002-2548-0704				Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293; [Anonymous], 2020, ESTUDIO ENE COVID19, P1; Boulware DR, 2020, NEW ENGL J MED, pNEJMoa2016638; Centro de Coordinacion de Alertas y Emergencias Sanitarias. Secretaria General de Sanidad. Direccion general de Salud Publica Calidad e Innovacion, 2020, ACT 123 ENF COR COVI, P1; Devaux Christian A, 2020, Int J Antimicrob Agents, V55, P105938, DOI 10.1016/j.ijantimicag.2020.105938; Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575; Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Hassani RTJ, 2020, J INFECT PUBLIC HEAL, V13, P865, DOI [10.1016/j.jiph.2020.05.005, 10.1016/j.ijph.2020.05.005]; Infante M, 2021, EXPERT REV ANTI-INFE, V19, P5, DOI 10.1080/14787210.2020.1799785; Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085; Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6; Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5; Thangaraju P, 2020, J INFECT PUBLIC HEAL, V13, P899, DOI 10.1016/j.jiph.2020.05.006; Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762	15	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2020	15	12							e0243598	10.1371/journal.pone.0243598	http://dx.doi.org/10.1371/journal.pone.0243598			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH1MP	33315903	Green Submitted, Green Published, gold			2023-01-03	WOS:000600186100032
J	At Thobari, J; Satria, CD; Ridora, Y; Watts, E; Handley, A; Standish, J; Bachtiar, NS; Buttery, JP; Soenarto, Y; Bines, JE				At Thobari, Jarir; Satria, Cahya Dewi; Ridora, Yohanes; Watts, Emma; Handley, Amanda; Standish, Jane; Bachtiar, Novilia S.; Buttery, Jim P.; Soenarto, Yati; Bines, Julie E.			Non-antibiotic medication use in an Indonesian community cohort 0-18 months of age	PLOS ONE			English	Article							COLD MEDICATIONS; CHILDREN; SAFETY; COUGH; PRESCRIPTION	Background Rational medication use for treatment is mandatory, particularly in children as they are vulnerable to possible hazards of drugs. Understanding the medication use pattern is of importance to identify the problems of drug therapy and to improve the appropriate use of medication among this population. Methods A post-hoc study of the RV3-BB Phase IIb trial to children aged 0-18 months which was conducted in Indonesia during January 2013 to July 2016. Any concomitant medication use and health events among 1621 trial participants during the 18 months of follow-up were documented. Information on medication use included the frequency, formulation, indication, duration of usage, number of regimens, medication types, and therapeutic classes. Results The majority of participants (N = 1333/1621; 82.2%) used at least one non-antibiotic medication for treatment during the 18-month observation period. A total of 7586 medication uses were recorded, mostly in oral formulation (90.5%). Of all illnesses recorded, 24.7% were treated with a single drug regimen of non-antibiotic medication. The most common therapeutic classes used were analgesics/antipyretics (30.1%), antihistamines for systemic use (17.4%), cough and cold preparations (13.5%), vitamins (8.6%), and antidiarrheals (6.6%). The main medication types used were paracetamol (29.9%), chlorpheniramine (16.8%), guaifenesin (8.9%), zinc (4.6%), and ambroxol (4.1%). Respiratory system disorder was the most common reason for medication use (51.9%), followed by gastrointestinal disorders (19.2%), pyrexia (16.9%), and skin disorders (7.0%). Conclusion A large number of children were exposed to at least one medication during their early life, including those where evidence of efficacy and safety in a pediatric population is lacking. This supports the need for further research on pediatric drug therapy to improve the appropriate use of medication in this population.	[At Thobari, Jarir] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Pharmacol & Therapy, Yogyakarta, Special Region, Indonesia; [At Thobari, Jarir; Satria, Cahya Dewi; Ridora, Yohanes; Soenarto, Yati] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Pediat Res Off, Yogyakarta, Special Region, Indonesia; [At Thobari, Jarir; Satria, Cahya Dewi; Soenarto, Yati] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Paediat, Yogyakarta, Special Region, Indonesia; [Watts, Emma; Handley, Amanda; Standish, Jane; Buttery, Jim P.; Bines, Julie E.] Murdoch Childrens Res Inst, RV3 Rotavirus Vaccine Program, Parkville, Vic, Australia; [Handley, Amanda] Med Dev Global Hlth, Melbourne, Vic, Australia; [Standish, Jane] Royal Childrens Hosp Melbourne, Dept Gen Med, Parkville, Vic, Australia; [Bachtiar, Novilia S.] PT Bio Farma, Bandung, West Java, Indonesia; [Buttery, Jim P.; Bines, Julie E.] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Buttery, Jim P.] Monash Univ, Dept Paediat, Clayton, Vic, Australia; [Buttery, Jim P.] Monash Univ, Sch Publ Hlth & Prevent Med, Clayton, Vic, Australia; [Buttery, Jim P.] Monash Childrens Hosp, Dept Infect & Immun, Clayton, Vic, Australia; [Bines, Julie E.] Royal Childrens Hosp Melbourne, Dept Gastroenterol & Clin Nutr, Parkville, Vic, Australia	Gadjah Mada University; Gadjah Mada University; Gadjah Mada University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Monash University; Monash University; Royal Children's Hospital Melbourne	At Thobari, J (corresponding author), Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Pharmacol & Therapy, Yogyakarta, Special Region, Indonesia.; At Thobari, J (corresponding author), Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Pediat Res Off, Yogyakarta, Special Region, Indonesia.; At Thobari, J (corresponding author), Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Paediat, Yogyakarta, Special Region, Indonesia.	j.atthobari@ugm.ac.id	At Thobari, Jarir/GOP-2379-2022	At Thobari, Jarir/0000-0002-7035-4846; Ridora, Yohanes/0000-0002-7104-9595; Bines, Julie/0000-0002-5452-6601	PT Biofarma; Murdoch Children's Research Institute	PT Biofarma; Murdoch Children's Research Institute	The vaccine company PT Bio Farma provided support for this study in the form of a salary for the author NSB. The specific role of this author is articulated in the 'author contributions' section. Additionally, PT Biofarma was one of the funders of the RV3-BB Phase IIb trial. Another funding source of the RV3-BB Phase IIb trial was Murdoch Children's Research Institute. The funders had roles in the study design, decision to publish, and preparation of the manuscript.	Allen S. J., 2011, COCHRANE REV J, V6, P1894, DOI DOI 10.1002/EBCH.873; At Thobari J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219097; Batchelor HK, 2015, BRIT J CLIN PHARMACO, V79, P395, DOI 10.1111/bcp.12267; beda A., 2015, PLOS ONE, V10, P1, DOI DOI 10.1371/J0URNAL.P0NE.0127296; Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804; Briars Leslie A, 2009, J Pediatr Pharmacol Ther, V14, P127, DOI 10.5863/1551-6776-14.3.127; Cazzato T, 2001, EUR J CLIN PHARMACOL, V57, P611, DOI 10.1007/s002280100356; Cheung K, 2018, INT J CLIN PHARM-NET, V40, P1137, DOI 10.1007/s11096-018-0717-6; Clavenna A, 2009, EUR J PEDIATR, V168, P173, DOI 10.1007/s00431-008-0725-y; Cruz Maria J.B., 2014, J. Pediatr. (Rio J.), V90, P608, DOI 10.1016/j.jped.2014.03.004; DALTON K, 1987, ACTA NEUROL SCAND, V76, P8, DOI 10.1111/j.1600-0404.1987.tb03536.x; Dart RC, 2009, ANN EMERG MED, V53, P411, DOI 10.1016/j.annemergmed.2008.09.015; Ernie HP, 2007, MEDIA LITBANG KESEHA, VXVII, P26; Fangky SM, 2017, KAJIAN INTERAKSI OBA, V6, P2302; Ferro A, 2015, BRIT J CLIN PHARMACO, V79, P351, DOI 10.1111/bcp.12540; Joseph F, 2015, ETHIOP J HEALTH SCI, V25, P73, DOI 10.4314/ejhs.v25i1.10; Kanabar DJ, 2017, INFLAMMOPHARMACOLOGY, V25, P1, DOI 10.1007/s10787-016-0302-3; Lowry JA, 2015, PEDIATR REV, V36, P286, DOI 10.1542/pir.36-7-286; Lubis IND, 2016, SARI PEDIAT, V12, P409; Luedtke Kyle E, 2014, J Pediatr Pharmacol Ther, V19, P296, DOI 10.5863/1551-6776-19.4.296; Mahmood I, 2006, BRIT J CLIN PHARMACO, V61, P545, DOI 10.1111/j.1365-2125.2006.02622.x; Nazarian LF, 1996, PEDIATRICS, V97, P424; Niclasen BVL, 2006, ACTA PAEDIATR, V95, P1456, DOI 10.1080/08035250600686946; OP026, 2016, J CROHNS COLITIS, V10, pS21; Pandey Anuja A, 2010, Indian J Community Med, V35, P70, DOI 10.4103/0970-0218.62564; Pudjiadi AH, 2009, DIARE AKUT PEDOMAN P, P58; Rahmawati F, 2006, MAJ FARM INDONES, V17, P177; Rashed Asia N, 2015, Drugs Real World Outcomes, V2, P397; RASMUSSEN F, 1989, J EPIDEMIOL COMMUN H, V43, P140, DOI 10.1136/jech.43.2.140; Rimsza ME, 2009, PEDIATRICS, V123, pe318; Rukmini S., 2004, B PENELITIAN SISTEM, V7, P130; Saraswat A, 2011, COCHRANE DB SYST REV, P2; Schaefer MK, 2008, PEDIATRICS, V121, P783, DOI 10.1542/peds.2007-3638; Schirm E, 2000, BRIT J CLIN PHARMACO, V50, P473, DOI 10.1046/j.1365-2125.2000.00275.x; Sharma A, 2016, NATL J PHYSL PHARM P, V6, P74, DOI [10.5455/njppp.2015.5.1110201581, DOI 10.5455/NJPPP.2015.5.1110201581]; Shefrin AE, 2009, CAN FAM PHYSICIAN, V55, P1081; Smith SM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub3; Soedibyo S, 2013, SARI PEDIAT, V14, P398, DOI 10.1016/j.jamda.2013.01.014; Sturkenboom MCJM, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2245; Ten Eick AP, 2001, DRUG SAFETY, V24, P119, DOI 10.2165/00002018-200124020-00003; Thiruthopu Nimbagiri Swamy, 2014, Perspect Clin Res, V5, P178, DOI 10.4103/2229-3485.140558; Thrane N, 1999, ACTA PAEDIATR, V88, P1131, DOI 10.1080/08035259950168216; van Riet-Nales DA, 2016, ARCH DIS CHILD, V101, P662, DOI 10.1136/archdischild-2015-308227; Vohora D, 2012, ACAD SCI ASIAN J PHA, V5, P146; Vorilhon P, 2019, EUR J CLIN PHARMACOL, V75, P303, DOI 10.1007/s00228-018-2601-7; Wimmer S, 2015, DTSCH ARZTEBL INT, V112, P781, DOI 10.3238/arztebl.2015.0781; World Health Organization, 2014, INTEGRATED MANAGEMEN	47	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2020	15	11							e0242410	10.1371/journal.pone.0242410	http://dx.doi.org/10.1371/journal.pone.0242410			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VG	33206684	Green Published, gold			2023-01-03	WOS:000595265900010
J	Bernal, HD; de Abreu, LC; Bezerra, IMP; Adami, F; Takasu, JM; Suh, JVJY; Ribeiro, SD; Santos, EFD				de Moraes Bernal, Henrique; de Abreu, Luiz Carlos; Pinheiro Bezerra, Italla Maria; Adami, Fernando; Takasu, Jessica Miwa; Ji Young Suh, Joao Victor; de Lira Ribeiro, Silmara; de Sousa Santos, Edige Felipe			Incidence of hospitalization and mortality due to stroke in young adults, residents of developed regions in Brazil, 2008-2018	PLOS ONE			English	Article							RISK-FACTORS; GLOBAL BURDEN; HEALTH; DISEASE; TRENDS; AGE	Introduction We evaluated trends in hospitalization incidence and mortality due to hemorrhagic and ischemic stroke in young adults, according to gender and developed regions in Brazil. Methods Between 2008-2018, we performed a population-based time-series study using official hospitalization and death data due to stroke, in individuals aged 10-49 years, from Southeast and South, Brazil. Data were based on reports from the Unified Health System of Hospital Information System and Mortality Information System. Stroke was defined by the International Classification of Diseases, 10(th) revision (I60-I63). A Prais-Winsten regression model was performed and the Annual Percentage Change was calculated. Results In total, 78,123 hospitalizations of individuals aged 10-49 years were recorded, of which 59,448 (76%) resulted from hemorrhagic stroke (HS). The hospitalizations for HS was significantly decreased (- 4.37%) among men and women in both regions. The hospitalizations for ischemic stroke (IS) was flat, except between 2011 and 2018, when IS hospitalization rates increased. In the analysis by states, HS hospitalizations declined across all states, except for Espirito Santo, where it remained unchanged (p > 0.05). IS flat hospitalizations were observed in all states, except Espirito Santo, where it increased by 24.93%. In terms of mortality, 28,625 deaths were recorded, of which 26,548 (92.7%) resulted from HS. HS mortality decreased significantly by -3.48%and IS mortality by -3.84%. Decreases also occurred in all Southeast and South states (p < 0.05). IS remained unchanged across all states, except Minas Gerais, where it decreased by -14.95%. Conclusions We identified a decline in the hospitalizations and mortality of HS and a flat trend for IS in developed regions of Brazil. The recent period (2011-2018) demonstrated increasing rates in the hospitalizations of IS in both regions and genders. The mortality rates for HS and IS decreased between 2008-2018 in Southeast and South Brazil for both genders.	[de Moraes Bernal, Henrique; de Abreu, Luiz Carlos; Pinheiro Bezerra, Italla Maria; Adami, Fernando; Takasu, Jessica Miwa; Ji Young Suh, Joao Victor; de Lira Ribeiro, Silmara; de Sousa Santos, Edige Felipe] Ctr Univ Saude ABC, Lab Delineamento Estudos & Escrita Cient, Santo Andre, SP, Brazil; [de Abreu, Luiz Carlos; Pinheiro Bezerra, Italla Maria] Escola Super Ciencias Santa Casa Misericordia, Programa Mestrado Polit Publ Desenvolvimento Loca, Vitoria, ES, Brazil; [de Abreu, Luiz Carlos] Univ Limerick, Grad Entry Med Sch, Limerick, Ireland; [de Sousa Santos, Edige Felipe] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, SP, Brazil	Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria; University of Limerick; Universidade de Sao Paulo	Bernal, HD (corresponding author), Ctr Univ Saude ABC, Lab Delineamento Estudos & Escrita Cient, Santo Andre, SP, Brazil.	henrique.bernal@aluno.fmabc.net	de Abreu, Luiz Carlos/AAL-8219-2021	de Abreu, Luiz Carlos/0000-0002-7618-2109; de Moraes Bernal, Henrique/0000-0001-5899-8633	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [800308/2018-2, 165364/2019-0]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/21424-4]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) provided funds for the study by granting a two-year Scientific Initiation scholarship to Henrique de Moraes Bernal (process number: 800308/2018-2 and 165364/2019-0). Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) provided funds for the study by granting a Scientific Initiation scholarship to Jessica Miwa Takasu (process number: 2017/21424-4).	Abdalla RR, 2014, ADDICT BEHAV, V39, P297, DOI 10.1016/j.addbeh.2013.10.019; Adami F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152739; Ahmad OB, 2001, PAPER SERIES GENEVA, V31, P1; Andrade Mônica Viegas, 2013, Econ. Apl., V17, P623, DOI 10.1590/S1413-80502013000400005; [Anonymous], 2004, Am J Transplant, V4 Suppl 10, P95; [Anonymous], 2019, CIRCULATION, V2019; Bhatnagar A, 2017, CIRC RES, V121, P162, DOI 10.1161/CIRCRESAHA.117.306458; Boo S, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013713; Cabral NL, 2017, STROKE, V48, P2925, DOI 10.1161/STROKEAHA.117.018531; Santos EFD, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00227718, 10.1590/0102-311x00227718]; de Souza W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224889; Ekker MS, 2019, NEUROLOGY, V92, pE2444, DOI 10.1212/WNL.0000000000007533; Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Antunes JLF, 2015, EPIDEMIOL SERV SAUDE, V24, P565, DOI 10.5123/S1679-49742015000300024; Fullerton HJ, 2002, NEUROLOGY, V59, P34, DOI 10.1212/WNL.59.1.34; Geldsetzer P, 2019, LANCET, V394, P652, DOI 10.1016/S0140-6736(19)30955-9; Hathidara MY, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-1004-1; IBGE, 2012, CENS DEM 2010 RES GE; IPEA, ATL DES HUM BRAS; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Lecoffre C, 2017, STROKE, V48, P2939, DOI 10.1161/STROKEAHA.117.017640; Lessa I, 1998, EPIDEMIOLOGIA DOENCA, P97; Li Wenwen, 2018, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V43, P1246, DOI 10.11817/j.issn.1672-7347.2018.11.013; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lotufo PA, 2000, REV BRAS HIPERTENS, V4, P387; Maaijwee NAMM, 2014, NAT REV NEUROL, V10, P315, DOI 10.1038/nrneurol.2014.72; Marini C, 2001, STROKE, V32, P52, DOI 10.1161/01.STR.32.1.52; Marini C, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/535672; Minelli C, 2020, NEUROEPIDEMIOLOGY, V54, P75, DOI 10.1159/000503005; Ministerio da Saude do Brasil, 2013, CONS BAS DAD 2011, P0; Monteiro CN, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00078015, 10.1590/0102-311x00078015]; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; QURESHI AI, 1995, STROKE, V26, P1995, DOI 10.1161/01.STR.26.11.1995; Rolim Cristina Lúcia Rocha Cubas, 2012, Rev. bras. epidemiol., V15, P179, DOI 10.1590/S1415-790X2012000100016; Sipila JOT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201633; Smajlovic D, 2015, VASC HEALTH RISK MAN, V11, P157, DOI 10.2147/VHRM.S53203; Steglich RB, 2018, AN BRAS DERMATOL, V93, P507, DOI 10.1590/abd1806-4841.20185767; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	40	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2020	15	11							e0242248	10.1371/journal.pone.0242248	http://dx.doi.org/10.1371/journal.pone.0242248			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OZ9VP	33196650	Green Published, gold			2023-01-03	WOS:000595266800032
J	Zheng, JY; Ding, JX; Liao, MY; Qiu, ZH; Yuan, QC; Mai, WQ; Dai, Y; Zhang, HR; Wu, HL; Wang, YX; Liao, YH; Chen, X; Cheng, X				Zheng, Jiayu; Ding, Jiaxing; Liao, Mengyang; Qiu, Zhihua; Yuan, Qingchen; Mai, Wuqian; Dai, Yong; Zhang, Hongrong; Wu, Hailang; Wang, Yingxuan; Liao, Yuhua; Chen, Xiao; Cheng, Xiang			Immunotherapy against angiotensin II receptor ameliorated insulin resistance in a leptin receptor-dependent manner	FASEB JOURNAL			English	Article						angiotensin II type 1 receptor; immunotherapy; insulin resistance; leptin receptor; skeletal muscle	METABOLIC SYNDROME; SKELETAL-MUSCLE; AT(1) RECEPTORS; OBESITY; HYPERTENSION; CELLS; VALSARTAN; MICE	The angiotensin II type 1 receptor (AT1R) signaling pathway is reported to modulate glucose metabolism. Targeting AT1R, our group invented ATRQ beta-001 vaccine, a novel immunotherapeutic strategy to block the activation of AT1R. Here, we evaluated the therapeutic efficacy of ATRQ beta-001 vaccine in insulin resistance, and investigated the mechanism. Our results showed that ATRQ beta-001 vaccine and specific monoclonal antibody against epitope ATR-001 (McAb-ATR) decreased fasting serum insulin concentration and improved glucose and insulin tolerance in ob/ob mice. These beneficial effects were verified in high-fat diet-induced obese mice. McAb-ATR activated insulin signaling in skeletal muscle and insulin-resistant C2C12 myotubes without affecting liver or white adipose tissue of ob/ob mice. Mechanistically, the favorable impact of McAb-ATR on insulin resistance was abolished in db/db mice and in C2C12 myotubes with leptin receptor knockdown. AT1R knockdown also eradicated the effects of McAb-ATR in C2C12 myotubes. Furthermore, McAb-ATR treatment was able to activate the leptin receptor-mediated JAK2/STAT3 signaling in skeletal muscle of ob/ob mice and C2C12 myotubes. Additionally, angiotensin II downregulated the leptin signaling in skeletal muscle of ob/ob and diet-induced obese mice. We demonstrated that ATRQ beta-001 vaccine and McAb-ATR improved whole-body insulin resistance and regulated glucose metabolism in skeletal muscle in a leptin receptor-dependent manner. Our data suggest that immunotherapy targeting AT1R is a novel strategy for treating insulin resistance.	[Zheng, Jiayu; Ding, Jiaxing; Liao, Mengyang; Qiu, Zhihua; Yuan, Qingchen; Mai, Wuqian; Dai, Yong; Zhang, Hongrong; Wu, Hailang; Wang, Yingxuan; Liao, Yuhua; Chen, Xiao; Cheng, Xiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan 430022, Hubei, Peoples R China; [Zheng, Jiayu; Ding, Jiaxing; Liao, Mengyang; Qiu, Zhihua; Yuan, Qingchen; Mai, Wuqian; Dai, Yong; Zhang, Hongrong; Wu, Hailang; Wang, Yingxuan; Liao, Yuhua; Chen, Xiao; Cheng, Xiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Key Lab Mol Biol Targeted Therapies,Minist Educ, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Chen, X; Cheng, X (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan 430022, Hubei, Peoples R China.	skycreeper@126.com; nathancx@hust.edu.cn			National Natural Science Foundation of China (NSFC) [81974106, 91439207, 81670461]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	National Natural Science Foundation of China (NSFC), Grant/Award Number: 81974106, 91439207 and 81670461	Bates SH, 2005, CELL METAB, V1, P169, DOI 10.1016/j.cmet.2005.02.001; Chen X, 2013, HYPERTENSION, V61, P408, DOI 10.1161/HYPERTENSIONAHA.112.201020; Claflin KE, 2017, J CLIN INVEST, V127, P1414, DOI 10.1172/JCI88641; Coppari R, 2012, NAT REV DRUG DISCOV, V11, P692, DOI 10.1038/nrd3757; D'souza AM, 2017, MOL METAB, V6, P1052, DOI 10.1016/j.molmet.2017.04.011; DeFronzo RA, 2009, DIABETES CARE, V32, pS157, DOI 10.2337/dc09-S302; Denroche HC, 2012, J DIABETES INVEST, V3, P115, DOI 10.1111/j.2040-1124.2012.00203.x; German JP, 2010, DIABETES, V59, P1626, DOI 10.2337/db09-1918; Hall JE, 2019, NAT REV NEPHROL, V15, P367, DOI 10.1038/s41581-019-0145-4; Hall JE, 2015, CIRC RES, V116, P991, DOI 10.1161/CIRCRESAHA.116.305697; Haywood NJ, 2017, DIABETES, V66, P287, DOI 10.2337/db16-0997; He HB, 2010, HYPERTENSION, V55, P869, DOI 10.1161/HYPERTENSIONAHA.109.143958; Hilzendeger AM, 2010, J MOL MED, V88, P899, DOI 10.1007/s00109-010-0649-7; Huynh FK, 2010, DIABETES, V59, P3032, DOI 10.2337/db10-0074; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Knowles JW, 2016, J AM COLL CARDIOL, V67, P1656, DOI 10.1016/j.jacc.2015.12.065; Koh KK, 2008, CIRCULATION, V117, P3238, DOI 10.1161/CIRCULATIONAHA.107.741645; Koo YD, 2019, METABOLISM, V95, P27, DOI 10.1016/j.metabol.2019.03.004; Li H, 2016, HYPERTENSION, V68, P478, DOI 10.1161/HYPERTENSIONAHA.116.07008; Li L, 2013, DIABETES, V62, P762, DOI 10.2337/db12-0570; Luther JM, 2011, TRENDS PHARMACOL SCI, V32, P734, DOI 10.1016/j.tips.2011.07.006; McMurray JJ, 2010, NEW ENGL J MED, V362, P1477, DOI 10.1056/NEJMoa1001121; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moon HS, 2013, ENDOCR REV, V34, P377, DOI 10.1210/er.2012-1053; Muller-Fielitz H, 2015, BRIT J PHARMACOL, V172, P857, DOI 10.1111/bph.12949; Muller-Fielitz H, 2014, BRIT J PHARMACOL, V171, P746, DOI 10.1111/bph.12510; Nozhenko Y, 2015, CELL PHYSIOL BIOCHEM, V35, P92, DOI 10.1159/000369678; Roman EAFR, 2010, MOL CELL ENDOCRINOL, V314, P62, DOI 10.1016/j.mce.2009.08.007; Rong X, 2010, DIABETOLOGIA, V53, P1727, DOI 10.1007/s00125-010-1744-6; Rong X, 2009, J PHARMACOL EXP THER, V331, P1096, DOI 10.1124/jpet.109.157099; Savarese G, 2013, J AM COLL CARDIOL, V61, P131, DOI 10.1016/j.jacc.2012.10.011; Shiota A, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-139; Skurk T, 2005, OBES RES, V13, P969, DOI 10.1038/oby.2005.113; Soleimani M, 2015, KIDNEY INT, V87, P497, DOI 10.1038/ki.2014.392; Taylor R, 2012, DIABETES, V61, P778, DOI 10.2337/db12-0073; van der Zijl NJ, 2011, DIABETES CARE, V34, P845, DOI 10.2337/dc10-2224; Wang ZX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010095; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Younis F, 2010, METABOLISM, V59, P1200, DOI 10.1016/j.metabol.2009.11.013; Zhang HR, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012341; Zhao SG, 2019, CELL METAB, V30, P706, DOI 10.1016/j.cmet.2019.08.005	42	3	3	4	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2021	35	1								10.1096/fj.202000300R	http://dx.doi.org/10.1096/fj.202000300R		NOV 2020	15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	PP1KD	33155736				2023-01-03	WOS:000592446700001
J	Moridi, M; Pazandeh, F; Hajian, S; Potrata, B				Moridi, Maryam; Pazandeh, Farzaneh; Hajian, Sepideh; Potrata, Barbara			Development and psychometric properties of Midwives' Knowledge and Practice Scale on Respectful Maternity Care (MKP-RMC)	PLOS ONE			English	Article								Objective To develop a scale for evaluating knowledge and practice of midwives on Respectful Maternity Care (RMC). Methods An exploratory sequential mixed method study was conducted from January 2018 to July 2019 in two non-teaching public hospitals in Tehran, Iran. In the first part of the study, a literature review and qualitative study were carried out in order to develop the preliminary item pool. Then face, content and construct validity and reliability (internal consistency and test-retest) were assessed. Results The MKP-RMC scale has 23-item in knowledge and 23-item in practice section that loaded in three factors: Giving emotional support, providing safe care and preventing mistreatment. Exploratory factor analysis accounted for 43.47% and 58.62% of observed variance in knowledge and practice sections, respectively. The internal consistency and internal correlation coefficient of both section of MKP-RMC indicated acceptable reliability. Conclusion The MKP-RMC is a valid and reliable tool for measuring midwives' knowledge and practice of respectful care during labor and childbirth. The MKP-RMC could be used in maternity services to evaluate and improve quality of childbirth care through development of educational interventions for effective behavioral change. Confirmation of validity and reliability of translated version of the scale in other maternity care providers and different contexts is recommended.	[Moridi, Maryam] Shahid Beheshti Univ Med Sci, Sch Nursing & Midwifery, Dept Midwifery & Reprod Hlth, Student Res Comm, Tehran, Iran; [Pazandeh, Farzaneh] Univ Nottingham, Sch Hlth Sci, Nottingham, England; [Pazandeh, Farzaneh; Hajian, Sepideh] Shahid Beheshti Univ Med Sci, Midwifery & Reprod Hlth Res Ctr, Sch Nursing & Midwifery, Tehran, Iran	Shahid Beheshti University Medical Sciences; University of Nottingham; Shahid Beheshti University Medical Sciences	Pazandeh, F (corresponding author), Univ Nottingham, Sch Hlth Sci, Nottingham, England.; Pazandeh, F (corresponding author), Shahid Beheshti Univ Med Sci, Midwifery & Reprod Hlth Res Ctr, Sch Nursing & Midwifery, Tehran, Iran.	Farzaneh.Pazandeh@nottingham.ac.uk		Pazandeh, Farzaneh/0000-0002-1955-5220				Afulani PA, 2019, LANCET, V394, P1692, DOI 10.1016/S0140-6736(19)32258-5; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2009, J APPL SOC PSYCHOL, V39, P1356, DOI 10.1111/j.1559-1816.2009.00485.x; Argimon-Pallas JM, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-37; Ayoubi S, 2020, MIDWIFERY, V80, DOI 10.1016/j.midw.2019.102573; Aziato L, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0920-1; Behruzi R, 2014, HEALTH CARE WOMEN IN, V35, P127, DOI 10.1080/07399332.2013.857321; Bohren MA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003766.pub6; Bohren MA, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-71; Bradfield Z, 2019, WOMEN BIRTH, V32, P157, DOI 10.1016/j.wombi.2018.07.013; Cristobal E., 2007, MANAG SERV QUAL, V17, P317, DOI [10.1108/09604520710744326, DOI 10.1108/09604520710744326]; Dickson N, 1997, Aust Coll Midwives Inc J, V10, P23, DOI 10.1016/S1031-170X(97)80043-8; Fagermoen MS, 1997, J ADV NURS, V25, P434, DOI 10.1046/j.1365-2648.1997.1997025434.x; Halldorsdottir S, 2011, SCAND J CARING SCI, V25, P806, DOI 10.1111/j.1471-6712.2011.00886.x; Harrington D., 2009, CONFIRMATORY FACTOR, DOI DOI 10.1093/ACPROF:OSO/9780195339888.001.0001; Kumbani LC, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-30; LAWSHE CH, 1975, PERS PSYCHOL, V28, P563, DOI 10.1111/j.1744-6570.1975.tb01393.x; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; Mohale H, 2017, WOMEN BIRTH, V30, P298, DOI 10.1016/j.wombi.2016.11.011; Moridi M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229941; Ndwiga C, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0364-8; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Schellings G, 2011, METACOGN LEARN, V6, P83, DOI 10.1007/s11409-011-9081-9; Shakibazadeh E, 2018, BJOG-INT J OBSTET GY, V125, P932, DOI 10.1111/1471-0528.15015; Sheferaw ED, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0848-5; Van Lerberghe W, 2014, LANCET, V384, P1215, DOI 10.1016/S0140-6736(14)60919-3; Vedam S, 2017, SSM-POPUL HLTH, V3, P201, DOI 10.1016/j.ssmph.2017.01.005; Vogel JP, 2016, BJOG-INT J OBSTET GY, V123, P671, DOI 10.1111/1471-0528.13750; Waltz CF, 2017, MEASUREMENT NURSING, VFifth; Warren CE, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1288-6; White Ribbon Alliance, 2011, RESP MAT CAR UN RIGH; WHO Reproductive Health Library, 2018, WHO REC EFF COMM MAT; World Health Organization, 2019, WHO REC RESP MAT CAR	33	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2020	15	11							e0241219	10.1371/journal.pone.0241219	http://dx.doi.org/10.1371/journal.pone.0241219			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8YL	33141835	Green Published, gold			2023-01-03	WOS:000588376700036
J	Gilbert, A; Robertson, L; Heron, JE; Chadban, S; Ndhlovu, C; Dahwa, RF; Gracey, DM				Gilbert, Alexander; Robertson, Lindsey; Heron, Jack E.; Chadban, Steve; Ndhlovu, Chiratidzo; Dahwa, Rumbi F.; Gracey, David M.			Risk factors for development of acute kidney injury in hospitalised adults in Zimbabwe	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; SUB-SAHARAN AFRICA; INTERNATIONAL SOCIETY; EPIDEMIOLOGY; MANAGEMENT; NEPHROLOGY; OUTCOMES; DISEASE; CARE	Background Acute kidney injury (AKI) is predominantly a disease of low and middle-income countries. Despite this, there is a particular paucity of data regarding AKI in Africa. Most published studies were conducted prior to the most recent Kidney Disease: Improving Global Outcomes (KDIGO) definition of AKI. This prospective, observational, cohort study examines AKI amongst newly admitted acute medical inpatients in a large, urban, tertiary hospital in Harare, Zimbabwe. Methods All newly admitted, adult, medical patients in separate, randomly selected, 24-hour periods were included. Baseline demographic information, comorbidities, nephrotoxic medication use, and reason for admission were recorded on a standardised data capture record. A serum creatinine measurement was performed on all patients at the time of admission and again after 48 hours. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and AKI was defined using the most recent KDIGO definition as an increase in the serum creatinine of greater than 26.5 mu mol/L within 48 hours, with admission creatinine used as a baseline measurement. Results 253 patients were included in the analysis; 137 patients (54.2%) were female; 100 patients (39.5%) had HIV infection. 36 patients (14.2%) met the KDIGO criteria for AKI during the 48-hour follow-up period. AKI was more common among males (19.8% vs 9.5%; p = 0.019). The AKI group had a higher serum creatinine at presentation than those without AKI (296.5 mu mol/L vs 91.0 mu mol/L; p<0.001) and at 48 hours (447.7 mu mol/L vs 77.1 mu mol/L; p<0.001). In logistic regression, AKI was related negatively to female sex (OR 0.461, 95% CI 0.211, 1.003; p = 0.051) and positively predicted by the presence of comorbid hypertension (OR 3.292, 95% CI 1.52, 7.128; p = 0.003) and chronic kidney disease (OR 6.034, 95% 1.792, 20.313; p = 0.004). Conclusions KDIGO-defined AKI was common in hospitalised patients in Sub-Saharan Africa and was predicted by male sex, a history of comorbid hypertension and a history of comorbid chronic kidney disease.	[Gilbert, Alexander; Heron, Jack E.; Chadban, Steve; Gracey, David M.] Royal Prince Alfred Hosp, Dept Renal Med, Camperdown, NSW, Australia; [Robertson, Lindsey; Ndhlovu, Chiratidzo; Dahwa, Rumbi F.] Univ Zimbabwe, Dept Med, Coll Hlth Sci, Harare, Zimbabwe; [Chadban, Steve] Univ Sydney, Charles Perkins Ctr, Kidney Node, Sydney, NSW, Australia; [Gracey, David M.] Univ Sydney, Fac Med, Cent Clin Sch, Sydney, NSW, Australia	University of Sydney; University of Zimbabwe; University of Sydney; University of Sydney	Gilbert, A; Gracey, DM (corresponding author), Royal Prince Alfred Hosp, Dept Renal Med, Camperdown, NSW, Australia.; Gracey, DM (corresponding author), Univ Sydney, Fac Med, Cent Clin Sch, Sydney, NSW, Australia.	Alexander.Gilbert@health.nsw.gov.au; David.Gracey@health.nsw.gov.au	; Ndhlovu, Chiratidzo Ellen/N-8763-2013	Heron, Jack/0000-0002-6641-4754; Ndhlovu, Chiratidzo Ellen/0000-0001-7863-7974	Renal Department, Royal Prince Alfred Hospital, Sydney, Australia	Renal Department, Royal Prince Alfred Hospital, Sydney, Australia	Funding for the ongoing research was provided by the Renal Department, Royal Prince Alfred Hospital, Sydney, Australia.	Adu D, 2016, CLIN NEPHROL, V86, pS48, DOI 10.5414/CNP86S121; [Anonymous], 2017, LANCET ONCOL, V18, P1, DOI 10.1016/S1470-2045(16)30642-8; [Anonymous], 2016, DIABETES CARE S1, V39, pS1, DOI 10.2337/dc16-S001; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Aylward RE, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1620-7; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Emem-Chioma Pedro Chimezie, 2013, ISRN Nephrol, V2013, P540526, DOI 10.5402/2013/540526; Emmett L, 2017, NEPHRON, V136, P202, DOI 10.1159/000460266; Esezobor C I, 2012, West Afr J Med, V31, P181; Halle MPE, 2018, RENAL FAILURE, V40, P30, DOI 10.1080/0886022X.2017.1419970; Kaballo BG, 2007, SAUDI J KIDNEY DIS T, V18, P220; Kellum JA, 2013, CRIT CARE, V17, DOI 10.1186/cc11454; KILONZO SB, 2016, TANZAN J HLTH RES, V18, P3; Lameire NH, 2013, LANCET, V382, P170, DOI 10.1016/S0140-6736(13)60647-9; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Mehta RL, 2016, LANCET, V387, P2017, DOI 10.1016/S0140-6736(16)30240-9; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Naicker S, 2008, SEMIN NEPHROL, V28, P348, DOI 10.1016/j.semnephrol.2008.04.003; Olowu WA, 2016, LANCET GLOB HEALTH, V4, pE242, DOI 10.1016/S2214-109X(15)00322-8; Riley S, 2013, NEPHROLOGY, V18, P92, DOI 10.1111/nep.12002; Stanifer JW, 2014, LANCET GLOB HEALTH, V2, pE174, DOI 10.1016/S2214-109X(14)70002-6; Susantitaphong P, 2013, CLIN J AM SOC NEPHRO, V8, P1482, DOI 10.2215/CJN.00710113; Swanepoel CR, 2013, NAT REV NEPHROL, V9, P610, DOI 10.1038/nrneph.2013.168; Yao KH, 2018, NEPHROLOGY, V23, P653, DOI 10.1111/nep.13064; Yousif DE, 2018, BLOOD PURIFICAT, V45, P201, DOI 10.1159/000485214; Zachor H, 2016, AIDS, V30, P1221, DOI 10.1097/QAD.0000000000001041	26	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2020	15	10							e0241229	10.1371/journal.pone.0241229	http://dx.doi.org/10.1371/journal.pone.0241229			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OP8VY	33104756	Green Published, gold			2023-01-03	WOS:000588370000055
J	Keisari, S; Gesser-Edelsburg, A; Yaniv, D; Palgi, Y				Keisari, Shoshi; Gesser-Edelsburg, Anat; Yaniv, Dani; Palgi, Yuval			Playback theatre in adult day centers: A creative group intervention for community-dwelling older adults	PLOS ONE			English	Article							MENTAL-HEALTH; SOCIAL-ISOLATION; DEMENTIA CARE; DAY SERVICES; THERAPY; DEPRESSION; ARTS; LONELINESS; PEOPLE; DRAMA	The literature indicates that theatre and drama-based interventions have the potential to improve older adults' well-being and health. The goal of the current study was to characterize the process of a creative group intervention in adult day centers (ADCs), which integrates playback theatre and life-review principles. Our objective was to provide an evidence-informed framework for drama therapy interventions, which would allow older adults to bring up and explore their life-stories in a dramatic creative process in their own community. A total of 27 participants ranging in age from 63 to 91, took part in one of three playback theatre groups. The playback theatre group intervention comprised 12 weekly sessions. All sessions were videotaped to capture the lived experience of the creative process and were analyzed in post-intervention interviews. In addition, focus group meetings were conducted with 13 ADC staff members to decipher further the effects of the participation as perceived by people outside the groups. Three types of potential transformation were identified in the qualitative analysis: the evolution of life stories, evolution of playfulness, and expansion of social engagement. The results indicate the potential of the integrative framework to serve as a creative intervention in ADC communities, as well as its potential to bring about a personal transformation and expand it to enable a person's social engagement in the community. The findings imply the potential benefits of using playback theatre groups to supplement the routine care provided in ADCs.	[Keisari, Shoshi; Palgi, Yuval] Univ Haifa, Dept Gerontol, Haifa, Israel; [Gesser-Edelsburg, Anat] Univ Haifa, Sch Publ Hlth, Haifa, Israel; [Gesser-Edelsburg, Anat] Univ Haifa, Hlth & Risk Commun Res Ctr, Haifa, Israel; [Yaniv, Dani] Univ Haifa, Sch Creat Arts Therapies, Emili Sagol Creat Arts Therapies Res Ctr, Haifa, Israel; [Palgi, Yuval] Univ Haifa, Ctr Res & Study Aging, Haifa, Israel; [Yaniv, Dani] Univ Haifa, Sch Creat Arts Therapies, Haifa, Israel	University of Haifa; University of Haifa; University of Haifa; University of Haifa; University of Haifa; University of Haifa	Keisari, S (corresponding author), Univ Haifa, Dept Gerontol, Haifa, Israel.	skeisari@gmail.com		Keisari, Shoshi/0000-0003-1988-7601; Gesser-Edelsburg, PhD, Prof. Anat/0000-0003-4467-8799	Shalhevet the association; Emili Sagol Creative Arts Therapies Research Centre, University of Haifa	Shalhevet the association; Emili Sagol Creative Arts Therapies Research Centre, University of Haifa	The authors would like to sincerely thank all of the study participants. We are also indebted to the management and staff at MATAV the association for welfare and treatment services; ALEH the Kiryat Ono association for senior citizens; and Shalhevet the association for the elderly in Kiryat Tivon, for their support and commitment to this project. We also want to thank the therapist Rachel Levi for her professional conduct and her significant contribution to the project. In addition, we would like to thank the Emili Sagol Creative Arts Therapies Research Centre, University of Haifa, for their help and support, which enabled us to complete our study and maintain high standards of research throughout the project.	Albisu L. M., 1999, Options Mediterraneennes. Serie A, Seminaires Mediterraneens, P9; Ayalon L, 2020, J COMMUNITY PSYCHOL, V48, P437, DOI 10.1002/jcop.22268; Ayalon L, 2018, INNOV AGING, V2, DOI 10.1093/geroni/igy021; Ayalon L, 2018, INNOV AGING, V2, DOI 10.1093/geroni/igy024; Ayalon L, 2017, EUR J AGEING, V14, P1, DOI 10.1007/s10433-016-0409-9; Basting A, 2018, DEMENTIA-LONDON, V17, P744, DOI 10.1177/1471301217740959; Basting Anne Davis, 1998, STAGES AGE PERFORMIN; Beard REL, 2012, DEMENTIA-LONDON, V11, P633, DOI 10.1177/1471301211421090; Ben Ezra M., 2010, TRAUMATOLOGY, V16, P7, DOI [10.1177/1534765609358465, DOI 10.1177/1534765609358465]; Bernard M, 2017, GERONTOLOGIST, V57, pE1, DOI 10.1093/geront/gnw093; Blagov PS, 2004, J PERS, V72, P481, DOI 10.1111/j.0022-3506.2004.00270.x; Boal A., 2000, THEATER OPPRESSED; Boeije H, 2002, QUAL QUANT, V36, P391, DOI 10.1023/A:1020909529486; Bohlmeijer E, 2007, AGING MENT HEALTH, V11, P291, DOI 10.1080/13607860600963547; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; BUTLER RN, 1963, PSYCHIATR, V26, P65, DOI 10.1080/00332747.1963.11023339; Cacioppo JT, 2010, PSYCHOL AGING, V25, P453, DOI 10.1037/a0017216; Cameron E, 2019, J WOMEN AGING, V31, P3, DOI 10.1080/08952841.2018.1449586; Chung KSY, 2018, AUSTRALAS J AGEING, V37, pE33, DOI 10.1111/ajag.12498; Ciasca EC, 2018, REV BRAS PSIQUIATR, V40, P256, DOI 10.1590/1516-4446-2017-2250; Courtin E, 2017, HEALTH SOC CARE COMM, V25, P799, DOI 10.1111/hsc.12311; Dabelko-Schoeny H, 2013, AGING MENT HEALTH, V17, P207, DOI 10.1080/13607863.2012.724653; Dauber H., 1999, GATHERING VOICES ESS, P67; de Medeiros K, 2014, GERONTOLOGIST, V54, P344, DOI 10.1093/geront/gnt055; de Medeiros Kate, 2014, NARRATIVE GERONTOLOG; Donovan NJ, 2017, INT J GERIATR PSYCH, V32, P564, DOI 10.1002/gps.4495; Dunphy K, 2019, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02655; Ellen ME, 2017, GERONTOLOGIST, V57, pE85, DOI 10.1093/geront/gnw165; Elliott R., 1989, ENTERING CIRCLE HERM, P165; Erel U, 2017, QUAL RES, V17, P302, DOI 10.1177/1468794117696029; Erikson E.H., 1982, LIFE CYCLE COMPLETED; Erikson E. H., 1959, PSYCHOL ISSUES, V1, P1; Feniger-Schaal R, 2019, PSYCHOL AESTHET CREA, V4, P68, DOI DOI 10.1037/ACA0000257; Fields NL, 2014, J APPL GERONTOL, V33, P130, DOI 10.1177/0733464812443308; Fox H, 2007, TDR-DRAMA REV-J PERF, V51, P89, DOI 10.1162/dram.2007.51.4.89; Fox J., 1994, ACTS SERVICE SPONTAN; Fraser KD, 2015, GERONTOLOGIST, V55, P719, DOI 10.1093/geront/gnv027; Freire P., 1970, PEDAGOGY OPPRESSED; Gonyea JG, 2018, J AGING HEALTH, V30, P458, DOI 10.1177/0898264316682908; Haber D, 2006, INT J AGING HUM DEV, V63, P153, DOI 10.2190/DA9G-RHK5-N9JP-T6CC; Haigh EAP, 2018, AM J GERIAT PSYCHIAT, V26, P107, DOI 10.1016/j.jagp.2017.06.011; Harel D., 2016, SELF PERFORMANCE, P213, DOI DOI 10.1057/978-1-137-53593-1_15; Hendriks L, 2019, INT PSYCHOGERIATR, V31, P1801, DOI 10.1017/S1041610219000218; Hofmeier SM, 2017, J WOMEN AGING, V29, P3, DOI 10.1080/08952841.2015.1065140; Huizinga J., 1998, HOMOLUDENS STUDY PLA; Johnson KJ, 2014, GERONTOLOGIST, V54, P93, DOI 10.1093/geront/gnt099; Keisari S, CLIN GERONTOL; Keisari S, 2020, PSYCHOL AESTHETICS C; Keisari S, 2018, ART PSYCHOTHER, V60, P72, DOI 10.1016/j.aip.2018.07.002; Keisari S, 2017, AGING MENT HEALTH, V21, P1079, DOI 10.1080/13607863.2016.1199012; Kellermann P. F., 1994, PSYCHODRAMA MORENO I, P263; Kenyon G.M., 2010, STORYING LATER LIFE; Keyes CLM, 2005, J CONSULT CLIN PSYCH, V73, P539, DOI 10.1037/0022-006X.73.3.539; Keyes CLM, 2002, J HEALTH SOC BEHAV, V43, P207, DOI 10.2307/3090197; Killick J, 2012, PLAYFULNESS DEMENTIA; Kindler RC, 2010, PSYCHOANAL INQ, V30, P254, DOI 10.1080/07351690903206223; Kipper D. A., 2006, J GROUP PSYCHOTHERAP, V59, P117, DOI [10.3200/JGPP.59.3.117-126, DOI 10.3200/JGPP.59.3.117-126]; Korte J, 2012, PSYCHOL MED, V42, P1163, DOI 10.1017/S0033291711002042; Kowalsky R, 2019, ART PSYCHOTHER, V66, DOI 10.1016/j.aip.2019.101577; Kvale S., 1996, INTERVIEWS INTRO QUA; Landy R, 1993, PERSONA PERFORMANCE; Landy R.J., 2008, COUCH STAGE INTEGRAT; Landy R. J, 2009, CURRENT APPROACHES D, V2, P65; Langellier K., 2006, SAGE HDB PERFORMANCE, P151; Leavy P., 2015, METHOD MEETS ART ART; McAdams D. P., 2019, QUAL PSYCHOL, V6, P206, DOI [10.1037/qup0000151, DOI 10.1037/QUP0000151]; McNiff S., 2008, HDB ARTS QUALITATIVE; Meeks TW, 2011, J AFFECT DISORDERS, V129, P126, DOI 10.1016/j.jad.2010.09.015; Moore RC, 2017, ART PSYCHOTHER, V52, P1, DOI 10.1016/j.aip.2016.09.007; Moran GS, 2011, ART PSYCHOTHER, V38, P318, DOI 10.1016/j.aip.2011.09.002; MORENO JL, 1961, AM J PSYCHIAT, V118, P518, DOI 10.1176/ajp.118.6.518; Moreno JL, 1985, PSYCHODRAMA, V1; Moreno JL., 1953, MORENO DESCRIBES SUR; Moreno Z, 2013, PSYCHODRAMA SURPLUS; Ng HC, 2016, PERS-CENTERED EXP PS, V15, P126, DOI 10.1080/14779757.2016.1172252; Noice T., 2006, CLIN GERONTOLOGIST, V29, P59, DOI DOI 10.1300/J018V29N03_05; Noice T, 2015, ACT ADAPT AGING, V39, P19, DOI 10.1080/01924788.2015.994440; Noice T, 2014, GERONTOLOGIST, V54, P741, DOI 10.1093/geront/gnt138; Norris, 2000, YOUTH THEATRE JOURNA, V14, P40, DOI DOI 10.1080/08929092.2000.10012516; Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847; Onwuegbuzie AJ, 2007, QUAL QUANT, V41, P105, DOI 10.1007/s11135-005-1098-1; Orkibi H, 2014, ART PSYCHOTHER, V41, P458, DOI 10.1016/j.aip.2014.08.006; Palgi S, 2014, J CONTEMP PSYCHOTHER, V44, P173, DOI 10.1007/s10879-014-9262-3; Patton M.Q., 2014, UTILIZATION FOCUSED, V4th; Pendzik S, 2006, ART PSYCHOTHER, V33, P271, DOI 10.1016/j.aip.2006.03.001; Pillemer DB., 2001, REV GEN PSYCHOL, V5, P123, DOI [10.1037/1089-2680.5.2.123, DOI 10.1037/1089-2680.5.2.123]; Rickett M, 2014, AGEING DRAMA CREATIV; Roe B, 2016, DEMENTIA-LONDON, V15, P539, DOI 10.1177/1471301214528927; Rowe N., 2007, PLAYING OTHER DRAMAT; SALAS J, 1983, DRAMA REV, V27, P15, DOI 10.2307/1145490; Salas J., 2009, CURRENT APPROACHES D, P445; Salas J., 1999, GATHERING VOICES ESS; Salas J., 1993, IMPROVISING REAL LIF; Salas J., 2007, DO MY STORY SING MY; Shafir T, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00068; Sneed JR, 2005, J SOC ISSUES, V61, P375, DOI 10.1111/j.1540-4560.2005.00411.x; Stevens J, 2012, DEMENTIA-LONDON, V11, P61, DOI 10.1177/1471301211418160; Swinnen A, 2018, GERONTOLOGIST, V58, P261, DOI 10.1093/geront/gnw196; Twigg J, 2004, J AGING STUD, V18, P59, DOI 10.1016/j.jaging.2003.09.001; Waldman-Levi A, 2015, HEALTHY AGING RES, V4, DOI 10.12715/har.2015.4.8; Westerhof GJ, 2019, CLIN PSYCHOL-SCI PR, V26, DOI 10.1111/cpsp.12301; Westerhof GJ, 2014, J AGING STUD, V29, P107, DOI 10.1016/j.jaging.2014.02.003; Westerhof GJ, 2015, ENCY ADULTHOOD AGING, P1, DOI [10.1002/9781118521373.wbeaa209, DOI 10.1002/9781118521373.WBEAA209]; Whitbourne SK, 1996, AGING INDIVIDUAL PHY; WHO, 2019, MENT HLTH STAT WELL; Winnicott D., 2005, PLAYING REALITY; Woodbury MG, 2014, WOUND CARE CANADA, V12, P26; Woodford HJ, 2007, QJM-INT J MED, V100, P469, DOI 10.1093/qjmed/hcm051; World Health Organization, 2015, AG HLTH; World Health Organization (WHO), 2017, MENT HLTH OLD AD; Yaniv D, 2011, ART PSYCHOTHER, V38, P52, DOI 10.1016/j.aip.2010.12.001; Yaniv D, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02083; Yaniv D, 2014, ART PSYCHOTHER, V41, P336, DOI 10.1016/j.aip.2014.03.005; Yaniv D, 2012, REV GEN PSYCHOL, V16, P70, DOI 10.1037/a0026580; Yarnal C, 2007, OLDER ADULT PLAYFULN, V4, P52; Yarnal C, 2011, AM J PLAY, V4, P52; Young R, 2016, AGING MENT HEALTH, V20, P337, DOI 10.1080/13607863.2015.1011080; Zeisel J, 2018, AM J ALZHEIMERS DIS, V33, P232, DOI 10.1177/1533317518755994; Zhao K, 2016, INT J GERIATR PSYCH, V31, P1188, DOI 10.1002/gps.4494	119	6	6	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2020	15	10							e0239812	10.1371/journal.pone.0239812	http://dx.doi.org/10.1371/journal.pone.0239812			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OS6KJ	33002024	gold, Green Published			2023-01-03	WOS:000590270000062
J	Choi, J; Zamary, K; Barreto, NB; Tennakoon, L; Davis, KM; Trickey, AW; Spain, DA				Choi, Jeff; Zamary, Kirellos; Barreto, Nicolas B.; Tennakoon, Lakshika; Davis, Kristen M.; Trickey, Amber W.; Spain, David A.			Intravenous lidocaine as a non-opioid adjunct analgesic for traumatic rib fractures	PLOS ONE			English	Article							POSTOPERATIVE ANALGESIA; SYSTEMIC LIDOCAINE; PAIN; SURGERY; METAANALYSIS; RECOVERY; REQUIREMENTS; INFUSION; IMPACT	Introduction Pain management is the pillar of caring for patients with traumatic rib fractures. Intravenous lidocaine (IVL) is a well-established non-opioid analgesic for post-operative pain, yet its efficacy has yet to be investigated in trauma patients. We hypothesized that IVL is associated with decreased inpatient opioid requirements among patients with rib fractures. Methods We retrospectively evaluated adult patients presenting to our Level 1 trauma center with isolated chest wall injuries. After 1:1 propensity score matching patients who received vs did not receive IVL, we compared the two groups' average daily opioid use, opioid use in the last 24 hours of admission, and pain scores during admissions hours 24-48. We performed multivariable linear regression for these outcomes (with sensitivity analysis for the opioid use outcomes), adjusting for age as a moderating factor and controlling for hospital length of stay and injury severity. Results We identified 534 patients, among whom 226 received IVL. Those who received IVL were older and had more serious injury. Compared to propensity-score matched patients who did not receive IVL, patients who received IVL had similar average daily opioid use and pain scores, but 40% lower opioid use during the last 24 hours of admission (p = 0.002). Multivariable regression-with and without sensitivity analysis-did not show an effect of IVL on any outcomes. Conclusion IVL was crudely associated with decreased opioid requirements in the last 24 hours of admission, the time period associated with opioid use at 90 days post-discharge. However, we did not observe beneficial effects of IVL on multivariable adjusted analyses; we are conducting a randomized control trial to further evaluate IVL's opioid-sparing effects for patients with rib fractures.	[Choi, Jeff; Zamary, Kirellos; Tennakoon, Lakshika; Spain, David A.] Stanford Univ, Dept Surg, Div Gen Surg, Stanford, CA 94305 USA; [Choi, Jeff] Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA; [Zamary, Kirellos] St Joseph Hlth Med Grp, Dept Surg, Santa Rosa, CA USA; [Barreto, Nicolas B.; Davis, Kristen M.; Trickey, Amber W.] Stanford Univ, Dept Surg, Stanford Surg Policy Improvement Res & Educ Ctr, Stanford, CA USA	Stanford University; Stanford University; Stanford University	Choi, J (corresponding author), Stanford Univ, Dept Surg, Div Gen Surg, Stanford, CA 94305 USA.; Choi, J (corresponding author), Stanford Univ, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA.	jc2226@stanford.edu	Davis, Kristen/GRN-7861-2022	Davis, Kristen/0000-0002-5595-2450; Choi, Jeff/0000-0003-1639-8781				Adhikary SD, 2019, ANAESTHESIA, V74, P585, DOI 10.1111/anae.14579; [Anonymous], **DATA OBJECT**; [Anonymous], 2011, WAS FORDERT LEIBNIZ, V42, P1; Baker DW, 2017, JAMA-J AM MED ASSOC, V317, P1117, DOI 10.1001/jama.2017.0935; Barry R, 2018, AM J SURG, V215, P1020, DOI 10.1016/j.amjsurg.2018.03.011; Brasel KJ, 2006, CRIT CARE MED, V34, P1642, DOI 10.1097/01.CCM.0000217926.40975.4B; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Chang YC, 2017, PAIN PRACT, V17, P336, DOI 10.1111/papr.12442; Cui WH, 2010, EUR J ANAESTH, V27, P41, DOI 10.1097/EJA.0b013e32832d5426; Donohue JM, 2019, ANN INTERN MED, V171, P81, DOI 10.7326/M18-2864; Elmistekawy Elsayed M, 2007, Ann Thorac Med, V2, P166, DOI 10.4103/1817-1737.36552; Flagel BT, 2005, SURGERY, V138, P717, DOI 10.1016/j.surg.2005.07.022; Gorlin AW, 2016, J PAIN RES, V9, P693, DOI 10.2147/JPR.S113216; Grigoras A, 2012, CLIN J PAIN, V28, P567, DOI 10.1097/AJP.0b013e31823b9cc8; Groban L, 2001, ANESTH ANALG, V92, P37; Hernandez N, 2019, LOCAL REG ANESTH, V12, P59, DOI 10.2147/LRA.S207791; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Hwang EG, 2014, J EXERC REHABIL, V10, P241, DOI 10.12965/jer.140137; Ibrahim A, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010229; Kent Richard, 2008, Ann Adv Automot Med, V52, P73; Kugler NW, 2019, J TRAUMA ACUTE CARE, V87, P1181, DOI 10.1097/TA.0000000000002479; Marret E, 2008, BRIT J SURG, V95, P1331, DOI 10.1002/bjs.6375; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; McKay A, 2009, ANESTH ANALG, V109, P1805, DOI 10.1213/ANE.0b013e3181be371b; Nationwide Emergency Department Sample (NEDS), 2006, HEALTHC COST UT PROJ, P2006; Nielsen S, 2016, PHARMACOEPIDEM DR S, V25, P733, DOI 10.1002/pds.3945; R Core Team, 2021, R LANG ENV STAT COMP; Shi Helen H, 2017, Trauma Surg Acute Care Open, V2, pe000074, DOI 10.1136/tsaco-2016-000074; Sun YX, 2012, DIS COLON RECTUM, V55, P1183, DOI 10.1097/DCR.0b013e318259bcd8; Ventham NT, 2015, WORLD J SURG, V39, P2220, DOI 10.1007/s00268-015-3105-6	30	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2020	15	9							e0239896	10.1371/journal.pone.0239896	http://dx.doi.org/10.1371/journal.pone.0239896			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY3AW	32986770	gold, Green Published			2023-01-03	WOS:000576267900044
J	Meng, J; Lv, ZY; Sun, CX; Qiao, XH; Chen, C				Meng, Jiao; Lv, Zhenyu; Sun, Chuanxin; Qiao, Xinhua; Chen, Chang			An extract ofLycium barbarummimics exercise to improve muscle endurance through increasing type IIa oxidative muscle fibers by activating ERR gamma	FASEB JOURNAL			English	Article						Chinese traditional medicine; exercise mimetic; skeletal muscle remodeling	SKELETAL-MUSCLE; MITOCHONDRIAL BIOGENESIS; HEPATIC STEATOSIS; HEALTH; SIRT1; EXPRESSION; CAPACITY; PROTECTS; IMPACT; FRUIT	Lycium barbarumberry (gouqi, Goji, goji berry, or wolfberry), a traditional medicine and functional food, has a wide range of biological effects, including immuno-modulation, anti-aging, antitumor, neuro-protection, and hepato-protection. However, thus far, little is known about the traditional effects ofL. barbarumon strengthening muscles. Therefore, this study focused on the effects of an extract ofL. barbarumon skeletal muscles. First, the extract ofL. barbarumsignificantly increased the mass of the tibial anterior muscle and gastrocnemius muscle and improved the average running distance of mice. Then, in vivo and in vitro experiments showed that the extract enhanced muscle endurance by increasing the proportion of type IIa oxidative muscle fibers and aerobic respiration. In an in-depth study of the molecular mechanism of these effects, we found that the extract upregulated the proportion of type IIa oxidative muscle fibers by activating ERR gamma and that the PKA-CREB signaling pathway was involved in its activation. This study is the first to show thatL. barbarumextract modulates skeletal muscle remodeling and has mimetic effects on skeletal muscles in a manner similar to exercise. It provides a scientific explanation based on modern biological technologies and concepts for the traditional function ofL. barbarumin improving muscle fitness. This study lays a theoretical foundation for the application ofL. barbarumin skeletal muscles as an exercise mimetic.	[Meng, Jiao; Lv, Zhenyu; Sun, Chuanxin; Qiao, Xinhua; Chen, Chang] Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Lv, Zhenyu; Chen, Chang] Univ Chinese Acad Sci, Beijing, Peoples R China; [Chen, Chang] Beijing Inst Brain Disorders, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Chen, C (corresponding author), Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.	changchen@moon.ibp.ac.cn			Ningxia Key Research and Development Program Grant; Regional key projects of science and technology service network plan of Chinese Academy of Science [KFJ-STS-QYZD-181]; National Key R&D Program of China [2017YFA0504000]; NSFC \ National Natural Science Foundation of China-Key program project [91849203]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB39000000]; Goji Berry Technology Cooperation Project in Agricultural Comprehensive Development of Ningxia Autonomous Region [NTKJ-2015-05]	Ningxia Key Research and Development Program Grant; Regional key projects of science and technology service network plan of Chinese Academy of Science; National Key R&D Program of China; NSFC \ National Natural Science Foundation of China-Key program project(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Goji Berry Technology Cooperation Project in Agricultural Comprehensive Development of Ningxia Autonomous Region	Ningxia Key Research and Development Program Grant; Regional key projects of science and technology service network plan of Chinese Academy of Science, Grant/Award Number: KFJ-STS-QYZD-181; National Key R&D Program of China, Grant/Award Number: 2017YFA0504000; NSFC vertical bar National Natural Science Foundation of China-Key program project, Grant/Award Number: 91849203; The Strategic Priority Research Program of the Chinese Academy of Sciences, Grant/Award Number: XDB39000000; Goji Berry Technology Cooperation Project in Agricultural Comprehensive Development of Ningxia Autonomous Region, Grant/Award Number: NTKJ-2015-05	Ahn M, 2014, ACTA HISTOCHEM, V116, P1104, DOI 10.1016/j.acthis.2014.05.004; Argiles JM, 2016, J AM MED DIR ASSOC, V17, P789, DOI 10.1016/j.jamda.2016.04.019; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; Calabrese EJ, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0013-z; Cheng J, 2015, DRUG DES DEV THER, V9, P33, DOI [10.2147/DDDT.572892, 10.2147/DDDT.S72892]; Fan WW, 2017, CELL METAB, V25, P242, DOI 10.1016/j.cmet.2016.10.022; Fan WW, 2015, CURR OPIN CELL BIOL, V33, P49, DOI 10.1016/j.ceb.2014.11.002; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fielding RA, 2015, CALCIFIED TISSUE INT, V96, P181, DOI 10.1007/s00223-015-9964-x; Gouspillou G, 2014, AGING CELL, V13, P39, DOI 10.1111/acel.12147; Guerrieri Davide, 2017, Brain Plast, V2, P153, DOI 10.3233/BPL-160043; Gundersen K, 2011, BIOL REV, V86, P564, DOI 10.1111/j.1469-185X.2010.00161.x; Ha KT, 2005, J ETHNOPHARMACOL, V96, P529, DOI 10.1016/j.jep.2004.09.054; Hawley JA, 2014, CELL, V159, P738, DOI 10.1016/j.cell.2014.10.029; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jia L, 2016, SCI REP-UK, V6, DOI 10.1038/srep36209; Kim DK, 2012, J BIOL CHEM, V287, P21628, DOI 10.1074/jbc.M111.315168; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Li S. Z., 1982, COMPENDIUM MAT MED; Lin DB, 2014, MOL NUTR FOOD RES, V58, P1005, DOI 10.1002/mnfr.201300186; Ljubicic V, 2014, AM J PHYSIOL-CELL PH, V307, pC66, DOI 10.1152/ajpcell.00357.2013; Martel J, 2019, TRENDS ENDOCRIN MET, V30, P335, DOI 10.1016/j.tem.2019.04.001; Merritt EK, 2013, J APPL PHYSIOL, V115, P937, DOI 10.1152/japplphysiol.00019.2013; Murase T, 2006, AM J PHYSIOL-REG I, V290, pR1550, DOI 10.1152/ajpregu.00752.2005; Murase T, 2005, AM J PHYSIOL-REG I, V288, pR708, DOI 10.1152/ajpregu.00693.2004; Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051; Picard M, 2011, AGING CELL, V10, P1047, DOI 10.1111/j.1474-9726.2011.00745.x; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Seifarth C, 2013, EXP CLIN ENDOCR DIAB, V121, P27, DOI 10.1055/s-0032-1327734; Son TG, 2008, NEUROMOL MED, V10, P236, DOI 10.1007/s12017-008-8037-y; Wang YC, 2013, CURR OPIN CLIN NUTR, V16, P243, DOI 10.1097/MCO.0b013e328360272d; Yan Z, 2011, J APPL PHYSIOL, V110, P264, DOI 10.1152/japplphysiol.00993.2010; Yu HF, 2013, MOL NUTR FOOD RES, V57, P1158, DOI 10.1002/mnfr.201200642; Zierath JR, 2004, PLOS BIOL, V2, P1523, DOI 10.1371/journal.pbio.0020348	34	7	7	4	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2020	34	9					11460	11473		10.1096/fj.202000136R	http://dx.doi.org/10.1096/fj.202000136R		JUL 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NK8TC	33411401				2023-01-03	WOS:000556804700001
J	Allen, KD; Woolson, S; Hoenig, HM				Allen, K. D.; Woolson, S.; Hoenig, H. M.			Summary for Patients: A Stepped Exercise Program for Patients With Knee Osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR	2021	174	3					I15	I15		10.7326/P20-0013	http://dx.doi.org/10.7326/P20-0013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TS0RZ	33370172				2023-01-03	WOS:000679365400002
J	Rosen, DL; Travers, D				Rosen, David L.; Travers, Debbie			Emergency department visits among patients transported by law enforcement officers	PLOS ONE			English	Article								Law enforcement officers frequently encounter people with health conditions. We sought to estimate the rates, diagnoses, and characteristics of emergency department (ED) visits among patients transported directly by law enforcement. We analyzed statewide North Carolina Emergency Department data for adults, aged 18+ years, from 2009 to 2016. We estimated transport rates using census data; categorized primary ED diagnoses into 13 major and 8 substituent categories; compared county transport rates by rurality; and examined patient characteristics. There were 136,240 patients transported by law enforcement; annual rates increased from 186.9 (per 100,000 adult residents) in 2009 to 279.2 in 2016. Among visits, 67.7% were among men, the median age was 37 years, and 20.4% resulted in a hospital admission. Most common primary diagnoses were Mental Health Diagnoses (43.1%)-including Schizophrenia and other Psychotic Disorders (7.6%), Mood Disorders (9.7%), and Alcohol and Substance Use (10.7%)-followed by Injury and Poisoning (12.4%) and Circulatory conditions (4.1%). Involuntary commitments constituted 22% of all visits. The median transport rate in rural counties, 291.1, was 2 times that of large metro counties, 145.1. The visit rate increased by nearly 50% during the study period, with the highest rates in rural counties. Many transports were for Mental Illness and involuntary commitments. The relatively common occurrence of law enforcement transports suggests the need for greater research to understand factors influencing law enforcement transport decisions, the impact of these transports on patient health and safety, and the repercussions on patient care of a growing officer presence in EDs.	[Rosen, David L.] Univ North Carolina Chapel Hill, Sch Med, Div Infect Dis, Carrboro, NC USA; [Travers, Debbie] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Rosen, DL (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Div Infect Dis, Carrboro, NC USA.	drosen@med.unc.edu			National Institute on Minority Health and Health Disparities of the National Institutes of Health [1R01MD012469-01]; North Carolina Division of Public Health (NC DPH); Public Health Emergency Preparedness Grant (PHEP)	National Institute on Minority Health and Health Disparities of the National Institutes of Health; North Carolina Division of Public Health (NC DPH); Public Health Emergency Preparedness Grant (PHEP)	DR, DT, 1R01MD012469-01, National Institute on Minority Health and Health Disparities of the National Institutes of Health, https://www.nimhd.nih.gov/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The North Carolina Disease Event Tracking and Epidemiologic Collection Tool (NC DETECT) is an advanced, statewide public health surveillance system. NC DETECT is funded with federal funds by North Carolina Division of Public Health (NC DPH), Public Health Emergency Preparedness Grant (PHEP), and managed through a collaboration between NC DPH and the University of North Carolina at Chapel Hill Department of Emergency Medicine's Carolina Center for Health Informatics (UNC CCHI). The NC Office of Emergency Medical Services (NC OEMS) and NC DETECT Data Oversight Committees do not take responsibility for the scientific validity or accuracy of methodology, results, statistical analyses, or conclusions presented.	Allen L, 2014, BILL HLTH; Baker EF, 2016, ANN EMERG MED, V68, P599, DOI 10.1016/j.annemergmed.2016.02.013; Band RA, 2014, ANN EMERG MED, V63, P608, DOI 10.1016/j.annemergmed.2013.11.008; Caldwell EW, 2018, E COMMUNICATION; Craver R, 2018, WINSTON SALEM J 1103; Davis E, 2018, 251145 NCJ US DEP JU; Department rather than EMS, 2019, COMMUNICATION; Gainor D, 2019, COMMUNICATION; Harmon KJ, 2017, REPORT VIOLENT INJUR; Hawkins SC, 2007, RESUSCITATION, V72, P386, DOI 10.1016/j.resuscitation.2006.07.021; Huybrechts I, 2019, EUR J NUTR, P1; Ingram Deborah D, 2014, Vital Health Stat 2, P1; Kansagra Susan M, 2018, N C Med J, V79, P157, DOI 10.18043/ncm.79.3.157; Klassen AB, 2018, PREHOSP DISASTER MED, V33, P165, DOI 10.1017/S1049023X18000213; Kurtz R, 2015, RESULTS 2014 END YEA; Morrison J, 2018, 915 WUNC N CAR PUBL; North Carolina College of Emergency Physicians Standards for Medical Oversight and Data Collection, 2019, EMS PAT CAR TREATM P; Reaves B. A., 2011, 233982 NCJ US DEP JU; The UNC Department of Emergency Medicine Carolina Center for Health Informatics Report, 2011, OV AN NC DETECT EM D; United States Department of Health and Human Services (US DHHS) Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), BRIDG RAC POP EST US; University of Memphis CIT CENTER, WELC U MEMPH CIT CTR; Wandling MW, 2016, J TRAUMA ACUTE CARE, V81, P931, DOI 10.1097/TA.0000000000001228; Watson AC, 2014, INT J LAW PSYCHIAT, V37, P351, DOI 10.1016/j.ijlp.2014.02.005; Watson AC, 2011, INT J LAW PSYCHIAT, V34, P287, DOI 10.1016/j.ijlp.2011.07.008	24	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 13	2021	16	1							e0244679	10.1371/journal.pone.0244679	http://dx.doi.org/10.1371/journal.pone.0244679			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4UT	33439860	Green Published, gold			2023-01-03	WOS:000609985300005
J	Anzan, M; Alwhaibi, M; Almetwazi, M; Alhawassi, TM				Anzan, Mona; Alwhaibi, Monira; Almetwazi, Mansour; Alhawassi, Tariq M.			Prescribing errors and associated factors in discharge prescriptions in the emergency department: A prospective cross-sectional study	PLOS ONE			English	Article							MEDICATION ERRORS; PHARMACISTS	Objectives Evidence regarding the prevalence of medication prescribing errors (PEs) and potential factors that increase PEs among patients treated in the emergency department (ED) are limited. This study aimed to explore the prevalence and nature of PEs in discharge prescriptions in the ED and identify potential risk factors associated with PEs. Methods This was a prospective observational cross-sectional study in an ambulatory ED in a tertiary teaching hospital. Data were collected for six months using a customized reporting tool. All patients discharged from ED with a discharged prescription within the study period were enrolled in this study. Results About 13.5% (n = 68) of the 504 prescriptions reviewed (for 504 patients) had at least one error. Main PEs encountered were wrong dose (23.2%), wrong frequency (20.7%), and wrong strength errors (14.6%). About 36.8% of identified PEs were related to pediatric prescriptions, followed by the acute care emergency unit (26.5%) and the triage emergency unit (20.6%). The main leading human-related causes associated with PEs were lack of knowledge (40.9%) followed by an improper selection from a computer operator list (31.8%). The leading contributing systems related factors were pre-printed medication orders (50%), lack of training (31.5%), noise level (13.0%), and frequent interruption of prescriber and distraction (11.1%). Prescribers' involved with the identified errors were resident physicians (39.4%), specialists (30.3%), and (24.4%) were made by general practitioners. Physicians rejected around 12% of the pharmacist-raised recommendations related to the identified PEs as per their clinical judgment. Conclusion PEs in ED setting are common, and multiple human and systems-related factors may contribute to the development of PEs. Further training to residents and proper communication between the healthcare professionals may reduce the risk of PEs in ED.	[Anzan, Mona; Alhawassi, Tariq M.] King Saud Univ Med City, Pharm Serv, Riyadh, Saudi Arabia; [Anzan, Mona; Alwhaibi, Monira; Almetwazi, Mansour; Alhawassi, Tariq M.] King Saud Univ, Dept Clin Pharm, Coll Pharm, Riyadh, Saudi Arabia; [Alwhaibi, Monira; Alhawassi, Tariq M.] King Saud Univ, Coll Pharm, Medicat Safety Res Chair, Riyadh, Saudi Arabia	King Saud University; King Saud University; King Saud University	Alhawassi, TM (corresponding author), King Saud Univ Med City, Pharm Serv, Riyadh, Saudi Arabia.; Alhawassi, TM (corresponding author), King Saud Univ, Dept Clin Pharm, Coll Pharm, Riyadh, Saudi Arabia.; Alhawassi, TM (corresponding author), King Saud Univ, Coll Pharm, Medicat Safety Res Chair, Riyadh, Saudi Arabia.	Tarriq@ksu.edu.sa		Alwhaibi, Monira/0000-0003-3707-0582	Vice Deanship of Research Chairs, King Saud University Riyadh, Saudi Arabia	Vice Deanship of Research Chairs, King Saud University Riyadh, Saudi Arabia	The project was fully supported financially by the Vice Deanship of Research Chairs, King Saud University Riyadh, Saudi Arabia.	Alanazi MQ, 2015, DRUG HEALTHC PATIENT, V7, P103, DOI 10.2147/DHPS.S83770; Alshaikh M, 2013, J PATIENT SAF, V9, P145, DOI 10.1097/PTS.0b013e3182845044; Alsulami Z, 2013, EUR J CLIN PHARMACOL, V69, P995, DOI 10.1007/s00228-012-1435-y; [Anonymous], 2015, NATL COORDINATING CO; Perez-Moreno MA, 2017, EMERG MED J, V34, P495, DOI 10.1136/emermed-2015-204726; Aronson JK, 2009, QJM-INT J MED, V102, P513, DOI 10.1093/qjmed/hcp052; Aronson JK, 2009, BRIT J CLIN PHARMACO, V67, P599, DOI 10.1111/j.1365-2125.2009.03415.x; Benjamin L, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-4066; Brown JN, 2008, AM J HEALTH-SYST PH, V65, P330, DOI 10.2146/ajhp070391; Choi I, 2016, RES SOC ADMIN PHARM, V12, P428, DOI 10.1016/j.sapharm.2015.08.006; Dabaghzadeh F, 2013, IRAN J PHARM RES, V12, P937; Farmer BM, 2018, J MED TOXICOL, V14, P114, DOI 10.1007/s13181-017-0634-4; Flynn EA, 2010, AM J HEALTH-SYST PH, V67, P347, DOI 10.2146/ajhp090623; Honey BL, 2015, J PATIENT SAF, V11, P100, DOI 10.1097/PTS.0000000000000048; Izadpanah Fatemeh, 2018, J Med Life, V11, P299, DOI 10.25122/jml-2018-0046; Khattab E, 2019, INT J EMERG MED, V12, DOI 10.1186/s12245-019-0232-0; Larose G, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-3200; Murray KA, 2017, BAYL U MED CTR P; Murray Kelly A, 2017, Proc (Bayl Univ Med Cent), V30, P143; National Coordinating Council for Medication Error Reporting and Prevention, TAX MED ERR; Patanwala AE, 2010, ANN EMERG MED, V55, P522, DOI 10.1016/j.annemergmed.2009.12.017; Poornima P, 2015, J YOUNG PHARM, V7, P241, DOI 10.5530/jyp.2015.3.15; Sanguansak T, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000539; Shaw KN, 2013, EMERG MED J, V30, P815, DOI 10.1136/emermed-2012-201642; Shitu Z, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-4921-4; Stang AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074214; Surgeons AAO, 2013, EMERGENCY CARE TRANS, DOI [10.1007/s00068-018-0992-x, DOI 10.1007/S00068-018-0992-X]; Thomas B, 2019, EUR J CLIN PHARMACOL, V75, P1269, DOI 10.1007/s00228-019-02689-y; Weant KA, 2014, OPEN ACCESS EMERG M, V6, P45, DOI 10.2147/OAEM.S64174; Wittich CM, 2014, MAYO CLIN PROC, V89, P1116, DOI 10.1016/j.mayocp.2014.05.007; World Health Organization, 2016, MED ERRORS	31	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2021	16	1							e0245321	10.1371/journal.pone.0245321	http://dx.doi.org/10.1371/journal.pone.0245321			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV4SP	33434202	Green Published, gold			2023-01-03	WOS:000609979700008
J	Takele, GM; Weldesenbet, NA; Girmay, N; Degefe, H; Kinfe, R				Molalign Takele, Goitom; Abreha Weldesenbet, Negash; Girmay, Nahom; Degefe, Habtamu; Kinfe, Rigbe			Assessment patient satisfaction towards emergency medical care and its determinants at Ayder comprehensive specialized hospital, Mekelle, Northern Ethiopia	PLOS ONE			English	Article								Background As the healthcare industry shifts toward patient-centered models, providers will need to fully understand patient satisfaction and how they affect their practices. This study aimed to assess patient satisfaction towards the emergency medical care and factors associated with at Ayder specialized comprehensive hospital, Emergency room, Mekelle, Ethiopia. Methods An institution-based cross-sectional study was conducted from March 1-30, 2019. A systematic random sampling method was used to enroll 299 study participants. Data were collected using a standard Brief Emergency Department Patient Satisfaction Scale questionnaire by trained data collectors. Data was entered into EpiData 3.1 then exported and analyzed by SPSS version 22. Binary and multiple logistic regression were used to assess the factors associated with patient satisfaction. Where the p-value of Results A total of 299 participants were enrolled in the study with a response rate of 99.3%. On overall patient satisfaction score majority (81.9%) of them were satisfied with the emergency medical care provided. The satisfaction rate towards emergency staff courtesy, emergency room environment, physician care satisfaction, general patient satisfaction, and patient family satisfaction was 80.3%, 37.5%, 75.9%, 70.9%, and 49.8% respectively. Those who arrived during the morning time of the day tend to be satisfied more with the emergency services (AOR = 4.8, 95% CI: 2.08, 11.4), while having low educational status (able to read and write) (AOR = 0.12, 95% CI: 0.03, 0.50) and waiting time till seen by a doctor (AOR = 1.3, 95% CI: 1.003, 1.4) was found to affect patient satisfaction negatively. Conclusions The total patient satisfaction score towards emergency medical care was found to be good. The hospital management and emergency room staff should act on the identified factors especially on minimizing the patients waiting time to improve the quality of care in the emergency department.	[Molalign Takele, Goitom; Abreha Weldesenbet, Negash] Mekelle Univ, Coll Hlth Sci, Sch Nursing, Dept Emergency & Crit Care Nursing, Mekelle, Ethiopia; [Girmay, Nahom; Degefe, Habtamu; Kinfe, Rigbe] Mekelle Univ, Ayder Comprehens Specialized Hosp, Coll Hlth Sci, Mekelle, Ethiopia	Mekelle University; Mekelle University	Takele, GM (corresponding author), Mekelle Univ, Coll Hlth Sci, Sch Nursing, Dept Emergency & Crit Care Nursing, Mekelle, Ethiopia.	goitommolalign49@gmail.com		molalign, goitom/0000-0002-9344-3390				Abolfotouh MA, 2017, EMERG MED J, V34, P27, DOI 10.1136/emermed-2015-204954; [Anonymous], 2014, AUST LIT STUD, V29, p[128, 33, 3]; [Anonymous], 2014, C ORG MISS U SCI TEC, V4, P2, DOI DOI 10.1109/TTHZ.2014.2308491; Assefa F, ASSESSMENT CLIENTS S, P101; Bjertnaes OA, 2012, BMJ QUAL SAF, V21, P39, DOI 10.1136/bmjqs-2011-000137; Brief Emergency Department Patient Satisfaction Scale (BEPSS), 2015, DEV NEW PRACT INSTR, V3, P103; Chandra S, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00183; Fontova-Almato A, 2019, NURS OPEN, V6, P834, DOI 10.1002/nop2.261; Ganey P, 2009, EMERGENCY DEP PULSE; de la Orden SG, 2011, EMERG MED J, V28, P770, DOI 10.1136/emj.2009.084996; Hornsby ASCJ, 2019, OXFORD ADV LEARNER D; Mattsson MS, 2013, SCAND J TRAUMA RE S2, V21, P2013; Mercer MP, 2014, J EMERG MED, V46, P711, DOI 10.1016/j.jemermed.2013.08.036; Messina G, 2014, FACTORS AFFECTING PA, DOI [10.5539/gjhs.v7n4p30, DOI 10.5539/GJHS.V7N4P30]; Paul A., 2015, ELECT J MATH ANAL AP, V3, P179; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Soleimanpour H, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-8; Sorup CM, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-62; Taye BW, 2014, BMC EMERG MED, V14, DOI 10.1186/1471-227X-14-2; Worku M, 2017, ASSESSMENT CLIENT SA, P1; Zohrevandi B, 2014, EMERGENCY, V2, P162; Zrenner E, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.7.3; 2013, CLIN MED INSIGHTS GA, V6, P1	23	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2021	16	1							e0243764	10.1371/journal.pone.0243764	http://dx.doi.org/10.1371/journal.pone.0243764			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PS6NW	33411806	gold, Green Published			2023-01-03	WOS:000608044300037
J	Pearson, SD; Patel, BK				Pearson, Steven D.; Patel, Bhakti K.			Inpatient Notes: Corticosteroids and COVID-19-Calming the Storm?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Pearson, Steven D.; Patel, Bhakti K.] Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Pearson, SD (corresponding author), Univ Chicago, Pulm & Crit Care Med Sect, Dept Med, 5841 South Maryland Ave,MC 6076, Chicago, IL 60637 USA.	steven.pearson@uchospitals.edu		Pearson, Steven/0000-0003-4384-5874				Alhazzani Waleed, 2020, Crit Care Med, V48, pe440, DOI [10.1007/s00134-020-06022-5, 10.1097/CCM.0000000000004363]; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN	2021	174	1					HO2	HO3		10.7326/M20-7671	http://dx.doi.org/10.7326/M20-7671			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ1XX	33460551	Green Accepted			2023-01-03	WOS:000619485200001
J	Rourke, EJ				Rourke, Elizabeth J.			Whiteout	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Two New England blizzards, two patients dying alone, and one resident desperate to bring their loved ones safely to their side for a final goodbye. Could one patient's "good" death undo the harm of the other patient's "bad" death?	[Rourke, Elizabeth J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Rourke, Elizabeth J.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rourke, EJ (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.; Rourke, EJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2020	383	27					2600	2601		10.1056/NEJMp2031266	http://dx.doi.org/10.1056/NEJMp2031266			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP1SJ	33369364				2023-01-03	WOS:000605648000009
J	Bonfim, AP; Sakita, KM; Faria, DR; Arita, GS; Vendramini, FAVR; Capoci, IRG; Braga, AG; dos Santos, RS; Bruschi, ML; Becker, TCA; de Oliveira, AG; Kioshima, ES; Bonfim-Mendonca, PD; Svidzinski, TIE				Bonfim, Amanda Pohlmann; Sakita, Karina Mayumi; Faria, Daniella Renata; Arita, Glaucia Sayuri; Vilugron Rodrigues Vendramini, Franciele Abigail; Grenier Capoci, Isis Regina; Braga, Andressa Gimenes; dos Santos, Rafaela Said; Bruschi, Marcos Luciano; Alexandrino Becker, Tania Cristina; de Oliveira Junior, Admilton Goncalves; Kioshima, Erika Seki; Bonfim-Mendonca, Patricia de Souza; Estivalet Svidzinski, Terezinha Inez			Preclinical approaches in vulvovaginal candidiasis treatment with mucoadhesive thermoresponsive systems containing propolis	PLOS ONE			English	Article							ALBICANS; PREVALENCE; RESISTANCE; PLATFORMS; EFFICACY; NITRATE	Vulvovaginal candidiasis (VVC) is a common vaginitis that affects women, especially in childbearing age, caused by Candida albicans in almost 80% of cases. Considering the limited drug arsenal available and the increasing fungal resistance profile, the search for new therapeutic sources with low toxicity and easy administration should be supported. Propolis has been used as a traditional medicine for multiple diseases, considering its particular composition and pharmaceutical properties that permits its wide applicability; it has also emerged as a potential antifungal agent. Thus, this study performed an in vitro and in vivo investigation into the efficacy of a new mucoadhesive thermoresponsive platform for propolis delivery (MTS-PRPe) in a preclinical murine model of VVC treatment caused by C. albicans. The methodologies involved chemical analysis, an assessment of the rheological and mucoadhesive properties of propolis formulations, in vitro and in vivo antifungal evaluations, histological evaluations and electron microscopy of the vaginal mucosa. The results demonstrated the antifungal activity of propolis extract and MTS-PRP against the standard strain and a fluconazole-resistant clinical isolate of C. albicans, in both in vitro and in vivo assays. These results were similar and even better, depending on the propolis concentration, when compared to nystatin. Thus, the formulation containing propolis exhibited good performance against C. albicans in a vulvovaginal candidiasis experimental model, representing a promising opportunity for the treatment of this infection.	[Bonfim, Amanda Pohlmann; Sakita, Karina Mayumi; Faria, Daniella Renata; Arita, Glaucia Sayuri; Vilugron Rodrigues Vendramini, Franciele Abigail; Grenier Capoci, Isis Regina; Braga, Andressa Gimenes; Kioshima, Erika Seki; Bonfim-Mendonca, Patricia de Souza; Estivalet Svidzinski, Terezinha Inez] Univ Estadual Maringa, Clin Anal & Biomed Dept, Med Mycol Lab, Maringa, Parana, Brazil; [dos Santos, Rafaela Said; Bruschi, Marcos Luciano] Univ Estadual Maringa, Dept Pharm, Maringa, Parana, Brazil; [Alexandrino Becker, Tania Cristina] Univ Estadual Maringa, Hlth Basic Sci Dept, Gen Pathol Lab, Maringa, Parana, Brazil; [de Oliveira Junior, Admilton Goncalves] Univ Estadual Londrina, Electron Microscopy & Microanal Lab, Londrina, Parana, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Maringa; Universidade Estadual de Londrina	Svidzinski, TIE (corresponding author), Univ Estadual Maringa, Clin Anal & Biomed Dept, Med Mycol Lab, Maringa, Parana, Brazil.	tiesvidzinski@uem.br	Bruschi, Marcos Luciano/J-1871-2012	Bruschi, Marcos Luciano/0000-0002-4838-5742; Sakita, Karina/0000-0003-2899-2657; Arita, Glaucia Sayuri/0000-0002-0334-7566	Laboratory of Medical Mycology and Laboratory of Research and Development of Drug Delivery Systems of Universidade Estadual de Maringa	Laboratory of Medical Mycology and Laboratory of Research and Development of Drug Delivery Systems of Universidade Estadual de Maringa	This study was supported by efforts from the Laboratory of Medical Mycology and Laboratory of Research and Development of Drug Delivery Systems of Universidade Estadual de Maringa, with own resources.	Andrews GP, 2009, EUR J PHARM BIOPHARM, V71, P505, DOI 10.1016/j.ejpb.2008.09.028; [Anonymous], 2015, AM J KIDNEY DIS, V66, pS79; [Anonymous], 2015, US PHARM CONV; Berretta AA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/641480; Bruschi ML, 2007, J PHARM SCI-US, V96, P2074, DOI 10.1002/jps.20843; Bruschi Marcos Luciano, 2006, Rev. Bras. Cienc. Farm., V42, P29, DOI 10.1590/S1516-93322006000100004; Carvalho FC, 2013, DRUG DEV IND PHARM, V39, P1750, DOI 10.3109/03639045.2012.734510; Choi HG, 1999, INT J PHARM, V190, P13, DOI 10.1016/S0378-5173(99)00225-2; Clinical and Laboratory Standards Institute, 2008, M38A2 CLSI; Clinical and Laboratory Standards Institute`, 2008, REF METH BROTH DIL A; Dalben-Dota KF, 2010, J ALTERN COMPLEM MED, V16, P285, DOI 10.1089/acm.2009.0281; Pereira RRD, 2013, J PHARM SCI-US, V102, P1222, DOI 10.1002/jps.23451; de Oliveira AG, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00113; Ferreira SBD, 2016, J MECH BEHAV BIOMED, V55, P164, DOI 10.1016/j.jmbbm.2015.10.026; Fan SR, 2015, GYNECOL OBSTET INVES, V80, P113, DOI 10.1159/000371759; Fatahinia M, 2012, J MYCOL MED, V22, P237, DOI 10.1016/j.mycmed.2012.05.004; Fidel PL, 1997, ANTIMICROB AGENTS CH, V41, P1455, DOI 10.1128/AAC.41.7.1455; Foxman B, 2013, J LOW GENIT TRACT DI, V17, P340, DOI 10.1097/LGT.0b013e318273e8cf; Capoci IRG, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/287693; Guinea J, 2014, CLIN MICROBIOL INFEC, V20, P5, DOI 10.1111/1469-0691.12539; HEMPHILL T, 1993, OIL GAS J, V91, P45; Hiller E, 2011, INT J MED MICROBIOL, V301, P384, DOI 10.1016/j.ijmm.2011.04.004; Hosnuter M, 2004, BURNS, V30, P121, DOI 10.1016/j.burns.2003.09.022; HUPPERT M, 1978, J CLIN MICROBIOL, V8, P598; Ilkit M, 2011, CRIT REV MICROBIOL, V37, P250, DOI 10.3109/1040841X.2011.576332; Institute of Laboratory Animal Resources (US). Committee on Care Use of Laboratory Animals & National Institutes of Health (US). Division of Research Resources., 1985, GUIDE CARE USE LAB A; Jastrzebska-Stojko Z, 2013, MOLECULES, V18, P14397, DOI 10.3390/molecules181114397; Jones DS, 2009, INT J PHARMACEUT, V372, P49, DOI 10.1016/j.ijpharm.2009.01.006; Khosravi A R, 2014, J Mycol Med, V24, pe143, DOI 10.1016/j.mycmed.2014.05.002; Marchaim D, 2012, OBSTET GYNECOL, V120, P1407, DOI [10.1097/AOG.0b013e31827307b2, http://10.1097/AOG.0b013e31827307b2]; Naglik JR, 2003, MICROBIOL MOL BIOL R, V67, P400, DOI 10.1128/MMBR.67.3.400-428.2003; Nash EE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147969; Olczyk P, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/290675; Oryan A, 2018, BIOMED PHARMACOTHER, V98, P469, DOI 10.1016/j.biopha.2017.12.069; Perea S, 2001, ANTIMICROB AGENTS CH, V45, P2676, DOI 10.1128/AAC.45.10.2676-2684.2001; Pfaller MA, 2004, J CLIN MICROBIOL, V42, P4419, DOI 10.1128/JCM.42.10.4419-4431.2004; Rocha BA, 2012, J THERM ANAL CALORIM, V108, P87, DOI 10.1007/s10973-011-1713-4; Sobel JD, 2014, PATIENT PREFER ADHER, V8, P31, DOI 10.2147/PPA.S38984; Swiss Re Report, 2018, SIGMA, V3148; Tobaldini-Valerio FK, 2016, FUTURE MICROBIOL, V11, P1035, DOI 10.2217/fmb-2015-0016; Pessolato AGT, 2011, BURNS, V37, P1192, DOI 10.1016/j.burns.2011.05.016; Veiga FF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00779; Volpi N, 2006, J PHARMACEUT BIOMED, V42, P354, DOI 10.1016/j.jpba.2006.04.017; Xuan HZ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/280120; Yano J, 2011, JOVE-J VIS EXP, DOI 10.3791/3382	45	6	6	3	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2020	15	12							e0243197	10.1371/journal.pone.0243197	http://dx.doi.org/10.1371/journal.pone.0243197			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH0WM	33306677	Green Published, gold			2023-01-03	WOS:000600144200030
J	Hamm-Faber, TE; Engels, Y; Vissers, KCP; Henssen, DJHA				Hamm-Faber, Tanja E.; Engels, Yvonne; Vissers, Kris C. P.; Henssen, Dylan J. H. A.			Views of patients suffering from Failed Back Surgery Syndrome on their health and their ability to adapt to daily life and self-management: A qualitative exploration	PLOS ONE			English	Article							SPINAL-CORD STIMULATION; CHRONIC PAIN; ACCEPTANCE; EXPERIENCES; MULTICENTER; NEEDS	Background The clinical outcomes of Spinal Cord Stimulation (SCS) therapy in patients with a Failed Back Surgery Syndrome (FBSS) is mostly done by standardized pain and quality of life measurements instruments and hardly account for personal feelings and needs as a basis for a patient-centred approach and shared decision making. Objectives The objective of this study is to explore perspectives on personal health and quality of life (QoL) in FBSS patients concerning their physical-, psychological and spiritual well-being prior to receiving an SCS system. Methods We performed face-to-face, semi-structured, in-depth interviews to obtain descriptive and detailed data on personal health, guided by the Web diagram of Positive Health (Huber et al.) and a topic list. The following main topics were assessed qualitatively: 1) Bodily functioning, 2) Mental function and perception 3) Spiritual dimension, 4) Quality of life, 5) Social and societal participation and 6) Daily functioning. Results Seventeen FBSS patients (eight male, nine female) were included from April-November 2019 at the department of pain medicine in the Albert Schweitzer Hospital in the Netherlands. Median age 49 years; range 28 to 67 years, and patients underwent between one and five lumbar surgical operations. The duration of their chronic pain was between four and 22 years. After analyzing the interviews, three themes emerged: 1) dealing with chronic pain, 2) the current situation regarding aspects of positive health, and 3) future perspectives on health and quality of life. These themes arose from eleven categories and a hundred ninety codes. Conclusion This qualitative study explored FBSS patients 'views on their health and the ability to adapt to daily life having complex chronic pain, and showed that patients experienced shortcomings in daily life within the six dimensions of the Web diagram of Positive Health before the SCS implant.	[Hamm-Faber, Tanja E.] Albert Schweitzer Hosp, Dept Pain Med, Zwijndrecht, Netherlands; [Engels, Yvonne; Vissers, Kris C. P.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, Nijmegen, Netherlands; [Henssen, Dylan J. H. A.] Radboud Univ Nijmegen, Med Ctr, Dept Med Imaging, Nijmegen, Netherlands	Albert Schweitzer Ziekenhuis; Radboud University Nijmegen; Radboud University Nijmegen	Hamm-Faber, TE (corresponding author), Albert Schweitzer Hosp, Dept Pain Med, Zwijndrecht, Netherlands.	tefaber01@gmail.com	Hamm-Faber, Tanja/A-5171-2019; Vissers, Kris/D-3569-2009	Henssen, Dylan/0000-0002-3915-3034; Vissers, Kris/0000-0002-2919-6356				[Anonymous], 2017, PALLIATIVE MED, DOI DOI 10.1177/0269216316676648; [Anonymous], 2006, HUMANITAS, V58, P481; Boutevillain L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179826; Bussing A, 2009, PAIN MED, V10, P327, DOI 10.1111/j.1526-4637.2009.00572.x; Bunzli S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008847; Cheatle MD, 2016, SLEEP MED CLIN, V11, P531, DOI 10.1016/j.jsmc.2016.08.004; Damsgard E, 2011, SCAND J CARING SCI, V25, P108, DOI 10.1111/j.1471-6712.2010.00798.x; de Boer MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087445; de Heer EW, 2018, PAIN, V159, P712, DOI 10.1097/j.pain.0000000000001133; Doleys Daniel M, 2006, Neurosurg Focus, V21, pE1; Duenas M, 2020, PAIN PRACT, V20, P179, DOI 10.1111/papr.12842; Eldabe S, 2010, NEUROMODULATION, V13, P201, DOI 10.1111/j.1525-1403.2009.00271.x; Epstein RM, 2010, HEALTH AFFAIR, V29, P1489, DOI 10.1377/hlthaff.2009.0888; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Goudman L, 2020, PAIN PRACT, V20, P247, DOI 10.1111/papr.12845; Henssen DJHA, 2018, PAIN PRACT, V18, P452, DOI 10.1111/papr.12617; Huber M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010091; Huber M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4163; Iddon JE, 2019, BRIT J PAIN, V13, P230, DOI 10.1177/2049463718824857; Kumar K, 2005, NEUROMODULATION, V8, P213, DOI 10.1111/j.1525-1403.2005.00027.x; McCracken LM, 2010, EUR J PAIN, V14, P170, DOI 10.1016/j.ejpain.2009.03.004; McCracken LM, 1998, PAIN, V74, P21, DOI 10.1016/S0304-3959(97)00146-2; North RB, 2011, NEUROMODULATION, V14, P330, DOI 10.1111/j.1525-1403.2011.00371.x; Pope JE, 2019, NEUROMODULATION, V22, P119, DOI 10.1111/ner.12907; Ryan CG, 2019, NEUROMODULATION, V22, P295, DOI 10.1111/ner.12885; Saunders S, 2018, DISABIL REHABIL, V40, P2144, DOI 10.1080/09638288.2017.1327986; Sparkes E, 2012, CHRONIC ILLN, V8, P239, DOI 10.1177/1742395311433132; Tang NKY, 2007, J SLEEP RES, V16, P85, DOI 10.1111/j.1365-2869.2007.00571.x; Turk DC, 2008, PAIN, V137, P276, DOI 10.1016/j.pain.2007.09.002; Viane I, 2003, PAIN, V106, P65, DOI 10.1016/S0304-3959(03)00291-4	30	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2020	15	12							e0243329	10.1371/journal.pone.0243329	http://dx.doi.org/10.1371/journal.pone.0243329			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PD8LW	33284851	Green Published, gold			2023-01-03	WOS:000597930500040
J	Cloutier, MM; Dixon, AE; Krishnan, JA; Lemanske, RF; Pace, W; Schatz, M				Cloutier, Michelle M.; Dixon, Anne E.; Krishnan, Jerry A.; Lemanske, Robert F., Jr.; Pace, Wilson; Schatz, Michael			Managing Asthma in Adolescents and Adults 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EXHALED NITRIC-OXIDE; HEALTH WORKER INTERVENTION; MODERATE PERSISTENT ASTHMA; MILD-TO-MODERATE; DOUBLE-BLIND; SUBLINGUAL IMMUNOTHERAPY; RELIEVER THERAPY; BUDESONIDE/FORMOTEROL MAINTENANCE; DERMATOPHAGOIDES-PTERONYSSINUS; ENVIRONMENTAL INTERVENTION	This guideline summarizes updated recommendations for management of asthma in adolescents and adults, focusing on evidence for use of inhaled corticosteroids (ICSs), add-on long-acting muscarinic antagonists (LAMAs), fractional exhaled nitric oxide (FeNO) testing, indoor allergen mitigation, immunotherapy, and evidence against use of bronchial thermoplasty. Importance Asthma is a major public health problem worldwide and is associated with excess morbidity, mortality, and economic costs associated with lost productivity. The National Asthma Education and Prevention Program has released the 2020 Asthma Guideline Update with updated evidence-based recommendations for treatment of patients with asthma. Objective To report updated recommendations for 6 topics for clinical management of adolescents and adults with asthma: (1) intermittent inhaled corticosteroids (ICSs); (2) add-on long-acting muscarinic antagonists; (3) fractional exhaled nitric oxide; (4) indoor allergen mitigation; (5) immunotherapy; and (6) bronchial thermoplasty. Evidence Review The National Heart, Lung, and Blood Advisory Council chose 6 topics to update the 2007 asthma guidelines based on results from a 2014 needs assessment. The Agency for Healthcare Research and Quality conducted systematic reviews of these 6 topics based on literature searches up to March-April 2017. Reviews were updated through October 2018 and used by an expert panel (n = 19) that included asthma content experts, primary care clinicians, dissemination and implementation experts, and health policy experts to develop 19 new recommendations using the GRADE method. The 17 recommendations for individuals aged 12 years or older are reported in this Special Communication. Findings From 20 572 identified references, 475 were included in the 6 systematic reviews to form the evidence basis for these recommendations. Compared with the 2007 guideline, there was no recommended change in step 1 (intermittent asthma) therapy (as-needed short-acting beta(2)-agonists [SABAs] for rescue therapy). In step 2 (mild persistent asthma), either daily low-dose ICS plus as-needed SABA therapy or as-needed concomitant ICS and SABA therapy are recommended. Formoterol in combination with an ICS in a single inhaler (single maintenance and reliever therapy) is recommended as the preferred therapy for moderate persistent asthma in step 3 (low-dose ICS-formoterol therapy) and step 4 (medium-dose ICS-formoterol therapy) for both daily and as-needed therapy. A short-term increase in the ICS dose alone for worsening of asthma symptoms is not recommended. Add-on long-acting muscarinic antagonists are recommended in individuals whose asthma is not controlled by ICS-formoterol therapy for step 5 (moderate-severe persistent asthma). Fractional exhaled nitric oxide testing is recommended to assist in diagnosis and monitoring of symptoms, but not alone to diagnose or monitor asthma. Allergen mitigation is recommended only in individuals with exposure and relevant sensitivity or symptoms. When used, allergen mitigation should be allergen specific and include multiple allergen-specific mitigation strategies. Subcutaneous immunotherapy is recommended as an adjunct to standard pharmacotherapy for individuals with symptoms and sensitization to specific allergens. Sublingual immunotherapy is not recommended specifically for asthma. Bronchial thermoplasty is not recommended as part of standard care; if used, it should be part of an ongoing research effort. Conclusions and Relevance Asthma is a common disease with substantial human and economic costs globally. Although there is no cure or established means of prevention, effective treatment is available. Use of the recommendations in the 2020 Asthma Guideline Update should improve the health of individuals with asthma.	[Cloutier, Michelle M.] UCONN Hlth, Farmington, CT USA; [Dixon, Anne E.] Univ Vermont, Burlington, VT 05405 USA; [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Pace, Wilson] Univ Colorado, Sch Med, Aurora, CO USA; [Schatz, Michael] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA	University of Vermont; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; Kaiser Permanente	Cloutier, MM (corresponding author), UCONN Hlth, Dept Pediat, 263 Farmington Ave, Farmington, CT 06030 USA.; Cloutier, MM (corresponding author), UCONN Hlth, Dept Med, 263 Farmington Ave, Farmington, CT 06030 USA.	cloutier@uchc.edu			NHLBI of the National Institutes of Health	NHLBI of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The 2020 Asthma Guideline Update report was funded by the NHLBI of the National Institutes of Health.	Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; Atienza T, 2013, RESPIROLOGY, V18, P354, DOI 10.1111/resp.12009; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Broek J, GRADEPRO GUIDELINE D; Bryant-Stephens T, 2009, AM J PUBLIC HEALTH, V99, pS657, DOI [DOI 10.2105/AJPH.2009.165423, 10.2105/AJPH.2009.165423]; Bryant-Stephens T, 2008, J NATL MED ASSOC, V100, P306, DOI 10.1016/S0027-9684(15)31243-8; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Camargos P, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0192-0; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; D'Anci KE, 2017, COMP EFFECTIVENESS R; de Blay F, 2014, RESP MED, V108, P1430, DOI 10.1016/j.rmed.2014.07.017; Devillier P, 2016, ALLERGY, V71, P249, DOI 10.1111/all.12791; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Expert Panel Working Group of the National Heart Lung and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), 2020, J ALLERGY CLIN IMMUN, V146, P1217; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Garcia-Robaina JC, 2006, J ALLERGY CLIN IMMUN, V118, P1026, DOI 10.1016/j.jaci.2006.07.043; Global Asthma Network, GLOB ASTHM REP 2018; Gomez Vera J, 2005, Rev Alerg Mex, V52, P231; Graham R, 2011, CLINICAL PRACTICE GUIDELINES WE CAN TRUST, P1; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hamelmann E, 2016, J ALLERGY CLIN IMMUN, V138, P441, DOI 10.1016/j.jaci.2016.01.011; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Honkoop PJ, 2015, J ALLERGY CLIN IMMUN, V135, P682, DOI 10.1016/j.jaci.2014.07.016; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kilic M, 2011, TURKISH J PEDIATR, V53, P285; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Lahdensuo A, 1996, BRIT MED J, V312, P748; Leas BF, 2018, COMP EFFECTIVENESS R; Lee LA, 2015, RESP MED, V109, P54, DOI 10.1016/j.rmed.2014.09.012; Lee YJ, 2018, IOP C SER EARTH ENV, V191, DOI 10.1088/1755-1315/191/1/012132; Lozano J, 2014, INT ARCH ALLERGY IMM, V165, P140, DOI 10.1159/000368832; Marogna M, 2013, ALLERGOL IMMUNOPATH, V41, P216, DOI 10.1016/j.aller.2012.07.004; Marogna M, 2010, J INVEST ALLERG CLIN, V20, P146; Marogna M, 2009, ANN ALLERG ASTHMA IM, V102, P69, DOI 10.1016/S1081-1206(10)60111-1; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; McKeever T, 2018, NEW ENGL J MED, V378, P902, DOI 10.1056/NEJMoa1714257; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; National Heart Lung and Blood Advisory Council Asthma Expert Working Group., 2014, DRAFT NEEDS ASS REP; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Ohta K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124109; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Paggiaro P, 2016, J ALLER CL IMM-PRACT, V4, P104, DOI 10.1016/j.jaip.2015.08.017; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Papi A, 2013, LANCET RESP MED, V1, P23, DOI 10.1016/S2213-2600(13)70012-2; Parker EA, 2008, HEALTH EDUC BEHAV, V35, P376, DOI 10.1177/1090198106290622; Patel M, 2013, LANCET RESP MED, V1, P32, DOI 10.1016/S2213-2600(13)70007-9; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Pike K, 2013, CLIN RESPIR J, V7, P204, DOI 10.1111/j.1752-699X.2012.00306.x; Qaseem A, 2019, ANN INTERN MED, V171, P354, DOI 10.7326/M18-3279; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rajanandh MG, 2014, CLIN THER, V36, P526, DOI 10.1016/j.clinthera.2014.02.006; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Sobieraj DM., 2018, COMP EFFECTIVENESS R, V194; Syk J, 2013, J ALLER CL IMM-PRACT, V1, P639, DOI 10.1016/j.jaip.2013.07.013; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8; Tripple JW, 2020, JAMA-J AM MED ASSOC, V323, P561, DOI 10.1001/jama.2019.19986; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; Wang Z, 2017, COMP EFFECTIVENESS R; Wechsler ME, 2015, JAMA-J AM MED ASSOC, V314, P1720, DOI 10.1001/jama.2015.13277; Wechsler ME, 2013, J ALLERGY CLIN IMMUN, V132, P1295, DOI 10.1016/j.jaci.2013.08.009	77	52	56	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2020	324	22					2301	2317		10.1001/jama.2020.21974	http://dx.doi.org/10.1001/jama.2020.21974		DEC 2020	17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD9VK	33270095				2023-01-03	WOS:000595484200001
J	Jung, SK; Park, YH; Shin, DH; Kim, HS; Jung, JH; Kim, TH; Moon, SH				Jung, Su-Kyung; Park, Young-Hoon; Shin, Dong-ho; Kim, Hak-Soo; Jung, Jong-Hwi; Kim, Tae-Hyun; Moon, Sung Ho			Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea	PLOS ONE			English	Article							UVEAL MELANOMA; OCULAR MELANOMA; RISK-FACTORS; RADIOTHERAPY; ACUITY; BRACHYTHERAPY; IRRADIATION; MANAGEMENT; PROGNOSIS; SURVIVAL	We evaluate the ocular effects of proton beam therapy (PBT) in a single institution, in Korea, and identify factors contributing to decreasing visual acuity (VA) after PBT. A total of 40 patients who received PBT for choroidal melanoma (20092016) were reviewed. Dose fractionation was 6070 cobalt gray equivalents (CGEs) over five fractions. Complete ophthalmic examinations including funduscopy and ultrasonography were performed at baseline and at 3, 6, and 12 months after PBT, then annually thereafter. Only patients with at least 12 months follow-up were included. During the follow-up, consecutive best-corrected visual acuity (BCVA) changes were determined, and univariate and multivariate logistic regression analyses were performed to identify predictors for VA loss. The median follow-up duration was 32 months (range: 1282 months). The final BCVA of nine patients was > 20/40. The main cause of vision loss was intraocular bleeding, such as neovascular glaucoma or retinal hemorrhage. Vision loss was correlated with the tumor size, tumor distance to the optic disc or fovea, maculae receiving 30 CGEs, optic discs receiving 30 CGEs, and retinas receiving 30 CGEs. Approximately one-third of PBT-treated choroidal melanoma patients with good pretreatment BCVA maintained their VA. The patients who finally lost vision (VA < count fingers) usually experienced rapid declines in VA from 612 months after PBT. Tumor size, tumor distance to the optic disc or fovea, volume of the macula, and optic discs or retinas receiving 30 CGEs affected the final VA.	[Jung, Su-Kyung] Natl Canc Ctr, Dept Ophthalmol, Gyeonggi Do, South Korea; [Park, Young-Hoon] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea; [Shin, Dong-ho; Kim, Hak-Soo; Jung, Jong-Hwi; Kim, Tae-Hyun; Moon, Sung Ho] Natl Canc Ctr, Res Inst & Hosp, Proton Therapy Ctr, Gyeonggi Do, South Korea	National Cancer Center - Korea (NCC); Catholic University of Korea; Seoul St. Mary's Hospital; National Cancer Center - Korea (NCC)	Moon, SH (corresponding author), Natl Canc Ctr, Res Inst & Hosp, Proton Therapy Ctr, Gyeonggi Do, South Korea.	shmoon@ncc.re.kr		Kim, Tae Hyun/0000-0001-8413-3385	National Cancer Center, Republic of Korea [1811050]	National Cancer Center, Republic of Korea	This work was supported by the research grant (No. 1811050) from the National Cancer Center, Republic of Korea.	Collaborative Ocular Melanoma Study Group, 2001, OPHTHALMOLOGY, V108, P348, DOI [10.1016/S0161-6420(00)00526-1, DOI 10.1016/S0161-6420(00)00526-1]; Daftari IK, 1997, INT J RADIAT ONCOL, V39, P997, DOI 10.1016/S0360-3016(97)00557-9; Dalvin LA, 2020, BRIT J OPHTHALMOL, V104, P697, DOI 10.1136/bjophthalmol-2019-314686; Damato B, 2005, INT J RADIAT ONCOL, V63, P392, DOI 10.1016/j.ijrobp.2005.02.059; Diener-West M, 2004, J CLIN ONCOL, V22, P2438, DOI 10.1200/jco.2004.08.194; DRZYMALA RE, 1991, INT J RADIAT ONCOL, V21, P71, DOI 10.1016/0360-3016(91)90168-4; Egger E, 2001, INT J RADIAT ONCOL, V51, P138, DOI 10.1016/S0360-3016(01)01560-7; Gragoudas E, 2002, ARCH OPHTHALMOL-CHIC, V120, P1665; Kim TW, 2018, CANCER RES TREAT, V50, P335, DOI 10.4143/crt.2017.070; KUO P K, 1982, International Ophthalmology Clinics, V22, P57, DOI 10.1097/00004397-198202230-00007; Kwon HJ, 2013, BRIT J OPHTHALMOL, V97, P653, DOI 10.1136/bjophthalmol-2012-302584; Meeralakshmi P, 2017, SOUTH ASIAN J CANCER, V6, P134, DOI 10.4103/sajc.sajc_160_16; Mishra KK, 2013, INT J RADIAT ONCOL, V87, P330, DOI 10.1016/j.ijrobp.2013.05.051; Park SJ, 2015, INVEST OPHTH VIS SCI, V56, P4719, DOI 10.1167/iovs.15-16532; Patel AV, 2016, OPHTHALMOLOGY, V123, P369, DOI 10.1016/j.ophtha.2015.09.031; Polishchuk AL, 2017, INT J RADIAT ONCOL, V97, P91, DOI 10.1016/j.ijrobp.2016.09.019; Rodrigues G, 2004, RADIOTHER ONCOL, V71, P127, DOI 10.1016/j.radonc.2004.02.015; SEDDON JM, 1987, OPHTHALMOLOGY, V94, P354; SEDDON JM, 1986, OPHTHALMOLOGY, V93, P666; Seibel I, 2016, GRAEF ARCH CLIN EXP, V254, P1787, DOI 10.1007/s00417-016-3429-4; Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1219; Shields JA, 2015, OPHTHALMOLOGY, V122, P414, DOI 10.1016/j.ophtha.2014.08.046; Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040; Thariat J, 2016, INT J RADIAT ONCOL, V95, P328, DOI 10.1016/j.ijrobp.2015.12.011; Toutee A, 2019, CANCERS, V11, DOI 10.3390/cancers11081047; Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032; Wisely CE, 2016, BRACHYTHERAPY, V15, P12, DOI 10.1016/j.brachy.2015.09.013; Wong W, 2019, SINGAP MED J, V60, P474, DOI 10.11622/smedj.2019054; Yue H, 2017, CURR EYE RES, V42, P759, DOI 10.1080/02713683.2016.1245422	29	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2020	15	12							e0242966	10.1371/journal.pone.0242966	http://dx.doi.org/10.1371/journal.pone.0242966			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB8MS	33264363	gold, Green Published			2023-01-03	WOS:000596569200071
J	Coathup, V; Boyle, E; Carson, C; Johnson, S; Kurinzcuk, JJ; Macfarlane, A; Petrou, S; Rivero-Arias, O; Quigley, MA				Coathup, Victoria; Boyle, Elaine; Carson, Claire; Johnson, Samantha; Kurinzcuk, Jennifer J.; Macfarlane, Alison; Petrou, Stavros; Rivero-Arias, Oliver; Quigley, Maria A.			Gestational age and hospital admissions during childhood: population based, record linkage study in England (TIGAR study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRETERM BIRTH; ASSOCIATION; OUTCOMES; HEALTH; RISK	OBJECTIVE To examine the association between gestational age at birth and hospital admissions to age 10 years and how admission rates change throughout childhood. DESIGN Population based, record linkage, cohort study in England. SETTING NHS hospitals in England, United Kingdom. PARTICIPANTS 1 018 136 live, singleton births in NHS hospitals in England between January 2005 and December 2006. MAIN OUTCOME MEASURES Primary outcome was all inpatient hospital admissions from birth to age 10, death, or study end (March 2015); secondary outcome was the main cause of admission, which was defined as the World Health Organization's first international classification of diseases, version 10 (ICD-10) code within each hospital admission record. RESULTS 1 315 338 admissions occurred between 1 January 2005 and 31 March 2015, and 831 729 (63%) were emergency admissions. 525 039 (52%) of 1 018 136 children were admitted to hospital at least once during the study period. Hospital admissions during childhood were strongly associated with gestational age at birth (<28, 28-29, 30-31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, and 42 weeks). In comparison with children born at full term (40 weeks' gestation), those born extremely preterm (<28 weeks) had the highest rate of hospital admission throughout childhood (adjusted rate ratio 4.92, 95% confidence interval 4.58 to 5.30). Even children born at 38 weeks had a higher rate of hospital admission throughout childhood (1.19, 1.16 to 1.22). The association between gestational age and hospital admission decreased with increasing age (interaction P<0.001). Children born earlier than 28 weeks had an adjusted rate ratio of 6.34 (95% confidence interval 5.80 to 6.85) at age less than 1 year, declining to 3.28 (2.82 to 3.82) at ages 7-10, in comparison with those born full term; whereas in children born at 38 weeks, the adjusted rate ratios were 1.29 (1.27 to 1.31) and 1.16 (1.13 to 1.19), during infancy and ages 7-10, respectively. Infection was the main cause of excess hospital admissions at all ages, but particularly during infancy. Respiratory and gastrointestinal conditions also accounted for a large proportion of admissions during the first two years of life. CONCLUSIONS The association between gestational age and hospital admission rates decreased with age, but an excess risk remained throughout childhood, even among children born at 38 and 39 weeks of gestation. Strategies aimed at the prevention and management of childhood infections should target children born preterm and those born a few weeks early.	[Coathup, Victoria; Carson, Claire; Kurinzcuk, Jennifer J.; Rivero-Arias, Oliver; Quigley, Maria A.] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Old Rd Campus, Oxford OX3 7FL, England; [Boyle, Elaine; Johnson, Samantha] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Macfarlane, Alison] City Univ London, Dept Hlth Sci, London, England; [Petrou, Stavros] Univ Oxford, Nuffield Dept Primary Care Hlth, Oxford, England	University of Oxford; University of Leicester; City University London; University of Oxford	Coathup, V (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Old Rd Campus, Oxford OX3 7FL, England.	victoria.coathup@npeu.ox.ac.uk	Petrou, Stavros/ABD-8323-2021; Boyle, Elaine/I-6298-2018	Petrou, Stavros/0000-0003-3121-6050; Rivero-Arias, Oliver/0000-0003-2233-6544; Boyle, Elaine/0000-0002-5038-3148; Quigley, Maria/0000-0002-8058-6181	MRC [MR/M01228X/1]	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The TIGAR study was funded by a research grant from the MRC (MR/M01228X/1). The funder had no role in the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.	Almqvist C, 2020, CLIN EXP ALLERGY, V50, P222, DOI 10.1111/cea.13542; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; [Anonymous], 2016, PEDIATRICS, V138; Bentley JP, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2002; Bentley JP, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0591-0; Blencowe H, 2013, PEDIATR RES, V74, P17, DOI 10.1038/pr.2013.204; Boland RA, 2016, AUST NZ J OBSTET GYN, V56, P274, DOI 10.1111/ajo.12448; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Calling S, 2013, ACTA PAEDIATR, V102, P287, DOI 10.1111/apa.12106; Chambers PL, 2011, PEDIATR EMERG CARE, V27, P1009, DOI 10.1097/PEC.0b013e318235bb4f; Chawanpaiboon S, 2019, LANCET GLOB HEALTH, V7, pE37, DOI 10.1016/S2214-109X(18)30451-0; Coathup V, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037885; Datta-Nemdharry P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001088; Dattani Nirupa, 2011, Health Stat Q, P53, DOI 10.1057/hsq.2011.3; Davidson R, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-14; Fraser J, 2004, BRIT MED J, V329, P962, DOI 10.1136/bmj.329.7472.962; Fuchs F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191002; Green CA, 2016, ARCH DIS CHILD, V101, P140, DOI 10.1136/archdischild-2015-308723; Herbert A, 2017, INT J EPIDEMIOL, V46, P1093, DOI 10.1093/ije/dyx015; Iacobelli S, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0787-y; Johnson L, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3922-7; Knight HE, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002425; Lain SJ, 2013, J PEDIATR-US, V163, P1014, DOI 10.1016/j.jpeds.2013.04.051; Li YM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195146; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; Macfarlane A., 2019, HEAL SERV DELIV RES, V7, P1, DOI [10.3310/hsdr07180, DOI 10.3310/HSDR07180]; MacLennan AH, 2015, AM J OBSTET GYNECOL, V213, P779, DOI 10.1016/j.ajog.2015.05.034; Melville JM, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00079; Mendola P, 2015, EPIDEMIOLOGY, V26, P17, DOI 10.1097/EDE.0000000000000213; Miller JE, 2016, LANCET INFECT DIS, V16, P952, DOI 10.1016/S1473-3099(16)00150-X; Moser Kath, 2008, Health Stat Q, P15; Murray J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089186; Nassar Natasha, 2013, PLoS One, V8, pe56238, DOI 10.1371/journal.pone.0056238; Natarajan G, 2016, AM J PERINAT, V33, P305, DOI 10.1055/s-0035-1571150; Ospina M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033296; Paranjothy S, 2013, PEDIATRICS, V132, pE1562, DOI 10.1542/peds.2013-1737; Poulsen G, 2011, J CLIN EPIDEMIOL, V64, P1444, DOI 10.1016/j.jclinepi.2011.03.007; Ray Kristin N, 2013, Hosp Pediatr, V3, P194; Royal College of Paediatrics and Child Health National Neonatal Audit Programme, 2015, ANN REPORT 2014 DATA; Santhakumaran S, 2018, ARCH DIS CHILD-FETAL, V103, pF208, DOI 10.1136/archdischild-2017-312748; Seaton SE, 2019, ARCH DIS CHILD-FETAL, V104, pF182, DOI 10.1136/archdischild-2017-314405; Shah PS, 2011, MATERN CHILD HLTH J, V15, P1097, DOI 10.1007/s10995-010-0654-z; Slimings C, 2014, PAEDIATR PERINAT EP, V28, P536, DOI 10.1111/ppe.12155; Srinivasjois R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130535; StataCorp, 2015, STAT STAT SOFTW REL; Stephens AS, 2015, PAEDIATR PERINAT EP, V29, P241, DOI 10.1111/ppe.12188; Walker KF, 2016, NEW ENGL J MED, V374, P813, DOI 10.1056/NEJMoa1509117; Zhang X, 2012, BJOG-INT J OBSTET GY, V119, P1309, DOI 10.1111/j.1471-0528.2012.03453.x	48	15	15	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	2020	371								m4075	10.1136/bmj.m4075	http://dx.doi.org/10.1136/bmj.m4075			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ6VP	33239272	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000595061600011
J	Turk, S; Turk, C; Akbar, MW; Kucukkaraduman, B; Isbilen, M; Canli, SD; Malkan, UY; Okay, M; Ucar, G; Sayinalp, N; Haznedaroglu, IC; Gure, AO				Turk, Seyhan; Turk, Can; Akbar, Muhammad Waqas; Kucukkaraduman, Baris; Isbilen, Murat; Demirkol Canli, Secil; Malkan, Umit Yavuz; Okay, Mufide; Ucar, Gulberk; Sayinalp, Nilgun; Haznedaroglu, Ibrahim Celalettin; Gure, Ali Osmay			Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide	PLOS ONE			English	Article							II TYPE-1 RECEPTOR; EXPRESSION SIGNATURE; TUMOR ANGIOGENESIS; DRUG-SENSITIVITY; CANCER; OVEREXPRESSION; ACTIVATION; INDUCTION; AUTOPHAGY; RAS	Despite the availability of various treatment protocols, response to therapy in patients with Acute Myeloid Leukemia (AML) remains largely unpredictable. Transcriptomic profiling studies have thus far revealed the presence of molecular subtypes of AML that are not accounted for by standard clinical parameters or by routinely used biomarkers. Such molecular subtypes of AML are predicted to vary in response to chemotherapy or targeted therapy. The Renin-Angiotensin System (RAS) is an important group of proteins that play a critical role in regulating blood pressure, vascular resistance and fluid/electrolyte balance. RAS pathway genes are also known to be present locally in tissues such as the bone marrow, where they play an important role in leukemic hematopoiesis. In this study, we asked if the RAS genes could be utilized to predict drug responses in patients with AML. We show that the combined in silico analysis of up to five RAS genes can reliably predict sensitivity to Doxorubicin as well as Etoposide in AML. The same genes could also predict sensitivity to Doxorubicin when tested in vitro. Additionally, gene set enrichment analysis revealed enrichment of TNF-alpha and type-I IFN response genes among sensitive, and TGF-beta and fibronectin related genes in resistant cancer cells. However, this does not seem to reflect an epithelial to mesenchymal transition per se. We also identified that RAS genes can stratify patients with AML into subtypes with distinct prognosis. Together, our results demonstrate that genes present in RAS are biomarkers for drug sensitivity and the prognostication of AML.	[Turk, Seyhan; Ucar, Gulberk] Hacettepe Univ, Dept Biochem, Ankara, Turkey; [Turk, Can] Lokman Hekim Univ, Dept Med Microbiol, Ankara, Turkey; [Akbar, Muhammad Waqas; Kucukkaraduman, Baris; Isbilen, Murat; Gure, Ali Osmay] Bilkent Univ, Dept Mol Biol & Genet, Ankara, Turkey; [Demirkol Canli, Secil] Hacettepe Univ, Mol Pathol Applicat & Res Ctr, Ankara, Turkey; [Malkan, Umit Yavuz] Univ Hlth Sci, Dept Hematol, Ankara, Turkey; [Okay, Mufide; Sayinalp, Nilgun; Haznedaroglu, Ibrahim Celalettin] Hacettepe Univ, Dept Hematol, Ankara, Turkey	Hacettepe University; Lokman Hekim University; Ihsan Dogramaci Bilkent University; Hacettepe University; University of Health Sciences Turkey; Hacettepe University	Turk, S (corresponding author), Hacettepe Univ, Dept Biochem, Ankara, Turkey.	seyhan.turk@hacettepe.edu.tr	Malkan, Umit Yavuz/AAG-6203-2019; Türk, Can/AAZ-2390-2021; Turk, Seyhan/AAB-1996-2021; Canlı, Seçil Demirkol/AAG-8038-2020	Malkan, Umit Yavuz/0000-0001-5444-4895; Türk, Can/0000-0003-1514-7294; Canlı, Seçil Demirkol/0000-0003-0200-7962; Gure, Ali Osmay/0000-0002-4064-8608; Turk, Seyhan/0000-0003-3843-4173	Scientific and Technological Research Council of Turkey [116S350]	Scientific and Technological Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK))	This study was supported by The Scientific and Technological Research Council of Turkey (116S350).	Ager EI, 2008, CARCINOGENESIS, V29, P1675, DOI 10.1093/carcin/bgn171; Akbar MW, 2020, J CANCER, V11, P949, DOI 10.7150/jca.34649; Aksu S, 2006, LEUKEMIA LYMPHOMA, V47, P891, DOI 10.1080/10428190500399250; Bader M, 2010, ANNU REV PHARMACOL, V50, P439, DOI 10.1146/annurev.pharmtox.010909.105610; Beck B., 2004, ASSAY GUIDANCE MANUA; Beyazit Y, 2007, J NATL MED ASSOC, V99, P57; Campbell DJ, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00113; Casares MTG, 2002, LEUKEMIA LYMPHOMA, V43, P2377, DOI 10.1080/1042819021000040080; Chen SJ, 2013, NAT GENET, V45, P586, DOI 10.1038/ng.2651; Chiong Jun R, 2008, Int J Cardiol, V124, P6, DOI 10.1016/j.ijcard.2007.01.119; Chu E., 2017, PHYS CANC CHEMOTHERA; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Delforce SJ, 2017, ENDOCR CONNECT, V6, P9, DOI 10.1530/EC-16-0082; Demirkol S, 2017, J CANCER, V8, P1113, DOI 10.7150/jca.17872; Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965; Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645; Fujita M, 2005, CARCINOGENESIS, V26, P271, DOI 10.1093/carcin/bgh324; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Goussetis DJ, 2010, J BIOL CHEM, V285, P29989, DOI 10.1074/jbc.M109.090530; Haferlach T, 2020, BRIT J HAEMATOL, V188, P36, DOI 10.1111/bjh.16360; Hara M, 2004, CARDIOVASC DRUG THER, V18, P415, DOI 10.1007/s10557-004-6218-y; Hay ED, 1995, ACTA ANAT, V154, P8; Haznedaroglu IC, 2013, CLIN SCI, V124, P307, DOI 10.1042/CS20120300; Haznedaroglu IC, 1996, MED HYPOTHESES, V46, P507, DOI 10.1016/S0306-9877(96)90122-X; Haznedaroglu IC, 2003, INT J BIOCHEM CELL B, V35, P867, DOI 10.1016/S1357-2725(02)00278-9; Hubert C, 2006, NAT CLIN PRACT CARD, V3, P80, DOI 10.1038/ncpcardio0449; Ino K, 2006, BRIT J CANCER, V94, P552, DOI 10.1038/sj.bjc.6602961; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jokubaitis VJ, 2008, BLOOD, V111, P4055, DOI 10.1182/blood-2007-05-091710; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kato H, 2005, FASEB J, V19, P2023, DOI 10.1096/fj.05-3820fje; Kinoshita J, 2009, INT J ONCOL, V34, P1573, DOI 10.3892/ijo_00000287; Kouchi M, 2017, J NEUROSURG, V127, P819, DOI 10.3171/2016.9.JNS16431; Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001; Kwiatkowski BA, 2009, ASH ANN M, V114, P3606, DOI DOI 10.1182/blood.V114.22.3606.3606; Lin CT, 2011, FASEB J, V25, P1145, DOI 10.1096/fj.10-169433; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marcucci G, 2011, J CLIN ONCOL, V29, P475, DOI 10.1200/JCO.2010.30.2554; Metzeler KH, 2008, BLOOD, V112, P4193, DOI 10.1182/blood-2008-02-134411; Ni SJ, 2018, ONCOTARGETS THER, V11, P3835, DOI 10.2147/OTT.S172887; Park TS, 2009, HAEMATOL-HEMATOL J, V94, P745, DOI 10.3324/haematol.2009.006965; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Ristica B, 2014, EXP CELL RES, V326, P90, DOI 10.1016/j.yexcr.2014.05.021; Rocken C, 2005, CLIN CANCER RES, V11, P2526, DOI 10.1158/1078-0432.CCR-04-1922; Rujano MA, 2017, J EXP MED, V214, P3707, DOI 10.1084/jem.20170453; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Shen XZ, 2011, CELL CYCLE, V10, P1363, DOI 10.4161/cc.10.9.15444; Simon RM, 2011, DESIGN ANAL DNA MICR; Sinka L, 2012, BLOOD, V119, P3712, DOI 10.1182/blood-2010-11-314781; Stein G.S, 2019, CANC PREVENTION EARL; Strawn WB, 2004, BRIT J HAEMATOL, V126, P120, DOI 10.1111/j.1365-2141.2004.04998.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tavian M, 2010, INT J DEV BIOL, V54, P1061, DOI 10.1387/ijdb.103097mt; Tawinwung S, 2015, ANTICANCER RES, V35, P4789; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tian ZN, 2014, CELL PHYSIOL BIOCHEM, V34, P1578, DOI 10.1159/000366361; Toss MS, 2019, HISTOPATHOLOGY, V74, P1025, DOI 10.1111/his.13835; Uemura H, 2006, PROSTATE, V66, P822, DOI 10.1002/pros.20407; Venkova L, 2015, ONCOTARGET, V6, P27227, DOI 10.18632/oncotarget.4507; Wang J, 2019, BRIT J CANCER, V120, P229, DOI 10.1038/s41416-018-0350-0; Wu HL, 2017, INT J CLIN EXP MED, V10, P881; Wulf GG, 1998, BRIT J HAEMATOL, V100, P335, DOI 10.1046/j.1365-2141.1998.00565.x; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Zambidis ET, 2008, BLOOD, V112, P3601, DOI 10.1182/blood-2008-03-144766	66	11	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 25	2020	15	11							e0242497	10.1371/journal.pone.0242497	http://dx.doi.org/10.1371/journal.pone.0242497			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OX9PD	33237942	Green Published, gold			2023-01-03	WOS:000593887000017
J	Lagendijk, J; Sijpkens, MK; Ernst-Smelt, HE; Verbiest, SB; Been, JV; Steegers, EAP				Lagendijk, Jacqueline; Sijpkens, Meertien K.; Ernst-Smelt, Hiske E.; Verbiest, Sarah B.; Been, Jasper V.; Steegers, Eric A. P.			Risk-guided maternity care to enhance maternal empowerment postpartum: A cluster randomized controlled trial	PLOS ONE			English	Article							MULTIPLE IMPUTATION; WOMENS AUTONOMY; DECISION-MAKING; SELF-EFFICACY; HEALTH-CARE; FOLLOW-UP; ASSOCIATIONS; DETERMINANTS; EXPERIENCES	Objective To investigate whether a structured inquiry during pregnancy of medical factors and social factors associated with low socioeconomic status, and subsequent patient-centred maternity care could increase maternal empowerment. Design Cluster-randomised controlled trial. Setting This study was conducted among pregnant women in selected urban areas in the Netherlands. This study was part of the nationwide Healthy Pregnancy 4 All-2 programme. Population Pregnant women listed at one of the sixteen participating maternity care organisations between July 1, 2015, and Dec 31, 2016. Methods All practices were instructed to provide a systematic risk assessment during pregnancy. Practices were randomly allocated to continue usual care (seven practices), or to provide a patient-centred, risk-guided approach to addressing any risks (nine practices) identified via the risk assessment during pregnancy. Main outcome measures Low postpartum maternal empowerment score. Results We recruited 1579 participants; 879 participants in the intervention arm, and 700 participants in the control arm. The prevalence of one or more risk factors during pregnancy was similar between the two arms: 40% and 39%, respectively. In our intention-to-treat analysis, the intervention resulted in a significant reduction in the odds of having a low empowerment score [i.e. the primary outcome; adjusted OR 0.69 ((95% CI 0.47; 0.99), P 0.046)]. Conclusions Implementation of additional risk assessment addressing both medical and social factors and subsequent tailored preventive strategies into maternity care reduced the incidence of low maternal empowerment during the postpartum period. Introducing this approach in routine maternity care may help reduce early adversity during the postpartum period.	[Lagendijk, Jacqueline; Sijpkens, Meertien K.; Ernst-Smelt, Hiske E.; Been, Jasper V.; Steegers, Eric A. P.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Obstet & Gynaecol, Rotterdam, Netherlands; [Verbiest, Sarah B.] Univ N Carolina, UNC Sch Social Work, Chapel Hill, NC 27515 USA; [Been, Jasper V.] Univ Med Ctr Rotterdam, Erasmus MC, Sophia Childrens Hosp, Dept Paediat,Div Neonatol, Rotterdam, Netherlands; [Been, Jasper V.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of North Carolina; University of North Carolina Chapel Hill; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC	Lagendijk, J (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Obstet & Gynaecol, Rotterdam, Netherlands.	j.lagendijk.2@erasmusmc.nl	Been, Jasper/AFJ-5181-2022	Been, Jasper/0000-0002-4907-6466	Ministry of Health, Welfare and Sports [323911]; Netherlands Lung Foundation [4.2.14.063JO]; Erasmus MC	Ministry of Health, Welfare and Sports; Netherlands Lung Foundation; Erasmus MC	This study is funded by the Ministry of Health, Welfare and Sports (grant number: 323911). JVB is funded by personal fellowships from the Erasmus MC and the Netherlands Lung Foundation (4.2.14.063JO). The funding sources had no role in the design of this study or its execution, analyses, interpretation of the data, or decision to submit results.	Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Allin S, 2012, HEALTH ECON POLICY L, V7, P227, DOI 10.1017/S174413311100034X; Azur MJ, 2011, INT J METH PSYCH RES, V20, P40, DOI 10.1002/mpr.329; Bloom SS, 2001, DEMOGRAPHY, V38, P67, DOI 10.1353/dem.2001.0001; Caille A, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4291; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Carlson GJ, 2015, MATERN CHILD NUTR, V11, P452, DOI 10.1111/mcn.12113; Carroll C, 2007, IMPLEMENT SCI, V2, DOI 10.1186/1748-5908-2-40; Case A, 2006, FUTURE CHILD, V16, P151, DOI 10.1353/foc.2006.0014; Currie A, 2007, J HEALTH ECON, V26, P213, DOI 10.1016/j.jhealeco.2006.08.003; Data WLC-i-P, 2013, DATA WLC I P WHO REC; Denktas S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-253; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Ebrahim G.J., 2007, J TROP PEDIATRICS, V53, P294, DOI [DOI 10.1093/TROPEJ/FMM053, 10.1093/tropej/fmm053]; Fleuren MAH, 2014, INT J QUAL HEALTH C, V26, P501, DOI 10.1093/intqhc/mzu060; Hou XH, 2013, HEALTH POLICY PLANN, V28, P176, DOI 10.1093/heapol/czs042; Howe LD, 2013, EPIDEMIOLOGY, V24, P1, DOI 10.1097/EDE.0b013e31827623b1; Kim H, 2018, TOP SPINAL CORD INJ, V24, P97, DOI 10.1310/sci2402-97; Kondo N, 2012, J EPIDEMIOL, V22, P2, DOI 10.2188/jea.JE20110116; Lagendijk J, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-018-2155-9; Lagendijk J, 2019, EUR J PUBLIC HEALTH, V29, P849, DOI 10.1093/eurpub/ckz076; Leahy-Warren P, 2011, MIDWIFERY, V27, P802, DOI 10.1016/j.midw.2010.07.008; Lindquist A, 2015, BJOG-INT J OBSTET GY, V122, P1610, DOI 10.1111/1471-0528.13059; Lindquist A, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002742; Mackenbach JP, 2012, SOC SCI MED, V75, P761, DOI 10.1016/j.socscimed.2012.02.031; Marmot M G, 1997, J Health Psychol, V2, P283, DOI 10.1177/135910539700200302; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; Mirghafourvand M, 2018, J PSYCHOSOM OBST GYN, V39, P321, DOI 10.1080/0167482X.2017.1394290; Pratley P, 2016, SOC SCI MED, V169, P119, DOI 10.1016/j.socscimed.2016.08.001; Reck C, 2012, INFANT BEHAV DEV, V35, P264, DOI 10.1016/j.infbeh.2011.12.005; Ribeiro DC, 2018, MUSCULOSKEL SCI PRAC, V34, P108, DOI 10.1016/j.msksp.2017.10.002; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; Scheerhagen M, 2016, PEERJ, V4, DOI 10.7717/peerj.2092; Scheerhagen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117031; Siebenhofer A, 2017, J CLIN EPIDEMIOL; Steegers Eric A P, 2015, Ned Tijdschr Geneeskd, V160, pD83; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Waelput AJM, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1425-2; WHO, 1998, WHOHPRHEP981; Wiegers TA, 2006, J NEONATAL NURS, V12, P163, DOI [10.1016/j.jnn.2006.07.003, DOI 10.1016/J.JNN.2006.07.003]; Yonemoto Naohiro, 2014, Evid Based Child Health, V9, P5, DOI 10.1002/ebch.1960; Zuidgeest MGP, 2017, J CLIN EPIDEMIOL, V88, P7, DOI 10.1016/j.jclinepi.2016.12.023	42	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2020	15	11							e0242187	10.1371/journal.pone.0242187	http://dx.doi.org/10.1371/journal.pone.0242187			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	PA5CL	33216791	Green Published, gold			2023-01-03	WOS:000595653500016
J	Vroomen, JLM; Kjellstadli, C; Allore, HG; van der Steen, JT; Husebo, B				Vroomen, Janet L. MacNeil; Kjellstadli, Camilla; Allore, Heather G.; van der Steen, Jenny T.; Husebo, Bettina			Reform influences location of death: Interrupted time-series analysis on older adults and persons with dementia	PLOS ONE			English	Article							OF-LIFE CARE; IN-PLACE; PEOPLE; PREDICTORS; FLANDERS; CANCER; TRENDS	Background Norway instituted a Coordination Reform in 2012 aimed at maximizing time at home by providing in-home care through community services. Dying in a hospital can be highly stressful for patients and families. Persons with dementia are particularly vulnerable to negative outcomes in hospital. This study aims to describe changes in the proportion of older adults with and without dementia dying in nursing homes, home, hospital and other locations over an 11-year period covering the reform. Methods and findings This is a repeated cross-sectional, population-level study using mortality data from the Norwegian Cause of Death Registry hosted by the Norwegian Institute of Public Health. Participants were Norwegian older adults 65 years or older with and without dementia who died from 2006 to 2017. The policy intervention was the 2012 Coordination Reform that increased care infrastructure into communities. The primary outcome was location of death listed as a nursing home, home, hospital or other location. The trend in the proportion of location of death, before and after the reform was estimated using an interrupted time-series analysis. All analyses were adjusted for sex and seasonality. Of the 417,862 older adult decedents, 61,940 (14.8%) had dementia identified on their death certificate. Nursing home deaths increased over time while hospital deaths decreased for the total population (adjusted Relative Risk Ratio (aRRR) 0.87, 95% CI 0.82-0.92) and persons with dementia (aRRR: 0.93, 95%CI 0.91-0.96) after reform implementation. Conclusion This study provides evidence that the 2012 Coordination Reform was associated with decreased older adults dying in hospital and increased nursing home death; however, the number of people dying at home did not change.	[Vroomen, Janet L. MacNeil] Univ Amsterdam, Dept Internal Med, Amsterdam Publ Hlth Res Inst, Amsterdam Univ,Med Ctr,Sect Geriatr Med, Amsterdam, North Holland, Netherlands; [Kjellstadli, Camilla; Husebo, Bettina] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Allore, Heather G.] Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06510 USA; [Allore, Heather G.] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA; [van der Steen, Jenny T.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands; [van der Steen, Jenny T.] Radboud Univ Nijmegen, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands; [Husebo, Bettina] Municipal Bergen, Bergen, Norway	University of Amsterdam; Vrije Universiteit Amsterdam; University of Bergen; Yale University; Yale University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	Vroomen, JLM (corresponding author), Univ Amsterdam, Dept Internal Med, Amsterdam Publ Hlth Res Inst, Amsterdam Univ,Med Ctr,Sect Geriatr Med, Amsterdam, North Holland, Netherlands.	j.l.macneil-vroomen@amsterdamumc.nl	Kjellstadli, Camilla/X-6977-2019; Kjellstadli, Camilla/HGU-8464-2022; Husebø, Bettina Sandgathe/AFO-7402-2022; van der Steen, Jenny T./E-5118-2016; Kjellstadli, Camilla/AAN-6855-2021; Husebo, Bettina Sandgathe/AFP-1656-2022; Vroomen, Janet MacNeil/M-5358-2017	Kjellstadli, Camilla/0000-0002-1296-382X; van der Steen, Jenny T./0000-0002-9063-7501; Husebo, Bettina Sandgathe/0000-0002-6037-2864; Vroomen, Janet MacNeil/0000-0001-6400-7189	ZonMw career award [91619060]	ZonMw career award	JMV received a ZonMw career award, Veni grant #91619060. https://www.zonmw.nl/nl/onderzoek-resultaten/fundamenteel-onderzoek/programmas/programma-detail/veni/t/commissie13/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, BRAIN STIMUL MAR; Badrakalimuthu V, 2014, AGE AGEING, V43, P13, DOI 10.1093/ageing/aft151; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Bruvik F, 2017, SYKEPLEIEN FORSKNING, V12, P60613, DOI [10.4220/Sykepleienf.2017.60613, DOI 10.4220/SYKEPLEIENF.2017.60613]; C H A H., 2009, PROMOTING HIGH QUALI; Cohen J, 2015, BRIT J CANCER, V113, P1397, DOI 10.1038/bjc.2015.312; Dasch B, 2015, DTSCH ARZTEBL INT, V112, P496, DOI 10.3238/arztebl.2015.0496; Delamater PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054900; Faeo SE, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1171-6; Folkehelseinstituttet, 2019, FLEST SYK HJEMM 2018; Forskningsradet, 2016, SLUTTRAPPORT STYRING; Gao W, 2013, CHANGING PATTERNS PL, P1549; Gao W, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6030107; Gao W, 2014, SCI WORLD J, DOI 10.1155/2014/369798; Gaugler JE, 2009, MED CARE, V47, P191, DOI 10.1097/MLR.0b013e31818457ce; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Helvik AS, 2015, DEMENT GERIATR COGN, V40, P166, DOI 10.1159/000433525; Hines Sonia, 2011, JBI Libr Syst Rev, V9, P960; Hoogerduijn JG, 2007, J CLIN NURS, V16, P46, DOI 10.1111/j.1365-2702.2006.01579.x; Houttekier D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-228; Husebo BS, 2020, AM J GERIAT PSYCHIAT, V28, P792, DOI 10.1016/j.jagp.2020.04.016; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Kaasa S, 2017, PALLIATIVE CARE SERI; Kaasa SA S, 2017, NOU201716 MIN HLTH C; Kalseth J, 2017, PALLIATIVE MED, V31, P964, DOI 10.1177/0269216317691259; Kjellstadli C, 2020, FAM PRACT, V37, P340, DOI 10.1093/fampra/cmz059; Kjellstadli C, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4536-9; Kjelvik J, 2017, 022017 NORW DIR HLTH; Kua EH, 2014, PSYCHOGERIATRICS, V14, P196, DOI 10.1111/psyg.12053; LaMantia MA, 2016, ALZ DIS ASSOC DIS, V30, P35, DOI 10.1097/WAD.0000000000000118; Larson EB, 2004, ANN INTERN MED, V140, P501, DOI 10.7326/0003-4819-140-7-200404060-00008; Melby L., 2019, KARTLEGGING MEDISINS; MOrk EB S, 2016, SLO KONGSVINGER 2017; Norgwegian Directorate of Health, 2018, IS2836 NORGW DIR HLT; OECD, 2017, LONG TERM CAR BEDS I; OECD/European Observatory on Health Systems and Policies, 2019, EUR OBS HLTH SYST PO; Phelan EA, 2012, JAMA-J AM MED ASSOC, V307, P165, DOI 10.1001/jama.2011.1964; Reyniers T, 2015, J AM MED DIR ASSOC, V16, P165, DOI 10.1016/j.jamda.2014.11.003; Romoren Tor Inge, 2011, Int J Integr Care, V11, pe127; Sandvik RK, 2016, J AM MED DIR ASSOC, V17, P821, DOI 10.1016/j.jamda.2016.05.006; Saunders C, 2008, END LIF CAR STRAT PR; Smedslund G, 2014, 192014 NASJ KUNNSK H; Spasova S., 2018, Eurohealth, V24, P7; Statistics Norway, 2020, 09929 STAT NORW; Verhofstede R, 2017, J PAIN SYMPTOM MANAG, V53, P693, DOI 10.1016/j.jpainsymman.2016.10.363; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X	46	3	3	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2020	15	11							e0241132	10.1371/journal.pone.0241132	http://dx.doi.org/10.1371/journal.pone.0241132			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OR6WM	33147248	Green Published, gold			2023-01-03	WOS:000589609300025
J	Civaner, MM				Civaner, M. Murat			A follow-up study on the effects of an educational intervention against pharmaceutical promotion	PLOS ONE			English	Article							UNDERGRADUATE MEDICAL-EDUCATION; HIDDEN CURRICULUM; NURSING-STUDENTS; OF-INTEREST; INDUSTRY; ATTITUDES; PHYSICIANS; POLICIES; PRESCRIBERS; KNOWLEDGE	Background The promotion strategies of pharmaceutical companies create many problems including irrational prescribing, diminished trust in the patient-physician relationship and unnecessary increases in pharmaceutical costs. Educating prescribers is known to be one of the few potentially effective measures to counteract those impacts. However such educational programs are limited in the literature, and their effectiveness against the effects of hidden curriculum in the long term is unknown. This study aims to evaluate the effectiveness of an education program both in the short term and the long term after the students have been exposed to informal and hidden curriculum and various pharmaceutical promotion methods. Methods A longitudinal and controlled study was carried out in a school of medicine in Turkey where there are no restrictive policies for pharmaceutical promotion. A survey was applied to 123 students who attended the class throughout the terms of 2011-12, 2012-13, and 2013-14, evaluating the pre-educational status of students' opinions of promotion and any post-educational changes. A follow-up study four years later asked those three cohorts to fill out the same survey to see the possible effects of the clinical environment and various promotion methods. Also, the opinions of all 518 sixth-year students who had not taken the class in those three terms were compared to the educated students. Results The program was significantly effective in the short term in changing students' opinions and attitudes positively towards recognizing companies' discourse and promotion strategies. But in the long term, the education lost its ability to convince students of the importance of not getting financial support for scientific activities from pharmaceutical companies (p:0.006) and carrying out research (p<0.001). In addition, although the educated students were more aware that trivial gifts could influence prescriptions compared to the uneducated 6th year students (p<0.001), the difference between them and the uneducated students generally becomes less significant when they encounter the clinical environment. The study also evaluated students highly-exposed to promotion; for this sub-group, the educated students kept their consciousness level about the influences of trivial gifts (p<0.001) while the uneducated students were confident that they were immune to the influence of trivial gifts. Conclusions The education program could be used for creating awareness of, increasing skepticism towards, and inculcating disapproval about pharmaceutical promotion practices. However, the effectiveness of the educational intervention is susceptible to erosion after exposure to the informal and hidden curriculum together with exposure to promotion. The impact of role-models, organizational culture, and institutional policies could be important aspects to be addressed for sustaining the effectiveness of such education programs.	[Civaner, M. Murat] Bursa Uludag Univ, Dept Med Eth & Hist Med, Sch Med, Bursa, Turkey	Uludag University	Civaner, MM (corresponding author), Bursa Uludag Univ, Dept Med Eth & Hist Med, Sch Med, Bursa, Turkey.	mcivaner@gmail.com		Civaner, M. Murat/0000-0001-5376-3499	Uludag University Scientific Researches and Projects Unit [HDP(T)-2015/31]	Uludag University Scientific Researches and Projects Unit	This study was financially supported by Uludag University Scientific Researches and Projects Unit (No. HDP(T)-2015/31).	AE K B, 2017, PEDIAT DERMATOL, V34, pS203, DOI [10.1111/pde.13142, DOI 10.1111/PDE.13142]; Alvero R, 2007, TEACHING CRITICAL AP; Alves TL, 2019, SCI ENG ETHICS, V25, P1167, DOI 10.1007/s11948-018-0041-5; Angell M., 2005, TRUTH DRUG CO THEY D; [Anonymous], 2015, FORBES; [Anonymous], 2017, CANC DISCOVERY, V7, pOF12, DOI DOI 10.1158/2159-8290.CD-RW2016-234; Ashmore R, 2007, NURS EDUC TODAY, V27, P551, DOI 10.1016/j.nedt.2006.08.016; Bank W., 1993, COMMUNICATION; Brody H, 2007, HOOKED ETHICMED PR; budras Corinna, 2008, FRANKFURTER ALLGEMEI, V7, pC5; Buman MP, 2011, J PHYS ACT HEALTH, V8, pS257, DOI 10.1123/jpah.8.s2.s257; Civaner M, 2006, MARKETING METHODS PH; Civaner MM, 2016, J BIOETHIC INQ, V13, P261, DOI 10.1007/s11673-016-9704-6; Civaner M, 2008, NURS ETHICS, V15, P396, DOI 10.1177/0969733007088364; Civaner M, 2012, HEALTH POLICY, V106, P225, DOI 10.1016/j.healthpol.2012.05.006; Elliot C, 2011, BEYAZ ONLUK SIYAH SA; Epstein AJ, 2013, MED CARE, V51, P199, DOI 10.1097/MLR.0b013e318277eb19; Goldie J, 2008, MED TEACH, V30, P513, DOI 10.1080/01421590801995225; Goozner M, 2004, 800 MILLION (DOLLAR) PILL: THE TRUTH BEHIND THE COST OF NEW DRUGS, P1; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; Hafferty FW, 1998, ACAD MED, V73, P403, DOI 10.1097/00001888-199804000-00013; Hafferty FW, 2009, HDB SOCIOLOGY MED ED, P26; Institute for Health & Socio-Economic Policy, 2016, R D SMOK PRIOR MARK; Kahwati L, 2017, J CONTIN EDUC HEALTH, V37, P129, DOI 10.1097/CEH.0000000000000150; Kao AC, 2011, ACAD MED, V86, P1454, DOI 10.1097/ACM.0b013e3182303895; King M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f264; Koch C, 2020, J GEN INTERN MED, V35, P473, DOI 10.1007/s11606-019-05420-w; Lempp H, 2004, BMJ-BRIT MED J, V329, P770, DOI 10.1136/bmj.329.7469.770; Lewis S, 2001, CAN MED ASSOC J, V165, P783; LEXCHIN J, 1993, CAN MED ASSOC J, V149, P1401; Mansfield P., 2019, HLTH SKEPTICISM IS N; Mansfield PR, 2006, PLOS MED, V3, P1988, DOI 10.1371/journal.pmed.0030451; Marchand B, 2011, 3 INT C IMPR US MED; McCormick BB, 2001, JAMA-J AM MED ASSOC, V286, P1994, DOI 10.1001/jama.286.16.1994; Mintzes B, 2005, ED INITIATIVES MED P; Monaghan MS, 2003, TEACH LEARN MED, V15, P14, DOI 10.1207/S15328015TLM1501_04; Moynihan, 2005, SELLING SICKNESS WOR; Moynihan CK, 2018, J AM BOARD FAM MED, V31, P645, DOI 10.3122/jabfm.2018.04.170242; Mulder H, 2019, MED TEACH, V41, P36, DOI 10.1080/0142159X.2018.1436760; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nayak V., 2011, ONLINE J HLTH ALLIED, V10, P1; Norris P, 2005, DRUG PROMOTION WHAT; O'Donoghue AC, 2015, J HEALTH COMMUN, V20, P1330, DOI 10.1080/10810730.2015.1018649; PALMISANO P, 1980, J MED EDUC, V55, P453; Prescrire, 2020, DRUGS 2019 BRIEF REV; Sarikaya O, 2009, ADV HEALTH SCI EDUC, V14, P713, DOI 10.1007/s10459-009-9153-7; Shankar P Ravi, 2012, BMC Res Notes, V5, P8, DOI 10.1186/1756-0500-5-8; Sierles FS, 2005, JAMA-J AM MED ASSOC, V294, P1034, DOI 10.1001/jama.294.9.1034; Silveira GL., 2019, HLTH PROFESSIONS ED, V5, P198, DOI [DOI 10.1016/J.HPE.2018.07.003, 10.1016/j.hpe.2018.07.003]; Slattery-Moschka K, 2005, SIDE EFFECTS; Stanley AG, 2005, BRIT J CLIN PHARMACO, V59, P464, DOI 10.1111/j.1365-2125.2005.02374.x; Statista TSP, 2017, GLOB PHARM IND STAT; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; The European Federation of Pharmaceutical Industries, 2018, PHARM IND FIG KEY DA; Tichelaar J, 2010, EUR J CLIN PHARMACOL, V66, P407, DOI 10.1007/s00228-009-0743-3; US Government Accountability Office, 2017, DRUG IND PROF RES DE; Vinson D C, 1993, Fam Med, V25, P31; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; WHO, 2002, POL PERSP MED; Wilkes MS, 2001, ACAD MED, V76, P1271, DOI 10.1097/00001888-200112000-00026; Wofford James L, 2005, BMC Med Educ, V5, P5, DOI 10.1186/1472-6920-5-5; World Bank, 2003, INNOVATIONS HLTH SER	62	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2020	15	10							e0240713	10.1371/journal.pone.0240713	http://dx.doi.org/10.1371/journal.pone.0240713			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OP8XL	33112908	Green Published, gold			2023-01-03	WOS:000588374000043
J	Wen, LS; Sadeghi, NB				Wen, Leana S.; Sadeghi, Nakisa B.			The opioid crisis and the 2020 US election: crossroads for a national epidemic	LANCET			English	Editorial Material									[Wen, Leana S.] George Washington Univ, Milken Inst, Sch Publ Hlth, Washington, DC 20052 USA; [Sadeghi, Nakisa B.] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA	George Washington University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Wen, LS (corresponding author), George Washington Univ, Milken Inst, Sch Publ Hlth, Washington, DC 20052 USA.	lwen@gwu.edu		Sadeghi, Nakisa/0000-0002-0227-7498				Board TE, 2020, LOS ANGELES TIMES; Corallo B, 2020, COMMUNITY HLTH CTR M; Ferrer B, 2018, AM J PUBLIC HEALTH, V108, P968, DOI 10.2105/AJPH.2018.304575; Goodnough A., 2017, NY TIMES; Harris Biden., 2020, BIDEN PLAN END OPIOI; House Committee on Oversight and Reform, 2019, CUMM WARR INTR LANDM; Joudrey PJ, 2019, ADDICT SCI CLIN PRAC, V14, DOI 10.1186/s13722-019-0145-5; Katkov M., 2020, WASHINGTON POST; Katz J., 2020, NY TIMES; Kravitz-Wirtz N, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19066; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; National Institute on Drug Abuse, OP SUMM STAT; Office of Management and Budget US Government, 2020, AM BUDG FISC YEAR 20; Rappeport Alan, 2017, NY TIMES; Saloner B, 2019, HEALTH AFFAIR, V38, P633, DOI 10.1377/hlthaff.2018.05049; Sokolow A., 2020, STAT-US; Trust for America's Health, 2020, IMP CHRON UND AM PUB; US Centers for Disease Control and Prevention, 2020, VIT STAT RAP REL PRO; Wen L., 2018, HILL; Wen LS, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002380; White House, 2018, PRESIDENT DJ TRUMP I; Yamamoto A, 2019, SOC SCI MED, V242, DOI 10.1016/j.socscimed.2019.112585	22	15	16	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2020	396	10259					1316	1318		10.1016/S0140-6736(20)32113-9	http://dx.doi.org/10.1016/S0140-6736(20)32113-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OF2SS	33035495	Green Published, Bronze			2023-01-03	WOS:000581064900011
J	Park, ER; Perez, GK; Regan, S; Muzikansky, A; Levy, DE; Temel, JS; Rigotti, NA; Pirl, WF; Irwin, KE; Partridge, AH; Cooley, ME; Friedman, ER; Rabin, J; Ponzani, C; Hyland, KA; Holland, S; Borderud, S; Sprunck, K; Kwon, D; Peterson, L; Miller-Sobel, J; Gonzalez, I; Whitlock, CW; Malloy, L; de Leon-Sanchez, S; O'Brien, M; Ostroff, JS				Park, Elyse R.; Perez, Giselle K.; Regan, Susan; Muzikansky, Alona; Levy, Douglas E.; Temel, Jennifer S.; Rigotti, Nancy A.; Pirl, William F.; Irwin, Kelly E.; Partridge, Ann H.; Cooley, Mary E.; Friedman, Emily R.; Rabin, Julia; Ponzani, Colin; Hyland, Kelly A.; Holland, Susan; Borderud, Sarah; Sprunck, Kim; Kwon, Diana; Peterson, Lisa; Miller-Sobel, Jacob; Gonzalez, Irina; Whitlock, C. Will; Malloy, Laura; de Leon-Sanchez, Suhana; O'Brien, Maureen; Ostroff, Jamie S.			Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOBACCO USE; SELF; INTERVENTION; CIGARETTE; SURVIVORS; RELAPSE	Key PointsQuestionHow effective is sustained cessation telephone counseling plus medication treatment compared with shorter-term telephone counseling plus medication advice for smokers recently diagnosed with cancer? FindingsIn this randomized clinical trial of 303 patients, conducted at 2 National Cancer Institute-designated Comprehensive Cancer Centers, sustained telephone counseling over 6 months and provision of free medication compared with 4-week telephone counseling and medication advice resulted in 6-month biochemically confirmed quit rates of 34.5% vs 21.5%, a difference that was statistically significant. MeaningAmong patients recently diagnosed with cancer, sustained cessation counseling and free medication may increase the likelihood of smoking abstinence compared with shorter-term counseling, but the generalizability of the study findings is uncertain and requires further research. ImportancePersistent smoking may cause adverse outcomes among patients with cancer. Many cancer centers have not fully implemented evidence-based tobacco treatment into routine care. ObjectiveTo determine the effectiveness of sustained telephone counseling and medication (intensive treatment) compared with shorter-term telephone counseling and medication advice (standard treatment) to assist patients recently diagnosed with cancer to quit smoking. Design, Setting, and ParticipantsThis unblinded randomized clinical trial was conducted at Massachusetts General Hospital/Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center. Adults who had smoked 1 cigarette or more within 30 days, spoke English or Spanish, and had recently diagnosed breast, gastrointestinal, genitourinary, gynecological, head and neck, lung, lymphoma, or melanoma cancers were eligible. Enrollment occurred between November 2013 and July 2017; assessments were completed by the end of February 2018. InterventionsParticipants randomized to the intensive treatment (n=153) and the standard treatment (n=150) received 4 weekly telephone counseling sessions and medication advice. The intensive treatment group also received 4 biweekly and 3 monthly telephone counseling sessions and choice of Food and Drug Administration-approved cessation medication (nicotine replacement therapy, bupropion, or varenicline). Main Outcome and MeasuresThe primary outcome was biochemically confirmed 7-day point prevalence tobacco abstinence at 6-month follow-up. Secondary outcomes were treatment utilization rates. ResultsAmong 303 patients who were randomized (mean age, 58.3 years; 170 women [56.1%]), 221 (78.1%) completed the trial. Six-month biochemically confirmed quit rates were 34.5% (n=51 in the intensive treatment group) vs 21.5% (n=29 in the standard treatment group) (difference, 13.0% [95% CI, 3.0%-23.3%]; odds ratio, 1.92 [95% CI, 1.13-3.27]; P<.02). The median number of counseling sessions completed was 8 (interquartile range, 4-11) in the intensive treatment group. A total of 97 intensive treatment participants (77.0%) vs 68 standard treatment participants (59.1%) reported cessation medication use (difference, 17.9% [95% CI, 6.3%-29.5%]; odds ratio, 2.31 [95% CI, 1.32-4.04]; P=.003). The most common adverse events in the intensive treatment and standard treatment groups, respectively, were nausea (n=13 and n=6), rash (n=4 and n=1), hiccups (n=4 and n=1), mouth irritation (n=4 and n=0), difficulty sleeping (n=3 and n=2), and vivid dreams (n=3 and n=2). Conclusions and RelevanceAmong smokers recently diagnosed with cancer in 2 National Cancer Institute-designated Comprehensive Cancer Centers, sustained counseling and provision of free cessation medication compared with 4-week counseling and medication advice resulted in higher 6-month biochemically confirmed quit rates. However, the generalizability of the study findings is uncertain and requires further research. Trial RegistrationClinicalTrials.gov Identifier: NCT01871506 This randomized trial compares the effect of sustained telephone counseling and medication vs shorter-term telephone counseling and medication advice on 6-month smoking abstinence among patients at academic cancer hospitals recently diagnosed with cancer.	[Park, Elyse R.; Perez, Giselle K.; Levy, Douglas E.; Rigotti, Nancy A.; Friedman, Emily R.; Rabin, Julia; Ponzani, Colin; Gonzalez, Irina] Massachusetts Gen Hosp, Mongan Inst, Ctr Hlth Policy Res, 100 Cambridge St,Ste 1600, Boston, MA 02114 USA; [Park, Elyse R.; Perez, Giselle K.; Regan, Susan; Levy, Douglas E.; Temel, Jennifer S.; Rigotti, Nancy A.; Pirl, William F.; Irwin, Kelly E.; Partridge, Ann H.; Cooley, Mary E.] Harvard Med Sch, Boston, MA 02115 USA; [Park, Elyse R.; Perez, Giselle K.; Irwin, Kelly E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Park, Elyse R.; Regan, Susan; Levy, Douglas E.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Treatment & Res Ctr, Boston, MA 02114 USA; [Regan, Susan; Rigotti, Nancy A.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA; [Muzikansky, Alona] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA; [Temel, Jennifer S.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA; [Pirl, William F.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; [Partridge, Ann H.; Sprunck, Kim] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Cooley, Mary E.] Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA; [Hyland, Kelly A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA; [Holland, Susan; Borderud, Sarah; Kwon, Diana; Peterson, Lisa; Miller-Sobel, Jacob; Whitlock, C. Will; de Leon-Sanchez, Suhana; O'Brien, Maureen; Ostroff, Jamie S.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, Tobacco Treatment Program, 1275 York Ave, New York, NY 10021 USA; [Malloy, Laura] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; H Lee Moffitt Cancer Center & Research Institute; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital	Park, ER (corresponding author), Massachusetts Gen Hosp, Mongan Inst, Ctr Hlth Policy Res, 100 Cambridge St,Ste 1600, Boston, MA 02114 USA.	epark@mgh.harvard.edu	Levy, Douglas/W-1516-2019	Levy, Douglas/0000-0001-9446-7899; Hyland, Kelly/0000-0001-9864-5306; Kwon, Diana/0000-0001-6233-0695; Irwin, Kelly/0000-0002-4591-9876	NCATS NIH HHS [UL1 TR002384] Funding Source: Medline; NCI NIH HHS [P30 CA008748, K08 CA230185, K24 CA197382, R01 CA166147] Funding Source: Medline	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American Society of Clinical Oncology, 2012, TOB CESSGUID ONC PRO; BIENER L, 1991, HEALTH PSYCHOL, V10, P360, DOI 10.1037/0278-6133.10.5.360; Bluethmann SM, 2015, PSYCHO-ONCOLOGY, V24, P1250, DOI 10.1002/pon.3857; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; COHEN S, 1990, J CONSULT CLIN PSYCH, V58, P304, DOI 10.1037/0022-006X.58.3.304; CONDIOTTE MM, 1981, J CONSULT CLIN PSYCH, V49, P648, DOI 10.1037/0022-006X.49.5.648; Croyle RT, 2019, NEW ENGL J MED, V380, P512, DOI 10.1056/NEJMp1813913; Fife BL, 2000, J HEALTH SOC BEHAV, V41, P50, DOI 10.2307/2676360; Fiore M. C., 2008, TREATING TOBACCO USE; Goldstein AO, 2013, NICOTINE TOB RES, V15, P52, DOI 10.1093/ntr/nts083; Gritz ER, 2014, CANCER EPIDEM BIOMAR, V23, P1638, DOI 10.1158/1055-9965.EPI-14-0202; Guimond AJ, 2017, ANN BEHAV MED, V51, P117, DOI 10.1007/s12160-016-9834-4; Hall SM, 2011, AM J PUBLIC HEALTH, V101, P2349, DOI 10.2105/AJPH.2010.300084; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Holland JC, 2013, J NATL COMPR CANC NE, V11, P190, DOI 10.6004/jnccn.2013.0027; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Land SR, 2016, CANCER-AM CANCER SOC, V122, P1728, DOI 10.1002/cncr.29964; LEVENSTEIN S, 1993, J PSYCHOSOM RES, V37, P19, DOI 10.1016/0022-3999(93)90120-5; National Center for Chronic Disease Prevention and Health Promo- tion (U.S.) Office on Smoking and Health, 2014, HLTH CONSMOK 50 YE; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2020, SMOK CESS REP SURG G; National Institutes of Health, 2015, RAC ETHN CAT DEF DIV; Orleans CT., 2008, THEORY REASONED ACTI, V4th, P68; Ostroff JS, 2014, HEALTH PSYCHOL, V33, P737, DOI 10.1037/a0033186; Park ER, 2016, CONTEMP CLIN TRIALS, V50, P54, DOI 10.1016/j.cct.2016.07.016; Park ER, 2012, CANCER-AM CANCER SOC, V118, P3153, DOI 10.1002/cncr.26545; Park ER, 2011, J THORAC ONCOL, V6, P1059, DOI 10.1097/JTO.0b013e318215a4dc; Park ER, 2009, ANN BEHAV MED, V37, P268, DOI 10.1007/s12160-009-9112-9; Piper ME, 2020, NICOTINE TOB RES, V22, P1098, DOI 10.1093/ntr/ntz110; Ramaswamy AT, 2016, CANCER-AM CANCER SOC, V122, P1247, DOI 10.1002/cncr.29851; Schafer J., 1999, ANAL INCOMPLETE MULT; Schnoll R, 2019, PSYCHO-ONCOLOGY, V28, P561, DOI 10.1002/pon.4978; Sheeran P, 2019, HEALTH PSYCHOL, V38, P855, DOI 10.1037/hea0000757; Shields PG, 2016, J NATL COMPR CANC NE, V14, P1430, DOI 10.6004/jnccn.2016.0152; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub3; The Social Science Research Center, 2008, NAT SOC SOC CLIM TOB; Toll BA, 2013, CLIN CANCER RES, V19, P1941, DOI 10.1158/1078-0432.CCR-13-0666; West R, 2004, PSYCHOPHARMACOLOGY, V177, P195, DOI 10.1007/s00213-004-1923-6; Westmaas JL, 2014, CANCER EPIDEM BIOMAR, V23, P1783, DOI 10.1158/1055-9965.EPI-14-0046	39	33	33	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2020	324	14					1406	1418		10.1001/jama.2020.14581	http://dx.doi.org/10.1001/jama.2020.14581			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OS4TT	33048154	Bronze, Green Published			2023-01-03	WOS:000590158000017
J	Lui, TH; Pan, XH				Lui, Tun Hing; Pan, Xiaohua			A post-traumatic painful deformity of the elbow	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Lui, Tun Hing] North Dist Hosp, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China; [Pan, Xiaohua] Guangdong Prov Acad Workstn Wound Repair & Regene, Guangdong Prov Engn Res Ctr Wound Repair & Regene, Guangzhou, Guangdong, Peoples R China; [Pan, Xiaohua] Shenzhen Univ, Affiliated Hosp 2, Dept Trauma & Orthopaed, Shenzhen, Guangdong, Peoples R China; [Pan, Xiaohua] Southern Med Univ, Peoples Hosp Shenzhen 8, Affiliated Baoan Hosp Shenzhen, Shenzhen, Guangdong, Peoples R China	Shenzhen University; Southern Medical University - China	Lui, TH (corresponding author), North Dist Hosp, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.	luithderek@yahoo.co.uk						Robinson Paul M, 2017, Shoulder Elbow, V9, P195, DOI 10.1177/1758573217694163	1	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2020	371								m3494	10.1136/bmj.m3494	http://dx.doi.org/10.1136/bmj.m3494			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC9AX	33032989				2023-01-03	WOS:000579448400001
J	Dummer, R; Lebbe, C; Atkinson, V; Mandala, M; Nathan, PD; Arance, A; Richtig, E; Yamazaki, N; Robert, C; Schadendorf, D; Tawbi, HA; Ascierto, PA; Ribas, A; Flaherty, KT; Pakhle, N; Campbell, CD; Gusenleitner, D; Masood, A; Brase, JC; Gasal, E; Long, GV				Dummer, Reinhard; Lebbe, Celeste; Atkinson, Victoria; Mandala, Mario; Nathan, Paul D.; Arance, Ana; Richtig, Erika; Yamazaki, Naoya; Robert, Caroline; Schadendorf, Dirk; Tawbi, Hussein A.; Ascierto, Paolo A.; Ribas, Antoni; Flaherty, Keith T.; Pakhle, Neha; Campbell, Catarina D.; Gusenleitner, Daniel; Masood, Aisha; Brase, Jan C.; Gasal, Eduard; Long, Georgina, V			Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i	NATURE MEDICINE			English	Article							INVESTIGATOR-CHOICE CHEMOTHERAPY; ADVANCED METASTATIC MELANOMA; EXPRESSION; PEMBROLIZUMAB; DABRAFENIB; TRAMETINIB; SURVIVAL; UPDATE; IMMUNOTHERAPY; VEMURAFENIB	Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes(1,2). We report on the efficacy, safety and biomarker analysis from the single-arm safety run-in (part 1;n = 9) and biomarker (part 2;n = 27) cohorts of the randomized, placebo-controlled, phase 3 COMBI-i trial (NCT02967692) of the anti-PD-1 antibody spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Patients (n = 36) had previously untreated BRAF V600-mutant unresectable or metastatic melanoma. In part 1, the recommended phase 3 regimen was identified based on the incidence of dose-limiting toxicities (DLTs; primary endpoint): 400 mg of spartalizumab every 4 weeks plus 150 mg of dabrafenib twice daily plus 2 mg of trametinib once daily. Part 2 characterized changes in PD-L1 levels and CD8(+)cells following treatment (primary endpoint), and analyzed additional biomarkers. Assessments of efficacy and safety were key secondary endpoints (median follow-up, 24.3 months). Spartalizumab plus dabrafenib and trametinib led to an objective response rate (ORR) of 78%, including 44% complete responses (CRs). Grade >= 3 treatment-related adverse events (TRAEs) were experienced by 72% of patients. All patients had temporary dose modifications, and 17% permanently discontinued all three study drugs due to TRAEs. Early progression-free survival (PFS) events were associated with low tumor mutational burden/T cell-inflamed gene expression signature (GES) or high immunosuppressive tumor microenvironment (TME) GES levels at baseline; an immunosuppressive TME may also preclude CR. Overall, the efficacy, safety and on-treatment biomarker modulations associated with spartalizumab plus dabrafenib and trametinib are promising, and biomarkers that may predict long-term benefit were identified.	[Dummer, Reinhard] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland; [Lebbe, Celeste] Univ Paris, Hop St Louis, AP HP, Dermatol & CIC, Paris, France; [Atkinson, Victoria] Univ Queensland, Greenslopes Private Hosp, Gallipoli Med Res Fdn, Greenslopes, Qld, Australia; [Mandala, Mario] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy; [Nathan, Paul D.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Arance, Ana] Hosp Clin Barcelona, Barcelona, Spain; [Richtig, Erika] Med Univ Graz, Graz, Austria; [Yamazaki, Naoya] Natl Canc Ctr, Tokyo, Japan; [Robert, Caroline] Gustave Roussy, Villejuif, France; [Robert, Caroline] Paris Sud Paris Saclay Univ, Villejuif, France; [Schadendorf, Dirk] Univ Hosp Essen, Essen, Germany; [Schadendorf, Dirk] German Canc Consortium, Heidelberg, Germany; [Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA USA; [Flaherty, Keith T.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA; [Flaherty, Keith T.] Harvard Med Sch, Boston, MA 02115 USA; [Pakhle, Neha] Novartis Healthcare Private Ltd, Hyderabad, India; [Campbell, Catarina D.; Gusenleitner, Daniel] Novartis Inst BioMed Res Inc, Cambridge, MA USA; [Masood, Aisha; Gasal, Eduard] Novartis Pharmaceut, E Hanover, NJ USA; [Brase, Jan C.] Novartis Pharma AG, Basel, Switzerland; [Long, Georgina, V] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, Georgina, V] Royal North Shore & Mater Hosp, Sydney, NSW, Australia	University of Zurich; University Zurich Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Queensland; ASST Papa Giovanni XXIII; Mount Vernon Cancer Centre; University of Barcelona; Hospital Clinic de Barcelona; Medical University of Graz; National Cancer Center - Japan; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Texas System; UTMD Anderson Cancer Center; IRCCS Fondazione Pascale; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Novartis; Novartis; Novartis; Novartis; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital	Dummer, R (corresponding author), Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland.	Reinhard.Dummer@usz.ch	Robert, Caroline/G-6157-2018; mandala, mario/AAB-8637-2022	Robert, Caroline/0000-0002-9493-0238; Arance, Ana/0000-0003-2896-1957; Nathan, Paul/0000-0002-2327-3250; Schadendorf, Dirk/0000-0003-3524-7858	Novartis Pharmaceuticals Corporation; Novartis Pharmaceuticals	Novartis Pharmaceuticals Corporation(Novartis); Novartis Pharmaceuticals(Novartis)	We thank the patients and their families for their participation. We also thank the study site staff, additional investigators, R. Leary, C. Unitt and S. Mahan (Next Generation Diagnostics) for their contributions. We thank K. Gibbs for biomarker sample management, as well as A. Savchenko, J. Choi, C. Wong, B. Fu, G. Gorgun and R. Ramesh for support with biomarker analyses. We thank Navigate Biopharma for DNA and RNA extraction, as well as HistoGeneX and Bioagilytix for biomarker testing. We also thank M. Voi (Novartis Pharmaceuticals) for guidance and critical review. We thank A. Lytle and A. Ghiretti (ArticulateScience LLC) for providing medical writing support, which was funded by Novartis Pharmaceuticals Corporation in accordance with Good Publication Practice guidelines (http://www.ismpp.org/gpp3). COMBI-i (NCT02967692) is sponsored by Novartis Pharmaceuticals.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ascierto PA, 2020, EUR J CANCER, V126, P33, DOI 10.1016/j.ejca.2019.11.016; Ascierto PA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468955; Ascierto PA, 2019, NAT MED, V25, P941, DOI 10.1038/s41591-019-0448-9; Atkinson V, 2016, ASIA-PAC J CLIN ONCO, V12, P5, DOI 10.1111/ajco.12656; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dummer R, 2020, LANCET ONCOL, V21, P358, DOI 10.1016/S1470-2045(20)30062-0; Ferrucci PF, 2020, PIGM CELL MELANOMA R, V33, P148, DOI [10.1111/pcmr.12834, DOI 10.1111/PCMR.12834]; Gide TN, 2019, CANCER CELL, V35, P238, DOI 10.1016/j.ccell.2019.01.003; Hamid O, 2017, EUR J CANCER, V86, P37, DOI 10.1016/j.ejca.2017.07.022; Hodi FS, 2019, CANCER RES, V79, pCT037; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Kakavand H, 2015, CLIN CANCER RES, V21, P3140, DOI 10.1158/1078-0432.CCR-14-2023; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Lee JH, 2017, ANN ONCOL, V28, P1130, DOI 10.1093/annonc/mdx026; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; LIN CC, 2018, ANN ONCOL, V29, P413, DOI DOI 10.1093/ANNONC/MDY288.032; Long GV, 2020, PIGM CELL MELANOMA R, V33, P148, DOI [10.1111/pcmr.12834, DOI 10.1111/PCMR.12834]; Mandala M, 2017, LAB INVEST, V97, P166, DOI 10.1038/labinvest.2016.132; Massi D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0797-4; McArthur G, 2020, PIGM CELL MELANOMA R, V33, P148, DOI [10.1111/pcmr.12834, DOI 10.1111/PCMR.12834]; McArthur G. A, 2020, AM ASS CANC RES VIRT; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Menzies AM, 2015, ANN ONCOL, V26, P415, DOI 10.1093/annonc/mdu529; Oh S, 2020, JCO CLIN CANCER INFO, V4, P321, DOI 10.1200/CCI.19.00130; Osgood C, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9508; Ribas A, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-4217; Ribas A, 2019, NAT MED, V25, P936, DOI 10.1038/s41591-019-0476-5; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Riester M, 2016, SOURCE CODE BIOL MED, V11, DOI 10.1186/s13029-016-0060-z; Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059; Robert C, 2019, LANCET ONCOL, V20, P1239, DOI 10.1016/S1470-2045(19)30388-2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Santiago-Walker A, 2016, CLIN CANCER RES, V22, P567, DOI 10.1158/1078-0432.CCR-15-0321; Schroder J, 2014, BIOINFORMATICS, V30, P1064, DOI 10.1093/bioinformatics/btt767; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Ugurel S, 2020, EUR J CANCER, V130, P126, DOI 10.1016/j.ejca.2020.02.021; Ugurel S, 2017, EUR J CANCER, V83, P247, DOI 10.1016/j.ejca.2017.06.028; Vilain RE, 2017, CLIN CANCER RES, V23, P5024, DOI 10.1158/1078-0432.CCR-16-0698; Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4; Weber JS, 2019, ANN ONCOL, V30, P533; Wilmott JS, 2014, J IMMUNOL, V192, P2505, DOI 10.4049/jimmunol.1302616; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yu CE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00990	54	47	48	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2020	26	10					1557	+		10.1038/s41591-020-1082-2	http://dx.doi.org/10.1038/s41591-020-1082-2		OCT 2020	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	NX8MD	33020648				2023-01-03	WOS:000575801100006
J	Lu, R; Huang, TH; Hu, HQ; Liu, XP				Lu, Rui; Huang, Tianhui; Hu, Haiqing; Liu, Xiao-Ping			Patients with mild and general COVID-19 should be negative for at least 3 consecutive nucleic acid tests before discharged	PLOS ONE			English	Article								Given the global spread of coronavirus disease (COVID-19), strict discharge standard is of great significance for the prevention and control of the epidemic, thus, the purpose of this study is to formulate more strict and scientific discharge standards. A total of 845 patients with mild and general COVID-19 who were considered to be discharged from hospital were included in this study. The median time from the onset of COVID-19 to the occurrence of two consecutive negative nucleic acid tests of these patients was 21 days. 223 of the 845 patients were tested again after two consecutive negative nucleic acid tests and 17.49% of the patients were positive. Moreover, 82.51% (184 of 223) of these patients experienced negative results from three consecutive nucleic acid tests, the median time from the onset of COVID-19 to the occurrence of three consecutive negative nucleic acid tests was 23 days (range: 3-56 days), and 38 of which were further tested after three consecutive negative nucleic acid tests, while about 5.26% (2 of 38) patients showed positive nucleic acid test results. Thus, we suggested that the patient should be negative for at least 3 consecutive nucleic acid tests before discharge, and the test time should be no earlier than the 23rd day since the onset of the disease.	[Lu, Rui; Hu, Haiqing; Liu, Xiao-Ping] Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Orthoped, Wuhan, Peoples R China; [Huang, Tianhui] Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Tradit Chinese Med, Wuhan, Peoples R China; [Liu, Xiao-Ping] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University	Liu, XP (corresponding author), Wuhan Univ, Tongren Hosp, Wuhan Hosp 3, Dept Orthoped, Wuhan, Peoples R China.; Liu, XP (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China.	liuxiaoping@whu.edu.cn		Lu, Rui/0000-0003-0995-7880				[Anonymous], **NON-TRADITIONAL**; Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006; National Health Commission of the People's Republic of China, 2020, COR DIS 2019 COVID 1; National Health Commission of the People's Republic of China, 2020, UPD OUTBR NEW COR PN; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8	5	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2020	15	10							e0240081	10.1371/journal.pone.0240081	http://dx.doi.org/10.1371/journal.pone.0240081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ4YX	33007008	gold, Green Published			2023-01-03	WOS:000577103500028
J	Monteiro, AC; Suri, R; Emeruwa, IO; Stretch, RJ; Cortes-Lopez, RY; Sherman, A; Lindsay, CC; Fulcher, JA; Goodman-Meza, D; Sapru, A; Buhr, RG; Chang, SY; Wang, TS; Qadir, N				Monteiro, Ana C.; Suri, Rajat; Emeruwa, Iheanacho O.; Stretch, Robert J.; Cortes-Lopez, Roxana Y.; Sherman, Alexander; Lindsay, Catherine C.; Fulcher, Jennifer A.; Goodman-Meza, David; Sapru, Anil; Buhr, Russell G.; Chang, Steven Y.; Wang, Tisha; Qadir, Nida			Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study	PLOS ONE			English	Article							SEVERE ARDS; CARE; PATTERNS	Purpose To describe the trajectory of respiratory failure in COVID-19 and explore factors associated with risk of invasive mechanical ventilation (IMV). Materials and methods A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 between March 12 and April 16, 2020. Data were manually extracted from electronic medical records. Multivariable and Univariable regression were used to evaluate association between baseline characteristics, initial serum markers and the outcome of IMV. Results Our cohort had median age of 61 (IQR 45-74) and was 66% male. In-hospital mortality was 6% (7/112). ICU mortality was 12.8% (6/47), and 18% (5/28) for those requiring IMV. Obesity (OR 5.82, CI 1.74-19.48), former (OR 8.06, CI 1.51-43.06) and current smoking status (OR 10.33, CI 1.43-74.67) were associated with IMV after adjusting for age, sex, and high prevalence comorbidities by multivariable analysis. Initial absolute lymphocyte count (OR 0.33, CI 0.11-0.96), procalcitonin (OR 1.27, CI 1.02-1.57), IL-6 (OR 1.17, CI 1.03-1.33), ferritin (OR 1.05, CI 1.005-1.11), LDH (OR 1.57, 95% CI 1.13-2.17) and CRP (OR 1.13, CI 1.06-1.21), were associated with IMV by univariate analysis. Conclusions Obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19.	[Monteiro, Ana C.; Suri, Rajat; Emeruwa, Iheanacho O.; Stretch, Robert J.; Cortes-Lopez, Roxana Y.; Sherman, Alexander; Buhr, Russell G.; Chang, Steven Y.; Wang, Tisha; Qadir, Nida] UCLA, Med Ctr, Dept Med, Div Pulm & Crit Care, Los Angeles, CA 90024 USA; [Lindsay, Catherine C.] UCLA, Med Ctr, Dept Med, Los Angeles, CA 90024 USA; [Fulcher, Jennifer A.; Goodman-Meza, David] UCLA, Med Ctr, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA; [Sapru, Anil] UCLA, Med Ctr, Dept Pediat, Div Crit Care, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Monteiro, AC (corresponding author), UCLA, Med Ctr, Dept Med, Div Pulm & Crit Care, Los Angeles, CA 90024 USA.	acostamonteiro@mednet.ucla.edu	Fulcher, Jennifer A./AAG-1495-2020	Fulcher, Jennifer A./0000-0001-9895-8636; Sherman, Alexander/0000-0002-5622-2804; Emeruwa, Iheanacho/0000-0002-1424-6437; Stretch, Robert/0000-0002-0514-5925; Goodman, David/0000-0001-9382-3564; Costa Monteiro, Ana Carolina/0000-0002-1501-4435; sapru, anil/0000-0003-1528-8249; Buhr, Russell/0000-0001-6159-7435	National Institutes of Health (NIH) [T32 5T32HL072752-1]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	ACM is funded by the National Institutes of Health (NIH) training grant T32 5T32HL072752-1 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aboodi MS., 2019, A15 CRITICAL CARE BR, pcited, DOI DOI 10.1164/AJRCCM-C0NFERENCE.2019.199.1_MEETINGABSTRACTS.A1013; Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; [Anonymous], 2020, CHEMCATCHEM, V12, pXXX; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6; Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818; Diretrizes [Internet], DIR; Duggal A, 2020, CHEST, V157, P1497, DOI 10.1016/j.chest.2020.01.041; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Force ADT, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; GREENE R, 1981, AM REV RESPIR DIS, V124, P593; GREENE R, 1987, AM J ROENTGENOL, V148, P501, DOI 10.2214/ajr.148.3.501; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020; Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014; Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775; Luks AM, 2020, ANN AM THORAC SOC, V17, P918, DOI [10.1513/AnnalsATS.202004-327CME, 10.1513/AnnalsATS.202004-327FR]; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; Nahum J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10478; Neil-Sztramko S, 2020, J MED INTERNET RES, V22, DOI 10.2196/15125; Ryan DH, 2020, OBESITY, V28, P847, DOI 10.1002/oby.22808; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE	35	27	27	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2020	15	12							e0238552	10.1371/journal.pone.0238552	http://dx.doi.org/10.1371/journal.pone.0238552			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL4CG	33351817	Green Submitted, gold, Green Published			2023-01-03	WOS:000603071400016
J	Salama, C; Han, J; Yau, LD; Reiss, WG; Kramer, B; Neidhart, JD; Criner, GJ; Kaplan-Lewis, E; Baden, R; Pandit, L; Cameron, ML; Garcia-Diaz, J; Chavez, V; Mekebeb-Reuter, M; de Menezes, FL; Shah, R; Gonzalez-Lara, MF; Assman, B; Freedman, J; Mohan, SV				Salama, Carlos; Han, Jian; Yau, Linda; Reiss, William G.; Kramer, Benjamin; Neidhart, Jeffrey D.; Criner, Gerard J.; Kaplan-Lewis, Emma; Baden, Rachel; Pandit, Lavannya; Cameron, Miriam L.; Garcia-Diaz, Julia; Chavez, Victoria; Mekebeb-Reuter, Martha; de Menezes, Ferdinando Lima; Shah, Reena; Gonzalez-Lara, Maria F.; Assman, Beverly; Freedman, Jamie; Mohan, Shalini, V			Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OUTCOMES; DISEASE	BACKGROUND Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are hospitalized with Covid-19 pneumonia are unclear. METHODS We randomly assigned (in a 2:1 ratio) patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. Site selection was focused on the inclusion of sites enrolling high-risk and minority populations. The primary outcome was mechanical ventilation or death by day 28. RESULTS A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9% were Black, 12.7% were American Indian or Alaska Native, 12.7% were non-Hispanic White, and 3.7% were of other or unknown race or ethnic group. The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation or death, 0.56; 95% CI, 0.33 to 0.97; P=0.04 by the log-rank test). Clinical failure as assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.33 to 0.93). Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, -5.2 to 7.8). In the safety population, serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group. CONCLUSIONS In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival. No new safety signals were identified.	[Salama, Carlos] Mt Sinai Hosp, Icahn Sch Med, Elmhurst Hosp Ctr, New York, NY 10029 USA; [Kaplan-Lewis, Emma] New York City Hlth & Hosp, Elmhurst Hosp Ctr, New York, NY USA; [Han, Jian; Yau, Linda; Reiss, William G.; Kramer, Benjamin; Assman, Beverly; Freedman, Jamie; Mohan, Shalini, V] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA; [Baden, Rachel] Highland Hosp, Oakland, CA USA; [Neidhart, Jeffrey D.] San Juan Oncol Assoc, Farmington, NM USA; [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Pandit, Lavannya] Michael E DeBakey Houston VA Med Ctr, Houston, TX USA; [Cameron, Miriam L.] Holy Cross Hlth, Silver Spring, MD USA; [Garcia-Diaz, Julia] Ochsner Clin Fdn, New Orleans, LA USA; [Chavez, Victoria] Cent Mil Hosp, Lima, Peru; [Mekebeb-Reuter, Martha] Stellenbosch Univ, Cape Town, South Africa; [de Menezes, Ferdinando Lima] BR Trials Clin Res, Sao Paulo, Brazil; [Shah, Reena] Aga Khan Univ Hosp, Nairobi, Kenya; [Gonzalez-Lara, Maria F.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico	Icahn School of Medicine at Mount Sinai; Roche Holding; Genentech; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Ochsner Health System; Stellenbosch University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Mohan, SV (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	mohan.shalini@gene.com	Azañero, Johan/AAV-5606-2021	Azañero, Johan/0000-0003-3385-1891	Genentech	Genentech(Roche HoldingGenentech)	Supported by Genentech.	[Anonymous], 2019, ACT PRESCR INF; [Anonymous], 2020, ROACTEMRA SUMM PROD; [Anonymous], 2020, COVID 19 PUBL HLTH E; Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948; Centers for Disease Control and Prevention, 2020, CAS DAT SURV COVID 1; Centers for Medicare & Medicaid Services, 2019, COVID 19 FREQ ASK QU; Chastain DB, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2021971; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910; COVID-19 Treatment Guidelines Panel, 2020, COR DIS 2019 COVID 1; Department of Health and Human Services, 2020, SOCIAL DETERMINANTS; Egede LE, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2023616; El-Sadr WM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2008193; Evans MK, 2020, NEW ENGL J MED, V383, P408, DOI 10.1056/NEJMp2019445; Fan E, 2020, LANCET RESP MED, V8, P816, DOI 10.1016/S2213-2600(20)30304-0; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Golestaneh L, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100455; Gupta S, 2020, JAMA INTERN MED, V180, P1436, DOI 10.1001/jamainternmed.2020.3596; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Karaca-Mandic P, 2020, J GEN INTERN MED, DOI 10.1007/s11606-020-06084-7; Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7; Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Morrison AR, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102512; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosas I, 2020, PREPRINT, DOI DOI 10.1101/2020.08.27.20183442V2; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhu JY, 2020, J MED VIROL, V92, P1902, DOI [10.1002/jmv.25884, 10.1002/jmv.26085]	39	652	672	3	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	2021	384	1					20	30		10.1056/NEJMoa2030340	http://dx.doi.org/10.1056/NEJMoa2030340			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PS6FK	33332779	Green Published, Bronze			2023-01-03	WOS:000608021500007
